<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD005321.pub2" GROUP_ID="MUSKEL" ID="278900071114102803" MERGED_FROM="" MODIFIED="2014-11-12 13:43:35 +0000" MODIFIED_BY="Lara Maxwell" REVIEW_NO="A018-R" REVMAN_SUB_VERSION="5.3.4 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="4.0">
<COVER_SHEET MODIFIED="2014-11-12 08:34:45 -0500" MODIFIED_BY="Lara Maxwell">
<TITLE>Viscosupplementation for the treatment of osteoarthritis of the knee</TITLE>
<CONTACT>
<PERSON ID="6D28CA6782E26AA2008F53C8A280D6C1" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Nicholas</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Bellamy</LAST_NAME>
<SUFFIX/>
<POSITION>Director and Professor of Rehabilitation Medicine</POSITION>
<EMAIL_1>n.bellamy@uq.edu.au</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Centre of National Research on Disability and Rehabilitation Medicine</DEPARTMENT>
<ORGANISATION>Mayne Medical School, The University of Queensland</ORGANISATION>
<ADDRESS_1>Level 3</ADDRESS_1>
<ADDRESS_2>Herston Road</ADDRESS_2>
<CITY>Brisbane</CITY>
<ZIP>4006</ZIP>
<REGION>Queensland</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>+617 33655558</PHONE_1>
<PHONE_2/>
<FAX_1>+617 33464603</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2014-11-12 08:34:45 -0500" MODIFIED_BY="Lara Maxwell">
<PERSON ID="6D28CA6782E26AA2008F53C8A280D6C1" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Nicholas</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Bellamy</LAST_NAME>
<SUFFIX/>
<POSITION>Director and Professor of Rehabilitation Medicine</POSITION>
<EMAIL_1>n.bellamy@uq.edu.au</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Centre of National Research on Disability and Rehabilitation Medicine</DEPARTMENT>
<ORGANISATION>Mayne Medical School, The University of Queensland</ORGANISATION>
<ADDRESS_1>Level 3</ADDRESS_1>
<ADDRESS_2>Herston Road</ADDRESS_2>
<CITY>Brisbane</CITY>
<ZIP>4006</ZIP>
<REGION>Queensland</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>+617 33655558</PHONE_1>
<PHONE_2/>
<FAX_1>+617 33464603</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="14910" ROLE="AUTHOR">
<PREFIX>Mrs.</PREFIX>
<FIRST_NAME>Jane</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Campbell</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>jcampbel@julian.uwo.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Medicine</DEPARTMENT>
<ORGANISATION>London Health Sciences Center</ORGANISATION>
<ADDRESS_1>375 South Street, Victoria Campus</ADDRESS_1>
<ADDRESS_2>Suite 305, Colborne Building</ADDRESS_2>
<CITY>London</CITY>
<ZIP>N6A 4G5</ZIP>
<REGION>ON</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>519-685-8300 ext: 5501</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="13312" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Vivian</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Welch</LAST_NAME>
<SUFFIX/>
<POSITION>Associate Scientist</POSITION>
<EMAIL_1>vivian.welch@uottawa.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>1 613 219 9290</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Bruyère Research Institute</DEPARTMENT>
<ORGANISATION>University of Ottawa</ORGANISATION>
<ADDRESS_1>85 Primrose Street</ADDRESS_1>
<ADDRESS_2/>
<CITY>Ottawa</CITY>
<ZIP>K1N 5C8</ZIP>
<REGION>ON</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 613 562-6262 x1352</PHONE_1>
<PHONE_2>+1 613 562-5800 ext 2921</PHONE_2>
<FAX_1>+1 613 562-5659</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="14409" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Travis</FIRST_NAME>
<MIDDLE_INITIALS>L</MIDDLE_INITIALS>
<LAST_NAME>Gee</LAST_NAME>
<SUFFIX/>
<POSITION>Senior Statistician</POSITION>
<EMAIL_1>Gee@ccs.uq.edu.au</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Centre of National Research on Disability and Rehabiliation Medicine</DEPARTMENT>
<ORGANISATION>University of Queensland</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Brisbane</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="14904" ROLE="AUTHOR">
<PREFIX>Mr</PREFIX>
<FIRST_NAME>Robert</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Bourne</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1/>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Medicine</DEPARTMENT>
<ORGANISATION>London Health Sciences Center</ORGANISATION>
<ADDRESS_1>375 South Street, Suite 305 Colborne Bldg</ADDRESS_1>
<ADDRESS_2>Victoria Campus</ADDRESS_2>
<CITY>London</CITY>
<ZIP>N5A 4G5</ZIP>
<REGION>ON</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>519-685-8300</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="12662" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>George</FIRST_NAME>
<MIDDLE_INITIALS>A</MIDDLE_INITIALS>
<LAST_NAME>Wells</LAST_NAME>
<SUFFIX>MSc, PhD</SUFFIX>
<POSITION>Professor</POSITION>
<EMAIL_1>gawells@ottawaheart.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Epidemiology and Community Medicine</DEPARTMENT>
<ORGANISATION>University of Ottawa</ORGANISATION>
<ADDRESS_1>Room H1281</ADDRESS_1>
<ADDRESS_2>40 Ruskin Street</ADDRESS_2>
<CITY>Ottawa</CITY>
<ZIP>K1Y 4W7</ZIP>
<REGION>ON</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 613 798 5555 x18640</PHONE_1>
<PHONE_2>+1 613 798 5555 x18642</PHONE_2>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2008-11-09 22:50:18 -0500" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="21" MONTH="2" YEAR="2006"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="1" MONTH="1" YEAR="2006"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="30" MONTH="11" YEAR="2008"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="1998"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2005"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2006"/>
</DATES>
<WHATS_NEW MODIFIED="2014-11-06 03:41:36 -0500" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2014-11-06 03:41:36 -0500" MODIFIED_BY="[Empty name]">
<DATE DAY="6" MONTH="11" YEAR="2014"/>
<DESCRIPTION>
<P>Updated with Feedback and editorial response</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2014-11-06 03:36:07 -0500" MODIFIED_BY="[Empty name]">
<DATE DAY="6" MONTH="11" YEAR="2014"/>
<DESCRIPTION>
<P>Updated with Feedback and editorial response</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2014-11-06 03:36:23 -0500" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2014-11-06 03:36:23 -0500" MODIFIED_BY="[Empty name]">
<DATE DAY="10" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
<P>CMSG ID: A018-R</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Centre of National Research on Disability and Rehabilitation Medicine (CONROD)</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2014-11-12 08:42:09 -0500" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2008-11-09 22:56:45 -0500" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-11-09 22:56:45 -0500" MODIFIED_BY="[Empty name]">Viscosupplementation for the treatment of osteoarthritis of the knee</TITLE>
<SUMMARY_BODY>
<P>Osteoarthritis (OA) is the most common form of chronic arthritis worldwide. Hyaluronan and hylan (HA) products provide opportunity to treat OA in individual knee joints. To evaluate the efficacy, effectiveness and safety of HA products, in knee OA, we have conducted a systematic review using Cochrane methodology. The analyses support the contention that the HA class of products is superior to placebo. There is considerable between-product, between-variable and time-dependent variability in the clinical response. The clinical effect for some products against placebo on some variables at some time points is in the moderate to large effect size range. In general, sample size restrictions preclude any definitive comment on the safety of the HA class of products, however, within the constraints of the trial designs employed, no major safety issues were detected. The analyses suggest that viscosupplements are comparable in efficacy to systemic forms of active intervention, with more local reactions but fewer systemic adverse events, and that HA products have more prolonged effects than IA corticosteroids. Overall, the aforementioned analyses support the use of the HA class of products in the treatment of knee OA.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>Osteoarthritis (OA) is the most prevalent chronic joint disorder worldwide and is associated with significant pain and disability.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To assess the effects of viscosupplementation in the treatment of OA of the knee. The products were hyaluronan and hylan derivatives (Adant, Arthrum H, Artz (Artzal, Supartz), BioHy (Arthrease, Euflexxa, Nuflexxa), Durolane, Fermathron, Go-On, Hyalgan, Hylan G-F 20 (Synvisc Hylan G-F 20), Hyruan, NRD-101 (Suvenyl), Orthovisc, Ostenil, Replasyn, SLM-10, Suplasyn, Synject and Zeel compositum).</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>MEDLINE (up to January (week 1) 2006 for update), EMBASE, PREMEDLINE, Current Contents up to July 2003, and the Cochrane Central Register of Controlled Trials (CENTRAL) were searched. Specialised journals and reference lists of identified randomised controlled trials (RCTs) and pertinent review articles up to December 2005 were handsearched.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>RCTs of viscosupplementation for the treatment of people with a diagnosis of OA of the knee were eligible. Single and double-blinded studies, placebo-based and comparative studies were eligible. At least one of the four OMERACT III core set outcome measures had to be reported (Bellamy 1997).</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Each trial was assessed independently by two reviewers for its methodological quality using a validated tool. All data were extracted by one reviewer and verified by a second reviewer . Continuous outcome measures were analysed as weighted mean differences (WMD) with 95% confidence intervals (CI). However, where different scales were used to measure the same outcome, standardized mean differences (SMD) were used. Dichotomous outcomes were analyzed by relative risk (RR).</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Seventy-six trials with a median quality score of 3 (range 1 to 5) were identified. Follow-up periods varied between day of last injection and eighteen months. Forty trials included comparisons of hyaluronan/hylan and placebo (saline or arthrocentesis), ten trials included comparisons of intra-articular (IA) corticosteroids, six trials included comparisons of nonsteroidal anti-inflammatory drugs (NSAIDs), three trials included comparisons of physical therapy, two trials included comparisons of exercise, two trials included comparisons of arthroscopy, two trials included comparisons of conventional treatment, and fifteen trials included comparisons of other hyaluronans/hylan. The pooled analyses of the effects of viscosupplements against 'placebo' controls generally supported the efficacy of this class of intervention. In these same analyses, differential efficacy effects were observed for different products on different variables and at different timepoints. Of note is the 5 to 13 week post injection period which showed a percent improvement from baseline of 28 to 54% for pain and 9 to 32% for function. In general, comparable efficacy was noted against NSAIDs and longer-term benefits were noted in comparisons against IA corticosteroids. In general, few adverse events were reported in the hyaluronan/hylan trials included in these analyses.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Based on the aforementioned analyses, viscosupplementation is an effective treatment for OA of the knee with beneficial effects: on pain, function and patient global assessment; and at different post injection periods but especially at the 5 to 13 week post injection period. It is of note that the magnitude of the clinical effect, as expressed by the WMD and standardised mean difference (SMD) from the RevMan 4.2 output, is different for different products, comparisons, timepoints, variables and trial designs. However, there are few randomised head-to-head comparisons of different viscosupplements and readers should be cautious, therefore, in drawing conclusions regarding the relative value of different products. The clinical effect for some products, against placebo, on some variables at some timepoints is in the moderate to large effect-size range. Readers should refer to relevant tables to review specific detail given the heterogeneity in effects across the product class and some discrepancies observed between the RevMan 4.2 analyses and the original publications. Overall, the analyses performed are positive for the HA class and particularly positive for some products with respect to certain variables and timepoints, such as pain on weight bearing at 5 to 13 weeks postinjection. </P>
<P>In general, sample-size restrictions preclude any definitive comment on the safety of the HA class of products; however, within the constraints of the trial designs employed no major safety issues were detected. In some analyses viscosupplements were comparable in efficacy to systemic forms of active intervention, with more local reactions but fewer systemic adverse events. </P>
<P>In other analyses HA products had more prolonged effects than IA corticosteroids. Overall, the aforementioned analyses support the use of the HA class of products in the treatment of knee OA.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2014-11-12 08:42:09 -0500" MODIFIED_BY="[Empty name]">
<BACKGROUND>
<P>Of all of the specific joint diseases osteoarthritis (OA) is the most frequent cause of rheumatic complaints. OA of the knee is a major cause of pain and disability. Guidelines for the management of knee OA have been reported in four publications (<LINK REF="REF-ACR-Guidelines-2000" TYPE="REFERENCE">ACR Guidelines 2000</LINK>; <LINK REF="REF-Jordan-2003" TYPE="REFERENCE">Jordan 2003</LINK>; <LINK REF="REF-Pendleton-2000" TYPE="REFERENCE">Pendleton 2000</LINK>; <LINK REF="REF-Walker_x002d_Bone-2000" TYPE="REFERENCE">Walker-Bone 2000</LINK>). </P>
<P>Viscosupplementation is an intra-articular (IA) therapeutic modality for the treatment of knee OA based on the physiologic importance of hyaluronan in synovial joints. Its therapeutic goal is to restore the viscoelasticity of synovial hyaluronan, decrease pain, improve mobility and restore the natural protective functions of hyaluronan in the joint. The short-term mode of action of viscosupplementation is believed to be based on the pain-relieving effect of the elastoviscous fluid in the affected joint. In the long term, the restoration of joint mobility due to relief of pain is thought to trigger a sequence of events which restores the trans-synovial flow and subsequently the metabolic and rheological homeostases of the joint. </P>
<P>The principle of viscosupplementation was pioneered by Balazs and coworkers (<LINK REF="REF-Balazs-1982" TYPE="REFERENCE">Balazs 1982</LINK>; <LINK REF="REF-Denlinger-1998" TYPE="REFERENCE">Denlinger 1998</LINK>; <LINK REF="REF-Peyron-1974" TYPE="REFERENCE">Peyron 1974</LINK>; <LINK REF="STD-Weiss-1999" TYPE="STUDY">Weiss 1999</LINK>). There are now several different formulations of viscosupplements (hyaluronan and hylan) produced by different manufacturers and of widely different molecular weights. This difference in molecular weight (MW) is thought to be of importance with respect to the volume/amount and number of injections, the residue time in the joint and biologic effects. Aviad and Houpt found no correlation between MW and efficacy (<LINK REF="REF-Aviad-1994" TYPE="REFERENCE">Aviad 1994</LINK>). Lo et al. reported that at a higher MW HA may have greater effects, but the heterogeneity of the trials used in this meta-analysis limited this conclusion (<LINK REF="REF-Lo-2003" TYPE="REFERENCE">Lo 2003</LINK>). Based on results observed in vitro, Maneiro et al. concluded that HA products were different due to differences in biological activity that resulted from the difference in MW (<LINK REF="REF-Maneiro-2004" TYPE="REFERENCE">Maneiro 2004</LINK>). </P>
<P>Viscosupplementation as treatment for knee OA has been the focus of several review publications (<LINK REF="REF-Aggarwal-2004" TYPE="REFERENCE">Aggarwal 2004</LINK>; <LINK REF="REF-Altman-2003" TYPE="REFERENCE">Altman 2003</LINK>; <LINK REF="REF-Altman-2000" TYPE="REFERENCE">Altman 2000</LINK>; <LINK REF="REF-Ayral-2001" TYPE="REFERENCE">Ayral 2001</LINK>; <LINK REF="REF-Brandt-2000" TYPE="REFERENCE">Brandt 2000</LINK>; <LINK REF="REF-Collange-1999" TYPE="REFERENCE">Collange 1999</LINK>; <LINK REF="REF-Dougados-2000" TYPE="REFERENCE">Dougados 2000</LINK>; <LINK REF="REF-Espallargues-2003" TYPE="REFERENCE">Espallargues 2003</LINK>; <LINK REF="REF-Gossec-2006" TYPE="REFERENCE">Gossec 2006</LINK>; <LINK REF="REF-Haraoui-2002" TYPE="REFERENCE">Haraoui 2002</LINK>; <LINK REF="REF-Hochberg-2000" TYPE="REFERENCE">Hochberg 2000</LINK>; <LINK REF="REF-Kelly-2003" TYPE="REFERENCE">Kelly 2003</LINK>; <LINK REF="REF-Khanuja-2003" TYPE="REFERENCE">Khanuja 2003</LINK>; <LINK REF="REF-Kirwan-1997" TYPE="REFERENCE">Kirwan 1997</LINK>; <LINK REF="REF-Kirwan-2001" TYPE="REFERENCE">Kirwan 2001</LINK>; <LINK REF="STD-Lussier-1996" TYPE="STUDY">Lussier 1996</LINK>; <LINK REF="REF-Maheu-1994" TYPE="REFERENCE">Maheu 1994</LINK>; <LINK REF="REF-Maheu-1995" TYPE="REFERENCE">Maheu 1995</LINK>; <LINK REF="REF-Maheu-2003" TYPE="REFERENCE">Maheu 2003</LINK>; <LINK REF="REF-Marshall-2000" TYPE="REFERENCE">Marshall 2000</LINK>; <LINK REF="REF-MSAC-2003" TYPE="REFERENCE">MSAC 2003</LINK>; <LINK REF="REF-Moreland-2003" TYPE="REFERENCE">Moreland 2003</LINK>; <LINK REF="REF-Moskowitz-2000" TYPE="REFERENCE">Moskowitz 2000</LINK>; <LINK REF="REF-Peyron-1993" TYPE="REFERENCE">Peyron 1993</LINK>; <LINK REF="REF-Tehranzadeh-2005" TYPE="REFERENCE">Tehranzadeh 2005</LINK>; <LINK REF="REF-Uebelhart-1999" TYPE="REFERENCE">Uebelhart 1999</LINK>; <LINK REF="REF-Watterson-2000" TYPE="REFERENCE">Watterson 2000</LINK>). Four meta-analyses have been reported (<LINK REF="REF-Arrich-2005" TYPE="REFERENCE">Arrich 2005</LINK>; <LINK REF="REF-Lo-2003" TYPE="REFERENCE">Lo 2003</LINK>; <LINK REF="REF-Modawal-2005" TYPE="REFERENCE">Modawal 2005</LINK>; <LINK REF="REF-Wang-2004" TYPE="REFERENCE">Wang 2004</LINK>). A fifth meta-analysis has been reported only as an abstract (<LINK REF="REF-Choi-1999" TYPE="REFERENCE">Choi 1999</LINK>). These publications employ different methodologies and have shown conflicting results. The review by Espallargues and Pons concluded that a hylan (Hylan G-F 20) was a safe and well-tolerated therapy in the short term, but they recommended further work on the effect of multiple courses of hylan (<LINK REF="REF-Espallargues-2003" TYPE="REFERENCE">Espallargues 2003</LINK>). The Medical Services Advisory Committee (Australia) recommended that public funding should not support viscosupplementation for the treatment of knee OA, in March 2003 (<LINK REF="REF-MSAC-2003" TYPE="REFERENCE">MSAC 2003</LINK>). Choi et al. concluded from their meta-analysis of seven placebo-controlled trials that viscosupplementation significantly reduced pain in patients with knee OA, for a period of 5 to 10 weeks after the last injection (<LINK REF="REF-Choi-1999" TYPE="REFERENCE">Choi 1999</LINK>). Lo et al.'s meta-analysis of 18 trials of HA against IA placebo, using a hierarchical algorithm to select variables and timepoints from different trials to charcterise the clinical response across variables, timepoints, and studies to the HA class as a whole, indicated that HA had a small effect when compared to placebo (<LINK REF="REF-Lo-2003" TYPE="REFERENCE">Lo 2003</LINK>; <LINK REF="REF-Bernstein-2004" TYPE="REFERENCE">Bernstein 2004</LINK>; <LINK REF="REF-Hou-2004" TYPE="REFERENCE">Hou 2004</LINK>). The evidence from Arrich et al.'s systematic review and meta-analysis of 22 trials of HA against placebo suggested that HA was not clinically effective and that it could be associated with an increased risk of adverse events. The most recent meta-analysis by <LINK REF="REF-Modawal-2005" TYPE="REFERENCE">Modawal 2005</LINK>, based on nine randomised, double-blind, placebo-controlled trials, reported that viscosupplementation was moderately effective in relieving OA knee pain at five to seven and eight to ten weeks after the last injection but not at 15 to 22 weeks.</P>
<P>Given this diversity of opinion there is, therefore, a rational basis for performing a Cochrane review of viscosupplementation in knee OA.</P>
</BACKGROUND>
<OBJECTIVES>
<P>To assess the effects of viscosupplementation in the treatment of OA of the knee. The products were hyaluronan and hylan derivatives of widely different molecular weights and formulation (Adant, Arthrum H, Artz (Artzal, <LINK REF="REF-Supartz" TYPE="REFERENCE">Supartz</LINK>), BioHy (Arthrease, Euflexxa, Nuflexxa), Durolane, Fermathron, Go-On, <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK>, Hylan G-F 20 (<LINK REF="REF-Synvisc-Hylan-G_x002d_F-20" TYPE="REFERENCE">Synvisc Hylan G-F 20</LINK>), Hyruan, NRD-101, <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK>, Ostenil, Replasyn, SLM-10, Suplasyn, Synject and Zeel compositum). </P>
</OBJECTIVES>
<METHODS MODIFIED="2008-11-09 22:58:27 -0500" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>All randomised controlled clinical trials using one or more viscosupplements.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Participants were males and/or females with a diagnosis of OA of the knee. Diagnosis was classified as one of the following (any one of the diagnostic criteria below): </P>
<P>a) diagnosis according to published ACR classification criteria (<LINK REF="REF-Altman-1986" TYPE="REFERENCE">Altman 1986</LINK>); <BR/>b) diagnosis according to the algorithm developed by Altman (<LINK REF="REF-Altman-1991" TYPE="REFERENCE">Altman 1991</LINK>); <BR/>c) diagnosis on the basis of detailed clinical and/or radiographic information.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>All viscosupplements used for the treatment of OA of the knee in humans. <BR/>Control treatments included: placebo (saline, arthrocentesis) and active treatment.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>The OMERACT III core set of outcome measures was considered for analysis (<LINK REF="REF-Bellamy-1997" TYPE="REFERENCE">Bellamy 1997</LINK>): </P>
<P>a) pain; <BR/>b) physical function; <BR/>c) patient global assessment; <BR/>d) joint imaging (for studies of one year or longer). </P>
<P>The minimum criterion for inclusion of the trial in the systematic review was the adequate reporting of at least one of the outcome variables a) or b) or c). Information regarding other outcome measures was extracted and analysed when feasible. </P>
<P>The following variables were included for assessment of adverse reactions to IA injection: </P>
<P>1) by procedure; <BR/>a) infection; <BR/>b) needle breakage or separation; <BR/>c) hypersensitivity to local anaesthetic or preservative; <BR/>d) discomfort at site of injection; <BR/>2) by viscosupplement; <BR/>a) swelling; <BR/>b) pain; <BR/>3) by toxicity-related withdrawals; <BR/>4) by total number of withdrawals and dropouts.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-11-09 22:58:27 -0500" MODIFIED_BY="[Empty name]">
<P>MEDLINE and EMBASE were used initially to identify all clinical trials relating to the use of viscosupplementation therapy in OA. MEDLINE searches for clinical trials were based on the Cochrane search strategy (<LINK REF="REF-Dickerson-1994" TYPE="REFERENCE">Dickerson 1994</LINK>; <LINK REF="REF-Haynes-1994" TYPE="REFERENCE">Haynes 1994</LINK>). The MeSH heading osteoarthritis (degenerative arthritis, gonoarthrosis) (all subheadings) was added to the search. Similar searches were prepared for the other databases. The lists of references of retrieved publications were also manually checked to add any citations missed by the electronic searches. Abstracts from scientific meetings were included if enough information was available in the abstract.</P>
<P>MEDLINE (1966 to week 2 July 2003 (n = 156 identified)(for update to January (week 1) 2006 (n=92)), EMBASE (1988 to week 29 2003 (n = 255)), PREMEDLINE (to 21 July 2003 (n = 8)), Current Contents (to 17 September 2000 (n = 36)), and the Cochrane Central Register of Controlled Trials (CENTRAL) (to the second quarter 2003 (n = 52)) were searched. The electronic search was supplemented by handsearches of bibliographic references and abstracts published in conference proceedings or in special issues of specialized journals, up to the end of December 2005. One reviewer (JC) handsearched all relevant journals at The University of Western Ontario, London, Canada. The journals that were handsearched were: <I>Acta Orthopedica Scandinavica, Acta Rheumatologica Scandinavica, American Journal of Orthopedics, American Journal of Sports Medicine, Annals of the Rheumatic Diseases, Arthritis Care &amp; Research, Arthritis &amp; Rheumatism, Arthroscopy, Bailliere's Clinical Rheumatology, British Journal of Clinical Practice, British Journal of Rheumatology (now Rheumatology), British Journal of Sports Medicine, British Medical Journal (now BMJ), Bulletin - Hospital for Joint Diseases, Bulletin on the Rheumatic Diseases, Clinical and Experimental Rheumatology, Clinical Therapeutics, Current Medical Research and Opinion, Current Orthopaedics, Current Therapeutic Research Clinical and Experimental, Drugs, Drug and Therapeutics Bulletin, JAMA, The Journal of Bone and Joint Surgery (American and British), Journal of Bone and Mineral Research, Journal of Orthopaedic and Sports Physical Therapy, Journal of Orthopaedic Research, Journal of Orthopedic Rheumatology, Netherlands Journal of Medicine, New England Journal of Medicine, Orthopedics, Orthopaedic Review, Physiotherapy Practice, Physiotherapy Theory and Practice, Rheumatology and Physical Medicine, Rheumatology and Rehabilitation, Rheumatology International, Scandinavian Journal of Rheumatology, Seminars in Arthritis and Rheumatism, The Journal of Musculoskeletal Medicine, The Journal of Rheumatology and the Lancet.</I> Reference lists were handsearched for further identification of published work and presentations at scientific meetings (e.g. American College of Rheumatology (ACR), The Asia Pacific League of Associations for Rheumatology (APLAR), European League Against Rheumatism (EULAR), International League of Associations for Rheumatology (ILAR), Pan-American League of Associations for Rheumatology (PANLAR), OsteoArthritis Research Society International (OARSI), American Academy of Orthopaedic Surgeons (AAOS)). There were no language restrictions.</P>
<P>Industry representatives were contacted requesting reports on additional studies of their products that might meet eligibility criteria.</P>
<P>The search strategy used is in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.<BR/>
</P>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>Selection of trials </P>
<P>Inclusion criteria were based on the characteristics of interest. The inclusion criteria were: <BR/>a) diagnosis of OA of the knee in participants as specified earlier; <BR/>b) randomised controlled trial design; <BR/>c) specification of comparative treatment; <BR/>d) published data on relevant outcome measures; <BR/>e) statistical analysis including intention-to-treat approach. </P>
<P>Data collection </P>
<P>Data from the trials were extracted by one reviewer (JC) and verified by a second reviewer (VR). For the update one reviewer (JC) extracted the data and a second reviewer (NB) verified the data extraction. Trials were not blinded as to authors or institutions. Every effort was made to obtain translations. </P>
<P>A data collection form was developed to use for data collection and subsequent entry into Review Manager (RevMan) 4.2.8. </P>
<P>Data synthesis </P>
<P>Quantitative data were analysed as unadjusted post-test scores (<LINK REF="REF-Lund-1988" TYPE="REFERENCE">Lund 1988</LINK>). Selected timepoints defined a priori and reflecting short-term, intermediate-term and long-term follow-up were: 1 to 4 weeks postinjection (with respect to the last injection), 5 to 13 weeks postinjection, 14 to 26 weeks postinjection and 45 to 52 weeks postinjection. If two follow-up assessments were completed within one of the defined timepoints the results of the later of the two assessments were selected for inclusion. For continuous outcome data measured on the same scale weighted mean differences (WMD) were calculated. When pain and function were measured on different scales we defined a hierarchy of pain and function measures then used standardized mean differences (SMD) to pool across RCTs (<LINK REF="REF-Hedges-1985" TYPE="REFERENCE">Hedges 1985</LINK>; <LINK REF="REF-Petitti-1994" TYPE="REFERENCE">Petitti 1994</LINK>). In the event, a variable-by-variable approach to data extraction was pursued in order to avoid any potential bias resulting from the hierarchical approach, which might have excluded more or less responsive variables from consideration. The SMD controls for different units by calculating an effect size by dividing the mean difference between treatment and control by the standard deviation. For all pooled outcomes, heterogeneity was tested with a chi square test. A fixed-effect model was used unless heterogeneity was significant (P value &lt; 0.10), in which case a random-effects (RE) model was used. Since the RevMan Analyses window in RevMan 4.2.8 only permits one model to be set for an outcome, the text results present the correct model. If there is only one trial in a comparison the default is a fixed-effect model. Only P values less than 0.05 are reported in the text of the Results section.</P>
<P>For categorical outcome data with two categories, relative risk (RR) was calculated (<LINK REF="REF-Petitti-1994" TYPE="REFERENCE">Petitti 1994</LINK>). </P>
<P>In the Additional Tables section, clinical relevance tables are provided. For dichotomous outcome measures, the number needed to treat (NNT) has been provided. The NNT was calculated as one divided by the risk difference. For continuous outcome measures, the absolute benefit and the relative difference in the change from baseline are presented. The absolute benefit was calculated as the improvement in the treatment group (followup mean minus baseline line) less the improvement in the control group (followup mean minus baseline mean). The relative difference in the change from baseline was calculated as the absolute benefit divided by the baseline mean of the control group. Improvement is indicated by (I) while worsening is indicated by (W). Only if a comparison resulted in a statistically significant difference and baseline values were reported was the clinical relevance (i.e. NNT or benefit) reported in the text. </P>
<P>In other additional tables the results of analyses for continuous outcome measures based on effect size (SMD) are presented to allow reviewers an alternate appreciation of the magnitude of the effect (compared with WMD). </P>
<P>If the change of the standard deviation (SD) was reported in the publication the quadratic formula was used to convert the change SD to the raw SD; &#961; was set at 0.4, a conservative estimate of the correlation between baseline and post-test scores. This value for &#961; closely approximates values for &#961; generated from analyses based on PMA data of Hylan G-F 20 trials reporting both interval and change scores. If median rather than mean values were reported the median was extracted. If the range was reported the SD was calculated as range divided by 4. </P>
<P>In comparisons of two hyaluronans the 'new' hyaluronan was considered the treatment and the 'old' marketed hyaluronan was considered the control. </P>
<P>Cochrane policy is, where possible, to avoid the use of proprietary names of products under review. In the case of this viscosupplementation review, an exception has been made, for purposes of clarity, and to permit consumers to more easily identify the products being reviewed. HA products are normally identified by their proprietary names since this is the only exclusive label that allows readers/consumers a common language to understand which product is being described. We consider this preferable to circuitous descriptions based on method of manufacture and molecular weight. In this particular review, we have described the products according to the names commonly used by manufacturers, providers and consumers.</P>
<P>Evaluation of the data was by meta-analysis using RevMan 4.2.8). Readers should note that the analyses that follow were based on secondary, not primary, data and only use statistical methods contained within RevMan 4.2.8 software. As a result, some analyses may differ in level of significance (in either direction) from that reported in the original publication, based on primary data and other analytic techniques. These differences are apparent in some comparisons based on only a single study but may not be evident to the reader in comparisons based on meta-analyses where data from multiple studies were combined. Results and interpretations may need to take into account these analytic differences, which are summarised in Additional <LINK REF="TBL-50" TYPE="TABLE">Table 50</LINK>. This is potentially a generic issue and not necessarily limited to this particular review.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2014-11-12 08:42:09 -0500" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION>
<P>The following information was systematically extracted. </P>
<P>Trial methodology: <BR/>randomisation; <BR/>controlled; <BR/>blinding: single, double, masked observer; <BR/>design: parallel-group, cross-over; <BR/>number of centres; <BR/>stratification variables; <BR/>washout utilization; <BR/>type of analysis: per protocol, intent to treat. </P>
<P>Characteristics of the study population: <BR/>country where trial was completed; <BR/>mean age; <BR/>percentage of female patients; <BR/>mean disease duration; <BR/>number randomised; <BR/>inclusion/exclusion criteria; <BR/>baseline values of outcomes. </P>
<P>Interventions: <BR/>description of experimental and control treatments; <BR/>concurrent therapy usage. <BR/>Outcomes: <BR/>primary (when reported, a dash line followed);<BR/>secondary outcomes. </P>
<P>In notes: <BR/>Jadad score: randomisation (R), blinding (B), description of withdrawals/dropouts (W) (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>); <BR/>presence/absence of effusion; <BR/>if bilateral disease, selection criteria for injected joint(s); <BR/>trial affiliation with industry (e.g. sponsorship, authorship, statistical analysis). </P>
<P>Allocation concealment was evaluated using the following criteria: 1) adequately concealed trials (i.e. central randomisation; numbered or coded bottles or containers; drugs prepared by the pharmacy; serially numbered, opaque sealed envelopes; or other description that contained elements convincing of concealment), 2) inadequate (i.e. alternation or reference to case record numbers or to dates of birth), and 3) unclear (i.e. authors either did not report an allocation concealment approach at all or reported an approach that did not fall into one of the above two categories) (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>).</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>Methodological quality was assessed by two reviewers (NB and JC). A third reviewer (GW) re-evaluated these assessments and acted as adjudicator in cases of disagreement. The quality of the methodology of the trials was rated by the criteria recommended by Jadad et al. (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>). Briefly, this instrument has a maximum score of 5 points. A score of one point is given for each of the following: if the study was described as randomised (1 point), if the study was described as double blind (1 point), and if there was a description of withdrawals or dropouts (1 point). Two additional points are given if the method of randomisation was described and it was appropriate (e.g. computer generated) (1 point), and if the method of double blinding was described and it was appropriate (e.g. identical placebo) (1 point). Two points can be deducted if the method of randomisation was inappropriate (e.g. patients randomised according to date of birth) (-1 point), or if the method of blinding was inappropriate (e.g. comparison of an oral tablet versus IA injection with no double dummy) (-1 point).</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2014-11-12 08:42:09 -0500" MODIFIED_BY="[Empty name]">
<P>Results are presented by product. An independent evaluation by product is recommended rather than a by-class meta-analysis since these products differ in their MW, concentration, treatment schedules, and mode of production (<LINK REF="REF-Altman-2003" TYPE="REFERENCE">Altman 2003</LINK>; <LINK REF="REF-Blue-Cross-1998" TYPE="REFERENCE">Blue Cross 1998</LINK>). Furthermore, since the response is time-dependent, and may differ between outcome variables, the response has been presented on a by-product, by-variable and by-time basis for each individual product. At the end of the product-by-product evaluation there is a section based on the by-class (pooled) results. Readers are cautioned to note the many differences in study design while reading the results of this analysis. The Discussion section addresses some of these issues.</P>
<P>
<I>
<B>Product - Adant </B>
</I>
</P>
<P>
<I>Description of studies </I>
</P>
<P>One RCT was included: a comparison of Adant and another hyaluronan (<LINK REF="STD-Roman-2000" TYPE="STUDY">Roman 2000</LINK>).</P>
<P>Roman et al. reported a six-month, parallel-group, blind RCT performed at a single centre comparing five weekly injections of Adant (Treatment: MW 900,000 D biotechnically obtained) to five weekly injections of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> (Control: MW 800,000 D obtained from rooster crest) in 49 patients with OA of the knee (<LINK REF="STD-Roman-2000" TYPE="STUDY">Roman 2000</LINK>). The authors concluded that the efficacy of Adant was greater than with <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> at three months after treatment. They reported that maximum improvement was seen at five weeks with response decreasing over time resulting in almost 75% of patients reporting only 'fair' or 'no' clinical response at six months postinjection. Pain at the injection site was almost twice as great with Adant. The Jadad score for this study was 3 out of a maximum of 5; specific details of blinding and randomisation were not reported in the publication. The randomisation allocation was 1.6:1 (e.g. n = 30:19) in favour of the Adant group. Allocation concealment was unclear (i.e. not reported).</P>
<P>In this RCT several design issues were noted: 1) one and a half times as many patients were randomised to the Adant group compared to the <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> group; 2) eighty-four percent of the patients were female; 3) no exclusion criteria were reported in the Materials and Methods section of the publication; 4) details regarding presence or absence of effusion, uni- or bilateral disease, OA diagnosis criteria and disease duration were not published; 5) efficacy was assessed only by the patient subjective assessment, the details of which were not published. However, injection technique was standardised and the effect of concomitant analgesic and/or anti-inflammatory drugs was considered. Although the authors attributed the 'greater efficacy' with Adant at three months and the higher incidence of pain at the injection site to its greater viscosity and volume, there were no statistically significant differences between the products in either the efficacy or safety profiles.</P>
<P>Four trials were excluded: <LINK REF="STD-Couceiro-2003" TYPE="STUDY">Couceiro 2003</LINK>; <LINK REF="STD-Guerrero-1999" TYPE="STUDY">Guerrero 1999</LINK>; <LINK REF="STD-Guerrero-1999a" TYPE="STUDY">Guerrero 1999a</LINK>; <LINK REF="STD-Novaes-2005" TYPE="STUDY">Novaes 2005</LINK>. One trial is awaiting assessment: <LINK REF="STD-Blanco-Garcia-2004" TYPE="STUDY">Blanco Garcia 2004</LINK>.</P>
<P>Adant versus placebo: no trials included.</P>
<P>Adant versus corticosteroid: no trials included.</P>
<P>Adant versus NSAID: no trials included.</P>
<P>Adant versus other hyaluronan</P>
<P>
<I>Efficacy </I>
</P>
<P>The only efficacy outcome measure extracted from this trial (<LINK REF="STD-Roman-2000" TYPE="STUDY">Roman 2000</LINK>) was patient global assessment (e.g. number of patients excellent or good) (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). At each of the three timepoints there were no statistically significant differences between the two groups: at 1 to 4 weeks postinjection, 43% of the Adant patients and 37% of the <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> patients were excellent or good; at 5 to 13 weeks postinjection, 50% of the Adant patients and 21% of the <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> patients were excellent or good; and at 14 to 26 weeks postinjection, 33% of the Adant patients and 16% of the <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> patients were excellent or good.</P>
<P>The RevMan analysis differed from the publication analysis. The publication reported a significant difference in favour of Adant compared to <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> at three months in the number of patients rating the improvement as excellent or good (P value &lt; 0.05) whereas RevMan reported a P value of 0.07.</P>
<P>
<I>Safety </I>
</P>
<P>The number of patients reporting painful injections was almost twice as high in the Adant group (6/30, 20%) versus <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> (2/19, 11%). This difference was not statistically significant (<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>).</P>
<P>The RevMan analysis differed from the publication analysis. The publication reported a significant difference in favour of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> compared to Adant in the number of patients with painful infiltrations (P value &lt; 0.001) whereas RevMan detected a P value of 0.4.</P>
<P>
<I>
<B>Product - Arthrum H </B>
</I>
</P>
<P>
<I>Description of studies </I>
</P>
<P>One trial was excluded: <LINK REF="STD-Bardin-2004" TYPE="STUDY">Bardin 2004</LINK>.</P>
<P>
<I>
<B>Product - Artz (Artzal,</B>
</I>
<B> <I>Supartz)</I> </B>
</P>
<P>
<I>Description of studies </I>
</P>
<P>Nine trials of Artz (Seikagaku Corporation) have been included. Seven included comparisons of Artz against placebo (<LINK REF="STD-Day-2004" TYPE="STUDY">Day 2004</LINK>; <LINK REF="STD-Karlsson-2002" TYPE="STUDY">Karlsson 2002</LINK>; <LINK REF="STD-Lohmander-1996" TYPE="STUDY">Lohmander 1996</LINK>; <LINK REF="STD-Puhl-1993" TYPE="STUDY">Puhl 1993</LINK>; <LINK REF="STD-Shichikawa-1983a" TYPE="STUDY">Shichikawa 1983a</LINK>; <LINK REF="STD-Shichikawa-1983b" TYPE="STUDY">Shichikawa 1983b</LINK>; <LINK REF="STD-Wu-1997" TYPE="STUDY">Wu 1997</LINK>) and three included comparisons of Artz against three other hyaluronan/hylan products: Hylan G-F 20 (<LINK REF="STD-Karlsson-2002" TYPE="STUDY">Karlsson 2002</LINK>), NRD-101 (<LINK REF="STD-Tsukamoto-1995" TYPE="STUDY">Tsukamoto 1995</LINK> (abstract); <LINK REF="STD-Yamamoto-1994" TYPE="STUDY">Yamamoto 1994</LINK>) and SLM-10 (<LINK REF="STD-Kawabata-1993" TYPE="STUDY">Kawabata 1993</LINK>). Readers are directed to the Hylan G-F 20, NRD-101 and SLM-10 sections for results based on these products. With respect to methodological quality, the average Jadad score was 4.3 out of 5 with three trials scoring 5 (<LINK REF="STD-Day-2004" TYPE="STUDY">Day 2004</LINK>; <LINK REF="STD-Karlsson-2002" TYPE="STUDY">Karlsson 2002</LINK>; <LINK REF="STD-Puhl-1993" TYPE="STUDY">Puhl 1993</LINK>), three trials scoring 4 (<LINK REF="STD-Lohmander-1996" TYPE="STUDY">Lohmander 1996</LINK>; <LINK REF="STD-Shichikawa-1983a" TYPE="STUDY">Shichikawa 1983a</LINK>; <LINK REF="STD-Shichikawa-1983b" TYPE="STUDY">Shichikawa 1983b</LINK>) and one trial scoring 3 (<LINK REF="STD-Wu-1997" TYPE="STUDY">Wu 1997</LINK>). Allocation concealment was adequate in three trials (<LINK REF="STD-Puhl-1993" TYPE="STUDY">Puhl 1993</LINK>; <LINK REF="STD-Shichikawa-1983a" TYPE="STUDY">Shichikawa 1983a</LINK>; <LINK REF="STD-Shichikawa-1983b" TYPE="STUDY">Shichikawa 1983b</LINK>) and unclear (not reported) in four trials (<LINK REF="STD-Day-2004" TYPE="STUDY">Day 2004</LINK>; <LINK REF="STD-Karlsson-2002" TYPE="STUDY">Karlsson 2002</LINK>; <LINK REF="STD-Lohmander-1996" TYPE="STUDY">Lohmander 1996</LINK>; <LINK REF="STD-Wu-1997" TYPE="STUDY">Wu 1997</LINK>). Two randomised, double-blind, placebo-controlled, multicentre trials have been completed: one in France (<LINK REF="STD-Bourgeois-_x0028_Artz_x0029_" TYPE="STUDY">Bourgeois (Artz)</LINK>) and one in the United Kingdom (<LINK REF="STD-Byrd-_x0028_Artz_x0029_" TYPE="STUDY">Byrd (Artz)</LINK>) but have only been published as part of the Food and Drug Administration Pre-Market Approval Package (Number P980044, Docket #01M-0342). Seventeen studies, reported between 1982 and 2005, were excluded (<LINK REF="STD-Arizono-1997" TYPE="STUDY">Arizono 1997</LINK>; <LINK REF="STD-Dahlberg-1994" TYPE="STUDY">Dahlberg 1994</LINK>; <LINK REF="STD-Fuji-1994" TYPE="STUDY">Fuji 1994</LINK>; <LINK REF="STD-Hashimoto-1992" TYPE="STUDY">Hashimoto 1992</LINK>; <LINK REF="STD-Honma-1989" TYPE="STUDY">Honma 1989</LINK>; <LINK REF="STD-Igarashi-1983" TYPE="STUDY">Igarashi 1983</LINK>; <LINK REF="STD-Iseki-1983" TYPE="STUDY">Iseki 1983</LINK>; <LINK REF="STD-Iwasaki-1993" TYPE="STUDY">Iwasaki 1993</LINK>; <LINK REF="STD-Kawakami-1993" TYPE="STUDY">Kawakami 1993</LINK>; <LINK REF="STD-Namiki-1982" TYPE="STUDY">Namiki 1982</LINK>; <LINK REF="STD-Oshima-1983" TYPE="STUDY">Oshima 1983</LINK>; <LINK REF="STD-Shibata-1993" TYPE="STUDY">Shibata 1993</LINK>; <LINK REF="STD-Suzu-1990" TYPE="STUDY">Suzu 1990</LINK>; <LINK REF="STD-Takeuchi-1993" TYPE="STUDY">Takeuchi 1993</LINK>; <LINK REF="STD-Tang-2004" TYPE="STUDY">Tang 2004</LINK>; <LINK REF="STD-Tang-2005" TYPE="STUDY">Tang 2005</LINK>; <LINK REF="STD-Yoh-1989" TYPE="STUDY">Yoh 1989</LINK>).</P>
<P>Day et al. reported an 18-week, placebo-controlled, double-blind RCT performed at 17 centres in Australia comparing five weekly injections of Artz to five weekly injections of saline in 240 patients with OA of the knee (<LINK REF="STD-Day-2001" TYPE="STUDY">Day 2001</LINK>; <LINK REF="STD-Day-2004" TYPE="STUDY">Day 2004</LINK>). A significant difference between the two comparison groups for each outcome measure evaluated was reported. A total of 482 adverse events were reported but only 81 were possibly, probably or definitely related to study medication (Artz n = 50, saline n = 31). Tolerability was reported as being excellent since approximately 95% of patients completed the full treatment schedule. Injection site pain and inflammation, that was mild and of short duration, was the most frequent adverse event and occurred in approximately 10% of patients.</P>
<P>In the Discussion of the Day RCT (<LINK REF="STD-Day-2004" TYPE="STUDY">Day 2004</LINK>) the authors suggested that their positive result, in comparison to the Lohmander RCT (<LINK REF="STD-Lohmander-1996" TYPE="STUDY">Lohmander 1996</LINK>), may have been due to the inclusion criteria. Specifically, only patients with unilateral, mild-to-moderate disease, with no patellofemoral OA or clinically large effusions, and who were not morbidly obese were entered into the trial. Both lateral and medial approaches were utilised for IA injections in this trial. However, the same approach was used for all injections in one patient.</P>
<P>Karlsson et al. reported a one-year, placebo-controlled, parallel-group, double-blind RCT performed at 19 centres in Sweden comparing three weekly injections of Artzal (Astra Lakemedel) to three weekly injections of Hylan G-F 20 (Roche) and three weekly injections of placebo (phosphate-buffered saline solution) in 210 patients with OA of the knee (<LINK REF="STD-Karlsson-2002" TYPE="STUDY">Karlsson 2002</LINK>). All patients, regardless of treatment, showed clinical improvement during the first 26 weeks of the treatment. Neither hyaluronan/hylan product produced a longer duration of clinical benefit than placebo. However, a significantly longer duration of clinical benefit was achieved when data from the two hyaluronan products were pooled. No serious adverse events due to the treatments were reported. Treatment was discontinued due to adverse events in similar numbers of patients in each of the treatment groups. In this review the Karlsson 2002a reference refers to the Artzal versus placebo comparison (<LINK REF="STD-Karlsson-2002a-_x0028_AvP_x0029_" TYPE="STUDY">Karlsson 2002a (AvP)</LINK>, the Karlsson 2002b reference refers to the Hylan G-F 20 versus placebo comparison (<LINK REF="STD-Karlsson-2002b-_x0028_SvP_x0029_" TYPE="STUDY">Karlsson 2002b (SvP)</LINK>) and the Karlsson 2002c reference refers to the Artzal versus Hylan G-F 20 comparison (<LINK REF="STD-Karlsson-2002c-_x0028_AvS_x0029_" TYPE="STUDY">Karlsson 2002c (AvS)</LINK>).</P>
<P>The Karlsson RCT (<LINK REF="STD-Karlsson-2002" TYPE="STUDY">Karlsson 2002</LINK>) inclusion criteria were based on the Lohmander RCT (<LINK REF="STD-Lohmander-1996" TYPE="STUDY">Lohmander 1996</LINK>): patients aged 60 years or above, with a baseline Lequesne Index above 10, and radiographically verified OA as Ahlback grade I-II. A Lequesne score of 8 to 10 points represents severe handicap. Surgery is indicated for scores of 10 to 12 points and higher. An Ahlback Stage I is classified as narrowing of the joint space (with or without subchondral sclerosis); joint space narrowing is defined by a space inferior to 3 mm or inferior to the half of the space in the other compartment (or in the homologous compartment of the other knee). An Ahlback Stage II is classified as "obliteration of the joint space" (<LINK REF="STD-Karlsson-2003d" TYPE="STUDY">Karlsson 2003d</LINK>, <LINK REF="REF-Magilavy-2003" TYPE="REFERENCE">Magilavy 2003</LINK>).</P>
<P>Lohmander et al. reported a 20-week, placebo-controlled, double-blind RCT performed at eight centres in Denmark, Finland, Norway and Sweden comparing five weekly injections of Artzal to five weekly injections of saline in 240 patients with OA of the knee (<LINK REF="STD-Lohmander-1996" TYPE="STUDY">Lohmander 1996</LINK>). Prior to code break, patient data were stratified by age (40 to 60 y, 61 to 75 y) and Lequesne algofunctional index score (4 to 10, greater than 10). Although both groups improved from baseline at the end of the study there was no difference between the two groups. However, when the two stratification variables were utilised in the analyses Artzal was found to be more effective than saline in older (greater than 60 y) patients with more severe symptoms (Lequesne greater or equal to 10). Although no serious adverse events were reported seven patients (Artz n = 2, saline n = 5) withdrew from the trial due to adverse events. Severity of injection-site swelling was significantly greater in the Artz group. Dr. S. Lohmander kindly provided unpublished data from the trial for this review.</P>
<P>The well-designed Lohmander RCT (<LINK REF="STD-Lohmander-1996" TYPE="STUDY">Lohmander 1996</LINK>) had a pretrial meeting to standardize the injection procedure and assessment procedures. The discussion of this report summarises some of the difficulties in interpreting trials of HA. This is one of the few trials which stratified patients based on baseline age and Lequesne Index scores.</P>
<P>Puhl et al. reported an 18-week, parallel-group, double-blind RCT performed at 25 centres in Germany comparing five weekly injections of Artz to five weekly injections of suspending vehicle (0.25 mg of sodium hyaluronate per 2.5 ml) in 209 patients with OA of the knee (<LINK REF="STD-Puhl-1993" TYPE="STUDY">Puhl 1993</LINK>). A statistically significant difference was reported in the Lequesne Index (the primary outcome measure) in favour of the Artz group from the third injection to the end of the trial. In a subsequent publication (<LINK REF="REF-Puhl-1997" TYPE="REFERENCE">Puhl 1997</LINK>) a subgroup analysis confirmed the findings of the Lohmander et al. trial (<LINK REF="STD-Lohmander-1996" TYPE="STUDY">Lohmander 1996</LINK>) in that patients older than 60 y with a Lequesne score greater than 10 were the most likely to benefit from treatment. Local reactions at the injection site were reported in similar numbers in both groups (Artz n = 4, vehicle n = 5) and all were of short duration and minor severity.</P>
<P>This well-designed trial excluded patients with excessive (greater than 100 ml) joint effusion (<LINK REF="STD-Puhl-1993" TYPE="STUDY">Puhl 1993</LINK>).</P>
<P>Shichikawa et al. reported a five-week, parallel-group, double-blind RCT performed at 38 centres in Japan comparing five weekly injections of Artz (1.0% sodium hyaluronate) plus one placebo tablet (lactose coated) administered three times daily after every meal to five weekly injections of suspending vehicle (0.25 mg, 0.01% sodium hyaluronate) plus one placebo tablet (lactose coated) administered three times daily after every meal in 228 patients with OA of the knee (<LINK REF="STD-Shichikawa-1983a" TYPE="STUDY">Shichikawa 1983a</LINK>). Statistically significant differences in favour of Artz compared to control were reported for final effectiveness and usefulness. No systemic adverse events were reported. Local reactions were reported by four patients in the control group and one patient in the Artz group. One patient in the control group had treatment discontinued due to side effects.</P>
<P>The following design issues were noted: 1) follow-up was limited to one week after final injection; 2) patients with severe joint space narrowing and marked retention of synovial effusion were excluded; 3) patients recorded in symptom diaries at 10:00 daily; 4) authors attributed some of the local pain to injection procedure (<LINK REF="STD-Shichikawa-1983a" TYPE="STUDY">Shichikawa 1983a</LINK>).</P>
<P>Shichikawa et al. reported a five-week, parallel-group, double-blind RCT performed at 16 centres in Japan comparing five weekly injections of Artz (0.5% sodium hyaluronate) plus two placebo tablets (sugar coated lactose) administered three times daily to five weekly injections of suspending vehicle (0.01% sodium hyaluronate solution) plus two placebo tablets (sugar coated lactose) administered three times daily in 107 patients with OA of the knee (<LINK REF="STD-Shichikawa-1983b" TYPE="STUDY">Shichikawa 1983b</LINK>). Statistically significant differences in favour of Artz compared to control were reported for final effectiveness, pain in motion and usefulness. Treatment was discontinued in three patients (Artz n = 1, control n = 2) due to adverse events.</P>
<P>The following design issues were noted: 1) follow-up was limited to one week after final injection; 2) patients with moderate-to-severe joint space narrowing and synovial effusion were excluded (<LINK REF="STD-Shichikawa-1983b" TYPE="STUDY">Shichikawa 1983b</LINK>).</P>
<P>Wu et al. reported a 26-week, placebo-controlled, double-blind RCT performed at a single centre in China comparing five weekly injections of Artz to five weekly injections of the solvent for Artz in 90 patients with OA of the knee (<LINK REF="STD-Wu-1997" TYPE="STUDY">Wu 1997</LINK>). Statistically significant efficacy was reported for Artz compared to placebo beginning one week after the fifth injection and lasting up to three months. During the six-month trial no adverse events were reported.</P>
<P>The following design issue was noted: 1) patients with marked joint space narrowing and large amounts of synovial effusion were excluded (<LINK REF="STD-Wu-1997" TYPE="STUDY">Wu 1997</LINK>).</P>
<P>Artz versus placebo</P>
<P>
<I>Efficacy </I>
</P>
<P>With respect to the placebo comparisons at 1 to 4 weeks postinjection, there were no statistically significant differences between Artz and placebo for the following outcome measures: pain (0 to 3 scale) (<LINK REF="STD-Shichikawa-1983b" TYPE="STUDY">Shichikawa 1983b</LINK>); pain (0 to 100 mm VAS) (<LINK REF="STD-Karlsson-2002a-_x0028_AvP_x0029_" TYPE="STUDY">Karlsson 2002a (AvP)</LINK>; <LINK REF="STD-Lohmander-1996" TYPE="STUDY">Lohmander 1996</LINK>; <LINK REF="STD-Puhl-1993" TYPE="STUDY">Puhl 1993</LINK>); Lequesne Index (0 to 24) (<LINK REF="STD-Puhl-1993" TYPE="STUDY">Puhl 1993</LINK>); and range of motion (degrees) (<LINK REF="STD-Shichikawa-1983b" TYPE="STUDY">Shichikawa 1983b</LINK>). There was a statistically significant difference in favour of Artz for patient global assessment (RR 1.17; 95% CI 1.04 to 1.32, P value 0.008) (<LINK REF="STD-Lohmander-1996" TYPE="STUDY">Lohmander 1996</LINK>; <LINK REF="STD-Shichikawa-1983a" TYPE="STUDY">Shichikawa 1983a</LINK>; <LINK REF="STD-Shichikawa-1983b" TYPE="STUDY">Shichikawa 1983b</LINK>). With the exception of the Lohmander trial (<LINK REF="STD-Lohmander-1996" TYPE="STUDY">Lohmander 1996</LINK>), the NNT for patient global assessment was between 5 and 11 patients.(<LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>;<LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>)</P>
<P>The RevMan analysis differed from the Puhl et al. publication analysis (<LINK REF="STD-Puhl-1993" TYPE="STUDY">Puhl 1993</LINK>). The publication reported a statistically significant difference in favour of Artz compared to placebo for the Lequesne Index at 1 to 4 weeks postinjection (P value 0.043) compared to the RevMan analysis (P value 0.7).</P>
<P>At 5 to 13 weeks postinjection, there were no statistically significant differences between Artz and placebo for: WOMAC OA Index pain (0 to 20) (<LINK REF="STD-Day-2004" TYPE="STUDY">Day 2004</LINK>); WOMAC OA Index physical function (0 to 68) (<LINK REF="STD-Day-2004" TYPE="STUDY">Day 2004</LINK>); Lequesne Index (<LINK REF="STD-Puhl-1993" TYPE="STUDY">Puhl 1993</LINK>); and patient global assessment (<LINK REF="STD-Lohmander-1996" TYPE="STUDY">Lohmander 1996</LINK>; <LINK REF="STD-Puhl-1993" TYPE="STUDY">Puhl 1993</LINK>). However, Artz was better than placebo for pain (100 mm VAS) (WMD -4.55; 95% CI -9.09 to 0.00, P value 0.05) (<LINK REF="STD-Karlsson-2002a-_x0028_AvP_x0029_" TYPE="STUDY">Karlsson 2002a (AvP)</LINK>; <LINK REF="STD-Lohmander-1996" TYPE="STUDY">Lohmander 1996</LINK>; <LINK REF="STD-Puhl-1993" TYPE="STUDY">Puhl 1993</LINK>). Artz was between 5 and 20% more effective than saline in relieving pain at 5 to 13 weeks postinjection.</P>
<P>The RevMan analysis differed from the Day et al. publication analysis (<LINK REF="STD-Day-2004" TYPE="STUDY">Day 2004</LINK>). The publication reported statistically significant between-group differences in WOMAC pain (P value 0.045) and WOMAC stiffness (P value 0.024) in favour of the Artz group compared to the placebo group, whereas the RevMan analysis did not detect a significant difference (WOMAC pain P value 0.07, WOMAC stiffness P value 0.07). The RevMan analysis differed from the Puhl et al. publication analysis (<LINK REF="STD-Puhl-1993" TYPE="STUDY">Puhl 1993</LINK>). The publication reported a statistically significant difference in favour of Artz compared to placebo for the Lequesne Index at 5 to 13 weeks post injection (P value 0.0053) compared to the RevMan analysis which did not (P value 0.5).</P>
<P>At 14 to 26 weeks postinjection, no statistically significant differences were found between Artz and placebo for the Lequesne Index or pain (100 mm VAS) (<LINK REF="STD-Karlsson-2002a-_x0028_AvP_x0029_" TYPE="STUDY">Karlsson 2002a (AvP)</LINK>; <LINK REF="STD-Lohmander-1996" TYPE="STUDY">Lohmander 1996</LINK>). However, more patients improved in the Artz than placebo group for patient global assessment (<LINK REF="STD-Lohmander-1996" TYPE="STUDY">Lohmander 1996</LINK>). The number of clinical failures was higher in the saline group (11%) versus Artzal (2%) (<LINK REF="STD-Karlsson-2002a-_x0028_AvP_x0029_" TYPE="STUDY">Karlsson 2002a (AvP)</LINK>).</P>
<P>At 45 to 52 weeks postinjection there was no statistically significant difference in the number of clinical failures or in the number of survivors (i.e. patients not requiring additional treatment for study knee) (<LINK REF="STD-Karlsson-2002a-_x0028_AvP_x0029_" TYPE="STUDY">Karlsson 2002a (AvP)</LINK>).</P>
<P>
<I>Safety </I>
</P>
<P>There was no statistically significant difference in the number of withdrawals, overall, at 1 to 4 weeks postinjection (<LINK REF="STD-Shichikawa-1983a" TYPE="STUDY">Shichikawa 1983a</LINK>; <LINK REF="STD-Shichikawa-1983b" TYPE="STUDY">Shichikawa 1983b</LINK>); at 5 to 13 weeks postinjection (<LINK REF="STD-Day-2004" TYPE="STUDY">Day 2004</LINK>; <LINK REF="STD-Puhl-1993" TYPE="STUDY">Puhl 1993</LINK>); or at 14 to 26 weeks postinjection (<LINK REF="STD-Lohmander-1996" TYPE="STUDY">Lohmander 1996</LINK>). There was no statistically significant difference in the number of withdrawals due to adverse events at 1 to 4 weeks postinjection (<LINK REF="STD-Shichikawa-1983a" TYPE="STUDY">Shichikawa 1983a</LINK>; <LINK REF="STD-Shichikawa-1983b" TYPE="STUDY">Shichikawa 1983b</LINK>); at 5 to 13 weeks postinjection (<LINK REF="STD-Day-2004" TYPE="STUDY">Day 2004</LINK>); at 14 to 26 weeks postinjection (<LINK REF="STD-Lohmander-1996" TYPE="STUDY">Lohmander 1996</LINK>); or at 45 to 52 weeks postinjection (<LINK REF="STD-Karlsson-2002a-_x0028_AvP_x0029_" TYPE="STUDY">Karlsson 2002a (AvP)</LINK>). There were no statistically significant differences in the number of participants withdrawn overall at 5 to 13 or at 14 to 26 weeks postinjection. The number of adverse events probably or possibly related to treatment was statistically greater in the Artz group compared to the saline group at 5 to 13 weeks postinjection (RR 1.59; 95% CI 1.12 to 2.26, P value 0.009) (<LINK REF="STD-Day-2004" TYPE="STUDY">Day 2004</LINK>; <LINK REF="STD-Puhl-1993" TYPE="STUDY">Puhl 1993</LINK>), but there was no difference at 45 to 52 weeks postinjection (<LINK REF="STD-Karlsson-2002a-_x0028_AvP_x0029_" TYPE="STUDY">Karlsson 2002a (AvP)</LINK>). There was no statistically significant difference in the number of patients with local adverse events in whom the study treatment was continued at 1 to 4 weeks postinjection (<LINK REF="STD-Shichikawa-1983a" TYPE="STUDY">Shichikawa 1983a</LINK>). In Karlsson's trial (<LINK REF="STD-Karlsson-2002a-_x0028_AvP_x0029_" TYPE="STUDY">Karlsson 2002a (AvP)</LINK>) at 45 to 52 weeks postinjection there was no statistically significant difference in the number of patients reporting adverse events or in the number of serious adverse events. In Wu's study (<LINK REF="STD-Wu-1997" TYPE="STUDY">Wu 1997</LINK>), no side effects developed over a six-month period.</P>
<P>Artz versus corticosteroid: No trials included.</P>
<P>Artz versus NSAID: No trials included.</P>
<P>Artz versus other hyaluronan</P>
<P>One RCT included was a comparison of Artzal and Hylan G-F 20 (<LINK REF="STD-Karlsson-2002c-_x0028_AvS_x0029_" TYPE="STUDY">Karlsson 2002c (AvS)</LINK>). Readers are directed to the NRD-101 and SLM-10 sections for results based on comparisons of Artz and these products.</P>
<P>
<I>Efficacy </I>
</P>
<P>With respect to the Artzal comparison against Hylan G-F 20 (<LINK REF="STD-Karlsson-2002c-_x0028_AvS_x0029_" TYPE="STUDY">Karlsson 2002c (AvS)</LINK>), there were no statistically significant differences between the two products in pain on weight bearing (0 to 100 mm VAS) at the three assessment times: 1 to 4, 5 to 13, or 14 to 26 weeks postinjection. There was no statistically significant difference between the two products in the Lequesne Index at 14 to 26 weeks postinjection. There were no statistically significant differences between the two products in the number of clinical failures either at 14 to 26 or 45 to 52 weeks postinjection, or in the number of survivors (i.e. patients not requiring additional treatment to study knee) at 45 to 52 weeks postinjection.(<LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK>; <LINK REF="TBL-06" TYPE="TABLE">Table 6</LINK>)</P>
<P>
<I>Safety<BR/>
</I>
<BR/>There were no statistically significant differences between Artzal and Hylan G-F 20 at 45 to 52 weeks postinjection in the number of patients withdrawn due to adverse events, the number of adverse events related to treatment, or the number of patients reporting adverse events.</P>
<P>
<I>
<B>Product - Biohy (Arthrease, Euflexxa, Nuflexxa) </B>
</I>
</P>
<P>
<I>Description of studies </I>
</P>
<P>Two trials of BioHy have been included. One trial included a comparison against placebo (<LINK REF="STD-Tamir-2001" TYPE="STUDY">Tamir 2001</LINK>) and the other trial included a comparison against Hylan G-F 20 (<LINK REF="STD-Kirchner-2006" TYPE="STUDY">Kirchner 2006</LINK>; <LINK REF="STD-Thompson-2002" TYPE="STUDY">Thompson 2002</LINK> (abstract)).</P>
<P>Tamir et al. reported a 20-week, placebo-controlled, single-blind, open-label RCT performed at a single orthopaedic clinic in Turkey comparing three weekly injections of BioHy (Bio-Technology General, manufactured by bacterial fermentation of the non-hemolytic strain of Streptococcus zooepidemicus) to three weekly injections of phosphate-buffered saline in 49 patients with OA of the knee (<LINK REF="STD-Tamir-2001" TYPE="STUDY">Tamir 2001</LINK>). The authors reported that this feasibility study was not sufficiently powered to detect between-group differences. However, they found a 'favourable trend' for BioHy in decreasing pain. With respect to safety, they reported that BioHy was well tolerated and no HA-related adverse events were found. With respect to methodological quality, it scored 3 out of 5 on the Jadad scale; specific details of randomisation were not reported in the publication. Allocation concealment was unclear.</P>
<P>In this RCT, several design issues were noted: 1) patients with more than 15 ml of aspirated synovial fluid (SF) were excluded; 2) concurrent and escape medication such as paracetamol and NSAIDs were permitted throughout the trial; 3) although the AAOS MODEMS arthritic module was utilised for assessing pain, stiffness and physical function, all the pain variables were assessed and scored by the investigator and not by the patient; 4) in reporting the results the authors did not provide baseline means, rather they reported change in mean categorical scores without any measure of dispersion excluding this trial from the analysis; 5) the trial was found to be under powered.</P>
<P>The Thompson et al. trial, first published as an abstract (<LINK REF="STD-Thompson-2002" TYPE="STUDY">Thompson 2002</LINK>), has now been reported as a full-length article by Kirchner and Marshall (<LINK REF="STD-Kirchner-2006" TYPE="STUDY">Kirchner 2006</LINK>). Kirchner and Marshall reported a 12-week, parallel-group, double-blind, multicentre RCT performed at 10 centres in Germany comparing three weekly injections of Euflexxa (Arthrease) to three weekly injections of Hylan G-F 20 in 321 patients with OA of the knee. For the primary outcome measure, the WOMAC OA Index pain subscale, both groups reported statistically significant improvements from baseline. In addition, the criteria for non-inferiority were met. With regards to secondary outcome measures, statistically significant differences favoured Euflexxa for patient global satisfaction and the number of patients requiring acetaminophen for rescue analgesia. With respect to safety, a statistically significant difference was detected in the number of joint effusions; 0.6% in the Euflexxa group compared to 8.1% in the Synvisc group. The authors concluded that the effectiveness of Euflexxa was not inferior to that of Synvisc, but due to the higher incidence of effusions that Euflexxa had a safety advantage.</P>
<P>This trial scored 5 out of 5 on the Jadad scale; specific details of randomisation and blinding both were reported in the publication. Allocation concealment was adequate. One should note that this trial was designed and powered to test for non-inferiority. Ferring Pharmaceuticals Inc. kindly provided the means and standard errors for the WOMAC OA Index stiffness and physical function subscales for the ITT population. Biotechnology General (Israel) Ltd. kindly provided the poster of this trial that was presented at the OARSI 2002 Congress as well as an Excel file of the WOMAC OA Index pain subscale data.</P>
<P>BioHy versus placebo</P>
<P>
<I>Efficacy </I>
</P>
<P>No efficacy results have been extracted from this trial (<LINK REF="STD-Tamir-2001" TYPE="STUDY">Tamir 2001</LINK>). Pain and stiffness results were reported as change but neither baseline values nor measures of dispersion were reported.<BR/>
<I>
<BR/>Safety </I>
</P>
<P>There were no statistically significant differences in the safety profile of BioHy and placebo. There were a similar number of withdrawals overall in both groups: BioHy 12% and placebo 17%. The difference in the percentage of patients in the BioHy group (72%) who reported knee pain immediately after the injection, which was related to the injection procedure, was not significantly different from that in the placebo group (46%). No systemic adverse events were reported in either group.</P>
<P>BioHy versus corticosteroid: no trials included.</P>
<P>BioHy versus NSAID: no trials included.</P>
<P>BioHy versus other hyaluronan</P>
<P>One RCT was included comparing Euflexxa (syn: Arthrease, BioHy) and Hylan G-F 20 (<LINK REF="STD-Kirchner-2006" TYPE="STUDY">Kirchner 2006</LINK>; <LINK REF="STD-Thompson-2002" TYPE="STUDY">Thompson 2002</LINK> (abstract)).</P>
<P>
<I>Efficacy </I>
</P>
<P>There were no statistically significant differences in the WOMAC OA Index pain subscale either at 1 to 4 or 5 to 13 weeks postinjection. There were statistically significant differences in the WOMAC OA Index physical function subscale in favour of Euflexxa compared to Hylan G-F 20 both at 1 to 4 weeks postinjection (WMD -5.10; 95% CI -9.54 to -0.66, P value 0.02), and at 5 to 13 weeks postinjection (WMD -5.40; 95% CI,-9.83 to -0.97, P value 0.02). Euflexxa was 3% more effective than Hylan G-F 20 in improving WOMAC physical function. There were no statistically significant differences in the WOMAC stiffness subscale either at 1 to 4 or at 5 to 13 weeks postinjection. There was no statistically significant difference in the number of patients symptom-free (VAS score for the average of the five WOMAC pain questions less than 20 mm) in the WOMAC OA Index pain subscale at 5 to 13 weeks postinjection (Euflexxa 63%, Hylan G-F 20 52%). There was a statistically significant difference in favour of Euflexxa compared to Hylan G-F 20 for the number of patients who were symptom-free based on the WOMAC OA Index physical function subscale at 5 to 13 weeks postinjection (Euflexxa 64%, Hylan G-F 20 47%) (RR 1.36; 95% CI 1.11 to 1.66, P value 0.003). There was no statistically significant difference in the number of patients that assessed the treatment as 'very satisfied or satisfied' (Euflexxa 81%, Hylan G-F 20 75%). There were statistically significant differences in favour of Euflexxa compared to Hylan G-F 20 for the number of patients using acetaminophen (rescue medication) both at 1 to 4 weeks postinjection (RR 0.72, 95% CI 0.57 to 0.91, P value 0.006), and at 5 to 13 weeks postinjection (RR 0.71; 95% CI 0.56 to 0.89, P value 0.003), and also during the trial (RR 0.83; 95% CI 0.71 to 0.97, P value 0.02).</P>
<P>The RevMan analysis differed from the publication analysis for several analyses. The publication reported no statistically significant difference between groups in the WOMAC OA Index physical function subscale. RevMan detected a statistically significant difference both at 1 to 4 and 5 to 13 weeks postinjection (P value 0.02). The publication reported a statistically significant difference in the number of patients that were symptom-free with respect to the WOMAC OA Index pain subscale (95% CI 0.3 to 21.7, P value 0.038) whereas RevMan did not detect a statistically significant difference (RR 1.21; 95% CI 1.00 to 1.46, P value 0.05). The P value for the number of patients who required rescue medication during the study was smaller in the publication (0.013) compared to RevMan (0.02). The publication reported a statistically significant difference in favour of Euflexxa compared to Hylan G-F 20 for the number of patients that assessed the treatment as 'very satisfied' (P value 0.03) whereas RevMan detected no difference in the number 'very satisfied or satisfied' (P value 0.23). <LINK REF="TBL-10" TYPE="TABLE">Table 10</LINK>; <LINK REF="TBL-11" TYPE="TABLE">Table 11</LINK>
</P>
<P>
<I>Safety </I>
</P>
<P>There was no statistically significant difference between the two groups for the following safety outcomes: total withdrawals overall, withdrawals due to adverse events, withdrawals due to lack of efficacy (none in either group), number of patients with serious adverse events, number of patients reporting adverse events (Euflexxa 34%, Hylan G-F 20 40%). There was a statistically significant difference in the number of patients with joint effusion (Euflexxa 0.6%, Hylan G-F 20 8%) (RR 0.08; 95% CI 0.01 to 0.58, P value 0.01). The RevMan P value for this last comparison differed from the publication P value of 0.0015.<LINK REF="TBL-12" TYPE="TABLE">Table 12</LINK>
</P>
<P>
<I>
<B>Product - Durolane (NASHA - non-animal stabilized hyaluronic acid) </B>
</I>
</P>
<P>
<I>Description of studies </I>
</P>
<P>One RCT was included comparing Durolane to placebo (<LINK REF="STD-Altman-2004" TYPE="STUDY">Altman 2004</LINK>).</P>
<P>Altman et al. reported a 26-week, placebo-controlled, double-blind RCT performed at 18 centres in Canada (6 centres), Sweden (5 centres), and the United States (7 centres) comparing a single injection of Durolane (synthesized by Streptococci, 60 mg) to a single injection of saline (identical buffered sodium chloride vehicle) in 347 patients with OA of the knee (<LINK REF="STD-Altman-2004" TYPE="STUDY">Altman 2004</LINK>). The authors reported that although WOMAC scores and quality of life improved in both groups, there were no between-group differences. There were few treatment-related adverse events. The authors proposed that the efficacy data may have been confounded by the inclusion of patients with OA at other sites since an analysis based only on patients with knee OA showed a greater response to Durolane than placebo. With respect to methodological quality, the trial scored 5 out of 5 on the Jadad scale achieving points for both randomisation and blinding details. Allocation concealment was adequate.</P>
<P>The statistical analyses were performed using the change from baseline since raw means and standard deviations for unadjusted post-test scores were not available.</P>
<P>One trial is awaiting assessment: <LINK REF="STD-Sinha-2003" TYPE="STUDY">Sinha 2003</LINK>.</P>
<P>One trial was excluded: <LINK REF="STD-Akermark-2004" TYPE="STUDY">Akermark 2004</LINK>.</P>
<P>Durolane versus placebo</P>
<P>
<I>Efficacy</I>
</P>
<P>The primary outcome measure for this trial was a positive response to treatment where a responder was defined "as a reduction in the WOMAC pain score of at least 40% with an absolute improvement of at least 5 points compared with baseline for the study knee at the final visit". There were no statistically significant differences between Durolane and saline at any of the follow-up assessments: at week 2; week 6; week 13 or week 26. However, when the analysis was based only on patients with knee OA, a statistically significant difference in favour of Durolane was found at week 6 (RR 1.53; 95% CI 1.05 to 2.23, P value 0.03) (NNT was 7); but not at any of the other follow-up assessments: at week 2, week 13 or week 26.</P>
<P>Readers should note that the following efficacy results are based on change from baseline scores not unadjusted post-test scores. A statistically significant difference was detected in favour of saline for WOMAC OA Index pain subscale at week 2 (WMD 0.74; 95% CI 0.02 to 1.46, P value 0.04). Saline was 2% more effective than Durolane in improving pain. This differed from the publication which reported no significant between-group difference. A statistically significant difference was detected in favour of saline for WOMAC OA Index stiffness subscale at week 2 (WMD 0.51; 95% CI 0.16 to 0.86, P value 0.005). Saline was 4% better than Durolane in improving stiffness. The original publicaton reported statistically significant between-group differences both at 2 and 6 months. No statistically significant difference was detected for the WOMAC OA Index physical function subscale at any of the timepoints. This RevMan analysis differed from the publication in which a statistically significant between-group difference was reported at 2 weeks.(<LINK REF="TBL-07" TYPE="TABLE">Table 7</LINK>; <LINK REF="TBL-08" TYPE="TABLE">Table 8</LINK>)</P>
<P>
<I>Safety</I>
<BR/>
<I>
<B>
<BR/>
</B>
</I>There were no statistically significant differences in the safety outcomes reported: total withdrawals overall; withdrawals due to inefficacy; withdrawals due to adverse events; number of patients affected by device-related adverse events; number of patients with adverse events related to injection only; number of patients with non-serious treatment-related adverse events; number of patients with non-serious adverse events; number of patients with treated unrelated adverse events, and number of patients with serious treatment-unrelated adverse events.(<LINK REF="TBL-09" TYPE="TABLE">Table 9</LINK>)</P>
<P>
<I>
<B>Product - Fermathron<BR/>
</B>
<BR/>Description of studies </I>
</P>
<P>One RCT was included comparing Fermathron to another hyaluronan (<LINK REF="STD-McDonald-2000" TYPE="STUDY">McDonald 2000</LINK>).</P>
<P>McDonald et al. reported a six-month, parallel-group, double-blind RCT performed at 12 centres in Germany comparing five weekly injections of Fermathron (Fermentech Medical Ltd., manufactured by bacterial fermentation) to five weekly injections of Hyalart (Fidia SpA, obtained from rooster combs) in 256 patients with OA of the knee (<LINK REF="STD-McDonald-2000" TYPE="STUDY">McDonald 2000</LINK>). The authors reported that the products were similar in efficacy and that both were well tolerated. With respect to methodological quality, the trial scored 5 out of 5 on the Jadad scale achieving points for both randomisation and blinding details. Allocation concealment was adequate.</P>
<P>This was a well-designed and reported 'non-inferiority' study of two HA products. The importance of escape medication was addressed in the study design. Patients kept a daily diary which was declared as the secondary performance variable. Moreover, the authors investigated the correlation between the route of injection (knee straight or bent, medial or lateral approach) with the local adverse event incident rate. They found that the lowest risk was associated with a lateral approach to a straight knee (<LINK REF="REF-Jones-1993" TYPE="REFERENCE">Jones 1993</LINK>). Source of HA (i.e. bacterial fermentation versus rooster combs) did not affect the results.</P>
<P>One trial is awaiting assessment: <LINK REF="STD-Sinha-2003" TYPE="STUDY">Sinha 2003</LINK>.</P>
<P>Fermathron versus placebo: no trials included.</P>
<P>Fermathron versus corticosteroid: no trials included.</P>
<P>Fermathron versus NSAID: no trials included.</P>
<P>Fermathron versus other hyaluronan<BR/>
<I>
<BR/>Efficacy<BR/>
</I>
<BR/>The three efficacy outcome measures extracted from this trial were pain (0 to 100 mm VAS), the Lequesne Index (0 to 24), and patient global assessment (very good, good, average, poor, very poor). No statistically significant differences were found between the two products for pain or the Lequesne Index at 1 to 4 or 5 to 13 weeks postinjection. No statistically significant difference was found in the number of responders at 5 to 13 weeks postinjection with 72.4% in the Hyalart group and 69.6% in the Fermathron group that reported feeling better or much better.(<LINK REF="TBL-13" TYPE="TABLE">Table 13</LINK>; <LINK REF="TBL-14" TYPE="TABLE">Table 14</LINK>)<BR/>
<I>
<BR/>Safety<BR/>
</I>
<BR/>There was no statistically significant difference in the number of related adverse events (Fermathron 21% versus Hyalart 14%).<BR/>.<BR/>These results confirmed the results of the publication indicating that the two products were similar in performance and well tolerated.<BR/>
<I>
<B>
<BR/>Product - Go-On<BR/>
</B>
</I>
<BR/>There were no RCTs of Go-On available (correspondence from Rotta Research Laboratorium July 1, 2004).<BR/>
<I>
<B>
<BR/>Product - Hyalgan<BR/>
</B>
<BR/>Description of studies<BR/>
</I>
<BR/>Twenty-nine randomised controlled trials have been included with <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> (marketed also as Hyalart and Polyreumin) (Fidia Pharmaceutical Corporation, Italy, derived from rooster combs): 14 included comparisons against placebo (<LINK REF="STD-Altman-1998" TYPE="STUDY">Altman 1998</LINK>; <LINK REF="STD-Bragantini-1987" TYPE="STUDY">Bragantini 1987</LINK>; <LINK REF="STD-Bunyaratavej-2001" TYPE="STUDY">Bunyaratavej 2001</LINK>; <LINK REF="STD-Carrabba-1995" TYPE="STUDY">Carrabba 1995</LINK>; <LINK REF="STD-Corrado-1995" TYPE="STUDY">Corrado 1995</LINK>; <LINK REF="STD-Creamer-1994" TYPE="STUDY">Creamer 1994</LINK>; <LINK REF="STD-Dougados-1993" TYPE="STUDY">Dougados 1993</LINK>; <LINK REF="STD-Formiguera-Sala-1995" TYPE="STUDY">Formiguera Sala 1995</LINK>; <LINK REF="STD-Grecomoro-1987" TYPE="STUDY">Grecomoro 1987</LINK>; <LINK REF="STD-Henderson-1994" TYPE="STUDY">Henderson 1994</LINK>; <LINK REF="STD-Huskisson-1999" TYPE="STUDY">Huskisson 1999</LINK>; <LINK REF="STD-Jubb-2003" TYPE="STUDY">Jubb 2003</LINK>; <LINK REF="STD-St.-J.-Dixon-1988" TYPE="STUDY">St. J. Dixon 1988</LINK>; <LINK REF="STD-Tsai-2003" TYPE="STUDY">Tsai 2003</LINK>), one was a comparison against no treatment (<LINK REF="STD-Miltner-2002" TYPE="STUDY">Miltner 2002</LINK>; <LINK REF="STD-Schneider-1997" TYPE="STUDY">Schneider 1997</LINK>), one was a comparison against arthroscopic washout (<LINK REF="STD-Forster-2003" TYPE="STUDY">Forster 2003</LINK>), one was a comparison against exercise, exercise and ultrasound, and no treatment with only warmup exercises (<LINK REF="STD-Huang-2005" TYPE="STUDY">Huang 2005</LINK>), three were comparisons against other hyaluronan products (<LINK REF="STD-McDonald-2000" TYPE="STUDY">McDonald 2000</LINK>; <LINK REF="STD-Roman-2000" TYPE="STUDY">Roman 2000</LINK>; <LINK REF="STD-Brown-2003" TYPE="STUDY">Brown 2003</LINK>), five were comparisons against corticosteroids (<LINK REF="STD-Frizziero-2002" TYPE="STUDY">Frizziero 2002</LINK>; <LINK REF="STD-Leardini-1987" TYPE="STUDY">Leardini 1987</LINK>; <LINK REF="STD-Leardini-1991" TYPE="STUDY">Leardini 1991</LINK>; <LINK REF="STD-Pietrogrande-1991" TYPE="STUDY">Pietrogrande 1991</LINK>, against methylprednisolone acetate; <LINK REF="STD-Jones-1995" TYPE="STUDY">Jones 1995</LINK>, against triamcinolone acetate), one was a comparison against NSAID (<LINK REF="STD-Altman-1998" TYPE="STUDY">Altman 1998</LINK>), one was a comparison against a homeopathic preparation (Zeel Compositum) (<LINK REF="STD-Nahler-1998" TYPE="STUDY">Nahler 1998</LINK>) (readers are directed to the Zeel product section), one was a comparison against mucopolysaccaride polysulfuric acid ester (<LINK REF="STD-Graf-1993" TYPE="STUDY">Graf 1993</LINK>), one was a comparison against conventional therapy (<LINK REF="STD-Listrat-1997" TYPE="STUDY">Listrat 1997</LINK>) and one was a comparison of treatment regimens (<LINK REF="STD-Karras-2001" TYPE="STUDY">Karras 2001</LINK>). Except for three trials (<LINK REF="STD-Brown-2003" TYPE="STUDY">Brown 2003</LINK>; <LINK REF="STD-Karras-2001" TYPE="STUDY">Karras 2001</LINK>; <LINK REF="STD-Tsai-2003" TYPE="STUDY">Tsai 2003</LINK>) which have been published as abstracts the remaining trials have been published as journal articles. In three trials, <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> was the control intervention (<LINK REF="STD-McDonald-2000" TYPE="STUDY">McDonald 2000</LINK>; <LINK REF="STD-Nahler-1998" TYPE="STUDY">Nahler 1998</LINK>; <LINK REF="STD-Roman-2000" TYPE="STUDY">Roman 2000</LINK>). The frequency of injection varied between studies (3, 4 and 5 weekly injections). Considering only the 26 trials in which <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> was designated the experimental intervention (i.e. excluding <LINK REF="STD-McDonald-2000" TYPE="STUDY">McDonald 2000</LINK>; <LINK REF="STD-Nahler-1998" TYPE="STUDY">Nahler 1998</LINK>; <LINK REF="STD-Roman-2000" TYPE="STUDY">Roman 2000</LINK>), with respect to methodological quality the average Jadad score was 2.81 out of 5 with one trial scoring 5 (<LINK REF="STD-Henderson-1994" TYPE="STUDY">Henderson 1994</LINK>), 7 trials scoring 4 (<LINK REF="STD-Altman-1998" TYPE="STUDY">Altman 1998</LINK>; <LINK REF="STD-Bunyaratavej-2001" TYPE="STUDY">Bunyaratavej 2001</LINK>; <LINK REF="STD-Frizziero-2002" TYPE="STUDY">Frizziero 2002</LINK>; <LINK REF="STD-Huskisson-1999" TYPE="STUDY">Huskisson 1999</LINK>; <LINK REF="STD-Jones-1995" TYPE="STUDY">Jones 1995</LINK>; <LINK REF="STD-Jubb-2003" TYPE="STUDY">Jubb 2003</LINK>; <LINK REF="STD-St.-J.-Dixon-1988" TYPE="STUDY">St. J. Dixon 1988</LINK>), 6 trials scoring 3 (<LINK REF="STD-Carrabba-1995" TYPE="STUDY">Carrabba 1995</LINK>; <LINK REF="STD-Corrado-1995" TYPE="STUDY">Corrado 1995</LINK>; <LINK REF="STD-Formiguera-Sala-1995" TYPE="STUDY">Formiguera Sala 1995</LINK>; <LINK REF="STD-Forster-2003" TYPE="STUDY">Forster 2003</LINK>; <LINK REF="STD-Grecomoro-1987" TYPE="STUDY">Grecomoro 1987</LINK>; <LINK REF="STD-Huang-2005" TYPE="STUDY">Huang 2005</LINK>), 10 trials scoring 2 (<LINK REF="STD-Bragantini-1987" TYPE="STUDY">Bragantini 1987</LINK>; <LINK REF="STD-Creamer-1994" TYPE="STUDY">Creamer 1994</LINK>; <LINK REF="STD-Dougados-1993" TYPE="STUDY">Dougados 1993</LINK>; <LINK REF="STD-Graf-1993" TYPE="STUDY">Graf 1993</LINK>; <LINK REF="STD-Karras-2001" TYPE="STUDY">Karras 2001</LINK>; <LINK REF="STD-Leardini-1987" TYPE="STUDY">Leardini 1987</LINK>; <LINK REF="STD-Leardini-1991" TYPE="STUDY">Leardini 1991</LINK>; <LINK REF="STD-Listrat-1997" TYPE="STUDY">Listrat 1997</LINK>; <LINK REF="STD-Pietrogrande-1991" TYPE="STUDY">Pietrogrande 1991</LINK>; <LINK REF="STD-Tsai-2003" TYPE="STUDY">Tsai 2003</LINK>) and 2 trials scoring 1 (<LINK REF="STD-Brown-2003" TYPE="STUDY">Brown 2003</LINK>; <LINK REF="STD-Miltner-2002" TYPE="STUDY">Miltner 2002</LINK>). Again, considering only the 26 trials in which <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> was designated the experimental intervention allocation concealment was adequate in three trials (<LINK REF="STD-Forster-2003" TYPE="STUDY">Forster 2003</LINK>; <LINK REF="STD-Frizziero-2002" TYPE="STUDY">Frizziero 2002</LINK>; <LINK REF="STD-Huang-2005" TYPE="STUDY">Huang 2005</LINK>) and unclear (not reported) in 23 trials.</P>
<P>Twenty-three studies were excluded (<LINK REF="STD-Aglas-1997" TYPE="STUDY">Aglas 1997</LINK>; <LINK REF="STD-Carrabba-1992" TYPE="STUDY">Carrabba 1992</LINK>; <LINK REF="STD-D_x0027_Agnolo-1988" TYPE="STUDY">D'Agnolo 1988</LINK>; <LINK REF="STD-Dahlberg-1994" TYPE="STUDY">Dahlberg 1994</LINK>; <LINK REF="STD-Frizziero-1993" TYPE="STUDY">Frizziero 1993</LINK>; <LINK REF="STD-Frizziero-1997" TYPE="STUDY">Frizziero 1997</LINK>; <LINK REF="STD-Frizziero-1998" TYPE="STUDY">Frizziero 1998</LINK>; <LINK REF="STD-Grecomoro-1992" TYPE="STUDY">Grecomoro 1992</LINK>; <LINK REF="STD-Hamburger-2004" TYPE="STUDY">Hamburger 2004</LINK>; <LINK REF="STD-Kotz-1999" TYPE="STUDY">Kotz 1999</LINK>; <LINK REF="STD-Mazzocato-1987" TYPE="STUDY">Mazzocato 1987</LINK>; <LINK REF="STD-Mensitieri-1995" TYPE="STUDY">Mensitieri 1995</LINK>; <LINK REF="STD-Milini-1989" TYPE="STUDY">Milini 1989</LINK>; <LINK REF="STD-Pasquali-Ronchetti" TYPE="STUDY">Pasquali Ronchetti</LINK> 2001; <LINK REF="STD-Pavelka-2002" TYPE="STUDY">Pavelka 2002</LINK>; <LINK REF="STD-Pipino-1990" TYPE="STUDY">Pipino 1990</LINK>; <LINK REF="STD-Punzi-1988" TYPE="STUDY">Punzi 1988</LINK>; <LINK REF="STD-Rao-2001" TYPE="STUDY">Rao 2001</LINK>; <LINK REF="STD-Scali-1995" TYPE="STUDY">Scali 1995</LINK>; <LINK REF="STD-Sieliwonczyk-1997" TYPE="STUDY">Sieliwonczyk 1997</LINK>; <LINK REF="STD-Turajane-2005" TYPE="STUDY">Turajane 2005</LINK>; <LINK REF="STD-Turajane-2005a" TYPE="STUDY">Turajane 2005a</LINK>; <LINK REF="STD-Zamora_x002d_Quezada-2004" TYPE="STUDY">Zamora-Quezada 2004</LINK>). Four trials are awaiting assessment (<LINK REF="STD-Garcia-2004" TYPE="STUDY">Garcia 2004</LINK>; <LINK REF="STD-Joergensen-2005" TYPE="STUDY">Joergensen 2005</LINK>; <LINK REF="STD-Stitik-2004" TYPE="STUDY">Stitik 2004</LINK>; <LINK REF="STD-NCT00130468" TYPE="STUDY">NCT00130468</LINK>).</P>
<P>Altman et al. reported a 26-week, placebo- and naproxen-controlled, double-blind, double-dummy, stratified, parallel-group RCT performed at 15 centres in the United States comparing five weekly injections of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> plus oral placebo twice daily to five weekly injection of saline plus oral placebo or naproxen 500 mg twice daily in 495 patients with OA of the knee (<LINK REF="STD-Altman-1998" TYPE="STUDY">Altman 1998</LINK>). Only 67% of the patients completed the trial. <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> was more efficacious (pain relief and improved function) than placebo and as effective as naproxen with fewer side effects. Injection site pain was more common in the <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> group while gastrointestinal adverse events were more common in the naproxen group.</P>
<P>Several design issues are noted: 1) the placebo group received active treatment in the form of 4 g of acetaminophen and arthrocentesis with synovial fluid aspiration if necessary; 2) the naproxen group did not receive arthrocentesis, they received a subcutaneous injection; 3) a training video was provided to all sites; 4) one criterion of success was defined as an effect size of 0.25 of the standard deviation or 6 mm; 5) the data for all secondary outcome measures was analysed only for those patients who completed the 26 weeks of follow-up since the intent-to-treat analysis detected only a 1.5 mm difference between the <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> and placebo groups in the primary outcome measure (pain during the 50-foot walk test); and 6) escape analgesia, as 500 mg acetaminophen up to 4000 mg/day, was permitted. Analyses showed no statistically significant differences between the three arms of the trial.<BR/>Bragantini et al. reported a 60-day, placebo-controlled, single-blind, parallel-group RCT performed at a single centre in Italy comparing three weekly injections of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> (both 20 mg and 40 mg) to three weekly injections of saline in 55 patients with OA of the knee (<LINK REF="STD-Bragantini-1987" TYPE="STUDY">Bragantini 1987</LINK>). Both dosage levels of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> were significantly superior to placebo. Four patients experienced local pain and burning after injection with <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> but these reactions resolved within a short time. In this review, we have only used the <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> 20 mg arm for comparison against saline.</P>
<P>Brown and Beinat reported a six-week, parallel-group, RCT performed at a single centre in England comparing five weekly injections of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> to three weekly injections of Hylan G-F 20 in 54 patients with OA of the knee (<LINK REF="STD-Brown-2003" TYPE="STUDY">Brown 2003</LINK>). This trial was discontinued, with about 50% of enrolment completed, due to a high frequency of acute inflammatory reactions with Hylan G-F 20. The protocol called for a sample size of 100 patients with 50 to be randomised to each group. The trial was designed to last six months. The number of patients that developed an acutely inflamed painful knee was 6 out of 29 in the Hylan G-F 20 group compared to 0 of 25 in the <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> group. Statistically significant improvement in WOMAC pain and function was found for <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> while a trend of improvement was found for Hylan G-F 20.</P>
<P>Two study design points were noted: 1) this RCT was conducted in a clinical practice setting; 2) randomisation was based on the consultant to whom the patient was referred.</P>
<P>Bunyaratavej et al. reported a six-month, placebo-controlled, double-blind RCT performed at three centres in Asia (China, Malaysia, Thailand) comparing four weekly injections of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> to four weekly injections of saline in 49 patents with OA of the knee (<LINK REF="STD-Bunyaratavej-2001" TYPE="STUDY">Bunyaratavej 2001</LINK>). Statistically significant differences in favour of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> were reported one month after treatment as reflected by decreased pain and increased joint mobility. No local or systemic adverse events related to treatment were observed. No measure of dispersion was reported for the saline group for pain on active movement nor for either treatment group for day pain at baseline. Consequently, this review includes safety but not efficacy data.</P>
<P>This was one of two RCT where a four-injection schedule of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> was followed. In addition, acetaminophen (paracetamol) up to 3000 mg daily was permitted.</P>
<P>Carrabba et al. reported a six-month, placebo- and arthrocentesis-controlled, double-blind, parallel-group RCT performed at a single centre in Italy comparing three dose schedules of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> (one, three and five weekly injections) to five weekly arthrocentesis or five weekly injections of saline in 100 patients with OA of the knee (<LINK REF="STD-Carrabba-1995" TYPE="STUDY">Carrabba 1995</LINK>). All five groups received arthrocentesis at the baseline visit. A significantly superior effect of five and three injections of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> was shown in comparison with placebo, arthrocentesis and one injection of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK>. Four patients reported minor local reactions after injection (one patient each in the arthrocentesis group, the one, three and five injection <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> groups). This review does not report results based on the one injection <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> arm. The 1995 reference refers to the five injection <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> versus saline comparison (<LINK REF="STD-Carrabba-1995" TYPE="STUDY">Carrabba 1995</LINK>); the 1995a reference refers to the three injection <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> versus saline comparison (<LINK REF="STD-Carrabba-1995a" TYPE="STUDY">Carrabba 1995a</LINK>); the 1995b reference refers to the five injection <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> versus arthrocentesis comparison (<LINK REF="STD-Carrabba-1995b" TYPE="STUDY">Carrabba 1995b</LINK>); and the 1995c reference refers to the three injection <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> versus arthrocentesis comparison (<LINK REF="STD-Carrabba-1995c" TYPE="STUDY">Carrabba 1995c</LINK>).</P>
<P>In this RCT paracetamol (acetaminophen) was permitted. However, only 15% of the patients used it at baseline, and there was no change in usage over the duration of the trial.</P>
<P>Corrado et al. reported a two-month, placebo-controlled, double-blind RCT performed at a single centre in Italy comparing five weekly injections of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> to five weekly injections of placebo (water, sodium chloride, sodium phosphate) in 40 patients with OA of the knee (<LINK REF="STD-Corrado-1995" TYPE="STUDY">Corrado 1995</LINK>). A significant difference in favour of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> was reported for pain and range of motion. Two patients experienced 'accidental trauma' to the knee during treatment.</P>
<P>In order to study the possible anti-inflammatory activity of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK>, Corrado et al. completed a biochemical assessment of synovial fluid and plasma.</P>
<P>Creamer et al. reported a nine-week, placebo-controlled, single-blind, blind-observer RCT performed at a single centre in England comparing five weekly injections of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> to five weekly injections of saline in 12 patients with bilateral OA of the knee (<LINK REF="STD-Creamer-1994" TYPE="STUDY">Creamer 1994</LINK>). This study investigated the mode of action of HA. It was not designed to assess clinical efficacy. No beneficial clinical effect was found for <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> as compared to placebo. Twelve adverse events were reported by seven patients. Five local reactions (pain and swelling), graded as severe, occurred in three <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK>-treated knees and two placebo-treated knees.</P>
<P>Several design issues were noted: 1) each patient acted as his/her own control; 2) paracetamol up to 4 g daily was permitted; 3) imaging assessments, both MRI and 99m Tc scintigraphic bone scans, were performed; and 4) four of the treated knees and six of the placebo knees had only patellofemoral disease.</P>
<P>Dougados et al. reported a one-year, placebo-controlled, single-blind RCT performed at a single centre in France comparing four weekly injections of Hyalectin to four weekly injections of the vehicle in 110 patients with OA of the knee (<LINK REF="STD-Dougados-1993" TYPE="STUDY">Dougados 1993</LINK>). Greater improvement was found in the Hyalectin group compared to the placebo group for pain and function (Lequesne) in the early assessment and for physician's overall assessment of efficacy and the Lequesne Index in the long term. Nine patients did not receive all four injections: four in the Hyalectin group (two due to painful injection, one lack of efficacy, and one improved) and five in the placebo group (one due to painful injection, one lack of efficacy, three due to reasons unrelated to treatment (traumatic hemarthrosis in one, refusal to continue in two).</P>
<P>Several design issues were noted: 1) this RCT followed a four injection schedule of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK>; 2) one-sided tests were used in the statistical analysis; and 3) the physician that administered the injection also completed the clinical assessment. Fidia Spa kindly provided an in-house report of this trial.</P>
<P>Formiguera Sala and Esteve de Miguel reported a 90-day, placebo-controlled, double-blind RCT performed at a single centre in Spain comparing five weekly injections of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> to five weekly injections of saline in 36 patients with OA of the knee (<LINK REF="STD-Formiguera-Sala-1995" TYPE="STUDY">Formiguera Sala 1995</LINK>). There were no significant differences between the groups at day 35. However, at day 90, statistically significant differences in favour of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> were reported for pain outcome measures. Three patients in each group reported pain that "could be attributed to the route of administration and the individual idiosyncrasies of the patients".</P>
<P>Several design issues were noted: 1) the supero-external approach with the patient in a supine position was followed for injections; 2) study population consisted of 36 patients, but 40 joints; 3) four patients were recruited twice: two receiving placebo in one knee and <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> in the other, one patient receiving <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> in separate knees at both times, one patient receiving placebo in the same knee on two occasions; and 4) the treatment in the second knee took place some time after the first knee was treated.</P>
<P>Forster and Straw reported a one-year, parallel-group RCT performed at a single centre in England comparing five weekly injections of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> to arthroscopic washout (two litres 0.9% saline at least) with either general or spinal anaesthesia in 38 patients with OA of the knee (<LINK REF="STD-Forster-2003" TYPE="STUDY">Forster 2003</LINK>; <LINK REF="STD-Forster-2003a" TYPE="STUDY">Forster 2003a</LINK>). No significant differences between the two groups were found in any of the clinical outcome measures at any assessment point. Two patients in the <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> group reported pain at the injection site following one injection.</P>
<P>Dr. Forster kindly provided an Excel data file from which we calculated means and standard deviations.</P>
<P>Frizziero and <LINK REF="STD-Pasquali-Ronchetti" TYPE="STUDY">Pasquali Ronchetti</LINK> reported a six-month, parallel-group, single-blind RCT performed at a single centre in Italy comparing five weekly injections of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> to three weekly injections of methylprednisolone acetate in 99 patients with primary or secondary OA of the knee (<LINK REF="STD-Frizziero-2002" TYPE="STUDY">Frizziero 2002</LINK>). The authors found an initial statistically significant difference in favour of methylprednisolone acetate at day 35 but not at day 180. The clinical effect with <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> appeared more gradually but lasted longer than that of methylprednisolone acetate. Arthroscopic evaluations showed that <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> was superior to methylprednisolone acetate in reducing the extent and grade of cartilage damage. No adverse events were reported in the <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> group compared to two patients in the methylprednisolone acetate group, one resulting in withdrawal from the trial.</P>
<P>This RCT was one of the trials which examined the structural effects of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> using both arthroscopic and microarthroscopic examinations.</P>
<P>Graf et al. reported a six-month, verum-controlled, single-blind RCT performed at a single centre in Germany comparing <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> once per week (seven injections) to mucopolysaccharide polysulfuric acid (MPA) ester twice per week (13 injections) in 60 patients with OA of the knee (<LINK REF="STD-Graf-1993" TYPE="STUDY">Graf 1993</LINK>). At the end of the treatment phase the improvement in the modified total Larson rating score was significantly better in the <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> group. The authors reported a more rapid onset of pain relief with <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK>. At the end of the trial significantly more patients in the <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> group were symptom free or markedly improved. There was a causal relationship with study medication for six adverse events in the <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> group and for two adverse events in the MPA group.</P>
<P>This RCT was the only trial where a seven injection schedule of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> was followed.</P>
<P>Grecomoro et al. reported a 60-day, placebo-controlled, double-blind RCT performed at a single centre in Italy comparing three weekly injections of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> to three weekly injections of phosphate buffer in 34 patients with OA of the knee (<LINK REF="STD-Grecomoro-1987" TYPE="STUDY">Grecomoro 1987</LINK>). A significant difference between treatments was reported for all the clinical variables assessed. In the <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> group, pain relief was both rapid and long lasting. No 'untoward signs or symptoms' were reported. Two patients withdrew early in the placebo group for reasons unrelated to treatment.</P>
<P>In this RCT results were based on 40 joints of 34 patients.</P>
<P>Henderson et al. reported a five-month, placebo-controlled, double-blind RCT performed at a single centre in England comparing five weekly injections of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> to five weekly injections of vehicle in 91 patients with OA of the knee (<LINK REF="STD-Henderson-1994" TYPE="STUDY">Henderson 1994</LINK>). Patients were stratified into two groups based on radiological severity. In this review, the reference to <LINK REF="STD-Henderson-1994" TYPE="STUDY">Henderson 1994</LINK> refers to the milder severity group; while <LINK REF="STD-Henderson-1994a" TYPE="STUDY">Henderson 1994a</LINK> refers to the more severe group. No significant differences were found between the two groups. The rate of return to previously prescribed or other NSAIDs or analgesia was significantly slower in the <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> treated group in the subgroup of patients with mild disease. Local reactions (pain and swelling) were observed in 47% of the patients in the <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> group compared to 22% in the placebo group.</P>
<P>Several design issues were noted: 1) all but one patient had bilateral disease; 2) a clinical metrologist was used; 3) injections were into the patello-femoral space with a medial approach; and 4) there was a high percentage of withdrawals (38%).</P>
<P>Huang et al. reported a one-year, single-blind RCT performed at a single centre in Taiwan comparing isokinetic muscular strengthening exercises alone to: 1) isokinetic exercise and pulse ultrasound treatment for painful periarticular soft tissue, 2) isokinetic exercise, pulse ultrasound treatment for painful periarticular soft tissue and intraarticular <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> 5 weekly injections, and 3) no treatment other than warmup exercises (<LINK REF="STD-Huang-2005" TYPE="STUDY">Huang 2005</LINK>). All three active treatment groups showed significantly reduced pain and disability and increased muscle peak torques after treatment and at the end of the study. The active treatment group including <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> showed the greatest increase in walking speed and decrease in disability after treatment and at the one-year follow-up. The authors concluded that an "integrated therapy including ultrasound, isokinetic strengthening exercise, and intraarticular hyaluronan therapy is suggested for the management of knee OA". During the treatment phase, nine patients withdrew from the study due to intolerable pain induced to the prescribed exercise, while three patients withdrew because of muscle weakness. During the one-year follow-up period, 13 patients were lost to follow-up.</P>
<P>This trial used the same physiatrists (who were blinded to treatment) to perform all the evaluations. Measurement of knee range of motion was standardised. All patients received warmup exercises with 20 minutes of hot packs application followed by passive range of motion exercises on an electric stationary bicycle for 5 minutes to both knees before commencing the muscle strengthening exercises. Fidia Spa kindly provided page proofs of a manuscript which was in press.</P>
<P>Huskisson and Donnelly reported a six-month, placebo-controlled, blind-observer, parallel-group RCT performed at a single centre in England comparing five weekly injections of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> to five weekly injections of saline in 100 patients with OA of the knee (<LINK REF="STD-Huskisson-1999" TYPE="STUDY">Huskisson 1999</LINK>). Superiority of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> over placebo was demonstrated. Local reactions occurred in similar numbers in each group: seven patients in each group reported flare at the joint while effusion was present in three patients in the placebo group and one patient in the <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> group.</P>
<P>This trial was conducted in England to readdress the efficacy of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> over placebo (see: <LINK REF="STD-Henderson-1994" TYPE="STUDY">Henderson 1994</LINK>). Fidia Spa kindly provided an in-house statistical report providing means and standard deviations for pain on walking for all randomised patients for this trial.</P>
<P>Jones et al. reported a six-month, double-blind, parallel-group RCT performed at a single centre in England comparing five weekly injections of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> to one injection of triamcinolone hexacetonide followed by four injections of saline in 63 patients with bilateral OA of the knee (<LINK REF="STD-Jones-1995" TYPE="STUDY">Jones 1995</LINK>). Active treatment, which was randomised, was always given to the worst knee. The placebo therapy was not randomised, and, therefore, no data were extracted for comparisons between <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> and saline. No statistically significant differences were found between the groups in the intention-to-treat analysis. However, in the completer analysis significantly less pain was seen in the <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> group with other parameters showing a similar trend in favour of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK>. Sixty-eight percent of the patients dropped out of the study, the majority due to lack of efficacy. By week 29 only 26% of the triamcinolone hexacetonide patients and 38% of the <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> patients remained in the trial.</P>
<P>Jubb et al. reported a one-year, placebo-controlled, double-blind RCT performed at 17 centres in the United Kingdom comparing three weekly injections of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> to three weekly injections of saline (vehicle placebo) in 408 patients with OA of the knee (<LINK REF="STD-Jubb-2001a" TYPE="STUDY">Jubb 2001a</LINK>; <LINK REF="STD-Jubb-2001b" TYPE="STUDY">Jubb 2001b</LINK>; <LINK REF="STD-Jubb-2001c" TYPE="STUDY">Jubb 2001c</LINK>; <LINK REF="STD-Jubb-2001d" TYPE="STUDY">Jubb 2001d</LINK>; <LINK REF="STD-Jubb-2003" TYPE="STUDY">Jubb 2003</LINK>). The treatment schedule was repeated twice more at four-monthly intervals. The aim of the study was to investigate structural changes as measured by joint space narrowing (the primary outcome). Statistically significant differences in favour of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> were found for the pain outcome measures. Since the primary analysis did not show any differences between the two groups with respect to joint space narrowing, the authors performed a subgroup analysis based on baseline joint space width. Those patients with radiologically milder disease (less than 4.6 mm) had less progression of joint space narrowing when treated with <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK>. A total of 7.2% of the <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> patients and 3% of the saline patients withdrew prematurely due to adverse events; 2.4% and 1.5%, respectively, due to local adverse events. Local effects were reported by 36.1% of the <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> patients and 27.5% of the saline patients. Serious adverse events, all due to concomitant disease, were reported by 13% of the <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> patients and 7% of the saline patients.</P>
<P>In the Tables of Comparisons and data <LINK REF="STD-Jubb-2003" TYPE="STUDY">Jubb 2003</LINK> entries refer to the full journal publication; <LINK REF="STD-Jubb-2001a" TYPE="STUDY">Jubb 2001a</LINK> entries refer to the primary analysis population; <LINK REF="STD-Jubb-2001b" TYPE="STUDY">Jubb 2001b</LINK> entries refer to the subgroup with joint space width equal or greater than 4.6 mm; <LINK REF="STD-Jubb-2001c" TYPE="STUDY">Jubb 2001c</LINK> entries refer to the subgroup with joint space width less than 4.6 mm.</P>
<P>Since reduction of joint space width was the primary efficacy outcome measure in this trial evaluation was based on computerised digital image analysis of anteroposterior weight-bearing radiographs. The trial also addressed the safety of repeated cycles of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK>. Fidia Spa kindly provided an in-house statistical report for pain on walking.</P>
<P>Karras et al. reported a one-year, parallel-group RCT performed at a single centre in Greece comparing five weekly injections every six months of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> to three weekly injections every three months of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> in 200 patients with OA of the knee (<LINK REF="STD-Karras-2001" TYPE="STUDY">Karras 2001</LINK>). The objective was to compare the effectiveness of the two regimens. The authors reported that the three-injection regimen was more effective than the five-injection regimen. Except for three cases of local pain there were no side effects reported.</P>
<P>Leardini et al. reported a one-year, single-blind, parallel-group RCT performed at a single centre in Italy comparing three weekly injections of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> to three weekly injections of methylprednisolone acetate (MPA) in 36 patients with OA of the knee (<LINK REF="STD-Leardini-1987" TYPE="STUDY">Leardini 1987</LINK>). No statistically significant differences were found between the two groups in the clinical assessments. Local reactions were reported in three patients in the MPA group compared to four patients in the <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> group.</P>
<P>This trial reported results on 40 joints of 36 patients (four with bilateral disease).</P>
<P>Leardini et al. reported a 60-day, open, parallel-group RCT performed at a single centre in Italy comparing three weekly injections of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> to three weekly injections of 6-methylprednisolone acetate (6-MPA) in 40 patients with OA of the knee (<LINK REF="STD-Leardini-1991" TYPE="STUDY">Leardini 1991</LINK>). Assessments, completed one week after the end of treatment, showed that <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> was comparable to 6-MPA. In the longer term significant differences were found in favour of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> for the pain outcomes. All patients completed the treatment schedule. No local or systemic reactions were reported.</P>
<P>In this trial, all patients were kept 'at rest' for two days after injection.</P>
<P>Listrat et al. reported a one-year, open, parallel-group RCT performed at a single centre in France comparing three weekly injections of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> every three months for a total of nine injections to conventional therapy in 39 patients with OA of the knee (<LINK REF="STD-Listrat-1997" TYPE="STUDY">Listrat 1997</LINK>). All patients underwent knee arthroscopy before randomisation. A statistically significant difference in favour of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> was found for the quality of life index. A statistically significant difference for two of three structural parameters was found in favour of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK>. Forty percent of the <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> patients reported transient local reactions (pain) associated with the injection.</P>
<P>This study evaluated the potential structure-modifying effects of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK>. The arthroscopy was videotaped and assessed by a blinded assessor. The primary efficacy outcomes were the arthroscopic parameters.</P>
<P>Miltner et al. reported a seven-week, right to left comparison RCT performed at a single centre in Germany comparing five weekly injections of Hyalart in the impaired knee to no treatment in the contralateral, untreated knee in 43 patients with OA of the knee (<LINK REF="STD-Miltner-2002" TYPE="STUDY">Miltner 2002</LINK>; <LINK REF="STD-Schneider-1997" TYPE="STUDY">Schneider 1997</LINK>). The objective of this trial was to assess the effect of Hyalart on total work and isokinetic muscle strength. This pilot study showed that Hyalart was effective with regard to both clinical outcomes (e.g. relieving pain and improving function) as well as to functional outcomes (e.g. peak torque and total work). Schneider et al. published a preliminary evaluation of this trial in German based on 18 patients (<LINK REF="STD-Schneider-1997" TYPE="STUDY">Schneider 1997</LINK>).</P>
<P>Several design issues were noted: 1) all patients had bilateral disease; 2) the control group received no treatment; and 3) follow-up was limited to one week after the final injection.</P>
<P>Pietrogrande et al. reported a 60-day, open, parallel-group RCT performed at three centres in Italy comparing five weekly injections of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> to three weekly injections of 6-methylprednisolone acetate in 90 patients with OA of the knee (<LINK REF="STD-Pietrogrande-1991" TYPE="STUDY">Pietrogrande 1991</LINK>). Although both treatments reduced the disease symptoms 6-MPA had a more rapid action that did not last as long as that of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK>. At the final assessment significant differences were found between the treatments for most outcome measures. One patient in the <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> group had a local reaction which resolved spontaneously but the patient was withdrawn due to lack of efficacy. No systemic adverse reactions were reported in either group.</P>
<P>St. J. Dixon et al. reported a 48-week, placebo-controlled, double-blind, parallel-group RCT performed at three centres in England comparing <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> (up to eleven injections over 23 weeks) to vehicle (0.2 mg sodium hyaluronate) in 63 patients with OA of the knee (<LINK REF="STD-St.-J.-Dixon-1988" TYPE="STUDY">St. J. Dixon 1988</LINK>). Knee pain was significantly reduced in the <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> group compared to the placebo group. No between-group difference was found for function as measured by activities of daily living. Possible treatment-related (<LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK>) adverse events occurred in three patients: hemarthrosis developed in one patient, effusion volume increased in one patient, and phlebitis developed in one patient. Ten patients did not complete the trial. Five patients in the placebo group withdrew early because of increased pain; while five patients withdrew early in the <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> group: one because of a torn meniscus, one because knee was painless, one had increased pain, one defaulted and one had a hemarthrosis. No measure of dispersion was reported for pain on movement, pain at rest, or activities of daily living and, consequently, efficacy data are not included in this review. Only safety data are included in this review.</P>
<P>This is the only RCT where up to 11 injections of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> were used. Fidia Spa kindly provided an in-house clinical report for pain on movement and rest pain.</P>
<P>Tsai et al. reported a 25-week, placebo-controlled, multicentre, double-blind RCT performed in Taiwan comparing five weekly injections of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> to five weekly injections of saline in 200 patients with OA of the knee (<LINK REF="STD-Tsai-2003" TYPE="STUDY">Tsai 2003</LINK>). Statistically significant differences were found in favour of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> for pain on 50-foot walk, WOMAC OA Index pain and physical function. No differences between treatments were reported in adverse event occurrence.</P>
<P>Fidia Spa kindly provided an in-house report (<LINK REF="STD-Lin-2004" TYPE="STUDY">Lin 2004</LINK>) as only an abstract, based on this trial, had been published in 2003 (<LINK REF="STD-Tsai-2003" TYPE="STUDY">Tsai 2003</LINK>).</P>
<P>
<LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> versus placebo<BR/>
<I>
<BR/>Efficacy<BR/>
</I>
<LINK REF="TBL-15" TYPE="TABLE">Table 15</LINK>; <LINK REF="TBL-16" TYPE="TABLE">Table 16</LINK>; <LINK REF="TBL-17" TYPE="TABLE">Table 17</LINK>
<BR/>Based on 14 comparisons, there was a statistically significant difference in pain on weight bearing, measured on a 0 to 100 mm VAS, in favour of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> compared to placebo at 1 to 4 weeks postinjection (WMD (random-effects model) -6.20; 95% CI -11.02 to -1.38, P value 0.009). <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> was 2 to 31% more effective than placebo in improving pain. Based on 10 comparisons, there was a statistically significant difference in favour of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> compared to placebo at 5 to 13 weeks postinjection (WMD (random-effects model) -9.04; 95% CI -14.10 to -3.98; P value 0.0005). <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> was 18 to 44% more effective than placebo in improving pain. There was a statistically significant difference in favour of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> compared to placebo at 14 to 26 weeks postinjection (WMD -4.12; 95% CI -6.97 to -1.27, P value 0.005) (<LINK REF="STD-Altman-1998" TYPE="STUDY">Altman 1998</LINK>; <LINK REF="STD-Huskisson-1999" TYPE="STUDY">Huskisson 1999</LINK>; <LINK REF="STD-Jubb-2003" TYPE="STUDY">Jubb 2003</LINK>; <LINK REF="STD-Tsai-2003" TYPE="STUDY">Tsai 2003</LINK>). <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> was 3 to 26% more effective than placebo in improving pain. There was no statistically significant difference at 45 to 52 weeks postinjection (<LINK REF="STD-Dougados-1993" TYPE="STUDY">Dougados 1993</LINK>; <LINK REF="STD-Jubb-2003" TYPE="STUDY">Jubb 2003</LINK>; <LINK REF="STD-St.-J.-Dixon-1988" TYPE="STUDY">St. J. Dixon 1988</LINK>).</P>
<P>There was a statistically significant difference in spontaneous pain, measured on a 0 to 100 mm VAS, in favour of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> compared to placebo at 1 to 4 weeks postinjection (WMD -23.88; 95% CI -33.50 to -14.25, P value &lt; 0.00001), and at 5 to 13 weeks postinjection (WMD (random-effects model) -22.28; 95% CI -38.88 to -5.68, P value 0.009) (<LINK REF="STD-Bragantini-1987" TYPE="STUDY">Bragantini 1987</LINK>; <LINK REF="STD-Grecomoro-1987" TYPE="STUDY">Grecomoro 1987</LINK>). <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> was 38 to 67% more effective than placebo in improving pain.</P>
<P>There was a statistically significant difference in pain at rest, measured on a 0 to 100 mm VAS, in favour of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> compared to placebo at 1 to 4 weeks postinjection (WMD (random-effects model) -6.37; 95% CI -11.57 to -1.18, P value 0.02) (<LINK REF="STD-Carrabba-1995" TYPE="STUDY">Carrabba 1995</LINK>; <LINK REF="STD-Carrabba-1995a" TYPE="STUDY">Carrabba 1995a</LINK>; <LINK REF="STD-Carrabba-1995b" TYPE="STUDY">Carrabba 1995b</LINK>; <LINK REF="STD-Carrabba-1995c" TYPE="STUDY">Carrabba 1995c</LINK>; <LINK REF="STD-Corrado-1995" TYPE="STUDY">Corrado 1995</LINK>; <LINK REF="STD-Dougados-1993" TYPE="STUDY">Dougados 1993</LINK>; <LINK REF="STD-Henderson-1994" TYPE="STUDY">Henderson 1994</LINK>; <LINK REF="STD-Henderson-1994a" TYPE="STUDY">Henderson 1994a</LINK>; <LINK REF="STD-St.-J.-Dixon-1988" TYPE="STUDY">St. J. Dixon 1988</LINK>), and at 5 to 13 weeks postinjection (WMD -9.65; 95% CI -14.18 to -5.13, P value 0.00003) (<LINK REF="STD-Carrabba-1995" TYPE="STUDY">Carrabba 1995</LINK>; <LINK REF="STD-Carrabba-1995a" TYPE="STUDY">Carrabba 1995a</LINK>; <LINK REF="STD-Carrabba-1995b" TYPE="STUDY">Carrabba 1995b</LINK>; <LINK REF="STD-Carrabba-1995c" TYPE="STUDY">Carrabba 1995c</LINK>; <LINK REF="STD-Corrado-1995" TYPE="STUDY">Corrado 1995</LINK>). <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> was 13 to 116% more effective than placebo in improving pain. There was no statistically significant difference at 45 to 52 weeks postinjection (<LINK REF="STD-Dougados-1993" TYPE="STUDY">Dougados 1993</LINK>; <LINK REF="STD-St.-J.-Dixon-1988" TYPE="STUDY">St. J. Dixon 1988</LINK>).</P>
<P>There was no statistically significant difference in pain at night, measured on a 0 to 100 mm VAS, between <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> and placebo at 5 to 13 weeks post injection (<LINK REF="STD-Henderson-1994" TYPE="STUDY">Henderson 1994</LINK>; <LINK REF="STD-Henderson-1994a" TYPE="STUDY">Henderson 1994a</LINK>).</P>
<P>There were no statistically significant differences in WOMAC OA Index pain, measured on a 0 to 100 mm VAS, between <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> and placebo at 1 to 4 weeks or at 5 to 13 weeks postinjection. There was a statistically significant difference in favour of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> compared to saline at 14 to 26 weeks postinjection (WMD -5.66; 95% CI -10.06 to -1.26, P value 0.01) (<LINK REF="STD-Lin-2004" TYPE="STUDY">Lin 2004</LINK>, <LINK REF="STD-Tsai-2003" TYPE="STUDY">Tsai 2003</LINK>) with <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> being 14% more effective than saline.</P>
<P>Pain was measured using several dichotomous outcome measures.</P>
<P>There were statistically significant differences in favour of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> compared to placebo for the number of joints improved for walking pain at the end of treatment (RR 1.68; 95% CI 1.02 to 2.78, P value 0.04) (<LINK REF="STD-Bragantini-1987" TYPE="STUDY">Bragantini 1987</LINK>); at 1 week postinjection (RR 3.60; 95% CI 1.48 to 8.78, P value 0.005) (<LINK REF="STD-Grecomoro-1987" TYPE="STUDY">Grecomoro 1987</LINK>); and at 5 to 13 weeks postinjection (RR 2.30; 95% CI 1.26 to 4.19, P value 0.006) (<LINK REF="STD-Bragantini-1987" TYPE="STUDY">Bragantini 1987</LINK>). The NNT for walking pain was 2 to 3. Similarly, statistically significant differences in favour of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> compared to placebo were found for the number of joints improved for pain under load at the end of treatment (RR 0.37; 95% CI 0.19 to 0.73, P value 0.004) (<LINK REF="STD-Bragantini-1987" TYPE="STUDY">Bragantini 1987</LINK>); at 1 week postinjection (RR 3.60; 95% CI 1.48 to 8.78, P value 0.005) (<LINK REF="STD-Grecomoro-1987" TYPE="STUDY">Grecomoro 1987</LINK>); and at 5 to 13 weeks postinjection (RR 0.25; 95% CI 0.10 to 0.60, P value 0.002) (<LINK REF="STD-Bragantini-1987" TYPE="STUDY">Bragantini 1987</LINK>). The NNT for pain under load was 2.</P>
<P>There was no statistically significant difference in pain, expressed as the number of patients improved, at 5 to 13 weeks postinjection. The RevMan analysis differed from the publication analysis where the P value was 0.04 (chi square test). A significant difference in favour of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> compared to placebo was found at 32 weeks postinjection (RR 1.36; 95% CI 1.06 to 1.75, P value 0.02) (<LINK REF="STD-Jubb-2003" TYPE="STUDY">Jubb 2003</LINK>). The NNT for patient global assessment was 9.</P>
<P>There was no statistically significant difference in the number of patients who had moderate to marked pain or in those who had none to slight to mild pain at 14 to 26 weeks postinjection (<LINK REF="STD-Altman-1998" TYPE="STUDY">Altman 1998</LINK>).</P>
<P>There were no statistically significant differences in the number of knee joints without night pain at 1 to 4 or at 5 to 13 weeks postinjection (<LINK REF="STD-Creamer-1994" TYPE="STUDY">Creamer 1994</LINK>). There were no statistically significant differences in the number of participants without rest pain at 1 to 4 or at 5 to 13 weeks postinjection (<LINK REF="STD-Creamer-1994" TYPE="STUDY">Creamer 1994</LINK>).</P>
<P>There was a statistically significant difference in the number of joints with improvement in pain on touch in favour of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> compared to placebo (RR 2.25; 95% CI 1.12 to 4.53, P value 0.02) (<LINK REF="STD-Grecomoro-1987" TYPE="STUDY">Grecomoro 1987</LINK>). The NNT for pain on touch was 2.</P>
<P>There were no statistically significant differences in WOMAC OA Index physical function, measured on a 0 to 100 mm VAS, between <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> and saline at 1 to 4, 5 to 13, or 14 to 26 weeks postinjection (<LINK REF="STD-Lin-2004" TYPE="STUDY">Lin 2004</LINK>; <LINK REF="STD-Tsai-2003" TYPE="STUDY">Tsai 2003</LINK>). The RevMan analysis (WMD -4.05; 95% CI -8.38 to 0.28, P value 0.07) differed from the publication analysis where a statistically significant difference was found in favour of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> in WOMAC physical function from baseline to week 25 (P value 0.0038 (ANOVA)).</P>
<P>Statistically significant differences in the Lequesne Index, measured on a 0 to 24 scale, in favour of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> compared to placebo were found at 1 to 4 weeks postinjection (WMD -1.50; 95% CI -2.36 to -0.65, P value 0.0006) (<LINK REF="STD-Carrabba-1995" TYPE="STUDY">Carrabba 1995</LINK>; <LINK REF="STD-Carrabba-1995a" TYPE="STUDY">Carrabba 1995a</LINK>; <LINK REF="STD-Carrabba-1995b" TYPE="STUDY">Carrabba 1995b</LINK>; <LINK REF="STD-Carrabba-1995c" TYPE="STUDY">Carrabba 1995c</LINK>; <LINK REF="STD-Dougados-1993" TYPE="STUDY">Dougados 1993</LINK>; <LINK REF="STD-Huskisson-1999" TYPE="STUDY">Huskisson 1999</LINK>), and at 5 to 13 weeks postinjection (WMD -2.34; 95% CI -3.41 to -1.27, P value 0.00002) (<LINK REF="STD-Carrabba-1995" TYPE="STUDY">Carrabba 1995</LINK>; <LINK REF="STD-Carrabba-1995a" TYPE="STUDY">Carrabba 1995a</LINK>; <LINK REF="STD-Carrabba-1995b" TYPE="STUDY">Carrabba 1995b</LINK>; <LINK REF="STD-Carrabba-1995c" TYPE="STUDY">Carrabba 1995c</LINK>; <LINK REF="STD-Huskisson-1999" TYPE="STUDY">Huskisson 1999</LINK>). <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> was 11 to 25% more effective than placebo. No statistically significant difference was found at 14 to 26 weeks postinjection (<LINK REF="STD-Huskisson-1999" TYPE="STUDY">Huskisson 1999</LINK>) or at 45 to 52 weeks postinjection (<LINK REF="STD-Dougados-1993" TYPE="STUDY">Dougados 1993</LINK>). The RevMan analysis (WMD -1.11; 95% CI -2.70 to 0.48, P value 0.17) differed from the Dougados publication (<LINK REF="STD-Dougados-1993" TYPE="STUDY">Dougados 1993</LINK>) which reported a statistically significant difference (P value 0.046) in the Lequesne Index at week 52.</P>
<P>Although not recommended as core-set outcome measures, data were extracted on range of motion, synovial fluid volume, and joint space width. There was no statistically significant difference in flexion, measured in degrees, between <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> and placebo at 1 to 4 weeks postinjection, but <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> was significantly better than placebo at 5 to 13 weeks postinjection (WMD 7.60; 95% CI 0.46 to 14.74, P value 0.04) (<LINK REF="STD-Corrado-1995" TYPE="STUDY">Corrado 1995</LINK>). <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> was 6% more effective in improving flexion than placebo. There were no statistically significant differences in synovial fluid volume, measured in ml, between <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> and placebo at 1 to 4 weeks postinjection (<LINK REF="STD-Corrado-1995" TYPE="STUDY">Corrado 1995</LINK>; <LINK REF="STD-Creamer-1994" TYPE="STUDY">Creamer 1994</LINK>; <LINK REF="STD-Dougados-1993" TYPE="STUDY">Dougados 1993</LINK>), or at 5 to 13 weeks postinjection (<LINK REF="STD-Corrado-1995" TYPE="STUDY">Corrado 1995</LINK>; <LINK REF="STD-Creamer-1994" TYPE="STUDY">Creamer 1994</LINK>). There was a statistically significant difference in joint space width, measured in mm, in favour of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> compared to placebo at 45 to 52 weeks postinjection (WMD 0.40; 95% CI 0.03 to 0.77, P value 0.03) (<LINK REF="STD-Jubb-2003" TYPE="STUDY">Jubb 2003</LINK>). However, when the treatment groups were stratified by baseline joint space width, there was no statistically significant difference (<LINK REF="STD-Jubb-2003" TYPE="STUDY">Jubb 2003</LINK>). These RevMan analyses differed from the Jubb publication (<LINK REF="STD-Jubb-2003" TYPE="STUDY">Jubb 2003</LINK>) analysis where no difference was found in the total population but a difference in favour of the subgroup with joint space width equal to or greater than 4.6 mm at baseline was reported.</P>
<P>There was no statistically significant difference between <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> and placebo in patient global assessment, measured as number of patients improved, at 1 to 4 weeks postinjection (<LINK REF="STD-Corrado-1995" TYPE="STUDY">Corrado 1995</LINK>; <LINK REF="STD-Creamer-1994" TYPE="STUDY">Creamer 1994</LINK>; <LINK REF="STD-Formiguera-Sala-1995" TYPE="STUDY">Formiguera Sala 1995</LINK>). A statistically significant difference was found in favour of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> compared to placebo at 5 to 13 weeks postinjection (RR 2.44; 95% CI 1.43 to 4.16, P value 0.0010) (<LINK REF="STD-Corrado-1995" TYPE="STUDY">Corrado 1995</LINK>; <LINK REF="STD-Formiguera-Sala-1995" TYPE="STUDY">Formiguera Sala 1995</LINK>). The NNT for patient global assessment was 10. A statistically significant difference was found in favour of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> compared to placebo at 14 to 26 weeks postinjection (RR 1.24; 95% CI 1.03 to 1.50, P value 0.02) (<LINK REF="STD-Henderson-1994" TYPE="STUDY">Henderson 1994</LINK>; <LINK REF="STD-Huskisson-1999" TYPE="STUDY">Huskisson 1999</LINK>; <LINK REF="STD-Lin-2004" TYPE="STUDY">Lin 2004</LINK>). No statistically significant difference was found at 45 to 52 weeks postinjection in the number of patients rating treatment effective (<LINK REF="STD-Dougados-1993" TYPE="STUDY">Dougados 1993</LINK>). When patient global assessment was measured by the number of joints that were fairly good to very good, a statistically significant difference in favour of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> compared to placebo was found at 5 to 13 weeks postinjection (RR 2.12; 95% CI 1.22 to 3.70, P value 0.008) (<LINK REF="STD-Bragantini-1987" TYPE="STUDY">Bragantini 1987</LINK>; <LINK REF="STD-Creamer-1994" TYPE="STUDY">Creamer 1994</LINK>). The NNT for patient global assessment was 11.<BR/>
<I>
<BR/>Safety<BR/>
</I>
<BR/>There were no statistically significant differences in the total number of withdrawals overall at 5 to 13 weeks postinjection (<LINK REF="STD-Carrabba-1995" TYPE="STUDY">Carrabba 1995</LINK>; <LINK REF="STD-Corrado-1995" TYPE="STUDY">Corrado 1995</LINK>); at 14 to 26 weeks postinjection (<LINK REF="STD-Altman-1998" TYPE="STUDY">Altman 1998</LINK>; <LINK REF="STD-Henderson-1994" TYPE="STUDY">Henderson 1994</LINK>; <LINK REF="STD-Huskisson-1999" TYPE="STUDY">Huskisson 1999</LINK>; <LINK REF="STD-Lin-2004" TYPE="STUDY">Lin 2004</LINK>); or at 45 at 52 weeks postinjection (<LINK REF="STD-Dougados-1993" TYPE="STUDY">Dougados 1993</LINK>; <LINK REF="STD-Jubb-2003" TYPE="STUDY">Jubb 2003</LINK>; <LINK REF="STD-St.-J.-Dixon-1988" TYPE="STUDY">St. J. Dixon 1988</LINK>). There were no statistically significant differences in the number of withdrawals due to lack of efficacy during the treatment phase (<LINK REF="STD-Dougados-1993" TYPE="STUDY">Dougados 1993</LINK>) or 14 to 26 weeks postinjection (<LINK REF="STD-Altman-1998" TYPE="STUDY">Altman 1998</LINK>; <LINK REF="STD-Huskisson-1999" TYPE="STUDY">Huskisson 1999</LINK>; <LINK REF="STD-Lin-2004" TYPE="STUDY">Lin 2004</LINK>). A statistically significant difference in favour of placebo compared to <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> was found in the number of patients with local adverse events that caused discontinuation of study drug (RR 3.34; 95% CI 1.31 to 8.56, P value 0.01) (<LINK REF="STD-Altman-1998" TYPE="STUDY">Altman 1998</LINK>; <LINK REF="STD-Dougados-1993" TYPE="STUDY">Dougados 1993</LINK>; <LINK REF="STD-Henderson-1994" TYPE="STUDY">Henderson 1994</LINK>; <LINK REF="STD-Jubb-2003" TYPE="STUDY">Jubb 2003</LINK>). Similarly, there was a statistically significant difference in favour of placebo compared to <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> found in the number of patients with local adverse events but the study drug was continued (RR 1.42; 95% CI 1.10 to 1.84, P value 0.007). There was no statistically significant difference in the number of patients with serious adverse events at 14 to 26 weeks postinjection (<LINK REF="STD-Huskisson-1999" TYPE="STUDY">Huskisson 1999</LINK>; <LINK REF="STD-Lin-2004" TYPE="STUDY">Lin 2004</LINK>). There was a trend of more serious adverse events in the <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> group compared to the placebo group at 45 to 52 weeks postinjection (RR 1.85; 95% CI 1.00 to 34.3, P value 0.05) (<LINK REF="STD-Dougados-1993" TYPE="STUDY">Dougados 1993</LINK>, <LINK REF="STD-Jubb-2003" TYPE="STUDY">Jubb 2003</LINK>). There was a trend of more patients withdrawing due to adverse events in the <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> group compared to the placebo group (RR 2.35; 95% CI 0.99 to 5.56, P value 0.05) (<LINK REF="STD-Huskisson-1999" TYPE="STUDY">Huskisson 1999</LINK>, <LINK REF="STD-Jubb-2003" TYPE="STUDY">Jubb 2003</LINK>). There was no statistically significant difference in the number of knee joints with local adverse events (<LINK REF="STD-Bragantini-1987" TYPE="STUDY">Bragantini 1987</LINK>; <LINK REF="STD-Creamer-1994" TYPE="STUDY">Creamer 1994</LINK>). There was no statistically significant difference in the number of patients with injection site pain (<LINK REF="STD-Altman-1998" TYPE="STUDY">Altman 1998</LINK>; <LINK REF="STD-Dougados-1993" TYPE="STUDY">Dougados 1993</LINK>; <LINK REF="STD-Formiguera-Sala-1995" TYPE="STUDY">Formiguera Sala 1995</LINK>). There was no statistically significant difference in the number of patients with treatment-related adverse events at 5 to 13 weeks postinjection, 0% in both the <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> and control groups (<LINK REF="STD-Formiguera-Sala-1995" TYPE="STUDY">Formiguera Sala 1995</LINK>). There was a statistically significant difference in the number of patients with treatment-related adverse events at 14 to 26 weeks postinjection (RR 2.19; 95% CI 1.18 to 4.07, P value 0.01) (<LINK REF="STD-Bunyaratavej-2001" TYPE="STUDY">Bunyaratavej 2001</LINK>; <LINK REF="STD-Henderson-1994" TYPE="STUDY">Henderson 1994</LINK>; <LINK REF="STD-Huskisson-1999" TYPE="STUDY">Huskisson 1999</LINK>) but not at 45 to 52 weeks postinjection. In the Altman trial (<LINK REF="STD-Altman-1998" TYPE="STUDY">Altman 1998</LINK>) at 14 to 26 week postinjection, there was a statistically significant difference in the number of patients with gastrointestinal complaints in favour of placebo compared to <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> (RR 1.89; 95% CI 1.24 to 2.90, P value 0.003). There was no statistically significant difference in the number of patients with local skin rash at 14 to 26 weeks postinjection (<LINK REF="STD-Altman-1998" TYPE="STUDY">Altman 1998</LINK>).</P>
<P>
<LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> versus arthroscopy</P>
<P>
<LINK REF="TBL-18" TYPE="TABLE">Table 18</LINK>
</P>
<P>One trial was included which was a comparison of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> and arthroscopy (<LINK REF="STD-Forster-2003" TYPE="STUDY">Forster 2003</LINK>; <LINK REF="STD-Forster-2003a" TYPE="STUDY">Forster 2003a</LINK>).<BR/>
<I>
<BR/>Efficacy<BR/>
</I>
<BR/>In the comparison against arthroscopy, there was no statistically significant difference between <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> and arthroscopy in pain (0 to 10 cm VAS) or in the Lequesne Index (0 to 24) at any of the four assessments: 1 to 4, 5 to 13, 14 to 26 or 45 to 52 weeks postinjection. Although there was a statistically significant difference between groups pre-trial for the Knee Society Function scale score (i.e. <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> group better score), except for the 14 to 26 week assessment (WMD 23.50; 95% CI 1.68 to 45.32, P value 0.03) (i.e. <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> was 2% more effective than arthroscopy), there was no statistically significant difference between <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> and arthroscopy at 1 to 4, 5 to 13 or 45 to 52 weeks postinjection. There was no statistically significant difference between the number of patients requiring further intervention.</P>
<P>The RevMan analysis differed from the Forster publication (<LINK REF="STD-Forster-2003" TYPE="STUDY">Forster 2003</LINK>) analysis. The publication reported no difference in the Knee Society Function scale at six months whereas the RevMan analysis detected a statistically significant difference (P value 0.03) in favour of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> over arthroscopy.<BR/>
<I>
<BR/>Safety<BR/>
</I>
<BR/>There was no statistically significant difference in the number of withdrawals overall: <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> 2 out of 19 versus arthroscopy 4 of 19. There was no statistically significant difference in the number of patients with pain at the injection site: <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> 2 out of 19 versus arthroscopy 0 out of 19.</P>
<P>
<LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> versus corticosteroid</P>
<P/>
<P>Five RCTs that were included were comparisons of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> and IA corticosteroid.</P>
<P>Four RCT were comparisons of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> and methylprednisolone acetate (Depomedrol, MPA) (<LINK REF="STD-Frizziero-2002" TYPE="STUDY">Frizziero 2002</LINK>; <LINK REF="STD-Leardini-1987" TYPE="STUDY">Leardini 1987</LINK>; <LINK REF="STD-Leardini-1991" TYPE="STUDY">Leardini 1991</LINK>; <LINK REF="STD-Pietrogrande-1991" TYPE="STUDY">Pietrogrande 1991</LINK>) and one RCT was a comparison of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> and triamcinolone hexacetonide (<LINK REF="STD-Jones-1995" TYPE="STUDY">Jones 1995</LINK>).<BR/>
<I>
<BR/>Efficacy </I>
</P>
<P>
<LINK REF="TBL-19" TYPE="TABLE">Table 19</LINK>; <LINK REF="TBL-20" TYPE="TABLE">Table 20</LINK>
<BR/>
</P>
<P>There was no statistically significant difference in spontaneous pain intensity (0 to 100 mm VAS) at 1 to 4 weeks postinjection (<LINK REF="STD-Leardini-1987" TYPE="STUDY">Leardini 1987</LINK>; <LINK REF="STD-Leardini-1991" TYPE="STUDY">Leardini 1991</LINK>; <LINK REF="STD-Pietrogrande-1991" TYPE="STUDY">Pietrogrande 1991</LINK>). There was a statistically significant difference in favour of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> at 5 to 13 weeks postinjection (WMD -7.73; 95% CI -12.81 to -2.64, P value 0.003) (<LINK REF="STD-Leardini-1987" TYPE="STUDY">Leardini 1987</LINK>; <LINK REF="STD-Leardini-1991" TYPE="STUDY">Leardini 1991</LINK>; <LINK REF="STD-Pietrogrande-1991" TYPE="STUDY">Pietrogrande 1991</LINK>). <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> was 11 to 41% more effective than MPA. At 45 to 52 weeks postinjection, there was no statistically significant difference (<LINK REF="STD-Leardini-1987" TYPE="STUDY">Leardini 1987</LINK>). For pain expressed as the number of joints with moderate or severe pain under load (<LINK REF="STD-Leardini-1987" TYPE="STUDY">Leardini 1987</LINK>), there was no statistically significant difference at 1 to 4, 5 to 13, or 45 to 52 weeks postinjection. For pain expressed as the number of patients with moderate or severe pain under load (<LINK REF="STD-Leardini-1991" TYPE="STUDY">Leardini 1991</LINK>; <LINK REF="STD-Pietrogrande-1991" TYPE="STUDY">Pietrogrande 1991</LINK>), there was no statistically significant difference at 1 to 4 weeks postinjection. There was a statistically significant difference in favour of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> at 5 to 13 weeks postinjection (RR 0.61; 95% CI 0.44 to 0.84, P value 0.003). The NNT for moderate to severe pain under load was 10. For the number of joints with moderate or severe walking pain, no statistically significant differences were detected at three timepoints: 1 to 4, 5 to 13, or 45 to 52 weeks postinjection (<LINK REF="STD-Leardini-1987" TYPE="STUDY">Leardini 1987</LINK>). For the number of patients with moderate or greater night pain, there was no statistically significant difference at 1 to 4 or 5 to 13 weeks postinjection (<LINK REF="STD-Leardini-1991" TYPE="STUDY">Leardini 1991</LINK>; <LINK REF="STD-Pietrogrande-1991" TYPE="STUDY">Pietrogrande 1991</LINK>). For the number of patients with moderate or greater rest pain, there was no statistically significant difference at 1 to 4 weeks postinjection, but a statistically significant difference in favour of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> at 5 to 13 weeks postinjection (RR 0.39; 95% CI 0.19 to 0.78, P value 0.008) (<LINK REF="STD-Leardini-1991" TYPE="STUDY">Leardini 1991</LINK>; <LINK REF="STD-Pietrogrande-1991" TYPE="STUDY">Pietrogrande 1991</LINK>). The NNT for rest pain was 20.</P>
<P>Statistically significant differences in range of motion (flexion) in favour of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> were found at 1 to 4 weeks postinjection (WMD 5.93; 95% CI 0.71 to 11.14, P value 0.03), and at 5 to 13 weeks post injection (WMD 5.41; 95% CI 0.54 to 10.28, P value 0.03) (<LINK REF="STD-Leardini-1987" TYPE="STUDY">Leardini 1987</LINK>; <LINK REF="STD-Pietrogrande-1991" TYPE="STUDY">Pietrogrande 1991</LINK>) (i.e. <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> was 2% more effective than MPA), but no statistically significant difference was detected at 45 to 52 weeks postinjection (<LINK REF="STD-Leardini-1987" TYPE="STUDY">Leardini 1987</LINK>).</P>
<P>The global assessment, expressed by number of patients good or very good, was not significantly different between groups at 1 to 4 weeks postinjection (<LINK REF="STD-Frizziero-2002" TYPE="STUDY">Frizziero 2002</LINK>; <LINK REF="STD-Leardini-1991" TYPE="STUDY">Leardini 1991</LINK>; <LINK REF="STD-Pietrogrande-1991" TYPE="STUDY">Pietrogrande 1991</LINK>). There was a statistically significant difference in favour of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> at 5 to 13 weeks postinjection (WMD 1.86; 95% CI 1.26 to 2.75, P value 0.002) (<LINK REF="STD-Leardini-1991" TYPE="STUDY">Leardini 1991</LINK>; <LINK REF="STD-Pietrogrande-1991" TYPE="STUDY">Pietrogrande 1991</LINK>). The NNT for patient global assessment was 7. At 45 to 52 weeks postinjection, there was no statistically significant difference (<LINK REF="STD-Frizziero-2002" TYPE="STUDY">Frizziero 2002</LINK>).</P>
<P>One RCT was a comparison of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> and triamcinolone hexacetonide (<LINK REF="STD-Jones-1995" TYPE="STUDY">Jones 1995</LINK>). Except for pain at night at 14 to 26 weeks postinjection (WMD -20.70; 95% CI -37.74 to -3.66, P value 0.02), there were no statistically significant differences between treatment detected by the three pain measures: pain on nominated activity, pain at rest, and pain at night (all measured on a 100 mm VAS) at the end of treatment or at 14 to 26 weeks postinjection. <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> was 26% more effective than triamcinolone hexacetonide in relieving pain at night at 14 to 26 weeks postinjection. The RevMan analysis differed from the Jones publication (<LINK REF="STD-Jones-1995" TYPE="STUDY">Jones 1995</LINK>) analysis. The publication reported significant differences in favour of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> in pain on nominated activity and pain at rest at 14 to 26 weeks postinjection.<BR/>
<I>
<BR/>Safety</I>
</P>
<P>There were no statistically significant differences in any of the extracted safety outcomes. There was no difference in the total number of withdrawals overall at 1 to 4 weeks postinjection (<LINK REF="STD-Frizziero-2002" TYPE="STUDY">Frizziero 2002</LINK>); at 5 to 13 weeks postinjection (<LINK REF="STD-Leardini-1991" TYPE="STUDY">Leardini 1991</LINK>; <LINK REF="STD-Pietrogrande-1991" TYPE="STUDY">Pietrogrande 1991</LINK>); at 14 to 26 weeks postinjection (<LINK REF="STD-Frizziero-2002" TYPE="STUDY">Frizziero 2002</LINK>); or at 45 to 52 weeks postinjection (<LINK REF="STD-Leardini-1987" TYPE="STUDY">Leardini 1987</LINK>). There was no difference in the number of patients withdrawn due to lack of efficacy at 5 to 13 weeks postinjection (<LINK REF="STD-Pietrogrande-1991" TYPE="STUDY">Pietrogrande 1991</LINK>). There was no difference in the number of joints with local reactions at 1 to 4 weeks postinjection (<LINK REF="STD-Leardini-1987" TYPE="STUDY">Leardini 1987</LINK>). There was no difference in the number of patients with local or systemic reactions at 5 to 13 weeks postinjection (<LINK REF="STD-Leardini-1991" TYPE="STUDY">Leardini 1991</LINK>, <LINK REF="STD-Pietrogrande-1991" TYPE="STUDY">Pietrogrande 1991</LINK>). There was no difference in the number of patients withdrawn due to adverse events after the first injection in the Frizziero trial (<LINK REF="STD-Frizziero-2002" TYPE="STUDY">Frizziero 2002</LINK>).</P>
<P>There were no statistically significant differences between <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> and triamcinolone hexacetonide (<LINK REF="STD-Jones-1995" TYPE="STUDY">Jones 1995</LINK>) in the total number of withdrawals overall, in the number of withdrawals due to lack of efficacy, or in the number of withdrawals due to adverse events at the end of treatment or at 14 to 26 weeks postinjection.</P>
<P>
<LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> versus other IA therapy</P>
<P>
<LINK REF="TBL-19" TYPE="TABLE">Table 19</LINK>; <LINK REF="TBL-20" TYPE="TABLE">Table 20</LINK>
<BR/>
</P>
<P>One RCT included was a comparison of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> and mucopolysaccharide polysulfuric acid ester (<LINK REF="STD-Graf-1993" TYPE="STUDY">Graf 1993</LINK>).<BR/>
<I>
<BR/>Efficacy<BR/>
</I>
<BR/>The results were presented as change scores. The six-month data reported in the publication were not used since it was presented as the change from end of treatment not the change from baseline. For the Larson rating scale, a higher score indicated improvement. At the end of treatment (week 6), there was a statistically significant difference in favour of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> compared to mucopolysaccharide polysulfuric acid ester for pain (0 to 30) (WMD 4.00; 95% CI 0.98 to 7.02, P value 0.009), and for the total Larson rating score (0 to 77) (WMD 5.90; 95% CI1.31 to 10.49, P value 0.01). This means that <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> was 25% more effective than mucopolysaccharide polysulfuric acid ester in relieving pain and 13% more effective in improving 'overall' function. There was no statistically significant difference for function (0-30) or for range of motion (0 to 10). The global assessment, expressed by the number of patients symptom free or markedly improved, was significantly better in the <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> group (76%) compared to the mucopolysaccharide polysulfuric acid ester group (46%) (RR 1.65; 95% CI 1.03 to 2.66, P value 0.04) at 14 to 26 weeks postinjection. The NNT for patient global assessment was 3.<BR/>
<I>
<BR/>Safety<BR/>
</I>
<BR/>There were no statistically significant differences between <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> and mucopolysaccharide polysulfuric acid ester at 14 to 26 weeks postinjection either in the total number of withdrawals overall or in the number of adverse events due to study medication.</P>
<P>
<LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> versus NSAID</P>
<P>
<LINK REF="TBL-21" TYPE="TABLE">Table 21</LINK>; <LINK REF="TBL-22" TYPE="TABLE">Table 22</LINK>
</P>
<P>One RCT included was a comparison of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> and naproxen (<LINK REF="STD-Altman-1998" TYPE="STUDY">Altman 1998</LINK>).<BR/>
<I>
<BR/>Efficacy<BR/>
</I>
<BR/>No statistically significant difference was found between <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> and naproxen for pain after a 50 foot walk measured on a 100 mm VAS at any of the three assessment times: 1 to 4, 5 to 13, or 14 to 26 weeks postinjection. There was no statistically significant difference in the number of patients with moderate to marked pain at 14 to 26 weeks postinjection or in those with none to slight to mild pain.<BR/>
<I>
<BR/>Safety<BR/>
</I>
<BR/>There was a statistically significant difference in the number of patients with gastrointestinal complaints reported in the <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> group (29%) compared to the naproxen group (42%) (RR 0.70; 95% CI 0.52 to 0.95, P value 0.02). There was a statistically significant difference in the number of adverse events for injection site pain reported in the naproxen group (9%) compared to <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> (23%) (RR 2.70; 95% CI 1.52 to 4.79, P value 0.0007). There were more adverse events due to local joint pain and swelling reported in the <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> group (13%) than the naproxen group (6%) (RR 2.09; 95% CI 1.01 to 4.29, P value 0.05).</P>
<P>There were no statistically significant differences for the other safety outcome measures: total withdrawals overall, withdrawals due to lack of efficacy, number of adverse events of local skin rash, or pruritis.</P>
<P>
<LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> versus conventional therapy<BR/>
<LINK REF="TBL-23" TYPE="TABLE">Table 23</LINK>
</P>
<P>One RCT included was a comparison of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> and conventional therapy (<LINK REF="STD-Listrat-1997" TYPE="STUDY">Listrat 1997</LINK>).<BR/>
<I>
<BR/>Efficacy<BR/>
</I>
<BR/>There were no statistically significant differences between <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> and conventional care at 45 to 52 weeks postinjection in overall pain (measured on 0 to 100 mm VAS) or in function (assessed by the Lequesne Index). Since the arthroscopic outcome measures were chosen a priori as the primary efficacy variables in this trial, their results are also reported. Joint space width, measured in mm, was greater at 45 to 52 weeks postinjection, in the <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> group (WMD 1.10; 95% CI -0.01 to 2.21, P value 0.05). A statistically significant difference in favour of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK>, at 45 to 52 weeks postinjection, was found for both the arthroscopy overall assessment (0 to 100 mm VAS) (WMD -22.30; 95% CI -40.52 to -4.08, P value 0.02) and the SFA system score (0 to 100 mm VAS) (WMD -18.20; 95% CI -31.27 to -5.13, P value 0.006). Therefore, <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> was 14 to 22% more effective than conventional therapy in improving these arthroscopy parameters at 45 to 52 weeks postinjection. This trial also utilised a quality of life outcome measure, the Arthritis Impact Measurement Scales (AIMS), based on the total of 12 items. There was no statistically significant difference between groups.</P>
<P>The RevMan analysis differed from the Listrat publication (<LINK REF="STD-Listrat-1997" TYPE="STUDY">Listrat 1997</LINK>) analysis. The publication reported a statistically significant difference in favour of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> for AIMS (P value 0.047) at 45 to 52 weeks postinjection whereas the RevMan analysis detected no difference (P value 0.6).<BR/>
<I>
<BR/>Safety<BR/>
</I>
<BR/>Safety, as assessed by total withdrawals overall, was similar in the two groups. One patient in the <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> group withdrew because of lack of pain while two patients in the conventional therapy group withdrew: one because of osteotomy performed on the study knee and one because of relocation.</P>
<P>
<LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> versus homeopathic treatment</P>
<P>Readers are directed to the Zeel section for results based on a comparison of Zeel compositum and Hyalart (<LINK REF="STD-Nahler-1998" TYPE="STUDY">Nahler 1998</LINK>).<BR/>
<BR/>
<LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> plus exercise plus ultrasound versus exercise plus ultrasound</P>
<P>
<LINK REF="TBL-24" TYPE="TABLE">Table 24</LINK>
</P>
<P>
<I>Efficacy</I>
</P>
<P>One RCT included was a comparison of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> plus exercise plus ultrasound and exercise plus ultrasound (<LINK REF="STD-Huang-2005" TYPE="STUDY">Huang 2005</LINK>). There were no statistically significant differences between the two groups either at the end of the treatment or at the one-year follow-up for the following outcome measures: pain (0 to 10 cm VAS); range of motion (degrees); and the Lequesne Index at the end of treatment. Statistically significant differences were detected for the following outcome measures in favour of the <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> plus exercise plus ultrasound group: Lequesne Index at one-year follow-up (WMD -0.80; 95% CI -1.58 to -0.02, P value 0.04) (<LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> plus exercise plus ultrasound was 77% more effective than exercise plus ultrasound); and ambulation speed (metres per minute) both at the end of treatment and at one-year follow-up (WMD 5.40; 95% CI 3.99 to 6.81, P &lt; 0.00001 and WMD 5.00; 95% CI 1.58 to 8.42, P value 0.004) (<LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> plus exercise plus ultrasound was 39% more effective than exercise plus ultrasound).</P>
<P>
<I>Safety</I>
</P>
<P>There were no statistically significant differences in the total number of withdrawals either during treatment or overall.</P>
<P>
<LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> plus exercise plus ultrasound versus exercise</P>
<P>
<LINK REF="TBL-25" TYPE="TABLE">Table 25</LINK>
</P>
<P>
<I>Efficacy</I>
</P>
<P>One RCT included was a comparison of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> plus exercise plus ultrasound and exercise alone (<LINK REF="STD-Huang-2005" TYPE="STUDY">Huang 2005</LINK>). There were statistically significant differences between the two groups both at the end of treatment and at the one-year follow-up in favour of the <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> plus exercise plus ultrasound group for the following outcome measures: pain (0 to 10 cm VAS) (WMD -1.60; 95% CI -2.18 to -1.02, P &lt; 0.00001 and WMD -1.90; 95% CI -2.60 to -1.20, P &lt; 0.00001) (<LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> plus exercise plus ultrasound was 36 to 42% more effective than exercise); Lequesne Index (0 to 26) (WMD -2.10; 95% CI -2.50 to -1.70, P &lt; 0.00001 and WMD -3.30; 95% CI -4.19 to -2.41, P &lt; 0.00001) (<LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> plus exercise plus ultrasound was 42 to 66% more effective than exercise); range of motion (degrees) (WMD 12.00; 95% CI 4.51 to 19.49, P value 0.002 and WMD 14.00; 95% CI 5.76 to 22.24, P value 0.0009) (<LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> plus exercise plus ultrasound was 21 to 27% more effective than exercise); and ambulation speed (metres per minute) (WMD 12.70; 95% CI 10.60 to 14.80, P &lt; 0.00001 and WMD 14.00; 95% CI 10.57 to 17.43, P &lt; 0.00001) (<LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> plus exercise plus ultrasound was 18 to 20% more effective than exercise).</P>
<P>
<I>Safety</I>
</P>
<P>There were no statistically significant differences in the total number of withdrawals either during treatment or overall.</P>
<P>
<LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> plus exercise plus ultrasound versus control warmup exercises</P>
<P>
<LINK REF="TBL-26" TYPE="TABLE">Table 26</LINK>
</P>
<P>
<I>Efficacy</I>
</P>
<P>One RCT included was a comparison of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> plus exercise plus ultrasound and control warmup exercises (<LINK REF="STD-Huang-2005" TYPE="STUDY">Huang 2005</LINK>). There were statistically significant differences between the two groups both at the end of treatment and at the one-year follow-up in favour of the <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> plus exercise plus ultrasound group for the following outcome measures: pain (0 to 10 cm VAS) (WMD -2.40; 95% CI -3.08 to -1.72, P &lt; 0.00001 and WMD -4.60; 95% CI -5.32 to -3.88, P &lt; 0.00001) (<LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> plus exercise plus ultrasound was 46 to 89% more effective than control warmup exercises); Lequesne Index (0 to 26) (WMD -2.90; 95% CI -3.41 to -2.39, P &lt; 0.00001 and WMD -5.60; 95% CI -6.38 to -4.82, P &lt; 0.00001) (<LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> plus exercise plus ultrasound was 34 to 77% more effective than control warmup exercises); range of motion (degrees) (WMD 22; 95% CI 16.42 to 27.58, P &lt; 0.00001 and WMD 26; 95% CI 17.14 to 34.86, P &lt; 0.00001) (<LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> plus exercise plus ultrasound was 20 to 24% more effective than control warmup execises); and ambulation speed (metres per minute) (WMD 19.80; 95% CI 18.17 to 21.43, P &lt; 0.00001 and WMD 29.20; 95% CI 26.18 to 32.22, P &lt; 0.00001) (<LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> plus exercise plus ultrasound was 29 to 42% more effective than control warmup exercises).</P>
<P>
<I>Safety<BR/>
</I>
<BR/>There were no statistically significant differences in the total number of withdrawals either during treatment or overall.</P>
<P>
<LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> versus <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK>
</P>
<P>One RCT included was a schedule comparison of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> (<LINK REF="STD-Karras-2001" TYPE="STUDY">Karras 2001</LINK>).<BR/>
<I>
<BR/>Efficacy<BR/>
</I>
<BR/>There was no statistically significant difference in the number of patients assessing the response as satisfactory between the five injection <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> schedule (67%) and the three injection <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> schedule (79%).<BR/>
<I>
<BR/>Safety<BR/>
</I>
<BR/>From the abstract it was not possible to ascertain to which group the patients belonged that experienced three cases of local pain.</P>
<P>
<LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> versus other hyaluronans</P>
<P>Readers are directed to the Adant and Fermathron product results for comparisons of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> against these two HA products, respectively.</P>
<P>One RCT included was a comparison of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> and Hylan G-F 20 (<LINK REF="STD-Brown-2003" TYPE="STUDY">Brown 2003</LINK>). This trial was discontinued on ethical grounds due to the frequency of acute inflammatory reactions with Hylan G-F 20 (21%) compared to <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> (0%); this difference was not statistically significant. No efficacy data were extracted from the abstract.<BR/>
<I>
<B>
<BR/>Product - Hylan G-F 20 (Synvisc)<BR/>
</B>
<BR/>Description of studies<BR/>
</I>
<BR/>Twenty-four RCTs were included (<LINK REF="STD-Adams-1995" TYPE="STUDY">Adams 1995</LINK>; <LINK REF="STD-Atamaz-2005" TYPE="STUDY">Atamaz 2005</LINK>; <LINK REF="STD-Auerbach-2002" TYPE="STUDY">Auerbach 2002</LINK>; <LINK REF="STD-Bayramoglu-2003" TYPE="STUDY">Bayramoglu 2003</LINK>; <LINK REF="STD-Brown-2003" TYPE="STUDY">Brown 2003</LINK>; <LINK REF="STD-Caborn-2004" TYPE="STUDY">Caborn 2004</LINK>; <LINK REF="STD-Cubukcu-2004" TYPE="STUDY">Cubukcu 2004</LINK> (abstract - <LINK REF="STD-Ardic-2001" TYPE="STUDY">Ardic 2001</LINK>); <LINK REF="STD-Dickson-2001" TYPE="STUDY">Dickson 2001</LINK>; <LINK REF="STD-Groppa-2001" TYPE="STUDY">Groppa 2001</LINK>; <LINK REF="STD-Kahan-2003a" TYPE="STUDY">Kahan 2003a</LINK>; <LINK REF="STD-Karatay-2004" TYPE="STUDY">Karatay 2004</LINK>; <LINK REF="STD-Karatosun-2005" TYPE="STUDY">Karatosun 2005</LINK>; <LINK REF="STD-Karatosun-2005a" TYPE="STUDY">Karatosun 2005a</LINK>; <LINK REF="STD-Karlsson-2002" TYPE="STUDY">Karlsson 2002</LINK>; <LINK REF="STD-Kotevoglu-2005" TYPE="STUDY">Kotevoglu 2005</LINK>; <LINK REF="STD-Leopold-2003" TYPE="STUDY">Leopold 2003</LINK>; <LINK REF="STD-Moreland-1993" TYPE="STUDY">Moreland 1993</LINK>; <LINK REF="STD-Raynauld-2002" TYPE="STUDY">Raynauld 2002</LINK>; <LINK REF="STD-Rejaili-2005" TYPE="STUDY">Rejaili 2005</LINK>; <LINK REF="STD-Scale-1994a-_x0028_2-inj_x0029_" TYPE="STUDY">Scale 1994a (2 inj)</LINK>; <LINK REF="STD-Scale-1994b-_x0028_3-inj_x0029_" TYPE="STUDY">Scale 1994b (3 inj)</LINK>; <LINK REF="STD-Kirchner--2005" TYPE="STUDY">Kirchner 2005</LINK> (abstract - <LINK REF="STD-Thompson-2002" TYPE="STUDY">Thompson 2002</LINK>); <LINK REF="STD-Wobig-1998" TYPE="STUDY">Wobig 1998</LINK>; <LINK REF="STD-Wobig-1999" TYPE="STUDY">Wobig 1999</LINK>). Considering only the 17 trials in which Hylan G-F 20 was designated the experimental intervention, the Jadad score ranged from 1 to 5 with an average quality of 3. One trial scored 5 (<LINK REF="STD-Moreland-1993" TYPE="STUDY">Moreland 1993</LINK>), five scored 4 (<LINK REF="STD-Dickson-2001" TYPE="STUDY">Dickson 2001</LINK>; <LINK REF="STD-Scale-1994a-_x0028_2-inj_x0029_" TYPE="STUDY">Scale 1994a (2 inj)</LINK>; <LINK REF="STD-Scale-1994b-_x0028_3-inj_x0029_" TYPE="STUDY">Scale 1994b (3 inj)</LINK>; <LINK REF="STD-Wobig-1998" TYPE="STUDY">Wobig 1998</LINK>; <LINK REF="STD-Wobig-1999" TYPE="STUDY">Wobig 1999</LINK>), five scored 3 (<LINK REF="STD-Adams-1995" TYPE="STUDY">Adams 1995</LINK>; <LINK REF="STD-Kahan-2003a" TYPE="STUDY">Kahan 2003a</LINK>; <LINK REF="STD-Karatosun-2005" TYPE="STUDY">Karatosun 2005</LINK>; <LINK REF="STD-Leopold-2003" TYPE="STUDY">Leopold 2003</LINK>; <LINK REF="STD-Raynauld-2002" TYPE="STUDY">Raynauld 2002</LINK>), five scored 2 (<LINK REF="STD-Atamaz-2005" TYPE="STUDY">Atamaz 2005</LINK>; <LINK REF="STD-Auerbach-2002" TYPE="STUDY">Auerbach 2002</LINK>; <LINK REF="STD-Caborn-2004" TYPE="STUDY">Caborn 2004</LINK>; <LINK REF="STD-Cubukcu-2004" TYPE="STUDY">Cubukcu 2004</LINK>; <LINK REF="STD-Rejaili-2005" TYPE="STUDY">Rejaili 2005</LINK>), and one scored 1 (<LINK REF="STD-Groppa-2001" TYPE="STUDY">Groppa 2001</LINK>). Allocation concealment was adequate in nine trials and inadequate (not reported) in eight trials (<LINK REF="STD-Atamaz-2005" TYPE="STUDY">Atamaz 2005</LINK>; <LINK REF="STD-Auerbach-2002" TYPE="STUDY">Auerbach 2002</LINK>; <LINK REF="STD-Caborn-2004" TYPE="STUDY">Caborn 2004</LINK>; <LINK REF="STD-Cubukcu-2004" TYPE="STUDY">Cubukcu 2004</LINK>; <LINK REF="STD-Dickson-2001" TYPE="STUDY">Dickson 2001</LINK>; <LINK REF="STD-Groppa-2001" TYPE="STUDY">Groppa 2001</LINK>; <LINK REF="STD-Karatosun-2005" TYPE="STUDY">Karatosun 2005</LINK>; <LINK REF="STD-Rejaili-2005" TYPE="STUDY">Rejaili 2005</LINK>).</P>
<P>Hylan G-F 20 has been compared against IA control treatment (<LINK REF="STD-Ardic-2001" TYPE="STUDY">Ardic 2001</LINK>; <LINK REF="STD-Cubukcu-2004" TYPE="STUDY">Cubukcu 2004</LINK>; <LINK REF="STD-Dickson-2001" TYPE="STUDY">Dickson 2001</LINK>; <LINK REF="STD-Groppa-2001" TYPE="STUDY">Groppa 2001</LINK>; <LINK REF="STD-Karlsson-2002b-_x0028_SvP_x0029_" TYPE="STUDY">Karlsson 2002b (SvP)</LINK>; <LINK REF="STD-Kotevoglu-2005" TYPE="STUDY">Kotevoglu 2005</LINK>; <LINK REF="STD-Moreland-1993" TYPE="STUDY">Moreland 1993</LINK>; <LINK REF="STD-Scale-1994a-_x0028_2-inj_x0029_" TYPE="STUDY">Scale 1994a (2 inj)</LINK>; <LINK REF="STD-Scale-1994b-_x0028_3-inj_x0029_" TYPE="STUDY">Scale 1994b (3 inj)</LINK>; <LINK REF="STD-Wobig-1998" TYPE="STUDY">Wobig 1998</LINK>; <LINK REF="STD-Wobig-1999c-_x0028_NEhyl_x0029_" TYPE="STUDY">Wobig 1999c (NEhyl)</LINK>), IA corticosteroid (<LINK REF="STD-Caborn-2004" TYPE="STUDY">Caborn 2004</LINK>; <LINK REF="STD-Leopold-2003" TYPE="STUDY">Leopold 2003</LINK>), nonsteroidal anti-inflammatory drug (<LINK REF="STD-Adams-1995" TYPE="STUDY">Adams 1995</LINK>; <LINK REF="STD-Dickson-2001" TYPE="STUDY">Dickson 2001</LINK>), IA gaseous oxygen (<LINK REF="STD-Auerbach-2002" TYPE="STUDY">Auerbach 2002</LINK>), physiotherapy (<LINK REF="STD-Bayramoglu-2003" TYPE="STUDY">Bayramoglu 2003</LINK>), appropriate care (<LINK REF="STD-Kahan-2003a" TYPE="STUDY">Kahan 2003a</LINK>; <LINK REF="STD-Raynauld-2002" TYPE="STUDY">Raynauld 2002</LINK>), exercise programme (<LINK REF="STD-Karatosun-2005" TYPE="STUDY">Karatosun 2005</LINK>), in combination with arthroscopy (<LINK REF="STD-Rejaili-2005" TYPE="STUDY">Rejaili 2005</LINK>), and hyaluronan (<LINK REF="STD-Atamaz-2005" TYPE="STUDY">Atamaz 2005</LINK>; <LINK REF="STD-Bayramoglu-2003" TYPE="STUDY">Bayramoglu 2003</LINK>; <LINK REF="STD-Karatay-2004" TYPE="STUDY">Karatay 2004</LINK>; <LINK REF="STD-Karatosun-2005a" TYPE="STUDY">Karatosun 2005a</LINK>; <LINK REF="STD-Kotevoglu-2005" TYPE="STUDY">Kotevoglu 2005</LINK> [<LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK>]; <LINK REF="STD-Brown-2003" TYPE="STUDY">Brown 2003</LINK> [<LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK>]; <LINK REF="STD-Karlsson-2002c-_x0028_AvS_x0029_" TYPE="STUDY">Karlsson 2002c (AvS)</LINK> [Artzal]; <LINK REF="STD-Kirchner-2005" TYPE="STUDY">Kirchner 2005</LINK> (<LINK REF="STD-Thompson-2002" TYPE="STUDY">Thompson 2002</LINK>) [BioHy (Arthrease, Euflexxa, Nuflexxa)]; <LINK REF="STD-Wobig-1999" TYPE="STUDY">Wobig 1999</LINK> [Artz, Healon]). The draft manuscript for the abstract presented by Moreland et al. (<LINK REF="STD-Moreland-1993" TYPE="STUDY">Moreland 1993</LINK>) was kindly provided by Biomatrix, Inc. as were the Pre-Market Approval (PMA) data for the studies by Adams et al. (<LINK REF="STD-Adams-1995" TYPE="STUDY">Adams 1995</LINK>), Scale et al. (<LINK REF="STD-Scale-1994a-_x0028_2-inj_x0029_" TYPE="STUDY">Scale 1994a (2 inj)</LINK>; <LINK REF="STD-Scale-1994b-_x0028_3-inj_x0029_" TYPE="STUDY">Scale 1994b (3 inj)</LINK>), and Wobig et al. (<LINK REF="STD-Wobig-1998" TYPE="STUDY">Wobig 1998</LINK>; <LINK REF="STD-Wobig-1999" TYPE="STUDY">Wobig 1999</LINK>). The trials were completed in nine countries: Brazil (<LINK REF="STD-Rejaili-2005" TYPE="STUDY">Rejaili 2005</LINK>), Canada (<LINK REF="STD-Adams-1995" TYPE="STUDY">Adams 1995</LINK>; <LINK REF="STD-Raynauld-2002" TYPE="STUDY">Raynauld 2002</LINK>), England (<LINK REF="STD-Dickson-2001" TYPE="STUDY">Dickson 2001</LINK>), France (<LINK REF="STD-Kahan-2003a" TYPE="STUDY">Kahan 2003a</LINK>), Germany (<LINK REF="STD-Auerbach-2002" TYPE="STUDY">Auerbach 2002</LINK>; <LINK REF="STD-Scale-1994a-_x0028_2-inj_x0029_" TYPE="STUDY">Scale 1994a (2 inj)</LINK>; <LINK REF="STD-Scale-1994b-_x0028_3-inj_x0029_" TYPE="STUDY">Scale 1994b (3 inj)</LINK>; <LINK REF="STD-Wobig-1998" TYPE="STUDY">Wobig 1998</LINK>; <LINK REF="STD-Wobig-1999" TYPE="STUDY">Wobig 1999</LINK>), Republic of Moldova (<LINK REF="STD-Groppa-2001" TYPE="STUDY">Groppa 2001</LINK>), Scotland (<LINK REF="STD-Dickson-2001" TYPE="STUDY">Dickson 2001</LINK>), Turkey (<LINK REF="STD-Atamaz-2005" TYPE="STUDY">Atamaz 2005</LINK>; <LINK REF="STD-Cubukcu-2004" TYPE="STUDY">Cubukcu 2004</LINK>; <LINK REF="STD-Karatosun-2005" TYPE="STUDY">Karatosun 2005</LINK>), and the United States (<LINK REF="STD-Caborn-2004" TYPE="STUDY">Caborn 2004</LINK>; <LINK REF="STD-Leopold-2003" TYPE="STUDY">Leopold 2003</LINK>; <LINK REF="STD-Moreland-1993" TYPE="STUDY">Moreland 1993</LINK>). They were published over a twelve-year period: 1993 through 2005. Sample size per group varied from 10 (<LINK REF="STD-Cubukcu-2004" TYPE="STUDY">Cubukcu 2004</LINK>; <LINK REF="STD-Rejaili-2005" TYPE="STUDY">Rejaili 2005</LINK>) to 253 (<LINK REF="STD-Kahan-2003a" TYPE="STUDY">Kahan 2003a</LINK>) while sample size per trial varied from 20 to 518. One trial was eight weeks in duration (<LINK REF="STD-Cubukcu-2004" TYPE="STUDY">Cubukcu 2004</LINK> (<LINK REF="STD-Ardic-2001" TYPE="STUDY">Ardic 2001</LINK>), two trials were twelve weeks in duration (<LINK REF="STD-Dickson-2001" TYPE="STUDY">Dickson 2001</LINK>; <LINK REF="STD-Wobig-1999" TYPE="STUDY">Wobig 1999</LINK>), four trials were 12 weeks in duration with a telephone interview at 26 weeks (<LINK REF="STD-Adams-1995" TYPE="STUDY">Adams 1995</LINK>; <LINK REF="STD-Scale-1994a-_x0028_2-inj_x0029_" TYPE="STUDY">Scale 1994a (2 inj)</LINK>; <LINK REF="STD-Scale-1994b-_x0028_3-inj_x0029_" TYPE="STUDY">Scale 1994b (3 inj)</LINK>; <LINK REF="STD-Wobig-1998" TYPE="STUDY">Wobig 1998</LINK>), two trials were 24 weeks in duration (<LINK REF="STD-Leopold-2003" TYPE="STUDY">Leopold 2003</LINK>; <LINK REF="STD-Rejaili-2005" TYPE="STUDY">Rejaili 2005</LINK>), one trial was 26 weeks in duration (<LINK REF="STD-Caborn-2004" TYPE="STUDY">Caborn 2004</LINK>), one trial was 34 weeks in duration (<LINK REF="STD-Moreland-1993" TYPE="STUDY">Moreland 1993</LINK>), one trial was 36 weeks in duration (<LINK REF="STD-Kahan-2003a" TYPE="STUDY">Kahan 2003a</LINK>), four trials were 52 weeks in duration (<LINK REF="STD-Atamaz-2005" TYPE="STUDY">Atamaz 2005</LINK>; <LINK REF="STD-Auerbach-2002" TYPE="STUDY">Auerbach 2002</LINK>; <LINK REF="STD-Groppa-2001" TYPE="STUDY">Groppa 2001</LINK>; <LINK REF="STD-Raynauld-2002" TYPE="STUDY">Raynauld 2002</LINK>), and one trial was 18 months in duration (<LINK REF="STD-Karatosun-2005" TYPE="STUDY">Karatosun 2005</LINK>).</P>
<P>For the six trials that were included in the PMA P940015 (<LINK REF="STD-Adams-1995" TYPE="STUDY">Adams 1995</LINK>; <LINK REF="STD-Moreland-1993" TYPE="STUDY">Moreland 1993</LINK>; <LINK REF="STD-Scale-1994a-_x0028_2-inj_x0029_" TYPE="STUDY">Scale 1994a (2 inj)</LINK>; <LINK REF="STD-Scale-1994b-_x0028_3-inj_x0029_" TYPE="STUDY">Scale 1994b (3 inj)</LINK>; <LINK REF="STD-Wobig-1998" TYPE="STUDY">Wobig 1998</LINK>; <LINK REF="STD-Wobig-1999" TYPE="STUDY">Wobig 1999</LINK>), control and Hylan G-F 20 treatments were prepared in syringes that had identical appearances and which were coded only by random numbers. All subjects participating in these trials received arthrocentesis with removal of effusion if present. All IA procedures were performed in an identical manner for treatment and control study groups in these trials. A screen, blinding the patient from the procedure, was utilised in four trials (<LINK REF="STD-Adams-1995" TYPE="STUDY">Adams 1995</LINK>; <LINK REF="STD-Dickson-2001" TYPE="STUDY">Dickson 2001</LINK>; <LINK REF="STD-Moreland-1993" TYPE="STUDY">Moreland 1993</LINK>; <LINK REF="STD-Wobig-1998" TYPE="STUDY">Wobig 1998</LINK>).</P>
<P>Twenty-six studies were excluded (<LINK REF="STD-Bell-1999" TYPE="STUDY">Bell 1999</LINK>; <LINK REF="STD-Bellamy-2000" TYPE="STUDY">Bellamy 2000</LINK>; <LINK REF="STD-Bruce-2004" TYPE="STUDY">Bruce 2004</LINK>; <LINK REF="STD-Chhabra-2000" TYPE="STUDY">Chhabra 2000</LINK>; <LINK REF="STD-Clarke-2001" TYPE="STUDY">Clarke 2001</LINK>; <LINK REF="STD-Evanich-2001" TYPE="STUDY">Evanich 2001</LINK>; <LINK REF="STD-Goorman-2000" TYPE="STUDY">Goorman 2000</LINK>; <LINK REF="STD-Ines-2002" TYPE="STUDY">Ines 2002</LINK>; <LINK REF="STD-Koyuncu-2003" TYPE="STUDY">Koyuncu 2003</LINK>; <LINK REF="STD-Legre-2001" TYPE="STUDY">Legre 2001</LINK>; <LINK REF="STD-Lee-2004" TYPE="STUDY">Lee 2004</LINK>; <LINK REF="STD-Lussier-1996" TYPE="STUDY">Lussier 1996</LINK>; <LINK REF="STD-Magobotha-2001" TYPE="STUDY">Magobotha 2001</LINK>; <LINK REF="STD-Mathieu-2001" TYPE="STUDY">Mathieu 2001</LINK>; <LINK REF="STD-Miller-1999" TYPE="STUDY">Miller 1999</LINK>; <LINK REF="STD-Myburgh-2001" TYPE="STUDY">Myburgh 2001</LINK>; <LINK REF="STD-Olszynski-2002" TYPE="STUDY">Olszynski 2002</LINK>; <LINK REF="STD-Sripada-1999" TYPE="STUDY">Sripada 1999</LINK>; <LINK REF="STD-Stambuk-2001" TYPE="STUDY">Stambuk 2001</LINK>; <LINK REF="STD-Torrance-2002" TYPE="STUDY">Torrance 2002</LINK>; <LINK REF="STD-Vad-2000" TYPE="STUDY">Vad 2000</LINK>; <LINK REF="STD-Waddell-2001a" TYPE="STUDY">Waddell 2001a</LINK>; <LINK REF="STD-Waddell-2001b" TYPE="STUDY">Waddell 2001b</LINK>; <LINK REF="STD-Weiss-1999" TYPE="STUDY">Weiss 1999</LINK>; <LINK REF="STD-Wobig-1999d" TYPE="STUDY">Wobig 1999d</LINK>; <LINK REF="STD-Wulwik-2001" TYPE="STUDY">Wulwik 2001</LINK>). Two trials are awaiting assessment (<LINK REF="STD-Russell-2003" TYPE="STUDY">Russell 2003</LINK> (<LINK REF="STD-Talwalkar-2005" TYPE="STUDY">Talwalkar 2005</LINK>); <LINK REF="STD-Shariati-2001" TYPE="STUDY">Shariati 2001</LINK>). These trials have been published only as abstracts with no extractable data, and at the closure of the database for this review no full length manuscripts have been published.</P>
<P>Adams et al. reported a 26-week, parallel-group RCT performed at six centres in Canada comparing three weekly injections of Hylan G-F 20 to either NSAID continuation plus three weekly control arthrocenteses or NSAID continuation plus three weekly injections of Hylan G-F 20 in 102 patients with OA of the knee (<LINK REF="STD-Adams-1995" TYPE="STUDY">Adams 1995</LINK>). All groups showed significant improvement from baseline at 12 weeks but did not differ from each other. The two groups receiving Hylan G-F 20 were significantly better than the NSAID alone group at Week 26.</P>
<P>Several design issues are noted for the Adams et al. RCT (<LINK REF="STD-Adams-1995" TYPE="STUDY">Adams 1995</LINK>). This trial was designed to evaluate viscosupplementation with Hylan G-F 20 as a replacement for continuous NSAID therapy. There was no washout period. The concomitant use of acetaminophen for analgesia was permitted and recorded by pill counts. However, usage was not reported since it was documented in different formats by the treating physicians and could not be standardised into a single format for purposes of uniform analysis. The resumption of NSAID between weeks 12 and 26 was reported. 55.6% of patients in the Hylan G-F 20 group only resumed taking NSAID compared to 84.4% in the NSAID plus Hylan G-F 20 group and 96.8% in the NSAID group. Fifteen per cent of the included patients presented with effusion at the first visit. The Hylan G-F 20 only group may not have been blinded since they were instructed to discontinue their NSAID. The authors addressed this concern in the publication by commenting that, "if incomplete blinding introduced a bias, it would be against the Hylan G-F 20-only group in that patients recognized that they were discontinuing an active medication, and consequently may have expected their condition to worsen". The method of assessment at 26 weeks was by telephone follow-up which differed from that of baseline (i.e. office visit). A subsequent study showed that there was no significant difference in results obtained by telephone compared to office visits for the WOMAC 3.0 Osteoarthritis Index (<LINK REF="REF-Bellamy-2002" TYPE="REFERENCE">Bellamy 2002</LINK>).</P>
<P>Atamaz et al. reported a one-year, parallel-group (three-arm), single-blind RCT performed at a single centre in Turkey comparing three weekly injections followed by one additional injection at six months of Hylan G-F 20 (Synvisc) or hyaluronan (Orthovisc) to a physical therapy programme five times a week for three weeks with a series of infrared, short-wave diathermy pulsed patterns and interferential therapy in 85 patients with OA of the knee (<LINK REF="STD-Atamaz-2005" TYPE="STUDY">Atamaz 2005</LINK>). The authors reported significant improvement in all variables measured in both groups during the follow-up except for range of motion and the WOMAC OA Index stiffness subscale. Patients in the physical therapy group had greater improvement in pain (at rest, at night, SF-36) and SF-36 social functioning. This improvement was not different between the physical therapy group and the Hylan G-F 20 group, but the physical therapy group was superior to the Orthovisc group for non-activity-related pain and functional performance. Based on subgroup analyses, the decrease in pain on touch and WOMAC OA Index physical function was greater in the Hylan G-F 20 group compared to the Orthovisc group. With respect to safety, the authors reported that no serious local or systemic adverse events were observed following injections. Dr. F. Atamaz kindly provided a copy of the manuscript which is in press.</P>
<P>This trial used repeat injection but only one injection at six months. Although the trial was single-blind, the same physicians administered the injections and the same observer performed clinical assessments. Of the 85 patients enrolled, three did not meet the inclusion criteria and were not included in the analyses. Local reactions consisting of mild swelling, warmth and pain at the injection site were reported by one patient in the Synvisc group and three patients in the Orthovisc group, but all four patients had relief within a few days after application of cold packs. Paracetamol up to a maximum of 2 grams daily was permitted during the trial. Dr. F. Atamaz kindly provided a manuscript of this trial which has been accepted for publication in Rheumatology International.</P>
<P>Auerbach et al. reported a one-year, parallel-group RCT performed at a single centre in Germany comparing three weekly injections of Hylan G-F 20 plus an exercise programme to five weekly IA injections of gaseous oxygen (three days per week) plus an exercise programme in 111 patients with OA of the knee (<LINK REF="STD-Auerbach-2002" TYPE="STUDY">Auerbach 2002</LINK>; <LINK REF="STD-Auerbach-2002a" TYPE="STUDY">Auerbach 2002a</LINK>). Both treatments were effective in relieving pain and improving joint function. Pain relief by Hylan G-F 20 and improvement in function by oxygen treatment were shown for more severe levels of cartilage damage.</P>
<P>The Auerbach trial was one of the few trials not published in English. Both the thesis (<LINK REF="STD-Auerbach-2002a" TYPE="STUDY">Auerbach 2002a</LINK>) and the journal article (<LINK REF="STD-Auerbach-2002" TYPE="STUDY">Auerbach 2002</LINK>) were published in German. An English abstract was provided in the journal article. It was the only trial in which HA was compared to IA injection of gaseous oxygen. The authors studied the relation between treatment effect and severity of cartilage damage.</P>
<P>Caborn et al. reported a 26-week, parallel group, single-blind RCT performed at 14 centres in the United States comparing three weekly injections of Hylan G-F 20 to one IA injection of triamcinolone hexacetonide (Aristospan) in 218 patients with OA of the knee (<LINK REF="STD-Caborn-2003" TYPE="STUDY">Caborn 2003</LINK>; <LINK REF="STD-Caborn-2004" TYPE="STUDY">Caborn 2004</LINK>; <LINK REF="STD-Lanzer-2002" TYPE="STUDY">Lanzer 2002</LINK>). Treatment with Hylan G-F 20 resulted in a longer duration of effect than triamcinolone hexacetonide. Both treatments were well tolerated with 10% of patients in each group reporting an adverse event that resulted in withdrawal from the trial.</P>
<P>The Caborn et al. trial was single-blind and details regarding the method of randomisation were not published (<LINK REF="STD-Caborn-2004" TYPE="STUDY">Caborn 2004</LINK>). The triamcinolone hexacetonide group received only one injection compared to the three injections administered to the Hylan G-F 20 group. Analgesic and NSAID usage were monitored throughout this trial. Patients with effusion of greater than 10 ml were excluded. Almost 30% of each treatment group had severe radiological ratings while approximately 60% in each group had moderate ratings.</P>
<P>Cubukcu et al. reported an eight-week, placebo-controlled RCT performed at one centre in Turkey comparing three weekly injections of Hylan G-F 20 to three weekly injections of saline in 30 patients with OA of the knee (<LINK REF="STD-Cubukcu-2004" TYPE="STUDY">Cubukcu 2004</LINK>; <LINK REF="STD-Ardic-2001" TYPE="STUDY">Ardic 2001</LINK> (abstract)). The authors reported a statistically significant between-group difference at the end of the trial (i.e. eight weeks) for WOMAC pain, WOMAC physical function, night pain, rest pain, walking pain, need for paracetamol and evaluation of treatment by the patient. With respect to safety, no patients dropped out of the study and no systemic adverse events were reported. One patient complained of mild transient local pain in the injected area a day after the first injection. Details regarding methods of blinding and randomisation were not reported.</P>
<P>No explanation was given for the unequal group allocation (i.e. 2:1 patients or 3:1 knees). A major limitation of this study is the small sample size particularly in the placebo group.</P>
<P>Dickson et al. reported a 12-week, parallel-group, double-blind RCT performed at 18 centres in England and Scotland comparing three weekly injections of Hylan G-F 20 and dummy capsules taken once daily to either Diclofenac retard 100 mg taken once daily and three weekly arthrocenteses or dummy capsules taken once daily and three weekly arthrocenteses in 165 patients with OA of the knee (<LINK REF="STD-Dickson-2001" TYPE="STUDY">Dickson 2001</LINK>). Patients, completing the 12-week study, could enter an open-label study in which they received treatment with up to four additional courses of Hylan G-F 20 over a one-year period. Hylan G-F 20 was significantly better than either diclofenac or arthrocentesis in reducing WOMAC pain. The diclofenac group had significantly more total and gastrointestinal adverse events than the Hylan G-F 20 or control groups.</P>
<P>The Dickson et al. trial was one of the few trials conducted in general practice (<LINK REF="STD-Dickson-2001" TYPE="STUDY">Dickson 2001</LINK>). To ensure blinding, all three arms of the trial received arthrocentesis. The diclofenac sodium dosage of 100 mg daily may be considered by some as subtherapeutic but the Diclomax Retard 1993 product label indicated this to be the recommended adult dosage. The mean number of paracetamol tablets taken for analgesic rescue medication (3000 mg daily permitted) was published.</P>
<P>Groppa and Moshneaga reported a one-year, blind CT performed at a single centre in The Republic of Moldova comparing three weekly injections of Hylan G-F 20 to three weekly injections of placebo in 25 patients with OA of knee (<LINK REF="STD-Groppa-2001" TYPE="STUDY">Groppa 2001</LINK>). Courses were repeated at six and 12 months. After the first course, one-third of the patients treated with Hylan G-F 20 had decreased pain and improved joint function compared to none in the placebo group. After three courses, 87% of the Hylan G-F 20 patients had moderate or very good effect compared to only 20% of the patients in the control group who had moderate effect. No safety data were reported in the abstract.</P>
<P>The Groppa trial randomised a sample size of 25 patients (<LINK REF="STD-Groppa-2001" TYPE="STUDY">Groppa 2001</LINK>). However, the control group was matched by gender, disease duration and x-ray date. The study was designed to address the important issue of repeat treatment with a second and third course repeated at six and 12 months, respectively. Radiography, ultrasonography and scintigraphy with Te 99m were all utilised in evaluation.</P>
<P>Kahan et al. reported a nine-month, open-label, parallel-group, RCT performed with 81 rheumatologists (21 hospital based, 60 office based) in France comparing three weekly injections of Hylan G-F 20 to conventional treatment in 518 patients with OA of the knee (<LINK REF="STD-Kahan-2003" TYPE="STUDY">Kahan 2003</LINK> [article published in French]; <LINK REF="STD-Kahan-2003a" TYPE="STUDY">Kahan 2003a</LINK>). The authors reported that Hylan G-F 20 viscosupplementation was more effective than conventional treatment at no additional cost.</P>
<P>The Kahan et al. trial provided medicoeconomic data on viscosupplementation for OA (<LINK REF="STD-Kahan-2003a" TYPE="STUDY">Kahan 2003a</LINK>; <LINK REF="STD-Kahan-2003" TYPE="STUDY">Kahan 2003</LINK>). The design was very similar to the Raynauld et al. trial (<LINK REF="STD-Raynauld-2002" TYPE="STUDY">Raynauld 2002</LINK>). The study was completed under conditions of actual practice.</P>
<P>Karatosun et al. reported an eighteen-month, single-blind, parallel group, RCT performed at a single centre in Turkey comparing three weekly injections of Hylan G-F 20 to an exercise programme that included a series of progressive simple range of motion and resistance exercises for six weeks (<LINK REF="STD-Karatosun-2005" TYPE="STUDY">Karatosun 2005</LINK>). The authors reported no statistically significant differences between the two groups. However, both groups had improved Hospital for Special Surgery scores at the end of the trial. While all patients in the exercise group completed the trial, 21 patients in the Hylan G-F 20 did not. With respect to safety, no adverse events were reported that were related to ia injection of Hylan G-F 20.</P>
<P>This trial enrolled only patients with Kellgren-Lawrence Grade III knee OA. All radiographs were evaluated by two of the authors and concensus had to be reached in order for a patient to be enrolled in the trial. In addition, 91% of the patients had bilateral knee OA. A blinded physical therapist completed patient evaluations. Approximately 60 per cent of the Hylan G-F 20 patients completed the trial. The authors acknowledged the "relatively high" drop out rate, noting that these patients had statistically significant improvement from baseline. They suggested that the reasons for seeking other forms of treatment in this group might have been due to their increased satisfaction levels. Dr. Vasfi Karatosun kindly provided means and standard deviations for the reported outcome measures.</P>
<P>Leopold et al. reported a six-month, single-blind, parallel-group, RCT performed at a single centre in the United States comparing three weekly injections of Hylan G-F 20 to one injection of betamethasone sodium phosphate-betamethasone acetate (Celestone Soluspan), which could be repeated during the study, in 100 patients with OA of the knee (<LINK REF="STD-Leopold-2003" TYPE="STUDY">Leopold 2003</LINK>; <LINK REF="STD-Redd-2003" TYPE="STUDY">Redd 2003</LINK>). No differences in pain or function were found between the two groups at the six months follow-up. Neither treatment worked well in females. One patient in the Hylan G-F 20 group withdrew because of an acute local reaction. One-fifth of the study population withdrew because of a lack of treatment efficacy. Only safety data have been extracted from this trial. Since the outcome variables had results that were not normally distributed, nonparametric statistical methods were used to analyze the data (e.g. change in median outcomes scores).</P>
<P>The Leopold et al. trial was an independent trial not funded by the manufacturer of the hyaluronate-based product under study (<LINK REF="STD-Leopold-2003" TYPE="STUDY">Leopold 2003</LINK>). The injection procedure was standardised by: 1) patient was in the supine position, 2) the injection was made superolaterally into the suprapatellar notch, and 3) patients were encouraged to refrain from strenuous activity for a day. However, effusions were aspirated in the HA group whereas they were not in the corticosteroid group. In addition, patients in the corticosteroid group were permitted to have one more injection any time during the study. The authors chose not to use the Ahlback radiographic grading system, "because three of the four stages include knees with a completely obliterated joint space". This was the only trial to find a gender difference in treatment response.</P>
<P>Moreland et al. reported a 34-week, parallel-group, double-blind RCT performed at five centres in the United States comparing three weekly injections of Hylan G-F 20 to three weekly arthrocenteses in 94 patients with OA of the knee (<LINK REF="STD-Moreland-1993" TYPE="STUDY">Moreland 1993</LINK>). This trial had two phases. Phase I lasted 10 weeks, after which patients could enter Phase II in which all patients received treatment with Hylan G-F 20. For this analysis, the Phase II data were not included because, although patient blinding was maintained during this Phase, treatment was not randomised. Analyses were based on the week eight evaluation endpoint which was two weeks after the third injection in Phase I. A statistically significant difference, in favour of Hylan G-F 20, was detected in overall pain only in a predefined 'flare' population but not in the 'intent-to-treat' population. During the two phases approximately 7% of patients receiving Hylan G-F 20 discontinued treatment due to local adverse reactions (pain or swelling) in the injected knee.</P>
<P>The Moreland et al. trial was only published as an abstract but an in-house unpublished manuscript allowed this trial to be included in the review (<LINK REF="STD-Moreland-1993" TYPE="STUDY">Moreland 1993</LINK>). This trial examined the "clinimetric utility" of identifying a flare population. Despite a four-week washout of all anti-inflammatory medication, only 30% of patients demonstrated a flare in pain symptoms. However, patients were randomised regardless of flare criteria. The authors noted that the final evaluation for Phase I of the trial was only two weeks after completing treatment. This may have minimised any between-group differences, and could have maximised the short-term effect of arthrocentesis. Acetaminophen usage was permitted throughout the entire trial duration but there was no significant difference between the groups in daily usage.</P>
<P>Raynauld et al. reported a one-year, open-label, parallel-group, RCT performed at 14 centres in Canada comparing appropriate care with Hylan G-F 20 (AC + H) to appropriate care without Hylan G-F 20 (AC) in 255 patients with OA of the knee (<LINK REF="STD-Raynauld-2002" TYPE="STUDY">Raynauld 2002</LINK>; <LINK REF="REF-Bellamy-2005a" TYPE="REFERENCE">Bellamy 2005a</LINK>; <LINK REF="REF-Bellamy-2005b" TYPE="REFERENCE">Bellamy 2005b</LINK>; <LINK REF="REF-Hamburger-2005" TYPE="REFERENCE">Hamburger 2005</LINK>; <LINK REF="REF-Raynauld-2005" TYPE="REFERENCE">Raynauld 2005</LINK>; <LINK REF="REF-Raynauld-2005a" TYPE="REFERENCE">Raynauld 2005a</LINK>). For all the primary and secondary effectiveness outcome measures the AC + H group was superior to the AC group. Safety differences favoured the AC + H group.</P>
<P>The Raynauld et al. trial was an effectiveness study that also included an economic evaluation (<LINK REF="STD-Torrance-2002" TYPE="STUDY">Torrance 2002</LINK>). The study was strengthened by the expertise of an independent, academic Steering Committee. This 'pragmatic' study operated under 'a real world scenario'. The trial highlighted the difference between radiologic grading completed by a central reader and that done by site investigators. Although Kellgren and Lawrence Grade 4 was an entry exclusion criteria, 20% of the appropriate care plus Hylan G-F 20 group and 33% of the appropriate care without Hylan G-F 20 group were rated as Grade 4 by the central reader. However, when Grade 4 was used as a covariate there was no significant difference in the analysis results. Repeat treatment was permitted to either or both knees as required during the trial.</P>
<P>The Rejaili et al. trial was a 24-week, parallel-group RCT performed at a single centre in Brazil comparing arthroscopy (articular lavage and debridement) followed by three weekly postoperative injections of Hylan G-F 20 to arthroscopy alone in 20 patients with OA of the knee (<LINK REF="STD-Rejaili-2005" TYPE="STUDY">Rejaili 2005</LINK>). The authors reported that statistically significant differences were found in favour of the group receiving Hylan G-F 20 postoperatively following arthroscopy for pain during rest at night, pain during movement with a 10% overload of the corporal weight, reduction of pain during the most painful movements of the knee, and in the number of potassium diclofenac tablets ingested daily for pain relief in the affected knee. With respect to safety, it was reported that postinjection synovitis did not occur during the trial.</P>
<P>The publication by Scale et al. reported two separate trials (<LINK REF="STD-Scale-1994a-_x0028_2-inj_x0029_" TYPE="STUDY">Scale 1994a (2 inj)</LINK>; <LINK REF="STD-Scale-1994b-_x0028_3-inj_x0029_" TYPE="STUDY">Scale 1994b (3 inj)</LINK>). One was a comparison of two biweekly injections of Hylan G-F 20 versus two biweekly injections of saline in 50 patients with OA of the knee (<LINK REF="STD-Scale-1994a-_x0028_2-inj_x0029_" TYPE="STUDY">Scale 1994a (2 inj)</LINK>), and the other was a comparison of three weekly injections of Hylan G-F 20 versus three weekly injections of saline in 30 patients with OA of the knee (<LINK REF="STD-Scale-1994b-_x0028_3-inj_x0029_" TYPE="STUDY">Scale 1994b (3 inj)</LINK>). Both studies were 26-week, parallel-group, double-blind RCTs performed at a single centre in Germany. Patients were excluded if effusion was present in the joint. For most outcome measures, the Hylan G-F 20 treatment showed statistically significant superiority over saline treatment for both treatment regimens. The three-injection treatment regimen was statistically more effective than the two-injection treatment regimen. One local, treatment-related, adverse event represented 1% of all the Hylan G-F 20 injections or 2.5% of all the knees treated with Hylan G-F 20 in this study.</P>
<P>Scale et al. published the first RCTs of Hylan G-F 20. Continuous outcome measures were transformed into categorical scores. '"Successful treatment' (i.e. responder) was defined as a score of 0 to 20 mm on the VAS for the pain and activity reduction outcome measures, and a score of 80 to 100 mm for the improvement of the most painful knee movement. Although the journal publication reported results based on a combined control group, the PMA report provided results based on the separate randomised control groups which were used in this review. The three-injection trial randomised 30 patients in total.</P>
<P>Wobig et al. reported a 26-week, parallel-group, double-blind RCT performed at four centres in Germany comparing three weekly injections of Hylan G-F 20 to three weekly injections of saline in 110 patients with OA of the knee (<LINK REF="STD-Wobig-1998" TYPE="STUDY">Wobig 1998</LINK>). Statistically significant differences between Hylan G-F 20 and saline treatment were reported for all outcome measures. No adverse events were observed in the injected joint after Hylan G-F 20 treatment.</P>
<P>In the Wobig et al. RCT, patients with effusion were excluded (<LINK REF="STD-Wobig-1998" TYPE="STUDY">Wobig 1998</LINK>). Again a categorical analysis was completed based on the same responder criteria as Scale et al. above. 98% of the randomised patients completed all follow-up visits. Only one Hylan G-F 20 patient did not participate in the telephone interview and one saline patient, who missed the visits at weeks eight and 12, did participate in the telephone interview at week 26.</P>
<P>The 1999 Wobig publication reported the results of two arms (Hylan G-F 20 versus Artz) of a four-arm trial (Artz, Healon, Hylan G-F 20, nonelastoviscous hylan) (<LINK REF="STD-Wobig-1999" TYPE="STUDY">Wobig 1999</LINK>). This was a 12-week, parallel-group, double-blind RCT performed at six centres in Germany comparing three weekly injections of Hylan G-F 20 to either three weekly injections of Artz (<LINK REF="STD-Wobig-1999b-_x0028_Artz_x0029_" TYPE="STUDY">Wobig 1999b (Artz)</LINK>), three weekly injections of Healon (<LINK REF="STD-Wobig-1999a-_x0028_Healon_x0029_" TYPE="STUDY">Wobig 1999a (Healon)</LINK>), or three weekly injections of nonelastoviscous (denatured) hylan (<LINK REF="STD-Wobig-1999c-_x0028_NEhyl_x0029_" TYPE="STUDY">Wobig 1999c (NEhyl)</LINK>) in 109 knees. Considering only the published Hylan G-F 20 versus Artz comparison, significantly greater pain-relieving effects were detected in favour of Hylan G-F 20. No statistically significant differences in the incidence of adverse events between these two groups were detected.</P>
<P>In an attempt to explain the mechanism of action of viscosupplementation, the objective of the Wobig et al. trial (<LINK REF="STD-Wobig-1999b-_x0028_Artz_x0029_" TYPE="STUDY">Wobig 1999b (Artz)</LINK>) was to determine if a correlation existed between clinical effectiveness and elastoviscosity. Patients were once again categorised as 'symptom-free' based on the Scale et al. criteria above.</P>
<P>Descriptions of the seven RCT in which Hylan G-F 20 was the control treatment are found in the other product results sections: BioHy (Arthrease, Euflexxa, Nuflexxa) (<LINK REF="STD-Kirchner-2006" TYPE="STUDY">Kirchner 2006</LINK>, (<LINK REF="STD-Thompson-2002" TYPE="STUDY">Thompson 2002</LINK> - abstract), Artz (Artzal, <LINK REF="REF-Supartz" TYPE="REFERENCE">Supartz</LINK>) (<LINK REF="STD-Karlsson-2002" TYPE="STUDY">Karlsson 2002</LINK>), <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> (<LINK REF="STD-Brown-2003" TYPE="STUDY">Brown 2003</LINK>), and <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> (<LINK REF="STD-Bayramoglu-2003" TYPE="STUDY">Bayramoglu 2003</LINK>; <LINK REF="STD-Karatay-2005" TYPE="STUDY">Karatay 2005</LINK>; <LINK REF="STD-Karatosun-2005a" TYPE="STUDY">Karatosun 2005a</LINK>; <LINK REF="STD-Kotevoglu-2005" TYPE="STUDY">Kotevoglu 2005</LINK>).</P>
<P>Hylan G-F 20 (Synvisc) versus placebo</P>
<P>Nine RCTs included were comparisons of Hylan G-F 20 and placebos (<LINK REF="STD-Cubukcu-2004" TYPE="STUDY">Cubukcu 2004</LINK>; <LINK REF="STD-Dickson-2001" TYPE="STUDY">Dickson 2001</LINK>; <LINK REF="STD-Groppa-2001" TYPE="STUDY">Groppa 2001</LINK>; <LINK REF="STD-Karlsson-2002b-_x0028_SvP_x0029_" TYPE="STUDY">Karlsson 2002b (SvP)</LINK>; <LINK REF="STD-Moreland-1993" TYPE="STUDY">Moreland 1993</LINK>; <LINK REF="STD-Scale-1994a-_x0028_2-inj_x0029_" TYPE="STUDY">Scale 1994a (2 inj)</LINK>; <LINK REF="STD-Scale-1994b-_x0028_3-inj_x0029_" TYPE="STUDY">Scale 1994b (3 inj)</LINK>; <LINK REF="STD-Wobig-1998" TYPE="STUDY">Wobig 1998</LINK>, <LINK REF="STD-Wobig-1999c-_x0028_NEhyl_x0029_" TYPE="STUDY">Wobig 1999c (NEhyl)</LINK>). Control treatments included IA saline, arthrocentesis, arthrocentesis and placebo capsules taken once daily, and nonelastoviscous (NE) denatured hylan fluid. The current product monograph for Synvisc (<LINK REF="REF-Synvisc-Hylan-G_x002d_F-20" TYPE="REFERENCE">Synvisc Hylan G-F 20</LINK>) indicates administration by IA injection once a week (one week apart) for a total of three injections.<BR/>
<I>
<BR/>Efficacy<BR/>
</I>
<LINK REF="TBL-27" TYPE="TABLE">Table 27</LINK>; <LINK REF="TBL-28" TYPE="TABLE">Table 28</LINK>; <LINK REF="TBL-33" TYPE="TABLE">Table 33</LINK>; <LINK REF="TBL-34" TYPE="TABLE">Table 34</LINK>
<BR/>Statistically significant differences in favour of Hylan G-F 20 compared to placebo were found in pain on weight bearing (measured on 0 to 100 mm VAS) at 1 to 4 weeks postinjection (WMD (random-effects model) -12.54; 95% CI -20.39 to -4.69, P value 0.002) (<LINK REF="STD-Karlsson-2002b-_x0028_SvP_x0029_" TYPE="STUDY">Karlsson 2002b (SvP)</LINK>; <LINK REF="STD-Moreland-1993" TYPE="STUDY">Moreland 1993</LINK>; <LINK REF="STD-Scale-1994a-_x0028_2-inj_x0029_" TYPE="STUDY">Scale 1994a (2 inj)</LINK>; <LINK REF="STD-Scale-1994b-_x0028_3-inj_x0029_" TYPE="STUDY">Scale 1994b (3 inj)</LINK>; <LINK REF="STD-Wobig-1998" TYPE="STUDY">Wobig 1998</LINK>; <LINK REF="STD-Wobig-1999c-_x0028_NEhyl_x0029_" TYPE="STUDY">Wobig 1999c (NEhyl)</LINK>). With the exception of the Karlsson RCT (<LINK REF="STD-Karlsson-2002b-_x0028_SvP_x0029_" TYPE="STUDY">Karlsson 2002b (SvP)</LINK>), Hylan G-F 20 was 4 to 24% more effective than placebo. With five trials, a statistically significant difference in favour of Hylan G-F 20 compared to placebo was found at 5 to 13 weeks postinjection (WMD (random-effects model) -22.46; 95% CI -35.24 to -9.68, P value 0.0006) (<LINK REF="STD-Karlsson-2002b-_x0028_SvP_x0029_" TYPE="STUDY">Karlsson 2002b (SvP)</LINK>; <LINK REF="STD-Scale-1994a-_x0028_2-inj_x0029_" TYPE="STUDY">Scale 1994a (2 inj)</LINK>; <LINK REF="STD-Scale-1994b-_x0028_3-inj_x0029_" TYPE="STUDY">Scale 1994b (3 inj)</LINK>; <LINK REF="STD-Wobig-1998" TYPE="STUDY">Wobig 1998</LINK>; <LINK REF="STD-Wobig-1999c-_x0028_NEhyl_x0029_" TYPE="STUDY">Wobig 1999c (NEhyl)</LINK>). Hylan G-F 20 was 1 to 43% more effective than placebo. At 14 to 26 weeks postinjection, there was a statistically significant difference in favour of Hylan G-F 20 compared to placebo (WMD (random-effects model) -20.70; 95% CI -35.56 to -5.83, P value 0.006) (<LINK REF="STD-Karlsson-2002b-_x0028_SvP_x0029_" TYPE="STUDY">Karlsson 2002b (SvP)</LINK>; <LINK REF="STD-Scale-1994a-_x0028_2-inj_x0029_" TYPE="STUDY">Scale 1994a (2 inj)</LINK>; <LINK REF="STD-Scale-1994b-_x0028_3-inj_x0029_" TYPE="STUDY">Scale 1994b (3 inj)</LINK>; <LINK REF="STD-Wobig-1998" TYPE="STUDY">Wobig 1998</LINK>). Hylan G-F 20 was 1 to 49% more effective than placebo.</P>
<P>Statistically significant differences in favour of Hylan G-F 20 compared to placebo were found in pain at night (measured on 0 to 100 mm VAS) at 1 to 4 weeks postinjection (WMD -8.03; 95% CI -11.95 to -4.12, P &lt; 0.0001) (<LINK REF="STD-Cubukcu-2004" TYPE="STUDY">Cubukcu 2004</LINK>; <LINK REF="STD-Moreland-1993" TYPE="STUDY">Moreland 1993</LINK>; <LINK REF="STD-Scale-1994a-_x0028_2-inj_x0029_" TYPE="STUDY">Scale 1994a (2 inj)</LINK>; <LINK REF="STD-Scale-1994b-_x0028_3-inj_x0029_" TYPE="STUDY">Scale 1994b (3 inj)</LINK>; <LINK REF="STD-Wobig-1998" TYPE="STUDY">Wobig 1998</LINK>; <LINK REF="STD-Wobig-1999c-_x0028_NEhyl_x0029_" TYPE="STUDY">Wobig 1999c (NEhyl)</LINK>). Hylan G-F 20 was 13 to 31% more effective than placebo. With five trials, a statistically significant difference in favour of Hylan G-F 20 compared to placebo was found at 5 to 13 weeks postinjection (WMD (random-effects model) -13.08; 95% CI -20.35 to -5.80, P value 0.0004) (<LINK REF="STD-Cubukcu-2004" TYPE="STUDY">Cubukcu 2004</LINK>; <LINK REF="STD-Scale-1994a-_x0028_2-inj_x0029_" TYPE="STUDY">Scale 1994a (2 inj)</LINK>; <LINK REF="STD-Scale-1994b-_x0028_3-inj_x0029_" TYPE="STUDY">Scale 1994b (3 inj)</LINK>; <LINK REF="STD-Wobig-1998" TYPE="STUDY">Wobig 1998</LINK>; <LINK REF="STD-Wobig-1999c-_x0028_NEhyl_x0029_" TYPE="STUDY">Wobig 1999c (NEhyl)</LINK>). Hylan G-F 20 was 28 to 50% more effective than placebo. At 14 to 26 weeks postinjection, based on three trials, there was a statistically significant difference in favour of Hylan G-F 20 compared to placebo (WMD -17.12; 95% CI -23.22 to -11.02, P &lt; 0.00001) (<LINK REF="STD-Scale-1994a-_x0028_2-inj_x0029_" TYPE="STUDY">Scale 1994a (2 inj)</LINK>; <LINK REF="STD-Scale-1994b-_x0028_3-inj_x0029_" TYPE="STUDY">Scale 1994b (3 inj)</LINK>; <LINK REF="STD-Wobig-1998" TYPE="STUDY">Wobig 1998</LINK>). Hylan G-F 20 was 28 to 96% more effective than placebo.</P>
<P>Statistically significant differences in favour of Hylan G-F 20 compared to saline were detected in pain at rest (0 - 100 mm VAS) both at 1 to 4 weeks postinjection (WMD -9.44; 95% CI -14.07 to -4.82, P &lt; 0.0001)(<LINK REF="STD-Cubukcu-2004" TYPE="STUDY">Cubukcu 2004</LINK>; <LINK REF="STD-Moreland-1993" TYPE="STUDY">Moreland 1993</LINK>); and at 5 to 13 weeks postinjection (WMD -18.67; 95% CI -23.32 to -14.02, P &lt; 0.00001) (<LINK REF="STD-Cubukcu-2004" TYPE="STUDY">Cubukcu 2004</LINK>). Statistically significant differences in favour of Hylan G-F 20 compared to saline were detected in pain walking (0-100 mm VAS) at 5 to 13 weeks postinjection (WMD -13.80; 95% CI -19.74 to -7.86, P &lt; 0.00001) (<LINK REF="STD-Cubukcu-2004" TYPE="STUDY">Cubukcu 2004</LINK>); but not at 1 to 4 weeks postinjection (<LINK REF="STD-Cubukcu-2004" TYPE="STUDY">Cubukcu 2004</LINK>; <LINK REF="STD-Moreland-1993" TYPE="STUDY">Moreland 1993</LINK>). No statistically significant difference was detected at 1 to 4 weeks postinjection in pain overall (0 to 100 mm VAS) (<LINK REF="STD-Moreland-1993" TYPE="STUDY">Moreland 1993</LINK>).</P>
<P>Statistically significant differences were detected in WOMAC OA Index pain at 1 to 4 week postinjection (SMD -1.26; 95% CI -1.86 to -0.66, P &lt; 0.0001) (<LINK REF="STD-Cubukcu-2004" TYPE="STUDY">Cubukcu 2004</LINK>; <LINK REF="STD-Kotevoglu-2005" TYPE="STUDY">Kotevoglu 2005</LINK>), at 5 to 13 weeks postinjection (SMD -0.69; 95% CI -1.02 to -0.36, P &lt; 0.0001)(<LINK REF="STD-Cubukcu-2004" TYPE="STUDY">Cubukcu 2004</LINK>; <LINK REF="STD-Dickson-2001" TYPE="STUDY">Dickson 2001</LINK>; <LINK REF="STD-Kotevoglu-2005" TYPE="STUDY">Kotevoglu 2005</LINK>), and at 14 to 26 weeks postinjection (WMD -1.09; 95% CI -1.92 to -0.25, P value 0.01)(<LINK REF="STD-Kotevoglu-2005" TYPE="STUDY">Kotevoglu 2005</LINK>).</P>
<P>A statistically significant difference in favour of Hylan G-F 20 was detected in the WOMAC OA Index physical function subscale at 1 to 4 weeks postinjection (WMD (RE) -9.42; 95% CI -18.46 to -0.37, P value 0.04 (<LINK REF="STD-Cubukcu-2004" TYPE="STUDY">Cubukcu 2004</LINK>; <LINK REF="STD-Kotevoglu-2005" TYPE="STUDY">Kotevoglu 2005</LINK>), at 5 to 13 weeks postinjection (WMD -11.91; 95% CI -15.06 to -8.76, P &lt; 0.00001) (<LINK REF="STD-Cubukcu-2004" TYPE="STUDY">Cubukcu 2004</LINK>; <LINK REF="STD-Dickson-2001" TYPE="STUDY">Dickson 2001</LINK>; <LINK REF="STD-Kotevoglu-2005" TYPE="STUDY">Kotevoglu 2005</LINK>), at 14 to 26 weeks postinjection (WMD -17.00; 95% CI -26.90 to -7.10, P value 0.0008)(<LINK REF="STD-Kotevoglu-2005" TYPE="STUDY">Kotevoglu 2005</LINK>).</P>
<P>A statistically significant difference in favour of Hylan G-F was detected in the Lequesne Index at 5 to 13 weeks postinjection (WMD -1.60; 95% CI -2.99 to -0.21, P value 0.02) (<LINK REF="STD-Dickson-2001" TYPE="STUDY">Dickson 2001</LINK>). Hylan G-F 20 was 7% more effective than placebo.The RevMan analysis differed from the publication analysis (<LINK REF="STD-Dickson-2001" TYPE="STUDY">Dickson 2001</LINK>). The publication reported no difference in the Lequesne Index at 5 to 13 weeks (P value 0.17) whereas RevMan detected a statistically significant difference in favour of Hylan G-F 20. No statistically significant difference was detected in the Lequesne Index at 14 to 26 weeks postinjection (<LINK REF="STD-Karlsson-2002b-_x0028_SvP_x0029_" TYPE="STUDY">Karlsson 2002b (SvP)</LINK>).</P>
<P>A statistically significant difference in favour of Hylan G-F 20 compared to placebo was detected in improvement in the most painful knee movement (0 to 100 mm VAS) both at 1 to 4 weeks postinjection (WMD 19.29; 95% CI 12.16 to 26.31, P &lt; 0.00001) and at 5 to 13 weeks postinjection (WMD (random-effects model) 33.87; 95% CI 21.19 to 46.55, P &lt; 0.00001) (<LINK REF="STD-Scale-1994a-_x0028_2-inj_x0029_" TYPE="STUDY">Scale 1994a (2 inj)</LINK>; <LINK REF="STD-Scale-1994b-_x0028_3-inj_x0029_" TYPE="STUDY">Scale 1994b (3 inj)</LINK>; <LINK REF="STD-Wobig-1998" TYPE="STUDY">Wobig 1998</LINK>; <LINK REF="STD-Wobig-1999c-_x0028_NEhyl_x0029_" TYPE="STUDY">Wobig 1999c (NEhyl)</LINK>).</P>
<P>No statistically significant difference in 15 metre walking time was detected between Hylan G-F 20 and saline either at 1 to 4 or 5 to 13 weeks postinjection (<LINK REF="STD-Cubukcu-2004" TYPE="STUDY">Cubukcu 2004</LINK>).</P>
<P>Statistically significant differences were detected in WOMAC OA Index stiffness (Likert) at 1 to 4 weeks postinjection (WMD -1.08; 95% CI -1.73 to -0.44, P value 0.001), at 5 to 13 weeks postinjection (WMD -1.34; 95% CI -2.13 to -0.55, P value 0.0009) (<LINK REF="STD-Cubukcu-2004" TYPE="STUDY">Cubukcu 2004</LINK>; <LINK REF="STD-Kotevoglu-2005" TYPE="STUDY">Kotevoglu 2005</LINK>), and at 14 to 26 weeks postinjection (WMD -1.00; 95% CI -1.89 to -0.11, P value 0.03) (<LINK REF="STD-Kotevoglu-2005" TYPE="STUDY">Kotevoglu 2005</LINK>).</P>
<P>When patient global assessment data were dichotomised into improved or not improved by classifying responses of 'very poor', 'poor' and 'fair' as 'not improved' and 'good' and 'very good' as 'improved', more patients in the Hylan G-F 20 group were either 'very good' or 'good' (69%) than in the double control group (48%) at 5 to 13 weeks postinjection (RR 1.44; 95% CI 1.01 to 2.06, P value 0.05) (<LINK REF="STD-Dickson-2001" TYPE="STUDY">Dickson 2001</LINK>).</P>
<P>A statistically significant difference in favour of Hylan G-F 20 compared to placebo was detected for patient global assessment of treatment efficacy (0 to 100 mm VAS) both at 1 to 4 weeks postinjection (SMD 0.70; 95% CI 0.46 to 0.93, P &lt; 0.00001) and at 5 to 13 weeks postinjection (SMD (random effects) 1.54; 95% CI 0.84 to 2.24, P &lt; 0.0001) (<LINK REF="STD-Cubukcu-2004" TYPE="STUDY">Cubukcu 2004</LINK>; <LINK REF="STD-Scale-1994a-_x0028_2-inj_x0029_" TYPE="STUDY">Scale 1994a (2 inj)</LINK>; <LINK REF="STD-Scale-1994b-_x0028_3-inj_x0029_" TYPE="STUDY">Scale 1994b (3 inj)</LINK>; <LINK REF="STD-Wobig-1998" TYPE="STUDY">Wobig 1998</LINK>; <LINK REF="STD-Wobig-1999c-_x0028_NEhyl_x0029_" TYPE="STUDY">Wobig 1999c (NEhyl)</LINK>).</P>
<P>Statistically significant differences were detected in patient global assessment (measured 0 to 100 mm VAS, where 100 was worst severity) in favour of Hylan G-F 20 compared to saline both at 1 to 4 weeks postinjection (WMD -20.00; 95% CI -33.16 o -6.84, P value 0.003) and at 5 to 13 weeks postinjection (WMD -20.00; 95% CI -30.57 to -9.43, P value 0.0002); but not at 14 to 26 weeks postinjection (<LINK REF="STD-Kotevoglu-2005" TYPE="STUDY">Kotevoglu 2005</LINK>). Similarly, statistically significant differences were detected in physican global assessment (measured 0 to 100 mm VAS, where 100 was worst severity) in favour of Hylan G-F 20 compared to saline both at 1 to 4 weeks postinjection (WMD -20.00; 95% CI -37.64 to -2.36, P value 0.03) and at 5 to 13 weeks postinjection (WMD -20.00; 95% CI -36.10 to -3.90, P value 0.01) but not at 14 to 26 weeks postinjection (<LINK REF="STD-Kotevoglu-2005" TYPE="STUDY">Kotevoglu 2005</LINK>).</P>
<P>No statistically significant difference was noted in the number of clinical failures at 14 to 26 weeks postinjection: Hylan G-F 20 7% and Saline 11%, or at 45 to 52 weeks postinjection: Hylan G-F 20 46% and saline 54% (<LINK REF="STD-Karlsson-2002b-_x0028_SvP_x0029_" TYPE="STUDY">Karlsson 2002b (SvP)</LINK>), or in the number of survivors (i.e. patients not requiring additional treatment to study knee): Hylan G-F 20 44% and saline 33% (<LINK REF="STD-Karlsson-2002b-_x0028_SvP_x0029_" TYPE="STUDY">Karlsson 2002b (SvP)</LINK>).</P>
<P>In the Cubukcu et al. RCT, the need for paracetamol tablets was measured by pill counts (means and standard deviations reported). The original publication reported a statistically significant difference between Hylan G-F 20 and saline at 5 to 13 weeks postinjection in favour of Hylan G-F 20 (P &lt; 0.05) but no significant difference at 1 to 4 weeks postinjection (<LINK REF="STD-Cubukcu-2004" TYPE="STUDY">Cubukcu 2004</LINK>). The RevMan software is unable to provide an estimate of this difference.</P>
<P>Considering only the two most homogeneous trials, i.e., the three-injection trial of Scale (<LINK REF="STD-Scale-1994b-_x0028_3-inj_x0029_" TYPE="STUDY">Scale 1994b (3 inj)</LINK>) and the Wobig trial (<LINK REF="STD-Wobig-1998" TYPE="STUDY">Wobig 1998</LINK>), a statistically significant difference in favour of Hylan G-F 20 compared to saline was detected in pain on weight bearing (0 to 100 mm VAS) at 1 to 4 weeks postinjection (WMD -22.00; 95% CI -29.13 to -14.87, P &lt; 0.00001), at 5 to 13 weeks postinjection (WMD -35.68; 95% CI -42.81 to -28.55, P &lt; 0.00001), and at 14 to 26 weeks postinjection (WMD -21.62; 95% CI -30.84 to -12.39, P &lt; 0.00001). A statistically significant difference in favour of Hylan G-F 20 compared to saline was detected in pain at night (0 to 100 mm VAS) at 1 to 4 weeks postinjection (WMD -10.64; 95% CI -17.29 to -3.99, P value 0.002), at 5 to 13 weeks postinjection (WMD -15.50; 95% CI -21.38 to -9.62, P &lt; 0.00001), and at 14 to 26 weeks postinjection (WMD -16.20; 95% CI -22.85 to -9.55, P &lt; 0.00001). A statistically significant difference in favour of Hylan G-F 20 compared to saline was detected in improvement in the most painful knee movement (0 to 100 mm VAS) both at 1 to 4 weeks postinjection (WMD 23.97; 95% CI 14.34 to 33.60, P &lt; 0.00001) and at 5 to 13 weeks postinjection (WMD 40.56; 95% CI 31.11 to 50.01, P &lt; 0.00001). A statistically significant difference in favour of Hylan G-F 20 compared to saline was detected for the variable treatment efficacy (improvement on a 0 to 100 mm VAS) both at 1 to 4 weeks postinjection (WMD 26.62; 95% CI 17.39 to 35.84, P &lt; 0.00001) and at 5 to 13 weeks postinjection (WMD 43.85; 95% CI 34.62 to 53.07, P &lt; 0.00001).<BR/>
<I>
<BR/>Safety</I>
</P>
<P>No statistically significant differences were detected in the total number of withdrawals overall at 1 to 4 weeks postinjection (<LINK REF="STD-Moreland-1993" TYPE="STUDY">Moreland 1993</LINK>), at 5 to 13 weeks (<LINK REF="STD-Cubukcu-2004" TYPE="STUDY">Cubukcu 2004</LINK>; <LINK REF="STD-Dickson-2001" TYPE="STUDY">Dickson 2001</LINK>; <LINK REF="STD-Wobig-1998" TYPE="STUDY">Wobig 1998</LINK>; <LINK REF="STD-Wobig-1999c-_x0028_NEhyl_x0029_" TYPE="STUDY">Wobig 1999c (NEhyl)</LINK>, or at 14 to 26 weeks postinjection (<LINK REF="STD-Kotevoglu-2005" TYPE="STUDY">Kotevoglu 2005</LINK>). No statistically significant differences were detected in the number of withdrawals due to adverse events. The number of local reactions was significantly higher in the Hylan G-F 20 plus arthrocentesis group compared to arthrocentesis (RR 30.23; 95% CI 1.86 to 492.59, P value 0.02) (<LINK REF="STD-Dickson-2001" TYPE="STUDY">Dickson 2001</LINK>).</P>
<P>No significant differences were detected in the number of patients with local reactions (<LINK REF="STD-Cubukcu-2004" TYPE="STUDY">Cubukcu 2004</LINK>; <LINK REF="STD-Dickson-2001" TYPE="STUDY">Dickson 2001</LINK>; <LINK REF="STD-Kotevoglu-2005" TYPE="STUDY">Kotevoglu 2005</LINK>; <LINK REF="STD-Moreland-1993" TYPE="STUDY">Moreland 1993</LINK>; <LINK REF="STD-Wobig-1998" TYPE="STUDY">Wobig 1998</LINK>; <LINK REF="STD-Wobig-1999c-_x0028_NEhyl_x0029_" TYPE="STUDY">Wobig 1999c (NEhyl)</LINK>); number of patients with local adverse reaction at 1 to 4 weeks postinjection but study drug continued (<LINK REF="STD-Scale-1994b-_x0028_3-inj_x0029_" TYPE="STUDY">Scale 1994b (3 inj)</LINK>); number of patients with one or more probable or possible related systemic adverse events at 5 to 13 weeks postinjection (<LINK REF="STD-Dickson-2001" TYPE="STUDY">Dickson 2001</LINK>); number of patients reporting systemic adverse reactions at 5 to 13 weeks postinjection (<LINK REF="STD-Cubukcu-2004" TYPE="STUDY">Cubukcu 2004</LINK>; <LINK REF="STD-Wobig-1998" TYPE="STUDY">Wobig 1998</LINK>; <LINK REF="STD-Wobig-1999c-_x0028_NEhyl_x0029_" TYPE="STUDY">Wobig 1999c (NEhyl)</LINK>); or number of patients withdrawn due to noncompliance (<LINK REF="STD-Kotevoglu-2005" TYPE="STUDY">Kotevoglu 2005</LINK>).</P>
<P>Hylan G-F 20 (Synvisc) versus corticosteroid</P>
<P>
<LINK REF="TBL-29" TYPE="TABLE">Table 29</LINK>
</P>
<P>Two RCTs included were comparisons of Hylan G-F 20 and IA corticosteroid.</P>
<P>One RCT was a comparison of Hylan G-F 20 and betamethasone sodium phosphate - betamethasone acetate (<LINK REF="STD-Leopold-2003" TYPE="STUDY">Leopold 2003</LINK>). One RCT was a comparison of Hylan G-F 20 and triamcinolone hexacetonide (<LINK REF="STD-Caborn-2004" TYPE="STUDY">Caborn 2004</LINK>).<BR/>
<I>
<BR/>Efficacy<BR/>
</I>
<BR/>The efficacy outcome measure results in the Leopold trial (<LINK REF="STD-Leopold-2003" TYPE="STUDY">Leopold 2003</LINK>) were presented as changes in median scores because the data were not normally distributed. Therefore, only safety data for this RCT are reported.</P>
<P>A statistically significant difference in favour of Hylan G-F 20 compared to triamcinolone hexacetonide was found for WOMAC pain walking on a flat surface (scored 0 to 4) in the Caborn trial (<LINK REF="STD-Caborn-2004" TYPE="STUDY">Caborn 2004</LINK>) (WMD -0.40; 95% CI -0.65 to -0.15, P value 0.002) at 5 to 13 weeks postinjection and (WMD -0.40; 95% CI -0.68 to -0.12, P value 0.005) at 14 to 26 weeks postinjection. Hylan G-F 20 was 17% more effective than triamcinolone hexacetonide. A statistically significant difference in favour of Hylan G-F 20 compared to triamcinolone hexacetonide was found for the WOMAC physical function subscale (scored 0 to 68) (WMD -5.00; 95% CI -8.86 to -1.14, P value 0.01) at 5 to 13 weeks postinjection and (WMD -5.20; 95% CI -9.10 to -1.30, P value 0.009) at 14 to 26 weeks postinjection. Hylan G-F 20 was, on average, 17% more effective than triamcinolone hexacetonide. A statistically significant difference in favour of Hylan G-F 20 compared to triamcinolone hexacetonide was found for WOMAC total score (scored 0-96) (WMD -7.40; 95% CI -12.74 to -2.06, P value 0.007) at 5 to 13 weeks postinjection and (WMD -7.30; 95% CI -12.76 to -1.84, P value 0.009) at 14 to 26 weeks postinjection. Hylan G-F 20 was 15% more effective than triamcinolone hexacetonide. A statistically significant difference in favour of Hylan G-F 20 compared to triamcinolone hexacetonide was found for for patient global assessment (scored 0 to 100 mm VAS) (WMD -13.40; 95% CI -20.03 to -6.77, P value 0.00007) at 5 to 13 weeks postinjection and (WMD -15.10; 95% CI -22.17 to -8.03, P value 0.00003) at 14 to 26 week postinjection. Hylan G-F 20 was approximately 23% more effective than triamcinolone hexacetonide.</P>
<P>In the Caborn trial (<LINK REF="STD-Caborn-2004" TYPE="STUDY">Caborn 2004</LINK>) there was no statistically significant difference in the number of responders defined as at least a one-point improvement in the WOMAC pain walking on a flat surface at 1 to 4 weeks postinjection. However, there was a statistically significant difference in favour of Hylan G-F 20 at 5 to 13 weeks postinjection (RR 1.44; 95% CI 1.09 to 1.90, P value 0.01). The NNT for the number of responders was 5. At 14 to 26 weeks postinjection, the RR was 1.44 (95% CI 1.00 to 2.09) P value 0.05. There was no statistically significant difference in analgesic usage between week 0 and prior to week 12 or between week 12 and prior to week 26.<BR/>
<I>
<BR/>Safety<BR/>
</I>
<BR/>With respect to the Leopold trial (<LINK REF="STD-Leopold-2003" TYPE="STUDY">Leopold 2003</LINK>), there were no statistically significant differences in the safety outcomes: total withdrawals overall; withdrawals due to lack of efficacy; or withdrawals due to acute local reactions.</P>
<P>With respect to the Caborn trial (<LINK REF="STD-Caborn-2004" TYPE="STUDY">Caborn 2004</LINK>), there was a statistically significant difference in favour of Hylan G-F 20 compared to triamcinolone hexacetonide in the number of withdrawals due to lack of efficacy (RR 0.03; 95% CI 0.00 to 0.48, P value 0.01). There were no statistically significant differences in the total number of withdrawals overall or the number of withdrawals due to adverse events.</P>
<P>Hylan G-F 20 (Synvisc) versus NSAID</P>
<P>
<LINK REF="TBL-30" TYPE="TABLE">Table 30</LINK>
</P>
<P>Two trials included were comparisons of Hylan G-F 20 and NSAID (<LINK REF="STD-Adams-1995" TYPE="STUDY">Adams 1995</LINK>; <LINK REF="STD-Dickson-2001" TYPE="STUDY">Dickson 2001</LINK>). In the Adams trial (<LINK REF="STD-Adams-1995" TYPE="STUDY">Adams 1995</LINK>), the early 5 to 13 weeks postinjection follow-up assessment was reported as change (improvement) scores, while the 14 to 26 week follow-up was based on difference scores. The Dickson trial (<LINK REF="STD-Dickson-2001" TYPE="STUDY">Dickson 2001</LINK>) results were reported as change (improvement) scores.<BR/>
<I>
<BR/>Efficacy<BR/>
</I>
<BR/>There were no statistically significant differences in any of the efficacy measures scored on a 0 to 100 mm VAS at either 5 to 13 or 14 to 26 weeks postinjection: pain on motion; pain at rest; pain at night; pain overall (0 to 100 mm VAS) (<LINK REF="STD-Adams-1995" TYPE="STUDY">Adams 1995</LINK>).</P>
<P>The RevMan analysis differed from the Adams publication (<LINK REF="STD-Adams-1995" TYPE="STUDY">Adams 1995</LINK>) analysis. The publication reported a statistically significant difference (P value 0.05) in favour of Hylan G-F 20 over NSAID in pain at rest at 5 to 13 weeks whereas the RevMan analysis detected no difference (P value 0.6).</P>
<P>There was a statistically significant difference in favour of Hylan G-F 20 compared to NSAID in the WOMAC OA Index pain subscale (0 to 100 mm VAS) (WMD -12.00; 95% CI -23.09 to -0.91, P value 0.03) at 5 to 13 weeks postinjection (<LINK REF="STD-Dickson-2001" TYPE="STUDY">Dickson 2001</LINK>). Hylan G-F 20 was 16% more effective than NSAID. There were no statistically significant differences in physical function measured either on the WOMAC OA Index physical function subscale (0 to 100 mm VAS) or on the Lequesne Index (0 to 24) at 5 to 13 weeks postinjection (<LINK REF="STD-Dickson-2001" TYPE="STUDY">Dickson 2001</LINK>).</P>
<P>There were no statistically significant differences in the patient global assessment, measured as the number of patients assessing the treatment as excellent, very good or good, either at 5 to 13 weeks postinjection (<LINK REF="STD-Dickson-2001" TYPE="STUDY">Dickson 2001</LINK>) or at 14 to 26 weeks postinjection (<LINK REF="STD-Adams-1995" TYPE="STUDY">Adams 1995</LINK>).<BR/>
<I>
<BR/>Safety<BR/>
</I>
<BR/>There were no statistically significant differences in the following safety outcome measures: total withdrawals overall at 5 to 13 weeks postinjection (<LINK REF="STD-Dickson-2001" TYPE="STUDY">Dickson 2001</LINK>) or at 14 to 26 weeks postinjection (<LINK REF="STD-Adams-1995" TYPE="STUDY">Adams 1995</LINK>); withdrawals due to adverse events at 14 to 26 weeks postinjection (<LINK REF="STD-Adams-1995" TYPE="STUDY">Adams 1995</LINK>); or the number of patients with local reactions at 5 to 13 weeks postinjection (<LINK REF="STD-Dickson-2001" TYPE="STUDY">Dickson 2001</LINK>). There was a statistically significant difference in favour of Hylan G-F 20 compared to NSAID for the number of patients with possible or probable related systemic adverse events at 5 to 13 weeks postinjection (RR 0.46; 95% CI 0.25 to 0.83, P value 0.01) (<LINK REF="STD-Dickson-2001" TYPE="STUDY">Dickson 2001</LINK>). The NNT was 4.</P>
<P>Hylan G-F 20 (Synvisc) + NSAID versus NSAID alone</P>
<P>The second comparison that was made from the Adams trial (<LINK REF="STD-Adams-1995" TYPE="STUDY">Adams 1995</LINK>) was Hylan G-F 20 plus NSAID and arthrocentesis versus NSAID and arthrocentesis alone.<BR/>
<I>
<BR/>Efficacy<BR/>
</I>
<BR/>There were no statistically significant differences between the two groups at 5 to 13 weeks postinjection for the following pain outcomes (0 to 100 mm VAS): pain on motion; pain at rest; pain at night; or pain overall. There were statistically significant differences in favour of Hylan G-F 20+NSAID+arthrocentesis compared to NSAID+arthrocentesis at 14 to 26 weeks postinjection for pain on motion (WMD -15.00; 95% CI -26.09 to -3.91, P value 0.008); pain at rest (WMD -11.00; 95% CI -19.31 to -2.69, P value 0.01); pain at night (WMD -19.00; 95% CI -30.09 to -7.91, P value 0.0008); and pain overall (WMD -15.00; 95% CI -26.09 to -3.91, P value 0.008). Hylan G-F 20+NSAID+arthrocentesis was approximately 10% more effective than NSAID+arthrocentesis. There was no statistically significant difference in the number of patients reporting that they were 'excellent, very good, or good' .<BR/>
<I>
<BR/>Safety<BR/>
</I>
<BR/>There was no statistically significant difference in the total withdrawals overall.</P>
<P>Hylan G-F 20 (Synvisc) versus physical therapy</P>
<P>One RCT included a comparison of Hylan G-F 20 to physical therapy (<LINK REF="STD-Atamaz-2005" TYPE="STUDY">Atamaz 2005</LINK>).</P>
<P>
<I>Efficacy</I>
</P>
<P>There was a statistically significant between-group difference in favour of physical therapy compared to Hylan G-F 20 in spontaneous pain (0 to 100 mm VAS) at 1 to 4 weeks postinjection (WMD 20.50; 95% CI 10.21 to 30.79, P &lt; 0.0001) (physicl therapy was 5% more effective than Hylan G-F 20), but not at 5 to 13, 14 to 26, 37, or 45 to 52 weeks postinjection. Statistically significant differences in favour of Hylan G-F 20 were detected in WOMAC pain (Likert) at 1 to 4 weeks postinjection (WMD -3.00; 95% CI -4.85 to -1.15, P value 0.001), at 5 to 13 weeks postinjection (WMD -3.10; 95% CI -5.12 to -1.08, P value 0.003) (Hylan G-F 20 was 9% more effective than physical therapy), at 37 weeks postinjection (WMD -1.90; 95% CI -3.71 to -0.09, P value 0.04) (Hylan G-F 20 was 1% more effective than physical therapy), and at 45 to 52 weeks postinjection (WMD -5.30; 95% CI -7.50 to -3.10, P &lt; 0.00001) (Hylan G-F 20 was 25% more effective than physical therapy), but not at 14 to 26 weeks postinjection. There were no statistically significant differences detected in WOMAC physical function (Likert), SF-36 pain or SF-36 physical functioning at any of the time-points: 1 to 4, 5 to 13, 14 to 26, 36, or 45 to 52 weeks postinjection.<BR/>
<I>
<BR/>Safety </I>
</P>
<P>In the Atamaz et al. RCT, while one patient in the Hylan G-F 20 group reported a local reaction which resolved within a few days, no serious local or systemic adverse events were observed following injections (<LINK REF="STD-Atamaz-2005" TYPE="STUDY">Atamaz 2005</LINK>).<I>
<BR/>
</I>
<BR/>Hylan G-F 20 (Synvisc) + physiotherapy versus physiotherapy alone</P>
<P>One RCT included a comparison of Hylan G-F 20 plus physiotherapy to physiotherapy alone (<LINK REF="STD-Bayramoglu-2003" TYPE="STUDY">Bayramoglu 2003</LINK>).<BR/>
<I>
<BR/>Efficacy<BR/>
</I>
<BR/>There was no statistically significant difference in the Lequesne Index (scored 0 to 24) either at the end of treatment or at 5 to 13 weeks post injection.<BR/>
<I>
<BR/>Safety<BR/>
</I>
<BR/>There was no statistically significant difference in the number of total withdrawals overall at 5 to 13 weeks postinjection.</P>
<P>Hylan G-F 20 (Synvisc) versus exercise programme</P>
<P>One RCT included was a comparison of Hylan G-F 20 to an exercise programme (<LINK REF="STD-Karatosun-2005" TYPE="STUDY">Karatosun 2005</LINK>).</P>
<P>
<I>Efficacy</I>
</P>
<P>The primary outcome measure for this trial was the Hospital for Special Surgery Knee Score. There were no statistically significant differences in the Score at any of the assessment times: 1 to 4, 5 to 13, 14 to 26, 45 to 52, or 74 weeks postinjection. By analysing the separate categories that make up the Score, the following statistically significant differences were detected in favour of Hylan G-F 20 for pain during activity at 1 to 4 weeks postinjection (WMD 1.90; 95% CI 0.19 to 3.61, P value 0.03) (Hylan G-F 20 was 53% more effective than exercise); at 5 to 13 weeks postinjection (WMD 1.70; 95% CI 0.17 to 3.23, P value 0.03) (Hylan G-F 20 was 49% more effective than exercise); and at 14 to 26 weeks postinjection (WMD 2.50; 95% CI 0.85 to 4.15, P value 0.003) (Hylan G-F 20 was 27% more effective than exercise). A statistically significant difference in favour of exercise was detected for pain during transfer activity at 45 to 52 weeks postinjection (WMD -0.50; 95% CI -0.95 to -0.05, P value 0.03) (exercise was 10% more effective than Hylan G-F 20).</P>
<P>
<I>Safety</I>
</P>
<P>A statistically significant difference was detected in the total withdrawals overall in favour of the exercise group (RR 43.81; 95% CI 2.72 to 704.87, P value 0.008).</P>
<P>Hylan G-F 20 (Synvisc) versus IA gaseous oxygen</P>
<P>One RCT was a comparison of Hylan G-F 20 plus an exercise programme to IA gaseous oxygen plus an exercise programme (<LINK REF="STD-Auerbach-2002" TYPE="STUDY">Auerbach 2002</LINK>; <LINK REF="STD-Auerbach-2002a" TYPE="STUDY">Auerbach 2002a</LINK>).<BR/>
<I>
<BR/>Efficacy<BR/>
</I>
<BR/>A between-group difference was found for pain under load (0 to 100 mm VAS) at 5 to 13 weeks postinjection in favour of the oxygen group (WMD 12.83; 95% CI 1.96 to 23.70, P value 0.02) but no statistically significant differences were found at the other assessments: end of treatment, 14 to 26 weeks postinjection, or 45 to 52 weeks postinjection. There were no statistically significant differences between the groups for pain at rest (0 to 100 mm VAS); WOMAC OA Index pain (0 to 20); or WOMAC OA Index physical function (0 to 68) at any of the assessments: end of treatment, 5 to 13, 14 to 26, or 45 to 52 weeks postinjection.</P>
<P>The RevMan analysis differed from the Auerbach publication (<LINK REF="STD-Auerbach-2002" TYPE="STUDY">Auerbach 2002</LINK>) analysis. In the publication, statistically significant differences were found at 45 to 52 weeks postinjection in favour of Hylan G-F 20 compared to IA gaseous oxygen for pain under load (P value 0.001), WOMAC pain (P value 0.003), and WOMAC function (P value 0.001) whereas the RevMan analysis did not detect any significant differences (pain under load P value 0.2, WOMAC pain P value 0.3, WOMAC function P value 0.2).<BR/>
<I>
<BR/>Safety<BR/>
</I>
<BR/>There was no statistically significant difference in the total number of withdrawals overall or in the number of patients having total knee replacements.</P>
<P>Hylan G-F 20 (Synvisc) + appropriate care versus appropriate care alone<BR/>
<LINK REF="TBL-31" TYPE="TABLE">Table 31</LINK>; <LINK REF="TBL-32" TYPE="TABLE">Table 32</LINK>
<BR/>Two trials included were comparisons of the combination of Hylan G-F 20 and appropriate care (AC) to appropriate care alone (<LINK REF="STD-Kahan-2003a" TYPE="STUDY">Kahan 2003a</LINK>; <LINK REF="STD-Raynauld-2002" TYPE="STUDY">Raynauld 2002</LINK>).<BR/>
<I>
<BR/>Efficacy<BR/>
</I>
<BR/>A statistically significant difference in favour of Hylan G-F 20 and AC compared to AC alone was found in the WOMAC OA Index pain subscale (0 to 20 Likert) at 45 to 52 weeks postinjection (WMD -3.16; 95% CI -4.17 to -2.15, P &lt; 0.00001) (<LINK REF="STD-Raynauld-2002" TYPE="STUDY">Raynauld 2002</LINK>). The combination group was 22% more effective than AC alone group. A statistically significant difference in favour of Hylan G-F 20 and AC compared to AC alone was found in the WOMAC OA Index physical function subscale (0 to 68 Likert) at 45 to 52 weeks postinjection (WMD -9.61; 95% CI -13.09 to -6.13, P &lt; 0.00001) (<LINK REF="STD-Raynauld-2002" TYPE="STUDY">Raynauld 2002</LINK>). The combination group was 22% more effective than AC alone group. The patient global assessment, based on the number of patients improved in the study knee, was statistically better for the Hylan G-F 20 and AC group (73%) compared to AC alone (27%) (RR 2.68; 95% CI 1.98 to 3.62, P &lt; 0.00001) (<LINK REF="STD-Raynauld-2002" TYPE="STUDY">Raynauld 2002</LINK>). The NNT for patient global assessment was 2.</P>
<P>A statistically significant difference in favour of Hylan G-F 20 and AC compared to AC alone was found in the WOMAC OA Index pain subscale (0 to 100 mm VAS) (WMD -12.70; 95% CI -16.41 to -8.99, P &lt; 0.00001) (<LINK REF="STD-Kahan-2003a" TYPE="STUDY">Kahan 2003a</LINK>). The combination group was 25% more effective than AC alone. A statistically significant difference in favour of Hylan G-F 20 and AC compared to AC alone was found in the WOMAC OA Index physical function subscale (WMD -13.20; 95% CI -17.02 to -9.38, P &lt; 0.00001) (<LINK REF="STD-Kahan-2003a" TYPE="STUDY">Kahan 2003a</LINK>). The combination group was 24% more effective than AC alone. A statistically significant difference was found in favour of Hylan G-F 20 and AC compared to AC alone in the Lequesne Index (0 to 24) (WMD -2.20; 95% CI -2.98 to -1.42, P &lt; 0.00001) (<LINK REF="STD-Kahan-2003a" TYPE="STUDY">Kahan 2003a</LINK>). The combination group was 18% more effective than AC alone. The patient global assessment, based on effectiveness rated as good or satisfactory, was statistically better for the Hylan G-F 20 and AC group (74%) compared to AC alone (51%) (RR 1.44; 95% CI 1.25 to 1.66, P &lt; 0.00001) (<LINK REF="STD-Kahan-2003a" TYPE="STUDY">Kahan 2003a</LINK>). The NNT for patient global assessment was 4. The number of responders, defined as those patients with at least a 20% decrease in pain on walking, was significantly higher in the Hylan G-F 20 and AC group (88%) compared to AC alone (68%) (RR 1.30; 95% CI 1.18 to 1.43, P &lt; 0.00001) (<LINK REF="STD-Kahan-2003a" TYPE="STUDY">Kahan 2003a</LINK>).<BR/>
<I>
<BR/>Safety<BR/>
</I>
<BR/>There was no statistically significant difference in the total withdrawals overall, the number of patients reporting side effects from baseline (<LINK REF="STD-Kahan-2003a" TYPE="STUDY">Kahan 2003a</LINK>; <LINK REF="STD-Raynauld-2002" TYPE="STUDY">Raynauld 2002</LINK>), or the number of patients withdrawn due to adverse events in the Kahan trial (<LINK REF="STD-Kahan-2003a" TYPE="STUDY">Kahan 2003a</LINK>). The number of patients reporting mild, moderate or severe side effects at the end of the study was significantly higher in the AC alone group (68%) compared to the Hylan G-F 20 and AC group (52%) (RR 0.76; 95% CI 0.61 to 0.94, P value 0.01) (<LINK REF="STD-Raynauld-2002" TYPE="STUDY">Raynauld 2002</LINK>). There was a statistically significant difference in the number of patients with gastrointestinal adverse events in favour of the Hylan G-F 20 and AC group compared to AC alone (RR 0.38; 95% CI 0.25 to 0.60, P value 0.00002) (<LINK REF="STD-Kahan-2003a" TYPE="STUDY">Kahan 2003a</LINK>; <LINK REF="STD-Raynauld-2002" TYPE="STUDY">Raynauld 2002</LINK>). Significantly fewer patients withdrew due to lack of effectiveness in the Hylan G-F 20 and AC group (2%) compared to the AC alone group (7%) (RR 0.35; 95% CI 0.14 to 0.88, P value 0.03) (<LINK REF="STD-Kahan-2003a" TYPE="STUDY">Kahan 2003a</LINK>).</P>
<P>Hylan G-F 20 (Synvisc) plus arthroscopy versus arthroscopy alone</P>
<P>One RCT has been a comparison of Hylan G-F 20 following arthroscopy and arthroscopy alone (<LINK REF="STD-Rejaili-2005" TYPE="STUDY">Rejaili 2005</LINK>).</P>
<P>
<I>Efficacy</I>
</P>
<P>Results have not been reported for the four efficacy outcomes since only means, but not standard deviations, were reported at the 24-week follow-up.</P>
<P>
<I>Safety</I>
</P>
<P>No postinjection synovitis was observed during the trial. With respect to the arthroscopy procedure, there were no intra or postoperative complications in the patients. These are the only data that were reported with respect to safety.</P>
<P>Hylan G-F 20 (Synvisc) versus other hyaluronan</P>
<P>
<LINK REF="TBL-35" TYPE="TABLE">Table 35</LINK>
</P>
<P>Nine RCTs have been comparisons of Hylan G-F 20 and hyaluronan: 1) Artzal (<LINK REF="STD-Karlsson-2002" TYPE="STUDY">Karlsson 2002</LINK>) - readers are directed to the Artz product results, 2) Artz (<LINK REF="STD-Wobig-1999b-_x0028_Artz_x0029_" TYPE="STUDY">Wobig 1999b (Artz)</LINK>) and Healon (<LINK REF="STD-Wobig-1999a-_x0028_Healon_x0029_" TYPE="STUDY">Wobig 1999a (Healon)</LINK>), 3) <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> (<LINK REF="STD-Brown-2003" TYPE="STUDY">Brown 2003</LINK>) - readers are directed to the <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> product results, 4) <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> (<LINK REF="STD-Atamaz-2005" TYPE="STUDY">Atamaz 2005</LINK>; <LINK REF="STD-Bayramoglu-2003" TYPE="STUDY">Bayramoglu 2003</LINK>; <LINK REF="STD-Karatay-2004" TYPE="STUDY">Karatay 2004</LINK>; <LINK REF="STD-Karatosun-2005a" TYPE="STUDY">Karatosun 2005a</LINK>; <LINK REF="STD-Kotevoglu-2005" TYPE="STUDY">Kotevoglu 2005</LINK>) - readers are directed to the <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> product results, and 5) Arthrease (<LINK REF="STD-Kirchner--2005" TYPE="STUDY">Kirchner 2005</LINK>; <LINK REF="STD-Thompson-2002" TYPE="STUDY">Thompson 2002</LINK>) - readers are directed to the BioHy (Arthrease, Euflexxa, Nuflexxa) product results.</P>
<P>The Wobig 199 trial had two active arms: Artz (<LINK REF="STD-Wobig-1999b-_x0028_Artz_x0029_" TYPE="STUDY">Wobig 1999b (Artz)</LINK> and Healon (<LINK REF="STD-Wobig-1999a-_x0028_Healon_x0029_" TYPE="STUDY">Wobig 1999a (Healon)</LINK>). Since Healon is not indicated for the treatment of knee OA we have completed the analysis both including and excluding this arm.<BR/>
<I>
<BR/>Efficacy<BR/>
</I>
<BR/>There was no statistically significant difference in pain on weight bearing (0 to 100 mm VAS) at 1 to 4 weeks postinjection (<LINK REF="STD-Karlsson-2002c-_x0028_AvS_x0029_" TYPE="STUDY">Karlsson 2002c (AvS)</LINK>, <LINK REF="STD-Wobig-1999a-_x0028_Healon_x0029_" TYPE="STUDY">Wobig 1999a (Healon)</LINK>, <LINK REF="STD-Wobig-1999b-_x0028_Artz_x0029_" TYPE="STUDY">Wobig 1999b (Artz)</LINK>), or at 14 to 26 weeks postinjection (<LINK REF="STD-Karlsson-2002c-_x0028_AvS_x0029_" TYPE="STUDY">Karlsson 2002c (AvS)</LINK>). There was a statistically significant difference in favour of Hylan G-F 20 compared to other hyaluronans at 5 to 13 weeks postinjection (WMD -6.59; 95% CI -12.46 to -0.73, P value 0.03) (<LINK REF="STD-Karlsson-2002c-_x0028_AvS_x0029_" TYPE="STUDY">Karlsson 2002c (AvS)</LINK>; <LINK REF="STD-Wobig-1999a-_x0028_Healon_x0029_" TYPE="STUDY">Wobig 1999a (Healon)</LINK>; <LINK REF="STD-Wobig-1999b-_x0028_Artz_x0029_" TYPE="STUDY">Wobig 1999b (Artz)</LINK>). There was a statistically significant difference in favour of Hylan G-F 20 in pain at night (0 to 100 mm VAS) at 1 to 4 weeks postinjection (WMD -7.07; 95% CI -13.41 to -0.73, P value 0.03), but no difference at 5 to 13 weeks postinjection (<LINK REF="STD-Wobig-1999a-_x0028_Healon_x0029_" TYPE="STUDY">Wobig 1999a (Healon)</LINK>; <LINK REF="STD-Wobig-1999b-_x0028_Artz_x0029_" TYPE="STUDY">Wobig 1999b (Artz)</LINK>). There was no significant difference in improvement in knee movement (0 to 100 mm VAS) at 1 to 4 weeks postinjection, but there was a statistically significant difference in favour of Hylan G-F 20 at 5 to 13 weeks postinjection (WMD 12.50; 95% CI 2.70 to 22.30, P value 0.01). There was no significant difference in the patient global evaluation of treatment efficacy (0 to 100 mm VAS) at 1 to 4 or at 5-13 weeks postinjection.</P>
<P>When excluding the Healon arm, there was no statistically significant difference in pain on weight bearing at 1 to 4 or at 5 to 13 weeks postinjection (<LINK REF="STD-Karlsson-2002c-_x0028_AvS_x0029_" TYPE="STUDY">Karlsson 2002c (AvS)</LINK>, <LINK REF="STD-Wobig-1999b-_x0028_Artz_x0029_" TYPE="STUDY">Wobig 1999b (Artz)</LINK>). There was no statistically significant difference in pain at night at 1 to 4 or at 5 to 13 weeks postinjection (<LINK REF="STD-Wobig-1999b-_x0028_Artz_x0029_" TYPE="STUDY">Wobig 1999b (Artz)</LINK>). There was no significant difference in improvement in knee movement (0 to 100 mm VAS) at 1 to 4 weeks postinjection. There was a significant difference in improvement in knee movement in favour of Hylan G-F 20 at 5 to 13 weeks postinjection (WMD 17.00; 95% CI 3.14 to 30.66, P value 0.02). There was no significant difference in patient global evaluation of treatment efficacy at 1 to 4 weeks postinjection. There was a statistically significant difference in patient global evaluation of treatment efficacy in favour of Hylan G-F 20 at 5 to 13 weeks postinjection (WMD 16.00; 95% CI 2.14 to 29.86, P value 0.02).<BR/>
<I>
<BR/>Safety<BR/>
</I>
<BR/>The safety profile of the three groups (Artz, Healon and Hylan G-F 20) was very similar (<LINK REF="STD-Wobig-1999" TYPE="STUDY">Wobig 1999</LINK>). No patients reported systemic reactions. Two Hylan G-F 20 patients and one Artz patient reported local reactions. One Hylan G-F 20 patient and two Healon patients withdrew from the trial.</P>
<P>
<I>
<B>Product - Hyruan</B>
</I>
</P>
<P>
<I>Description of studies:</I>
</P>
<P>Three studies were excluded (<LINK REF="STD-Lee-1999" TYPE="STUDY">Lee 1999</LINK>; <LINK REF="STD-Oberoi-2004" TYPE="STUDY">Oberoi 2004</LINK>; <LINK REF="STD-Rastogi-2005" TYPE="STUDY">Rastogi 2005</LINK>). One study is awaiting assessment (<LINK REF="STD-Lee-2002" TYPE="STUDY">Lee 2002</LINK>).<BR/>
<I>
<B>
<BR/>Product - NRD-101 (Suvenyl)<BR/>
</B>
<BR/>Description of studies:<BR/>
</I>
<BR/>Two RCTs have been included (<LINK REF="STD-Pham-2003" TYPE="STUDY">Pham 2003</LINK> (abstract); <LINK REF="STD-Pham-2004" TYPE="STUDY">Pham 2004</LINK> (final publication); <LINK REF="STD-Tsukamoto-1995" TYPE="STUDY">Tsukamoto 1995</LINK>(abstract); <LINK REF="STD-Yamamoto-1994" TYPE="STUDY">Yamamoto 1994</LINK> (final publication)).</P>
<P>Pham et al. reported a one-year, parallel-group, double-blind, placebo-controlled, multicentre (46 rheumatology departments) RCT performed in France comparing three weekly injections of NRD-101 plus oral placebo to: 1) three weekly injections of saline solution plus Diacerein 50 mg twice daily, and 2) three weekly IA injections of saline solution plus oral placebo (<LINK REF="STD-Pham-2004" TYPE="STUDY">Pham 2004</LINK>, <LINK REF="STD-Pham-2003" TYPE="STUDY">Pham 2003</LINK>). The objective was to evaluate long-term structural and symptomatic efficacy of three courses (every three months) of three weekly IA injections of NRD-101over a one-year period. No statistically significant between-group differences were found for pain. There was a statistically significant deterioration in joint space width but no difference between the three groups. The trial did not find any structural and/or symptomatic effect for NRD-101 and Diacerein. With respect to safety, patients in the NRD-101 group had significantly more knee pain during or after intraarticular injection, while patients in the Diacerein group had more diarrhoea and urine colouration. With respect to methodological quality, the trial scored 5 out of 5 on the Jadad scale achieving points for both randomisation and blinding details. Allocation concealment was adequate.</P>
<P>The statistical analyses were performed using the change between baseline and the final visit since raw means and standard deviations for unadjusted post-test scores were not available.</P>
<P>Yamamoto et al. reported a five-week, parallel-group, double-blind RCT performed at 31 centres in Japan comparing five weekly injections of NRD-101 (produced by fermentation using Streptococcus equi, a type of lactobacilli, Denki Kagaku Kogyo) to five weekly injections of Artz in 203 patients with OA of the knee (<LINK REF="STD-Tsukamoto-1995" TYPE="STUDY">Tsukamoto 1995</LINK>; <LINK REF="STD-Yamamoto-1994" TYPE="STUDY">Yamamoto 1994</LINK>). Statistically significant differences in favour of NRD-101 were reported for 'final global improvement' and 'usefulness' but not for evaluation of improvement in clinical symptoms. Adverse events were reported for 2 of 100 NRD-101 patients and 3 of 99 Artz patients.</P>
<P>This comparative HA trial was of short duration with the longest assessment only one week postinjection. The 31 trial sites were all Departments of Orthopedic Surgery. Almost all of the clinical evaluations were based on physician ratings rather than on patient ratings.</P>
<P>With respect to methodological quality, the average Jadad score was 5 out of 5; both the Pham trial and the Yamamoto trial scoring 5. Allocation concealment was adequate for both trials. One trial was excluded (<LINK REF="STD-Kurokawa-1994" TYPE="STUDY">Kurokawa 1994</LINK>).</P>
<P>NRD-101 (Suvenyl) versus placebo<BR/>
<I>
<BR/>Efficacy</I>
</P>
<P>
<LINK REF="TBL-36" TYPE="TABLE">Table 36</LINK>; <LINK REF="TBL-37" TYPE="TABLE">Table 37</LINK>
</P>
<P>Readers should note that the results of the efficacy data on the symptomatic outcome measures were reported as change between baseline and the final visit for the Pham trial (<LINK REF="STD-Pham-2004" TYPE="STUDY">Pham 2004</LINK>). There were no statistically significant differences between NRD-101 and placebo for pain (0-100 mm VAS), the Lequesne Index (0-100 modified scale), patient global assessment (0-100 mm VAS), or the percentage of painful days (0-100 mm VAS.</P>
<P>Data were reported on the percentage of progressors (joint space narrowing greater than 0.5 mm). There was no statistically significant difference between NRD 101 + oral placebo 23 of 131 (17.6%) and saline injection + oral placebo 17 out of 85 (20.3%).<BR/>
<I>
<BR/>Safety </I>
</P>
<P>No statistically significant differences were detected for the following safety variables between NRD-101 and placebo: total wihdrawals overall, withdrawals due to inefficacy, number of withdrawals due to adverse events, number of patients reporting knee pain during or after IA injection, or number of patients reporting diarrhoea (<LINK REF="STD-Pham-2004" TYPE="STUDY">Pham 2004</LINK>).</P>
<P>NRD-101 (Suvenyl) versus corticosteroid: no trials included.</P>
<P>NRD-101 (Suvenyl) versus NSAID (Diacerein)<BR/>
<I>
<BR/>Efficacy</I>
</P>
<P>
<LINK REF="TBL-38" TYPE="TABLE">Table 38</LINK>; <LINK REF="TBL-39" TYPE="TABLE">Table 39</LINK>
<I>
<BR/>
</I>
<BR/>Readers should note that the results of the efficacy data on the symptomatic outcome measures were reported as change between baseline and the final visit for the Pham trial (<LINK REF="STD-Pham-2004" TYPE="STUDY">Pham 2004</LINK>). There were no statistically significant differences between NRD-101 and Diacerein for any of the efficacy outcome measures: pain (0-100 mm VAS), Lequesne Index (0-100 modified scale), patient global assessment (0-100 mm VAS) or the percentage of painful days (0-100 mm VAS).</P>
<P>Data were reported on the percentage of progressors (joint space narrowing greater than 0.5 mm) (<LINK REF="STD-Pham-2003" TYPE="STUDY">Pham 2003</LINK>). There was no statistically significant difference between NRD 101 + oral placebo 23 of 131 (17.6%) and Diacerein + saline injection 16 of 85 (18.9%).<BR/>
<I>
<BR/>Safety </I>
</P>
<P>A statistically significant difference in favour of NRD-101 compared to Diacerein was detected in the number of patients that reported diarrhoea (RR 0.22; 95% CI 0.12 to 0.40, P &lt; 0.00001) (41% versus 9%). A statistically significant difference in favour of Diacerein compared to NRD-101 was detected in the number of patients that reported knee pain during or after IA injection (RR 2.51; 95% CI 1.21 to 5.21, P value 0.01) (24% versus 9%). There were no statistically significant differences between NRD-101 and Diacerein for the total withdrawals overall, withdrawals due to inefficacy, or the number of withdrawals due to adverse events (<LINK REF="STD-Pham-2004" TYPE="STUDY">Pham 2004</LINK>).</P>
<P>NRD-101 (Suvenyl) versus other hyaluronans<BR/>
<I>
<BR/>Efficacy<BR/>
</I>
<LINK REF="TBL-40" TYPE="TABLE">Table 40</LINK>; <LINK REF="TBL-41" TYPE="TABLE">Table 41</LINK>
<BR/>For the NRD-101 comparison against Artz (<LINK REF="STD-Tsukamoto-1995" TYPE="STUDY">Tsukamoto 1995</LINK>; <LINK REF="STD-Yamamoto-1994" TYPE="STUDY">Yamamoto 1994</LINK>) there were no statistically significant differences between the two products in any measure of efficacy at 1 to 4 weeks postinjection: spontaneous pain, pain on pressure, pain during the night, passive movement pain, passive flexion, passive extension, and patient global assessment.<BR/>
<I>
<BR/>Safety </I>
</P>
<P>There was a trend of more withdrawals overall in the Artz group (15%) compared to the NRD-101 group (6%) (RR 0.40; 95% CI 0.16 to 1.00, P value 0.05) (<LINK REF="STD-Yamamoto-1994" TYPE="STUDY">Yamamoto 1994</LINK>). There were a similar number of adverse events reported in the two groups: 2 of 100 in NRD-101 and 3 of 99 in the Artz group.<BR/>
<I>
<B>
<BR/>Product -</B>
</I> <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK>
<BR/>
<I>
<BR/>Description of studies<BR/>
</I>
<BR/>Fourteen randomised controlled trials of <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> (Anika Therapeutics, Inc., Woburn, MA) have been included. Eleven have been reported as journal articles (<LINK REF="STD-Bayramoglu-2003" TYPE="STUDY">Bayramoglu 2003</LINK>; <LINK REF="STD-Brandt-2001" TYPE="STUDY">Brandt 2001</LINK>; <LINK REF="STD-Karatay-2005a" TYPE="STUDY">Karatay 2005a</LINK>; <LINK REF="STD-Karatosun-2005a" TYPE="STUDY">Karatosun 2005a</LINK>; <LINK REF="STD-Kotevoglu-2005" TYPE="STUDY">Kotevoglu 2005</LINK>; <LINK REF="STD-Neustadt-2005a-_x002d_3inj" TYPE="STUDY">Neustadt 2005a -3inj</LINK>; <LINK REF="STD-Ozturk-2005" TYPE="STUDY">Ozturk 2005</LINK>; <LINK REF="STD-Sezgin-2005" TYPE="STUDY">Sezgin 2005</LINK>; <LINK REF="STD-Tascioglu-2003" TYPE="STUDY">Tascioglu 2003</LINK>; <LINK REF="STD-Tekeoglu-1998" TYPE="STUDY">Tekeoglu 1998</LINK>; <LINK REF="STD-Yentur-2003" TYPE="STUDY">Yentur 2003</LINK>), one was the basis of a specialization thesis (<LINK REF="STD-Kalay-1997" TYPE="STUDY">Kalay 1997</LINK>), one was presented as a poster at the 10th National Rheumatology Congress in Turkey (<LINK REF="STD-Guler-1996" TYPE="STUDY">Guler 1996</LINK>), and one remains unpublished (<LINK REF="STD-Hizmetli-1999" TYPE="STUDY">Hizmetli 1999</LINK>). <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> has been compared against placebo (<LINK REF="STD-Brandt-2001" TYPE="STUDY">Brandt 2001</LINK>; <LINK REF="STD-Guler-1996" TYPE="STUDY">Guler 1996</LINK>; <LINK REF="STD-Hizmetli-1999" TYPE="STUDY">Hizmetli 1999</LINK>; <LINK REF="STD-Kotevoglu-2005" TYPE="STUDY">Kotevoglu 2005</LINK>; <LINK REF="STD-Sezgin-2005" TYPE="STUDY">Sezgin 2005</LINK>), arthrocentesis (<LINK REF="STD-Neustadt-2005a-_x002d_3inj" TYPE="STUDY">Neustadt 2005a -3inj</LINK>), betamethasone (<LINK REF="STD-Tekeoglu-1998" TYPE="STUDY">Tekeoglu 1998</LINK>), 6-methylprednisolone acetate (<LINK REF="STD-Tascioglu-2003" TYPE="STUDY">Tascioglu 2003</LINK>), in combination with triamcinolone acetonide (<LINK REF="STD-Ozturk-2005" TYPE="STUDY">Ozturk 2005</LINK>), IA hylan (<LINK REF="STD-Bayramoglu-2003" TYPE="STUDY">Bayramoglu 2003</LINK>; <LINK REF="STD-Karatay-2004" TYPE="STUDY">Karatay 2004</LINK>; <LINK REF="STD-Karatosun-2005a" TYPE="STUDY">Karatosun 2005a</LINK>; <LINK REF="STD-Kotevoglu-2005" TYPE="STUDY">Kotevoglu 2005</LINK>), physical therapy (<LINK REF="STD-Bayramoglu-2003" TYPE="STUDY">Bayramoglu 2003</LINK>; <LINK REF="STD-Kalay-1997" TYPE="STUDY">Kalay 1997</LINK>), and in combination with lidocaine (<LINK REF="STD-Yentur-2003" TYPE="STUDY">Yentur 2003</LINK>). With the exception of the Brandt RCT (<LINK REF="STD-Brandt-2001" TYPE="STUDY">Brandt 2001</LINK>), which was conducted in the United States, and the Neustadt RCT (<LINK REF="STD-Neustadt-2005a-_x002d_3inj" TYPE="STUDY">Neustadt 2005a -3inj</LINK>), which was conducted in Canada and the United States, the other twelve RCT were conducted in Turkey. With respect to methodological quality, the average Jadad score was 2.9 out of 5, with one trial scoring 5 (<LINK REF="STD-Neustadt-2005a-_x002d_3inj" TYPE="STUDY">Neustadt 2005a -3inj</LINK>), two trials scoring 4 (<LINK REF="STD-Brandt-2001" TYPE="STUDY">Brandt 2001</LINK>; <LINK REF="STD-Hizmetli-1999" TYPE="STUDY">Hizmetli 1999</LINK>), three trials scoring 3 (<LINK REF="STD-Guler-1996" TYPE="STUDY">Guler 1996</LINK>; <LINK REF="STD-Kotevoglu-2005" TYPE="STUDY">Kotevoglu 2005</LINK>; <LINK REF="STD-Ozturk-2005" TYPE="STUDY">Ozturk 2005</LINK>), six trials scoring 2 (<LINK REF="STD-Bayramoglu-2003" TYPE="STUDY">Bayramoglu 2003</LINK>; <LINK REF="STD-Kalay-1997" TYPE="STUDY">Kalay 1997</LINK>; <LINK REF="STD-Sezgin-2005" TYPE="STUDY">Sezgin 2005</LINK>; <LINK REF="STD-Tascioglu-2003" TYPE="STUDY">Tascioglu 2003</LINK>; <LINK REF="STD-Tekeoglu-1998" TYPE="STUDY">Tekeoglu 1998</LINK>; <LINK REF="STD-Yentur-2003" TYPE="STUDY">Yentur 2003</LINK>), and one trial scoring 1 (<LINK REF="STD-Karatay-2005a" TYPE="STUDY">Karatay 2005a</LINK>). Allocation concealment was adequately described in four trials (<LINK REF="STD-Brandt-2001" TYPE="STUDY">Brandt 2001</LINK>; <LINK REF="STD-Karatosun-2005a" TYPE="STUDY">Karatosun 2005a</LINK>; <LINK REF="STD-Neustadt-2005a-_x002d_3inj" TYPE="STUDY">Neustadt 2005a -3inj</LINK>; <LINK REF="STD-Ozturk-2005" TYPE="STUDY">Ozturk 2005</LINK>) and unclear (not reported) in the remaining ten trials. Seven trials were excluded (<LINK REF="STD-Ates-2001" TYPE="STUDY">Ates 2001</LINK>; <LINK REF="STD-Birbara-2004" TYPE="STUDY">Birbara 2004</LINK>; <LINK REF="STD-Koyuncu-2002" TYPE="STUDY">Koyuncu 2002</LINK>; <LINK REF="STD-Olszynski-2002" TYPE="STUDY">Olszynski 2002</LINK>; <LINK REF="STD-Oron-2003" TYPE="STUDY">Oron 2003</LINK>; <LINK REF="STD-Sepici-2002" TYPE="STUDY">Sepici 2002</LINK>; <LINK REF="STD-Toh-2002" TYPE="STUDY">Toh 2002</LINK>; <LINK REF="STD-Toh-2003" TYPE="STUDY">Toh 2003</LINK>). Three trials are awaiting assessment (<LINK REF="STD-Gur-2002" TYPE="STUDY">Gur 2002</LINK>; <LINK REF="STD-Kilinc-2002" TYPE="STUDY">Kilinc 2002</LINK>; <LINK REF="STD-Renk_x005b_inodot_x005d_tepe-20" TYPE="STUDY">Renk[inodot]tepe 20</LINK>). These trials have only been published as abstracts with no extractable data, and at the closure of the database for this review no full length manuscripts have been published.</P>
<P>Bayramoglu et al. reported a three-month, parallel-group RCT performed at a single centre in Turkey comparing three weekly injections of <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> plus a physical therapy programme to three weekly injections of Hylan G-F 20 plus a physical therapy programme to a physical therapy programme alone (deep tissue heating with short wave diathermy, transcutaneous electrical neuromuscular stimulation and exercises) in 46 patients with OA of the knee (<LINK REF="STD-Bayramoglu-2003" TYPE="STUDY">Bayramoglu 2003</LINK>). The authors were particularly interested in examining the effect of IA HA injection on muscular strength; testing the hypothesis that if patients were relieved of pain and disability then indirectly they would build stronger quadriceps muscles. They reported within-group improvement in the Lequesne score for all three groups but no between-group difference. No within- or between-group difference was detected in muscular strength. No between-group differences were reported for range of motion, knee instability, existing deformities and radiographic grade. No adverse events were associated with the IA hyaluronic acid injections.</P>
<P>The Bayramoglu et al. RCT had a small sample size. However, it was classified as a pilot study. The presence or absence of effusion, usage of rescue and concomitant medications, and OA diagnosis criteria were not reported. There was a difference in the number of patients with bilateral disease: 100% physical therapy (PT) group, 75% <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> group and 67% Hylan G-F 20 group. No difference was found with respect to the MW of the HA products. Since PT is part of the first line nonpharmacologic therapy in the medical management of patients with OA of the knee, the designation of PT alone as a treatment group in comparison to the two combination groups (pharmacologic + nonpharmacologic groups) was a particular interest in this trial.</P>
<P>Brandt et al. reported a 27-week, placebo-controlled, double-blind RCT performed at 10 centres in the United States comparing three weekly injections of <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> to three weekly injections of saline in 226 patients with OA of the knee (<LINK REF="STD-Brandt-2001" TYPE="STUDY">Brandt 2001</LINK>). The authors examined the influence of contralateral knee pain in a post hoc analysis of patients who completed at least 15 weeks of the trial, had no major protocol violations, and a WOMAC OA Index pain score less than 12 in the contralateral knee. This 'effectiveness' population controlled for the severity in the contralateral knee. The authors concluded that, in patients with mild to moderate OA of the knee, <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> produced statistically and clinically significant improvement. No side effects were attributed to treatment. The incidence of injection site reaction was similar in both groups: 2.1% <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> and 1.5% saline.</P>
<P>The Brandt et al. RCT did not report the presence or absence of effusion or disease duration (<LINK REF="STD-Brandt-2001" TYPE="STUDY">Brandt 2001</LINK>). In this trial, acetaminophen was permitted at the recommended treatment dosage of 1 g four times daily, but was restricted 24 h before assessment visits. Patients in this trial had a high percentage of bilateral knee disease, but only the index knee received treatment. WOMAC OA Index questionnaires were completed by patients for each knee separately. The severity of pain in the contralateral knee confounded the outcome measurements in the index knee. The authors discussed how the pain response may be affected by severity of contralateral knee pain. They also noted the large placebo response detected in this trial. Although 78% of the patients randomised completed the trial, results were based only on the effectiveness population (i.e. 60%). It is of note that no significant difference was detected in the intent-to-treat population between <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> and placebo. The authors defined a clinically meaningful improvement as a decrease of at least three units in the WOMAC pain subscale score. They utilised a 1 to 5 scoring system for the Likert version of the WOMAC OA Index resulting in a score range of 5 to 25 for the pain subscale of the Index.</P>
<P>Guler et al. reported a 10-week, placebo-controlled, double-blind RCT performed at one centre in Turkey comparing three weekly injections of <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> to three weekly injections of saline in 30 patients with OA of the knee (<LINK REF="STD-Guler-1996" TYPE="STUDY">Guler 1996</LINK>). Statistically significant improvement was reported in the <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> group for the WOMAC pain and physical function subscales, walking time, and acetaminophen usage compared to the saline group. No adverse events were reported.</P>
<P>The small trial by Guler et al. demonstrated between-group differences (<LINK REF="STD-Guler-1996" TYPE="STUDY">Guler 1996</LINK>). Of particular note, there was a statistically significant decrease in the use of acetaminophen in the <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> group. Although the abstract reported WOMAC OA Index subscale ranges with the minimum set at zero, it appeared that the score was based on 1 to 5.</P>
<P>Hizmetli et al. completed a one-year, placebo-controlled, double-blind RCT in Turkey comparing three weekly injections of <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> to saline in 50 patients with OA of the knee (<LINK REF="STD-Hizmetli-1999" TYPE="STUDY">Hizmetli 1999</LINK>). A fourth injection was given at six months. Statistically significant differences in all subscales of the WOMAC OA Index in favour of <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> were reported. No local or systemic side effects were observed. This unpublished report was kindly provided by Anika Therapeutics Inc.</P>
<P>The Hizmetli et al. trial was one of a few unpublished trials included in this review (<LINK REF="STD-Hizmetli-1999" TYPE="STUDY">Hizmetli 1999</LINK>). The manuscript did not report presence or absence of effusion, disease duration, or presence of uni/bilateral disease. The trial addressed repeat treatment at six months. Analgesics were restricted for the first four weeks of the trial.</P>
<P>Kalay reported a 56-day, parallel-group, open-label RCT performed at a single centre in Turkey comparing two weekly injections of <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> plus a physical therapy programme to a physical therapy programme (paraffin, short wave, quadriceps exercises) in 40 patients with OA of the knee (<LINK REF="STD-Kalay-1997" TYPE="STUDY">Kalay 1997</LINK>). Statistically significant improvement was reported in the <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> group compared to the physical therapy alone group for the following clinical outcome measures: pain, paracetamol usage, walk time, and patient and investigator evaluation of treatment. Two patients in the <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> group had local pain and swelling which resolved within 24 hours.</P>
<P>The Kalay trial utilised a two-injection schedule rather than a three-injection schedule (<LINK REF="STD-Kalay-1997" TYPE="STUDY">Kalay 1997</LINK>). The publication did not report the presence or absence of effusion or disease duration. However, supplemental use of paracetamol as rescue medication was graded and recorded. Statistically significant decreases in consumption were seen in both groups at the end of the study compared to baseline. As well, a statistically significant between-group difference in favour of <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> was found at the eighth week.</P>
<P>Karatay et al. reported a three-week, parallel group RCT performed at a single centre in Turkey comparing three weekly injections of <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> to three weekly injections of hylan G-F 20 in 40 patients with OA of the knee (<LINK REF="STD-Karatay-2004" TYPE="STUDY">Karatay 2004</LINK>; <LINK REF="STD-Karatay-2005" TYPE="STUDY">Karatay 2005</LINK>; <LINK REF="STD-Karatay-2005a" TYPE="STUDY">Karatay 2005a</LINK>). The objective of this trial was to evaluate the effects of HA on synovial fluid levels of intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (V-CAM-1). ICAM-1 and VCAM-1 levels were significantly reduced in both groups. Both groups showed within-group improvement in WOMAC pain and physical function scores with significant within-group improvement being detected for WOMAC stiffness. However, no signiifcant between-group differences were found for any of the outcome measures. Safety was not reported.</P>
<P>Karatosun et al. reported a one-year, double-blind, parallel-group RCT performed at a single centre in Turkey comparing three weekly injections of <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> to three weekly injections of Hylan G-F 20 in 92 patients with OA of the knee (<LINK REF="STD-Karatosun-2005a" TYPE="STUDY">Karatosun 2005a</LINK>). The authors reported no statistically significant differences between the groups as both groups improved in the Hospital for Special Surgery scores. Both HA products were well tolerated with no complications due to HA injection being reported. Approximately 30% of patients in each group (<LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> 30.4% and Hylan G-F 20 34.8%) withdrew early from the trial.</P>
<P>Patients with advanced (i.e. Kellgren-Lawrence Grade III) bilateral knee OA were enrolled in this trial. A blinded physical therapist assessed the efficacy and safety of the therapy. This is one of the longest trials comparing two HA products using the Hospital for Special Surgery Knee Score as the primary outcome measure. Dr. Karatosun kindly provided means and standard deviations for the reported outcome measures.</P>
<P>Kotevolgu et al. reported a six-month, parallel-group, placebo-controlled, double-blind RCT performed at a single centre in Turkey comparing three weekly injections of <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> to three weekly injections of <LINK REF="REF-Synvisc-Hylan-G_x002d_F-20" TYPE="REFERENCE">Synvisc Hylan G-F 20</LINK> or saline solution in 78 patients with OA of the knee without effusion (<LINK REF="STD-Kotevoglu-2005" TYPE="STUDY">Kotevoglu 2005</LINK>). The authors reported that all patients showed clinical improvement but that neither hyaluronan product was more effective than the other. With respect to safety, local adverse events were reported by two patients and these (transient pain at injection site or warm knee lasting for one night) resolved without sequelae. Dr. Nurdan Kotevoglu kindly provided an Excel worksheet with the means and standard deviations for the WOMAC OA Index, patient global assessment and physican global assessment; in addition clarified withdrawals.</P>
<P>Neustadt et al. (<LINK REF="STD-Neustadt-2005a-_x002d_3inj" TYPE="STUDY">Neustadt 2005a -3inj</LINK>) reported a six-month, double-blind, arthrocentesis-controlled RCT performed at 24 centres in Canada and the United States comparing four weekly injections of <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> to either three weekly injections of <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> followed by one arthrocentesis or four arthrocenteses without injection in 372 patients with OA of the knee. The authors reported that there was no statistically significant difference in the primary outcome (greater than or equal to 20% improvement in the WOMAC OA Index pain subscale score) between the 4-injection <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> group and the arthrocentesis group. With respect to safety, no between group differences were reported in the incidence of adverse events.</P>
<P>For the above RCT, the ITT population was used for safety analyses. However, the "primary planned analysis population" was the evaluable population which was defined as "patients who received all 4 treatments and at least one followup visit and who had no significant protocol deviation". One of the inclusion criteria for this trial was that patients had to score less than 150 mm out of 500 mm on the WOMAC OA Index pain subscale in the contralateral (untreated) knee. In the tables of comparisons and data, the 4 injection schedule comparison is referred to as <LINK REF="STD-Neustadt-2005b_x002d_4inj" TYPE="STUDY">Neustadt 2005b-4inj</LINK>, while the 3 injection schedule is referred to as <LINK REF="STD-Neustadt-2005a-_x002d_3inj" TYPE="STUDY">Neustadt 2005a -3inj</LINK>. The analyses were performed using the change from baseline and absolute means and standard deviations for unadjusted post-test score were not available from Anika Therapeutics, Inc.. Anika Therapeutics, Inc. kindly provided additional information regarding reasons for discontinuation and a patient tree. Withdrawals were separated into those who withdrew before 8 weeks (n=34) and those who withdrew after 8 weeks (n=78).</P>
<P>Ozturk et al. reported a one-year, parallel-group, single-blind RCT performed at a single centre in Turkey comparing three weekly injections of <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> followed by three weekly injections at six months of the same <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> regimen but in combination with one ml of triamcinolone acetonide (Kenacort-A) prior to the first and fourth injections of <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> after any effusion had been aspirated in 47 patients with OA of the knee (<LINK REF="STD-Ozturk-2005" TYPE="STUDY">Ozturk 2005</LINK>). The objective of this study was to assess the efficacy and safety of <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> with/without corticosteroid. Repeat treatment occurred at the sixth month. In addition, magnetic resonance imaging was used to evaluate the progression of OA. The authors reported that neither treatment showed progression of cartilage damage. With respect to efficacy, an improvement was reported in all patients for functional measures but pain decreased more rapidly and to lower levels in the combination treatment group. With respect to safety, one patient from the combination group and two patients from the <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> group reported adverse events (i.e. local reactions including mild swelling, warmth, pain at the injection site) after the third injection. However, these events resolved within a few days after application of cold packs. Dr. F. Atamaz kindly provided absolute means and standard deviations for both groups as well as clarified group allocation for withdrawals.</P>
<P>Sezgin et al. reported a four-week, placebo-controlled, single-blind RCT performed at a single centre in Turkey comparing three weekly injections of <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> to three weekly injections of sodium chloride (0.9%) in 41 patients with OA of the knee (<LINK REF="STD-Sezgin-2005" TYPE="STUDY">Sezgin 2005</LINK>). The objective of this study was to investigate whether hyaluronan had any effect on inflammatory cytokines. The authors reported that hyaluronan significantly decreased IL-6 levels which correlated with clinical improvement. WOMAC pain, stiffness and physical function scores decreased more in the hyaluronan group than the control group, as did flexion, walking time, knee circumference and amount of effusion. With respect to safety, no patients reported any adverse events during or after the treatment; albeit some patients reported short-lasting pain (one or 2 minutes) during the injections.</P>
<P>Tascioglu and Oner reported a six-month, parallel-group, open-label RCT performed at a single centre in Turkey comparing three weekly injections of <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> to three weekly injections of 6-methylprednisolone acetate (6-MPA) in 69 female patients with OA of the knee (<LINK REF="STD-Tascioglu-2003" TYPE="STUDY">Tascioglu 2003</LINK>). A significant improvement was reported in both groups at week four in pain and Lequesne outcome measures. At three months, a significant improvement in pain and Lequesne was reported in favour of <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> compared to 6-MPA. By six months, there was no difference between the two groups. No serious systemic adverse events were reported that could be related to the treatment. Similar percentages of patients reported knee pain after injection (<LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> 21%, 6-MPA 18%). There was no significant between-group difference with respect to adverse events.</P>
<P>In the Tascioglu and Oner trial paracetamol to a maximum of 3 g was permitted but with restriction 48 hours prior to an assessment (<LINK REF="STD-Tascioglu-2003" TYPE="STUDY">Tascioglu 2003</LINK>). The percentage of patients with uni and bilateral disease was not reported.</P>
<P>Tekeoglu et al. reported a 15-week, parallel-group, open-label RCT performed in Turkey comparing three weekly injections of <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> to three weekly injections of betamethasone in 40 female patients with OA of the knee (<LINK REF="STD-Tekeoglu-1998" TYPE="STUDY">Tekeoglu 1998</LINK>). In the short term (week 3), betamethasone was more effective than <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK>. In the long term (week 15), <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> was more effective than betamethasone. No local or systemic reactions were reported.</P>
<P>The Tekeoglu et al. trial allowed patients to take paracetamol as well (<LINK REF="STD-Tekeoglu-1998" TYPE="STUDY">Tekeoglu 1998</LINK>). Again, the percentage of patients with uni and bilateral disease was not reported. In this RCT, patients were advised to rest for one day after injection 'to avoid overcharging the injected joint'.</P>
<P>Yentur et al. reported a 21-day, parallel-group, single-blind RCT performed in Turkey comparing three weekly injections of <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> plus trigger point injections with 0.5% lidocaine to three weekly injections of <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> in 34 female patients with OA of the knee (<LINK REF="STD-Yentur-2003" TYPE="STUDY">Yentur 2003</LINK>). The authors reported that the combination therapy group had significantly reduced pain and improved function while pain reduction and function improvement were not significant in the <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> alone group. Although the authors reported that no local or systemic adverse events were observed, some patients reported local pain which only lasted for one day and ecchymosis which healed in a few days. Only one patient in the <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> group did not complete the trial.</P>
<P>This small trial addressed an interesting question whether injection of 15 specific trigger points with lidocaine in combination with hyaluronic acid was more effective than hyaluronic acid alone. In this design, symptoms arising from the soft tissues surrounding the knee and not just the joint were treated. A two-day rest period after each injection was utilised in the trial. In addition, a blinded physician completed all assessments.</P>
<P>
<LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> versus placebo<BR/>
<I>
<BR/>Efficacy<BR/>
</I>
<LINK REF="TBL-42" TYPE="TABLE">Table 42</LINK>; <LINK REF="TBL-43" TYPE="TABLE">Table 43</LINK>; <LINK REF="TBL-44" TYPE="TABLE">Table 44</LINK>; <LINK REF="TBL-45" TYPE="TABLE">Table 45</LINK>; <LINK REF="TBL-46" TYPE="TABLE">Table 46</LINK>
<BR/>A statistically significant difference was detected in pain, as measured by the WOMAC OA Index (scored 5 to 25), in favour of <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> compared to placebo (WMD (RE) -4.36; 95% CI -7.51 to -1.21, P &lt; 0.00001) at 1 to 4 weeks postinjection (<LINK REF="STD-Hizmetli-1999" TYPE="STUDY">Hizmetli 1999</LINK>; <LINK REF="STD-Kotevoglu-2005" TYPE="STUDY">Kotevoglu 2005</LINK>; <LINK REF="STD-Sezgin-2005" TYPE="STUDY">Sezgin 2005</LINK>); (WMD -5.40; 95% CI -6.92 to -3.89, P &lt; 0.00001) at 5 to 13 weeks postinjection; (WMD (RE) -4.41; 95% CI -6.95 to -1.88, P value 0.0007) at 14 to 26 weeks postinjection (<LINK REF="STD-Hizmetli-1999" TYPE="STUDY">Hizmetli 1999</LINK>; <LINK REF="STD-Kotevoglu-2005" TYPE="STUDY">Kotevoglu 2005</LINK>); and (WMD -5.30; 95% CI -7.02 to -3.58, P &lt; 0.00001) at 45 to 52 weeks postinjection (<LINK REF="STD-Hizmetli-1999" TYPE="STUDY">Hizmetli 1999</LINK>). <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> was between 23 and 45% more effective than saline in relieving pain as measured by the WOMAC OA Index pain subscale. Item five of the WOMAC OA Index pain subscale, pain on standing (measured on a 0 to 100 mm VAS), was utilised as a secondary outcome measure in the Neustadt et al. RCT. No statistically significant difference was detected in this outcome measure between <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> and arthrocentesis (<LINK REF="STD-Neustadt-2005a-_x002d_3inj" TYPE="STUDY">Neustadt 2005a -3inj</LINK>; <LINK REF="STD-Neustadt-2005b_x002d_4inj" TYPE="STUDY">Neustadt 2005b-4inj</LINK>).</P>
<P>The proportion of patients achieving a 20% relative and 50 mm absolute improvement from baseline in the WOMAC OA Index pain subscale (measured on a 0 to 500 mm VAS) was the primary outcome measure for the Neustadt et al. RCT. No statistically significant difference was detected between <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> and arthrocentesis either at 5 to 13 weeks postinjection (RE) or at 14 to 26 weeks postinjection. When evaluating the proportion of patients achieving a 40% relative improvement from baseline, a statistically significant difference was detected in favour of the <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> group compared to arthrocentesis at 5 to 13 weeks postinjection (RR 1.30; 95% CI 1.08 to 1.57, P value 0.006); while a trend was detected at 14 to 26 weeks postinjection (RR 1.22; 95% CI 1.00 to 1.49, P value 0.05). No statistically significant diference was detected in the 50% relative improvement comparison (<LINK REF="STD-Neustadt-2005a-_x002d_3inj" TYPE="STUDY">Neustadt 2005a -3inj</LINK>; <LINK REF="STD-Neustadt-2005b_x002d_4inj" TYPE="STUDY">Neustadt 2005b-4inj</LINK>).</P>
<P>In Brandt's trial (Brandt 2001), results are presented only for the effectiveness population which represents approximately a 40% loss of the initially randomised population. There was a trend in favour of Orthovisc compared to saline in the number of patients who achieved a greater than five-unit improvement in the WOMAC pain score relative to baseline score by 25 weeks postinjection (<LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> 58%, saline 40%) (RR 1.42; 95% CI 1.00 to 2.02, P value 0.05). The RevMan analysis (P value 0.05) disagreed with the publication analysis where a statistically significant difference was detected in favour of <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> (P value 0.04). There was no statistically significant difference in the number of patients who improved in the WOMAC pain subscale score at 14 to 26 weeks postinjection: <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> 92% versus saline 87%.</P>
<P>Physical function, as measured by the WOMAC OA Index (scored 17 to 85), improved significantly with <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> compared to placebo at three of four follow-up assessments: (WMD -7.20; 95% CI -8.84 to -5.56, P &lt; 0.00001) at 1 to 4 weeks postinjection (<LINK REF="STD-Hizmetli-1999" TYPE="STUDY">Hizmetli 1999</LINK>; <LINK REF="STD-Kotevoglu-2005" TYPE="STUDY">Kotevoglu 2005</LINK>; <LINK REF="STD-Sezgin-2005" TYPE="STUDY">Sezgin 2005</LINK>); (WMD -12.87; 95% CI -18.60 to -7.14, P &lt; 0.0001) at 5 to 13 weeks postinjection; and (WMD -10.88; 95% CI -16.97 to -4.79, P value 0.0005) at 14 to 26 weeks postinjection (<LINK REF="STD-Hizmetli-1999" TYPE="STUDY">Hizmetli 1999</LINK>; <LINK REF="STD-Kotevoglu-2005" TYPE="STUDY">Kotevoglu 2005</LINK>); but no statistically significant difference was detected at 45 to 52 weeks postinjection (<LINK REF="STD-Hizmetli-1999" TYPE="STUDY">Hizmetli 1999</LINK>). <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> was between 16 and 42% more effective than saline in improving physical function as measured by the WOMAC OA Index physical function subscale.</P>
<P>No statistically significant differences were detected in the WOMAC OA Index stiffness subscale (scored 2 to 10) between <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> and saline at 1 to 4 weeks postinjection (<LINK REF="STD-Kotevoglu-2005" TYPE="STUDY">Kotevoglu 2005</LINK>; <LINK REF="STD-Sezgin-2005" TYPE="STUDY">Sezgin 2005</LINK>). Statistically significant differences were detected in favour of Orthovisc compared to saline both at 5 to 13 weeks postinjection (WMD -1.50; 95% CI -2.84 to -0.16, P value 0.03)(<LINK REF="STD-Kotevoglu-2005" TYPE="STUDY">Kotevoglu 2005</LINK>) and at 14 to 26 weeks postinjection (WMD -1.50; 95% CI -2.71 to -0.29, P value 0.02) (<LINK REF="STD-Kotevoglu-2005" TYPE="STUDY">Kotevoglu 2005</LINK>).</P>
<P>No statistically significant differences were detected in the total score for the WOMAC OA Index (scored 0 to 2400 mm VAS) between <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> and arthrocentesis either at 5 to 13 or 14 to 26 weeks postinjection (<LINK REF="STD-Neustadt-2005a-_x002d_3inj" TYPE="STUDY">Neustadt 2005a -3inj</LINK>; <LINK REF="STD-Neustadt-2005b_x002d_4inj" TYPE="STUDY">Neustadt 2005b-4inj</LINK>. ).</P>
<P>A statistically significant difference in favour of <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> compared to saline was detected both in patient global assessment (0-100 mm, where 100 was worst severity) both at 1to 4 weeks postinjection (WMD -20.00; 95% CI, -33.22 to -6.78, P value 0.003) and at 5 to 13 weeks postinjection (WMD -20.00; 95% CI -30.63 to -9.37, P value 0.0002); but not at 14 to 26 weeks postinjection (<LINK REF="STD-Kotevoglu-2005" TYPE="STUDY">Kotevoglu 2005</LINK>). No statistically significant differences was detected between <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> and saline in physican global assessment (0-100 mm, where 100 was worst severity) in the Kotevoglu RCT. Similarly, no statistically significant differences were detected in either the patient or physician global assessments (measured on 0 to 100 mm VAS) between <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> and arthrocentesis either at 5 to 13 or 14 to 26 weeks postinjection (<LINK REF="STD-Neustadt-2005a-_x002d_3inj" TYPE="STUDY">Neustadt 2005a -3inj</LINK>; <LINK REF="STD-Neustadt-2005b_x002d_4inj" TYPE="STUDY">Neustadt 2005b-4inj</LINK>).</P>
<P>Patient satisfaction with treatment was similar in the <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> (73%) and saline (33%) groups (<LINK REF="STD-Guler-1996" TYPE="STUDY">Guler 1996</LINK>); (RR 2.20; 95% CI 1.01 to 4.79, P value 0.05) at 5 to 13 weeks postinjection.</P>
<P>Results for additional outcome measures utilised in the Sezgin RCT are as follows. Statistically significant difference were detected in favour of <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> compared to saline for range of motion (measured in degrees) (WMD 4.00; 95% CI 2.02 to 5.98, P &lt; 0.0001)(<LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> was 15% more effective than saline in improving flexion); volume of synovial fluid effusion (WMD -4.00; 95% CI -5.66 to -2.34, P &lt; 0.00001) (<LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> was 24% more effective than saline); interleukin 6 level in the synovial fluid (WMD -11.90; 95% CI -14.09 to -9.71, P &lt; 0.00001) (<LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> was 6% more effective than saline); and interleukin 8 level in the synovial fluid (WMD -4.80; 95% CI -6.54 to 3.06, P &lt; 0.00001) (<LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK>; <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> was 42% more effective than saline) (<LINK REF="STD-Sezgin-2005" TYPE="STUDY">Sezgin 2005</LINK>). No statistically significant differences were detected in 25 metre walking time (measured in seconds), knee circumference (measured in mm), tumor necrosis factor alpha levels in synovial fluid (<LINK REF="STD-Sezgin-2005" TYPE="STUDY">Sezgin 2005</LINK>); or WOMAC OA Index stiffness subscale score (<LINK REF="STD-Kotevoglu-2005" TYPE="STUDY">Kotevoglu 2005</LINK>; <LINK REF="STD-Sezgin-2005" TYPE="STUDY">Sezgin 2005</LINK>).</P>
<P>
<I>Safety<BR/>
</I>
<BR/>No local or systemic adverse events were observed in the Hizmetli trial (<LINK REF="STD-Hizmetli-1999" TYPE="STUDY">Hizmetli 1999</LINK>). No complications (e.g. during or after intraarticular injection) were reported in the Guler trial (<LINK REF="STD-Guler-1996" TYPE="STUDY">Guler 1996</LINK>).</P>
<P>The safety data was based on the intention to treat population in the Brandt trial (<LINK REF="STD-Brandt-2001" TYPE="STUDY">Brandt 2001</LINK>). There were no statistically significant differences between <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> and saline or arthrocentesis in the safety profile for the following outcome measures: total withdrawals overall (<LINK REF="STD-Brandt-2001" TYPE="STUDY">Brandt 2001</LINK>; <LINK REF="STD-Kotevoglu-2005" TYPE="STUDY">Kotevoglu 2005</LINK>; <LINK REF="STD-Neustadt-2005a-_x002d_3inj" TYPE="STUDY">Neustadt 2005a -3inj</LINK>; <LINK REF="STD-Neustadt-2005b_x002d_4inj" TYPE="STUDY">Neustadt 2005b-4inj</LINK>; <LINK REF="STD-Sezgin-2005" TYPE="STUDY">Sezgin 2005</LINK>); withdrawals due to lack of efficacy (<LINK REF="STD-Brandt-2001" TYPE="STUDY">Brandt 2001</LINK>; <LINK REF="STD-Neustadt-2005a-_x002d_3inj" TYPE="STUDY">Neustadt 2005a -3inj</LINK>; <LINK REF="STD-Neustadt-2005b_x002d_4inj" TYPE="STUDY">Neustadt 2005b-4inj</LINK>; <LINK REF="STD-Sezgin-2005" TYPE="STUDY">Sezgin 2005</LINK>); number of patients with local skin rash (<LINK REF="STD-Brandt-2001" TYPE="STUDY">Brandt 2001</LINK>; <LINK REF="STD-Neustadt-2005a-_x002d_3inj" TYPE="STUDY">Neustadt 2005a -3inj</LINK>; <LINK REF="STD-Neustadt-2005b_x002d_4inj" TYPE="STUDY">Neustadt 2005b-4inj</LINK>); number of patients with treatment related adverse events (<LINK REF="STD-Brandt-2001" TYPE="STUDY">Brandt 2001</LINK>); number of patients with musculoskeletal adverse events; number of patients with respiratory adverse events; number of patients with general body adverse events; number of patients with nervous system adverse events (<LINK REF="STD-Brandt-2001" TYPE="STUDY">Brandt 2001</LINK>; <LINK REF="STD-Neustadt-2005a-_x002d_3inj" TYPE="STUDY">Neustadt 2005a -3inj</LINK>; <LINK REF="STD-Neustadt-2005b_x002d_4inj" TYPE="STUDY">Neustadt 2005b-4inj</LINK>); number of patients with local reaction or number of patients withdrawn due to noncompliance (<LINK REF="STD-Kotevoglu-2005" TYPE="STUDY">Kotevoglu 2005</LINK>).</P>
<P>
<LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> versus corticosteroid<BR/>
<I>
<BR/>Efficacy<BR/>
</I>
<BR/>In the <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK>/betamethasone comparison (<LINK REF="STD-Tekeoglu-1998" TYPE="STUDY">Tekeoglu 1998</LINK>), at 1 to 4 weeks postinjection, there were no statistically significant differences for: WOMAC OA Index physical function (scored 17 to 85); the number of patients good or very good; and maximum flexion. At 5 to 13 weeks postinjection, <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> was significantly better than betamethasone for WOMAC function (WMD -9.00; 95% CI -14.15 to -3.85, P value 0.0006). <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> was 20% more effective than betamethasone in improving physical function. <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> was significantly better than betamethasone for patient global assessment (i.e. number of patients good/very good) (RR 1.88; 95% CI 1.04 to 3.39, P value 0.04). The NNT for patient global assessment was 3. There was no statistically significant between-group difference for maximum flexion at 5 to 13 weeks.</P>
<P>In the <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK>/6-methylprednisolone acetate (6-MPA) comparison (<LINK REF="STD-Tascioglu-2003" TYPE="STUDY">Tascioglu 2003</LINK>), there were no statistically significant differences between the two groups for any of the pain outcome measures (0 to 100 mm VAS), the Lequesne Index (0 to 24), or flexion outcome measures at 1 to 4 weeks postinjection. However, at 5 to 13 weeks postinjection, statistically significant differences were detected in all outcome measures, except flexion, in favour of the <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> group: pain on weight bearing (WMD -15.64; 95% CI -24.51 to -6.77, P value 0.0006); pain at rest (WMD -7.70; 95% CI -13.50 to -1.90, P value 0.009); pain on walking (WMD -18.43; 95% CI -29.19 to -7.67, P value 0.0008); and the Lequesne Index (WMD -1.40; 95% CI -2.13 to -0.67, P value 0.0002). <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> was between 25 and 32% more effective than 6-MPA in relieving pain. <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> was 18% more effective than 6-MPA in improving function (Lequesne). At 14 to 26 weeks postinjection, statistically significant differences in all outcome measures, except pain on rest, were detected in favour of the <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> group: pain on weight bearing (WMD -15.40; 95% CI -25.91 to -4.89, P value 0.004); pain on walking (WMD -14.90; 95% CI -25.91 to -3.89, P value 0.008); Lequesne Index (WMD -1.14; 95% CI -2.16 to -0.12, P value 0.03), and flexion (WMD 5.00; 95% CI 0.19 to 9.81, P value 0.04). <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> was between 20 and 31% more effective than 6-MPA in relieving pain and between 4 and 15% more effective than 6-MPA in improving function.</P>
<P>The RevMan analysis differed from the publication analysis (<LINK REF="STD-Tascioglu-2003" TYPE="STUDY">Tascioglu 2003</LINK>). The publication reported no statistically significant between-group difference at six months in pain on weight bearing whereas RevMan detected a statistically significant difference (P value 0.004) in favour of <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> compared to 6-MPA. The publication reported no statistically significant between-group difference at six months in pain on walking whereas RevMan detected a statistically significant difference (P value 0.008) in favour of <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> compared to 6-MPA. The publication reported no statistically significant between-group difference at six months in the Lequesne Index whereas RevMan detected a statistically significant difference (P value 0.03) in favour of <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> compared to 6-MPA. The publication reported no statistically significant between-group difference at six months in flexion whereas RevMan detected a statistically significant difference (P value 0.04) in favour of <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> compared to 6-MPA.</P>
<P>When assessing the combination of trimacinolone acetonide with <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> to <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> alone (<LINK REF="STD-Ozturk-2005" TYPE="STUDY">Ozturk 2005</LINK>), a statistically significant difference in favour of the combination group was found for pain (0 to 100 mm VAS) at 1 to 4 weeks postinjection (WMD 13.00; 95% CI 3.77 to 22.23, P value 0.006) (combination was 26% more effective than <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> alone), but not at any of the other time-points: 5 to 13, 14 to 26, 34, or 45 to 52 weeks postinjection. A statistically significant difference was detected in favour of the combination treatment group compared to <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> alone for the WOMAC OA Index stiffness subscale (0 to 8 Likert) at 1 to 4 weeks postinjection (WMD 0.80; 95% CI 0.02 to 1.58, P value 0.04), at 34 weeks postinjection (WMD 0.80; 95% CI 0.12 to 1.48, P value 0.02), and at 45 to 52 weeks postinjection (WMD 0.80; 95% CI 0.06 to 1.54, P value 0.04) (combination was 20% more effective than <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> alone), but not at 5 to 13 or 14 to 26 weeks postinjection. No statistically significant differences were noted between the groups for the following outcome measures at any of the timepoints: WOMAC OA Index pain subscale (0 to 20 Likert), WOMAC OA Index physical function subscale (0 to 68 Likert), WOMAC OA Index total score (0 to 96 Likert), 50 foot walking time (seconds), and range of motion (degrees).</P>
<P>
<I>Safety<BR/>
</I>
<BR/>There were no adverse local (e.g. postinjection synovitis) or systemic reactions reported in either the <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> or betamethasone group with all patients completing the trial (<LINK REF="STD-Tekeoglu-1998" TYPE="STUDY">Tekeoglu 1998</LINK>). There were no statistically significant differences in the safety profile of <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> compared to 6-MPA (<LINK REF="STD-Tascioglu-2003" TYPE="STUDY">Tascioglu 2003</LINK>). A similar number of patients were withdrawn overall: <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> 6.7% and 6-MPA 10%. One patient in each group withdrew due to increased pain. A similar number of patients reported musculoskeletal adverse events: <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> 25% and 6-MPA 19%; skin adverse events: <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> 7% and 6-MPA 4%; gastrointestinal adverse events: <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> 11% and 6-MPA 7%; general adverse events: <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> 14% and 6-MPA 19%; and knee pain after injection: <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> 21% and 6-MPA 19%.</P>
<P>In the <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> plus triamcinolone acetonide versus <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> alone RCT, a statistically significant difference was detected in favour of <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> alone for the number of total withdrawals overall (RR 0.12, 95% CI 0.02 to 0.88, P value 0.04), but not for the number of withdrawals due to lack of efficacy or in the number of patients reporting adverse events (<LINK REF="STD-Ozturk-2005" TYPE="STUDY">Ozturk 2005</LINK>).</P>
<P>
<LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> versus NSAID: no trials included.</P>
<P>
<LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> versus physiotherapy</P>
<P>Three RCT included comparisons of Orthovisc and physical therapy (<LINK REF="STD-Atamaz-2005" TYPE="STUDY">Atamaz 2005</LINK>; <LINK REF="STD-Bayramoglu-2003" TYPE="STUDY">Bayramoglu 2003</LINK>; <LINK REF="STD-Kalay-1997" TYPE="STUDY">Kalay 1997</LINK>).<BR/>
<I>
<BR/>Efficacy </I>
</P>
<P>There was a statistically significant difference in spontaneous pain (0 to 100 mm VAS) in favour of physical therapy compared to <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> at 14 to 26 weeks postinjection (WMD 17.70; 95% CI 3.70 to 31.70, P value 0.01), but not at any of the other timepoints: 1 to 4, 5 to 13, 37, or 45 to 52 weeks postinjection (<LINK REF="STD-Atamaz-2005" TYPE="STUDY">Atamaz 2005</LINK>). There were statistically significant differences in WOMAC OA Index pain (Likert) in favour of <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> compared to physical therapy at 1 to 4 weeks postinjection (WMD -2.00; 95% CI -3.61 to -0.39, P value 0.02), and at 45 to 52 weeks postinjection (WMD -4.30; 95% CI -6.66 to -1.94, P value 0.0004), but not at 5 to 13, 14 to 26, or 37 weeks postinjection. There were no statistically significant differences between <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> and physical therapy in WOMAC OA Index physical function (Likert) at any of the timepoints: 1 to 4, 5 to 13, 14 to 26, 37, or 45 to 52 weeks postinjection. There were statistically significant differences in favour of physical therapy compared to <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> for SF-36 pain at two of the five timepoints: 5 to 13 weeks postinjection (WMD -28.20; 95% CI -38.98 to -17.42, P &lt; 0.00001), and 14 to 26 weeks postinjection (WMD -18.70; 95% CI -31.67 to -5.73, P value 0.005); while a trend was detected at 45 to 52 weeks postinjection (WMD -12.50; 95% CI -25.03 to 0.03, P value 0.05), but not at 1 to 4 or 37 weeks postinjection. Statistically significant differences in favour of physical therapy compared to <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> were detected in SF-36 physical functioning at 5 to 13 weeks postinjection (WMD -12.00; 95% CI -23.25 to -0.75, P value 0.04), and at 45 to 52 weeks postinjection (WMD -22.00; 95% CI -33.76 to -10.24, P value 0.0002), but not at the other timepoints: 1 to 4, 14 to 26, or 37 weeks postinjection.<I>
<BR/>
</I>
<BR/>In the <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> plus physiotherapy versus physiotherapy comparison (<LINK REF="STD-Kalay-1997" TYPE="STUDY">Kalay 1997</LINK>), there were no statistically significant differences at 1 to 4 weeks postinjection for: activity pain (VAS); spontaneous pain (VAS); night pain (VAS); 25 m walk time (sec); and flexion WMD was not estimable as the SD of the treatment group was zero. At 5 to 13 weeks postinjection, the combination of <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> and physiotherapy was significantly better than physiotherapy alone for activity pain (WMD -6.50; 95% CI -11.93 to -1.07, P value 0.02) and spontaneous pain (WMD -4.10; 95% CI -7.43 to -0.77, P value 0.02). <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> plus physiotherapy was between 16 and 44% more effective than physiotherapy alone in relieving pain. No statistically significant differences were found for night pain; walk time; and flexion WMD was not estimable again due to the SD of the treatment group being zero. The number of patients rating the treatment as effective or very effective was significantly higher in the <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> plus physiotherapy arm (95%) compared to the physiotherapy group (60%) (RR 1.58; 95% CI 1.09 to 2.30, P value 0.02). The NNT for patient global assessment was 3.</P>
<P>The RevMan analysis differed from the publication analysis. The publication reported a statistically significant difference in activity pain at day 21 (1 to 4 weeks postinjection) in favour of <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> plus physiotherapy compared to physiotherapy alone (P value 0.03) whereas RevMan detected no difference (P value 0.5). The publication reported a statistically significant difference in night pain at day 56 (5 to 13 weeks postinjection) in favour of <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> plus physiotherapy compared to physiotherapy alone (P value 0.02) whereas RevMan detected no difference (P value 0.7). The publication reported a statistically significant difference in walk time both at day 21 (P value 0.0049) and day 56 (P value 0.0001) in favour of <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> plus physiotherapy compared to physiotherapy alone whereas RevMan detected no difference (P value 0.4 and 0.2).</P>
<P>In the <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> plus physical therapy versus physical therapy comparison (<LINK REF="STD-Bayramoglu-2003" TYPE="STUDY">Bayramoglu 2003</LINK>), there were no statistically significant differences in the Lequesne Index at the end of treatment at three weeks or at three months.<BR/>
<I>
<BR/>Safety<BR/>
</I>
<BR/>With respect to safety, two patients in the <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> plus physiotherapy group (<LINK REF="STD-Kalay-1997" TYPE="STUDY">Kalay 1997</LINK>) experienced local pain and swelling several hours after the IA injections which resolved in 24 hours with cold application; however, this difference was not statistically significant. In this trial the treatment schedule differed from the other four trials, in that only two injections were given on days 0 and 7. There were no adverse events associated with the IA hyaluronic acid injections in the second trial (<LINK REF="STD-Bayramoglu-2003" TYPE="STUDY">Bayramoglu 2003</LINK>). There was no statistically detectable difference in the number of withdrawals overall. No patients in either trial withdrew because of adverse events or experienced any systemic adverse events.</P>
<P>In the Atamaz et al. RCT, while three patients in the <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> group reported local reactions which resolved within a few days, no serious local or systemic adverse events were observed (<LINK REF="STD-Atamaz-2005" TYPE="STUDY">Atamaz 2005</LINK>).</P>
<P>
<LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> plus trigger point injection with lidocaine versus <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK>
</P>
<P>
<I>Efficacy</I>
</P>
<P>In the one trial included (<LINK REF="STD-Yentur-2003" TYPE="STUDY">Yentur 2003</LINK>
<I>), </I>there were statistically significant differences in favour of <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> plus lidocaine versus <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> alone at one week postinjection for the following outcome measures: pain at rest (WMD -1.73; 95% CI, -2.21 to -1.25, P &lt; 0.00001); pain/restrictions walking (WMD -1.12; 95% CI, -1.60 to -0.64, P &lt; 0.00001), and pain/restrictions going up or down stairs (WMD -1.49; 95% CI, -1.97 to -1.01, P &lt; 0.00001). There was no statistically significant difference in range of motion.</P>
<P>
<I>Safety</I>
</P>
<P>Only one patient in the <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> alone group did not complete the trial (<LINK REF="STD-Yentur-2003" TYPE="STUDY">Yentur 2003</LINK>).</P>
<P>
<LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> verus <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK>
</P>
<P>
<I>Efficacy</I>
</P>
<P>In the Neustadt et al. trial, which compared Orthovisc given as a four-injection regimen to Orthovisc given as a three-injection regimen plus one arthrocentesis, statistically significant differences in favour of the four-injection regimen were detected in the number of patients achieving a 20% relative improvement from baseline in the WOMAC OA Index pain score at 5 to 13 weeks postinjection (RR 1.26; 95% CI 1.07 to 1.49, P value 0.005), and in the patient global assessment (measured on a 0 to 100 mm VAS) (WMD -8.80; 95% CI -16.61 to -0.99, P value 0.03)(<LINK REF="STD-Neustadt-2005a-_x002d_3inj" TYPE="STUDY">Neustadt 2005a -3inj</LINK>; <LINK REF="STD-Neustadt-2005b_x002d_4inj" TYPE="STUDY">Neustadt 2005b-4inj</LINK>. No statistically significant differences were detected for any of the other outcome measures: WOMAC OA Index pain on standing item, WOMAC OA Index total score, physician global assessment, or number of patients achieving a 40% or 50% relative improvement from baseline in the WOMAC OA Index pain score.</P>
<P>
<I>Safety<BR/>
</I>
<BR/>There were no statistically significant differences in the number of total withdrawals overall; number of withdrawals due to lack of efficacy; number of patients reporting adverse events; number of patients with gastrointestinal adverse events; number of patients with general body adverse events; number of patients with infections; number of patients with musculoskeletal adverse events; number of patients with nervous system adverse events; number of patients with respiratory adverse events; or number of patients with skin adverse events (<LINK REF="STD-Neustadt-2005a-_x002d_3inj" TYPE="STUDY">Neustadt 2005a -3inj</LINK>; <LINK REF="STD-Neustadt-2005b_x002d_4inj" TYPE="STUDY">Neustadt 2005b-4inj</LINK> .</P>
<P>
<LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> versus other hyaluronans<BR/>
<I>
<BR/>Efficacy </I>
</P>
<P>In the Atamaz et al. trial (<LINK REF="STD-Atamaz-2005" TYPE="STUDY">Atamaz 2005</LINK>), a statistically significant difference in favour of Orthovisc compared to Hylan G-F 20 were detected for spontaneous pain (0 to 100 mm VAS) at 1 to 4 weeks postinjection (WMD -21.10; 95% CI -33.08 to -9.12, P value 0.0006) (Orthovisc was 8% more effective than Hylan G-F 20). However, a statistically significant difference in favour of Hylan G-F 20 compared to Orthovisc was detected both at 5 to 13 weeks postinjection (WMD 12.90; 95% CI 0.85 to 24.95, P value 0.04) and at 14 to 26 weeks postinjection (WMD 15.50; 95% CI 0.80 to 30.20, P value 0.04) (Hylan G-F 20 was 33 to 36% more effective than Orthovisc, respectively). No statistically significant differences were detected at 37 weeks or 45 to 52 weeks postinjection.</P>
<P>In one trial included (<LINK REF="STD-Bayramoglu-2003" TYPE="STUDY">Bayramoglu 2003</LINK>), there were no statistically significant differences between <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> plus a physical therapy programme versus Hylan G-F 20 plus a physical therapy programme in the Lequesne Index either at the end of the treatment schedule or at three months.</P>
<P>There were no statistically significant differences between <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> and Hylan G-F 20 in the WOMAC OA Index pain or physical function subscales at 1 to 4 weeks postinjection (<LINK REF="STD-Atamaz-2005" TYPE="STUDY">Atamaz 2005</LINK>; <LINK REF="STD-Karatay-2004" TYPE="STUDY">Karatay 2004</LINK>;<LINK REF="STD-Kotevoglu-2005" TYPE="STUDY">Kotevoglu 2005</LINK>); at 5 to 13 or 14 to 26 weeks postinjection (<LINK REF="STD-Atamaz-2005" TYPE="STUDY">Atamaz 2005</LINK>; <LINK REF="STD-Kotevoglu-2005" TYPE="STUDY">Kotevoglu 2005</LINK>); and at 37 or 45 to 52 weeks postinjection (<LINK REF="STD-Atamaz-2005" TYPE="STUDY">Atamaz 2005</LINK>). There was no statistically significant difference detected in the WOMAC OA Index stiffness subscale (Likert scale) either at 1 to 4 weeks postinjection (<LINK REF="STD-Karatay-2004" TYPE="STUDY">Karatay 2004</LINK>; <LINK REF="STD-Kotevoglu-2005" TYPE="STUDY">Kotevoglu 2005</LINK>); 5 to 13 or 14 to 26 weeks postinjection (<LINK REF="STD-Kotevoglu-2005" TYPE="STUDY">Kotevoglu 2005</LINK>).</P>
<P>There was no statistically significant difference in the patient global assessment (100 mm VAS, where 100 was the worst severity) at 1 to 4, 5 to 13, or 14 to 26 weeks postinjection (<LINK REF="STD-Kotevoglu-2005" TYPE="STUDY">Kotevoglu 2005</LINK>). However, in the physician global assessment (100 mm VAS, where 100 was the worst severity), there were statistically significant differences in favour of Hylan G-F 20 both at 1 to 4 weeks postinjection (WMD 20.00; 95% CI 7.27 to 32.73, P value 0.002) and at 5 to 13 weeks postinjection (WMD 20.00; 95% CI 8.06 to 31.94, p=0.001), but not at 14 to 26 weeks postinjection (<LINK REF="STD-Kotevoglu-2005" TYPE="STUDY">Kotevoglu 2005</LINK>).</P>
<P>In the Karatay et al. trial, there were no statistically significant differences between <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> and Hylan G-F 20 at one week postinjection for synovial fluid intercellular adhesion molecule-1 or synovial fluid vascular cell adhesion molecule-1 (<LINK REF="STD-Karatay-2004" TYPE="STUDY">Karatay 2004</LINK>).</P>
<P>With respect to the SF-36, statistically significant differences were detected in favour of Hylan G-F 20 compared to Orthovisc in SF-36 pain both at 5 to 13 weeks postinjection (WMD -30.80; 95% CI -43.03 to -18.57, P &lt; 0.00001) and at 14 to 26 weeks postinjection (WMD -19.80; 95% CI -35.52 to -4.08, P value 0.01) but not at 1 to 4, 37, or 45 to 52 weeks postinjection (<LINK REF="STD-Atamaz-2005" TYPE="STUDY">Atamaz 2005</LINK>). For SF-36 physical functioning, statistically significant differences were detected in favour of Hylan G-F 20 compared to Orthovisc both at 5 to 13 weeks postinjection (WMD -20.20; 95% CI -29.47 to -10.93, P &lt; 0.0001) and at 45 to 52 weeks postinjection (WMD -23.00; 95% CI -35.97 to -10.03, P value 0.0005) (<LINK REF="STD-Atamaz-2005" TYPE="STUDY">Atamaz 2005</LINK>).</P>
<P>In the Karatosun et al. trial (<LINK REF="STD-Karatosun-2005a" TYPE="STUDY">Karatosun 2005a</LINK>), there were no statistically significant differences between <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> and Hylan G-F 20 in any of the efficacy outcome measures reported at 1 to 4, 5 to 13, 14 to 26, or 45 to 52 weeks postinjection: Hospital for Special Surgery Knee Score (HSSKS), pain during activity (part of the HSSKS); pain at rest (part of the HSSKS); pain during transfer activity (part of the HSSKS); walking distance; or range of motion.</P>
<P>
<I>Safety<BR/>
</I>
<BR/>There were no adverse events associated with either of the IA hyaluronic acid injections (<LINK REF="STD-Bayramoglu-2003" TYPE="STUDY">Bayramoglu 2003</LINK>). No safety outcome measures were reported in the Karatay et al. trial (<LINK REF="STD-Karatay-2004" TYPE="STUDY">Karatay 2004</LINK>). There were no statistically significant differences in the number of total withdrawals overall (<LINK REF="STD-Karatosun-2005a" TYPE="STUDY">Karatosun 2005a</LINK>; <LINK REF="STD-Kotevoglu-2005" TYPE="STUDY">Kotevoglu 2005</LINK>); number of withdrawals due to lack of efficacy (<LINK REF="STD-Karatosun-2005a" TYPE="STUDY">Karatosun 2005a</LINK>); number of patients wih local adverse events (<LINK REF="STD-Atamaz-2005" TYPE="STUDY">Atamaz 2005</LINK>; <LINK REF="STD-Kotevoglu-2005" TYPE="STUDY">Kotevoglu 2005</LINK>); number of withdrawals due to noncompliance (<LINK REF="STD-Kotevoglu-2005" TYPE="STUDY">Kotevoglu 2005</LINK>).</P>
<P>
<I>
<B>Product - Ostenil<BR/>
</B>
<BR/>Description of studies<BR/>
</I>
<BR/>One RCT was excluded: <LINK REF="STD-Uebelhart-2003" TYPE="STUDY">Uebelhart 2003</LINK>.<BR/>
<I>
<B>
<BR/>Product - Replasyn<BR/>
</B>
<BR/>Description of studies<BR/>
</I>
<BR/>One RCT has been reported.</P>
<P>Cohen et al. reported an eight-week, placebo-controlled, double-blind RCT performed at four centres in Canada and the United States comparing three weekly injections of Replasyn to placebo (not specified) in 39 patients with OA of the knee (<LINK REF="STD-Cohen-1994" TYPE="STUDY">Cohen 1994</LINK>). A significant within group difference was found for pain on walking by week 8 in the Replasyn group. However, no between-group differences were found in pain on walking, range of motion, the WOMAC functional index, or patient and physician global assessments. Transient joint pain or swelling was reported in 3 of 19 Replasyn and 6 of 20 placebo patients.</P>
<P>An abstract is the only publication of this trial.</P>
<P>Replasyn versus placebo<BR/>
<I>
<BR/>Efficacy<BR/>
</I>
<BR/>Since no measure of dispersion was reported in the abstract (<LINK REF="STD-Cohen-1994" TYPE="STUDY">Cohen 1994</LINK>) this review does not report efficacy data.<BR/>
<I>
<BR/>Safety<BR/>
</I>
<BR/>There was no statistically significant difference in the number of patients with local adverse reactions: Replasyn 16% versus placebo 30%.</P>
<P>Replasyn versus corticosteroid: no trials included.</P>
<P>Replasyn versus NSAID: no trials included.</P>
<P>Replasyn versus other hyaluronan: no trials included.<BR/>
<I>
<B>
<BR/>Product - SLM-10<BR/>
</B>
<BR/>Description of studies<BR/>
</I>
<BR/>One RCT has been included.</P>
<P>Kawabata et al. reported a five-week, parallel-group, single-blind RCT performed at 23 centres in Japan comparing five weekly injections of SLM-10 (developed and produced by fermentation with Streptococcus zooepidemicus of Lancefield's group C, Shiseido Co., Ltd.) to five-weekly injections of Artz in 172 patients with OA of the knee (<LINK REF="STD-Kawabata-1993" TYPE="STUDY">Kawabata 1993</LINK>). No statistically significant between-group differences were reported for patients' impression, final global improvement and utility, leading the authors to conclude that SLM-10 was as useful as Artz. Adverse events were reported in one SLM-10 patient and two Artz patients. The Jadad score for this trial was 2 out of 5; single-blind and no specific details regarding randomisation were reported. Allocation concealment was adequate.</P>
<P>This comparative HA trial was of short duration with the longest assessment only one week postinjection. In addition, it was single-blind because of differences in the HA; SLM-10 was provided in a syringe while Artz was provided in an ampoule. The 23 trial sites were all Departments of Orthopedic Surgery. Almost all of the clinical evaluations were based on attending physician or committee ratings rather than on patient ratings. The case study committee, as well as the attending physician, assessed overall severity, final global improvement, overall safety and usefulness. Differences in results were noted in assessments made by the attending physician compared to those made by the committee. In the analysis method section of the publication, it reports that "cases which deviated from the protocol or those judged to be inappropriate as the subjects of assessment were excluded from the analysis of corresponding assessment item". However, no definition of appropriateness was reported.</P>
<P>Five trials were excluded (<LINK REF="STD-Minami-1993" TYPE="STUDY">Minami 1993</LINK>; <LINK REF="STD-Ono-1993" TYPE="STUDY">Ono 1993</LINK>; <LINK REF="STD-Ono-1993a" TYPE="STUDY">Ono 1993a</LINK>; <LINK REF="STD-Suzu-1993" TYPE="STUDY">Suzu 1993</LINK>; <LINK REF="STD-Taneda-1993" TYPE="STUDY">Taneda 1993</LINK>).</P>
<P>SLM-10 versus placebo: no trials included.</P>
<P>SLM-10 versus corticosteroid: no trials included.</P>
<P>SLM-10 versus NSAID: no trials included.</P>
<P>SLM-10 versus other hyaluronan<BR/>
<I>
<BR/>Efficacy</I>
<BR/>
<LINK REF="TBL-47" TYPE="TABLE">Table 47</LINK>
<I>
<BR/>
</I>
<BR/>Regarding the SLM-10 comparison against Artz (<LINK REF="STD-Kawabata-1993" TYPE="STUDY">Kawabata 1993</LINK>), significantly more patients improved on pain on pressure in the Artz group (82%) compared to the SLM-10 group (64%) (RR 0.78; 95% CI 0.64 to 0.96, P value 0.02). The NNT for pain on pressure was 2. No statistically significant between-group differences were found for pain in movement, pain when resting, and patient global assessment.<BR/>
<I>
<BR/>Safety<BR/>
</I>
<BR/>There was no statistically significant difference in the total number of withdrawals overall in the Artz group (12%) compared to SLM-10 group (3%). The incidence of local adverse events related to study drug, resulting in withdrawal, was similar in the Artz (3%) and the SLM-10 (1%) groups. One patient in each group had a local adverse event with no specific causal relationship to the study drug and continued in the trial.<BR/>
<I>
<B>
<BR/>Product - Suplasyn<BR/>
</B>
<BR/>Description of studies<BR/>
</I>
<BR/>One RCT has been included.</P>
<P>Petrella et al. reported a 12-week, placebo-controlled, double-blind RCT performed at a single centre in Canada comparing Suplasyn (a bacterial source HA) plus placebo (lactose), placebo (lactose plus saline), NSAID (Arthrotec plus saline), and Suplasyn plus NSAID in 120 patients with OA of the knee (<LINK REF="STD-Petrella-2002" TYPE="STUDY">Petrella 2002</LINK>). The authors reported that Suplasyn was superior to placebo alone or NSAIDs alone for pain with physical activity and functional performance. Suplasyn was as effective as NSAID for resting pain relief. With respect to safety, Petrella reported that two patients had moderate gastrointestinal irritation resulting in their withdrawal, and that most adverse events occurred in the NSAID plus saline group. No<BR/>serious adverse events occurred.</P>
<P>The efficacy outcome measures extracted from this trial were pain after walking (0 to 100 mm VAS), WOMAC pain (0 to 10 cm) and WOMAC function (0 to 10 cm), pain at rest (0 to 100 mm VAS), and walk time (seconds). Of the four groups, three comparisons are reported: (Suplasyn plus lactose) versus (saline plus lactose), (Suplasyn plus lactose) versus (NSAID plus saline), and (Suplasyn plus NSAID) versus (NSAID plus saline); not reporting the combination of (NSAID plus saline) versus placebo (lactose plus saline). With respect to methodological quality, it scored 5 out of 5 on the Jadad scale achieving bonus points for providing details of appropriate randomisation and blinding. Allocation concealment was adequate. An editorial reported the results obtained from this trial using a factorial design analysis (<LINK REF="REF-Felson-2002" TYPE="REFERENCE">Felson 2002</LINK>). Two trials were excluded (Olszynski 2002; <LINK REF="STD-Payne-2000" TYPE="STUDY">Payne 2000</LINK>).</P>
<P>Some design points were noted: 1) a medial approach was utilised for injections; 2) rescue medication with 2600 mg (650 g x 4) of acetaminophen was permitted; 3) a 10-minute home-based resistance exercise programme was part of the treatment and was monitored by a patient diary; 4) patients were recruited from a primary care referral centre; 5) no details were published regarding the presence or absence of effusion, disease duration, and OA diagnosis criteria. The only significant results reported were based on within-group comparisons. No information on rescue medication usage was reported.</P>
<P>A randomised, double-blind trial comparing three and six injections of Suplasyn is awaiting assessment (<LINK REF="STD-Petrella-2002" TYPE="STUDY">Petrella 2002</LINK>). This trial has only been published as an abstract with no extractable data and at the closure of the database for this review no full length manuscript had been published. Three trials were excluded (<LINK REF="STD-Mazieres-2004" TYPE="STUDY">Mazieres 2004</LINK>; <LINK REF="STD-Petrella-2003a" TYPE="STUDY">Petrella 2003a</LINK>; <LINK REF="STD-Petrella-2003b" TYPE="STUDY">Petrella 2003b</LINK>).</P>
<P>Suplasyn versus placebo<BR/>
<I>
<BR/>Efficacy<BR/>
</I>
<LINK REF="TBL-48" TYPE="TABLE">Table 48</LINK>
<BR/>No statistically significant differences were found between Suplasyn and placebo for the following outcome measures: pain after walking; WOMAC OA Index pain; WOMAC OA Index physical function; and walk time. A statistically significant difference, in favour of the placebo group (saline + lactose) compared to the treatment group (Suplasyn + lactose), was found for the primary outcome measure, pain at rest (WMD 0.83; 95% CI 0.03 to 1.63, P value 0.04). Suplasyn plus lactose was 25% less effective than saline plus lactose in relieving pain at rest.</P>
<P>The RevMan analysis differed from the publication analysis. The publication reported that Suplasyn may be superior to placebo for pain with physical activity and functional performance whereas the RevMan analysis detected no difference.<BR/>
<I>
<BR/>Safety </I>
</P>
<P>There was no statistically significant difference in the number of withdrawals overall: Suplasyn 17% versus placebo 7%.<BR/>
<BR/>Suplasyn versus corticosteroid: no trials included.</P>
<P>Suplasyn versus NSAID<BR/>
<I>
<BR/>Efficacy<BR/>
</I>
<BR/>No statistically significant differences were found between Suplasyn and NSAID for: WOMAC OA Index pain; WOMAC OA Index physical function; walk time; pain at rest; and pain after walking.</P>
<P>The RevMan analysis differed from the publication analysis. The publication reported that Suplasyn may be superior to NSAID alone for pain relief, pain with physical activity, and functional performance whereas the RevMan analysis detected no difference.<BR/>
<I>
<BR/>Safety<BR/>
</I>
<BR/>There was no statistically significant difference in the number of withdrawals overall: Suplasyn 17% versus NSAID 3%.</P>
<P>Suplasyn + NSAID versus NSAID alone<BR/>
<I>
<BR/>Efficacy<BR/>
</I>
<BR/>No statistically significant differences were found between Suplasyn plus NSAID versus NSAID alone for pain after walking; WOMAC OA Index pain; WOMAC OA Index physical function; pain at rest; and walk time.<BR/>
<I>
<BR/>Safety<BR/>
</I>
<BR/>There was no statistically significant difference in the number of withdrawals overall: Suplasyn plus NSAID 13% versus NSAID alone 3%.<BR/>
<BR/>Suplasyn versus other hyaluronan: no trials included.<BR/>
<I>
<B>
<BR/>Product - Synject<BR/>
</B>
<BR/>Description of studies </I>
</P>
<P>One trial was excluded: <LINK REF="STD-Alonge-2004" TYPE="STUDY">Alonge 2004</LINK>.<BR/>
<I>
<B>
<BR/>Product - Zeel compositum<BR/>
</B>
<BR/>Description of studies </I>
</P>
<P>One RCT included was a comparison of Zeel compositum and Hyalart (<LINK REF="STD-Nahler-1996" TYPE="STUDY">Nahler 1996</LINK> [article published in German with English abstract]; <LINK REF="STD-Nahler-1998" TYPE="STUDY">Nahler 1998</LINK>). With respect to methodological quality, the Jadad score was 4 out of 5. Allocation concealment was unclear.</P>
<P>Nahler et al. reported a five-week, parallel-group, single-blind RCT performed at twelve centres in Germany and Austria comparing 10 injections (two injections a week for five weeks) of Zeel compositum to five weekly injections of Hyalart in 121 patients with OA of the knee (<LINK REF="STD-Nahler-1998" TYPE="STUDY">Nahler 1998</LINK>). Both treatments were equally effective in treating patients. Undesirable side effects were reported by 11% of Zeel patients and 23% of Hyalart patients; the most frequent being local inflammation or irritation following the injection. One patient withdrew from the study early due to suspected allergic reaction after injection with Hyalart. For this trial, Zeel was the treatment group and Hyalart was the control group.</P>
<P>This is the only RCT in the review comparing homeopathy drug therapy to HA. It was designed as a clinical equivalence study. The follow-up assessment was short, one week following the treatment. As the authors noted, the design was single-blind due to the imbalance in number of injections (Hyalart n = 5 versus Zeel n = 10). It was deemed 'unethical' to equalise the frequency of injections with additional injections of a placebo.</P>
<P>Zeel versus placebo: no trials included.</P>
<P>Zeel versus corticosteroid: no trials included.</P>
<P>Zeel versus NSAID: no trials included.</P>
<P>Zeel versus other hyaluronans<BR/>
<I>
<BR/>Efficacy<BR/>
</I>
<LINK REF="TBL-49" TYPE="TABLE">Table 49</LINK>
<BR/>At the end of treatment (i.e. last injection), there were no statistically significant between-group differences in any of the efficacy outcome measures: pain during movement, pain during the night, assessment of improvement, and assessment of tolerance all scored on a 0 to 100 mm VAS. There was no statistically significant difference in the number of patients who reported noticeable improvement in symptoms: Zeel 87% versus Hyalart 93%.<BR/>
<I>
<BR/>Safety<BR/>
</I>
<BR/>There was no statistically significant difference in the number of patients with side effects: Zeel 11% versus Hyalart 23%; or in the number of patients withdrawn due to lack of efficacy: Zeel 4% versus Hyalart 2%.</P>
<P>
<I>
<B>Product - Hyaluronan (brand name not identified)</B>
</I>
</P>
<P>
<I>Description of studies</I>
</P>
<P>One RCT included was a comparison of hyaluronan and different dosages of celecoxib (<LINK REF="STD-Wu-2004" TYPE="STUDY">Wu 2004</LINK>). The article was published in Chinese with an abstract in English. Dr. H. Qian of The University of Western Ontario, London, Canada, kindly provided an English translation of the article.</P>
<P>Wu et al. reported a 16-week, parallel-group, single-blind RCT performed in China comparing hyaluronan to: 1) hyaluronan plus low dose celecoxib, 2) hyaluronan plus self-controlled dose celecoxib, 3) regular dose celecoxib, and 4) self-controlled celecoxib in 150 patients with OA of the knee (<LINK REF="STD-Wu-2004" TYPE="STUDY">Wu 2004</LINK>). Outcome measures included WOMAC Osteoarthritis Index physical function subscale, degree of satisfaction at the end of treatment, and totally used dosage of celecoxib. The authors reported that the clinical symptoms improved by the fourth week in the hyaluronan group, at the second week in the hyaluronan plus low dosage celecoxib, and at the first week in the other three groups. In addition, the improvement was maintained until the end of the treatment in all five groups. They concluded that hyaluronan plus self-controlled celecoxib can improve the clinical symptoms of OA and also significantly decrease the amount of required celecoxib to maintain good therapeutic effects. With respect to safety, all patients completed the trial except seven patients in the hyaluronan group that discontinued early because of inefficacy. In addition, no treatment was discontinued due to severe side effects in any of the five groups. The trial scored 2 out of 5 on the Jadad scale; details regarding method of randomisation were not reported and the trial was single-blind. Details regarding allocation concealment were not reported.</P>
<P>The results of the WOMAC OA Index physical function subscale were presented as means in Figure 2 with no measure of dispersion reported. Consequently, we were not able to include this outcome measure in our analyses.</P>
<P>
<I>Efficacy<BR/>
</I>
<BR/>A statistically significant difference in favour of regular dose celecoxib compared to hyaluronan was detected in patient general satisfaction with treatment (RR 0.62; 95% CI 0.46 to 0.84, P value 0.002) (<LINK REF="STD-Wu-2004" TYPE="STUDY">Wu 2004</LINK>). No statistically significant differences were detected for any of the other comparisons: regular dose celecoxib versus hyaluronan plus low dose celecoxib or regular dose celecoxib versus hyaluronan plus voluntary dose of celecoxib.</P>
<P>
<I>Safety</I>
</P>
<P>When comparing hyaluronan to regular dose celecoxib, no statisticaly significant difference was detected in the number of withdrawals due to inefficacy (<LINK REF="STD-Wu-2004" TYPE="STUDY">Wu 2004</LINK>
<I>).</I>
</P>
<P>By-class (pooled) analysis</P>
<P>
<LINK REF="TBL-51" TYPE="TABLE">Table 51</LINK>; <LINK REF="TBL-52" TYPE="TABLE">Table 52</LINK>; <LINK REF="TBL-53" TYPE="TABLE">Table 53</LINK>; <LINK REF="TBL-54" TYPE="TABLE">Table 54</LINK>
<BR/>
</P>
<P>Forty-two trials included comparisons of hyaluronan/hylan and placebo (<LINK REF="STD-Altman-1998" TYPE="STUDY">Altman 1998</LINK>; <LINK REF="STD-Altman-2004" TYPE="STUDY">Altman 2004</LINK>; <LINK REF="STD-Ardic-2001" TYPE="STUDY">Ardic 2001</LINK>; <LINK REF="STD-Bragantini-1987" TYPE="STUDY">Bragantini 1987</LINK>; <LINK REF="STD-Brandt-2001" TYPE="STUDY">Brandt 2001</LINK>; <LINK REF="STD-Bunyaratavej-2001" TYPE="STUDY">Bunyaratavej 2001</LINK>; <LINK REF="STD-Carrabba-1995" TYPE="STUDY">Carrabba 1995</LINK>; <LINK REF="STD-Cohen-1994" TYPE="STUDY">Cohen 1994</LINK>; <LINK REF="STD-Corrado-1995" TYPE="STUDY">Corrado 1995</LINK>; <LINK REF="STD-Creamer-1994" TYPE="STUDY">Creamer 1994</LINK>; <LINK REF="STD-Cubukcu-2004" TYPE="STUDY">Cubukcu 2004</LINK>; <LINK REF="STD-Day-2004" TYPE="STUDY">Day 2004</LINK>; <LINK REF="STD-Dickson-2001" TYPE="STUDY">Dickson 2001</LINK>; <LINK REF="STD-Dougados-1993" TYPE="STUDY">Dougados 1993</LINK>; <LINK REF="STD-Formiguera-Sala-1995" TYPE="STUDY">Formiguera Sala 1995</LINK>; <LINK REF="STD-Grecomoro-1987" TYPE="STUDY">Grecomoro 1987</LINK>; <LINK REF="STD-Groppa-2001" TYPE="STUDY">Groppa 2001</LINK>; <LINK REF="STD-Guler-1996" TYPE="STUDY">Guler 1996</LINK>; <LINK REF="STD-Henderson-1994" TYPE="STUDY">Henderson 1994</LINK>; <LINK REF="STD-Hizmetli-1999" TYPE="STUDY">Hizmetli 1999</LINK>; <LINK REF="STD-Huskisson-1999" TYPE="STUDY">Huskisson 1999</LINK>; <LINK REF="STD-Jubb-2003" TYPE="STUDY">Jubb 2003</LINK>; <LINK REF="STD-Karlsson-2002" TYPE="STUDY">Karlsson 2002</LINK>; <LINK REF="STD-Kotevoglu-2005" TYPE="STUDY">Kotevoglu 2005</LINK>; <LINK REF="STD-Lohmander-1996" TYPE="STUDY">Lohmander 1996</LINK>; <LINK REF="STD-Moreland-1993" TYPE="STUDY">Moreland 1993</LINK>; <LINK REF="STD-Neustadt-2005a-_x002d_3inj" TYPE="STUDY">Neustadt 2005a -3inj</LINK>; <LINK REF="STD-Petrella-2002" TYPE="STUDY">Petrella 2002</LINK>; <LINK REF="STD-Pham-2003" TYPE="STUDY">Pham 2003</LINK>; <LINK REF="STD-Pham-2004" TYPE="STUDY">Pham 2004</LINK>; <LINK REF="STD-Puhl-1993" TYPE="STUDY">Puhl 1993</LINK>; <LINK REF="STD-Scale-1994a-_x0028_2-inj_x0029_" TYPE="STUDY">Scale 1994a (2 inj)</LINK>; <LINK REF="STD-Scale-1994b-_x0028_3-inj_x0029_" TYPE="STUDY">Scale 1994b (3 inj)</LINK>; <LINK REF="STD-Shichikawa-1983a" TYPE="STUDY">Shichikawa 1983a</LINK>; <LINK REF="STD-Shichikawa-1983b" TYPE="STUDY">Shichikawa 1983b</LINK>; <LINK REF="STD-St.-J.-Dixon-1988" TYPE="STUDY">St. J. Dixon 1988</LINK>; <LINK REF="STD-Tamir-2001" TYPE="STUDY">Tamir 2001</LINK>; <LINK REF="STD-Tsai-2003" TYPE="STUDY">Tsai 2003</LINK>; <LINK REF="STD-Wobig-1998" TYPE="STUDY">Wobig 1998</LINK>; <LINK REF="STD-Wobig-1999c-_x0028_NEhyl_x0029_" TYPE="STUDY">Wobig 1999c (NEhyl)</LINK>; <LINK REF="STD-Wu-1997" TYPE="STUDY">Wu 1997</LINK>). In the figures, the <LINK REF="STD-Kotevoglu-2002" TYPE="STUDY">Kotevoglu 2002</LINK> citation refers to the Hylan G-F 20 versus saline comparison while the <LINK REF="STD-Kotevoglu-2005" TYPE="STUDY">Kotevoglu 2005</LINK> citation refers to the Orthovisc versus saline comparison.</P>
<P>In this section, we report only analyses based on multiple studies. Analyses based on single products and/or studies can be found in the relevant by-product results section. This section is most informative when read in combination with the relevant by-product section(s).</P>
<P>There was a statistically significant difference in favour of HA compared to placebo for pain on weight bearing (0 to100 mm VAS) at three assessments: at 1 to 4 weeks postinjection, based on 22 trials (WMD (random-effects model) -7.70; 95% CI -11.29 to -4.10, P &lt; 0.0001); at 5 to 13 weeks postinjection, based on 17 trials (WMD (random-effects model) -13.00; 95% CI -17.77 to -8.23, P &lt; 0.00001); at 14 to 26 weeks postinjection, based on 9 trials (WMD (random-effects model) -9.04; 95% CI -14.83 to -3.24, P value 0.002); but not at 45 to 52 weeks postinjection based on 3 trials.</P>
<P>There was a statistically significant difference in pain at rest (0 to 100 mm VAS) at 1 to 4 weeks postinjection based on eight trials (WMD (random-effects model) -5.37; 95% CI -9.90 to -0.85, P value 0.02).</P>
<P>There were statistically significant differences in the WOMAC OA Index pain subscale in favour of HA versus placebo at 1 to 4 weeks postinjection based on six trials (SMD (random-effects model) -1.22; 95% CI -1.93 to -0.52, P value 0.0007) (<LINK REF="STD-Cubukcu-2004" TYPE="STUDY">Cubukcu 2004</LINK>; <LINK REF="STD-Hizmetli-1999" TYPE="STUDY">Hizmetli 1999</LINK>; <LINK REF="STD-Kotevoglu-2005" TYPE="STUDY">Kotevoglu 2005</LINK>; <LINK REF="STD-Petrella-2002" TYPE="STUDY">Petrella 2002</LINK>; <LINK REF="STD-Sezgin-2005" TYPE="STUDY">Sezgin 2005</LINK>; <LINK REF="STD-Tsai-2003" TYPE="STUDY">Tsai 2003</LINK>) at 5 to 13 weeks postinjection based on five trials (SMD -1.02 (random-effects model); 95% CI -1.57 to -0.47, P value 0.003) (<LINK REF="STD-Cubukcu-2004" TYPE="STUDY">Cubukcu 2004</LINK>; <LINK REF="STD-Day-2004" TYPE="STUDY">Day 2004</LINK>; <LINK REF="STD-Dickson-2001" TYPE="STUDY">Dickson 2001</LINK>; <LINK REF="STD-Hizmetli-1999" TYPE="STUDY">Hizmetli 1999</LINK>; <LINK REF="STD-Kotevoglu-2005" TYPE="STUDY">Kotevoglu 2005</LINK>; <LINK REF="STD-Tsai-2003" TYPE="STUDY">Tsai 2003</LINK>); and at 14 to 26 weeks postinjection based on three trials (SMD -1.04 (random-effects model); 95% CI -1.75 to -0.32, P value 0.005) (<LINK REF="STD-Hizmetli-1999" TYPE="STUDY">Hizmetli 1999</LINK>; <LINK REF="STD-Kotevoglu-2005" TYPE="STUDY">Kotevoglu 2005</LINK>; <LINK REF="STD-Tsai-2003" TYPE="STUDY">Tsai 2003</LINK>).</P>
<P>There were statistically significant differences in the WOMAC OA Index physical function subscale in favour of HA versus placebo at 1 to 4 weeks postinjection based on six trials (SMD -1.02; 95% CI -1.62 to -0.42, P value 0.0008); at 5 to 13 weeks postinjection based on 6 trials (SMD -0.85; 95% CI -1.31 to -0.39, P value 0.0003); and at 14 to 26 weeks postinjection based on three trials (SMD -0.80; 95% CI -1.37 to -0.24, P value 0.005) (<LINK REF="STD-Hizmetli-1999" TYPE="STUDY">Hizmetli 1999</LINK>; <LINK REF="STD-Kotevoglu-2002" TYPE="STUDY">Kotevoglu 2002</LINK>; <LINK REF="STD-Kotevoglu-2005" TYPE="STUDY">Kotevoglu 2005</LINK>; <LINK REF="STD-Tsai-2003" TYPE="STUDY">Tsai 2003</LINK>).</P>
<P>There was a statistically significant difference in the Lequesne Index both at 1 to 4 weeks postinjection (WMD -0.82; 95% CI -1.48 to -0.16, P value 0.02) (<LINK REF="STD-Carrabba-1995" TYPE="STUDY">Carrabba 1995</LINK>; <LINK REF="STD-Dougados-1993" TYPE="STUDY">Dougados 1993</LINK>; <LINK REF="STD-Huskisson-1999" TYPE="STUDY">Huskisson 1999</LINK>; <LINK REF="STD-Puhl-1993" TYPE="STUDY">Puhl 1993</LINK>); and at 5 to 13 weeks postinjection (WMD -1.38; 95% CI -2.04 to -0.73, P &lt; 0.0001) (<LINK REF="STD-Carrabba-1995" TYPE="STUDY">Carrabba 1995</LINK>; <LINK REF="STD-Dickson-2001" TYPE="STUDY">Dickson 2001</LINK>; <LINK REF="STD-Huskisson-1999" TYPE="STUDY">Huskisson 1999</LINK>; <LINK REF="STD-Puhl-1993" TYPE="STUDY">Puhl 1993</LINK>). There was no statistically significant difference either at 14 to 26 weeks postinjection (<LINK REF="STD-Huskisson-1999" TYPE="STUDY">Huskisson 1999</LINK>; <LINK REF="STD-Karlsson-2002" TYPE="STUDY">Karlsson 2002</LINK>; <LINK REF="STD-Lohmander-1996" TYPE="STUDY">Lohmander 1996</LINK>) or 45 to 52 weeks postinjection (<LINK REF="STD-Dougados-1993" TYPE="STUDY">Dougados 1993</LINK>).</P>
<P>With respect to patient global assessment (expressed as the number of patients improved), there were no statistically significant differences between HA and placebo at any of the four assessment times: at 1 to 4 weeks post injection (<LINK REF="STD-Corrado-1995" TYPE="STUDY">Corrado 1995</LINK>; <LINK REF="STD-Creamer-1994" TYPE="STUDY">Creamer 1994</LINK>; <LINK REF="STD-Lohmander-1996" TYPE="STUDY">Lohmander 1996</LINK>; <LINK REF="STD-Shichikawa-1983a" TYPE="STUDY">Shichikawa 1983a</LINK>; <LINK REF="STD-Shichikawa-1983b" TYPE="STUDY">Shichikawa 1983b</LINK>); at 5 to 13 weeks postinjection (<LINK REF="STD-Corrado-1995" TYPE="STUDY">Corrado 1995</LINK>; <LINK REF="STD-Dickson-2001" TYPE="STUDY">Dickson 2001</LINK>; <LINK REF="STD-Guler-1996" TYPE="STUDY">Guler 1996</LINK>; <LINK REF="STD-Lohmander-1996" TYPE="STUDY">Lohmander 1996</LINK>; <LINK REF="STD-Puhl-1993" TYPE="STUDY">Puhl 1993</LINK>); at 14 to 26 weeks postinjection (<LINK REF="STD-Henderson-1994" TYPE="STUDY">Henderson 1994</LINK>; <LINK REF="STD-Huskisson-1999" TYPE="STUDY">Huskisson 1999</LINK>; <LINK REF="STD-Lohmander-1996" TYPE="STUDY">Lohmander 1996</LINK>); and at 45 to 52 weeks postinjection (<LINK REF="STD-Dougados-1993" TYPE="STUDY">Dougados 1993</LINK>; <LINK REF="STD-Pham-2004" TYPE="STUDY">Pham 2004</LINK>).</P>
<P>There was a statistically significant difference in flexion (degrees) in favour of HA versus placeo at 1 to 4 weeks postinjection (WMD 3.87; 95% CI 2.06 to 5.68, P &lt; 0.0001) (<LINK REF="STD-Corrado-1995" TYPE="STUDY">Corrado 1995</LINK>; <LINK REF="STD-Sezgin-2005" TYPE="STUDY">Sezgin 2005</LINK>; <LINK REF="STD-Shichikawa-1983a" TYPE="STUDY">Shichikawa 1983a</LINK>; <LINK REF="STD-Shichikawa-1983b" TYPE="STUDY">Shichikawa 1983b</LINK>); and at 5 to 13 weeks postinjection (WMD 7.60; 95% CI 0.46 to 14.74, P value 0.04) (<LINK REF="STD-Corrado-1995" TYPE="STUDY">Corrado 1995</LINK>).</P>
<P>In safety analyses in HA versus placebo comparisons, no statistically significant differences were detected in the following: total withdrawals overall (1 to 4 weeks, 5 to 13 weeks, 14 to 26 weeks, 45 to 52 weeks postinjection), patients with local adverse reaction and study drug discontinued, number of patients with local adverse reaction but study drug continued, number of patients discontinued due to adverse events, withdrawals due to lack of efficacy, number of adverse events due to local skin reaction, number of patients with gastro-intestinal complaints, number of patients with treatment related adverse events, number of patients with possible study medication related events, number of serious adverse events, number of adverse events probably/possibly related to treatment, and number of patients reporting adverse events. A statistically significant event favouring placebo was noted in the number of adverse events for injection site pain (RR 1.70; 95%CI 1.19 to 2.44, P value 0.004).</P>
<P>In comparative studies of HA versus NSAID, no statistically significant differences were detected in pain on walking at 1 to 4 weeks post-injection or total withdrawals overall at 14 to 26 weeks postinjection.</P>
<P>In comparative studies of HA versus methylprednisolone acetate, statistically significant differences in favour of IA steroid were detected in range of motion (degrees of flexion) at 1 to 4 weeks postinjection (WMD 3.87; 95%CI 0.36 to 7.37, P value 0.03) and 5 to 13 weeks postinjection (WMD 3.66; 95%CI 0.48 to 6.83, P value 0.02).</P>
<P>In six comparative studies of selected HA products, no statistically significant differences were detected between the products concerned in: pain on movement (number of patients improved) (1 to 4 weeks postinjection), pressure pain (number of patients improved) (1 to 4 weeks postinjection), Lequesne Index (1 to 4 weeks and 5 to 13 weeks postinjection), or patient global assessment (1 to 4 weeks, 5 to 13 weeks, 14 to 26 weeks and 45 to 52 weeks postinjection).</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>This review is current as of the end of December 2005, and contains both by-product and by-class analyses. It is comprehensive and more current than preceding systematic reviews and avoids limiting the review to a single product, variable or timepoint, or forcing different variables assessed using different instruments through a hierarchical algorithm in a reductionist manner, that attempts to obtain a single value capturing complex, dynamic, and heterogeneous phenomena. In developing a strategy for conducting this review, we have considered the complexity of the HA class of interventions, issues relating to the design, execution, analysis and interpretation of clinical trials, and the nuances of systematic reviews and meta-analytic techniques. It is recognized in combining studies using different designs that any resulting heterogeneity may be in part or in whole attributable to design elements, or characteristics of the patient population, rather than to variability in the efficacy of the HA product. This heterogeneity can in part be addressed by recognizing the presence and potential determinants of the heterogeneity and conducting the review in a manner that attempts to minimize the influence of any existent heterogeneity. </P>
<P>Previous systematic reviews by Lo et al. (<LINK REF="REF-Lo-2003" TYPE="REFERENCE">Lo 2003</LINK>), Wang et al. (<LINK REF="REF-Wang-2004" TYPE="REFERENCE">Wang 2004</LINK>), Arrich et al. (<LINK REF="REF-Arrich-2005" TYPE="REFERENCE">Arrich 2005</LINK>) and Modawal et al. (<LINK REF="REF-Modawal-2005" TYPE="REFERENCE">Modawal 2005</LINK>) have differed regarding the magnitude of clinical benefit of HA products. Lo et al. (<LINK REF="REF-Lo-2003" TYPE="REFERENCE">Lo 2003</LINK>), in particular, concluded that the effect size may be small at the class level. Bernstein (<LINK REF="REF-Bernstein-2004" TYPE="REFERENCE">Bernstein 2004</LINK>) has drawn attention to the discrepancy between the Lo et al. (<LINK REF="REF-Lo-2003" TYPE="REFERENCE">Lo 2003</LINK>) and Wang et al. (<LINK REF="REF-Wang-2004" TYPE="REFERENCE">Wang 2004</LINK>) commentaries on effect size. Hou and Wang (<LINK REF="REF-Hou-2004" TYPE="REFERENCE">Hou 2004</LINK>) have correctly asserted that the reviews differ in the approach to effect size estimation, search date and searching source, and in their interpretation of funnel plot distortion. The use of a hierarchy to identify a single time point and variable, from each study, in a phenomenon that is time and variable dependent, may also contribute in part to the small effect size observed in the Lo et al. meta-analysis. Arrich et al. reported reasons for discrepancies between their systematic review and three other relevant reviews. Some of these discrepancies were attributable to differences in the literature search, trial selection criteria, quality scoring, quantitative summary expressed as number of positive trials, use of change scores, and mixing of end (time) points (<LINK REF="REF-Arrich-2005" TYPE="REFERENCE">Arrich 2005</LINK>). Modawal et al. confirmed that the treatment effect was time dependent. Among the limitations of their meta-analysis, they reported heterogeneity of trials, trial quality, confounding by use of rescue analgesia during trial, and lack of intention-to-treat analyses (<LINK REF="REF-Modawal-2005" TYPE="REFERENCE">Modawal 2005</LINK>). Brandt (<LINK REF="REF-Brandt-2004" TYPE="REFERENCE">Brandt 2004</LINK>) reported that Dieppe et al. found a pooled effect size of -0.48 with a confidence interval of -0.72 to -0.23 in an analysis of 11 clinical trials. It appears, therefore, that the results of the meta-analyses may be, significantly method dependent, and reviewers should be aware of the nuances associated with the method used in this and other meta-analyses. </P>
<P>HA products differ in their origin, method of production, molecular weights (MW), biologic characteristics, rheologic properties, residence time in the joint and pharmacodynamic properties. As a consequence, any by-class analysis needs to be approached with due recognition that the products may differ in important respects, and that this may restrict the valuation of individual products, particularly where patients have not been randomised to receive the competing alternatives. The by-class analysis is also less informative to clinicians, since practitioners generally seek to make evidence-based decisions in treating individual patients with specific products, and are interested in the time course and dimensionality of the clinical response to individual products. In this review, we have presented both by-product analyses and by-class analyses in order that readers can make their own judgement regarding individual products as well as the class as a whole. The provision of separate within-product by-variable and by-time analyses, for different comparisons, permits the reader to appreciate the time-dependency of the response and the differential effects detected on different outcome variables.</P>
<P>The clinical epidemiology toolbox contains numerous alternative approaches to the design, execution and analysis of clinical trials. It is our understanding that traditionally, this class of intervention was considered as a device class and originally was not generally subject to the same evaluation guidelines that then existed for pharmacologic agents. This may explain, in part, the heterogeneity in research designs and outcome measurement techniques used, particularly in some of the earlier studies, a phenomenon, however, not peculiar to this class of interventions. Our review detected differences in at least nineteen areas of trial design including: clinical environment, sample size, number of study arms, number of centres, nature of the placebo comparator, inclusion and exclusion criteria, washout period, re-treatment opportunity, concomitant therapy, follow-up schedule, duration of follow-up, outcome measures, age, gender balance, disease duration, baseline pain severity, radiographic grade, treatment schedule, rescue medication. These differences were sometimes evident, even when comparing different trials involving the same HA product. </P>
<P>The nuances of systematic reviews and meta-analysis require due consideration of any assumptions, implicit or explicit that are made to combine information and data from diverse sources into valid and meaningful summary statistics. In particular, it is necessary to be familiar with a number of factors including, but not limited to the following: RevMan 4.2 software and its operations; assumptions, if any, regarding the value of &#961; in imputations which require converting between change scores and post-test scores; the significance of the test for heterogeneity and its implications both on the appropriateness of combining studies and the use of fixed-effect versus random-effects models of analysis; the consequence of basing analyses on transformed data, for example where different outcomes (pain walking, pain at night, global pain) measured on different instruments, have been filtered through a hierarchical algorithm to obtain a single measure of pain suitable for meta-analysis. This latter issue is particularly concerning given the differential impact of interventions on different components of the symptom complex and between-instrument differences in responsiveness (synonym: sensitivity to change). Other methodologic issues include the potential for publication bias, and the interpretation of the clinical importance of the observed treatment effects. In an attempt to address potential publication bias, we have searched abstract books, as well as published manuscripts, corresponded with manufacturers, and contacted investigators in the search for additional information or unpublished studies.</P>
<P>This review highlights the challenge of interpreting the results of clinical trials of intra-articular (IA) injections of hyaluronan and hylan in knee OA. Greater standardisation in methodology would facilitate assessment of these trials. Complete descriptions of blinding, randomisation, withdrawals and dropout would improve reporting quality. There was wide variation in the method of assessment of outcome. The distinction between primary and secondary outcome measures was infrequently reported. The utilisation of local anaesthetic also varied as well as description of the injection technique employed. The inclusion/exclusion criterion of presence of effusion at study entry was variable with some trials limiting the entry of subjects with a predefined volume of effusion. Different osteoarthritic populations were included in the trials; some subjects had unilateral disease while others had bilateral disease. Variability was noted in both timing and method (e.g. office versus telephone) of assessments, and in the opportunity for retreatment. In some trials, a per protocol rather than intent-to-treat statistical analysis was reported. </P>
<P>Safety was reported in variable formats, e.g. number of adverse events per number of injections, number of 'related' adverse events, number of subjects reporting adverse events, number of serious adverse events, number of local (injection site) reactions, number of systemic reactions, number of patients withdrawing due to adverse events. The denominator for safety analyses was frequently based on the intent-to-treat population. However, in some trials it was difficult to ascertain the denominator (patients versus injections). Ideally, the following should be reported: 1) withdrawals overall, 2) withdrawals due to all adverse events, 3) withdrawals due to system specific adverse events (e.g. gastrointestinal related grouped, cardiovascular grouped, etc.), and 4) withdrawals due to lack of efficacy. </P>
<P>Safety of hyaluronan and hylan in the general population for approved products in the U.S.A. can be examined by review of the U.S.A. Food and Drug Administration Manufacturers and User Device Experience (MAUDE) database available online at http://www.fda.gov/cdrh/maude.html. Large pharmacoepidemiologic databases are generally better sources of safety data than small individual clinical trials. An article by Hammesfahr, Knopf and Stitik reviews the safety data for the three products marketed in the United States, e.g. <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK>, <LINK REF="REF-Supartz" TYPE="REFERENCE">Supartz</LINK> and Synvisc (<LINK REF="REF-Hammesfahr-2003" TYPE="REFERENCE">Hammesfahr 2003</LINK>). They concluded that HA therapy is a safe treatment for OA of the knee. In addition, Hamburger et al. also concluded that HA therapy is a safe treatment for knee OA, but that there may be interproduct variability in safety profiles (<LINK REF="REF-Albert-2005" TYPE="REFERENCE">Albert 2005</LINK>; <LINK REF="REF-Hamburger-2003" TYPE="REFERENCE">Hamburger 2003</LINK>; <LINK REF="REF-Hamburger-2005" TYPE="REFERENCE">Hamburger 2005</LINK>; <LINK REF="REF-Raynauld-2005a" TYPE="REFERENCE">Raynauld 2005a</LINK>). </P>
<P>The possibility of publication bias exists if reviewers choose to exclude unpublished studies. McAuley et al. recommend the inclusion of all reports, grey and published, that meet predefined inclusion criteria in meta-analyses (<LINK REF="REF-McAuley-2000" TYPE="REFERENCE">McAuley 2000</LINK>). In this review, nine included studies (<LINK REF="STD-Ardic-2001" TYPE="STUDY">Ardic 2001</LINK>; <LINK REF="STD-Brown-2003" TYPE="STUDY">Brown 2003</LINK>; <LINK REF="STD-Cohen-1994" TYPE="STUDY">Cohen 1994</LINK>; <LINK REF="STD-Groppa-2001" TYPE="STUDY">Groppa 2001</LINK>; <LINK REF="STD-Guler-1996" TYPE="STUDY">Guler 1996</LINK>; <LINK REF="STD-Karras-2001" TYPE="STUDY">Karras 2001</LINK>; <LINK REF="STD-Moreland-1993" TYPE="STUDY">Moreland 1993</LINK>; <LINK REF="STD-Pham-2003" TYPE="STUDY">Pham 2003</LINK>; <LINK REF="STD-Tsai-2003" TYPE="STUDY">Tsai 2003</LINK>) were published only as abstracts. However, an in-house manuscript by Moreland (<LINK REF="STD-Moreland-1993" TYPE="STUDY">Moreland 1993</LINK>) was provided. The articles by Hizmetli (<LINK REF="STD-Hizmetli-1999" TYPE="STUDY">Hizmetli 1999</LINK>) and Lin (<LINK REF="STD-Lin-2004" TYPE="STUDY">Lin 2004</LINK>) were in-house publications. Two specialization thesis (<LINK REF="STD-Auerbach-2002a" TYPE="STUDY">Auerbach 2002a</LINK>; <LINK REF="STD-Kalay-1997" TYPE="STUDY">Kalay 1997</LINK>) were included. Published articles have the advantage of having undergone the peer review process. Frequently, abstracts do not provide enough information to be included in reviews, and, consequently, are excluded. </P>
<P>The method of statistical analysis can affect the result. The utilisation of follow-up (difference) scores, change (improvement) scores, or unadjusted post-test (synonym: final value) scores for continuous outcome measures can influence the result. Vickers and Altman (<LINK REF="REF-Vickers-2001" TYPE="REFERENCE">Vickers 2001</LINK>), Norman (<LINK REF="REF-Norman-1989" TYPE="REFERENCE">Norman 1989</LINK>), Lund (<LINK REF="REF-Lund-1988" TYPE="REFERENCE">Lund 1988</LINK>) and Stucki et al. (<LINK REF="REF-Stucki-1996" TYPE="REFERENCE">Stucki 1996</LINK>) have discussed this issue. </P>
<P>A high placebo effect has been noted in HA clinical trials (<LINK REF="REF-Bhogal-2000" TYPE="REFERENCE">Bhogal 2000</LINK>). This response may be attributed to a number of factors including: 1) removal of excess synovial fluid, 2) patient expectation, 3) Hawthorne effect of participating in a clinical trial, or 4) active treatment effect of saline and/or arthrocentesis (<LINK REF="REF-Kaptchuk-2000" TYPE="REFERENCE">Kaptchuk 2000</LINK>). The modulating effects of rescue analgesia and co-therapy with other OA treatments on outcome variables also should be considered. </P>
<P>The effect of treating both unilateral and bilateral disease in the same trial is problematic. Generally, efficacy results were based on analyses of the worse joint, while safety results were based on analyses of both joints. In some patients both knees received the same intervention, while for other patients they received one intervention in one knee and the comparative intervention in the other knee. The time between treatment of the knees varied considerably with some knees both being treated the same day, while other knees had a 210-day difference between initiation of treatment. The selection of a target joint (e.g. study knee) is one method of resolving this controversy. The problem of analysing the person versus the joint(s) has been reported in the literature (<LINK REF="REF-Sutton-1997" TYPE="REFERENCE">Sutton 1997</LINK>; <LINK REF="REF-Zhang-1996" TYPE="REFERENCE">Zhang 1996</LINK>). </P>
<P>Some trials used the Ahlback classification of knee OA. A recent publication, suggested that this classification had some 'major limitations' (<LINK REF="REF-Galli-2004" TYPE="REFERENCE">Galli 2004</LINK>). Even low grade Ahlback grades reflect substantial structural damage. Patients with higher grade structural damage may be generally less responsive to treatment (<LINK REF="STD-Barrett-2002" TYPE="STUDY">Barrett 2002</LINK>; <LINK REF="STD-Evanich-2001" TYPE="STUDY">Evanich 2001</LINK>; <LINK REF="STD-Lussier-1996" TYPE="STUDY">Lussier 1996</LINK>; <LINK REF="REF-Magilavy-2003" TYPE="REFERENCE">Magilavy 2003</LINK>; <LINK REF="STD-Toh-2002" TYPE="STUDY">Toh 2002</LINK>; <LINK REF="STD-Vad-2003" TYPE="STUDY">Vad 2003</LINK>). </P>
<P>Limitations of this review are the omission of open trials and case series, the omission of studies that failed to meet inclusion criteria, the lack of standard outcome measures restricting pooling opportunities, and restricted access to source data. Strengths of the review are the inclusion of only randomised controlled trials, the focus on four core OARSI and OMERACT outcome measures, and adherence to the principles of Cochrane systematic reviews. </P>
<P>A product-based discussion is followed by a class-based discussion. All comments are based on the trials that could be included in this review, the data that could be extracted and the analyses that could be performed, and should be interpreted and utilized by readers with the understanding that the review was conducted using the methodology described in the earlier part of this document, a methodology anchored to the Cochrane review process using RevMan 4.2 software, and limited potentially by restricted access to both unpublished studies and primary data. It should be recalled that HA products are not generally immediate in their onset, and that the 5 to 13 week time period may be one of the more relevant for single course studies, while later periods may be particularly relevant for studies allowing more than a single course. Statistically detectable differences seen in the 1 to 4 week postinjection period represent a relatively early onset of action and are not necessarily expected in all responding patients or all studies. It should also be noted that statistically detectable improvement may not necessarily be detected on all variables or at the same point in time. Function may improve more slowly than pain, and it may be more difficult to detect an effect on night pain than on walking pain. Finally, comparisons against other efficacious forms of treatment are likely to result in either no statistically detectable difference in efficacy or in relatively small differences (cf studies of HA products against placebo). The inability to show a statistically detectable difference between an HA product and placebo, in at least one key variable such as pain, function or patient global assessment from about 5 to 13 weeks onwards might be regarded with some degree of concern. </P>
<P>RevMan output for continuous data can be in the form of the WMD or SMD. The WMD provides a summary statistic whose magnitude is related to a number of factors including the treatment effect and the scale length of the instrument on which the underlying data were collected. What constitutes a minimum clinically important difference (MCID) is subject to ongoing debate (<LINK REF="REF-Bellamy-1993" TYPE="REFERENCE">Bellamy 1993</LINK>). The value for the minimum perceptible clinical improvement (MPCI) for the WOMAC Index is approximately 10 normalised units (0 to 100). This may serve as one indicator of the clinical importance of the WMD for pain, stiffness and function measured on 0 to 100 normalised unit scales. Tubach and colleagues have proposed definitions of Minimal Clinically Important Improvement (MCII) (<LINK REF="REF-Tubach-2005" TYPE="REFERENCE">Tubach 2005</LINK>), for pain, WOMAC function and patient global assessment. In contrast, the SMD provides a summary statistic adjusted by the variance, is of a different order of magnitude to the WMD and expresses the effect size as a unitless measure. What constitutes a small, medium, or large effect size is a matter for debate. We have used the proposals advanced by Cohen (<LINK REF="REF-Cohen-1977" TYPE="REFERENCE">Cohen 1977</LINK>), and operationalised in a recent publications by Jordan et al. (<LINK REF="REF-Jordan-2003" TYPE="REFERENCE">Jordan 2003</LINK>), and Mazieres et al. (<LINK REF="REF-Mazieres-2001" TYPE="REFERENCE">Mazieres 2001</LINK>) i.e. small effect size = 0.2, moderate effect size, i.e. clinically recognisable = 0.5, large effect size = 0.8. Other measures of clinical value are the percentage superiority in response and the NNT. We are not aware of published critical values for these parameters in OA management. Nevertheless, tables have been provided for all the aforementioned parameters, in order that readers can make informed decisions. It should be noted that the magnitude of these parameters differs with product, comparison, variable and time period. </P>
<P>We have observed that in some analyses, the RevMan 4.2 output differs from the original publication (<LINK REF="TBL-50" TYPE="TABLE">Table 50</LINK>). The discrepancies are likely due to the use of secondary data and the statistical methods available within the software programme. Reviewers are advised to consider these disparities when making product-based evaluations. <BR/>
<B>
<I>
<BR/>Product - Adant <BR/>
</I>
</B>
<BR/>No placebo-controlled trials were included in this review. The only data that could be included in the review suggested that Adant is not different to <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> with respect to patient global assessment at 1 to 4 weeks, 5 to 13 weeks, and 14 to 26 weeks, or with respect to the risk of experiencing injection-related pain. This review provides some supportive evidence for the efficacy and safety of Adant, but is based on limited data, and does not include placebo-controlled trials. <BR/>
<B>
<I>
<BR/>Product - Artz (Artzal) <BR/>
</I>
</B>
<BR/>In comparative studies of Artz and placebo included in this review, several outcome measures (Lequesne Index, range of motion, WOMAC OA Index), failed to detect a statistically significant difference at 1 to 4 weeks, 5 to 13 weeks, 14 to 26 weeks and 45 to 52 weeks, with the exception of patient global assessment at 1 to 4 weeks and 5 to 13 weeks and pain and the number of clinical failures at 5 to 13 weeks postinjection. Given the inclusion of single course studies, and the time-dependent dynamics of HA therapy, the positive effects of Artz on pain and patient global assessment seen at 5 to 13 weeks postinjection are expected. It is of note that statistically significant differences were detected on one pain measure but not another at 5 to 13 weeks. Significant effects on physical function cannot be confirmed from these analyses. It should be noted that the original analyses give a more positive result than the RevMan analyses we have performed. Taken collectively, the data generally support the efficacy of Artz (Artzal). </P>
<P>Analyses supported the safety of Artz, with no statistically significant differences from placebo being detected for the majority of safety variables. </P>
<P>No trials of Artzal against either corticosteroid or NSAID therapy were reported and no comment can be made on the relative effectiveness or safety against these two classes of <BR/>interventions. </P>
<P>In comparative analyses of Artz and Hylan G-F 20, there were no statistically significant differences at any of the four time periods in any of the four efficacy or three safety variables. This analysis derives from an ostensibly negative study. The two products could not be differentiated based on this single study. <BR/>
<B>
<I>
<BR/>Product - BioHy (Arthrease, Euflexxa, Nuflexxa)<BR/>
</I>
</B>
<BR/>The placebo-controlled study is inconclusive for efficacy, likely as a result of previously described methodologic issues. There was no statistically significant between-group difference in the proportion of patients experiencing postinjection pain, or in overall withdrawals and there were no systemic reactions in either group, providing some support for the safety of <BR/>BioHy within the limits of the available data. </P>
<P>No trials of BioHy against either corticosteroid or NSAID therapy were reported and no comment can be made on the relative effectiveness or safety against these two classes of interventions. </P>
<P>In comparative analyses of BioHy and Hylan G-F 20, pre-specified criteria for non-inferiority were met. Joint effusion was significantly less likely in the BioHy group. Statistically significant differences in favour of Bio-Hy were detected in the RevMan analyses for WOMAC function and number of patients using rescue analgesia at 1 to 4 and 5 to 13 weeks, but not in other efficacy variables including pain. There were a number of instances in which the RevMan analyses differed from the original publication. The two products could not be differentiated based on this single study. </P>
<P>
<B>
<I>Product - Durolane<BR/>
</I>
</B>
<BR/>The placebo controlled trial of Durolane was essentially negative, no statistically significant differences being detected on any efficacy variable in analyses based on all patients. The RevMan subanalysis of patients differed from the original publication. On the basis of RevMan analysis of this single study, no comment can be made regarding the relative efficacy of Durolane versus placebo. Evaluation of the efficacy of Durolane in patients with isolated knee OA requires further study.</P>
<P>
<B>
<I>Product - Fermathron <BR/>
</I>
</B>
<BR/>No trials of Fermathron against placebo were reported and efficacy against placebo cannot, therefore, be assessed. No trials of Fermathron against either corticosteroid or NSAID therapy were reported and no comment can be made on the relative effectiveness or safety against these two classes of interventions. </P>
<P>In comparative analyses of Fermathron and Hyalart, there were no statistically significant differences at either of the time periods in any of the three efficacy variables, or in the safety variable. The two products could not be differentiated based on this single study. <BR/>
<B>
<I>
<BR/>Product - </I>
</B>
<LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> </P>
<P>In comparative studies of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> and placebo included in this review, statistically significant differences were detected at 1 to 4 weeks (pain on weight-bearing, spontaneous pain, pain at rest, Lequesne Index, number of joints improved for walking pain, number of joints improved for weight under load), 5 to 13 weeks (pain on weight-bearing, spontaneous pain, pain at rest, Lequesne Index, number of joints improved for walking pain, number of joints improved for weight under load, flexion, patient global assessment), 14 to 26 weeks (pain on weight-bearing, WOMAC pain). Statistically significant differences were not detected for pain at rest at 14 to 26 weeks, pain on weight bearing at 45 to 52 weeks, night pain, WOMAC pain at 1 to 4 weeks or 5 to 13 weeks, WOMAC function, Lequesne Index at 14 to 26 weeks, flexion at 1 to 4 weeks, or patient global assessment at 1 to 4 weeks, 14 to 26 weeks and 45 to 52 weeks. Many of the aforementioned statistically significant differences were highly significant, and clinically important (WMD (disregarding sign) for pain (0 to 100 mm) varying from 3.93 to 33.50). Overall, these analyses strongly support the evidence for efficacy of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK>. No statistically significant differences from placebo were detected in the majority of safety variables although number of patients with local adverse events, number of patients with local adverse events that caused discontinuation, and number of patients with treatment-related adverse events was significantly greater with <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK>. Analyses of safety data also support the safety of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK>. </P>
<P>Comparative studies of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> against IA methylprednisolone suggest that <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> is superior to methylprednisolone at 5 to 13 weeks postinjection on spontaneous pain intensity, number of patients with moderate to severe pain under load, number of patients with moderate or greater rest pain, flexion, patient global assessment, but with the exception of flexion was not different at 1 to 4 weeks. No statistically significant differences were detected at 14 to 26 weeks or 45 to 52 weeks postinjection. These differences are probably due to the quick onset but often relatively short duration of the response to IA corticosteroid treatment. Overall, these analyses suggest that <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> is comparable, or superior in efficacy to methylprednisolone, notwithstanding that the latter has a faster onset of action but the former a longer duration of action. Analyses of safety data also supported the safety of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK>, with no statistically significant differences from IA methylprednisolone being detected in safety variables. The comparative study of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> against IA triamcinolone hexacetonide suggests that <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> is not different in efficacy to triamcinolone hexacetonide, except in pain at night at 14 to 26 weeks. Analyses of safety data supported the safety of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK>, with no statistically significant differences from IA triamcinolone hexacetonide being detected in safety variables. Collectively these data support the efficacy and safety of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK>, and show some 5 to 13 week postinjection advantages in favour of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> over methylprednisolone. </P>
<P>The comparative study of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> against NSAID suggests that <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> is comparable in efficacy to NSAID therapy at 1 to 4 weeks, 5 to 13 weeks, and 14 to 26 weeks postinjection, based on pain after a 50-feet walk and number of patients with moderate to marked pain. There were significantly fewer patients with gastrointestinal complaints, but more injection-site pain on <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK>; otherwise there were no statistically detectable differences in safety. Overall, these analyses suggest that <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> is comparable in efficacy to NSAID therapy and similar in safety, with the exception of more injection-site pain events but fewer gastrointestinal adverse events than NSAID. </P>
<P>The comparative study of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> against mucopolysaccharide polysulfuric acid ester detected statistically significant differences in pain, Larson rating and patient global assessment, but no difference in function or range of motion. There was no difference in safety profile. The data are limited and no conclusion can be reached from this review regarding relative efficacy and safety. </P>
<P>The comparative study of <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> versus conventional therapy detected statistically significant differences in arthroscopy score but not in clinical outcomes at 45 to 52 weeks. The data are limited, but are of interest in terms of potential structure modification effects. </P>
<P>Huang et al.'s comparative study of combining <LINK REF="REF-Hyalgan" TYPE="REFERENCE">Hyalgan</LINK> therapy with ultrasound and exercise versus physiotherapy programmes without Hyalgan co-therapy, suggested positive clinical benefits in some outcome variables both at end of study and 1-year follow-up. This interesting observation requires confirmation, but may suggest a role for Hyalgan as a co-therapy, in some patients requiring physical forms of therapy for knee OA.</P>
<P>
<B>
<I>Product - Hylan G-F 20 (Synvisc)<BR/>
</I>
</B>
<BR/>In comparative studies of Hylan G-F 20 and placebo included in this review, statistically significant differences were detected at 1 to 4 weeks (WOMAC OA Index pain, pain on weight-bearing, night pain, rest pain, improvement in most painful knee movement, WOMAC OA Index stiffness, WOMAC OA Index physical function, patient global assessment of treatment efficacy, physician global assessment), 5 to 13 weeks (WOMAC pain, pain on weight-bearing, rest pain, pain walking, night pain, WOMAC OA Index stiffness, WOMAC function, Lequesne Index, improvement in most painful knee movement, patient global assessment of treatment efficacy, physician global assessment), 14 to 26 weeks (WOMAC pain, pain on weight-bearing, night pain, WOMAC function). Statistically significant differences were not detected for pain overall , 15 metre walking time, number of clinical failures or number of survivors. Many of the aforementioned statistically significant differences were highly significant, and clinically important (WMD (disregarding sign) for pain (0 to 100 mm) varying from 8.03 to 35.68). Overall, these analyses strongly support the evidence for efficacy of Hylan G-F 20. Analyses of safety data also support the safety of Hylan G-F 20, with no statistically significant differences from placebo being detected in the majority of safety variables. </P>
<P>Comparative studies of Hylan G-F 20 against corticosteroid suggest that Hylan G-F 20 is superior to triamcinolone hexacetonide at 5 to 13 weeks, and 14 to 26 weeks post injection on WOMAC pain walking on a flat surface, WOMAC function and total WOMAC score, but not at 1 to 4 weeks. This difference is probably due to the quick onset but often relatively short duration of the response to IA corticosteroid treatment. Overall, these analyses suggest that Hylan G-F 20 is comparable in efficacy to IA corticosteroid, notwithstanding that the latter has a faster onset of action but the former a longer duration of action. Analyses of safety data also supported the safety of Hylan G-F 20, with no statistically significant differences from IA corticosteroid being detected in the majority of safety variables. </P>
<P>Comparative studies of Hylan G-F20 against NSAID suggest that Hylan G-F 20 is comparable in efficacy to NSAID therapy at 5 to 13 weeks, and 14 to 26 weeks postinjection, based on the majority of variables. There were significantly fewer patients with possible or probable related systemic adverse events on Hylan G-F 20 but otherwise there were no statistically detectable differences in safety. Overall, these analyses suggest that Hylan G-F 20 is comparable in efficacy to NSAID therapy and similar or slightly superior in safety. </P>
<P>The comparative study of Hylan G-F 20 plus physiotherapy against physiotherapy alone detected no difference in Lequesne score or withdrawals but is limited in its scope and generalisability (<LINK REF="STD-Bayramoglu-2003" TYPE="STUDY">Bayramoglu 2003</LINK>). In contrast, in the comparative study of Hylan G-F20 vs physiotherapy (<LINK REF="STD-Atamaz-2005" TYPE="STUDY">Atamaz 2005</LINK>), while there was an early effect in favour of physiotherapy at 1 to 4 weeks, other analyses favoured Hylan G-F 20 (WOMAC pain at 1at 4 weeks and 5 to 13 weeks, 37 weeks and 45 to 52 weeks). In the comparative study of Hylan G-F 20 versus an exercise programme (<LINK REF="STD-Karatosun-2005" TYPE="STUDY">Karatosun 2005</LINK>), statistically significant differences in favour of Hylan G-F 20 were detected in several pain components of the Hospital for Special Surgery Knee Score, but not in the overall score at any of the time points. There were fewer withdrawals in the exercise group. Taken collectively, and recognizing the disparate nature of the physiotherapy interventions and comparisons analysed, Hylan G-F 20 may be superior to physiotherapy alone or an exercise programme in some knee OA patients with respect to pain relief. </P>
<P>The comparative study of Hylan G-F 20 and intra-articular gaseous oxygen, detected no statistically significant differences on the majority of variables. Indeed the only variable on which a difference was detected was pain under load at 5 to 13 weeks and was in favour of intra-articular gaseous oxygen. The two treatments could not be differentiated based on this single study. </P>
<P>Two comparative studies of Hylan G-F 20 plus appropriate care versus appropriate care alone both confirm the superiority of adding Hylan G-F 20 to appropriate care as assessed by the WOMAC OA Index, Lequesne Index and patient global assessment. Safety variables either detected no statistically significant difference or were in favour of Hylan G-F 20 plus appropriate care. These studies provide strong support for the incorporation of Hylan G-F 20 into routine clinical care treatment paradigms. <BR/>
<B>
<I>
<BR/>Product - NRD-101 </I>
</B>
</P>
<P> In the comparative study of NRD-101 plus oral placebo versus intra-articular saline and oral placebo, performed by Pham (<LINK REF="STD-Pham-2004" TYPE="STUDY">Pham 2004</LINK>), no statistically significant between-group differences were detected in pain, Lequesne index, patient global assessment, percentage of painful days or radiographic progressors. On the basis of RevMan analysis of this single study, no comment can be made regarding the relative efficacy of NRD-101 versus placebo.</P>
<P>In the comparative analyses against Artz, no statistically significant differences were detected between the products in improvement in clinical symptoms or safety. The two products could not be differentiated based on this single study. </P>
<P> The comparative study performed by Pham (<LINK REF="STD-Pham-2004" TYPE="STUDY">Pham 2004</LINK>) detected no statistically significant differences on clinical outcome variables or radiographic progression between NRD-101 and Diacerein. However, NRD-101 was associated with significantly more local reactions and Diacerien with significantly more diarrhea. On the basis of RevMan analysis of this single study, no comment can be made regarding the relative efficacy of NRD-101 versus Diacerein.<BR/>
<B>
<I>
<BR/>Product - </I>
</B>
<LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> </P>
<P>In comparative studies of <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> and placebo included in this review, statistically significant differences in WOMAC pain and WOMAC function were detected at 1 to 4 weeks, 5 to 13 weeks, and 14 to 26 weeks postinjection, WOMAC stiffness at 5 to 13 weeks and 14 to 26 weeks postinjection, and patient global assessment at 1 to 4 weeks and 5 to 13 weeks postinjection. These analyses support the evidence for efficacy of <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK>. Analyses of safety data also supported the safety of <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK>, with no statistically significant differences from placebo being detected in the safety profile. </P>
<P>Comparative studies of <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> against corticosteroid suggest that <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> is superior to 6-MPA at 5 to 13 weeks and 14 to 26 weeks postinjection and superior to betamethasone at 5 to 13 weeks postinjection. No statistically significant differences were detected at 1 to 4 weeks against either corticosteroid. This time-dependent difference is probably due to the quick onset but often relatively short duration of the response to IA corticosteroid treatment. Overall, these analyses suggest that <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> is comparable in efficacy to IA corticosteroids at 1 to 4 weeks and superior at 5 to 13 weeks and 14 to 26 weeks, notwithstanding that the latter have a faster onset of action but the former a longer duration of action. Analyses of safety data also support the safety of <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK>, with no statistically significant differences from either IA corticosteroid preparation being detected in the safety profile. In the study performed by Ozturk (<LINK REF="STD-Ozturk-2005" TYPE="STUDY">Ozturk 2005</LINK>), in which Orthovisc was compared in combination with triamcinolone acetonide to Orthovisc alone, statistically significant differences, in favour of the combination, were detected for pain (1 to 4 weeks) and WOMAC stiffness (1 to 4, 34 and 45 to 52 weeks), although there were fewer withdrawals in the Orthovisc alone group. Given that significant differences were not noted on the majority of outcome variables, but acknowledging the apparent clinical benefit of the combination on some variables, the value of combination therapy merits further evaluation. </P>
<P>No trials of <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> against either NSAID therapy were reported and no comment can be made on the relative effectiveness or safety against this class of intervention. </P>
<P>In the comparative study of <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> plus physiotherapy against physiotherapy alone, no statistically significant differences in efficacy variables were detected at 1 to 4 weeks postinjection. Statistically significant differences in favour of <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> were noted in some, but not all, variables at 5 to 13 weeks postinjection. There were no statistically significant differences in safety profile. These analyses suggest that adding <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> to physiotherapy may be beneficial with respect to activity pain and spontaneous pain, at 5 to 13 weeks postinjection. The more recent study of Orthovisc versus physiotherapy by Atamaz (<LINK REF="STD-Atamaz-2005" TYPE="STUDY">Atamaz 2005</LINK>), detected statistically significant differences in favour of Orthovisc for spontaneous pain (14 to 26 weeks), WOMAC pain (1 to 4 and 45 to 52 weeks), SF-36 pain (5 to 13 and 14 to 26 weeks), SF-36 physical function (5 to 13 and 45 to 52 weeks). The comparison of Orthovisc plus physiotherapy versus physiotherapy alone (<LINK REF="STD-Bayramoglu-2003" TYPE="STUDY">Bayramoglu 2003</LINK>) failed to detect between group differences using the Lequesne index. Taken collectively, the studies of Kalay (<LINK REF="STD-Kalay-1997" TYPE="STUDY">Kalay 1997</LINK>) and Atamaz (<LINK REF="STD-Atamaz-2005" TYPE="STUDY">Atamaz 2005</LINK>), suggest that Orthovisc offers clinical benefit compared to physiotherapy.</P>
<P> In a comparative analysis of Orthovisc plus physical therapy versus Hylan G-F 20 plus physical therapy (<LINK REF="STD-Bayramoglu-2003" TYPE="STUDY">Bayramoglu 2003</LINK>), there were no statistically significant differences in efficacy or safety. Several studies have compared Orthovisc and Hylan G-F 20 (<LINK REF="STD-Atamaz-2005" TYPE="STUDY">Atamaz 2005</LINK>; <LINK REF="STD-Bayramoglu-2003" TYPE="STUDY">Bayramoglu 2003</LINK>; <LINK REF="STD-Karatay-2004" TYPE="STUDY">Karatay 2004</LINK>; <LINK REF="STD-Karatosun-2005" TYPE="STUDY">Karatosun 2005</LINK>; <LINK REF="STD-Kotevoglu-2005" TYPE="STUDY">Kotevoglu 2005</LINK>). Statistically significant differences have not generally been detected, but where detected, the majority have been in favour of Hylan G-F20. The two products could not be clearly differentiated based on these studies. </P>
<P>The comparative study of Orthovisc alone versus Orthovisc plus co-treatment with trigger point injections (<LINK REF="STD-Yentur-2003" TYPE="STUDY">Yentur 2003</LINK>), suggested clinical benefit in pain relief with the combination programme. No recommendation can be made on the basis of this single study, but the concept merits further evaluation in relevant knee OA patients.</P>
<P>The comparison of Orthovisc treatment schedules conducted by Neustadt (<LINK REF="STD-Neustadt-2005" TYPE="STUDY">Neustadt 2005</LINK>) detected statistically significant differences in favour of the 4-injection regimen in WOMAC 20% pain response at 5 to 13 weeks and in the patient global assessment. </P>
<P>In a comparative analysis of <LINK REF="REF-Orthovisc" TYPE="REFERENCE">Orthovisc</LINK> plus physical therapy versus Hylan G-F 20 plus physical therapy there were no statistically significant differences in efficacy or safety. The two products could not be differentiated based on this single study. <BR/>
<B>
<I>
<BR/>Product - Replasyn <BR/>
</I>
</B>
<BR/>It was not possible to conduct informative analysis of Replasyn as part of this review, and therefore no conclusion can be reached regarding efficacy or safety, based on our review. The original publication, referred to previously, noted a significant difference in only one of six variables. <BR/>
<B>
<I>
<BR/>Product - SLM-10 <BR/>
</I>
</B>
<BR/>SLM-10 was comparable in efficacy to Artz on three outcome measures and statistically significantly inferior on pain on pressure. There was no difference in safety profile. This review provides some supportive evidence for the efficacy and safety of SLM-10, but is based on limited data, and does not include placebo-controlled trials or studies against NSAID, IA corticosteroid or appropriate care. <BR/>
<B>
<I>
<BR/>Product - Suplasyn <BR/>
</I>
</B>
<BR/>No statistically significant differences were detected in our analyses between Suplasyn and placebo for four of the five efficacy measures and for the fifth favoured the control group. No statistically detectable differences were noted in the safety profile. The review does not incontrovertibly support the efficacy of Suplasyn, given negative outcomes for the majority of variables in our RevMan analyses, which are somewhat at variance with the original publication. However, Felson and Anderson (<LINK REF="REF-Felson-2002" TYPE="REFERENCE">Felson 2002</LINK>) published an editorial on HA injections for OA in the same issue of Archives of Internal Medicine in which the Petrella trial (<LINK REF="STD-Petrella-2002" TYPE="STUDY">Petrella 2002</LINK>) was published. They re-evaluated the data of Petrella analysing it as a factorial experiment, and noted that Suplasyn had no "significant or important clinical effect on pain" and "there [were] null results for disability and other outcomes". </P>
<P>No statistically significant differences in efficacy or safety variables were detected between Suplasyn and NSAID. The two treatment strategies could not be differentiated based on this single study. <BR/>
<B>
<I>
<BR/>Product - Zeel compositum <BR/>
</I>
</B>
<BR/>No statistically significant differences in efficacy or safety variables were detected between Zeel compositum and Hyalart. The two products could not be differentiated based on this study. </P>
<P>
<B>
<I>Product - Hyaluronan (brand name not identified)</I>
</B>
</P>
<P>The interpretation of the study reported by Wu (<LINK REF="STD-Wu-2004" TYPE="STUDY">Wu 2004</LINK>) is problematic since the exact nature of the HA product could not be identified. The authors concluded that HA plus self-controlled celecoxib could improve the clinical symptoms of knee OA. We are not able to reach a conclusion based on this study due to lack of sufficient information. </P>
<P>
<B>
<I>By-class analyses </I>
</B>
</P>
<P>The pooled analyses address issues relating to class characteristics and may not be shared to the same extent by each individual HA product. Readers including practitioners, regulators and third party payers should be cautious in extrapolating from the class to an individual product or vice versa, as the class-based analysis may either under-estimate or over-estimate the performance of individual component products. For product-based information, readers are referred to the relevant preceding sections. Only comparisons against placebo are discussed, because of the relatively large number of studies available for some of these analyses. The other comparisons were limited, in some cases, by a relative paucity of studies. </P>
<P>Statistically significant differences were detected between HA and placebo at 1 to 4 weeks (WOMAC pain, pain on weight bearing, pain at rest, WOMAC function, Lequesne Index, flexion), 5 to 13 weeks (pain on weight bearing, WOMAC pain, WOMAC function, Lequesne Index, flexion), and 14 to 26 weeks (pain on weight bearing, WOMAC pain, WOMAC function, flexion) postinjection. Apart from a higher incidence of injection site pain, no statistically significant differences versus placebo were noted in the safety profile variables. These data generally support the evidence for the efficacy and safety (versus placebo) of the HA class of intervention.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>The review presented is comprehensive and permits practitioners to more fully consider the therapeutic profile of HA products. Each analysis addresses a different issue, and practitioners are recommended to review those analyses specifically relating to their questions. This should involve examining the original publication, the methodology employed in conducting the review, the results for the product(s) of interest, with attention to the relevant variables and timepoints. Readers should consider the clinical importance as well as the statistical significance of any differences detected. Readers should be aware that the results of our review derive from a defined approach to the analysis of selected studies, that selected studies vary in quality and that the analyses do not consider studies excluded from consideration. Nevertheless, the approach is traditional, follows Cochrane guidelines and uses RevMan 4.2 software. </P>
<P>Controversy in the existing literature is part due to a combination of the heterogeneous time-dependant nature of the response to the HA class of products, diversity in protocol design in the contributing studies, and the different approaches taken to the conduct of systematic reviews. We have attempted to dissect out the effect of these issues by performing multiple analyses on a by-product, by-comparison, by-variable, by-timepoint basis. While this does not provide a single answer to questions of efficacy, effectiveness and safety, the analyses permit the complexity of the HA effect to be appreciated. </P>
<P>The analyses suggest that there is considerable heterogeneity in the clinical response, such that there are differential therapeutic effects by different HA products, on different variables and that the response is time dependent. For example, when pain on weight bearing at 5 to 13 weeks postinjection is considered the evidence is very supportive of therapeutic benefit over placebo, and the effect size (SRM) may be as high as 0.94 depending on the product and is 0.61 for the HA class in general. Given that effect sizes can be classified as small (0.2), medium (0.5) or large (0.8), these analyses suggest a range of effect sizes up to large product-based effect on pain on weight bearing, and a moderate class-based effect on pain on weight bearing. </P>
<P>The dynamics of the response are such that a statistically significant, clinically important, effect 1 to 4 weeks postinjection versus placebo is not necessarily achievable, but should be evident by the 5 to 13 week time point. Nevertheless, early responses are observed in some comparisons. In contrast, in comparisons against placebo there may be a more durable, albeit slower response compared to IA corticosteroids. In long-term studies, the effects of combining single course with repeat treatment studies in our analyses deserve due consideration, particularly when reviewing the late stage endpoints, for example 45 to 52 weeks. In single course studies the last course may have been almost one year prior when a persisting effect might not be expected, while in repeat-course studies the last course may have been recent, or even 5 to 13 weeks prior, when a clinical benefit might well be anticipated. These nuances deserve due recognition since they account for some of the diversity in the responses reported in the literature. </P>
<P>These issues notwithstanding, HA products generally appear superior to placebo on multiple efficacy variables, providing support for the use of those HA products for which the effect is not only statistically significant but also clinically important. These benefits appear to be achievable without attributable systemic adverse events but with occasional local reactions which tend, for the most part, to be relatively transient, resolving without sequelae either spontaneously or with simple intervention. It should be noted that this review is not the premier source of safety data, since sample sizes are relatively small in the trials reported, particularly for detecting less frequent or even rare adverse events. Readers are referred to the general literature and the surveillance literature for a more comprehensive appreciation of safety issues. Nevertheless, based on the evidence reviewed, HA products appear in general to be safe.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>The following types of studies would be informative: long-term trials (up to one year) including repeat course studies, head-to-head comparisons of different HA products, effectiveness, cost-effectiveness and cost-utility studies, studies of different OA subgroups, dissection of the determinants of the response to HA products, exploration of the apparently differential effect of HA products on different variables. The aforementioned studies should follow OARSI and other similar guidelines for the conduct and design of OA studies. The use of standardized outcome measures is encouraged to facilitate meta-analyses and between trial comparisons.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>The authors are grateful to Jessie McGowan for conducting the search strategy. We acknowledge the translation of the <LINK REF="STD-Wu-2004" TYPE="STUDY">Wu 2004</LINK> article by Dr. Hua Qian, MD, PhD, The Robarts Research Institute, The University of Western Ontario. We acknowledge the assistance of former Musculoskeletal Review Group Co-ordinator Maria Judd and current Musculoskeletal Review Group Co-ordinator Lara Maxwell for their guidance in completing this review. </P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>The original review was externally supported by Genzyme Biosurgery [formerly Biomatrix, Inc] and Wyeth-Ayerst as an unrestricted educational grant. Finances supported research staff to research this treatment area for all products, not just that manufactured by Genzyme BioSurgery [formerly Biomatrix, Inc]. The interpretation of the results are those of the reviewers who retain the right to publish. </P>
<P>Dr. Nicholas Bellamy and Dr. Robert Bourne participated in the Raynauld (<LINK REF="STD-Raynauld-2002" TYPE="STUDY">Raynauld 2002</LINK>) trial. Dr. Bellamy was a co-investigator on the Steering Committee of the Raynauld (<LINK REF="STD-Raynauld-2002" TYPE="STUDY">Raynauld 2002</LINK>) trial, and previously provided consulting services to Biomatrix and Genzyme Inc.</P>
<P>Dr. Bourne was a clinical investigator in the Raynauld (<LINK REF="STD-Raynauld-2002" TYPE="STUDY">Raynauld 2002</LINK>) trial. </P>
<P>Product-based analyses were circulated to each respective manufacturer prior to finalisation of the original review to permit any factual errors to be addressed. Comments were received from some but not all manufacturers.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>NB filed the protocol for the review with The Cochrane Collaboration. JC coordinated the review under NB's supervision. JC searched the literature and extracted data. NB and JC performed the methodological review. JC entered and analysed the data. VR checked data extraction. GAW provided statistical and methodological support. TG provided statistical support. NB is the guarantor for the review.</P>
<P>For the update, JC completed data extraction and NB verified data extraction. NB and JC performed the methodological review. VR provided methodological support. GAW provided statistical and methodological support. TG provided statistical support. NB is the guarantor for the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES MODIFIED="2008-11-09 22:52:58 -0500" MODIFIED_BY="[Empty name]">
<P>This update was required as the Cochrane Funding Arbitration Panel ruled that the original review contravened the "current" sponsorship policy. In order to have the review reinstated into the Cochrane Library, the review was updated using no commercial sources of support and the electronic literature search was updated (Medline). The financial support for the original review is now disclosed in the "conflict of interest" statement.<BR/>
<BR/>This update includes 16 "new" RCT: Altman 2004, Atamaz (accepted for publication), Cubukcu 2005, Huang 2005, Karatay 2004, Karatosun 2005, Karatosun 2005a, Kirchner 2006, Kotevoglu 2005, Neustadt 2005, Ozturk 2005, Pham 2004, Rejaili 2005, Sezgin 2005, Wu 2004, and Yentur 2003.<BR/>
<BR/>In the original review, only limited information was included for three of the "new" RCT based on the following abstracts: Ardic 2001 (Cubukcu 2005), Pham 2003 (Pham 2004), and Thompson 2002 (Kirchner 2006).<BR/>
</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-11-09 23:54:05 -0500" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2008-11-09 23:51:30 -0500" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2008-11-09 23:51:30 -0500" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Adams-1995" NAME="Adams 1995" YEAR="1995">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Adams ME, Atkinson MH, Lussier AJ, Schulz JI, Siminovitch KA, Wade JP, Zummer M</AU>
<TI>The role of viscosupplementation with hylan G-F 20 (Synvisc) in the treatment of osteoarthritis of the knee: a Canadian multicenter trial comparing hylan G-F 20 alone, hylan G-F 20 with non-steroidal anti-inflammatory drugs (NSAIDs) and NSAIDs alone</TI>
<SO>Osteoarthritis and Cartilage</SO>
<YR>1995</YR>
<VL>3</VL>
<PG>213-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Altman-1998" NAME="Altman 1998" YEAR="1998">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Altman RD, Moskowitz R, the Hyalgan Study Group</AU>
<TI>Intraarticular sodium hyaluronate (Hyalgan) in the treatment of patients with osteoarthritis of the knee: a randomized clinical trial [published erratum appears in J Rheumatol 1999;26:1216]</TI>
<SO>The Journal of Rheumatology</SO>
<YR>1998</YR>
<VL>25</VL>
<NO>11</NO>
<PG>2203-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Altman-2004" MODIFIED="2008-11-09 23:08:42 -0500" MODIFIED_BY="[Empty name]" NAME="Altman 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-11-09 23:08:42 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Altman RD, Akermark C, Beaulieu AD, Schnitzer T for the Durolane International Study Group</AU>
<TI>Efficacy and safety of a single intra-articular injection of non-animal stabilized hyaluronic acid (NASHA) in patients with osteoarthritis of the knee</TI>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2004</YR>
<VL>12</VL>
<NO>8</NO>
<PG>642-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ardic-2001" NAME="Ardic 2001" YEAR="2001">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ardic F, Bolulu D, Topuz O, Cubukcu S</AU>
<TI>Efficacy of intra-articular hyaluronic acid injections in knee osteoarthritis</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2001</YR>
<VL>60 Suppl (1)</VL>
<PG>232</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Atamaz-2004" MODIFIED="2008-11-09 23:09:09 -0500" MODIFIED_BY="[Empty name]" NAME="Atamaz 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-11-09 23:09:09 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Atamaz F, Kirazli Y, Akkoc Y</AU>
<TI>A comparative study between intra-articular hylan G-F 20 and Na-hyaluronate and physical therapy in the management of knee osteoarthritis</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2004</YR>
<VL>EULAR, Berlin, June 9-12</VL>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Atamaz-2005" MODIFIED="2008-11-09 23:13:10 -0500" MODIFIED_BY="[Empty name]" NAME="Atamaz 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-11-09 23:13:10 -0500" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Unpublished manuscript accepted for publication in Rheumatology International&lt;/p&gt;" NOTES_MODIFIED="2008-11-09 23:13:10 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Atamaz F, Kirazli Y, Akkoca Y</AU>
<TI>A comparison of two different intra-articular hyaluronan drugs and physical therapy in the management of knee osteoarthritis</TI>
<SO>Rheumatology International</SO>
<YR>2006</YR>
<VL>26</VL>
<NO>10</NO>
<PG>873-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Auerbach-2002" NAME="Auerbach 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Auerbach B, Melzer C</AU>
<TI>Cross-linked hyaluronic acid in the treatment of osteoarthritis of th eknee - results of a prospective randomized trial</TI>
<TO>Die Behandlung der Gonarthrose mit hochvernetzter Hyaluronsaure - Ergebnisse einer prospektiven randomisierten Studie</TO>
<SO>Zentralblatt fur Chirurgie</SO>
<YR>2002</YR>
<VL>127</VL>
<NO>10</NO>
<PG>895-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Auerbach-2002a" NAME="Auerbach 2002a" YEAR="2002">
<REFERENCE PRIMARY="YES" TYPE="OTHER">
<AU>Auerbach B</AU>
<TO>Ergebnisse einer prospektiven randomisierten Studie zur Wirksamkei hochvernetzter Hyaluronsaure bei der Behandlung der Gonarthrose</TO>
<SO>Inaugural-Dissertation zur Erlangung des Grades eines Doktors der Medizin des Fachbereichs Humanmedizin der Justus-Liebig-Universitat Giessen</SO>
<YR>2002</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bayramoglu-2003" MODIFIED="2008-11-09 23:13:55 -0500" MODIFIED_BY="[Empty name]" NAME="Bayramoglu 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-11-09 23:13:55 -0500" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bayramoglu M, Karatas M, Cetin N, Akman N</AU>
<TI>Comparison of two different viscosupplements in knee osteoarthritis - a pilot study</TI>
<SO>Clinical Rheumatology</SO>
<YR>2003</YR>
<VL>22</VL>
<PG>118-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bragantini-1987" NAME="Bragantini 1987" YEAR="1987">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bragantini A, Cassini M, De Bastiani G</AU>
<TI>Controlled single-blind trial of intra-articularly injected hyaluronic acid (Hyalgan) in osteo-arthritis of the knee</TI>
<SO>Clinical Trials Journal</SO>
<YR>1987</YR>
<VL>24</VL>
<NO>4</NO>
<PG>333-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brandt-2001" NAME="Brandt 2001" YEAR="2001">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Brandt KD, Block JA, Michalski JP, Moreland LW, Caldwell JR, Lavin PT, the ORTHOVISC Study Group</AU>
<TI>Efficacy and safety of intraarticular sodium hyaluronate in knee osteoarthritis</TI>
<SO>Clinical Orthopaedics and Related Research</SO>
<YR>2001</YR>
<VL>385</VL>
<PG>130-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brown-2003" MODIFIED="2008-11-09 23:14:28 -0500" MODIFIED_BY="[Empty name]" NAME="Brown 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-11-09 23:14:28 -0500" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Brown DJ, Beinat L</AU>
<TI>Safety and efficacy of an hyaluronan of 500-730 KDa and Hylan G-F 20 in clinical practice</TI>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2003</YR>
<VL>11 Suppl (A)</VL>
<PG>118</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="OARSI October 2003 Berlin"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bunyaratavej-2001" NAME="Bunyaratavej 2001" YEAR="2001">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bunyaratavej N, Chang KM, Subramanian N</AU>
<TI>Treatment of painful osteoarthritis of the knee with hyaluronic acid results of a multicenter Asian study</TI>
<SO>Journal of the Medical Association of Thailand</SO>
<YR>2001</YR>
<VL>84 Suppl (2)</VL>
<PG>576-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Caborn-2003" MODIFIED="2008-11-09 23:14:59 -0500" MODIFIED_BY="[Empty name]" NAME="Caborn 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-11-09 23:14:59 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Caborn DN</AU>
<TI>Efficacy and tolerability of hylan G-F 20 compared to intra-articular triamcinolone hexacetonide in patients with osteoarthritis of the knee in a randomized, evaluator-blinded study</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2003</YR>
<VL>EULAR, Lisbon, Portugal,June 18-21</VL>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Caborn-2004" MODIFIED="2008-11-09 23:15:17 -0500" MODIFIED_BY="[Empty name]" NAME="Caborn 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-11-09 23:15:17 -0500" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Caborn D, Rush J, Lanzer W, Parenti D, Murray C on Behalf of the Synvisc 901 Study Group</AU>
<TI>A randomized, single-blind comparison of the efficacy and tolerability of hylan G-F 20 and triamcinolone hexacetonide in patients with osteoarthritis of the knee</TI>
<SO>The Journal of Rheumatology</SO>
<YR>2004</YR>
<VL>31</VL>
<NO>2</NO>
<PG>333-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carrabba-1995" NAME="Carrabba 1995" YEAR="1995">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Carrabba M, Paresce E, Angelini M, Re KA, Torchiana EEM, Perbellini A</AU>
<TI>The safety and efficacy of different dose schedules of hyaluronic acid in the treatment of painful osteoarthritis of the knee with joint effusion</TI>
<SO>European Journal of Rheumatology and Inflammation</SO>
<YR>1995</YR>
<VL>15</VL>
<NO>1</NO>
<PG>25-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carrabba-1995a" NAME="Carrabba 1995a" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reference same as Carrabba 1995; multiple arm trial</AU>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carrabba-1995b" NAME="Carrabba 1995b" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reference same as Carrabba 1995; multiple arm trial</AU>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carrabba-1995c" NAME="Carrabba 1995c" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reference same as Carrabba 1995; multiple arm trial</AU>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cohen-1994" NAME="Cohen 1994" YEAR="1994">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Cohen MA, Shiroky JB, Ballachey ML, Neville C, Esdaile JM</AU>
<TI>Double-blind randomized trial of intra-articular (I/A) hyaluronate in the treatment of osteoarthritis of the knee</TI>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>1994</YR>
<VL>37 Suppl 6</VL>
<PG>R31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Corrado-1995" NAME="Corrado 1995" YEAR="1995">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Corrado EM, Peluso GF, Gigliotti S, de Durante C, Palmieri D, Savoia M, Oriani GO, Tajana GF</AU>
<TI>The effects of intra-articular administration of hyaluronic acid on osteoarthritis of the knee: a clinical study with immunological and biochemical evaluations</TI>
<SO>European Journal of Rheumatology and Inflammation</SO>
<YR>1995</YR>
<VL>15</VL>
<NO>1</NO>
<PG>47-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Creamer-1994" NAME="Creamer 1994" YEAR="1994">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Creamer P, Sharif M, George E, Meadows K, Cushnaghan J, Shinmei M, Dieppe P</AU>
<TI>Intra-articular hyaluronic acid in osteoarthritis of the knee: an investigation into mechanisms of action</TI>
<SO>Osteoarthritis and Cartilage</SO>
<YR>1994</YR>
<VL>2</VL>
<PG>133-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cubukcu-2004" NAME="Cubukcu 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cubukcu D, Ardic F, Karabulut N, Topuz O</AU>
<TI>Hylan G-F 20 efficacy on articular cartilage quality in patients with knee osteoarthritis: clinical and MRI assessment</TI>
<SO>Clinical Rheumatology</SO>
<YR>2005</YR>
<VL>24</VL>
<NO>4</NO>
<PG>336-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Day-2001" NAME="Day 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Day R, Brooks P, Petersen M, The Australian Multicentre Trial Group</AU>
<TI>A randomised multicentre parallel group study of the effectiveness and tolerance of intra-articular injections of sodium hyaluronate in osteoarthritis of the knee</TI>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Day-2004" MODIFIED="2008-11-09 23:16:50 -0500" MODIFIED_BY="[Empty name]" NAME="Day 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-11-09 23:16:50 -0500" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Day R, Brooks P, Conaghan PG, Petersen M for the Multicenter Trial Group</AU>
<TI>A double blind, randomized, multicenter, parallel group study of the effectiveness and tolerance of intraarticular hyaluronan in osteoarthritis of the knee</TI>
<SO>The Journal of Rheumatology</SO>
<YR>2004</YR>
<VL>31</VL>
<NO>4</NO>
<PG>775-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Dickson-2001" NAME="Dickson 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;Also published in Journal of Drug Assessment 2001;4:179-190.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Dickson DJ, Hosie G, English JR, and the Primary Care Rheumatology Society</AU>
<TI>A double-blind, placebo-controlled comparison of hylan G-F 20 against diclofenac in knee osteoarthritis</TI>
<SO>Journal of Clinical Research</SO>
<YR>2001</YR>
<VL>4</VL>
<PG>41-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Dougados-1993" NAME="Dougados 1993" YEAR="1993">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Dougados M, Nguyen M, Listrat V, Amor B</AU>
<TI>High molecular weight sodium hyaluronate (hyalectin) in osteoarthritis of the knee: a 1 year placebo-controlled trial</TI>
<SO>Osteoarthritis and Cartilage</SO>
<YR>1993</YR>
<VL>1</VL>
<PG>97-103</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Formiguera-Sala-1995" MODIFIED="2008-11-09 23:17:27 -0500" MODIFIED_BY="[Empty name]" NAME="Formiguera Sala 1995" YEAR="1995">
<REFERENCE MODIFIED="2008-11-09 23:17:27 -0500" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sala S, de Miguel RE</AU>
<TI>Intra-articular hyaluronic acid in the treatment of osteoarthritis of the knee: a short term study</TI>
<SO>European Journal of Rheumatology and Inflammation</SO>
<YR>1995</YR>
<VL>15</VL>
<NO>1</NO>
<PG>33-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Forster-2003" MODIFIED="2008-11-09 23:17:51 -0500" MODIFIED_BY="[Empty name]" NAME="Forster 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-11-09 23:17:51 -0500" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Forster MC, Straw R</AU>
<TI>A prospective randomised trial comparing intra-articular Hyalgan injection and arthroscopic washout for knee osteoarthritis</TI>
<SO>The Knee</SO>
<YR>2003</YR>
<VL>10</VL>
<PG>291-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Forster-2003a" MODIFIED="2008-11-09 23:18:09 -0500" MODIFIED_BY="[Empty name]" NAME="Forster 2003a" YEAR="2003">
<REFERENCE MODIFIED="2008-11-09 23:18:09 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Forster MC, Straw R, Rowles JM</AU>
<TI>A prospective randomised trial comparing intra-articular sodium hyaluronate injection and arthro-scopic washout for knee osteoarthritis</TI>
<SO>The Journal of Bone and Joint Surgery</SO>
<YR>2003</YR>
<VL>85-B Suppl (II)</VL>
<PG>103</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Frizziero-2002" MODIFIED="2008-11-09 23:18:23 -0500" MODIFIED_BY="[Empty name]" NAME="Frizziero 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-11-09 23:18:23 -0500" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Frizziero L, Pasquali Rochetti I</AU>
<TI>Intra-articular treatment of osteoarthritis of the knee: an arthroscopic and clinical comparison between sodium hyaluronate (500-730 kDa) and methylprednisolone acetate</TI>
<SO>Journal of Orthopaedics and Traumatology</SO>
<YR>2002</YR>
<VL>3</VL>
<PG>89-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Graf-1993" NAME="Graf 1993" YEAR="1993">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Graf J, Neusel E, Schneider E, Niethard FU</AU>
<TI>Intra-articular treatment with hyaluronic acid in osteoarthritis of the knee joint: a controlled clinical trial versus mucopolysaccharide polysulfuric acid ester</TI>
<SO>Clinical and Experimental Rheumatology</SO>
<YR>1993</YR>
<VL>11</VL>
<PG>367-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grecomoro-1987" NAME="Grecomoro 1987" YEAR="1987">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Grecomoro G, Martorana U, Di Marco C</AU>
<TI>Intra-articular treatment with sodium hyaluronate in gonarthrosis: a controlled clinical trial versus placebo</TI>
<SO>Pharmatherapeutica</SO>
<YR>1987</YR>
<VL>5</VL>
<NO>2</NO>
<PG>137-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Groppa-2001" MODIFIED="2008-11-09 23:18:54 -0500" MODIFIED_BY="[Empty name]" NAME="Groppa 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-11-09 23:18:54 -0500" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Groppa LG, Moshneaga M</AU>
<TI>Studying of the efficiency of the Synvisc in osteoarthrosis</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2001</YR>
<VL>60 Suppl (1)</VL>
<PG>230</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guler-1996" MODIFIED="2008-11-09 23:20:06 -0500" MODIFIED_BY="[Empty name]" NAME="Guler 1996" YEAR="1996">
<REFERENCE MODIFIED="2008-11-09 23:20:06 -0500" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Guler M, Kuran B, Parlar D, Guler M, Saglam H, Yapici S, Guzeloglu S, Ozgul Mese F, Bonveval F</AU>
<SO>Clinical trial of intra-articular injection of hyaluronic acid in patients with osteoarthritis of the knee. X National Rheumatology Congress, Turkey</SO>
<YR>October 29-November 3, 1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Henderson-1994" NAME="Henderson 1994" YEAR="1994">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Henderson EB, Smith EC, Pegley F, Blake DR</AU>
<TI>Intra-articular injections of 750 kD hyaluronan in the treatment of osteoarthritis: a randomised single centre double-blind placebo-controlled trial of 91 patients demonstrating lack of efficacy</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>1994</YR>
<VL>53</VL>
<PG>529-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Henderson-1994a" NAME="Henderson 1994a" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>See Henderson 1994</AU>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Hizmetli-1999" MODIFIED="2008-11-09 23:20:35 -0500" MODIFIED_BY="[Empty name]" NAME="Hizmetli 1999" YEAR="1999">
<REFERENCE MODIFIED="2008-11-09 23:20:35 -0500" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="UNPUBLISHED">
<AU>Hizmetli S, Kocagil S, Kaptanoglu E, Elden H, Nacitarhan V</AU>
<TI>The efficacy and safety of intra-articular hyaluronic acid in osteoarthritis of the knee: a prospective, double-blind trial</TI>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Huang-2005" MODIFIED="2008-11-09 23:22:50 -0500" MODIFIED_BY="[Empty name]" NAME="Huang 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-11-09 23:22:50 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huang M-H, Yang R-C, Lee C-L, Chen T-W, Wang M-C</AU>
<TI>Preliminary results of integrated therapy for patients with knee osteoarthritis</TI>
<SO>Arthritis Care &amp; Research</SO>
<YR>2005</YR>
<VL>53</VL>
<NO>6</NO>
<PG>812-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Huskisson-1999" NAME="Huskisson 1999" YEAR="1999">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Huskisson EC, Donnelly S</AU>
<TI>Hyaluronic acid in the treatment of osteoarthritis of the knee</TI>
<SO>Rheumatology</SO>
<YR>1999</YR>
<VL>38</VL>
<PG>602-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jones-1995" NAME="Jones 1995" YEAR="1995">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jones AC, Pattrick M, Doherty S, Doherty M</AU>
<TI>Intra-articular hyaluronic acid compared to intra-articular triamcinolone hexacetonide in inflammatory knee osteoarthritis</TI>
<SO>Osteoarthritis and Cartilage</SO>
<YR>1995</YR>
<VL>3</VL>
<PG>269-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jubb-2001a" MODIFIED="2008-11-09 23:23:30 -0500" MODIFIED_BY="[Empty name]" NAME="Jubb 2001a" YEAR="2001">
<REFERENCE MODIFIED="2008-11-09 23:23:30 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jubb RW, Piva S, Beinat L, Dacre J, Gishen P on behalf of the UK Hyalgan Study Group</AU>
<TI>Effect of sodium hyaluronate (500-730 KDa, HyalganR) on joint space width in osteoarthritis of the knee</TI>
<SO>The Journal of Rheumatology</SO>
<YR>2001</YR>
<VL>28 Suppl (63)</VL>
<PG>8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jubb-2001b" MODIFIED="2008-11-09 23:24:00 -0500" MODIFIED_BY="[Empty name]" NAME="Jubb 2001b" YEAR="2001">
<REFERENCE MODIFIED="2008-11-09 23:24:00 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jubb RW, Piva S, Beinat L, Dacre J, Gishen P for the UK Hyalgan Study Group</AU>
<TI>Structure modifying study of hyaluronan (500-730 KDa, HyalganR) on osteoarthritis of the knee</TI>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2001</YR>
<VL>9 Suppl (B)</VL>
<PG>16</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jubb-2001c" MODIFIED="2008-11-09 23:24:23 -0500" MODIFIED_BY="[Empty name]" NAME="Jubb 2001c" YEAR="2001">
<REFERENCE MODIFIED="2008-11-09 23:24:23 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jubb RW, Piva S, Beinat L, Dacre J, Gishen P</AU>
<TI>Structure modifying study of hyaluronan (500-730 KDa, HyalganR) on osteoarthritis of the knee</TI>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>2001</YR>
<VL>44 Suppl (9)</VL>
<PG>155</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jubb-2001d" MODIFIED="2008-11-09 23:24:46 -0500" MODIFIED_BY="[Empty name]" NAME="Jubb 2001d" YEAR="2001">
<REFERENCE MODIFIED="2008-11-09 23:24:46 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jubb RW, Piva S, Beinat L, Dacre J, Gishen P, on behalf of the UK Hyalgan Study Group</AU>
<TI>Structure modification in osteoarthritis with intra-articular sodium hyaluronate of mol. 500-730 KDA</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2001</YR>
<VL>60 Suppl (I)</VL>
<PG>46</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Jubb-2003" MODIFIED="2008-11-09 23:25:05 -0500" MODIFIED_BY="[Empty name]" NAME="Jubb 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-11-09 23:25:05 -0500" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jubb RW, Piva S, Beinat L, Dacre J, Gishen P</AU>
<TI>A one-year, randomised, placebo (saline) controlled clinical trial of 500-730 kDa sodium hyaluronate (Hyalgan) on the radiological change in osteoarthritis of the knee</TI>
<SO>International Journal of Clinical Practice</SO>
<YR>2003</YR>
<VL>57</VL>
<NO>6</NO>
<PG>467-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kahan-2001" NAME="Kahan 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kahan A, Guemas E, Lieu PL</AU>
<TI>Patients with knee osteoarthritis treated by hylan G-F 20 versus usual treatments: a medico-economic, prospective, randomised large scale trial in France, efficacy and safety outcomes</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2001</YR>
<VL>60 Suppl (1)</VL>
<PG>232</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kahan-2003" NAME="Kahan 2003" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;Joint Bone Spine 2003;70:276-281&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kahan A, Lleu P-L, Salin L</AU>
<TI>Prospective randomised study comparing the medico-economic benefits of hylan GF-20 versus conventional treatment in knee osteoarthritis</TI>
<TO>Etude prospective randomisee comparant le benefice medico-economique de Synvisc a celui des traitements usuels chez des patients souffrant de gonarthrose</TO>
<SO>Revue du rhumatisme</SO>
<YR>2003</YR>
<VL>70</VL>
<PG>588-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kahan-2003a" MODIFIED="2008-11-09 23:25:31 -0500" MODIFIED_BY="[Empty name]" NAME="Kahan 2003a" YEAR="2003a">
<REFERENCE MODIFIED="2008-11-09 23:25:31 -0500" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kahan A, Lleu P-L, Salin L</AU>
<TI>Prospective randomized study comparing the medicoeconomic benefits of Hylan G-F 20 vs. conventional treatment in knee osteoarthritis</TI>
<SO>Joint Bone Spine</SO>
<YR>2003</YR>
<VL>70</VL>
<PG>276-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kalay-1997" NAME="Kalay 1997" YEAR="1997">
<REFERENCE PRIMARY="YES" TYPE="BOOK">
<AU>Kalay S</AU>
<SO>The effectiveness of intraarticular hyaluronic acid treatment in primary gonarthrosis [specialization thesis]</SO>
<YR>1997</YR>
<PB>Ministry of Health, Republic of Turkey</PB>
<CY>Ankara, Turkey</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Karatay-2004" MODIFIED="2008-11-09 23:26:04 -0500" MODIFIED_BY="[Empty name]" NAME="Karatay 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-11-09 23:26:04 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Karatay S, Kiziltunc A, Yildirim K, Karanfil RC, Senel K</AU>
<TI>Effects of different hyaluronic acid products on synovial fluid levels of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in knee osteoarthritis</TI>
<SO>Annals of Clinical &amp; Laboratory Science</SO>
<YR>2004</YR>
<VL>34</VL>
<NO>3</NO>
<PG>330-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Karatay-2005" NAME="Karatay 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Karatay S, Kiziltunc A, Yildirim K, Karanfil RC, Senel K</AU>
<TI>Effects of different hyaluronic acid products on synovial fluid NO levels in knee osteoarthritis</TI>
<SO>Osteoporosis International</SO>
<YR>2005</YR>
<VL>16</VL>
<NO>3</NO>
<PG>S71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Karatay-2005a" NAME="Karatay 2005a" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Karatay S, Yildirim K, Yildiz L, Karanfil RC, Senel K</AU>
<TI>The effect of hyaluronic acid on levels of IFG-1 and IGFBP-3 in synovial fluids of patients with knee osteoarthritis</TI>
<SO>Osteoporosis International</SO>
<YR>2005</YR>
<VL>16</VL>
<NO>3</NO>
<PG>S72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Karatosun-2005" MODIFIED="2008-11-09 23:26:32 -0500" MODIFIED_BY="[Empty name]" NAME="Karatosun 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-11-09 23:26:32 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Karatosun V, Unver B, Gocen Z, Sen A, Gunal I</AU>
<TI>Intra-articular hyaluronic acid compared with progressive knee exercises in osteoarthritis of the knee: a prospective randomized trial with long-term follow-up</TI>
<SO>Clinical &amp; Experimental Rheumatology</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Karatosun-2005a" MODIFIED="2008-11-09 23:26:46 -0500" MODIFIED_BY="[Empty name]" NAME="Karatosun 2005a" YEAR="2005">
<REFERENCE MODIFIED="2008-11-09 23:26:46 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Karatosun V, Unver B, Gocen Z, Sen A</AU>
<TI>Comparison of two hyaluronan drugs in patients with advanced osteoarthritis of the knee. A prospective, randomized, double-blind study with long term follow-up</TI>
<SO>Clinical and Experimental Rheumatology</SO>
<YR>2005</YR>
<VL>23</VL>
<NO>2</NO>
<PG>213-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Karlsson-1999" NAME="Karlsson 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Karlsson J, Selin-Sjogren L</AU>
<TI>A comparison of two hyaluronan drugs and placebo in patients with mild to moderate osteoarthritis of the knee - a controlled, randomised, parallel-design multicenter study</TI>
<SO>Acta orthopaedica Scandinavica</SO>
<YR>1999</YR>
<VL>70 Suppl (287)</VL>
<PG>62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Karlsson-2002" MODIFIED="2008-11-09 23:27:07 -0500" MODIFIED_BY="[Empty name]" NAME="Karlsson 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-11-09 23:27:07 -0500" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Karlsson J, Sjogren LS, Lohmander LS</AU>
<TI>Comparison of two hyaluronan drugs and placebo in patients with knee osteoarthritis. A controlled, randomized, double-blind, parallel-design multicentre study</TI>
<SO>Rheumatology</SO>
<YR>2002</YR>
<VL>41</VL>
<NO>11</NO>
<PG>1240-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Karlsson-2002a-_x0028_AvP_x0029_" NAME="Karlsson 2002a (AvP)" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>See Karlsson 2002</AU>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Karlsson-2002b-_x0028_SvP_x0029_" NAME="Karlsson 2002b (SvP)" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>See Karlsson 2002</AU>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Karlsson-2002c-_x0028_AvS_x0029_" NAME="Karlsson 2002c (AvS)" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>See Karlsson 2002</AU>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Karlsson-2003d" MODIFIED="2008-11-09 23:27:39 -0500" MODIFIED_BY="[Empty name]" NAME="Karlsson 2003d" YEAR="2003">
<REFERENCE MODIFIED="2008-11-09 23:27:39 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Karlsson J, Sjogren LS, Lohmander S</AU>
<TI>Comparison of two hyaluronan drugs and placebo in patients with knee osteoarthritis. A controlled, randomized, double-blind, parallel-design multicentre study</TI>
<SO>Rheumatology</SO>
<YR>2003</YR>
<VL>42</VL>
<NO>10</NO>
<PG>1262-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Karras-2001" MODIFIED="2008-11-09 23:27:56 -0500" MODIFIED_BY="[Empty name]" NAME="Karras 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-11-09 23:27:56 -0500" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Karras D, Basilakos J, Diaourta V, Kedikoglou S, Iliopoulos A</AU>
<TI>Comparative study of 2 regimens of intraarticular infusion of hyaluronan (Hyalart, Fidia, SPA) in knee osteoarthritis</TI>
<SO>The Journal of Rheumatology</SO>
<YR>2001</YR>
<VL>28 Suppl (63)</VL>
<PG>6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kawabata-1993" NAME="Kawabata 1993" YEAR="1993">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kawabata M, Igarashi M, Mikami R, Ninomiya S, Oda H, Hoshino Y, Yamamoto S, Kurokawa T, Ogawa N</AU>
<TI>Clinical evaluation of SLM-10 (sodium hyaluronate injection) in patients with osteoarthritis of the knee - a mutli-center comparative trial with Artz as control drug</TI>
<SO>Japanese Pharmacology &amp; Therapeutics</SO>
<YR>1993</YR>
<VL>21</VL>
<NO>1</NO>
<PG>257-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kirchner-2005" NAME="Kirchner 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kirchner--2005" MODIFIED="2008-11-09 23:28:35 -0500" MODIFIED_BY="[Empty name]" NAME="Kirchner  2005" YEAR="2005">
<REFERENCE MODIFIED="2008-11-09 23:28:35 -0500" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kirchner M, Marshall D</AU>
<TI>A double-blind randomized controlled trial comparing alternate forms of high molecular weight hyaluronan for the treatment of osteoarthritis of the knee</TI>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2006</YR>
<VL>14</VL>
<NO>2</NO>
<PG>154-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Kirchner-2006" MODIFIED="2008-11-09 23:28:54 -0500" MODIFIED_BY="[Empty name]" NAME="Kirchner 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-11-09 23:28:54 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kirchner M, Marshall D</AU>
<TI>A double-blind randomized controlled trial comparing alternate forms of high molecular weight hyaluronan for the treatment of osteoarthritis of the knee</TI>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2006</YR>
<VL>14</VL>
<NO>2</NO>
<PG>154-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kotevoglu-2002" MODIFIED="2008-11-09 23:29:24 -0500" MODIFIED_BY="[Empty name]" NAME="Kotevoglu 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-11-09 23:29:24 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kotevoglu N, Iyibozkurt P, Hiz O, Kuran B</AU>
<TI>Viscosupplementation treatment for osteoarthritis of the knee</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2002</YR>
<VL>61 Suppl</VL>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kotevoglu-2005" NAME="Kotevoglu 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kotevoglu N, Iybozkurt PC, Hz O, Toktas H, Kuran B</AU>
<TI>A prospective randomised controlled clinical trial comparing the efficacy of different molecular weight hyaluronan solutions in the treatment of knee osteoarthritis</TI>
<SO>Rheumatology International</SO>
<YR>2005</YR>
<VL>4</VL>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lanzer-2002" NAME="Lanzer 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Lanzer WL, Schuster R</AU>
<TI>A randomized, single-blind comparison of the efficacy and safety of Synvisc Hylan G-F 20 and Aristospan Triamcinolone Hexacetonide in patients with osteoarthritis (OA) of the knee</TI>
<SO>American Academy of Orthopaedic Surgeons Annual Meeting</SO>
<YR>February 13-17, 2002</YR>
<PG>Paper No. 135</PG>
<PB>AAOS</PB>
<CY>Dallas, Texas</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leardini-1987" NAME="Leardini 1987" YEAR="1987">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Leardini G, Franceschini M, Mattara L, Bruno R, Perbellini A</AU>
<TI>Intra-articular sodium hyaluronate (Hyalgan) in gonarthrosis. A controlled study comparing methylprednisolone acetate</TI>
<SO>Clinical Trials Journal</SO>
<YR>1987</YR>
<VL>24</VL>
<NO>4</NO>
<PG>341-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leardini-1991" NAME="Leardini 1991" YEAR="1991">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Leardini G, Mattara L, Franceschini M, Perbellini A</AU>
<TI>Intra-articular treatment of knee osteoarthritis. A comparative study between hyaluronic acid and 6-methyl prednisolone acetate</TI>
<SO>Clinical and Experimental Rheumatology</SO>
<YR>1991</YR>
<VL>9</VL>
<PG>375-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leopold-2003" MODIFIED="2008-11-09 23:36:05 -0500" MODIFIED_BY="[Empty name]" NAME="Leopold 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-11-09 23:36:05 -0500" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Leopold SS, Redd BB, Warme WJ, Wehrle PA, Pettis PD, Shott S</AU>
<TI>Corticosteroid compared with hyaluronic acid injections for the treatment of osteoarthritis of the knee. A prospective, randomized trial</TI>
<SO>The Journal of Bone and Joint Surgery</SO>
<YR>2003</YR>
<VL>85-A</VL>
<NO>7</NO>
<PG>1197-203</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Lin-2004" NAME="Lin 2004" YEAR="2004">
<REFERENCE PRIMARY="YES" TYPE="UNPUBLISHED">
<AU>Lin C-C, Tsai C-L, Lee C-H, Chang C-C, Chen S-C, Lai C-H, Beinat L</AU>
<TI>Efficacy and safety of intra-articular injections of sodium hyaluronate (Hyalgan) in the treatment of osteoarthritis of the knee. A randomized, controlled trial</TI>
<SO>The Journal of Bone and Joint Surgery</SO>
<YR>in Preparation</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Listrat-1997" NAME="Listrat 1997" YEAR="1997">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Listrat V, Ayral X, Patarnello F, Bonvarlet JP, Simonnet J, Amor B, Dougados M</AU>
<TI>Arthroscopic evaluation of potential structure modifying activity of hyaluronan (Hyalgan) in osteoarthritis of the knee</TI>
<SO>Osteoarthritis and Cartilage</SO>
<YR>1997</YR>
<VL>5</VL>
<PG>153-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lohmander-1996" MODIFIED="2008-11-09 23:36:57 -0500" MODIFIED_BY="[Empty name]" NAME="Lohmander 1996" YEAR="1996">
<REFERENCE MODIFIED="2008-11-09 23:36:57 -0500" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lohmander LS, Dalen N, Englund G, Hamalainen M, Jensen EM, Karlsson K, et al</AU>
<TI>Intra-articular hyaluronan injections in the treatment of osteoarthritis of the knee: a randomised, double blind, placebo controlled multicentre trial</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>1996</YR>
<VL>55</VL>
<PG>424-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-McDonald-2000" NAME="McDonald 2000" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>McDonald C, Hantel S, Strohmeier M</AU>
<TI>A randomised, controlled study to compare the performance and safety of two sources of sodium hyaluronate given as a viscosupplement by intra-articular injection to patients with osteoarthritis of the knee</TI>
<SO>Journal of Clinical Research</SO>
<YR>2000</YR>
<VL>3</VL>
<PG>41-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Miltner-2002" NAME="Miltner 2002" YEAR="2002">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Miltner O, Schneider U, Siebert CH, Niedhart C, Niethard FU</AU>
<TI>Efficacy of intrarticular hyaluronic acid in patients with osteoarthritis - a prospective clinical trial</TI>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2002</YR>
<VL>10</VL>
<NO>9</NO>
<PG>680-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Moreland-1993" NAME="Moreland 1993" YEAR="1993">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Moreland LW, Arnold WJ, Saway A, Savory C, Sikes D</AU>
<TI>Efficacy and safety of intra-articular hylan G-F 20 (Synvisc), a viscoelastic derivative of hyaluronan, in patients with osteoarthritis of the knee</TI>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>1993</YR>
<VL>36 Suppl (9)</VL>
<PG>165</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nahler-1996" NAME="Nahler 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nahler von G, Metelmann H, Sperber H</AU>
<TI>Treatment of gonarthrosis with Zeel comp. - Results of a randomised, controlled, comparative clinical trial with hyaluronic acid</TI>
<TO>Behandlung der Gonarthrose mit Zeel comp. - Ergebnisse einer randomisierten, kontrollierten klinischen Prufung im Vergleich zu Hyaluronsaure</TO>
<SO>Orthopadische Praxis</SO>
<YR>1996</YR>
<VL>32</VL>
<NO>5</NO>
<PG>354-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nahler-1998" NAME="Nahler 1998" YEAR="1998">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Nahler G, Metelmann H, Sperber H</AU>
<TI>Treating osteoarthritis of the knee with a homeopathic preparation. Results of a randomized, controlled, clinical trial in comparison to hyaluronic acid</TI>
<SO>Biomedical Therapy</SO>
<YR>1998</YR>
<VL>XVI</VL>
<NO>2</NO>
<PG>186-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Neustadt-2004" MODIFIED="2008-11-09 23:39:30 -0500" MODIFIED_BY="[Empty name]" NAME="Neustadt 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-11-09 23:39:30 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Neustadt D, Wade J, Gimbel J, Bell M, Caldwell J</AU>
<TI>Clinical effects of intra-articular high molecular weight hyaluronan (Orthovisc) in osteoarthritis of the knee</TI>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>2004</YR>
<VL>50 Suppl (9)</VL>
<PG>144</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Neustadt-2005" MODIFIED="2008-11-09 23:40:39 -0500" MODIFIED_BY="[Empty name]" NAME="Neustadt 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-11-09 23:40:39 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Neustadt DH, Caldwell JR, Burnette MC, Block JA, Bhirangi K, Lavin PT, Broderick JN</AU>
<TI>Intra-articular high molecular weight hyaluronan (Orthovisc) is effective in the treatment of pain of knee osteoarthritis</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2005</YR>
<VL>64</VL>
<NO>Suppl III</NO>
<PG>EULAR, June 8-11, Vienna, Austria</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Neustadt-2005a-_x002d_3inj" MODIFIED="2008-11-09 23:41:07 -0500" MODIFIED_BY="[Empty name]" NAME="Neustadt 2005a -3inj" YEAR="2005">
<REFERENCE MODIFIED="2008-11-09 23:41:07 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Neustadt D, Caldwell J, Bell M, Wade J, Gimbel J</AU>
<TI>Clinical effects of intraarticular injection of high molecular weight hyaluronan (Orthovisc) in osteoarthritis of the knee: a randomized, controlled multicenter trial</TI>
<SO>The Journal of Rheumatology</SO>
<YR>2005</YR>
<VL>32</VL>
<NO>10</NO>
<PG>1928-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Neustadt-2005b_x002d_4inj" NAME="Neustadt 2005b-4inj" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ozturk-2005" MODIFIED="2008-11-09 23:45:49 -0500" MODIFIED_BY="[Empty name]" NAME="Ozturk 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-11-09 23:45:49 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ozturk C, Atamaz F, Hepguler S, Argin M, Arkun R</AU>
<TI>The safety and efficacy of intraarticular hyaluronan with/without corticosteroid in knee osteoarthritis: 1-year, single-blind, randomized study</TI>
<SO>Rheumatology International</SO>
<YR>2005 February 10</YR>
<VL>Epub ahead of print</VL>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Petrella-2002" NAME="Petrella 2002" YEAR="2002">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Petrella RJ, DiSilvestro MD, Hildebrand C</AU>
<TI>Effect of hyaluronate sodium on pain and physical functioning in osteoarthritis of the knee. A randomized, double-blind, placebo-controlled clinical trial</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2002</YR>
<VL>162</VL>
<PG>292-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pham-2003" MODIFIED="2008-11-09 23:46:14 -0500" MODIFIED_BY="[Empty name]" NAME="Pham 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-11-09 23:46:14 -0500" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pham T, Le Henanff A, Ravaud P, Dieppe P, Brin S, Paolozzi L, Dougados M</AU>
<TI>Lack of symptomatic and structural efficacy of a new hyaluronic acid (HA) compund (NRD101) when compared to diacerein and placebo in a one-year controlled study in symptomatic knee osteoarthritis</TI>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>2003</YR>
<VL>48 Suppl (9)</VL>
<PG>698</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pham-2004" MODIFIED="2008-11-09 23:46:37 -0500" MODIFIED_BY="[Empty name]" NAME="Pham 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-11-09 23:46:37 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pham T, Le Henanff A, Ravaud Ph, Dieppe P, Paolozzi L, Dougados M</AU>
<TI>Evaluation of the symptomatic and structural efficacy of a new hyaluronic acid compound, NRD101, in comparison with diacerein and placebo in a 1 year randomised controlled study in symptomatic knee osteoarthritis</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2004</YR>
<VL>63</VL>
<PG>1611-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pietrogrande-1991" NAME="Pietrogrande 1991" YEAR="1991">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pietrogrande V, Melanotte PL, D'Agnolo B, Ulivi M, Benigni GA, Turchetto L, Pierfederici P, Perbellini A</AU>
<TI>Hyaluronic acid versus methylprednisolone intra-articularly injected for treatment of osteoarthritis of the knee</TI>
<SO>Current Therapeutic Research</SO>
<YR>1991</YR>
<VL>50</VL>
<NO>5</NO>
<PG>691-701</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Puhl-1993" NAME="Puhl 1993" YEAR="1993">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Puhl W, Bernau A, Greiling H, Kopcke W, Pforringer W, Steck KJ, Zacher J, Scharf HP</AU>
<TI>Intra-articular sodium hyaluronate in osteoarthritis of the knee: a multicenter, double-blind study</TI>
<SO>Osteoarthritis and Cartilage</SO>
<YR>1993</YR>
<VL>1</VL>
<PG>233-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Raynauld-2002" NAME="Raynauld 2002" YEAR="2002">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Raynauld JP, Torrance GW, Band PA, Goldsmith CH, Tugwell P, Walker V, Schultz M, Bellamy N</AU>
<TI>A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 1 of 2): clinical results</TI>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2002</YR>
<VL>10</VL>
<NO>7</NO>
<PG>506-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Redd-2003" MODIFIED="2008-11-09 23:47:08 -0500" MODIFIED_BY="[Empty name]" NAME="Redd 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-11-09 23:47:08 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Redd BB, Leopold SS, Warme WJ, Pettis PD, Wehrle PA, Shott S</AU>
<TI>Corticosteroid vs. Synvisc injections for knee arthritis: a randomized, controlled trial demonstrating similar overall efficacy but significant gender-related treatment differences</TI>
<SO>American Academy of Orthopaedic Surgeons</SO>
<YR>Feb.5-9, 2003</YR>
<PB>AAOS</PB>
<CY>New Orleans</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rejaili-2005" MODIFIED="2008-11-09 23:47:32 -0500" MODIFIED_BY="[Empty name]" NAME="Rejaili 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-11-09 23:47:32 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rejaili WA, Chueire AG, Cordeiro JA, Petean FC, De Carvalho Filho G</AU>
<TI>The evaluation of hilan GF-20 in the postoperative knee arthroscopies for arthrosis</TI>
<SO>Acta Ortop Bras</SO>
<YR>2005</YR>
<VL>13</VL>
<NO>1</NO>
<PG>20-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Roman-2000" NAME="Roman 2000" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Roman JA, Chismol J, Morales M, Donderis JL</AU>
<TI>Intra-articular treatment with hyaluronic acid. Comparative study of hyalgan and adant</TI>
<SO>Clinical Rheumatology</SO>
<YR>2000</YR>
<VL>19</VL>
<PG>204-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Scale-1994a-_x0028_2-inj_x0029_" NAME="Scale 1994a (2 inj)" YEAR="1994">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Scale D, Wobig M, Wolpert W</AU>
<TI>Viscosupplementation of osteoarthritic knees with hylan: a treatment schedule study</TI>
<SO>Current Therapeutic Research</SO>
<YR>1994</YR>
<VL>55</VL>
<NO>3</NO>
<PG>220-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Scale-1994b-_x0028_3-inj_x0029_" MODIFIED="2008-11-09 23:48:20 -0500" MODIFIED_BY="[Empty name]" NAME="Scale 1994b (3 inj)" YEAR="1994">
<REFERENCE MODIFIED="2008-11-09 23:48:20 -0500" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Scale D, Wobig M, Wolpert W</AU>
<TI>Viscosupplementation of osteoarthritis knees with hylan: a treatment schedule study</TI>
<SO>Current Therapeutic Research</SO>
<YR>1994</YR>
<VL>55</VL>
<NO>3</NO>
<PG>220-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schneider-1997" NAME="Schneider 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schneider U, Miltner O, Graf J, Thomsen M, Niethard FU</AU>
<TI>The efficacy of hyaluronic acid in patients with osteoarthritis of both knees in right/left-comparison - examination with dynamometry, synovial oxygen partial pressure, intraarticular temperature and Lequesne score</TI>
<TO>Wirkungsweise von Hyaluronsaure bei Gonarthrose beider Kniegelenke im Rechts/Links-Vergleich. Untersuchung mit Dynamometrie, Sauerstoffpartialdruck, Temperatur und Lequesne score</TO>
<SO>Zeitschrift Orthop</SO>
<YR>1997</YR>
<VL>135</VL>
<PG>341-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sezgin-2005" NAME="Sezgin 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sezgin M, Demirel AC, Karaca C, Ortancil O, Ulkar GB, Kamk A, Cakci A</AU>
<TI>Does hyaluronan affect inflammatory cytokines in knee osteoarthritis?</TI>
<SO>Rheumatology International</SO>
<YR>2005</YR>
<VL>25</VL>
<NO>4</NO>
<PG>264-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shichikawa-1983a" NAME="Shichikawa 1983a" YEAR="1983">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Shichikawa K</AU>
<TI>Evaluation of the effect of sodium hyaluronate (SPH) to osteoarthritis of the knee</TI>
<SO>The Ryumachi</SO>
<YR>1983</YR>
<VL>23</VL>
<NO>4</NO>
<PG>280-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shichikawa-1983b" NAME="Shichikawa 1983b" YEAR="1983">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Shichikawa K, Igarashi M, Sugawara S, Iwasaki Y</AU>
<TI>Clinical evaluation of high molecular weight sodium hyaluronate (SPH) on osteoarthritis of the knee - a mutli-center well controlled comparative study</TI>
<SO>Japanese Journal of Clinical Pharmacology and Therapeutics</SO>
<YR>1983</YR>
<VL>14</VL>
<NO>3</NO>
<PG>545-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-St.-J.-Dixon-1988" NAME="St. J. Dixon 1988" YEAR="1988">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>St. J. Dixon A, Jacoby RK, Berry H, Hamilton EBD</AU>
<TI>Clinical trial of intra-articular injection of sodium hyaluronate in patients with osteoarthritis of the knee</TI>
<SO>Current Medical Research and Opinion</SO>
<YR>1988</YR>
<VL>11</VL>
<NO>4</NO>
<PG>205-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tamir-2001" NAME="Tamir 2001" YEAR="2001">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tamir E, Robinson D, Koren R, Agar G, Halperin N</AU>
<TI>Intra-articular hyaluronan injections for the treatment of osteoarthritis of the knee: a randomized, double blind, placebo controlled study</TI>
<SO>Clinical and Experimental Rheumatology</SO>
<YR>2001</YR>
<VL>19</VL>
<PG>265-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tascioglu-2003" MODIFIED="2008-11-09 23:49:11 -0500" MODIFIED_BY="[Empty name]" NAME="Tascioglu 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-11-09 23:49:11 -0500" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tascioglu F, Oner C</AU>
<TI>Efficacy of intra-articular sodium hyaluroante in the treatment of knee osteoarthritis</TI>
<SO>Clinical Rheumatology</SO>
<YR>2003</YR>
<VL>22</VL>
<PG>112-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tekeoglu-1998" NAME="Tekeoglu 1998" YEAR="1998">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tekeoglu I, Adak B, Goksoy T, Tosun N</AU>
<TI>Effects of intra-articular injections of sodium hyaluronate (Orthovisc) and betamethasone on osteoarthritis of the knee</TI>
<SO>The Journal of Rheumatology &amp; Medical Rehabilitation</SO>
<YR>1998</YR>
<VL>9</VL>
<NO>4</NO>
<PG>220-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thompson-2002" NAME="Thompson 2002" YEAR="2002">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Thompson JI, Huang YW, Zaibel R</AU>
<TI>Safety and efficacy of fermentation-derived high molecular weight sodium hyaluronate - a clinical trial in patients with osteoarthritis of the knee</TI>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2002</YR>
<VL>10 Suppl (A)</VL>
<PG>70-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Tsai-2003" MODIFIED="2008-11-09 23:49:40 -0500" MODIFIED_BY="[Empty name]" NAME="Tsai 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-11-09 23:49:40 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tsai C-L, Chang C-C, Chen S-C, Beinat L, Piva S</AU>
<TI>Treatment of knee osteoarthritis in Asian population with an intra-articular hyaluronan of MW 500-730 KDa</TI>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2003</YR>
<VL>11 Suppl (A)</VL>
<PG>119</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="OARSI October 2003 Berlin"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tsukamoto-1995" NAME="Tsukamoto 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tsukamoto Y, Yamamoto M, Motegi M, Iwata H, Ryu J, Takagishi K, Sugawara S</AU>
<TI>A double-blind trial of intra-articular higher molecular weight hyaluronic acid (NRD 101) versus lower molecular weight hyaluronic acid (Artz) in knee osteoarthritis</TI>
<SO>Rheumatology in Europe</SO>
<YR>1995</YR>
<VL>24</VL>
<NO>EULAR, Amsterdam</NO>
<PG>333</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wobig-1998" NAME="Wobig 1998" YEAR="1998">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wobig M, Dickhut A, Maier R, Vetter G</AU>
<TI>Viscosupplementation with hyaln G-F 20: a 26-week controlled trial of efficacy and safety in the osteoarthritic knee</TI>
<SO>Clinical Therapeutics</SO>
<YR>1998</YR>
<VL>20</VL>
<NO>3</NO>
<PG>410-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wobig-1999" MODIFIED="2008-11-09 23:50:18 -0500" MODIFIED_BY="[Empty name]" NAME="Wobig 1999" YEAR="1999">
<REFERENCE MODIFIED="2008-11-09 23:50:18 -0500" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wobig M, Bach G, Beks P, Dickhut A, Runzheimer J, Schwieger G, Vetter G, Balazs E</AU>
<TI>The role of elastoviscosity in the efficacy of viscosupplementation for osteoarthritis of the knee: a comparison of hylan G-F 20 and a lower-molecular-weight hyaluronan</TI>
<SO>Clinical Therapeutics</SO>
<YR>1999</YR>
<VL>21</VL>
<NO>9</NO>
<PG>1549-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Wobig-1999a-_x0028_Healon_x0029_" NAME="Wobig 1999a (Healon)" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>See Wobig 1999</AU>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Wobig-1999b-_x0028_Artz_x0029_" NAME="Wobig 1999b (Artz)" YEAR="1999">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>See Wobig 1999</AU>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wobig-1999c-_x0028_NEhyl_x0029_" NAME="Wobig 1999c (NEhyl)" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>See Wobig 1999</AU>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wu-1997" NAME="Wu 1997" YEAR="1997">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wu JJ, Shih LY, Hsu HC, Chen TH</AU>
<TI>The double-blind test of sodium hyaluronate (Artz) on osteoarthritis knee</TI>
<SO>Chinese Medical Journal (Taipei)</SO>
<YR>1997</YR>
<VL>59</VL>
<PG>99-106</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wu-2004" NAME="Wu 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wu H-B, Du J-Y, Yang S-H, Shao Z-W, Xiong X-Q</AU>
<TI>Evaluation on the effects of hyaluronan combined with different dosages of celecoxib for relieving pain and ankylosis induced by knee osteoarthritis</TI>
<SO>Chinese Journal of Clinical Rehabilitation [Zhongguo lin Chuang Kang fu]</SO>
<YR>2004</YR>
<VL>8</VL>
<NO>26</NO>
<PG>5491-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yamamoto-1994" NAME="Yamamoto 1994" YEAR="1994">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Yamamoto M, Sugawara Y, Tsukamoto Y, Motegi M, Iwata H, Rye J, Takagishi K, Nakashima M</AU>
<TI>Clinical evaluation of high molecular weight sodium hyaluronate (NRD 101) on osteoarthritis of the knee. A phase III comparative clinical study with Artz as a control drug</TI>
<SO>Japanese Pharmacology &amp; Therapeutics</SO>
<YR>1994</YR>
<VL>22</VL>
<NO>9</NO>
<PG>4059-87</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yentur-2003" MODIFIED="2008-11-09 23:51:30 -0500" MODIFIED_BY="[Empty name]" NAME="Yentur 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-11-09 23:51:30 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yentur EA, Okcu G, Yegul I</AU>
<TI>The role of trigger point therapy in knee osteoarthritis</TI>
<SO>The Pain Clinic</SO>
<YR>2003</YR>
<VL>15</VL>
<NO>4</NO>
<PG>385-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Aglas-1997" NAME="Aglas 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aglas F, Hermann J, Uitz E, Rainer F</AU>
<TI>Long-term benefits of a single treatment cycle with hyaluronan (Hyalgan) in patients with osteoarthritis of the knee</TI>
<SO>Rheumatology in Europe</SO>
<YR>1997</YR>
<VL>26 Suppl (2)</VL>
<PG>46</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Akermark-2002" NAME="Akermark 2002" YEAR="2002">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Akermark C, Berg P, Bjorkman A, Malm P</AU>
<TI>Non-animal stabilised hyaluronic acid in the treatment of osteoarthritis of the knee. A tolerability study</TI>
<SO>Clinical Drug Investigation</SO>
<YR>2002</YR>
<VL>22</VL>
<NO>3</NO>
<PG>157-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Akermark-2004" NAME="Akermark 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Akermark C, Adalberth T, Ericsater J, Isacsson J</AU>
<TO>Patient-perceived efficacy of non-animal stabilized hyaluronic acid in the treatment of osteoarthritis of the knee</TO>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2004</YR>
<VL>12 Suppl (2)</VL>
<PG>147</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Alonge-2004" NAME="Alonge 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alonge TO, Akinpelu A, Ogunlade SO, Akinosun OM</AU>
<TO>Intra-articular Synject in the management of knee OA in Nigeria - an intial report</TO>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2004</YR>
<VL>12 Suppl (2)</VL>
<PG>148</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Angel-2001" NAME="Angel 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Angel K, Campbell D, Dobson P, Lewis P, Nisyrios G, Tandon S</AU>
<TO>Does viscosupplementation work? A preliminary study</TO>
<SO>The Journal of Bone and Joint Surgery</SO>
<YR>2001</YR>
<VL>83-B</VL>
<NO>Suppl III</NO>
<PG>324</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Arizono-1997" NAME="Arizono 1997" YEAR="1997">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Arizono T, Hara T, Hara Y</AU>
<TI>Effect of high-molecular-weight sodium hyaluronate on osteoarthrosis</TI>
<SO>Orthop Surg Traumatol</SO>
<YR>1997</YR>
<VL>46 Suppl (1)</VL>
<PG>207-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ates-2001" NAME="Ates 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ates A, Kinikli G, Turgay M, Duman M</AU>
<TI>Viscosupplementation with sodium hyaluronate for the treatment of osteoarthritis</TI>
<SO>The Journal of Rheumatology</SO>
<YR>2001</YR>
<VL>28 Suppl (63)</VL>
<PG>8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bagga-2003" NAME="Bagga 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bagga H, Burkhardt D, Morris D, Ghosh P, Sambrook P, March L</AU>
<TO>Long term effects of intra-articular hylan G-F 20 (Synvisc) on synovial fluid hyaluronan and sulfated glycosaminoglycans levels</TO>
<SO>Annals of the Rheumatic DIseases</SO>
<YR>2003</YR>
<VL>EULAR, Lisbon, Portugal, June 18-21</VL>
<PB>EULAR</PB>
<CY>Lisbon, Portugal</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bardin-2004" NAME="Bardin 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bardin T, Kieffer P, Hassaynia K, Vincent P, Vincent Aubrey F</AU>
<TO>A large study phase IV of intraarticular arthrum H in knee OA patients</TO>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2004</YR>
<VL>12 Suppl (2)</VL>
<PG>145</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barrett-2002" NAME="Barrett 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barrett JP, Siviero P</AU>
<TO>Retrospective study of outcomes in Hyalgan-treated patients with osteoarthritis of the knee</TO>
<SO>Clinical Drug Investigation</SO>
<YR>2002</YR>
<VL>23</VL>
<PG>87-97</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bell-1999" NAME="Bell 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bell M, Fallaha M, Lenczner E, Ranger P, Welsh P</AU>
<TI>Viscosupplementation with hylan G-F 20 in total knee replacement candidates: an effective pain management therapy that may delay surgery</TI>
<SO>Osteoarthritis and Cartilage</SO>
<YR>1999</YR>
<VL>7 Suppl (A)</VL>
<PG>30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bellamy-2000" NAME="Bellamy 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bellamy N, Goldstein LD, Tekanoff RA</AU>
<TI>Continuing medical education-driven skills acquisition and impact on improved patient outcomes in family practice setting</TI>
<SO>The Journal of Continuing Education in the Health Professions</SO>
<YR>2000</YR>
<VL>20</VL>
<PG>52-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Birbara-2004" NAME="Birbara 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Birbara CA, Bell M, Caldwell JR</AU>
<TO>Effectiveness and safety of retreatment with high molecular weight hyaluronan (HMWH; Orthovisc): results from an extension of a randomized controlled trial</TO>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2004</YR>
<VL>12 Suppl (2)</VL>
<PG>127</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bolgen-Cimen" NAME="Bolgen Cimen" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bolgen CImen O, Gulaldi NCM, Ozisik S, Bagis S, Kanik A, Erdogan C</AU>
<TO>Clinical and scintigraphic evaluation in intra-articular hyaluronate therapy</TO>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2003</YR>
<VL>EULAR, Lisbon, Portugal, June 18-2</VL>
<CY>Lisbon, Portugal</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bruce-2004" NAME="Bruce 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bruce B, Singh G, Sato R, Waddell DD</AU>
<TO>Hylan G-F 20 significantly improves pain, function and patient global after 6 months in knee OA</TO>
<SO>American Academy of Orthopaedic Surgeons (AAOS) On-Line Service</SO>
<YR>2004</YR>
<VL>Annual Meeting Podium Presentations</VL>
<NO>71st Annual Meeting, March 10-14, San Francisco</NO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carrabba-1992" NAME="Carrabba 1992" YEAR="1992">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Carrabba M, Paresce E, Angelini M, Zamboni AM, Bragantini A, Paissan A, Molinaroli F, Perbellini A</AU>
<TI>The intra-articular treatment of osteoarthritis of the knee. A comparative study between hyaluronic acid (Hyalgan) and Orgotein</TI>
<SO>European Journal of Rheumatology and Inflammation</SO>
<YR>1992</YR>
<VL>12</VL>
<PG>47-57</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chhabra-2000" NAME="Chhabra 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chhabra SR, Newlove R, Montgomery S</AU>
<TI>Intraarticular hylan injections in the treatment of osteoarthritis of the knee: a prospective study of 120 patients</TI>
<SO>The Journal of Bone and Joint Surgery</SO>
<YR>2000</YR>
<VL>82-B Suppl (I)</VL>
<PG>68</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Clarke-2001" NAME="Clarke 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clarke S, Lock V, Duddy J, Newman J, Kirwan JR</AU>
<TI>Intra-articular hylan GF20 (Synvisc) in the management of patellofemoral osteoarthritis of the knee (POAK)</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2001</YR>
<VL>60</VL>
<PG>230-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Clarke-2005" NAME="Clarke 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clarke S, Lock V, Duddy J, Sharif M, Newman JH, Kirwan JR</AU>
<TO>Intra-articular hylan G-F 20 (Synvisc) in the management of patellofemoral osteoarthritis of the knee (POAK)</TO>
<SO>The Knee</SO>
<YR>2005</YR>
<VL>12</VL>
<PG>57-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Conrozier-2003" NAME="Conrozier 2003" YEAR="2033">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Conrozier T, Mathieu P, Schott A-M, Laurent I, Hajri T, Crozes P, et al Meignan F, Noel E, Rozand Y, Savoye J-F, Vignon E</AU>
<TI>Is there predictive factors of long term efficacy of viscosupplementation with hylan GF-20 in knee osteoarthritis?</TI>
<TO>Existe-t-il des facteurs predictifs de l'efficacite a long terme de la viscosupplementation par hylane GF-20 dans la gonarthrose?</TO>
<SO>Revue du rhumatisme</SO>
<YR>2003</YR>
<VL>70</VL>
<PG>253-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Couceiro-2003" NAME="Couceiro 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Couceiro JM, Coton F, Fernandez A, Collado A, Usabiaga J, Coronel P, Llorens MA and the Adant Study Group</AU>
<TI>Multicenter clinical trial on the efficacy of intra-articular hyaluronic acid (Adant) in osteoarthritis of the knee</TI>
<TO>Estudio multicentrico de la eficacia del tratamiento intraarticular con acido hialuronico (Adant) en artrosis de rodilla</TO>
<SO>Revista Espanola de Reumatologia</SO>
<YR>2003</YR>
<VL>320</VL>
<NO>2</NO>
<PG>57-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-D_x0027_Agnolo-1988" NAME="D'Agnolo 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>D'Agnolo B, Perbellini A</AU>
<TI>Intra-articular hyaluronic acid treatment in gonarthritis. Results of an open trial on 30 patients</TI>
<SO>Reumatismo</SO>
<YR>1988</YR>
<VL>40</VL>
<PG>57-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dahlberg-1994" NAME="Dahlberg 1994" YEAR="1994">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Dahlberg L, Lohmander LS, Ryd L</AU>
<TI>Intraarticular injections of hyaluronan in patients with cartilage abnormalities and knee pain. A one-year double-blind, placebo-controlled study</TI>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>1994</YR>
<VL>37</VL>
<NO>4</NO>
<PG>521-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Evanich-2001" NAME="Evanich 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Evanich JD, Evanich CJ, Wright MB, Rydlewicz JA</AU>
<TO>Effficacy of intraarticular hyaluronic acid injections in knee osteoarthritis</TO>
<SO>Clinical Orthopaedics and Related Research</SO>
<YR>2001</YR>
<NO>390</NO>
<PG>173-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Faraawi-2003" NAME="Faraawi 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Faraawi R</AU>
<TO>Retrospective study in intra-articular injection with hylan G-F 20 (patient perspective)</TO>
<SO>The Journal of Rheumatology</SO>
<YR>2003</YR>
<VL>30</VL>
<NO>8</NO>
<PG>1880</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Faus-2002" NAME="Faus 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Faus S, Fiter J, Canellas</AU>
<TI>Ultrasound measuring of the thickness of articular cartilage in patients with severe knee osteoarthritis treated with hyaluronic acid</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2002</YR>
<VL>61 Suppl</VL>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Frizziero-1993" NAME="Frizziero 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Frizziero L, Focherini MC, Govoni E</AU>
<TI>Hyaluronic acid versus methylprednisolone intra-articular treatment in knee osteoarthritis: a comparative, integrated in vivo and ex vivo morphological assessment by arthroscopy and histopathology</TI>
<SO>Revista Espanola de Rheumatologia</SO>
<YR>1993</YR>
<VL>20 Suppl (1)</VL>
<PG>575</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Frizziero-1997" NAME="Frizziero 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Frizziero L, Pasquali Ronchetti I, Guerra D, Guidolin D</AU>
<TI>Intra-articular treatment with hyalonic acid: a clinical endoscopic and histological study in osteoarthritis of the knee</TI>
<SO>Rheumatology in Europe</SO>
<YR>1997</YR>
<VL>26 Suppl (2)</VL>
<PG>47</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Frizziero-1998" NAME="Frizziero 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Frizziero L, Govoni E, Bacchini P</AU>
<TI>Intra-articular hyaluronic acid in the treatment of osteoarthritis of the knee: clinical and morphological study</TI>
<SO>Clinical and Experimental Rheumatology</SO>
<YR>1998</YR>
<VL>16</VL>
<PG>441-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fuji-1994" NAME="Fuji 1994" YEAR="1994">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Fuji T, Matsui S, Fujita S, Hirota S</AU>
<TI>Clinical effect of intra-articular injection of sodium hyaluronate (Artz) on osteoarthritis of the knee. A study comparing between independently using and combined using local anesthetic</TI>
<SO>Japanese Journal of Medicine and Pharmaceutical Sciences</SO>
<YR>1994</YR>
<VL>32</VL>
<NO>3</NO>
<PG>507-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goorman-2000" NAME="Goorman 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goorman SD, Watanabe TK, Miller EH, Perry C</AU>
<TI>Functional outcome in knee osteoarthritis after treatment with hylan G-F 20: a prospective study</TI>
<SO>Archives of Physical Medicine and Rehabilitation</SO>
<YR>2000</YR>
<VL>81</VL>
<PG>479-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grecomoro-1992" NAME="Grecomoro 1992" YEAR="1992">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Grecomoro G, Piccione F, Letizia G</AU>
<TI>Therapeutic synergism between hyaluronic acid and dexamethasone in the intra-articular treatment of osteoarthritis of the knee: a preliminary open study</TI>
<SO>Current Medical Research and Opinion</SO>
<YR>1992</YR>
<VL>13</VL>
<NO>1</NO>
<PG>49-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guerrero-1999" NAME="Guerrero 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guerrero R, Sanchez-Pernaute O, Acebes C, Llorens MA, Mas S, Palacios I, et al</AU>
<TI>Modification of synovial cartilage markers after repetitive intraarticular administration of hyaluronate (Adant) in knee OA patients</TI>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>1999</YR>
<VL>42 Suppl (9)</VL>
<PG>253</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guerrero-1999a" NAME="Guerrero 1999a" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guerrero R, Herreo-Beaumont G, Acebes C, Sanchez-Pernaute O, Llorens MA, Blazquez AB, Palacios I, Egido J, Vivanco F</AU>
<TI>Cartilage turnover and symptomatic relief observed in patients with knee OA after intra-articular administration of a hyaluronate polymer (Adant)</TI>
<SO>Osteoarthritis and Cartilage</SO>
<YR>1999</YR>
<VL>7 Suppl (A)</VL>
<PG>32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hamburger-2004" NAME="Hamburger 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hamburger MI, Hamburger MK, Brandt L, Kaell AT, Bennett RS, Johnson S, Rumore P, Schulman P</AU>
<TO>Retrospective comparative analysis of the safety and efficacy of intra-articular hyaluronan therapies in clinical practice</TO>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2004</YR>
<VL>12 Suppl (2)</VL>
<PG>146</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hashimoto-1992" NAME="Hashimoto 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hashimoto Y et al.</AU>
<TI>Multicenter clinical studies of ARTZ (high molecular weight sodium hyaluronate) in the long term treatment of osteoarthritis of the knee: including x-ray analysis</TI>
<SO>Japanese Pharmacology &amp; Therapeutics</SO>
<YR>1992</YR>
<VL>20</VL>
<NO>7</NO>
<PG>2699-712</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Honma-1989" NAME="Honma 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Honma T, Sakurai M, Maeda I et al</AU>
<TI>Clinical effects of high molecular weight sodium hyaluronate (Artz) injected into osteoarthritis knee joint</TI>
<SO>Japanese Pharmacology &amp; Therapeutics</SO>
<YR>1989</YR>
<VL>17</VL>
<NO>10</NO>
<PG>5057-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Igarashi-1983" NAME="Igarashi 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Igarashi M, Onozawa T, Murata M et al</AU>
<TI>Multicentre clinical studies of high molecular weight sodium hyaluronate in the long-term treatment of osteoarthritis of the knee</TI>
<SO>Japanese Pharmacology &amp; Therapeutics</SO>
<YR>1983</YR>
<VL>11</VL>
<NO>11</NO>
<PG>4871-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ines-2002" NAME="Ines 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ines LS, Reis P, Santos MJ, Alexandre M, Silva C, Brana A, Barcelos A, Nour D, Silva JAP, Malcata A, Porto A</AU>
<TI>Joint lavage and infiltration as treatment for knee arthritis: an open follow-up evaluation in the clinical setting</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2002</YR>
<VL>61 Suppl</VL>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Iseki-1983" NAME="Iseki 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Iseki F, Hosokawa M, Shibata H, et al.</AU>
<TI>Clinical study of high molecular weight sodium hyaluronate (SPH) on osteoarthritis of the knee</TI>
<SO>Japanese Pharmacology &amp; Therapeutics</SO>
<YR>1983</YR>
<VL>11</VL>
<NO>8</NO>
<PG>401(3283)-15(97)</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Iwasaki-1993" NAME="Iwasaki 1993" YEAR="1993">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Iwaskai K, Norimatsu T, Matsuzaka N, Teramoto T</AU>
<TI>Usefulness of sodium hyaluronate (Artz) in osteoarthritis of the knee. Comparison between monotherapy and combination therapy with a local anesthetic</TI>
<SO>Medical Consultation &amp; New Remedies</SO>
<YR>1993</YR>
<VL>30</VL>
<NO>8</NO>
<PG>1469-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Johnson-2004" NAME="Johnson 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Johnson DM</AU>
<TO>Audit of the effect on pain scores of intra-articular hyalgan injection in patients with osteoarthritis of the knee in a nurse-led clinic</TO>
<SO>Rheumatology</SO>
<YR>2004</YR>
<VL>43</VL>
<NO>Suppl 2</NO>
<PG>ii156</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kawakami-1993" NAME="Kawakami 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kawakami K et al</AU>
<TI>Clinical evaluation of intra-articlar injection therapy of high-molecular Na-hyaluronate for osteoarthritis of the knee joint</TI>
<SO>Journal of Medicine and Pharmaceutical Science</SO>
<YR>1993</YR>
<VL>29</VL>
<NO>5</NO>
<PG>1309</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kolarz-1995" NAME="Kolarz 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kolarz G, Kotz R, Broll H, Dunky A, Landsiedl F, Mayrhofer F, Rainer F, Ramach W, Singer F, Metz M</AU>
<TO>Hyaluronic acid in the treatment of osteoarthritis of the knee joint: interim results of a comparative clinical study</TO>
<SO>European Journal of Rheumatology and Inflammation</SO>
<YR>1995</YR>
<VL>15</VL>
<NO>1</NO>
<PG>39-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kolarz-2003" NAME="Kolarz 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kolarz G, Kotz R, Hochmayer I</AU>
<TO>Long-term benefits and repeated treatment cycles of intra-articular sodium hyaluronate (Hyalgan) in patients with osteoarthritis of the knee</TO>
<SO>Seminars in Arthritis and Rheumatism</SO>
<YR>2003</YR>
<VL>32</VL>
<NO>5</NO>
<PG>310-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kotz-1999" NAME="Kotz 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kotz R, Kolarz G</AU>
<TI>Intra-articular hyaluronic acid: duration of effect and results of repeated treatment cycles</TI>
<SO>American Journal of Orthopedics</SO>
<YR>1999</YR>
<VL>28 Suppl (11)</VL>
<PG>5-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koyuncu-2002" NAME="Koyuncu 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koyuncu H, Dinc A, Ozkul Y, Yucel E</AU>
<TI>Clinical, functional and radiological efficacy and tolerability of hyaluronate in osteoarthritis - an open study</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2002</YR>
<VL>61 Suppl (EULAR)</VL>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koyuncu-2003" NAME="Koyuncu 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koyuncu H, Uludag M, Cakmak B, Yucel E, Dinc A, Toros H</AU>
<TO>The efficacy and safety of viscosupplementation with hylan G-F 20 in osteoarthritic knee</TO>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2003</YR>
<VL>11 Suppl (A)</VL>
<PG>45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kumar-2003" NAME="Kumar 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kumar N, Rao C, Marshall NJ, Griffiths ID</AU>
<TO>Results of one year follow up after treatment with viscosupplementation</TO>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2003</YR>
<VL>EULAR, Lisbon, Portugal, June 18-21</VL>
<CY>Lisbon, Portugal</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kurokawa-1994" NAME="Kurokawa 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kurokawa T et al</AU>
<TI>Clinical evaluation of high molecular weight sodium hyaluronate (NRD101) on osteoarthritis of the knee: phase III long-term clinical study</TI>
<SO>Jpn Pharmacol Ther</SO>
<YR>1994</YR>
<VL>22</VL>
<NO>9</NO>
<PG>4007-28</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lee-1999" NAME="Lee 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lee S-S, Joo Y-S, Kim W-U, Park S-H, Cho C-S, Kim H-Y, Kim H-J, Kim S-J</AU>
<TI>Clinical efficacy and safety of hyruan (sodium hyaluronate) in patients with osteoarthritis of the knee</TI>
<SO>J Korean Rheum Assoc</SO>
<YR>1999</YR>
<VL>6</VL>
<NO>1</NO>
<PG>53-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lee-2004" NAME="Lee 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lee S, Park D, Chmell SJ</AU>
<TI>Viscosupplementation with hylan G-F 20 (Synvisc)</TI>
<SO>The Journal of Knee Surgery</SO>
<YR>2004</YR>
<VL>17</VL>
<NO>2</NO>
<PG>73-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Legre-2001" NAME="Legre 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Legre V, Pham T, Lafforgue P</AU>
<TI>Evaluation of safety and efficacy of hylan GF-20 in knee osteoarthritis with chondrocalcinosis</TI>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2001</YR>
<VL>9 Suppl (B)</VL>
<PG>47</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leopold-2002" NAME="Leopold 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leopold SS, Warme WJ, Pettis PD, Shott S</AU>
<TO>Increased frequency of acute local reaction to intra-articular hylan GF-20 (Synvisc) in patients receiving more than one course of treatment</TO>
<SO>The Journal of Bone and Joint Surgery</SO>
<YR>2002</YR>
<VL>83-A</VL>
<NO>9</NO>
<PG>1619-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lussier-1996" NAME="Lussier 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lussier A, Cividino AA, McFarlane CA, Olszynski WP, Potashner WJ, De Medicis R</AU>
<TI>Viscosupplementation with hylan for the treatment of osteoarthritis: findings from clinical practice in Canada</TI>
<SO>The Journal of Rheumatology</SO>
<YR>1996</YR>
<VL>23</VL>
<NO>9</NO>
<PG>1579-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Magobotha-2001" NAME="Magobotha 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Magobotha SK, Rogan IM</AU>
<TO>Viscosupplementation: an alternative method of treating osteoarthritis of the knee</TO>
<SO>The Journal of Bone and Joint Surgery</SO>
<YR>2001</YR>
<VL>83-B Suppl (1)</VL>
<PG>10-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mathieu-2001" NAME="Mathieu 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mathieu P, Conrozier T, Schott AM, Laurent I, Marc JF, Vignon E</AU>
<TO>Viscosupplementation with hylan GF-20 in knee osteoarthritis: assessment of the predictive factors of long-term efficacy</TO>
<SO>Osteoarthritis and Cartilge</SO>
<YR>2001</YR>
<VL>9 Suppl (B)</VL>
<PG>27</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mazieres-2004" NAME="Mazieres 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mazieres B, Bacri A, Bard H, Le Pen C, Riviere M</AU>
<TO>French pharmacoeconomic study of hyaluronic acid for osteoarthritis of the knee. An interim analysis</TO>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2004</YR>
<VL>EULAR, Berlin, June 9-12</VL>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mazzocato-1987" NAME="Mazzocato 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mazzocato G, Melanotte PL, Perbellini A</AU>
<TO>Efficacia terapeutica dello ialuronato di sodio nell-arthrosi del ginocchio. Risultati di uno studio in aperto</TO>
<SO>Ortopedia e traumatologia oggi</SO>
<YR>1987</YR>
<VL>VII</VL>
<NO>6</NO>
<PG>333-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Megyeri--1993" NAME="Megyeri  1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Megyeri A, Genti G</AU>
<TO>Intra-articular treatment with sodium hyaluronate in osteoarthritis of the knee: short-term clinical study</TO>
<SO>Revista Espanola de Reumatologia</SO>
<YR>1993</YR>
<VL>20 Suppl (1)</VL>
<PG>329</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mensitieri-1995" NAME="Mensitieri 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mensitieri M, Ambrosio L, Iannace S, Nicolais L</AU>
<TI>Viscoelastic evaluation of different knee osteoarthritis therapies</TI>
<SO>Journal of Materials Science: Materials in Medicine</SO>
<YR>1995</YR>
<VL>6</VL>
<PG>130-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Milini-1989" NAME="Milini 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Milini C, Monini L, Brunelli G</AU>
<TI>Hyaluronic acid in the treatment of gonarthrosis. Findings of an open study</TI>
<TO>L'acido ialuronico nel trattamento della gonartrosi. Risultati di uno studio in aperto</TO>
<SO>Farmaci</SO>
<YR>1989</YR>
<VL>13</VL>
<PG>1-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Miller-1999" NAME="Miller 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Miller EH, Snyder MA, Heidt RS, Welch MC</AU>
<TI>Analysis of the results of viscosupplementation with hylan G-F 20 in the treatment of osteoarthritis of the knee: a prospective study of 108 patients</TI>
<SO>66th Annual Meeting Proceedings, American Academy of Orthopaedic Surgeons</SO>
<YR>February 4-8, 1999</YR>
<PG>233</PG>
<CY>Anaheim, CA</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Minami-1993" NAME="Minami 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Minami S, Okazaki, T, Tanaka T, Isobe K, Tsuchida T, Saegusa O, Fujitsuka M, Moriya H</AU>
<TI>A study of the effect of intra-articular injection of SLM-10 (sodium hyaluronate) on osteoarthritis of the knee</TI>
<SO>Japanese Pharmacology &amp; Therapeutics</SO>
<YR>1993</YR>
<VL>21 Suppl (2)</VL>
<PG>565-79</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moller-2001" NAME="Moller 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moller I, Moragues C, Marti N, Alegre JJ</AU>
<TO>Intra-articular hyaluronate efficacy and safety in treatment of knee OA</TO>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2001</YR>
<VL>9 Suppl (B)</VL>
<PG>51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Monfort-2000" NAME="Monfort 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Monfort J, Benito P</AU>
<TO>Treatment with hyaluronic acid in patients affected with gonarthrosis with and without chondrocalcinosis</TO>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2000</YR>
<VL>8 Suppl (B)</VL>
<PG>70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Myburgh-2001" NAME="Myburgh 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Myburgh JG</AU>
<TO>Viscosupplementation with hylan G-F 20 in the treatment of osteoarthritis</TO>
<SO>The Journal of Bone and Joint Surgery</SO>
<YR>2001</YR>
<VL>83-B Suppl (1)</VL>
<PG>10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Namiki-1982" NAME="Namiki 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Namiki O, Toyoshima H, Morisaki N</AU>
<TI>Therapeutic effect of intra-articular injection of high molecular weight hyaluronic acid on osteoarthritis of the knee</TI>
<SO>International Journal of Clinical Pharmacology, Therapy and Toxicology</SO>
<YR>1982</YR>
<VL>20</VL>
<NO>11</NO>
<PG>501-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Neustadt-2001" NAME="Neustadt 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Neustadt DH</AU>
<TO>Clinical experience with intra-articular hyaluronate in osteoarthritis of the knee</TO>
<SO>The Journal of Rheumatology</SO>
<YR>2001</YR>
<VL>28 Suppl (63)</VL>
<PG>6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Neustadt-2003" NAME="Neustadt 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Neustadt DH</AU>
<TO>Long-term efficacy and safety of intra-articular sodium hyaluroante (Hyalgan) in patients with osteoarthritis of the knee</TO>
<SO>Clinical and Experimental Rheumatology</SO>
<YR>2003</YR>
<VL>21</VL>
<PG>307-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Novaes-2005" NAME="Novaes 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Novaes AC, Schaiquevich P, Nasswetter G, The Latin American Group of Quality of Life in Rheumatology</AU>
<TO>Multicenter study of hyaluronic acid obtained by biotechnology to evaluate clinical efficacy and safety in knee osteoarthritis</TO>
<SO>International Journal of Clinical and Pharmacology Research</SO>
<YR>2005</YR>
<VL>XXV</VL>
<NO>1</NO>
<PG>1-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oberoi-2004" NAME="Oberoi 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Oberoi IS</AU>
<TO>Gains of viscosupplementation following arthroscopic assisted surgery in gonarthrosis in femoro-tibial joints</TO>
<SO>International Cartilage Repair Society, 5th Symposium</SO>
<YR>May 26-29, 2004</YR>
<PG>20-1</PG>
<CY>Gent, Belgium</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Olszynski-2002" NAME="Olszynski 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Olszynski WP, Olszynski M</AU>
<TI>The effect of viscosupplementation therapy among patients suffering from degenerative joint disease of the knees</TI>
<SO>The Journal of Rheumatology</SO>
<YR>2002</YR>
<VL>29</VL>
<NO>7</NO>
<PG>1572</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ono-1993" NAME="Ono 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ono K, Nakahara H, Yonenobu K, Ochi T, Hongo I, Mizushima T, et al</AU>
<TO>A study of the effect of intra-articular injection of high molecular weight sodium hyaluronate (SLM-10) on osteoarthritis of the knee joint</TO>
<SO>Japanese Pharmacology &amp; Therapeutics</SO>
<YR>1993</YR>
<VL>21 Suppl (2)</VL>
<PG>611-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ono-1993a" NAME="Ono 1993a" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ono K, Hirasawa Y, Matsui N, Moriya H</AU>
<TO>A study of the effect of intra-articular long term injection of high molecular weight sodium hyaluronate (SLM-10) on osteoarthritis of the knee joint</TO>
<SO>Japanese Pharmacology &amp; Therapeutics</SO>
<YR>1993</YR>
<VL>21 Suppl (2)</VL>
<PG>687-702</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oron-2003" NAME="Oron 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oron A, Mirovsky Y, Agar G, Halperin N</AU>
<TO>Viscosupplementation with Orthovisc vs. Synvisc for the treatment of osteoarthritis: findings from clinical practice in Israel</TO>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2003</YR>
<VL>11 Suppl (A)</VL>
<PG>46</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oshima-1983" NAME="Oshima 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oshima Y, Azuma H, Namiki O, Aoki T, Azuma T, Irie N, et al</AU>
<TI>Intra-articular injection therapy of high molecular weight sodium hyaluronate (SPH) on osteoarthritis of the knee joint - phase II clinical study</TI>
<SO>Japanese Pharmacology &amp; Therapeutics</SO>
<YR>1983</YR>
<VL>11</VL>
<NO>6</NO>
<PG>2253-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pasquali-Ronchetti" NAME="Pasquali Ronchetti" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pasquali Ronchetti I, Guerra D, Taparelli F, Boraldi F, Bergamini G, Mori G, Zizzi F, Frizziero L</AU>
<TO>Morphological analysis of knee synovial membrane biopsies from a randomized controlled clinial study comparing the effects of sodium hyaluronate (HyalganR) and methylprednisolone acetate (DepomedrolR) in osteoarthritis</TO>
<SO>Rheumatology</SO>
<YR>2001</YR>
<VL>40</VL>
<PG>158-69</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pavelka-2002" NAME="Pavelka 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pavelka K</AU>
<TI>Intraarticular sodium hyaluronate (Hyalgan) in the treatment of patients with osteoarthritis of the knee: findings from clinical practise in Czech Republic</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2002</YR>
<VL>61 Suppl</VL>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pavelka-2002a" NAME="Pavelka 2002a" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pavelka K</AU>
<TI>Intraarticular sodium hyaluronate (Hyalgan) in the treatment of patients with osteoarthritis of the knee: findings from clinical practise in Czech Republic</TI>
<SO>Czech Acta Chir Orthop Traumatol Cech</SO>
<YR>2002</YR>
<VL>69</VL>
<PG>302-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Payne-2000" NAME="Payne 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Payne MW, Petrella RJ</AU>
<TO>Viscosupplementation effect on proprioception in the osteoarthritic knee</TO>
<SO>Archives of Physical Medicine and Rehabilitation</SO>
<YR>2000</YR>
<VL>81</VL>
<PG>598-603</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Petrella-2003" NAME="Petrella 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Petrella RJ, Cogliano A</AU>
<TO>Sodium hyaluronate (Suplasyn) viscosupplementation for treatment of knee osteoarthritis: clinical and functional outcomes and treatment satisfaction from routine clinical practice</TO>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2003</YR>
<VL>EULAR, Lisbon, Portugal, June 18-21</VL>
<CY>Lisbon</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Petrella-2003a" NAME="Petrella 2003a" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Petrella RJ, Riviere M</AU>
<TI>The utilization of hyaluronic acid for the treatment of osteoarthritis within the primary care experience (methodology of data mining of a large database &gt;53 000)</TI>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2003</YR>
<VL>11 Suppl (A)</VL>
<PG>83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Petrella-2003b" NAME="Petrella 2003b" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Petrella RJ, Cogliano A</AU>
<TO>Sodium hyaluronate viscosupplementation for treatment of knee osteoarthritis: clinical and functional outcomes and treatment satisfaction from routine clinical practices</TO>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2003</YR>
<VL>11 Suppl (A)</VL>
<PG>101</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Petrella-2005" NAME="Petrella 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Petrella RJ</AU>
<TI>Hyaluronic acid for the treatment of knee osteoarthritis: long-term outcomes from a naturalistic primary care experience</TI>
<SO>American Journal of Physical Medicine &amp; Rehabilitation</SO>
<YR>2005</YR>
<VL>84</VL>
<NO>4</NO>
<PG>278-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pipino-1990" NAME="Pipino 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pipino F, Molfetta L, Berlingerio G</AU>
<TI>Hyaluronic acid in the treatment of gonarthrosis. Results of an open trial</TI>
<TO>L'acido ialuronico nella terapia della gonartrosi</TO>
<SO>Minerva Ortopedica e Traumatologica</SO>
<YR>1990</YR>
<VL>41</VL>
<NO>11</NO>
<PG>655-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Punzi-1988" NAME="Punzi 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Punzi L, Schiavon F, Ramonda R, Malatesta V, Gambari P, Todesco S</AU>
<TI>Intra-articular hyaluronic acid in the treatment of inflammatory and noninflammatory knee effusions</TI>
<SO>Current Therapeutic Research</SO>
<YR>1988</YR>
<VL>43</VL>
<NO>4</NO>
<PG>643-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rao-2001" NAME="Rao 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rao C, Kumar N, Young-Min S, Marshall NJ, Platt PN, Griffiths ID</AU>
<TI>Experiences with a viscosupplementation (Hyalgan) clinic</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2001</YR>
<VL>60 Suppl (1)</VL>
<PG>233</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rastogi-2005" NAME="Rastogi 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rastogi S, Sharma VK, Chandra R, Sivaraman ST</AU>
<TO>Open label multicentre trial on safety and efficacy of intra-articular hyaluronic acid in the treatment of osteoarthritis of the knee - a prospective study</TO>
<SO>Journal, Indian Academy of Clinical Medicine</SO>
<YR>2005</YR>
<VL>6</VL>
<NO>3</NO>
<PG>232-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Russell-1992" NAME="Russell 1992" YEAR="1992">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Russell IJ, Michalek JE, Lawrence VA, Lessard JA, Briggs BT, May GS</AU>
<TI>A randomized, placebo (PL) and no-intervention (NI) controlled, trial of intra-articular (IA) 1% sodium hyaluronate (HA) in the treatment of knee osteoarthritis (OA)</TI>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>1992</YR>
<VL>35 Suppl</VL>
<PG>132</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Scali-1995" NAME="Scali 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Scali JJ</AU>
<TI>Intra-articular hyaluronic acid in the treatment of osteoarthritis of the knee: a long term study</TI>
<SO>European Journal of Rheumatology and Inflammation</SO>
<YR>1995</YR>
<VL>15</VL>
<NO>1</NO>
<PG>57-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sepici-2002" NAME="Sepici 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sepici V, Sepici A, Acikgoz S, Tali T</AU>
<TI>The role of viscosupplementation with sodium hyaluronate (Orthovisc) in urine gag levels and magnetic resonance imaging (MRI) features of osteoarthritis of the knee</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2002</YR>
<VL>61 Suppl</VL>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shibata-1993" NAME="Shibata 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shibata S</AU>
<TI>Using experience and significance of sodium hyaluronate (Artz) for osteoarthritis of the knee</TI>
<SO>Journal of New Remedies &amp; Clinics</SO>
<YR>1993</YR>
<VL>42</VL>
<NO>3</NO>
<PG>598</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sieliwonczyk-1997" NAME="Sieliwonczyk 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sieliwonczyk P, Mazurkiewicz S, Ostojski R, Kusiak A</AU>
<TI>The value of intraarticular Hyalgan injections in treatment of osteoarthritis of the knee</TI>
<TO>Ocena wartosci dostawowych iniekcji preparatu Hyalgan w leczeniu zmian zwyrodnieniowych stawu kolanowego</TO>
<SO>Chir Narz Ruchu Ortop Pol</SO>
<YR>1997</YR>
<VL>LXIII</VL>
<NO>4</NO>
<PG>337-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Singh-2004" NAME="Singh 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Singh G, Bruce B, Sato R, Waddell DD</AU>
<TO>Treatment satisfaction in patients treated with hylan G-F 20 vs. intra-articular steroids at 6 months</TO>
<SO>American Academy of Orthopaedic Surgeons (AAOS) On-Line Service</SO>
<YR>2004</YR>
<VL>Annual Meeting Podium Presentations</VL>
<NO>71st Annual Meeting, March 10-14, San Francisco</NO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sripada-1999" NAME="Sripada 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sripada P, Pritchard C, Bankes PF</AU>
<TI>Comparison efficacy of hyaluronan and hylan G-F 20 in osteoarthritis</TI>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>1999</YR>
<VL>42 Suppl (9)</VL>
<PG>296</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stambuk-2001" NAME="Stambuk 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stambuk B, Gnjidic Z, Brencic-Dlesk M</AU>
<TO>Efficacy and safety of intra-articular injection of hylan GF-20 (Synvisc) for the knee</TO>
<SO>The Journal of Rheumatology</SO>
<YR>2001</YR>
<VL>28 Suppl (63)</VL>
<PG>10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Suzu-1990" NAME="Suzu 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Suzu F, Hirasawa Y</AU>
<TI>Results of long term treatment with ARTZ for the knee osteoarthritis</TI>
<SO>Japanese Pharmacology &amp; Therapeutics</SO>
<YR>1990</YR>
<VL>18</VL>
<NO>12</NO>
<PG>4979-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Suzu-1993" NAME="Suzu 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Suzu F, Hirasawa Y</AU>
<TI>A study of the effect of high molecular weight sodium hyaluronate (SLM-10) on osteoarthritis of the knee joint</TI>
<SO>Japanese Pharmacology &amp; Therapeutics</SO>
<YR>1993</YR>
<VL>21 Suppl (2)</VL>
<PG>595-610</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Takeuchi-1993" NAME="Takeuchi 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Takeuchi H, Yamaguchi I, Morita S, Kawagoe S, Chosa E, Maehara T, Kuroki T, Kuwahara S</AU>
<TI>Multicenter clinical study in intraarticular injection of high molecular sodium hyaluronate (ARTZ) for osteoarthritis of the knee</TI>
<SO>Journal of Medicine and Pharmaceutical Science</SO>
<YR>1993</YR>
<VL>29</VL>
<NO>6</NO>
<PG>1517-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Taneda-1993" NAME="Taneda 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Taneda Y, Matsui N, Nakane K, Takai Y, Suzuki H, Hongoh N</AU>
<TI>A study of the effect of SLM-10 on osteoarthritis of the knee</TI>
<SO>Japanese Pharmacology &amp; Therapeutics</SO>
<YR>1993</YR>
<VL>21 Suppl (2)</VL>
<PG>581-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tang-2004" NAME="Tang 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tang SF, Chen CP, Chen MJ, Pei Y-C, Lau Y-C, Leong C-P</AU>
<TO>Changes in sagittal ground reaction forces after intra-articular hyaluronate injections for knee osteoarthritis</TO>
<SO>Archives Physical Medicine and Rehabilitation</SO>
<YR>2004</YR>
<VL>85</VL>
<NO>6</NO>
<PG>951-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tang-2005" NAME="Tang 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tang SFT, Chen CPC, Chen MJL, Hong WH, Yu TY, Tsai WC</AU>
<TO>Improvement of muscle strength in osteoarthritic knee patients after intraarticular knee injection of hyaluronan</TO>
<SO>American Journal of Physical Medicine &amp; Rehabilitation</SO>
<YR>2005</YR>
<VL>84</VL>
<NO>4</NO>
<PG>274-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Toh-2002" NAME="Toh 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Toh EM, Prasad PS, Teanby D</AU>
<TO>Correlating the efficacy of knee viscosupplementation with osteoarthritic changes on roentgenological examination</TO>
<SO>The Knee</SO>
<YR>2002</YR>
<VL>9</VL>
<PG>321-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Toh-2003" NAME="Toh 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Toh EM, Prasad P, Teanby D</AU>
<TO>Correlating the outcome of knee intraarticular viscosupplementation with radiological changes of osteoarthritis</TO>
<SO>The Journal of Bone and Joint Surgery</SO>
<YR>2003</YR>
<VL>85-B Suppl (II)</VL>
<PG>178</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Torrance-2002" NAME="Torrance 2002" YEAR="2002">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Torrance GW, Raynauld JP, Walker V, Goldsmith CH, Bellamy N, Band PA, Schultz M, Tugwell P</AU>
<TI>A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 2 of 2): economic results</TI>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2002</YR>
<VL>10</VL>
<NO>7</NO>
<PG>518-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Turajane-2005" NAME="Turajane 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Turajane T, Labpiboonpong V, Maungsiri S, Sattayathum P</AU>
<TO>Therapeutic effects of intra-articular hyaluronan on failed conservative treatment of knee osteoarthritis with minimum two years follow up</TO>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2005</YR>
<VL>64</VL>
<NO>Suppl III</NO>
<PG>EULAR, June 8-11, Vienna, Austria</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Turajane-2005a" NAME="Turajane 2005a" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Turajane T, Labpiboonpong V, Maungsiri S, Sattayathum P.</AU>
<TO>Medico-economic analysis of sodium hyaluronate (Hyalgan) treatment in an Asian population over 65 yrs with Kellgren-Lawrence grade 4 knee OA who failed conservative treatment</TO>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2005</YR>
<VL>64</VL>
<NO>Suppl III</NO>
<PG>EULAR, June 8-11, Vienna, Austria</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Uebelhart-2003" NAME="Uebelhart 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Uebelhart D, Berz S</AU>
<TO>Safety and efficacy of fermentative hyaluronan in knee osteoarthritis: a retrospective study</TO>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2003</YR>
<VL>11 Suppl (A)</VL>
<PG>80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vad-2000" NAME="Vad 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Vad VB, Cooke PM, Wickiewicz TL, Sculco TP, Warren RF, Althek DW</AU>
<TI>Hylan versus knee lavage and hylan in management of knee osteoarthritis</TI>
<SO>67th Annual Meeting Proceedings, American Academy of Orthopedic Surgeons</SO>
<YR>March 15-19, 2000</YR>
<PG>456</PG>
<CY>Orlando, FL</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vad-2003" NAME="Vad 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vad VB, Bhat AL, Sculco TP, Wickiewicz TL</AU>
<TO>Management of knee osteoarthritis: knee lavage combined with hylan versus hylan alone</TO>
<SO>Archives of Physical Medicine and Rehabilitation</SO>
<YR>2003</YR>
<VL>84</VL>
<PG>634-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Waddell-2001a" NAME="Waddell 2001a" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Waddell DD, Estey DJ, Bricker D</AU>
<TO>Retrospective tolerance of hylan G-F 20 using fluoroscopically-confirmed injection and effectiveness of retreatment of knee osteoarthritis</TO>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>2001</YR>
<VL>44 Suppl (9)</VL>
<PG>48</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Waddell-2001b" NAME="Waddell 2001b" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Waddell DD, Bricker D</AU>
<TO>Hylan G-F 20 reduces the probability of progression to total knee replacement in knee osteoarthritis</TO>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>2001</YR>
<VL>44 Suppl (9)</VL>
<PG>49</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Waddell-2001c" NAME="Waddell 2001c" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Waddell D, Rein A, Panarites C, Coleman PM, Weiss C</AU>
<TO>Cost implications of introducing an alternative treatment for patients with osteoarthritis of the knee in a managed care setting</TO>
<SO>American Journal of Management and Care</SO>
<YR>2001</YR>
<VL>7</VL>
<NO>10</NO>
<PG>981-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Waddell-2003" NAME="Waddell 2003" YEAR="2003">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Waddell DD, Cefalu CA, Bricker DC</AU>
<TO>A 52-week, open-label study of a second course of hylan G-F 20 for the treatment of pain associated with osteoarthritis of the knee</TO>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2003</YR>
<VL>EULAR, Lisbon, Portugal, June 18-21</VL>
<CY>Lisbon, Portugal</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Waddell-2003a" NAME="Waddell 2003a" YEAR="2003a">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Waddell DD, Bricker DC</AU>
<TO>Hylan G-F 20 reduces the probability of progression to total knee replacement in knee osteoarthritis</TO>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2003</YR>
<VL>EULAR, Lisbon, Portugal, June 18-21</VL>
<PB>EULAR</PB>
<CY>Lisbon, Portugal</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Waddell-2003b" NAME="Waddell 2003b" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Waddell DD, Bricker DC</AU>
<TO>Hylan G-F 20 in knee osteoarthritis patients: low incidence and clinical management of local adverse events</TO>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>2003</YR>
<VL>48 Suppl (9)</VL>
<PG>486</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Waddell-2003c" NAME="Waddell 2003c" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Waddell DD, Cefalu CA, Bricker DC</AU>
<TO>An open-label study of a second course of hylan G-F 20 for the treatment of pain associated with knee osteoarthritis</TO>
<SO>Current Medical Research and Opinion</SO>
<YR>2003</YR>
<VL>19</VL>
<NO>6</NO>
<PG>499-507</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weiss-1999" NAME="Weiss 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weiss C, Tillero W, Balazs L</AU>
<TI>The treatment of osteoarthritis of the knee with hylan GF20 in orthopaedic practice</TI>
<SO>Osteoarthritis and Cartilage</SO>
<YR>1999</YR>
<VL>7 Suppl (A)</VL>
<PG>37</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wobig-1999d" NAME="Wobig 1999d" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wobig M, Beks P, Dickhut A, Maier R, Vetter</AU>
<TI>Open-label multicenter trial of the safety and efficacy of viscosupplementation with hylan G-F20 (Synvisc) in primary osteoarthritis of the knee</TI>
<SO>Journal of Clinical Rheumatology</SO>
<YR>1999</YR>
<VL>5 Suppl (6)</VL>
<PG>24-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wulwik-2001" NAME="Wulwik 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wulwik A, Bertocci S, Raude-Leroy V, Lleu PL</AU>
<TO>Efficacy and safety of Synvisc in severe knee osteoarthritis (OA): experience from a large cohort of patients followed in private rheumatological practice</TO>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2001</YR>
<VL>60 Suppl (I)</VL>
<PG>226</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yoh-1989" NAME="Yoh 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yoh K, Tsuji H, Maruoka T, Tateishi H</AU>
<TI>Clinical results of intra-articular treatment with sodium hyaluronate in osteoarthritis of the knee</TI>
<SO>Clinical Rheumatology</SO>
<YR>1989</YR>
<VL>2</VL>
<NO>2</NO>
<PG>132-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zamora_x002d_Quezada-2004" NAME="Zamora-Quezada 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zamora-Quezada J</AU>
<TO>Clinical practice adoption of a Touch-Screen Outcome Patient Surveys (TOPS) in the management of chronic pain of osteoarthriis</TO>
<SO>Arthritis and Rheumatism</SO>
<YR>2004</YR>
<VL>50</VL>
<NO>9(Suppl)</NO>
<PG>S468-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Anand-2004" NAME="Anand 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anand S, Mitchell S, Bamforth C, Asumu T, Buch KA</AU>
<TO>Effect of intra-articular injection of sodum hyaluronate on recovery after arthroscopic knee surgery</TO>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2004</YR>
<VL>12 Suppl (2)</VL>
<PG>141</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blanco-Garcia-2004" NAME="Blanco Garcia 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blanco Garcia FJ, Fernandez Sueiro JL, Pinto JA, Fernandez Lopez JC, Ramos M, Gimeno M, Coronel P, Galdo F</AU>
<TO>Treating of patients with knee osteoarthritis waiting by replacement surgery with intra-articular hyaluronic acid (Adant)</TO>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2004</YR>
<VL>12 Suppl (2)</VL>
<PG>142-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Bourgeois-_x0028_Artz_x0029_" NAME="Bourgeois (Artz)" YEAR="200?">
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Briliantono-1996" NAME="Briliantono 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Randomised, double-blind, placebo-controlled study. 20 mg/2 ml of a 1% HA solution or 2 ml placebo (physiological saline) injection per wk for 5 weeks. 9 controlled visits. 44 pts (60 knees). HA &amp;gt; PL.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Soenarwo Briliantono M</AU>
<TO>Treatment of osteoarthritis of the knee by intra-articular hyaluronic acid</TO>
<SO>Immunology and Cell Biology</SO>
<YR>1996</YR>
<VL>74</VL>
<PG>A16</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Byrd-_x0028_Artz_x0029_" NAME="Byrd (Artz)" YEAR="200?">
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Caracuel-2001" NAME="Caracuel 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Caracuel MA, Munoz-Villanueva MC, Escudero A, Veroz R, Frias G, Vacas J, et al</AU>
<TO>Effects of joint lavage and hyaluronic acid infiltration in patients with osteoarthritis of the knee</TO>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2001</YR>
<VL>60 Suppl (I)</VL>
<PG>236-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Castro-2005" NAME="Castro 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Castro C, Font P, Munoz E, Frias G, Caracuel MA, Vacas J, Perez V, Escudero A, Lopez P, Collantes E</AU>
<TI>Efficacy and safety of intra-articular hyaluronic acid compared (HA) to steroid injections in patients with knee osteoarthritis</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2005</YR>
<VL>64</VL>
<NO>Suppl III</NO>
<PG>EULAR, June 8-11, Austria, Vienna</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garcia-2004" NAME="Garcia 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Garcia B</AU>
<TO>A comparative study: adverse reactions to Synvisc(R) but not Hyalgan(R)</TO>
<SO>American Academy of Orthopaedic Surgeons (AAOS) On-Line Service</SO>
<YR>2004</YR>
<VL>71st Annual Meeting, March 10-14, San Francisco</VL>
<NO>Annual Meeting Poster Presentations</NO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gur-2002" NAME="Gur 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gur A, Kylync S, Sarac AJ, Nas K, Cevik R</AU>
<TI>Effects of intra-articular hyaluronic acid and corticosteroid in the patients with serious knee osteoarthritis</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2002</YR>
<VL>61 Suppl (EULAR)</VL>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Joergensen-2005" NAME="Joergensen 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Joergensen A, Stengaard-Pedersen K</AU>
<TO>Hyaluronan intra-articular is without clinical effect in knee osteoarthritis (OA). A multicentre, randomised, placebo controlled, double-blind study</TO>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2005</YR>
<VL>64</VL>
<NO>Suppl III</NO>
<PG>EULAR, June 8-11, Vienna, Austria</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kilinc-2002" NAME="Kilinc 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kilinc S, Gur A, Sarac AJ, Nas K, Cevik R</AU>
<TI>Comparison of intra-articular hyaluronic acid and physiotherapy in the management of serious knee osteoarthritis</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2002</YR>
<VL>61 Suppl (EULAR)</VL>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kim-2000" NAME="Kim 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;Article is in Korean. Needs to be translated.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kim SB, Yoon K, Park HS, Kwak H, Ha NJ, Park JS</AU>
<TI>The effect of intra-articular hyaluronic acid and steroid injection in osteoarthritis of the knee</TI>
<SO>Journal of the Korean Academy of Rehabilition Medicine</SO>
<YR>2000</YR>
<VL>24</VL>
<NO>4</NO>
<PG>747-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koyuncu-2002a" NAME="Koyuncu 2002a" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koyunci H, Kinc A, Ozkul Y, Yucel E</AU>
<TI>Clinical, functional and radiological efficacy and tolerability of hyaluronate in osteoarthritis - an open study</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2002</YR>
<VL>61 Suppl (EULAR)</VL>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kuzmanova-2005" NAME="Kuzmanova 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kuzmanova SI, Solakov PT</AU>
<TO>Sodium hyaluronate 500-730 KDA (Hyalgan) intra-articularly after treatment of synovitis in primary active osteoarthritis of the knee joint with betamethasone</TO>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2005</YR>
<VL>64</VL>
<NO>Suppl III</NO>
<PG>EULAR, June 8-11, Vienna, Austria</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lee-2002" NAME="Lee 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;[Korean] Hyruan vs saline in 73 patients with OA of the knee. 27 week duration. VAS pain, Lequesne Index, Tegner activity score for activity outcome measures. Kellgren and Lawrence scoring. Translation into English required.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lee DC, Beak SH, Sohn WJ, Shin KS, Han JH</AU>
<TI>Effect of the hyaluronic acid on osteoarthritis of the knee</TI>
<SO>Journal of the Korean Knee Society</SO>
<YR>2002</YR>
<VL>14</VL>
<NO>2</NO>
<PG>213-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lucangeli-2001" NAME="Lucangeli 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lucangeli A, Gugelmetto M, Primon D</AU>
<TI>Physical therapy and intraarticular hyaluronic acid in the treatment of osteoarthritis</TI>
<TO>Terapia fisica e acido ialuronico per via intra-articolare nel trattamento della gonartrosi</TO>
<SO>Revista Italiana di Biologia e Medicina</SO>
<YR>2001</YR>
<VL>21</VL>
<NO>1-2</NO>
<PG>5-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Petrella-2002a" NAME="Petrella 2002a" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Petrella RJ, Alkemade SJ, Salvatori VA</AU>
<TI>Sodium hyaluronate for functional improvement of the osteoarthritic knee - three and six injections</TI>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2002</YR>
<VL>10 Suppl (A)</VL>
<PG>71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Renk_x005b_inodot_x005d_tepe-20" NAME="Renk[inodot]tepe 20" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Renkl[inodot]tepe N, Atalay E</AU>
<TI>The effect of intra-articular sodium hyaluronate therapy in knee osteoarthritis</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2000</YR>
<VL>59 Suppl (1)</VL>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Russell-2003" NAME="Russell 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Russell ID, Baker D, Johnson SR</AU>
<TO>A comparison of synvisc and arthroscopic lavage in the mangement of osteoarthritis of the knee</TO>
<SO>The Journal of Bone and Joint Surgery</SO>
<YR>2003</YR>
<VL>85-B Suppl (II)</VL>
<PG>106</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shariati-2001" NAME="Shariati 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shariati J, Hatef M, Jokar M</AU>
<TI>Intraarticular Hylan G-F20 (Synvisc) in the treatment of patients with osteoarthritis of the knee</TI>
<SO>The Journal of Rheumatology</SO>
<YR>2001</YR>
<VL>28 Suppl (63)</VL>
<PG>3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sinha-2003" NAME="Sinha 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sinha S, Singh BJ, Thilagarajah M, Housden P</AU>
<TO>Single vs multiple dose intra-articular hyaluronic acid in patients with osteoarthritis knee - a prospective clinical trial</TO>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2003</YR>
<VL>11 Suppl (A)</VL>
<PG>43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stitik-2004" NAME="Stitik 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stitik TP, Foye PM, Stiskal DM, Nadler SF, Chen B, Schoenherr L</AU>
<TO>Intra-articular hyaluronate (MW 500-730 KDA) therapy and concomitant home exercise strengthening: an effective additive therapeutic algorithm for osteoarthritis of the knee</TO>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2004</YR>
<VL>12 Suppl (2)</VL>
<PG>84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Talwalkar-2005" NAME="Talwalkar 2005" YEAR="2005">
<REFERENCE NOTES="&lt;p&gt;This is the same trial as Russell 2003.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Talwalkar NC, Russell DI, Johnson S</AU>
<TO>Management of osteoarthritis of the knee, knee lavage compared with intraarticular hylan G-F 20 (Synvisc) injections</TO>
<SO>Journal of the Japanese Orthopaedic Association</SO>
<YR>2005</YR>
<VL>79</VL>
<NO>3</NO>
<PG>S57</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xu-2005" NAME="Xu 2005" YEAR="2005">
<REFERENCE NOTES="&lt;p&gt;Publication in Chinese with English abstract. Awaiting complete translation.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Xu P, Guo X, Jin WZ, Yao J, Zhang Y, Cai Q</AU>
<TI>Clinical observaion on effect of intra-articular injection of sodium hyaluronate accompanied with external application of sanhua ointment for knee osteoarthritis</TI>
<TO>[Chinese]</TO>
<SO>Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi [Chinese Journal of Integrated Traditional &amp; Western Medicine]</SO>
<YR>2005</YR>
<VL>25</VL>
<NO>7</NO>
<PG>620-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Za-2002" NAME="Za 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Za ZG, Song YC, Zao MJ, Liu CF</AU>
<TI>Comparison of therapeutic results of Danshen and sodium hyaluronate injection for knee osteoarthritis</TI>
<SO>Chinese Journal of Clinical Rehabilitation</SO>
<YR>2002</YR>
<VL>6</VL>
<NO>24</NO>
<PG>3746-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Anonymous-1999" NAME="Anonymous 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;This prospective, randomised, double-blind trial was designed to assess the safety and effectiveness of Orthovisc in comparison to saline. This Phase III trial completed enrollment of 375 patients in 22 centres in the United States and Canada with both rheumatologists and orthopaedic surgeons.&lt;/p&gt;" PRIMARY="NO" TYPE="OTHER">
<TI>Orthovisc compared to saline: a double-blind, randomised controlled trial</TI>
<SO>Anika Therapeutics Press Release</SO>
<YR>August 1999</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Hempfling-2003" NAME="Hempfling 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hempfling H</AU>
<TI>Long-term outcome of synovial fluid substitution with Viscoseal post-arthroscopy</TI>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2003</YR>
<VL>11 Suppl (A)</VL>
<PG>79</PG>
<EN>OARSI, Berlin, Oct. 12-15, 2003</EN>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ISRCTN43185756" NAME="ISRCTN43185756" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Department of Health, London, UK Phase III trial</AU>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ISRCTN51421587" NAME="ISRCTN51421587" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Protocol only.&lt;/p&gt;" PRIMARY="NO" TYPE="OTHER">
<AU>Juni P, Villiger PM, Dieppe PA, Zullig M, Egger M for the SVISCOT Group</AU>
<TO>Viscosupplementation for osteoarthritis of the knee: protocol for the Swiss viscosupplementation trial (SVISCOT)</TO>
<YR>May 15, 2003</YR>
<VL>Draft #22</VL>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ISRCTN82192623" NAME="ISRCTN82192623" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<TI>Prospective randomised single blind trial comparing the effectiveness of combined arthroscopic washout and intra articular hyaluronan injection to intra articular hyaluronan injection and arthroscopic washout in isolation, for osteoarthritis of the knee</TI>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00130468" NAME="NCT00130468" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sanofi-Aventis Phase IV trial</AU>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00131352" NAME="NCT00131352" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Genzyme Phase III trial</AU>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00139295" NAME="NCT00139295" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Genzyme Phase III trial.</AU>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00144820" NAME="NCT00144820" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Glostrup University Hospital, Phase IV trial</AU>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Russell-2001" NAME="Russell 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Russell ID, Baker D, Johnson SR</AU>
<TI>A comparison of Synvisc and arthroscopic lavage in the management of osteoarthritis of the knee</TI>
<SO>The Journal of Bone and Joint Surgery</SO>
<YR>2001</YR>
<VL>83-B Suppl (II)</VL>
<PG>213</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-11-09 23:54:05 -0500" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2008-11-09 23:54:05 -0500" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-ACR-Guidelines-2000" NAME="ACR Guidelines 2000" TYPE="JOURNAL_ARTICLE">
<AU>American College of Rheumatology Subcommittee on osteoarthritis guidelines</AU>
<TI>Recommendations for the medical management of osteoarthritis of the hip and knee. 2000 Update</TI>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>2000</YR>
<VL>43</VL>
<NO>9</NO>
<PG>1905-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Adams-2000" NAME="Adams 2000" TYPE="JOURNAL_ARTICLE">
<AU>Adams ME, Lussier AJ, Peyron JG</AU>
<TO>A risk-benefit assessment of injections of hyaluronan and derivatives in the treatment of osteoarthritis of the knee</TO>
<SO>Drug Safety</SO>
<YR>2000</YR>
<VL>23</VL>
<NO>2</NO>
<PG>115-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Aggarwal-2004" NAME="Aggarwal 2004" TYPE="JOURNAL_ARTICLE">
<AU>Aggarwal A, Sempowski IP</AU>
<TO>Hyaluronic acid injections for knee osteoarthritis. Systematic review of the literature</TO>
<SO>Canadian Family Physician</SO>
<YR>2004</YR>
<VL>50</VL>
<PG>249-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Albert-2005" MODIFIED="2008-11-09 23:54:05 -0500" MODIFIED_BY="[Empty name]" NAME="Albert 2005" TYPE="JOURNAL_ARTICLE">
<AU>Albert C, Brocq O, Gerard D, Roux C, Euller-Ziegler L</AU>
<TO>Septic knee arthritis after intra-articular hyaluronate injection. Two case reports</TO>
<SO>Joint Bone Spine</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Altman-1986" NAME="Altman 1986" TYPE="JOURNAL_ARTICLE">
<AU>Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, et al</AU>
<TO>Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee</TO>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>1986</YR>
<VL>29</VL>
<NO>8</NO>
<PG>1039-49</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Altman-1991" NAME="Altman 1991" TYPE="JOURNAL_ARTICLE">
<AU>Altman RD</AU>
<TO>Criteria for classification of clinical osteoarthritis</TO>
<SO>The Journal of Rheumatology</SO>
<YR>1991</YR>
<VL>18 Suppl (27)</VL>
<PG>10-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Altman-2000" NAME="Altman 2000" TYPE="JOURNAL_ARTICLE">
<AU>Altman RD</AU>
<TI>Intra-articular sodium hyaluronate in osteoarthritis of the knee</TI>
<SO>Seminars in Arthritis and Rheumatism</SO>
<YR>2000</YR>
<VL>30 Suppl (1)</VL>
<PG>11-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Altman-2002" NAME="Altman 2002" TYPE="JOURNAL_ARTICLE">
<AU>Altman R, Moskowitz R</AU>
<TO>Hyaluronate sodium injections for osteoarthritis: the truth</TO>
<SO>Archives of Internal Medicine</SO>
<YR>2002</YR>
<VL>162</VL>
<PG>2498-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Altman-2003" NAME="Altman 2003" TYPE="JOURNAL_ARTICLE">
<AU>Altman RD</AU>
<TO>Status of hyaluronan supplementation therapy in osteoarthritis</TO>
<SO>Current Rheumatology Reports</SO>
<YR>2003</YR>
<VL>5</VL>
<PG>7-14</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN 1523-3774"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Arrich-2005" NAME="Arrich 2005" TYPE="JOURNAL_ARTICLE">
<AU>Arrich J, Piribauer F, Mad P, Schmid D, Klaushofer K, Mullner M</AU>
<TO>Intra-articular hyaluronic acid for the treatment of osteoarthritis of the knee: systematic review and meta-analysis</TO>
<SO>Canadian Medical Association Journal</SO>
<YR>2005</YR>
<VL>172(8)</VL>
<PG>1039-1043</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="DOI:10.1503/cmaj.1041203"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Aviad-1994" NAME="Aviad 1994" TYPE="JOURNAL_ARTICLE">
<AU>Aviad AD, Houpt JB</AU>
<TO>The molecular weight of therapeutic hyaluronan (sodium hyaluronate): how significant is it?</TO>
<SO>The Journal of Rheumatology</SO>
<YR>1994</YR>
<VL>21</VL>
<NO>2</NO>
<PG>297-301</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ayral-2001" NAME="Ayral 2001" TYPE="JOURNAL_ARTICLE">
<AU>Ayral X</AU>
<TI>Injections in the treatment of osteoarthritis</TI>
<SO>Bailliere's Best Practice &amp; Research in Clinical Rheumatology</SO>
<YR>2001</YR>
<VL>15</VL>
<NO>4</NO>
<PG>609-26</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="DOI: 10.1053/berh.2001.0177"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bachinger-1996" NAME="Bachinger 1996" TYPE="JOURNAL_ARTICLE">
<AU>Bachinger A, Rappenhoner B, Rychlik R</AU>
<TO>Zur soziookonomischen Effizienz einer Zeel comp.-Therapie im Vergleich zu Hyaluronsaure bei Patienten mit Gonarthrose</TO>
<SO>Zeitschrift fur Orthopadie und ihre Grenzgebiete</SO>
<YR>1996</YR>
<VL>134</VL>
<NO>4</NO>
<PG>Oa20-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Balazs-1982" NAME="Balazs 1982" TYPE="BOOK_SECTION">
<AU>Balazs EA</AU>
<TO>The physical properites of synovial fluid and the special role of hyaluronic acid</TO>
<SO>Disorders of the Knee</SO>
<YR>1982</YR>
<PG>61-74</PG>
<EN>2</EN>
<ED>Helfet AJ</ED>
<PB>J. B. Lippincott Company</PB>
<CY>Philadelphia</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Band-2005" NAME="Band 2005" TYPE="JOURNAL_ARTICLE">
<AU>Band PA</AU>
<TI>Comparing different therapeutic classes for the treatment of osteoarthritis of the knee: data from the OMERACT-OARSI responder criteria analysis</TI>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bell-2003" NAME="Bell 2003" TYPE="CONFERENCE_PROC">
<AU>Bell MJ, Bellamy N, Goldsmith CH, Tugwell P, Torrance GW, Raynauld J-P, Polisson R, Pericak D, Walker V</AU>
<TO>Evaluation of the OARSI and OMERACT-OARSI set of responder criteria in patients treated with hylan G-F 20 for knee osteoarthritis</TO>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>2003</YR>
<VL>48 Suppl (9)</VL>
<PG>482</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bellamy-1993" NAME="Bellamy 1993" TYPE="BOOK">
<AU>Bellamy N</AU>
<SO>Musculoskeletal Clinical Metrology</SO>
<YR>1993</YR>
<PB>Kluwer Academic Publishers</PB>
<CY>Dordrecht</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bellamy-1997" NAME="Bellamy 1997" TYPE="JOURNAL_ARTICLE">
<AU>Bellamy N, Kirwan J, Boers M, Brooks P, Strand V, Tugwell P, Altman R, Brandt K, Dougados M, Lequesne M</AU>
<TO>Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip, and hand osteoarthritis. Consensus development at OMERACT III</TO>
<SO>The Journal of Rheumatology</SO>
<YR>1997</YR>
<VL>24</VL>
<NO>4</NO>
<PG>799-802</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bellamy-2002" NAME="Bellamy 2002" TYPE="JOURNAL_ARTICLE">
<AU>Bellamy N, Campbell J, Hill J, Band P</AU>
<TO>A comparative study of telephone versus onsite completion of the WOMAC 3.0 Osteoarthritis Index</TO>
<SO>The Journal of Rheumatology</SO>
<YR>2002</YR>
<VL>29</VL>
<NO>4</NO>
<PG>783-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bellamy-2003" NAME="Bellamy 2003" TYPE="JOURNAL_ARTICLE">
<AU>Bellamy N, Campbell J, Gee T, Robinson V, Wells G, Bourne RB</AU>
<TO>Hylan G-F 20 for knee osteoarthritis (OA): a Cochrane review</TO>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>2003</YR>
<VL>48 Suppl (9)</VL>
<PG>697</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bellamy-2003a" NAME="Bellamy 2003a" TYPE="JOURNAL_ARTICLE">
<AU>Bellamy N, Bell MJ, Goldsmith CH, Tugwell P, Torrance GW, Raynauld JP, Polisson R, Pericak D, Walker V</AU>
<TO>WOMAC 20, 50, 70 response levels in patients treated with hylan G-F 20 for knee osteoarthritis</TO>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2003</YR>
<VL>11 Suppl (A)</VL>
<PG>82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bellamy-2003b" NAME="Bellamy 2003b" TYPE="JOURNAL_ARTICLE">
<AU>Bellamy N, Bell MJ, Goldsmith CH, Tugwell P, Torrance GW, Raynauld JP, Polisson R, Pericak D, Walker V</AU>
<TO>Symptom free response using the WOMAC pain score in patients treated with hylan G-F 20 for knee osteoarthritis</TO>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2003</YR>
<VL>11 Suppl (A)</VL>
<PG>42-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bellamy-2004" NAME="Bellamy 2004" TYPE="JOURNAL_ARTICLE">
<AU>Bellamy N, Bell MJ, Goldsmith CH, Torrance GW, Raynauld J, Tugwell P, Polisson R, Pericak D, Walker V</AU>
<TO>Examining minimal perceptible clinical improvement criteria in patients treated with hylan G-F 20 for knee osteoarthritis</TO>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2004</YR>
<VL>EULAR, Berlin, June 9-12</VL>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bellamy-2005" NAME="Bellamy 2005" TYPE="JOURNAL_ARTICLE">
<AU>Bellamy N, Campbell J, Robinson V, Wells GA, Bourne RB</AU>
<TI>A Cochrane review of viscosupplementation: hylan G-F 20 versus placebo</TI>
<SO>Osteoporosis International</SO>
<YR>2005</YR>
<VL>16</VL>
<NO>3</NO>
<PG>S12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bellamy-2005a" NAME="Bellamy 2005a" TYPE="JOURNAL_ARTICLE">
<AU>Bellamy N, Bell MJ, Goldsmith CH, Pericak D, Walker V, Raynauld J-P, Torrance GW, Tugwell P, Polisson R</AU>
<TI>The effectiveness of hylan G-F 20 in patients with knee osteoarthritis: an application of two sets of response criteria developed by the OARSI and one set developed by OMERACT-OARSI</TI>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2005</YR>
<VL>13</VL>
<NO>2</NO>
<PG>104-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bellamy-2005b" NAME="Bellamy 2005b" TYPE="JOURNAL_ARTICLE">
<AU>Bellamy N, Bell MJ, Goldsmith CH, Pericak D, Walker V, Raynauld JP, TorranceGW, Tugwell P, Polisson R</AU>
<TO>Evaluation of WOMAC 20, 50, 70 response criteria in patients treated with hylan G-F 20 for knee osteoarthritis</TO>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2005</YR>
<VL>64</VL>
<PG>881-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bernstein-2004" MODIFIED="2008-11-09 23:53:53 -0500" MODIFIED_BY="[Empty name]" NAME="Bernstein 2004" TYPE="JOURNAL_ARTICLE">
<AU>Berstein J</AU>
<TO>Therapeutic effects of hyaluronic acid on osteoarthritis of the knee</TO>
<SO>The Journal of Bone and Joint Surgery</SO>
<YR>2004</YR>
<VL>86-A</VL>
<NO>11</NO>
<PG>2567</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bhogal-2000" NAME="Bhogal 2000" TYPE="OTHER">
<AU>Bhogal SSSK</AU>
<TI>Expectation and the placebo effect: how patients' expectation of receiving an active drug versus a placebo influences subjective and objective outcome measures</TI>
<SO>Senior Honours Thesis, Department of Psychology, The University of Western Ontario, London, Ontario, Canada</SO>
<YR>April 2000</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Blue-Cross-1998" NAME="Blue Cross 1998" TYPE="OTHER">
<AU>Blue Cross Blue Shield Association Technology Evaluation Center</AU>
<TO>Intra-articular hyaluronan injections for treatment of osteoarthritis of the knee</TO>
<SO>TEC Assessment Program</SO>
<YR>1998</YR>
<VL>15</VL>
<NO>17</NO>
<PG>1-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Blue-Cross-2004" NAME="Blue Cross 2004" TYPE="OTHER">
<AU>Blue Cross Blue Shield Technology Evaluation Center</AU>
<TO>Special Report: Intra-articular hyaluronan for osteoarthritis of the knee</TO>
<SO>TEC Assessment Program</SO>
<YR>December 2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brandt-2000" NAME="Brandt 2000" TYPE="JOURNAL_ARTICLE">
<AU>Brandt KD, Smith GN Jr, Simon LS</AU>
<TI>Intraarticular injection of hyaluronan as treatment for knee osteoarthritis. What is the evidence?</TI>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>2000</YR>
<VL>43</VL>
<NO>6</NO>
<PG>1192-203</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brandt-2004" NAME="Brandt 2004" TYPE="JOURNAL_ARTICLE">
<AU>Brandt KD</AU>
<TO>Non-surgical treatment of osteoarthritis: a half century of "advances"</TO>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2004</YR>
<VL>63</VL>
<PG>117-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brown-2004" NAME="Brown 2004" TYPE="JOURNAL_ARTICLE">
<AU>Brown DJ, Wood EV, Hannah HM, Rao VS, Teanby D</AU>
<TO>Prospective comparison of sodium hyaluronate and hylan G-F 20 in a clinical practice: comment on the concise communication by Martens</TO>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>2004</YR>
<VL>50</VL>
<NO>5</NO>
<PG>1697-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brys-2003" MODIFIED="2008-11-09 23:53:41 -0500" MODIFIED_BY="[Empty name]" NAME="Brys 2003" TYPE="JOURNAL_ARTICLE">
<AU>Brys DA</AU>
<TO>Corticosteroid compared with hyaluronic acid injections for the treatment of osteoarthritis of the knee</TO>
<SO>The Journal of Bone and Joint Surgery</SO>
<YR>2003</YR>
<VL>85-A</VL>
<NO>4</NO>
<PG>874-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Burns-2005" NAME="Burns 2005" TYPE="JOURNAL_ARTICLE">
<AU>Burns JW, Kraines JL, Magilavy DB, Murray CW, Richards SM</AU>
<TO>Response to: identification of an immunogenic candidate for the elicitation of severe acute inflammatory reactions (SAIRs) to hylan G-F 20</TO>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2005</YR>
<VL>13</VL>
<NO>12</NO>
<PG>1128-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Charalambous-2003" MODIFIED="2008-11-09 23:53:34 -0500" MODIFIED_BY="[Empty name]" NAME="Charalambous 2003" TYPE="JOURNAL_ARTICLE">
<AU>Charalambous CP</AU>
<TO>Corticosteroid compared with hyaluronic acid injections for the treatment of osteoarthritis of the knee</TO>
<SO>The Journal of Bone and Joint Surgery</SO>
<YR>2003</YR>
<VL>85-A</VL>
<NO>4</NO>
<PG>874</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Choi-1999" NAME="Choi 1999" TYPE="JOURNAL_ARTICLE">
<AU>Choi HK, Modawal A, Ferrer M, Caron JA</AU>
<TO>A meta-analysis on the efficacy of intra-articular viscosupplementation therapy for knee osteoarthritis</TO>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>1999</YR>
<VL>42 Suppl (9)</VL>
<PG>293</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cohen-1977" NAME="Cohen 1977" TYPE="BOOK">
<AU>Cohen J</AU>
<SO>Statistical power analysis for the behavioural sciences</SO>
<YR>1977</YR>
<PB>Academic Press</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Collange-1999" NAME="Collange 1999" TYPE="BOOK_SECTION">
<AU>Collange C, Weyl-Clerc D</AU>
<TO>Que penser des injections intra-articulaires dans le traitement de la gonarthrose</TO>
<SO>L'actualities rhumatologique</SO>
<YR>1999</YR>
<PG>422-34</PG>
<ED>MF Kahn, D Kuntz, O Meyer, Th Bardin, Ph Orcel, CI Guerin</ED>
<PB>Expansion Scientifique Francaise</PB>
<CY>Paris</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Denlinger-1998" NAME="Denlinger 1998" TYPE="BOOK_SECTION">
<AU>Denlinger JL</AU>
<TO>Hyaluronan and its derivatives as viscoelastics in medicine</TO>
<SO>The Chemistry, Biology and Medical Applications of Hyaluronan and its Derivatives</SO>
<YR>1998</YR>
<ED>Laurent TC</ED>
<PB>Portland Press Ltd.</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dickerson-1994" NAME="Dickerson 1994" TYPE="JOURNAL_ARTICLE">
<AU>Dickerson K, Scherer R, Lefevbre C</AU>
<TO>Identifying relevant studies for systematic reviews</TO>
<SO>BMJ</SO>
<YR>1994</YR>
<VL>309</VL>
<PG>1286-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dougados-2000" NAME="Dougados 2000" TYPE="JOURNAL_ARTICLE">
<AU>Dougados M</AU>
<TI>Sodium hyaluronate therapy in osteoarthritis: arguments for a potential beneficial structural effect</TI>
<SO>Seminars in Arthritis and Rheumatism</SO>
<YR>2000</YR>
<VL>30 Suppl (1)</VL>
<PG>19-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dougados-2005" NAME="Dougados 2005" TYPE="JOURNAL_ARTICLE">
<AU>Dougados M</AU>
<TI>Comparing different therapeutic classes for the treatment of osteoarthritis of the knee: data from the OMERACT-OARSI responder criteria analysis</TI>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dubey-2003" NAME="Dubey 2003" TYPE="JOURNAL_ARTICLE">
<AU>Dubey V, Glazier RH</AU>
<TO>Intra-articular hyaluronic acid injections. Are they effective treatment for osteoarthritis of the knee?</TO>
<SO>Canadian Family Physician</SO>
<YR>2003</YR>
<VL>49</VL>
<NO>April</NO>
<PG>435-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Espallargues-2003" NAME="Espallargues 2003" TYPE="JOURNAL_ARTICLE">
<AU>Espallargues M, Pons J.M.V.</AU>
<TI>Efficacy and safety of viscosupplementation with Hylan G-F 20 for the treatment of knee osteoarthritis. A systematic review</TI>
<SO>International Journal of Technology Assessment in Health Care</SO>
<YR>2003</YR>
<VL>19</VL>
<NO>1</NO>
<PG>41-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Felson-2002" NAME="Felson 2002" TYPE="JOURNAL_ARTICLE">
<AU>Felson DT, Anderson JJ</AU>
<TO>Hyaluronate sodium injections for osteoarthritis. Hope, hype, and hard truths</TO>
<SO>Archives of Internal Medicine</SO>
<YR>2002</YR>
<VL>162</VL>
<PG>245-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Felson-2002a" NAME="Felson 2002a" TYPE="JOURNAL_ARTICLE">
<AU>Felson DT, Anerson JJ</AU>
<TO>Hyaluronate sodium injections for osteoarthritis: the truth (In reply)</TO>
<SO>Archives of Internal Medicine</SO>
<YR>2002</YR>
<VL>162</VL>
<PG>2499-500</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Galli-2004" NAME="Galli 2004" TYPE="JOURNAL_ARTICLE">
<AU>Galli M, De Santis V, Tafuro L</AU>
<TO>Reliability of the Ahlback classification of knee osteoarthritis</TO>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2003</YR>
<VL>11</VL>
<PG>580-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ghosh-2002" NAME="Ghosh 2002" TYPE="JOURNAL_ARTICLE">
<AU>Ghosh P, Guidolin D</AU>
<TO>Potential mechanism of action of intra-articular hyaluronan therapy in osteoarthritis: are the effects molecular weight dependent?</TO>
<SO>Seminars in Arthritis and Rheumatism</SO>
<YR>2002</YR>
<VL>32</VL>
<NO>1</NO>
<PG>10-37</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="doi:10.1053/sarh.2002.32549"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Goldsmith-2004" NAME="Goldsmith 2004" TYPE="JOURNAL_ARTICLE">
<AU>Goldsmith CH, Bellamy N, Pericak D, Torrance GW, Raynauld JP, Bell M, Polisson R</AU>
<TO>Predictors of osteoarthritis (OA) improvement in patients treated with hylan G-F 20 for knee OA</TO>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2004</YR>
<VL>12 Suppl (2)</VL>
<PG>77</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gossec-2006" NAME="Gossec 2006" TYPE="JOURNAL_ARTICLE">
<AU>Gossec L, Dougados M</AU>
<TO>Do intra-articular therapies work and who will benefit most?</TO>
<SO>Best Practice &amp; Research Clinical Rheumatology</SO>
<YR>2006</YR>
<VL>20</VL>
<NO>1</NO>
<PG>131-144</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hamburger-2003" NAME="Hamburger 2003" TYPE="JOURNAL_ARTICLE">
<AU>Hamburger MI, Lakhanpal S, Mooar PA, Oster D</AU>
<TO>Intra-articular hyaluronans: a review of product-specific safety profiles</TO>
<SO>Seminars in Arthritis and Rheumatism</SO>
<YR>2003</YR>
<VL>32</VL>
<PG>296-309</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hamburger-2005" NAME="Hamburger 2005" TYPE="JOURNAL_ARTICLE">
<AU>Hamburger MI</AU>
<TO>Letter to the Editor: Response to the article by Raynauld et al.</TO>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2005</YR>
<VL>13</VL>
<NO>11</NO>
<PG>1039-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hamburger-2005a" NAME="Hamburger 2005a" TYPE="JOURNAL_ARTICLE">
<AU>Hamburger M, Settles M, Teutsch J</AU>
<TO>Author's reply to letter by Burns et al</TO>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2005</YR>
<VL>13</VL>
<NO>12</NO>
<PG>1130-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hammesfahr-2003" NAME="Hammesfahr 2003" TYPE="JOURNAL_ARTICLE">
<AU>Hammesfahr JFR, Knopf AB, Stitik T</AU>
<TO>Safety of intra-articular hyaluronates for pain associated with osteoarthritis of the knee</TO>
<SO>The American Journal of Orthopedics</SO>
<YR>2003</YR>
<VL>32</VL>
<NO>6</NO>
<PG>277-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Haraoui-2002" NAME="Haraoui 2002" TYPE="BOOK_SECTION">
<AU>Haraoui B, Raynauld J-P</AU>
<TO>Intra-articular therapy in osteoarthritis</TO>
<SO>Modern Therapeutics in Rheumatic Diseases</SO>
<YR>2002</YR>
<PG>193-200</PG>
<ED>G.C. Tsokos</ED>
<PB>Humana Press, Inc.</PB>
<CY>Totowa, NJ</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Haynes-1994" NAME="Haynes 1994" TYPE="JOURNAL_ARTICLE">
<AU>Haynes RB, Wilczynski N, McKibbon KA, WalkerCJ, Sinclair JC</AU>
<TO>Developing optimal search strategies for detecting clinically sound studies in MEDLINE</TO>
<SO>Journal of the American Medical Informatics Association</SO>
<YR>1994</YR>
<VL>1</VL>
<PG>447-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hedges-1985" NAME="Hedges 1985" TYPE="BOOK">
<AU>Hedges LV, Olkin I</AU>
<SO>Statistical methods for metaanalysis</SO>
<YR>1985</YR>
<PB>Academic Press</PB>
<CY>Orlando, FL</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TO>Measuring inconsistency in meta-analyses</TO>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hochberg-2000" NAME="Hochberg 2000" TYPE="JOURNAL_ARTICLE">
<AU>Hochberg MC</AU>
<TI>Role of intra-articular hyaluronic acid preparations in medical management of osteoarthritis of the knee</TI>
<SO>Seminars in Arthritis and Rheumatism</SO>
<YR>2000</YR>
<VL>30 Suppl (1)</VL>
<PG>2-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hou-2004" MODIFIED="2008-11-09 23:53:20 -0500" MODIFIED_BY="[Empty name]" NAME="Hou 2004" TYPE="JOURNAL_ARTICLE">
<AU>Hou S-M, Wang C-T</AU>
<TO>Therapeutic effects of hyaluronic acid on osteoarthritis of the knee</TO>
<SO>The Journal of Bone and Joint Surgery</SO>
<YR>2004</YR>
<VL>86-A</VL>
<NO>11</NO>
<PG>2567</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hyalgan" NAME="Hyalgan" TYPE="OTHER">
<TI>Hyalgan Premarket Approval Application: Summary of safety and effectiveness data</TI>
<SO>http://www.fda.gov/cdrh/pdf/p950027.pdf</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ikeda-1998" NAME="Ikeda 1998" TYPE="JOURNAL_ARTICLE">
<AU>Ikeda K et al</AU>
<TI>Changes in synovial fluid markers and clinical effect after intra-articular injection of sodium hyaluronate: with particulr reference to the anti-inflammatory effect in terms of prostaglandin E2 concentration</TI>
<SO>Journal of Tokyo Womens' Medical College</SO>
<YR>1998</YR>
<VL>68</VL>
<NO>1/2</NO>
<PG>22-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996" NAME="Jadad 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, McQuay HJ</AU>
<TI>Assessing the quality of reports of randomized clinical trials: is blinding necessary</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1996</YR>
<VL>17</VL>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jones-1993" NAME="Jones 1993" TYPE="JOURNAL_ARTICLE">
<AU>Jones A, Regan M, Ledingham J, Pattrick M, Mantire A, Doherty M</AU>
<TO>Importance of placement of intra-articular steroid injections</TO>
<SO>BMJ</SO>
<YR>1993</YR>
<VL>307</VL>
<PG>1329-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jordan-2003" NAME="Jordan 2003" TYPE="JOURNAL_ARTICLE">
<AU>Jordan KM, Arden NK, Doherty M, Bannwarth B, Bijlsma JWJ, Dieppe P, et al</AU>
<TO>EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT)</TO>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2003</YR>
<VL>62</VL>
<PG>1145-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kaptchuk-2000" NAME="Kaptchuk 2000" TYPE="JOURNAL_ARTICLE">
<AU>Kaptchuk TJ, Goldman P, Stone DA, Stason WB</AU>
<TO>Do medical devices have enhanced placebo effects?</TO>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2000</YR>
<VL>53</VL>
<PG>786-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kelly-2003" NAME="Kelly 2003" TYPE="JOURNAL_ARTICLE">
<AU>Kelly MA, Goldberg VM, Healy WL, Pagnano MW, Hamburger MI</AU>
<TO>Osteoarthritis and beyond: a consensus on the past, present and future of hyaluronans in orthopedics</TO>
<SO>Orthopedics</SO>
<YR>2003</YR>
<VL>26</VL>
<NO>10</NO>
<PG>1064-79</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Khanuja-2003" NAME="Khanuja 2003" TYPE="JOURNAL_ARTICLE">
<AU>Khanuja HS, Hungerford MW, Manjoo A</AU>
<TO>Intraarticular injections for the treatment of osteoarthritis of the knee: basic science, results, and indications</TO>
<SO>Current Opinion in Orthopaedics</SO>
<YR>2003</YR>
<VL>14</VL>
<NO>1</NO>
<PG>62-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kirwan-1997" NAME="Kirwan 1997" TYPE="JOURNAL_ARTICLE">
<AU>Kirwan JR, Rankin E</AU>
<TI>Intra-articular therapy in osteoarthritis</TI>
<SO>Bailliere's Clinical Rheumatology</SO>
<YR>1997</YR>
<VL>11</VL>
<NO>4</NO>
<PG>769-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kirwan-2001" NAME="Kirwan 2001" TYPE="JOURNAL_ARTICLE">
<AU>Kirwan J</AU>
<TI>Is there a place for intra-articular hyaluronate in osteoarthritis of the knee?</TI>
<SO>The Knee</SO>
<YR>2001</YR>
<VL>8</VL>
<NO>2</NO>
<PG>93-101</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lequesne-1996" NAME="Lequesne 1996" TYPE="JOURNAL_ARTICLE">
<AU>Lequesne M</AU>
<TI>Clinical outcomes of intra-articular hyaluronan in the treatment of osteoarthritis of the knee</TI>
<SO>Immunology and Cell Biology</SO>
<YR>1996</YR>
<VL>74</VL>
<PG>A13-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lo-2002" NAME="Lo 2002" TYPE="JOURNAL_ARTICLE">
<AU>Lo GH, LaValley MP, McAlindon TE, Felson DT</AU>
<TO>Is intra-articular (IA) hyaluronic acid (HA) efficacious in treating knee osteoarthritis (OA)?</TO>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>2002</YR>
<VL>47 Suppl (9)</VL>
<PG>576</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lo-2003" NAME="Lo 2003" TYPE="JOURNAL_ARTICLE">
<AU>Lo GH, La Valley M, McAlindon T, Felson DT</AU>
<TO>Intra-articular hyaluronic acid in treatment of knee osteoarthritis. A meta-analysis</TO>
<SO>JAMA</SO>
<VL>290</VL>
<NO>23</NO>
<PG>3115-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lo-2003a" NAME="Lo 2003a" TYPE="JOURNAL_ARTICLE">
<AU>Lo GH, La Valley M, Felson DT</AU>
<TO>Importance of intra-articular placebos in trials evaluating intra-articular therapies</TO>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>2003</YR>
<VL>48</VL>
<NO>12</NO>
<PG>3618</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lund-1988" NAME="Lund 1988" TYPE="JOURNAL_ARTICLE">
<AU>Lund T</AU>
<TO>Some metrical issues with meta-analysis of therapy effects</TO>
<SO>Scandinavian Journal of Psychology</SO>
<YR>1988</YR>
<VL>29</VL>
<PG>1-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lussier-1996" NAME="Lussier 1996" TYPE="JOURNAL_ARTICLE">
<AU>Lussier A, Cividino AA, McFarlane CA, Olszynski WP, Potashner WJ, De Medicis R</AU>
<TI>Viscosupplementation with Hylan for the treatment of osteoarthritis: findings from clinical practice in Canada</TI>
<SO>The Journal of Rheumatology</SO>
<YR>1996</YR>
<VL>23</VL>
<NO>9</NO>
<PG>1579-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Magilavy-2003" NAME="Magilavy 2003" TYPE="JOURNAL_ARTICLE">
<AU>Magilavy D, Polisson R, Parenti D</AU>
<TI>Re: Karlsson et al. Comparison of two hyaluronan drugs and placebo in patients with knee osteoarthritis. A controlled, randomized, double-blind, parallel-design multicentre study</TI>
<SO>Rheumatology</SO>
<YR>2003</YR>
<VL>42</VL>
<NO>10</NO>
<PG>1262</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Maheu-1994" NAME="Maheu 1994" TYPE="BOOK_SECTION">
<AU>Maheu E, Lamotte J, Lequesne M</AU>
<TO>Sel sodiuque de l'acide hyaluronique (hyaluronan) et gonarthrose</TO>
<SO>L'actualite rhumatologique</SO>
<YR>1994</YR>
<PG>324-39</PG>
<ED>S De Seze, A Ryckewaert, MF Kahn, D Kuntz, A Dryll, O Meyer, Th Bardin, CI Guerin</ED>
<PB>Expansion Scientifique Francaise ed.</PB>
<CY>Paris</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Maheu-1995" NAME="Maheu 1995" TYPE="JOURNAL_ARTICLE">
<AU>Maheu E</AU>
<TI>Hyaluronan in knee osteoarthritis: a review of the clinical trials with Hyalgan</TI>
<SO>European Journal of Rheumatology and Inflammation</SO>
<YR>1995</YR>
<VL>15</VL>
<NO>1</NO>
<PG>17-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Maheu-2002" NAME="Maheu 2002" TYPE="JOURNAL_ARTICLE">
<AU>Maheu E, Ayral X, Dougados M</AU>
<TO>A hyaluronan preparation (500-730 KDA) in the treatment of osteoarthritis: a review of clinical trials with hyalgan</TO>
<SO>International Journal of Clinical Practice</SO>
<YR>2002</YR>
<VL>56</VL>
<NO>10</NO>
<PG>804-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Maheu-2003" NAME="Maheu 2003" TYPE="JOURNAL_ARTICLE">
<AU>Maheu E, Bonvarlet</AU>
<TO>Acute pseudo-septic arthritis post hyaluronate (HA) intra-articular (IA) injections. Results of a French survey in rheumatology practice</TO>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2003</YR>
<VL>EULAR, Lisbon, Portugal, June 18-21</VL>
<CY>Lisbon</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Maheu-200_x003f_" NAME="Maheu 200?" TYPE="JOURNAL_ARTICLE">
<AU>Maheu E</AU>
<TI>Hyaluronic acid in the treatment of osteoarthritis of the knee</TI>
<TO>L'acide hyaluronique dans le traitement de la gonarthrose</TO>
<SO>Le journal francais de l'orthopedie [The French Orthopaedic web journal] at www.maitrise-orthop.com</SO>
<YR>2003</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Maneiro-2004" NAME="Maneiro 2004" TYPE="JOURNAL_ARTICLE">
<AU>Maneiro E, de Andres MC, Fernandez-Sueiro JL, Galdo F, Blanco FJ</AU>
<TO>The biological action of hyaluronan on human osteoarthritic articular chondrocytes: the importance of molecular weight</TO>
<SO>Clinical and Experimental Rheumatology</SO>
<YR>2004</YR>
<VL>22</VL>
<PG>307-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marshall-2000" NAME="Marshall 2000" TYPE="JOURNAL_ARTICLE">
<AU>Marshall KW</AU>
<TI>Intra-articular hyaluronan therapy</TI>
<SO>Current Opinion in Rheumatology</SO>
<YR>2000</YR>
<VL>12</VL>
<PG>468-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mazieres-2001" NAME="Mazieres 2001" TYPE="JOURNAL_ARTICLE">
<AU>Mazieres B, Bannwarth B, Dougados M, Lequesne M</AU>
<TO>EULAR recommendations for the management of knee osteoarthritis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials</TO>
<SO>Joint Bone Spine</SO>
<YR>2001</YR>
<VL>68</VL>
<PG>231-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McAuley-2000" NAME="McAuley 2000" TYPE="JOURNAL_ARTICLE">
<AU>McAuley L, Pham B, Tugwell P, Moher D</AU>
<TO>Does the inclusion of grey literature influence estimates of intervention effectiveness reported in meta-analyses?</TO>
<SO>Lancet</SO>
<YR>2000</YR>
<VL>356</VL>
<NO>9237</NO>
<PG>1228-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Middel-2002" NAME="Middel 2002" TYPE="JOURNAL_ARTICLE">
<AU>Middel B, van Sonderen E</AU>
<TO>Statistical significant change versus relevant or important change in (quasi) experimental design: some conceptual and methodological problems in estimating magnitude of intervention-related change in health services research</TO>
<SO>International Journal of Integrated Care</SO>
<YR>2002</YR>
<VL>2</VL>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Modawal-2005" NAME="Modawal 2005" TYPE="JOURNAL_ARTICLE">
<AU>Modawal A, Ferrer M, Choi HK, Castle JA</AU>
<TO>Hyaluronic acid injections relieve knee pain</TO>
<SO>The Journal of Family Practice</SO>
<YR>2005</YR>
<VL>54</VL>
<NO>9</NO>
<PG>758-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-MOHLTC-2005" NAME="MOHLTC 2005" TYPE="OTHER">
<AU>Ontario Ministry of Health and Long-Term Care</AU>
<TI>Intra-articular injection of hylan G-F 20 for osteoarthritis of the knee</TI>
<SO>Government of Ontario, Canada</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moreland-2003" NAME="Moreland 2003" TYPE="JOURNAL_ARTICLE">
<AU>Moreland LW</AU>
<TO>Intra-articular hyaluronan (hyaluronic acid) and hylans for the treatment of osteoarthritis: mechanisms of action</TO>
<SO>Arthritis Research &amp; Therapy</SO>
<YR>2003</YR>
<VL>5</VL>
<NO>2</NO>
<PG>54-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moskowitz-2000" NAME="Moskowitz 2000" TYPE="JOURNAL_ARTICLE">
<AU>Moskowitz RW</AU>
<TO>Hyaluronic acid supplementation</TO>
<SO>Current Review of Rheumatology</SO>
<YR>2000</YR>
<VL>2</VL>
<PG>466-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-MSAC-2003" NAME="MSAC 2003" TYPE="OTHER">
<AU>Medical Services Advisory Committee</AU>
<TI>Intra-articular viscosupplementation for treatment of osteoarthritis of the knee</TI>
<SO>Commonwealth of Australia</SO>
<YR>March 2003</YR>
<VL>MSAC application 1045</VL>
<NO>Assessment Report</NO>
<PG>88 pages</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Namiki-1983" NAME="Namiki 1983" TYPE="JOURNAL_ARTICLE">
<AU>Namiki O, Akiyama F, Hasegawa K, Rikimaru Y, Takahashi S</AU>
<TI>Properties of osteoarthritic synovial fluid and the metabolism of injected sodium hyaluronate</TI>
<SO>The Knee</SO>
<YR>1983</YR>
<VL>9</VL>
<NO>1</NO>
<PG>69-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Norman-1989" NAME="Norman 1989" TYPE="JOURNAL_ARTICLE">
<AU>Norman GR</AU>
<TO>Issues in the use of change scores in randomized trials</TO>
<SO>Journal of Clinical Epidemiology</SO>
<YR>1989</YR>
<VL>42</VL>
<NO>11</NO>
<PG>1097-105</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Orthovisc" NAME="Orthovisc" TYPE="OTHER">
<TI>Orthovisc Premarket Approval Application: Summary of safety and effectiveness data</TI>
<SO>http://www.fda.gov/cdrh/pdf/p030019.pdf</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pagnano-2005" NAME="Pagnano 2005" TYPE="JOURNAL_ARTICLE">
<AU>Pagnano M, Westrich G</AU>
<TI>Successful nonoperative management of chronic osteoarthritis pain of the knee: safety and efficacy of retreatment with intra-articular hyaluronans</TI>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2005</YR>
<VL>13</VL>
<NO>9</NO>
<PG>751-761</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pendleton-2000" NAME="Pendleton 2000" TYPE="JOURNAL_ARTICLE">
<AU>Pendleton A, Arden N, Dougados M, Doherty M, Bannwarth B, Bijlsma JWJ, et alelka K, Serni U, Swoboda B, Verbruggen AA, Weseloh G, Zimmermann-Gorska I</AU>
<TO>EULAR recommendations for the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT)</TO>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2000</YR>
<VL>43</VL>
<PG>1905-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Petitti-1994" NAME="Petitti 1994" TYPE="BOOK">
<AU>Petitti DB</AU>
<SO>Meta-analysis, decision analysis, and cost-effectiveness analysis. Methods for quantitative synthesis in medicine</SO>
<YR>1994</YR>
<VL>24</VL>
<EN>Monographs in epidemiology and biostatistics</EN>
<PB>Oxford University Press, Inc.</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Peyron-1974" NAME="Peyron 1974" TYPE="JOURNAL_ARTICLE">
<AU>Peyron JG, Balazs EA</AU>
<TI>Preliminary clinical assessment of Na-hyaluronate injection into human arthritic joints</TI>
<SO>Pathologie-Biologie (Paris)</SO>
<YR>1974</YR>
<VL>22</VL>
<NO>8</NO>
<PG>731-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Peyron-1993" NAME="Peyron 1993" TYPE="JOURNAL_ARTICLE">
<AU>Peyron JG</AU>
<TI>Intraarticular hyaluronan injections in the treatment of osteoarthritis: state-of-the-art review</TI>
<SO>The Journal of Rheumatology</SO>
<YR>1993</YR>
<VL>20 Suppl (39)</VL>
<PG>10-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pisoni-2004" NAME="Pisoni 2004" TYPE="JOURNAL_ARTICLE">
<AU>Pisoni L, Schito E, De Lucia O, Murgo A, Paresce E</AU>
<TI>Osteoarthritis of the knee and local treatment</TI>
<TO>La gonartrosi ed il trattamento locale</TO>
<SO>Artroscopia</SO>
<YR>2004</YR>
<VL>5</VL>
<NO>3</NO>
<PG>176-188</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Puhl-1997" NAME="Puhl 1997" TYPE="JOURNAL_ARTICLE">
<AU>Puhl W, Scharf P</AU>
<TO>Intra-articular hyaluronan treatment for osteoarthritis</TO>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>1997</YR>
<VL>56</VL>
<NO>7</NO>
<PG>441</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Punzi-2001" NAME="Punzi 2001" TYPE="JOURNAL_ARTICLE">
<AU>Punzi L</AU>
<TI>The complexity of the mechanisms of action of hyaluronan in joint diseases</TI>
<SO>Clinical and Experimental Rheumatology</SO>
<YR>2001</YR>
<VL>19</VL>
<PG>242-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Puttick-1995" NAME="Puttick 1995" TYPE="JOURNAL_ARTICLE">
<AU>Puttick MPE, Wade JP, Chalmers A, Connell DG, Rangno KK</AU>
<TI>Acute local reactions after intraarticular hylan for osteoarthritis of the knee</TI>
<SO>The Journal of Rheumatology</SO>
<YR>1995</YR>
<VL>22</VL>
<NO>7</NO>
<PG>1311-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Raynauld-2003" NAME="Raynauld 2003" TYPE="CONFERENCE_PROC">
<AU>Raynauld JP, Olszynski WP, Goldsmith CH, Torrance GW, Bellamy N, Polission R, Pericak D, Walker V</AU>
<TO>Effectiveness and safety of hylan G-F 20 compared to steroid injections in patients with knee osteoarthritis</TO>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>2003</YR>
<VL>48 Suppl (9)</VL>
<PG>484</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Raynauld-2005" NAME="Raynauld 2005" TYPE="JOURNAL_ARTICLE">
<AU>Raynauld JP, Goldsmith CH, Bellamy N, Torrance GW, Polisson R, Belovich D, Pericak D, Tugwell P</AU>
<TI>Effectiveness and safety of repeat courses of hylan G-F 20 in patients with knee osteoarthritis</TI>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2005</YR>
<VL>13</VL>
<NO>2</NO>
<PG>111-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Raynauld-2005a" NAME="Raynauld 2005a" TYPE="JOURNAL_ARTICLE">
<AU>Raynauld J-P, Goldsmith CH, Torrance GW for the Steering Committee and Clinical Investigators of the Canadian Knee OA Study Group</AU>
<TO>Letter to the Editor: Reply to the letter by Max I. Hamburger</TO>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2005</YR>
<VL>13</VL>
<NO>12</NO>
<PG>1037-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman DG</AU>
<TO>Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TO>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<NO>5</NO>
<PG>408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schumacher-2003" NAME="Schumacher 2003" TYPE="JOURNAL_ARTICLE">
<AU>Schumacher Jr HR</AU>
<TO>Aspiration and injection therapies for joints</TO>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>2003</YR>
<VL>49</VL>
<NO>3</NO>
<PG>413-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shinmei-1983" NAME="Shinmei 1983" TYPE="JOURNAL_ARTICLE">
<AU>Shinmei M, Inaoka M, Ukon Y, Shimomura Y, Tsuru S</AU>
<TI>Intra-articular injection therapy of high molecular weight sodium hyaluronate on osteoarthritis of the knee - clinical effects and change in synovial fluid properties</TI>
<SO>The Knee</SO>
<YR>1983</YR>
<VL>9</VL>
<NO>1</NO>
<PG>108-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sokoloff-2001" NAME="Sokoloff 2001" TYPE="JOURNAL_ARTICLE">
<AU>Sokoloff L.</AU>
<TI>Some highlights in the emergence of modern concepts of osteoarthritis</TI>
<SO>Seminars in Arthritis and Rheumatism</SO>
<YR>2001</YR>
<VL>31</VL>
<NO>2</NO>
<PG>71-107</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stucki-1996" NAME="Stucki 1996" TYPE="JOURNAL_ARTICLE">
<AU>Stucki G, Daltroy L, Katz JN, Johannesson M, Liang MH</AU>
<TO>Interpretation of change scores in ordinal clinical scales and health status measures: the whole may not equal the sum of the parts</TO>
<SO>Journal of Clinical Epidemiology</SO>
<YR>1996</YR>
<VL>49</VL>
<NO>7</NO>
<PG>711-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Supartz" NAME="Supartz" TYPE="OTHER">
<TI>Supartz Premarket Approval Application: Summary of safety and effectiveness data</TI>
<SO>http://www.fda.gov/cdrh/pdf/p980044.pdf</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sutton-1997" NAME="Sutton 1997" TYPE="JOURNAL_ARTICLE">
<AU>Sutton AJ, Muir KR, Jones AC</AU>
<TO>Two knees or one person: data analysis strategies for paired joints or organs</TO>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>1997</YR>
<VL>56</VL>
<PG>401-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Synvisc-Hylan-G_x002d_F-20" NAME="Synvisc Hylan G-F 20" TYPE="OTHER">
<TI>Synvisc Hylan G-F 20 Premarket Approval Application: Summary of safety and effectiveness data</TI>
<SO>http://www.fda.gov/cdrh/pdf/p940015.pdf</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tehranzadeh-2005" NAME="Tehranzadeh 2005" TYPE="JOURNAL_ARTICLE">
<AU>Tehranzadeh J, Booya F, Root J</AU>
<TI>Cartilage metabolism in osteoarthritis and the influence of viscosupplementation and steroid: a review</TI>
<SO>Acta Radiologica</SO>
<YR>2005</YR>
<VL>46</VL>
<NO>3</NO>
<PG>288-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Terrin-2005" NAME="Terrin 2005" TYPE="JOURNAL_ARTICLE">
<AU>Terrin N, Schmid CH, Lau J</AU>
<TO>In an empirical evaluation of the funnel plot, researchers could not visually identify publication bias</TO>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2005</YR>
<VL>58</VL>
<PG>894-01</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Towheed-1997" NAME="Towheed 1997" TYPE="JOURNAL_ARTICLE">
<AU>Towheed TE, Hochberg MC</AU>
<TI>A systematic review of randomized controlled trials of pharmacological therapy in osteoarthritis of the knee, with an emphasis on trial methodology</TI>
<SO>Seminars in Arthritis and Rheumatism</SO>
<YR>1997</YR>
<VL>25</VL>
<NO>5</NO>
<PG>755-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tubach-2005" NAME="Tubach 2005" TYPE="JOURNAL_ARTICLE">
<AU>Tubach F, Ravaud P, Baron G, Falissard B, Logeart I, Bellamy N, Bombardier C, Felson DT, Hochberg M, van der Heijde D, Dougados M</AU>
<TO>Evaluation of clinically relevant changes in patient reported outcomes in knee and hip osteoarthritis: the Minimal Clinically Important Improvement</TO>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2005</YR>
<VL>64</VL>
<NO>1</NO>
<PG>29-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Uebelhart-1999" NAME="Uebelhart 1999" TYPE="JOURNAL_ARTICLE">
<AU>Uebelhart D, WilliamsJM</AU>
<TO>Effects of hyaluronic acid on cartilage degradation</TO>
<SO>Current Opinion in Rheumatology</SO>
<YR>1999</YR>
<VL>11</VL>
<PG>427-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ueno-1995" NAME="Ueno 1995" TYPE="JOURNAL_ARTICLE">
<AU>Ueno Y, Kuramoto K, Konno N, Koizumi T, Hoshiba T, Kamohara S, Koono M, Nunomura T, Futami M</AU>
<TI>Investigations on result of use after launch of ARTZ and ARTZ Dispo - evaluation on the efficacy, safety and utility in the medications for osteoarthritis of the knee and periarthritis of the shoulder</TI>
<SO>Japanese Pharmacology &amp; Therapeutics</SO>
<YR>1995</YR>
<VL>23</VL>
<NO>8</NO>
<PG>2151-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vickers-2001" NAME="Vickers 2001" TYPE="JOURNAL_ARTICLE">
<AU>Vickers AJ, Altman DG</AU>
<TO>Analysing controlled trials with baseline and follow up measurements</TO>
<SO>BMJ</SO>
<YR>2001</YR>
<VL>323</VL>
<PG>1123-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Waddell-2003" NAME="Waddell 2003" TYPE="JOURNAL_ARTICLE">
<AU>Waddell DD</AU>
<TO>The tolerability of viscosupplementation: low incidence and clinical management of local adverse events</TO>
<SO>Current Medical Research and Opinion</SO>
<YR>2003</YR>
<VL>19</VL>
<NO>7</NO>
<PG>575-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Walker_x002d_Bone-2000" NAME="Walker-Bone 2000" TYPE="JOURNAL_ARTICLE">
<AU>Walker-Bone K, Javaid K, Arden N, Cooper C</AU>
<TI>Medical management of osteoarthritis</TI>
<SO>BMJ</SO>
<YR>2000</YR>
<VL>321</VL>
<PG>936-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wang-2004" NAME="Wang 2004" TYPE="JOURNAL_ARTICLE">
<AU>Wang C-T, Lin J, Chang C-J, Lin Y-T, Hou S-M</AU>
<TO>Therapeutic effects of hyaluronic acid on osteoarthritis of the knee. A meta-analysis of randomized controlled trials</TO>
<SO>The Journal of Bone and Joint Surgery</SO>
<YR>2004</YR>
<VL>86-A</VL>
<NO>3</NO>
<PG>538-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Watterson-2000" NAME="Watterson 2000" TYPE="JOURNAL_ARTICLE">
<AU>Watterson JR, Esdaile JM</AU>
<TI>Viscosupplementation: Therapeutic mechanisms and clinical potential in osteoarthritis of the knee</TI>
<SO>Journal of the American Academy of Orthopedic Surgeons</SO>
<YR>2000</YR>
<VL>8</VL>
<NO>5</NO>
<PG>277-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Weiss-1999" NAME="Weiss 1999" TYPE="JOURNAL_ARTICLE">
<AU>Weiss C, Band P</AU>
<TO>Basic principles underlying the development of viscosupplementation for the treatment of osteoarthritis</TO>
<SO>Journal of Clinical Rheumatology</SO>
<YR>1999</YR>
<VL>5 Suppl</VL>
<PG>2-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wen-2000" NAME="Wen 2000" TYPE="JOURNAL_ARTICLE">
<AU>Wen DY</AU>
<TO>Intra-articular hyaluronic acid injections for knee osteoarthritis</TO>
<SO>American Family Physician</SO>
<YR>2000</YR>
<VL>62</VL>
<NO>3</NO>
<PG>565-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WInd-2004" NAME="WInd 2004" TYPE="JOURNAL_ARTICLE">
<AU>Wind Jr. WM, Smolinski RJ</AU>
<TO>Reliability of common knee injection sites with low-volume injections</TO>
<SO>The Journal of Arthroplasty</SO>
<YR>2004</YR>
<VL>19</VL>
<NO>7</NO>
<PG>858-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zhang-1996" NAME="Zhang 1996" TYPE="JOURNAL_ARTICLE">
<AU>Zhang Y, Glynn RJ, Felson DT</AU>
<TO>Musculoskeletal disease research: should we analyze the joint or the person?</TO>
<SO>The Journal of Rheumatology</SO>
<YR>1996</YR>
<VL>23</VL>
<NO>7</NO>
<PG>1130-4</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES>
<REFERENCE ID="REF-Bellamy-2005c" NAME="Bellamy 2005c" TYPE="JOURNAL_ARTICLE">
<AU>Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells G</AU>
<TO>Viscosupplementation for the treatment of osteoarthritis of the knee</TO>
<SO>The Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>2</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="CD005321"/>
<IDENTIFIER TYPE="OTHER" VALUE="DOI:10.1002/14651858.CD005321"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES>
<REFERENCE ID="REF-Allhoff-1998" NAME="Allhoff 1998" TYPE="JOURNAL_ARTICLE">
<AU>Allhoff P, Graf von der Schulenberg J-M</AU>
<TO>Zur kostenwirksamkeit einer konservativen Gonarthrose-Therapie</TO>
<SO>Zeitschrift Orthopadische</SO>
<YR>1998</YR>
<VL>136</VL>
<PG>288-92</PG>
<IDENTIFIERS/>
</REFERENCE>
</PENDING_REFERENCES>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Adams-1995">
<CHAR_METHODS>
<P>Randomised<BR/>Controlled<BR/>Trial<BR/>2/3-arms blinded<BR/>Hylan G-F 20 <BR/>group not blinded<BR/>Blinded assessor<BR/>Screen blinded patient<BR/>Parallel-group<BR/>Multicentre<BR/>No washout<BR/>Efficacy analysis: Per protocol: n=93<BR/>Safety analysis:<BR/>ITT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country:<BR/>Canada<BR/>Mean age:61<BR/>% Female:65<BR/>Mean disease duration:6 y<BR/>Disease duration<BR/>statistically significantly<BR/>longer for NSAID only group<BR/>Duration:12 wk<BR/>Telephone follow-up at 26 weeks<BR/>Number <BR/>randomised:102<BR/>(NSAID 34, HA 31, NSAID+HA 37)<BR/>Inclusion:<BR/>18-75 y<BR/>chronic, idiopathic knee OA on radiographic examination<BR/>Kellgren and Lawrence Grade 1 to 3 in no more than 2 compartments and not 3 in patellofemoral<BR/>4 of 6: ESR&lt;30mm/h, RF&lt;1:160,<BR/>morning stiffness&lt;=30 min, crepitus on active motion, tenderness of bony margins, MD absence of rheumatoid disease<BR/>tolerant of NSAID for at least 30 days<BR/>using joint actively on daily basis<BR/>score &gt;50/100 on VAS for pain on motion with weight bearing<BR/>Exclusion:<BR/>serious systemic disease, depression or neuroses<BR/>acute synovitis <BR/>excessive effusion<BR/>clinically obese<BR/>varus/valgus of &gt;15<BR/>pregnant or not using effective contraception<BR/>chronic daily steroid therapy<BR/>surgery or joint injection within previous 3 mths<BR/>Baseline values:<BR/>pain on motion<BR/>NSAID: 63<BR/>Hylan G-F 20: 61<BR/>NSAID+Hylan G-F 20: 60</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Usual<BR/>NSAID-only + 3 weekly arthrocentesis<BR/>(NSAID-only group)<BR/>Hylan G-F 20 <BR/>(2 ml) 3 weekly injections + arthrocentesis<BR/>(Hylan G-F only group),<BR/>Usual NSAID+ Hylan G-F20<BR/> (2 ml) 3 weekly injections + arthrocentesis<BR/>(Hylan G-F 20 +<BR/>NSAID group)<BR/>Concurrent therapy:<BR/>acetaminophen usage for analgesia documented in weekly diaries (pill counts).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pain on motion with weight bearing (100 mm VAS)-----------------<BR/>Pain at rest, night, restriction of activity, pt's overall assessment of arthritic pain, pain during 50 foot walk, medial and lateral joint tenderness, evaluator's overall assessment of treatment : 100 mm VAS;<BR/>level of activity for each of standing, sitting, walking, climbing stairs (1=never able to perform,2=occa-<BR/>sionally able to perform,3=fre-<BR/>quently able to <BR/>perform); pt. pain severity (1=none,<BR/>2=only on starting activity after rest,3=during day when active,4=during day at rest,5=all day and waking pt at night); support used; level of activity for running; 50 foot walk time, evaluator scored effusion, medial and lateral joint tenderness, pain while walking, overall assessment, 50 foot walk time on 100 mm VAS<BR/>Assessments:<BR/>Wk 0,<BR/>1(baseline),<BR/>2,3,7,12,26</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad's:3/5<BR/>R-2,B-0,W-1<BR/>13 pts had bilateral OA, <BR/>both treated but only most painful evaluated for efficacy while both evaluated for safety.<BR/>Arthrocentesis with removal of effusion if present before treatment.<BR/>15% subjects presented wtih an effusion.<BR/>Incomplete blinding of hylan G-F 20 only group with instruction to discontinue NSAID therapy may have introduced bias.<BR/>Work supported by Biomatrix, Inc.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Altman-1998">
<CHAR_METHODS>
<P>Randomised<BR/>Controlled<BR/>Trial<BR/>Double-blind<BR/>Masked observer<BR/>Parallel-group<BR/>Multicentre (n=15)<BR/>Double-dummy<BR/>Stratified by pain severity<BR/>Placebo and<BR/>naproxen controlled<BR/>2 week washout<BR/>Both per protocol n=333 (HA 105, PL 115,<BR/>naproxen 113) and post-hoc ITT analyses</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country:<BR/>United States<BR/>Mean age:64<BR/>% Female:58<BR/>Mean disease duration:NR<BR/>Duration:26 wk<BR/>Number randomised:495<BR/>(HA 164, PL 168, naproxen 163)<BR/>Inclusion:<BR/>&gt;= 40 y<BR/>knee OA (ACR criteria)<BR/>knee pain &gt;= 1 y<BR/>knee pain &gt;= 20/100 mm VAS on 50 foot walk <BR/>pain &gt;= 20 mm on &gt;= 1 WOMAC pain items<BR/>moderate or marked pain on 6 point categorical scale<BR/>xray &gt;= 1 osteophyte and Kellgren and Lawrence Grade 2 to 3<BR/>no prior IA HA within 1 y<BR/>no other IA injection within 3 mth<BR/>Exclusion:<BR/>NR<BR/>Baseline values:<BR/>50 foot walk pain HA: 54<BR/>PL: 55<BR/>Naproxen: 54</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Hyalgan 2 ml (20 mg) 5 weekly injections in <BR/>saline vehicle<BR/>+lidocaine and SF aspiration<BR/>+oral placebo bid<BR/>Placebo=lidocaine + SF aspiration<BR/>+ 2 ml saline 5 weekly injections<BR/>+oral placebo bid<BR/>naproxen 500 mg bid + lidocaine ( 5 weekly sham injection) + SF aspirated only if effusion <BR/>Concurrent therapy:<BR/>acetaminophen 2000 mg daily per-<BR/>mitted, aspirin &lt;=<BR/>650 mg permitted</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pain on 50 foot walk on 10 cm VAS immediately after walk-----------------<BR/>Pt. and observer global assess-<BR/>ments of knee pain six point categorical scale<BR/>(none,slight,mild,<BR/>moderate, <BR/>marked)<BR/>50 foot walk time<BR/>WOMAC VAS<BR/>heel to buttock distance (cm)<BR/>knee range of motion (degrees)<BR/>by goniometry<BR/>midpatellar knee circumference<BR/>synovial effusion (presence/absence)<BR/>acetaminophen tablet count<BR/>overall evaluation of treatment by pt. and observer</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad's:4/5<BR/>R-1,B-2,W-1<BR/>Worse knee selected for study if bilateral.<BR/>Sponsored by Fidia Pharma-<BR/>ceutical Corporation.<BR/>R. Fiorentini (Fidia) provided guidance. F. Dosey &amp; F.<BR/>Patarnello (Fidia) provided statistical support. D. Westcott (Fidia) provided secretarial <BR/>assistance.<BR/>Comparison of the decrease from baseline from the HA versus PL revealed a difference of only 1.5 mm, which was not statistically significant, therefore because statistical significance for this ITT analysis was not achieved, the data for all 2o effectiveness variables was analysed only for completers (333/495).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Altman-2004">
<CHAR_METHODS>
<P>Randomised<BR/>Controlled<BR/>Trial <BR/>Double blind<BR/>Multicentre (n=18)<BR/>1 wk washout NSAID</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: <BR/>Canada (6 sites),<BR/>Sweden (5 sites),<BR/>United States (7 sites)<BR/>Mean age: 63.1<BR/>% Female: 55<BR/>Mean disease<BR/>duration: 5.75 y<BR/>Duration: 26 wk<BR/>Number randomised: 347<BR/>(HA 173, PL 174)<BR/>Inclusion:<BR/>OA of the knee as defined by the ACR criteria that was refractory to non-pharmacologic therapies,<BR/>a WOMAC pain subscale score greater than or equal to 7 in one knee and no greater than 15 in either knee (range 0 to 20 Likert scale),<BR/>significant knee pain in the signal knee for the majority of the preceding 3 mth,<BR/>pts had to be normally active and able to walk 50 m unaided<BR/>Exclusion:<BR/>Isolated patello-<BR/>femoral OA, use of systemic steroids, glucosamine or chondroitin within the past 3 mth,<BR/>intra-articular injection into the knee of corticosteroids in the past 3 mth or intra-articular HA within the last 9 mth,<BR/>treatment with oral or topical NSAIDs during the previous wk,<BR/>use of topical non-NSAIDs within the previous 3 days,<BR/>arthroscopy or other surgical procedure within the last 12 mth and anticoagulant treatment (except acetylsalicyclic acid less than or equal to 325 mg per day),<BR/>presented with a systemic active inflammatory condition or infection,<BR/>septic knee arthritis within the previous 3 month,<BR/>significant venous or lymphatic stasis of the legs, active skin disease or infection at the injectione site, or any other medical condition rendering the pt unsuitble for inclusion according to the investigator, pregnant or breast-feeding women and those of childbearing potential not practicicing adequate contraception<BR/>Baseline values:<BR/>WOMAC pain:<BR/>HA: 9.90, PL 10.42<BR/>WOMAC stiffness<BR/>HA: 3.91, PL 4.30<BR/>WOMAC function<BR/>HA: 30.70<BR/>PL: 32.16<BR/>Pt global<BR/>HA: 3.23<BR/>PL: 3.17<BR/>SF-36 physical component summary<BR/>HA: 33.54,<BR/>PL: 32.91<BR/>SF-36 mental component summary<BR/>HA: 55.55,<BR/>PL: 55.92</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>NASHA (non-animal stabilized hyaluronic acid) Durolane, a single 3 ml injection containing HA 60 mg in buffered sodium chloride 0.9% (pH 7), <BR/>Placebo: saline, identifical buffered sodium chloride vehicle <BR/>Both NASHA and saline supplied in identical 3 ml syringes; an 18-22 G needle<BR/>Concurrent therapy: acetaminophen (paracetamol maximum daily dose 4 g) was permitted as rescue medication except during the 48 h period prior to each study visit</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Responder (positive response to treatment) was defined as a reduction in the WOMAC pain score of at least 40% with an absolute improvement of at least 5 points compared with baseline for the study knee at the final visit------------<BR/>WOMAC stiffness, WOMC physical function score,<BR/>pt assessment of global disease status ona 5-point scale,<BR/>SF-36</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad's: 5/5<BR/>R-2, B-2, W-1<BR/>This study was supported by Q-Med AB, Uppsala, Sweden.<BR/>Formal statistical comparison of groups at baseline not completed, but authors noted there was a trend towards higher WOMAC pain, stiffness and function scores in PL group and also more females than males in the PL group, and also higher incidence of joint effusion in PL group.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Ardic-2001">
<CHAR_METHODS>
<P>See<BR/>Cubukcu 2004</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Atamaz-2004">
<CHAR_METHODS>
<P>See<BR/>Atamaz 2005</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Atamaz-2005">
<CHAR_METHODS>
<P>Controlled<BR/>Trial<BR/>Single blind<BR/>Single centre<BR/>1 wk washout<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country:<BR/>Turkey<BR/>Mean age: 60.5<BR/>% Female: 81.7<BR/>Mean disease duration: NR<BR/>Number enrolled: 85 of whom 3 did not meet inclusion criteria leaving number randomised: 82<BR/>(Group 1 - 40;<BR/>Group 2 - 42)<BR/>Inclusion: <BR/>age 40 to 80 y,<BR/>clinically (criteria of the ACR) and radiological (grade 2 or 3 on Kellgen-Lawrence) OA of the knee for at least 6 months duration<BR/>Exclusion:<BR/>had received intra-articular injection in the joint and/or attended to physiotherapy on the affected knee within 6 months prior to study, history of allergy or hypersensitive to drugs or eggs, ascertained or suspected pregnancy or lactating, known or suspected joint infection or a specific condition (neoplasm, diabetes mellitus, paresis, osteonecrosis, recent trauma) or poor general health status that would interfere with the functional assessments during the study<BR/>Baseline values:<BR/>WOMAC pain<BR/>OR: 13.4<BR/>SY: 12.4<BR/>PT: 14.2<BR/>Spontaneous pain (VAS)<BR/>OR: 70.3<BR/>SY: 85.0<BR/>PT: 93.5<BR/>SF-36 pain<BR/>OR: 36.4<BR/>SY: 25.6<BR/>PT: 29.6<BR/>WOMAC function<BR/>OR: 41.5<BR/>SY: 58.3<BR/>PT: 49.9<BR/>SF-36 physical function<BR/>OR: 44.5<BR/>SY: 35.5<BR/>PT: 31.7<BR/>15 meter walking time<BR/>OR: 24.4<BR/>SY: 22.8<BR/>PT: 22.5<BR/>Range of motion<BR/>OR: 118.6<BR/>SY: 123.0<BR/>PT: 121.3<BR/>Stiffness (minutes)<BR/>OR: 9.6<BR/>SY: 6.5<BR/>PT: 10.5<BR/>Peripheral measurement of knee (centimetre)<BR/>OR: 42.6<BR/>SY: 41.0<BR/>PT: 41.2<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group I: (hyaluronan or hylan G-F 20):<BR/>HA intraarticular injection (Orthovisc 15 mg/2 ml) or hylan G-F 20 (Synvisc 16 mg/2 ml) 3 weekly injections at day 0, 7, 14 and then on 6th month for a total of 4 injections; if effusion present joint was aspirated; all injections given by same physicians using aseptic procedures<BR/>Group II: Physical therapy five times a week at day 3 weeks with a series of infrared, short-wave diathermy pulsed patterns and interferential therapy; each of which were continued approximately 20 seconds with a total one hour<BR/>Concurrent therapy:<BR/>Paracetamol (to a maxium of 2 g daily) as considered appropriate by the physician</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Range of motion (flexion with a goniometer), time to walk a distance of 15 m (seconds), amount of soft tissue swelling and swelling and synovial effusion (measured by a meter on volar patellar area and noted if patellar click sign was present b bimanual examination), spontaneous day pain (100 mm VAS), night pain, pain at rest, pain on movement, pain on touch assessed by a 4-point scoring system where 0= no pain, 1= slight pain, 2=<BR/>moderate pain, 3=strong pain,<BR/>WOMAC OA Index, SF-36</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad's: 2/5<BR/>R-1, B-0, W-1<BR/>No industry funding; supported by University.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Auerbach-2002">
<CHAR_METHODS>
<P>Randomised<BR/>Controlled<BR/>Trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country:<BR/>Germany<BR/>Mean age: 47<BR/>% Female: 51<BR/>Disease duration: NR<BR/>Duration: 1 y<BR/>Number randomised: 111<BR/>(HA 56, O2 53)<BR/>Inclusion: NR<BR/>Exclusion: NR<BR/>Baseline values:<BR/>Rest pain:<BR/>GF: 29.03<BR/>O2: 28.89<BR/>Movement pain:<BR/>GF: 58.57<BR/>O2: 47.40<BR/>WOMAC Pain<BR/>GF: 8.2<BR/>O2: 6.8<BR/>WOMAC Function<BR/>GF: 22.5<BR/>O2: 20.6<BR/>WOMAC Stiffness:<BR/>GF: 2.7<BR/>O2: 2.7</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Hylan G-F 20 3 weekly injections + exercise programme,<BR/>IA gaseous oxygen + exercise programme</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pain at rest and under strain (100 mm VAS),<BR/>WOMAC OA Index,<BR/>Lysholm score,<BR/>Tegner Activity Index</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad's:2/5<BR/>R-1,B-0,W-1</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Auerbach-2002a">
<CHAR_METHODS>
<P>See Auerbach 2002.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Bayramoglu-2003">
<CHAR_METHODS>
<P>Randomised<BR/>Controlled<BR/>Trial (Pilot study)<BR/>Parallel-group<BR/>Blinded technician (muscle strength)<BR/>Single centre<BR/>Per protocol n=37 (OR 16, GF 12, PT 9)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country:<BR/>Turkey<BR/>Mean age: 62<BR/>% Female: 95<BR/>Mean disease duration: 5.8 y<BR/>Duration: 3 mth<BR/>Number randomised: 46<BR/>(OR 16, GF 15,<BR/>PT 15)<BR/>Inclusion:<BR/>presence of definite osteo-<BR/>phytes in medial and/or lateral tibiofemoral compartment,<BR/>pain and/or difficulty in activities of daily living due to knee OA<BR/>Exclusion:<BR/>ia corticosteroid injection into either knee within 3 mth prior to study,<BR/>uncomplicated knee surgery within 6 mth of study,<BR/>complicated knee surgery within previous y,<BR/>bilateral or unilateral TKA,<BR/>history of avascular necrosis, RA or any other systemic inflam-<BR/>matory arthropathy,<BR/>periarticular fracture,<BR/>Paget's disease,<BR/>villonodular synovitis, joint infection, ochronosis, neuropathic arthropathy, acromegaly, hemochroma-<BR/>tosis, gout or recurrent pseudogout and osteopetrosis<BR/>Baseline values:<BR/>Lequesne<BR/>OR: 12.4<BR/>GF: 12.8<BR/>PT: 11.6</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Orthovisc once per wk for 3 wk plus 3 wk physical therapy programme,<BR/>Hylan G-F 20 once per wk for 3 wk plus 3 wk PT,<BR/>PT alone (deep tissue heating with short-wave diathermy, TENS and exercises.<BR/>All groups were to continue resistive exercises at home.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Lequesne Index<BR/>Range of motion<BR/>static knee stability in frontal and sagittal planes, existing deformities assessed,<BR/>x-ray Kellgren and Lawrence grading,<BR/>flexor and extensor muscle strength by computerised isokinetic dynamometer</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad's:2/5<BR/>R-1,B-0,W-1<BR/>From publication, blinded technician only assessed muscle strength outcome.<BR/>Bilateral OA in 12 OR, 8 GF, 9 PT<BR/>and injections performed "accordingly".</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Bragantini-1987">
<CHAR_METHODS>
<P>Randomised<BR/>Controlled<BR/>Trial<BR/>Single-blind<BR/>Parallel-group<BR/>Single centre<BR/>3 mth washout of IA treatments<BR/>Per protocol<BR/>analysis, n=52</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country:<BR/>Italy<BR/>Mean age:57<BR/>% Female:75<BR/>Mean disease<BR/>duration:44% <BR/>1-5 y<BR/>Duration:60 days<BR/>Number randomised:55<BR/>[57 joints:HA40 20, HA20 19, PL 18]<BR/>Inclusion:<BR/>knee OA on basis of clinical &amp; radiological <BR/>(Kellgren Grade 2 to 4)<BR/>findings<BR/>Exclusion:<BR/>NR</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Hyalgan 40 mg<BR/>3 weekly injections<BR/>Hyalgan 20 mg<BR/>3 weekly injections<BR/>Placebo = saline 2 ml 3 weekly injections<BR/>Concurrent therapy:<BR/>Not reported</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Spontaneous pain on 10 cm VAS, walking and under load pain on 1-5 scale<BR/>(1=none, 5=severe), pt. and MD global assessment on 1-5 scale (1=very poor, 5=very good)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad's:2/5<BR/>R-1,B-0,W-1<BR/>5 pt had bilateral OA - knees treated at different times.<BR/>A. Perbellini (Fidia S.p.A.)<BR/>C. Baggio and E. Palin provided statistical analysis. A. Babolin provided secretarial assistance.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Brandt-2001">
<CHAR_METHODS>
<P>Randomised<BR/>Controlled<BR/>Trial<BR/>Parallel-group<BR/>Double blind<BR/>Masked observer<BR/>Adverse events monitor<BR/>Placebo-controlled<BR/>Multicentre (n=10)<BR/>2 wk washout<BR/>Per protocol analysis, n=181<BR/>Post-hoc retrospective subgroup effectiveness population, n=135 (OR 66, PL 69)<BR/>ITT (safety)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country:<BR/>United States<BR/>Mean age: 66<BR/>% Female: 63<BR/>Mean disease duration: NR<BR/>Duration: 27 wk<BR/>Number randomised: 226<BR/>(OR 114, PL 112)<BR/>Inclusion:<BR/>idiopathic knee OA<BR/>Kellgren and Lawrence Grade 2 or 3<BR/>significant pain (WOMAC pain &gt;= 13/20) in index knee<BR/>WOMAC pain &lt;13/20 in contra-<BR/>lateral knee<BR/>able to walk 50 ft unassisted<BR/>discontinue anal-<BR/>gesics (2 wk) and NSAIDS for 5 half-lives<BR/>not pregnant or planning a pregnancy<BR/>Exclusion:<BR/>contralateral knee WOMAC pain score &gt;= 13/20<BR/>contralateral knee Kellgren and Lawrence &lt; Grade 4 in either knee<BR/>initiation of quads exercise within 4 mths<BR/>oral or IM steroid use within 2 mth<BR/>IA injection of HA within 21 y<BR/>allergy to lidocaine<BR/>clinically signifi-<BR/>cant comorbidity (renal/hepatic) or abnormal lab tests<BR/>treatment with anticoagulants, immunosuppressives or muscle<BR/>relaxants<BR/>inability to tolerate aceta-<BR/>minophen<BR/>Baseline values:<BR/>WOMAC pain<BR/>OR:16.4, PL:16.3<BR/>WOMAC stiffness<BR/>OR: 7.0, PL: 6.8<BR/>WOMAC function<BR/>OR: 54.8,PL:54.5</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Orthovisc 15 mg/ml<BR/>2 ml once per week<BR/>3 weekly injections<BR/>plus 1% lidocaine HCI 3-5 ml<BR/>Placebo: Saline 2 ml 3 weekly injections<BR/>plus 1% lidocaine HCI 3-5 ml<BR/>Concurrent therapy:<BR/>acetaminophen max<BR/>of 4 g/day; however not 24 hr before visit</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>WOMAC pain (5-25)<BR/>pain on standing<BR/>pt and investigator global assessment<BR/>WOMAC stiffness (2-10) and function (17-85)<BR/>pain after a 50 foot walk (1=none,2=mild,3=moderate,4=severe,5=extreme)<BR/>time to walk 50'<BR/>vital signs, labs, MedDRA adverse events<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad's: 4/5<BR/>R-1,B-2,W-1<BR/>Treated index knee exclusively<BR/>Bilateral OA in 89 OR and 99 PL pts.<BR/>Effectiveness population: completed minimum of 15 wks, no major protocol violations, WOMAC pain score for contra-<BR/>lateral knee &lt;12<BR/>Severity of contra lateral knee pain confounded out-<BR/>come measure-<BR/>ment in the index knee.<BR/>Supported in part by a grant from Anika Thera-<BR/>peutics, Inc. Data management and statistical analyses by Boston Bio-<BR/>statistics, Inc.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Brown-2003">
<CHAR_METHODS>
<P>Randomised<BR/>Controlled<BR/>Trial<BR/>Parallel-group<BR/>Unblinded</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country:<BR/>England<BR/>Mean age: NR<BR/>% Female: NR<BR/>Mean disease duration: NR<BR/>Duration: 6 wk<BR/>(Planned 6 mth)<BR/>Number randomised: 54<BR/>(HA 25, GF 29)<BR/>Planned: 100<BR/>(HA 50, GF 50)<BR/>Inclusion:<BR/>knee OA<BR/>Exclusion: NR<BR/>Baseline values:<BR/>NR</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Hyalgan <BR/>5 weekly injections<BR/>Hylan G-F 20<BR/>3 weekly injections</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>WOMAC OA Index</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad's:1/5<BR/>R-1,B-0 ,W-0<BR/>Trial discontinued due to safety concerns with Hylan G-F 20.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Bunyaratavej-2001">
<CHAR_METHODS>
<P>Randomised<BR/>Controlled<BR/>Trial<BR/>Double-blind<BR/>Masked observer<BR/>Placebo-controlled<BR/>Multicentre (n=3)<BR/>2 wk washout of NSAIDs</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Countries:<BR/>Thailand,<BR/>Hong Kong,<BR/>Malaysia<BR/>Mean age: 60<BR/>% Female: 78<BR/>Mean disease duration: 33 mth<BR/>Duration: 6 mth<BR/>Number randomised: 49<BR/>(HA 24, PL 25)<BR/>[59 screened but 10 not eligible]<BR/>Inclusion:<BR/>male and female<BR/>patients between 50 to 75 yr of age<BR/>mono or bilateral congenital or locally acquired painful OA of the knee<BR/>pain on movement &gt;40 mm on VAS scale<BR/>meet clinical and radiological ACR criteria within previous 6 mth<BR/>Exclusion:<BR/>patients with rapid, destructive or evolving arthritis requiring surgery within the following few months<BR/>patients treated with intra-articular injection (e.g. steroids or chondroprotectives) within previous 3 mth<BR/>patiens treated with NSAIDs in previous 7 days<BR/>those with painful knee conditions not due to OA such as Sudeks atrophy, i-a neoplasm, villonodular synovitis and Paget's disease and those with recent knee trauma<BR/>pregnant women and women of child bearing age<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Hyalgan 20 mg/<BR/>2 ml<BR/>4 injections<BR/>(Days 0, 7, 14 and 21)<BR/>Saline solution<BR/>2 ml<BR/>Concurrent therapy: paracetamol maximum of six 500 mg tablets daily and number taken recorded</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pain on movement (100 mm VAS), day pain (100 mm VAS), night pain, pain on touch, joint circumference (mm), intake of paracetamol tablets (mg/day), overall efficacy judgement by patient and investigator<BR/>morning stiffness<BR/>joint extension</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad's: 4/5<BR/>R-1,B-2,W-1<BR/>If bilateral, only the most severely affected knee was treated.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Caborn-2003">
<CHAR_METHODS>
<P>See Caborn 2004.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Caborn-2004">
<CHAR_METHODS>
<P>Randomised<BR/>Controlled <BR/>Trial<BR/>Single-blind<BR/>(Blinded evaluator)<BR/>Parallel-group<BR/>Multicentre (n=14)<BR/>ITT analysis n=215,<BR/>Safety analysis n=216,<BR/>Valid for efficacy n=177</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country:<BR/>United States<BR/>Mean age: 63<BR/>% Female: 57<BR/>Mean disease duration: NR<BR/>Duration: 26 wk<BR/>Number randomised: 218<BR/>(HA 113, TH 105)<BR/>Inclusion: <BR/>ambulatory males and females<BR/>&gt;= 40 yrs of age<BR/>in generally good health<BR/>diagnosed with knee OA (ACR criteria) at least 3 mth prior to study entry, required to have been taking analgesics/<BR/>NSAIDs to control knee pain at least 3 days/wk for a minimum of 2 mth before study entry<BR/>score &gt;= 2 on Q1 of WOMAC Pain subscale at screening,<BR/>score of 50-90/100 mm VAS on both pt and investigator overall assessment,<BR/>females of child-<BR/>bearing potential required to use adequate means of contraception.<BR/>Exclusion:<BR/>any unstable medical condition,<BR/>acute synovitis, allergy to avian products/hyaluronan-based injection components/corticosteroid injections/acetaminophen, inflamatory arthropathy or infection in the area of the injection site, a clinical diagnosis of primarily patello-<BR/>femoral knee pain,<BR/>effusion of &gt;10 ml at screening or baseline,<BR/>venous or lymphatic statis in the leg,<BR/>claudication or peripheral vascular disease, malignancy within 5 y, diabetic neuropathy or related infections, laboratory abnormalities<BR/>use of glucosamine and/or chondroitin sulfate prohibited,<BR/>exposure to prior viscosupplementation in target knee, <BR/>oral corticosteroids or IA corticosteroid injection of a target knee within 3 mth of screening or a nontarget joint within 4 wk,<BR/>pts with a history of target joint arthroplasty<BR/>Baseline values:<BR/>WOMAC Pain Ql:<BR/>HA: 2.12<BR/>TH: 2.15<BR/>Pt VAS score:<BR/>HA: 68.4<BR/>TH: 67.3<BR/>Iv VAS score:<BR/>HA: 69.0<BR/>TH: 69.6<BR/>WOMAC Pain:<BR/>HA: 10.7<BR/>TH: 10.4<BR/>WOMAC Stiffness:<BR/>HA: 4.7<BR/>TH: 4.9<BR/>WOMAC Function<BR/>HA: 38.6<BR/>TH: 37.9<BR/>WOMAC Total:<BR/>HA: 54.0<BR/>TH: 53.1<BR/>% pt analgesics:<BR/>HA: 98.2<BR/>TH: 97.1</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Hylan G-F 20<BR/>(Synvisc) three weekly injections.<BR/>Triamcinolone hexacetonide (Aristospan) a single ia injection of 40 mg (2 ml of a 20 mg/ml suspension).<BR/>Injection approach not standardised.<BR/>18-22 gauge needle used. Subcutaneous local anaesthetics and anaesthetic skin spray were permitted.<BR/>Concurrent therapy: Medications for preexisting conditions were permitted. Except for within 24 h of study visit, the following oral pain medications were allowed: acetaminophen (up to 4000 mg/day); analgesics or short-acting NSAID with a washout of at least 24 h (according to product labelling) for pain other than in the target knee, but not for more than 3 consecutive days or 10 days per month, and low dose aspirin (&lt;= 325 mg/day) for antithrombotic prophylaxis.<BR/>NSAID with once-daily dose regimens were prohibited.<BR/>Longer-acting analgesics and NSAID (e.g. rofecoxib) were to be discontinued at least 7 days before baseline and not permitted during the study.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pain walking on a flat surface (WOMAC Pain Q1), Pt and investigator overall assessments (0-100 mm VAS)<BR/>-----------------------<BR/>WOMAC total score (0-96),<BR/>WOMAC pain<BR/>(0-20), WOMAC stiffness (0-8),<BR/>WOMAC physical function subscale (0-68),<BR/>use of analgesics, rate of early withdrawals, responder rate (pt improved from baseline by at least one point on WOMAC Q1 at a given visit).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad's:2/5<BR/>R-1,B-0,W-1<BR/>If effusion present, aspirated and assessed for infection &amp; crystals.<BR/>Fourth author, D. Parenti is Asst. VP of Musculoskeletal Products, McNeil Pharmaceuticals, 5th author, C.W. Murray is Director of Musculoskeletal Products, Wyeth Pharmaceuticals.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Carrabba-1995">
<CHAR_METHODS>
<P>Randomised<BR/>Controlled <BR/>Trial<BR/>Double-blind<BR/>Blind observer<BR/>Parallel-group<BR/>Placebo- and arthrocentesis- controlled<BR/>Single centre<BR/>ITT analysis<BR/>(5 inj HA versus PL)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country:<BR/>Italy<BR/>Mean age: 60<BR/>% Female:63<BR/>Mean disease<BR/>duration: NR<BR/>Duration:60 days<BR/>Phase 1, 6 mth Phase 2<BR/>Number randomised:100<BR/>(20/group)<BR/>Inclusion:<BR/>&gt;= 40 y<BR/>ACR diagnosis of knee OA<BR/>clinical history of<BR/>painful knee OA for &gt; 6 mth<BR/>+ knee effusion (&gt; 3 ml)<BR/>pain on movement (&gt; 40/100 mm VAS)<BR/>Exclusion:<BR/>generalised OA<BR/>secondary knee OA<BR/>known or suspected joint infection<BR/>poor general health status or specific condition that would interfere with functional assessments<BR/>arthrocentesis and/or IA injection within 3 mth<BR/>very severe knee OA (planned intra-medicinal product)<BR/>Baseline values:<BR/>pain on movement<BR/>PL: 64.4, AR:64.5<BR/>HA1:61.7,HA3:<BR/>64.1,HA5: 63.3<BR/>Lequesne<BR/>PL:14.5,AR:14.3<BR/>HA1:14.0,HA3:<BR/>14.9, HA5:15.0<BR/>pain at rest<BR/>PL:45.6,AR:43.3<BR/>HA1:40.5, HA3:<BR/>44.7, HA5:43.6</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Hyalgan 20mg/2 ml 1 injection and arthrocentesis + 4 weekly arthrocentesis,<BR/>Hyalgan 20mg/2 ml and arthro-<BR/>centesis + 2 HA weekly injections+<BR/>2 arthrocentesis,<BR/>Hyalgan 20mg/2<BR/>ml and arthro-<BR/>centesis + 4 HA weekly injections,<BR/>Arthrocentesis=5 weekly arthrocentesis,<BR/>Placebo= Arthro-<BR/>centesis and 2 ml<BR/>saline + 4 weekly saline injections<BR/>Concurrent therapy:<BR/>paracetamol permitted</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>pain at rest by pt on 100 mm VAS<BR/>pain on movement by pt<BR/>on 100 mm VAS<BR/>Lequesne Index<BR/>----------------------<BR/>Range of motion by goniometer (flexion)<BR/>daily paracet-<BR/>amol consumption<BR/>presence<BR/>joint effusion (volume)<BR/>global pt and observer assessment of treatment efficacy</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad's:3/5<BR/>R-1,B-1,W-1<BR/>Effusions<BR/>aspirated at Visit 1, but no aspira-<BR/>tion at other visits except Day 35 (one wk after last injection) and 2 mth after beginning of study.<BR/>Dr. G.B. Guillou and Dr. E. Maheu assisted in preparing paper. J.M. Grouin (Fidia France) provided statistical analysis.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Carrabba-1995a">
<CHAR_METHODS>
<P>See Carrabba 1995 (HA 3 inj versus Placebo)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Carrabba-1995b">
<CHAR_METHODS>
<P>See Carrabba<BR/>1995 (HA 5 inj versus Arthrocentesis)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Carrabba-1995c">
<CHAR_METHODS>
<P>See Carrabba<BR/>1995 (HA 3 inj versus<BR/>Arthrocentesis)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Cohen-1994">
<CHAR_METHODS>
<P>Randomised<BR/>Controlled<BR/>Trial<BR/>Double-blind<BR/>Blinded assessor<BR/>Placebo- controlled<BR/>Multicentre (n=4)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Canada and USA<BR/>Mean age: NR<BR/>% Female: NR<BR/>Mean disease duration: NR<BR/>Duration: 8 wk<BR/>Number randomised:<BR/>(HA 19, PL 20)<BR/>Inclusion:<BR/>NR<BR/>Exclusion:<BR/>NR<BR/>Baseline values:<BR/>NR</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Replasyn/<BR/>Hyalgan (20 mg)<BR/>3 weekly injections<BR/>Placebo (not specified) <BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Knee pain when walking (100 mm VAS),<BR/>Range of motion,<BR/>WOMAC OA functional Index,<BR/>Pt and MD overall global</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad's:4/5<BR/>No baseline differences between groups.<BR/>Supported by a grant from Bioniche Pharm-<BR/>aceuticals, London, ON, Canada.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Corrado-1995">
<CHAR_METHODS>
<P>Randomised<BR/>Controlled<BR/>Trial<BR/>Double-blind<BR/>Efficacy analysis:<BR/>per protocol n=35, tolerance analysis, ITT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country:<BR/>Italy<BR/>Mean age:61<BR/>% Female:78<BR/>Mean disease<BR/>duration:<BR/>Duration:60 days<BR/>Number randomised:40<BR/>(PL 19 / HA 21)<BR/>Inclusion:<BR/>&gt;40 y<BR/>clinically &amp; radio-<BR/>logically OA knee (Altman criteria) of at least 6 mth duration<BR/>&gt;= 3 ml effusion<BR/>pain on movement &gt;40 <BR/>mm on VAS<BR/>Exclusion:<BR/>NR<BR/>Baseline values:<BR/>pain on movement<BR/>PL:62.3, HA:68.7<BR/>pain at rest<BR/>PL:16.8, HA:22.8<BR/>flexion<BR/>PL:113.3,<BR/>HA:114.7</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Hyalgan 20 mg/2 ml after arthro-<BR/>centesis at baseline 5 weekly injections,<BR/>Placebo=0.2mg/2 ml (2 ml water with 17 mg sodium chloride, 0.1 mg monobasic sodium phosphate, 1.2 mg bibasic sodium phosphate) 5 weekly injections<BR/>Concurrent therapy:<BR/>no painkillers during treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>pain on movement (100 mm VAS)-----------<BR/>pain at rest (VAS)<BR/>joint mobility on flexion<BR/>efficacy of treatment by pt and MD on 5 point scale (0=none,1=poor,2=fair,3=good,4=excellent)<BR/>volume of joint effusion<BR/>immunological and biochemical<BR/>evaluations</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad's:3/5<BR/>R-1,B-1,W-1<BR/>All pts had effusion at baseline</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Creamer-1994">
<CHAR_METHODS>
<P>Randomised<BR/>Controlled<BR/>Trial<BR/>Single-blind<BR/>Blind observer<BR/>Parallel-group<BR/>Single centre<BR/>Each pt own control<BR/>ITT analysis</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country:<BR/>England<BR/>Mean age:72<BR/>% Female:100<BR/>Mean disease<BR/>duration:22 y<BR/>Duration:9 wk<BR/>Number randomised:12<BR/>(HA 12 knees, <BR/>PL 12 knees)<BR/>Inclusion:<BR/>use-related pain in both knees<BR/>no steroid injection at least 3 mths prior to study<BR/>xray evidence of OA (joint space narrowing + sclerosis<BR/>or osteophytosis,<BR/>Kellgren and Lawrence Grade 2 to 4)<BR/>presence of bi-<BR/>lateral synovial <BR/>effusions as judged clinically<BR/>Exclusion:<BR/>NR<BR/>Baseline values:<BR/>rest pain<BR/>HA:10/12,<BR/>PL: 10/12<BR/>night pain<BR/>HA:7/12, PL:9/12<BR/>EMS<BR/>HA:10, PL:6 min<BR/>Inactivity stiffness<BR/>HA:4.1,PL:4.0min</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Hyalgan (20mg/2 ml) 5 weekly injections<BR/>Placebo= 2 ml<BR/>saline 5 weekly injections<BR/>Concurrent therapy:<BR/>paracetamol 4000 mg daily permitted</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>use-related pain (100 mm VAS)<BR/>rest and night pain (present/absent)<BR/>duration of early morning stiffness and inactivity<BR/>stiffness<BR/>pt opinion of disease severity<BR/>(none,mild,moderate,severe)<BR/>pt choice of worse knee<BR/>pt preferred treatment<BR/>pt overall change in each knee<BR/>Synovial fluid keratan sulfate<BR/>RF, CRP, plasma<BR/>viscosity, chondroitin sulfate 3B3, CPII</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad's:2/5<BR/>R-1,B-0,W-1<BR/>All bilateral knee OA with effusions<BR/>synovial fluid aspirated prior to each <BR/>injection<BR/>Wk 0-4 max 5ml<BR/>Wk 5 and 9 aspira-<BR/>ted to dryness.<BR/>Study not designed to assess clinical efficacy (cf small patient numbers and advanced disease)<BR/>Work was partially supported by a grant from Fidia SpA.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Cubukcu-2004">
<CHAR_METHODS>
<P>Randomised<BR/>Controlled<BR/>Trial<BR/>Placebo controlled<BR/>Single centre</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country:<BR/>Turkey<BR/>Mean age: 55.1<BR/>% Female: 80<BR/>Mean disease duration: 2.25 y<BR/>Duration: 8 wk<BR/>Number randomised: 30<BR/>(HA 20 (30 knees), PL 10 (10 knees))<BR/>Inclusion:<BR/>fulfill ACR criteria for knee OA with radiological evidence and symptoms<BR/>knee pain persisting for more than one year and pain &gt;40/100 (VAS) for more than 15 days in the last month<BR/>Exclusion:<BR/>any other serious systemic diseases, depression, avian allergy, other arthropathies, neoplasms, recent trauma, knee instability, effusion in the knee, a varus or valgus deformity of &gt;15 degrees, flexion contracture of &gt;20 degrees,<BR/>had received intraarticular corticosteroids within the 6 mth prior to start of study<BR/>Baseline values:<BR/>Walking pain<BR/>HA: 71.0,<BR/>PL: 67.0<BR/>Night pain<BR/>HA: 45.0<BR/>PL: 54.0<BR/>Rest pain<BR/>HA: 46.7<BR/>PL: 51.0<BR/>Need for paracetamol<BR/>HA: 1.0<BR/>PL: 0.9<BR/>WOMAC pain<BR/>HA: 15.7<BR/>PL: 17.6<BR/>WOMAC stiffness<BR/>HA: 6.3<BR/>PL: 6.1<BR/>WOMAC function<BR/>HA: 49.6<BR/>PL: 47.8<BR/>15 m walk time<BR/>HA: 20.6<BR/>PL: 17.9<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Hylan G-F 20 <BR/>(2 ml 10 mg/ml) (Synvisc) 3 weekly injections,<BR/>Saline 2 ml <BR/>3 weekly injections<BR/>Both medial approach, after injection, knees wrapped with bandage and patients instructed to rest for 24h.<BR/>Concurrent therapy: Paracetamol permitted for analgesia. No additional physiotherapy or anti-inflammatory drugs.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pain at rest, at night and on walking (0-100 mm VAS), WOMAC pain (5-25), WOMAC stiffness (2-10), WOMAC physical function (17-85), walking time for 15 m, need for paracetamol, evaluation of treatment by patient (1=treatment is not effective, 2=less effective, 3=effective, and 4=very effective)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad's: 2/5<BR/>R-1, B-0, W-1<BR/>If bilateral, both knees injected.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Day-2001">
<CHAR_METHODS>
<P>See Day 2004</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Day-2004">
<CHAR_METHODS>
<P>Randomised<BR/>Controlled<BR/>Trial<BR/>Double-blind<BR/>Parallel-group<BR/>Multicentre (n=17)<BR/>1 wk washout<BR/>Efficacy analysis:<BR/>both per protocol n=208, modified ITT n=223<BR/>Safety analysis:<BR/>ITT, n=223</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country:<BR/>Australia<BR/>Mean age: 62<BR/>% Female: 56<BR/>Mean disease duration: NR<BR/>Duration:18 wk<BR/>Number randomised:240<BR/>(HA - 116, PL 124)<BR/>Inclusion:<BR/>40-75 y<BR/>BMI &lt; 40<BR/>appropriate contraception<BR/>mild to moderate idiopathic painful femoro-tibial OA knee defined by:<BR/>knee pain while standing, walking and/or in motion of at least 3 mth duration, &gt;=1 features on xray in past 6 mth: femoro-tibial, osteophytes, osteosclerosis of femoral or tibial endplates or JSN<BR/>unilateral or predominantly unilateral symptomatology<BR/>informed written consent<BR/>willing to discontinue current OA treatment for study<BR/>Exclusion:<BR/>pregnant and lactating females<BR/>severe malalignment of knee<BR/>severe, tight effusion<BR/>clinical manifestations of OA of the hip and/or history of joint replacement in lower extremities<BR/>history of surgery on knee within last 12 mth or arthroscopy within last 6 mth<BR/>IA injection or treatment with long-acting OA therapy in previous 3 mth<BR/>Baseline values:<BR/>WOMAC pain<BR/>HA: 7.96<BR/>PL: 8.68<BR/>WOMAC function<BR/>HA: 28.07<BR/>PL: 31.25<BR/>WOMAC stiffness<BR/>HA: 3.70<BR/>PL: 3.79</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Artz (25mg/2.5 ml)<BR/>5 weekly injections<BR/>local anesthesia 1% xylocaine,<BR/>Placebo= phosphate buffered saline vehicle (2.5 ml) 5 weekly injections<BR/>Concurrent therapy:<BR/>paracetamol, standard physical therapy exercises<BR/>permitted</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>WOMAC -----------<BR/>Lequesne Index<BR/>knee examination (4 point categorical scale for pain, stiffness, effusion and range of motion)<BR/>pt and MD global assessment<BR/>paracetamol consumption</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad's:5/5<BR/>R-2,B-2,W-1<BR/>Bilateral disease in 66% Artz and 64% PL.<BR/>Effusions were aspirated.<BR/>Work was supporated by Seikagaku Corporation. Test medications provided by Seikagaku.<BR/>A CRO,<BR/>Omnicare Clinical Research, was responsible for management, monitoring and safety reporting of study. Study statistician was Dr. Philip McCloud and associates of the Monash University Statistical Consuting Group.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Dickson-2001">
<CHAR_METHODS>
<P>Randomised<BR/>Controlled<BR/>Trial<BR/>Double-blind<BR/>Blind observer<BR/>Screen blinded patient<BR/>Parallel-group<BR/>Multicentre<BR/>(n=18)<BR/>3-7 day washout<BR/>Efficacy analysis:<BR/>both ITT n=165 and per protocol n=134<BR/>Safety analysis:<BR/>ITT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country:<BR/>England and<BR/>Scotland<BR/>Mean age:63<BR/>% Female:53<BR/>Mean disease<BR/>duration:NR<BR/>Duration:12 wk<BR/>Number randomised:165<BR/>(HA - 53, DI - 55, CN - 57)<BR/>Inclusion:<BR/>35-80 y<BR/>radiologically<BR/>confirmed knee OA (tibofemoral compartment) and no other OA joint likely to warrant escape analgesia<BR/>knee had to be most painful joint<BR/>xray report &lt;2 y<BR/>end of washout 2/5 WOMAC pain &gt;40/100 mm VAS<BR/>Exclusion:<BR/>bed ridden pts<BR/>pts in wheelchair<BR/>or unable to walk 50 steps unaided<BR/>other jt disease<BR/>clinically significant renal, hepatic or haematological disorders<BR/>any contraindication to study treatments<BR/>Baseline values:<BR/>WOMAC pain<BR/>HA:59, DI:61, CN:58<BR/>WOMAC function<BR/>HA: 54, DI: 56,<BR/>CN: 56<BR/>Lequesne<BR/>HA: 13.9, DI: 13.9<BR/>CN: 14.5</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Hylan G-F 20 (2 ml) 3 weekly injections+arthro-<BR/>centesis + placebo capsules od<BR/>Diclofenac retard<BR/>100 mg od + arthrocentesis<BR/>Control: Arthro-<BR/>centesis + placebo capsules od<BR/>Concurrent therapy:<BR/>paracetamol 3000 mg daily permitted</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>WOMAC pain subscale-----------<BR/>WOMAC stiffness<BR/>and function<BR/>Lequesne Index<BR/>pt. and blinded observer overall opinion of treatment (5-pt verbal scale:very<BR/>poor, poor, fair,<BR/>good,very good)<BR/>Assessments:<BR/>Wk 0,1,2,4,8,12</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad's:4/5<BR/>R-1,B-2,W-1<BR/>17 bilateral <BR/>injections<BR/>target knee<BR/>Arthrocentesis removing all joint<BR/>fluid in all 3 groups.<BR/>At end of 12 DBRCT, patients could enter an open label one-year extension study in which they could receive up to four repeat courses of Hylan G-F 20.<BR/>Syntex Pharma-<BR/>ceuticals Ltd. and Roche Products Ltd provided financial support. Biomatrix, Inc. supplied hylan G-F 20 and Dr. Arnold Goldman provided statistical analysis.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Dougados-1993">
<CHAR_METHODS>
<P>Randomised<BR/>Controlled<BR/>Trial<BR/>Single-blind<BR/>Parallel-group<BR/>Multicentre<BR/>Placebo- controlled<BR/>Efficacy analysis:<BR/>per protocol n=95, ITT done to check consistency of <BR/>per protocol</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country:<BR/>France<BR/>Mean age: 68<BR/>% Female:71<BR/>Mean disease duration:<BR/>Duration: 1 y<BR/>Number randomised:110<BR/>(HA 55, PL 55)<BR/>Inclusion:<BR/>ACR criteria for<BR/>knee OA<BR/>Femorotibial localisation of disease<BR/>+ knee effusion<BR/>painful knee (&gt;= 40/100 mm VAS)<BR/>stable dose of OA therapy for 3 mth<BR/>NSAID, analgesics, physiotherapy stable for one mth<BR/>Exclusion:<BR/>serious concomitant illness<BR/>secondary OA of knees by ACR<BR/>knee with prothesis<BR/>any IA surgery of evaluated knee,<BR/>menisectomy in 10 y prior<BR/>any extra-articular surgery of evaluated knee,<BR/>osteotomy last 2 y<BR/>arthrocentesis of evaluated knee in previous 3 mth<BR/>Baseline values:<BR/>Lequesne<BR/>HA:11.6, PL:10.9<BR/>Pain at rest<BR/>HA:31.4, PL:28.0<BR/>Pain after exercise<BR/>HA:67.6, PL:61.9</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Hyalgan (20 mg/2ml) 4 weekly injections<BR/>Placebo:saline vehicle (2 ml) 4 weekly injections<BR/>Concurrent therapy:<BR/>previous treatment continued at same dose schedule; between Wks 7-52, corticosteroid injection, SF aspira-<BR/>tion, total knee re-<BR/>placement allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>degree of inflam-<BR/>mation by presence and amount of synovial fluid effusion by<BR/>arthrocentesis----<BR/>pain at rest and after exercise on 100 mm VAS<BR/>Lequesne Index<BR/>overall pt and MD assessment<BR/>requirement for local therapies between Wk 7 &amp; Wk 52 (number and time)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad's:2/5<BR/>R-1,B-0,W-1<BR/>The MD who did injection was also the assessor and therefore may not have remained blind.<BR/>Dr. G.B. Buillou and J.M. Grouin (Fidia, France) provided statistical analysis. Helpful assistance from: V. Figeac, C. Strauss, C. Kubiak, and N. Chevalier.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Formiguera-Sala-1995">
<CHAR_METHODS>
<P>Randomised<BR/>Controlled<BR/>Trial<BR/>Double-blind<BR/>Placebo- controlled<BR/>Single centre<BR/>Washout<BR/>ITT analysis</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country:<BR/>Spain<BR/>Mean age: 62<BR/>% Female:73<BR/>Mean disease <BR/>duration:<BR/>Duration:90 days<BR/>Number randomised:36<BR/>[40 jts: HA 20, PL 20]<BR/>Inclusion:<BR/>adult pt. with mono or bilateral knee OA<BR/>painful limitation<BR/>of movement<BR/>narrowing of femorotibial space and osteophytes, subchondral sclerosis or cysts<BR/>Exclusion:<BR/>secondary knee OA<BR/>nonarthritic arthropathies<BR/>large volume of joint effusion<BR/>severe systemic diseases<BR/>pregnancy or lactation<BR/>inexplicable biochemical or <BR/>haematological<BR/>abnormalities</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Hyalgan (20mg/2ml)<BR/>5 weekly injections<BR/>Placebo: saline<BR/>(2 ml) 5 weekly<BR/>injections<BR/>Concurrent therapy:<BR/>not reported</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>pain on walking--<BR/>spontaneous pain, pain on load, pain on palpation:100 mm VAS<BR/>active and passive<BR/>flexion in degrees<BR/>pt and MD overall judgement on evolution of disease<BR/>standard severity scale (0-25) for level of pain, max<BR/>distance walked and activities of daily living</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad's:3/5<BR/>R-1,B-1,W-1<BR/>Most cases "dry" knees.<BR/>4 pts bilateral knee OA with second knee treated some time after first</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Forster-2003">
<CHAR_METHODS>
<P>Randomised<BR/>Controlled<BR/>Trial<BR/>Single centre<BR/>Parallel-group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country:<BR/>England<BR/>Mean age: 62<BR/>% Female: NR<BR/>Disease duration: NR<BR/>Duration: 1 yr<BR/>Number randomised: 38<BR/>(HA 19, AR 19)<BR/>Inclusion:<BR/>Symptomatic knee OA with radiographic evidence of some remaining joint space on weight bearing films<BR/>Be fit for regional or general anaesthesia.<BR/>Exclusion:<BR/>Pts with mechanical symptoms<BR/>IA injection within last 6 mths<BR/>Previous arthro-<BR/>scopic surgery<BR/>Hypersensitivity to avian proteins<BR/>Baseline:<BR/>Pain<BR/>HA: 7.6<BR/>AR: 7.5<BR/>Lequesne<BR/>HA: 10.5<BR/>AR: 13.0<BR/>Knee Society ftn:<BR/>HA: 65<BR/>AR: 45</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Hyalgan<BR/>20 mg <BR/>5 weekly injections<BR/>Arthroscopic washout with either general or spinal anaesthesia 2 l 0.9% saline at least<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pain (10 cm VAS)<BR/>Function score from the Knee Society rating system<BR/>Lequesne</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad's:3/5<BR/>R-2,B-0,W-1<BR/>The Knee Society function score was significantly worse in the AR group at baseline.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Forster-2003a">
<CHAR_METHODS>
<P>See Forster 2003</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Frizziero-2002">
<CHAR_METHODS>
<P>Randomised<BR/>Controlled<BR/>Trial<BR/>Single-blind<BR/>Blinded assessor for<BR/>arthroscopic assessment.<BR/>Parallel-group<BR/>Single centre</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country:<BR/>Italy<BR/>Mean age: 50<BR/>% Female: 53<BR/>Mean disease<BR/>duration: 25 mth<BR/>Duration: 6 mth<BR/>Number randomised: 99<BR/>(HA 52, MP 47)<BR/>Inclusion:<BR/>Outpatient re-<BR/>ferred to Rheumatology <BR/>Unit for OA over a 3 yr period<BR/>Primary OA or OA secondary to traumatic events to the knee.<BR/>Kellgren and <BR/>Lawrence Grades I to III<BR/>Fulfill clinical and radiological criteria of ACR<BR/>Exclusion:<BR/>Pt judged not<BR/>controllable or<BR/>unreliable.<BR/>Presence of severe concom-<BR/>itant diseases,<BR/>suspected joint infection.<BR/>Concomitant treatment with NSAID<BR/>IA steroid treatment in previous 3 mth<BR/>Pregnancy and breast feeding<BR/>Baseline:<BR/>Pain after spontaneous movement:<BR/>HA: NR<BR/>MP: NR<BR/>Pain after forced movement<BR/>HA: NR<BR/>MP: NR</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Hyalgan<BR/>(20 mg/2ml)<BR/>5 weekly injections<BR/>Methylpredniso-<BR/>lone acetate<BR/>3 weekly injections</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Noctural pain,<BR/>pain at rest,<BR/>pain on spontan-<BR/>eous or forced<BR/>movement,<BR/>pain on touch (all on 100 mm VAS)<BR/>morning stiffness (min),<BR/>joint motion <BR/>(max active flexion/extension)<BR/>pt and MD opinion of efficacy (0=poor (unsatisfactory),<BR/>1=scarce,2=fair,<BR/>3=good,4=excel-<BR/>lent)<BR/>use of analgesic<BR/>or NSAID<BR/>cartilage damage (modified version of the Outer-<BR/>bridge &amp; Noyes scales): degree of cartilage damage (5 point scale) and extent of cartilage lesions<BR/>(6 point scale)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad's:4/5<BR/>R-2,B-1,W-1<BR/>When OA was bilateral, most severely affected knee selected for treatment.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Graf-1993">
<CHAR_METHODS>
<P>Randomised <BR/>Controlled<BR/>Trial<BR/>Single-blind<BR/>Parallel-group<BR/>Verum- controlled<BR/>ITT analysis</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country:<BR/>Germany<BR/>Mean age: NR<BR/>% Female:55<BR/>Mean disease<BR/>duration:<BR/>Duration: 6 mth<BR/>Number randomised:60<BR/>(HA 33, MPA 27)<BR/>Inclusion:<BR/>outpatients<BR/>&gt;= 18 y<BR/>clinical &amp; radiological signs of OA<BR/>written informed consent<BR/>Exclusion:<BR/>radiographically<BR/>no cartilage lesions<BR/>arthropathy other than OA<BR/>tubercular osteopathy<BR/>peripheral neuropathy with pain<BR/>severe, decompensated <BR/>concomitant disease<BR/>pregnant/nursing<BR/>recd IA corticosteroids in last 3 mth or NSAID within 14 days<BR/>Baseline values:<BR/>pain<BR/>HA: 14.1,<BR/>MPA: 16.2<BR/>function<BR/>HA: 18.0,<BR/>MPA: 16.9<BR/>ROM<BR/>HA: 8.8,<BR/>MPA: 8.7<BR/>Larson<BR/>HA: 45.7,<BR/>MPA: 46.6</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Hyalgan (20mg/2ml) once a wk for 6 wk - 7 injections<BR/>Mucopolysacchar-<BR/>ide polysulfuric<BR/>acid ester (MPA)<BR/>50mg/1 ml twice/wk -<BR/>13 injections over 6 weeks<BR/>Concurrent therapy:<BR/>no additional anal-<BR/>gescis, NSAIDS, physical therapy</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Larson rating scale shortened (77 points:pain severity (0-30), ROM (0-10), function (0-30), anatomy (0-7))<BR/>extension deficit<BR/>crepitation<BR/>ligament loosening<BR/>extensor &amp; flexor<BR/>muscle strength<BR/>pt &amp; MD global:<BR/>unchanged,<BR/>slightly improved,<BR/>significantly<BR/>improved, and<BR/>symptom-free<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad's:2/5<BR/>R-1,B-0,W-1</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Grecomoro-1987">
<CHAR_METHODS>
<P>Randomised<BR/>Controlled<BR/>Trial<BR/>Double-blind<BR/>Parallel-group<BR/>Placebo- controlled<BR/>Single centre,<BR/>ITT analysis</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Italy<BR/>Mean age:65<BR/>% Female:56<BR/>Mean disease duration: NR<BR/>Duration:60 days<BR/>Number randomised:34<BR/>[40 jts: HA 20, PL 20]<BR/>Inclusion:<BR/>gonarthrosis<BR/>pain with clinical signs, e.g. limitation of joint function and of unaided walking<BR/>Exclusion:<BR/>NR<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Hyalgan (20mg/2ml)<BR/>3 weekly injections<BR/>Placebo: phosphate buffer<BR/>2 ml 3 weekly injections<BR/>Concurrent therapy:<BR/>not reported</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>spontaneous pain intensity VAS -----------------<BR/>pain on touch<BR/>pain under load<BR/>pain while walking (1=none,<BR/>2=mild,3=moder-<BR/>ate,4=severe,5=<BR/>very severe)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad's:3/5<BR/>R-1,B-1,W-1<BR/>6 pts had bilateral disease each knee ran-<BR/>domised</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Groppa-2001">
<CHAR_METHODS>
<P>Blind<BR/>Controlled<BR/>Trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country:<BR/>Republic of Moldova<BR/>Mean age: 61<BR/>% Female: 64<BR/>Mean disease duration: 5.8 y<BR/>Duration: 1 y<BR/>Number randomised: 25<BR/>(HA -?, PL-?)<BR/>Inclusion:NR<BR/>Exclusion:NR<BR/>Baseline values:<BR/>NR<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Hylan G-F 20<BR/>3 weekly injections<BR/>Placebo <BR/>3 weekly injections<BR/>Repeat courses given at 6 and 12 months.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pain<BR/>Lequesne<BR/>Volume of movement on affected joints<BR/>xray parameters<BR/>functional methods (US, scintigraphy with Te99m)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad's:1/5<BR/>R-0,B-1,W-0<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Guler-1996">
<CHAR_METHODS>
<P>Randomised<BR/>Controlled<BR/>Trial<BR/>Double-blind<BR/>Placebo- controlled<BR/>Parallel-group<BR/>ITT analysis</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country:<BR/>Turkey<BR/>Mean age: NR<BR/>% Female: NR<BR/>Mean disease<BR/>duration: NR<BR/>Duration: 10 wk<BR/>Number randomised: 30<BR/>(HA 15, PL 15)<BR/>Inclusion:<BR/>Exclusion:<BR/>Baseline values:<BR/>WOMAC pain<BR/>HA: 16.87<BR/>WOMAC stiffness<BR/>HA: 6.47<BR/>WOMAC function<BR/>HA: 59.00</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Orthovisc 15 mg/ml<BR/>2 ml once per week for 3 weeks<BR/>Placebo: physiologic saline 2 ml<BR/>Concurrent therapy: acetaminophen use recorded</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>WOMAC<BR/>pain(5-25),<BR/>stiffness (2-10)<BR/>function (17-85)<BR/>-----------------------<BR/>quantity of acetaminophen use<BR/>time for 15 meter walk<BR/>range of joint mobility <BR/>patella ciricumference<BR/>pt assessment of degree of<BR/>arthrosis<BR/>satisfaction with<BR/>treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad's: 3/5<BR/>R-1,B-1,W-1</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Henderson-1994">
<CHAR_METHODS>
<P>Randomised<BR/>Controlled<BR/>Trial<BR/>Double-blind<BR/>Blinded metrologist<BR/>Parallel-group<BR/>Placebo- controlled<BR/>Single centre,<BR/>2 wk washout<BR/>Per protocol analysis: n=84</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country:<BR/>England<BR/>Mean age: 65<BR/>% Female: 69<BR/>Mean disease<BR/>duration:NR<BR/>Duration:5 mth<BR/>Number randomised:91<BR/>(HA 45, PL 46)<BR/>Inclusion:<BR/>clinical history of knee OA<BR/>radiological evidence of knee OA (Kellgren and<BR/>Lawrence 1-4)<BR/>pain in at least one knee &gt;= 30 mm on a VAS for at least 1/5 activities in prior 2 wk<BR/>Exclusion:<BR/>pts with inflammatory bowel disease, anserine bursitis or pain referred from other structures (e.g. ipsilateral hip or lumbar spine)<BR/>Baseline values:<BR/>pain on active<BR/>movement<BR/>HA: mild 43.7<BR/>moderate 48.5<BR/>PL: mild 53.0<BR/>moderate 49.3<BR/>pain at rest<BR/>HA: mild 20.8<BR/>moderate 25.2<BR/>PL: mild 30.3<BR/>moderate 38.9</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Hyalgan (20mg/2ml) 5 weekly injections<BR/>Placebo:saline 2 ml 5 weekly injections<BR/>Concurrent therapy:<BR/>paracetamol permitted</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>daily VAS pain in the am, pm, getting up from chair, climbing stairs, painful activity, at rest for 20 min, active and passive movement, patellofemoral tenderness, flexion by goniometer, morning stiffness (min), interference with activity of daily living, escape analgesia count,<BR/>pt and metrologist global assessment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad's:5/5<BR/>R-2,B-2,W-1<BR/>Most affected knee studied.<BR/>90 pts had bilateral disease<BR/>Effusions aspirated to dryness<BR/>Stratification by<BR/>xray severity</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Henderson-1994a">
<CHAR_METHODS>
<P>See Henderson 1994 (severity group 2)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Hizmetli-1999">
<CHAR_METHODS>
<P>Randomised<BR/>Controlled<BR/>Trial<BR/>Double-blind<BR/>Placebo- controlled<BR/>2 wk washout<BR/>Per protocol analysis (n=40)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country:<BR/>Turkey<BR/>Mean age: 56<BR/>% Female: 68<BR/>Mean disease<BR/>duration:<BR/>Duration: 1 yr<BR/>Number randomised: 50<BR/>(HA 25, PL 25)<BR/>Inclusion:<BR/>knee OA according to ACR criteria<BR/>Kellgren and Lawrence Grades 1 and 2<BR/>Exclusion:<BR/>pts who had undergone extra- or intra-articular surgery, arthrocentesis &amp; physical therapy<BR/>Baseline values:<BR/>WOMAC pain<BR/>HA: 17.75<BR/>PL: 17.45<BR/>WOMAC stiffness<BR/>HA:5.65, PL:5.55<BR/>WOMAC function<BR/>HA:53.15,<BR/>PL:52.00</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Hyaluronic acid<BR/>2 ml<BR/>Placebo: sterile physiological saline 2 ml<BR/>Injections done on 1st,2nd,3rd wks one wk apart and a 4th injection at 6 mth<BR/>Concurrent therapy: no analgesics, NSAIDs, steroids first 4 wks of study</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>WOMAC<BR/>pain (5-25)<BR/>stiffness (2-10)<BR/>function (17-85)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad's: 4/5<BR/>R-1,B-2,W-1<BR/>clinical evaluation and injection done by 2 different researchers<BR/>Although report states that WOMAC mean and sd are presented in tables, wonder if the sd is really se due to their small values.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Huang-2005">
<CHAR_METHODS>
<P>Randomised<BR/>Controlled<BR/>Trial<BR/>Single-blind<BR/>Single centre<BR/>Blinded physiatrists</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country:<BR/>Taiwan<BR/>Mean age: 65.0<BR/>% Female: 80.7<BR/>Mean disease duration: range 5 mth to 12 y<BR/>Duration: 1 y<BR/>Number randomised: 140<BR/>(35 in each of 4groups)<BR/>Inclusion:<BR/>patients with bilateral moderate knee OA (Altman grade II)<BR/>Exclusion:<BR/>Not reported<BR/>Baseline values:<BR/>Range of motion<BR/>EX: 103<BR/>EX+US: 104<BR/>EX+US+HA: 103<BR/>CT: 101<BR/>Pain (10 cm VAS)<BR/>EX: 5.3<BR/>EX+US: 5.5<BR/>EX+US+HA: 5.6<BR/>CT: 5.4<BR/>Lequesne Index<BR/>EX: 7.6<BR/>EX+US: 7.4<BR/>EX+US+HA: 7.5<BR/>CT: 7.4<BR/>Ambulation speed (metres/minute)<BR/>EX: 72.6<BR/>EX+US: 71.3<BR/>EX+US+HA: 72.4<BR/>CT: 73.9<BR/>Mean peak torque at 60 degrees/second<BR/>EX: 230.4<BR/>EX+US: 232.7<BR/>EX+US+HA: 230.4<BR/>CT: 229.3<BR/>Mean peak torque at 180 degrees/second<BR/>EX: 181.5<BR/>EX+US: 183.3<BR/>EX+US+HA: 180.1<BR/>CT: 182.3<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1) EX: isokinetic muscular strengthening exercises,<BR/>2) EX+US: isokinetic exercise and pulse ultrasound treatment for painful periarticular soft tissue,<BR/>3) EX+US+HA: isokinetic exercise, pulse ultrasound treatment for painful periarticular soft tissue and intra-<BR/>articular Hyalgan 20 mg/2ml 5 weekly injections,<BR/>4) CT: no treatment other than warmup exercises.<BR/>Patients received treatments 3 times weekly for 8 weeks. Patients in all groups received a warmup exercise with 20 minutes of hot packs and underwent passive range of motion exercises on an electric stationary bike (20 cycles per minute) for 5 minutes to both knees before undergoing muscle strengthening exercises.<BR/>Concurrent therapy: None reported.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Active range of motion (standardised method for flexion, extension, excursion range),<BR/>Pain severity by 10 cm VAS (0=no pain, 10=maximum pain) after patient had remained in a weight-bearing position (walking or standing) for 5 minutes,<BR/>Disability by the Lequesne Index (score: 1-3 mild dysfunction, less than 7 functional status acceptable for isokinetic exercise, maximum score 26),<BR/>Ambulation speed - 50 metres on treadmill at self-selected pace - walking time,<BR/>Muscle peak torque of knee flexion and extension with an isokinetic dynamometer</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad's: 3/5<BR/>R-2, B-0, -1<BR/>Supported by a project grant from the National Science Counil of Taiwan.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Huskisson-1999">
<CHAR_METHODS>
<P>Randomised<BR/>Controlled<BR/>Trial<BR/>Blind observer<BR/>Parallel-group<BR/>Placebo- controlled<BR/>Single centre,<BR/>Principal efficacy criteria: ITT<BR/>all other efficacy: per protocol n=81</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country:<BR/>England<BR/>Mean age: 65<BR/>% Female: 67<BR/>Mean disease duration: NR<BR/>Duration:6 mth<BR/>Number randomised:100<BR/>(HA 50, PL 50)<BR/>Inclusion:<BR/>fully ambulant<BR/>mono or bilateral knee OA<BR/>Grade 2 to 3 Kellgren and Lawrence within 6 mth prior<BR/>consistent pain for 3 mth prior<BR/>moderate or severe pain on walking at screen and baseline visits<BR/>Exclusion:<BR/>Grade 4 Kellgren and Lawrence<BR/>serious functional impair-<BR/>ment at knee<BR/>associated OA of hip that interferes with knee assessment<BR/>OA of any other jt that affect knee assessment<BR/>psoriasis<BR/>radiographic evidence of sacroilitis or any other joint disease other than OA<BR/>known or suspected jt infection<BR/>poor general health or other conditions preventing hospital attendance<BR/>skin conditions overlying jt affecting injection<BR/>painful knee conditons other than OA<BR/>severe hepatic or renal disease or major medical<BR/>conditions<BR/>use of IA steroid or radiocolloid within 3 mth<BR/>Baseline values:<BR/>pain on walking<BR/>HA:65.8, PL:61.9<BR/>Lequesne<BR/>HA:13.4, PL:14.0</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Hyalgan (20mg/2 ml) 5 weekly injections<BR/>Placebo: saline<BR/>2 ml 5 weekly injections<BR/>Concurrent therapy:<BR/>Existing analgesic &amp; NSAID continued as considered appro-<BR/>priate by referring physician</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>pain on walking (100 mm VAS)<BR/>Lequesne ---------<BR/>knee pain at rest (100 mm VAS)<BR/>joint tenderness,<BR/>swelling (4 point:<BR/>none,mild,mod-<BR/>erate, severe)<BR/>am stiffness, in-<BR/>activity stiffness<BR/>(min), pt. global impression (excellent, fair,<BR/>poor, useless)<BR/>satisfaction index</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad's:4/5<BR/>R-1,B-2,W-1<BR/>Effusions aspirated</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Jones-1995">
<CHAR_METHODS>
<P>Randomised<BR/>Controlled<BR/>Trial<BR/>Double-blind<BR/>Parallel-group<BR/>Both per protocol and ITT analyses</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: <BR/>England<BR/>Mean age:71<BR/>% Female:62<BR/>Mean disease duration: NR<BR/>Duration:6 mth<BR/>Number randomised:63<BR/>(HA 32, TH 31)<BR/>Inclusion:<BR/>bilateral effusions<BR/>bilateral sympto-<BR/>matic knee OA<BR/>(ARA criteria)<BR/>self-selected knee pain average of &gt;30 mm during 2 wk run-in<BR/>Exclusion:<BR/>Coexistent rheumatological or serious medical disease<BR/>Baseline values:<BR/>pain on nomina-<BR/>ted activity<BR/>HA:77.2, TH:75.8<BR/>pain at rest<BR/>HA:53.2, TH:55.3<BR/>pain at night<BR/>HA:57.8, TH:62.2</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Hyalgan (20mg)<BR/>5 weekly injections<BR/>Triamcinolone hexacetonide 20 mg followed by 4 placebo (1 ml of 0.9% saline) injections<BR/>Concurrent therapy:<BR/>Paracetamol per-<BR/>mitted</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>pain on self-selected activity (10 cm VAS)-----------------<BR/>pain at rest, night<BR/>duration of stiffness <BR/>range of motion<BR/>joint effusion<BR/>local heat<BR/>synovial thickening<BR/>joint line and periarticular tenderness<BR/>xray score<BR/>synovial fluid volume</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad's:4/5<BR/>R-1,B-2,W-1<BR/>Active treatment was always given to worse knee with contra-<BR/>lateral knee re-<BR/>ceiving 5 placebo<BR/>injections<BR/>Joint aspirated to dryness before<BR/>injection.<BR/>Study sponsored by Fidia SPA. Drs. B. Guillou and J.M. Grouin of Fidia S.p.A. provided statistical analysis.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Jubb-2001a">
<CHAR_METHODS>
<P>See Jubb 2003</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Jubb-2001b">
<CHAR_METHODS>
<P>See Jubb 2003</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Jubb-2001c">
<CHAR_METHODS>
<P>See Jubb 2003</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Jubb-2001d">
<CHAR_METHODS>
<P>See Jubb 2003</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Jubb-2003">
<CHAR_METHODS>
<P>Randomised<BR/>Controlled<BR/>Trial<BR/>Double-blind<BR/>Masked-observer<BR/>Placebo controlled<BR/>Parallel group<BR/>Multicentre (n=17)<BR/>Primary analysis population n=273<BR/>ITT for safety n=408</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country:<BR/>England<BR/>Mean age: 64<BR/>% Female: 68<BR/>Mean disease duration: 8 y<BR/>Duration: 1 y<BR/>Number randomised: 408<BR/>(HA 208, PL 200)<BR/>Inclusion:<BR/>primary OA of the knee by ACR criteria,<BR/>grade II or III Kellgren and Lawrence in medial tibiofemoral compartment<BR/>Exclusion:<BR/>OA of the hip or other joint disease severe enough to prevent assess-<BR/>ment of knee,<BR/>psoriasis, sacro-<BR/>ilitis, other joint disease, known or suspected joint infection, disease of skin overlying knee joint that prevented injections, other painful knee conditions or severe concurrent illnesses,<BR/>ia corticosteroid or radiocolloid treatment in 3 mths before study or ia or new/rearrange-<BR/>ment surgical procedures on legs,<BR/>evidence of clinically important axial deviation of the legs (valgus or varus deformities),<BR/>history of allergic reactions to avian proteins, pregnant or breast-feeding<BR/>Baseline values:<BR/>JSW<BR/>HA: 4.9<BR/>PL: 4.5<BR/>JSW&gt;=4.6 mm<BR/>HA: 5.9<BR/>PL: 5.9<BR/>JSW&lt;4.6 mm<BR/>HA: 3.5<BR/>PL: 3.4</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Hyalgan (20 mg/2 ml) 3 weekly injections<BR/>Placebo: saline<BR/>Course was repeated twice more at four-monthly intervals. <BR/>Concurrent therapy: Free concomitant use of analgesics and NSAIDs, except indomethacin, was allowed but regimens had to be stable for at least one month before study entry. Concurrent treatment with corticosteroids, glucosamine or chondroitin sulphate was not permitted.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mean joint space width at 52 wk by computerised DIA-------------------<BR/>pain on walking (VAS), <BR/>knee pain (6 point categorical scale), Pt and investigator global impression of efficacy (5 point categorical scale), Lequesene Index, SF-36</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad's:4/5<BR/>R-1,B-2,W-1<BR/>If bilateral OA, more painful knee was treated.<BR/>Subgroups defined by joint space wideth &gt;= or &lt;4.6 mm at baseline.<BR/>The trial was supported by a grant from Fidia SpA, Abano Terme, Italy.<BR/>Second and third authors are affiliated with Sponsor.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Kahan-2001">
<CHAR_METHODS>
<P>See Kahan 2003a</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Kahan-2003">
<CHAR_METHODS>
<P>See Kahan<BR/>2003a</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Kahan-2003a">
<CHAR_METHODS>
<P>Randomised<BR/>Controlled<BR/>Trial<BR/>Open-label<BR/>Parallel-group<BR/>Multicentre (n=81)<BR/>Stratified<BR/>Effectiveness<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country:<BR/>France<BR/>Mean age: 66<BR/>% Female: 68<BR/>Mean disease<BR/>duration: 5.9 y<BR/>Duration: 9 mth<BR/>Number randomised:<BR/>518<BR/>(HA 258, CT 260)<BR/>Inclusion:<BR/>&gt;18 y of age<BR/>predominantly<BR/>femorotibial OA meeting ACR criteria<BR/>pain upon walking &gt;= 40/<BR/>100 mm VAS<BR/>had to have received at least 2 courses of NSAID therapy each at least 10 d long within the last 3 mth and/or <BR/>a symptomatic slow-acting drug taken continu-<BR/>ously during the last 2 mth<BR/>Exclusion:<BR/>inflammatory flare in the target knee (effusion with nocturnal pain, local heat or redness, morning stiffness for longer than 45 min or greater than 50% increase in the VAS pain score as compared to the previous wk<BR/>viscosupple-<BR/>mentation in the target knee within the last 3 mth, ia procedure (arthroscopy, lavage, menis-<BR/>ectomy, etc.) within the last year,<BR/>history of syno-<BR/>vectomy, tibial osteotomy, or knee replace-<BR/>ment surgery scheduled within the next 9 mth<BR/>Baseline values:<BR/>Lequesne:<BR/>HA 11.1 CT 11.3<BR/>WOMAC:<BR/>HA 46.3 CT 47.9<BR/>Pain walking:<BR/>HA 61.1<BR/>CT 60.3</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Hylan G-F 20 <BR/>3 weekly injections in target knee<BR/>(encouraged to stop or spare any other OA treat-<BR/>ments) [Synvisc could also be given in other knee]<BR/>Conventional treatment for knee OA<BR/>Concurrent therapy: NSAID:<BR/>HA 87%, CT 82%<BR/>Symptomatic slow-acting drugs: HA 69%, CT 76%</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Lequesne ---------<BR/>WOMAC OA Index, SF-12,<BR/>medico-<BR/>economic evaluation,<BR/>pt rating of effectiveness on a 4-category Likert scale</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad's:3/5<BR/>R-2,B-0,W-1<BR/>Bilateral OA in 72% HA, 76% CT<BR/>Synvisc given to both knees in 45 pts.<BR/>Second and third authors are affiliated with Boehringer Ingelheim.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Kalay-1997">
<CHAR_METHODS>
<P>Randomised<BR/>Controlled<BR/>Trial<BR/>Open-label<BR/>Parallel-group<BR/>1 wk washout<BR/>ITT analysis</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country:<BR/>Turkey<BR/>Mean age: 61<BR/>% Female: 78<BR/>Mean disease duration: NR<BR/>Duration: 56 days<BR/>Number randomised: 40<BR/>(HA 20, PT 20)<BR/>Inclusion:<BR/>idiopathic OA according ACR criteria<BR/>AP xray Kellgren and Lawrence 2 or 3 study knee and &lt;4 other knee<BR/>&gt;40 yr<BR/>walk 25 m without help<BR/>stop all NSAIDs and muscle relaxants 1 wk before study<BR/>Exclusion:<BR/>ia inj or important trauma episode within last 3 mths<BR/>oral or im steroid episode within last 2 mths<BR/>HA inj within last 12 mths<BR/>start of quadriceps exercise program in last 4 mths<BR/>presence of fixed flexion contracture at knee &gt;10 degrees<BR/>valgus/varus &gt;15 degrees on standing knee xrays<BR/>anticoagulant treatment<BR/>knee surgery episode<BR/>joint diseases: secondary OA or inflammatory jt disease, pseudo<BR/>-gout attack in last 3 mths, FM, intrajoint tumor, excessive symptoms in same hip or other knee that may interfere with study, anserine bursitis<BR/>functional damages: hemi-<BR/>paresis episode<BR/>others: multiple i-a inj or aspiration,liver or kidney disease, pregnancy, lacta-<BR/>tion, insufficient contraception, peripheral neuropathy or vascular inadequacy, osteonecrosis, immune suppresive disease, diabetes mellitus<BR/>Baseline values:<BR/>spontaneous pain<BR/>HA:2.61, PT:2.21<BR/>activity pain<BR/>HA:4.68, PT:3.71<BR/>night pain<BR/>HA:2.43, PT:2.17<BR/>25 m walk time<BR/>HA:22.4, PL:18.6</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Sodium hyaluronate 1.5% 15 mg/ml<BR/>2 ml Orthovisc<BR/>2 weekly injections<BR/>+ 5 days/wk for a total of 10 sessions in-patient physical therapy program (paraffin, short wave, quadriceps exercises) directed towards knees<BR/>Physical therapy program only<BR/>Concurrent therapy:<BR/>Paracetamol per-<BR/>mitted</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>spontaneous pain, pain during daily activities and night pain (0-4:<BR/>0=none,1=light, 2=medium, 3=<BR/>strong, 4=very<BR/>strong and 100 mm VAS)<BR/>paracetamol use<BR/>morning stiffness (min)<BR/>range of motion: flexion/extension goniometer<BR/>knee circumfer-<BR/>ence<BR/>25 metre walk time<BR/>pt global (1-4)<BR/>MD global (1-4)<BR/>(1=ineffective,2=<BR/>slightly effective,<BR/>3=effective, 4=<BR/>very effective)<BR/>side effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad's: 2/5<BR/>R-1,B-0,W-1<BR/>If bilateral OA, more symptomatic knee in study</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Karatay-2004">
<CHAR_METHODS>
<P>Randomised<BR/>Controlled<BR/>Trial<BR/>Parallel group<BR/>Singel centre</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Turkey<BR/>Mean age: 61.5<BR/>% Female: 70<BR/>Mean disease duration: NR<BR/>Duration: 3 wk<BR/>Number randomised: 40<BR/>(Orthovisc 20, Hylan G-F 20 20)<BR/>Inclusion:<BR/>fulfill ACR criteria for knee OA,<BR/>Kellgren-Lawrence grade II or III<BR/>Exclusion:<BR/>use of analgesic or NSAID,<BR/>pts with concomitant rheumatological disease, active synovitis, surgical or arthroscopic interventions or ia steroid or HA treatment during the past 6 mth<BR/>Baseline values:<BR/>WOMAC pain:<BR/>OR: 11.2<BR/>GF: 10.8<BR/>WOMAC stiffness<BR/>OR: 3.8<BR/>GF: 3.6<BR/>WOMAC function<BR/>OR: 35<BR/>GF: 31.9<BR/>ICAM-1<BR/>OR: 19.2<BR/>GF: 17.8<BR/>VCAM-1<BR/>OR: 40.5<BR/>GF: 37.8<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Orthovisc<BR/>2 ml, 30 mg<BR/>(Anika Therapeutics)<BR/>3 weekly injections;<BR/>Hylan G-F 20<BR/>Synvisc <BR/>2 ml, 16 mg<BR/>(Wyeth)<BR/>3 weekly injections<BR/>Concurrent therapy: None permitted as per exclusion criteria</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>WOMAC OA Index<BR/>pain (0-20),<BR/>stiffness (0-8),<BR/>physical function (0-68)<BR/>biochemical measurements:<BR/>sICAM-1 and sVCAM-1 in SF samples</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad's: 1/5<BR/>R-1, B-0, W-0<BR/>No baseline differences between groups of demographic features, clinical indices or lab values.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Karatay-2005">
<CHAR_METHODS>
<P>See Karatay 2004.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Karatay-2005a">
<CHAR_METHODS>
<P>See Karatay 2004.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Karatosun-2005">
<CHAR_METHODS>
<P>Randomised<BR/>Controlled<BR/>Trial<BR/>Parallel group<BR/>Blinded physical therapist<BR/>Single centre</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country:<BR/>Turkey<BR/>Mean age: 56.6<BR/>% Female: 86<BR/>Mean disease duration: NR<BR/>Duration: 18 mth<BR/>Number randomised: 105<BR/>(200 knees)<BR/>(HA 52, PE 53)<BR/>Inclusion:<BR/>primary OA of the knee as defined by ACR criteria,<BR/>Kellgren Law-<BR/>rence grade III with joint space narrowing and sclerosis of the subchondral bone<BR/>Exclusion:<BR/>radiographic appearance of pseudocysts as defined by Kellgren Law-<BR/>rence Grade IV,<BR/>unable to discontinue NSAID for duration of study,<BR/>previous fracture around the knee,<BR/>inflammatory arthritis, previous intraarticular injections or any other invasive procedure in the knee,<BR/>significant comorbidity (renal, hepatic or heart disease),<BR/>chicken or egg allergy<BR/>Baseline values:<BR/>pain during activity<BR/>HA: 4.0, PE: 4.5<BR/>pain at rest<BR/>HA: 7.8, PE: 9.1<BR/>pain during climbing stairs<BR/>HA: 2.5, PE: 2.5<BR/>pain during transfer activity<BR/>HA: 2.9, PE: 3.1<BR/>walking distance<BR/>HA: 8.1, PE: 7.9<BR/>range of motion<BR/>HA: 113.2,<BR/>PE: 114.4<BR/>total HSS score<BR/>HA: 62.6, <BR/>PE: 65.4</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Hylan G-F 20<BR/>(Synvisc) 3 weekly injections at baseline, Week 1 and Week 3,<BR/>Exercise programme included a series of progressive, simple range of motion and resistance exercises for 6 wk. Home-based regimen but patients came to hospital at baseline and weeks 1, 2, 3 and 6 to learn the exercises.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Knee function evaluated by the Hospital for Special Surgery knee score criteria that is based on a total of 100 points with the score divided into 7 categories: pain, function, range of motion, muscle, strength, flexion deformity, instability, and subtractions. scores 85-100 excellent, 84-70 good, 60-69 fair and less than 60 poor-----------------<BR/>pain during activity, pain at rest,<BR/>pain during climbing stairs, pain during transfer activity, walking distance and range of motion all but walking distance and ROM are graded by HSS score (i.e. pain)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad's: 3/5<BR/>R-2, B-0, W-1<BR/>95 patients had bilateral OA; 48 in the HA group and 47 in the PE group. 10 patients had unilateral OA: 4 HA and 6 PE</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Karatosun-2005a">
<CHAR_METHODS>
<P>Randomised<BR/>Controlled<BR/>Trial<BR/>Parallel group<BR/>Double blind<BR/>15 day washout of NSAID</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country:<BR/>Turkey<BR/>Mean age: 60.55<BR/>% Female: 81.5<BR/>Mean disease<BR/>duration: NR<BR/>Duration: 1 y<BR/>Number randomised: 92<BR/>(184 knees)<BR/>(OR 46, GF 46)<BR/>Inclusion:<BR/>primary OA of the knee as defined by ACR criteria,<BR/>all seeking treatment,<BR/>Kellgren-<BR/>Lawrence stage III OA with joint space narrowing and sclerosis of subchondral bone<BR/>Exclusion:<BR/>any pt with radiographic appearance of pseudocysts was defined as Kellgren-<BR/>Lawrence grade IV,<BR/>if pt could not discontinue NSAID beginning 15 days prior to the study due to presence of other diseases,<BR/>previous fracture around the knee, joint effusion, inflammatory arthritis, previous intraarticular injection or any other invasive procedure in the knee,<BR/>significant comorbidity (renal, hepatic or heart disease),<BR/>chicken or egg allergy<BR/>Baseline values:<BR/>pain at activity<BR/>OR: 4.4, GF 5.2<BR/>pain at rest<BR/>OR: 9.1, GF 8.1<BR/>pain during climbing stairs<BR/>OR: 2.1, GF 2.1<BR/>pain during transfer activities<BR/>OR: 2.5, GF 2.6<BR/>walking distance<BR/>OR: 5.4, GF 8.3<BR/>range of motion<BR/>OR: 113.0,<BR/>GF: 114.4<BR/>total HSS score<BR/>OR: 67.7,<BR/>GF: 70.1<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Orthovisc <BR/>3 weekly injections,<BR/>Hylan G-F 20<BR/>(Synvisc) 3 weekly injections<BR/>Concurrent therapy: NSAID not permitted</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Hospital for Special Surgery Knee Score which includes pain at activity, pain at rest, pain during climbing stairs, pain during transfer activities, walking distance, and range of motion</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad's: 5/5<BR/>R-2, B-2, W-1<BR/>All radiographs (AP, lateral and Merchant) evaluated by 2 orthoopaedic surgeons and if consensus not achieved pt not included.<BR/>Statistically significant difference at baseline in walking distance.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Karlsson-1999">
<CHAR_METHODS>
<P>See Karlsson 2002a</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Karlsson-2002">
<CHAR_METHODS>
<P>See Karlsson 2002a</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Karlsson-2002a-_x0028_AvP_x0029_">
<CHAR_METHODS>
<P>Randomised<BR/>Controlled<BR/>Trial<BR/>Double-blind<BR/>Parallel-group<BR/>Multicentre (n=19)<BR/>2 wk washout<BR/>Both per protocol n=210 (Artzal 76, Synvisc 77, PL 57) and<BR/>ITT n=242 (Artzal 90, Synvisc 86, PL 66) analyses completed <BR/>PP analysis planned a priori as high drop-out rate expected.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country:<BR/>Sweden <BR/>Mean age: 71<BR/>% Female: 65<BR/>Mean disease duration: NR<BR/>Duration: 1 yr<BR/>Number randomised: 246<BR/>(Artzal 92<BR/>Synvisc 88<BR/>Placebo 66)<BR/>Inclusion:<BR/>age at least 60 y<BR/>Lequesne Index score at least 10<BR/>weight bearing pain at least 40/100 mm VAS<BR/>normal general physical exam<BR/>dominant pain in one knee due to OA<BR/>radiologically verified OA of grade I or II by Ahlback criteria<BR/>(50-100% joint space narrowing but no bone erosion)<BR/>Exclusion:<BR/>bone attrition in either knee (Ahlback grade III to V)<BR/>previous ia fracture of knee<BR/>RA or other inflammatory joint disease as defined by ACR criteria<BR/>ia injections of steroids or HA or other invasive procedure (arthroscopy, arthrography, surgery) in knee less than 6 mths prior to study<BR/>known alcohol or drug abuse<BR/>known allergy to any substance related to study <BR/>(disinfectants, adhesives)<BR/>any clinically relevant haematological or known clinical chemistry values outside the reference values<BR/>any disabling problem of the musculoskeletal system or other organ system which could interfere with the assessment of efficacy<BR/>Baseline values:<BR/>Weight bearing pain:<BR/>A: 64<BR/>S: 63<BR/>PL: 65<BR/>Total WOMAC<BR/>A: 48.7<BR/>S: 48.7<BR/>PL: 48.9<BR/>Total Lequesne:<BR/>A: 13.9<BR/>S: 13.4<BR/>PL: 13.6</P>
<P>
<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Artzal 2.5 ml (1% hyaluronan, Astra Lakemedel)<BR/>3 weekly injections (7 days apart)<BR/>Synvisc 2.0 ml (0.8% hyaluronan, Roche) 3 weekly injections (7 days apart)<BR/>Placebo (phosphate-<BR/>buffered saline solution - 3 ml solution in 5 ml ampoules, Astra Lakemedel) 3 weekly injections (7 days apart)<BR/>Concurrent therapy: Paracetamol (acetaminophen) up to 4 g/day permitted; analgesics not permitted 12 h prior to clinical assessment; pt recoded use of analgesics on diary card during wk 0-26</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Wk 0-26 primary outcome was weight bearing pain and Wk 0-52 was duration of clinical benefit<BR/>Clinical failure defined as use of concurrent treatment for study knee, i.e. more than 4g/day, surgery or new injections. <BR/>*******************<BR/>Patient rated weight bearing pain, resting pain and maximum pain of knee on 100 mm VAS<BR/>WOMAC OA Index (Likert), SF 36, global evaluation of overall response to treatment at Wk 26 (8-point ordinal scale),<BR/>Examiner completed the Lequesne Index,<BR/>evaluated change in intake of concurrent analgesic medication (much more, more, unchanged, less, much less),</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad's:5/5<BR/>R-2,B-2,W-1<BR/>Study was supported by grants from Astra Lakemedel.<BR/>Second author affiliated with Clinical Research Medical Dept. of AstraZeneca.<BR/>These pts had significant knee pain and impairment as reflected by high WOMAC and Lequesne scores.<BR/>By Wk 26 approx. 20-30% dropouts By Wk 52 approx. 60-70% dropouts<BR/>Study pts from a community-<BR/>based outpatient<BR/>population cared for by family doctors, GPs and orthopaedic surgeons in private practice.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Karlsson-2002b-_x0028_SvP_x0029_">
<CHAR_METHODS>
<P>See Karlsson 2002a</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Karlsson-2002c-_x0028_AvS_x0029_">
<CHAR_METHODS>
<P>See Karlsson 2002a</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Karlsson-2003d">
<CHAR_METHODS>
<P>See Karlsson 2002a</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Karras-2001">
<CHAR_METHODS>
<P>Randomised<BR/>Controlled<BR/>Trial<BR/>Parallel-group<BR/>SIngle centre</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country:<BR/>Greece<BR/>Mean age: NR<BR/>% Female: NR<BR/>Disease duration: NR<BR/>Duration: 1 y<BR/>Number randomised: 200<BR/>(HA5: NR<BR/>HA3: NR )<BR/>Inclusion:<BR/>Suffering from OA of the knee<BR/>Exclusion:<BR/>NR<BR/>Baseline values:<BR/>NR</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Hyalgan 5 weekly injections every 6 months<BR/>Hyalgan 3 weekly injections every 3 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Lequesne,<BR/>Pain (VAS),<BR/>Clinical response by pt and physician.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad's:2/5</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Kawabata-1993">
<CHAR_METHODS>
<P>Randomised<BR/>Controlled<BR/>Trial<BR/>Parallel-group<BR/>Multicentre (n=23)<BR/>Safety analysis: ITT, n=164,<BR/>Pt. impression &amp; global: per proto-<BR/>col, n=156<BR/>Usefulness: per <BR/>protocol, n=159<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country:<BR/>Japan<BR/>Mean age: 67<BR/>% Female: 75<BR/>Mean disease<BR/>duration: NR<BR/>Duration: 5 wk<BR/>Number randomised: 172<BR/>(SLM 87, Artz 85)<BR/>Inclusion:<BR/>diagnosis of knee OA on basis of clinical and xray<BR/>informed consent<BR/>pain during movement<BR/>xray findings: one of osteophyte, JSN, osteoscl-<BR/>erosis<BR/>Exclusion:<BR/>considered to require an operation<BR/>received ia injection of steroid within 2 wks of start<BR/>newly administered analgesic, NSAID within 2 wk of start<BR/>new PT within 2 wk<BR/>pregnant, lactating, or may become pregnant<BR/>serious complications such as definite hepatic and renal ftn. disorders<BR/>have or have history of hyper-<BR/>sensitivity to drug<BR/>those judged by the physi-<BR/>cian in charge to be inappro-<BR/>priate as trial subjects<BR/>Baseline values:<BR/>movement pain<BR/>mild SLM 39%<BR/>Artz 35%,<BR/>moderate SLM<BR/>55%, Artz 61%<BR/>severe SLM 6%,<BR/>Artz 4%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>SLM-10 (25 mg/2.5 ml)<BR/>5 weekly injections<BR/>Artz (25 mg/2.5 ml)<BR/>5 weekly injections<BR/>Concurrent therapy:<BR/>"New" analgesics, NSAIDs, steroids and physiotherapy to be avoided</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>assessment by attending physician:<BR/>daily activity dis-<BR/>order:standing up from chair,up/<BR/>down stairs,<BR/>squatting, sitting<BR/>up straight (easy,<BR/>mild,moderate,<BR/>severe), walking ftn disorder, pain<BR/>(in movement,<BR/>when resting,<BR/>pressure), knee jt findings (swel-<BR/>ling,feverish<BR/>feeling,floating<BR/>patella), range of motion: all on 4-point scales (none,mild,mod-<BR/>erate,severe), +/- stagnant synovial fluid,<BR/>if present, volume <BR/>pt's impression: 7 grades:much<BR/>better,better,<BR/>slightly better,<BR/>unchanged,<BR/>slightly worse,<BR/>worse, much<BR/>worse<BR/>pt global improvement : 7 grades:markedly<BR/>improved, im-<BR/>proved,slightly<BR/>improved, un-<BR/>changed,slightly<BR/>deteriorated, de-<BR/>teriorated, mark-<BR/>edly deteriorated<BR/>overall safety: 3 grades: safe,<BR/>continued use <BR/>despite some<BR/>problem, discon-<BR/>tinued due to<BR/>problem<BR/>usefulness: 7 grades:very use-<BR/>ful,useful,slightly<BR/>useful,cannot say useful or not,<BR/>slightly undesir-<BR/>able, undesir-<BR/>able, very unde-<BR/>sirable<BR/>Committee assessment: pain, daily activity disorder, knee jt findings, walking ftn: score/100,<BR/>overall severity: 3 grades (mild &gt;=60/100, moderate 30-50/<BR/>100, severe &lt;= 29/100) and global improvement: 7 grades, overall safety &amp; usefulness</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad's: 2/5<BR/>R-1,B-0,W-1<BR/>Pt observation and assessment done by physician other than physician in charge (injection)<BR/>Synovial fluid removed as required.<BR/>Significant group difference in baseline +/- of complications.<BR/>Artz provided by Seikagaku Corp-<BR/>oration.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Kirchner--2005">
<CHAR_METHODS>
<P>Randomised<BR/>Controlled<BR/>Trial<BR/>Parallel-group<BR/>Double-blind<BR/>Multicentre (n=10)<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country:<BR/>Germany<BR/>Mean age: 63.2<BR/>% Female: 64.5<BR/>Mean disease duration: 58.9 mth<BR/>Duration: 12 wk<BR/>Number randomised: 321<BR/>(EUF 160, SYN 161)<BR/>Inclusion:<BR/>either sex,<BR/>age 50 to 80 y,<BR/>confirmed OA in one or both knees,<BR/>clinical evidence of chronic idiopathic OA of the study knee according to criteria of Altman, radiologically verified OA of the study knee by modified Kellgren-Lawrence (grade 2 or 3),<BR/>symptoms in study knee for at least 1 y,<BR/>willingness to discontinue all OA treatments other than acetaminophen, moderate to severe knee pain as reflected by a VAS pain score of 41 to 80 out of 100 mm for the average of the WOMAC OA Index pain subscale with only one pain item permitted to be below 20 mm or above 80 mm<BR/>Exclusion:<BR/>secondary OA originating from a known injury to the knee, RA,<BR/>history of joint infection, dermatologic disorders or skin infection in proximity to study knee, osteonecrosis, chronic active fibromyalgia, any inflammatory or metabolic arthrides and known sensitivity to acetaminophen or hyaluronan,<BR/>hyaluronan injection to study knee within 6 mth of screening, corticosteroid injection and surgery or arthroscopy to study knee within 3 mth of screening, nonambulatory patients: inability to perform a 50 foot walk test, patients with symptomatic OA of the hip or any other health condition that would have interfered with study assessments including patients with uncontrolled hematological, cardiovascular, neoplastic, pulmonary, neurological, renal, hepatic or systemic disease,<BR/>clinical lab values: fasting blood glucose concentration greater than 160mg/dl, alkaline phosphatase greater than 250 U/I, alanine aminotransferase greater than 30 U/I, or aspartate aminotransferase greater than 30 U/I,<BR/>participation in another study during the study period and during the 4 wk prior to study enrollment<BR/>Baseline values:<BR/>WOMAC pain<BR/>EUF 49.2<BR/>SYN 51.9<BR/>WOMAC stiffness<BR/>EUF 43.2<BR/>SYN 47.8<BR/>WOMAC function<BR/>EUF 47.0<BR/>SYN 50.8<BR/>WOMAC total<BR/>EUF 47.2<BR/>SYN 50.8</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Euflexxa (bioengineered 1% sodium hyaluronate)<BR/>(20 mg/2 ml)<BR/>3 weekly injections,<BR/>Synvisc<BR/>(16 mg/2 ml)<BR/> 3 weekly injections<BR/>Both groups advised to rest for 24 h following each injection. Before each injection, any SF that was present was aspirated.<BR/>Concurrent therapy:<BR/>acetaminophen (500 mg tablets) up to 4 g daily was permitted as rescue medication;<BR/>NSAIDs and other non-acetaminophen pain medications were prohibited</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>WOMAC OA Index pain subscale-----------<BR/>WOMAC stiffness,<BR/>WOMAC physical function,<BR/>patient global assessment of treatment, "Are you satisfied with the results of the injections?" with response graded on a 4-point ordinal scale: 1=dissatisfied, 2=slightly satisfied, 3=satisfied,<BR/>4=very satisfied;<BR/>patient consumption of acetaminophen for pain relief as quantified by pill counts</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad's: 5/5<BR/>R-2, B-2, W-1<BR/>Study supported by Ferring Pharmaceuticals, Inc.<BR/>Statistical review by W. Huang, PhD, Savient Pharmaceuticals, clinical and regulatory support by R. Zaibel, Bio-Technology General (Israel) Ltd., editorial assistance in manuscript preparation provided by BioScience Communications, New York</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Kirchner-2005">
<CHAR_METHODS>
<P>See Kirchner 2005 above.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Kirchner-2006">
<CHAR_METHODS>
<P>See Kirchner 2005 above.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Kotevoglu-2002">
<CHAR_METHODS>
<P>See<BR/>Kotevoglu 2005.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Kotevoglu-2005">
<CHAR_METHODS>
<P>Randomised<BR/>Controlled<BR/>Trial<BR/>Double blind<BR/>Parallel group<BR/>Single centre<BR/>Placebo and active controlled<BR/>Blinded evaluator<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Turkey<BR/>Mean age: 59.5<BR/>% Female: 88<BR/>Mean disease duration: 4 y<BR/>Duration: 6 mth<BR/>Number randomdised:<BR/>(Orthovisc 26,<BR/>Synvisc 26,<BR/>Saline 26)<BR/>Inclusion:<BR/>patients with knee OA according to ACR criteria,<BR/>Kellgren- Lawrence grades II-IV<BR/>Exclusion:<BR/>renal and hepatic comorbidity,<BR/>abnormal lab tests,<BR/>treatment with anticoagulants or immunosuppressives, intra-articular injection of HA or steroids within the past 12 mth,<BR/>any quadriceps exercise programe within the last 4 mth<BR/>Baseline values:<BR/>WOMAC pain<BR/>OR: 16.5<BR/>SYN: 18<BR/>PL: 20<BR/>WOMAC stiffness<BR/>OR: 6.5<BR/>SYN: 7<BR/>PL: 6<BR/>WOMAC function<BR/>OR: 52.5<BR/>SYN: 55<BR/>PL: 59.5<BR/>Patient global<BR/>OR: 90<BR/>SYN: 80<BR/>PL: 90<BR/>Physician global<BR/>OR: 95<BR/>SYN: 80<BR/>PL: 90<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Synvisc 3 weekly injections,<BR/>Orthovisc 3 weekly injections,<BR/>Saline 3 weekly injections<BR/>All injections injections performed by 2 physicians in anterolateral approach (along the patellar tendon) with knee in 90 degrees of flexion<BR/>Concurrent therapy: aceta-<BR/>minophen up to 4 mg/day permitted<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>WOMAC pain (5-25), WOMAC stiffness (2-10), WOMAC physical function (17-85), patient and physician global assessments on a 0-100 mm VAS scale; for both the question was, "How do you grade the severity of your (or the patient's)<BR/>knee OA according to a 0-100 scale, 100 being the worst</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad's: 3/5<BR/>R-1, B-1, W-1<BR/>Patients did not have effusion. In bilateral disease, the more painful knee was treated.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Lanzer-2002">
<CHAR_METHODS>
<P>See Caborn 2004.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Leardini-1987">
<CHAR_METHODS>
<P>Randomised<BR/>Controlled<BR/>Trial<BR/>Single-blind<BR/>Parallel-group<BR/>Washout<BR/>Mth 2: ITT analysis,<BR/>Mth 12: Per protocol</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country:<BR/>Italy<BR/>Mean age: 64<BR/>% Female:81<BR/>Disease <BR/>duration: NR<BR/>Duration:1 y<BR/>Number randomised:36<BR/>(HA 20, MPA 16)<BR/>[40 jts: HA 20, MPA 20]<BR/>Inclusion:<BR/>active gonarthrosis<BR/>Kellgren Grade 2 or 3<BR/>Exclusion:<BR/>no other joint disease<BR/>Baseline values:<BR/>spontaneous pain<BR/>HA:41.3, <BR/>MPA: 33.4<BR/>passive movement<BR/>HA:115.8<BR/>MPA:109.0<BR/>active movement<BR/>HA:108.4<BR/>MPA:104.2<BR/>ring size<BR/>HA: 43.0,<BR/>MPA: 42.6<BR/># jts.pain under load<BR/>HA:18, MPA:19<BR/># jts walking pain<BR/>HA:20, MPA:20</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Hyalgan (20 mg/2ml) 3 weekly injections<BR/>Methylpredniso-<BR/>lone acetate (MPA) 40 mg/1 ml<BR/>(Depo-Medrol)<BR/>3 weekly injections<BR/>Concurrent therapy:<BR/>simple analgesics permitted for most severe pain, no NSAIDs for first 2 mths then allowed for short periods (&lt;2 wk) between end of mth 2 and mth 12</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>spontaneous pain on VAS<BR/>pain under load and on walking (1=absent to 5=<BR/>very severe)<BR/>active and passive movement in degrees<BR/>ring size in cm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad's:2/5<BR/>R-1,B-0,W-1<BR/>4 pts had bilateral OA; each knee counted as 'one' case.<BR/>R. Bruno and A. Perbellini, Fidia SpA. C. Baggio and C. Zanetti provided statistical analysis. A. Babolin provided secretarial assistance.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Leardini-1991">
<CHAR_METHODS>
<P>Randomised<BR/>Controlled<BR/>Trial<BR/>Open-label<BR/>Parallel-group<BR/>ITT analysis</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country:<BR/>Italy<BR/>Mean age: 65<BR/>% Female:88<BR/>Mean disease duration: 99 mth<BR/>(range 12-300)<BR/>Duration:60 days<BR/>Number randomised:40<BR/>(HA 20, MPA 20)<BR/>Inclusion:<BR/>painful idiopathic OA of the knee by ARA criteria and radiologically assessed by Kellgren<BR/>previous NSAID treatment with poor results suggesting the usefulness of IA treatment<BR/>Exclusion:<BR/>serious concomitant disorders<BR/>ongoing infections<BR/>pregnancy<BR/>allergy or hypersensitivity to drugs<BR/>treatment with any IA drug in last 3 mth<BR/>Baseline values:<BR/>% pts with strong<BR/>pain under load<BR/>HA:65, MPA:55<BR/>% pts with strong<BR/>rest pain<BR/>HA:60, MPA:70</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Hyalgan (20 mg/2ml) 3 weekly injections<BR/>6-methylpredniso-<BR/>lone acetate (6-MPA) 40 mg/1 ml 3 weekly injections (Depo-<BR/>Medrol)<BR/>Concurrent therapy:<BR/>Analagesic &amp; NSAID<BR/>permitted</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>spontaneous pain (100 mm VAS), am stiffness, flexion (degrees)-----------------------<BR/>night pain, pain under load, touch pain (0-4:<BR/>0=none,1=slight,<BR/>2=moderate, 3=<BR/>strong, 4 = very<BR/>strong)<BR/>analgesic or NSAID consumption (0-3: 0=none, 1=<BR/>occasional low<BR/>doses, 2=regular<BR/>low doses, 3 =<BR/>regular high doses)<BR/>joint effusion volume (ml)<BR/>pt and MD global efficacy (0-4: 0 =<BR/>unsatisfactory, 1 = poor, 2 = fair,<BR/>3 = good, 4 = excellent)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad's:2/5<BR/>R-1,B-0,W-1<BR/>Arthrocentesis performed if<BR/>effusion present and measured.<BR/>Pts kept at rest for 2 days after injection.<BR/>A. Perbellini,<BR/>Fidia S.p.A.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Leopold-2003">
<CHAR_METHODS>
<P>Randomised<BR/>Controlled<BR/>Trial<BR/>Single-blind<BR/>Blinded assessor<BR/>Parallel-group<BR/>Single centre</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country:<BR/>USA<BR/>Mean age: 65<BR/>% Female: 54<BR/>Disease duration: NR<BR/>Duration: 6 mth<BR/>Number randomised: 100<BR/>(HA 50, CS 50)<BR/>Inclusion:<BR/>&gt;18 y<BR/>x-ray evidence of symptomatic OA of the knee<BR/>dissatisfaction with prior attempts at non-<BR/>operative management modalities (e.g.<BR/>NSAID, oral<BR/>analgesics, nutritional supplements, PT, braces)<BR/>symptomatic=<BR/>pain with weight<BR/>bearing at TB and/or PF with one or more of:<BR/>loss of cartilage thickness, osteo-<BR/>phyte formation, subchondral sclerosis, cysts<BR/>Exclusion:<BR/>pregnant<BR/>lactating<BR/>x-ray signs of bone-on-bone<BR/>arthritis, chrondrocalcin-<BR/>osis,<BR/>physical exam showed an insufficiency of collateral ligament or insufficiency of anterior or posterior cruciate ligament with concomitant symtomatic giving-way of the affected extremity, or current infection in affected extremity<BR/>history of crystalline arthropathy or inflammatory arthritis, neuropathic arthropathy, an ia injection with any<BR/>corticosteroid or any HA within the previous 3 mth<BR/>allergy or hyper-<BR/>sensitivity to study medications, eggs, feathers, avian proteins, or chickens</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Hylan G-F 20<BR/>3 weekly injections (with effusion aspiration)<BR/>Betamethasone sodium phos-<BR/>phate-betameth-<BR/>asone acetate 2 ml mixed in 4 ml of Marcaine (bupivacaine) and 4 ml of lido-<BR/>caine (effusion not aspirated) &amp; could have 2nd injection at any time (48%)<BR/>(Celestone <BR/>Soluspan)<BR/>Concurrent therapy: NSAID permitted but tracked (HA - 64%, CS -56% usage)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Modified Knee Society clinical rating scale (100 points),<BR/>WOMAC OA Index (Likert),<BR/>pain (100 mm VAS)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad's:3/5<BR/>R-2,B-0,W-1<BR/>Study was independently funded. Base-<BR/>line significant<BR/>difference in x-ray severity: more moderate in HA; more mild or severe in CS.<BR/>If bilateral, only one knee analysed.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Lin-2004">
<CHAR_METHODS>
<P>See Tsai 2003.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Listrat-1997">
<CHAR_METHODS>
<P>Randomised<BR/>Controlled<BR/>Trial<BR/>Per protocol: n=36<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country:<BR/>France and Italy<BR/>Mean age: 62<BR/>% Female:67<BR/>Mean disease duration: 3 y<BR/>Duration: 1 y<BR/>Number randomised:39<BR/>(HA 20, CT 19)<BR/>Inclusion:<BR/>primary OA defined by ACR<BR/>clinical involvement of medial compartment<BR/>active disease justifying local therapy<BR/>absence of advanced disease (Kellgren and Lawrence Grade 4)<BR/>absence of contraindication of arthroscopy<BR/>presence of chondropathy of medial comparment at arthroscopy<BR/>Exclusion:<BR/>any IA surgery in past 5 y (including arthroscopy)<BR/>any IA treatment prescribed in past 3 mths<BR/>any concurrent<BR/>symptomatic treatment had to be stable for at least one mth before study<BR/>Baseline values:<BR/>pain<BR/>HA:49.2, CT:52.1<BR/>Lequesne<BR/>HA:8.9, CT:9.4<BR/>arthroscopy overall assessment<BR/>HA:41.8, CT:52.6<BR/>AIMS2<BR/>HA:2.6, CT:2.2<BR/>Joint space width (mm) HA: 4.5,<BR/>CT: 3.5<BR/>SFA scoring<BR/>HA: 26.1, <BR/>CT: 39.0</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Hyalgan (20 mg/2ml) 3 weekly injections every 3 mth for total of 9 injections with 1st injection 1 mth after arthroscopy and last 3 mth before final visit<BR/>Conventional therapy but all pts had arthroscopy with lavage 2 litres saline serum <BR/>before randomisation<BR/>Concurrent therapy: analgesics &amp; NSAID<BR/>permitted</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>arthroscopy scored MD overall assess-<BR/>ment (100 mm VAS), revised SFA scoring and SFA grading-------<BR/>global pain 100 mm VAS<BR/>Lequesne Index<BR/>AIMS2<BR/>analgesic/NSAID score<BR/>AP wt bearing knee xrays - joint space narrowing by 7-grade and joint space width (mm)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad's:2/5<BR/>R-1,B-0,W-1<BR/>Synovial fluid aspirated before injection.<BR/>Imbalance at entry in severity of chondropathy .<BR/>Imbalance in amount of rescue treatment.<BR/>Study supported by a grant from Fidia S.p.A. and in part from a grant from the Societe Francaise de Rhumatologie.<BR/>Hyalgan supplied by Fidia S.p.A.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Lohmander-1996">
<CHAR_METHODS>
<P>Randomised<BR/>Controlled<BR/>Trial<BR/>Double-blind<BR/>Multicentre (n=8)<BR/>Placebo- controlled<BR/>Stratified<BR/>Efficacy analysis: per protocol n=189, safety analysis: ITT, n=239</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Denmark, Finland, Norway,<BR/>Sweden<BR/>Mean age: 58<BR/>% Female:56<BR/>Mean disease duration:<BR/>Duration:20 wk<BR/>Number randomised:240<BR/>(HA 120, PL 120)<BR/>Inclusion:<BR/>40-75 y<BR/>symptomatic, radiologically verified knee OA <BR/>(Ahlback stage 1 to 2)<BR/>knee pain on day of examination &gt;10/100 mm VAS<BR/>Lequesne score &gt;= 4 baseline<BR/>Exclusion:<BR/>significant symptoms of bilateral knee OA<BR/>previous IA fracture of knee<BR/>RA or other inflammatory arthritis<BR/>IA injection of steroids or other invasive procedure in knee in past 6 mth<BR/>any other condition that in-<BR/>terferes with efficacy assessment or completion of trial<BR/>Baseline values:<BR/>pain<BR/>HA:44.4, PL: 42.3<BR/>activity level<BR/>HA:60.7, PL:60.7<BR/>knee function<BR/>HA:51.2, PL:49.3<BR/>ROM<BR/>HA:33.8, PL:38.5<BR/>Lequesne<BR/>HA:9.9, PL:9.6<BR/>Lysholm<BR/>HA:54.1, PL:57.9<BR/>Tegner<BR/>HA:2.7, PL: 2.6<BR/>Clincial exam<BR/>HA:20.8, PL:21.0</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Artzal (25 mg/2.5 ml) 5 weekly injections<BR/>Placebo:saline 2.5 ml 5 weekly injections<BR/>Local anaesthetic used.<BR/>Concurrent therapy:<BR/>analgesics &amp; NSAID<BR/>permitted and monitored.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Lequesne index<BR/>100 mm VAS for knee pain, ROM, activity level and total knee function-------------<BR/>Tegner activity score, Lysholm knee function score<BR/>clinical exam<BR/>quantity of con-<BR/>current medication<BR/>pt and examiner global (7 stages:<BR/>from much im-<BR/>proved to much<BR/>worse)<BR/>volume of fluid aspirated<BR/>number of leuco-<BR/>cytes in joint fluid</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad's:4/5<BR/>R-1,B-2,W-1<BR/>Effusion aspirated before injection<BR/>Stratification by age and Lequesne score<BR/>into 4 groups:<BR/>40-60 y, Lequesne 4-10;<BR/>40-60 y,<BR/>Lequesne &gt;10,<BR/>61-75 y, Lequesne 4-10,<BR/>61-75 y, Lequesne &gt;10<BR/>Standardisation meeting for injection tech-<BR/>nique and assessment procedures.<BR/>Work supported by Medical Faculty of Lund University, the Swedish MRC, KaroBio AB and Astra Lakemedel AB.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-McDonald-2000">
<CHAR_METHODS>
<P>Randomised<BR/>Controlled<BR/>Trial<BR/>Double-blind<BR/>Multicentre (n=12)<BR/>2 wk washout<BR/>Both ITT n=256<BR/>and per protocol, n=233 with publication based on PP.<BR/>analyses done</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country:<BR/>Germany<BR/>Mean age: 62<BR/>% Female: 61<BR/>Mean disease<BR/>duration: 4.4 y<BR/>Duration:6 mth<BR/>Number randomised:256<BR/>(FM 127, HA 129)<BR/>Inclusion:<BR/>radiologically confirmed knee OA (Ahlback 1 to 3) and ACR diagnostic criteria<BR/>investigator approval of with-<BR/>drawal of analgesic medication<BR/>with escape medication being acetaminophen for study<BR/>Exclusion:<BR/>IA injections or arthroplasty to affected knee in last 3 mth<BR/>concomitant medical condi-<BR/>tions that could interfere with study assessments such as hip OA<BR/>Baseline values:<BR/>pain<BR/>FM:56.2,HA:57.2<BR/>Lequesne<BR/>FM:11.2,HA:11.1</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Fermathron 2 ml<BR/>5 weekly injections<BR/>Hyalart 2 ml<BR/>5 weekly injections<BR/>Concurrent therapy:<BR/>Paracetamol,<BR/>Aspirin up to 150 mg<BR/>daily</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Lequesne ---------<BR/>use of escape medication by pt daily diary<BR/>VAS pain assess-<BR/>ment of affected<BR/>knee <BR/>pt global (very good, good,<BR/>average, poor, very poor)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad's:5/5<BR/>R-2,B-2,W-1<BR/>First author of publication is affiliated with Fermentech Medical Ltd.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Miltner-2002">
<CHAR_METHODS>
<P>Randomised<BR/>Controlled<BR/>Trial<BR/>Single-blind<BR/>Blinded clinical assessor<BR/>Right/left comparison<BR/>Single centre<BR/>Stratified on more impaired knee</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country:<BR/>Germany<BR/>Mean age: 67<BR/>% Female: 53<BR/>Mean disease duration: NR<BR/>Duration: 7 wk<BR/>Number randomised: 43<BR/>(HA: 24 knees most impaired, 19 knees less impaired;<BR/>No treatment: 19 knees most impaired; 24 knees less impaired)<BR/>Inclusion:<BR/>Adults of both genders with a minimum age of 50 yr<BR/>OA of both knees<BR/>Radiographic changes = Kell-<BR/>gren and Lawrence stage II to III bilat-<BR/>erally<BR/>Symptomatic gonarthrosis for a minimum of 12 months<BR/>Pain during wt bearing &gt;=4/10 cm VAS bilaterally<BR/>Lequesene score not different by more than +/- 2 points in total value<BR/>Exclusion:<BR/>Pts who do not meet all inclusion criteria<BR/>Neurological deficits in lower extremities<BR/>Underlying diseases such as: primary <BR/>inflammatory joint disease, joint infections, crystalline arthritis, ia tumors, axis deviation of &gt;15o varus or valgus malalignment, ligamentous instability, previous fractures of the joint, arthroscop-<BR/>ic surgery on the knee in the previous 12 mths<BR/>IA injections of the knee joint in 3 mth prior to study<BR/>Baseline values:<BR/>Pain at rest<BR/>HA: 3.83<BR/>NT: 3.67<BR/>Pain wt bearing<BR/>HA: 7.57<BR/>NT: 7.43<BR/>Lequesne<BR/>HA: 13.57<BR/>NT: 12.48<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Hyalart 20 mg<BR/>5 weekly injections<BR/>No treatment<BR/>Concurrent therapy: NSAID &amp; analgesics to be avoided.<BR/>Paracetamol 500 mg was permitted as pain medication.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Lequesne (max score 26),<BR/>pain (10 cm VAS)<BR/>isokinetic test (maximum peak torque for extensors and<BR/>flexors), total work</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad's:1/5<BR/>R-1,B-0,W-0<BR/>Baseline difference between groups in initial values for total work of the knee flexor and extensor. This may be possibly due to the fact that the more impaired knee was entered in the treatment group more often than in the control group. This trial was piloted by the trial by Schneider (1997).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Moreland-1993">
<CHAR_METHODS>
<P>Randomised<BR/>Controlled<BR/>Trial<BR/>Double-blind<BR/>Blinded assessor<BR/>Screen blinded pt<BR/>Parallel-group<BR/>Multicentre (n=5)<BR/>4 wk washout of NSAID but permitted acetaminophen as analgesia.</P>
<P>Analysis: ITT<BR/>Phase I efficacy:<BR/>per protocol<BR/>Flare population: n=30 (31 knees)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country:<BR/>U.S.A.<BR/>Mean age: NR<BR/>% Female:67<BR/>Mean disease<BR/>duration: NR<BR/>Duration:34 wk<BR/>Number randomised:94<BR/>(HA 46, AR 48)<BR/>[104 knees:<BR/>HA 52, AR 52]<BR/>Inclusion:<BR/>chronic idiopathic OA of knee confirmed by xray<BR/>Kellgren and Lawrence Grade 2 to 4 in no more than 2 compartments<BR/>symptoms of inflammation and/or advanced disease which included rest pain during day of at least moderate severity (&gt;=40/<BR/>100 mm VAS) or pain awakening them at night<BR/>Exclusion:<BR/>pregnant or of childbearing potential not using effective contraception<BR/>varus or valgus deformity &gt;=10o<BR/>surgery on knee in past 3 mth or planning surgery<BR/>chondromalacia as primary contributor to symptoms<BR/>&lt;18 y<BR/>unavailable for 26 wk follow-up<BR/>RA, AS, gout, IBD,<BR/>pseudogout, <BR/>psoriatic arthritis,<BR/>peripheral neuropathy causing pain or diastasis distal to knee<BR/>metabolic disease associ-<BR/>ated with joint abnormalities<BR/>liver disease<BR/>cancer<BR/>diabetes mellitus, drug abuse<BR/>Baseline values:<BR/>pain with motion<BR/>HA: 69, AR: 70</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Hylan G-F 20<BR/>(2 ml)<BR/>3 weekly arthro-<BR/>centeses followed by injection<BR/>Arthrocentesis<BR/>3 weekly<BR/>Concurrent therapy:<BR/>Acetaminophen<BR/>usage for analgesia documented (pill counts)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>pain with walking, at rest, at night, with motion and overall ( 100 mm VAS)<BR/>activity restriction<BR/>joint tenderness<BR/>(100 mm VAS)<BR/>joint effusion (+/-,<BR/>volume)<BR/>pt and evaluator global assess-<BR/>ments (100 mm VAS)<BR/>Assessments:<BR/>Phase I<BR/>Wk 0,2,4,5,6,8,10<BR/>Phase II<BR/>Wk 10-18,11-19,12-<BR/>20,16-22,18-26,<BR/>26-34</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad's:5/5<BR/>R-2,B-2,W-1<BR/>If bilateral OA, both knees could be treated and evaluated.<BR/>10 pts had both knees treated -<BR/>(5 AR, 1 HA, 4 both)<BR/>34% patients presented with an effusion.<BR/>Each knee randomised<BR/>Arthrocentesis with removal of effusion if present.<BR/>In Phase II, evaluated repeat treatment with a second course of three hylan G-F 20 injections but no control group.<BR/>Biomatrix, Inc. sponsored work.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Nahler-1996">
<CHAR_METHODS>
<P>See Nahler 1998.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Nahler-1998">
<CHAR_METHODS>
<P>Randomised<BR/>Controlled<BR/>Trial<BR/>Single-blind<BR/>Parallel-group<BR/>Multicentre (n=12)<BR/>Stratified by pain severity<BR/>Equivalence study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country:<BR/>Germany and Austria<BR/>Mean age: 67<BR/>% Female: 80<BR/>Mean disease duration: 68% &lt;1 year<BR/>Duration: 5 wk<BR/>Number randomised: 121<BR/>(ZL 57, HY 57)<BR/>Inclusion:<BR/>presence of primary (idio-<BR/>pathic) arthritis verified by:<BR/>pain in 1 or 2 knees<BR/>a typical xray (medial narrow-<BR/>ing of the joint<BR/>cavity, peripheral<BR/>osteophyte de-<BR/>velopment, com-<BR/>pact ossification of subchondral bone)<BR/>chronic pain in 1 or 2 knee joints for at least 3 mth with no sign of acute inflamma-<BR/>tion<BR/>written statement of patient consent<BR/>Exclusion:<BR/>age &lt;35 or &gt;85 y<BR/>arthritis resulting from prior defor-<BR/>mations, injuries<BR/>or metabolic causes (secon-<BR/>dary arthritis)<BR/>other ailments with symptoms similar to arthritis of the knee such as arthritis of the hip, varicosis, bone &amp; muscle disorders, RA<BR/>signs of acute inflammation (acute active arthritis)<BR/>nonambulatory or bedridden pts<BR/>pts who stated their intention to change level of physical activity during the study<BR/>probable surgical treatment of the arthritic joint in the near future<BR/>i-a corticosteroid treatment of the arthritic joint within the past 2 mth<BR/>low grade pain (&lt;25 mm on the 100 mm VAS)<BR/>a history of aller-<BR/>gic reactions to Zeel or Hyalart<BR/>serious liver or kidney disease<BR/>long term treat-<BR/>ment with immu-<BR/>nosuppressives during last mth<BR/>ongoing concom<BR/>itant therapy with <BR/>analgesics/anti-<BR/>inflammatories</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Zeel compositum<BR/>10 injections (two 2 ml injections/wk)<BR/>Hyalart (2 ml)<BR/>5 weekly injection<BR/>Concurrent therapy:<BR/>Analgesics &amp; anti-<BR/>inflammatories <BR/>prohibited</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pain during active movement on 100 mm VAS (0=pain free, 100=worst pain to date)<BR/>pt final assess-<BR/>ment of toler-<BR/>ance on 100 mm VAS (0=ex-<BR/>tremely poorly tolerated, 100= extremely well tolerated)--------pain during night on 100 mm VAS<BR/>duration of morning stiff-<BR/>ness (min)<BR/>maximum dis-<BR/>tance capable of walking<BR/>time (sec) to walk up and down a stand-<BR/>ard series (1 flight) of stairs<BR/>final assess-<BR/>ment of efficacy<BR/>by MD and pt on 100 mm VAS (0=no improve-<BR/>ment, 100=ex-<BR/>treme improve-<BR/>ment)<BR/>final assess-<BR/>ment of toler-<BR/>ance by MD and pt on 100 mm VAS as above<BR/>drop-out rate <BR/>resulting from inadequate efficacy<BR/>reporting of un-<BR/>desired side effects (weekly)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad's:4/5<BR/>R-2,B-1,W-1<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Neustadt-2004">
<CHAR_METHODS>
<P>See Neustadt 2005a-3inj.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Neustadt-2005">
<CHAR_METHODS>
<P>See Neustadt 2005a-3inj</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Neustadt-2005a-_x002d_3inj">
<CHAR_METHODS>
<P>Randomised<BR/>Controlled <BR/>Trial<BR/>Arthrocentesis controlled<BR/>Multicentre n=24, (Canada n=3, USA n=21)<BR/>Double-blind<BR/>7-day washout<BR/>NSAID and analgesics<BR/>January 2001 to December 2002<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country:<BR/>Canada and the United States<BR/>Mean age: 176.4<BR/>% Female: 47.9<BR/>Mean disease duration: NR<BR/>Duration:28 wk<BR/>Number randomised: 372<BR/>(O4 128,<BR/>O3A1 120, and<BR/>A4 124)<BR/>Inclusion:<BR/>greater than or equal to 40 y of age,<BR/>willing to discontinue all analgesics and NSAID 7 days before the first injection and for the duration of the study,<BR/>diagnosis of knee OA according to ACR criteria,<BR/>Kellgren-Lawrence grade 1,2 or 3,<BR/>a summed WOMAC pain score greater than or equal to 200 mm and less than 400 mm (maximum 500) in the index (treated) knee and less than 150 mm in the contralateral (untreated) knee<BR/>Exclusion:<BR/>patients who initiated an exercise or physical therapy program within 3 mth,<BR/>oral or parenteral corticosteroid use within 30 days,<BR/>intraarticular injection of steroids into the index knee within 90 days,<BR/>intraarticulr injection of any hyaluronic substanced within the past 9 mth or operative arthroscopy within 6 mth,<BR/>treatment with anticoagulants,<BR/>clinically significant comorbidity (fibromyalgia, peripheral neuropathy, vascular insufficiency or hemiparesis) severe enough to interferewith accurate evaluation<BR/>Baseline values:<BR/>(based on evaluable (per protocol) population)<BR/>WOMAC pain<BR/>index knee<BR/>O4: 286.6<BR/>O3A1: 289.0<BR/>A4: 294.1<BR/>contralateral knee<BR/>O4: 66.8<BR/>O3A1: 69.3<BR/>A4: 64.6<BR/>Patient global<BR/>O4: 67.5<BR/>O3A1: 62.4<BR/>A4: 64.4<BR/>Investigator global<BR/>O4: 58.8<BR/>O3A1:57.0<BR/>A4: 57.6<BR/>Pain on standing<BR/>O4: 65.2<BR/>O3A1: 65.7<BR/>A4: 65.5<BR/>Synovial fluid volume (ml)<BR/>O4: 0.9<BR/>O3A1: 1.0<BR/>A4: 0.9<BR/>Mean analgesic usage (tablets/day):<BR/>O4: 2.08<BR/>O3A1: 2.48<BR/>A4: 2.05<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1) O4: Orthovisc 2 ml (30 mg) 4 weekly injections<BR/>2) O3A1: Orthovisc 2 ml (30 mg) 3 weekly injections plus one control arthrocentesis procedure<BR/>3) A4: 4 control arthrocentesis<BR/>All injections were administered by either lateral or medial approach after instillation of 1% lidocaine hydrochloride solution. If fluid present, joint space aspirated to dryness.<BR/>Concurrent therapy: Acetaminophen up to 4 g/day allowed but not permitted for at least 24h prior to each study assessment visit.<BR/>NSAIDs and other analgesics not permitted during the study.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>The proportion of patients achieving a 20% relative and 50 mm absolute improvement from baseline in WOMAC pain score at weeks 8, 12, 16 and 22 post baseline in the Index Knee (0-500 mm VAS)<BR/>-----------------------<BR/>patient global score,<BR/>investigator global score and pain on standing score all scored on a 0 to 100 mm VAS</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad's: 5/5<BR/>R-2, B-2, W-1<BR/>The evaluable poulation (patients who received all 4 treatments and at least one followup visit and who had no significant protocol deviation) was considered the primary planned analysis population NOT the intent to treat population.<BR/>Screend patients: 888;<BR/>Randomised patients: 372;<BR/>ITT (safety) O4: 128, O3A1: 119, A4: 123;<BR/>Evaluable: 336<BR/>O4: 115, O3A1: 107, A4: 114;<BR/>Per protocol: 258<BR/>O4: 93, O3A1: 76, A4: 89</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Neustadt-2005b_x002d_4inj">
<CHAR_METHODS>
<P>See Neustadt 2005a-3inj.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Ozturk-2005">
<CHAR_METHODS>
<P>Randomised<BR/>Controlled<BR/>Trial<BR/>Single-blind<BR/>Single centre<BR/>7-day washout of NSAID</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Turkey<BR/>Mean age: 58.03<BR/>% Female: 97.5<BR/>Mean disease duration: NR<BR/>Duration: 1 y<BR/>Number randomised: 47<BR/>(HA: 24, HA+TA: 23)<BR/>Inclusion:<BR/>OA of the knee according to ACR criteria,<BR/>Kellgren-Lawrence grades II or III radiographically confirmed,<BR/>pain in affected knee for at least 6 mth<BR/>Exclusion:<BR/>received intra-<BR/>articular injection in the joint and/or attend physiotherapy for the affected knee within 6 mth prior to study,<BR/>history of allergy or hypersensitive to drugs or eggs,<BR/>ascertained or suspected to be pregnant or lactacting,<BR/>known or suspected joint infection or a specific condition (neoplasms, diabetes mellitus, paresis, osteonecrosis, recent trauma) or poor general health that would interfere with the functional assessments during the study<BR/>Baseline values:<BR/>range of motion<BR/>HA: 112.0<BR/>HA+TA: 118.8<BR/>50-foot walking time<BR/>HA: 23.7<BR/>HA+TA: 22.6<BR/>pain (VAS)<BR/>HA: 66.7<BR/>HA+TA: 72.6<BR/>WOMAC pain<BR/>HA: 14.3<BR/>HA+TA: 16.3<BR/>WOMAC stiffness<BR/>HA: 4.1<BR/>HA+TA: 4.1<BR/>WOMAC function<BR/>HA: 53.3<BR/>HA+TA: 49.0<BR/>WOMAC total<BR/>HA: 71.8<BR/>HA+TA: 69.6</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Orthovisc (2 ml Biomeks) alone 3 weekly injections<BR/>(Days 0,7,14) then 3 injections at month 6,<BR/>Combined group: same as above but prior to lst and 4th HA injection, effusions aspirated and then 1 ml triamcinolone acetonid (Kenacort-A, Bristol Myers Squibb)<BR/>Concurrent therapy: paracetamol to a maximum of 2 g daily as considered appropriate by the physician was permitted;<BR/>NSAID not permitted.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>WOMAC OA Index (Likert),<BR/>pain (0-100 mm VAS), ROM - flexion only with a goniometer,<BR/>50 foot walking time (sec), assessment of effusion (peri-<BR/>pheral measurement of knee),<BR/>MRI - cartilage evaluated with an eight grade system by 2 independent observers</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad's: 3/5<BR/>R-2, B-0, W-1<BR/>No statistically significant differences in demographic or clinical data at baseline.<BR/>Although 47 patients enrolled, 7 in the HA+TA group were withdrawn as they did not meet inclusion criteria.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Petrella-2002">
<CHAR_METHODS>
<P>Randomised<BR/>Controlled<BR/>Trial<BR/>Double-blind<BR/>Placebo- controlled<BR/>Parallel-group<BR/>2 wk washout all OA medications<BR/>ITT analysis</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country:<BR/>Canada<BR/>Mean age: 65.5<BR/>% Female: 46<BR/>Mean disease<BR/>duration: NR<BR/>Duration: 12 wk<BR/>Number randomised: 120<BR/>(30/group)<BR/>Inclusion:<BR/>radiographic evidence of Grade 1 to 3 medial compartment unilateral knee OA [Grade 1-23%,<BR/>Grade 2 - 45%,<BR/>Grade 3 - 32%]<BR/>&gt;=3 cm current rest pain<BR/>absence of non-OA arthritides<BR/>Exclusion:<BR/>previous NSAID intolerance<BR/>gastrointestinal hemorrhage<BR/>peptic ulcer disease<BR/>avian allergy<BR/>intraarticular injection of HA or corticosteroid in previous 6 mth<BR/>regular con-<BR/>consumption of "herbal" OA products (e.g. glucosamine sulfate)<BR/>Baseline values:<BR/>WOMAC pain<BR/>HA+PL: 3.32<BR/>NSAID+PL: 4.22<BR/>NSAID+HA: 3.65<BR/>PL: 3.62<BR/>WOMAC function<BR/>HA+PL: 4.10<BR/>NSAID+PL: 4.32<BR/>NSAID+HA: 3.90<BR/>PL: 4.72<BR/>Rest pain:<BR/>HA+PL:3.29<BR/>NSAID+PL:3.34<BR/>NSAID+HA:3.60<BR/>PL:3.30<BR/>Baseline xray:<BR/>HA+PL: 2.2 (0.3)<BR/>NSAID+HA: 2.2 (0.5)<BR/>NSAID+PL: 2.3 (0.4)<BR/>PL: 2.2 (0.2) based on Altman et al 1987 Arthritis Rheum.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Suplasyn 20 mg<BR/>3 weekly injections<BR/>+ placebo (lactose 100 mg po bid)<BR/>Suplasyn 20 mg<BR/>3 weekly injections + 75 mg diclofenac/<BR/>200 ug misoprostol<BR/>po bid (Arthrotec)<BR/>Saline 2 ml<BR/>3 weekly injections + 75 mg diclofenac/<BR/>200 ug misoprostol<BR/>po bid (Arthrotec)<BR/>Saline 2 ml<BR/>3 weekly injections<BR/>+ placebo (lactose 100 mg po bid)<BR/>All pts received 10 min home-based resistance exercise program to be done at least 3x/wk but preferably most days/wk<BR/>Concurrent therapy:<BR/>325 mg acetaminophen</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>self-report of cur-<BR/>rent pain at rest on VAS<BR/>WOMAC OA Index<BR/>functional perfor-<BR/>mance of self-<BR/>paced walking test and a self-<BR/>paced stepping test - VAS scale<BR/>of pain after completion and performance time<BR/>range of motion<BR/>VO2 max</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad's:5/5<BR/>R-2,B-2,W-1<BR/>Unilateral only<BR/>Discrepancy between abstract and paper for rest pain mean and sd at baseline and sd at 4 wk. The sd for SPW and SPS pain at wk4 changed as well but WOMAC pain and function and walk time values did not change.<BR/>Results only presented for Week 4 not Week 12.<BR/>Study supported by Bioniche Life Sciences Inc.<BR/>Dr. Hildebrand is affiliated with Bioniche Life Sciences Inc.<BR/>Editorial reports that a factorial design analysis most efficient; a reanalysis found no evidence that Suplasyn had a signficant or important clinical effect on pain.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Pham-2003">
<CHAR_METHODS>
<P>See Pham 2004</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES>
<P>One author of abstract, S. Brin, affiliated with Aventis, Paris, France.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Pham-2004">
<CHAR_METHODS>
<P>Randomised<BR/>Controlled<BR/>Trial<BR/>Double-blind<BR/>X-ray scorers blinded<BR/>Placebo- controlled<BR/>Parallel group<BR/>Multicentre (46 rheumatology departments)<BR/>Parallel-group<BR/>Multicentre<BR/>ITT (LOCF)<BR/>Repeat treatme</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country:<BR/>France<BR/>Mean age: 64.8<BR/>% Female: 68<BR/>Mean disease duration: NR<BR/>Duration: 1 y<BR/>Number randomised: 301<BR/>(NRD+PLDIA 131, PLINJ+DIA<BR/>85, PLINJ+PLDIA 85)<BR/>Inclusion:<BR/>outpt fulfilling the ACR clinical or radiological criteria for the diagnosis of knee OA,<BR/>presenc eof a symptomatic primary painful medial femorotibial knee OA defined by a daily pain VAS score &gt;30 mm in the previous mth,<BR/>medial joint space width &gt;2mm,<BR/>radiographic evidence of knee OA, eligibility criteria and quality of radiographic films were verified by a central reader<BR/>Exclusion:<BR/>evidence of secondary knee OA (possibly due to injury, inflam-<BR/>mation or meta-<BR/>bolic rheumatic disease, osteonecrosis, Paget's disease, villonodular synovitis, haemophilia),<BR/>prior ia HA treatment, other ia injection including lavage and corticosteroids within the previous 3 mth,<BR/>treatment with diacerein in the 3 mth before inclusion and use of any other anti-osteoarthritic drugs in the 2 mth before inclusion,<BR/>contraindication to IA injection (anticoagulants, haematological anomalies),<BR/>severe knee OA (JSW &lt;2 mm, surgery required on the evaluated knee in the year)<BR/>Baseline values:<BR/>Pain (0-100)<BR/>NRD: 61.7<BR/>DIA: 59.6<BR/>PL: 59.1<BR/>Lequesne<BR/>NRD: 11.1<BR/>DIA: 10.5<BR/>PL: 10.5<BR/>Pt global (0-100)<BR/>NRD: 59.7<BR/>DIA: 59.0<BR/>PL: 57.3<BR/>% of painful days during previous mth (0-100)<BR/>NRD: 85.5<BR/>DIA: 83.0<BR/>PL: 82.6<BR/>JSW (mm)<BR/>NRD: 4.5<BR/>DIA: 4.5<BR/>PL: 4.7</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1) NRD 101 - 3 courses of 3 IA injections+ oral placebo,<BR/>2) IA injections of saline + Diacerein 50 mg twice daily,<BR/>3) IA injections of saline + oral placebo<BR/>Concurrent therapy: Allowed to take analgesics as rescue drugs but 2-day washout before evaluation visit; aspirin &lt;500 mg/day allowed; NSAID allowed but 7-day washout requied before each evaluation visit; no systemic corticosteroid, IA treatment or any potential symptom modifying drug was allowed during the study</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pain (0-100 mm VAS), <BR/>Lequesne,<BR/>Pt. global assessment of disease activity (0-100 mm VAS),<BR/>% of painful days during previous months (0-100 mm VAS),<BR/>use of concomitant treatments (analgesics and NSAIDs) evaluated by numbers of days of intake between each clinic visit,<BR/>pt and investigator global assessment of treatment efficacy (5 point Likert: very good, good, moderate, bad, very bad),<BR/>investigator global assessment of treatment safety on 5 level Likert scale,<BR/>Structural:<BR/>JSW, Kellgren Lawrence grade,<BR/>osteophyte score on antero-posterior X-ray,<BR/>% of progressors (joint space narrowing 0.5 mm)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad's: 5/5<BR/>R-2, B-2, W-1<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Pietrogrande-1991">
<CHAR_METHODS>
<P>Randomised<BR/>Controlled<BR/>Trial<BR/>Open-label<BR/>Parallel-group<BR/>Multicentre<BR/>ITT analysis</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country:<BR/>Italy<BR/>Mean age: NR<BR/>% Female:73<BR/>Mean disease<BR/>duration: NR<BR/>Duration:60 days<BR/>Number randomised: 90<BR/>(HA 45, MPA 45)<BR/>Inclusion:<BR/>confirmed radiological signs of knee OA (Kellgren) and presence of pain<BR/>Exclusion:<BR/>knee joint disease other than OA<BR/>severe concomitant diseases or diseases inter-<BR/>fering with evaluation of knee joint OA<BR/>pregnancy<BR/>allergy<BR/>skin infections<BR/>other IA treatments in past 3 mth<BR/>Baseline values:<BR/>% pt pain under load strong<BR/>HA:40, MPA: 64<BR/>% pt rest pain strong<BR/>HA: 20, MPA: 22<BR/>% pt pain on touch strong<BR/>HA: 18, MPA: 22<BR/>% pt night pain strong<BR/>HA: 16, MPA: 11</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Hyalgan (20mg/2ml)<BR/>5 weekly injections<BR/>at 7 day intervals<BR/>6-methylprednis-<BR/>olone acetate<BR/>(40mg/1 ml) 3 weekly injections (Depo-Medrol)<BR/>Concurrent therapy:<BR/>Analgesic &amp; NSAID consumption assessed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>daytime spon-<BR/>taneous pain on <BR/>100 mm VAS<BR/>morning stiffness (min)<BR/>range of motion (goniometer)<BR/>pt and MD efficacy<BR/>assessment (0=<BR/>unsatisfactory,1=poor,2=fair,3=<BR/>good,4=excellent)-----------------<BR/>night pain, rest pain, pain under load, touch pain (0=absent,1= slight, 2=moder-<BR/>ate,3=strong,4= very strong)<BR/>NSAID,analgesic<BR/>consumption,0-3:0=none,1=occa-<BR/>sional,2=continu-<BR/>ous low doses,<BR/>3=continuous high doses)<BR/>effusion volume<BR/>(ml)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad's:2/5<BR/>R-1,B-0,W-1<BR/>Drugs supplied by Fidia S.p.A.<BR/>P. Pierfederici and A. Perbellini, Fidia S.p.A.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Puhl-1993">
<CHAR_METHODS>
<P>Randomised<BR/>Controlled<BR/>Trial<BR/>Double-blind<BR/>Parallel-group<BR/>Multicentre (n=24)<BR/>Efficacy analysis: per protocol, n=195, safety analysis: ITT, n=209</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country:<BR/>Germany<BR/>Mean age: 62<BR/>% Female: 64<BR/>Mean disease<BR/>duration: NR<BR/>Duration:18 wk<BR/>(Wk 18 either in person or <BR/>telephone follow-up)<BR/>Number randomised:209<BR/>(HA 102, PL 107)<BR/>Inclusion:<BR/>40-75 y<BR/>informed consent<BR/>idiopathic OA of knee defined by clinical and xray criteria (Lequesne)<BR/>Exclusion:<BR/>inflammatory jt disease<BR/>ESR&gt;40 mm<BR/>RF &gt;1:40<BR/>specific arthropathies (chondrocalcinosis, jt effusion &gt;100 ml)<BR/>excessive obesity<BR/>severe axis deviations or instabilities<BR/>protheses of lower limbs<BR/>symptomatic hip<BR/>IA injection in prior 3 mth<BR/>infectious or febrile diseases<BR/>joint or skin infections pregnancy<BR/>contraindication to paracetamol<BR/>Baseline values:<BR/>pain <BR/>HA:54.1, PL:51.4<BR/>Lequesne<BR/>HA:10.4, PL:9.4<BR/>pain under load<BR/>(% pt moderate/ severe)<BR/>HA:90.5, PL:87.0<BR/>pain at rest<BR/>(% pt moderate/<BR/>severe)<BR/>HA:41.1, PL:35.0<BR/>pain starting to walk (% pt mod-<BR/>erate/severe)<BR/>HA: 73.3, PL:63.0</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Artz (25mg/2.5 ml)<BR/>5 weekly injections<BR/>Placebo:sodium hyaluronate 0.25mg/2.5 ml<BR/>5 weekly injections<BR/>Concurrent therapy:<BR/>Paracetamol up to 1-2 tabs of 500 mg tid daily permitted</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Lequesne<BR/>paracetamol consumption-----<BR/>modified Lequesne<BR/>pain last week,at rest, under load, starting (100 mm VAS)<BR/>crepitation<BR/>joint effusion<BR/>joint mobility<BR/>pt and MD global<BR/>efficacy rating<BR/>overall tolerance</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad's:5/5<BR/>R-2,B-2,W-1<BR/>Significantly more females in Artz group (73% versus 55%, P value 0.011)<BR/>Retrospective analysis indicated patients &gt;60 y and Lequesne &gt;10 most likely to benefit from treatment.<BR/>Work sponsored by Luitpold Pharma Munich. Statistical evaluations performed by Mr. Elsasser.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Raynauld-2002">
<CHAR_METHODS>
<P>Randomised<BR/>Controlled<BR/>Trial<BR/>Steering Committee blinded<BR/>Multicentre (n=14)<BR/>Parallel-group<BR/>Open-label<BR/>ITT analysis</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country:<BR/>Canada<BR/>Mean age: 63<BR/>% Female: 70<BR/>Mean disease duration: 9.5 y<BR/>Duration: 1 y<BR/>Number randomised: 255<BR/>(AC+H 127, AC 128)<BR/>Inclusion:<BR/>&gt;40 y<BR/>primary diagnosis of radiologically verified OA in study knee<BR/>symptomatic (&gt;175/500 WOMAC pain) despite prior treatment with NSAIDs or acetaminophen<BR/>ambulatory<BR/>willing to participate<BR/>sign informed consent<BR/>Exclusion:<BR/>Grade 4 (Kellgren)<BR/>contraindicated per Hylan G-F20 label<BR/>inflammatory arthropathies<BR/>tense effusion in study knee at baseline<BR/>chondrocalcinosis<BR/>varus or valgus deformity &gt;12o in study knee<BR/>steroid inj in prior 3 mths in study knee<BR/>prior viscosupplementation<BR/>isolated patello-femoral OA<BR/>uncontrolled morbidity particularly that in any joint which would impede measurements in study knee<BR/>Baseline values:<BR/>WOMAC pain<BR/>AC+H: 11.35<BR/>AC: 11.94<BR/>WOMAC function<BR/>AC+H: 39.54<BR/>AC: 40.20</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Appropriate care with hylan G-F20<BR/>(AC+H)<BR/>Appropriate care without hylan G-F20<BR/>(AC)<BR/>Concurrent therapy:<BR/>Standard care</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mean change in WOMAC LK3.0 pain score in study knee baseline to termination--------<BR/>% pts improved at termination from baseline for 1) 20% improve-<BR/>ment WOMAC pain in study knee, 2) 20% WOMAC pain and either 20% ftn or stiffness in study knee<BR/>pt global assessment of effectiveness for 1) OA in study knee, 2) OA in all jts, 3) overall health<BR/>HRQOL: WOMAC, SF-36, HUI3<BR/>safety: pt. self report during telephone inter-<BR/>view and global assessments of side effects<BR/>Assessments:<BR/>Wk0,Mth1,2,4,6,8,19,12 (Wk 0 and<BR/>Mth 12 at site; others by telephone interview)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad's: 3/5<BR/>R-2,B-0,W-1<BR/>109 AC+H and 108 AC had bilateral knee OA.<BR/>Tense effusion at baseline excluded pt.<BR/>Although Grade IV xray grade was to be excluded, 20% of AC+H and 33% of AC had grade IV.<BR/>An independent Steering Committee designed the study, developed analysis plan, resolved methodological issues and interpreted and disseminated results. <BR/>A CRO, Innovus Research Inc., managed the study.<BR/>Study was funded by Biomatrix, Inc.and Rhone-Poulenc Rorer Canada Inc. Dan Pericak provided statistical analysis.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Redd-2003">
<CHAR_METHODS>
<P>See<BR/>Leopold 2003.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Rejaili-2005">
<CHAR_METHODS>
<P>Randomised<BR/>Controlled <BR/>Trial<BR/>Single centre<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country:<BR/>Brazil<BR/>Mean age: 54.5<BR/>% Female: 80<BR/>Mean disease duration: NR<BR/>Duration: 6 mth<BR/>Number randomised: 20<BR/>(HA 10, AR 10)<BR/>Inclusion:<BR/>knee arthrosis refractory to conservative treatment with blockage and pain symptoms,<BR/>grade 3 Kellgren and Lawrence radiological classification<BR/>Exclusion:<BR/>NR<BR/>Baseline values (preoperative):<BR/>Pain in rest<BR/>HA 7.90<BR/>AR 8.30<BR/>Pain with load<BR/>HA 8.60<BR/>AR 9.20<BR/>Pain upon movement<BR/>HA 8.40<BR/>AR 9.10<BR/>Diclofenac used<BR/>HA 2.80<BR/>AR 2.50<BR/>Postoperative values:<BR/>Pain in rest<BR/>HA 3.20<BR/>AR 4.00<BR/>Pain with load<BR/>HA 3.80<BR/>AR 4.50<BR/>Pain upon movement<BR/>HA 3.90<BR/>AR 5.20<BR/>Diclofenac usage<BR/>HA 0.90<BR/>AR 0.80</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Arthroscopy (articular lavage and debridement) plus 3 weekly injections of hylan G-F 20,<BR/>Arthroscopy alone<BR/>Both groups instructed to stroll first postoperative day. Stitches removed at first visit after 2 weeks at which time the course of Hylan G-F 20 was started.<BR/>Concurrent therapy: potassium diclofenac permitted with daily usage recorded.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>VAS (patient saw "faces" and colours ranging from blue to red as pain increased while observer side showed absolute numerical value (0-10)<BR/>pain during the night,<BR/>pain during movement with a 10% overload of weight on affected knee, pain reduction during the most painful movements of the knee, daily amount of potassium diclofenac used to relieve pain of the injured knee, chondral lesions at time of arthroscopy scored by Noyes and Stabler appud Lemark (grades I to III)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad's: 2/5<BR/>R-1, B-0, W-1<BR/>No between group differences at baseline. Statistical analyses completed at Laboratory for Study Design and Data Analyses of the Dept. of Epidemiology and Public Health of the Medical School of Sao Jose do rio Preto.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Roman-2000">
<CHAR_METHODS>
<P>Randomised<BR/>Controlled<BR/>Trial<BR/>Blind<BR/>Parallel-group<BR/>ITT analysis</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country:<BR/>Spain<BR/>Mean age: 65<BR/>% Female:84<BR/>Mean disease<BR/>duration:NR<BR/>Duration: 6 mth<BR/>Number randomised:49<BR/>(AD 30, HY 19)<BR/>Inclusion:<BR/>gonarthrosis by clinical and radiological criteria<BR/>(Kellgren and Lawrence Grade 2 to 3)<BR/>Exclusion:<BR/>NR</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Adant (25 mg/2.5 ml) 5 weekly injections<BR/>Hyalgan (20 mg/2 ml) 5 weekly injections<BR/>Concurrent therapy:<BR/>Analgesics and/or<BR/>NSAIDs monitored</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>pt efficacy assessment<BR/>(clinical improvement crieria rated as: excellent &gt;75, good 50 to 75,<BR/>fair 25 to 50, no clinical<BR/>response &lt;25)<BR/>consumption of analgesic and/or NSAIDS</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad's:3/5<BR/>R-1,B-1,W-1<BR/>Imbalance in sample size per group.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Scale-1994a-_x0028_2-inj_x0029_">
<CHAR_METHODS>
<P>Randomised<BR/>Controlled<BR/>Trial<BR/>Double-blind<BR/>Blinded assessor<BR/>Placebo- controlled<BR/>Single centre<BR/>2 wk washout of NSAID and analgesics.<BR/>ITT analysis</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country:<BR/>Germany<BR/>Mean age: 60<BR/>%Female:<BR/>Study A: 57<BR/>(37/65)<BR/>Mean disease<BR/>duration: 5.6 y<BR/>Duration: 12 wk<BR/>Telephone follow-up<BR/>at 26 wk<BR/>Number randomised:<BR/>Study A: 50<BR/>(HA 25, PL 25)<BR/>Inclusion:<BR/>&gt;18 y<BR/>male and female<BR/>diagnosis of OA of the knee<BR/>Grade 2 to 4 Larsen scale<BR/>Exclusion:<BR/>RA<BR/>unreliable<BR/>pain under weight bearing &lt;40/100 mm VAS<BR/>effusion present in the joint<BR/>Baseline group differences:<BR/>1) Significantly more pts had Grade 4 xray in PL group <BR/>2) females in 2 inj group weighed significantly less than PL group<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Study A:<BR/>Hylan G-F 20<BR/>2 ml<BR/>(2 inj: end of washout and 2 wks later)<BR/>Placebo: Phosphate-<BR/>buffered saline 2.0 ml<BR/>Concurrent therapy:<BR/>No medication to treat arthritis pain allowed.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>weight bearing pain by pt and MD on VAS<BR/>night pain pt and MD on VAS<BR/>reduction of activity while performing daily tasks (joint mobility) assessed by MD during examination<BR/>improvement in most painful knee movement by pt on VAS<BR/>global evaluation of efficacy due to<BR/>treatment by pt and MD on VAS<BR/>Assessments:<BR/>Wk 0,2,4,8,12,26</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad's:4/5<BR/>R-1,B-2,W-1<BR/>Control groups combined for analyses in publication. Separate group results in PMA.<BR/>Excluded pts with effusions.<BR/>Arthrocentesis with removal of effusion if present.<BR/>If bilateral OA, only most painful knee treated.<BR/>Research was supported by Biomatrix, Inc.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Scale-1994b-_x0028_3-inj_x0029_">
<CHAR_METHODS>
<P>See Scale 1994a<BR/>above.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country:<BR/>Germany<BR/>Mean age: 59<BR/>% Female:<BR/>Study B: 44<BR/>(24/55) <BR/>Mean disease duration: 4.2 y<BR/>Duration: 12 wk<BR/>Telephone follow-up<BR/>at 26 wk<BR/>Number randomised: 30<BR/>(HA 15, Pl 15)<BR/>Inclusion/<BR/>Exclusion as above (Scale 1994a).<BR/>Baseline group differences:<BR/>1) Significantly more patients had Grade 4 xray in PL group.<BR/>2) 3 inj group had significantly shorter disease duration at baseline.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Hylan G-F 20<BR/>(2 ml) 3 weekly injections<BR/>Placebo:<BR/>Phosphate-<BR/>buffered saline 2.0 ml <BR/>Concurrent therapy:<BR/>No medication to treat arthritis pain allowed.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>See Scale 1994a above.<BR/>Assessments:<BR/>Wk 0,1,2,3,8,12,<BR/>26</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad's:4/5<BR/>R-1,B-2,W-1<BR/>See Scale 1994a above.</P>
<P>Excluded pts with effusions.<BR/>Arthrocentesis <BR/>with removal of effusion if present.<BR/>If bilateral OA only most painful knee treated.<BR/>Research was supported by <BR/>Biomatrix, Inc.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Schneider-1997">
<CHAR_METHODS>
<P>See Miltner 2002.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Sezgin-2005">
<CHAR_METHODS>
<P>Randomised<BR/>Controlled<BR/>Trial<BR/>Single-blind<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country:<BR/>Turkey<BR/>Mean age: 59.7<BR/>% Female: 75.6<BR/>Duration: 4 wk<BR/>Number randomised: 41<BR/>(HA 22, PL 19)<BR/>Inclusion:<BR/>diagnosis of primary gonarthrosis based on modified ACR criteria,<BR/>Kellgren-<BR/>Lawrence grade II or III on plain x-ray,<BR/>presence of effusion in the painful and swollen kne,<BR/>total pain score of 15 or over on the WOMAC OA Index,<BR/>not receiving NSAIDs<BR/>Exclusion:<BR/>in the previous year, injection of HA or application of physiotherapy to the knees included in the study,<BR/>administration of ia medicine to the knees included in the study or exposure to trauma within the previous 3 mth,<BR/>oral or intramuscular administration of carticosteroids in the previous 2 mth,<BR/>pregnancy or lactation,<BR/>history of allergy and the preence of infectious, inflammatory, metabolic or malignant disease,<BR/>presence of OA of the hip and the opposite knee severe enough to affect the evaluation of functions<BR/>Baseline values:<BR/>WOMAC pain<BR/>HA: 18.9,<BR/>PL: 17.2<BR/>WOMAC stiffness<BR/>HA: 6.5<BR/>PL: 4.5<BR/>WOMAC function<BR/>HA: 64.1<BR/>PL: 50.0<BR/>Flexion<BR/>HA: 95.9<BR/>PL: 108.4<BR/>Walk time<BR/>HA: 43.1<BR/>PL: 31.5<BR/>Knee circumference<BR/>HA: 41.5<BR/>PL: 41.3<BR/>Effusion volume<BR/>HA: 19.0<BR/>PL: 18.5<BR/>IL-6 in pg/ml<BR/>HA: 42.8<BR/>PL: 51.7<BR/>IL-8 in pg/ml<BR/>HA: 20.6<BR/>PL: 17.9<BR/>TNF-alpha in pg/ml<BR/>HA: 77.0<BR/>PL: 80.8</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Orthovisc<BR/>(15 mg/ml)<BR/>2 ml three weekly injections,<BR/>NaCl 0.9% 2 ml three weekly injections<BR/>Both groups had any effusion aspirated before injection. All patients recommended to use bandages and apply cold and rest for 48h. All instructed to do isometric quadriceps exercises.<BR/>Concurrent therapy: acetaminophen permitted but no other analgesics or NSAID allowed.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>IL-6, IL-8, TNF-alpha,<BR/>WOMAC OA Index (Likert: pain (5-25), stiffness (2-10), function (17-85)),<BR/>flexion,<BR/>25 m walking time (sec),<BR/>circumference of knee measured in the middle of the patella (cm),<BR/>amount of effusion (ml)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad's: 2/5<BR/>R-1, B-0, W-1<BR/>Statistically significant poorer values in the HA group verus PL group for WOMAC pain, stiffness, function, flexion, and walking time</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Shichikawa-1983a">
<CHAR_METHODS>
<P>Randomised<BR/>Controlled<BR/>Trial<BR/>Double-blind<BR/>Multicentre (n=38)<BR/>Safety analysis: ITT, n=219<BR/>Efficacy analysis: per protocol, n=208</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country:<BR/>Japan<BR/>Mean age: NR<BR/>% Female: NR<BR/>Mean disease<BR/>duration: NR<BR/>Duration:5 wk<BR/>Number randomised: 228<BR/>(HA 114, PL 114)<BR/>Inclusion:<BR/>knee OA with clinical symptoms with exercise pain &amp; at least 1/3 radiographic change: joint space narrowing, sclerosis, bony spur formation<BR/>written or oral consent<BR/>Exclusion:<BR/>severe JSN<BR/>marked retention of synovial effuson<BR/>IA corticosteroids or any other drug within 2 wk<BR/>serious concurrent diseases<BR/>drug allergy<BR/>pregnant or lactating females<BR/>pt whose info was difficult to obtain<BR/>doctors judged unsuitable</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>sodium hyaluronate<BR/>(25 mg/2.5 ml) <BR/>1.0% SPH (Artz)<BR/>5 weekly injections<BR/>+ placebo tablet 3T/day<BR/>Placebo:sodium<BR/>hyaluronate<BR/>(0.25mg/2.5 ml)<BR/>0.01% SPH<BR/>5 weekly injections<BR/>+ placebo tablet 3T/day<BR/>No local anesthesia.<BR/>Concurrent therapy:<BR/>No "new" arthritis treatment permitted. Physio that had been in effect &gt;2 wk continued but no "new" PT.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>pain at rest, walking,up and down stairs, flexion and extension pain,<BR/>oppressive pain,<BR/>swelling, ballote-<BR/>ment of patella,<BR/>presence/absence of synovial effu-<BR/>sion and volume<BR/>range of motion: no symptom, mild,<BR/>moderate, <BR/>marked<BR/>overall severity:<BR/>mild, moderate,<BR/>severe<BR/>diary: VAS pain and<BR/>activities of daily living: 10 min walk, up/down <BR/>stairs,squat to pick up some-<BR/>thing on floor,<BR/>sit on floor or ta-<BR/>tami, 5 classes:<BR/>possible to do as<BR/>normal person,<BR/>fairly possible to do alone without much difficulty, fairly possible to do alone but often with difficul-<BR/>ty, needed help of others, impos-<BR/>sible<BR/>subjective change in symptoms (1-7:<BR/>excellently im-<BR/>proved,improved,fairly improved,<BR/>unchanged,<BR/>slightly worsened,<BR/>worsened,<BR/>markedly wor-<BR/>sened)<BR/>global effective-<BR/>ness (1-7: excel-<BR/>lent improvement,<BR/>good improve-<BR/>ment,fair improvement,<BR/>poor improve-<BR/>ment,slight aggravation,moderate aggravation,marked aggravation)<BR/>overall evaluation: final effectiveness (1-7: excellent improvement,<BR/>good improve-<BR/>ment, fair improvement,<BR/>poor improve-<BR/>ment, slight aggravation,<BR/>moderate aggravation, ex-<BR/>treme aggrava-<BR/>tion) + safety (1-3:no side<BR/>effect, side effect but drug contin-<BR/>ued, drug dis-<BR/>continued due to side effect) + usefulness (1-7:<BR/>extremely useful,<BR/>useful,fairly use-<BR/>ful,uncertain,<BR/>slightly unfavor-<BR/>able,unfavorable,<BR/>extremely unfa-<BR/>vorable)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad's:4/5<BR/>R-1,B-2,W-1<BR/>In case of bilateral OA, worst side "mainly evaluated".<BR/>Excluded marked synovial effusion.<BR/>Synovial effusion aspirated and volume measured. Baseline pain going up and down stairs significantly more severe in Artz group (p&lt;0.05).<BR/>Work sponsored by Seikagaku Corporation.<BR/>N. Ogawa in change of statistical analysis.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Shichikawa-1983b">
<CHAR_METHODS>
<P>Randomised<BR/>Controlled<BR/>Double-blind<BR/>Multicentre (n=16)<BR/>Safety analysis:<BR/>ITT, n=103<BR/>Efficacy analysis:<BR/>per protocol, n=98</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country:<BR/>Japan<BR/>Mean age: 62<BR/>% Female: 83<BR/>Mean disease<BR/>duration: NR<BR/>Duration: 5 wk<BR/>Number randomised:107<BR/>(HA 52, PL 55)<BR/>Inclusion:<BR/>apparent clinical signs with pain on movement<BR/>xray at least 1 of joint space narrowing, spur formation, osteosclerosis<BR/>consent<BR/>Exclusion:<BR/>moderate to severe JSN<BR/>varus or valgus<BR/>deformities<BR/>synovial effusion<BR/>IA corticosteroid injection in past 2 wk<BR/>pregnant or lactating females<BR/>hard to communicate<BR/>cases thought to be inadequate for trial by doctors in charge<BR/>Baseline values:<BR/>% pt moderate<BR/>walking pain<BR/>HA:52, PL:46<BR/>ROM<BR/>HA:133.4,<BR/>PL:128.6<BR/>pain score<BR/>HA:1.03, PL:1.12</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>sodium hyaluronate 5.0 ml of 0.5% SPH solution <BR/>5 weekly injections<BR/>+ 2 sugar coated lactose pills tid<BR/>Placebo: 5.0 ml of 0.01% SPH solution 5 weekly injections <BR/>+ 2 sugar coated lactose pills tid<BR/>Concurrent therapy:<BR/>No "new" arthritis therapy permitted</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>pain: rest, walking, up and down stairs, press, flexion and extension, sense of fever, swelling, range of motion, ballotement of patella<BR/>(4 point scale:<BR/>no symptom, mild, moderate, severe)<BR/>disturbance of 4 activities of daily living: walk 10 min,<BR/>up/down stairs,<BR/>squat to pick up<BR/>things from floor,<BR/>sitting on floor or<BR/>tatami: 5 ranks:<BR/>can do as the<BR/>normal people,<BR/>scarcely possible by one-<BR/>self and not so in-<BR/>convenient,<BR/>scarcely possible<BR/>by oneself but inconvenience necessary for aid, totally impossible<BR/>diary for activities of daily living and pain (knee pain at rest and at the beginning of<BR/>motion:0=no pain,1=mild, 2=<BR/>painful but mo-<BR/>bile,3=painful &amp;<BR/>immobile,4=un-<BR/>endurable pain &amp; can do nothing)<BR/>general improve-<BR/>ment (1-7: sig.<BR/>improved,moder-ately improved, lightly improved,<BR/>no change,lightly worsened, mod-<BR/>erately worsened<BR/>sig. worsened)<BR/>impression by pt<BR/>(1-7:sig. improved,fairly<BR/>improved,slightly<BR/>improved, no<BR/>change,slightly<BR/>worsened, fairly<BR/>worsened, sig.<BR/>worsened)<BR/>general evalua-<BR/>tion (1-7: sig.<BR/>improved,moder-ately improved,<BR/>slightly improved,<BR/>no change, slightly worsened,<BR/>moderately worsened, sig.<BR/>worsened)<BR/>general safety<BR/>(1-3: no side<BR/>effect,side effect seen but can continue treat-<BR/>ment, stop treat-<BR/>ment because of side effect) <BR/>usefulness judged on general improvement and general safety: 7 ranks:<BR/>extremely useful,<BR/>fairly useful,<BR/>slightly useful,<BR/>cannot judge<BR/>whether useful or<BR/>not useful, <BR/>slightly undesir-<BR/>able, fairly unde-<BR/>sirable, extremely unde-<BR/>sirable</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad's:4/5<BR/>R-1,B-2,W-1<BR/>Pt with moderate to severe synovial effusion excluded.<BR/>If bilateral, evaluation completed on knee fulfilling entry criteria.<BR/>Test drug provided by Seikagaku Kogyo Co., Ltd.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-St.-J.-Dixon-1988">
<CHAR_METHODS>
<P>Randomised<BR/>Controlled<BR/>Trial<BR/>Double-blind<BR/>Parallel-group<BR/>Multicentre (n=3)<BR/>Placebo- controlled<BR/>Per protocol analysis</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country:<BR/>England<BR/>Mean age: 69<BR/>% Female: 54<BR/>Mean disease<BR/>duration: NR<BR/>Duration: 48 wk<BR/>Number randomised: 63<BR/>(HA 30, PL 33)<BR/>Inclusion:<BR/>outpatients of either sex and any age<BR/>symptomatic OA of one of both knees<BR/>informed consent<BR/>Exclusion:<BR/>inflammatory knee conditions,<BR/>e.g. RA, psoriatic, pseudo-<BR/>gout or joint infection<BR/>OA of the hip which could confuse assessment<BR/>poor general health<BR/>skin conditions which would deter injection<BR/>receiving regular analgesic therapy for reasons other than painful OA of the knee<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Hyalgan (20 mg/2 ml)<BR/>up to 11 injections over a 23 week period<BR/>Placebo: l/100th of active, e.g. 0.2 mg sodium hyaluronate<BR/>Concurrent therapy:<BR/>Paracetamol 3000 mg daily permitted</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>pain at rest and on movement (100 mm VAS)<BR/>activities of daily living (6 activities<BR/>scored 0=no diff-<BR/>iculty to 7=activity<BR/>impossible, total = 42)<BR/>questioned and ex-<BR/>amined for local or systemic adverse reactions <BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad's:4/5<BR/>R-1,B-2,W-1<BR/>Dr. M. Massarotti, Dr. D. Massari and Dr. U. Cornelli of Fidia S.p.A. supported study and supplied clinical trial material. Dr. R. Kohn and Dr. J.F. Harper of Advisory Services, London helped with trial organisation.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Tamir-2001">
<CHAR_METHODS>
<P>Randomised<BR/>Controlled<BR/>Trial<BR/>Single-blind<BR/>Parallel-group<BR/>Open-label<BR/>Placebo- controlled<BR/>Single centre</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country:<BR/>Israel<BR/>Mean age: 71<BR/>(BH: 71, PL: 70)<BR/>% Female: 73<BR/>Mean disease duration: NR<BR/>Duration: 20 wk<BR/>Number randomised: 49<BR/>(BH 25, PL 24)<BR/>Inclusion:<BR/>adults of either sex <BR/>between 60-85 y<BR/>evidence of idio-<BR/>pathic sympto-<BR/>matic clinical OA of the knee as per Altman criteria and radiologically verified<BR/>OA of the knee<BR/>(stages 2 to 4: Kellgren &amp; Lawrence: BH:<BR/>2-6, 3-16, 4-3,<BR/>PL: 2-5, 3-11,4-7)<BR/>in good general health<BR/>no previous history of surgical treatment of joint or arthroscopy or injections to the knee in 6 mth prior to study start<BR/>Exclusion:<BR/>pts with knee OA<BR/>originating from an i-a fracture, RA, joint infection, other inflammatory &amp; metabolic arthritis or OA of the hip joint,<BR/>pt with significant systemic diseases <BR/>allergy or atrophy or skin conditions overlying the joint which could cause adminis-<BR/>tration of injections to be problematic,<BR/>pt with copious joint exudates (&gt;15 ml of aspirated synovial fluid)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>BioHy 20 mg<BR/>(10 mg/ml)<BR/>5 weekly injections<BR/>Placebo: 2 ml of phosphate buffered saline <BR/>5 weekly injections<BR/>Concurrent therapy: Para-<BR/>cetamol and<BR/>NSAIDs were permitted</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>pain at rest and during activity-----<BR/>stiffness and physical function as per the MODEMS arthritic model (none=1, mild=2,moderate<BR/>=3, severe=4, extreme=5)<BR/>[looks like WOMAC]<BR/>muscle strength, stiffness, and tenderness of joint upon palpation scored on same scale,<BR/>active range of motion: <BR/>1= &gt;135.2; 2=90 to 135;<BR/>3=45 to 90;<BR/>4= &lt;45</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad's:3/5<BR/>R-1,B-1,W-1<BR/>Third author is affiliated with Bio-Technology General.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Tascioglu-2003">
<CHAR_METHODS>
<P>Randomised<BR/>Controlled<BR/>Trial<BR/>Blinded observer<BR/>Open-label<BR/>Parallel-group<BR/>Single centre<BR/>Per protocol n=55 (OR 28, 6-MPA 27)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country:<BR/>Turkey<BR/>Mean age: 59<BR/>% Female: 100<BR/>Duration: 6 mth<BR/>Number recruited: 69<BR/>Number randomised: 60<BR/>Inclusion:<BR/>ambulant patients with idiopathic OA as per ACR criteria,<BR/>Grade II or III<BR/>knee OA by Kellgren and Lawrence system,<BR/>pain under weight bearing &gt;40/100 mm VAS<BR/>Exclusion:<BR/>Kellgren-Lawrence Grade IV,<BR/>knee joint disease other than OA,<BR/>OA of the hip,<BR/>OA of the feet,<BR/>serious concomitant systemic diseases,<BR/>ia injections within 3 mth prior to study start,<BR/>skin infections overlying the joint,<BR/>ia fluid effusion,<BR/>history of allergy or hypersensitivity to drugs,<BR/>treatment with anticoagulants,<BR/>previous knee surgery<BR/>Baseline values:<BR/>Weight bearing pain 100mmVAS<BR/>OR: 54.26<BR/>6-MPA: 53.10<BR/>Walking pain<BR/>OR: 67.60<BR/>6-MPA: 69.00<BR/>Rest pain <BR/>OR: 30.43<BR/>6-MPA: 29.90<BR/>Lequesne<BR/>OR: 10.23<BR/>6-MPA: 9.86<BR/>Flexion<BR/>OR: 108.70<BR/>6-MPA: 108.06</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Orthovisc <BR/>15 mg/ml<BR/>2 ml once per wk for 3 wk,<BR/>6-methylprednis-olone acetate<BR/>(6-MPA)<BR/>40 mg/ml<BR/>l ml once per wk for 3 wk<BR/>Depo-Medrol<BR/>Concurrent therapy: paracetamol (maximum of 3 g/day) but not permitted 48 h before each injection and clinical assessment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pain at rest, at weight-bearing, and on walking <BR/>(100 mm VAS),<BR/>Lequesne Index<BR/>Flexion (degrees)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad's: 2/5<BR/>R-1,B-0,W-1<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Tekeoglu-1998">
<CHAR_METHODS>
<P>Randomised<BR/>Controlled<BR/>Trial <BR/>Parallel-group<BR/>Open-label<BR/>ITT analysis</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country:<BR/>Turkey<BR/>Mean age: 58<BR/>% Female: 100<BR/>Mean disease duration: 54 wk<BR/>Duration:15 wk<BR/>Number randomised: 40<BR/>(HA 20, BA 20)<BR/>Inclusion:<BR/>presence of pain<BR/>Kellgren scale<BR/>(result:Gr. 2 or 3)<BR/>Exclusion:<BR/>knee jt disease other than OA<BR/>history of allergy, skin infections<BR/>other i-a treatments in the 3 mths prior to study<BR/>Baseline values:<BR/>WOMAC function<BR/>HA:45.5, BA:45.6<BR/>maximum flexion<BR/>HA:110.5,<BR/>BA:116.0</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Sodium hyaluronate 20 mg (Orthovisc)<BR/>3 injections: 1 every 7 days<BR/>Betamethasone 3 mg/ml (Celestone choronodose)<BR/>3 injections: 1 every 7 days<BR/>Concurrent therapy:<BR/>Paracetamol per-<BR/>mitted</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Kellgren and Lawrence rating<BR/>intensity of spontaneous pain and clinical severity in terms of pain felt during normal living activities(1=slight<BR/>,2=moderate,3=<BR/>severe)<BR/>WOMAC function subscale for ADL<BR/>(1=none,2=mild,<BR/>3=moderate,<BR/>4=severe,<BR/>5=extreme)<BR/>joint flexion in o<BR/>NSAID use<BR/>(0=none,<BR/>1=occasional,<BR/>2=continuous low doses,<BR/>3=continuous high doses)<BR/>pt and investigator<BR/>judgement of efficacy (0=un-<BR/>satisfactory,1=<BR/>poor,2=fair,3=<BR/>good,4=excellent)<BR/>morning stiffness<BR/>effusion (presence/absence)<BR/>Blood pressure and heart rate,<BR/>blood and urine study start and end</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad's: 2/5<BR/>R-1,B-0,W-1<BR/>When present effusion extracted by arthrosynthesis to dryness<BR/>Pt kept in rest for one day after inj<BR/>Trial population consisted of all female.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Thompson-2002">
<CHAR_METHODS>
<P>Randomised<BR/>Controlled<BR/>Trial<BR/>Double-blind<BR/>Parallel-group<BR/>Multicentre (n=10)<BR/>Non-inferiority study<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country:<BR/>Germany<BR/>Mean age: NR<BR/>% Female: 64.5<BR/>Mean disease duration: NR<BR/>Duration: 12 wk<BR/>Number randomised: 321<BR/>(AR 160, GF20 161)<BR/>Inclusion:<BR/>Scored a total of between 41-80 mm based on WOMAC OA Index mean pain subscale.<BR/>Exclusion:<BR/>NR<BR/>Baseline values:<BR/>WOMAC pain:<BR/>AR: 49.20<BR/>GF20: 51.90<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Arthrease (20 mg/2 ml)<BR/>3 weekly injections<BR/>Hylan G-F 20<BR/>(16mg/2 ml)<BR/>3 weekly injections<BR/>Concurrent therapy: acetaminophen up to 4 g daily after 1st injection.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>WOMAC OA Index Pain VA -----------------------<BR/>Escape medication usage,<BR/>pt assessment of treatment (very satisfied, satisfied, slightly satisfied, dissatisfied),<BR/>Global WOMAC including stiffness and physical function.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad's: 2/5<BR/>R-1,B-1,W-0<BR/>The 3 authors of the abstract are affiliated with industry: J.I. Thompson, DePuy International Ltd.,<BR/>Y.W. Huang and R. Zaibel, Biotechnology General.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Tsai-2003">
<CHAR_METHODS>
<P>Randomised<BR/>Controlled<BR/>Trial<BR/>Double-blind<BR/>(masked observer)<BR/>Placebo- controlled<BR/>Parallel-group<BR/>Multicentre (n=3 hospitals, 6 investigators)<BR/>Both ITT and <BR/>per protocol analyses.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country:<BR/>Taiwan<BR/>Mean age: 65<BR/>% Female: 76<BR/>Mean disease<BR/>duration: 427 days<BR/>Duration: 25 wk<BR/>Number randomised: 200<BR/>(HA 100,PL 100)<BR/>Inclusion:<BR/>&gt;50 years of age,<BR/>diagnosed with<BR/>knee OA (ACR criteria: &gt;50 y, crepitus, morning stiffness&lt;30 min in duration)<BR/>pain &gt;= 40/100 mm VAS on 50 foot walk<BR/>radiographic evidence Kellgren Lawrence II to III with predominance in TB compartment<BR/>acute disease or trauma leading to secondary OA must have occurred at least 5 y before study entry<BR/>Exclusion:<BR/>severe degeneration of knee joint with marked joint narrowing, varus, or valgus deformity of knee (&gt;12o) or other joint deformities, or other joint disorders (e.g. inflammatory joint disease, specific arthropathy, severe axis deviations or instabilities, joint or skin infections, joint prostheses of the lower limbs or symptomatic hip)<BR/>ia steroid injections within the 2 wks prior to study entry<BR/>Baseline values:<BR/>Pain 50' walk<BR/>HA: 47.85<BR/>PL: 45.65<BR/>WOMAC Pain<BR/>HA: 45.73<BR/>PL: 45.39<BR/>WOMAC Function<BR/>HA: 46.54<BR/>PL: 45.45<BR/>WOMAC Stiffness<BR/>HA: 43.35<BR/>PL: 44.46</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Hyalgan<BR/>20 mg/2ml<BR/>5 weekly injections<BR/>Saline 2 ml<BR/>5 weekly <BR/>injections<BR/>Concurrent therapy: acetaminophen permitted as escape medica-<BR/>tion up to max 3 g/day but not on the day before study visit<BR/>Not permitted:<BR/>oral &amp; parenteral corticosteroids, ia corticosteroid injections, NSAIDs or analgesics other than acetaminophen, topical analgesic preparations, rehabiliation, physical therapy, acupuncture<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pain during 50 foot walk (100 mm VAS)-----------<BR/>WOMAC (VAS),<BR/>pt and iv overall effectiveness (1-6:1=gravely worsened, 6=<BR/>excellent improvement),<BR/>acetaminophen<BR/>consumption,<BR/>50 ft walk time, volume of synovial effusion in study knee,<BR/>safety</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad's: 2/5<BR/>R-1,B-1,W-0<BR/>Fourth and fifth authors of abstract are affiliated with Fidia SpA, Italy.<BR/>One author of manuscript is affiliated with Fidia S.p.A.<BR/>Work supported by a grant from Medpharma.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Tsukamoto-1995">
<CHAR_METHODS>
<P>See Yamamoto 1994</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Wobig-1998">
<CHAR_METHODS>
<P>Randomised<BR/>Controlled<BR/>Trial<BR/>Double-blind <BR/>Screen blinded patient<BR/>Blinded assessor<BR/>Multicentre (n=4)<BR/>2 wk washout<BR/>of NSAID and analgesics.<BR/>ITT analysis</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country:<BR/>Germany<BR/>Mean age: 62<BR/>% Female: 65<BR/>Mean disease duration: 6 y<BR/>Duration: 12 wk<BR/>Telephone follow-up<BR/>at 26 wk<BR/>Number randomised: 110<BR/>(HA 52, PL 54,<BR/>HA+PL 4)<BR/>[117 knees:<BR/>HA 57, PL 60]<BR/>Inclusion:<BR/>&gt; 18 y<BR/>male &amp; female<BR/>chronic primary OA of knee of Larsen Grade 1-3<BR/>ESR &lt; 40 mm/h<BR/>RF &lt; 1:160<BR/>daily pain on activity and persistent pain despite use of NSAIDs or analgesics<BR/>Exclusion:<BR/>pts with effusion in knee<BR/>Baseline values:<BR/>pt wtbearing pain<BR/>HA:71, PL:75<BR/>pt night pain<BR/>HA:42, PL:47<BR/>MD wtbearing <BR/>pain<BR/>HA:71, PL:75<BR/>MD night pain<BR/>HA:41, PL:47<BR/>MD loss of <BR/>activity<BR/>HA:59, PL:67</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Hylan G-F 20<BR/>(2 ml)<BR/>3 weekly injections<BR/>Placebo: phosphate-<BR/>buffered saline<BR/>2 ml <BR/>3 weekly injections<BR/>Concurrent therapy:<BR/>Standard care per-<BR/>mitted: steroids, <BR/>NSAIDs, analgesics,<BR/>PT, surgery</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>pt: pain wt bearing, at rest during night, decrease during most painful movement, treatment success<BR/>MD: extent of pt's loss of activity while performing difficult daily tasks &amp; treatment success<BR/>all above on 100 mm VAS<BR/>Assessments:<BR/>Wk 0,1,2,3,8,12,<BR/>26</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad's:4/5<BR/>R-1,B-2,W-1<BR/>Local analgesia was optional.<BR/>If bilateral OA, only most painful knee treated.<BR/>7 pts bilateral - 14 knees: 6 HA , 8 PL. Each knee randomised and analysed independently for efficacy but for safety these pts. were considered individuals. Time between treatment of two knees varied from 0 to 153 days.<BR/>Pts with effusions excluded. <BR/>Arthrocentesis with removal of effusion if present. At baseline, Larsen xray grade III to IV:<BR/>HA: 28% versus PL:57%(p&lt;0.05),<BR/>duration of OA &lt;1 y: HA: 28% versus PL: 10% (p&lt;0.025)<BR/>Work was supported by Biomatrix, Inc.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Wobig-1999">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Wobig-1999a-_x0028_Healon_x0029_">
<CHAR_METHODS>
<P>See Wobig 1999</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number randomised:<BR/>Healon: 39 knees</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Wobig-1999b-_x0028_Artz_x0029_">
<CHAR_METHODS>
<P>Randomised<BR/>Controlled<BR/>Trial<BR/>Double-blind<BR/>Blinded assessor<BR/>Multicentre (n=6)<BR/>2 wk washout<BR/>of NSAIDs and analgesics.<BR/>Efficacy analysis:<BR/>both ITT and per protocol.<BR/>Tolerability analysis: ITT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country:<BR/>Germany<BR/>Mean age: 60<BR/>% Female: 51<BR/>Mean disease duration: 4.6 y<BR/>Duration: 12 wk<BR/>Number randomised: <BR/>132 pts (148 knees) in 4 arms of trial.<BR/>In 2 arms GF/AR:<BR/>70 patients<BR/>(GF 38, AR 32)<BR/>[73 knees:<BR/>GF 38, AR 35]<BR/>[Healon 39 knees, NE hylan 36 knees]<BR/>Inclusion:<BR/>&gt; 18 y<BR/>primary OA knee (Larsen 1 to 3)<BR/>ESR &lt; 40 mm/h<BR/>RF &lt; 1:160<BR/>daily, persistent pain despite use of pain relieving<BR/>medications<BR/>Exclusion:<BR/>free of pain in OA knee<BR/>detectable effusion in joint at time of first treatment<BR/>considered unreliable by the<BR/>investigator<BR/>Baseline values:<BR/>pt wtbearing pain<BR/>HA:70, AR:72<BR/>MD wtbearing pain<BR/>HA:69, PL:72</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Hylan G-F 20<BR/>(2 ml)<BR/>3 weekly injections,<BR/>Artz<BR/>(2 ml)<BR/>3 weekly injections,<BR/>Healon<BR/>3 weekly injections,<BR/>Nonelastoviscous denatured hylan fluid<BR/>3 weekly injections<BR/>Subcutaneous local anesthetic optional in both groups.<BR/>Concurrent therapy:<BR/>Standard care per-<BR/>mitted</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>wt bearing pain by pt and MD on 100 mm VAS<BR/>overall treatment response by pt &amp; MD(100mmVAS)<BR/>improvement on most painful knee movement by pt 100 mm VAS<BR/>Assessments:<BR/>Wk 0,1,2,3,8,12</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad's:4/5<BR/>R-1,B-2,W-1<BR/>Pt with detectable effusion excluded<BR/>Arthocentesis with removal of effusion if present.<BR/>If bilateral OA both knees could be treated and evaluated. 16 patients had bilateral OA. Each knee randomised and independently evaluated for efficacy. Time between treatment of two knees varied from 0 to 23 days but 11/16 had the same day.<BR/>4-arm study but only 2 arms reported in publication (Hylan G-F 20 and Artz). Biomatrix, Inc. provided support for this work and performed all elastoviscosity analyses.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Wobig-1999c-_x0028_NEhyl_x0029_">
<CHAR_METHODS>
<P>See Wobig 1999</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number randomised:<BR/>NE hylan fluid:<BR/>36 knees</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Wu-1997">
<CHAR_METHODS>
<P>Randomised<BR/>Controlled<BR/>Trial<BR/>Double-blind<BR/>Placebo- controlled<BR/>Single centre<BR/>Per protocol analysis: n=111 knees (60 Artz, 51 Placebo)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country:<BR/>China<BR/>Mean age: 69<BR/>% Female: 28<BR/>Mean disease<BR/>duration: 19 mth<BR/>Duration: 26 wk<BR/>Number randomised: 90<BR/>[116 knees: Artz 62, PL 54]<BR/>Inclusion:<BR/>adults diagnosed as early OA (mild to moderate) by 4 senior orthopedic surgeons<BR/>clinical symptoms with exercise pain, limitation of joint function and radiologic findings of bone spur, JSN, or osteosclerosis<BR/>Exclusion:<BR/>steroid IA injection<BR/>functional disturbance of liver and kidney<BR/>pregnancy<BR/>severe degeneration of knee joints with marked joint narrowing, marked varus or valgus deformity or a large amount synovial effusion<BR/>Baseline values:<BR/>% pt moderate<BR/>walking pain<BR/>Artz: 36, PL:41<BR/>% pt mild rest pain<BR/>Artz:53, PL:54</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Artz 2.5 ml<BR/>5 weekly injections<BR/>Placebo:solvent for Artz (sodium chloride phosphate solution) 2.5 ml<BR/>5 weekly injections<BR/>No local anesthetic drugs.<BR/>Concurrent therapy:<BR/>No antiinflammatory<BR/>agent or physical therapy permitted</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>pain: rest, walking, up/down stairs, flexion and extension, oppressive; swelling, ballote-<BR/>ment of patella<BR/>(4 grades: no symptoms, mild, moderate,severe symptoms);<BR/>synovial fluid (vol), range of motion (degrees), actvities of daily living (walk 10 min, up/down stairs,squat to pick up some-<BR/>thing, sitting on floor) impair-<BR/>ment (1:no problem to do,2=<BR/>fairly possible to<BR/>do alone,3=pos-<BR/>sible to do but <BR/>often with incon-<BR/>venience,4=need<BR/>help,5=complete<BR/>ly impossible)<BR/>radiographic<BR/>change (mild,<BR/>moderate,severe), general<BR/>improvement by pt and MD (1-7:<BR/>excellent improvement,<BR/>improved, fair<BR/>improvement, unchanged, <BR/>slightly worsened, wor-<BR/>sened, markedly<BR/>worsened),<BR/>overall evaluation<BR/>effectiveness (1-7:excellent improvement, improved, fair improvement, no change, slightly<BR/>worsened, wor-<BR/>sened, extremely<BR/>worsened), usefulness<BR/>(1-7: extremely good, good, fairly<BR/>good, uncertain,<BR/>slightly unfavor-<BR/>able, unfavor-<BR/>able, extremely unfavorable), and safety (1-3):no <BR/>side effect, side<BR/>effect but treat-<BR/> ment continued,<BR/>stop treatment due to side effect<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad's:3/5<BR/>R-1,B-1,W-1<BR/>Pts with large amount synovial effusion excluded</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Wu-2004">
<CHAR_METHODS>
<P>Randomised<BR/>Controlled<BR/>Trial<BR/>Single-blind<BR/>Parallel group<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country:<BR/>China<BR/>Mean age: 67<BR/>% Female: 55<BR/>Mean disease duration: 3 y<BR/>Duration: 16 wk<BR/>Number randomised: 150<BR/>5 groups with 50 per group<BR/>1) HA, <BR/>2) HA+low dose celecoxib (HALC),<BR/>3) HA + self-<BR/>selected dose celecoxib (HASCC), <BR/>4) celecoxib (CEL), 5) Self-selected celecoxib (SCC)<BR/>Inclusion: NR<BR/>Exclusion: NR<BR/>Baseline values:<BR/>WOMAC function<BR/>HA: 67.7,<BR/>HALC: 68.3,<BR/>HASCC: 70.2,<BR/>CEL: 71.3,<BR/>SCC: 70.4<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1) HA 2 ml (10mg/L) 5 weekly injections,<BR/>2) HA+low dose celecoxib (one course HA + 100 mg celecoxib once per day for 4 mth),<BR/>3) regular dose celecoxib 100 mg/day for 4 mth,<BR/>4) HA + self-controlled dose of celecoxib<BR/>(one course of HA + celecoxib 100 mg bid) and dosage could be decreased once symptoms well controlled),<BR/>5) voluntary celecoxib 100 mg bid and dosage could be decreased with symptom control<BR/>Concurrent therapy: NR</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>WOMAC physical function subscale-----------<BR/>weekly dosage of celecoxib,<BR/>total dosage of celecoxib,<BR/>satisfaction level to the treatment protocol (bad, fine, good, and excellent)<BR/>Assessments at baseline, Wks 1,2,4,,8,10,12,14,16</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad's: 2/5<BR/>R-1, B-0, W-1</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Yamamoto-1994">
<CHAR_METHODS>
<P>Randomised<BR/>Controlled<BR/>Trial<BR/>Double-blind<BR/>Blinded assessor.<BR/>Parallel-group<BR/>Multicentre (n=31)<BR/>Safety analysis:<BR/>ITT, n=199<BR/>Efficacy analysis:<BR/>per protocol, n= 182-184</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country:<BR/>Japan<BR/>Mean age: 66<BR/>% Female: 78<BR/>Mean disease<BR/>duration: Not reported<BR/>Duration: 5 wk<BR/>Number randomised:203<BR/>(NRD 102, Artz 101)<BR/>Inclusion:<BR/>knee OA with definite pain or inflammatory symptom &amp; demonstrating on xray 1 of:<BR/>osteophyte formation, joint space narrowing,<BR/>osteosclerosis<BR/>age &gt;=20 &lt; 80 y<BR/>if bilateral lesions, only one of lesions which satisfied criteria was selected<BR/>Exclusion:<BR/>definite 2o knee OA<BR/>operation indicated<BR/>oral or IV steroid or ia steroid or other drug within 2 wk of start of study<BR/>NSAID or new PT within 2 wk<BR/>lesion in hip or ankle of affected side<BR/>RA<BR/>pregnant, breast feeding or possibly pregnant<BR/>judged by physician to be in-<BR/>appropriate as study subject<BR/>Baseline values:<BR/>% pt moderate<BR/>spontaneous pain<BR/>NRD:31, Artz:31<BR/>% pt moderate walking disorder<BR/>NRD:40, Artz:41</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>NRD101 (25 mg/2.5 ml)<BR/>5 weekly injections<BR/>Artz (25 mg/2.5 ml)<BR/>5 weekly injections<BR/>No local anesthetics.<BR/>Concurrent therapy:<BR/>Analgesics, NSAIDs<BR/>&amp; physical therapy continued but no "new" therapy per-<BR/>mitted</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>clinical findings:4 grades of none, mild, moderate, severe for pain:spontaneous, pressure,night, on passive movement, inflammation: swelling of soft part of jt, floating patella, local feverish feeling, synovial fluid retention,<BR/>activities of daily living disorder: sitting upright, up/down stairs, standing up, squatting, walking<BR/>passive movement: flexion/extension,<BR/>drainage: volume<BR/>efficacy assessed by MD: overall im-<BR/>provement: 7 grades: marked<BR/>improvement,<BR/>moderate im-<BR/>provement,<BR/>slight improve-<BR/>ment, un-<BR/>changed,slight<BR/>aggravation,moderate aggrava-<BR/>tion, marked<BR/>aggravation)<BR/>pt. impression - how they felt about changes in symptoms (very good, good,fair,<BR/>cannot say good or not, bad)<BR/>comprehensive assessment based on 3: final overall improvement ratings (8 grades: same as above+<BR/>unassessable),<BR/>global safety (5 grades: no <BR/>adverse reaction,mild AR,<BR/>moderate AR,<BR/>severe AR, <BR/>unassessable),<BR/>usefulness (8 <BR/>grades:very use-<BR/>ful,useful,slightly<BR/>useful,cannot say useful or not,<BR/>slightly undesir-<BR/>able, undesirable, very<BR/>undesirable, un-<BR/>assessable)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad's: 5/5<BR/>R-2,B-2,W-1<BR/>MD who did inj<BR/>different from MD who did assess-<BR/>ment<BR/>In case of bilateral OA, only one knee was evaluated.<BR/>Bilateral: NRD 53, Artz 44;<BR/>Unilateral: NRD 42, Artz 43<BR/>Puncture and<BR/>drainage done as required.<BR/>Artz provided by Seikagaku Corporation. M. Nakajima performed statistical analysis.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Yentur-2003">
<CHAR_METHODS>
<P>Randomised<BR/>Controlled<BR/>Trial<BR/>SIngle-blind<BR/>Blinded physician completed assessments<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country:<BR/>Turkey<BR/>Mean age: 60.95<BR/>% Female: 100<BR/>Mean disease duration: NR<BR/>Duration: 21 days<BR/>Number randomised:<BR/>34<BR/>(HA 17, TP+HA 17)<BR/>Inclusion:<BR/>diagnosis according to ACR criteria,<BR/>painful idiopathic knee OA with moderate to very severe pain (pain all the day under weight bearing or at rest) with x-ray confirmation (Kellgren Lawrence grade 3 - moderate joint space narrowing, osteophytes, subchondral sclerosis),<BR/>all patients were using NSAIDs for more than one year, but stated that they did not have any beneficial effect<BR/>Exclusion:<BR/>intraarticular injection or physical therapy at least within the previous 6 mth,<BR/>patients who had knee joint diseases other than OA, severe concomitant diseases, diseases interfering with the evaluation of knee joint function, skin infections, joint instability, hemorrhagic diathesis or major neuroses<BR/>Baseline values:<BR/>pain at rest:<BR/>HA: weak 2, moderate 4, severe 9, very severe 1<BR/>HA+TP: moderate 2, severe 14, very severe 1<BR/>knee ROM<BR/>HA: 116.2<BR/>HA+TP: 103.8<BR/>walking<BR/>HA: weak 2, moderate 7, severe 6, very severe 1<BR/>HA+TP: weak 2, moderate 7, severe 8<BR/>stairs ascending/<BR/>descending<BR/>HA: weak 1, moderate 5, severe 9, very severe 1<BR/>HA+TP: moderate 6,<BR/>severe 11</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Orthovisc 2 ml three weekly injections plus at each session following IA injetion, trigger point (TP) injections with 0.5% lidocaine were performed in relevant TP according to Travell and SImons' guide-<BR/>lines (rectus femoris, vastus medialis, vastus lateralis, sartorius, adductor longus, tensor fasciae latae, gracilis, pectineus, iliopsoas, biceps femoris, semitendinosus, semimembranosus, adductor magnus, gastrocnemius, soleus. Local twitch responses were induced on introducint the needle into the muscle. <BR/>All patients were kept at rest for 2 days after each injection to avoid overcharging of the injected joint.<BR/>Concurrent therapy:<BR/>No other treatment modalities were permitted during the trial.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Intensity of local pain at rest or during normal daily activities and activit restrictions (squatting, sitting down, ascending and descending stairs, walking, taking off socks, rising from bed, getting in or out of a car) were evaluated by a 5-point scale (0= no pain, 1=mild, 2=moderate, 3=severe, 4=very severe),<BR/>range of movement (flexion-degrees)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad's: 2/5<BR/>R-1, B-0, W-1</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Aglas-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, prospective study of HA in two subjects conducted in Austria with a 56-month observation period.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Akermark-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, non-blind, prospective study of non-animal stabilised hyaluronic acid (NASHA) (Durolane) in 103 subjects conducted at five centres in Sweden. Primary outcome was frequency of device-related, unanticipated adverse events. Primary study involved a single injection of 60 mg/3 ml and follow-up was for 3 months. In extension to primary study, 53 subjects received a second injection approximately 6 mths after the 1st and were followed up over a 1-month period.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Akermark-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, prospective, 12-week study of non-animal stabilized hyaluronic acid (NASHA) in 149 subjects conducted in Sweden.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Alonge-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, prospective, 12-week study of Synject in 20 subjects conducted in Nigeria.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Angel-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Retrospective telephone survey of 69 patients with knee OA who had ia injections of Synvisc conducted South Australia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Arizono-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomised, three-month trial of Artz versus mepivacaine in 38 knees conducted in Japan.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ates-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, prospective, 21-week study of Orthovisc (five weekly injections) in 21 subjects conducted in Turkey.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bagga-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, prospective, 6-month study of Hylan G-F 20 in 30 subjects conducted in Australia. Primary endpoints were synovial fluid HA concentration, molecular weight determination, viscosity and sulfated glycosaminoglycan levels.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bardin-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, prospective, 90-day phase IV trial of Arthrum H in 3349 subjects conducted in France and Spain.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Barrett-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled, retrospective, 18-month study of Hyalgan in 249 subjects conducted at a single orthopaedic practice in Florida, USA.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bell-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, prospective, multicenter, 12-month study in 60 subjects conducted in Canada.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bellamy-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, prospective, 6-week study of Hylan G-F 20 in 445 subjects conducted in Canada. This was a study of a learning intervention which tested the impact of an injection skills-acquisition programme for family physicians.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Birbara-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, multicentre extension study in 190 subjects conducted in Canada and the United States. This is an extension of the OAK0101 Orthovisc randomised, controlled trial (Neustadt 2004).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bolgen-Cimen">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, prospective, six-month study in 14 female subjects conducted in Turkey.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bruce-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, controlled, prospective, four-year observational cohort study in 1860 subjects (1301 treated with Hylan G-F 20 and 559 control) conducted in United States</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Carrabba-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, randomized, 60-day, controlled study comparing Hyalgan and Orgotein (superoxide dismutase) in 118 subjects conducted in three centers in Italy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chhabra-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, prospective, six-month study of Hylan G-F 20 in 120 subjects conducted in England.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Clarke-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>See Clarke 2005.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Clarke-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled, prospective, 26-week, pilot study of Hylan G-F 20 in 43 subjects with patellofemoral osteoarthritis of the knee conducted in England.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Conrozier-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, retrospective, 14-month study of Hylan G-F 20 in 155 subjects conducted in France. Objective was to identify factors predicting efficacy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Couceiro-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, prospective, non-controlled, six-month, multicentre study of Adant in 112 subjects conducted in Spain.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-D_x0027_Agnolo-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, prospective, 60-day study of Hyalgan in 30 subjects conducted in Italy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dahlberg-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Radiographs, obtained in a standardized manner at the time of arthroscopic examination, did not show any evidence of OA.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Evanich-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomized, single-blind, 26-week controlled trial of Synvisc (hylan G-F 20) and Aristospan 40 mg (triamcinolone hexacetonide) in 220 subjects with OA of the knee conducted in Seattle, WA. Abstract reports interim results for over 100 subjects; means and p values up to Week 12.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Faraawi-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Retrospective telephone survey of 127 patients assessing satisfaction wih hylan G-F 20 therapy. Patients treated from January 1999 to April 2002. Study conducted in Kitchener, Ontario, Canada.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Faus-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, prospective, one-year study of 35 subjects with severe knee OA conducted in Spain. Ultrasound was used to measure thickness of articular cartilage of lateral and medial femoral condyles. Femoral articular cartilage of contralateral knee was used as control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Frizziero-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>No clinical outcomes reported in abstract. Six-month study comparing HA versus methylprednisolone in 24 subjects conducted in Italy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Frizziero-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>No clinical outcome reported in abstract. Six-month study comparing Hyalgan versus methylprednisolone in 99 subjects conducted in Italy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Frizziero-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, prospective, six-month, pilot study of 40 subjects conducted in Italy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fuji-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>This study addresses the effect of concomitant use of local anesthetic with Artz.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Goorman-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, prospective, six-month, case series of Hylan G-F 20 in 84 subjects conducted in USA.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Grecomoro-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study studies synergism between Hyalgan and dexamethasone.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Guerrero-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, prospective, cohort study of Adant 10 mg/ml, 2.5 ml, five injections, in 20 subjects conducted in Madrid, Spain. Outcome based on cartilage markers (ACR abstract).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Guerrero-1999a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, prospective, cohort study of Adant 10 mg/ml, 2.5 ml, five injections, in 20 subjects conducted in Madrid Spain. Outcome based on cartilage markers (OARSI abstract).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hamburger-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Retrospective review of 171 subjects between 1997-2002 comparing Hyalgan and Synvisc conducted in New York.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hashimoto-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, prospective (up to two years and 11 months) study of Artz in 35 knee joints conducted in Japan.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Honma-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, prospective study of Artz in 83 subjects conducted at 13 institutions in Japan.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Igarashi-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, prospective, 40-week study of Artz in 43 subjects conducted at 19 centers in Japan.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ines-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, prospective, six-month, rheumatology clinical study of Synvisc, triamcinolone hexacetonide and methylprednisolone acetate with and without joint lavage in 85 subjects of a mixed population (34% OA) conducted in Portugal.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Iseki-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Sodium hyaluronate 25 mg versus sodium hyaluronate 1%. Article is in Japanese.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Iwasaki-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>This study addresses the effect of concomitant use of local anesthetic with Artz.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Johnson-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>This was an audit of clinical practice in 40 patients with knee OA who had received Hyalgan conducted in England.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kawakami-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, prospective clinical evaluation of Artz in 45 subjects with moderate or severe OA of the knee conducted in Japan.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kolarz-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomised, controlled, multicentre, comparative, phase III trial with a masked observer design conducted in Austria and Germany. Comparison of five intra-articular injections of Hyalgan and 10 intra-articular injections of the glycosaminoglycan polysulphase (Arteparon). The planned sample size was 144 subjects. Due to the withdrawal of Arteparon from the Austrian and German markets, the design of the trial was changed; data from only 53 patients who had completed the first treatment cycle (day 0-35) were analysed.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kolarz-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, multicenter, observational study conducted at 14 Austrian rheumatologic and orthopedic centers. 108 patients were treated with Hyalgan once weekly for five weeks. A repeat course was administered if patients continued to fulfill the inclusion criteria but not earlier than month 4.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kotz-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, multicenter, prospective, 12-month study of Hyalgan in 108 subjects conducted at 14 centers in Austria.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Koyuncu-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, prospective, one-year study of hyaluronate in 21 subjects conducted in Turkey.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Koyuncu-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, prospective, three-week study of Hylan G-F 20 conducted in Turkey.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kumar-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, prospective, one-year clinical service study of Hyalgan in 91 subjects conducted at one rheumatology department in England.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kurokawa-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, prospective, 12-week study of NRD-101 in 114 subjects conducted in Japan.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lee-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, prospective, 12-week study of Hyruan in 48 subjects with OA of the knee conducted in Korea. [English abstract, article in Korean]</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lee-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, prospective, one-year study of Hylan G-F 20 in 74 patients in an orthopaedic surgery clinic conducted in the United States.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Legre-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study subjects had both osteoarthritis of the knee and calcium pyrophosphate dihydrate (CPPD) deposition diseases. Open, prospective, six-month study of Hylan GF-20 in 21 subjects conducted in France.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Leopold-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>This is not a randomised controlled trial. Objective of trial was to test hypothesis that the likelihood of a painful reaction to Hylan G-F 20 did not increase in patients who received more than one course of treatment. The single course group (n=42) was prospectively followed as part of a randomised trial. The repeat course group (n=19) was retrospectively identified from a chart review. This was a 15-month, single centre study conducted in the USA.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lussier-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Retrospective review of clinical practice of Hylan G-F 20 in 336 subjects conducted at five Canadian centers with 2.5 yr follow-up.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Magobotha-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, prospective, six-month study of Hylan G-F 20 in 166 subjects conducted in South Africa.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mathieu-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, prospective, 14-month study of Hylan GF-20 in 155 subjects conducted in France. Assessed predictive factors of long-term efficacy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mazieres-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>An observational, naturalistic, open-label, multicentre, nine-month study of Suplasyn in 232 subjects conducted in France.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mazzocato-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, prospective, 60-day study of Hyalgan in 22 subjects.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Megyeri--1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, prospective, four-week study of sodium hyaluronate 20 mg in 23 subjects conducted in Hungary.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mensitieri-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>No clinical outcomes reported. Study of Hyalgan, arthrocentesis, and placebo in 60 subjects conducted in Italy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Milini-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, prospective, 60-day study of Hyalgan in 23 subjects.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Miller-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, prospective, one-year study of Hylan G-F 20 in 108 subjects conducted in the USA.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Minami-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, prospective study of SLM-10 in 33 subjects conducted in Japan.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Moller-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, prospective, six-month study of Ostenil in 40 subjects conducted in Spain.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Monfort-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, prospective, three-month study of hyaluronic acid (three injections) in 50 subjects conducted in Barcelona, Spain. Studied treatment with HA in subjects with gonarthrosis with and without chondrocalcinosis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Myburgh-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, prospective, 24-week case series of Hylan G-F 20 in 18 subjects conducted in South Africa.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Namiki-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, prospective study of Artz in 43 subjects conducted in Japan.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Neustadt-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, prospective, greater than two-year study of intra-articular hyaluronate (five weekly injections) in 92 subjects conducted in Louisville, USA.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Neustadt-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, prospective, two-year study of intra-articular hyaluronate (Hyalgan) in 76 patients (92 knees) conducted in Louisville, KT, USA. 13 patients had a repeat treatment course.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Novaes-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, prospective, multicentre, four-week study of 25 mg/2.5 ml of hyaluronan (Meiji Seika Kasha, Ltd., Tokyo, Japan, MW 900 kDa 5 intraarticular injections) in 365 subjects conducted in seven Latin American countries.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Oberoi-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, prospective, four-year sudy in 75 subjects of Hyruan plus arthroscopic joint debridement compared to arthroscopic joint debridement alone conducted in India.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Olszynski-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, prospective, clinical practice study of Synvisc, Suplasyn, Orthovisc and Neovisc in 267 subjects in a Canadian rheumatology practice.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ono-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, prospective study in 72 subjects conducted in Japan.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ono-1993a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, prospective, multicentre study in 26 subjects conducted in Japan.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Oron-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, prospective, clinical practice study of Orthovisc and Synvisc in 522 subjects conducted in Israel.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Oshima-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, prospective study of Artz in 206 subjects conducted in Japan.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pasquali-Ronchetti">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomized, open-label, six-month study of Hyalgan and Depomedrol in 99 subjects conducted at one centre in Bologna, Italy. This paper reports the structural varibles of the synovial membrane. Clinical and arthroscopic findings will be the subject of a separate publication.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pavelka-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Multicenter, open, prospective, 17-week, observational study of Hyalgan in 601 subjects conducted at 35 centers in the Czech Republic.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pavelka-2002a">
<CHAR_REASON_FOR_EXCLUSION>
<P>See Pavelka 2002.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Payne-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomised, doube blind, placebo-controlled, three-month trial of Suplasyn (three weekly injections) and saline (three weekly injections) in 46 subjects (40 randomised) conducted in Canada. Both groups given a programme of flexibility and stretching exercises. Acetaminophen was permitted for pain. The objective was to test if Suplasyn improved proprioception. No OMERACT efficacy outcome measures were reported. Primary outcome was absolute angular error measured with an electrogoniometer.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Petrella-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Retrospective study of 493 patients with unilateral knee OA treated with Suplasyn was conducted over 4.5 years in London, Canada.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Petrella-2003a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Cross-sectional, retrospective cohort analysis of 53000 subjects in more than 35 famly practice clinics in Southwestern Ontario, Canada. Aim is to determine and compare the tolerance and efficacy of intra-articular viscosupplementation of HA for the treatment of OA with other products for the same indication. Safety profile of Suplasyn versus other treatment options studied. VAS walking and rest pain, BMI, comorbidity, global assessment as well as pharmacoeconomic parameters collected.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Petrella-2003b">
<CHAR_REASON_FOR_EXCLUSION>
<P>A retrospective study of 537 subjects with unilateral OA of the knee treated with Suplasyn conducted over 4.5 years in Canada. 481 subjects received a second series. Improved walking and rest pain reported for both first- and second-time subjects with low incidence of adverse events and high treatment satisfaction.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Petrella-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>A prospective, naturalistic cohort study of 537 subjects with unilateral OA of the knee treated with Suplasyn conducted over 6.7 years in Canada. Repeat injection was permitted.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pipino-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, prospective, 35-day study in 100 subjects.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Punzi-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, prospective, seven-day, single centre study in mixed study population of 17 subjects (seven OA) conducted in Italy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rao-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, prospective, six-month study of dedicated viscosupplementation clinic ascertaining which patient groups would derive the most benefit from Hyalgan conducted in England.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rastogi-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, prospective, six-month study conducted of 30 patients conducted at two orthopaedic centres in New Delhi. Patients received a series of five Hyruan ia injections (25 mg/2.5 ml).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Russell-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Abstract only published. 210 subjects randomised to either HA or Placebo or No-intervention. Two centers in USA conducted this 14-week study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Scali-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, prospective, three-month study of Hyalart in 75 subjects conducted in Argentina.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sepici-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, prospective, case-control, one-month study of Orthovisc in 15 female subjects and 16 age-matched healthy controls conducted in Turkey.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Shibata-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, case series of Artz in 532 subjects conducted in Japan</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sieliwonczyk-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, prospective case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Singh-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>See Bruce 2004. This is the same study as the Bruce 2004 reference (Measurement of Outcomes from Viscosupplementation Effectiveness Study (MOVE)). This is a longitudinal observational cohort study of 1860 subjects conducted in the United States.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sripada-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Retrospective pilot study of Hylan G-F 20 and hyaluronan in 100 subjects conducted in the USA.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Stambuk-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, prospective, 12-week study of Hylan G-F 20 in 35 subjects with bilateral knee OA with effusion conducted in Zagreb, Croatia. Control group was contralateral knee of same subject.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Suzu-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, prospective, 18-month study of ARTZ in 15 subjects conducted in Japan.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Suzu-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, prospective study in 43 subjects conducted in Japan.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Takeuchi-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, prospective study of 82 subjects conducted in Japan.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Taneda-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, prospective study of 28 subjects conducted in Japan.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tang-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>A case-comparison study of 15 subjects (30 knees) with symptomatic knee OA and 15 age-, mass- and gender-matched non-OA control subjects (30 knees). Gait patterns and sagittal ground force reaction forces after intraarticular injection of Artz or 2.5 mL of .01% sodium hyaluronate/ampoule; MW 860 kd was injected once a week for a total of 5 injections.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tang-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, prospective study of 25 subjects conducted in Taiwan. HA with a MW of 860 kd (Artz) was injected once a week for five consecutive weeks. Main purpose of study was to demonstrate if knee muscle strength could be increased in patients with knee OA after injection of HA.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Toh-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, prospective, 12-week study of Orthovisc in 60 patients conducted in the United Kingdom. Patients with a minimal to mild loss in joint space are most likely to benefit from HA supplementation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Toh-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>A prospective cohort of 60 patients received a standard course of ia viscosupplement. Followup was for 12 weeks. WOMAC was outcome. Concluded that only patients with a minimal to mild loss in joint space on radiological examination are most likely to benefit from ia viscosupplementation (cf not those with moderate to severe OA changes in joint space).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Torrance-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>This paper reports the economic results of the trial. The clinical results and health-related quality of life outcomes for this trial are reported in the Raynauld 2000 manuscript. This prospective, one-year, open-label health economic trial compared Appropriate Care with Hylan G-F 20 to Appropriate Care without Hylan G-F 20 in 255 subjects at 14 sites in Canada.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Turajane-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>An uncontrolled, retrospective cohort study of 83 subjects conducted at a single centre in Bangkok, Thailand between 1998 and 2002. Purpose was to determine the clinical factors that may influence results of treatment with Hyalgan for subjects who had failed conservative treatment and who were recommended for surgical treatment.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Turajane-2005a">
<CHAR_REASON_FOR_EXCLUSION>
<P>A retrospective cohort study carried out between 1998 and 2004 of 109 Kellgren Lawrence grade 4 knee OA patients who failed conservative treatment. Conducted at a single centre in Bangkok, Thailand. A pharmacoeconomic analysis of Hyalgan was completed. A second objective was to determine the clinical indicators for successful outcomes and patient satisfaction.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Uebelhart-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Retrospective survey of 467 subjects conducted at 23 centres in Switzerland. Previous 15-month data extracted. Ostenil and Synvisc were the main products evaluated.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Vad-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, prospective, one-year study of knee lavage plus Hylan G-F 20 versus Hylan G-F 20 in 81 subjects conducted in the USA. Both groups received an eight-week home rehabilitation programme and knee cryobrace.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Vad-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Nonrandomized, prospective, one- year study of knee lavage plus Hylan G-F 20 versus Hylan G-F 20 in 81 subjects conducted by a single physician in faculty practice at a major teaching hospital in the USA. All participants received an 8-week programme of home knee rehabilitation exercise combined with aquatherapy and use of a knee cryobrace 15 minutes a night.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Waddell-2001a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Retrospective study from November 1, 1997 to February 29, 2000 of tolerance of Hylan G-F 20 using fluoroscopically-confirmed injection and effectiveness of retreatment in 598 subjects conducted in the USA.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Waddell-2001b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Retrospective study from 1997 to 2000 of Hylan G-F 20 to assess the effect of several independent factors on probability of progression to total knee replacement in 1253 subjects conducted in the USA.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Waddell-2001c">
<CHAR_REASON_FOR_EXCLUSION>
<P>Pharmacoeconomic model with inputs obtained from peer reviewed medical literature, clinical trial data, clinical expert opinion, and claims data. A hypothetical cohort of subjects was followed over a three year period. Analysis conducted from the perspective of a managed care plan.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Waddell-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, prospective, one-year study of hylan G-F 20 in 70 subjects conducted in the USA. Objective was to evaluate a second course of hylan G-F 20.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Waddell-2003a">
<CHAR_REASON_FOR_EXCLUSION>
<P>A retrospective, case-control study of 110 who had undergone TKR and 1151 who had not undergone TKR. Effects of age, gender, BMI, and viscosupplementation with hylan G-F 20 were evaluated on the probabilit of progression to TKR. Repeat treatment with hylan G-F 20 was also analysed. Conducted in USA.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Waddell-2003b">
<CHAR_REASON_FOR_EXCLUSION>
<P>A retrospective, four and a half year study of 1047 patients (1489 knees) who had received at least one intraarticular injection of hylan G-F 20 conducted at an orthopaedic practice in the USA.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Waddell-2003c">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, prospective, 26-week study of Hylan G-F 20 in 85 patients conducted at an orthopaedic practice in the USA.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Weiss-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, prospective, 12-month study of Hylan G-F 20 in 93 subjects conducted in the USA.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wobig-1999d">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, prospective, 12-week, multicenter study of Hylan G-F 20 in 222 subjects conducted in Germany.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wulwik-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, prospective, cohort, two-year study of Synvisc in 117 subjects with severe knee OA conducted in France.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Yoh-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, prospective, six-month study of Artz in 35 subjects conducted in Japan.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Zamora_x002d_Quezada-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, prospective study of an electronic data capture system involving Hyalgan in 43 subjects conducted in the United States.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR STUDY_ID="STD-Anand-2004">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Blanco-Garcia-2004">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Bourgeois-_x0028_Artz_x0029_">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Briliantono-1996">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Byrd-_x0028_Artz_x0029_">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Caracuel-2001">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Castro-2005">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Garcia-2004">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Gur-2002">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Joergensen-2005">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Kilinc-2002">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Kim-2000">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Koyuncu-2002a">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Kuzmanova-2005">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Lee-2002">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Lucangeli-2001">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Petrella-2002a">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Renk_x005b_inodot_x005d_tepe-20">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Russell-2003">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Shariati-2001">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Sinha-2003">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Stitik-2004">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Talwalkar-2005">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Xu-2005">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Za-2002">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR STUDY_ID="STD-Anonymous-1999">
<CHAR_STUDY_NAME>
<P>Orthovisc versus<BR/>saline: a double- blind randomised controlled trial</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS>
<P>Orthovisc versus<BR/>saline</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES/>
<CHAR_STARTING_DATE/>
<CHAR_CONTACT_INFORMATION>
<P>Anika Therapeutics<BR/>Press Release<BR/>August 1999</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-Hempfling-2003">
<CHAR_STUDY_NAME>
<P>Long-term outcome of synovial fluid substitution with Viscoseal post-<BR/>arthroscopy<BR/>Prospective, randomised, masked-observer study</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>80 patients with severe pain in knee joint persisting for at least six months (VAS pain greater than 50 mm)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>arthroscopic lavage versus Viscoseal (50 mg/10 ml) one intra-articular injection immediately after arthroscopy</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Outerbridge,<BR/>VAS (investigator)<BR/>VAS (pain diary) by patient daily, clinical global impression, problems when walking 100 m, Pain when walking 100 m, pain at night, safety</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE/>
<CHAR_CONTACT_INFORMATION>
<P>Prof. Dr. med. Harald Hempfling, Berufsgenossenschaftliche Unfallklinik, D-82418 Murnau am Staffelsee</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-ISRCTN43185756">
<CHAR_STUDY_NAME>
<P>Comparative study between intraarticular ostenil versus orthovisc</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>73 patients with OA of the knee both male and female.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Ostenil or Orthovisc a single course</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>WOMAC/VAS pain scale is primary outcome outcome.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>01/05/2004</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Mr. David Teanby, Consultant Orthopaedic Surgeon, St Helens &amp; Knowsley Hospitals NHS Trust, Whiston Hospital, Prescot, Merseyside L35 5DR, United Kingdom</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>Sources of funding: St. Helens &amp; Knowsley Hospitals NHS Trust, NHS R&amp;D Support Funding.<BR/>Prospective masked observer RCT.</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-ISRCTN51421587">
<CHAR_STUDY_NAME>
<P>Viscosupplementation for osteoarthritis of the knee: protocol for the Swiss viscosupplementation trial (SVISCOT)</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>Males and females with radiologically confirmed symptomatic OA of the knee for at least six months, with pain on most days for the previous three months, will be eligible for trial if they fulfill ACR clinical criteria for OA of the knee; have an ACR functional class rating of II to IV, and have failed to respond sufficiently or were intolerant to conservative treatment.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Synvisc, Orthovisc or Ostenil <BR/>Up to three treatment cycles per knee (one cycle consisting of three injections)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcome is rate of patients who reach a WOMAC total score of 39 or greater plus the rate of individuals who have undergone tootal knee replacement surgery after 24 months of follow-up.<BR/>Secondary outcomes will be (1) the severity of OA symptoms based on the WOMAC pain sub-scale and the WOMAC global scale on pain, stiffness and disability, (2) the cost-utility based on health related quality of life measured by EuroQol and self-reported healthcare utilisation for OA, <BR/>(3) the frequency of local side effects, (4) serious adverse events, (5) the rate of surgical interventions for knee OA other than total knee replacement, and (6) overall mortality</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>July 2002</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>juni@ispm.unibe.ch<BR/>Maya Zullig MD, Research Officer Swiss Federal Office of Social Insurance (OFAS), Berne,<BR/>Switzerland</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>Pilot trial of 600 patients (200/group); main trial 9000 to be randomised<BR/>ISRCTN51421587</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-ISRCTN82192623">
<CHAR_STUDY_NAME>
<P>Prospective randomised single-blind trial comparing the effectiveness of combined arthroscopic washout and intra articular hyaluronan injection to intra articular hyaluronan injection and arthroscopic washout in isolation, for osteoarthritis of knee</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>219 patients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Arthroscopic washout followed by intra-articular HA injection versus arthroscopic washout and intra-articular HA injection in isolation</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES/>
<CHAR_STARTING_DATE>
<P>01 Jan 2002</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Mr. A. Mohsen<BR/>Orthopaedic Department, Hull Royal Infirmary, Anlaby Road,<BR/>Hull HU3 2JZ <BR/>UK<BR/>Tel:+44 01482 328541</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>End date: 31 Mar 2005<BR/>ISRCTN82192623</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-NCT00130468">
<CHAR_STUDY_NAME>
<P>A double blind, randomized trial of intra-articular injections of 20 mg of Hyalgan for the treatment of knee pain due to osteoarthritis (three injection-regimen for efficacy and duration - 20 mg/2ml dose: Tread-20)</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>Phase IV randomised, double-blind, placebo controlled, parallel group<BR/>Inclusion criteria:<BR/>12 criteria:<BR/>written consent,<BR/>40 yr of age and above,<BR/>of sufficient good health to be able to complet 6-month follow-up,<BR/>signs and symptoms of OA of at least one knee according to ACR criteria,<BR/>Kellgren-Lawrence Grade II or III,<BR/>symptoms including knee joint pain, crepitus, swelling, and/or effusion of the knee for at least 6 mths,<BR/>pts on analgesic/NSAID VAS pain score after walking on a 50 foot flat surface of greater than or equal to 30 mm but less than 90 mm,<BR/>if not taking analgesic/NSAIDVAS pain score after walking of greater than 40 mm but less than 90 mm,<BR/>if bilateral knee pain is present, investigator will select the more painful knee<BR/>Exclusion criteria:<BR/>4 general,<BR/>28 musculoskeletal related,<BR/>16 concomitant conditions, diseases, medications and/or clinical history related<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Hyalgan</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES/>
<CHAR_STARTING_DATE/>
<CHAR_CONTACT_INFORMATION>
<P>Suzanne Meeves<BR/>Study Director<BR/>Sanofi-Aventis</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>Sponsored by Sanofi-Aventis<BR/>ClinicalTrials.gov Identifier:<BR/>NCT00130468</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-NCT00131352">
<CHAR_STUDY_NAME>
<P>A study of the safety and efficacy of Synvisc in patients with symptomatic osteoarthritis of the knee</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>Country: Belgium (4 sites), Czech Republic (4 sites), France (5 sites), Germany (1 site), Netherlands (2 sites), United Kingdom (5 sites)<BR/>Duration: 26 wk with possible repeat treatment after this time<BR/>Inclusion criteria:<BR/>age 40 years and above,<BR/>pts with symptomatic OA pain of the knee<BR/>Exclusion criteria:<BR/>Pts with current or prior conditions or treatment that would impede measurement of efficacy or safety</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Hylan G-F 20<BR/>Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pain relief</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>May 2005</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>David Perkins<BR/>Study Director<BR/>Genzyme</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>Sponsored by Genzyme.<BR/>ClinicalTrialsgov. Identifier: NCT00131352<BR/>Expected completion: December 2006</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-NCT00139295">
<CHAR_STUDY_NAME>
<P>Comparison of the efficacy and safety of Hylastan to methylprednisolone acetate in patients with symptomatic osteoarthritis of the knee</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>Males and females 40 years and above diagnosed with OA of the knee. Have tried but not been sufficiently helped by conservative treatment such as weight reduction and pain medications. Exclusion: prior or concomitant treatments that would impede measuremen tof safety and efficacy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Hylastan and active control</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pain relief</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>October 2004</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>David Perkins, R.Ph., Study Director, Genzyme</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>Expected completion: March 2007, Data entry closure: December 2006</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-NCT00144820">
<CHAR_STUDY_NAME>
<P>Intra-articular injections of hyaluronan versus 20 MI NaCl versus placebo in treatment of knee osteoarthritis: a randomised, double-blind, placebo controlled single centre trial</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>Males and females 60 years and above with clinical, radiological and possible arthroscopical verified knee OA; knee pain on the day of examination scoring more than 20 mm on a VAS at baseline.<BR/>Exclusion: less than 60 y, unconsciousness, psychosis, demens, ingestion of drugs that may influence the results of the clinical examinations, inflammatory diseases of the joints, RA or other inflammatory arthritis as diagnosed by ACR criteria, contraindication to Hyalgan treatment, previous intra-articular fracture of a knee joint, infection or skin disease located at the place of injection and invasive procedures done to the knee joint within previous 2 mth inclusive intra-articular injections of steroids, any other condition that might interfere with the efficacy assessment or completion of the trial</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>4 weekly injections of :<BR/>Hyaluronan (2 ml sodium hyaluronate),<BR/>Placebo (2 ml isotonic saline), Excessive saline (20 ml isotonic saline)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pain measured on a VAS on movement; at rest and during the night; KOOS scores; daily consumption of analgesics; cartilage and bone degradation markers; quadriceps circumference (cm); abililty to bend (degrees flexion); and stretch (degrees extension); global assessment patient; global assessment investigator</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>This study is no longer recruiting patients.</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Charlotte Lundsgaard, MD, Principal Investigator, Copenhagen Trial Unit (CTU), H:S Rigshospitalet. dept. 7102, Copenhagen, Copenhagen 0, 2100, Denmark</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>251 consecutive patients were randomised. Results were evaluated at weeks 1,2,3,4,8,12,16 and 26. Biochemical markers for bone and cartilage degradation were measured in urine/blood.</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-Russell-2001">
<CHAR_STUDY_NAME>
<P>A comparison of Hylan G-F 20 and arthroscopic lavage in the management of osteoarthritis of the knee</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>50 patients with knee OA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Hylan G-F 20<BR/>Arthroscopic lavage</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>WOMAC</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE/>
<CHAR_CONTACT_INFORMATION>
<P>4 Rural Way, Ty Coch, Swansea<BR/>SA2 9NA<BR/>Wales</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>Synvisc group showed greater and more consistent improvement in WOMAC scores at all assessments post treatment. At 6 months (p&lt;0.05) and 1 yr (p=0.0018)</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Adams-1995">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Altman-1998">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Altman-2004">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Ardic-2001">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Atamaz-2004">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Atamaz-2005">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Auerbach-2002">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Auerbach-2002a">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Bayramoglu-2003">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Bragantini-1987">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Brandt-2001">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Brown-2003">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Bunyaratavej-2001">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Caborn-2003">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Caborn-2004">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Carrabba-1995">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Carrabba-1995a">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Carrabba-1995b">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Carrabba-1995c">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Cohen-1994">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Corrado-1995">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Creamer-1994">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Cubukcu-2004">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Day-2001">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Day-2004">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Dickson-2001">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Dougados-1993">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Formiguera-Sala-1995">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Forster-2003">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Forster-2003a">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Frizziero-2002">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Graf-1993">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Grecomoro-1987">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Groppa-2001">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Guler-1996">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Henderson-1994">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Henderson-1994a">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hizmetli-1999">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Huang-2005">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Huskisson-1999">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Jones-1995">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Jubb-2001a">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Jubb-2001b">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Jubb-2001c">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Jubb-2001d">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Jubb-2003">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kahan-2001">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kahan-2003">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Kahan-2003a">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kalay-1997">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Karatay-2004">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Karatay-2005">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Karatay-2005a">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Karatosun-2005">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Karatosun-2005a">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Karlsson-1999">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Karlsson-2002">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Karlsson-2002a-_x0028_AvP_x0029_">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Karlsson-2002b-_x0028_SvP_x0029_">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Karlsson-2002c-_x0028_AvS_x0029_">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Karlsson-2003d">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Karras-2001">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Kawabata-1993">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Kirchner--2005">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Kirchner-2005">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Kirchner-2006">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kotevoglu-2002">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kotevoglu-2005">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Lanzer-2002">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Leardini-1987">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Leardini-1991">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Leopold-2003">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Lin-2004">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Listrat-1997">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Lohmander-1996">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-McDonald-2000">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Miltner-2002">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Moreland-1993">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Nahler-1996">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Nahler-1998">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Neustadt-2004">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Neustadt-2005">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Neustadt-2005a-_x002d_3inj">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Neustadt-2005b_x002d_4inj">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Ozturk-2005">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Petrella-2002">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Pham-2003">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Pham-2004">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Pietrogrande-1991">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Puhl-1993">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Raynauld-2002">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Redd-2003">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Rejaili-2005">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Roman-2000">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Scale-1994a-_x0028_2-inj_x0029_">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Scale-1994b-_x0028_3-inj_x0029_">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Schneider-1997">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Sezgin-2005">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Shichikawa-1983a">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Shichikawa-1983b">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-St.-J.-Dixon-1988">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Tamir-2001">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Tascioglu-2003">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Tekeoglu-1998">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Thompson-2002">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Tsai-2003">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Tsukamoto-1995">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Wobig-1998">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Wobig-1999">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Wobig-1999a-_x0028_Healon_x0029_">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Wobig-1999b-_x0028_Artz_x0029_">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Wobig-1999c-_x0028_NEhyl_x0029_">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Wu-1997">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Wu-2004">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Yamamoto-1994">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Yentur-2003">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES>
<ADDITIONAL_TABLE ID="TBL-01" NO="1">
<TITLE>Clinical benefit table: Adant. Patient global assessment</TITLE>
<TABLE COLS="9" ROWS="7">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Time</P>
</TH>
<TH>
<P>Treatment</P>
</TH>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>No. of pts improved</P>
</TH>
<TH>
<P>No. of pts</P>
</TH>
<TH>
<P>Risk (%)</P>
</TH>
<TH>
<P>Risk difference</P>
</TH>
<TH>
<P>NNT</P>
</TH>
</TR>
<TR>
<TD>
<P>Roman 2000</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Adant</P>
</TD>
<TD>
<P>Number of patients excellent/good</P>
</TD>
<TD>
<P>13</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>43</P>
</TD>
<TD>
<P>6</P>
</TD>
<TD>
<P>16.7</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hyalgan</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>7</P>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>37</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Adant</P>
</TD>
<TD>
<P>Number of patients excellent/good</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>50</P>
</TD>
<TD>
<P>29</P>
</TD>
<TD>
<P>3.5</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hyalgan</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>21</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Adant</P>
</TD>
<TD>
<P>Number of patients excellent/good</P>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>33</P>
</TD>
<TD>
<P>17</P>
</TD>
<TD>
<P>5.9</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hyalgan</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" NO="2">
<TITLE>Clinical benefit table: Adant. Safety</TITLE>
<TABLE COLS="8" ROWS="2">
<TR>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>Event rate Hyalgan</P>
</TH>
<TH>
<P>Event rate Adant</P>
</TH>
<TH>
<P>Relative risk 95%CI</P>
</TH>
<TH>
<P>Abs risk diff 95% CI</P>
</TH>
<TH>
<P>NNH (95% CI)</P>
</TH>
<TH>
<P>#/100 Adant with AE</P>
</TH>
<TH>
<P>#/100 Hyalgan withAE</P>
</TH>
</TR>
<TR>
<TD>
<P>Painful injection</P>
</TD>
<TD>
<P>10.5% 2/19</P>
</TD>
<TD>
<P>20% 6/30</P>
</TD>
<TD>
<P>190% (43 to 846%)</P>
</TD>
<TD>
<P>9% (-10% to 29%)</P>
</TD>
<TD>
<P>11</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>11</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" NO="3">
<TITLE>Clinical benefit table: Artz versus placebo. Dichotomous outcome measures</TITLE>
<TABLE COLS="9" ROWS="19">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Time</P>
</TH>
<TH>
<P>Treatment</P>
</TH>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>No. improved</P>
</TH>
<TH>
<P>No. of pts</P>
</TH>
<TH>
<P>Risk (%)</P>
</TH>
<TH>
<P>Risk difference</P>
</TH>
<TH>
<P>NNT</P>
</TH>
</TR>
<TR>
<TD>
<P>Lohmander 1996</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Artzal</P>
</TD>
<TD>
<P>Number of patients improved</P>
</TD>
<TD>
<P>59</P>
</TD>
<TD>
<P>96</P>
</TD>
<TD>
<P>61</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>100</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>56</P>
</TD>
<TD>
<P>93</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Shichikawa 1983a</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Artz</P>
</TD>
<TD>
<P>Number of patients improved</P>
</TD>
<TD>
<P>87</P>
</TD>
<TD>
<P>103</P>
</TD>
<TD>
<P>84</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>5</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Vehicle</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>67</P>
</TD>
<TD>
<P>105</P>
</TD>
<TD>
<P>64</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Shichikawa 1983b</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Artz</P>
</TD>
<TD>
<P>Number of patients improved</P>
</TD>
<TD>
<P>38</P>
</TD>
<TD>
<P>48</P>
</TD>
<TD>
<P>79</P>
</TD>
<TD>
<P>9</P>
</TD>
<TD>
<P>11</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Vehicle</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>35</P>
</TD>
<TD>
<P>50</P>
</TD>
<TD>
<P>70</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Lohmander 1996</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Artzal</P>
</TD>
<TD>
<P>Number of patients improved</P>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>96</P>
</TD>
<TD>
<P>55</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>51</P>
</TD>
<TD>
<P>93</P>
</TD>
<TD>
<P>55</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Puhl 1993</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Artz</P>
</TD>
<TD>
<P>Number of patients improved</P>
</TD>
<TD>
<P>86</P>
</TD>
<TD>
<P>95</P>
</TD>
<TD>
<P>91</P>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>10</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Vehicle</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>81</P>
</TD>
<TD>
<P>100</P>
</TD>
<TD>
<P>81</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Lohmander 1996</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Artzal</P>
</TD>
<TD>
<P>Number of patients improved</P>
</TD>
<TD>
<P>58</P>
</TD>
<TD>
<P>96</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>14</P>
</TD>
<TD>
<P>7.1</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>43</P>
</TD>
<TD>
<P>93</P>
</TD>
<TD>
<P>46</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karlsson 2002a</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Artzal</P>
</TD>
<TD>
<P>Number of clinical failures</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>90</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>-9</P>
</TD>
<TD>
<P>11</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>7</P>
</TD>
<TD>
<P>66</P>
</TD>
<TD>
<P>11</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karlsson 2002a</P>
</TD>
<TD>
<P>45-52 wk</P>
</TD>
<TD>
<P>E: Artzal</P>
</TD>
<TD>
<P>Number of clinical failures</P>
</TD>
<TD>
<P>26</P>
</TD>
<TD>
<P>66</P>
</TD>
<TD>
<P>39</P>
</TD>
<TD>
<P>-15</P>
</TD>
<TD>
<P>6.7</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>26</P>
</TD>
<TD>
<P>48</P>
</TD>
<TD>
<P>54</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karlsson 2002a</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Artzal</P>
</TD>
<TD>
<P>Number of survivors</P>
</TD>
<TD>
<P>39</P>
</TD>
<TD>
<P>90</P>
</TD>
<TD>
<P>43</P>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>10</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>22</P>
</TD>
<TD>
<P>66</P>
</TD>
<TD>
<P>33</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-04" NO="4">
<TITLE>Clinical benefit table: Artz versus placebo. Continuous outcome measures</TITLE>
<TABLE COLS="9" ROWS="51">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Time</P>
</TH>
<TH>
<P>Treatment</P>
</TH>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>N of Pts</P>
</TH>
<TH>
<P>Baseline Mean</P>
</TH>
<TH>
<P>End of Study Mean</P>
</TH>
<TH>
<P>Absolute Benefit</P>
</TH>
<TH>
<P>Relative Difference</P>
</TH>
</TR>
<TR>
<TD>
<P>Lohmander 1996</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Artzal</P>
</TD>
<TD>
<P>Pain (0-100 mm VAS)</P>
</TD>
<TD>
<P>96</P>
</TD>
<TD>
<P>49.76</P>
</TD>
<TD>
<P>36.64</P>
</TD>
<TD>
<P>2.48 (W)</P>
</TD>
<TD>
<P>5.2% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>93</P>
</TD>
<TD>
<P>47.84</P>
</TD>
<TD>
<P>32.24</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Lohmander 1996</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Artzal</P>
</TD>
<TD>
<P>Pain (0-100 mm VAS)</P>
</TD>
<TD>
<P>96</P>
</TD>
<TD>
<P>49.76</P>
</TD>
<TD>
<P>34.69</P>
</TD>
<TD>
<P>-2.46 (I)</P>
</TD>
<TD>
<P>-5.1% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>93</P>
</TD>
<TD>
<P>47.84</P>
</TD>
<TD>
<P>35.23</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Lohmander 1996</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Artzal</P>
</TD>
<TD>
<P>Pain (0-100 mm VAS)</P>
</TD>
<TD>
<P>96</P>
</TD>
<TD>
<P>49.76</P>
</TD>
<TD>
<P>33.65</P>
</TD>
<TD>
<P>-3.67 (I)</P>
</TD>
<TD>
<P>-7.7% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>93</P>
</TD>
<TD>
<P>47.84</P>
</TD>
<TD>
<P>35.40</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Lohmander 1996</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Artzal</P>
</TD>
<TD>
<P>Activity level (0-100 mm VAS)</P>
</TD>
<TD>
<P>96</P>
</TD>
<TD>
<P>62.98</P>
</TD>
<TD>
<P>43.69</P>
</TD>
<TD>
<P>4.77 (W)</P>
</TD>
<TD>
<P>7.4% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>93</P>
</TD>
<TD>
<P>64.71</P>
</TD>
<TD>
<P>40.65</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Lohmander 1996</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Artzal</P>
</TD>
<TD>
<P>Activity level (0-100 mm VAS)</P>
</TD>
<TD>
<P>96</P>
</TD>
<TD>
<P>62.98</P>
</TD>
<TD>
<P>45.17</P>
</TD>
<TD>
<P>4.71 (W)</P>
</TD>
<TD>
<P>7.3% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>93</P>
</TD>
<TD>
<P>64.71</P>
</TD>
<TD>
<P>42.19</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Lohmander 1996</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Artzal</P>
</TD>
<TD>
<P>Activity level (0-100 mm VAS)</P>
</TD>
<TD>
<P>96</P>
</TD>
<TD>
<P>62.98</P>
</TD>
<TD>
<P>41.67</P>
</TD>
<TD>
<P>-0.68 (I)</P>
</TD>
<TD>
<P>-1.1% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>93</P>
</TD>
<TD>
<P>64.71</P>
</TD>
<TD>
<P>44.08</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Lohmander 1996</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Artzal</P>
</TD>
<TD>
<P>Lequesne (0-24)</P>
</TD>
<TD>
<P>120</P>
</TD>
<TD>
<P>9.89</P>
</TD>
<TD>
<P>7.98</P>
</TD>
<TD>
<P>-0.17 (I)</P>
</TD>
<TD>
<P>-1.8% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>120</P>
</TD>
<TD>
<P>9.56</P>
</TD>
<TD>
<P>7.82</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Lohmander 1996</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Artzal</P>
</TD>
<TD>
<P>Knee function (0-100 mm VAS)</P>
</TD>
<TD>
<P>96</P>
</TD>
<TD>
<P>53.76</P>
</TD>
<TD>
<P>38.00</P>
</TD>
<TD>
<P>2.17 (W)</P>
</TD>
<TD>
<P>4.1% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>93</P>
</TD>
<TD>
<P>53.02</P>
</TD>
<TD>
<P>35.09</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Lohmander 1996</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Artzal</P>
</TD>
<TD>
<P>Knee function (0-100 mm VAS)</P>
</TD>
<TD>
<P>96</P>
</TD>
<TD>
<P>53.76</P>
</TD>
<TD>
<P>42.34</P>
</TD>
<TD>
<P>4.09 (W)</P>
</TD>
<TD>
<P>7.7% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>93</P>
</TD>
<TD>
<P>53.02</P>
</TD>
<TD>
<P>37.51</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Lohmander 1996</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Artzal</P>
</TD>
<TD>
<P>Knee function (0-100 mm VAS)</P>
</TD>
<TD>
<P>96</P>
</TD>
<TD>
<P>53.76</P>
</TD>
<TD>
<P>38.27</P>
</TD>
<TD>
<P>-2.3 (I)</P>
</TD>
<TD>
<P>-4.3% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>93</P>
</TD>
<TD>
<P>53.02</P>
</TD>
<TD>
<P>39.83</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karlsson 2002a</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Artzal</P>
</TD>
<TD>
<P>Pain on weight bearing (0-100 mm VAS)</P>
</TD>
<TD>
<P>92</P>
</TD>
<TD>
<P>64</P>
</TD>
<TD>
<P>44</P>
</TD>
<TD>
<P>1.0 (W)</P>
</TD>
<TD>
<P>1.5% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>66</P>
</TD>
<TD>
<P>65</P>
</TD>
<TD>
<P>44</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karlsson 2002a</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Artzal</P>
</TD>
<TD>
<P>Pain on weight bearing (0-100 mm VAS)</P>
</TD>
<TD>
<P>92</P>
</TD>
<TD>
<P>64</P>
</TD>
<TD>
<P>42</P>
</TD>
<TD>
<P>-3 (I)</P>
</TD>
<TD>
<P>-4.6% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>66</P>
</TD>
<TD>
<P>65</P>
</TD>
<TD>
<P>46</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karlsson 2002a</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Artzal</P>
</TD>
<TD>
<P>Pain on weight bearing (0-100 mm VAS)</P>
</TD>
<TD>
<P>92</P>
</TD>
<TD>
<P>64</P>
</TD>
<TD>
<P>48</P>
</TD>
<TD>
<P>5 (W)</P>
</TD>
<TD>
<P>7.7% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>66</P>
</TD>
<TD>
<P>65</P>
</TD>
<TD>
<P>44</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karlsson 2002a</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Artzal</P>
</TD>
<TD>
<P>WOMAC (0-100 mm VAS)</P>
</TD>
<TD>
<P>92</P>
</TD>
<TD>
<P>48.7</P>
</TD>
<TD>
<P>34.7</P>
</TD>
<TD>
<P>4.2 (W)</P>
</TD>
<TD>
<P>8.6% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>66</P>
</TD>
<TD>
<P>48.9</P>
</TD>
<TD>
<P>30.7</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karlsson 2002a</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Artzal</P>
</TD>
<TD>
<P>WOMAC (0-100 mm VAS)</P>
</TD>
<TD>
<P>92</P>
</TD>
<TD>
<P>48.7</P>
</TD>
<TD>
<P>37.4</P>
</TD>
<TD>
<P>5.5 (W)</P>
</TD>
<TD>
<P>11.2% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>66</P>
</TD>
<TD>
<P>48.9</P>
</TD>
<TD>
<P>32.1</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karlsson 2002a</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Artzal</P>
</TD>
<TD>
<P>Lequesne Index (0-24)</P>
</TD>
<TD>
<P>92</P>
</TD>
<TD>
<P>13.9</P>
</TD>
<TD>
<P>10.0</P>
</TD>
<TD>
<P>0.8 (W)</P>
</TD>
<TD>
<P>5.9% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>66</P>
</TD>
<TD>
<P>13.6</P>
</TD>
<TD>
<P>8.9</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Puhl 1993</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Artz</P>
</TD>
<TD>
<P>Pain (0-100 mm VAS)</P>
</TD>
<TD>
<P>95</P>
</TD>
<TD>
<P>54.10</P>
</TD>
<TD>
<P>29.14</P>
</TD>
<TD>
<P>-4.96 (I)</P>
</TD>
<TD>
<P>-9.6% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Vehicle</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>100</P>
</TD>
<TD>
<P>51.40</P>
</TD>
<TD>
<P>31.40</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Puhl 1993</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Artz</P>
</TD>
<TD>
<P>Pain (0-100 mm VAS)</P>
</TD>
<TD>
<P>95</P>
</TD>
<TD>
<P>54.10</P>
</TD>
<TD>
<P>26.50</P>
</TD>
<TD>
<P>-10.2 (I)</P>
</TD>
<TD>
<P>-19.8 (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Vehicle</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>100</P>
</TD>
<TD>
<P>51.40</P>
</TD>
<TD>
<P>34.00</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Puhl 1993</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Artz</P>
</TD>
<TD>
<P>Lequesne Index (0-24)</P>
</TD>
<TD>
<P>95</P>
</TD>
<TD>
<P>10.4</P>
</TD>
<TD>
<P>7.19</P>
</TD>
<TD>
<P>-0.81 (I)</P>
</TD>
<TD>
<P>-8.6% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Vehicle</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>100</P>
</TD>
<TD>
<P>9.4</P>
</TD>
<TD>
<P>7.00</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Puhl 1993</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Artz</P>
</TD>
<TD>
<P>Lequesne Index (0-24)</P>
</TD>
<TD>
<P>95</P>
</TD>
<TD>
<P>10.4</P>
</TD>
<TD>
<P>6.43</P>
</TD>
<TD>
<P>-1.36 (I)</P>
</TD>
<TD>
<P>-14.5% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Vehicle</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>100</P>
</TD>
<TD>
<P>9.4</P>
</TD>
<TD>
<P>6.79</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Shichikawa 1983b</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Artz</P>
</TD>
<TD>
<P>Pain (0-3)</P>
</TD>
<TD>
<P>52</P>
</TD>
<TD>
<P>1.03</P>
</TD>
<TD>
<P>0.66</P>
</TD>
<TD>
<P>0.02 (W)</P>
</TD>
<TD>
<P>1.8% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Vehicle</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>55</P>
</TD>
<TD>
<P>1.12</P>
</TD>
<TD>
<P>0.73</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Shichikawa 1983b</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Artz</P>
</TD>
<TD>
<P>Range of motion (flexion degrees)</P>
</TD>
<TD>
<P>52</P>
</TD>
<TD>
<P>133.4</P>
</TD>
<TD>
<P>135.65</P>
</TD>
<TD>
<P>-1.75 (W)</P>
</TD>
<TD>
<P>-1.4% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Vehicle</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>55</P>
</TD>
<TD>
<P>128.6</P>
</TD>
<TD>
<P>132.60</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Day 2004</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Artz</P>
</TD>
<TD>
<P>WOMAC pain (0-20 Likert)</P>
</TD>
<TD>
<P>116</P>
</TD>
<TD>
<P>7.96</P>
</TD>
<TD>
<P>3.84</P>
</TD>
<TD>
<P>-0.05 (I)</P>
</TD>
<TD>
<P>-0.6% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>124</P>
</TD>
<TD>
<P>8.68</P>
</TD>
<TD>
<P>4.61</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Day 2004</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>E: Artz</P>
</TD>
<TD>
<P>WOMAC function (0-68 Likert)</P>
</TD>
<TD>
<P>116</P>
</TD>
<TD>
<P>28.07</P>
</TD>
<TD>
<P>11.41</P>
</TD>
<TD>
<P>4.06 (W)</P>
</TD>
<TD>
<P>13% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>124</P>
</TD>
<TD>
<P>31.25</P>
</TD>
<TD>
<P>10.53</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Day 2004</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>E: Artz</P>
</TD>
<TD>
<P>WOMAC stiffness (0-8)</P>
</TD>
<TD>
<P>116</P>
</TD>
<TD>
<P>3.70</P>
</TD>
<TD>
<P>1.42</P>
</TD>
<TD>
<P>0.07 (W)</P>
</TD>
<TD>
<P>1.8% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>124</P>
</TD>
<TD>
<P>3.79</P>
</TD>
<TD>
<P>1.44</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-05" NO="5">
<TITLE>Clinical benefit table. Artz versus Hylan G-F 20. Dichotomous outcome measure</TITLE>
<TABLE COLS="9" ROWS="7">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Time</P>
</TH>
<TH>
<P>Treatment</P>
</TH>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>No. improved</P>
</TH>
<TH>
<P>No. of pts</P>
</TH>
<TH>
<P>Risk (%)</P>
</TH>
<TH>
<P>Risk difference</P>
</TH>
<TH>
<P>NNT</P>
</TH>
</TR>
<TR>
<TD>
<P>Karlsson 2002c</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Artzal</P>
</TD>
<TD>
<P>Number of clinical failures</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>90</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>-5</P>
</TD>
<TD>
<P>20</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hylan G-F 20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>6</P>
</TD>
<TD>
<P>86</P>
</TD>
<TD>
<P>7</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karlsson 2002c</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Artzal</P>
</TD>
<TD>
<P>Number of survivors</P>
</TD>
<TD>
<P>39</P>
</TD>
<TD>
<P>90</P>
</TD>
<TD>
<P>43</P>
</TD>
<TD>
<P>-1</P>
</TD>
<TD>
<P>100</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hylan G-F 20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>38</P>
</TD>
<TD>
<P>86</P>
</TD>
<TD>
<P>44</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karlsson 2002c</P>
</TD>
<TD>
<P>45-52 wk</P>
</TD>
<TD>
<P>E: Artzal</P>
</TD>
<TD>
<P>Number of clinical failures</P>
</TD>
<TD>
<P>26</P>
</TD>
<TD>
<P>66</P>
</TD>
<TD>
<P>39</P>
</TD>
<TD>
<P>-7</P>
</TD>
<TD>
<P>14.3</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hylan G-F 20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>32</P>
</TD>
<TD>
<P>70</P>
</TD>
<TD>
<P>46</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-06" NO="6">
<TITLE>Clinical benefit table: Artz versus Hylan G-F 20. Continuous outcome measure</TITLE>
<TABLE COLS="9" ROWS="13">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Time</P>
</TH>
<TH>
<P>Treatment</P>
</TH>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>N of Pts</P>
</TH>
<TH>
<P>Baseline Mean</P>
</TH>
<TH>
<P>End of Study Mean</P>
</TH>
<TH>
<P>Absolute Benefit</P>
</TH>
<TH>
<P>Relative Difference</P>
</TH>
</TR>
<TR>
<TD>
<P>Karlsson 2002c</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Artzal</P>
</TD>
<TD>
<P>Pain on weight bearing (0-100 mm VAS)</P>
</TD>
<TD>
<P>92</P>
</TD>
<TD>
<P>64</P>
</TD>
<TD>
<P>44</P>
</TD>
<TD>
<P>-2 (I)</P>
</TD>
<TD>
<P>-3.2% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hylan G-F 20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>88</P>
</TD>
<TD>
<P>63</P>
</TD>
<TD>
<P>45</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karlsson 2002c</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Artzal</P>
</TD>
<TD>
<P>Pain on weight bearing (0-100 mm VAS)</P>
</TD>
<TD>
<P>92</P>
</TD>
<TD>
<P>64</P>
</TD>
<TD>
<P>42</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0%</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hylan G-F 20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>88</P>
</TD>
<TD>
<P>63</P>
</TD>
<TD>
<P>41</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karlsson 2002c</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Artzal</P>
</TD>
<TD>
<P>Pain on weight bearing (0-100 mm VAS)</P>
</TD>
<TD>
<P>92</P>
</TD>
<TD>
<P>64</P>
</TD>
<TD>
<P>48</P>
</TD>
<TD>
<P>4 (W)</P>
</TD>
<TD>
<P>6.3% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hylan G-F 20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>88</P>
</TD>
<TD>
<P>63</P>
</TD>
<TD>
<P>43</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karlsson 2002c</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Artzal</P>
</TD>
<TD>
<P>WOMAC (0-100 mm VAS)</P>
</TD>
<TD>
<P>92</P>
</TD>
<TD>
<P>48.7</P>
</TD>
<TD>
<P>34.7</P>
</TD>
<TD>
<P>3.0 (W)</P>
</TD>
<TD>
<P>6.2% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hylan G-F 20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>88</P>
</TD>
<TD>
<P>48.7</P>
</TD>
<TD>
<P>31.7</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karlsson 2002c</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Artzal</P>
</TD>
<TD>
<P>WOMAC (0-100 mm VAS)</P>
</TD>
<TD>
<P>92</P>
</TD>
<TD>
<P>48.7</P>
</TD>
<TD>
<P>37.4</P>
</TD>
<TD>
<P>5.5 (W)</P>
</TD>
<TD>
<P>11.3% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hylan G-F 20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>88</P>
</TD>
<TD>
<P>48.7</P>
</TD>
<TD>
<P>31.9</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karlsson 2002c</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Artzal</P>
</TD>
<TD>
<P>Lequesne Index (0-24)</P>
</TD>
<TD>
<P>92</P>
</TD>
<TD>
<P>13.9</P>
</TD>
<TD>
<P>10.0</P>
</TD>
<TD>
<P>0.5 (W)</P>
</TD>
<TD>
<P>3.7% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hylan G-F 20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>88</P>
</TD>
<TD>
<P>13.4</P>
</TD>
<TD>
<P>9.0</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-07" NO="7">
<TITLE>Clinical benefit table: Durolane. Continuous outcome measures</TITLE>
<TABLE COLS="9" ROWS="19">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Time</P>
</TH>
<TH>
<P>Treatment</P>
</TH>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>N of Pts</P>
</TH>
<TH>
<P>Baseline Mean</P>
</TH>
<TH>
<P>End of Study Mean</P>
</TH>
<TH>
<P>Absolute Benefit</P>
</TH>
<TH>
<P>Relative Difference</P>
</TH>
</TR>
<TR>
<TD>
<P>Altman 2004</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Durolane</P>
</TD>
<TD>
<P>WOMAC pain (0-20)</P>
</TD>
<TD>
<P>172</P>
</TD>
<TD>
<P>9.90</P>
</TD>
<TD>
<P>6.75</P>
</TD>
<TD>
<P>0.24 (W)</P>
</TD>
<TD>
<P>2.3% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>174</P>
</TD>
<TD>
<P>10.42</P>
</TD>
<TD>
<P>7.03</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Altman 2004</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Durolane</P>
</TD>
<TD>
<P>WOMAC function (0-68)</P>
</TD>
<TD>
<P>172</P>
</TD>
<TD>
<P>30.70</P>
</TD>
<TD>
<P>23.18</P>
</TD>
<TD>
<P>1.00 (W)</P>
</TD>
<TD>
<P>3.1% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>174</P>
</TD>
<TD>
<P>32.16</P>
</TD>
<TD>
<P>23.64</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Altman 2004</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Durolane</P>
</TD>
<TD>
<P>WOMAC stiffness (0-8)</P>
</TD>
<TD>
<P>172</P>
</TD>
<TD>
<P>3.91</P>
</TD>
<TD>
<P>3.04</P>
</TD>
<TD>
<P>0.16 (W)</P>
</TD>
<TD>
<P>3.7% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>174</P>
</TD>
<TD>
<P>4.30</P>
</TD>
<TD>
<P>3.27</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Altman 2004</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Durolane</P>
</TD>
<TD>
<P>WOMAC pain (0-20)</P>
</TD>
<TD>
<P>172</P>
</TD>
<TD>
<P>9.90</P>
</TD>
<TD>
<P>7.03</P>
</TD>
<TD>
<P>0.55 (W)</P>
</TD>
<TD>
<P>5.3% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>174</P>
</TD>
<TD>
<P>10.42</P>
</TD>
<TD>
<P>7.00</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Altman 2004</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Durolane</P>
</TD>
<TD>
<P>WOMAC function (0-68)</P>
</TD>
<TD>
<P>172</P>
</TD>
<TD>
<P>30.70</P>
</TD>
<TD>
<P>23.72</P>
</TD>
<TD>
<P>1.74 (W)</P>
</TD>
<TD>
<P>5.4% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>174</P>
</TD>
<TD>
<P>32.16</P>
</TD>
<TD>
<P>23.44</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Altman 2004</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Durolane</P>
</TD>
<TD>
<P>WOMAC stiffness (0-8)</P>
</TD>
<TD>
<P>172</P>
</TD>
<TD>
<P>3.91</P>
</TD>
<TD>
<P>3.20</P>
</TD>
<TD>
<P>0.34 (W)</P>
</TD>
<TD>
<P>7.9% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>174</P>
</TD>
<TD>
<P>4.30</P>
</TD>
<TD>
<P>3.25</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Altman 2004</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Durolane</P>
</TD>
<TD>
<P>WOMAC pain (0-20)</P>
</TD>
<TD>
<P>172</P>
</TD>
<TD>
<P>9.90</P>
</TD>
<TD>
<P>7.40</P>
</TD>
<TD>
<P>0.39 (W)</P>
</TD>
<TD>
<P>3.7% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>174</P>
</TD>
<TD>
<P>10.42</P>
</TD>
<TD>
<P>7.53</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Altman 2004</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Durolane</P>
</TD>
<TD>
<P>WOMAC function (0-68)</P>
</TD>
<TD>
<P>172</P>
</TD>
<TD>
<P>30.70</P>
</TD>
<TD>
<P>24.88</P>
</TD>
<TD>
<P>1.60 (W)</P>
</TD>
<TD>
<P>5.0% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>174</P>
</TD>
<TD>
<P>32.16</P>
</TD>
<TD>
<P>24.74</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Altman 2004</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Durolane</P>
</TD>
<TD>
<P>WOMAC stiffness (0-8)</P>
</TD>
<TD>
<P>172</P>
</TD>
<TD>
<P>3.91</P>
</TD>
<TD>
<P>3.44</P>
</TD>
<TD>
<P>0.35 (W)</P>
</TD>
<TD>
<P>8.1% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>174</P>
</TD>
<TD>
<P>4.30</P>
</TD>
<TD>
<P>3.48</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-08" NO="8">
<TITLE>Clinical benefit table. Durolane. Dichotomous outcome measures</TITLE>
<TABLE COLS="9" ROWS="13">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Time</P>
</TH>
<TH>
<P>Treatment</P>
</TH>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>No. improved</P>
</TH>
<TH>
<P>No. of pts</P>
</TH>
<TH>
<P>Risk (%)</P>
</TH>
<TH>
<P>Risk difference</P>
</TH>
<TH>
<P>NNT</P>
</TH>
</TR>
<TR>
<TD>
<P>Altman 2004</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Durolane</P>
</TD>
<TD>
<P>Responder: reduction in WOMAC pain score of at least 40% with an absolute improvement of at least 5 points</P>
</TD>
<TD>
<P>63</P>
</TD>
<TD>
<P>172</P>
</TD>
<TD>
<P>37</P>
</TD>
<TD>
<P>7</P>
</TD>
<TD>
<P>14</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>52</P>
</TD>
<TD>
<P>174</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Altman 2004</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Durolane</P>
</TD>
<TD>
<P>Responder: reduction in WOMAC pain score of at least 40% with an absolute improvement of at least 5 points</P>
</TD>
<TD>
<P>55</P>
</TD>
<TD>
<P>172</P>
</TD>
<TD>
<P>32</P>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>33</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>61</P>
</TD>
<TD>
<P>174</P>
</TD>
<TD>
<P>35</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Altman 2004</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Durolane</P>
</TD>
<TD>
<P>Responder: reduction in WOMAC pain score of at least 40% with an absolute improvement of at least 5 points</P>
</TD>
<TD>
<P>50</P>
</TD>
<TD>
<P>172</P>
</TD>
<TD>
<P>29</P>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>33</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>56</P>
</TD>
<TD>
<P>174</P>
</TD>
<TD>
<P>32</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Altman 2004</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Durolane</P>
</TD>
<TD>
<P>Responder: patients only with knee OA, reduction in WOMAC pain score of at least 40% with an absolute improvement of at least 5 points</P>
</TD>
<TD>
<P>45</P>
</TD>
<TD>
<P>107</P>
</TD>
<TD>
<P>42</P>
</TD>
<TD>
<P>14</P>
</TD>
<TD>
<P>7</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>109</P>
</TD>
<TD>
<P>28</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Altman 2004</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Durolane</P>
</TD>
<TD>
<P>Responder: patients only with knee OA, reduction in WOMAC pain score of at least 40% with an absolute improvement of at least 5 points</P>
</TD>
<TD>
<P>38</P>
</TD>
<TD>
<P>107</P>
</TD>
<TD>
<P>36</P>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>33</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>36</P>
</TD>
<TD>
<P>109</P>
</TD>
<TD>
<P>33</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Altman 2004</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Durolane</P>
</TD>
<TD>
<P>Responder: patients only with knee OA, reduction in WOMAC pain score of at least 40% with an absolute improvement of at least 5 points</P>
</TD>
<TD>
<P>33</P>
</TD>
<TD>
<P>107</P>
</TD>
<TD>
<P>31</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>100</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>35</P>
</TD>
<TD>
<P>109</P>
</TD>
<TD>
<P>32</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-09" NO="9">
<TITLE>Clinical benefit table. Durolane. Safety</TITLE>
<TABLE COLS="8" ROWS="10">
<TR>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>Event rate Durolane</P>
</TH>
<TH>
<P>Event rate Saline</P>
</TH>
<TH>
<P>RR (95% CI)</P>
</TH>
<TH>
<P>AR diff (95% CI)</P>
</TH>
<TH>
<P>NNH (95% CI)</P>
</TH>
<TH>
<P>No. pts taking Durol</P>
</TH>
<TH>
<P>No. pts taking Salin</P>
</TH>
</TR>
<TR>
<TD>
<P>Total withdrawals overall</P>
</TD>
<TD>
<P>39</P>
</TD>
<TD>
<P>35</P>
</TD>
<TD>
<P>1.12 (0.75,1.68)</P>
</TD>
<TD>
<P>0.02 (-0.06,0.11)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>173</P>
</TD>
<TD>
<P>174</P>
</TD>
</TR>
<TR>
<TD>
<P>Withdrawals due to inefficacy</P>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>6</P>
</TD>
<TD>
<P>1.68 (0.62,4.51)</P>
</TD>
<TD>
<P>0.02 (-0.02,0.07)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>173</P>
</TD>
<TD>
<P>174</P>
</TD>
</TR>
<TR>
<TD>
<P>Withdrawals due to adverse events</P>
</TD>
<TD>
<P>13</P>
</TD>
<TD>
<P>6</P>
</TD>
<TD>
<P>2.18 (0.85,5.60)</P>
</TD>
<TD>
<P>0.04 (-0.01,0.09)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>173</P>
</TD>
<TD>
<P>174</P>
</TD>
</TR>
<TR>
<TD>
<P>Number of patients affected by device-related adverse events</P>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>1.51 (0.26,8.92)</P>
</TD>
<TD>
<P>0.01 (-0.02,0.03)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>173</P>
</TD>
<TD>
<P>174</P>
</TD>
</TR>
<TR>
<TD>
<P>Number of patients with injection only adverse events</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>0.50 (0.05,5.49)</P>
</TD>
<TD>
<P>-0.01 (-0.03,0.01)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>173</P>
</TD>
<TD>
<P>174</P>
</TD>
</TR>
<TR>
<TD>
<P>Number of patients with non-serious treatment-related adverse events</P>
</TD>
<TD>
<P>22</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>1.48 (0.79,2.75)</P>
</TD>
<TD>
<P>0.04 (-0.02,0.11)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>173</P>
</TD>
<TD>
<P>174</P>
</TD>
</TR>
<TR>
<TD>
<P>Number of patients with non-serious adverse events</P>
</TD>
<TD>
<P>112</P>
</TD>
<TD>
<P>114</P>
</TD>
<TD>
<P>0.99 (0.85,1.15)</P>
</TD>
<TD>
<P>-0.01 (-0.11,0.09)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>173</P>
</TD>
<TD>
<P>174</P>
</TD>
</TR>
<TR>
<TD>
<P>Number of patients with treated unrelated adverse events</P>
</TD>
<TD>
<P>101</P>
</TD>
<TD>
<P>109</P>
</TD>
<TD>
<P>0.93 (0.79,1.10)</P>
</TD>
<TD>
<P>-0.04 (-0.15,0.06)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>173</P>
</TD>
<TD>
<P>174</P>
</TD>
</TR>
<TR>
<TD>
<P>Number of patientts with serious treatment-unrelated adverse events</P>
</TD>
<TD>
<P>7</P>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>2.35(0.62,8.93)</P>
</TD>
<TD>
<P>0.02 (-0.01,0.06)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>173</P>
</TD>
<TD>
<P>174</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-10" NO="10">
<TITLE>Clinical benefit table: Euflexxa (Arthrease, BioHy, Nuflexxa) versus placebo</TITLE>
<TABLE COLS="8" ROWS="2">
<TR>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>Event rate PL group</P>
</TH>
<TH>
<P>Event rate TR group</P>
</TH>
<TH>
<P>RR (95% CI)</P>
</TH>
<TH>
<P>AR difference (95%CI</P>
</TH>
<TH>
<P>NNH (95% CI)</P>
</TH>
<TH>
<P>No. pt taking BioHy</P>
</TH>
<TH>
<P>No. pt taking PL</P>
</TH>
</TR>
<TR>
<TD>
<P>Painful injection</P>
</TD>
<TD>
<P>11/24 (45.8 %)</P>
</TD>
<TD>
<P>18/25 (72.0%)</P>
</TD>
<TD>
<P>157% (95% to 259%)</P>
</TD>
<TD>
<P>-26% (0% to53%)</P>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>72</P>
</TD>
<TD>
<P>46</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-11" NO="11">
<TITLE>Clinical benefit table: Euflexxa (Arthrease, BioHy) versus Hylan G-F 20</TITLE>
<TABLE COLS="9" ROWS="13">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Time</P>
</TH>
<TH>
<P>Treatment</P>
</TH>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>N of Pts</P>
</TH>
<TH>
<P>Baseline Mean</P>
</TH>
<TH>
<P>End of Study Mean</P>
</TH>
<TH>
<P>Absolute Benefit</P>
</TH>
<TH>
<P>Relative Difference</P>
</TH>
</TR>
<TR>
<TD>
<P>Thompson 2002</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: BioHy (Arthrease)</P>
</TD>
<TD>
<P>WOMAC pain (0-100 mm VAS)</P>
</TD>
<TD>
<P>160</P>
</TD>
<TD>
<P>49.20</P>
</TD>
<TD>
<P>21.70</P>
</TD>
<TD>
<P>-1.00 (I)</P>
</TD>
<TD>
<P>-1.9% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hylan G-F 20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>161</P>
</TD>
<TD>
<P>51.90</P>
</TD>
<TD>
<P>25.40</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Thompson 2002</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: BioHy (Arthrease)</P>
</TD>
<TD>
<P>WOMAC pain (0-100 mm VAS)</P>
</TD>
<TD>
<P>160</P>
</TD>
<TD>
<P>49.20</P>
</TD>
<TD>
<P>19.20</P>
</TD>
<TD>
<P>-1.10 (I)</P>
</TD>
<TD>
<P>-2.1% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hylan G-F 20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>161</P>
</TD>
<TD>
<P>51.90</P>
</TD>
<TD>
<P>23.00</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Kirchner 2005</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Euflexxa</P>
</TD>
<TD>
<P>WOMAC physical function (0-100 mm VAS)</P>
</TD>
<TD>
<P>160</P>
</TD>
<TD>
<P>47.0</P>
</TD>
<TD>
<P>22.3</P>
</TD>
<TD>
<P>-1.30 (I)</P>
</TD>
<TD>
<P>-2.6% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hylan G-F 20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>161</P>
</TD>
<TD>
<P>50.8</P>
</TD>
<TD>
<P>27.4</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Kirchner 2005</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Euflexxa</P>
</TD>
<TD>
<P>WOMAC physical function (0-100 mm VAS)</P>
</TD>
<TD>
<P>157</P>
</TD>
<TD>
<P>47.0</P>
</TD>
<TD>
<P>20.0</P>
</TD>
<TD>
<P>-1.60 (I)</P>
</TD>
<TD>
<P>-3.1% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hylan G-F 20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>158</P>
</TD>
<TD>
<P>50.8</P>
</TD>
<TD>
<P>25.4</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Kirchner 2005</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Euflexxa</P>
</TD>
<TD>
<P>WOMAC stiffness (0-100 mm VAS)</P>
</TD>
<TD>
<P>160</P>
</TD>
<TD>
<P>43.2</P>
</TD>
<TD>
<P>21.2</P>
</TD>
<TD>
<P>1.6 (W)</P>
</TD>
<TD>
<P>3.3% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hylan G-F 20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>161</P>
</TD>
<TD>
<P>47.8</P>
</TD>
<TD>
<P>24.2</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Kirchner 2005</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Euflexxa</P>
</TD>
<TD>
<P>WOMAC stiffness (0-100 mm VAS)</P>
</TD>
<TD>
<P>157</P>
</TD>
<TD>
<P>43.2</P>
</TD>
<TD>
<P>18.2</P>
</TD>
<TD>
<P>0.8 (W)</P>
</TD>
<TD>
<P>1.7% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hylan G-F 20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>158</P>
</TD>
<TD>
<P>47.8</P>
</TD>
<TD>
<P>22.0</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-12" NO="12">
<TITLE>Clinical benefit table: Euflexxa (BioHy, Arthrease) versus Hylan G-F 20. Safety</TITLE>
<TABLE COLS="8" ROWS="7">
<TR>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>Event rate in BioHy</P>
</TH>
<TH>
<P>Event rate in Hylan</P>
</TH>
<TH>
<P>RR (95% CI)</P>
</TH>
<TH>
<P>AR difference (95%CI</P>
</TH>
<TH>
<P>NNH (95%CI)</P>
</TH>
<TH>
<P>No. pts taking BioHy</P>
</TH>
<TH>
<P>No. pts taking Hylan</P>
</TH>
</TR>
<TR>
<TD>
<P>Total withdrawals overall</P>
</TD>
<TD>
<P>2.5% 4/160</P>
</TD>
<TD>
<P>1.9% 3/161</P>
</TD>
<TD>
<P>134% (31 to 590%)</P>
</TD>
<TD>
<P>1% (-3% to 4%)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>2</P>
</TD>
</TR>
<TR>
<TD>
<P>Withdrawals due to adverse events</P>
</TD>
<TD>
<P>0% 0/160</P>
</TD>
<TD>
<P>0.6% 1/161</P>
</TD>
<TD>
<P>34% (1 to 817%)</P>
</TD>
<TD>
<P>-1% (-2% to 1%)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>1</P>
</TD>
</TR>
<TR>
<TD>
<P>Withdrawals due to lack of efficacy</P>
</TD>
<TD>
<P>0% 0/160</P>
</TD>
<TD>
<P>0% 0/161</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>0% (-1% to 1%)</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P>Number of patients with serious adverse events</P>
</TD>
<TD>
<P>1.9% 3/160</P>
</TD>
<TD>
<P>1.2% 2/161</P>
</TD>
<TD>
<P>151% (26 to 891%)</P>
</TD>
<TD>
<P>1% (-2% to 3%)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>1</P>
</TD>
</TR>
<TR>
<TD>
<P>Joint effusion</P>
</TD>
<TD>
<P>0.6% 1/160</P>
</TD>
<TD>
<P>8% 13/161</P>
</TD>
<TD>
<P>8% (1 to 58%)</P>
</TD>
<TD>
<P>-7% (-12% to -3%)</P>
</TD>
<TD>
<P>14 (13-30)</P>
</TD>
<TD>
<P>8</P>
</TD>
<TD>
<P>8</P>
</TD>
</TR>
<TR>
<TD>
<P>Number of pts reporting adverse events</P>
</TD>
<TD>
<P>34% 54/160</P>
</TD>
<TD>
<P>40% 65/161</P>
</TD>
<TD>
<P>84% (63 to 111%)</P>
</TD>
<TD>
<P>-7% (-17% to 4%)</P>
</TD>
<TD>
<P>16 (ns)</P>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>40</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-13" NO="13">
<TITLE>Clinical benefit table: Fermathron. Continuous outcome measures</TITLE>
<TABLE COLS="9" ROWS="9">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Time</P>
</TH>
<TH>
<P>Treatment</P>
</TH>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>N of Pts</P>
</TH>
<TH>
<P>Baseline Mean</P>
</TH>
<TH>
<P>End of Study Mean</P>
</TH>
<TH>
<P>Absolute Benefit</P>
</TH>
<TH>
<P>Relative Difference</P>
</TH>
</TR>
<TR>
<TD>
<P>McDonald 2000</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Fermathron</P>
</TD>
<TD>
<P>Lequesne Index (0-24)</P>
</TD>
<TD>
<P>114</P>
</TD>
<TD>
<P>11.21</P>
</TD>
<TD>
<P>7.92</P>
</TD>
<TD>
<P>0.37 (W)</P>
</TD>
<TD>
<P>3.3% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hyalart</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>119</P>
</TD>
<TD>
<P>11.12</P>
</TD>
<TD>
<P>7.46</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>McDonald 2000</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Fermathron</P>
</TD>
<TD>
<P>Lequesne Index (0-24)</P>
</TD>
<TD>
<P>114</P>
</TD>
<TD>
<P>11.21</P>
</TD>
<TD>
<P>6.91</P>
</TD>
<TD>
<P>0.46 (W)</P>
</TD>
<TD>
<P>4.1% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hyalart</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>119</P>
</TD>
<TD>
<P>11.12</P>
</TD>
<TD>
<P>6.36</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>McDonald 2000</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Fermathron</P>
</TD>
<TD>
<P>Pain (0-100 mm VAS)</P>
</TD>
<TD>
<P>114</P>
</TD>
<TD>
<P>56.2</P>
</TD>
<TD>
<P>31.3</P>
</TD>
<TD>
<P>3.3 (W)</P>
</TD>
<TD>
<P>5.8% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hyalart</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>119</P>
</TD>
<TD>
<P>57.2</P>
</TD>
<TD>
<P>29.0</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>McDonald 2000</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Fermathron</P>
</TD>
<TD>
<P>Pain (0-100 mm VAS)</P>
</TD>
<TD>
<P>114</P>
</TD>
<TD>
<P>56.2</P>
</TD>
<TD>
<P>25.4</P>
</TD>
<TD>
<P>1.8 (W)</P>
</TD>
<TD>
<P>3.1% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hyalart</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>119</P>
</TD>
<TD>
<P>57.2</P>
</TD>
<TD>
<P>24.6</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-14" NO="14">
<TITLE>Clinical benefit table: Fermathron. Dichotomous outcome measures</TITLE>
<TABLE COLS="9" ROWS="3">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Time</P>
</TH>
<TH>
<P>Treatment</P>
</TH>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>No. improved</P>
</TH>
<TH>
<P>No. of pts</P>
</TH>
<TH>
<P>Risk (%)</P>
</TH>
<TH>
<P>Risk difference</P>
</TH>
<TH>
<P>NNT</P>
</TH>
</TR>
<TR>
<TD>
<P>McDonald 2000</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Fermathron</P>
</TD>
<TD>
<P>Number of patients much better/better</P>
</TD>
<TD>
<P>87</P>
</TD>
<TD>
<P>125</P>
</TD>
<TD>
<P>70</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>50</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hyalart</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>92</P>
</TD>
<TD>
<P>127</P>
</TD>
<TD>
<P>72</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-15" NO="15">
<TITLE>Clinical benefit table: Hyalgan versus placebo. Continuous outcome measures (1)</TITLE>
<TABLE COLS="9" ROWS="95">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Time</P>
</TH>
<TH>
<P>Treatment</P>
</TH>
<TH>
<P>Outcome (scale)</P>
</TH>
<TH>
<P>N of Pts</P>
</TH>
<TH>
<P>Baseline Mean</P>
</TH>
<TH>
<P>End of Study Mean</P>
</TH>
<TH>
<P>Absolute Benefit</P>
</TH>
<TH>
<P>Relative Difference</P>
</TH>
</TR>
<TR>
<TD>
<P>Carrabba 1995</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hyalgan (5)</P>
</TD>
<TD>
<P>Pain on movement (0-100 mm VAS)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>63.3</P>
</TD>
<TD>
<P>41.8</P>
</TD>
<TD>
<P>-13.5 (I)</P>
</TD>
<TD>
<P>-21% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>64.4</P>
</TD>
<TD>
<P>56.4</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Carrabba 1995a</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hyalgan (3)</P>
</TD>
<TD>
<P>Pain on movement (0-100 mm VAS)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>64.2</P>
</TD>
<TD>
<P>46.0</P>
</TD>
<TD>
<P>-10.2 (I)</P>
</TD>
<TD>
<P>-15.8% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>64.4</P>
</TD>
<TD>
<P>56.4</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Carrabba 1995b</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hyalgan (5)</P>
</TD>
<TD>
<P>Pain on movement (0-100 mm VAS)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>63.3</P>
</TD>
<TD>
<P>41.8</P>
</TD>
<TD>
<P>-16.7 (I)</P>
</TD>
<TD>
<P>-25.9% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Arthrocentesis</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>64.5</P>
</TD>
<TD>
<P>59.7</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Carrabba 1995c</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hyalgan (3)</P>
</TD>
<TD>
<P>Pain on movement (0-100 mm VAS)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>64.2</P>
</TD>
<TD>
<P>46.0</P>
</TD>
<TD>
<P>-13.4 (I)</P>
</TD>
<TD>
<P>-20.8% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Arthrocentesis</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>64.5</P>
</TD>
<TD>
<P>59.7</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Corrado 1995</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hyalgan</P>
</TD>
<TD>
<P>Pain on movement (0-100 mm VAS)</P>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>71.2</P>
</TD>
<TD>
<P>35.4</P>
</TD>
<TD>
<P>-18.5 (I)</P>
</TD>
<TD>
<P>-31.4% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>58.9</P>
</TD>
<TD>
<P>41.6</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Creamer 1994</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hyalgan</P>
</TD>
<TD>
<P>Pain use related (0-100 mm VAS)</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>52.58</P>
</TD>
<TD>
<P>41.12</P>
</TD>
<TD>
<P>8.99 (W)</P>
</TD>
<TD>
<P>16.5% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>54.38</P>
</TD>
<TD>
<P>33.93</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Henderson 1994</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hyalgan</P>
</TD>
<TD>
<P>Pain active movement (0-100 mm VAS)</P>
</TD>
<TD>
<P>18</P>
</TD>
<TD>
<P>43.7</P>
</TD>
<TD>
<P>28.1</P>
</TD>
<TD>
<P>-1.4 (I)</P>
</TD>
<TD>
<P>-2.3% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>53.0</P>
</TD>
<TD>
<P>38.8</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Henderson 1994a</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hyalgan</P>
</TD>
<TD>
<P>Pain active movement (0-100 mm VAS)</P>
</TD>
<TD>
<P>22</P>
</TD>
<TD>
<P>48.5</P>
</TD>
<TD>
<P>39.8</P>
</TD>
<TD>
<P>9.3 (W)</P>
</TD>
<TD>
<P>18.9% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>25</P>
</TD>
<TD>
<P>49.3</P>
</TD>
<TD>
<P>31.3</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Huskisson 1999</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hyalgan</P>
</TD>
<TD>
<P>Pain walking (0-100 mm VAS)</P>
</TD>
<TD>
<P>45</P>
</TD>
<TD>
<P>67.20</P>
</TD>
<TD>
<P>35.29</P>
</TD>
<TD>
<P>-15.41 (I)</P>
</TD>
<TD>
<P>-23.88% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>48</P>
</TD>
<TD>
<P>64.52</P>
</TD>
<TD>
<P>48.02</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Jubb 2003</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hyalgan</P>
</TD>
<TD>
<P>Pain on walking (0-100 mm VAS)</P>
</TD>
<TD>
<P>208</P>
</TD>
<TD>
<P>56.95</P>
</TD>
<TD>
<P>43.87</P>
</TD>
<TD>
<P>-1.8 (I)</P>
</TD>
<TD>
<P>-3.3% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>200</P>
</TD>
<TD>
<P>55.15</P>
</TD>
<TD>
<P>43.88</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Tsai 2003</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hyalgan</P>
</TD>
<TD>
<P>Pain on 50 foot walk (0-100 mm VAS)</P>
</TD>
<TD>
<P>100</P>
</TD>
<TD>
<P>47.85</P>
</TD>
<TD>
<P>22.60</P>
</TD>
<TD>
<P>-4.0 (I)</P>
</TD>
<TD>
<P>-8.9% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>98</P>
</TD>
<TD>
<P>45.15</P>
</TD>
<TD>
<P>23.92</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Carrabba 1995</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hyalgan (5)</P>
</TD>
<TD>
<P>Pain on movement (0-100 mm VAS)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>63.3</P>
</TD>
<TD>
<P>42.10</P>
</TD>
<TD>
<P>-16.6 (I)</P>
</TD>
<TD>
<P>-25.8% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>64.4</P>
</TD>
<TD>
<P>59.80</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Carrabba 1995a</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hyalgan (3)</P>
</TD>
<TD>
<P>Pain on movement (0-100 mm VAS)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>64.2</P>
</TD>
<TD>
<P>47.80</P>
</TD>
<TD>
<P>-11.8 (I)</P>
</TD>
<TD>
<P>-18.3% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>64.4</P>
</TD>
<TD>
<P>59.80</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Carrabba 1995b</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hyalgan (5)</P>
</TD>
<TD>
<P>Pain on movement (0-100 mm VAS)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>63.3</P>
</TD>
<TD>
<P>42.10</P>
</TD>
<TD>
<P>-19.9 (I)</P>
</TD>
<TD>
<P>-30.9% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Arthrocentesis</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>64.5</P>
</TD>
<TD>
<P>63.20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Carrabba 1995c</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hyalgan (3)</P>
</TD>
<TD>
<P>Pain on movement (0-100 mm VAS)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>64.2</P>
</TD>
<TD>
<P>47.80</P>
</TD>
<TD>
<P>-15.1 (I)</P>
</TD>
<TD>
<P>-23.4% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Arthrocentesis</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>64.5</P>
</TD>
<TD>
<P>63.20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Corrado 1995</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hyalgan</P>
</TD>
<TD>
<P>Pain on movement (0-100 mm VAS)</P>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>71.2</P>
</TD>
<TD>
<P>29.70</P>
</TD>
<TD>
<P>-25.8 (I)</P>
</TD>
<TD>
<P>-43.8% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>58.9</P>
</TD>
<TD>
<P>43.20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Creamer 1994</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hyalgan</P>
</TD>
<TD>
<P>Pain use related (0-100 mm VAS)</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>52.58</P>
</TD>
<TD>
<P>41.80</P>
</TD>
<TD>
<P>1.80 (W)</P>
</TD>
<TD>
<P>3.3% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>54.38</P>
</TD>
<TD>
<P>41.80</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Huskisson 1999</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hyalgan</P>
</TD>
<TD>
<P>Pain walking (0-100 mm VAS)</P>
</TD>
<TD>
<P>43</P>
</TD>
<TD>
<P>67.20</P>
</TD>
<TD>
<P>37.40</P>
</TD>
<TD>
<P>-15.46 (I)</P>
</TD>
<TD>
<P>-23.96% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>45</P>
</TD>
<TD>
<P>64.52</P>
</TD>
<TD>
<P>50.18</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Jubb 2003</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hyalgan</P>
</TD>
<TD>
<P>Pain on walking (0-100 mm VAS)</P>
</TD>
<TD>
<P>208</P>
</TD>
<TD>
<P>56.95</P>
</TD>
<TD>
<P>46.51</P>
</TD>
<TD>
<P>-4.89 (I)</P>
</TD>
<TD>
<P>-8.9% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>200</P>
</TD>
<TD>
<P>55.15</P>
</TD>
<TD>
<P>50.20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Tsai 2003</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hyalgan</P>
</TD>
<TD>
<P>Pain on 50 foot walk (0-100 mm VAS)</P>
</TD>
<TD>
<P>100</P>
</TD>
<TD>
<P>47.85</P>
</TD>
<TD>
<P>19.32</P>
</TD>
<TD>
<P>-3.16 (I)</P>
</TD>
<TD>
<P>-7.0% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>98</P>
</TD>
<TD>
<P>45.15</P>
</TD>
<TD>
<P>19.78</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Huskisson 1999</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Hyalgan</P>
</TD>
<TD>
<P>Pain walking (0-100 mm VAS)</P>
</TD>
<TD>
<P>39</P>
</TD>
<TD>
<P>67.20</P>
</TD>
<TD>
<P>39.44</P>
</TD>
<TD>
<P>-16.92 (I)</P>
</TD>
<TD>
<P>-26.22% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>64.52</P>
</TD>
<TD>
<P>53.68</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Jubb 2003</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Hyalgan</P>
</TD>
<TD>
<P>Pain on walking (0-100 mm VAS)</P>
</TD>
<TD>
<P>208</P>
</TD>
<TD>
<P>56.95</P>
</TD>
<TD>
<P>50.06</P>
</TD>
<TD>
<P>-1.88 (I)</P>
</TD>
<TD>
<P>-3.4% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>200</P>
</TD>
<TD>
<P>55.15</P>
</TD>
<TD>
<P>50.14</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Tsai 2003</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Hyalgan</P>
</TD>
<TD>
<P>Pain on 50 foot walk (0-100 mm VAS)</P>
</TD>
<TD>
<P>100</P>
</TD>
<TD>
<P>47.85</P>
</TD>
<TD>
<P>15.57</P>
</TD>
<TD>
<P>-7.8 (I)</P>
</TD>
<TD>
<P>-17.3% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>98</P>
</TD>
<TD>
<P>45.15</P>
</TD>
<TD>
<P>20.68</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Jubb 2003</P>
</TD>
<TD>
<P>45-52 wk (RC)</P>
</TD>
<TD>
<P>E: Hyalgan</P>
</TD>
<TD>
<P>Pain on walking (0-100 mm VAS)</P>
</TD>
<TD>
<P>208</P>
</TD>
<TD>
<P>56.95</P>
</TD>
<TD>
<P>47.59</P>
</TD>
<TD>
<P>-4.7 (I)</P>
</TD>
<TD>
<P>-8.4% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>200</P>
</TD>
<TD>
<P>55.15</P>
</TD>
<TD>
<P>50.45</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Bragantini 1987</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hyalgan</P>
</TD>
<TD>
<P>Pain spontaneous (0-100 mm VAS)</P>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>47.74</P>
</TD>
<TD>
<P>17.12</P>
</TD>
<TD>
<P>-29.5 (I)</P>
</TD>
<TD>
<P>-62.5% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>18</P>
</TD>
<TD>
<P>47.29</P>
</TD>
<TD>
<P>46.21</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Grecomoro 1987</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hyalgan</P>
</TD>
<TD>
<P>Pain intensity (0-100 mm VAS)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>50.71</P>
</TD>
<TD>
<P>14.55</P>
</TD>
<TD>
<P>-22.9 (I)</P>
</TD>
<TD>
<P>-48.3% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Phosphate buffer</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>18</P>
</TD>
<TD>
<P>47.32</P>
</TD>
<TD>
<P>34.02</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Bragantini 1987</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hyalgan</P>
</TD>
<TD>
<P>Pain spontaneous (0-100 mm VAS)</P>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>47.74</P>
</TD>
<TD>
<P>15.59</P>
</TD>
<TD>
<P>-31.8 (I)</P>
</TD>
<TD>
<P>-67.3% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>18</P>
</TD>
<TD>
<P>47.29</P>
</TD>
<TD>
<P>46.95</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Grecomoro 1987</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hyalgan</P>
</TD>
<TD>
<P>Pain intensity (0-100 mm VAS)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>50.71</P>
</TD>
<TD>
<P>20.80</P>
</TD>
<TD>
<P>-17.8 (I)</P>
</TD>
<TD>
<P>-37.6% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Phosphate buffer</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>18</P>
</TD>
<TD>
<P>47.32</P>
</TD>
<TD>
<P>35.18</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Tsai 2003</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hyalgan</P>
</TD>
<TD>
<P>WOMAC pain (0-100 mm VAS)</P>
</TD>
<TD>
<P>100</P>
</TD>
<TD>
<P>45.73</P>
</TD>
<TD>
<P>23.21</P>
</TD>
<TD>
<P>-3.31 (I)</P>
</TD>
<TD>
<P>-7.3% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>98</P>
</TD>
<TD>
<P>45.09</P>
</TD>
<TD>
<P>25.88</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Tsai 2003</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hyalgan</P>
</TD>
<TD>
<P>WOMAC pain (0-100 mm VAS)</P>
</TD>
<TD>
<P>100</P>
</TD>
<TD>
<P>45.73</P>
</TD>
<TD>
<P>21.48</P>
</TD>
<TD>
<P>-2.13 (I)</P>
</TD>
<TD>
<P>-4.7% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>98</P>
</TD>
<TD>
<P>45.09</P>
</TD>
<TD>
<P>22.97</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Tsai 2003</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Hyalgan</P>
</TD>
<TD>
<P>WOMAC pain (0-100 mm VAS)</P>
</TD>
<TD>
<P>100</P>
</TD>
<TD>
<P>45.73</P>
</TD>
<TD>
<P>16.48</P>
</TD>
<TD>
<P>-6.30 (I)</P>
</TD>
<TD>
<P>-14.0% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>98</P>
</TD>
<TD>
<P>45.09</P>
</TD>
<TD>
<P>22.14</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Tsai 2003</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hyalgan</P>
</TD>
<TD>
<P>WOMAC function (0-100 mm VAS)</P>
</TD>
<TD>
<P>100</P>
</TD>
<TD>
<P>46.54</P>
</TD>
<TD>
<P>26.91</P>
</TD>
<TD>
<P>-2.83 (I)</P>
</TD>
<TD>
<P>-6.3% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>98</P>
</TD>
<TD>
<P>45.01</P>
</TD>
<TD>
<P>28.21</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Tsai 2003</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hyalgan</P>
</TD>
<TD>
<P>WOMAC function (0-100 mm VAS)</P>
</TD>
<TD>
<P>100</P>
</TD>
<TD>
<P>46.54</P>
</TD>
<TD>
<P>24.25</P>
</TD>
<TD>
<P>-2.59 (I)</P>
</TD>
<TD>
<P>-5.8% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>98</P>
</TD>
<TD>
<P>45.01</P>
</TD>
<TD>
<P>25.31</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Tsai 2003</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Hyalgan</P>
</TD>
<TD>
<P>WOMAC function (0-100 mm VAS)</P>
</TD>
<TD>
<P>100</P>
</TD>
<TD>
<P>46.54</P>
</TD>
<TD>
<P>20.85</P>
</TD>
<TD>
<P>-5.58 (I)</P>
</TD>
<TD>
<P>-12.4% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>98</P>
</TD>
<TD>
<P>45.01</P>
</TD>
<TD>
<P>24.90</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Carrabba 1995</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hyalgan (5)</P>
</TD>
<TD>
<P>Lequesne Index (0-24)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>15.1</P>
</TD>
<TD>
<P>11.5</P>
</TD>
<TD>
<P>-2.5 (I)</P>
</TD>
<TD>
<P>-17.2% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>14.5</P>
</TD>
<TD>
<P>13.4</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Carrabba 1995a</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hyalgan (3)</P>
</TD>
<TD>
<P>Lequesne Index (0-24)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>14.9</P>
</TD>
<TD>
<P>11.6</P>
</TD>
<TD>
<P>-2.2 (I)</P>
</TD>
<TD>
<P>-15.2% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>14.5</P>
</TD>
<TD>
<P>13.4</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Carrabba 1995b</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hyalgan (5)</P>
</TD>
<TD>
<P>Lequesne Index (0-24)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>15.1</P>
</TD>
<TD>
<P>11.5</P>
</TD>
<TD>
<P>-3.4 (I)</P>
</TD>
<TD>
<P>-23.8% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Arthrocentesis</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>14.3</P>
</TD>
<TD>
<P>14.1</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Carrabba 1995c</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hyalgan (3)</P>
</TD>
<TD>
<P>Lequesne Index (0-24)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>14.9</P>
</TD>
<TD>
<P>11.6</P>
</TD>
<TD>
<P>-3.1 (I)</P>
</TD>
<TD>
<P>-21.7% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Arthrocentesis</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>14.3</P>
</TD>
<TD>
<P>14.1</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Dougados 1993</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hyalectin</P>
</TD>
<TD>
<P>Lequesne Index (0-24)</P>
</TD>
<TD>
<P>49</P>
</TD>
<TD>
<P>11.71</P>
</TD>
<TD>
<P>8.53</P>
</TD>
<TD>
<P>-1.02 (I)</P>
</TD>
<TD>
<P>-9.32% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>50</P>
</TD>
<TD>
<P>10.94</P>
</TD>
<TD>
<P>8.78</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Huskisson 1999</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hyalgan</P>
</TD>
<TD>
<P>Lequesne Index (0-24)</P>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>13.4</P>
</TD>
<TD>
<P>10.0</P>
</TD>
<TD>
<P>-1.5 (I)</P>
</TD>
<TD>
<P>-10.7% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>41</P>
</TD>
<TD>
<P>14.0</P>
</TD>
<TD>
<P>12.1</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Carrabba 1995</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hyalgan (5)</P>
</TD>
<TD>
<P>Lequesne Index (0-24)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>15.1</P>
</TD>
<TD>
<P>11.6</P>
</TD>
<TD>
<P>-2.9 (I)</P>
</TD>
<TD>
<P>-20% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>14.5</P>
</TD>
<TD>
<P>13.9</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Carrabba 1995a</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hyalgan (3)</P>
</TD>
<TD>
<P>Lequesne Index (0-24)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>14.9</P>
</TD>
<TD>
<P>12.0</P>
</TD>
<TD>
<P>-2.3 (I)</P>
</TD>
<TD>
<P>-15.9% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>14.5</P>
</TD>
<TD>
<P>13.9</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Carrabba 1995b</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hyalgan (5)</P>
</TD>
<TD>
<P>Lequesne Index (0-24)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>15.1</P>
</TD>
<TD>
<P>11.6</P>
</TD>
<TD>
<P>-3.6 (I)</P>
</TD>
<TD>
<P>-25.2% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Arthrocentesis</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>14.3</P>
</TD>
<TD>
<P>14.4</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Carrabba 1995c</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hyalgan (3)</P>
</TD>
<TD>
<P>Lequesne Index (0-24)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>14.9</P>
</TD>
<TD>
<P>12.0</P>
</TD>
<TD>
<P>-3.0 (I)</P>
</TD>
<TD>
<P>-21% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Arthrocentesis</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>14.3</P>
</TD>
<TD>
<P>14.4</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Huskisson 1999</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hyalgan</P>
</TD>
<TD>
<P>Lequesne Index (0-24)</P>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>13.4</P>
</TD>
<TD>
<P>10.2</P>
</TD>
<TD>
<P>-1.6 (I)</P>
</TD>
<TD>
<P>-11.4% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>41</P>
</TD>
<TD>
<P>14.0</P>
</TD>
<TD>
<P>12.4</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Huskisson 1999</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Hyalgan</P>
</TD>
<TD>
<P>Lequesne Index (0-24)</P>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>13.4</P>
</TD>
<TD>
<P>11.2</P>
</TD>
<TD>
<P>-0.8 (I)</P>
</TD>
<TD>
<P>-5.7% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>41</P>
</TD>
<TD>
<P>14.0</P>
</TD>
<TD>
<P>12.6</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Dougados 1993</P>
</TD>
<TD>
<P>45-52 wk</P>
</TD>
<TD>
<P>E: Hyalectin</P>
</TD>
<TD>
<P>Lequesne Index (0-24)</P>
</TD>
<TD>
<P>47</P>
</TD>
<TD>
<P>11.71</P>
</TD>
<TD>
<P>7.06</P>
</TD>
<TD>
<P>-1.88 (I)</P>
</TD>
<TD>
<P>-17.18% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>47</P>
</TD>
<TD>
<P>10.94</P>
</TD>
<TD>
<P>8.17</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-16" NO="16">
<TITLE>Clinical benefit table: Hyalgan versus placebo. Continuous outcome measures (2)</TITLE>
<TABLE COLS="9" ROWS="67">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Time</P>
</TH>
<TH>
<P>Treatment</P>
</TH>
<TH>
<P>Outcome (scale)</P>
</TH>
<TH>
<P>N of Pts</P>
</TH>
<TH>
<P>Baseline Mean</P>
</TH>
<TH>
<P>End of Study Mean</P>
</TH>
<TH>
<P>Absolute Benefit</P>
</TH>
<TH>
<P>Relative Difference</P>
</TH>
</TR>
<TR>
<TD>
<P>Altman 1998</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hyalgan</P>
</TD>
<TD>
<P>Pain after walking 50 feet (0-100 mm VAS)</P>
</TD>
<TD>
<P>163</P>
</TD>
<TD>
<P>54</P>
</TD>
<TD>
<P>25</P>
</TD>
<TD>
<P>1 (W)</P>
</TD>
<TD>
<P>1.8% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>167</P>
</TD>
<TD>
<P>55</P>
</TD>
<TD>
<P>25</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Altman 1998</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hyalgan</P>
</TD>
<TD>
<P>Pain after walking 50 feet (0-100 mm VAS)</P>
</TD>
<TD>
<P>163</P>
</TD>
<TD>
<P>54</P>
</TD>
<TD>
<P>23</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>167</P>
</TD>
<TD>
<P>55</P>
</TD>
<TD>
<P>24</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Altman 1998</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Hyalgan</P>
</TD>
<TD>
<P>Pain after walking 50 feet (0-100 mm VAS)</P>
</TD>
<TD>
<P>163</P>
</TD>
<TD>
<P>54</P>
</TD>
<TD>
<P>18</P>
</TD>
<TD>
<P>-2 (I)</P>
</TD>
<TD>
<P>-3.6% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>167</P>
</TD>
<TD>
<P>55</P>
</TD>
<TD>
<P>21</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Dougados 1993</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hyalectin</P>
</TD>
<TD>
<P>Pain on movement (0-100 mm VAS)</P>
</TD>
<TD>
<P>52</P>
</TD>
<TD>
<P>67.85</P>
</TD>
<TD>
<P>34.13</P>
</TD>
<TD>
<P>-7.52 (I)</P>
</TD>
<TD>
<P>-12.16% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>50</P>
</TD>
<TD>
<P>61.82</P>
</TD>
<TD>
<P>35.62</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Dougados 1993</P>
</TD>
<TD>
<P>45-52 wk</P>
</TD>
<TD>
<P>E: Hyalectin</P>
</TD>
<TD>
<P>Pain on movement (0-100 mm VAS)</P>
</TD>
<TD>
<P>47</P>
</TD>
<TD>
<P>67.85</P>
</TD>
<TD>
<P>28.51</P>
</TD>
<TD>
<P>-6.87(I)</P>
</TD>
<TD>
<P>-11.11% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>48</P>
</TD>
<TD>
<P>61.82</P>
</TD>
<TD>
<P>29.35</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Carrabba 1995</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hyalgan (5)</P>
</TD>
<TD>
<P>Pain at rest (0-100 mm VAS)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>43.6</P>
</TD>
<TD>
<P>28.3</P>
</TD>
<TD>
<P>-7.1 (I)</P>
</TD>
<TD>
<P>-15.6% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>45.6</P>
</TD>
<TD>
<P>37.4</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Carrabba 1995a</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hyalgan (3)</P>
</TD>
<TD>
<P>Pain at rest (0-100 mm VAS)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>44.7</P>
</TD>
<TD>
<P>30.3</P>
</TD>
<TD>
<P>-6.2 (I)</P>
</TD>
<TD>
<P>-13.6% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>45.6</P>
</TD>
<TD>
<P>37.4</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Carrabba 1995b</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hyalgan (5)</P>
</TD>
<TD>
<P>Pain at rest (0-100 mm VAS)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>43.6</P>
</TD>
<TD>
<P>28.3</P>
</TD>
<TD>
<P>-12.4 (I)</P>
</TD>
<TD>
<P>-28.6% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Arthrocentesis</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>43.3</P>
</TD>
<TD>
<P>40.4</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Carrabba 1995c</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hyalgan (3)</P>
</TD>
<TD>
<P>Pain at rest (0-100 mm VAS)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>44.7</P>
</TD>
<TD>
<P>30.3</P>
</TD>
<TD>
<P>-11.5 (I)</P>
</TD>
<TD>
<P>-26.6% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Arthrocentesis</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>43.3</P>
</TD>
<TD>
<P>40.4</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Corrado 1995</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hyalgan</P>
</TD>
<TD>
<P>Pain at rest (0-100 mm VAS)</P>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>22.5</P>
</TD>
<TD>
<P>9.4</P>
</TD>
<TD>
<P>-8.5 (I)</P>
</TD>
<TD>
<P>-62% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>13.7</P>
</TD>
<TD>
<P>9.1</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Dougados 1993</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hyalectin</P>
</TD>
<TD>
<P>Pain at rest (0-100 mm VAS)</P>
</TD>
<TD>
<P>52</P>
</TD>
<TD>
<P>31.44</P>
</TD>
<TD>
<P>10.87</P>
</TD>
<TD>
<P>-7.72 (I)</P>
</TD>
<TD>
<P>-28.03% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>48</P>
</TD>
<TD>
<P>27.54</P>
</TD>
<TD>
<P>14.69</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Henderson 1994</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hyalgan</P>
</TD>
<TD>
<P>Pain at rest (0-100 mm VAS)</P>
</TD>
<TD>
<P>18</P>
</TD>
<TD>
<P>20.8</P>
</TD>
<TD>
<P>17.7</P>
</TD>
<TD>
<P>-4.1 (I)</P>
</TD>
<TD>
<P>-13.5% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>30.3</P>
</TD>
<TD>
<P>31.3</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Henderson 1994a</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hyalgan</P>
</TD>
<TD>
<P>Pain at rest (0-100 mm VAS)</P>
</TD>
<TD>
<P>22</P>
</TD>
<TD>
<P>25.2</P>
</TD>
<TD>
<P>25.3</P>
</TD>
<TD>
<P>15 (W)</P>
</TD>
<TD>
<P>38.5% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>25</P>
</TD>
<TD>
<P>38.9</P>
</TD>
<TD>
<P>24.0</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Carrabba 1995</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hyalgan (5)</P>
</TD>
<TD>
<P>Pain at rest (0-100 mm VAS)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>43.6</P>
</TD>
<TD>
<P>29.3</P>
</TD>
<TD>
<P>-8.6 (I)</P>
</TD>
<TD>
<P>-18.9% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>45.6</P>
</TD>
<TD>
<P>39.9</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Carrabba 1995a</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hyalgan (3)</P>
</TD>
<TD>
<P>Pain at rest (0-100 mm VAS)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>44.7</P>
</TD>
<TD>
<P>33.0</P>
</TD>
<TD>
<P>-6 (I)</P>
</TD>
<TD>
<P>-13.2% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>45.6</P>
</TD>
<TD>
<P>39.9</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Carrabba 1995b</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hyalgan (5)</P>
</TD>
<TD>
<P>Pain at rest (0-100 mm VAS)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>43.6</P>
</TD>
<TD>
<P>29.3</P>
</TD>
<TD>
<P>-14.2 (I)</P>
</TD>
<TD>
<P>-32.8% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Arthrocentesis</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>43.3</P>
</TD>
<TD>
<P>43.2</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Carrabba 1995c</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hyalgan (3)</P>
</TD>
<TD>
<P>Pain at rest (0-100 mm VAS)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>44.7</P>
</TD>
<TD>
<P>33.0</P>
</TD>
<TD>
<P>-11.6 (I)</P>
</TD>
<TD>
<P>-26.8% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Arthrocentesis</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>43.3</P>
</TD>
<TD>
<P>43.2</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Corrado 1995</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hyalgan</P>
</TD>
<TD>
<P>Pain at rest (0-100 mm VAS)</P>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>22.5</P>
</TD>
<TD>
<P>5.1</P>
</TD>
<TD>
<P>-15.9 (I)</P>
</TD>
<TD>
<P>-116.1% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>13.7</P>
</TD>
<TD>
<P>12.2</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Dougados 1993</P>
</TD>
<TD>
<P>45-52 wk</P>
</TD>
<TD>
<P>E: Hyalectin</P>
</TD>
<TD>
<P>Pain at rest (0-100 mm VAS)</P>
</TD>
<TD>
<P>47</P>
</TD>
<TD>
<P>31.44</P>
</TD>
<TD>
<P>11.87</P>
</TD>
<TD>
<P>-1.68 (I)</P>
</TD>
<TD>
<P>-6.10% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>48</P>
</TD>
<TD>
<P>27.54</P>
</TD>
<TD>
<P>9.65</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Henderson 1994</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hyalgan</P>
</TD>
<TD>
<P>Pain at night (0-100 mm VAS)</P>
</TD>
<TD>
<P>18</P>
</TD>
<TD>
<P>69.6</P>
</TD>
<TD>
<P>45.50</P>
</TD>
<TD>
<P>-10.3 (I)</P>
</TD>
<TD>
<P>-15.1% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>68.0</P>
</TD>
<TD>
<P>54.20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Henderson 1994a</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hyalgan</P>
</TD>
<TD>
<P>Pain at night (0-100 mm VAS)</P>
</TD>
<TD>
<P>22</P>
</TD>
<TD>
<P>68.3</P>
</TD>
<TD>
<P>60.20</P>
</TD>
<TD>
<P>4.4 (W)</P>
</TD>
<TD>
<P>6% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>25</P>
</TD>
<TD>
<P>73.3</P>
</TD>
<TD>
<P>60.80</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Corrado 1995</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hyalgan</P>
</TD>
<TD>
<P>Flexion (degrees)</P>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>114.7</P>
</TD>
<TD>
<P>123.5</P>
</TD>
<TD>
<P>2.1 (I)</P>
</TD>
<TD>
<P>1.9% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>113.3</P>
</TD>
<TD>
<P>120.0</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Corrado 1995</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hyalgan</P>
</TD>
<TD>
<P>Flexion (degrees)</P>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>114.7</P>
</TD>
<TD>
<P>125.5</P>
</TD>
<TD>
<P>6.2 (I)</P>
</TD>
<TD>
<P>5.5% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>113.3</P>
</TD>
<TD>
<P>117.9</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Corrado 1995</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hyalgan</P>
</TD>
<TD>
<P>Synovial fluid volume (ml)</P>
</TD>
<TD>
<P>21</P>
</TD>
<TD>
<P>20.3</P>
</TD>
<TD>
<P>14.10</P>
</TD>
<TD>
<P>-2.3 (I)</P>
</TD>
<TD>
<P>-15% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>15.3</P>
</TD>
<TD>
<P>11.40</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Dougados 1993</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hyalectin</P>
</TD>
<TD>
<P>Synovial fluid volume (ml)</P>
</TD>
<TD>
<P>55</P>
</TD>
<TD>
<P>18.5</P>
</TD>
<TD>
<P>6.10</P>
</TD>
<TD>
<P>-6.4 (I)</P>
</TD>
<TD>
<P>-46% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>55</P>
</TD>
<TD>
<P>13.9</P>
</TD>
<TD>
<P>7.90</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Corrado 1995</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hyalgan</P>
</TD>
<TD>
<P>Synovial fluid volume (ml)</P>
</TD>
<TD>
<P>21</P>
</TD>
<TD>
<P>20.3</P>
</TD>
<TD>
<P>2.30</P>
</TD>
<TD>
<P>-13.1 (I)</P>
</TD>
<TD>
<P>-85.6% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>15.3</P>
</TD>
<TD>
<P>10.40</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Jubb 2001a</P>
</TD>
<TD>
<P>45-52 wk</P>
</TD>
<TD>
<P>E: Hyalgan</P>
</TD>
<TD>
<P>Joint space width (mm)</P>
</TD>
<TD>
<P>136</P>
</TD>
<TD>
<P>4.9</P>
</TD>
<TD>
<P>4.80</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>137</P>
</TD>
<TD>
<P>4.5</P>
</TD>
<TD>
<P>4.40</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Jubb 2001b</P>
</TD>
<TD>
<P>45-52 wk</P>
</TD>
<TD>
<P>E: Hyalgan</P>
</TD>
<TD>
<P>Joint space width (mm)</P>
</TD>
<TD>
<P>76</P>
</TD>
<TD>
<P>5.9</P>
</TD>
<TD>
<P>5.80</P>
</TD>
<TD>
<P>0.4 (I)</P>
</TD>
<TD>
<P>6.8% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>63</P>
</TD>
<TD>
<P>5.9</P>
</TD>
<TD>
<P>5.40</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Jubb 2001c</P>
</TD>
<TD>
<P>45-52 wk</P>
</TD>
<TD>
<P>E: Hyalgan</P>
</TD>
<TD>
<P>Joint space width (mm)</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>3.5</P>
</TD>
<TD>
<P>3.50</P>
</TD>
<TD>
<P>-0.2 (W)</P>
</TD>
<TD>
<P>-5.9% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>74</P>
</TD>
<TD>
<P>3.4</P>
</TD>
<TD>
<P>3.60</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>St. J. Dixon 1988</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hyalgan</P>
</TD>
<TD>
<P>Pain on movement (0-100 mm VAS)</P>
</TD>
<TD>
<P>28</P>
</TD>
<TD>
<P>66.52</P>
</TD>
<TD>
<P>50.54</P>
</TD>
<TD>
<P>-14.13 (I)</P>
</TD>
<TD>
<P>-21.17% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Vehicle</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>33</P>
</TD>
<TD>
<P>66.76</P>
</TD>
<TD>
<P>64.91</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>St. J. Dixon 1988</P>
</TD>
<TD>
<P>45-52 wk (repeat)</P>
</TD>
<TD>
<P>E: Hyalgan</P>
</TD>
<TD>
<P>Pain on movement (0-100 mm VAS)</P>
</TD>
<TD>
<P>11</P>
</TD>
<TD>
<P>66.52</P>
</TD>
<TD>
<P>48.45</P>
</TD>
<TD>
<P>-8.31(I)</P>
</TD>
<TD>
<P>-12.45% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Vehicle</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>13</P>
</TD>
<TD>
<P>66.76</P>
</TD>
<TD>
<P>57.00</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>St. J. Dixon 1988</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hyalgan</P>
</TD>
<TD>
<P>Pain at rest (0-100 mm VAS)</P>
</TD>
<TD>
<P>29</P>
</TD>
<TD>
<P>30.86</P>
</TD>
<TD>
<P>20.50</P>
</TD>
<TD>
<P>-11.61 (I)</P>
</TD>
<TD>
<P>-54.28% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Vehicle</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>33</P>
</TD>
<TD>
<P>21.39</P>
</TD>
<TD>
<P>22.64</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>St. J. Dixon 1988</P>
</TD>
<TD>
<P>45-52 wk (repeat)</P>
</TD>
<TD>
<P>E: Hyalgan</P>
</TD>
<TD>
<P>Pain at rest (0-100 mm VAS)</P>
</TD>
<TD>
<P>11</P>
</TD>
<TD>
<P>30.86</P>
</TD>
<TD>
<P>25.36</P>
</TD>
<TD>
<P>-4.97 (I)</P>
</TD>
<TD>
<P>-23.24% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Vehicle</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>14</P>
</TD>
<TD>
<P>21.39</P>
</TD>
<TD>
<P>20.86</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-17" NO="17">
<TITLE>Clinical benefit table: Hyalgan versus placebo. Dichotomous outcome measures</TITLE>
<TABLE COLS="9" ROWS="49">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Time</P>
</TH>
<TH>
<P>Treatment group</P>
</TH>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>No. improved</P>
</TH>
<TH>
<P>No. of pts</P>
</TH>
<TH>
<P>Risk (%)</P>
</TH>
<TH>
<P>Risk Difference</P>
</TH>
<TH>
<P>NNT</P>
</TH>
</TR>
<TR>
<TD>
<P>Creamer 1994</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Number of joints without night pain</P>
</TD>
<TD>
<P>7</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>58</P>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>6.3</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>42</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Creamer 1994</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Number of joints without night pain</P>
</TD>
<TD>
<P>7</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>58</P>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>6.3</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>42</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Creamer 1994</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Number of joints without rest pain</P>
</TD>
<TD>
<P>6</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>50</P>
</TD>
<TD>
<P>8</P>
</TD>
<TD>
<P>12.5</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>42</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Creamer 1994</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Number of joints without rest pain</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>42</P>
</TD>
<TD>
<P>25</P>
</TD>
<TD>
<P>4</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>17</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Grecomoro 1987</P>
</TD>
<TD>
<P>1 wk</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Number of joints with improvement in pain under load/walking</P>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>80</P>
</TD>
<TD>
<P>58</P>
</TD>
<TD>
<P>1.7</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Phosphate buffer</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>18</P>
</TD>
<TD>
<P>22</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Grecomoro 1987</P>
</TD>
<TD>
<P>1 wk</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Number of joints with improvement on pain on touch</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>75</P>
</TD>
<TD>
<P>42</P>
</TD>
<TD>
<P>2.4</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Phosphate buffer</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>6</P>
</TD>
<TD>
<P>18</P>
</TD>
<TD>
<P>33</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Altman 1998</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Number of patients with moderate/marked pain</P>
</TD>
<TD>
<P>36</P>
</TD>
<TD>
<P>105</P>
</TD>
<TD>
<P>34</P>
</TD>
<TD>
<P>-12</P>
</TD>
<TD>
<P>-8.3</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>115</P>
</TD>
<TD>
<P>46</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Corrado 1995</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Patient global assessment (number of patients improved)</P>
</TD>
<TD>
<P>6</P>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>32</P>
</TD>
<TD>
<P>-43</P>
</TD>
<TD>
<P>-2.3</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>75</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Creamer 1994</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Patient global assessment (number of patients improved)</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>42</P>
</TD>
<TD>
<P>9</P>
</TD>
<TD>
<P>11.1</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>33</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Formiguera Sala 1995</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Patient global assessment (number of patients improved)</P>
</TD>
<TD>
<P>8</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>-15</P>
</TD>
<TD>
<P>-6.7</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>11</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>55</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Corrado 1995</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Patient global assessment (number of patients improved)</P>
</TD>
<TD>
<P>14</P>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>74</P>
</TD>
<TD>
<P>-1</P>
</TD>
<TD>
<P>-10</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>75</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Formiguera Sala 1995</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Patient global assessment (number of patients improved)</P>
</TD>
<TD>
<P>6</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>-35</P>
</TD>
<TD>
<P>-2.9</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>13</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>65</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Henderson 1994</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Patient global assessment (number of patients improved)</P>
</TD>
<TD>
<P>17</P>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>43</P>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>25</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>17</P>
</TD>
<TD>
<P>44</P>
</TD>
<TD>
<P>39</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Huskisson 1999</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Patient global assessment (number of patients improved)</P>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>25</P>
</TD>
<TD>
<P>-32</P>
</TD>
<TD>
<P>-3.1</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>22</P>
</TD>
<TD>
<P>41</P>
</TD>
<TD>
<P>57</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Dougados 1993</P>
</TD>
<TD>
<P>45-52 wk</P>
</TD>
<TD>
<P>T: Hyalectin</P>
</TD>
<TD>
<P>Number of patients rating treatment effective</P>
</TD>
<TD>
<P>31</P>
</TD>
<TD>
<P>47</P>
</TD>
<TD>
<P>66</P>
</TD>
<TD>
<P>-10</P>
</TD>
<TD>
<P>-10</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>27</P>
</TD>
<TD>
<P>48</P>
</TD>
<TD>
<P>56</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Bragantini 1987</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Number of joints fairly good, good, very good</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>11</P>
</TD>
<TD>
<P>-56</P>
</TD>
<TD>
<P>-1.8</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>18</P>
</TD>
<TD>
<P>67</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Creamer 1994</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Number of joints fairly good, good, very good</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>42</P>
</TD>
<TD>
<P>9</P>
</TD>
<TD>
<P>11.1</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>33</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Jubb 2003</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Pain (number of patients improved)</P>
</TD>
<TD>
<P>88</P>
</TD>
<TD>
<P>208</P>
</TD>
<TD>
<P>42</P>
</TD>
<TD>
<P>6</P>
</TD>
<TD>
<P>16.7</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>71</P>
</TD>
<TD>
<P>200</P>
</TD>
<TD>
<P>36</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Jubb 2003</P>
</TD>
<TD>
<P>32 wk</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Pain (number of patients improved)</P>
</TD>
<TD>
<P>92</P>
</TD>
<TD>
<P>208</P>
</TD>
<TD>
<P>44</P>
</TD>
<TD>
<P>11</P>
</TD>
<TD>
<P>9.1</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>65</P>
</TD>
<TD>
<P>200</P>
</TD>
<TD>
<P>33</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Bragantini 1987</P>
</TD>
<TD>
<P>End of treatment</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Number of joints improved in walking pain</P>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>84</P>
</TD>
<TD>
<P>34</P>
</TD>
<TD>
<P>2.9</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>9</P>
</TD>
<TD>
<P>18</P>
</TD>
<TD>
<P>50</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Bragantini 1987</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Number of joints improved in walking pain</P>
</TD>
<TD>
<P>17</P>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>89</P>
</TD>
<TD>
<P>50</P>
</TD>
<TD>
<P>2</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>7</P>
</TD>
<TD>
<P>18</P>
</TD>
<TD>
<P>39</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Grecomoro 1987</P>
</TD>
<TD>
<P>1 wk</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Number of joints improved in walking pain</P>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>80</P>
</TD>
<TD>
<P>58</P>
</TD>
<TD>
<P>1.7</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Phosphate buffer</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>18</P>
</TD>
<TD>
<P>22</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Bragantini 1987</P>
</TD>
<TD>
<P>End of treatment</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Number of joints with improvement in pain under load</P>
</TD>
<TD>
<P>6</P>
</TD>
<TD>
<P>18</P>
</TD>
<TD>
<P>33</P>
</TD>
<TD>
<P>-56</P>
</TD>
<TD>
<P>-1.8</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>17</P>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>89</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Bragantini 1987</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Number of joints with improvement in pain under load</P>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>18</P>
</TD>
<TD>
<P>22</P>
</TD>
<TD>
<P>-67</P>
</TD>
<TD>
<P>-1.5</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>17</P>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>89</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-18" NO="18">
<TITLE>Clinical benefit table: Hyalgan versus arthroscopy. Continuous outcome measures</TITLE>
<TABLE COLS="9" ROWS="25">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>TIme</P>
</TH>
<TH>
<P>Treatment</P>
</TH>
<TH>
<P>Outcome (scale)</P>
</TH>
<TH>
<P>N of Pts</P>
</TH>
<TH>
<P>Baseline Mean</P>
</TH>
<TH>
<P>End of Study Mean</P>
</TH>
<TH>
<P>Absolute Benefit</P>
</TH>
<TH>
<P>Relative Difference</P>
</TH>
</TR>
<TR>
<TD>
<P>Forster 2003</P>
</TD>
<TD>
<P>1 wk</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Pain (0-10 cm VAS)</P>
</TD>
<TD>
<P>18</P>
</TD>
<TD>
<P>7.6</P>
</TD>
<TD>
<P>6.6</P>
</TD>
<TD>
<P>1.0 (W)</P>
</TD>
<TD>
<P>13.4% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Arthroscopy</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>7.5</P>
</TD>
<TD>
<P>5.4</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Forster 2003</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Pain (0-10 cm VAS)</P>
</TD>
<TD>
<P>18</P>
</TD>
<TD>
<P>7.6</P>
</TD>
<TD>
<P>6.0</P>
</TD>
<TD>
<P>-0.1 (I)</P>
</TD>
<TD>
<P>-1.5% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Arthroscopy</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>7.5</P>
</TD>
<TD>
<P>6.0</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Forster 2003</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Pain (0-10 cm VAS)</P>
</TD>
<TD>
<P>18</P>
</TD>
<TD>
<P>7.6</P>
</TD>
<TD>
<P>5.3</P>
</TD>
<TD>
<P>-1.1 (I)</P>
</TD>
<TD>
<P>-14.1% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Arthroscopy</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>7.5</P>
</TD>
<TD>
<P>6.2</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Forster 2003</P>
</TD>
<TD>
<P>45-52 wk</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Pain (0-10 cm VAS)</P>
</TD>
<TD>
<P>18</P>
</TD>
<TD>
<P>7.6</P>
</TD>
<TD>
<P>5.7</P>
</TD>
<TD>
<P>-0.2 (I)</P>
</TD>
<TD>
<P>-2.3% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Arthroscopy</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>7.5</P>
</TD>
<TD>
<P>5.7</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Forster 2003</P>
</TD>
<TD>
<P>1 wk</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Knee Society Function Scale</P>
</TD>
<TD>
<P>18</P>
</TD>
<TD>
<P>64.4</P>
</TD>
<TD>
<P>66.5</P>
</TD>
<TD>
<P>-5.6 (W)</P>
</TD>
<TD>
<P>-13.3% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Arthroscopy</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>42.0</P>
</TD>
<TD>
<P>49.6</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Forster 2003</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Knee Society Function Scale</P>
</TD>
<TD>
<P>18</P>
</TD>
<TD>
<P>64.4</P>
</TD>
<TD>
<P>67.5</P>
</TD>
<TD>
<P>6.3 (W)</P>
</TD>
<TD>
<P>14.9% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Arthroscopy</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>42.0</P>
</TD>
<TD>
<P>51.3</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Forster 2003</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Knee Society Function Scale</P>
</TD>
<TD>
<P>18</P>
</TD>
<TD>
<P>64.4</P>
</TD>
<TD>
<P>73.5</P>
</TD>
<TD>
<P>1.0 (I)</P>
</TD>
<TD>
<P>2.4% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Arthroscopy</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>42.0</P>
</TD>
<TD>
<P>50.0</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Forster 2003</P>
</TD>
<TD>
<P>45-52 wk</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Knee Society Function Scale</P>
</TD>
<TD>
<P>18</P>
</TD>
<TD>
<P>64.4</P>
</TD>
<TD>
<P>75.0</P>
</TD>
<TD>
<P>1.5 (I)</P>
</TD>
<TD>
<P>3.5% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Arthroscopy</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>42.0</P>
</TD>
<TD>
<P>51.1</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Forster 2003</P>
</TD>
<TD>
<P>1 wk</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Lequesne Index (0-24)</P>
</TD>
<TD>
<P>18</P>
</TD>
<TD>
<P>11.4</P>
</TD>
<TD>
<P>11.1</P>
</TD>
<TD>
<P>2.4 (W)</P>
</TD>
<TD>
<P>18.1% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Arthroscopy</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>13.3</P>
</TD>
<TD>
<P>10.5</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Forster 2003</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Lequesne Index (0-24)</P>
</TD>
<TD>
<P>18</P>
</TD>
<TD>
<P>11.4</P>
</TD>
<TD>
<P>10.9</P>
</TD>
<TD>
<P>1.3 (W)</P>
</TD>
<TD>
<P>9.8% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Arthroscopy</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>13.3</P>
</TD>
<TD>
<P>11.5</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Forster 2003</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Lequesne Index (0-24)</P>
</TD>
<TD>
<P>18</P>
</TD>
<TD>
<P>11.4</P>
</TD>
<TD>
<P>8.7</P>
</TD>
<TD>
<P>-1.2 (I)</P>
</TD>
<TD>
<P>-8.6% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Arthroscopy</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>13.3</P>
</TD>
<TD>
<P>11.7</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Forster 2003</P>
</TD>
<TD>
<P>45-52 wk</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Lequesne Index (0-24)</P>
</TD>
<TD>
<P>18</P>
</TD>
<TD>
<P>11.4</P>
</TD>
<TD>
<P>8.3</P>
</TD>
<TD>
<P>-1.1 (I)</P>
</TD>
<TD>
<P>-7.9% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Arthroscopy</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>13.3</P>
</TD>
<TD>
<P>11.2</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-19" NO="19">
<TITLE>Clinical benefit table: Hyalgan versus corticosteroids and other IA therapy. Dic</TITLE>
<TABLE COLS="9" ROWS="51">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Time</P>
</TH>
<TH>
<P>Treatment group</P>
</TH>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>No. improved</P>
</TH>
<TH>
<P>No. of pts</P>
</TH>
<TH>
<P>Risk (%)</P>
</TH>
<TH>
<P>Risk Difference</P>
</TH>
<TH>
<P>NNT</P>
</TH>
</TR>
<TR>
<TD>
<P>Leardini 1987</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Number of joints with moderate/severe pain under load</P>
</TD>
<TD>
<P>8</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: MPA</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>8</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Leardini 1991</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Number of patients with moderate/severe pain under load</P>
</TD>
<TD>
<P>14</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>70</P>
</TD>
<TD>
<P>25</P>
</TD>
<TD>
<P>4</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: MPA</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>95</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Pietrogrande 1991</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Number of patients with moderate/severe pain under load</P>
</TD>
<TD>
<P>21</P>
</TD>
<TD>
<P>45</P>
</TD>
<TD>
<P>47</P>
</TD>
<TD>
<P>7</P>
</TD>
<TD>
<P>14.3</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: MPA</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>18</P>
</TD>
<TD>
<P>45</P>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Leardini 1987</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Number of joints with moderate/severe pain under load</P>
</TD>
<TD>
<P>6</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>20</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: MPA</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>7</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>35</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Leardini 1991</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Number of patients with moderate/severe pain under load</P>
</TD>
<TD>
<P>13</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>65</P>
</TD>
<TD>
<P>35</P>
</TD>
<TD>
<P>2.9</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: MPA</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>100</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Pietrogrande 1991</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Number of patients with moderate/severe pain under load</P>
</TD>
<TD>
<P>13</P>
</TD>
<TD>
<P>44</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>21</P>
</TD>
<TD>
<P>4.8</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: MPA</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>23</P>
</TD>
<TD>
<P>45</P>
</TD>
<TD>
<P>51</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Leardini 1987</P>
</TD>
<TD>
<P>45-52 wk</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Number of joints with moderate/severe pain under load</P>
</TD>
<TD>
<P>8</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>8.3</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: MPA</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>11</P>
</TD>
<TD>
<P>17</P>
</TD>
<TD>
<P>65</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Leardini 1987</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Number of joints with moderate/severe walking pain</P>
</TD>
<TD>
<P>11</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>55</P>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>10</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: MPA</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>9</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>45</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Leardini 1987</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Number of joints with moderate/severe walking pain</P>
</TD>
<TD>
<P>8</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>10</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: MPA</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>50</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Leardini 1987</P>
</TD>
<TD>
<P>45-52 wk</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Number of joints with moderate/severe walking pain</P>
</TD>
<TD>
<P>11</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>73</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>50</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: MPA</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>17</P>
</TD>
<TD>
<P>71</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Leardini 1991</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Number of patients with at least moderate or greater night pain</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>6.7</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: MPA</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Pietrogrande 1991</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Number of patients with at least moderate or greater night pain</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>45</P>
</TD>
<TD>
<P>11</P>
</TD>
<TD>
<P>9</P>
</TD>
<TD>
<P>11.1</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: MPA</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>45</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Leardini 1991</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Number of patients with at least moderate or greater night pain</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>5</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: MPA</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Pietrogrande 1991</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Number of patients with at least moderate or greater night pain</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>44</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: MPA</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>45</P>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>25</P>
</TD>
</TR>
<TR>
<TD>
<P>Leardini 1991</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Number of patients with moderate or greater rest pain</P>
</TD>
<TD>
<P>6</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>3.3</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: MPA</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Pietrogrande 1991</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Number of patients with moderate or greater rest pain</P>
</TD>
<TD>
<P>7</P>
</TD>
<TD>
<P>45</P>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: MPA</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>7</P>
</TD>
<TD>
<P>45</P>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Leardini 1991</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Number of patients with moderate or greater rest pain</P>
</TD>
<TD>
<P>6</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>45</P>
</TD>
<TD>
<P>2.2</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: MPA</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>75</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Pietrogrande 1991</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Number of patients with moderate or greater rest pain</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>44</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>20</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: MPA</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>45</P>
</TD>
<TD>
<P>7</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Frizziero 2002</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Patient global (number of patients very good/good)</P>
</TD>
<TD>
<P>21</P>
</TD>
<TD>
<P>46</P>
</TD>
<TD>
<P>46</P>
</TD>
<TD>
<P>-40</P>
</TD>
<TD>
<P>2.5</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: MPA</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>32</P>
</TD>
<TD>
<P>37</P>
</TD>
<TD>
<P>86</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Leardini 1991</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Patient global (number of patients very good/good)</P>
</TD>
<TD>
<P>11</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>55</P>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>10</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: MPA</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>9</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>45</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Pietrogrande 1991</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Patient global (number of patients very good/good)</P>
</TD>
<TD>
<P>32</P>
</TD>
<TD>
<P>45</P>
</TD>
<TD>
<P>71</P>
</TD>
<TD>
<P>24</P>
</TD>
<TD>
<P>4.2</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C:MPA</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>21</P>
</TD>
<TD>
<P>45</P>
</TD>
<TD>
<P>47</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Leardini 1991</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Patient global (number of patients very good/good)</P>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>50</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>6.7</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: MPA</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>7</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>35</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Pietrogrande 1991</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Patient global (numbe of patients very good/good)</P>
</TD>
<TD>
<P>31</P>
</TD>
<TD>
<P>45</P>
</TD>
<TD>
<P>69</P>
</TD>
<TD>
<P>36</P>
</TD>
<TD>
<P>2.8</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: MPA</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>45</P>
</TD>
<TD>
<P>33</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Frizziero 2002</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Patient global (number of patients very good/good)</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>38</P>
</TD>
<TD>
<P>79</P>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>25</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: MPA</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>24</P>
</TD>
<TD>
<P>32</P>
</TD>
<TD>
<P>75</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Graf 1993 (other ia therapy)</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Patient global (number of patients symptom free/markedly improved)</P>
</TD>
<TD>
<P>25</P>
</TD>
<TD>
<P>33</P>
</TD>
<TD>
<P>76</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>3.3</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Mucopolysaccharide polysulfuric acid ester</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>11</P>
</TD>
<TD>
<P>24</P>
</TD>
<TD>
<P>46</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-20" NO="20">
<TITLE>Clinical benefit table: Hyalgan vs corticosteroids and other IA therapy. Continu</TITLE>
<TABLE COLS="9" ROWS="45">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Time</P>
</TH>
<TH>
<P>Treatment</P>
</TH>
<TH>
<P>Outcome (scale)</P>
</TH>
<TH>
<P>N of Pts</P>
</TH>
<TH>
<P>Baseline Mean</P>
</TH>
<TH>
<P>End of Study Mean</P>
</TH>
<TH>
<P>Absolute Benefit</P>
</TH>
<TH>
<P>Relative Difference</P>
</TH>
</TR>
<TR>
<TD>
<P>Leardini 1987</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Pain intensity (0-100 mm VAS)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>41.30</P>
</TD>
<TD>
<P>13.00</P>
</TD>
<TD>
<P>-4.5 (I)</P>
</TD>
<TD>
<P>-13.5% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: MPA</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>33.40</P>
</TD>
<TD>
<P>9.60</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Leardini 1991</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Pain intensity (0-100 mm VAS)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>47.40</P>
</TD>
<TD>
<P>10.73</P>
</TD>
<TD>
<P>-14.0 (I)</P>
</TD>
<TD>
<P>-32.1% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: MPA</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>43.54</P>
</TD>
<TD>
<P>20.83</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Pietrogrande 1991</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Pain intensity (0-100 mm VAS)</P>
</TD>
<TD>
<P>45</P>
</TD>
<TD>
<P>64.89</P>
</TD>
<TD>
<P>20.00</P>
</TD>
<TD>
<P>-5.3 (I)</P>
</TD>
<TD>
<P>-8.2% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: MPA</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>45</P>
</TD>
<TD>
<P>64.89</P>
</TD>
<TD>
<P>25.32</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Leardini 1987</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Pain intensity (0-100 mm VAS)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>41.30</P>
</TD>
<TD>
<P>11.20</P>
</TD>
<TD>
<P>-5.8 (I)</P>
</TD>
<TD>
<P>-17.4% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: MPA</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>33.40</P>
</TD>
<TD>
<P>9.10</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Leardini 1991</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Pain intensity (0-100 mm VAS)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>47.40</P>
</TD>
<TD>
<P>9.48</P>
</TD>
<TD>
<P>-17.7 (I)</P>
</TD>
<TD>
<P>-40.7% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: MPA</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>43.54</P>
</TD>
<TD>
<P>23.33</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Pietrogrande 1991</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Pain intensity (0-100 mm VAS)</P>
</TD>
<TD>
<P>45</P>
</TD>
<TD>
<P>64.89</P>
</TD>
<TD>
<P>19.71</P>
</TD>
<TD>
<P>-7.3 (I)</P>
</TD>
<TD>
<P>-11.3% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: MPA</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>45</P>
</TD>
<TD>
<P>64.89</P>
</TD>
<TD>
<P>27.05</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Leardini 1987</P>
</TD>
<TD>
<P>45-52 wk</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Pain intensity (0-100 mm VAS)</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>41.30</P>
</TD>
<TD>
<P>20.30</P>
</TD>
<TD>
<P>-5.4 (I)</P>
</TD>
<TD>
<P>-16.2% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: MPA</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>17</P>
</TD>
<TD>
<P>33.40</P>
</TD>
<TD>
<P>17.80</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Leardini 1987</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Range of motion (flexion in degrees)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>108.40</P>
</TD>
<TD>
<P>113.40</P>
</TD>
<TD>
<P>-3.2 (W)</P>
</TD>
<TD>
<P>-3.1% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: MPA</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>104.20</P>
</TD>
<TD>
<P>112.40</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Pietrogrande 1991</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Range of motion (flexion in degrees)</P>
</TD>
<TD>
<P>45</P>
</TD>
<TD>
<P>114.13</P>
</TD>
<TD>
<P>121.38</P>
</TD>
<TD>
<P>3.3 (I)</P>
</TD>
<TD>
<P>3% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: MPA</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>45</P>
</TD>
<TD>
<P>108.81</P>
</TD>
<TD>
<P>112.75</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Leardini 1987</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Range of motion (flexion in degrees)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>108.40</P>
</TD>
<TD>
<P>116.70</P>
</TD>
<TD>
<P>-1.8 (W)</P>
</TD>
<TD>
<P>-1.7% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: MPA</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>104.20</P>
</TD>
<TD>
<P>114.30</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Pietrogrande 1991</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Range of motion (flexion in degrees)</P>
</TD>
<TD>
<P>45</P>
</TD>
<TD>
<P>114.13</P>
</TD>
<TD>
<P>121.10</P>
</TD>
<TD>
<P>2.4 (I)</P>
</TD>
<TD>
<P>2.2% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: MPA</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>45</P>
</TD>
<TD>
<P>108.81</P>
</TD>
<TD>
<P>113.35</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Leardini 1987</P>
</TD>
<TD>
<P>45-52 wk</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Range of motion (flexion in degrees)</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>108.40</P>
</TD>
<TD>
<P>109.60</P>
</TD>
<TD>
<P>-2.7 (W)</P>
</TD>
<TD>
<P>-2.6% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: MPA</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>17</P>
</TD>
<TD>
<P>104.20</P>
</TD>
<TD>
<P>108.10</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Jones 1995</P>
</TD>
<TD>
<P>End of treatment</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Pain on nominated activity (0-100 mm VAS)</P>
</TD>
<TD>
<P>32</P>
</TD>
<TD>
<P>77.2</P>
</TD>
<TD>
<P>56.5</P>
</TD>
<TD>
<P>-1.6 (I)</P>
</TD>
<TD>
<P>-2.1% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Triamcinolone hexacetonide</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>31</P>
</TD>
<TD>
<P>75.8</P>
</TD>
<TD>
<P>56.7</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Jones 1995</P>
</TD>
<TD>
<P>End of treatment</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Pain at rest (0-100 mm VAS)</P>
</TD>
<TD>
<P>32</P>
</TD>
<TD>
<P>53.2</P>
</TD>
<TD>
<P>39.9</P>
</TD>
<TD>
<P>1.4 (W)</P>
</TD>
<TD>
<P>2.5% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Triamcinolone hexacetonide</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>31</P>
</TD>
<TD>
<P>55.3</P>
</TD>
<TD>
<P>40.6</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Jones 1995</P>
</TD>
<TD>
<P>End of treatment</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Pain at night (0-100 mm VAS)</P>
</TD>
<TD>
<P>32</P>
</TD>
<TD>
<P>57.8</P>
</TD>
<TD>
<P>35.9</P>
</TD>
<TD>
<P>-2.7 (I)</P>
</TD>
<TD>
<P>-4.3% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Triamcinolone hexacetonide</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>31</P>
</TD>
<TD>
<P>62.2</P>
</TD>
<TD>
<P>43.0</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Jones 1995</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Pain on nominated activity (0-100 mm VAS)</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>77.2</P>
</TD>
<TD>
<P>44.3</P>
</TD>
<TD>
<P>-11.4 (I)</P>
</TD>
<TD>
<P>-15.0% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Triamcinolone hexacetonide</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>8</P>
</TD>
<TD>
<P>75.8</P>
</TD>
<TD>
<P>54.3</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Jones 1995</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Pain at rest (0-100 mm VAS)</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>53.2</P>
</TD>
<TD>
<P>28.2</P>
</TD>
<TD>
<P>-18.3 (I)</P>
</TD>
<TD>
<P>-33.1% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Triamcinolone hexacetonide</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>8</P>
</TD>
<TD>
<P>55.3</P>
</TD>
<TD>
<P>48.6</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Jones 1995</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Pain at night (0-100 mm VAS)</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>57.8</P>
</TD>
<TD>
<P>15.4</P>
</TD>
<TD>
<P>-16.3 (I)</P>
</TD>
<TD>
<P>-26.2% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Triamcinolone hexacetonide</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>8</P>
</TD>
<TD>
<P>62.2</P>
</TD>
<TD>
<P>36.1</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Graf 1993 (other ia therapy)</P>
</TD>
<TD>
<P>End of treatment</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Pain (0-30)</P>
</TD>
<TD>
<P>33</P>
</TD>
<TD>
<P>14.1</P>
</TD>
<TD>
<P>19.6</P>
</TD>
<TD>
<P>4 (I)</P>
</TD>
<TD>
<P>24.7% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: MPAE</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>27</P>
</TD>
<TD>
<P>16.2</P>
</TD>
<TD>
<P>17.7</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Graf 1993 (other ia therapy)</P>
</TD>
<TD>
<P>End of treatment</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Larson function (0-30)</P>
</TD>
<TD>
<P>33</P>
</TD>
<TD>
<P>18.0</P>
</TD>
<TD>
<P>19.1</P>
</TD>
<TD>
<P>0.6 (I)</P>
</TD>
<TD>
<P>3.6% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: MPAE</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>27</P>
</TD>
<TD>
<P>16.9</P>
</TD>
<TD>
<P>17.4</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Graf 1993 (other ia therapy)</P>
</TD>
<TD>
<P>End of treatment</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Larson total (0-77)</P>
</TD>
<TD>
<P>33</P>
</TD>
<TD>
<P>45.7</P>
</TD>
<TD>
<P>54.1</P>
</TD>
<TD>
<P>5.9 (I)</P>
</TD>
<TD>
<P>12.7% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: MPAE</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>27</P>
</TD>
<TD>
<P>46.6</P>
</TD>
<TD>
<P>49.1</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Graf 1993 (other ia therapy)</P>
</TD>
<TD>
<P>End of treatment</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Range of motion (0-10)</P>
</TD>
<TD>
<P>33</P>
</TD>
<TD>
<P>8.8</P>
</TD>
<TD>
<P>9.1</P>
</TD>
<TD>
<P>0.3 (I)</P>
</TD>
<TD>
<P>3.5% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: MPAE</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>27</P>
</TD>
<TD>
<P>8.7</P>
</TD>
<TD>
<P>8.7</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-21" NO="21">
<TITLE>Clinical benefit table: Hyalgan versus NSAID. Dichotomous outcome measures</TITLE>
<TABLE COLS="9" ROWS="3">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Time</P>
</TH>
<TH>
<P>Treatment group</P>
</TH>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>No. improved</P>
</TH>
<TH>
<P>No. of pts</P>
</TH>
<TH>
<P>Risk (%)</P>
</TH>
<TH>
<P>Risk Difference</P>
</TH>
<TH>
<P>NNT</P>
</TH>
</TR>
<TR>
<TD>
<P>Altman 1998</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>T: Hyalgan</P>
</TD>
<TD>
<P>Number of patients with moderate/marked pain</P>
</TD>
<TD>
<P>69</P>
</TD>
<TD>
<P>105</P>
</TD>
<TD>
<P>66</P>
</TD>
<TD>
<P>4%</P>
</TD>
<TD>
<P>25</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Naproxen</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>70</P>
</TD>
<TD>
<P>113</P>
</TD>
<TD>
<P>62</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-22" NO="22">
<TITLE>Clinical benefit table: Hyalgan versus NSAID. Continuous outcome measures</TITLE>
<TABLE COLS="9" ROWS="7">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Time</P>
</TH>
<TH>
<P>Treatment</P>
</TH>
<TH>
<P>Outcome (scale)</P>
</TH>
<TH>
<P>N of Pts</P>
</TH>
<TH>
<P>Baseline Mean</P>
</TH>
<TH>
<P>End of Study Mean</P>
</TH>
<TH>
<P>Absolute Benefit</P>
</TH>
<TH>
<P>Relative Difference</P>
</TH>
</TR>
<TR>
<TD>
<P>Altman 1998</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hyalgan</P>
</TD>
<TD>
<P>Pain after 50 foot walk (0-100 mm VAS)</P>
</TD>
<TD>
<P>163</P>
</TD>
<TD>
<P>54</P>
</TD>
<TD>
<P>25</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Naproxen</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>162</P>
</TD>
<TD>
<P>54</P>
</TD>
<TD>
<P>25</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Altman 1998</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hyalgan</P>
</TD>
<TD>
<P>Pain after 50 foot walk (0-100 mm VAS)</P>
</TD>
<TD>
<P>115</P>
</TD>
<TD>
<P>54</P>
</TD>
<TD>
<P>23</P>
</TD>
<TD>
<P>2 (W)</P>
</TD>
<TD>
<P>3.7% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Naproxen</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>125</P>
</TD>
<TD>
<P>54</P>
</TD>
<TD>
<P>21</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Altman 1998</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Hyalgan</P>
</TD>
<TD>
<P>Pain after 50 foot walk (0-100 mm VAS)</P>
</TD>
<TD>
<P>105</P>
</TD>
<TD>
<P>54</P>
</TD>
<TD>
<P>18</P>
</TD>
<TD>
<P>-3 (I)</P>
</TD>
<TD>
<P>-5.6% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Naproxen</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>111</P>
</TD>
<TD>
<P>54</P>
</TD>
<TD>
<P>21</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-23" NO="23">
<TITLE>Clinical benefit table: Hyalgan versus conventional care. Continuous outcome mea</TITLE>
<TABLE COLS="9" ROWS="13">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Time</P>
</TH>
<TH>
<P>Treatment</P>
</TH>
<TH>
<P>Outcome (scale)</P>
</TH>
<TH>
<P>N of Pts</P>
</TH>
<TH>
<P>Baseline Mean</P>
</TH>
<TH>
<P>End of Study Mean</P>
</TH>
<TH>
<P>Absolute Benefit</P>
</TH>
<TH>
<P>Relative Difference</P>
</TH>
</TR>
<TR>
<TD>
<P>Listrat 1997</P>
</TD>
<TD>
<P>45-52 wk</P>
</TD>
<TD>
<P>E: Hyalgan</P>
</TD>
<TD>
<P>Pain overall (0-100 mm VAS)</P>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>49.2</P>
</TD>
<TD>
<P>32.4</P>
</TD>
<TD>
<P>-11.5 (I)</P>
</TD>
<TD>
<P>-22.1% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Conventional therapy</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>17</P>
</TD>
<TD>
<P>52.1</P>
</TD>
<TD>
<P>46.8</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Listrat 1997</P>
</TD>
<TD>
<P>45-52 wk</P>
</TD>
<TD>
<P>E: Hyalgan</P>
</TD>
<TD>
<P>Lequesne Index (0-24)</P>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>8.9</P>
</TD>
<TD>
<P>7.2</P>
</TD>
<TD>
<P>-0.4 (I)</P>
</TD>
<TD>
<P>-4.3% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Conventional therapy</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>17</P>
</TD>
<TD>
<P>9.4</P>
</TD>
<TD>
<P>8.1</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Listrat 1997</P>
</TD>
<TD>
<P>45-52 wk</P>
</TD>
<TD>
<P>E: Hyalgan</P>
</TD>
<TD>
<P>Joint space width (mm)</P>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>4.5</P>
</TD>
<TD>
<P>4.0</P>
</TD>
<TD>
<P>0.1 (I)</P>
</TD>
<TD>
<P>2.9% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Conventional therapy</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>17</P>
</TD>
<TD>
<P>3.5</P>
</TD>
<TD>
<P>2.9</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Listrat 1997</P>
</TD>
<TD>
<P>45-52 wk</P>
</TD>
<TD>
<P>E: Hyalgan</P>
</TD>
<TD>
<P>Arthroscopy assessment (0-100 mm VAS)</P>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>41.8</P>
</TD>
<TD>
<P>47.0</P>
</TD>
<TD>
<P>-11.5 (I)</P>
</TD>
<TD>
<P>-21.9% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Conventional therapy</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>17</P>
</TD>
<TD>
<P>52.6</P>
</TD>
<TD>
<P>69.3</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Listrat 1997</P>
</TD>
<TD>
<P>45-52 wk</P>
</TD>
<TD>
<P>E: Hyalgan</P>
</TD>
<TD>
<P>SFA scoring system (0-100 mm VAS)</P>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>26.1</P>
</TD>
<TD>
<P>29.8</P>
</TD>
<TD>
<P>-5.3 (I)</P>
</TD>
<TD>
<P>-13.6% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Conventional therapy</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>17</P>
</TD>
<TD>
<P>39.0</P>
</TD>
<TD>
<P>48.0</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Listrat 1997</P>
</TD>
<TD>
<P>45-52 wk</P>
</TD>
<TD>
<P>E: Hyalgan</P>
</TD>
<TD>
<P>Quality of life (AIMS: 12 item total)</P>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>2.6</P>
</TD>
<TD>
<P>2.2</P>
</TD>
<TD>
<P>-0.6 (I)</P>
</TD>
<TD>
<P>-27.3% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Conventional therapy</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>17</P>
</TD>
<TD>
<P>2.2</P>
</TD>
<TD>
<P>2.4</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-24" NO="24">
<TITLE>Clinical benefit table: Hyalgan+exercise+ultrasound versus exercise+ultrasound.</TITLE>
<TABLE COLS="9" ROWS="17">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Time</P>
</TH>
<TH>
<P>Treatment</P>
</TH>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>N of Pts</P>
</TH>
<TH>
<P>Baseline Mean</P>
</TH>
<TH>
<P>End of Study Mean</P>
</TH>
<TH>
<P>Absolute Benefit</P>
</TH>
<TH>
<P>Relative Difference</P>
</TH>
</TR>
<TR>
<TD>
<P>Huang 2005</P>
</TD>
<TD>
<P>End of treatment</P>
</TD>
<TD>
<P>E: Hyalgan+exercise+ultrasound</P>
</TD>
<TD>
<P>Pain (0-10 cm VAS)</P>
</TD>
<TD>
<P>34</P>
</TD>
<TD>
<P>5.6</P>
</TD>
<TD>
<P>2.5</P>
</TD>
<TD>
<P>-2.5 (I)</P>
</TD>
<TD>
<P>-45.5% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Exercise+ultrasound</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>32</P>
</TD>
<TD>
<P>5.5</P>
</TD>
<TD>
<P>4.9</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Huang 2005</P>
</TD>
<TD>
<P>52 wk</P>
</TD>
<TD>
<P>E: Hyalgan+exercise+ultrasound</P>
</TD>
<TD>
<P>Pain (0-10 cm VAS)</P>
</TD>
<TD>
<P>32</P>
</TD>
<TD>
<P>5.6</P>
</TD>
<TD>
<P>2.0</P>
</TD>
<TD>
<P>-4.7 (I)</P>
</TD>
<TD>
<P>-85.5% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Exercise+ultrasound</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>28</P>
</TD>
<TD>
<P>5.5</P>
</TD>
<TD>
<P>6.6</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Huang 2005</P>
</TD>
<TD>
<P>End of treatment</P>
</TD>
<TD>
<P>E: Hyalgan+exercise+ultrasound</P>
</TD>
<TD>
<P>Lequesne Index (0-26)</P>
</TD>
<TD>
<P>34</P>
</TD>
<TD>
<P>7.5</P>
</TD>
<TD>
<P>4.0</P>
</TD>
<TD>
<P>-3.0 (I)</P>
</TD>
<TD>
<P>-40.5% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Exercise+ultrasound</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>32</P>
</TD>
<TD>
<P>7.4</P>
</TD>
<TD>
<P>6.9</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Huang 2005</P>
</TD>
<TD>
<P>52 wk</P>
</TD>
<TD>
<P>E: Hyalgan+Exercise+ultrasound</P>
</TD>
<TD>
<P>Lequesne Index (0-26)</P>
</TD>
<TD>
<P>32</P>
</TD>
<TD>
<P>7.5</P>
</TD>
<TD>
<P>2.5</P>
</TD>
<TD>
<P>-5.7 (I)</P>
</TD>
<TD>
<P>-77.0% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Exercise+ultrasound</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>28</P>
</TD>
<TD>
<P>7.4</P>
</TD>
<TD>
<P>8.1</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Huang 2005</P>
</TD>
<TD>
<P>End of treatment</P>
</TD>
<TD>
<P>E: Hyalgan+exercise+ultrasound</P>
</TD>
<TD>
<P>Range of motion (degrees)</P>
</TD>
<TD>
<P>34</P>
</TD>
<TD>
<P>103</P>
</TD>
<TD>
<P>120</P>
</TD>
<TD>
<P>23 (I)</P>
</TD>
<TD>
<P>22.1% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Exercise+ultrasound</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>32</P>
</TD>
<TD>
<P>104</P>
</TD>
<TD>
<P>98</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Huang 2005</P>
</TD>
<TD>
<P>52 wk</P>
</TD>
<TD>
<P>E: Hyalgan+exercise+ultrasound</P>
</TD>
<TD>
<P>Range of motion (degrees)</P>
</TD>
<TD>
<P>32</P>
</TD>
<TD>
<P>103</P>
</TD>
<TD>
<P>124</P>
</TD>
<TD>
<P>27 (I)</P>
</TD>
<TD>
<P>26.0% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Exercise+ultrasound</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>28</P>
</TD>
<TD>
<P>104</P>
</TD>
<TD>
<P>98</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Huang 2005</P>
</TD>
<TD>
<P>End of treatment</P>
</TD>
<TD>
<P>E: Hyalgan+exercise+ultrasound</P>
</TD>
<TD>
<P>Ambulation speed (metres per minute)</P>
</TD>
<TD>
<P>34</P>
</TD>
<TD>
<P>72.4</P>
</TD>
<TD>
<P>95.6</P>
</TD>
<TD>
<P>27.7 (I)</P>
</TD>
<TD>
<P>38.8% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Exercise+ultrasound</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>32</P>
</TD>
<TD>
<P>71.3</P>
</TD>
<TD>
<P>75.8</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Huang 2005</P>
</TD>
<TD>
<P>52 wk</P>
</TD>
<TD>
<P>E: Hyalgan+exercise+ultrasound</P>
</TD>
<TD>
<P>Ambulation speed (metres per minute)</P>
</TD>
<TD>
<P>32</P>
</TD>
<TD>
<P>72.4</P>
</TD>
<TD>
<P>99.3</P>
</TD>
<TD>
<P>28.1 (I)</P>
</TD>
<TD>
<P>39.4 (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Exercise+ultrasound</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>28</P>
</TD>
<TD>
<P>71.3</P>
</TD>
<TD>
<P>70.1</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-25" NO="25">
<TITLE>Clinical benefit table: Hyalgan plus exercise plus ultrasound versus exercise</TITLE>
<TABLE COLS="9" ROWS="17">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Time</P>
</TH>
<TH>
<P>Treatment</P>
</TH>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>N of Pts</P>
</TH>
<TH>
<P>Baseline Mean</P>
</TH>
<TH>
<P>End of Study Mean</P>
</TH>
<TH>
<P>Absolute Benefit</P>
</TH>
<TH>
<P>Relative Difference</P>
</TH>
</TR>
<TR>
<TD>
<P>Huang 2005</P>
</TD>
<TD>
<P>End of treatment</P>
</TD>
<TD>
<P>E: Hyalgan+exercise+ultrasound</P>
</TD>
<TD>
<P>Pain (0-10 cm VAS)</P>
</TD>
<TD>
<P>34</P>
</TD>
<TD>
<P>5.6</P>
</TD>
<TD>
<P>2.5</P>
</TD>
<TD>
<P>-1.9 (I)</P>
</TD>
<TD>
<P>-35.8% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Exercise</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>5.3</P>
</TD>
<TD>
<P>4.1</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Huang 2005</P>
</TD>
<TD>
<P>52 wk</P>
</TD>
<TD>
<P>E: Hyalgan+exercise+ultrasound</P>
</TD>
<TD>
<P>Pain (0-10 cm VAS)</P>
</TD>
<TD>
<P>32</P>
</TD>
<TD>
<P>5.6</P>
</TD>
<TD>
<P>2.0</P>
</TD>
<TD>
<P>-2.2 (I)</P>
</TD>
<TD>
<P>-41.5% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Exercise</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>26</P>
</TD>
<TD>
<P>5.3</P>
</TD>
<TD>
<P>3.9</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Huang 2005</P>
</TD>
<TD>
<P>End of treatment</P>
</TD>
<TD>
<P>E: Hyalgan+exercise+ultrasound</P>
</TD>
<TD>
<P>Lequesne Index (0-26)</P>
</TD>
<TD>
<P>34</P>
</TD>
<TD>
<P>7.5</P>
</TD>
<TD>
<P>4.0</P>
</TD>
<TD>
<P>-5.0 (I)</P>
</TD>
<TD>
<P>-65.8% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Exercise</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>7.6</P>
</TD>
<TD>
<P>6.1</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Huang 2005</P>
</TD>
<TD>
<P>52 wk</P>
</TD>
<TD>
<P>E: Hyalgan+exercise+ultrasound</P>
</TD>
<TD>
<P>Lequesne Index (0-26)</P>
</TD>
<TD>
<P>32</P>
</TD>
<TD>
<P>7.5</P>
</TD>
<TD>
<P>2.5</P>
</TD>
<TD>
<P>-3.2 (I)</P>
</TD>
<TD>
<P>-42.1% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Exercise</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>26</P>
</TD>
<TD>
<P>7.6</P>
</TD>
<TD>
<P>5.8</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Huang 2005</P>
</TD>
<TD>
<P>End of treatment</P>
</TD>
<TD>
<P>E: Hyalgan+exercise+ultrasound</P>
</TD>
<TD>
<P>Range of motion (degrees)</P>
</TD>
<TD>
<P>34</P>
</TD>
<TD>
<P>103</P>
</TD>
<TD>
<P>120</P>
</TD>
<TD>
<P>22 (I)</P>
</TD>
<TD>
<P>21.4% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Exercise</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>103</P>
</TD>
<TD>
<P>108</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Huang 2005</P>
</TD>
<TD>
<P>52 wk</P>
</TD>
<TD>
<P>E: Hyalgan+exercise+ultrasound</P>
</TD>
<TD>
<P>Range of motion (degrees)</P>
</TD>
<TD>
<P>32</P>
</TD>
<TD>
<P>103</P>
</TD>
<TD>
<P>124</P>
</TD>
<TD>
<P>28 (I)</P>
</TD>
<TD>
<P>27.2% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Exercise</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>26</P>
</TD>
<TD>
<P>103</P>
</TD>
<TD>
<P>110</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Huang 2005</P>
</TD>
<TD>
<P>End of treatment</P>
</TD>
<TD>
<P>E: Hyalgan+exercise+ultrasound</P>
</TD>
<TD>
<P>Ambulation speed (metres per minute)</P>
</TD>
<TD>
<P>34</P>
</TD>
<TD>
<P>72.4</P>
</TD>
<TD>
<P>95.6</P>
</TD>
<TD>
<P>12.9 (I)</P>
</TD>
<TD>
<P>17.8% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Exercise</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>72.6</P>
</TD>
<TD>
<P>82.9</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Huang 2005</P>
</TD>
<TD>
<P>52 wk</P>
</TD>
<TD>
<P>E: Hyalgan+exercise+ultrasound</P>
</TD>
<TD>
<P>Ambulation speed (metres per minute)</P>
</TD>
<TD>
<P>32</P>
</TD>
<TD>
<P>72.4</P>
</TD>
<TD>
<P>99.3</P>
</TD>
<TD>
<P>14.2 (I)</P>
</TD>
<TD>
<P>19.6% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Exercise</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>26</P>
</TD>
<TD>
<P>72.6</P>
</TD>
<TD>
<P>85.3</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-26" NO="26">
<TITLE>Clinical benefit table: Hyalgan plus exercise plus ultrasound versus control exe</TITLE>
<TABLE COLS="9" ROWS="17">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Time</P>
</TH>
<TH>
<P>Treatment</P>
</TH>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>N of Pts</P>
</TH>
<TH>
<P>Baseline Mean</P>
</TH>
<TH>
<P>End of Study Mean</P>
</TH>
<TH>
<P>Absolute Benefit</P>
</TH>
<TH>
<P>Relative Difference</P>
</TH>
</TR>
<TR>
<TD>
<P>Huang 2005</P>
</TD>
<TD>
<P>End of treatment</P>
</TD>
<TD>
<P>E: Hyalgan+exercise+ultrasound</P>
</TD>
<TD>
<P>Pain (0-10 cm VAS)</P>
</TD>
<TD>
<P>34</P>
</TD>
<TD>
<P>5.6</P>
</TD>
<TD>
<P>2.5</P>
</TD>
<TD>
<P>-2.5 (I)</P>
</TD>
<TD>
<P>-46.3% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Warmup exercises</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>32</P>
</TD>
<TD>
<P>5.4</P>
</TD>
<TD>
<P>4.9</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Huang 2005</P>
</TD>
<TD>
<P>52 wk</P>
</TD>
<TD>
<P>E: Hyalgan+exercise+ultrasound</P>
</TD>
<TD>
<P>Pain (0-10 cm VAS)</P>
</TD>
<TD>
<P>32</P>
</TD>
<TD>
<P>5.6</P>
</TD>
<TD>
<P>2.0</P>
</TD>
<TD>
<P>-4.8 (I)</P>
</TD>
<TD>
<P>-88.9% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Warmup exercises</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>28</P>
</TD>
<TD>
<P>5.4</P>
</TD>
<TD>
<P>6.6</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Huang 2005</P>
</TD>
<TD>
<P>End of treatment</P>
</TD>
<TD>
<P>E: Hyalgan+exercise+ultrasound</P>
</TD>
<TD>
<P>Lequesne Index (0-26)</P>
</TD>
<TD>
<P>34</P>
</TD>
<TD>
<P>7.5</P>
</TD>
<TD>
<P>4.0</P>
</TD>
<TD>
<P>-2.5 (I)</P>
</TD>
<TD>
<P>-33.8% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Warmup exercises</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>32</P>
</TD>
<TD>
<P>7.4</P>
</TD>
<TD>
<P>6.9</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Huang 2005</P>
</TD>
<TD>
<P>52 wk</P>
</TD>
<TD>
<P>E: Hyalgan+exercise+ultrasound</P>
</TD>
<TD>
<P>Lequesne Index (0-26)</P>
</TD>
<TD>
<P>32</P>
</TD>
<TD>
<P>7.5</P>
</TD>
<TD>
<P>2.5</P>
</TD>
<TD>
<P>-5.7 (I)</P>
</TD>
<TD>
<P>-77.0% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Warmup exercises</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>28</P>
</TD>
<TD>
<P>7.4</P>
</TD>
<TD>
<P>8.1</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Huang 2005</P>
</TD>
<TD>
<P>End of treatment</P>
</TD>
<TD>
<P>E: Hyalgan+exercise+ultrasound</P>
</TD>
<TD>
<P>Range of motion (degrees)</P>
</TD>
<TD>
<P>34</P>
</TD>
<TD>
<P>103</P>
</TD>
<TD>
<P>120</P>
</TD>
<TD>
<P>20 (I)</P>
</TD>
<TD>
<P>19.8% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Warmup exercises</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>32</P>
</TD>
<TD>
<P>101</P>
</TD>
<TD>
<P>98</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Huang 2005</P>
</TD>
<TD>
<P>52 wk</P>
</TD>
<TD>
<P>E: Hyalgan+exercise+ultrasound</P>
</TD>
<TD>
<P>Range of motion (degrees)</P>
</TD>
<TD>
<P>32</P>
</TD>
<TD>
<P>103</P>
</TD>
<TD>
<P>124</P>
</TD>
<TD>
<P>24 (I)</P>
</TD>
<TD>
<P>23.8% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Warmup exercises</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>28</P>
</TD>
<TD>
<P>101</P>
</TD>
<TD>
<P>98</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Huang 2005</P>
</TD>
<TD>
<P>End of treatment</P>
</TD>
<TD>
<P>E: Hyalgan+exercise+ultrasound</P>
</TD>
<TD>
<P>Ambulation speed (metres per minute)</P>
</TD>
<TD>
<P>34</P>
</TD>
<TD>
<P>72.4</P>
</TD>
<TD>
<P>95.6</P>
</TD>
<TD>
<P>21.3 (I)</P>
</TD>
<TD>
<P>28.8% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Warmup exercises</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>32</P>
</TD>
<TD>
<P>73.9</P>
</TD>
<TD>
<P>75.8</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Huang 2005</P>
</TD>
<TD>
<P>52 wk</P>
</TD>
<TD>
<P>E: Hyalgan+exercise+ultrasound</P>
</TD>
<TD>
<P>Ambulation speed (metres per minute)</P>
</TD>
<TD>
<P>32</P>
</TD>
<TD>
<P>72.4</P>
</TD>
<TD>
<P>99.3</P>
</TD>
<TD>
<P>30.7 (I)</P>
</TD>
<TD>
<P>41.5% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Warmup exercises</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>28</P>
</TD>
<TD>
<P>73.9</P>
</TD>
<TD>
<P>70.1</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-27" NO="27">
<TITLE>Clinical benefit table: Hylan G-F 20 versus placebo. Continuous outcome measures</TITLE>
<TABLE COLS="9" ROWS="97">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Time</P>
</TH>
<TH>
<P>Treatment group</P>
</TH>
<TH>
<P>Outcome (scale)</P>
</TH>
<TH>
<P>N of Pts</P>
</TH>
<TH>
<P>Baseline Mean</P>
</TH>
<TH>
<P>End of Study Mean</P>
</TH>
<TH>
<P>Absolute Benefit</P>
</TH>
<TH>
<P>Relative Difference</P>
</TH>
</TR>
<TR>
<TD>
<P>Scale 1994a</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Weight bearing pain (0-100 mm VAS)</P>
</TD>
<TD>
<P>25</P>
</TD>
<TD>
<P>61</P>
</TD>
<TD>
<P>27</P>
</TD>
<TD>
<P>-20 (I)</P>
</TD>
<TD>
<P>-29.9% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>25</P>
</TD>
<TD>
<P>67</P>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Scale 1994a</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Pain at night (0-100 mm VAS)</P>
</TD>
<TD>
<P>25</P>
</TD>
<TD>
<P>29</P>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>-13 (I)</P>
</TD>
<TD>
<P>-50.0% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>25</P>
</TD>
<TD>
<P>26</P>
</TD>
<TD>
<P>26</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Scale 1994b</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Weight bearing pain (0-100 mm VAS)</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>65</P>
</TD>
<TD>
<P>11</P>
</TD>
<TD>
<P>-27 (I)</P>
</TD>
<TD>
<P>-38.6% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>70</P>
</TD>
<TD>
<P>43</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Scale 1994b</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Pain at night (0-100 mm VAS)</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>-10 (I)</P>
</TD>
<TD>
<P>-30.3% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>33</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Wobig 1998</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Weight bearing pain (0-100 mm VAS)</P>
</TD>
<TD>
<P>57</P>
</TD>
<TD>
<P>70</P>
</TD>
<TD>
<P>23</P>
</TD>
<TD>
<P>-32 (I)</P>
</TD>
<TD>
<P>-42.7% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>75</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Wobig 1998</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Pain at night (0-100 mm VAS)</P>
</TD>
<TD>
<P>57</P>
</TD>
<TD>
<P>41</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>-13 (I)</P>
</TD>
<TD>
<P>-28.3% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>46</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Wobig 1999</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Weight bearing pain (0-100 mm VAS)</P>
</TD>
<TD>
<P>38</P>
</TD>
<TD>
<P>70</P>
</TD>
<TD>
<P>32</P>
</TD>
<TD>
<P>-1 (I)</P>
</TD>
<TD>
<P>-1.3% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Nonelastoviscous Hylan G-F 20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>36</P>
</TD>
<TD>
<P>80</P>
</TD>
<TD>
<P>43</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Wobig 1999</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Pain at night (0-100 mm VAS)</P>
</TD>
<TD>
<P>38</P>
</TD>
<TD>
<P>26</P>
</TD>
<TD>
<P>13</P>
</TD>
<TD>
<P>2 (W)</P>
</TD>
<TD>
<P>7.4% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Nonelastoviscous Hylan G-F 20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>36</P>
</TD>
<TD>
<P>27</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Moreland 1993</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hylan GF 20</P>
</TD>
<TD>
<P>Pain on motion (0-100 mm VAS)</P>
</TD>
<TD>
<P>46</P>
</TD>
<TD>
<P>69</P>
</TD>
<TD>
<P>47</P>
</TD>
<TD>
<P>-3 (I)</P>
</TD>
<TD>
<P>-4.3% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Arthrocentesis</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>48</P>
</TD>
<TD>
<P>70</P>
</TD>
<TD>
<P>51</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Moreland 1993</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Pain at night (0-100 mm VAS)</P>
</TD>
<TD>
<P>46</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>36</P>
</TD>
<TD>
<P>6 (W)</P>
</TD>
<TD>
<P>8% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Arthrocentesis</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>48</P>
</TD>
<TD>
<P>75</P>
</TD>
<TD>
<P>45</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Moreland 1993</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hylan GF 20</P>
</TD>
<TD>
<P>Pain at rest (0-100 mm VAS)</P>
</TD>
<TD>
<P>46</P>
</TD>
<TD>
<P>61</P>
</TD>
<TD>
<P>39</P>
</TD>
<TD>
<P>-2 (I)</P>
</TD>
<TD>
<P>-3.1% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Arthrocentesis</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>48</P>
</TD>
<TD>
<P>64</P>
</TD>
<TD>
<P>44</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Moreland 1993</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Pain walking (0-100 mm VAS)</P>
</TD>
<TD>
<P>46</P>
</TD>
<TD>
<P>79</P>
</TD>
<TD>
<P>57</P>
</TD>
<TD>
<P>-2 (I)</P>
</TD>
<TD>
<P>-2.5% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Arthrocentesis</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>48</P>
</TD>
<TD>
<P>80</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Moreland 1993</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hylan GF 20</P>
</TD>
<TD>
<P>Pain overall (0-100 mm VAS)</P>
</TD>
<TD>
<P>46</P>
</TD>
<TD>
<P>78</P>
</TD>
<TD>
<P>55</P>
</TD>
<TD>
<P>-2 (I)</P>
</TD>
<TD>
<P>-2.6% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Arthrocentesis</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>48</P>
</TD>
<TD>
<P>78</P>
</TD>
<TD>
<P>57</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Dickson 2001</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>WOMAC pain (0-100 mm VAS)</P>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>59</P>
</TD>
<TD>
<P>26</P>
</TD>
<TD>
<P>-9 (I)</P>
</TD>
<TD>
<P>-15.5% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Arthrocentesis + Placebo capsules</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>57</P>
</TD>
<TD>
<P>58</P>
</TD>
<TD>
<P>34</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Dickson 2001</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>WOMAC function (0-100 VAS)</P>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>54</P>
</TD>
<TD>
<P>38</P>
</TD>
<TD>
<P>-7 (I)</P>
</TD>
<TD>
<P>-12.5% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Arthrocentesis + Placebo capsules</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>57</P>
</TD>
<TD>
<P>56</P>
</TD>
<TD>
<P>47</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Dickson 2001</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Lequesne Index (0-24)</P>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>13.9</P>
</TD>
<TD>
<P>10.9</P>
</TD>
<TD>
<P>-1 (I)</P>
</TD>
<TD>
<P>-6.9% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Arthrocentesis + Placebo capsules</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>57</P>
</TD>
<TD>
<P>14.5</P>
</TD>
<TD>
<P>12.5</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karlsson 2002b</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Pain on weight bearing (0-100 mm VAS)</P>
</TD>
<TD>
<P>88</P>
</TD>
<TD>
<P>63</P>
</TD>
<TD>
<P>45</P>
</TD>
<TD>
<P>3.0 (W)</P>
</TD>
<TD>
<P>4.6% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>66</P>
</TD>
<TD>
<P>65</P>
</TD>
<TD>
<P>44</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karlsson 2002b</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Pain on weight bearing (0-100 mm VAS)</P>
</TD>
<TD>
<P>88</P>
</TD>
<TD>
<P>63</P>
</TD>
<TD>
<P>41</P>
</TD>
<TD>
<P>-3.0 (I)</P>
</TD>
<TD>
<P>-4.6% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>66</P>
</TD>
<TD>
<P>65</P>
</TD>
<TD>
<P>46</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karlsson 2002b</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Pain on weight bearing (0-100 mm VAS)</P>
</TD>
<TD>
<P>88</P>
</TD>
<TD>
<P>63</P>
</TD>
<TD>
<P>43</P>
</TD>
<TD>
<P>1.0 (W)</P>
</TD>
<TD>
<P>1.5% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>66</P>
</TD>
<TD>
<P>65</P>
</TD>
<TD>
<P>44</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karlsson 2002b</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>WOMAC (0-100 mm VAS)</P>
</TD>
<TD>
<P>88</P>
</TD>
<TD>
<P>48.7</P>
</TD>
<TD>
<P>31.7</P>
</TD>
<TD>
<P>1.2 (W)</P>
</TD>
<TD>
<P>2.5% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>66</P>
</TD>
<TD>
<P>48.9</P>
</TD>
<TD>
<P>30.7</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karlsson 2002b</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>WOMAC (0-100 mm VAS)</P>
</TD>
<TD>
<P>88</P>
</TD>
<TD>
<P>48.7</P>
</TD>
<TD>
<P>31.9</P>
</TD>
<TD>
<P>-1.0 (I)</P>
</TD>
<TD>
<P>-2.0% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>66</P>
</TD>
<TD>
<P>48.9</P>
</TD>
<TD>
<P>33.1</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karlsson 2002b</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Lequesne Index (0-24)</P>
</TD>
<TD>
<P>88</P>
</TD>
<TD>
<P>13.4</P>
</TD>
<TD>
<P>9.0</P>
</TD>
<TD>
<P>0.3 (W)</P>
</TD>
<TD>
<P>2.2% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>66</P>
</TD>
<TD>
<P>13.6</P>
</TD>
<TD>
<P>8.9</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Scale 1994a</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Pain on weight bearing (0-100 mm VAS)</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>61</P>
</TD>
<TD>
<P>18</P>
</TD>
<TD>
<P>-33 (I)</P>
</TD>
<TD>
<P>-49.3 (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>21</P>
</TD>
<TD>
<P>67</P>
</TD>
<TD>
<P>57</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Scale 1994a</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Pain at night (0-100 mm VAS)</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>29</P>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>-25 (I)</P>
</TD>
<TD>
<P>-96.2 (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>21</P>
</TD>
<TD>
<P>26</P>
</TD>
<TD>
<P>32</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Scale 1994b</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Pain on weight bearing (0-100 mm VAS)</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>65</P>
</TD>
<TD>
<P>22</P>
</TD>
<TD>
<P>-18 (I)</P>
</TD>
<TD>
<P>-25.7 (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>70</P>
</TD>
<TD>
<P>45</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Scale 1994b</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Pain at night (0-100 mm VAS)</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>-10 (I)</P>
</TD>
<TD>
<P>-30.3 (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>33</P>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Wobig 1998</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Pain on weight bearing (0-100 mm VAS)</P>
</TD>
<TD>
<P>56</P>
</TD>
<TD>
<P>70</P>
</TD>
<TD>
<P>35</P>
</TD>
<TD>
<P>-16 (I)</P>
</TD>
<TD>
<P>-21.3 (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>75</P>
</TD>
<TD>
<P>56</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Wobig 1998</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Pain at night (0-100 mm VAS)</P>
</TD>
<TD>
<P>56</P>
</TD>
<TD>
<P>41</P>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>-13 (I)</P>
</TD>
<TD>
<P>-28.3% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>46</P>
</TD>
<TD>
<P>34</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Scale 1994a</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Weight bearing pain (0-100 mm VAS)</P>
</TD>
<TD>
<P>25</P>
</TD>
<TD>
<P>61</P>
</TD>
<TD>
<P>32</P>
</TD>
<TD>
<P>-9 (I)</P>
</TD>
<TD>
<P>-13.4% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>25</P>
</TD>
<TD>
<P>67</P>
</TD>
<TD>
<P>47</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Scale 1994a</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Pain at night (0-100 mm VAS)</P>
</TD>
<TD>
<P>25</P>
</TD>
<TD>
<P>29</P>
</TD>
<TD>
<P>18</P>
</TD>
<TD>
<P>-8 (I)</P>
</TD>
<TD>
<P>-30.8% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>25</P>
</TD>
<TD>
<P>26</P>
</TD>
<TD>
<P>23</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Scale 1994b</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Weight bearing pain (0-100 mm VAS)</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>65</P>
</TD>
<TD>
<P>22</P>
</TD>
<TD>
<P>-17 (I)</P>
</TD>
<TD>
<P>-24.3% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>70</P>
</TD>
<TD>
<P>44</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Scale 1994b</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Pain at night (0-100 mm VAS)</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>7</P>
</TD>
<TD>
<P>-7 (I)</P>
</TD>
<TD>
<P>-21.2% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>33</P>
</TD>
<TD>
<P>17</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Wobig 1998</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Weight bearing pain (0-100 mm VAS)</P>
</TD>
<TD>
<P>57</P>
</TD>
<TD>
<P>70</P>
</TD>
<TD>
<P>31</P>
</TD>
<TD>
<P>-17 (I)</P>
</TD>
<TD>
<P>-22.7% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>75</P>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Wobig 1998</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Pain at night (0-100 mm VAS)</P>
</TD>
<TD>
<P>57</P>
</TD>
<TD>
<P>41</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>-6 (I)</P>
</TD>
<TD>
<P>-13.0% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>46</P>
</TD>
<TD>
<P>26</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Wobig 1999</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Weight bearing pain (0-100 mm VAS)</P>
</TD>
<TD>
<P>38</P>
</TD>
<TD>
<P>70</P>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>-3 (I)</P>
</TD>
<TD>
<P>-3.8% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>36</P>
</TD>
<TD>
<P>80</P>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Wobig 1998</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Pain at night (0-100 mm VAS)</P>
</TD>
<TD>
<P>38</P>
</TD>
<TD>
<P>26</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>1 (W)</P>
</TD>
<TD>
<P>3.7% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>36</P>
</TD>
<TD>
<P>27</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Cubukcu 2004</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Pain at night (0-100 mm VAS)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>45</P>
</TD>
<TD>
<P>27</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>54</P>
</TD>
<TD>
<P>37</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Cubukcu 2004</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Pain at night (0-100 mm VAS)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>45</P>
</TD>
<TD>
<P>23</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>54</P>
</TD>
<TD>
<P>44</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Cubukcu 2004</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Pain at rest (0-100 mm VAS)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>47</P>
</TD>
<TD>
<P>29</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>51</P>
</TD>
<TD>
<P>39</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Cubukcu 2004</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Pain at rest (0-100 mm VAS)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>47</P>
</TD>
<TD>
<P>22</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>51</P>
</TD>
<TD>
<P>41</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Cubukcu 2004</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Pain walking (0-100 mm VAS)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>71</P>
</TD>
<TD>
<P>47</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>67</P>
</TD>
<TD>
<P>51</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Cubukcu 2004</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Pain walking (0-100 mm VAS)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>71</P>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>67</P>
</TD>
<TD>
<P>54</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Cubukcu 2004</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Need for paracetamol (pill count)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>1.0</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>0.9</P>
</TD>
<TD>
<P>0.1</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Cubukcu 2004</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Need for paracetamol (pill count)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>1.0</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>0.9</P>
</TD>
<TD>
<P>0.7</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Cubukcu 2004</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>WOMAC pain (5-25)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>11</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>18</P>
</TD>
<TD>
<P>14</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Cubukcu 2004</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>WOMAC pain (5-25)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>9</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>18</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Cubukcu 2004</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>WOMAC function (17-85)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>50</P>
</TD>
<TD>
<P>41</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>48</P>
</TD>
<TD>
<P>47</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Cubukcu 2004</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>WOMAC function (17-85)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>50</P>
</TD>
<TD>
<P>36</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>48</P>
</TD>
<TD>
<P>47</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-28" NO="28">
<TITLE>Clinical benefit table: Hylan G-F 20. Patient global assessment</TITLE>
<TABLE COLS="9" ROWS="11">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Time</P>
</TH>
<TH>
<P>Treat group</P>
</TH>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>No.improved</P>
</TH>
<TH>
<P>No.of pts.</P>
</TH>
<TH>
<P>Risk (% occurrence)</P>
</TH>
<TH>
<P>Risk Difference</P>
</TH>
<TH>
<P>NNT</P>
</TH>
</TR>
<TR>
<TD>
<P>Dickson 2001</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Number of patients very good/good</P>
</TD>
<TD>
<P>29</P>
</TD>
<TD>
<P>42</P>
</TD>
<TD>
<P>69</P>
</TD>
<TD>
<P>21</P>
</TD>
<TD>
<P>4.8</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Arthrocentesis</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>23</P>
</TD>
<TD>
<P>48</P>
</TD>
<TD>
<P>48</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Dickson 2001</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Number of patients very good/good</P>
</TD>
<TD>
<P>29</P>
</TD>
<TD>
<P>42</P>
</TD>
<TD>
<P>69</P>
</TD>
<TD>
<P>14</P>
</TD>
<TD>
<P>7.1</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C:Diclofenac + arthrocentesis</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>35</P>
</TD>
<TD>
<P>42</P>
</TD>
<TD>
<P>83</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Adams 1995</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Number of patients rating treatment excellent, very good, good</P>
</TD>
<TD>
<P>17</P>
</TD>
<TD>
<P>27</P>
</TD>
<TD>
<P>63</P>
</TD>
<TD>
<P>24</P>
</TD>
<TD>
<P>4.2</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: NSAID + arthrocentesis</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>31</P>
</TD>
<TD>
<P>39</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Adams 1995</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20 + NSAID</P>
</TD>
<TD>
<P>Number of patients rating treatment excellent, very good, good</P>
</TD>
<TD>
<P>17</P>
</TD>
<TD>
<P>27</P>
</TD>
<TD>
<P>63</P>
</TD>
<TD>
<P>7</P>
</TD>
<TD>
<P>14.3</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: NSAID + arthrocentesis</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>18</P>
</TD>
<TD>
<P>32</P>
</TD>
<TD>
<P>56</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Raynauld 2002</P>
</TD>
<TD>
<P>45-52 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20 + Appropriate Care</P>
</TD>
<TD>
<P>Number of patients improved in study knee</P>
</TD>
<TD>
<P>93</P>
</TD>
<TD>
<P>127</P>
</TD>
<TD>
<P>73</P>
</TD>
<TD>
<P>46</P>
</TD>
<TD>
<P>2.2</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Appropriate care</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>35</P>
</TD>
<TD>
<P>128</P>
</TD>
<TD>
<P>27</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-29" NO="29">
<TITLE>Clinical benefit table: Hylan G-F 20 versus triamcinolone hexacetonide. Continuo</TITLE>
<TABLE COLS="9" ROWS="17">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Time</P>
</TH>
<TH>
<P>Treatment group</P>
</TH>
<TH>
<P>Outcome (scale)</P>
</TH>
<TH>
<P>N of Pts</P>
</TH>
<TH>
<P>Baseline Mean</P>
</TH>
<TH>
<P>End of Study</P>
</TH>
<TH>
<P>Absolute Benefit</P>
</TH>
<TH>
<P>Relative Benefit</P>
</TH>
</TR>
<TR>
<TD>
<P>Caborn 2004</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>WOMAC - pain walking on a flat surface (0-4 Likert)</P>
</TD>
<TD>
<P>113</P>
</TD>
<TD>
<P>2.12</P>
</TD>
<TD>
<P>1.20</P>
</TD>
<TD>
<P>-0.37 (I)</P>
</TD>
<TD>
<P>-17.2% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Triamcinolone hexacetonide</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>102</P>
</TD>
<TD>
<P>2.15</P>
</TD>
<TD>
<P>1.60</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Caborn 2004</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>WOMAC - pain walking on a flat surface (0-4 Likert)</P>
</TD>
<TD>
<P>113</P>
</TD>
<TD>
<P>2.12</P>
</TD>
<TD>
<P>1.40</P>
</TD>
<TD>
<P>-0.37 (I)</P>
</TD>
<TD>
<P>-17.2% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Triamcinolone hexacetonide</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>102</P>
</TD>
<TD>
<P>2.15</P>
</TD>
<TD>
<P>1.80</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Caborn 2004</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>WOMAC physical function (0-68 Likert)</P>
</TD>
<TD>
<P>113</P>
</TD>
<TD>
<P>38.60</P>
</TD>
<TD>
<P>23.50</P>
</TD>
<TD>
<P>-5.70 (I)</P>
</TD>
<TD>
<P>-15.0% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Triamcinolone hexacetonide</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>102</P>
</TD>
<TD>
<P>37.90</P>
</TD>
<TD>
<P>28.50</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Caborn 2004</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>WOMAC physical function (0-68 Likert)</P>
</TD>
<TD>
<P>113</P>
</TD>
<TD>
<P>38.60</P>
</TD>
<TD>
<P>25.50</P>
</TD>
<TD>
<P>-7.20 (I)</P>
</TD>
<TD>
<P>-19.0% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Triamcinolone hexacetonide</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>102</P>
</TD>
<TD>
<P>37.90</P>
</TD>
<TD>
<P>30.70</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Caborn 2004</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>WOMAC total score (0-96 Likert)</P>
</TD>
<TD>
<P>113</P>
</TD>
<TD>
<P>54.00</P>
</TD>
<TD>
<P>32.70</P>
</TD>
<TD>
<P>-8.30 (I)</P>
</TD>
<TD>
<P>-15.6% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Triamcinolone hexacetonide</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>102</P>
</TD>
<TD>
<P>53.10</P>
</TD>
<TD>
<P>40.10</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Caborn 2004</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>WOMAC total score (0-96)</P>
</TD>
<TD>
<P>113</P>
</TD>
<TD>
<P>54.00</P>
</TD>
<TD>
<P>35.60</P>
</TD>
<TD>
<P>-8.20 (I)</P>
</TD>
<TD>
<P>-15.4% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Triamcinolone hexacetonide</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>102</P>
</TD>
<TD>
<P>53.10</P>
</TD>
<TD>
<P>42.90</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Caborn 2004</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Patient global assessment (0-100 mm VAS)</P>
</TD>
<TD>
<P>113</P>
</TD>
<TD>
<P>68.40</P>
</TD>
<TD>
<P>36.70</P>
</TD>
<TD>
<P>-14.50 (I)</P>
</TD>
<TD>
<P>-21.5% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Triamcinolone hexacetonide</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>102</P>
</TD>
<TD>
<P>67.30</P>
</TD>
<TD>
<P>50.10</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Caborn 2004</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Patient global assessment (0-100 mm VAS)</P>
</TD>
<TD>
<P>113</P>
</TD>
<TD>
<P>68.40</P>
</TD>
<TD>
<P>40.30</P>
</TD>
<TD>
<P>-16.20 (I)</P>
</TD>
<TD>
<P>-24.1% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Triamcinolone hexacetonide</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>102</P>
</TD>
<TD>
<P>67.30</P>
</TD>
<TD>
<P>55.40</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-30" NO="30">
<TITLE>Clinical benefit table: Hylan G-F 20 versus NSAID. Continuous outcome measures</TITLE>
<TABLE COLS="9" ROWS="31">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>TIme</P>
</TH>
<TH>
<P>Treatment</P>
</TH>
<TH>
<P>Outcome (scale)</P>
</TH>
<TH>
<P>N of pts</P>
</TH>
<TH>
<P>Baseline Mean</P>
</TH>
<TH>
<P>End of Study Mean</P>
</TH>
<TH>
<P>Absolute Benefit</P>
</TH>
<TH>
<P>Relative Difference</P>
</TH>
</TR>
<TR>
<TD>
<P>Adams 1995</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Pain on motion (0-100 mm VAS)</P>
</TD>
<TD>
<P>29</P>
</TD>
<TD>
<P>61</P>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>-10 (I)</P>
</TD>
<TD>
<P>-15.9% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: NSAID</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>33</P>
</TD>
<TD>
<P>63</P>
</TD>
<TD>
<P>52</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Adams 1995</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Pain at night (0-100 mm VAS)</P>
</TD>
<TD>
<P>29</P>
</TD>
<TD>
<P>35</P>
</TD>
<TD>
<P>25</P>
</TD>
<TD>
<P>-4 (I)</P>
</TD>
<TD>
<P>-11.7% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: NSAID</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>33</P>
</TD>
<TD>
<P>34</P>
</TD>
<TD>
<P>28</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Adams 1995</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Pain at rest (0-100 mm VAS)</P>
</TD>
<TD>
<P>29</P>
</TD>
<TD>
<P>36</P>
</TD>
<TD>
<P>25</P>
</TD>
<TD>
<P>-4 (I)</P>
</TD>
<TD>
<P>-13.8% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: NSAID</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>33</P>
</TD>
<TD>
<P>29</P>
</TD>
<TD>
<P>22</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Adams 1995</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Pain overall (0-100 mm VAS)</P>
</TD>
<TD>
<P>29</P>
</TD>
<TD>
<P>62</P>
</TD>
<TD>
<P>47</P>
</TD>
<TD>
<P>-5 (I)</P>
</TD>
<TD>
<P>-8.1% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: NSAID</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>33</P>
</TD>
<TD>
<P>62</P>
</TD>
<TD>
<P>52</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Dickson 2001</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>WOMAC pain (0-100 mm VAS)</P>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>59</P>
</TD>
<TD>
<P>26</P>
</TD>
<TD>
<P>-10 (I)</P>
</TD>
<TD>
<P>-16.4% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Diclofenac</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>55</P>
</TD>
<TD>
<P>61</P>
</TD>
<TD>
<P>38</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Dickson 2001</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>WOMAC function (0-100 mm VAS)</P>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>54</P>
</TD>
<TD>
<P>38</P>
</TD>
<TD>
<P>-2 (I)</P>
</TD>
<TD>
<P>-3.6% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Diclofenac</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>55</P>
</TD>
<TD>
<P>56</P>
</TD>
<TD>
<P>42</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Dickson 2001</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Lequesne Index (0-24)</P>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>13.9</P>
</TD>
<TD>
<P>10.9</P>
</TD>
<TD>
<P>-1 (I)</P>
</TD>
<TD>
<P>-7.2% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Diclofenac</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>55</P>
</TD>
<TD>
<P>13.9</P>
</TD>
<TD>
<P>11.9</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Adams 1995</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20 + NSAID</P>
</TD>
<TD>
<P>Pain on motion (0-100 mm VAS)</P>
</TD>
<TD>
<P>34</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>34</P>
</TD>
<TD>
<P>-7 (I)</P>
</TD>
<TD>
<P>-11.1% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: NSAID</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>33</P>
</TD>
<TD>
<P>63</P>
</TD>
<TD>
<P>44</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Adams 1995</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hylan GF 20 + NSAID</P>
</TD>
<TD>
<P>Pain at night (0-100 mm VAS)</P>
</TD>
<TD>
<P>34</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>3 (W)</P>
</TD>
<TD>
<P>8.8% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: NSAID</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>33</P>
</TD>
<TD>
<P>34</P>
</TD>
<TD>
<P>21</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Adams 1995</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20 + NSAID</P>
</TD>
<TD>
<P>Pain at rest (0-100 mm VAS)</P>
</TD>
<TD>
<P>34</P>
</TD>
<TD>
<P>26</P>
</TD>
<TD>
<P>14</P>
</TD>
<TD>
<P>-3 (I)</P>
</TD>
<TD>
<P>-10.3% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: NSAID</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>33</P>
</TD>
<TD>
<P>29</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Adams 1995</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20 + NSAID</P>
</TD>
<TD>
<P>Pain overall (0-100 mm VAS)</P>
</TD>
<TD>
<P>34</P>
</TD>
<TD>
<P>57</P>
</TD>
<TD>
<P>31</P>
</TD>
<TD>
<P>-7 (I)</P>
</TD>
<TD>
<P>-11.3% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: NSAID</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>33</P>
</TD>
<TD>
<P>62</P>
</TD>
<TD>
<P>43</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Adams 1995</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20 + NSAID</P>
</TD>
<TD>
<P>Pain on motion (0-100 mm VAS)</P>
</TD>
<TD>
<P>32</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>37</P>
</TD>
<TD>
<P>-12 (I)</P>
</TD>
<TD>
<P>-19% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: NSAID</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>31</P>
</TD>
<TD>
<P>63</P>
</TD>
<TD>
<P>52</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Adams 1995</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20 + NSAID</P>
</TD>
<TD>
<P>Pain at night (0-100 mm VAS)</P>
</TD>
<TD>
<P>32</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>9</P>
</TD>
<TD>
<P>-5 (I)</P>
</TD>
<TD>
<P>-14.7% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: NSAID</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>31</P>
</TD>
<TD>
<P>34</P>
</TD>
<TD>
<P>28</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Adams 1995</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20 + NSAID</P>
</TD>
<TD>
<P>Pain at rest (0-100 mm VAS)</P>
</TD>
<TD>
<P>32</P>
</TD>
<TD>
<P>26</P>
</TD>
<TD>
<P>11</P>
</TD>
<TD>
<P>-8 (I)</P>
</TD>
<TD>
<P>-27.6% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: NSAID</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>31</P>
</TD>
<TD>
<P>29</P>
</TD>
<TD>
<P>22</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Adams 1995</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20 + NSAID</P>
</TD>
<TD>
<P>Pain overall (0-100 mm VAS)</P>
</TD>
<TD>
<P>32</P>
</TD>
<TD>
<P>57</P>
</TD>
<TD>
<P>37</P>
</TD>
<TD>
<P>-10 (I)</P>
</TD>
<TD>
<P>-16.1% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: NSAID</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>31</P>
</TD>
<TD>
<P>62</P>
</TD>
<TD>
<P>52</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-31" NO="31">
<TITLE>Clinical benefit table: Hylan G-F 20 versus appropriate care. Continuous outcome</TITLE>
<TABLE COLS="9" ROWS="21">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>TIme</P>
</TH>
<TH>
<P>Treatment</P>
</TH>
<TH>
<P>Outcome (scale)</P>
</TH>
<TH>
<P>N of Pts</P>
</TH>
<TH>
<P>Baseline Mean</P>
</TH>
<TH>
<P>End of Study Mean</P>
</TH>
<TH>
<P>Absolute Benefit</P>
</TH>
<TH>
<P>Relative Difference</P>
</TH>
</TR>
<TR>
<TD>
<P>Raynauld 2002</P>
</TD>
<TD>
<P>45-52 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20 + appropriate care</P>
</TD>
<TD>
<P>WOMAC pain (0-20 Likert)</P>
</TD>
<TD>
<P>127</P>
</TD>
<TD>
<P>11.35</P>
</TD>
<TD>
<P>6.94</P>
</TD>
<TD>
<P>-2.57 (I)</P>
</TD>
<TD>
<P>-21.5% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Appropriate care</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>127</P>
</TD>
<TD>
<P>11.94</P>
</TD>
<TD>
<P>10.10</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Raynauld 2002</P>
</TD>
<TD>
<P>45-52 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20 + appropriate care</P>
</TD>
<TD>
<P>WOMAC function (0-68 Likert)</P>
</TD>
<TD>
<P>127</P>
</TD>
<TD>
<P>39.54</P>
</TD>
<TD>
<P>24.26</P>
</TD>
<TD>
<P>-8.95 (I)</P>
</TD>
<TD>
<P>-22.3% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Appropriate care</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>127</P>
</TD>
<TD>
<P>40.20</P>
</TD>
<TD>
<P>33.87</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Raynauld 2002</P>
</TD>
<TD>
<P>45-52 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20 + appropriate care</P>
</TD>
<TD>
<P>SF-36 Function</P>
</TD>
<TD>
<P>127</P>
</TD>
<TD>
<P>28.33</P>
</TD>
<TD>
<P>33.24</P>
</TD>
<TD>
<P>5.31 (I)</P>
</TD>
<TD>
<P>18.8% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Appropriate care</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>126</P>
</TD>
<TD>
<P>28.18</P>
</TD>
<TD>
<P>27.78</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Raynauld 2002</P>
</TD>
<TD>
<P>45-52 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20 + appropriate care</P>
</TD>
<TD>
<P>SF-36 Mental</P>
</TD>
<TD>
<P>127</P>
</TD>
<TD>
<P>51.74</P>
</TD>
<TD>
<P>55.29</P>
</TD>
<TD>
<P>0.81 (I)</P>
</TD>
<TD>
<P>1.6% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Appropriate care</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>126</P>
</TD>
<TD>
<P>49.91</P>
</TD>
<TD>
<P>52.65</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Kahan 2003a</P>
</TD>
<TD>
<P>36 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20 + appropriate care</P>
</TD>
<TD>
<P>WOMAC pain (0-100 mm VAS)</P>
</TD>
<TD>
<P>251</P>
</TD>
<TD>
<P>50.00</P>
</TD>
<TD>
<P>25.40</P>
</TD>
<TD>
<P>-12.4 (I)</P>
</TD>
<TD>
<P>-24.7% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Appropriate care</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>246</P>
</TD>
<TD>
<P>50.30</P>
</TD>
<TD>
<P>38.10</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Kahan 2003a</P>
</TD>
<TD>
<P>36 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20 + appropriate care</P>
</TD>
<TD>
<P>Pain on walking (0-100 mm VAS)</P>
</TD>
<TD>
<P>253</P>
</TD>
<TD>
<P>61.10</P>
</TD>
<TD>
<P>23.80</P>
</TD>
<TD>
<P>-12.9 (I)</P>
</TD>
<TD>
<P>-21.4% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Appropriate care</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>253</P>
</TD>
<TD>
<P>60.30</P>
</TD>
<TD>
<P>35.90</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Kahan 2003a</P>
</TD>
<TD>
<P>36 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20 + appropriate care</P>
</TD>
<TD>
<P>WOMAC function (0-100 mm VAS)</P>
</TD>
<TD>
<P>251</P>
</TD>
<TD>
<P>45.50</P>
</TD>
<TD>
<P>27.10</P>
</TD>
<TD>
<P>-11.3 (I)</P>
</TD>
<TD>
<P>-23.8% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Appropriate care</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>247</P>
</TD>
<TD>
<P>47.40</P>
</TD>
<TD>
<P>40.30</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Kahan 2003a</P>
</TD>
<TD>
<P>36 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20 + appropriate care</P>
</TD>
<TD>
<P>WOMAC stiffness (0-100 mm VAS)</P>
</TD>
<TD>
<P>252</P>
</TD>
<TD>
<P>45.00</P>
</TD>
<TD>
<P>24.40</P>
</TD>
<TD>
<P>-12.9 (I)</P>
</TD>
<TD>
<P>-28.7% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Appropriate care</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>246</P>
</TD>
<TD>
<P>44.90</P>
</TD>
<TD>
<P>37.20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Kahan 2003a</P>
</TD>
<TD>
<P>36 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20 + appropriate care</P>
</TD>
<TD>
<P>WOMAC total (0-100 mm VAS)</P>
</TD>
<TD>
<P>250</P>
</TD>
<TD>
<P>46.30</P>
</TD>
<TD>
<P>26.50</P>
</TD>
<TD>
<P>-11.6 (I)</P>
</TD>
<TD>
<P>-24.2% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Appropriate care</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>245</P>
</TD>
<TD>
<P>47.90</P>
</TD>
<TD>
<P>39.70</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Kahan 2003a</P>
</TD>
<TD>
<P>36 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20 + appropriate care</P>
</TD>
<TD>
<P>Lequesne Index (0-24)</P>
</TD>
<TD>
<P>253</P>
</TD>
<TD>
<P>11.10</P>
</TD>
<TD>
<P>7.50</P>
</TD>
<TD>
<P>-2 (I)</P>
</TD>
<TD>
<P>-17.7% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Appropriate care</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>253</P>
</TD>
<TD>
<P>11.30</P>
</TD>
<TD>
<P>9.70</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-32" NO="32">
<TITLE>Clinical benefit table: Hylan G-F 20 versus appropriate care. Dichotomous outcom</TITLE>
<TABLE COLS="9" ROWS="7">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Time</P>
</TH>
<TH>
<P>Treatment</P>
</TH>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>No. improved</P>
</TH>
<TH>
<P>No. of pts.</P>
</TH>
<TH>
<P>Risk (%)</P>
</TH>
<TH>
<P>Risk difference</P>
</TH>
<TH>
<P>NNT</P>
</TH>
</TR>
<TR>
<TD>
<P>Raynauld 2002</P>
</TD>
<TD>
<P>45-52 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20 + appropriate care</P>
</TD>
<TD>
<P>Patient global (Number of patients improved in study knee)</P>
</TD>
<TD>
<P>93</P>
</TD>
<TD>
<P>127</P>
</TD>
<TD>
<P>73</P>
</TD>
<TD>
<P>46</P>
</TD>
<TD>
<P>2</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Appropriate care</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>35</P>
</TD>
<TD>
<P>128</P>
</TD>
<TD>
<P>27</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Kahan 2003a</P>
</TD>
<TD>
<P>36 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20 + appropriate care</P>
</TD>
<TD>
<P>Patient global (Number of patients rating effectiveness good or satisfactory)</P>
</TD>
<TD>
<P>186</P>
</TD>
<TD>
<P>253</P>
</TD>
<TD>
<P>74</P>
</TD>
<TD>
<P>23</P>
</TD>
<TD>
<P>4.3</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Appropriate care</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>129</P>
</TD>
<TD>
<P>253</P>
</TD>
<TD>
<P>51</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Kahan 2003a</P>
</TD>
<TD>
<P>36 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20 + appropriate care</P>
</TD>
<TD>
<P>Number of responders (20% decrease in pain on walking)</P>
</TD>
<TD>
<P>223</P>
</TD>
<TD>
<P>253</P>
</TD>
<TD>
<P>88</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>5</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Appropriate care</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>172</P>
</TD>
<TD>
<P>253</P>
</TD>
<TD>
<P>68</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-33" NO="33">
<TITLE>Clinical benefit table. Hylan G-F 20. Continuous outcome measures</TITLE>
<TABLE COLS="9" ROWS="79">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>TIme</P>
</TH>
<TH>
<P>Treatment</P>
</TH>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>N of Pts</P>
</TH>
<TH>
<P>Baseline Mean</P>
</TH>
<TH>
<P>End of Study Mean</P>
</TH>
<TH>
<P>Absolute Benefit</P>
</TH>
<TH>
<P>Relative Difference</P>
</TH>
</TR>
<TR>
<TD>
<P>Cubukcu 2004</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>WOMAC stiffness (2-10)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>6</P>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>-1 (I)</P>
</TD>
<TD>
<P>-16.7% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>6</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Cubukcu 2004</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>WOMAC stiffness (2-10)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>6</P>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>-1 (I)</P>
</TD>
<TD>
<P>-16.7% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>6</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Cubukcu 2004</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>15 m walking time</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>21</P>
</TD>
<TD>
<P>17</P>
</TD>
<TD>
<P>-3 (I)</P>
</TD>
<TD>
<P>-16.72% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>18</P>
</TD>
<TD>
<P>17</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Cubukcu 2004</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>15 m walking time</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>21</P>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>-4 (I)</P>
</TD>
<TD>
<P>-22.2% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>18</P>
</TD>
<TD>
<P>17</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karatosun 2005</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Pain during activity</P>
</TD>
<TD>
<P>52</P>
</TD>
<TD>
<P>4.0</P>
</TD>
<TD>
<P>10.8</P>
</TD>
<TD>
<P>2.4 (I)</P>
</TD>
<TD>
<P>53.3% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Exercise</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>4.5</P>
</TD>
<TD>
<P>8.9</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karatosun 2005</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Pain during activity</P>
</TD>
<TD>
<P>52</P>
</TD>
<TD>
<P>4.0</P>
</TD>
<TD>
<P>10.8</P>
</TD>
<TD>
<P>2.2 (I)</P>
</TD>
<TD>
<P>48.9% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Exercise</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>4.5</P>
</TD>
<TD>
<P>9.1</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karatosun 2005</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Pain during activity</P>
</TD>
<TD>
<P>52</P>
</TD>
<TD>
<P>4.0</P>
</TD>
<TD>
<P>11.1</P>
</TD>
<TD>
<P>3.0 (I)</P>
</TD>
<TD>
<P>66.7% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Exercise</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>4.5</P>
</TD>
<TD>
<P>8.6</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karatosun 2005</P>
</TD>
<TD>
<P>45-52 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Pain during activity</P>
</TD>
<TD>
<P>46</P>
</TD>
<TD>
<P>4.0</P>
</TD>
<TD>
<P>8.5</P>
</TD>
<TD>
<P>-1.2 (W)</P>
</TD>
<TD>
<P>-26.7% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Exercise</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>4.5</P>
</TD>
<TD>
<P>10.2</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karatosun 2005</P>
</TD>
<TD>
<P>74 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Pain during activity</P>
</TD>
<TD>
<P>31</P>
</TD>
<TD>
<P>4.0</P>
</TD>
<TD>
<P>12.9</P>
</TD>
<TD>
<P>1.3 (I)</P>
</TD>
<TD>
<P>28.9% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Exercise</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>4.5</P>
</TD>
<TD>
<P>12.1</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karatosun 2005</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Pain at rest</P>
</TD>
<TD>
<P>52</P>
</TD>
<TD>
<P>7.8</P>
</TD>
<TD>
<P>13.1</P>
</TD>
<TD>
<P>2.1 (I)</P>
</TD>
<TD>
<P>23.1% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Exercise</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>9.1</P>
</TD>
<TD>
<P>12.2</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karatosun 2005</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Pain at rest</P>
</TD>
<TD>
<P>52</P>
</TD>
<TD>
<P>7.8</P>
</TD>
<TD>
<P>12.7</P>
</TD>
<TD>
<P>1.3 (I)</P>
</TD>
<TD>
<P>14.3% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Exercise</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>9.1</P>
</TD>
<TD>
<P>12.7</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karatosun 2005</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Pain at rest</P>
</TD>
<TD>
<P>52</P>
</TD>
<TD>
<P>7.8</P>
</TD>
<TD>
<P>12.8</P>
</TD>
<TD>
<P>1.7 (I)</P>
</TD>
<TD>
<P>18.7% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Exercise</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>9.1</P>
</TD>
<TD>
<P>12.4</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karatosun 2005</P>
</TD>
<TD>
<P>45-52 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Pain at rest</P>
</TD>
<TD>
<P>46</P>
</TD>
<TD>
<P>7.8</P>
</TD>
<TD>
<P>11.7</P>
</TD>
<TD>
<P>0.1 (I)</P>
</TD>
<TD>
<P>1.1% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Exercise</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>9.1</P>
</TD>
<TD>
<P>12.9</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karatosun 2005</P>
</TD>
<TD>
<P>74 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Pain at rest</P>
</TD>
<TD>
<P>31</P>
</TD>
<TD>
<P>7.8</P>
</TD>
<TD>
<P>13.7</P>
</TD>
<TD>
<P>1.8 (I)</P>
</TD>
<TD>
<P>19.8% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Exercise</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>9.1</P>
</TD>
<TD>
<P>13.2</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karatosun 2005</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Pain during climbing stairs</P>
</TD>
<TD>
<P>52</P>
</TD>
<TD>
<P>2.5</P>
</TD>
<TD>
<P>3.2</P>
</TD>
<TD>
<P>0.2 (I)</P>
</TD>
<TD>
<P>8% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Exercise</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>2.5</P>
</TD>
<TD>
<P>3.0</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karatosun 2005</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Pain during climbing stairs</P>
</TD>
<TD>
<P>52</P>
</TD>
<TD>
<P>2.5</P>
</TD>
<TD>
<P>3.3</P>
</TD>
<TD>
<P>0.1 (I)</P>
</TD>
<TD>
<P>4% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Exercise</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>2.5</P>
</TD>
<TD>
<P>3.2</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karatosun 2005</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Pain during climbing stairs</P>
</TD>
<TD>
<P>52</P>
</TD>
<TD>
<P>2.5</P>
</TD>
<TD>
<P>3.2</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0%</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Exercise</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>2.5</P>
</TD>
<TD>
<P>3.2</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karatosun 2005</P>
</TD>
<TD>
<P>45-52 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Pain during climbing stairs</P>
</TD>
<TD>
<P>46</P>
</TD>
<TD>
<P>2.5</P>
</TD>
<TD>
<P>3.1</P>
</TD>
<TD>
<P>-0.1 (W)</P>
</TD>
<TD>
<P>-4% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Exercise</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>2.5</P>
</TD>
<TD>
<P>3.2</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karatosun 2005</P>
</TD>
<TD>
<P>74 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Pain during climbing stairs</P>
</TD>
<TD>
<P>31</P>
</TD>
<TD>
<P>2.5</P>
</TD>
<TD>
<P>3.9</P>
</TD>
<TD>
<P>0.2 (I)</P>
</TD>
<TD>
<P>8% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Exercise</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>2.5</P>
</TD>
<TD>
<P>3.7</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karatosun 2005</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Pain during transfer activity</P>
</TD>
<TD>
<P>52</P>
</TD>
<TD>
<P>2.9</P>
</TD>
<TD>
<P>4.0</P>
</TD>
<TD>
<P>-0.1 (W)</P>
</TD>
<TD>
<P>-3.2% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Exercise</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>3.1</P>
</TD>
<TD>
<P>4.3</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karatosun 2005</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Pain during transfer activity</P>
</TD>
<TD>
<P>52</P>
</TD>
<TD>
<P>2.9</P>
</TD>
<TD>
<P>4.2</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0%</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Exercise</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>3.1</P>
</TD>
<TD>
<P>4.4</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karatosun 2005</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Pain during transfer activity</P>
</TD>
<TD>
<P>52</P>
</TD>
<TD>
<P>2.9</P>
</TD>
<TD>
<P>4.3</P>
</TD>
<TD>
<P>0.2 (I)</P>
</TD>
<TD>
<P>6.5% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Exercise</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>3.1</P>
</TD>
<TD>
<P>4.3</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karatosun 2005</P>
</TD>
<TD>
<P>45-52 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Pain during transfer activity</P>
</TD>
<TD>
<P>46</P>
</TD>
<TD>
<P>2.9</P>
</TD>
<TD>
<P>4.1</P>
</TD>
<TD>
<P>-0.3 (W)</P>
</TD>
<TD>
<P>-9.7% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Exercise</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>3.1</P>
</TD>
<TD>
<P>4.6</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karatosun 2005</P>
</TD>
<TD>
<P>74 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Pain during transfer activity</P>
</TD>
<TD>
<P>31</P>
</TD>
<TD>
<P>2.9</P>
</TD>
<TD>
<P>4.1</P>
</TD>
<TD>
<P>0.1 (I)</P>
</TD>
<TD>
<P>3.2% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Exercise</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>3.1</P>
</TD>
<TD>
<P>4.2</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karatosun 2005</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Walkiing distance</P>
</TD>
<TD>
<P>52</P>
</TD>
<TD>
<P>8.1</P>
</TD>
<TD>
<P>10.2</P>
</TD>
<TD>
<P>0.7 (I)</P>
</TD>
<TD>
<P>8.9% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Exercise</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>7.9</P>
</TD>
<TD>
<P>9.3</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karatosun 2005</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Walking distance</P>
</TD>
<TD>
<P>52</P>
</TD>
<TD>
<P>8.1</P>
</TD>
<TD>
<P>10.5</P>
</TD>
<TD>
<P>0.2 (I)</P>
</TD>
<TD>
<P>2.5% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Exercise</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>7.9</P>
</TD>
<TD>
<P>10.1</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karatosun 2005</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Walking distance</P>
</TD>
<TD>
<P>52</P>
</TD>
<TD>
<P>8.1</P>
</TD>
<TD>
<P>10.4</P>
</TD>
<TD>
<P>0.5 (I)</P>
</TD>
<TD>
<P>6.3% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Exercise</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>7.9</P>
</TD>
<TD>
<P>9.7</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karatosun 2005</P>
</TD>
<TD>
<P>45-52 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Walking distance</P>
</TD>
<TD>
<P>46</P>
</TD>
<TD>
<P>8.1</P>
</TD>
<TD>
<P>9.6</P>
</TD>
<TD>
<P>-0.5 (W)</P>
</TD>
<TD>
<P>-6.3% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Exercise</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>7.9</P>
</TD>
<TD>
<P>9.9</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karatosun 2005</P>
</TD>
<TD>
<P>74 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Walking distance</P>
</TD>
<TD>
<P>31</P>
</TD>
<TD>
<P>8.1</P>
</TD>
<TD>
<P>10.4</P>
</TD>
<TD>
<P>-0.1 (W)</P>
</TD>
<TD>
<P>-1.3% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Exercise</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>7.9</P>
</TD>
<TD>
<P>10.3</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karatosun 2005</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Range of motion</P>
</TD>
<TD>
<P>52</P>
</TD>
<TD>
<P>113.2</P>
</TD>
<TD>
<P>116.3</P>
</TD>
<TD>
<P>0.4 (I)</P>
</TD>
<TD>
<P>0.3% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Exercise</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>114.4</P>
</TD>
<TD>
<P>117.1</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karatosun 2005</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Range of motion</P>
</TD>
<TD>
<P>52</P>
</TD>
<TD>
<P>113.2</P>
</TD>
<TD>
<P>117.1</P>
</TD>
<TD>
<P>0.4 (I)</P>
</TD>
<TD>
<P>0.3% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Exercise</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>114.4</P>
</TD>
<TD>
<P>117.9</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karatosun 2005</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Range of motion</P>
</TD>
<TD>
<P>52</P>
</TD>
<TD>
<P>113.2</P>
</TD>
<TD>
<P>117.8</P>
</TD>
<TD>
<P>1.2 (I)</P>
</TD>
<TD>
<P>1.0% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Exercise</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>114.4</P>
</TD>
<TD>
<P>117.8</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karatosun 2005</P>
</TD>
<TD>
<P>45-52 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Range of motion</P>
</TD>
<TD>
<P>46</P>
</TD>
<TD>
<P>113.2</P>
</TD>
<TD>
<P>117.2</P>
</TD>
<TD>
<P>0.6 (I)</P>
</TD>
<TD>
<P>0.5% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Exercise</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>114.4</P>
</TD>
<TD>
<P>117.8</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karatosun 2005</P>
</TD>
<TD>
<P>74 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Range of motion</P>
</TD>
<TD>
<P>31</P>
</TD>
<TD>
<P>113.2</P>
</TD>
<TD>
<P>118.6</P>
</TD>
<TD>
<P>1.9 (I)</P>
</TD>
<TD>
<P>1.7% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Exercise</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>114.4</P>
</TD>
<TD>
<P>117.9</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karatosun 2005</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Total Hospital for Special Surgery Knee Score</P>
</TD>
<TD>
<P>52</P>
</TD>
<TD>
<P>62.6</P>
</TD>
<TD>
<P>81.3</P>
</TD>
<TD>
<P>4.3 (I)</P>
</TD>
<TD>
<P>6.6% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Exercise</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>65.4</P>
</TD>
<TD>
<P>79.8</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karatosun 2005</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Total Hospital for Special Surgery Knee Score</P>
</TD>
<TD>
<P>52</P>
</TD>
<TD>
<P>62.6</P>
</TD>
<TD>
<P>82.2</P>
</TD>
<TD>
<P>3.48 (I)</P>
</TD>
<TD>
<P>5.3% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Exercise</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>65.4</P>
</TD>
<TD>
<P>81.52</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karatosun 2005</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Total Hospital for Special Surgery Knee Score</P>
</TD>
<TD>
<P>52</P>
</TD>
<TD>
<P>62.6</P>
</TD>
<TD>
<P>82.7</P>
</TD>
<TD>
<P>5.5 (I)</P>
</TD>
<TD>
<P>8.4% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Exercise</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>65.4</P>
</TD>
<TD>
<P>80.0</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karatosun 2005</P>
</TD>
<TD>
<P>45-52 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Total Hospital for Special Surgery Knee Score</P>
</TD>
<TD>
<P>46</P>
</TD>
<TD>
<P>62.6</P>
</TD>
<TD>
<P>78.8</P>
</TD>
<TD>
<P>-1.16 (W)</P>
</TD>
<TD>
<P>-1.8% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Exercise</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>65.4</P>
</TD>
<TD>
<P>82.76</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karatosun 2005</P>
</TD>
<TD>
<P>74 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Total Hospital for Special Surgery Knee Score</P>
</TD>
<TD>
<P>31</P>
</TD>
<TD>
<P>62.6</P>
</TD>
<TD>
<P>88.8</P>
</TD>
<TD>
<P>3.3 (I)</P>
</TD>
<TD>
<P>5.0 (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Exercise</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>65.4</P>
</TD>
<TD>
<P>88.3</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-34" NO="34">
<TITLE>Clinical benefit table: Hylan G-F 20. Continuous outcome measures</TITLE>
<TABLE COLS="9" ROWS="51">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Time</P>
</TH>
<TH>
<P>Treatment</P>
</TH>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>N of Pts</P>
</TH>
<TH>
<P>Baseline Mean</P>
</TH>
<TH>
<P>End of Study Mean</P>
</TH>
<TH>
<P>Absolute Benefit</P>
</TH>
<TH>
<P>Relative Difference</P>
</TH>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>WOMAC pain (Likert)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>12.4</P>
</TD>
<TD>
<P>8.3</P>
</TD>
<TD>
<P>-1.2 (I)</P>
</TD>
<TD>
<P>-8.5% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Physical Therapy</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>14.2</P>
</TD>
<TD>
<P>11.3</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>WOMAC pain (Likert)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>12.4</P>
</TD>
<TD>
<P>8.7</P>
</TD>
<TD>
<P>-1.3 (I)</P>
</TD>
<TD>
<P>-9.2% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Physical Therapy</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>14.2</P>
</TD>
<TD>
<P>11.8</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>WOMAC pain (Likert)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>12.4</P>
</TD>
<TD>
<P>10.4</P>
</TD>
<TD>
<P>0.9 (W)</P>
</TD>
<TD>
<P>6.3% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Physical Therapy</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>14.2</P>
</TD>
<TD>
<P>11.3</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>37 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>WOMAC pain (Likert)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>12.4</P>
</TD>
<TD>
<P>10.4</P>
</TD>
<TD>
<P>-0.1 (I)</P>
</TD>
<TD>
<P>-0.7% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Physical Therapy</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>14.2</P>
</TD>
<TD>
<P>12.3</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>45-52 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>WOMAC pain (Likert)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>12.4</P>
</TD>
<TD>
<P>10.2</P>
</TD>
<TD>
<P>-3.5 (I)</P>
</TD>
<TD>
<P>-24.6% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Physical Therapy</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>14.</P>
</TD>
<TD>
<P>15.5</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Spontaneous pain (0-100 mm VAS)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>85.0</P>
</TD>
<TD>
<P>64.0</P>
</TD>
<TD>
<P>29.0 (W)</P>
</TD>
<TD>
<P>31.0% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Physical Therapy</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>93.5</P>
</TD>
<TD>
<P>43.5</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Spontaneous pain (0-100 mm VAS)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>85.0</P>
</TD>
<TD>
<P>45.5</P>
</TD>
<TD>
<P>4.5 (W)</P>
</TD>
<TD>
<P>4.8% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Physical Therapy</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>93.5</P>
</TD>
<TD>
<P>49.5</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Spontaneous pain (0-100 mm VAS)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>85.0</P>
</TD>
<TD>
<P>50.7</P>
</TD>
<TD>
<P>10.7 (W)</P>
</TD>
<TD>
<P>11.4% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Physical Therap</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>93.5</P>
</TD>
<TD>
<P>48.5</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>37 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Spontaneous pain (0-100 mm VAS)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>85.0</P>
</TD>
<TD>
<P>51.7</P>
</TD>
<TD>
<P>9.5 (W)</P>
</TD>
<TD>
<P>10.2% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Physical Therapy</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>93.5</P>
</TD>
<TD>
<P>50.7</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>45-52 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Spontaneous pain (0-100 mm VAS)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>85.0</P>
</TD>
<TD>
<P>49.0</P>
</TD>
<TD>
<P>-2 (I)</P>
</TD>
<TD>
<P>-2.1% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Physical Therapy</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>93.5</P>
</TD>
<TD>
<P>59.5</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>SF-36 pain</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>25.6</P>
</TD>
<TD>
<P>59.4</P>
</TD>
<TD>
<P>4.3 (I)</P>
</TD>
<TD>
<P>14.5% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Physical Therapy</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>29.6</P>
</TD>
<TD>
<P>59.1</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>SF-36 pain</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>25.6</P>
</TD>
<TD>
<P>58.8</P>
</TD>
<TD>
<P>6.6 (I)</P>
</TD>
<TD>
<P>22.3% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Physical Therapy</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>29.6</P>
</TD>
<TD>
<P>56.2</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>SF-36 pain</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>25.6</P>
</TD>
<TD>
<P>55.7</P>
</TD>
<TD>
<P>5.1 (I)</P>
</TD>
<TD>
<P>17.2% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Physical Therapy</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>29.6</P>
</TD>
<TD>
<P>54.6</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>37 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>SF-36 pain</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>25.6</P>
</TD>
<TD>
<P>43.8</P>
</TD>
<TD>
<P>-3.5 (W)</P>
</TD>
<TD>
<P>-11.8% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Physical Therapy</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>29.6</P>
</TD>
<TD>
<P>51.3</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>45-52 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>SF-36 pain</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>25.6</P>
</TD>
<TD>
<P>46.7</P>
</TD>
<TD>
<P>0.5 (I)</P>
</TD>
<TD>
<P>1.7% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Physical Therapy</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>29.6</P>
</TD>
<TD>
<P>50.2</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>WOMAC physical function (Likert)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>58.3</P>
</TD>
<TD>
<P>40.1</P>
</TD>
<TD>
<P>-5.9 (I)</P>
</TD>
<TD>
<P>-11.8% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Physical Therapy</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>49.9</P>
</TD>
<TD>
<P>37.6</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>WOMAC physical function</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>58.3</P>
</TD>
<TD>
<P>41.7</P>
</TD>
<TD>
<P>-5.6 (I)</P>
</TD>
<TD>
<P>-11.2% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Physical Therapy</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>49.9</P>
</TD>
<TD>
<P>38.9</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>WOMAC physical function</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>58.3</P>
</TD>
<TD>
<P>41.9</P>
</TD>
<TD>
<P>-8.4 (I)</P>
</TD>
<TD>
<P>-16.8% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Physical Therapy</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>49.9</P>
</TD>
<TD>
<P>41.9</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>37 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>WOMAC physical function</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>58.3</P>
</TD>
<TD>
<P>38.6</P>
</TD>
<TD>
<P>-8.0 (I)</P>
</TD>
<TD>
<P>-16.0% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Physical Therapy</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>49.9</P>
</TD>
<TD>
<P>38.2</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>45-52 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>WOMAC physical function</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>58.3</P>
</TD>
<TD>
<P>38.9</P>
</TD>
<TD>
<P>-7.7 (I)</P>
</TD>
<TD>
<P>-15.4% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Physical Therapy</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>49.9</P>
</TD>
<TD>
<P>38.2</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>SF-36 physical functioning</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>35.5</P>
</TD>
<TD>
<P>57.2</P>
</TD>
<TD>
<P>-0.3 (W)</P>
</TD>
<TD>
<P>-0.9% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Physical Therapy</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>31.7</P>
</TD>
<TD>
<P>53.7</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>SF-36 physical functioning</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>35.5</P>
</TD>
<TD>
<P>61.7</P>
</TD>
<TD>
<P>4.4 (I)</P>
</TD>
<TD>
<P>13.9% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Physical Therapy</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>31.7</P>
</TD>
<TD>
<P>53.5</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>SF-36 physical functioning</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>35.5</P>
</TD>
<TD>
<P>55.7</P>
</TD>
<TD>
<P>-2.0 (W)</P>
</TD>
<TD>
<P>-6.3% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Physical Therapy</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>31.7</P>
</TD>
<TD>
<P>54.0</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>37 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>SF-36 physical functioning</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>35.5</P>
</TD>
<TD>
<P>45.0</P>
</TD>
<TD>
<P>-8.0 (W)</P>
</TD>
<TD>
<P>-25.2% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Physical Therapy</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>31.7</P>
</TD>
<TD>
<P>49.2</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>45-52 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>SF-36 physical functioning</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>35.5</P>
</TD>
<TD>
<P>54.0</P>
</TD>
<TD>
<P>-2.8 (W)</P>
</TD>
<TD>
<P>-8.8% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Physical Therapy</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>31.7</P>
</TD>
<TD>
<P>53.0</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-35" NO="35">
<TITLE>Clinical benefit table: Hylan G-F20 versus hyaluronan.Continuous outcome measure</TITLE>
<TABLE COLS="9" ROWS="67">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>TIme</P>
</TH>
<TH>
<P>Treatment</P>
</TH>
<TH>
<P>Outcome (scale)</P>
</TH>
<TH>
<P>N of Pts</P>
</TH>
<TH>
<P>Baseline Mean</P>
</TH>
<TH>
<P>End of Study Mean</P>
</TH>
<TH>
<P>Absolute Benefit</P>
</TH>
<TH>
<P>Relative Difference</P>
</TH>
</TR>
<TR>
<TD>
<P>Wobig 1999</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Weight bearing pain (0-100 mm VAS)</P>
</TD>
<TD>
<P>38</P>
</TD>
<TD>
<P>70</P>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>-1 (I)</P>
</TD>
<TD>
<P>-1.4% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Artz</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>35</P>
</TD>
<TD>
<P>72</P>
</TD>
<TD>
<P>43</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Wobig 1999</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Pain at night (0-100 mm VAS)</P>
</TD>
<TD>
<P>38</P>
</TD>
<TD>
<P>26</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>1 (W)</P>
</TD>
<TD>
<P>3.3% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Artz</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>35</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Wobig 1999</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Weight bearing pain (0-100 mm VAS)</P>
</TD>
<TD>
<P>38</P>
</TD>
<TD>
<P>70</P>
</TD>
<TD>
<P>32</P>
</TD>
<TD>
<P>-14 (I)</P>
</TD>
<TD>
<P>-19.4% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Artz</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>35</P>
</TD>
<TD>
<P>72</P>
</TD>
<TD>
<P>48</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Wobig 1999</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Pain at night (0-100 mm VAS)</P>
</TD>
<TD>
<P>38</P>
</TD>
<TD>
<P>26</P>
</TD>
<TD>
<P>13</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0%</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Artz</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>35</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>17</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Wobig 1999</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Weight bearing pain (0-100 mm VAS)</P>
</TD>
<TD>
<P>38</P>
</TD>
<TD>
<P>70</P>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>-7 (I)</P>
</TD>
<TD>
<P>-9.9% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Healon</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>39</P>
</TD>
<TD>
<P>71</P>
</TD>
<TD>
<P>48</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Wobig 1999</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Pain at night (0-100 mm VAS)</P>
</TD>
<TD>
<P>38</P>
</TD>
<TD>
<P>26</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>-1 (I)</P>
</TD>
<TD>
<P>-2.9% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Healon</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>39</P>
</TD>
<TD>
<P>35</P>
</TD>
<TD>
<P>22</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Wobig 1999</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Weight bearing pain (0-100 mm VAS)</P>
</TD>
<TD>
<P>38</P>
</TD>
<TD>
<P>70</P>
</TD>
<TD>
<P>32</P>
</TD>
<TD>
<P>-5 (I)</P>
</TD>
<TD>
<P>-7.0% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Healon</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>39</P>
</TD>
<TD>
<P>71</P>
</TD>
<TD>
<P>38</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Wobig 1999</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Pain at night (0-100 mm VAS)</P>
</TD>
<TD>
<P>38</P>
</TD>
<TD>
<P>26</P>
</TD>
<TD>
<P>13</P>
</TD>
<TD>
<P>6 (W)</P>
</TD>
<TD>
<P>17.1% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Healon</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>39</P>
</TD>
<TD>
<P>35</P>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>WOMAC pain (Likert)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>12.4</P>
</TD>
<TD>
<P>8.3</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Orthovisc</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>13.4</P>
</TD>
<TD>
<P>9.3</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>WOMAC pain (Likert)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>12.4</P>
</TD>
<TD>
<P>8.7</P>
</TD>
<TD>
<P>-1.5 (I)</P>
</TD>
<TD>
<P>-11.2% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Orthovisc</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>13.4</P>
</TD>
<TD>
<P>11.2</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>WOMAC pain (Likert)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>12.4</P>
</TD>
<TD>
<P>10.4</P>
</TD>
<TD>
<P>-0.5 (I)</P>
</TD>
<TD>
<P>-3.7% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Orthovisc</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>13.4</P>
</TD>
<TD>
<P>11.9</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>36 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>WOMAC pain (Likert)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>12.4</P>
</TD>
<TD>
<P>10.4</P>
</TD>
<TD>
<P>1.0 (W)</P>
</TD>
<TD>
<P>7.5% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Orthovisc</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>13.4</P>
</TD>
<TD>
<P>10.4</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>45-52 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>WOMAC pain (Likert)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>12.4</P>
</TD>
<TD>
<P>10.2</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Orthovisc</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>13.4</P>
</TD>
<TD>
<P>11.2</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Spontaneous pain (0-100 mm VAS)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>85.0</P>
</TD>
<TD>
<P>64.0</P>
</TD>
<TD>
<P>6.4 (W)</P>
</TD>
<TD>
<P>9.1% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Orthovisc</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>70.3</P>
</TD>
<TD>
<P>42.9</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Spontaneous pain (0-100 mm VAS)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>85.0</P>
</TD>
<TD>
<P>50.7</P>
</TD>
<TD>
<P>-22.4 (I)</P>
</TD>
<TD>
<P>-31.9% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Orthovisc</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>70.3</P>
</TD>
<TD>
<P>58.4</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Spontaneous pain (0-100 mm VAS)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>85.0</P>
</TD>
<TD>
<P>51.7</P>
</TD>
<TD>
<P>-29.2 (I)</P>
</TD>
<TD>
<P>-41.5% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Orthovisc</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>70.3</P>
</TD>
<TD>
<P>66.2</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>36 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Spontaneous pain (0-100 mm VAS)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>85.0</P>
</TD>
<TD>
<P>51.7</P>
</TD>
<TD>
<P>-15.2 (I)</P>
</TD>
<TD>
<P>-21.6% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Orthovisc</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>70.3</P>
</TD>
<TD>
<P>52.2</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>45-52 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>Spontaneous pain (0-100 mm VAS)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>85.0</P>
</TD>
<TD>
<P>49.0</P>
</TD>
<TD>
<P>-22.4 (I)</P>
</TD>
<TD>
<P>-31.9% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Orthovisc</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>70.3</P>
</TD>
<TD>
<P>56.7</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>SF-36 pain</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>25.6</P>
</TD>
<TD>
<P>59.4</P>
</TD>
<TD>
<P>22.7 (I)</P>
</TD>
<TD>
<P>62.4% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Orthovisc</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>36.4</P>
</TD>
<TD>
<P>47.5</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>SF-36 pain</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>25.6</P>
</TD>
<TD>
<P>58.8</P>
</TD>
<TD>
<P>41.6 (I)</P>
</TD>
<TD>
<P>114.3% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Orthovisc</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>36.4</P>
</TD>
<TD>
<P>28.0</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>SF-36 pain</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>25.6</P>
</TD>
<TD>
<P>55.7</P>
</TD>
<TD>
<P>30.6 (I)</P>
</TD>
<TD>
<P>84.1% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Orthovisc</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>36.4</P>
</TD>
<TD>
<P>35.9</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>36 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>SF-36 pain</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>25.6</P>
</TD>
<TD>
<P>43.8</P>
</TD>
<TD>
<P>9.3 (I)</P>
</TD>
<TD>
<P>25.5% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Orthovisc</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>36.4</P>
</TD>
<TD>
<P>45.3</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>45-52 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>SF-36 pain</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>25.6</P>
</TD>
<TD>
<P>46.7</P>
</TD>
<TD>
<P>19.8 (I)</P>
</TD>
<TD>
<P>54.4% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Orthovisc</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>36.4</P>
</TD>
<TD>
<P>37.7</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>WOMAC function (Likert)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>58.3</P>
</TD>
<TD>
<P>40.1</P>
</TD>
<TD>
<P>-11.9 (I)</P>
</TD>
<TD>
<P>-28.7% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Orthovisc</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>41.5</P>
</TD>
<TD>
<P>35.2</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>WOMAC function (Likert)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>58.3</P>
</TD>
<TD>
<P>41.7</P>
</TD>
<TD>
<P>-11.3 (I)</P>
</TD>
<TD>
<P>-27.2% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Orthovisc</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>41.5</P>
</TD>
<TD>
<P>36.2</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>WOMAC function (Likert)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>58.3</P>
</TD>
<TD>
<P>41.9</P>
</TD>
<TD>
<P>-16.7 (I)</P>
</TD>
<TD>
<P>-40.2% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Orthovisc</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>41.5</P>
</TD>
<TD>
<P>41.8</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>36 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>WOMAC function (Likert)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>58.3</P>
</TD>
<TD>
<P>38.6</P>
</TD>
<TD>
<P>-17.8 (I)</P>
</TD>
<TD>
<P>-42.9% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Orthovisc</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>41.5</P>
</TD>
<TD>
<P>39.6</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>45-52 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>WOMAC function (Likert)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>58.3</P>
</TD>
<TD>
<P>38.9</P>
</TD>
<TD>
<P>-15.5 (I)</P>
</TD>
<TD>
<P>-37.3% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Orthovisc</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>41.5</P>
</TD>
<TD>
<P>37.6</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>SF-36 physical functioning</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>35.5</P>
</TD>
<TD>
<P>57.2</P>
</TD>
<TD>
<P>12.0 (I)</P>
</TD>
<TD>
<P>27.0 (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Orthovisc</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>44.5</P>
</TD>
<TD>
<P>54.2</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>SF-36 physical functioning</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>35.5</P>
</TD>
<TD>
<P>61.7</P>
</TD>
<TD>
<P>29.2 (I)</P>
</TD>
<TD>
<P>65.6% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Orthovisc</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>44.5</P>
</TD>
<TD>
<P>41.5</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>SF-36 physical functioning</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>35.5</P>
</TD>
<TD>
<P>55.7</P>
</TD>
<TD>
<P>20.2 (I)</P>
</TD>
<TD>
<P>56.9% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Orthovisc</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>44.5</P>
</TD>
<TD>
<P>44.5</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>36 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>SF-36 physical functioning</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>35.5</P>
</TD>
<TD>
<P>45.0</P>
</TD>
<TD>
<P>4.8 (I)</P>
</TD>
<TD>
<P>10.8 (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Orthovisc</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>44.5</P>
</TD>
<TD>
<P>49.2</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>45-52 wk</P>
</TD>
<TD>
<P>E: Hylan G-F 20</P>
</TD>
<TD>
<P>SF-36 physical functioning</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>35.5</P>
</TD>
<TD>
<P>54.0</P>
</TD>
<TD>
<P>32.0 (I)</P>
</TD>
<TD>
<P>71.9% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Orthovisc</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>44.5</P>
</TD>
<TD>
<P>31.0</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-36" NO="36">
<TITLE>Clinical benefit table: NRD-101 (Suvenyl) versus placebo. Continuous outcome mea</TITLE>
<TABLE COLS="9" ROWS="25">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Time</P>
</TH>
<TH>
<P>Treatment</P>
</TH>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>N of Pts</P>
</TH>
<TH>
<P>Baseline Mean</P>
</TH>
<TH>
<P>End of Study Mean</P>
</TH>
<TH>
<P>Absolute Benefit</P>
</TH>
<TH>
<P>Relative Difference</P>
</TH>
</TR>
<TR>
<TD>
<P>Pham 2004</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: NRD-101</P>
</TD>
<TD>
<P>Pain (0-100 mm VAS)</P>
</TD>
<TD>
<P>131</P>
</TD>
<TD>
<P>61.7</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Placebo</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>85</P>
</TD>
<TD>
<P>59.1</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Pham 2004</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: NRD-101</P>
</TD>
<TD>
<P>Pain (0-100 mm VAS)</P>
</TD>
<TD>
<P>131</P>
</TD>
<TD>
<P>61.7</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Placebo</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>85</P>
</TD>
<TD>
<P>59.1</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Pham 2004</P>
</TD>
<TD>
<P>45-52 wk</P>
</TD>
<TD>
<P>E: NRD-101</P>
</TD>
<TD>
<P>Pain (0-100 mm VAS)</P>
</TD>
<TD>
<P>131</P>
</TD>
<TD>
<P>61.7</P>
</TD>
<TD>
<P>28.2</P>
</TD>
<TD>
<P>1.0 (W)</P>
</TD>
<TD>
<P>1.7% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Placebo</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>85</P>
</TD>
<TD>
<P>59.1</P>
</TD>
<TD>
<P>24.6</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Pham 2004</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: NRD-101</P>
</TD>
<TD>
<P>Lequesne Index (0-24)</P>
</TD>
<TD>
<P>131</P>
</TD>
<TD>
<P>11.1</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Placebo</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>85</P>
</TD>
<TD>
<P>10.5</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Pham 2004</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: NRD-101</P>
</TD>
<TD>
<P>Lequesne Index (0-24)</P>
</TD>
<TD>
<P>131</P>
</TD>
<TD>
<P>11.1</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Placebo</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>85</P>
</TD>
<TD>
<P>10.5</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Pham 2004</P>
</TD>
<TD>
<P>45-52 wk</P>
</TD>
<TD>
<P>E: NRD-101</P>
</TD>
<TD>
<P>Lequesne Index (0-24)</P>
</TD>
<TD>
<P>131</P>
</TD>
<TD>
<P>11.1</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Placebo</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>85</P>
</TD>
<TD>
<P>10.5</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Pham 2004</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: NRD-101</P>
</TD>
<TD>
<P>Patient global assessment (0-100 mm VAS)</P>
</TD>
<TD>
<P>131</P>
</TD>
<TD>
<P>59.7</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Placebo</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>85</P>
</TD>
<TD>
<P>57.3</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Pham 2004</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: NRD-101</P>
</TD>
<TD>
<P>Patient global assessment</P>
</TD>
<TD>
<P>131</P>
</TD>
<TD>
<P>59.7</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Placebo</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>85</P>
</TD>
<TD>
<P>57.3</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Pham 2004</P>
</TD>
<TD>
<P>45-52 wk</P>
</TD>
<TD>
<P>E: NRD-101</P>
</TD>
<TD>
<P>Patient global assessment (0-100 mm VAS)</P>
</TD>
<TD>
<P>131</P>
</TD>
<TD>
<P>59.7</P>
</TD>
<TD>
<P>30.0</P>
</TD>
<TD>
<P>1.4 (W)</P>
</TD>
<TD>
<P>2.4% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Placebo</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>85</P>
</TD>
<TD>
<P>57.3</P>
</TD>
<TD>
<P>26.2</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Pham 2004</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: NRD-101</P>
</TD>
<TD>
<P>Percentage of painful days during the previous month (0-100 mm VAS)</P>
</TD>
<TD>
<P>131</P>
</TD>
<TD>
<P>85.5</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Placebo</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>85</P>
</TD>
<TD>
<P>82.6</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Pham 2004</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: NRD-101</P>
</TD>
<TD>
<P>Percentage of painful days during the previous month (0-100 mm VAS)</P>
</TD>
<TD>
<P>131</P>
</TD>
<TD>
<P>85.5</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Placebo</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>85</P>
</TD>
<TD>
<P>82.6</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Pham 2004</P>
</TD>
<TD>
<P>45-52 wk</P>
</TD>
<TD>
<P>E: NRD-101</P>
</TD>
<TD>
<P>Percentage of painful days during the previous month (0-100 mm VAS)</P>
</TD>
<TD>
<P>131</P>
</TD>
<TD>
<P>85.5</P>
</TD>
<TD>
<P>42.0</P>
</TD>
<TD>
<P>3.1 (W)</P>
</TD>
<TD>
<P>3.8% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Placebo</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>85</P>
</TD>
<TD>
<P>82.6</P>
</TD>
<TD>
<P>36.0</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-37" NO="37">
<TITLE>Clinical benefit table: NRD-101 (Suvenyl) versus placebo. Dichotomous outcome me</TITLE>
<TABLE COLS="9" ROWS="5">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Time</P>
</TH>
<TH>
<P>Treatment</P>
</TH>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>No. improved</P>
</TH>
<TH>
<P>No. of pts</P>
</TH>
<TH>
<P>Risk (%)</P>
</TH>
<TH>
<P>Risk difference</P>
</TH>
<TH>
<P>NNT</P>
</TH>
</TR>
<TR>
<TD>
<P>Pham 2004</P>
</TD>
<TD>
<P>45-52 wk</P>
</TD>
<TD>
<P>E: NRD-101</P>
</TD>
<TD>
<P>Patient assessment of treatment efficacy (no. pts rating very good or good versus moderate, bad or very ad)</P>
</TD>
<TD>
<P>86</P>
</TD>
<TD>
<P>120</P>
</TD>
<TD>
<P>72</P>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>25</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Placebo (saline + oral placebo)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>57</P>
</TD>
<TD>
<P>75</P>
</TD>
<TD>
<P>76</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Pham 2004</P>
</TD>
<TD>
<P>45-52 wk</P>
</TD>
<TD>
<P>E: NRD-101</P>
</TD>
<TD>
<P>Joint space width (percentage of progressors: joint space narrowing greater than 0.5 mm)</P>
</TD>
<TD>
<P>23</P>
</TD>
<TD>
<P>131</P>
</TD>
<TD>
<P>18</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>50</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Placebo (saline plus oral placebo)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>17</P>
</TD>
<TD>
<P>85</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-38" NO="38">
<TITLE>Clinical benefit table: NRD-101 (Suvenyl) versus Diacerein. Continuous outcome m</TITLE>
<TABLE COLS="9" ROWS="25">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Time</P>
</TH>
<TH>
<P>Treatment</P>
</TH>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>N of Pts</P>
</TH>
<TH>
<P>Baseline Mean</P>
</TH>
<TH>
<P>End of Study Mean</P>
</TH>
<TH>
<P>Absolute Benefit</P>
</TH>
<TH>
<P>Relative Difference</P>
</TH>
</TR>
<TR>
<TD>
<P>Pham 2004</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: NRD-101</P>
</TD>
<TD>
<P>Pain (0-100 mm VAS)</P>
</TD>
<TD>
<P>131</P>
</TD>
<TD>
<P>61.7</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Diacerein</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>85</P>
</TD>
<TD>
<P>59.6</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Pham 2004</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: NRD-101</P>
</TD>
<TD>
<P>Pain (0-100 mm VAS)</P>
</TD>
<TD>
<P>131</P>
</TD>
<TD>
<P>61.7</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Diacerein</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>85</P>
</TD>
<TD>
<P>59.6</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Pham 2004</P>
</TD>
<TD>
<P>45-52 wk</P>
</TD>
<TD>
<P>E: NRD-101</P>
</TD>
<TD>
<P>Pain (0-100 mm VAS)</P>
</TD>
<TD>
<P>131</P>
</TD>
<TD>
<P>61.7</P>
</TD>
<TD>
<P>28.2</P>
</TD>
<TD>
<P>0.4 (W)</P>
</TD>
<TD>
<P>0.7% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Diacerein</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>85</P>
</TD>
<TD>
<P>59.6</P>
</TD>
<TD>
<P>25.7</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Pham 2004</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: NRD-101</P>
</TD>
<TD>
<P>Lequesne Index (0-24)</P>
</TD>
<TD>
<P>131</P>
</TD>
<TD>
<P>11.1</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Diacerein</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>85</P>
</TD>
<TD>
<P>10.5</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Pham 2004</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: NRD-101</P>
</TD>
<TD>
<P>Lequesne Index (0-24)</P>
</TD>
<TD>
<P>131</P>
</TD>
<TD>
<P>11.1</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Diacerein</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>85</P>
</TD>
<TD>
<P>10.5</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Pham 2004</P>
</TD>
<TD>
<P>45-52 wk</P>
</TD>
<TD>
<P>E: NRD-101</P>
</TD>
<TD>
<P>Lequesne Index (0-24)</P>
</TD>
<TD>
<P>131</P>
</TD>
<TD>
<P>11.1</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Diacerein</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>85</P>
</TD>
<TD>
<P>10.5</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Pham 2004</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: NRD-101</P>
</TD>
<TD>
<P>Patient global assessment (0-100 mm VAS)</P>
</TD>
<TD>
<P>131</P>
</TD>
<TD>
<P>59.7</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Diacerein</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>85</P>
</TD>
<TD>
<P>57.3</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Pham 2004</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: NRD-101</P>
</TD>
<TD>
<P>Patient global assessment (0-100 mm VAS)</P>
</TD>
<TD>
<P>131</P>
</TD>
<TD>
<P>59.7</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Diacerein</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>85</P>
</TD>
<TD>
<P>57.3</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Pham 2004</P>
</TD>
<TD>
<P>45-52 wk</P>
</TD>
<TD>
<P>E: NRD-101</P>
</TD>
<TD>
<P>Patient global assessment</P>
</TD>
<TD>
<P>131</P>
</TD>
<TD>
<P>59.7</P>
</TD>
<TD>
<P>30.0</P>
</TD>
<TD>
<P>3.1 (W)</P>
</TD>
<TD>
<P>5.4% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Diacerein</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>85</P>
</TD>
<TD>
<P>57.3</P>
</TD>
<TD>
<P>24.5</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Pham 2004</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: NRD-101</P>
</TD>
<TD>
<P>Percentage of painful days during the previous month (0-100 mm VAS)</P>
</TD>
<TD>
<P>131</P>
</TD>
<TD>
<P>85.5</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Diacerein</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>85</P>
</TD>
<TD>
<P>83.0</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Pham 2004</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: NRD-101</P>
</TD>
<TD>
<P>Percentage of painful days durign the previous month (0-100 mm VAS)</P>
</TD>
<TD>
<P>131</P>
</TD>
<TD>
<P>85.5</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Diacerein</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>85</P>
</TD>
<TD>
<P>83.0</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Pham 2004</P>
</TD>
<TD>
<P>45-52 wk</P>
</TD>
<TD>
<P>E: NRD-101</P>
</TD>
<TD>
<P>Percentage of painful days during the previous month (0-100 mm VAS)</P>
</TD>
<TD>
<P>131</P>
</TD>
<TD>
<P>85.5</P>
</TD>
<TD>
<P>42.0</P>
</TD>
<TD>
<P>2.1 (W)</P>
</TD>
<TD>
<P>2.5% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Diacerein</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>85</P>
</TD>
<TD>
<P>83.0</P>
</TD>
<TD>
<P>37.4</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-39" NO="39">
<TITLE>Clinical benefit table: NRD-101 (Suvenyl) versus Diacerein. Dichotomous outcome</TITLE>
<TABLE COLS="9" ROWS="5">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Time</P>
</TH>
<TH>
<P>Treatment</P>
</TH>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>No. improved</P>
</TH>
<TH>
<P>No. of pts</P>
</TH>
<TH>
<P>Risk (%)</P>
</TH>
<TH>
<P>Risk difference</P>
</TH>
<TH>
<P>NNT</P>
</TH>
</TR>
<TR>
<TD>
<P>Pham 2004</P>
</TD>
<TD>
<P>45-52 wk</P>
</TD>
<TD>
<P>E: NRD-101</P>
</TD>
<TD>
<P>Patient assessment of treatment efficacy (no. pts rating very good or good versus moderate, bad or very bad)</P>
</TD>
<TD>
<P>86</P>
</TD>
<TD>
<P>120</P>
</TD>
<TD>
<P>72</P>
</TD>
<TD>
<P>7</P>
</TD>
<TD>
<P>14</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Diacerein</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>49</P>
</TD>
<TD>
<P>75</P>
</TD>
<TD>
<P>65</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Pham 2004</P>
</TD>
<TD>
<P>45-52 wk</P>
</TD>
<TD>
<P>E: NRD-101</P>
</TD>
<TD>
<P>Joint space width (percentage progressors: joint space narrowing greater than 0.5 mm)</P>
</TD>
<TD>
<P>23</P>
</TD>
<TD>
<P>131</P>
</TD>
<TD>
<P>18</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>100</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Diacerein</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>85</P>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-40" NO="40">
<TITLE>Clinical benefit table: NRD-101 (Suvenyl) versus Artz. Dichotomous outcome measu</TITLE>
<TABLE COLS="9" ROWS="11">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>TIme</P>
</TH>
<TH>
<P>Treatment</P>
</TH>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>No. improved</P>
</TH>
<TH>
<P>No. of pts.</P>
</TH>
<TH>
<P>Risk (%)</P>
</TH>
<TH>
<P>Risk difference</P>
</TH>
<TH>
<P>NNT</P>
</TH>
</TR>
<TR>
<TD>
<P>Yamamoto 1994</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: NRD-101</P>
</TD>
<TD>
<P>Spontaneous pain (number of patients improved)</P>
</TD>
<TD>
<P>48</P>
</TD>
<TD>
<P>67</P>
</TD>
<TD>
<P>72</P>
</TD>
<TD>
<P>11</P>
</TD>
<TD>
<P>9.1</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Artz</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>43</P>
</TD>
<TD>
<P>70</P>
</TD>
<TD>
<P>61</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Yamamoto 1994</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: NRD-101</P>
</TD>
<TD>
<P>Pain during night (number of patients improved)</P>
</TD>
<TD>
<P>39</P>
</TD>
<TD>
<P>54</P>
</TD>
<TD>
<P>72</P>
</TD>
<TD>
<P>-2</P>
</TD>
<TD>
<P>50</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Artz</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>39</P>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>74</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Yamamoto 1994</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: NRD-101</P>
</TD>
<TD>
<P>Pressure pain (number of patients improved)</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>94</P>
</TD>
<TD>
<P>64</P>
</TD>
<TD>
<P>7</P>
</TD>
<TD>
<P>14.3</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Artz</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>48</P>
</TD>
<TD>
<P>84</P>
</TD>
<TD>
<P>57</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Yamamoto 1994</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: NRD-101</P>
</TD>
<TD>
<P>Passive movement pain (number of patients improved)</P>
</TD>
<TD>
<P>31</P>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>58</P>
</TD>
<TD>
<P>-8</P>
</TD>
<TD>
<P>12.5</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Artz</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>57</P>
</TD>
<TD>
<P>86</P>
</TD>
<TD>
<P>66</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Yamamoto 1994</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: NRD-101</P>
</TD>
<TD>
<P>Number of patients good/very good</P>
</TD>
<TD>
<P>50</P>
</TD>
<TD>
<P>81</P>
</TD>
<TD>
<P>62</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>50</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Artz</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>43</P>
</TD>
<TD>
<P>72</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-41" NO="41">
<TITLE>Clinical benefit table: NRD-101 (Suvenyl) versus Artz. Continuous outcome measur</TITLE>
<TABLE COLS="9" ROWS="5">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Time</P>
</TH>
<TH>
<P>Treatment</P>
</TH>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>N of Pts</P>
</TH>
<TH>
<P>Baseline Mean</P>
</TH>
<TH>
<P>End of Study Mean</P>
</TH>
<TH>
<P>Absolute Benefit</P>
</TH>
<TH>
<P>Relative Benefit</P>
</TH>
</TR>
<TR>
<TD>
<P>Yamamoto 1994</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: NRD-101</P>
</TD>
<TD>
<P>Passive flexion (degrees)</P>
</TD>
<TD>
<P>95</P>
</TD>
<TD>
<P>132.30</P>
</TD>
<TD>
<P>137.10</P>
</TD>
<TD>
<P>1.4 (I)</P>
</TD>
<TD>
<P>1.1% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Artz</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>86</P>
</TD>
<TD>
<P>132.70</P>
</TD>
<TD>
<P>136.10</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Yamamoto 1994</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: NRD-101</P>
</TD>
<TD>
<P>Passive extension (degrees)</P>
</TD>
<TD>
<P>95</P>
</TD>
<TD>
<P>4.8</P>
</TD>
<TD>
<P>4.0</P>
</TD>
<TD>
<P>0.2 (I)</P>
</TD>
<TD>
<P>3.8% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Artz</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>86</P>
</TD>
<TD>
<P>5.2</P>
</TD>
<TD>
<P>4.2</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-42" NO="42">
<TITLE>Clinical benefit table: Orthovisc. Continuous outcome measures (1)</TITLE>
<TABLE COLS="9" ROWS="93">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Time</P>
</TH>
<TH>
<P>Treatment</P>
</TH>
<TH>
<P>Outcome (scale)</P>
</TH>
<TH>
<P>N of Pts</P>
</TH>
<TH>
<P>Baseline Mean</P>
</TH>
<TH>
<P>End of Study Mean</P>
</TH>
<TH>
<P>Absolute Benefit</P>
</TH>
<TH>
<P>Relative Difference</P>
</TH>
</TR>
<TR>
<TD>
<P>Bayramoglu 2003</P>
</TD>
<TD>
<P>End of treatment</P>
</TD>
<TD>
<P>E: Orthovisc + PT</P>
</TD>
<TD>
<P>Lequesene Index (0-24)</P>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>12.4</P>
</TD>
<TD>
<P>9.1</P>
</TD>
<TD>
<P>-1.00 (I)</P>
</TD>
<TD>
<P>-8.6% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: PT</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>11.6</P>
</TD>
<TD>
<P>9.3</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Bayramoglu 2003</P>
</TD>
<TD>
<P>End of treatment</P>
</TD>
<TD>
<P>E: Orthovisc + PT</P>
</TD>
<TD>
<P>Lequesne Index (0-24)</P>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>12.4</P>
</TD>
<TD>
<P>9.1</P>
</TD>
<TD>
<P>0.9 (W)</P>
</TD>
<TD>
<P>7.0% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hylan G-F 20 + PT</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>12.8</P>
</TD>
<TD>
<P>8.6</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Bayramoglu 2003</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Orthovisc + PT</P>
</TD>
<TD>
<P>Lequesene Index (0-24)</P>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>12.4</P>
</TD>
<TD>
<P>7.6</P>
</TD>
<TD>
<P>-2.6 (I)</P>
</TD>
<TD>
<P>-22.4% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: PT</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>11.6</P>
</TD>
<TD>
<P>9.4</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Bayramoglu 2003</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Orthovisc + PT</P>
</TD>
<TD>
<P>Lequesne Index (0-24)</P>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>12.4</P>
</TD>
<TD>
<P>7.6</P>
</TD>
<TD>
<P>-0.6 (I)</P>
</TD>
<TD>
<P>-4.7% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hylan G-F 20 + PT</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>12.8</P>
</TD>
<TD>
<P>8.6</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Tascioglu 2003</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>Pain on weight bearing (0-100 mm VAS)</P>
</TD>
<TD>
<P>28</P>
</TD>
<TD>
<P>54.26</P>
</TD>
<TD>
<P>31.83</P>
</TD>
<TD>
<P>3.87 (W)</P>
</TD>
<TD>
<P>7.3% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: 6-MPA</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>27</P>
</TD>
<TD>
<P>53.10</P>
</TD>
<TD>
<P>26.80</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Tascioglu 2003</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>Pain at rest (0-100 mm VAS)</P>
</TD>
<TD>
<P>28</P>
</TD>
<TD>
<P>30.43</P>
</TD>
<TD>
<P>11.83</P>
</TD>
<TD>
<P>3.00 (W)</P>
</TD>
<TD>
<P>10.0% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: 6-MPA</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>27</P>
</TD>
<TD>
<P>29.90</P>
</TD>
<TD>
<P>8.30</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Tascioglu 2003</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>Pain on walking (0-100 mm VAS)</P>
</TD>
<TD>
<P>28</P>
</TD>
<TD>
<P>67.60</P>
</TD>
<TD>
<P>37.60</P>
</TD>
<TD>
<P>1.00 (W)</P>
</TD>
<TD>
<P>1.5% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: 6-MPA</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>27</P>
</TD>
<TD>
<P>69.00</P>
</TD>
<TD>
<P>38.00</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Tascioglu 2003</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>Lequesne Index (0-24)</P>
</TD>
<TD>
<P>28</P>
</TD>
<TD>
<P>10.23</P>
</TD>
<TD>
<P>7.86</P>
</TD>
<TD>
<P>-0.47 (I)</P>
</TD>
<TD>
<P>-4.8% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: 6-MPA</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>27</P>
</TD>
<TD>
<P>9.86</P>
</TD>
<TD>
<P>7.96</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Tascioglu 2003</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>Flexion (degrees)</P>
</TD>
<TD>
<P>28</P>
</TD>
<TD>
<P>108.70</P>
</TD>
<TD>
<P>116.36</P>
</TD>
<TD>
<P>1.52 (I)</P>
</TD>
<TD>
<P>1.4% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: 6-MPA</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>27</P>
</TD>
<TD>
<P>108.06</P>
</TD>
<TD>
<P>114.20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Tascioglu 2003</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>Pain on weight bearing (0-100 mm VAS)</P>
</TD>
<TD>
<P>28</P>
</TD>
<TD>
<P>54.26</P>
</TD>
<TD>
<P>22.86</P>
</TD>
<TD>
<P>-16.80 (I)</P>
</TD>
<TD>
<P>-31.6% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: 6-MPA</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>27</P>
</TD>
<TD>
<P>53.10</P>
</TD>
<TD>
<P>38.50</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Tascioglu 2003</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>Pain at rest (0-100 mm VAS)</P>
</TD>
<TD>
<P>28</P>
</TD>
<TD>
<P>30.43</P>
</TD>
<TD>
<P>12.00</P>
</TD>
<TD>
<P>-8.23 (I)</P>
</TD>
<TD>
<P>-27.5% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: 6-MPA</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>27</P>
</TD>
<TD>
<P>29.90</P>
</TD>
<TD>
<P>19.70</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Tascioglu 2003</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>Pain on walking (0-100 mm VAS)</P>
</TD>
<TD>
<P>28</P>
</TD>
<TD>
<P>67.60</P>
</TD>
<TD>
<P>32.03</P>
</TD>
<TD>
<P>-17.03 (I)</P>
</TD>
<TD>
<P>-24.7% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: 6-MPA</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>27</P>
</TD>
<TD>
<P>69.00</P>
</TD>
<TD>
<P>50.46</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Tascioglu 2003</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>Lequesne Index (0-24)</P>
</TD>
<TD>
<P>28</P>
</TD>
<TD>
<P>10.23</P>
</TD>
<TD>
<P>7.66</P>
</TD>
<TD>
<P>-1.77 (I)</P>
</TD>
<TD>
<P>-17.9% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: 6-MPA</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>27</P>
</TD>
<TD>
<P>9.86</P>
</TD>
<TD>
<P>9.06</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Tascioglu 2003</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>Flexion (degrees)</P>
</TD>
<TD>
<P>28</P>
</TD>
<TD>
<P>108.70</P>
</TD>
<TD>
<P>115.76</P>
</TD>
<TD>
<P>1.72 (I)</P>
</TD>
<TD>
<P>1.6% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: 6-MPA</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>27</P>
</TD>
<TD>
<P>108.06</P>
</TD>
<TD>
<P>113.40</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Tascioglu 2003</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>Pain on weight bearing (0-100 mm VAS)</P>
</TD>
<TD>
<P>28</P>
</TD>
<TD>
<P>54.26</P>
</TD>
<TD>
<P>40.96</P>
</TD>
<TD>
<P>-16.56 (I)</P>
</TD>
<TD>
<P>-31.2% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: 6-MPA</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>27</P>
</TD>
<TD>
<P>53.10</P>
</TD>
<TD>
<P>56.36</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Tascioglu 2003</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>Pain at rest (0-100 mm VAS)</P>
</TD>
<TD>
<P>28</P>
</TD>
<TD>
<P>30.43</P>
</TD>
<TD>
<P>23.56</P>
</TD>
<TD>
<P>-3.43 (I)</P>
</TD>
<TD>
<P>-11.5% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: 6-MPA</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>27</P>
</TD>
<TD>
<P>29.90</P>
</TD>
<TD>
<P>26.46</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Tascioglu 2003</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>Pain on walking (0-100 mm VAS)</P>
</TD>
<TD>
<P>28</P>
</TD>
<TD>
<P>67.60</P>
</TD>
<TD>
<P>51.16</P>
</TD>
<TD>
<P>-13.50 (I)</P>
</TD>
<TD>
<P>-19.6% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: 6-MPA</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>27</P>
</TD>
<TD>
<P>69.00</P>
</TD>
<TD>
<P>66.06</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Tascioglu 2003</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>Lequesne Index (0-24)</P>
</TD>
<TD>
<P>28</P>
</TD>
<TD>
<P>10.23</P>
</TD>
<TD>
<P>8.46</P>
</TD>
<TD>
<P>-1.51 (I)</P>
</TD>
<TD>
<P>-15.3% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: 6-MPA</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>27</P>
</TD>
<TD>
<P>9.86</P>
</TD>
<TD>
<P>9.60</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Tascioglu 2003</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>Flexion (degrees)</P>
</TD>
<TD>
<P>28</P>
</TD>
<TD>
<P>108.70</P>
</TD>
<TD>
<P>114.60</P>
</TD>
<TD>
<P>4.36 (I)</P>
</TD>
<TD>
<P>4.0% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: 6-MPA</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>27</P>
</TD>
<TD>
<P>108.06</P>
</TD>
<TD>
<P>109.60</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Hizmetli 1999</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>WOMAC pain (5-25 Likert)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>17.75</P>
</TD>
<TD>
<P>10.20</P>
</TD>
<TD>
<P>-7.80 (I)</P>
</TD>
<TD>
<P>-44.6% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>17.45</P>
</TD>
<TD>
<P>17.70</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Hizmetli 1999</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>WOMAC pain (5-25 Likert)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>17.75</P>
</TD>
<TD>
<P>11.75</P>
</TD>
<TD>
<P>-6.25 (I)</P>
</TD>
<TD>
<P>-35.4% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>17.45</P>
</TD>
<TD>
<P>17.70</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Hizmetli 1999</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>WOMAC pain (5-25 Likert)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>17.75</P>
</TD>
<TD>
<P>12.80</P>
</TD>
<TD>
<P>-5.90 (I)</P>
</TD>
<TD>
<P>-33.7% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>17.45</P>
</TD>
<TD>
<P>18.40</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Hizmetli 1999</P>
</TD>
<TD>
<P>45-52 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>WOMAC pain (5-25 Likert)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>17.75</P>
</TD>
<TD>
<P>13.80</P>
</TD>
<TD>
<P>-5.60 (I)</P>
</TD>
<TD>
<P>-32% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>17.45</P>
</TD>
<TD>
<P>19.10</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Hizmetli 1999</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>WOMAC function (17-85 Likert)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>53.15</P>
</TD>
<TD>
<P>39.85</P>
</TD>
<TD>
<P>-13.40 (I)</P>
</TD>
<TD>
<P>-25.8% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>52.00</P>
</TD>
<TD>
<P>52.10</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Hizmetli 1999</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>WOMAC function (17-85 Likert)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>53.15</P>
</TD>
<TD>
<P>41.35</P>
</TD>
<TD>
<P>-11.30 (I)</P>
</TD>
<TD>
<P>-21.7 (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>52.00</P>
</TD>
<TD>
<P>51.50</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Hizmetli 1999</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>WOMAC function (17-85 Likert)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>53.15</P>
</TD>
<TD>
<P>43.20</P>
</TD>
<TD>
<P>-10.45 (I)</P>
</TD>
<TD>
<P>-20.2 (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>52.00</P>
</TD>
<TD>
<P>52.50</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Hizmetli 1999</P>
</TD>
<TD>
<P>46-52 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>WOMAC function (17-85 Likert)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>53.15</P>
</TD>
<TD>
<P>45.80</P>
</TD>
<TD>
<P>-8.25 (I)</P>
</TD>
<TD>
<P>-16.0 (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>52.00</P>
</TD>
<TD>
<P>52.90</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Tekeoglu 1998</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>WOMAC function (17-85 Likert)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>45.50</P>
</TD>
<TD>
<P>34.30</P>
</TD>
<TD>
<P>3.10 (W)</P>
</TD>
<TD>
<P>6.8% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Betamethasone</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>45.60</P>
</TD>
<TD>
<P>31.30</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Tekeoglu 1998</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>WOMAC function (17-85 Likert)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>45.50</P>
</TD>
<TD>
<P>30.90</P>
</TD>
<TD>
<P>-8.90 (I)</P>
</TD>
<TD>
<P>-19.5% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Betamethasone</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>45.60</P>
</TD>
<TD>
<P>39.90</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Tekeoglu 1998</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>Maximum flexion (degrees)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>110.50</P>
</TD>
<TD>
<P>117.30</P>
</TD>
<TD>
<P>0.60 (I)</P>
</TD>
<TD>
<P>0.5% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Betamethsone</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>116.00</P>
</TD>
<TD>
<P>122.20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Tekeoglu 1998</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>Maximum flexion (degrees)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>110.50</P>
</TD>
<TD>
<P>121.20</P>
</TD>
<TD>
<P>-1.55 (W)</P>
</TD>
<TD>
<P>-1.3% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Betamethasone</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>116.00</P>
</TD>
<TD>
<P>128.25</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Kalay 1997</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Orthovisc + PT</P>
</TD>
<TD>
<P>Activity pain (0-100 mm VAS)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>46.8</P>
</TD>
<TD>
<P>12.50</P>
</TD>
<TD>
<P>-11.4 (I)</P>
</TD>
<TD>
<P>-30.7% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: PT</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>37.1</P>
</TD>
<TD>
<P>14.20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Kalay 1997</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Orthovisc + PT</P>
</TD>
<TD>
<P>Spontaneous pain (0-100 mm VAS)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>26.1</P>
</TD>
<TD>
<P>5.80</P>
</TD>
<TD>
<P>-3.6 (W)</P>
</TD>
<TD>
<P>-16.3% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: PT</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>22.1</P>
</TD>
<TD>
<P>5.40</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Kalay 1997</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Orthovisc + PT</P>
</TD>
<TD>
<P>Night pain (0-100 mm VAS)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>24.3</P>
</TD>
<TD>
<P>5.40</P>
</TD>
<TD>
<P>-2.8 (I)</P>
</TD>
<TD>
<P>-12.9% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: PT</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>21.7</P>
</TD>
<TD>
<P>5.60</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Kalay 1997</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Orthovisc + PT</P>
</TD>
<TD>
<P>25 m walk time (sec)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>22.4</P>
</TD>
<TD>
<P>15.30</P>
</TD>
<TD>
<P>-3.10 (I)</P>
</TD>
<TD>
<P>-16.7% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: PT</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>18.6</P>
</TD>
<TD>
<P>14.60</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Kalay 1997</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Orthovisc + PT</P>
</TD>
<TD>
<P>Flexion (degrees)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>126.00</P>
</TD>
<TD>
<P>130.00</P>
</TD>
<TD>
<P>2.70 (I)</P>
</TD>
<TD>
<P>2.1% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: PT</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>128.50</P>
</TD>
<TD>
<P>129.80</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Kalay 1997</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Orthovisc + PT</P>
</TD>
<TD>
<P>Activity pain (0-100 mm VAS)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>46.8</P>
</TD>
<TD>
<P>6.10</P>
</TD>
<TD>
<P>-16.2 (I)</P>
</TD>
<TD>
<P>-43.7% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: PT</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>37.1</P>
</TD>
<TD>
<P>12.60</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Kalay 1997</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Orthovisc + PT</P>
</TD>
<TD>
<P>Spontaneous pain (0-100 mm VAS)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>26.1</P>
</TD>
<TD>
<P>1.70</P>
</TD>
<TD>
<P>-8.1 (I)</P>
</TD>
<TD>
<P>-16.3% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: PT</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>22.1</P>
</TD>
<TD>
<P>5.80</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Kalay 1997</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Orthovisc + PT</P>
</TD>
<TD>
<P>Night pain (0-100 mm VAS)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>24.3</P>
</TD>
<TD>
<P>1.60</P>
</TD>
<TD>
<P>-5.9 (I)</P>
</TD>
<TD>
<P>-27.2% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: PT</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>21.7</P>
</TD>
<TD>
<P>4.90</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Kalay 1997</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Orthovisc + PT</P>
</TD>
<TD>
<P>25 m walk time (sec)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>22.4</P>
</TD>
<TD>
<P>13.30</P>
</TD>
<TD>
<P>-4.90 (I)</P>
</TD>
<TD>
<P>-26.3% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: PT</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>18.6</P>
</TD>
<TD>
<P>14.40</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Kalay 1997</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Orthovisc + PT</P>
</TD>
<TD>
<P>Flexion (degrees)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>126.00</P>
</TD>
<TD>
<P>130.00</P>
</TD>
<TD>
<P>2.70 (I)</P>
</TD>
<TD>
<P>2.1% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: PT</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>128.50</P>
</TD>
<TD>
<P>129.80</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karatay 2004</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>WOMAC pain (0-20 Likert)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>11.2</P>
</TD>
<TD>
<P>6.4</P>
</TD>
<TD>
<P>-0.8 (I)</P>
</TD>
<TD>
<P>-7.4% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hylan G-F 20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>10.8</P>
</TD>
<TD>
<P>6.2</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karatay 2004</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>WOMAC function (0-68 Likert)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>35.0</P>
</TD>
<TD>
<P>7.4</P>
</TD>
<TD>
<P>-3.2 (I)</P>
</TD>
<TD>
<P>-10.0% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hylan G-F 20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>31.9</P>
</TD>
<TD>
<P>7.5</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karatay 2004</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>WOMAC stiffness (0-8 Likert)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>3.8</P>
</TD>
<TD>
<P>1.8</P>
</TD>
<TD>
<P>-0.2 (I)</P>
</TD>
<TD>
<P>-5.6% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hylan G-F 20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>3.6</P>
</TD>
<TD>
<P>1.8</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karatay 2004</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>SF intercellular adhesion molecule-1 (ICAM-1)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>19.2</P>
</TD>
<TD>
<P>11.1</P>
</TD>
<TD>
<P>-0.3 (I)</P>
</TD>
<TD>
<P>-1.7% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hylan G-F 20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>17.8</P>
</TD>
<TD>
<P>10.0</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karatay 2004</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>SF vascular cell adhesion molecule-1 (VCAM)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>40.5</P>
</TD>
<TD>
<P>14.2</P>
</TD>
<TD>
<P>1.3 (W)</P>
</TD>
<TD>
<P>3.4% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hylan G-F 20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>37.8</P>
</TD>
<TD>
<P>10.2</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-43" NO="43">
<TITLE>Clinical benefit table: Orthovisc. Continuous outcome measures (2)</TITLE>
<TABLE COLS="9" ROWS="93">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Time</P>
</TH>
<TH>
<P>Treatment</P>
</TH>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>N of Pts</P>
</TH>
<TH>
<P>Baseline Mean</P>
</TH>
<TH>
<P>End of Study Mean</P>
</TH>
<TH>
<P>Absolute Benefit</P>
</TH>
<TH>
<P>Relative Difference</P>
</TH>
</TR>
<TR>
<TD>
<P>Sezgin 2005</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>WOMAC pain (5-25 LIkert)</P>
</TD>
<TD>
<P>22</P>
</TD>
<TD>
<P>18.9</P>
</TD>
<TD>
<P>8.9</P>
</TD>
<TD>
<P>-3.9 (I)</P>
</TD>
<TD>
<P>-22.7% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>17.2</P>
</TD>
<TD>
<P>11.1</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Sezgin 2005</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>WOMAC stiffness (2-10 Likert)</P>
</TD>
<TD>
<P>22</P>
</TD>
<TD>
<P>6.5</P>
</TD>
<TD>
<P>3.4</P>
</TD>
<TD>
<P>-2.0 (I)</P>
</TD>
<TD>
<P>-44.4% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>4.5</P>
</TD>
<TD>
<P>3.4</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Sezgin 2005</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>WOMAC physical function (17-85 Likert)</P>
</TD>
<TD>
<P>22</P>
</TD>
<TD>
<P>64.1</P>
</TD>
<TD>
<P>32.2</P>
</TD>
<TD>
<P>-20.9 (I)</P>
</TD>
<TD>
<P>-41.8% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>50.0</P>
</TD>
<TD>
<P>39.0</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Sezgin 2005</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>Flexion (degrees)</P>
</TD>
<TD>
<P>22</P>
</TD>
<TD>
<P>95.9</P>
</TD>
<TD>
<P>125.2</P>
</TD>
<TD>
<P>16.5 (I)</P>
</TD>
<TD>
<P>15.2% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>108.4</P>
</TD>
<TD>
<P>121.2</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Sezgin 2005</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>25 metre walking time (sec)</P>
</TD>
<TD>
<P>22</P>
</TD>
<TD>
<P>43.1</P>
</TD>
<TD>
<P>26.4</P>
</TD>
<TD>
<P>-11.2 (I)</P>
</TD>
<TD>
<P>-35.6% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>31.5</P>
</TD>
<TD>
<P>26.0</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Sezgin 2005</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>Knee cirumference (cm)</P>
</TD>
<TD>
<P>22</P>
</TD>
<TD>
<P>41.5</P>
</TD>
<TD>
<P>40.0</P>
</TD>
<TD>
<P>-0.5 (I)</P>
</TD>
<TD>
<P>-1.2% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>41.3</P>
</TD>
<TD>
<P>40.3</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Sezgin 2005</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>Synovial fluid effusion volume (ml)</P>
</TD>
<TD>
<P>22</P>
</TD>
<TD>
<P>19.0</P>
</TD>
<TD>
<P>7.6</P>
</TD>
<TD>
<P>-4.5 (I)</P>
</TD>
<TD>
<P>-24.3% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>18.5</P>
</TD>
<TD>
<P>11.6</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Sezgin 2005</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>Interleukin 6 level in synovial fluid (pg/ml)</P>
</TD>
<TD>
<P>22</P>
</TD>
<TD>
<P>42.8</P>
</TD>
<TD>
<P>22.3</P>
</TD>
<TD>
<P>-3.0 (I)</P>
</TD>
<TD>
<P>-5.8% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>51.7</P>
</TD>
<TD>
<P>34.2</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Sezgin 2005</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>Interleukin 8 level in synovial fluid (pg/ml)</P>
</TD>
<TD>
<P>22</P>
</TD>
<TD>
<P>20.6</P>
</TD>
<TD>
<P>17.0</P>
</TD>
<TD>
<P>-7.5 (I)</P>
</TD>
<TD>
<P>-41.9% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>17.9</P>
</TD>
<TD>
<P>21.8</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Sezgin 2005</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>Tumor necrosis factor alpha levels in synovial fluid (pg/ml)</P>
</TD>
<TD>
<P>22</P>
</TD>
<TD>
<P>77.0</P>
</TD>
<TD>
<P>58.7</P>
</TD>
<TD>
<P>-5.5 (I)</P>
</TD>
<TD>
<P>-6.8% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>80.8</P>
</TD>
<TD>
<P>68.0</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Neustadt 2005a</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Orthovisc (4 injections)</P>
</TD>
<TD>
<P>WOMAC pain (0-500 mm VAS)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Arthrocentesis</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Neustadt 2005a</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Orthovisc (3 injections)</P>
</TD>
<TD>
<P>WOMAC pain (0-500 mm VAS)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Arthrocentesis</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Neustadt 2005a</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Orthovisc (4 injections)</P>
</TD>
<TD>
<P>WOMAC pain (0-500 mm VAS)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Arthrocentesis</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Neustadt 2005a</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Orthovisc (3 injections)</P>
</TD>
<TD>
<P>WOMAC pain (0-500 mm VAS)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Arthrocentesis</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Neustadt 2005a</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Orthovisc (4 injections)</P>
</TD>
<TD>
<P>Pain on standing (0-100 mm VAS)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Arthrocentesis</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Neustadt 2005a</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Orthovisc (3 injections)</P>
</TD>
<TD>
<P>Pain on standing (0-100 mm VAS)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Arthrocentesis</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Neustadt 2005a</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Orthovisc (4 injections)</P>
</TD>
<TD>
<P>Pain on standing (0-100 mm VAS)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Arthrocentesis</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Neustadt 2005a</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Orthovisc (3 injections)</P>
</TD>
<TD>
<P>Pain on standing (0-100 mm VAS)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Arthrocentesis</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Neustadt 2005a</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Orthovisc (4 injections)</P>
</TD>
<TD>
<P>Patient global score (0-100 mm VAS)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Arthrocentesis</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Neustadt 2005a</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Orthovisc (3 injections)</P>
</TD>
<TD>
<P>Patient global score (0-100 mm VAS)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Arthrocentesis</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Neustadt 2005a</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Orthovisc (4 injections)</P>
</TD>
<TD>
<P>Patient global score (0-100 mm VAS)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Arthrocentesis</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Neustadt 2005a</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Orthovisc (3 injections)</P>
</TD>
<TD>
<P>Patient global score (0-100 mm VAS)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Arthrocentesis</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Neustadt 2005a</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Orthovisc (4 injections)</P>
</TD>
<TD>
<P>Investigator global score (0-100 mm VAS)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Arthrocentesis</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Neustadt 2005a</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Orthovisc (3 injections)</P>
</TD>
<TD>
<P>Investigator global score (0-100 mm VAS)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Arthrocentesis</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Neustadt 2005a</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Orthovisc (4 injections)</P>
</TD>
<TD>
<P>Investigator global score (0-100 mm VAS)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Arthrocentesis</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Neustadt 2005a</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Orthovisc (3 injections)</P>
</TD>
<TD>
<P>Investigator global score (0-100 mm VAS)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Arthrocentesis</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Yentur 2003</P>
</TD>
<TD>
<P>1 wk</P>
</TD>
<TD>
<P>E: Orthovisc+lidocaine</P>
</TD>
<TD>
<P>Pain at rest (0-4 point scale)</P>
</TD>
<TD>
<P>17</P>
</TD>
<TD>
<P>2.90</P>
</TD>
<TD>
<P>0.52</P>
</TD>
<TD>
<P>-2.07 (I)</P>
</TD>
<TD>
<P>-80.9% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Orthovisc</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>2.56</P>
</TD>
<TD>
<P>2.25</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Yentur 2003</P>
</TD>
<TD>
<P>1 wk</P>
</TD>
<TD>
<P>E: Orthovisc+lidocaine</P>
</TD>
<TD>
<P>Pain/restrictions walking (0-4 point scale)</P>
</TD>
<TD>
<P>17</P>
</TD>
<TD>
<P>2.35</P>
</TD>
<TD>
<P>0.88</P>
</TD>
<TD>
<P>-1.10 (I)</P>
</TD>
<TD>
<P>-46.4% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Orthovisc</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>2.37</P>
</TD>
<TD>
<P>2.00</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Yentur 2003</P>
</TD>
<TD>
<P>1 wk</P>
</TD>
<TD>
<P>E: Orthovisc+lidocaine</P>
</TD>
<TD>
<P>Pain/restrictions going up or down stairs (0-4 point scale)</P>
</TD>
<TD>
<P>17</P>
</TD>
<TD>
<P>2.60</P>
</TD>
<TD>
<P>0.88</P>
</TD>
<TD>
<P>-1.47 (I)</P>
</TD>
<TD>
<P>-56.1% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Orthovisc</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>2.62</P>
</TD>
<TD>
<P>2.37</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Yentur 2003</P>
</TD>
<TD>
<P>1 wk</P>
</TD>
<TD>
<P>E: Orthovisc+lidocaine</P>
</TD>
<TD>
<P>Range of motion (degrees)</P>
</TD>
<TD>
<P>17</P>
</TD>
<TD>
<P>103.8</P>
</TD>
<TD>
<P>124.4</P>
</TD>
<TD>
<P>21.2 (I)</P>
</TD>
<TD>
<P>18.2% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Orthovisc</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>116.2</P>
</TD>
<TD>
<P>116.8</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karatosun 2005a</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>Hospital for Special Surgery Knee Score</P>
</TD>
<TD>
<P>39</P>
</TD>
<TD>
<P>67.7</P>
</TD>
<TD>
<P>86.5</P>
</TD>
<TD>
<P>2.2 (I)</P>
</TD>
<TD>
<P>3.1% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hylan G-F 20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>70.1</P>
</TD>
<TD>
<P>86.7</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karatosun 2005a</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>Hospital for Special Surgery Knee Score</P>
</TD>
<TD>
<P>39</P>
</TD>
<TD>
<P>67.7</P>
</TD>
<TD>
<P>87.3</P>
</TD>
<TD>
<P>3.4 (I)</P>
</TD>
<TD>
<P>4.9% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hylan G-F 20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>34</P>
</TD>
<TD>
<P>70.1</P>
</TD>
<TD>
<P>86.3</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karatosun 2005a</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>Hospital for Special Surgery Knee Score</P>
</TD>
<TD>
<P>37</P>
</TD>
<TD>
<P>67.7</P>
</TD>
<TD>
<P>84.7</P>
</TD>
<TD>
<P>1.4 (I)</P>
</TD>
<TD>
<P>2.0% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hylan G-F 20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>34</P>
</TD>
<TD>
<P>70.1</P>
</TD>
<TD>
<P>85.7</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karatosun 2005</P>
</TD>
<TD>
<P>45-52 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>Hospital for Special Surgery Knee Score</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>67.7</P>
</TD>
<TD>
<P>86.6</P>
</TD>
<TD>
<P>2.3 (I)</P>
</TD>
<TD>
<P>3.3% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hylan G-F 20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>32</P>
</TD>
<TD>
<P>70.1</P>
</TD>
<TD>
<P>86.7</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karatosun 2005a</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>Pain during activity (HSSKS)</P>
</TD>
<TD>
<P>39</P>
</TD>
<TD>
<P>4.4</P>
</TD>
<TD>
<P>11.2</P>
</TD>
<TD>
<P>0.8 (I)</P>
</TD>
<TD>
<P>15.4% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hylan G-F 20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>5.2</P>
</TD>
<TD>
<P>11.2</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karatosun 2005a</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>Pain during activity (HSSKS)</P>
</TD>
<TD>
<P>39</P>
</TD>
<TD>
<P>4.4</P>
</TD>
<TD>
<P>11.3</P>
</TD>
<TD>
<P>1.8 (I)</P>
</TD>
<TD>
<P>34.6% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hylan G-F 20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>34</P>
</TD>
<TD>
<P>5.2</P>
</TD>
<TD>
<P>10.3</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karatosun 2005a</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>Pain during activity (HSSKS)</P>
</TD>
<TD>
<P>37</P>
</TD>
<TD>
<P>4.4</P>
</TD>
<TD>
<P>10.5</P>
</TD>
<TD>
<P>0.7 (I)</P>
</TD>
<TD>
<P>13.5% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hylan G-F 20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>34</P>
</TD>
<TD>
<P>5.2</P>
</TD>
<TD>
<P>10.6</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karatosun 2005a</P>
</TD>
<TD>
<P>45-52 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>Pain during activity (HSSKS)</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>4.4</P>
</TD>
<TD>
<P>10.8</P>
</TD>
<TD>
<P>0.5 (I)</P>
</TD>
<TD>
<P>9.6% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hylan G-F 20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>32</P>
</TD>
<TD>
<P>5.2</P>
</TD>
<TD>
<P>11.1</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karatosun 2005a</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>Pain at rest (HSSKS)</P>
</TD>
<TD>
<P>39</P>
</TD>
<TD>
<P>9.1</P>
</TD>
<TD>
<P>14.1</P>
</TD>
<TD>
<P>0.1 (I)</P>
</TD>
<TD>
<P>1.2% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hylan G-F 20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>8.1</P>
</TD>
<TD>
<P>13.0</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karatosun 2005a</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>Pain at rest (HSSKS)</P>
</TD>
<TD>
<P>39</P>
</TD>
<TD>
<P>9.1</P>
</TD>
<TD>
<P>13.4</P>
</TD>
<TD>
<P>-0.8 (W)</P>
</TD>
<TD>
<P>-9.9% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hylan G-F 20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>34</P>
</TD>
<TD>
<P>8.1</P>
</TD>
<TD>
<P>13.2</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karatosun 2005a</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>Pain at rest (HSSKS)</P>
</TD>
<TD>
<P>37</P>
</TD>
<TD>
<P>9.1</P>
</TD>
<TD>
<P>13.2</P>
</TD>
<TD>
<P>-1.3 (W)</P>
</TD>
<TD>
<P>-16.0% W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hylan G-F 20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>34</P>
</TD>
<TD>
<P>8.1</P>
</TD>
<TD>
<P>13.5</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karatosun 2005a</P>
</TD>
<TD>
<P>45-52 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>Pain at rest (HSSKS)</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>9.1</P>
</TD>
<TD>
<P>13.4</P>
</TD>
<TD>
<P>-0.7 (W)</P>
</TD>
<TD>
<P>-8.6% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hylan G-F 20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>32</P>
</TD>
<TD>
<P>8.1</P>
</TD>
<TD>
<P>13.1</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karatosun 2005a</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>Pain during climbing stairs (HSSKS)</P>
</TD>
<TD>
<P>39</P>
</TD>
<TD>
<P>2.1</P>
</TD>
<TD>
<P>3.5</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0%</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hylan G-F 20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>2.1</P>
</TD>
<TD>
<P>3.5</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karatosun 2005a</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>Pain during climbing stairs (HSSKS)</P>
</TD>
<TD>
<P>39</P>
</TD>
<TD>
<P>2.1</P>
</TD>
<TD>
<P>3.5</P>
</TD>
<TD>
<P>-0.1 (W)</P>
</TD>
<TD>
<P>-4.8% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hylan G-F 20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>34</P>
</TD>
<TD>
<P>2.1</P>
</TD>
<TD>
<P>3.6</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karatosun 2005a</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>Pain during climbing stairs (HSSKS)</P>
</TD>
<TD>
<P>37</P>
</TD>
<TD>
<P>2.1</P>
</TD>
<TD>
<P>3.0</P>
</TD>
<TD>
<P>-0.1 (W)</P>
</TD>
<TD>
<P>-4.8% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hylan G-F 20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>34</P>
</TD>
<TD>
<P>2.1</P>
</TD>
<TD>
<P>3.1</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karatosun 2005a</P>
</TD>
<TD>
<P>45-52 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>Pain during climbing stairs (HSSKS)</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>2.1</P>
</TD>
<TD>
<P>3.0</P>
</TD>
<TD>
<P>-0.4 (W)</P>
</TD>
<TD>
<P>-19.0% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hylan G-F 20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>32</P>
</TD>
<TD>
<P>2.1</P>
</TD>
<TD>
<P>3.4</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-44" NO="44">
<TITLE>Clinical benefit table: Orthovisc. Continuous outcome measures (3)</TITLE>
<TABLE COLS="9" ROWS="95">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Time</P>
</TH>
<TH>
<P>Treatment</P>
</TH>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>N of Pts</P>
</TH>
<TH>
<P>Baseline Mean</P>
</TH>
<TH>
<P>End of Study Mean</P>
</TH>
<TH>
<P>Absolute Benefit</P>
</TH>
<TH>
<P>Relative Difference</P>
</TH>
</TR>
<TR>
<TD>
<P>Karatosun 2005a</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>Pain during transfer activity</P>
</TD>
<TD>
<P>39</P>
</TD>
<TD>
<P>2.5</P>
</TD>
<TD>
<P>4.0</P>
</TD>
<TD>
<P>-1.1 (W)</P>
</TD>
<TD>
<P>-42.3% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hylan G-F 0</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>2.6</P>
</TD>
<TD>
<P>4.2</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karatosun 2005a</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>Pain during transfer activity</P>
</TD>
<TD>
<P>39</P>
</TD>
<TD>
<P>2.5</P>
</TD>
<TD>
<P>4.5</P>
</TD>
<TD>
<P>0.5 (I)</P>
</TD>
<TD>
<P>19.25 (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hylan G-F 20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>34</P>
</TD>
<TD>
<P>2.6</P>
</TD>
<TD>
<P>4.1</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karatosun 2005a</P>
</TD>
<TD>
<P>14-26 wj</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>Pain during transfer activity</P>
</TD>
<TD>
<P>37</P>
</TD>
<TD>
<P>2.5</P>
</TD>
<TD>
<P>3.9</P>
</TD>
<TD>
<P>0.2 (I)</P>
</TD>
<TD>
<P>7.7% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hylan G-F 20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>34</P>
</TD>
<TD>
<P>2.6</P>
</TD>
<TD>
<P>3.8</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karatosun 2005a</P>
</TD>
<TD>
<P>45-52 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>Pain during transfer activity</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>2.5</P>
</TD>
<TD>
<P>4.3</P>
</TD>
<TD>
<P>0.3 (I)</P>
</TD>
<TD>
<P>11.5% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hylan G-F 20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>32</P>
</TD>
<TD>
<P>2.6</P>
</TD>
<TD>
<P>4.1</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karatosun 2005a</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>Walking distance</P>
</TD>
<TD>
<P>39</P>
</TD>
<TD>
<P>5.4</P>
</TD>
<TD>
<P>8.7</P>
</TD>
<TD>
<P>1.7 (I)</P>
</TD>
<TD>
<P>20.5% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hylan G-F 20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>8.3</P>
</TD>
<TD>
<P>9.9</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karatosun 2005a</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>Walking distance</P>
</TD>
<TD>
<P>39</P>
</TD>
<TD>
<P>5.4</P>
</TD>
<TD>
<P>9.2</P>
</TD>
<TD>
<P>2.0 (I)</P>
</TD>
<TD>
<P>24.2% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hylan G-F 20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>34</P>
</TD>
<TD>
<P>8.3</P>
</TD>
<TD>
<P>10.1</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karatosun 2005a</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>Walking distance</P>
</TD>
<TD>
<P>37</P>
</TD>
<TD>
<P>5.4</P>
</TD>
<TD>
<P>9.1</P>
</TD>
<TD>
<P>2.0 (I)</P>
</TD>
<TD>
<P>24.2% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hylan G-F 20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>34</P>
</TD>
<TD>
<P>8.3</P>
</TD>
<TD>
<P>10.0</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karatosun 2005a</P>
</TD>
<TD>
<P>45-52 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>Walking distance</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>5.4</P>
</TD>
<TD>
<P>9.6</P>
</TD>
<TD>
<P>2.3 (I)</P>
</TD>
<TD>
<P>27.7% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hylan G-F 20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>32</P>
</TD>
<TD>
<P>8.3</P>
</TD>
<TD>
<P>10.2</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karatosun 2005a</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>Range of motion</P>
</TD>
<TD>
<P>39</P>
</TD>
<TD>
<P>113.0</P>
</TD>
<TD>
<P>123.0</P>
</TD>
<TD>
<P>3.8 (I)</P>
</TD>
<TD>
<P>3.3% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hylan G-F 20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>114.4</P>
</TD>
<TD>
<P>120.6</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karatosun 2005a</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>Range of motion</P>
</TD>
<TD>
<P>39</P>
</TD>
<TD>
<P>113.0</P>
</TD>
<TD>
<P>121.9</P>
</TD>
<TD>
<P>2.3 (I)</P>
</TD>
<TD>
<P>2.0% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hylan G-F 20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>34</P>
</TD>
<TD>
<P>114.4</P>
</TD>
<TD>
<P>121.0</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karatosun 2005a</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>Range of motion</P>
</TD>
<TD>
<P>37</P>
</TD>
<TD>
<P>113.0</P>
</TD>
<TD>
<P>118.0</P>
</TD>
<TD>
<P>-0.4 (W)</P>
</TD>
<TD>
<P>-0.3% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hylan G-F 20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>34</P>
</TD>
<TD>
<P>114.4</P>
</TD>
<TD>
<P>119.8</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Karatosun 2005a</P>
</TD>
<TD>
<P>45-52 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>Range of motion</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>113.0</P>
</TD>
<TD>
<P>122.0</P>
</TD>
<TD>
<P>2.1 (I)</P>
</TD>
<TD>
<P>1.8% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hylan G-F 20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>32</P>
</TD>
<TD>
<P>114.4</P>
</TD>
<TD>
<P>121.3</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>WOMAC pain (Likert)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>13.4</P>
</TD>
<TD>
<P>9.3</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0%</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hylan G-F 20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>12.4</P>
</TD>
<TD>
<P>8.3</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>WOMAC pain (Likert)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>13.4</P>
</TD>
<TD>
<P>11.2</P>
</TD>
<TD>
<P>1.5 (W)</P>
</TD>
<TD>
<P>12.1% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hylan G-F 20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>12.4</P>
</TD>
<TD>
<P>8.7</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>WOMAC pain (Likert)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>13.4</P>
</TD>
<TD>
<P>11.9</P>
</TD>
<TD>
<P>0.5 (W)</P>
</TD>
<TD>
<P>4.0% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hylan G-F 20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>12.4</P>
</TD>
<TD>
<P>10.4</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>36 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>WOMAC pain (Likert)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>13.4</P>
</TD>
<TD>
<P>10.4</P>
</TD>
<TD>
<P>-1.0 (I)</P>
</TD>
<TD>
<P>8.1% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hylan G-F 20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>12.4</P>
</TD>
<TD>
<P>10.4</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>45-52 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>WOMAC pain (Likert)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>13.4</P>
</TD>
<TD>
<P>11.2</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0%</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hylan G-F 20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>12.4</P>
</TD>
<TD>
<P>10.2</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>Spontaneous pain (0-100 mm VAS)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>70.3</P>
</TD>
<TD>
<P>42.9</P>
</TD>
<TD>
<P>-6.4 (I)</P>
</TD>
<TD>
<P>-7.5% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hylan G-F 20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>85.0</P>
</TD>
<TD>
<P>64.0</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>Spontaneous pain (0-100 mm VAS)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>70.3</P>
</TD>
<TD>
<P>58.4</P>
</TD>
<TD>
<P>27.6 (W)</P>
</TD>
<TD>
<P>32.5% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hylan G-F 20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>85.0</P>
</TD>
<TD>
<P>45.5</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>Spontaneous pain (0-100 mm VAS)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>70.3</P>
</TD>
<TD>
<P>66.2</P>
</TD>
<TD>
<P>30.2 (W)</P>
</TD>
<TD>
<P>35.5% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hylan G-F 20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>85.0</P>
</TD>
<TD>
<P>50.7</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>36 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>Spontaneous pain (0-100 mm VAS)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>70.3</P>
</TD>
<TD>
<P>52.2</P>
</TD>
<TD>
<P>15.2 (W)</P>
</TD>
<TD>
<P>17.9% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hylan G-F 20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>85.0</P>
</TD>
<TD>
<P>51.7</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>45-52 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>Spontaneous pain (0-100 mm VAS)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>70.3</P>
</TD>
<TD>
<P>56.7</P>
</TD>
<TD>
<P>22.4 (W)</P>
</TD>
<TD>
<P>26.4% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hylan G-F 20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>85.0</P>
</TD>
<TD>
<P>49.0</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>SF-36 pain</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>36.4</P>
</TD>
<TD>
<P>47.5</P>
</TD>
<TD>
<P>-22.7 (W)</P>
</TD>
<TD>
<P>-88.7% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hylan G-F 20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>25.6</P>
</TD>
<TD>
<P>59.4</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>SF-36 pain</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>36.4</P>
</TD>
<TD>
<P>28.0</P>
</TD>
<TD>
<P>24.8 (W)</P>
</TD>
<TD>
<P>96.9% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hylan G-F 20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>25.6</P>
</TD>
<TD>
<P>58.8</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>SF-36 pain</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>36.4</P>
</TD>
<TD>
<P>35.9</P>
</TD>
<TD>
<P>29.6 (W)</P>
</TD>
<TD>
<P>115.6% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hylan G-F 20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>25.6</P>
</TD>
<TD>
<P>55.7</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>36 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>SF-36 pain</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>36.4</P>
</TD>
<TD>
<P>45.3</P>
</TD>
<TD>
<P>9.3 (W)</P>
</TD>
<TD>
<P>36.3% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hylan G-F 20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>25.6</P>
</TD>
<TD>
<P>43.8</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>45-52 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>SF-36 pain</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>36.4</P>
</TD>
<TD>
<P>37.7</P>
</TD>
<TD>
<P>19.8 (W)</P>
</TD>
<TD>
<P>77.3% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hylan G-F 20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>25.6</P>
</TD>
<TD>
<P>46.7</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>WOMAC physical function</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>41.5</P>
</TD>
<TD>
<P>35.2</P>
</TD>
<TD>
<P>11.9 (W)</P>
</TD>
<TD>
<P>20.4% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hylan G-F 20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>58.3</P>
</TD>
<TD>
<P>40.1</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>WOMAC physical function</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>41.5</P>
</TD>
<TD>
<P>36.2</P>
</TD>
<TD>
<P>11.3 (W)</P>
</TD>
<TD>
<P>19.4% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hylan G-F 20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>58.3</P>
</TD>
<TD>
<P>41.7</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>WOMAC physical function</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>41.5</P>
</TD>
<TD>
<P>41.8</P>
</TD>
<TD>
<P>16.1 (W)</P>
</TD>
<TD>
<P>27.6% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hylan G-F 20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>58.3</P>
</TD>
<TD>
<P>41.9</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>36 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>WOMAC physical function</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>41.5</P>
</TD>
<TD>
<P>39.6</P>
</TD>
<TD>
<P>17.8 (W)</P>
</TD>
<TD>
<P>30.5% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hylan G-F 20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>58.3</P>
</TD>
<TD>
<P>38.6</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>45-52 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>WOMAC physical function</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>41.5</P>
</TD>
<TD>
<P>37.6</P>
</TD>
<TD>
<P>15.5 (W)</P>
</TD>
<TD>
<P>26.6% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hylan G-F 20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>58.3</P>
</TD>
<TD>
<P>38.9</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>SF-36 physical functioning</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>44.5</P>
</TD>
<TD>
<P>54.2</P>
</TD>
<TD>
<P>-12.0 (W)</P>
</TD>
<TD>
<P>-33.8% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hylan G-F 20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>35.5</P>
</TD>
<TD>
<P>57.2</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>SF-36 physical functioning</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>44.5</P>
</TD>
<TD>
<P>41.5</P>
</TD>
<TD>
<P>-23.2 (W)</P>
</TD>
<TD>
<P>-65.4% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hylan G-F 20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>35.5</P>
</TD>
<TD>
<P>61.7</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>SF-36 physical functionin</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>44.5</P>
</TD>
<TD>
<P>44.5</P>
</TD>
<TD>
<P>-20.2 (W)</P>
</TD>
<TD>
<P>-56.9% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hylan G-F 20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>35.5</P>
</TD>
<TD>
<P>55.7</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>36 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>SF-36 physical functioning</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>44.5</P>
</TD>
<TD>
<P>49.2</P>
</TD>
<TD>
<P>-4.8 (W)</P>
</TD>
<TD>
<P>-13.5% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hylan G-F 20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>35.5</P>
</TD>
<TD>
<P>45.0</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>45-52 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>SF-36 physical functioning</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>44.5</P>
</TD>
<TD>
<P>31.0</P>
</TD>
<TD>
<P>-32.0 (W)</P>
</TD>
<TD>
<P>-90.1% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hylan G-F 20</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>35.5</P>
</TD>
<TD>
<P>54.0</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>WOMAC pain (Likert)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>13.4</P>
</TD>
<TD>
<P>9.3</P>
</TD>
<TD>
<P>-1.2 (I)</P>
</TD>
<TD>
<P>-8.5% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Physical therapy</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>14.2</P>
</TD>
<TD>
<P>11.3</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>WOMAC pain (Likert)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>13.4</P>
</TD>
<TD>
<P>11.2</P>
</TD>
<TD>
<P>0.2 (W)</P>
</TD>
<TD>
<P>1.4% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Physical therapy</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>14.2</P>
</TD>
<TD>
<P>11.8</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>WOMAC pain (Likert)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>13.4</P>
</TD>
<TD>
<P>11.9</P>
</TD>
<TD>
<P>1.4 (W)</P>
</TD>
<TD>
<P>9.9% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Physical therapy</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>14.2</P>
</TD>
<TD>
<P>11.3</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>36 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>WOMAC pain (Likert)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>13.4</P>
</TD>
<TD>
<P>10.4</P>
</TD>
<TD>
<P>-1.1 (I)</P>
</TD>
<TD>
<P>-7.7% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Physical therapy</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>14.2</P>
</TD>
<TD>
<P>12.3</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>45-52 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>WOMAC pain (Likert)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>13.4</P>
</TD>
<TD>
<P>11.2</P>
</TD>
<TD>
<P>-3.5 (I)</P>
</TD>
<TD>
<P>-24.6% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Physical therapy</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>14.2</P>
</TD>
<TD>
<P>15.5</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>Spontaneous pain (0-100 mm VAS)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>70.3</P>
</TD>
<TD>
<P>42.9</P>
</TD>
<TD>
<P>-6.4 (I)</P>
</TD>
<TD>
<P>-7.5% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Physical therapy</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>93.5</P>
</TD>
<TD>
<P>43.5</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>Spontaneous pain (0-100 mm VAS)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>70.3</P>
</TD>
<TD>
<P>58.4</P>
</TD>
<TD>
<P>22.4 (W)</P>
</TD>
<TD>
<P>26.4% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Physical therapy</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>93.5</P>
</TD>
<TD>
<P>49.5</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>Spontaneous pain (0-100 mm VAS)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>70.3</P>
</TD>
<TD>
<P>66.2</P>
</TD>
<TD>
<P>29.2 (W)</P>
</TD>
<TD>
<P>34.4% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Physical therapy</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>93.5</P>
</TD>
<TD>
<P>48.5</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>36 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>Spontaneous pain (0-100 mm VAS)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>70.3</P>
</TD>
<TD>
<P>52.2</P>
</TD>
<TD>
<P>15.2 (W)</P>
</TD>
<TD>
<P>17.9% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Physical therapy</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>93.5</P>
</TD>
<TD>
<P>50.7</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>45-52 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>Spontaneous pain (0-100 mm VAS)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>70.3</P>
</TD>
<TD>
<P>56.7</P>
</TD>
<TD>
<P>22.4 (W)</P>
</TD>
<TD>
<P>26.4% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Physical therapy</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>93.5</P>
</TD>
<TD>
<P>59.5</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-45" NO="45">
<TITLE>Clinical benefit table: Orthovisc. Continuous outcome measures (4)</TITLE>
<TABLE COLS="9" ROWS="39">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Time</P>
</TH>
<TH>
<P>Treatment</P>
</TH>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>N of Pts</P>
</TH>
<TH>
<P>Baseline Mean</P>
</TH>
<TH>
<P>End of Study Mean</P>
</TH>
<TH>
<P>Absolute Benefit</P>
</TH>
<TH>
<P>Relative Difference</P>
</TH>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>SF-36 pain</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>36.4</P>
</TD>
<TD>
<P>47.5</P>
</TD>
<TD>
<P>-18.4 (W)</P>
</TD>
<TD>
<P>-62.2% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Physical therapy</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>29.6</P>
</TD>
<TD>
<P>59.1</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>SF-36 pain</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>36.4</P>
</TD>
<TD>
<P>28.0</P>
</TD>
<TD>
<P>18.2 (W)</P>
</TD>
<TD>
<P>61.5% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Physical therapy</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>29.6</P>
</TD>
<TD>
<P>56.2</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>SF-36 pain</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>36.4</P>
</TD>
<TD>
<P>35.9</P>
</TD>
<TD>
<P>24.5 (W)</P>
</TD>
<TD>
<P>82.8% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Physical therapy</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>29.6</P>
</TD>
<TD>
<P>54.6</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>36 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>SF-36 pain</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>36.4</P>
</TD>
<TD>
<P>45.3</P>
</TD>
<TD>
<P>-12.8 (W)</P>
</TD>
<TD>
<P>-43.2% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Physical therapy</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>29.6</P>
</TD>
<TD>
<P>51.3</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>45-52 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>SF-36 pain</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>36.4</P>
</TD>
<TD>
<P>37.7</P>
</TD>
<TD>
<P>-19.3 (W)</P>
</TD>
<TD>
<P>-65.2% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Physical therapy</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>46.7</P>
</TD>
<TD>
<P>50.2</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>WOMAC physical function</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>41.5</P>
</TD>
<TD>
<P>35.2</P>
</TD>
<TD>
<P>6.0 (W)</P>
</TD>
<TD>
<P>12.0% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Physical therapy</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>49.9</P>
</TD>
<TD>
<P>37.6</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>WOMAC physical function</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>41.5</P>
</TD>
<TD>
<P>36.2</P>
</TD>
<TD>
<P>5.7 (W)</P>
</TD>
<TD>
<P>11.4% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Physical therapy</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>49.9</P>
</TD>
<TD>
<P>38.9</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>WOMAC physical function</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>41.5</P>
</TD>
<TD>
<P>41.8</P>
</TD>
<TD>
<P>7.7 (W)</P>
</TD>
<TD>
<P>15.% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Physical therapy</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>49.9</P>
</TD>
<TD>
<P>41.9</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>36 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>WOMAC physical function</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>41.5</P>
</TD>
<TD>
<P>39.6</P>
</TD>
<TD>
<P>9.8 (W)</P>
</TD>
<TD>
<P>19.6% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Physical therapy</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>49.9</P>
</TD>
<TD>
<P>38.2</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>45-52 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>WOMAC physical function</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>41.5</P>
</TD>
<TD>
<P>37.6</P>
</TD>
<TD>
<P>7.8 (W)</P>
</TD>
<TD>
<P>15.6% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Physical therapy</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>49.9</P>
</TD>
<TD>
<P>38.2</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>SF-36 physical functioning</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>44.5</P>
</TD>
<TD>
<P>54.2</P>
</TD>
<TD>
<P>-12.3 (W)</P>
</TD>
<TD>
<P>-38.8% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Physical therapy</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>31.7</P>
</TD>
<TD>
<P>53.7</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>SF-36 physical functioning</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>44.5</P>
</TD>
<TD>
<P>41.5</P>
</TD>
<TD>
<P>-24.8 (W)</P>
</TD>
<TD>
<P>-78.2% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Physical therapy</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>31.7</P>
</TD>
<TD>
<P>53.5</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>SF-36 physical functioning</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>44.5</P>
</TD>
<TD>
<P>44.5</P>
</TD>
<TD>
<P>-22.3 (W)</P>
</TD>
<TD>
<P>-70.3% (WO</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Physical therapy</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>31.7</P>
</TD>
<TD>
<P>54.0</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>36 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>SF-36 physical functioning</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>44.5</P>
</TD>
<TD>
<P>49.2</P>
</TD>
<TD>
<P>-12.8 (W)</P>
</TD>
<TD>
<P>-40.4% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Physical therapy</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>31.7</P>
</TD>
<TD>
<P>49.2</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2005</P>
</TD>
<TD>
<P>45-52 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>SF-36 physical functioning</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>44.5</P>
</TD>
<TD>
<P>31.0</P>
</TD>
<TD>
<P>-34.8 (W)</P>
</TD>
<TD>
<P>-109.8% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Physical therapy</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>31.7</P>
</TD>
<TD>
<P>53.0</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Ozturk 2005</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>Pain (0-100 mm VAS)</P>
</TD>
<TD>
<P>24</P>
</TD>
<TD>
<P>66.7</P>
</TD>
<TD>
<P>53.5</P>
</TD>
<TD>
<P>18.9 (W)</P>
</TD>
<TD>
<P>-26.0% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Orthovisc+triamcinolone acetonide</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>72.6</P>
</TD>
<TD>
<P>40.5</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Ozturk 2005</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>WOMAC OA Index stiffness subscale</P>
</TD>
<TD>
<P>24</P>
</TD>
<TD>
<P>4.1</P>
</TD>
<TD>
<P>3.9</P>
</TD>
<TD>
<P>0.8 (W)</P>
</TD>
<TD>
<P>-19.5% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Orthovisc+triamcinolone acetonide</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>4.1</P>
</TD>
<TD>
<P>3.1</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Ozturk 2005</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>WOMAC OA Index stiffness subscale</P>
</TD>
<TD>
<P>24</P>
</TD>
<TD>
<P>4.1</P>
</TD>
<TD>
<P>3.9</P>
</TD>
<TD>
<P>0.8 (W)</P>
</TD>
<TD>
<P>-19.5% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Orthovisc+triamcinolone acetonide</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>4.1</P>
</TD>
<TD>
<P>3.1</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Ozturk 2005</P>
</TD>
<TD>
<P>45-52 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>WOMAC OA Index stiffness subscale</P>
</TD>
<TD>
<P>24</P>
</TD>
<TD>
<P>4.1</P>
</TD>
<TD>
<P>3.9</P>
</TD>
<TD>
<P>0.8 (W)</P>
</TD>
<TD>
<P>-19.5% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Orthovisc+triamcinolone acetonide</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>4.1</P>
</TD>
<TD>
<P>3.1</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-46" NO="46">
<TITLE>Clinical benefit table: Orthovisc. Dichotomous outcome measures</TITLE>
<TABLE COLS="9" ROWS="13">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Time</P>
</TH>
<TH>
<P>Treatment</P>
</TH>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>No. improved</P>
</TH>
<TH>
<P>No. of pts.</P>
</TH>
<TH>
<P>Risk (%)</P>
</TH>
<TH>
<P>Risk difference</P>
</TH>
<TH>
<P>NNT</P>
</TH>
</TR>
<TR>
<TD>
<P>Brandt 2001</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>WOMAC pain (number of patients improved)</P>
</TD>
<TD>
<P>61</P>
</TD>
<TD>
<P>66</P>
</TD>
<TD>
<P>92</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>20</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>69</P>
</TD>
<TD>
<P>87</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Brandt 2001</P>
</TD>
<TD>
<P>14-26 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>WOMAC pain greater than 5 unit improvement</P>
</TD>
<TD>
<P>38</P>
</TD>
<TD>
<P>66</P>
</TD>
<TD>
<P>58</P>
</TD>
<TD>
<P>17</P>
</TD>
<TD>
<P>5.9</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>28</P>
</TD>
<TD>
<P>69</P>
</TD>
<TD>
<P>41</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Tekeoglu 1998</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>Patient global (number of patients good/very good)</P>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>50</P>
</TD>
<TD>
<P>-10</P>
</TD>
<TD>
<P>10</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Betamethasone</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Tekeoglu 1998</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>Patient global (number of patients good/very good)</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>75</P>
</TD>
<TD>
<P>35</P>
</TD>
<TD>
<P>2.9</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Betamethasone</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>8</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Kalay 1997</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Orthovisc + PT</P>
</TD>
<TD>
<P>Number of patients rating treatment effective/very effective</P>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>95</P>
</TD>
<TD>
<P>35</P>
</TD>
<TD>
<P>2.9</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: PT</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Guler 1996</P>
</TD>
<TD>
<P>5-13 wk</P>
</TD>
<TD>
<P>E: Orthovisc</P>
</TD>
<TD>
<P>Number of patients rating treatment effective/very effective</P>
</TD>
<TD>
<P>11</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>73</P>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>2.5</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>33</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-47" NO="47">
<TITLE>Clinical benefit table: SLM-10 versus Artz. Dichotomous outcome measures</TITLE>
<TABLE COLS="9" ROWS="9">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Time</P>
</TH>
<TH>
<P>Treatment</P>
</TH>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>No. improved</P>
</TH>
<TH>
<P>No. of pts</P>
</TH>
<TH>
<P>Risk (%)</P>
</TH>
<TH>
<P>Risk difference</P>
</TH>
<TH>
<P>NNT</P>
</TH>
</TR>
<TR>
<TD>
<P>Kawabata 1993</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: SLM-10</P>
</TD>
<TD>
<P>Pain in movement (number of patients improved)</P>
</TD>
<TD>
<P>59</P>
</TD>
<TD>
<P>82</P>
</TD>
<TD>
<P>72</P>
</TD>
<TD>
<P>-9</P>
</TD>
<TD>
<P>11.1</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Artz</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>74</P>
</TD>
<TD>
<P>81</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Kawabata 1993</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: SLM-10</P>
</TD>
<TD>
<P>Pain when resting (number of patietns improved)</P>
</TD>
<TD>
<P>33</P>
</TD>
<TD>
<P>93</P>
</TD>
<TD>
<P>85</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>20</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Artz</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>33</P>
</TD>
<TD>
<P>41</P>
</TD>
<TD>
<P>80</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Kawabata 1993</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: SLM-10</P>
</TD>
<TD>
<P>Pressure pain (number of patients improved)</P>
</TD>
<TD>
<P>48</P>
</TD>
<TD>
<P>75</P>
</TD>
<TD>
<P>64</P>
</TD>
<TD>
<P>-18</P>
</TD>
<TD>
<P>5.6</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Artz</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>54</P>
</TD>
<TD>
<P>66</P>
</TD>
<TD>
<P>82</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Kawabata 1993</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: SLM-10</P>
</TD>
<TD>
<P>Number of patients better/much better</P>
</TD>
<TD>
<P>56</P>
</TD>
<TD>
<P>82</P>
</TD>
<TD>
<P>68</P>
</TD>
<TD>
<P>-4</P>
</TD>
<TD>
<P>25</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Artz</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>74</P>
</TD>
<TD>
<P>72</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-48" NO="48">
<TITLE>Clinical benefit table: Suplasyn. Continuous outcome measures</TITLE>
<TABLE COLS="9" ROWS="25">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Time</P>
</TH>
<TH>
<P>Treatment</P>
</TH>
<TH>
<P>Outcome (scale)</P>
</TH>
<TH>
<P>N of Pts</P>
</TH>
<TH>
<P>Baseline Mean</P>
</TH>
<TH>
<P>End of Study Mean</P>
</TH>
<TH>
<P>Absolute Benefit</P>
</TH>
<TH>
<P>Relative Difference</P>
</TH>
</TR>
<TR>
<TD>
<P>Petrella 2002</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Suplasyn+lactose</P>
</TD>
<TD>
<P>WOMAC pain (0-10 cm)</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>3.32</P>
</TD>
<TD>
<P>2.42</P>
</TD>
<TD>
<P>-0.47 (I)</P>
</TD>
<TD>
<P>-13% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline+lactose</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>3.62</P>
</TD>
<TD>
<P>3.19</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline+NSAID</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>4.22</P>
</TD>
<TD>
<P>2.86</P>
</TD>
<TD>
<P>0.46 (W)</P>
</TD>
<TD>
<P>11% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Suplasyn+NSAID</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>3.65</P>
</TD>
<TD>
<P>2.59</P>
</TD>
<TD>
<P>0.16 (W)</P>
</TD>
<TD>
<P>4% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P>Petrella 2002</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Suplasyn+lactose</P>
</TD>
<TD>
<P>WOMAC function (0-10 cm)</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>4.10</P>
</TD>
<TD>
<P>2.45</P>
</TD>
<TD>
<P>-0.66 (I)</P>
</TD>
<TD>
<P>-14% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline+lactose</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>4.72</P>
</TD>
<TD>
<P>3.73</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline+NSAID</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>4.32</P>
</TD>
<TD>
<P>2.76</P>
</TD>
<TD>
<P>-0.09 (I)</P>
</TD>
<TD>
<P>-2% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Suplasyn+NSAID</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>3.90</P>
</TD>
<TD>
<P>2.73</P>
</TD>
<TD>
<P>-0.48 (I)</P>
</TD>
<TD>
<P>-12% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P>Petrella 2002</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Suplasyn+lactose</P>
</TD>
<TD>
<P>WOMAC stiffness (0-10 cm)</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>4.60</P>
</TD>
<TD>
<P>2.95</P>
</TD>
<TD>
<P>-1.53 (I)</P>
</TD>
<TD>
<P>-30% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline+lactose</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>5.12</P>
</TD>
<TD>
<P>5.00</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline+NSAID</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>5.14</P>
</TD>
<TD>
<P>2.80</P>
</TD>
<TD>
<P>0.69 (W)</P>
</TD>
<TD>
<P>13% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Suplasyn+NSAID</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>4.82</P>
</TD>
<TD>
<P>2.71</P>
</TD>
<TD>
<P>0.46 (W)</P>
</TD>
<TD>
<P>10% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P>Petrella 2002</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Suplasyn+lactose</P>
</TD>
<TD>
<P>Rest pain (0-10 cm)</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>3.29</P>
</TD>
<TD>
<P>2.60</P>
</TD>
<TD>
<P>0.84 (W)</P>
</TD>
<TD>
<P>25% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline+lactose</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>3.30</P>
</TD>
<TD>
<P>1.77</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline + NSAID</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>3.34</P>
</TD>
<TD>
<P>1.58</P>
</TD>
<TD>
<P>1.07 (W)</P>
</TD>
<TD>
<P>32% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Suplasyn+NSAID</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>3.60</P>
</TD>
<TD>
<P>1.56</P>
</TD>
<TD>
<P>1.35 (W)</P>
</TD>
<TD>
<P>38% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P>Petrella 2002</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Suplasyn+lactose</P>
</TD>
<TD>
<P>Self-paced walk pain (0-10 cm)</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>3.94</P>
</TD>
<TD>
<P>2.89</P>
</TD>
<TD>
<P>-1.08 (I)</P>
</TD>
<TD>
<P>-31% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline+lactose</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>3.53</P>
</TD>
<TD>
<P>3.56</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline+NSAID</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>3.78</P>
</TD>
<TD>
<P>1.81</P>
</TD>
<TD>
<P>0.92 (W)</P>
</TD>
<TD>
<P>24% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Suplasyn+NSAID</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>3.84</P>
</TD>
<TD>
<P>2.05</P>
</TD>
<TD>
<P>0.74 (W)</P>
</TD>
<TD>
<P>19% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P>Petrella 2002</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>E: Suplasyn+lactose</P>
</TD>
<TD>
<P>Walk time (sec)</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>77.23</P>
</TD>
<TD>
<P>74.21</P>
</TD>
<TD>
<P>-3.53 (I)</P>
</TD>
<TD>
<P>-5% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline+lactose</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>70.56</P>
</TD>
<TD>
<P>71.07</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Saline+NSAID</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>77.64</P>
</TD>
<TD>
<P>75.70</P>
</TD>
<TD>
<P>-1.08 (I)</P>
</TD>
<TD>
<P>-1% (I)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Suplasyn+NSAID</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>78.81</P>
</TD>
<TD>
<P>72.22</P>
</TD>
<TD>
<P>3.57 (W)</P>
</TD>
<TD>
<P>5% (W)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-49" NO="49">
<TITLE>Clinical benefit table: Zeel versus Hyalgan. Continuous outcome measures</TITLE>
<TABLE COLS="9" ROWS="5">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Time</P>
</TH>
<TH>
<P>Treatment</P>
</TH>
<TH>
<P>Outcome (scale)</P>
</TH>
<TH>
<P>N of Pts</P>
</TH>
<TH>
<P>Baseline Mean</P>
</TH>
<TH>
<P>End of Study Mean</P>
</TH>
<TH>
<P>Absolute Benefit</P>
</TH>
<TH>
<P>Relative Difference</P>
</TH>
</TR>
<TR>
<TD>
<P>Nahler 1998</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>T: Zeel</P>
</TD>
<TD>
<P>Pain during movement (0-100 mm VAS)</P>
</TD>
<TD>
<P>57</P>
</TD>
<TD>
<P>67</P>
</TD>
<TD>
<P>31</P>
</TD>
<TD>
<P>1 (W)</P>
</TD>
<TD>
<P>1.6% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hyalgan</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>57</P>
</TD>
<TD>
<P>63</P>
</TD>
<TD>
<P>26</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Nahler 1998</P>
</TD>
<TD>
<P>1-4 wk</P>
</TD>
<TD>
<P>T: Zeel</P>
</TD>
<TD>
<P>Pain at night (0-100 mm VAS)</P>
</TD>
<TD>
<P>57</P>
</TD>
<TD>
<P>33</P>
</TD>
<TD>
<P>9</P>
</TD>
<TD>
<P>4 (W)</P>
</TD>
<TD>
<P>11.4% (W)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>C: Hyalgan</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>57</P>
</TD>
<TD>
<P>35</P>
</TD>
<TD>
<P>7</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-50" NO="50">
<TITLE>Discrepancies between RevMan analysis and published reports</TITLE>
<TABLE COLS="7" ROWS="42">
<TR>
<TH>
<P>Product</P>
</TH>
<TH>
<P>Study ID</P>
</TH>
<TH>
<P>Outcome measure</P>
</TH>
<TH>
<P>p value</P>
</TH>
<TH>
<P>Analysis population</P>
</TH>
<TH>
<P>Statistical test</P>
</TH>
<TH>
<P>Description</P>
</TH>
</TR>
<TR>
<TD>
<P>Adant</P>
</TD>
<TD>
<P>Roman 2000</P>
</TD>
<TD>
<P>Patient global assessment</P>
</TD>
<TD>
<P>P (paper): &lt;0.05, R (report):0.07</P>
</TD>
<TD>
<P>ITT</P>
</TD>
<TD>
<P>chi-square of 95% CI</P>
</TD>
<TD>
<P>At three months P reports significance, 50% versus 21.1%</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Painful injection</P>
</TD>
<TD>
<P>P:&lt;0.001, R:0.4</P>
</TD>
<TD>
<P>ITT</P>
</TD>
<TD>
<P>chi-square of 95% CI</P>
</TD>
<TD>
<P>8 of 49=16.3% Total population, 6 of 30=20% Adant, and 2 of 19=10.5% Hyalgan. Appears an error in P as they report 8 of 49=20% Total population and 16.3% Adant.</P>
</TD>
</TR>
<TR>
<TD>
<P>BioHy (Euflexxa)</P>
</TD>
<TD>
<P>Thompson 2002</P>
</TD>
<TD>
<P>Patient global (subjective) assessment</P>
</TD>
<TD>
<P>P:0.03, R:0.5</P>
</TD>
<TD>
<P>ITT</P>
</TD>
<TD>
<P>Wilcoxon's two-sample test</P>
</TD>
<TD>
<P>P reports significance comparing number of patients very satisfied between groups. R compares very satisfied and satisfied versus slightly satisfied and dissatisfied.</P>
</TD>
</TR>
<TR>
<TD>
<P>Euflexxa</P>
</TD>
<TD>
<P>Kirchner 2005</P>
</TD>
<TD>
<P>WOMAC OA Index physical function subscale</P>
</TD>
<TD>
<P>P: ns, R: 0.02</P>
</TD>
<TD>
<P>ITT</P>
</TD>
<TD>
<P>one-way ANOVA (GLM)</P>
</TD>
<TD>
<P>P reports no statistically significant between group difference whereas RevMan detected a statistically significant between group difference both at 1 to 4 and 5 to 13 weeks postinjection</P>
</TD>
</TR>
<TR>
<TD>
<P>Euflexxa</P>
</TD>
<TD>
<P>Kirchner 2005</P>
</TD>
<TD>
<P>Number of patients symptom-free (WOMAC pain)</P>
</TD>
<TD>
<P>P: 0.038, R: 0.05</P>
</TD>
<TD>
<P>ITT</P>
</TD>
<TD>
<P>Cochran-Mantel-Haenszel test</P>
</TD>
<TD>
<P>P reports significance. R no statistically significant difference.</P>
</TD>
</TR>
<TR>
<TD>
<P>Euflexxa</P>
</TD>
<TD>
<P>Kirchner 2005</P>
</TD>
<TD>
<P>Number of patients assessing the treatment as 'very satisfied' (P) or 'very satisfied or satisfied' (R)</P>
</TD>
<TD>
<P>P: 0.03, R: 0.23</P>
</TD>
<TD>
<P>ITT</P>
</TD>
<TD>
<P>Wilcoxon's two-sample test</P>
</TD>
<TD>
<P>P reports significance whereas R detects no difference but this may be attributable to the categories which were compared.</P>
</TD>
</TR>
<TR>
<TD>
<P>Euflexxa</P>
</TD>
<TD>
<P>Kirchner 2005</P>
</TD>
<TD>
<P>Number of patients requiring rescue medication during trial</P>
</TD>
<TD>
<P>P: 0.013, R: 0.02</P>
</TD>
<TD>
<P>ITT</P>
</TD>
<TD>
<P>Cochran-Mantel-Haenszel test</P>
</TD>
<TD>
<P>Both P and R report significance, but P values differ.</P>
</TD>
</TR>
<TR>
<TD>
<P>Durolane</P>
</TD>
<TD>
<P>Altman 2004</P>
</TD>
<TD>
<P>WOMAC OA Index pain subscale</P>
</TD>
<TD>
<P>P: ns; R:0.04</P>
</TD>
<TD>
<P>ITT</P>
</TD>
<TD>
<P>Wilcoxon rank sum test for change from baseline</P>
</TD>
<TD>
<P>P reports no statistically significant between-group difference while R detected a statistically significant difference at week 2 in favour of saline</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Altman 2004</P>
</TD>
<TD>
<P>WOMAC OA Index stiffness subscale</P>
</TD>
<TD>
<P>P:s; R: ns</P>
</TD>
<TD>
<P>ITT</P>
</TD>
<TD>
<P>Wilcoxon rank sum test for change from baseline</P>
</TD>
<TD>
<P>P reports a statistically significant between-group difference at week 26 while R detected no statistically significant between-group difference</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Altman 2004</P>
</TD>
<TD>
<P>WOMAC OA Index physical function subscale</P>
</TD>
<TD>
<P>P:s; R:ns</P>
</TD>
<TD>
<P>ITT</P>
</TD>
<TD>
<P>Wilcoxon rank sum test for change from baseline</P>
</TD>
<TD>
<P>P reports a statistically significant between-group difference at week 2 while R detected no statistically significant between-group difference</P>
</TD>
</TR>
<TR>
<TD>
<P>Suplasyn</P>
</TD>
<TD>
<P>Petrella 2002</P>
</TD>
<TD>
<P>Pain relief</P>
</TD>
<TD>
<P>P:HA=NSAID</P>
</TD>
<TD>
<P>ITT</P>
</TD>
<TD>
<P>within-group repeated ANOVA</P>
</TD>
<TD>
<P>P concludes HA=NSAID for resting pain relief. R finds no difference.</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Pain with physical activity</P>
</TD>
<TD>
<P>HA&gt;PL</P>
</TD>
<TD>
<P>ITT</P>
</TD>
<TD>
<P>within-group repeated ANOVA</P>
</TD>
<TD>
<P>P concludes HA may be superior to PL alone/NSAID alone. R no difference.</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Pain at rest</P>
</TD>
<TD>
<P>PL&gt;HA P value 0.04</P>
</TD>
<TD>
<P>ITT</P>
</TD>
<TD>
<P>within-group repeated ANOVA</P>
</TD>
<TD>
<P>P does not report between-group comparisons. R found difference in favour of PL.</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Functional performance</P>
</TD>
<TD>
<P>HA&gt;PL</P>
</TD>
<TD>
<P>ITT</P>
</TD>
<TD>
<P>within-group repeated ANOVA</P>
</TD>
<TD>
<P>P concludes HA may be superior to PL alone/NSAID alone. R finds no difference.</P>
</TD>
</TR>
<TR>
<TD>
<P>Orthovisc</P>
</TD>
<TD>
<P>Brandt 2001</P>
</TD>
<TD>
<P>WOMAC pain categoric improvement</P>
</TD>
<TD>
<P>P:0.04, R:0.05</P>
</TD>
<TD>
<P>Effectiveness</P>
</TD>
<TD>
<P>Wilcoxon rank sum tests</P>
</TD>
<TD>
<P>P concludes HA&gt;PL. R RR of 58% versus 40% no significant difference.</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Six month pain on walking</P>
</TD>
<TD>
<P>P:ns, R:0.008</P>
</TD>
<TD>
<P>ITT</P>
</TD>
<TD>
<P>one-way ANOVA</P>
</TD>
<TD>
<P>P: no significant difference, R: significant difference in favour of Orthovisc</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Six month Lequesne Index</P>
</TD>
<TD>
<P>P:ns, R:0.03</P>
</TD>
<TD>
<P>ITT</P>
</TD>
<TD>
<P>one-way ANOVA</P>
</TD>
<TD>
<P>P: no significant difference, R: significant difference in favour of Orthovisc</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Six month flexion</P>
</TD>
<TD>
<P>P:ns, R:0.04</P>
</TD>
<TD>
<P>ITT</P>
</TD>
<TD>
<P>one-way ANOVA</P>
</TD>
<TD>
<P>P: no significant difference, R: significant difference in favour of Orthovisc</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Kalay 1997</P>
</TD>
<TD>
<P>Activity pain 21st day (1 to 4 weeks)</P>
</TD>
<TD>
<P>P:0.0303, R:0.5</P>
</TD>
<TD>
<P>ITT</P>
</TD>
<TD>
<P>Mann-Whitney U test</P>
</TD>
<TD>
<P>P: significant difference in favour of OR+PT, R: no significant difference</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Night pain 56th day (5 to 13 weeks)</P>
</TD>
<TD>
<P>P:0.0284, R:0.07</P>
</TD>
<TD>
<P>ITT</P>
</TD>
<TD>
<P>Mann-Whitney U test</P>
</TD>
<TD>
<P>P: significant difference in favour of OR+PT, R: no significant difference</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Walk time 21st day (1 to 4weeks)</P>
</TD>
<TD>
<P>P:0.0049, R: 0.4</P>
</TD>
<TD>
<P>ITT</P>
</TD>
<TD>
<P>Mann-Whitney U test</P>
</TD>
<TD>
<P>P: significant difference in favour of OR+PT, R: no significant difference</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Walk time 56th day (5 to 13 weeks)</P>
</TD>
<TD>
<P>P:0.0001, R:0.2</P>
</TD>
<TD>
<P>ITT</P>
</TD>
<TD>
<P>Mann-Whitney U test</P>
</TD>
<TD>
<P>P: significant difference in favour of OR+PT, R: no significant difference</P>
</TD>
</TR>
<TR>
<TD>
<P>Hylan G-F 20</P>
</TD>
<TD>
<P>Dickson 2001</P>
</TD>
<TD>
<P>WOMAC pain (5 to 13 weeks)</P>
</TD>
<TD>
<P>P:0.04, R:0.11</P>
</TD>
<TD>
<P>ITT</P>
</TD>
<TD>
<P>repeated measures ANOVA corrected for statistically significant covariates</P>
</TD>
<TD>
<P>P: significant difference in favour of Hylan G-F 20 compared to PL, R: no significant difference</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>WOMAC function (5 to 13 weeks)</P>
</TD>
<TD>
<P>P:0.05, R:0.01</P>
</TD>
<TD>
<P>ITT</P>
</TD>
<TD>
<P>repeated measures ANOVA</P>
</TD>
<TD>
<P>P: 0.05 which we would classify as not significant; Hylan G-F 20 &gt; PL</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Lequesne Index (5 to 13 weeks)</P>
</TD>
<TD>
<P>P:0.17, R:0.02</P>
</TD>
<TD>
<P>ITT</P>
</TD>
<TD>
<P>repeated measures ANOVA</P>
</TD>
<TD>
<P>P: no significnt difference, R: significant difference in favour of Hylan G-F 20 compared to PL</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Adams 1995</P>
</TD>
<TD>
<P>Pain at rest (5 to 13 weeks)</P>
</TD>
<TD>
<P>P:0.05, R:0.6</P>
</TD>
<TD>
<P>ITT</P>
</TD>
<TD>
<P>ANOVA</P>
</TD>
<TD>
<P>P: Hylan G-F 20 &gt; NSAID, R: no significant difference</P>
</TD>
</TR>
<TR>
<TD>
<P>Hyalgan</P>
</TD>
<TD>
<P>Dougados 1993</P>
</TD>
<TD>
<P>Lequesne Index (45 to 52 weeks)</P>
</TD>
<TD>
<P>P:0.046,R:0.17</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>One-sided Student's t-test</P>
</TD>
<TD>
<P>P: Hyalgectin &gt; PL, R: no significant difference</P>
</TD>
</TR>
<TR>
<TD>
<P>Hyalgan</P>
</TD>
<TD>
<P>Tsai 2003</P>
</TD>
<TD>
<P>WOMAC function (14 to 26 weeks)</P>
</TD>
<TD>
<P>P:0.0038, R:0.07</P>
</TD>
<TD>
<P>ITT</P>
</TD>
<TD>
<P>ANOVA</P>
</TD>
<TD>
<P>P: Hyalgan &gt; PL, R: no significant difference</P>
</TD>
</TR>
<TR>
<TD>
<P>Hyalgan</P>
</TD>
<TD>
<P>Jubb 2003</P>
</TD>
<TD>
<P>Joint space width (week 52)</P>
</TD>
<TD>
<P>P:ns,R:0.03</P>
</TD>
<TD>
<P>ITT</P>
</TD>
<TD>
<P>t-test</P>
</TD>
<TD>
<P>P: No significant difference in total population, but significant difference in &gt;=4.6 mm subgroup; R: difference in total population but not in the 2 subgroups</P>
</TD>
</TR>
<TR>
<TD>
<P>Hylan G-F 20</P>
</TD>
<TD>
<P>Auerbach 2002</P>
</TD>
<TD>
<P>Pain under load (45 to 52 weeks)</P>
</TD>
<TD>
<P>P:0.001, R:0.2</P>
</TD>
<TD>
<P>ITT</P>
</TD>
<TD>
<P>Wilcoxon test</P>
</TD>
<TD>
<P>P: Hylan G-F 20 &gt; O2; R: no significant difference</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>WOMAC pain (45 to 52 weeks)</P>
</TD>
<TD>
<P>P:0.003, R:0.3</P>
</TD>
<TD>
<P>ITT</P>
</TD>
<TD>
<P>Wilcoxon test</P>
</TD>
<TD>
<P>P: Hylan G-F 20 &gt; O2; R: no significant difference</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>WOMAC function (45 to 52 weeks)</P>
</TD>
<TD>
<P>P:0.001, R:0.16</P>
</TD>
<TD>
<P>ITT</P>
</TD>
<TD>
<P>Wilcoxon test</P>
</TD>
<TD>
<P>P: Hylan G-F 20 &gt; O2; R: no significant difference</P>
</TD>
</TR>
<TR>
<TD>
<P>Artz</P>
</TD>
<TD>
<P>Day 2004</P>
</TD>
<TD>
<P>WOMAC pain (5 to 13 weeks)</P>
</TD>
<TD>
<P>P:0.045, R:0.07</P>
</TD>
<TD>
<P>ITT</P>
</TD>
<TD>
<P>Repeated measures ANCOVA</P>
</TD>
<TD>
<P>P: Artz &gt; PL; R: no significant difference</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>WOMAC stiffness (5 to 13 weeks)</P>
</TD>
<TD>
<P>P:0.024, R:0.07</P>
</TD>
<TD>
<P>ITT</P>
</TD>
<TD>
<P>Repeated measures ANCOVA</P>
</TD>
<TD>
<P>P: Artz &gt; PL; R: no significant difference</P>
</TD>
</TR>
<TR>
<TD>
<P>Artz</P>
</TD>
<TD>
<P>Puhl 1993</P>
</TD>
<TD>
<P>Lequesne Index (1 to 4 weeks) [t6]</P>
</TD>
<TD>
<P>P:0.043, R:0.7</P>
</TD>
<TD>
<P>ITT</P>
</TD>
<TD>
<P>Simultaneous t-tests, MANOVA</P>
</TD>
<TD>
<P>P: Artz &gt; PL; R: no significant difference</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Lequesne Index (5 to 13 weeks) [t14]</P>
</TD>
<TD>
<P>P:0.0053, R: 0.5</P>
</TD>
<TD>
<P>ITT</P>
</TD>
<TD>
<P>Simultaneous t-tests, MANOVA</P>
</TD>
<TD>
<P>P: Artz &gt; PL; R: no significant difference</P>
</TD>
</TR>
<TR>
<TD>
<P>Hyalgan</P>
</TD>
<TD>
<P>Jubb 2003</P>
</TD>
<TD>
<P>Pain (number of patients improved)(5-13 wk)</P>
</TD>
<TD>
<P>P:0.04, R:0.16</P>
</TD>
<TD>
<P>ITT</P>
</TD>
<TD>
<P>Chi-square</P>
</TD>
<TD>
<P>P: HA &gt; PL; R: no significant difference</P>
</TD>
</TR>
<TR>
<TD>
<P>Hyalgan</P>
</TD>
<TD>
<P>Forster 2003</P>
</TD>
<TD>
<P>Knee Society Score (six months)</P>
</TD>
<TD>
<P>P: ns, R:0.03</P>
</TD>
<TD>
<P>ITT</P>
</TD>
<TD>
<P>Mann-Whitney</P>
</TD>
<TD>
<P>P: no significant difference; R: HA&gt;Arthroscopy</P>
</TD>
</TR>
<TR>
<TD>
<P>Hyalgan</P>
</TD>
<TD>
<P>Jones 1995</P>
</TD>
<TD>
<P>Pain at rest (week 29)</P>
</TD>
<TD>
<P>P:significant; R:0.09</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Not reported in publication.</P>
</TD>
<TD>
<P>P: significant difference in favour of HA versus TH (Table III) but with ITT, LOCF no statistically significant difference. R: based on Table III, no significant difference.</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Pain on nominated activity (week 29)</P>
</TD>
<TD>
<P>P:significant, R: 0.4</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Not reported in publication.</P>
</TD>
<TD>
<P>P: significant difference in favour of HA versus TH (Table III) but with ITT, LOCF no statistically significant difference. R: based on Table III, no significant difference.</P>
</TD>
</TR>
<TR>
<TD>
<P>Hyalgan</P>
</TD>
<TD>
<P>Listrat 1997</P>
</TD>
<TD>
<P>AIMS (45 to 52 weeks)</P>
</TD>
<TD>
<P>P:0.047, R:0.6</P>
</TD>
<TD>
<P>ITT</P>
</TD>
<TD>
<P>ANCOVA</P>
</TD>
<TD>
<P>P: HA &gt; conventional care; R: no significant difference</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-51" NO="51">
<TITLE>Trials that utilised repeat courses of treatment</TITLE>
<TABLE COLS="2" ROWS="12">
<TR>
<TH>
<P>Study ID</P>
</TH>
<TH>
<P>Product</P>
</TH>
</TR>
<TR>
<TD>
<P>Jubb 2003</P>
</TD>
<TD>
<P>Hyalgan</P>
</TD>
</TR>
<TR>
<TD>
<P>Karras 2001</P>
</TD>
<TD>
<P>Hyalgan</P>
</TD>
</TR>
<TR>
<TD>
<P>Listrat 1997</P>
</TD>
<TD>
<P>Hyalgan</P>
</TD>
</TR>
<TR>
<TD>
<P>St. J. Dixon 1988</P>
</TD>
<TD>
<P>Hyalgan</P>
</TD>
</TR>
<TR>
<TD>
<P>Groppa 2001</P>
</TD>
<TD>
<P>Hylan G-F 20 (Synvisc)</P>
</TD>
</TR>
<TR>
<TD>
<P>Leopold 2003</P>
</TD>
<TD>
<P>Hylan G-F 20 (Synvisc)</P>
</TD>
</TR>
<TR>
<TD>
<P>Raynauld 2002</P>
</TD>
<TD>
<P>Hylan G-F 20 (Synvisc)</P>
</TD>
</TR>
<TR>
<TD>
<P>Pham 2004</P>
</TD>
<TD>
<P>NRD-101 (Suvenyl)</P>
</TD>
</TR>
<TR>
<TD>
<P>Hizmetli 1999</P>
</TD>
<TD>
<P>Orthovisc</P>
</TD>
</TR>
<TR>
<TD>
<P>Ozturk 2005</P>
</TD>
<TD>
<P>Orthovisc</P>
</TD>
</TR>
<TR>
<TD>
<P>Atamaz 2006</P>
</TD>
<TD>
<P>Hylan G-F 20 and Orthovisc</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-52" NO="52">
<TITLE>Effect size based on Standardised Mean Difference - Part I</TITLE>
<TABLE COLS="7" ROWS="100">
<TR>
<TH>
<P>Product</P>
</TH>
<TH>
<P>Comparison</P>
</TH>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>1-4 wk</P>
</TH>
<TH>
<P>5-13 wk</P>
</TH>
<TH>
<P>14-26 wk</P>
</TH>
<TH>
<P>45-52 wk</P>
</TH>
</TR>
<TR>
<TD>
<P>Artz, Artzal</P>
</TD>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>Pain (VAS)</P>
</TD>
<TD>
<P>0.02 (-0.16,0.20) P value 0.8</P>
</TD>
<TD>
<P>-0.19 (-0.37,-0.01) P value 0.04</P>
</TD>
<TD>
<P>0.00 (-0.24,0.23) P value 1</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Pain (0-3)</P>
</TD>
<TD>
<P>-0.14 (-0.54,0.26) P value 0.5</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>WOMAC pain (Likert)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>-0.24 (-0.50,0.02) P value 0.07</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>WOMAC function (Likert)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>-0.22 (-0.49,0.04) P value 0.10</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>WOMAC stiffness (Likert)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>-0.24 (-0.51,0.02) P value 0.07</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Lequesne Index (0-24)</P>
</TD>
<TD>
<P>0.06 (-0.23,0.34) P value 0.7</P>
</TD>
<TD>
<P>-0.11 (-0.39,0.17) P value 0.5</P>
</TD>
<TD>
<P>0.11 (-0.09,0.31) P value 0.3</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Range of motion (degrees)</P>
</TD>
<TD>
<P>0.22 (-0.18,0.61) P value 0.3</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Hylan G-F 20</P>
</TD>
<TD>
<P>Pain weight bearing (VAS)</P>
</TD>
<TD>
<P>-0.04 (-0.34,0.26) P value 0.8</P>
</TD>
<TD>
<P>0.03 (-0.26,0.33) P value 0.8</P>
</TD>
<TD>
<P>0.15 (-0.15,0.44) P value 0.3</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Lequesne Index (0-24)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>0.21 (-0.08,0.50) P value 0.16</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>BioHy (Arthrease)</P>
</TD>
<TD>
<P>Hylan G-F 20</P>
</TD>
<TD>
<P>WOMAC pain (VAS)</P>
</TD>
<TD>
<P>-0.18 (-0.40,0.04) P value 0.10</P>
</TD>
<TD>
<P>-0.19 (-0.41,0.03) P value 0.08</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Fermathron</P>
</TD>
<TD>
<P>Hyalart</P>
</TD>
<TD>
<P>Pain (VAS)</P>
</TD>
<TD>
<P>0.11 (-0.14,0.37) P value 0.4</P>
</TD>
<TD>
<P>0.04 (-0.22,0.30) P value 0.8</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Lequesne Index (0-24)</P>
</TD>
<TD>
<P>0.11 (-0.14,0.37) P value 0.4</P>
</TD>
<TD>
<P>0.14 (-0.12,0.39) P value 0.3</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Hyalgan</P>
</TD>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>Pain weight bearing (VAS)</P>
</TD>
<TD>
<P>-0.32 (-0.58,-0.05) P value 0.02</P>
</TD>
<TD>
<P>-0.41 (-0.66,-0.16) P value 0.001</P>
</TD>
<TD>
<P>-0.22 (-0.43,-0.02) P value 0.03</P>
</TD>
<TD>
<P>-0.07 (-0.24,0.10) P value 0.4</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Pain spontaneous (VAS)</P>
</TD>
<TD>
<P>-1.14 (-1.64,-0.64) P value 0.00001</P>
</TD>
<TD>
<P>-1.07 (-1.56,-0.57) P value 0.00003</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Pain at rest (VAS)</P>
</TD>
<TD>
<P>-0.49 (-0.88,-0.10) P value 0.01</P>
</TD>
<TD>
<P>-0.72 (-1.06,-0.38) P value 0.00004</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>0.07 (-0.29,0.43) P value 0.7</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Pain at night (VAS)</P>
</TD>
<TD>
<P>-0.69 (-1.88,0.50) P value 0.3</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>WOMAC pain (VAS)</P>
</TD>
<TD>
<P>-0.18 (-0.47,0.10) P value 0.2</P>
</TD>
<TD>
<P>-0.10 (-0.40,0.19) P value 0.5</P>
</TD>
<TD>
<P>-0.38 (-0.68,-0.08) P value 0.01</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>WOMAC function (VAS)</P>
</TD>
<TD>
<P>-0.09 (=0.37,0.20) P value 0.5</P>
</TD>
<TD>
<P>-0.07 (-0.37,0.22) P value 0.6</P>
</TD>
<TD>
<P>-0.28 (-0.57,0.02) P value 0.07</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Lequesne Index (0-24)</P>
</TD>
<TD>
<P>-0.39 (-0.63,-0.16) P value 0.0010</P>
</TD>
<TD>
<P>-0.60 (-0.89,-0.31) P value 0.00006</P>
</TD>
<TD>
<P>-0.30 (-0.74,0.14) P value 0.18</P>
</TD>
<TD>
<P>-0.28 (-0.69,0.13) P value 0.18</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Flexion (degrees)</P>
</TD>
<TD>
<P>0.30 (-0.37,0.97) P value 0.4</P>
</TD>
<TD>
<P>0.70 (0.01,1.39) P value 0.05</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Synovial fluid volume (ml)</P>
</TD>
<TD>
<P>-0.07 (-0.39,0.24) P value 0.6</P>
</TD>
<TD>
<P>-0.51 (-1.02,-0.01) P value 0.04</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Joint space width (total population)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>0.26 (0.02,0.49) P value 0.04</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Joint space width (subgroups)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>0.12 (-0.28,0.52) P value 0.6</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Arthroscopy</P>
</TD>
<TD>
<P>Pain (VAS)</P>
</TD>
<TD>
<P>0.42 (-0.31,1.15) P value 0.3</P>
</TD>
<TD>
<P>0.00 (-0.70,0.70) P value 1</P>
</TD>
<TD>
<P>-0.25 (-1.00,0.49) P value 0.5</P>
</TD>
<TD>
<P>0.00 (-0.79,0.79) P value 1</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Knee Society Function Scale</P>
</TD>
<TD>
<P>0.53 (-0.21,1.26) P value 0.16</P>
</TD>
<TD>
<P>0.49 (-0.23,1.21) P value 0.18</P>
</TD>
<TD>
<P>0.77 (0.00,1.54) P value 0.05</P>
</TD>
<TD>
<P>0.72 (-0.10,1.54) P value 0.08</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Lequesne Index (0-24)</P>
</TD>
<TD>
<P>0.53 (-0.21,1.26) P value 0.16</P>
</TD>
<TD>
<P>0.49 (-0.23,1.21) P value 0.18</P>
</TD>
<TD>
<P>0.77 (0.00,1.54) P value 0.05</P>
</TD>
<TD>
<P>0.72 (-0.10,1.54) P value 0.08</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>NSAID</P>
</TD>
<TD>
<P>Pain after 50 foot walk (VAS)</P>
</TD>
<TD>
<P>0.00 (-0.23,0.23) P value 1</P>
</TD>
<TD>
<P>0.08 (-0.17,0.33) P value 0.5</P>
</TD>
<TD>
<P>-0.13 (-0.40,0.14) P value 0.3</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Methylprednisolone acetate</P>
</TD>
<TD>
<P>Spontaneous pain intensity (VAS)</P>
</TD>
<TD>
<P>-0.27 (-0.58,0.03) P value 0.08</P>
</TD>
<TD>
<P>-0.41 (-0.90,0.08) P value 0.10</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>0.10 (-0.60,0.79) P value 0.8</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Range of motion (degrees)</P>
</TD>
<TD>
<P>0.39 (0.05,0.74) P value 0.03</P>
</TD>
<TD>
<P>0.40 (0.05,0.75) P value 0.02</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>0.07 (-0.62,0.77) P value 0.8</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Triamcinolone hexacetonide</P>
</TD>
<TD>
<P>Pain on nominated activity (VAS)</P>
</TD>
<TD>
<P>-0.01 (-0.53,0.52) P value 1 (end of treatment)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>-0.39 (-1.29,0.52) P value 0.4</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Pain at rest (VAS)</P>
</TD>
<TD>
<P>-0.02 (-0.54,0.50) P value 0.9 (end of treatment)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>-0.76 (-1.69,0.18) P value 0.11</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Pain at night (VAS)</P>
</TD>
<TD>
<P>-0.21 (-0.74,0.31) P value 0.4 (end of treatment)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>-1.11 (-2.09,-0.14) P value 0.03</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Mucopolysaccharide polysulfuric acid ester</P>
</TD>
<TD>
<P>Pain (0-30)</P>
</TD>
<TD>
<P>0.66 (0.14,1.19) P value 0.01 (end of treatment)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Function (0-30)</P>
</TD>
<TD>
<P>0.11 (-0.40,0.63) P value 0.7 (end of treatment)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Range of motion (0-10)</P>
</TD>
<TD>
<P>0.39 (-0.13,0.91) P value 0.14 (end of treatment)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Total Larson rating score (0-77)</P>
</TD>
<TD>
<P>0.63 (0.10,1.16) P value 0.02 (end of treatment)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Appropriate care</P>
</TD>
<TD>
<P>Pain overall (VAS)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>-0.53 (-1.20,0.14) P value 0.12</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Lequesne Index (0-24)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>-0.20 (-0.85,0.46) P value 0.6</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Joint space width (mm)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>0.63 (-0.04,1.30) P value 0.07</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Quality of life: AIMS</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>-0.16 (-0.82,0.49) P value 0.6</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Arthroscopy overall score (VAS)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>-0.79 (-1.47,-0.10) P value 0.02</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>SFA score (VAS)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>-0.90 (-1.59,-0.21) P value 0.01</P>
</TD>
</TR>
<TR>
<TD>
<P>Hylan G-F 20</P>
</TD>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>Pain weight bearing (VAS)</P>
</TD>
<TD>
<P>-0.51 (-0.87,-0.15) P value 0.006</P>
</TD>
<TD>
<P>-0.94 (-1.57,-0.31) P value 0.003</P>
</TD>
<TD>
<P>-0.77 (-1.38,-0.15) P value 0.01</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Pain at night (VAS)</P>
</TD>
<TD>
<P>-0.30 (-0.50,-0.09) P value 0.005</P>
</TD>
<TD>
<P>-0.52 (-1.00,-0.05) P value 0.03</P>
</TD>
<TD>
<P>-0.82 (-1.12,-0.51) p&lt;0.00001</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>WOMAC pain (VAS)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>-0.31 (-0.68,0.07) P value 0.11</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Pain at rest (VAS)</P>
</TD>
<TD>
<P>-0.14 (-0.55,0.26) P value 0.5</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Pain overall (VAS)</P>
</TD>
<TD>
<P>-0.07 (-0.48,0.33) P value 0.7</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Lequesne Index (0-24)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>0.02 (-0.30,0.34) P value 0.9</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>WOMAC function (VAS)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>-0.43 (-0.81,-0.05) P value 0.03</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Function: improvement (VAS)</P>
</TD>
<TD>
<P>0.63 (0.39,0.88) p&lt;0.00001</P>
</TD>
<TD>
<P>1.29 (0.97,1.60) p&lt;0.00001</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Patient global: treatment efficacy (VAS)</P>
</TD>
<TD>
<P>0.72 (0.47,0.96) p&lt;0.00001</P>
</TD>
<TD>
<P>1.19 (0.66,1.71) P value 0.00001</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>NSAID</P>
</TD>
<TD>
<P>Pain on motion (VAS)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>-0.27 (-0.80,0.25) P value 0.3</P>
</TD>
<TD>
<P>-0.49 (-1.02,0.03) P value 0.07</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Pain at rest (VAS)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>-0.14 (-0.66,0.39) P value 0.6</P>
</TD>
<TD>
<P>-0.15 (-0.67,0.36) P value 0.6</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Pain at night (VAS)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>-0.29 (-0.82,0.23) P value 0.3</P>
</TD>
<TD>
<P>-0.12 (-0.64,0.39) P value 0.6</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Pain overall (VAS)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>-0.18 (-0.71,0.34) P value 0.5</P>
</TD>
<TD>
<P>-0.23 (-0.75,0.29) P value 0.4</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>WOMAC pain (VAS)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>-0.41 (-0.79,-0.02) P value 0.04</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>WOMAC function (VAS)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>-0.21 (-0.59,0.16) P value 0.3</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Lequesne Index (0-24)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>-0.27 (-0.65,0.11) P value 0.16</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Hylan G-F 20 + NSAID</P>
</TD>
<TD>
<P>NSAID</P>
</TD>
<TD>
<P>Pain on motion (VAS)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>-0.44 (-0.93,0.06) P value 0.08</P>
</TD>
<TD>
<P>-0.66 (-1.17,-0.15) P value 0.01</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Pain at rest (VAS)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>-0.44 (-0.93,0.06) P value 0.08</P>
</TD>
<TD>
<P>-0.66 (-1.17,-0.15) P value 0.01</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Pain at night (VAS)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>-0.48 (-0.98,0.02) P value 0.06</P>
</TD>
<TD>
<P>-0.84 (-1.35,-0.32) P value 0.002</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Pain overall (VAS)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>-0.46 (-0.96,0.03) P value 0.07</P>
</TD>
<TD>
<P>-0.66 (-1.17,-0.15) P value 0.01</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Hylan G-F 20</P>
</TD>
<TD>
<P>Triamcinolone hexacetonide</P>
</TD>
<TD>
<P>WOMAC pain Q1 (Likert)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>-0.43 (-0.70,-0.16) P value 0.002</P>
</TD>
<TD>
<P>-0.38 (-0.65,-0.11) P value 0.005</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>WOMAC function (Likert)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>-0.35 (-0.62,-0.08) P value 0.01</P>
</TD>
<TD>
<P>-0.36 (-0.63,-0.09) P value 0.010</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>WOMAC total score (Likert)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>-0.37 (-0.64,-0.10) P value 0.007</P>
</TD>
<TD>
<P>-0.36 (-0.63,-0.09) P value 0.010</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Patient global (VAS)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>-0.54 (-0.81,-0.27) P value 0.0001</P>
</TD>
<TD>
<P>-0.57 (-0.84,-0.30) P value 0.00004</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Hylan G-F 20 + PT</P>
</TD>
<TD>
<P>Physiotherapy (PT)</P>
</TD>
<TD>
<P>Lequesne Index (0-24)</P>
</TD>
<TD>
<P>-0.24 (-1.11,0.63) P value0.6 (end of treatment)</P>
</TD>
<TD>
<P>-0.23 (-1.10,0.64) P value 0.6</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Hylan G-F 20</P>
</TD>
<TD>
<P>Appropriate care</P>
</TD>
<TD>
<P>WOMAC pain (Likert)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>-0.77 (-1.02,-0.51) p&lt;0.00001</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>WOMAC function (Likert)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>-0.72 (-0.98,-0.45) p&lt;0.00001</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>WOMAC pain (VAS)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>-0.60 (-0.78,-0.42) p&lt;0.00001 (36 wk)</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Pain walking (VAS)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>-0.53 (-0.71,-0.36) p&lt;0.00001 (36 wk)</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>WOMAC function (VAS)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>-0.61 (-0.79,-0.43) p&lt;0.00001 (36 wk)</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Lequesne Index (0-24)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>-0.49 (-0.67,-0.32) p&lt;0.00001 (36 wk)</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>WOMAC total (VAS)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>-0.63 (-0.81,-0.45) p&lt;0.00001 (36 wk)</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Gaseous oxygen</P>
</TD>
<TD>
<P>Pain under load (VAS)</P>
</TD>
<TD>
<P>0.30 (-0.08,0.68) P value 0.12 (end of treatment)</P>
</TD>
<TD>
<P>0.44 (0.06,0.82) P value 0.02</P>
</TD>
<TD>
<P>0.27 (-0.10,0.65) P value 0.16</P>
</TD>
<TD>
<P>0.24 (-0.14,0.61) P value 0.2</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Pain at rest (VAS)</P>
</TD>
<TD>
<P>0.06 (-0.32,0.43) P value 0.8 (end of treatment)</P>
</TD>
<TD>
<P>0.26 (-0.12,0.63) P value 0.18</P>
</TD>
<TD>
<P>0.10 (-0.28,0.48) P value 0.6</P>
</TD>
<TD>
<P>0.00 (-0.37,0.38) P value 1</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>WOMAC pain (Likert)</P>
</TD>
<TD>
<P>0.34 (-0.04,0.71) P value 0.08 (end of treatment)</P>
</TD>
<TD>
<P>0.35 (-0.03,0.73) P value 0.07</P>
</TD>
<TD>
<P>0.14 (-0.24,0.51) P value 0.5</P>
</TD>
<TD>
<P>0.20 (-0.18,0.57) P value 0.3</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>WOMAC function (Likert)</P>
</TD>
<TD>
<P>0.24 (-0.14,0.62) P value 0.2 (end of treatment)</P>
</TD>
<TD>
<P>0.21 (-0.17,0.58) P value 0.3</P>
</TD>
<TD>
<P>0.27 (-0.11,0.65) P value 0.16</P>
</TD>
<TD>
<P>0.26 (-0.11,0.64) P value 0.17</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>WOMAC stiffness (Likert)</P>
</TD>
<TD>
<P>0.10 (-0.27,0.48) P value 0.6 (end of treatment)</P>
</TD>
<TD>
<P>0.28 (-0.10,0.65) P value 0.15</P>
</TD>
<TD>
<P>0.47 (0.09,0.85) P value 0.02</P>
</TD>
<TD>
<P>0.25 (-0.13,0.63) P value 0.2</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Hyaluronan</P>
</TD>
<TD>
<P>Pain weight bearing (VAS)</P>
</TD>
<TD>
<P>-0.08 (-0.30,0.14) P value 0.5</P>
</TD>
<TD>
<P>-0.28 (-0.64,0.09) P value 0.13</P>
</TD>
<TD>
<P>-0.15 (-0.44,0.15) P value 0.3</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Pain at night (VAS)</P>
</TD>
<TD>
<P>-0.34 (-0.06,-0.01) P value 0.04</P>
</TD>
<TD>
<P>-0.14 (-0.47,0.18) P value 0.4</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Function: improvement (VAS)</P>
</TD>
<TD>
<P>-0.02 (-0.34,0.30) P value 0.9</P>
</TD>
<TD>
<P>0.41 (0.08,0.73) P value 0.02</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Patient global (treatment efficacy) (VAS)</P>
</TD>
<TD>
<P>0.06 (-0.26,0.38) P value 0.7</P>
</TD>
<TD>
<P>0.31 (-0.02,0.63) P value 0.07</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>NRD-101</P>
</TD>
<TD>
<P>Artz</P>
</TD>
<TD>
<P>Flexion (end of treatment)</P>
</TD>
<TD>
<P>0.08 (-0.21,0.37) P value 0.6</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Extension (end of treatment)</P>
</TD>
<TD>
<P>-0.04 (-0.33,0.26) P value 0.8</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Orthovisc</P>
</TD>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>WOMAC pain (Likert)</P>
</TD>
<TD>
<P>-1.68 (-2.41,-0.95) p&lt;0.00001</P>
</TD>
<TD>
<P>-1.88 (-2.64,-1.12) p&lt;0.00001</P>
</TD>
<TD>
<P>-1.86 (-2.61,-1.11) p&lt;0.00001</P>
</TD>
<TD>
<P>-1.87 (-2.63,-1.12) p&lt;0.00001</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>WOMAC function (Likert)</P>
</TD>
<TD>
<P>-0.87 (-1.46,-0.17) P value 0.009</P>
</TD>
<TD>
<P>-0.81 (-1.46,-0.17) P value 0.01</P>
</TD>
<TD>
<P>-0.73 (-1.38,-0.09) P value 0.03</P>
</TD>
<TD>
<P>-0.52 (-1.15,-0.11) P value 0.11</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Betamethasone</P>
</TD>
<TD>
<P>WOMAC function (VAS)</P>
</TD>
<TD>
<P>0.34 (-0.29,0.96) P value 0.3</P>
</TD>
<TD>
<P>-1.06 (-1.73,-0.40) P value 0.002</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Flexion (degrees)</P>
</TD>
<TD>
<P>-0.30 (-0.93,0.32) P value 0.3</P>
</TD>
<TD>
<P>-0.51 (-1.14,0.12) P value 0.11</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>6-MPA</P>
</TD>
<TD>
<P>Pain weight bearing (VAS)</P>
</TD>
<TD>
<P>0.26 (-0.27,0.79) P value 0.3</P>
</TD>
<TD>
<P>-0.92 (-1.48,-0.36) P value 0.001</P>
</TD>
<TD>
<P>-0.76 (-1.31,-0.21) P value 0.007</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Pain at rest (VAS)</P>
</TD>
<TD>
<P>0.33 (-0.21,0.86) P value 0.2</P>
</TD>
<TD>
<P>-0.69 (-1.24,-0.15) P value 0.01</P>
</TD>
<TD>
<P>-0.23 (-0.76,0.30) P value 0.4</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Pain on walking (VAS)</P>
</TD>
<TD>
<P>-0.02 (-0.55,0.51) P value 0.9</P>
</TD>
<TD>
<P>-0.89 (-1.45,-0.33) P value 0.002</P>
</TD>
<TD>
<P>-0.71 (-1.25,-0.16) P value 0.01</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Lequesne Index (0-24)</P>
</TD>
<TD>
<P>-0.06 (-0.59,0.46) P value 0.8</P>
</TD>
<TD>
<P>-0.99 (-1.56,-0.43) P value 0.0005</P>
</TD>
<TD>
<P>-0.58 (-1.12,-0.04) P value 0.04</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Flexion (degrees)</P>
</TD>
<TD>
<P>0.24 (-0.29,0.77) P value 0.4</P>
</TD>
<TD>
<P>0.29 (-0.24,0.83) P value 0.3</P>
</TD>
<TD>
<P>0.54 (0.00,1.08) P value 0.05</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Orthovisc + PT</P>
</TD>
<TD>
<P>Physiotherapy (PT)</P>
</TD>
<TD>
<P>Activity pain (VAS)</P>
</TD>
<TD>
<P>-0.19 (-0.81,0.43) P value 0.6</P>
</TD>
<TD>
<P>-0.73 (-1.37,-0.08) P value 0.03</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Spontaneous pain (VAS)</P>
</TD>
<TD>
<P>0.07 (-0.55,0.69) P value 0.8</P>
</TD>
<TD>
<P>-0.75 (-1.39,-0.10) P value 0.02</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Night pain (VAS)</P>
</TD>
<TD>
<P>-0.03 (-0.65,0.59) P value 0.9</P>
</TD>
<TD>
<P>-0.57 (-1.20,0.07) P value 0.08</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Lequesne Index (0-24)</P>
</TD>
<TD>
<P>-0.06 (-0.87,0.76) P value 0.9</P>
</TD>
<TD>
<P>-0.44 (-1.27,0.38) P value 0.3</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>25 m walk time</P>
</TD>
<TD>
<P>0.25 (-0.37,0.87) P value 0.4</P>
</TD>
<TD>
<P>-0.41 (-1.04,0.21) P value 0.19</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-53" NO="53">
<TITLE>Effect size based on Standardised Mean Difference - Part II</TITLE>
<TABLE COLS="7" ROWS="27">
<TR>
<TH>
<P>Product</P>
</TH>
<TH>
<P>Comparison</P>
</TH>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>1-4 wk</P>
</TH>
<TH>
<P>5-13 wk</P>
</TH>
<TH>
<P>14-26 wk</P>
</TH>
<TH>
<P>45-52 wk</P>
</TH>
</TR>
<TR>
<TD>
<P>Orthovisc+PT</P>
</TD>
<TD>
<P>Hylan G-F 20+PT</P>
</TD>
<TD>
<P>Lequesne Index (0-24)</P>
</TD>
<TD>
<P>0.16 (-0.59,0.91) P value 0.7 (End of treatment)</P>
</TD>
<TD>
<P>-0.30 (-1.05,0.45) P value 0.4</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Suplasyn</P>
</TD>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>Pain after walking (VAS)</P>
</TD>
<TD>
<P>-0.38 (-0.92,0.17) P value 0.17</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>WOMAC pain (VAS)</P>
</TD>
<TD>
<P>-0.29 (-0.83,0.25) P value 0.3</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Pain at rest (VAS)</P>
</TD>
<TD>
<P>0.56 (0.01,1.11) P value 0.05</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>WOMAC function (VAS)</P>
</TD>
<TD>
<P>-0.47 (-1.02,0.07) P value 0.09</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Walk time (sec)</P>
</TD>
<TD>
<P>0.18 (-0.36,0.72) P value 0.5</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>NSAID</P>
</TD>
<TD>
<P>Pain after walking (VAS)</P>
</TD>
<TD>
<P>0.39 (-0.15,0.93) P value 0.16</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>WOMAC pain (VAS)</P>
</TD>
<TD>
<P>-0.17 (-0.70,0.37) P value 0.5</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Pain at rest (VAS)</P>
</TD>
<TD>
<P>0.40 (-0.14,0.95) P value 0.14</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>WOMAC function (VAS)</P>
</TD>
<TD>
<P>-0.13 (-0.66,0.41) P value 0.6</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Walk time (sec)</P>
</TD>
<TD>
<P>-0.09 (-0.62,0.45) P value 0.7</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Suplasyn+NSAID</P>
</TD>
<TD>
<P>NSAID</P>
</TD>
<TD>
<P>Pain after walking (VAS)</P>
</TD>
<TD>
<P>0.09 (-0.44,0.62) P value 0.7</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>WOMAC pain (VAS)</P>
</TD>
<TD>
<P>-0.10 (-0.63,0.43) P value 0.7</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Pain at rest (VAS)</P>
</TD>
<TD>
<P>-0.01 (-0.54,0.52) P value 1</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>WOMAC function (VAS)</P>
</TD>
<TD>
<P>-0.01 (-0.54,0.52) P value 1</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Walk time (sec)</P>
</TD>
<TD>
<P>-0.21 (-0.74,0.32) P value 0.4</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Zeel</P>
</TD>
<TD>
<P>Hyalart</P>
</TD>
<TD>
<P>Pain during movement (VAS)</P>
</TD>
<TD>
<P>0.23 (-0.15,0.61) P value 0.2 (end of treatment)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Pain during night (VAS)</P>
</TD>
<TD>
<P>0.09 (-0.29,0.47) P value 0.6 (end of treatment)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Patient assessment of improvement (VAS)</P>
</TD>
<TD>
<P>-0.16 (-0.53,0.21) P value 0.4 (end of treatment)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Patient assessment of tolerance (VAS)</P>
</TD>
<TD>
<P>-0.16 (-0.53,0.21) P value 0.4 (end of treatment)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>HA/Hylan (Pooled)</P>
</TD>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>Pain weight bearing (VAS)</P>
</TD>
<TD>
<P>-0.37 (-0.55,-0.19) P &lt; 0.0001</P>
</TD>
<TD>
<P>-0.33 (-0.55,-0.11) P value 0.004</P>
</TD>
<TD>
<P>-0.33 (-0.55,-0.11) P value 0.004</P>
</TD>
<TD>
<P>-0.09 (-0.27,0.08) P value 0.3</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Pain at rest (VAS)</P>
</TD>
<TD>
<P>-0.27 (-0.65,0.11) P value 0.17</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>WOMAC pain (VAS)</P>
</TD>
<TD>
<P>-0.21 (-0.46,0.05) P value 0.11</P>
</TD>
<TD>
<P>-0.23 (-0.46,0.00) P value 0.05</P>
</TD>
<TD>
<P>-0.38 (-0.68,-0.08) P value 0.01</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>WOMAC function (VAS)</P>
</TD>
<TD>
<P>-0.17 (-0.42,0.08) P value 0.19</P>
</TD>
<TD>
<P>-0.75 (-1.12,-0.38) P value 0.00008</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Lequesne Index (0-24)</P>
</TD>
<TD>
<P>-0.21 (-0.39,-0.03) P value 0.02</P>
</TD>
<TD>
<P>-0.36 (-0.54,-0.18) P &lt; 0.0001</P>
</TD>
<TD>
<P>0.01 (-0.16,0.19) P value 0.9</P>
</TD>
<TD>
<P>-0.28 (-0.69,0.13) P value 0.18</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Flexion (degrees)</P>
</TD>
<TD>
<P>0.24 (-0.10,0.58) P value 0.17</P>
</TD>
<TD>
<P>0.70 (0.01,1.39) P value 0.05</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-54" NO="54">
<TITLE>Effect size based on Standardised Mean Difference - Part III</TITLE>
<TABLE COLS="7" ROWS="91">
<TR>
<TH>
<P>Product</P>
</TH>
<TH>
<P>Comparison</P>
</TH>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>1-4 wk</P>
</TH>
<TH>
<P>5-13 wk</P>
</TH>
<TH>
<P>14-26 wk</P>
</TH>
<TH>
<P>45-52 wk</P>
</TH>
</TR>
<TR>
<TD>
<P>NASHA (Durolane)</P>
</TD>
<TD>
<P>Saline</P>
</TD>
<TD>
<P>WOMAC pain (Likert: 0-20)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>WOMAC stiffness (Likert: 0-8)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>WOMAC physical function (Likert: 0-68)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Patient global assessment (Likert: 1-5)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>SF-36 physical componet summary ( )</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>SF-36 mental component summary ( )</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>NRD-101 (Suvenyl)</P>
</TD>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>Pain (0-100 mm VAS)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Lequesne Index (0-24)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Patient global assessment (0-100 mm VAS)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Percentage of painful days during the previous month (0-100 mm VAS)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>NRD-101 (Suvenyl)</P>
</TD>
<TD>
<P>Diacerein</P>
</TD>
<TD>
<P>Pain (0-100 mm VAS)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Lequesne Index (0-24)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Patient global assessment (0-100 mm VAS)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Percentage of painful days during the previous month (0-100 mm VAS)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Hyalgan+exercise+ultrasound</P>
</TD>
<TD>
<P>Exercise+ultrasound</P>
</TD>
<TD>
<P>Pain (0-10 cm VAS)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Lequesne Index (0-26)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Range of motion (degrees)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Ambulation speed (metres/minute)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Mean peak torque at 60 degrees per second (flexion/concentric)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Mean peak torque at 180 degrees per second (flexion/concentric)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Hyalgan+exercise+ultrasound</P>
</TD>
<TD>
<P>Exercise</P>
</TD>
<TD>
<P>Pain (0-10 cm VAS)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Lequesne Index (0-26)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Range of motion (degrees)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Ambulation speed (metres/minute)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Mean peak torque at 60 degrees per second (flexion/concentric)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Mean peak torque at 180 degrees per second (flexion/concentric)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Hyalgan+exercise+ultrasound</P>
</TD>
<TD>
<P>Control warmup exercises</P>
</TD>
<TD>
<P>Pain (0-10 cm)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Lequesne Index (0-26)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Range of motion (degrees)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Ambulation speed (metres/minute)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Mean peak torque at 60 degrees per second (flexion/concentric)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Mean peak torque at 180 degrees per second (flexion/concentric)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Hylan G-F 20</P>
</TD>
<TD>
<P>Exercise programme</P>
</TD>
<TD>
<P>Hospital for Special Surgery Knee Score</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2008-11-09 23:07:17 -0500" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Adant versus Hyalgan</NAME>
<DICH_OUTCOME CHI2="1.6505686341659636" CI_END="2.8712012200007475" CI_START="1.029229402651382" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.7190476190476192" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.4580636298610848" LOG_CI_START="0.012512184482392587" LOG_EFFECT_SIZE="0.23528790717173867" METHOD="MH" NO="1" P_CHI2="0.4381106460153501" P_Q="0.4488506860054162" P_Z="0.038448108262832036" Q="1.6021308021360303" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="90" TOTAL_2="57" WEIGHT="300.0" Z="2.070045238715167">
<NAME>Patient global assessment (number of patients excellent/good)</NAME>
<GROUP_LABEL_1>Adant</GROUP_LABEL_1>
<GROUP_LABEL_2>Hyalgan</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hyalgan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Adant</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.4090941719433214" CI_START="0.5742507089979075" DF="0" EFFECT_SIZE="1.1761904761904762" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="7" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="0.3818537769829685" LOG_CI_START="-0.24089845993147557" LOG_EFFECT_SIZE="0.07047765852574647" NO="1" P_CHI2="1.0" P_Z="0.6573150253268799" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="19" WEIGHT="100.00000000000001" Z="0.44362320755229245">
<NAME>1 to 4 weeks post-injection</NAME>
<DICH_DATA CI_END="2.4090941719433214" CI_START="0.5742507089979075" EFFECT_SIZE="1.1761904761904762" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="7" LOG_CI_END="0.3818537769829685" LOG_CI_START="-0.24089845993147557" LOG_EFFECT_SIZE="0.07047765852574647" ORDER="150358" O_E="0.0" SE="0.36580774663683385" STUDY_ID="STD-Roman-2000" TOTAL_1="30" TOTAL_2="19" VAR="0.13381530749951803" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.08846513166838" CI_START="0.9264444943046488" DF="0" EFFECT_SIZE="2.375" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="4" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.7845078231975742" LOG_CI_START="-0.03318059527580339" LOG_EFFECT_SIZE="0.3756636139608854" NO="2" P_CHI2="1.0" P_Z="0.07171879059121089" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="19" WEIGHT="100.00000000000001" Z="1.800899063827124">
<NAME>5 to 13 weeks post-injection</NAME>
<DICH_DATA CI_END="6.08846513166838" CI_START="0.9264444943046487" EFFECT_SIZE="2.375" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="4" LOG_CI_END="0.7845078231975742" LOG_CI_START="-0.03318059527580344" LOG_EFFECT_SIZE="0.3756636139608854" ORDER="150359" O_E="0.0" SE="0.4803142246342127" STUDY_ID="STD-Roman-2000" TOTAL_1="30" TOTAL_2="19" VAR="0.2307017543859649" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.701808202048378" CI_START="0.6650130814090729" DF="0" EFFECT_SIZE="2.111111111111111" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="3" I2="0.0" ID="CMP-001.01.03" LOG_CI_END="0.8261919946744322" LOG_CI_START="-0.17716981164742399" LOG_EFFECT_SIZE="0.3245110915135041" NO="3" P_CHI2="1.0" P_Z="0.20487011730702376" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="19" WEIGHT="100.0" Z="1.2677980125271489">
<NAME>14 to 26 weeks post-injection</NAME>
<DICH_DATA CI_END="6.701808202048378" CI_START="0.6650130814090729" EFFECT_SIZE="2.111111111111111" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="3" LOG_CI_END="0.8261919946744322" LOG_CI_START="-0.17716981164742399" LOG_EFFECT_SIZE="0.3245110915135041" ORDER="150360" O_E="0.0" SE="0.5893796917545019" STUDY_ID="STD-Roman-2000" TOTAL_1="30" TOTAL_2="19" VAR="0.3473684210526316" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="8.460605274215688" CI_START="0.4266834207478912" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.9" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" I2="0.0" I2_Q="100.0" ID="CMP-001.02" LOG_CI_END="0.9274014337067407" LOG_CI_START="-0.3698942318010828" LOG_EFFECT_SIZE="0.2787536009528289" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.3996278680452646" Q="2.1225959024545733E-32" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="30" TOTAL_2="19" WEIGHT="100.00000000000001" Z="0.8422860462029348">
<NAME>Safety: number of painful injections</NAME>
<GROUP_LABEL_1>Adant</GROUP_LABEL_1>
<GROUP_LABEL_2>Hyalgan</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Adant</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Hyalgan</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.460605274215688" CI_START="0.4266834207478912" DF="0" EFFECT_SIZE="1.9" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="0.9274014337067407" LOG_CI_START="-0.3698942318010828" LOG_EFFECT_SIZE="0.2787536009528289" NO="1" P_CHI2="1.0" P_Z="0.3996278680452646" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="19" WEIGHT="100.00000000000001" Z="0.8422860462029348">
<NAME>1 to 4 weeks post-injection</NAME>
<DICH_DATA CI_END="8.460605274215688" CI_START="0.4266834207478912" EFFECT_SIZE="1.9" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="0.9274014337067407" LOG_CI_START="-0.3698942318010828" LOG_EFFECT_SIZE="0.2787536009528289" ORDER="150361" O_E="0.0" SE="0.7620378956364079" STUDY_ID="STD-Roman-2000" TOTAL_1="30" TOTAL_2="19" VAR="0.5807017543859649" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2008-11-09 23:07:17 -0500" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Artz versus placebo</NAME>
<CONT_OUTCOME CHI2="7.021572301730814" CI_END="1.2171346863254022" CI_START="-4.456228131659686" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.619546722667142" ESTIMABLE="YES" I2="0.30722893397389117" I2_Q="25.144297240632493" ID="CMP-002.01" NO="1" P_CHI2="0.4266373066097844" P_Q="0.26292068199170504" P_Z="0.26313914187354537" Q="2.671807125275727" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="748" TOTAL_2="578" UNITS="" WEIGHT="300.0" Z="1.1190023799094249">
<NAME>Pain (100 mm VAS)</NAME>
<GROUP_LABEL_1>Artzal/Artz</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline/Vehicle</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Artzal/Artz</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours saline/vehic</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.875652668697564" CI_END="4.941720132137735" CI_START="-3.8280673444900875" DF="2" EFFECT_SIZE="0.5568263938238237" ESTIMABLE="YES" I2="0.0" ID="CMP-002.01.01" NO="1" P_CHI2="0.3914779151838189" P_Z="0.803445257989137" STUDIES="3" TAU2="0.0" TOTAL_1="281" TOTAL_2="226" WEIGHT="100.0" Z="0.24889079249515927">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="11.532726048091009" CI_START="-11.532726048091009" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="44.0" MEAN_2="44.0" ORDER="150362" SD_1="24.44" SD_2="30.39" SE="5.884152024761516" STUDY_ID="STD-Karlsson-2002a-_x0028_AvP_x0029_" TOTAL_1="90" TOTAL_2="33" WEIGHT="14.456201566168044"/>
<CONT_DATA CI_END="11.571109890444557" CI_START="-2.77110989044456" EFFECT_SIZE="4.399999999999999" ESTIMABLE="YES" MEAN_1="36.64" MEAN_2="32.24" ORDER="150363" SD_1="25.49" SD_2="24.81" SE="3.658796767190294" STUDY_ID="STD-Lohmander-1996" TOTAL_1="96" TOTAL_2="93" WEIGHT="37.38913270913552"/>
<CONT_DATA CI_END="4.05887678746089" CI_START="-8.578876787460885" EFFECT_SIZE="-2.259999999999998" ESTIMABLE="YES" MEAN_1="29.14" MEAN_2="31.4" ORDER="150364" SD_1="22.6" SD_2="22.4" SE="3.223975969611371" STUDY_ID="STD-Puhl-1993" TOTAL_1="95" TOTAL_2="100" WEIGHT="48.154665724696436"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.9361709566037706" CI_END="-0.00255888103419899" CI_START="-9.090791110237097" DF="2" EFFECT_SIZE="-4.546674995635648" ESTIMABLE="YES" I2="0.0" ID="CMP-002.01.02" NO="2" P_CHI2="0.37980957890587375" P_Z="0.049871128494945356" STUDIES="3" TAU2="0.0" TOTAL_1="281" TOTAL_2="226" WEIGHT="99.99999999999999" Z="1.9610676787550054">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="9.244501408129867" CI_START="-17.244501408129867" EFFECT_SIZE="-4.0" ESTIMABLE="YES" MEAN_1="42.0" MEAN_2="46.0" ORDER="150365" SD_1="28.07" SD_2="34.9" SE="6.757522848685386" STUDY_ID="STD-Karlsson-2002a-_x0028_AvP_x0029_" TOTAL_1="90" TOTAL_2="33" WEIGHT="11.771386319387698"/>
<CONT_DATA CI_END="6.980103345061149" CI_START="-8.060103345061147" EFFECT_SIZE="-0.5399999999999991" ESTIMABLE="YES" MEAN_1="34.69" MEAN_2="35.23" ORDER="150366" SD_1="27.25" SD_2="25.49" SE="3.8368579241143017" STUDY_ID="STD-Lohmander-1996" TOTAL_1="96" TOTAL_2="93" WEIGHT="36.51331154002559"/>
<CONT_DATA CI_END="-1.181123212539112" CI_START="-13.818876787460887" EFFECT_SIZE="-7.5" ESTIMABLE="YES" MEAN_1="26.5" MEAN_2="34.0" ORDER="150367" SD_1="22.6" SD_2="22.4" SE="3.223975969611371" STUDY_ID="STD-Puhl-1993" TOTAL_1="95" TOTAL_2="100" WEIGHT="51.715302140586694"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.5379415511537512" CI_END="6.056034157642509" CI_START="-6.898333119392756" DF="1" EFFECT_SIZE="-0.4211494808751239" ESTIMABLE="YES" I2="0.0" ID="CMP-002.01.03" NO="3" P_CHI2="0.4632871517126518" P_Z="0.8985939267640175" STUDIES="2" TAU2="0.0" TOTAL_1="186" TOTAL_2="126" WEIGHT="100.0" Z="0.12743776627149833">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="17.47355089842189" CI_START="-9.47355089842189" EFFECT_SIZE="4.0" ESTIMABLE="YES" MEAN_1="48.0" MEAN_2="44.0" ORDER="150368" SD_1="33.78" SD_2="33.78" SE="6.8743869809341085" STUDY_ID="STD-Karlsson-2002a-_x0028_AvP_x0029_" TOTAL_1="90" TOTAL_2="33" WEIGHT="23.110443810867412"/>
<CONT_DATA CI_END="5.63673524098208" CI_START="-9.13673524098208" EFFECT_SIZE="-1.75" ESTIMABLE="YES" MEAN_1="33.65" MEAN_2="35.4" ORDER="150369" SD_1="25.74" SD_2="26.06" SE="3.7688117226886337" STUDY_ID="STD-Lohmander-1996" TOTAL_1="96" TOTAL_2="93" WEIGHT="76.88955618913259"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.14048711377502174" CI_START="-0.28048711377502167" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.06999999999999995" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.02" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.5145241422114005" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="48" TOTAL_2="50" UNITS="" WEIGHT="100.0" Z="0.6518093980064105">
<NAME>Pain score (0-3)</NAME>
<GROUP_LABEL_1>Artz+lactose</GROUP_LABEL_1>
<GROUP_LABEL_2>Vehicle+lactose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Artz+lactose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours vehicle+lact</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.14048711377502174" CI_START="-0.28048711377502167" DF="0" EFFECT_SIZE="-0.06999999999999995" ESTIMABLE="YES" I2="0.0" ID="CMP-002.02.01" NO="1" P_CHI2="1.0" P_Z="0.5145241422114005" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="50" WEIGHT="100.0" Z="0.6518093980064105">
<NAME>1 to 4 weeks post -injection</NAME>
<CONT_DATA CI_END="0.14048711377502174" CI_START="-0.28048711377502167" EFFECT_SIZE="-0.06999999999999995" ESTIMABLE="YES" MEAN_1="0.66" MEAN_2="0.73" ORDER="150370" SD_1="0.56" SD_2="0.5" SE="0.10739335795724675" STUDY_ID="STD-Shichikawa-1983b" TOTAL_1="48" TOTAL_2="50" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.07242887693680033" CI_START="-1.6124288769368014" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.7700000000000005" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.03" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.07322052965356389" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="108" TOTAL_2="115" UNITS="" WEIGHT="100.0" Z="1.7914536282082614">
<NAME>WOMAC pain (0-20 Likert)</NAME>
<GROUP_LABEL_1>Artz</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Artz</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Saline</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.07242887693680033" CI_START="-1.6124288769368014" DF="0" EFFECT_SIZE="-0.7700000000000005" ESTIMABLE="YES" I2="0.0" ID="CMP-002.03.01" NO="1" P_CHI2="1.0" P_Z="0.07322052965356389" STUDIES="1" TAU2="0.0" TOTAL_1="108" TOTAL_2="115" WEIGHT="100.0" Z="1.7914536282082614">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="0.07242887693680033" CI_START="-1.6124288769368014" EFFECT_SIZE="-0.7700000000000005" ESTIMABLE="YES" MEAN_1="3.84" MEAN_2="4.61" ORDER="150371" SD_1="3.27" SD_2="3.14" SE="0.429818549515079" STUDY_ID="STD-Day-2004" TOTAL_1="108" TOTAL_2="115" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.44695916102202116" CI_START="-5.32695916102202" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.4399999999999995" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.04" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.09761610038476089" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="108" TOTAL_2="115" UNITS="" WEIGHT="100.0" Z="1.6565222628867156">
<NAME>WOMAC function (0-68 Likert)</NAME>
<GROUP_LABEL_1>Artz</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Artz</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Saline</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.44695916102202116" CI_START="-5.32695916102202" DF="0" EFFECT_SIZE="-2.4399999999999995" ESTIMABLE="YES" I2="0.0" ID="CMP-002.04.01" NO="1" P_CHI2="1.0" P_Z="0.09761610038476089" STUDIES="1" TAU2="0.0" TOTAL_1="108" TOTAL_2="115" WEIGHT="100.0" Z="1.6565222628867156">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="0.44695916102202116" CI_START="-5.32695916102202" EFFECT_SIZE="-2.4399999999999995" ESTIMABLE="YES" MEAN_1="15.37" MEAN_2="17.81" ORDER="150372" SD_1="11.41" SD_2="10.53" SE="1.4729654135453436" STUDY_ID="STD-Day-2004" TOTAL_1="108" TOTAL_2="115" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.399990509582335" CI_END="0.7226668859828554" CI_START="-0.4374006507393563" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="0.1426331176217496" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.05" NO="5" P_CHI2="0.4936365808279177" P_Q="0.4724271818671246" P_Z="0.6298310584436098" Q="1.4997437591777378" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="401" TOTAL_2="386" UNITS="" WEIGHT="300.0" Z="0.4819646523877112">
<NAME>Lequesne Index (0-24)</NAME>
<GROUP_LABEL_1>Artzal/Artz</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline/vehicle</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Artzal/Artz</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours saline/vehic</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.725964722477511E-33" CI_END="1.2319292110947269" CI_START="-0.8519292110947261" DF="0" EFFECT_SIZE="0.19000000000000036" ESTIMABLE="YES" I2="100.0" ID="CMP-002.05.01" NO="1" P_CHI2="0.0" P_Z="0.7207868766764216" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="100" WEIGHT="100.0" Z="0.3574073488844292">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="1.2319292110947269" CI_START="-0.8519292110947261" EFFECT_SIZE="0.1900000000000004" ESTIMABLE="YES" MEAN_1="7.19" MEAN_2="7.0" ORDER="150373" SD_1="3.9" SD_2="3.5" SE="0.5316063046634179" STUDY_ID="STD-Puhl-1993" TOTAL_1="95" TOTAL_2="100" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.6819292110947262" CI_START="-1.4019292110947268" DF="0" EFFECT_SIZE="-0.3600000000000003" ESTIMABLE="YES" I2="0.0" ID="CMP-002.05.02" NO="2" P_CHI2="1.0" P_Z="0.49828359446319614" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="100" WEIGHT="100.0" Z="0.6771928715704968">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="0.6819292110947262" CI_START="-1.4019292110947268" EFFECT_SIZE="-0.3600000000000003" ESTIMABLE="YES" MEAN_1="6.43" MEAN_2="6.79" ORDER="150374" SD_1="3.9" SD_2="3.5" SE="0.5316063046634179" STUDY_ID="STD-Puhl-1993" TOTAL_1="95" TOTAL_2="100" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.9002467504045968" CI_END="1.4544452285482181" CI_START="-0.42696797840230216" DF="1" EFFECT_SIZE="0.513738625072958" ESTIMABLE="YES" I2="0.0" ID="CMP-002.05.03" NO="3" P_CHI2="0.342715677365799" P_Z="0.28445038584505666" STUDIES="2" TAU2="0.0" TOTAL_1="211" TOTAL_2="186" WEIGHT="100.0" Z="1.0703753953573736">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="2.6334756270396795" CI_START="-0.43347562703968" EFFECT_SIZE="1.0999999999999996" ESTIMABLE="YES" MEAN_1="10.0" MEAN_2="8.9" ORDER="150375" SD_1="4.96" SD_2="4.77" SE="0.7823999007816163" STUDY_ID="STD-Karlsson-2002a-_x0028_AvP_x0029_" TOTAL_1="92" TOTAL_2="66" WEIGHT="37.631768624782765"/>
<CONT_DATA CI_END="1.3511665202998535" CI_START="-1.0311665202998532" EFFECT_SIZE="0.16000000000000014" ESTIMABLE="YES" MEAN_1="7.98" MEAN_2="7.82" ORDER="150376" SD_1="4.4" SD_2="4.98" SE="0.6077491880950991" STUDY_ID="STD-Lohmander-1996" TOTAL_1="119" TOTAL_2="120" WEIGHT="62.36823137521723"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.06" MODIFIED="2008-11-09 23:07:16 -0500" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="48" TOTAL_2="50" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Range of motion</NAME>
<GROUP_LABEL_1>Artz+lactose</GROUP_LABEL_1>
<GROUP_LABEL_2>Vehicle+Lactose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Vehicle+lact</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Artz+lactose</GRAPH_LABEL_2>
<CONT_DATA CI_END="8.58882608586999" CI_START="-2.4888260858699676" EFFECT_SIZE="3.0500000000000114" ESTIMABLE="YES" MEAN_1="135.65" MEAN_2="132.6" ORDER="150377" SD_1="14.48" SD_2="13.45" SE="2.8259836045761717" STUDY_ID="STD-Shichikawa-1983b" TOTAL_1="48" TOTAL_2="50" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="5.921688196148823" CI_END="1.250108992675965" CI_START="1.0600228939905896" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1511490573422876" ESTIMABLE="YES" EVENTS_1="381" EVENTS_2="333" I2="15.564618831978422" I2_Q="5.190829800681005" ID="CMP-002.07" LOG_CI_END="0.09694787929141295" LOG_CI_START="0.02531524510100726" LOG_EFFECT_SIZE="0.061131562196210125" METHOD="MH" MODIFIED="2008-11-09 23:07:16 -0500" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.3139139936298264" P_Q="0.34827956515703995" P_Z="8.219911978083484E-4" Q="2.109500585012362" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="534" TOTAL_2="534" WEIGHT="300.0" Z="3.345281423122368">
<NAME>Patient global assessment (number of patients improved)</NAME>
<GROUP_LABEL_1>Artzal/Artz</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline/vehicle</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours saline/vehic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Artz/Artzal</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.5521781196699607" CI_END="1.3192681485090534" CI_START="1.0417345831785403" DF="2" EFFECT_SIZE="1.1723170453370553" ESTIMABLE="YES" EVENTS_1="184" EVENTS_2="158" I2="43.69651710523391" ID="CMP-002.07.01" LOG_CI_END="0.12033307726123138" LOG_CI_START="0.017757081973057667" LOG_EFFECT_SIZE="0.06904507961714453" NO="1" P_CHI2="0.16929902677179054" P_Z="0.008326178898596997" STUDIES="3" TAU2="0.0" TOTAL_1="247" TOTAL_2="248" WEIGHT="100.0" Z="2.638548502095907">
<NAME>1 to 4 weeks post-injection</NAME>
<DICH_DATA CI_END="1.283147931553661" CI_START="0.8118479008713992" EFFECT_SIZE="1.0206473214285714" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="56" LOG_CI_END="0.10827672820183723" LOG_CI_START="-0.09052532790121633" LOG_EFFECT_SIZE="0.008875700150310464" ORDER="150378" O_E="0.0" SE="0.11677731184098247" STUDY_ID="STD-Lohmander-1996" TOTAL_1="96" TOTAL_2="93" VAR="0.013636940560806065" WEIGHT="36.11296540485342"/>
<DICH_DATA CI_END="1.5629983902311049" CI_START="1.121074612629637" EFFECT_SIZE="1.3237211998261122" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="67" LOG_CI_END="0.19395853072929037" LOG_CI_START="0.049634517835825565" LOG_EFFECT_SIZE="0.121796524282558" ORDER="150379" O_E="0.0" SE="0.08477663958900697" STUDY_ID="STD-Shichikawa-1983a" TOTAL_1="103" TOTAL_2="105" VAR="0.007187078620004384" WEIGHT="42.12252419490011"/>
<DICH_DATA CI_END="1.426768394289991" CI_START="0.896468756317216" EFFECT_SIZE="1.130952380952381" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="35" LOG_CI_END="0.15435348030082482" LOG_CI_START="-0.047464841846892605" LOG_EFFECT_SIZE="0.0534443192269661" ORDER="150380" O_E="0.0" SE="0.11854908144637581" STUDY_ID="STD-Shichikawa-1983b" TOTAL_1="48" TOTAL_2="50" VAR="0.014053884711779447" WEIGHT="21.76451040024648"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.7060247581598402" CI_END="1.212637248927091" CI_START="0.9506308175966264" DF="1" EFFECT_SIZE="1.073671429905669" ESTIMABLE="YES" EVENTS_1="139" EVENTS_2="132" I2="0.0" ID="CMP-002.07.02" LOG_CI_END="0.08373090445233128" LOG_CI_START="-0.021988110833162405" LOG_EFFECT_SIZE="0.030871396809584426" NO="2" P_CHI2="0.400767115896285" P_Z="0.25234485757329317" STUDIES="2" TAU2="0.0" TOTAL_1="191" TOTAL_2="193" WEIGHT="100.0" Z="1.1446725215105689">
<NAME>5 to 13 weeks post-injection</NAME>
<DICH_DATA CI_END="1.302855469951321" CI_START="0.7779265204588712" EFFECT_SIZE="1.0067401960784315" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="51" LOG_CI_END="0.11489624066726953" LOG_CI_START="-0.10906142263283067" LOG_EFFECT_SIZE="0.002917409017219421" ORDER="150381" O_E="0.0" SE="0.1315538400307916" STUDY_ID="STD-Lohmander-1996" TOTAL_1="96" TOTAL_2="93" VAR="0.01730641282684711" WEIGHT="39.63014850098067"/>
<DICH_DATA CI_END="1.2539112922540723" CI_START="0.9961227082399657" EFFECT_SIZE="1.1176088369070825" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="81" LOG_CI_END="0.09826681349050403" LOG_CI_START="-0.0016871593383636651" LOG_EFFECT_SIZE="0.048289827076070185" ORDER="150382" O_E="0.0" SE="0.05871345841982211" STUDY_ID="STD-Puhl-1993" TOTAL_1="95" TOTAL_2="100" VAR="0.00344727019961618" WEIGHT="60.36985149901933"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7159680784572462" CI_START="0.995023418899065" DF="0" EFFECT_SIZE="1.306686046511628" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="43" I2="0.0" ID="CMP-002.07.03" LOG_CI_END="0.2345092045623262" LOG_CI_START="-0.002166697566891321" LOG_EFFECT_SIZE="0.11617125349771745" NO="3" P_CHI2="1.0" P_Z="0.05434478109123707" STUDIES="1" TAU2="0.0" TOTAL_1="96" TOTAL_2="93" WEIGHT="100.0" Z="1.9240782086051726">
<NAME>14 to 26 weeks post-injection</NAME>
<DICH_DATA CI_END="1.7159680784572462" CI_START="0.995023418899065" EFFECT_SIZE="1.306686046511628" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="43" LOG_CI_END="0.2345092045623262" LOG_CI_START="-0.002166697566891321" LOG_EFFECT_SIZE="0.11617125349771745" ORDER="150383" O_E="0.0" SE="0.13902459647531268" STUDY_ID="STD-Lohmander-1996" TOTAL_1="96" TOTAL_2="93" VAR="0.019327838425123523" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.025483650883047493" CI_START="-0.7254836508830477" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.3500000000000001" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.08" MODIFIED="2008-11-09 23:07:17 -0500" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.06770827320359232" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="108" TOTAL_2="115" UNITS="" WEIGHT="100.0" Z="1.8269434447431763">
<NAME>WOMAC stiffness (0-8 Likert)</NAME>
<GROUP_LABEL_1>Artz</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Artz</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Saline</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.025483650883047493" CI_START="-0.7254836508830477" DF="0" EFFECT_SIZE="-0.3500000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-002.08.01" NO="1" P_CHI2="1.0" P_Z="0.06770827320359232" STUDIES="1" TAU2="0.0" TOTAL_1="108" TOTAL_2="115" WEIGHT="100.0" Z="1.8269434447431763">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="0.025483650883047493" CI_START="-0.7254836508830477" EFFECT_SIZE="-0.3500000000000001" ESTIMABLE="YES" MEAN_1="2.11" MEAN_2="2.46" ORDER="150384" SD_1="1.42" SD_2="1.44" SE="0.19157681153572959" STUDY_ID="STD-Day-2004" TOTAL_1="108" TOTAL_2="115" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="39" EVENTS_2="22" I2="0.0" I2_Q="0.0" ID="CMP-002.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2008-11-09 23:07:17 -0500" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="90" TOTAL_2="66" WEIGHT="0.0" Z="0.0">
<NAME>Number of survivors (patients not requiring additional treatment for study knee) 45 to 52 weeks post-injection</NAME>
<GROUP_LABEL_1>Artzal</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours saline</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Artzal</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.9686793808077159" CI_START="0.8584434908373051" EFFECT_SIZE="1.3" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="22" LOG_CI_END="0.2941749926825786" LOG_CI_START="-0.06628828806890504" LOG_EFFECT_SIZE="0.11394335230683679" ORDER="150385" O_E="0.0" SE="0.21173791543543835" STUDY_ID="STD-Karlsson-2002a-_x0028_AvP_x0029_" TOTAL_1="90" TOTAL_2="66" VAR="0.04483294483294484" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.5467869629497093" CI_END="0.9111734358034871" CI_START="0.41881711511097" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6177499734916765" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="33" I2="60.734839052191795" I2_Q="57.54267831986441" ID="CMP-002.10" LOG_CI_END="-0.04039895009239919" LOG_CI_START="-0.37797557903146345" LOG_EFFECT_SIZE="-0.20918726456193135" METHOD="MH" MODIFIED="2008-11-09 23:07:17 -0500" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.11051914098617366" P_Q="0.12485751409368506" P_Z="0.015137393285913818" Q="2.355306365139532" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="156" TOTAL_2="114" WEIGHT="200.0" Z="2.4290751753424624">
<NAME>Number of clinical failures</NAME>
<GROUP_LABEL_1>Artzal</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Artzal</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours saline</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9763980484313671" CI_START="0.04496140362826159" DF="0" EFFECT_SIZE="0.20952380952380953" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" I2="0.0" ID="CMP-002.10.01" LOG_CI_END="-0.010373097296978594" LOG_CI_START="-1.347160139198485" LOG_EFFECT_SIZE="-0.6787666182477319" NO="1" P_CHI2="1.0" P_Z="0.04654892182676307" STUDIES="1" TAU2="0.0" TOTAL_1="90" TOTAL_2="66" WEIGHT="100.0" Z="1.9903815401759741">
<NAME>14 to 26 weeks post-injection</NAME>
<DICH_DATA CI_END="0.9763980484313671" CI_START="0.04496140362826159" EFFECT_SIZE="0.20952380952380953" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="-0.010373097296978594" LOG_CI_START="-1.347160139198485" LOG_EFFECT_SIZE="-0.6787666182477319" ORDER="150386" O_E="0.0" SE="0.7852353256155231" STUDY_ID="STD-Karlsson-2002a-_x0028_AvP_x0029_" TOTAL_1="90" TOTAL_2="66" VAR="0.6165945165945166" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0812412150315869" CI_START="0.48918373854187475" DF="0" EFFECT_SIZE="0.7272727272727273" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="26" I2="0.0" ID="CMP-002.10.02" LOG_CI_END="0.033922591891317085" LOG_CI_START="-0.31052798822388" LOG_EFFECT_SIZE="-0.13830269816628143" NO="2" P_CHI2="1.0" P_Z="0.11550664520542404" STUDIES="1" TAU2="0.0" TOTAL_1="66" TOTAL_2="48" WEIGHT="100.0" Z="1.5739169739819867">
<NAME>45 to 52 weeks post-injection</NAME>
<DICH_DATA CI_END="1.0812412150315869" CI_START="0.4891837385418747" EFFECT_SIZE="0.7272727272727273" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="26" LOG_CI_END="0.033922591891317085" LOG_CI_START="-0.31052798822388" LOG_EFFECT_SIZE="-0.13830269816628143" ORDER="150387" O_E="0.0" SE="0.20233197581753717" STUDY_ID="STD-Karlsson-2002a-_x0028_AvP_x0029_" TOTAL_1="66" TOTAL_2="48" VAR="0.04093822843822845" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.7132369508169353" CI_END="1.4953138787372824" CI_START="0.6662503580951389" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9981249456723068" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="43" I2="0.0" I2_Q="0.0" ID="CMP-002.11" LOG_CI_END="0.17473236422946561" LOG_CI_START="-0.17636254454142983" LOG_EFFECT_SIZE="-8.150901559821219E-4" METHOD="MH" MODIFIED="2008-11-09 23:07:17 -0500" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.9496865634044557" P_Q="0.7534704558096387" P_Z="0.9927390529439409" Q="0.5661310018177754" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="501" TOTAL_2="518" WEIGHT="300.0" Z="0.00910037320376276">
<NAME>Safety: total withdrawals overall</NAME>
<GROUP_LABEL_1>Artz/Artzal</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline/vehicle</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Artz/Artzal</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours saline/vehic</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.14464374912637185" CI_END="2.220536988239914" CI_START="0.47500652815828076" DF="1" EFFECT_SIZE="1.0270197492896067" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" I2="0.0" ID="CMP-002.11.01" LOG_CI_END="0.34645801176085406" LOG_CI_START="-0.32330042169379425" LOG_EFFECT_SIZE="0.011578795033529902" NO="1" P_CHI2="0.7037075876987816" P_Z="0.9459704922219067" STUDIES="2" TAU2="0.0" TOTAL_1="163" TOTAL_2="167" WEIGHT="100.00000000000001" Z="0.0677677804907448">
<NAME>1 to 4 weeks post-injection</NAME>
<DICH_DATA CI_END="3.0719863976682027" CI_START="0.4328672143979603" EFFECT_SIZE="1.1531531531531531" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.4874192883677038" LOG_CI_START="-0.36364530664528194" LOG_EFFECT_SIZE="0.06188699086121093" ORDER="150388" O_E="0.0" SE="0.49991955594831694" STUDY_ID="STD-Shichikawa-1983a" TOTAL_1="111" TOTAL_2="112" VAR="0.2499195624195624" WEIGHT="58.914107951445246"/>
<DICH_DATA CI_END="2.9798976264045933" CI_START="0.24026876796596888" EFFECT_SIZE="0.8461538461538461" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.47420134426038957" LOG_CI_START="-0.6193026785576131" LOG_EFFECT_SIZE="-0.07255066714861173" ORDER="150389" O_E="0.0" SE="0.6423296759355064" STUDY_ID="STD-Shichikawa-1983b" TOTAL_1="52" TOTAL_2="55" VAR="0.4125874125874126" WEIGHT="41.08589204855477"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.001001059329416881" CI_END="1.7638853766705298" CI_START="0.6412855858380652" DF="1" EFFECT_SIZE="1.063557364287116" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="26" I2="0.0" ID="CMP-002.11.02" LOG_CI_END="0.24647035976581338" LOG_CI_START="-0.1929485216005246" LOG_EFFECT_SIZE="0.0267609190826444" NO="2" P_CHI2="0.9747595271329408" P_Z="0.8113177664673998" STUDIES="2" TAU2="0.0" TOTAL_1="218" TOTAL_2="231" WEIGHT="100.0" Z="0.2387263716665212">
<NAME>5 to 13 weeks post-injection</NAME>
<DICH_DATA CI_END="1.9155730159818447" CI_START="0.5965250436906131" EFFECT_SIZE="1.0689655172413792" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="19" LOG_CI_END="0.28229871065668155" LOG_CI_START="-0.22437131878604846" LOG_EFFECT_SIZE="0.028963695935316558" ORDER="150390" O_E="0.0" SE="0.2976204833517548" STUDY_ID="STD-Day-2004" TOTAL_1="116" TOTAL_2="124" VAR="0.08857795211053215" WEIGHT="72.88590434116672"/>
<DICH_DATA CI_END="2.8857455806366734" CI_START="0.38133719930936605" EFFECT_SIZE="1.0490196078431373" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.46025803923280545" LOG_CI_START="-0.4186908273862213" LOG_EFFECT_SIZE="0.0207836059232921" ORDER="150391" O_E="0.0" SE="0.516298915119076" STUDY_ID="STD-Puhl-1993" TOTAL_1="102" TOTAL_2="107" VAR="0.26656456975313486" WEIGHT="27.114095658833286"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.454657533133506" CI_START="0.146659969930893" DF="0" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" I2="0.0" ID="CMP-002.11.03" LOG_CI_END="0.3899909091493468" LOG_CI_START="-0.8336884083820596" LOG_EFFECT_SIZE="-0.2218487496163564" NO="3" P_CHI2="1.0" P_Z="0.4772892973498343" STUDIES="1" TAU2="0.0" TOTAL_1="120" TOTAL_2="120" WEIGHT="100.0" Z="0.7106691320737191">
<NAME>14 to 26 weeks post-injection</NAME>
<DICH_DATA CI_END="2.454657533133506" CI_START="0.146659969930893" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.3899909091493468" LOG_CI_START="-0.8336884083820596" LOG_EFFECT_SIZE="-0.2218487496163564" ORDER="150392" O_E="0.0" SE="0.7187952884282609" STUDY_ID="STD-Lohmander-1996" TOTAL_1="120" TOTAL_2="120" VAR="0.5166666666666667" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="55" EVENTS_2="33" I2="0.0" I2_Q="0.0" ID="CMP-002.12" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2008-11-09 23:07:17 -0500" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="90" TOTAL_2="66" WEIGHT="0.0" Z="0.0">
<NAME>Safety: number of patients reporting adverse events (45 to 52 weeks post- injection)</NAME>
<GROUP_LABEL_1>Artzal</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6369665683247576" CI_START="0.9125581361277179" EFFECT_SIZE="1.2222222222222223" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="33" LOG_CI_END="0.21403980993097635" LOG_CI_START="-0.03973945849317597" LOG_EFFECT_SIZE="0.0871501757189002" ORDER="150393" O_E="0.0" SE="0.14907119849998596" STUDY_ID="STD-Karlsson-2002a-_x0028_AvP_x0029_" TOTAL_1="90" TOTAL_2="66" VAR="0.02222222222222222" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.8950345392844733" CI_END="1.2529165173186723" CI_START="0.17607773449578004" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4696921352139235" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-002.13" LOG_CI_END="0.09792213462089258" LOG_CI_START="-0.7542955582688331" LOG_EFFECT_SIZE="-0.32818671182397025" METHOD="MH" MODIFIED="2008-11-09 23:07:17 -0500" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.9252721397705607" P_Q="0.8335128083011957" P_Z="0.13115737327874372" Q="0.8664624012428903" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="478" TOTAL_2="463" WEIGHT="400.0" Z="1.5095535817814565">
<NAME>Safety: withdrawals due to adverse events</NAME>
<GROUP_LABEL_1>Artz/Artzal</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline/Vehicle</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Artz/Artzal</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours saline/place</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.03964349111211785" CI_END="2.279569960825711" CI_START="0.02901078044987314" DF="1" EFFECT_SIZE="0.257161629434954" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" ID="CMP-002.13.01" LOG_CI_END="0.35785292539707697" LOG_CI_START="-1.5374405876222204" LOG_EFFECT_SIZE="-0.5897938311125717" NO="1" P_CHI2="0.8421793473564423" P_Z="0.22252665857364695" STUDIES="2" TAU2="0.0" TOTAL_1="160" TOTAL_2="162" WEIGHT="100.0" Z="1.2198370957783888">
<NAME>1 to 4 weeks post-injection</NAME>
<DICH_DATA CI_END="8.02101644252152" CI_START="0.013604027359635033" EFFECT_SIZE="0.3303303303303303" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9042294066142395" LOG_CI_START="-1.8663325033104288" LOG_EFFECT_SIZE="-0.4810515483480948" ORDER="150394" O_E="0.0" SE="1.6274417803923888" STUDY_ID="STD-Shichikawa-1983a" TOTAL_1="110" TOTAL_2="109" VAR="2.6485667485667483" WEIGHT="38.28843626806833"/>
<DICH_DATA CI_END="4.3053967308370975" CI_START="0.010415832375271113" EFFECT_SIZE="0.21176470588235294" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6340131767129504" LOG_CI_START="-1.9823060179349237" LOG_EFFECT_SIZE="-0.6741464206109866" ORDER="150395" O_E="0.0" SE="1.5368388459250457" STUDY_ID="STD-Shichikawa-1983b" TOTAL_1="50" TOTAL_2="53" VAR="2.3618736383442265" WEIGHT="61.71156373193167"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="16.81276819824312" CI_START="0.06743866188362661" DF="0" EFFECT_SIZE="1.0648148148148149" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-002.13.02" LOG_CI_END="1.2256392252922388" LOG_CI_START="-1.171091055558915" LOG_EFFECT_SIZE="0.027274084866662007" NO="2" P_CHI2="1.0" P_Z="0.964420064004912" STUDIES="1" TAU2="0.0" TOTAL_1="108" TOTAL_2="115" WEIGHT="100.0" Z="0.04460762604539923">
<NAME>5 to 13 weeks post-injection</NAME>
<DICH_DATA CI_END="16.81276819824312" CI_START="0.06743866188362661" EFFECT_SIZE="1.0648148148148149" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2256392252922388" LOG_CI_START="-1.171091055558915" LOG_EFFECT_SIZE="0.027274084866662007" ORDER="150396" O_E="0.0" SE="1.407851230978198" STUDY_ID="STD-Day-2004" TOTAL_1="108" TOTAL_2="115" VAR="1.9820450885668277" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.021608484389742" CI_START="0.0791448993390522" DF="0" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" I2="0.0" ID="CMP-002.13.03" LOG_CI_END="0.3056970515849466" LOG_CI_START="-1.1015770689290219" LOG_EFFECT_SIZE="-0.3979400086720376" NO="3" P_CHI2="1.0" P_Z="0.2676665664296731" STUDIES="1" TAU2="0.0" TOTAL_1="120" TOTAL_2="120" WEIGHT="100.0" Z="1.1084522533817305">
<NAME>14 to 26 weeks post-injection</NAME>
<DICH_DATA CI_END="2.021608484389742" CI_START="0.0791448993390522" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.3056970515849466" LOG_CI_START="-1.1015770689290219" LOG_EFFECT_SIZE="-0.3979400086720376" ORDER="150397" O_E="0.0" SE="0.8266397845091497" STUDY_ID="STD-Lohmander-1996" TOTAL_1="120" TOTAL_2="120" VAR="0.6833333333333333" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.072840513288492" CI_START="0.10601117389144188" DF="0" EFFECT_SIZE="0.7333333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-002.13.04" LOG_CI_END="0.7052512086041096" LOG_CI_START="-0.9746483563990221" LOG_EFFECT_SIZE="-0.13469857389745624" NO="4" P_CHI2="1.0" P_Z="0.7532858417457894" STUDIES="1" TAU2="0.0" TOTAL_1="90" TOTAL_2="66" WEIGHT="100.0" Z="0.31430968744542664">
<NAME>45 to 52 weeks post-injection</NAME>
<DICH_DATA CI_END="5.072840513288492" CI_START="0.10601117389144188" EFFECT_SIZE="0.7333333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.7052512086041096" LOG_CI_START="-0.9746483563990221" LOG_EFFECT_SIZE="-0.13469857389745624" ORDER="150398" O_E="0.0" SE="0.9867813201197992" STUDY_ID="STD-Karlsson-2002a-_x0028_AvP_x0029_" TOTAL_1="90" TOTAL_2="66" VAR="0.9737373737373738" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-002.14" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2008-11-09 23:07:17 -0500" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="110" TOTAL_2="109" WEIGHT="0.0" Z="0.0">
<NAME>Safety: number of patients with local adverse reaction but study drug continued</NAME>
<GROUP_LABEL_1>Artz</GROUP_LABEL_1>
<GROUP_LABEL_2>Vehicle</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Artz</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours vehicle</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.1810593797957405" CI_START="0.028137153083214017" EFFECT_SIZE="0.24772727272727274" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.33866748949735104" LOG_CI_START="-1.5507198465884786" LOG_EFFECT_SIZE="-0.6060261785455637" ORDER="150399" O_E="0.0" SE="1.109835473834967" STUDY_ID="STD-Shichikawa-1983a" TOTAL_1="110" TOTAL_2="109" VAR="1.2317347789824855" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.3675525793555003" CI_END="2.1418024625304524" CI_START="1.0800847030703542" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5209628781720996" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="38" I2="15.524579371984052" I2_Q="15.367019056089559" ID="CMP-002.15" LOG_CI_END="0.3307794135597807" LOG_CI_START="0.03345781533286376" LOG_EFFECT_SIZE="0.1821186144463222" METHOD="MH" MODIFIED="2008-11-09 23:07:17 -0500" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.3061206076480679" P_Q="0.27703616155704325" P_Z="0.016346926476554245" Q="1.1815724660138567" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="356" TOTAL_2="300" WEIGHT="200.0" Z="2.4010763251494778">
<NAME>Safety: number of adverse events probably/possibly related to treatment</NAME>
<GROUP_LABEL_1>Artz</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Artz</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Saline</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.11687230802326" CI_END="2.261428480900388" CI_START="1.1244818881283916" DF="1" EFFECT_SIZE="1.5946583860094263" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="36" I2="10.464249778930512" ID="CMP-002.15.01" LOG_CI_END="0.3543828574626765" LOG_CI_START="0.05095246470785063" LOG_EFFECT_SIZE="0.20266766108526357" NO="1" P_CHI2="0.29059296104462684" P_Z="0.0088393972928155" STUDIES="2" TAU2="0.0" TOTAL_1="210" TOTAL_2="222" WEIGHT="100.0" Z="2.6182038849288536">
<NAME>5 to 13 weeks post-injection</NAME>
<DICH_DATA CI_END="2.469075516500682" CI_START="1.194621750623882" EFFECT_SIZE="1.7174432497013141" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="31" LOG_CI_END="0.39253437300118943" LOG_CI_START="0.07723041773562675" LOG_EFFECT_SIZE="0.23488239536840808" ORDER="150400" O_E="0.0" SE="0.185211104102742" STUDY_ID="STD-Day-2004" TOTAL_1="108" TOTAL_2="115" VAR="0.034303153082956735" WEIGHT="86.01901502467233"/>
<DICH_DATA CI_END="3.038053123572457" CI_START="0.23182049142742697" EFFECT_SIZE="0.8392156862745098" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.48259536369156775" LOG_CI_START="-0.6348481778610964" LOG_EFFECT_SIZE="-0.07612640708476433" ORDER="150401" O_E="0.0" SE="0.6563918677427755" STUDY_ID="STD-Puhl-1993" TOTAL_1="102" TOTAL_2="107" VAR="0.4308502840388492" WEIGHT="13.980984975327674"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.719891046399816" CI_START="0.07672789329176388" DF="0" EFFECT_SIZE="0.5342465753424658" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-002.15.02" LOG_CI_END="0.570530219817302" LOG_CI_START="-1.1150467260052153" LOG_EFFECT_SIZE="-0.2722582530939567" NO="2" P_CHI2="1.0" P_Z="0.5266319403958775" STUDIES="1" TAU2="0.0" TOTAL_1="146" TOTAL_2="78" WEIGHT="100.0" Z="0.6331557534415079">
<NAME>45 to 52 weeks post-injection</NAME>
<DICH_DATA CI_END="3.719891046399816" CI_START="0.07672789329176388" EFFECT_SIZE="0.5342465753424658" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.570530219817302" LOG_CI_START="-1.1150467260052153" LOG_EFFECT_SIZE="-0.2722582530939567" ORDER="150402" O_E="0.0" SE="0.9901162417165946" STUDY_ID="STD-Karlsson-2002a-_x0028_AvP_x0029_" TOTAL_1="146" TOTAL_2="78" VAR="0.980330172110994" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="12" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-002.16" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2008-11-09 23:07:17 -0500" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="146" TOTAL_2="78" WEIGHT="0.0" Z="0.0">
<NAME>Safety: number of serious adverse events (45 to 52 weeks post-injection)</NAME>
<GROUP_LABEL_1>Artzal</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Artzal</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Saline</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2594656771213009" CI_START="0.2696958594714073" EFFECT_SIZE="0.5828144458281445" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" LOG_CI_END="0.10018633662973951" LOG_CI_START="-0.5691257210388533" LOG_EFFECT_SIZE="-0.2344696922045569" ORDER="150403" O_E="0.0" SE="0.3931572158226506" STUDY_ID="STD-Karlsson-2002a-_x0028_AvP_x0029_" TOTAL_1="146" TOTAL_2="78" VAR="0.15457259635341827" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.1313358518643906" CI_END="1.077621466690081" CI_START="0.5427192106749097" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7647521636506688" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="41" I2="68.06474784860264" I2_Q="65.6912539283378" ID="CMP-002.17" LOG_CI_END="0.03246623413678193" LOG_CI_START="-0.26542480539224916" LOG_EFFECT_SIZE="-0.11647928562773359" METHOD="MH" MODIFIED="2008-11-09 23:07:17 -0500" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="0.07680108709407785" P_Q="0.08777540855044619" P_Z="0.125339186581446" Q="2.9147086807289764" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="124" TOTAL_2="108" WEIGHT="200.0" Z="1.5327430132591364">
<NAME>Safety: total withdrawals overall (knees)</NAME>
<GROUP_LABEL_1>Artz</GROUP_LABEL_1>
<GROUP_LABEL_2>Vehicle (Placebo)</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Artz</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.984681670504945" CI_START="0.1641058575970782" DF="0" EFFECT_SIZE="0.40198511166253104" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="13" I2="0.0" ID="CMP-002.17.01" LOG_CI_END="-0.006704146240826038" LOG_CI_START="-0.7848759169561309" LOG_EFFECT_SIZE="-0.3957900315984785" NO="1" P_CHI2="1.0" P_Z="0.04618100552878188" STUDIES="1" TAU2="0.0" TOTAL_1="62" TOTAL_2="54" WEIGHT="100.0" Z="1.9937351535122472">
<NAME>5 to 13 weeks post-injection</NAME>
<DICH_DATA CI_END="0.9846816705049449" CI_START="0.1641058575970782" EFFECT_SIZE="0.40198511166253104" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="13" LOG_CI_END="-0.006704146240826088" LOG_CI_START="-0.7848759169561309" LOG_EFFECT_SIZE="-0.3957900315984785" ORDER="150404" O_E="0.0" SE="0.45710195013055954" STUDY_ID="STD-Wu-1997" TOTAL_1="62" TOTAL_2="54" VAR="0.20894219281316054" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.342269796401193" CI_START="0.6487700153058908" DF="0" EFFECT_SIZE="0.9331797235023042" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="28" I2="0.0" ID="CMP-002.17.02" LOG_CI_END="0.12783981785367707" LOG_CI_START="-0.18790923044936134" LOG_EFFECT_SIZE="-0.030034706297842145" NO="2" P_CHI2="1.0" P_Z="0.7092439344562385" STUDIES="1" TAU2="0.0" TOTAL_1="62" TOTAL_2="54" WEIGHT="100.0" Z="0.37287170267896885">
<NAME>14 to 26 weeks post-injection</NAME>
<DICH_DATA CI_END="1.342269796401193" CI_START="0.6487700153058907" EFFECT_SIZE="0.9331797235023042" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="28" LOG_CI_END="0.12783981785367707" LOG_CI_START="-0.1879092304493614" LOG_EFFECT_SIZE="-0.030034706297842145" ORDER="150405" O_E="0.0" SE="0.18547255395620135" STUDY_ID="STD-Wu-1997" TOTAL_1="62" TOTAL_2="54" VAR="0.03440006827103602" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>Artzal versus Hylan G-F 20 (Also see Hylan G-F 20 versus hyaluronan, NRD-101 versus Artz, SLM-10 versus Artz)</NAME>
<CONT_OUTCOME CHI2="0.8950809671243892" CI_END="6.026113421019099" CI_START="-3.844893313479904" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="1.0906100537695975" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.01" NO="1" P_CHI2="0.6391983655424357" P_Q="0.6391983655424357" P_Z="0.6649436079442463" Q="0.8950809671243892" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="270" TOTAL_2="258" UNITS="" WEIGHT="300.0" Z="0.43309795729243694">
<NAME>Pain on weight bearing (0-100 mm VAS)</NAME>
<GROUP_LABEL_1>Artzal</GROUP_LABEL_1>
<GROUP_LABEL_2>Synvisc</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Artzal</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Synvisc</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="6.411415152942711" CI_START="-8.41141515294271" DF="0" EFFECT_SIZE="-1.0" ESTIMABLE="YES" I2="0.0" ID="CMP-003.01.01" NO="1" P_CHI2="1.0" P_Z="0.7914316031281159" STUDIES="1" TAU2="0.0" TOTAL_1="90" TOTAL_2="86" WEIGHT="100.0" Z="0.2644520572784063">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="6.411415152942711" CI_START="-8.41141515294271" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="44.0" MEAN_2="45.0" ORDER="150406" SD_1="24.44" SD_2="25.67" SE="3.781403745886663" STUDY_ID="STD-Karlsson-2002c-_x0028_AvS_x0029_" TOTAL_1="90" TOTAL_2="86" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="9.833872958165959" CI_START="-7.8338729581659585" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" I2="0.0" ID="CMP-003.01.02" NO="2" P_CHI2="1.0" P_Z="0.8244157380817838" STUDIES="1" TAU2="0.0" TOTAL_1="90" TOTAL_2="86" WEIGHT="100.0" Z="0.221869161331812">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="9.833872958165959" CI_START="-7.8338729581659585" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="42.0" MEAN_2="41.0" ORDER="150407" SD_1="28.07" SD_2="31.53" SE="4.507160860019072" STUDY_ID="STD-Karlsson-2002c-_x0028_AvS_x0029_" TOTAL_1="90" TOTAL_2="86" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="14.983747525990264" CI_START="-4.983747525990264" DF="0" EFFECT_SIZE="5.0" ESTIMABLE="YES" I2="0.0" ID="CMP-003.01.03" NO="3" P_CHI2="1.0" P_Z="0.32630814881132686" STUDIES="1" TAU2="0.0" TOTAL_1="90" TOTAL_2="86" WEIGHT="100.0" Z="0.9815772982228185">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="14.983747525990264" CI_START="-4.983747525990264" EFFECT_SIZE="5.0" ESTIMABLE="YES" MEAN_1="48.0" MEAN_2="43.0" ORDER="150408" SD_1="33.78" SD_2="33.78" SE="5.093842338298454" STUDY_ID="STD-Karlsson-2002c-_x0028_AvS_x0029_" TOTAL_1="90" TOTAL_2="86" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.3739709287989577" CI_START="-0.37397092879895744" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.02" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.1537252310965391" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="92" TOTAL_2="88" UNITS="" WEIGHT="100.0" Z="1.4264959639672556">
<NAME>Lequesne Index (0-24)</NAME>
<GROUP_LABEL_1>Artzal</GROUP_LABEL_1>
<GROUP_LABEL_2>Synvisc</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Artzal</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Synvisc</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.02.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>1 to 4 weeks post-injection</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.02.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>5 to 13 weeks post-injection</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.3739709287989577" CI_START="-0.37397092879895744" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" I2="0.0" ID="CMP-003.02.03" NO="3" P_CHI2="1.0" P_Z="0.1537252310965391" STUDIES="1" TAU2="0.0" TOTAL_1="92" TOTAL_2="88" WEIGHT="100.0" Z="1.4264959639672556">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="2.3739709287989577" CI_START="-0.37397092879895744" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="10.0" MEAN_2="9.0" ORDER="150409" SD_1="4.96" SD_2="4.44" SE="0.7010184572964936" STUDY_ID="STD-Karlsson-2002c-_x0028_AvS_x0029_" TOTAL_1="92" TOTAL_2="88" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="1.5170155837054216" CI_END="1.1346408020411627" CI_START="0.5254293580365945" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7721227805333908" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="38" I2="34.08109905124199" I2_Q="30.928732536854465" ID="CMP-003.03" LOG_CI_END="0.054858396876059784" LOG_CI_START="-0.27948566493958343" LOG_EFFECT_SIZE="-0.11231363403176185" METHOD="MH" NO="3" P_CHI2="0.2180720905137783" P_Q="0.22888478573602322" P_Z="0.18790858631174046" Q="1.4477800056782968" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="156" TOTAL_2="156" WEIGHT="200.0" Z="1.316791310601742">
<NAME>Number of clinical failures</NAME>
<GROUP_LABEL_1>Artzal</GROUP_LABEL_1>
<GROUP_LABEL_2>Synvisc</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Artzal</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Synvisc</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.535261073297285" CI_START="0.06608260210840797" DF="0" EFFECT_SIZE="0.31851851851851853" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" I2="0.0" ID="CMP-003.03.01" LOG_CI_END="0.18618223847860838" LOG_CI_START="-1.1799128643094474" LOG_EFFECT_SIZE="-0.4968653129154196" NO="1" P_CHI2="1.0" P_Z="0.1539476745670452" STUDIES="1" TAU2="0.0" TOTAL_1="90" TOTAL_2="86" WEIGHT="99.99999999999999" Z="1.425725217071558">
<NAME>14 to 26 weeks post-injection</NAME>
<DICH_DATA CI_END="1.535261073297285" CI_START="0.06608260210840797" EFFECT_SIZE="0.31851851851851853" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.18618223847860838" LOG_CI_START="-1.1799128643094474" LOG_EFFECT_SIZE="-0.4968653129154196" ORDER="150410" O_E="0.0" SE="0.8024510256575235" STUDY_ID="STD-Karlsson-2002c-_x0028_AvS_x0029_" TOTAL_1="90" TOTAL_2="86" VAR="0.6439276485788114" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2770282834896651" CI_START="0.5815063106589526" DF="0" EFFECT_SIZE="0.8617424242424242" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="32" I2="0.0" ID="CMP-003.03.02" LOG_CI_END="0.10620051607897064" LOG_CI_START="-0.2354455678323704" LOG_EFFECT_SIZE="-0.06462252587669988" NO="2" P_CHI2="1.0" P_Z="0.4584168153396424" STUDIES="1" TAU2="0.0" TOTAL_1="66" TOTAL_2="70" WEIGHT="100.0" Z="0.7414563156017784">
<NAME>45 to 52 weeks post-injection</NAME>
<DICH_DATA CI_END="1.2770282834896651" CI_START="0.5815063106589526" EFFECT_SIZE="0.8617424242424242" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="32" LOG_CI_END="0.10620051607897064" LOG_CI_START="-0.2354455678323704" LOG_EFFECT_SIZE="-0.06462252587669988" ORDER="150411" O_E="0.0" SE="0.20068460086491197" STUDY_ID="STD-Karlsson-2002c-_x0028_AvS_x0029_" TOTAL_1="66" TOTAL_2="70" VAR="0.04027430902430903" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="39" EVENTS_2="38" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="90" TOTAL_2="86" WEIGHT="0.0" Z="0.0">
<NAME>Number of survivors (patients not requiring additional treatment for study knee) (45 to 52 weeks post-injectio</NAME>
<GROUP_LABEL_1>Artzal</GROUP_LABEL_1>
<GROUP_LABEL_2>Synvisc</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Synvisc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Artzal</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.370991161264624" CI_START="0.701518695546186" EFFECT_SIZE="0.980701754385965" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="38" LOG_CI_END="0.13703465491615416" LOG_CI_START="-0.15396075048829028" LOG_EFFECT_SIZE="-0.00846304778606808" ORDER="150412" O_E="0.0" SE="0.17093214158505868" STUDY_ID="STD-Karlsson-2002c-_x0028_AvS_x0029_" TOTAL_1="90" TOTAL_2="86" VAR="0.02921779702685455" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="90" TOTAL_2="86" WEIGHT="0.0" Z="0.0">
<NAME>Safety: number of patients withdrawn due to adverse events (45 to 52 weeks post-injection)</NAME>
<GROUP_LABEL_1>Artzal</GROUP_LABEL_1>
<GROUP_LABEL_2>Hylan G-F 20</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Artzal</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Hylan G-F 20</GRAPH_LABEL_2>
<DICH_DATA CI_END="20.69467648598593" CI_START="0.17648720826757794" EFFECT_SIZE="1.9111111111111112" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3158586415872584" LOG_CI_START="-0.7532867666508102" LOG_EFFECT_SIZE="0.28128593746822406" ORDER="150413" O_E="0.0" SE="1.215426255234" STUDY_ID="STD-Karlsson-2002c-_x0028_AvS_x0029_" TOTAL_1="90" TOTAL_2="86" VAR="1.4772609819121447" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-003.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="146" TOTAL_2="90" WEIGHT="0.0" Z="0.0">
<NAME>Safety: number of adverse events related to treatment (45 to 52 weeks post- injection)</NAME>
<GROUP_LABEL_1>Artzal</GROUP_LABEL_1>
<GROUP_LABEL_2>Hylan G-F 20</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Artzal</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Hylan G-F 20</GRAPH_LABEL_2>
<DICH_DATA CI_END="13.401836093720284" CI_START="0.11341617500566295" EFFECT_SIZE="1.2328767123287672" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.1271643021517448" LOG_CI_START="-0.9453250035140068" LOG_EFFECT_SIZE="0.09091964931886899" ORDER="150414" O_E="0.0" SE="1.2173904771355804" STUDY_ID="STD-Karlsson-2002c-_x0028_AvS_x0029_" TOTAL_1="146" TOTAL_2="90" VAR="1.4820395738203958" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="55" EVENTS_2="44" I2="0.0" I2_Q="0.0" ID="CMP-003.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="90" TOTAL_2="86" WEIGHT="0.0" Z="0.0">
<NAME>Safety: number of patients reporting adverse events (45 to 52 weeks post- injection)</NAME>
<GROUP_LABEL_1>Artzal</GROUP_LABEL_1>
<GROUP_LABEL_2>Hylan G-F 20</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Artzal</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Hylan G-F 20</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5556248395078174" CI_START="0.9171218500956754" EFFECT_SIZE="1.1944444444444444" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="44" LOG_CI_END="0.1919048691469647" LOG_CI_START="-0.03757295952236616" LOG_EFFECT_SIZE="0.07716595481229925" ORDER="150415" O_E="0.0" SE="0.13479641249393698" STUDY_ID="STD-Karlsson-2002c-_x0028_AvS_x0029_" TOTAL_1="90" TOTAL_2="86" VAR="0.01817007282123561" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" NO="4">
<NAME>BioHy (Arthrease, Euflexxa) versus placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.885527355394007" CI_START="0.17965520203124696" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.72" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.46022519586538974" LOG_CI_START="-0.7455602030028528" LOG_EFFECT_SIZE="-0.14266750356873156" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.6427892208253259" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="25" TOTAL_2="24" WEIGHT="100.0" Z="0.4638025456626188">
<NAME>Safety: total withdrawals overall</NAME>
<GROUP_LABEL_1>BioHy</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BioHy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Saline</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.885527355394007" CI_START="0.17965520203124696" DF="0" EFFECT_SIZE="0.72" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" ID="CMP-004.01.01" LOG_CI_END="0.46022519586538974" LOG_CI_START="-0.7455602030028528" LOG_EFFECT_SIZE="-0.14266750356873156" NO="1" P_CHI2="1.0" P_Z="0.6427892208253259" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="24" WEIGHT="100.0" Z="0.4638025456626188">
<NAME>14 to 26 weeks post-injection</NAME>
<DICH_DATA CI_END="2.885527355394007" CI_START="0.17965520203124696" EFFECT_SIZE="0.72" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.46022519586538974" LOG_CI_START="-0.7455602030028528" LOG_EFFECT_SIZE="-0.14266750356873156" ORDER="150416" O_E="0.0" SE="0.7082843120291925" STUDY_ID="STD-Tamir-2001" TOTAL_1="25" TOTAL_2="24" VAR="0.5016666666666666" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.279977753263357E-31" CI_END="2.587189341285821" CI_START="0.9538364017356236" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5709090909090906" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="11" I2="100.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="0.41282821335766934" LOG_CI_START="-0.02052610738837062" LOG_EFFECT_SIZE="0.19615105298464935" METHOD="MH" NO="2" P_CHI2="0.0" P_Q="1.0" P_Z="0.07601452199186945" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="25" TOTAL_2="24" WEIGHT="100.0" Z="1.774294063655226">
<NAME>Safety: number of adverse events for injection site pain</NAME>
<GROUP_LABEL_1>BioHy</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.279977753263357E-31" CI_END="2.587189341285821" CI_START="0.9538364017356236" DF="0" EFFECT_SIZE="1.5709090909090906" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="11" I2="100.0" ID="CMP-004.02.01" LOG_CI_END="0.41282821335766934" LOG_CI_START="-0.02052610738837062" LOG_EFFECT_SIZE="0.19615105298464935" NO="1" P_CHI2="0.0" P_Z="0.07601452199186945" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="24" WEIGHT="100.0" Z="1.774294063655226">
<NAME>14 to 26 weeks post-injection</NAME>
<DICH_DATA CI_END="2.5871893412858213" CI_START="0.9538364017356238" EFFECT_SIZE="1.5709090909090908" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="11" LOG_CI_END="0.41282821335766945" LOG_CI_START="-0.020526107388370518" LOG_EFFECT_SIZE="0.1961510529846494" ORDER="150417" O_E="0.0" SE="0.25455447314470786" STUDY_ID="STD-Tamir-2001" TOTAL_1="25" TOTAL_2="24" VAR="0.0647979797979798" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" NO="5">
<NAME>BioHy (Arthrease, Euflexxa) versus Hylan G-F 20 (Synvisc)</NAME>
<CONT_OUTCOME CHI2="0.00100708914444102" CI_END="-0.6650211771674956" CI_START="-6.8381032449681936" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.7515622110678444" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.01" NO="1" P_CHI2="0.9746836495557278" P_Q="0.9746836495557278" P_Z="0.017206992592209223" Q="0.00100708914444102" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="320" TOTAL_2="322" UNITS="" WEIGHT="200.0" Z="2.382254678844429">
<NAME>WOMAC pain (0-100 mm VAS)</NAME>
<GROUP_LABEL_1>Euflexxa</GROUP_LABEL_1>
<GROUP_LABEL_2>Synvisc</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Euflexxa</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Synvisc</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.7348598498308974" CI_START="-8.134859849830896" DF="0" EFFECT_SIZE="-3.6999999999999993" ESTIMABLE="YES" I2="0.0" ID="CMP-005.01.01" NO="1" P_CHI2="1.0" P_Z="0.10200788817740704" STUDIES="1" TAU2="0.0" TOTAL_1="160" TOTAL_2="161" WEIGHT="100.0" Z="1.6351963733588373">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="0.7348598498308974" CI_START="-8.134859849830896" EFFECT_SIZE="-3.6999999999999993" ESTIMABLE="YES" MEAN_1="21.7" MEAN_2="25.4" ORDER="150418" SD_1="20.24" SD_2="20.3" SE="2.262725174958573" STUDY_ID="STD-Kirchner--2005" TOTAL_1="160" TOTAL_2="161" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.49839466865402304" CI_START="-8.098394668654024" DF="0" EFFECT_SIZE="-3.8000000000000007" ESTIMABLE="YES" I2="0.0" ID="CMP-005.01.02" NO="2" P_CHI2="1.0" P_Z="0.08314756898594332" STUDIES="1" TAU2="0.0" TOTAL_1="160" TOTAL_2="161" WEIGHT="100.0" Z="1.7327080725196393">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="0.49839466865402304" CI_START="-8.098394668654024" EFFECT_SIZE="-3.8000000000000007" ESTIMABLE="YES" MEAN_1="19.2" MEAN_2="23.0" ORDER="150419" SD_1="20.24" SD_2="19.03" SE="2.193098803120472" STUDY_ID="STD-Kirchner--2005" TOTAL_1="160" TOTAL_2="161" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.008788310647211433" CI_END="-2.113933519636262" CI_START="-8.386086534854666" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-5.250010027245464" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.02" NO="2" P_CHI2="0.9253109368334038" P_Q="0.9253109368334038" P_Z="0.001033972378837499" Q="0.008788310647211433" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="316" TOTAL_2="316" UNITS="" WEIGHT="200.0" Z="3.281115925236066">
<NAME>WOMAC physical function (0-100 mm VAS)</NAME>
<GROUP_LABEL_1>Euflexxa</GROUP_LABEL_1>
<GROUP_LABEL_2>Synvisc</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Euflexxa</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Synvisc</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.6647698240162896" CI_START="-9.535230175983706" DF="0" EFFECT_SIZE="-5.099999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-005.02.01" NO="1" P_CHI2="1.0" P_Z="0.024213087658035537" STUDIES="1" TAU2="0.0" TOTAL_1="159" TOTAL_2="158" WEIGHT="100.0" Z="2.2537311310877475">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="-0.6647698240162896" CI_START="-9.535230175983706" EFFECT_SIZE="-5.099999999999998" ESTIMABLE="YES" MEAN_1="22.3" MEAN_2="27.4" ORDER="150420" SD_1="20.18" SD_2="20.11" SE="2.262914120345189" STUDY_ID="STD-Kirchner--2005" TOTAL_1="159" TOTAL_2="158" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.9650663017182639" CI_START="-9.834933698281734" DF="0" EFFECT_SIZE="-5.399999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-005.02.02" NO="2" P_CHI2="1.0" P_Z="0.017011315528926634" STUDIES="1" TAU2="0.0" TOTAL_1="157" TOTAL_2="158" WEIGHT="100.00000000000001" Z="2.3864630762387424">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="-0.9650663017182639" CI_START="-9.834933698281734" EFFECT_SIZE="-5.399999999999999" ESTIMABLE="YES" MEAN_1="20.0" MEAN_2="25.4" ORDER="150421" SD_1="20.05" SD_2="20.11" SE="2.2627628534319637" STUDY_ID="STD-Kirchner--2005" TOTAL_1="157" TOTAL_2="158" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.06249465349128111" CI_END="-0.26395023171204146" CI_START="-6.5361032469304465" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.4000267393212438" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.03" NO="3" P_CHI2="0.8025956212582527" P_Q="0.8025956212582527" P_Z="0.03359280281738341" Q="0.06249465349128111" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="316" TOTAL_2="316" UNITS="" WEIGHT="200.0" Z="2.1249258235166786">
<NAME>WOMAC stiffness (0-100 mm VAS)</NAME>
<GROUP_LABEL_1>Euflexxa</GROUP_LABEL_1>
<GROUP_LABEL_2>Synvisc</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Euflexxa</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Synvisc</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.4352301759837083" CI_START="-7.435230175983708" DF="0" EFFECT_SIZE="-3.0" ESTIMABLE="YES" I2="0.0" ID="CMP-005.03.01" NO="1" P_CHI2="1.0" P_Z="0.18493107024478306" STUDIES="1" TAU2="0.0" TOTAL_1="159" TOTAL_2="158" WEIGHT="100.0" Z="1.3257241947574991">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="1.4352301759837083" CI_START="-7.435230175983708" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="21.2" MEAN_2="24.2" ORDER="150422" SD_1="20.18" SD_2="20.11" SE="2.262914120345189" STUDY_ID="STD-Kirchner--2005" TOTAL_1="159" TOTAL_2="158" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.634933698281734" CI_START="-8.234933698281736" DF="0" EFFECT_SIZE="-3.8000000000000007" ESTIMABLE="YES" I2="0.0" ID="CMP-005.03.02" NO="2" P_CHI2="1.0" P_Z="0.09308133807424367" STUDIES="1" TAU2="0.0" TOTAL_1="157" TOTAL_2="158" WEIGHT="100.00000000000001" Z="1.679362905501338">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="0.634933698281734" CI_START="-8.234933698281736" EFFECT_SIZE="-3.8000000000000007" ESTIMABLE="YES" MEAN_1="18.2" MEAN_2="22.0" ORDER="150423" SD_1="20.05" SD_2="20.11" SE="2.2627628534319637" STUDY_ID="STD-Kirchner--2005" TOTAL_1="157" TOTAL_2="158" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.4622827540063748" CI_START="1.0010703631063815" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2098958333333334" ESTIMABLE="YES" EVENTS_1="101" EVENTS_2="84" I2="0.0" I2_Q="0.0" ID="CMP-005.04" LOG_CI_END="0.16503135800589458" LOG_CI_START="4.6460418747712847E-4" LOG_EFFECT_SIZE="0.08274798109668587" METHOD="MH" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.048720363348077673" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="160" TOTAL_2="161" WEIGHT="100.0" Z="1.9710307091778438">
<NAME>WOMAC pain (number of patients symptom free: VAS score below 20 mm)</NAME>
<GROUP_LABEL_1>Euflexxa</GROUP_LABEL_1>
<GROUP_LABEL_2>Synvisc</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Synvisc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Euflexxa</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4622827540063748" CI_START="1.0010703631063815" DF="0" EFFECT_SIZE="1.2098958333333334" ESTIMABLE="YES" EVENTS_1="101" EVENTS_2="84" I2="0.0" ID="CMP-005.04.01" LOG_CI_END="0.16503135800589458" LOG_CI_START="4.6460418747712847E-4" LOG_EFFECT_SIZE="0.08274798109668587" NO="1" P_CHI2="1.0" P_Z="0.048720363348077673" STUDIES="1" TAU2="0.0" TOTAL_1="160" TOTAL_2="161" WEIGHT="100.0" Z="1.9710307091778438">
<NAME>5 to 13 weeks post-injection</NAME>
<DICH_DATA CI_END="1.4622827540063748" CI_START="1.0010703631063815" EFFECT_SIZE="1.2098958333333334" ESTIMABLE="YES" EVENTS_1="101" EVENTS_2="84" LOG_CI_END="0.16503135800589458" LOG_CI_START="4.6460418747712847E-4" LOG_EFFECT_SIZE="0.08274798109668587" ORDER="150424" O_E="0.0" SE="0.09666732581150782" STUDY_ID="STD-Kirchner--2005" TOTAL_1="160" TOTAL_2="161" VAR="0.009344571879548205" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.6572508218170483" CI_START="1.1082732394625463" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.355244161358811" ESTIMABLE="YES" EVENTS_1="101" EVENTS_2="75" I2="0.0" I2_Q="0.0" ID="CMP-005.05" LOG_CI_END="0.2193882430526819" LOG_CI_START="0.04464684681958098" LOG_EFFECT_SIZE="0.13201754493613144" METHOD="MH" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.0030612957729896388" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="157" TOTAL_2="158" WEIGHT="100.00000000000001" Z="2.9615150042300207">
<NAME>WOMAC function (number of patients symptom free: VAS score below 20 mm)</NAME>
<GROUP_LABEL_1>Euflexxa</GROUP_LABEL_1>
<GROUP_LABEL_2>Synvisc</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Synvisc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Euflexxa</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6572508218170483" CI_START="1.1082732394625463" DF="0" EFFECT_SIZE="1.355244161358811" ESTIMABLE="YES" EVENTS_1="101" EVENTS_2="75" I2="0.0" ID="CMP-005.05.01" LOG_CI_END="0.2193882430526819" LOG_CI_START="0.04464684681958098" LOG_EFFECT_SIZE="0.13201754493613144" NO="1" P_CHI2="1.0" P_Z="0.0030612957729896388" STUDIES="1" TAU2="0.0" TOTAL_1="157" TOTAL_2="158" WEIGHT="100.00000000000001" Z="2.9615150042300207">
<NAME>5 to 13 weeks post-injection</NAME>
<DICH_DATA CI_END="1.6572508218170483" CI_START="1.1082732394625463" EFFECT_SIZE="1.355244161358811" ESTIMABLE="YES" EVENTS_1="101" EVENTS_2="75" LOG_CI_END="0.2193882430526819" LOG_CI_START="0.04464684681958098" LOG_EFFECT_SIZE="0.13201754493613144" ORDER="150425" O_E="0.0" SE="0.10264396113118514" STUDY_ID="STD-Kirchner--2005" TOTAL_1="157" TOTAL_2="158" VAR="0.010535782756700245" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.207635704696858" CI_START="0.9551958862712119" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0740245142643043" ESTIMABLE="YES" EVENTS_1="127" EVENTS_2="119" I2="0.0" I2_Q="0.0" ID="CMP-005.06" LOG_CI_END="0.08193594479789057" LOG_CI_START="-0.019907556580660717" LOG_EFFECT_SIZE="0.03101419410861495" METHOD="MH" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.23258452954894948" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="157" TOTAL_2="158" WEIGHT="100.0" Z="1.1937276829569328">
<NAME>Patient assessment of treatment (number of patients very satisfied or satisfied)</NAME>
<GROUP_LABEL_1>Euflexxa</GROUP_LABEL_1>
<GROUP_LABEL_2>Synvisc</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Synvisc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Euflexxa</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.207635704696858" CI_START="0.9551958862712119" DF="0" EFFECT_SIZE="1.0740245142643043" ESTIMABLE="YES" EVENTS_1="127" EVENTS_2="119" I2="0.0" ID="CMP-005.06.01" LOG_CI_END="0.08193594479789057" LOG_CI_START="-0.019907556580660717" LOG_EFFECT_SIZE="0.03101419410861495" NO="1" P_CHI2="1.0" P_Z="0.23258452954894948" STUDIES="1" TAU2="0.0" TOTAL_1="157" TOTAL_2="158" WEIGHT="100.0" Z="1.1937276829569328">
<NAME>5 to 13 weeks post-injection</NAME>
<DICH_DATA CI_END="1.207635704696858" CI_START="0.9551958862712119" EFFECT_SIZE="1.0740245142643043" ESTIMABLE="YES" EVENTS_1="127" EVENTS_2="119" LOG_CI_END="0.08193594479789057" LOG_CI_START="-0.019907556580660717" LOG_EFFECT_SIZE="0.03101419410861495" ORDER="150426" O_E="0.0" SE="0.05982337684322341" STUDY_ID="STD-Kirchner--2005" TOTAL_1="157" TOTAL_2="158" VAR="0.003578836416926319" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.872499132785344" CI_END="0.853634940007844" CI_START="0.6782697099296366" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7609170277664465" ESTIMABLE="YES" EVENTS_1="226" EVENTS_2="298" I2="0.0" I2_Q="0.0" ID="CMP-005.07" LOG_CI_END="-0.06872781717537131" LOG_CI_START="-0.16859757716193302" LOG_EFFECT_SIZE="-0.11866269716865215" METHOD="MH" NO="7" P_CHI2="0.39209567087151376" P_Q="0.40938421656636903" P_Z="3.199818871175241E-6" Q="1.7862025117336806" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="471" TOTAL_2="472" WEIGHT="300.0" Z="4.657558259682132">
<NAME>Rescue medication usage (number of patients using acetaminophen)</NAME>
<GROUP_LABEL_1>Euflexxa</GROUP_LABEL_1>
<GROUP_LABEL_2>Synvisc</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Euflexxa</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Synvisc</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.9979101941058767E-30" CI_END="0.9084021524864607" CI_START="0.5724051970089383" DF="0" EFFECT_SIZE="0.7210923055041956" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="89" I2="100.0" ID="CMP-005.07.01" LOG_CI_END="-0.04172184537713208" LOG_CI_START="-0.2422964318269045" LOG_EFFECT_SIZE="-0.14200913860201833" NO="1" P_CHI2="0.0" P_Z="0.005514155532261943" STUDIES="1" TAU2="0.0" TOTAL_1="158" TOTAL_2="156" WEIGHT="100.0" Z="2.7753545657212393">
<NAME>1 to 4 weeks post-injection</NAME>
<DICH_DATA CI_END="0.9084021524864608" CI_START="0.5724051970089383" EFFECT_SIZE="0.7210923055041957" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="89" LOG_CI_END="-0.04172184537713203" LOG_CI_START="-0.2422964318269045" LOG_EFFECT_SIZE="-0.14200913860201825" ORDER="150427" O_E="0.0" SE="0.1178185049408119" STUDY_ID="STD-Kirchner--2005" TOTAL_1="158" TOTAL_2="156" VAR="0.013881200106488118" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.0289422161225045E-30" CI_END="0.8901577269539414" CI_START="0.562901170760188" DF="0" EFFECT_SIZE="0.7078635650064222" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="91" I2="99.99999999999999" ID="CMP-005.07.02" LOG_CI_END="-0.050533033943136005" LOG_CI_START="-0.24956784806361995" LOG_EFFECT_SIZE="-0.15005044100337797" NO="2" P_CHI2="0.0" P_Z="0.0031247029847580837" STUDIES="1" TAU2="0.0" TOTAL_1="154" TOTAL_2="155" WEIGHT="100.0" Z="2.9551961703840024">
<NAME>5 to 13 weeks post-injection</NAME>
<DICH_DATA CI_END="0.8901577269539412" CI_START="0.5629011707601879" EFFECT_SIZE="0.7078635650064221" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="91" LOG_CI_END="-0.05053303394313606" LOG_CI_START="-0.24956784806362003" LOG_EFFECT_SIZE="-0.15005044100337803" ORDER="150428" O_E="0.0" SE="0.11691403505259192" STUDY_ID="STD-Kirchner--2005" TOTAL_1="154" TOTAL_2="155" VAR="0.01366889159227869" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9722797861884556" CI_START="0.7125998072294529" DF="0" EFFECT_SIZE="0.8323739473403688" ESTIMABLE="YES" EVENTS_1="97" EVENTS_2="118" I2="0.0" ID="CMP-005.07.03" LOG_CI_END="-0.01220874318782413" LOG_CI_START="-0.14715429946914046" LOG_EFFECT_SIZE="-0.0796815213284823" NO="3" P_CHI2="1.0" P_Z="0.020634492109495067" STUDIES="1" TAU2="0.0" TOTAL_1="159" TOTAL_2="161" WEIGHT="100.0" Z="2.3146062210691434">
<NAME>During the trial</NAME>
<DICH_DATA CI_END="0.9722797861884556" CI_START="0.7125998072294529" EFFECT_SIZE="0.8323739473403688" ESTIMABLE="YES" EVENTS_1="97" EVENTS_2="118" LOG_CI_END="-0.01220874318782413" LOG_CI_START="-0.14715429946914046" LOG_EFFECT_SIZE="-0.0796815213284823" ORDER="150429" O_E="0.0" SE="0.07926768775092202" STUDY_ID="STD-Kirchner--2005" TOTAL_1="159" TOTAL_2="161" VAR="0.006283366321377673" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-005.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="160" TOTAL_2="161" WEIGHT="0.0" Z="0.0">
<NAME>Safety: total withdrawals overall</NAME>
<GROUP_LABEL_1>Euflexxa</GROUP_LABEL_1>
<GROUP_LABEL_2>Synvisc</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Euflexxa</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Synvisc</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.899010459801187" CI_START="0.3051476949754572" EFFECT_SIZE="1.3416666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7707791662369405" LOG_CI_START="-0.5154899062684908" LOG_EFFECT_SIZE="0.12764462998422485" ORDER="150430" O_E="0.0" SE="0.7555608203242871" STUDY_ID="STD-Kirchner--2005" TOTAL_1="160" TOTAL_2="161" VAR="0.5708721532091097" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-005.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="160" TOTAL_2="161" WEIGHT="0.0" Z="0.0">
<NAME>Safety: withdrawals due to adverse events</NAME>
<GROUP_LABEL_1>Euflexxa</GROUP_LABEL_1>
<GROUP_LABEL_2>Synvisc</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Euflexxa</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Synvisc</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.1722722739376" CI_START="0.013765530089890357" EFFECT_SIZE="0.33540372670807456" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9123428275026073" LOG_CI_START="-1.8612070599203698" LOG_EFFECT_SIZE="-0.47443211620888115" ORDER="150431" O_E="0.0" SE="1.6291969331656226" STUDY_ID="STD-Kirchner--2005" TOTAL_1="160" TOTAL_2="161" VAR="2.65428264703627" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-005.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="160" TOTAL_2="161" WEIGHT="0.0" Z="0.0">
<NAME>Safety: withdrawals due to lack of efficacy</NAME>
<GROUP_LABEL_1>Euflexxa</GROUP_LABEL_1>
<GROUP_LABEL_2>Synvisc</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Euflexxa</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Synvisc</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="150432" O_E="0.0" SE="0.0" STUDY_ID="STD-Kirchner--2005" TOTAL_1="160" TOTAL_2="161" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-005.11" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="11" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="160" TOTAL_2="161" WEIGHT="0.0" Z="0.0">
<NAME>Safety: number of patients with serious adverse events</NAME>
<GROUP_LABEL_1>Euflexxa</GROUP_LABEL_1>
<GROUP_LABEL_2>Synvisc</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Euflexxa</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Synvisc</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.912565481115436" CI_START="0.25561808162332567" EFFECT_SIZE="1.509375" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9500027336574125" LOG_CI_START="-0.5924084287942001" LOG_EFFECT_SIZE="0.17879715243160615" ORDER="150433" O_E="0.0" SE="0.906019951882468" STUDY_ID="STD-Kirchner--2005" TOTAL_1="160" TOTAL_2="161" VAR="0.8208721532091097" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-005.12" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="12" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="160" TOTAL_2="161" WEIGHT="0.0" Z="0.0">
<NAME>Safety: number of patients with joint effusion</NAME>
<GROUP_LABEL_1>Euflexxa</GROUP_LABEL_1>
<GROUP_LABEL_2>Synvisc</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Euflexxa</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Synvisc</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.5847506181053206" CI_START="0.010246000968449034" EFFECT_SIZE="0.07740384615384616" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="13" LOG_CI_END="-0.233029310451536" LOG_CI_START="-1.9894456074102875" LOG_EFFECT_SIZE="-1.1112374589309117" ORDER="150434" O_E="0.0" SE="1.0317276272344622" STUDY_ID="STD-Kirchner--2005" TOTAL_1="160" TOTAL_2="161" VAR="1.0644618967988533" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="54" EVENTS_2="65" I2="0.0" I2_Q="0.0" ID="CMP-005.13" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="13" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="160" TOTAL_2="161" WEIGHT="0.0" Z="0.0">
<NAME>Safety: number of patients reporting adverse events</NAME>
<GROUP_LABEL_1>Euflexxa</GROUP_LABEL_1>
<GROUP_LABEL_2>Synvisc</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Euflexxa</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Synvisc</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1138541970663431" CI_START="0.627399614444653" EFFECT_SIZE="0.8359615384615384" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="65" LOG_CI_END="0.046828345636882984" LOG_CI_START="-0.2024557525248073" LOG_EFFECT_SIZE="-0.07781370344396216" ORDER="150435" O_E="0.0" SE="0.1464307132363641" STUDY_ID="STD-Kirchner--2005" TOTAL_1="160" TOTAL_2="161" VAR="0.021441953778910304" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" NO="6">
<NAME>Durolane versus placebo</NAME>
<DICH_OUTCOME CHI2="4.08957350857877" CI_END="1.1067304195297498" CI_START="0.8164634975582254" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9505813953488369" ESTIMABLE="YES" EVENTS_1="218" EVENTS_2="232" I2="26.642717297858873" I2_Q="26.641368696967124" ID="CMP-006.01" LOG_CI_END="0.0440418471040984" LOG_CI_START="-0.08806322692658677" LOG_EFFECT_SIZE="-0.02201068991124418" METHOD="MH" NO="1" P_CHI2="0.251952944125046" P_Q="0.2519607933120739" P_Z="0.5136796406429103" Q="4.089498327207709" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="688" TOTAL_2="696" WEIGHT="400.0" Z="0.6531188876348106">
<NAME>Responder: reduction in the WOMAC pain score of at least 40% with an absolute improvement of at least 5 points</NAME>
<GROUP_LABEL_1>Durolane</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Saline</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Durolane</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0898633013880739" CI_START="0.5914642281278111" DF="0" EFFECT_SIZE="0.8028792912513842" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="63" I2="0.0" ID="CMP-006.01.01" LOG_CI_END="0.03737202897196549" LOG_CI_START="-0.22807151645698975" LOG_EFFECT_SIZE="-0.09534974374251212" NO="1" P_CHI2="1.0" P_Z="0.15910918959025555" STUDIES="1" TAU2="0.0" TOTAL_1="172" TOTAL_2="174" WEIGHT="100.0" Z="1.4080738966053725">
<NAME>Week 2</NAME>
<DICH_DATA CI_END="1.0898633013880739" CI_START="0.5914642281278111" EFFECT_SIZE="0.8028792912513842" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="63" LOG_CI_END="0.03737202897196549" LOG_CI_START="-0.22807151645698975" LOG_EFFECT_SIZE="-0.09534974374251212" ORDER="150436" O_E="0.0" SE="0.1559228525517096" STUDY_ID="STD-Altman-2004" TOTAL_1="172" TOTAL_2="174" VAR="0.024311935947862174" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.655629827693811" CI_START="0.9073038889271503" DF="0" EFFECT_SIZE="1.2256261180679786" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="52" I2="0.0" ID="CMP-006.01.02" LOG_CI_END="0.21896324201365847" LOG_CI_START="-0.042247227625991736" LOG_EFFECT_SIZE="0.08835800719383338" NO="2" P_CHI2="1.0" P_Z="0.18484991707142853" STUDIES="1" TAU2="0.0" TOTAL_1="172" TOTAL_2="174" WEIGHT="100.0" Z="1.325969147289929">
<NAME>Week 6</NAME>
<DICH_DATA CI_END="1.655629827693811" CI_START="0.9073038889271503" EFFECT_SIZE="1.2256261180679786" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="52" LOG_CI_END="0.21896324201365847" LOG_CI_START="-0.042247227625991736" LOG_EFFECT_SIZE="0.08835800719383338" ORDER="150437" O_E="0.0" SE="0.15343632287900869" STUDY_ID="STD-Altman-2004" TOTAL_1="172" TOTAL_2="174" VAR="0.023542705178631402" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2279609369040525" CI_START="0.6775209989423174" DF="0" EFFECT_SIZE="0.9121235226839497" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="61" I2="0.0" ID="CMP-006.01.03" LOG_CI_END="0.0891845515308401" LOG_CI_START="-0.16907723981378486" LOG_EFFECT_SIZE="-0.03994634414147238" NO="3" P_CHI2="1.0" P_Z="0.5443087042969097" STUDIES="1" TAU2="0.0" TOTAL_1="172" TOTAL_2="174" WEIGHT="100.0" Z="0.6063103289394725">
<NAME>Week 13</NAME>
<DICH_DATA CI_END="1.2279609369040523" CI_START="0.6775209989423175" EFFECT_SIZE="0.9121235226839497" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="61" LOG_CI_END="0.08918455153084003" LOG_CI_START="-0.16907723981378478" LOG_EFFECT_SIZE="-0.03994634414147238" ORDER="150438" O_E="0.0" SE="0.15170425465231782" STUDY_ID="STD-Ardic-2001" TOTAL_1="172" TOTAL_2="174" VAR="0.023014180879615296" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2411781994688538" CI_START="0.6573117845342757" DF="0" EFFECT_SIZE="0.9032392026578073" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="56" I2="0.0" ID="CMP-006.01.04" LOG_CI_END="0.09383413886384633" LOG_CI_START="-0.18222858145410792" LOG_EFFECT_SIZE="-0.0441972212951308" NO="4" P_CHI2="1.0" P_Z="0.5302827208599841" STUDIES="1" TAU2="0.0" TOTAL_1="172" TOTAL_2="174" WEIGHT="100.0" Z="0.6275745008629424">
<NAME>Week 26</NAME>
<DICH_DATA CI_END="1.2411781994688538" CI_START="0.6573117845342757" EFFECT_SIZE="0.9032392026578073" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="56" LOG_CI_END="0.09383413886384633" LOG_CI_START="-0.18222858145410792" LOG_EFFECT_SIZE="-0.0441972212951308" ORDER="150439" O_E="0.0" SE="0.16216060844727104" STUDY_ID="STD-Altman-2004" TOTAL_1="172" TOTAL_2="174" VAR="0.026296062931989155" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.8555927823814873" CI_END="1.344073821159782" CI_START="0.9232512271518314" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1139649028440797" ESTIMABLE="YES" EVENTS_1="152" EVENTS_2="139" I2="22.19095300445636" I2_Q="22.18578655344559" ID="CMP-006.02" LOG_CI_END="0.1284231223204097" LOG_CI_START="-0.03468010642822692" LOG_EFFECT_SIZE="0.046871507946091386" METHOD="MH" NO="2" P_CHI2="0.277485692451912" P_Q="0.27751486462925945" P_Z="0.25996135692446753" Q="3.85533679147256" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="428" TOTAL_2="436" WEIGHT="400.0" Z="1.1264825127036606">
<NAME>Responder: patients only with knee OA, reduction in WOMAC pain score of at least 40%, abs improvement 5 points</NAME>
<GROUP_LABEL_1>Durolane</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Saline</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Durolane</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3967096559131311" CI_START="0.6668330450377163" DF="0" EFFECT_SIZE="0.9650762420068864" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="38" I2="0.0" ID="CMP-006.02.01" LOG_CI_END="0.14510613557732244" LOG_CI_START="-0.17598288676554025" LOG_EFFECT_SIZE="-0.015438375594108907" NO="1" P_CHI2="1.0" P_Z="0.850504148441444" STUDIES="1" TAU2="0.0" TOTAL_1="107" TOTAL_2="109" WEIGHT="99.99999999999999" Z="0.18847520804959234">
<NAME>Week 2</NAME>
<DICH_DATA CI_END="1.3967096559131311" CI_START="0.6668330450377163" EFFECT_SIZE="0.9650762420068864" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="38" LOG_CI_END="0.14510613557732244" LOG_CI_START="-0.17598288676554025" LOG_EFFECT_SIZE="-0.015438375594108907" ORDER="150440" O_E="0.0" SE="0.1886092811404919" STUDY_ID="STD-Altman-2004" TOTAL_1="107" TOTAL_2="109" VAR="0.035573460932333115" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.2281492656699156" CI_START="1.0479092583082152" DF="0" EFFECT_SIZE="1.52803738317757" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="30" I2="0.0" ID="CMP-006.02.02" LOG_CI_END="0.34794428124378424" LOG_CI_START="0.02032367737840614" LOG_EFFECT_SIZE="0.1841339793110952" NO="2" P_CHI2="1.0" P_Z="0.027585338961423816" STUDIES="1" TAU2="0.0" TOTAL_1="107" TOTAL_2="109" WEIGHT="100.0" Z="2.203133524093528">
<NAME>Week 6</NAME>
<DICH_DATA CI_END="2.2281492656699156" CI_START="1.0479092583082155" EFFECT_SIZE="1.52803738317757" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="30" LOG_CI_END="0.34794428124378424" LOG_CI_START="0.020323677378406232" LOG_EFFECT_SIZE="0.1841339793110952" ORDER="150441" O_E="0.0" SE="0.1924459644586674" STUDY_ID="STD-Altman-2004" TOTAL_1="107" TOTAL_2="109" VAR="0.03703544923642668" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5562104499525935" CI_START="0.7429837322796777" DF="0" EFFECT_SIZE="1.0752855659397715" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="36" I2="0.0" ID="CMP-006.02.03" LOG_CI_END="0.1920683272763682" LOG_CI_START="-0.1290206950664945" LOG_EFFECT_SIZE="0.03152381610493688" NO="3" P_CHI2="1.0" P_Z="0.7003486033438293" STUDIES="1" TAU2="0.0" TOTAL_1="107" TOTAL_2="109" WEIGHT="100.0" Z="0.38484993208496976">
<NAME>Week 13</NAME>
<DICH_DATA CI_END="1.5562104499525935" CI_START="0.7429837322796777" EFFECT_SIZE="1.0752855659397715" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="36" LOG_CI_END="0.1920683272763682" LOG_CI_START="-0.1290206950664945" LOG_EFFECT_SIZE="0.03152381610493688" ORDER="150442" O_E="0.0" SE="0.1886092811404919" STUDY_ID="STD-Altman-2004" TOTAL_1="107" TOTAL_2="109" VAR="0.035573460932333115" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.0544292904162324E-31" CI_END="1.4239060174458609" CI_START="0.6478819881041018" DF="0" EFFECT_SIZE="0.9604806408544725" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="35" I2="100.00000000000001" ID="CMP-006.02.04" LOG_CI_END="0.1534813253600877" LOG_CI_START="-0.18850409379403615" LOG_EFFECT_SIZE="-0.017511384216974228" NO="4" P_CHI2="0.0" P_Z="0.8409174027364537" STUDIES="1" TAU2="0.0" TOTAL_1="107" TOTAL_2="109" WEIGHT="100.00000000000001" Z="0.2007201504064402">
<NAME>Week 26</NAME>
<DICH_DATA CI_END="1.423906017445861" CI_START="0.6478819881041018" EFFECT_SIZE="0.9604806408544726" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="35" LOG_CI_END="0.15348132536008777" LOG_CI_START="-0.18850409379403615" LOG_EFFECT_SIZE="-0.017511384216974176" ORDER="150443" O_E="0.0" SE="0.2008839280662592" STUDY_ID="STD-Altman-2004" TOTAL_1="107" TOTAL_2="109" VAR="0.04035435255533" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.89200021988128" CI_END="0.900638587167365" CI_START="0.09465027627224426" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="0.49764443171980466" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.03" NO="3" P_CHI2="0.8273580114978676" P_Q="0.8273580114978676" P_Z="0.015507875717425817" Q="0.89200021988128" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="688" TOTAL_2="696" UNITS="" WEIGHT="400.0" Z="2.4202960516747214">
<NAME>WOMAC pain (change from baseline; 0 to 20 Likert)</NAME>
<GROUP_LABEL_1>Durolane</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Durolane</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Saline</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.4634300173216583" CI_START="0.016569982678342088" DF="0" EFFECT_SIZE="0.7400000000000002" ESTIMABLE="YES" I2="0.0" ID="CMP-006.03.01" NO="1" P_CHI2="1.0" P_Z="0.044978393820991024" STUDIES="1" TAU2="0.0" TOTAL_1="172" TOTAL_2="174" WEIGHT="100.0" Z="2.004856466876135">
<NAME>Week 2</NAME>
<CONT_DATA CI_END="1.4634300173216583" CI_START="0.016569982678342088" EFFECT_SIZE="0.7400000000000002" ESTIMABLE="YES" MEAN_1="-2.75" MEAN_2="-3.49" ORDER="150444" SD_1="3.27" SD_2="3.59" SE="0.3691037299807454" STUDY_ID="STD-Altman-2004" TOTAL_1="172" TOTAL_2="174" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.0525134525626867" CI_START="-0.5725134525626863" DF="0" EFFECT_SIZE="0.2400000000000002" ESTIMABLE="YES" I2="0.0" ID="CMP-006.03.02" NO="2" P_CHI2="1.0" P_Z="0.5626339652691035" STUDIES="1" TAU2="0.0" TOTAL_1="172" TOTAL_2="174" WEIGHT="100.0" Z="0.5789336223369448">
<NAME>Week 6</NAME>
<CONT_DATA CI_END="1.0525134525626867" CI_START="-0.5725134525626863" EFFECT_SIZE="0.2400000000000002" ESTIMABLE="YES" MEAN_1="-3.15" MEAN_2="-3.39" ORDER="150445" SD_1="3.9" SD_2="3.81" SE="0.4145552974297941" STUDY_ID="STD-Altman-1998" TOTAL_1="172" TOTAL_2="174" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.4003676722291938" CI_START="-0.30036767222919425" DF="0" EFFECT_SIZE="0.5499999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-006.03.03" NO="3" P_CHI2="1.0" P_Z="0.2049181144702863" STUDIES="1" TAU2="0.0" TOTAL_1="172" TOTAL_2="174" WEIGHT="100.0" Z="1.2676636550295488">
<NAME>Week 13</NAME>
<CONT_DATA CI_END="1.4003676722291938" CI_START="-0.30036767222919425" EFFECT_SIZE="0.5499999999999998" ESTIMABLE="YES" MEAN_1="-2.87" MEAN_2="-3.42" ORDER="150446" SD_1="3.97" SD_2="4.1" SE="0.4338690297050281" STUDY_ID="STD-Altman-1998" TOTAL_1="172" TOTAL_2="174" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.5969612828175713E-32" CI_END="1.2509563462020998" CI_START="-0.4709563462020994" DF="0" EFFECT_SIZE="0.3900000000000002" ESTIMABLE="YES" I2="100.0" ID="CMP-006.03.04" NO="4" P_CHI2="0.0" P_Z="0.37463028731573333" STUDIES="1" TAU2="0.0" TOTAL_1="172" TOTAL_2="174" WEIGHT="100.0" Z="0.8878335787203672">
<NAME>Week 26</NAME>
<CONT_DATA CI_END="1.2509563462020998" CI_START="-0.4709563462020995" EFFECT_SIZE="0.3900000000000001" ESTIMABLE="YES" MEAN_1="-2.5" MEAN_2="-2.89" ORDER="150447" SD_1="4.0" SD_2="4.17" SE="0.43927151365699235" STUDY_ID="STD-Altman-1998" TOTAL_1="172" TOTAL_2="174" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.856573711147401" CI_END="0.5284517648027864" CI_START="0.15287643664878098" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="0.3406641007257837" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.04" NO="4" P_CHI2="0.602702102091335" P_Q="0.602702102091335" P_Z="3.771820246255565E-4" Q="1.856573711147401" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="688" TOTAL_2="696" UNITS="" WEIGHT="400.0" Z="3.5555550016026296">
<NAME>WOMAC stiffness (change from baseline; 0 to 8 Likert)</NAME>
<GROUP_LABEL_1>Durolane</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Durolane</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Saline</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.8641393386778178" CI_START="0.15586066132218218" DF="0" EFFECT_SIZE="0.51" ESTIMABLE="YES" I2="0.0" ID="CMP-006.04.01" NO="1" P_CHI2="1.0" P_Z="0.004764102522800239" STUDIES="1" TAU2="0.0" TOTAL_1="172" TOTAL_2="174" WEIGHT="100.0" Z="2.8225659308208293">
<NAME>Week 2</NAME>
<CONT_DATA CI_END="0.8641393386778178" CI_START="0.15586066132218218" EFFECT_SIZE="0.51" ESTIMABLE="YES" MEAN_1="-0.48" MEAN_2="-0.99" ORDER="150448" SD_1="1.63" SD_2="1.73" SE="0.18068665621982022" STUDY_ID="STD-Altman-2004" TOTAL_1="172" TOTAL_2="174" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.5184050545588481" CI_START="-0.198405054558848" DF="0" EFFECT_SIZE="0.16000000000000003" ESTIMABLE="YES" I2="0.0" ID="CMP-006.04.02" NO="2" P_CHI2="1.0" P_Z="0.38158937777798885" STUDIES="1" TAU2="0.0" TOTAL_1="172" TOTAL_2="174" WEIGHT="100.0" Z="0.8749715818388895">
<NAME>Week 6</NAME>
<CONT_DATA CI_END="0.5184050545588481" CI_START="-0.198405054558848" EFFECT_SIZE="0.16000000000000003" ESTIMABLE="YES" MEAN_1="-0.87" MEAN_2="-1.03" ORDER="150449" SD_1="1.96" SD_2="1.39" SE="0.18286308186573905" STUDY_ID="STD-Altman-1998" TOTAL_1="172" TOTAL_2="174" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.7436239965643661" CI_START="-0.06362399656436585" DF="0" EFFECT_SIZE="0.3400000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-006.04.03" NO="3" P_CHI2="1.0" P_Z="0.09873627995160822" STUDIES="1" TAU2="0.0" TOTAL_1="172" TOTAL_2="174" WEIGHT="99.99999999999999" Z="1.6510112392124578">
<NAME>Week 13</NAME>
<CONT_DATA CI_END="0.7436239965643661" CI_START="-0.06362399656436585" EFFECT_SIZE="0.3400000000000001" ESTIMABLE="YES" MEAN_1="-0.71" MEAN_2="-1.05" ORDER="150450" SD_1="1.87" SD_2="1.96" SE="0.20593439458484977" STUDY_ID="STD-Altman-2004" TOTAL_1="172" TOTAL_2="174" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.7434243659243576" CI_START="-0.043424365924357555" DF="0" EFFECT_SIZE="0.35" ESTIMABLE="YES" I2="0.0" ID="CMP-006.04.04" NO="4" P_CHI2="1.0" P_Z="0.08122324390873502" STUDIES="1" TAU2="0.0" TOTAL_1="172" TOTAL_2="174" WEIGHT="100.0" Z="1.7436322048261537">
<NAME>Week 26</NAME>
<CONT_DATA CI_END="0.7434243659243576" CI_START="-0.043424365924357555" EFFECT_SIZE="0.35" ESTIMABLE="YES" MEAN_1="-0.47" MEAN_2="-0.82" ORDER="150451" SD_1="1.77" SD_2="1.96" SE="0.20073040577665646" STUDY_ID="STD-Altman-2004" TOTAL_1="172" TOTAL_2="174" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.4319546526169544" CI_END="2.932631725009749" CI_START="0.3795835067369777" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="1.6561076158733634" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.05" NO="5" P_CHI2="0.9335651314978883" P_Q="0.9335651314978883" P_Z="0.010997659131585293" Q="0.4319546526169544" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="688" TOTAL_2="696" UNITS="" WEIGHT="400.0" Z="2.54277319041805">
<NAME>WOMAC physical function (change from baseline; 0 to 68 Likert)</NAME>
<GROUP_LABEL_1>Durolane</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Durolane</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Saline</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="4.437409292956582" CI_START="-0.1374092929565811" DF="0" EFFECT_SIZE="2.1500000000000004" ESTIMABLE="YES" I2="0.0" ID="CMP-006.05.01" NO="1" P_CHI2="1.0" P_Z="0.0654422461825727" STUDIES="1" TAU2="0.0" TOTAL_1="172" TOTAL_2="174" WEIGHT="100.0" Z="1.8422249921501497">
<NAME>Week 2</NAME>
<CONT_DATA CI_END="4.437409292956582" CI_START="-0.1374092929565811" EFFECT_SIZE="2.1500000000000004" ESTIMABLE="YES" MEAN_1="-6.35" MEAN_2="-8.5" ORDER="150452" SD_1="10.48" SD_2="11.22" SE="1.1670670027609558" STUDY_ID="STD-Altman-2004" TOTAL_1="172" TOTAL_2="174" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.5847319836332097" CI_START="-1.5847319836332097" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" I2="0.0" ID="CMP-006.05.02" NO="2" P_CHI2="1.0" P_Z="0.44828027728672737" STUDIES="1" TAU2="0.0" TOTAL_1="172" TOTAL_2="174" WEIGHT="100.0" Z="0.7582851904765171">
<NAME>Week 6</NAME>
<CONT_DATA CI_END="3.5847319836332097" CI_START="-1.5847319836332097" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="-7.52" MEAN_2="-8.52" ORDER="150453" SD_1="12.12" SD_2="12.41" SE="1.3187650405932179" STUDY_ID="STD-Altman-2004" TOTAL_1="172" TOTAL_2="174" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="4.445688877578581" CI_START="-0.9656888775785806" DF="0" EFFECT_SIZE="1.7400000000000002" ESTIMABLE="YES" I2="0.0" ID="CMP-006.05.03" NO="3" P_CHI2="1.0" P_Z="0.2075135235060792" STUDIES="1" TAU2="0.0" TOTAL_1="172" TOTAL_2="174" WEIGHT="100.0" Z="1.2604321810095658">
<NAME>Week 13</NAME>
<CONT_DATA CI_END="4.445688877578581" CI_START="-0.9656888775785806" EFFECT_SIZE="1.7400000000000002" ESTIMABLE="YES" MEAN_1="-6.98" MEAN_2="-8.72" ORDER="150454" SD_1="12.27" SD_2="13.39" SE="1.3804788755919544" STUDY_ID="STD-Altman-2004" TOTAL_1="172" TOTAL_2="174" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="4.308868244655361" CI_START="-1.108868244655362" DF="0" EFFECT_SIZE="1.5999999999999996" ESTIMABLE="YES" I2="0.0" ID="CMP-006.05.04" NO="4" P_CHI2="1.0" P_Z="0.24700374318233853" STUDIES="1" TAU2="0.0" TOTAL_1="172" TOTAL_2="174" WEIGHT="100.0" Z="1.1576577714517302">
<NAME>Week 26</NAME>
<CONT_DATA CI_END="4.308868244655361" CI_START="-1.108868244655362" EFFECT_SIZE="1.5999999999999996" ESTIMABLE="YES" MEAN_1="-5.82" MEAN_2="-7.42" ORDER="150455" SD_1="12.16" SD_2="13.52" SE="1.3821010314590312" STUDY_ID="STD-Altman-2004" TOTAL_1="172" TOTAL_2="174" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="39" EVENTS_2="35" I2="0.0" I2_Q="0.0" ID="CMP-006.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="173" TOTAL_2="174" WEIGHT="0.0" Z="0.0">
<NAME>Safety: total withdrawals overall</NAME>
<GROUP_LABEL_1>Durolane</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Durolane</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Saline</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6801995878217237" CI_START="0.7475470669205133" EFFECT_SIZE="1.1207266721717588" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="35" LOG_CI_END="0.22536087383369227" LOG_CI_START="-0.12636145817363656" LOG_EFFECT_SIZE="0.04949970783002785" ORDER="150456" O_E="0.0" SE="0.20660343887472774" STUDY_ID="STD-Altman-1998" TOTAL_1="173" TOTAL_2="174" VAR="0.04268498095486336" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="10" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-006.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="173" TOTAL_2="174" WEIGHT="0.0" Z="0.0">
<NAME>Safety: withdrawals due to inefficacy</NAME>
<GROUP_LABEL_1>Durolane</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Durolane</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Saline</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.511333178647983" CI_START="0.6228721126648293" EFFECT_SIZE="1.676300578034682" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.6543049025366259" LOG_CI_START="-0.2056011129963045" LOG_EFFECT_SIZE="0.22435189477016065" ORDER="150457" O_E="0.0" SE="0.5051130501274698" STUDY_ID="STD-Altman-2004" TOTAL_1="173" TOTAL_2="174" VAR="0.2551391934090758" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="13" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-006.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="173" TOTAL_2="174" WEIGHT="0.0" Z="0.0">
<NAME>Safety: withdrawals due to adverse events</NAME>
<GROUP_LABEL_1>Durolane</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Durolane</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Saline</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.60200150707377" CI_START="0.8477099345987852" EFFECT_SIZE="2.179190751445087" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="6" LOG_CI_END="0.7483432213232749" LOG_CI_START="-0.07175272716928" LOG_EFFECT_SIZE="0.33829524707699743" ORDER="150458" O_E="0.0" SE="0.4817284196849432" STUDY_ID="STD-Altman-2004" TOTAL_1="173" TOTAL_2="174" VAR="0.23206227033215274" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-006.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="173" TOTAL_2="174" WEIGHT="0.0" Z="0.0">
<NAME>Safety: number of patients affected by device-related adverse events</NAME>
<GROUP_LABEL_1>Durolaje</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Durolane</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Saline</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.917404508485049" CI_START="0.2552409433091198" EFFECT_SIZE="1.5086705202312138" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9502384674177302" LOG_CI_START="-0.593049658998759" LOG_EFFECT_SIZE="0.17859440420948552" ORDER="150459" O_E="0.0" SE="0.9065350848564783" STUDY_ID="STD-Altman-2004" TOTAL_1="173" TOTAL_2="174" VAR="0.8218058600757423" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-006.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="173" TOTAL_2="174" WEIGHT="0.0" Z="0.0">
<NAME>Safety: number of patients with adverse events related to injection only</NAME>
<GROUP_LABEL_1>Durolane</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Durolane</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Saline</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.494957440545797" CI_START="0.04602374617984798" EFFECT_SIZE="0.5028901734104047" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7399643330820405" LOG_CI_START="-1.3370180341023943" LOG_EFFECT_SIZE="-0.29852685051017686" ORDER="150460" O_E="0.0" SE="1.220029723712668" STUDY_ID="STD-Altman-2004" TOTAL_1="173" TOTAL_2="174" VAR="1.488472526742409" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="22" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-006.11" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="11" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="173" TOTAL_2="174" WEIGHT="0.0" Z="0.0">
<NAME>Safety: number of patients with non-serious treatment-related adverse events</NAME>
<GROUP_LABEL_1>Durolane</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Durolane</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Saline</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.746667196556263" CI_START="0.792251541864663" EFFECT_SIZE="1.4751445086705202" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="15" LOG_CI_END="0.4388060407619577" LOG_CI_START="-0.10113690692129917" LOG_EFFECT_SIZE="0.16883456692032928" ORDER="150461" O_E="0.0" SE="0.31716516022984187" STUDY_ID="STD-Altman-2004" TOTAL_1="173" TOTAL_2="174" VAR="0.10059373886362127" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="112" EVENTS_2="114" I2="0.0" I2_Q="0.0" ID="CMP-006.12" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="12" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="173" TOTAL_2="174" WEIGHT="0.0" Z="0.0">
<NAME>Safety: number of patients with non-serious adverse events</NAME>
<GROUP_LABEL_1>Durolane</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Durolane</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Saline</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.152640955428154" CI_START="0.8471076157258853" EFFECT_SIZE="0.988135077578339" ESTIMABLE="YES" EVENTS_1="112" EVENTS_2="114" LOG_CI_END="0.06169404679179777" LOG_CI_START="-0.07206141381677104" LOG_EFFECT_SIZE="-0.005183683512486655" ORDER="150462" O_E="0.0" SE="0.07856861966168155" STUDY_ID="STD-Altman-2004" TOTAL_1="173" TOTAL_2="174" VAR="0.006173027995541973" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="101" EVENTS_2="109" I2="0.0" I2_Q="0.0" ID="CMP-006.13" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="13" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="173" TOTAL_2="174" WEIGHT="0.0" Z="0.0">
<NAME>Safety: number of patients with treated unrelated adverse events</NAME>
<GROUP_LABEL_1>Durolane</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Durolane</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Saline</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1049659973065602" CI_START="0.7860444907319112" EFFECT_SIZE="0.9319616057697406" ESTIMABLE="YES" EVENTS_1="101" EVENTS_2="109" LOG_CI_END="0.04334891384978033" LOG_CI_START="-0.10455287185813389" LOG_EFFECT_SIZE="-0.03060197900417678" ORDER="150463" O_E="0.0" SE="0.08687824105047563" STUDY_ID="STD-Altman-2004" TOTAL_1="173" TOTAL_2="174" VAR="0.00754782876802455" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-006.14" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="14" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="173" TOTAL_2="174" WEIGHT="0.0" Z="0.0">
<NAME>Safety: number of patients with serious treatment-unrelated adverse events</NAME>
<GROUP_LABEL_1>Durolane</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Durolane</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Saline</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.927125233438371" CI_START="0.6169475353714453" EFFECT_SIZE="2.346820809248555" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.9507116272808336" LOG_CI_START="-0.2097517663840362" LOG_EFFECT_SIZE="0.3704799304483987" ORDER="150464" O_E="0.0" SE="0.6816619418251875" STUDY_ID="STD-Altman-2004" TOTAL_1="173" TOTAL_2="174" VAR="0.4646630029328853" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" NO="7">
<NAME>Fermathron versus Hyalart</NAME>
<CONT_OUTCOME CHI2="0.15842686254396865" CI_END="5.265807740493064" CI_START="-2.1164599799960113" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="1.5746738802485263" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-007.01" NO="1" P_CHI2="0.6906092134262942" P_Q="0.6906092134262942" P_Z="0.40307624336231596" Q="0.15842686254396865" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="228" TOTAL_2="238" UNITS="" WEIGHT="200.0" Z="0.8361398447030535">
<NAME>Pain (0-100 mm VAS)</NAME>
<GROUP_LABEL_1>Fermathron</GROUP_LABEL_1>
<GROUP_LABEL_2>Hyalart</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fermathron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Hyalart</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="7.436247800781919" CI_START="-2.8362478007819174" DF="0" EFFECT_SIZE="2.3000000000000007" ESTIMABLE="YES" I2="0.0" ID="CMP-007.01.01" NO="1" P_CHI2="1.0" P_Z="0.38012425954026396" STUDIES="1" TAU2="0.0" TOTAL_1="114" TOTAL_2="119" WEIGHT="100.0" Z="0.8776673827450191">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="7.436247800781919" CI_START="-2.8362478007819174" EFFECT_SIZE="2.3000000000000007" ESTIMABLE="YES" MEAN_1="31.3" MEAN_2="29.0" ORDER="150465" SD_1="19.4" SD_2="20.6" SE="2.6205827460585933" STUDY_ID="STD-McDonald-2000" TOTAL_1="114" TOTAL_2="119" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="6.1080959700105435" CI_START="-4.508095970010549" DF="0" EFFECT_SIZE="0.7999999999999972" ESTIMABLE="YES" I2="0.0" ID="CMP-007.01.02" NO="2" P_CHI2="1.0" P_Z="0.7676941416721604" STUDIES="1" TAU2="0.0" TOTAL_1="114" TOTAL_2="119" WEIGHT="99.99999999999999" Z="0.29539239616063734">
<NAME>5 to13 weeks post-injection</NAME>
<CONT_DATA CI_END="6.1080959700105435" CI_START="-4.508095970010549" EFFECT_SIZE="0.7999999999999972" ESTIMABLE="YES" MEAN_1="25.4" MEAN_2="24.6" ORDER="150466" SD_1="19.3" SD_2="22.0" SE="2.7082619945469046" STUDY_ID="STD-McDonald-2000" TOTAL_1="114" TOTAL_2="119" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.014454468914886127" CI_END="1.2394401808126312" CI_START="-0.22737374723446935" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="0.5060332167890809" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-007.02" NO="2" P_CHI2="0.9043035390097541" P_Q="0.9043035390097541" P_Z="0.17627036431883397" Q="0.014454468914886127" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="228" TOTAL_2="238" UNITS="" WEIGHT="200.0" Z="1.352328145953766">
<NAME>Lequesne Index (0-24)</NAME>
<GROUP_LABEL_1>Fermathron</GROUP_LABEL_1>
<GROUP_LABEL_2>Hyalart</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fermathron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Hyalart</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.5093103054667574" CI_START="-0.5893103054667574" DF="0" EFFECT_SIZE="0.45999999999999996" ESTIMABLE="YES" I2="0.0" ID="CMP-007.02.01" NO="1" P_CHI2="1.0" P_Z="0.39022177147242876" STUDIES="1" TAU2="0.0" TOTAL_1="114" TOTAL_2="119" WEIGHT="100.0" Z="0.859215265676229">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="1.5093103054667574" CI_START="-0.5893103054667574" EFFECT_SIZE="0.45999999999999996" ESTIMABLE="YES" MEAN_1="7.92" MEAN_2="7.46" ORDER="150467" SD_1="4.09" SD_2="4.08" SE="0.5353722383388588" STUDY_ID="STD-McDonald-2000" TOTAL_1="114" TOTAL_2="119" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.5754880927563024" CI_START="-0.47548809275630277" DF="0" EFFECT_SIZE="0.5499999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-007.02.02" NO="2" P_CHI2="1.0" P_Z="0.2931725310644584" STUDIES="1" TAU2="0.0" TOTAL_1="114" TOTAL_2="119" WEIGHT="100.0" Z="1.051187428807329">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="1.5754880927563024" CI_START="-0.47548809275630277" EFFECT_SIZE="0.5499999999999998" ESTIMABLE="YES" MEAN_1="6.91" MEAN_2="6.36" ORDER="150468" SD_1="4.22" SD_2="3.74" SE="0.5232178248402632" STUDY_ID="STD-McDonald-2000" TOTAL_1="114" TOTAL_2="119" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="2.1441090364441658E-30" CI_END="1.1251161063215807" CI_START="0.8204515213900786" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.960782608695652" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="92" I2="100.0" I2_Q="0.0" ID="CMP-007.03" LOG_CI_END="0.05119734176553083" LOG_CI_START="-0.08594707532360361" LOG_EFFECT_SIZE="-0.017374866779036366" METHOD="MH" NO="3" P_CHI2="0.0" P_Q="1.0" P_Z="0.6194592814326558" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="125" TOTAL_2="127" WEIGHT="100.0" Z="0.49661683422315167">
<NAME>Patient global assessment (number of patients much better/better)</NAME>
<GROUP_LABEL_1>Fermathron</GROUP_LABEL_1>
<GROUP_LABEL_2>Hyalart</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hyalart</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Fermathron</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.1441090364441658E-30" CI_END="1.1251161063215807" CI_START="0.8204515213900786" DF="0" EFFECT_SIZE="0.960782608695652" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="92" I2="100.0" ID="CMP-007.03.01" LOG_CI_END="0.05119734176553083" LOG_CI_START="-0.08594707532360361" LOG_EFFECT_SIZE="-0.017374866779036366" NO="1" P_CHI2="0.0" P_Z="0.6194592814326558" STUDIES="1" TAU2="0.0" TOTAL_1="125" TOTAL_2="127" WEIGHT="100.0" Z="0.49661683422315167">
<NAME>5 to 13 weeks post-injection</NAME>
<DICH_DATA CI_END="1.1251161063215809" CI_START="0.8204515213900787" EFFECT_SIZE="0.9607826086956521" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="92" LOG_CI_END="0.05119734176553092" LOG_CI_START="-0.08594707532360356" LOG_EFFECT_SIZE="-0.017374866779036314" ORDER="150469" O_E="0.0" SE="0.08055930947397096" STUDY_ID="STD-McDonald-2000" TOTAL_1="125" TOTAL_2="127" VAR="0.006489802342923026" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.594764690736245" CI_START="0.8369719073594893" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4736842105263157" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-007.04" LOG_CI_END="0.4140979794683231" LOG_CI_START="-0.07728911868954261" LOG_EFFECT_SIZE="0.16840443038939024" METHOD="MH" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.17913997820027802" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="114" TOTAL_2="119" WEIGHT="100.0" Z="1.3434077518012022">
<NAME>Safety: number of related adverse events</NAME>
<GROUP_LABEL_1>Fermathron</GROUP_LABEL_1>
<GROUP_LABEL_2>Hyalart</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fermathron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Hyalart</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.594764690736245" CI_START="0.8369719073594893" DF="0" EFFECT_SIZE="1.4736842105263157" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="17" I2="0.0" ID="CMP-007.04.01" LOG_CI_END="0.4140979794683231" LOG_CI_START="-0.07728911868954261" LOG_EFFECT_SIZE="0.16840443038939024" NO="1" P_CHI2="1.0" P_Z="0.17913997820027802" STUDIES="1" TAU2="0.0" TOTAL_1="114" TOTAL_2="119" WEIGHT="100.0" Z="1.3434077518012022">
<NAME>5 to 13 weeks post-injection</NAME>
<DICH_DATA CI_END="2.5947646907362456" CI_START="0.8369719073594892" EFFECT_SIZE="1.4736842105263157" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="17" LOG_CI_END="0.41409797946832316" LOG_CI_START="-0.07728911868954266" LOG_EFFECT_SIZE="0.16840443038939024" ORDER="150470" O_E="0.0" SE="0.28864321386329556" STUDY_ID="STD-McDonald-2000" TOTAL_1="114" TOTAL_2="119" VAR="0.08331490490933216" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" NO="8">
<NAME>Hyalgan versus placebo</NAME>
<CONT_OUTCOME CHI2="107.8695624347921" CI_END="-3.101947494564471" CI_START="-7.768502378432387" CI_STUDY="95" CI_TOTAL="95" DF="29" EFFECT_MEASURE="MD" EFFECT_SIZE="-5.435224936498429" ESTIMABLE="YES" I2="73.11567846812143" I2_Q="15.576209657460126" ID="CMP-008.01" NO="1" P_CHI2="5.1872728334956264E-11" P_Q="0.3138894103464912" P_Z="4.980334661151277E-6" Q="3.553500722755805" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="14" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="34.47898634242621" TOTALS="SUB" TOTAL_1="1981" TOTAL_2="1917" UNITS="" WEIGHT="400.0" Z="4.565614415138398">
<NAME>Pain on weight bearing (walking) (0-100 mm VAS)</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hyalgan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="68.98839905285145" CI_END="-1.3768066180558653" CI_START="-11.021256307816277" DF="12" EFFECT_SIZE="-6.199031462936071" ESTIMABLE="YES" I2="82.60577116624071" ID="CMP-008.01.01" NO="1" P_CHI2="4.950008181126009E-10" P_Z="0.011750205716834808" STUDIES="14" TAU2="56.64862556236639" TOTAL_1="713" TOTAL_2="685" WEIGHT="100.0" Z="2.519558667880235">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="5.690624720637078" CI_START="-5.690624720637078" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="25.0" MEAN_2="25.0" ORDER="150471" SD_1="24.0" SD_2="25.0" SE="2.903433310777136" STUDY_ID="STD-Altman-1998" TOTAL_1="136" TOTAL_2="149" WEIGHT="9.301668524157364"/>
<CONT_DATA CI_END="-4.119597714777017" CI_START="-25.080402285222988" EFFECT_SIZE="-14.600000000000001" ESTIMABLE="YES" MEAN_1="41.8" MEAN_2="56.4" ORDER="150472" SD_1="14.4" SD_2="13.5" SE="5.347242279904662" STUDY_ID="STD-Carrabba-1995" TOTAL_1="20" TOTAL_2="10" WEIGHT="7.1014495708912815"/>
<CONT_DATA CI_END="0.6590435935414085" CI_START="-21.459043593541406" EFFECT_SIZE="-10.399999999999999" ESTIMABLE="YES" MEAN_1="46.0" MEAN_2="56.4" ORDER="150473" SD_1="16.5" SD_2="13.5" SE="5.642472862141209" STUDY_ID="STD-Carrabba-1995a" TOTAL_1="20" TOTAL_2="10" WEIGHT="6.841062386049321"/>
<CONT_DATA CI_END="-6.7146313278825325" CI_START="-29.08536867211748" EFFECT_SIZE="-17.900000000000006" ESTIMABLE="YES" MEAN_1="41.8" MEAN_2="59.7" ORDER="150474" SD_1="14.4" SD_2="14.9" SE="5.706925617177782" STUDY_ID="STD-Carrabba-1995b" TOTAL_1="20" TOTAL_2="10" WEIGHT="6.784972156076805"/>
<CONT_DATA CI_END="-1.9707167535723205" CI_START="-25.429283246427687" EFFECT_SIZE="-13.700000000000003" ESTIMABLE="YES" MEAN_1="46.0" MEAN_2="59.7" ORDER="150475" SD_1="16.5" SD_2="14.9" SE="5.984438152408295" STUDY_ID="STD-Carrabba-1995c" TOTAL_1="20" TOTAL_2="10" WEIGHT="6.5468871885671325"/>
<CONT_DATA CI_END="11.69620203698966" CI_START="-24.096202036989666" EFFECT_SIZE="-6.200000000000003" ESTIMABLE="YES" MEAN_1="35.4" MEAN_2="41.6" ORDER="150476" SD_1="28.6" SD_2="25.4" SE="9.13088310711453" STUDY_ID="STD-Corrado-1995" TOTAL_1="19" TOTAL_2="16" WEIGHT="4.323182144706424"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="41.12" MEAN_2="33.93" ORDER="150477" SD_1="0.0" SD_2="3.12" SE="0.0" STUDY_ID="STD-Creamer-1994" TOTAL_1="12" TOTAL_2="12" WEIGHT="0.0"/>
<CONT_DATA CI_END="7.666620266223497" CI_START="-10.646620266223486" EFFECT_SIZE="-1.4899999999999949" ESTIMABLE="YES" MEAN_1="34.13" MEAN_2="35.62" ORDER="150478" SD_1="23.49" SD_2="23.68" SE="4.671830879776232" STUDY_ID="STD-Dougados-1993" TOTAL_1="52" TOTAL_2="50" WEIGHT="7.71381923594773"/>
<CONT_DATA CI_END="-6.131739296864264" CI_START="-15.268260703135727" EFFECT_SIZE="-10.699999999999996" ESTIMABLE="YES" MEAN_1="28.1" MEAN_2="38.8" ORDER="150479" SD_1="7.6" SD_2="6.5" SE="2.3307880854799317" STUDY_ID="STD-Henderson-1994" TOTAL_1="18" TOTAL_2="19" WEIGHT="9.750763811276098"/>
<CONT_DATA CI_END="12.375911279045194" CI_START="4.624088720954799" EFFECT_SIZE="8.499999999999996" ESTIMABLE="YES" MEAN_1="39.8" MEAN_2="31.3" ORDER="150480" SD_1="7.3" SD_2="6.1" SE="1.9775420924149067" STUDY_ID="STD-Henderson-1994a" TOTAL_1="22" TOTAL_2="25" WEIGHT="9.99580778457447"/>
<CONT_DATA CI_END="-0.8904573366637738" CI_START="-24.569542663336236" EFFECT_SIZE="-12.730000000000004" ESTIMABLE="YES" MEAN_1="35.29" MEAN_2="48.02" ORDER="150481" SD_1="27.83" SD_2="30.42" SE="6.040693990667702" STUDY_ID="STD-Huskisson-1999" TOTAL_1="45" TOTAL_2="48" WEIGHT="6.4993358698226045"/>
<CONT_DATA CI_END="4.805741037713539" CI_START="-4.8257410377135495" EFFECT_SIZE="-0.010000000000005116" ESTIMABLE="YES" MEAN_1="43.87" MEAN_2="43.88" ORDER="150482" SD_1="24.05" SD_2="25.36" SE="2.4570558825057476" STUDY_ID="STD-Jubb-2003" TOTAL_1="205" TOTAL_2="200" WEIGHT="9.65672602252551"/>
<CONT_DATA CI_END="-0.2941778169601754" CI_START="-28.44582218303982" EFFECT_SIZE="-14.369999999999997" ESTIMABLE="YES" MEAN_1="50.54" MEAN_2="64.91" ORDER="150483" SD_1="29.11" SD_2="26.52" SE="7.181673895065476" STUDY_ID="STD-St.-J.-Dixon-1988" TOTAL_1="28" TOTAL_2="33" WEIGHT="5.593335540982506"/>
<CONT_DATA CI_END="2.861866541770418" CI_START="-5.5018665417704185" EFFECT_SIZE="-1.3200000000000003" ESTIMABLE="YES" MEAN_1="22.6" MEAN_2="23.92" ORDER="150484" SD_1="14.31" SD_2="15.0" SE="2.1336445846742325" STUDY_ID="STD-Tsai-2003" TOTAL_1="96" TOTAL_2="93" WEIGHT="9.890989764422752"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="28.311805378641154" CI_END="-3.9782489220575483" CI_START="-14.099145684246448" DF="9" EFFECT_SIZE="-9.038697303151999" ESTIMABLE="YES" I2="68.21114061913644" ID="CMP-008.01.02" NO="2" P_CHI2="8.458855738195936E-4" P_Z="4.638970139665111E-4" STUDIES="10" TAU2="38.771902104434254" TOTAL_1="564" TOTAL_2="531" WEIGHT="100.0" Z="3.5007809283306637">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="5.403743355349907" CI_START="-7.403743355349907" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="23.0" MEAN_2="24.0" ORDER="150485" SD_1="25.0" SD_2="26.0" SE="3.2672760345913585" STUDY_ID="STD-Altman-1998" TOTAL_1="115" TOTAL_2="129" WEIGHT="13.48161480884805"/>
<CONT_DATA CI_END="-7.174883908394788" CI_START="-28.2251160916052" EFFECT_SIZE="-17.699999999999996" ESTIMABLE="YES" MEAN_1="42.1" MEAN_2="59.8" ORDER="150486" SD_1="12.5" SD_2="14.5" SE="5.370055865631195" STUDY_ID="STD-Carrabba-1995" TOTAL_1="20" TOTAL_2="10" WEIGHT="9.859950191438363"/>
<CONT_DATA CI_END="-0.12813395451847676" CI_START="-23.871866045481525" EFFECT_SIZE="-12.0" ESTIMABLE="YES" MEAN_1="47.8" MEAN_2="59.8" ORDER="150487" SD_1="17.7" SD_2="14.5" SE="6.0571858152115485" STUDY_ID="STD-Carrabba-1995a" TOTAL_1="20" TOTAL_2="10" WEIGHT="8.833990869929485"/>
<CONT_DATA CI_END="-10.994964738197057" CI_START="-31.205035261802948" EFFECT_SIZE="-21.1" ESTIMABLE="YES" MEAN_1="42.1" MEAN_2="63.2" ORDER="150488" SD_1="12.5" SD_2="13.7" SE="5.155724973270005" STUDY_ID="STD-Carrabba-1995b" TOTAL_1="20" TOTAL_2="10" WEIGHT="10.2003157564374"/>
<CONT_DATA CI_END="-3.8989186463893297" CI_START="-26.90108135361068" EFFECT_SIZE="-15.400000000000006" ESTIMABLE="YES" MEAN_1="47.8" MEAN_2="63.2" ORDER="150489" SD_1="17.7" SD_2="13.7" SE="5.86800647579738" STUDY_ID="STD-Carrabba-1995c" TOTAL_1="20" TOTAL_2="10" WEIGHT="9.10623148099982"/>
<CONT_DATA CI_END="1.5140343122868245" CI_START="-28.51403431228683" EFFECT_SIZE="-13.500000000000004" ESTIMABLE="YES" MEAN_1="29.7" MEAN_2="43.2" ORDER="150490" SD_1="22.9" SD_2="22.3" SE="7.660362348857231" STUDY_ID="STD-Corrado-1995" TOTAL_1="19" TOTAL_2="16" WEIGHT="6.840476658521094"/>
<CONT_DATA CI_END="22.75925279680046" CI_START="-22.75925279680046" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="41.8" MEAN_2="41.8" ORDER="150491" SD_1="29.58" SD_2="27.26" SE="11.61207704647766" STUDY_ID="STD-Creamer-1994" TOTAL_1="12" TOTAL_2="12" WEIGHT="3.8397370757984737"/>
<CONT_DATA CI_END="0.48040130648918655" CI_START="-26.040401306489187" EFFECT_SIZE="-12.780000000000001" ESTIMABLE="YES" MEAN_1="37.4" MEAN_2="50.18" ORDER="150492" SD_1="32.44" SD_2="30.96" SE="6.765635190792046" STUDY_ID="STD-Huskisson-1999" TOTAL_1="43" TOTAL_2="45" WEIGHT="7.884790907179811"/>
<CONT_DATA CI_END="1.3279371002361273" CI_START="-8.707937100236137" EFFECT_SIZE="-3.690000000000005" ESTIMABLE="YES" MEAN_1="46.51" MEAN_2="50.2" ORDER="150493" SD_1="26.38" SD_2="25.27" SE="2.5602190345419507" STUDY_ID="STD-Jubb-2003" TOTAL_1="207" TOTAL_2="200" WEIGHT="14.707147458616037"/>
<CONT_DATA CI_END="3.9021575258539265" CI_START="-4.822157525853928" EFFECT_SIZE="-0.46000000000000085" ESTIMABLE="YES" MEAN_1="19.32" MEAN_2="19.78" ORDER="150494" SD_1="14.76" SD_2="14.85" SE="2.2256314709158276" STUDY_ID="STD-Tsai-2003" TOTAL_1="88" TOTAL_2="89" WEIGHT="15.245744792231461"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="5.456481036556541" CI_END="-0.4228240948802471" CI_START="-8.717237770214094" DF="3" EFFECT_SIZE="-4.57003093254717" ESTIMABLE="YES" I2="45.019510195288234" ID="CMP-008.01.03" NO="3" P_CHI2="0.14126491350681813" P_Z="0.030788926772007848" STUDIES="4" TAU2="7.7426910721878714" TOTAL_1="438" TOTAL_2="440" WEIGHT="100.0" Z="2.159790043427255">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="0.3966112686337935" CI_START="-12.396611268633794" EFFECT_SIZE="-6.0" ESTIMABLE="YES" MEAN_1="18.0" MEAN_2="24.0" ORDER="150495" SD_1="21.0" SD_2="27.0" SE="3.263637147972844" STUDY_ID="STD-Altman-1998" TOTAL_1="105" TOTAL_2="113" WEIGHT="24.341009769415326"/>
<CONT_DATA CI_END="-1.519673798801378" CI_START="-26.960326201198626" EFFECT_SIZE="-14.240000000000002" ESTIMABLE="YES" MEAN_1="39.44" MEAN_2="53.68" ORDER="150496" SD_1="27.81" SD_2="29.86" SE="6.490081604322801" STUDY_ID="STD-Huskisson-1999" TOTAL_1="39" TOTAL_2="40" WEIGHT="8.97902952597157"/>
<CONT_DATA CI_END="4.933680562726676" CI_START="-5.093680562726672" EFFECT_SIZE="-0.0799999999999983" ESTIMABLE="YES" MEAN_1="50.06" MEAN_2="50.14" ORDER="150497" SD_1="25.68" SD_2="25.79" SE="2.5580472918247206" STUDY_ID="STD-Jubb-2003" TOTAL_1="206" TOTAL_2="199" WEIGHT="31.339750499439965"/>
<CONT_DATA CI_END="-0.759754882886094" CI_START="-9.460245117113905" EFFECT_SIZE="-5.109999999999999" ESTIMABLE="YES" MEAN_1="15.57" MEAN_2="20.68" ORDER="150498" SD_1="13.88" SD_2="15.52" SE="2.2195535996722815" STUDY_ID="STD-Tsai-2003" TOTAL_1="88" TOTAL_2="88" WEIGHT="35.340210205173136"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.38379834242484934" CI_END="2.194529956632909" CI_START="-7.396198266183784" DF="2" EFFECT_SIZE="-2.6008341547754377" ESTIMABLE="YES" I2="0.0" ID="CMP-008.01.04" NO="4" P_CHI2="0.8253901462345212" P_Z="0.2877754208770005" STUDIES="3" TAU2="0.0" TOTAL_1="266" TOTAL_2="261" WEIGHT="100.0" Z="1.063014435336473">
<NAME>45 to 52 weeks post-injection</NAME>
<CONT_DATA CI_END="8.818260121201416" CI_START="-10.498260121201415" EFFECT_SIZE="-0.8399999999999999" ESTIMABLE="YES" MEAN_1="28.51" MEAN_2="29.35" ORDER="150499" SD_1="23.77" SD_2="24.26" SE="4.927774284315701" STUDY_ID="STD-Dougados-1993" TOTAL_1="47" TOTAL_2="48" WEIGHT="24.651615294441772"/>
<CONT_DATA CI_END="2.8249839003311923" CI_START="-8.544983900331191" EFFECT_SIZE="-2.8599999999999994" ESTIMABLE="YES" MEAN_1="47.59" MEAN_2="50.45" ORDER="150500" SD_1="29.37" SD_2="29.21" SE="2.9005552883489796" STUDY_ID="STD-Jubb-2003" TOTAL_1="208" TOTAL_2="200" WEIGHT="71.15160467527419"/>
<CONT_DATA CI_END="14.857955616414245" CI_START="-31.95795561641424" EFFECT_SIZE="-8.549999999999997" ESTIMABLE="YES" MEAN_1="48.45" MEAN_2="57.0" ORDER="150501" SD_1="28.89" SD_2="29.46" SE="11.943053954589578" STUDY_ID="STD-St.-J.-Dixon-1988" TOTAL_1="11" TOTAL_2="13" WEIGHT="4.1967800302840415"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.227205291866144" CI_END="-15.733196301772477" CI_START="-29.05322195873868" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-22.393209130255578" ESTIMABLE="YES" I2="29.031125936265603" I2_Q="0.0" ID="CMP-008.02" NO="2" P_CHI2="0.23795234440396873" P_Q="0.6755238873617235" P_Z="4.396491975868203E-11" Q="0.17520867973549004" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="78" TOTAL_2="68" UNITS="" WEIGHT="200.0" Z="6.590059887853234">
<NAME>Pain spontaneous (0-100 mm VAS)</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hyalgan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.9532528082428833" CI_END="-14.25450753595894" CI_START="-33.49799164047158" DF="1" EFFECT_SIZE="-23.876249588215263" ESTIMABLE="YES" I2="0.0" ID="CMP-008.02.01" NO="1" P_CHI2="0.32889288348686585" P_Z="1.1525251153738025E-6" STUDIES="2" TAU2="0.0" TOTAL_1="39" TOTAL_2="34" WEIGHT="100.0" Z="4.863629582318442">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="-14.873041393873494" CI_START="-43.30695860612651" EFFECT_SIZE="-29.09" ESTIMABLE="YES" MEAN_1="17.12" MEAN_2="46.21" ORDER="150502" SD_1="13.03" SD_2="28.04" SE="7.253683597386513" STUDY_ID="STD-Bragantini-1987" TOTAL_1="19" TOTAL_2="18" WEIGHT="45.803010272507926"/>
<CONT_DATA CI_END="-6.400284704048909" CI_START="-32.5397152959511" EFFECT_SIZE="-19.470000000000002" ESTIMABLE="YES" MEAN_1="14.55" MEAN_2="34.02" ORDER="150503" SD_1="18.78" SD_2="20.72" SE="6.668344622168234" STUDY_ID="STD-Grecomoro-1987" TOTAL_1="20" TOTAL_2="16" WEIGHT="54.19698972749208"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.0987438038877713" CI_END="-11.80112104025564" CI_START="-30.257032147756146" DF="1" EFFECT_SIZE="-21.029076594005893" ESTIMABLE="YES" I2="67.72885842497298" ID="CMP-008.02.02" NO="2" P_CHI2="0.0783530042002687" P_Z="7.95270033976121E-6" STUDIES="2" TAU2="0.0" TOTAL_1="39" TOTAL_2="34" WEIGHT="100.0" Z="4.466453323524673">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="-16.613339936162475" CI_START="-46.10666006383753" EFFECT_SIZE="-31.360000000000003" ESTIMABLE="YES" MEAN_1="15.59" MEAN_2="46.95" ORDER="150504" SD_1="8.11" SD_2="30.93" SE="7.523944409263283" STUDY_ID="STD-Bragantini-1987" TOTAL_1="19" TOTAL_2="18" WEIGHT="39.15828382806771"/>
<CONT_DATA CI_END="-2.5494546081667426" CI_START="-26.210545391833257" EFFECT_SIZE="-14.379999999999999" ESTIMABLE="YES" MEAN_1="20.8" MEAN_2="35.18" ORDER="150505" SD_1="16.77" SD_2="18.92" SE="6.03610346167128" STUDY_ID="STD-Grecomoro-1987" TOTAL_1="20" TOTAL_2="16" WEIGHT="60.84171617193228"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="41.26048206101189" CI_END="-3.2465706852940737" CI_START="-9.361979114398183" CI_STUDY="95" CI_TOTAL="95" DF="15" EFFECT_MEASURE="MD" EFFECT_SIZE="-6.304274899846129" ESTIMABLE="YES" I2="63.645601673243924" I2_Q="72.11049028419724" ID="CMP-008.03" NO="3" P_CHI2="2.9181716608206454E-4" P_Q="0.027720703938772906" P_Z="5.3226058124759686E-5" Q="7.1711551059169745" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="29.349303662984074" TOTALS="SUB" TOTAL_1="379" TOTAL_2="296" UNITS="" WEIGHT="300.0" Z="4.040989868651638">
<NAME>Pain at rest (0-100 mm VAS)</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hyalgan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="32.391461957112945" CI_END="-1.1752942013971674" CI_START="-11.569482419045947" DF="8" EFFECT_SIZE="-6.372388310221558" ESTIMABLE="YES" I2="75.30213359745174" ID="CMP-008.03.01" NO="1" P_CHI2="7.924086413413356E-5" P_Z="0.016252338639017892" STUDIES="9" TAU2="41.40434085415477" TOTAL_1="219" TOTAL_2="181" WEIGHT="100.00000000000001" Z="2.403199042005328">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="0.7967507572555448" CI_START="-18.99675075725554" EFFECT_SIZE="-9.099999999999998" ESTIMABLE="YES" MEAN_1="28.3" MEAN_2="37.4" ORDER="150506" SD_1="11.6" SD_2="13.7" SE="5.049455416181036" STUDY_ID="STD-Carrabba-1995" TOTAL_1="20" TOTAL_2="10" WEIGHT="10.509696098764216"/>
<CONT_DATA CI_END="3.505832190740861" CI_START="-17.705832190740857" EFFECT_SIZE="-7.099999999999998" ESTIMABLE="YES" MEAN_1="30.3" MEAN_2="37.4" ORDER="150507" SD_1="14.5" SD_2="13.7" SE="5.411238305600669" STUDY_ID="STD-Carrabba-1995a" TOTAL_1="20" TOTAL_2="10" WEIGHT="9.947009931277885"/>
<CONT_DATA CI_END="-1.6666199819037804" CI_START="-22.533380018096217" EFFECT_SIZE="-12.099999999999998" ESTIMABLE="YES" MEAN_1="28.3" MEAN_2="40.4" ORDER="150508" SD_1="11.6" SD_2="14.7" SE="5.323250886441479" STUDY_ID="STD-Carrabba-1995b" TOTAL_1="20" TOTAL_2="10" WEIGHT="10.081721291355388"/>
<CONT_DATA CI_END="1.008259067420349" CI_START="-21.208259067420343" EFFECT_SIZE="-10.099999999999998" ESTIMABLE="YES" MEAN_1="30.3" MEAN_2="40.4" ORDER="150509" SD_1="14.5" SD_2="14.7" SE="5.667583259203167" STUDY_ID="STD-Carrabba-1995c" TOTAL_1="20" TOTAL_2="10" WEIGHT="9.562797960674724"/>
<CONT_DATA CI_END="13.883122745417381" CI_START="-13.28312274541738" EFFECT_SIZE="0.3000000000000007" ESTIMABLE="YES" MEAN_1="9.4" MEAN_2="9.1" ORDER="150510" SD_1="22.2" SD_2="18.8" SE="6.930292011771297" STUDY_ID="STD-Corrado-1995" TOTAL_1="19" TOTAL_2="16" WEIGHT="7.8618686056487554"/>
<CONT_DATA CI_END="3.1932044397273325" CI_START="-10.833204439727332" EFFECT_SIZE="-3.8200000000000003" ESTIMABLE="YES" MEAN_1="10.87" MEAN_2="14.69" ORDER="150511" SD_1="16.94" SD_2="18.7" SE="3.578231281312613" STUDY_ID="STD-Dougados-1993" TOTAL_1="52" TOTAL_2="48" WEIGHT="12.97062654752555"/>
<CONT_DATA CI_END="-9.455872583719946" CI_START="-17.744127416280058" EFFECT_SIZE="-13.600000000000001" ESTIMABLE="YES" MEAN_1="17.7" MEAN_2="31.3" ORDER="150512" SD_1="5.6" SD_2="7.2" SE="2.114389574996481" STUDY_ID="STD-Henderson-1994" TOTAL_1="18" TOTAL_2="19" WEIGHT="15.326713988602766"/>
<CONT_DATA CI_END="4.892916330110964" CI_START="-2.2929163301109625" EFFECT_SIZE="1.3000000000000007" ESTIMABLE="YES" MEAN_1="25.3" MEAN_2="24.0" ORDER="150513" SD_1="6.5" SD_2="6.0" SE="1.8331542612269556" STUDY_ID="STD-Henderson-1994a" TOTAL_1="22" TOTAL_2="25" WEIGHT="15.706823960668473"/>
<CONT_DATA CI_END="11.17139038197434" CI_START="-15.451390381974342" EFFECT_SIZE="-2.1400000000000006" ESTIMABLE="YES" MEAN_1="20.5" MEAN_2="22.64" ORDER="150514" SD_1="24.69" SD_2="28.35" SE="6.791650503260718" STUDY_ID="STD-St.-J.-Dixon-1988" TOTAL_1="28" TOTAL_2="33" WEIGHT="8.03274161548225"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.2953414554170926" CI_END="-5.132986846553984" CI_START="-14.175547938609313" DF="4" EFFECT_SIZE="-9.654267392581648" ESTIMABLE="YES" I2="0.0" ID="CMP-008.03.02" NO="2" P_CHI2="0.8621654568076209" P_Z="2.8503915389346485E-5" STUDIES="5" TAU2="0.0" TOTAL_1="99" TOTAL_2="56" WEIGHT="100.0" Z="4.185101144233148">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="-0.6754383022720969" CI_START="-20.524561697727897" EFFECT_SIZE="-10.599999999999998" ESTIMABLE="YES" MEAN_1="29.3" MEAN_2="39.9" ORDER="150515" SD_1="9.3" SD_2="14.6" SE="5.0636449322597645" STUDY_ID="STD-Carrabba-1995" TOTAL_1="20" TOTAL_2="10" WEIGHT="20.753924854304685"/>
<CONT_DATA CI_END="4.494455898454305" CI_START="-18.294455898454302" EFFECT_SIZE="-6.899999999999999" ESTIMABLE="YES" MEAN_1="33.0" MEAN_2="39.9" ORDER="150516" SD_1="15.8" SD_2="14.6" SE="5.813604733725883" STUDY_ID="STD-Carrabba-1995a" TOTAL_1="20" TOTAL_2="10" WEIGHT="15.74474851253918"/>
<CONT_DATA CI_END="-3.862285983423524" CI_START="-23.93771401657648" EFFECT_SIZE="-13.900000000000002" ESTIMABLE="YES" MEAN_1="29.3" MEAN_2="43.2" ORDER="150517" SD_1="9.3" SD_2="14.8" SE="5.121376768018537" STUDY_ID="STD-Carrabba-1995b" TOTAL_1="20" TOTAL_2="10" WEIGHT="20.288655860106342"/>
<CONT_DATA CI_END="1.2931459143433894" CI_START="-21.693145914343397" EFFECT_SIZE="-10.200000000000003" ESTIMABLE="YES" MEAN_1="33.0" MEAN_2="43.2" ORDER="150518" SD_1="15.8" SD_2="14.8" SE="5.8639577078966045" STUDY_ID="STD-Carrabba-1995c" TOTAL_1="20" TOTAL_2="10" WEIGHT="15.475513587704276"/>
<CONT_DATA CI_END="1.4848059343310034" CI_START="-15.684805934331003" EFFECT_SIZE="-7.1" ESTIMABLE="YES" MEAN_1="5.1" MEAN_2="12.2" ORDER="150519" SD_1="12.3" SD_2="13.4" SE="4.380083512782305" STUDY_ID="STD-Corrado-1995" TOTAL_1="19" TOTAL_2="16" WEIGHT="27.737157185345517"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.29905167544295547" CI_END="8.51239162212295" CI_START="-5.284190343979029" DF="1" EFFECT_SIZE="1.6141006390719603" ESTIMABLE="YES" I2="0.0" ID="CMP-008.03.03" NO="3" P_CHI2="0.5844776351852616" P_Z="0.6465190563458556" STUDIES="2" TAU2="0.0" TOTAL_1="61" TOTAL_2="59" WEIGHT="100.0" Z="0.4586033160643701">
<NAME>45 to 52 weeks post-injection</NAME>
<CONT_DATA CI_END="9.452023935100001" CI_START="-5.012023935100004" EFFECT_SIZE="2.219999999999999" ESTIMABLE="YES" MEAN_1="11.87" MEAN_2="9.65" ORDER="150520" SD_1="20.01" SD_2="15.64" SE="3.689875932489211" STUDY_ID="STD-Dougados-1993" TOTAL_1="47" TOTAL_2="48" WEIGHT="90.98364046238038"/>
<CONT_DATA CI_END="18.473433048721148" CI_START="-27.473433048721148" EFFECT_SIZE="-4.5" ESTIMABLE="YES" MEAN_1="20.86" MEAN_2="25.36" ORDER="150521" SD_1="30.68" SD_2="27.78" SE="11.721354693215108" STUDY_ID="STD-St.-J.-Dixon-1988" TOTAL_1="14" TOTAL_2="11" WEIGHT="9.016359537619621"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="8.843194077255136" CI_END="3.3851302662606306" CI_START="-12.485768710481917" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.550319222110643" ESTIMABLE="YES" I2="88.69186867025775" I2_Q="0.0" ID="CMP-008.04" NO="4" P_CHI2="0.0029418617806039604" P_Q="1.0" P_Z="0.2610656223234661" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="29.09536751727811" TOTALS="SUB" TOTAL_1="40" TOTAL_2="44" UNITS="" WEIGHT="100.0" Z="1.123876071111841">
<NAME>Pain at night (0-100 mm VAS)</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hyalgan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="8.843194077255136" CI_END="3.3851302662606306" CI_START="-12.485768710481917" DF="1" EFFECT_SIZE="-4.550319222110643" ESTIMABLE="YES" I2="88.69186867025775" ID="CMP-008.04.01" NO="1" P_CHI2="0.0029418617806039604" P_Z="0.2610656223234661" STUDIES="2" TAU2="29.09536751727811" TOTAL_1="40" TOTAL_2="44" WEIGHT="100.0" Z="1.123876071111841">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="-4.534420903350043" CI_START="-12.865579096649963" EFFECT_SIZE="-8.700000000000003" ESTIMABLE="YES" MEAN_1="45.5" MEAN_2="54.2" ORDER="150522" SD_1="6.7" SD_2="6.2" SE="2.125334510994853" STUDY_ID="STD-Henderson-1994" TOTAL_1="18" TOTAL_2="19" WEIGHT="48.76937311247709"/>
<CONT_DATA CI_END="2.7389746381373374" CI_START="-3.938974638137326" EFFECT_SIZE="-0.5999999999999943" ESTIMABLE="YES" MEAN_1="60.2" MEAN_2="60.8" ORDER="150523" SD_1="6.4" SD_2="5.1" SE="1.7035897927077934" STUDY_ID="STD-Henderson-1994a" TOTAL_1="22" TOTAL_2="25" WEIGHT="51.2306268875229"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.8826887063454327" CI_END="-0.7496579059762412" CI_START="-5.6828240168566655" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.2162409614164535" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.05" NO="5" P_CHI2="0.3901031106054975" P_Q="0.3901031106054974" P_Z="0.010599047499024216" Q="1.8826887063454332" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="272" TOTAL_2="270" UNITS="" WEIGHT="300.0" Z="2.555647350319489">
<NAME>WOMAC pain (0-100 mm VAS)</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hyalgan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours saline</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="4.364892547727975E-32" CI_END="1.4961176838571748" CI_START="-6.83611768385717" DF="0" EFFECT_SIZE="-2.6699999999999977" ESTIMABLE="YES" I2="100.0" ID="CMP-008.05.01" NO="1" P_CHI2="0.0" P_Z="0.20907596288616281" STUDIES="1" TAU2="0.0" TOTAL_1="96" TOTAL_2="93" WEIGHT="100.0" Z="1.256110421220004">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="1.4961176838571744" CI_START="-6.836117683857171" EFFECT_SIZE="-2.669999999999998" ESTIMABLE="YES" MEAN_1="23.21" MEAN_2="25.88" ORDER="150524" SD_1="14.14" SD_2="15.05" SE="2.1256093054357" STUDY_ID="STD-Tsai-2003" TOTAL_1="96" TOTAL_2="93" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.041911329553614E-32" CI_END="2.7735654698291166" CI_START="-5.753565469829113" DF="0" EFFECT_SIZE="-1.4899999999999982" ESTIMABLE="YES" I2="100.0" ID="CMP-008.05.02" NO="2" P_CHI2="0.0" P_Z="0.4933729364927232" STUDIES="1" TAU2="0.0" TOTAL_1="88" TOTAL_2="89" WEIGHT="100.0" Z="0.6849540267718055">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="2.7735654698291166" CI_START="-5.753565469829113" EFFECT_SIZE="-1.4899999999999984" ESTIMABLE="YES" MEAN_1="21.48" MEAN_2="22.97" ORDER="150525" SD_1="14.5" SD_2="14.44" SE="2.175328477186099" STUDY_ID="STD-Tsai-2003" TOTAL_1="88" TOTAL_2="89" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-1.2636171466327681" CI_START="-10.056382853367232" DF="0" EFFECT_SIZE="-5.66" ESTIMABLE="YES" I2="0.0" ID="CMP-008.05.03" NO="3" P_CHI2="1.0" P_Z="0.01162589236413781" STUDIES="1" TAU2="0.0" TOTAL_1="88" TOTAL_2="88" WEIGHT="100.0" Z="2.5233007502975244">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="-1.2636171466327681" CI_START="-10.056382853367232" EFFECT_SIZE="-5.66" ESTIMABLE="YES" MEAN_1="16.48" MEAN_2="22.14" ORDER="150526" SD_1="14.53" SD_2="15.22" SE="2.2430936935807693" STUDY_ID="STD-Tsai-2003" TOTAL_1="88" TOTAL_2="88" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="2.431463429620449" CI_END="3.2965720420901734" CI_START="1.5903447995106748" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="2.2896912899669233" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="20" I2="17.74501003651946" I2_Q="10.542078147011352" ID="CMP-008.06" LOG_CI_END="0.5180625710975744" LOG_CI_START="0.20149129305678393" LOG_EFFECT_SIZE="0.35977693207717915" METHOD="MH" NO="6" P_CHI2="0.2964930573964679" P_Q="0.3269843223653659" P_Z="8.392455622574347E-6" Q="2.2356879732649224" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="58" TOTAL_2="54" WEIGHT="300.0" Z="4.4549198127110285">
<NAME>Number of joints improved for walking pain</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hyalgan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Saline</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.7804664144087416" CI_START="1.0201759971828668" DF="0" EFFECT_SIZE="1.6842105263157894" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="9" I2="0.0" ID="CMP-008.06.01" LOG_CI_END="0.4441176535488487" LOG_CI_START="0.008675101185305255" LOG_EFFECT_SIZE="0.226396377367077" NO="1" P_CHI2="1.0" P_Z="0.04154406061134104" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="18" WEIGHT="99.99999999999999" Z="2.0380587219199864">
<NAME>End of treatment</NAME>
<DICH_DATA CI_END="2.7804664144087416" CI_START="1.0201759971828668" EFFECT_SIZE="1.6842105263157894" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="9" LOG_CI_END="0.4441176535488487" LOG_CI_START="0.008675101185305255" LOG_EFFECT_SIZE="0.226396377367077" ORDER="150527" O_E="0.0" SE="0.25578111073374266" STUDY_ID="STD-Bragantini-1987" TOTAL_1="19" TOTAL_2="18" VAR="0.06542397660818713" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.78059295813221" CI_START="1.4759823239496601" DF="0" EFFECT_SIZE="3.6" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="4" I2="0.0" ID="CMP-008.06.02" LOG_CI_END="0.9435238450347408" LOG_CI_START="0.16908115649983374" LOG_EFFECT_SIZE="0.5563025007672873" NO="2" P_CHI2="1.0" P_Z="0.00486578995983351" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="18" WEIGHT="100.0" Z="2.8157870999496266">
<NAME>1 week post-injection</NAME>
<DICH_DATA CI_END="8.78059295813221" CI_START="1.4759823239496601" EFFECT_SIZE="3.6" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="4" LOG_CI_END="0.9435238450347408" LOG_CI_START="0.16908115649983374" LOG_EFFECT_SIZE="0.5563025007672873" ORDER="150528" O_E="0.0" SE="0.4549114687985394" STUDY_ID="STD-Grecomoro-1987" TOTAL_1="20" TOTAL_2="18" VAR="0.20694444444444446" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.1892785532550905" CI_START="1.263572986290582" DF="0" EFFECT_SIZE="2.300751879699248" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="7" I2="0.0" ID="CMP-008.06.03" LOG_CI_END="0.6221392384036186" LOG_CI_START="0.10160033262536976" LOG_EFFECT_SIZE="0.3618697855144942" NO="3" P_CHI2="1.0" P_Z="0.006428840269590448" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="18" WEIGHT="100.0" Z="2.7250671902852392">
<NAME>5 to 13 weeks post-injection</NAME>
<DICH_DATA CI_END="4.1892785532550905" CI_START="1.263572986290582" EFFECT_SIZE="2.300751879699248" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="7" LOG_CI_END="0.6221392384036186" LOG_CI_START="0.10160033262536976" LOG_EFFECT_SIZE="0.3618697855144942" ORDER="150529" O_E="0.0" SE="0.30576712996328365" STUDY_ID="STD-Bragantini-1987" TOTAL_1="19" TOTAL_2="18" VAR="0.0934935377659836" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.6056690506832196" CI_END="5.286992311108944" CI_START="2.0989523155991954" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="3.331237721021611" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-008.07" LOG_CI_END="0.7232086788096157" LOG_CI_START="0.32200257230923374" LOG_EFFECT_SIZE="0.5226056255594247" METHOD="MH" NO="7" P_CHI2="0.738721361493647" P_Q="0.7442197067886038" P_Z="3.289714920154823E-7" Q="0.5908380467374489" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="58" TOTAL_2="54" WEIGHT="300.0" Z="5.106044936100806">
<NAME>Number of joints improved for pain under load</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Saline</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Hyalgan</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.2522953747182175" CI_START="1.3717785530999445" DF="0" EFFECT_SIZE="2.6842105263157894" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="6" I2="0.0" ID="CMP-008.07.01" LOG_CI_END="0.7203491416373772" LOG_CI_START="0.1372840086528376" LOG_EFFECT_SIZE="0.4288165751451074" NO="1" P_CHI2="1.0" P_Z="0.00394007591562858" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="18" WEIGHT="100.0" Z="2.882919919962046">
<NAME>End of treatment</NAME>
<DICH_DATA CI_END="5.252295374718217" CI_START="1.3717785530999445" EFFECT_SIZE="2.6842105263157894" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="6" LOG_CI_END="0.7203491416373771" LOG_CI_START="0.1372840086528376" LOG_EFFECT_SIZE="0.4288165751451074" ORDER="150530" O_E="0.0" SE="0.3424953453340751" STUDY_ID="STD-Bragantini-1987" TOTAL_1="19" TOTAL_2="18" VAR="0.11730306157550738" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.78059295813221" CI_START="1.4759823239496601" DF="0" EFFECT_SIZE="3.6" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="4" I2="0.0" ID="CMP-008.07.02" LOG_CI_END="0.9435238450347408" LOG_CI_START="0.16908115649983374" LOG_EFFECT_SIZE="0.5563025007672873" NO="2" P_CHI2="1.0" P_Z="0.00486578995983351" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="18" WEIGHT="100.0" Z="2.8157870999496266">
<NAME>1 week post-injection</NAME>
<DICH_DATA CI_END="8.78059295813221" CI_START="1.4759823239496601" EFFECT_SIZE="3.6" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="4" LOG_CI_END="0.9435238450347408" LOG_CI_START="0.16908115649983374" LOG_EFFECT_SIZE="0.5563025007672873" ORDER="150531" O_E="0.0" SE="0.4549114687985394" STUDY_ID="STD-Grecomoro-1987" TOTAL_1="20" TOTAL_2="18" VAR="0.20694444444444446" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.686834842135442" CI_START="1.6735310450478749" DF="0" EFFECT_SIZE="4.026315789473684" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="4" I2="0.0" ID="CMP-008.07.03" LOG_CI_END="0.986181895198713" LOG_CI_START="0.22363377320286407" LOG_EFFECT_SIZE="0.6049078342007886" NO="3" P_CHI2="1.0" P_Z="0.00187361235345602" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="18" WEIGHT="100.0" Z="3.1095678680489254">
<NAME>5 to 13 weeks post-injection</NAME>
<DICH_DATA CI_END="9.686834842135442" CI_START="1.6735310450478749" EFFECT_SIZE="4.026315789473684" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="4" LOG_CI_END="0.986181895198713" LOG_CI_START="0.22363377320286407" LOG_EFFECT_SIZE="0.6049078342007886" ORDER="150532" O_E="0.0" SE="0.4479245415344428" STUDY_ID="STD-Bragantini-1987" TOTAL_1="19" TOTAL_2="18" VAR="0.20063639490884075" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.7678041299647945" CI_END="3.333165003916292" CI_START="0.7408537387740004" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5714285714285714" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-008.08" LOG_CI_END="0.522856813365476" LOG_CI_START="-0.13026752307753964" LOG_EFFECT_SIZE="0.1962946451439682" METHOD="MH" NO="8" P_CHI2="0.3808972593625416" P_Q="0.39139443402263185" P_Z="0.23874755383531743" Q="0.7346055681380594" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="24" TOTAL_2="24" WEIGHT="200.0" Z="1.178123102671478">
<NAME>Number of knee joints without rest pain</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Hyalgan</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.883036552964965" CI_START="0.499473375916472" DF="0" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" I2="0.0" ID="CMP-008.08.01" LOG_CI_END="0.4598501486838533" LOG_CI_START="-0.30148765658860377" LOG_EFFECT_SIZE="0.07918124604762482" NO="1" P_CHI2="1.0" P_Z="0.6835061309928882" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0" Z="0.4076833947548711">
<NAME>1 to 4 weeks post-injection</NAME>
<DICH_DATA CI_END="2.883036552964966" CI_START="0.4994733759164719" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.45985014868385343" LOG_CI_START="-0.3014876565886039" LOG_EFFECT_SIZE="0.07918124604762482" ORDER="150533" O_E="0.0" SE="0.44721359549995804" STUDY_ID="STD-Creamer-1994" TOTAL_1="12" TOTAL_2="12" VAR="0.20000000000000007" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="10.460916212812283" CI_START="0.5974620074238954" DF="0" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" I2="0.0" ID="CMP-008.08.02" LOG_CI_END="1.0195697236080177" LOG_CI_START="-0.22368970626394244" LOG_EFFECT_SIZE="0.3979400086720376" NO="2" P_CHI2="1.0" P_Z="0.20959397195137563" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0" Z="1.2546827577009818">
<NAME>5 to 13 weeks post-injection</NAME>
<DICH_DATA CI_END="10.460916212812283" CI_START="0.5974620074238954" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.0195697236080177" LOG_CI_START="-0.22368970626394244" LOG_EFFECT_SIZE="0.3979400086720376" ORDER="150534" O_E="0.0" SE="0.7302967433402214" STUDY_ID="STD-Creamer-1994" TOTAL_1="12" TOTAL_2="12" VAR="0.5333333333333332" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.504792883397317" CI_START="0.7824998278267223" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-008.09" LOG_CI_END="0.3987718206957058" LOG_CI_START="-0.10651574933922975" LOG_EFFECT_SIZE="0.146128035678238" METHOD="MH" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.25694795352408006" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="24" TOTAL_2="24" WEIGHT="200.0" Z="1.1336344056163048">
<NAME>Number of knee joints without night pain</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Hyalgan</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.187280626209864" CI_START="0.6149442831868628" DF="0" EFFECT_SIZE="1.4" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" I2="0.0" ID="CMP-008.09.01" LOG_CI_END="0.5034203028992136" LOG_CI_START="-0.21116423154273753" LOG_EFFECT_SIZE="0.146128035678238" NO="1" P_CHI2="1.0" P_Z="0.42278405181899825" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0" Z="0.8016005755976703">
<NAME>1 to 4 weeks post-injection</NAME>
<DICH_DATA CI_END="3.187280626209864" CI_START="0.6149442831868628" EFFECT_SIZE="1.4" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.5034203028992136" LOG_CI_START="-0.21116423154273753" LOG_EFFECT_SIZE="0.146128035678238" ORDER="150535" O_E="0.0" SE="0.4197504927816955" STUDY_ID="STD-Creamer-1994" TOTAL_1="12" TOTAL_2="12" VAR="0.17619047619047623" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.187280626209864" CI_START="0.6149442831868628" DF="0" EFFECT_SIZE="1.4" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" I2="0.0" ID="CMP-008.09.02" LOG_CI_END="0.5034203028992136" LOG_CI_START="-0.21116423154273753" LOG_EFFECT_SIZE="0.146128035678238" NO="2" P_CHI2="1.0" P_Z="0.42278405181899825" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0" Z="0.8016005755976703">
<NAME>5 to 13 weeks post-injection</NAME>
<DICH_DATA CI_END="3.187280626209864" CI_START="0.6149442831868628" EFFECT_SIZE="1.4" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.5034203028992136" LOG_CI_START="-0.21116423154273753" LOG_EFFECT_SIZE="0.146128035678238" ORDER="150536" O_E="0.0" SE="0.4197504927816955" STUDY_ID="STD-Creamer-1994" TOTAL_1="12" TOTAL_2="12" VAR="0.17619047619047623" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="15" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-008.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="20" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>Number of joints with improvement in pain on touch</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Hyalgan</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.533704102511529" CI_START="1.1166366144617896" EFFECT_SIZE="2.25" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="6" LOG_CI_END="0.6564531719793101" LOG_CI_START="0.047911864243414946" LOG_EFFECT_SIZE="0.3521825181113625" ORDER="150537" O_E="0.0" SE="0.3574601764921203" STUDY_ID="STD-Grecomoro-1987" TOTAL_1="20" TOTAL_2="18" VAR="0.1277777777777778" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.75626414384982E-31" CI_END="1.0352576800125077" CI_START="0.5345912965533425" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7439353099730459" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="53" I2="100.0" I2_Q="0.0" ID="CMP-008.11" LOG_CI_END="0.01504846098043482" LOG_CI_START="-0.2719781160800911" LOG_EFFECT_SIZE="-0.12846482754982813" METHOD="MH" NO="11" P_CHI2="0.0" P_Q="1.0" P_Z="0.07935397162577643" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="105" TOTAL_2="115" WEIGHT="100.0" Z="1.7544468380342164">
<NAME>Number of patients with moderate/marked pain</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hyalgan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="9.75626414384982E-31" CI_END="1.0352576800125077" CI_START="0.5345912965533425" DF="0" EFFECT_SIZE="0.7439353099730459" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="53" I2="100.0" ID="CMP-008.11.01" LOG_CI_END="0.01504846098043482" LOG_CI_START="-0.2719781160800911" LOG_EFFECT_SIZE="-0.12846482754982813" NO="1" P_CHI2="0.0" P_Z="0.07935397162577643" STUDIES="1" TAU2="0.0" TOTAL_1="105" TOTAL_2="115" WEIGHT="100.0" Z="1.7544468380342164">
<NAME>14 to 26 weeks post-injection</NAME>
<DICH_DATA CI_END="1.0352576800125075" CI_START="0.5345912965533425" EFFECT_SIZE="0.7439353099730458" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="53" LOG_CI_END="0.015048460980434726" LOG_CI_START="-0.2719781160800911" LOG_EFFECT_SIZE="-0.1284648275498282" ORDER="150538" O_E="0.0" SE="0.1686008321698238" STUDY_ID="STD-Altman-1998" TOTAL_1="105" TOTAL_2="115" VAR="0.028426240608357092" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.5492766124615418" CI_END="1.5166278633230346" CI_START="1.06787761861086" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2726244343891402" ESTIMABLE="YES" EVENTS_1="180" EVENTS_2="136" I2="0.0" I2_Q="0.0" ID="CMP-008.12" LOG_CI_END="0.18087903053507665" LOG_CI_START="0.02852148433353972" LOG_EFFECT_SIZE="0.10470025743430818" METHOD="MH" NO="12" P_CHI2="0.45861351536330175" P_Q="0.4586586140370349" P_Z="0.0070647117132176165" Q="0.5491663594299134" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="416" TOTAL_2="400" WEIGHT="200.0" Z="2.6937784029662453">
<NAME>Pain (number of patients improved)</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Hyalgan</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5228031693720905" CI_START="0.9326918808941664" DF="0" EFFECT_SIZE="1.191765980498375" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="71" I2="0.0" ID="CMP-008.12.01" LOG_CI_END="0.18264377202949642" LOG_CI_START="-0.030261803764870396" LOG_EFFECT_SIZE="0.076190984132313" NO="1" P_CHI2="1.0" P_Z="0.16067756864462535" STUDIES="1" TAU2="0.0" TOTAL_1="208" TOTAL_2="200" WEIGHT="100.0" Z="1.402796373827494">
<NAME>5 to 13 weeks post-injection</NAME>
<DICH_DATA CI_END="1.5228031693720903" CI_START="0.9326918808941664" EFFECT_SIZE="1.191765980498375" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="71" LOG_CI_END="0.18264377202949636" LOG_CI_START="-0.030261803764870396" LOG_EFFECT_SIZE="0.076190984132313" ORDER="150539" O_E="0.0" SE="0.1250617891212083" STUDY_ID="STD-Jubb-2003" TOTAL_1="208" TOTAL_2="200" VAR="0.015640451098197575" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7498567823555562" CI_START="1.0584729350037785" DF="0" EFFECT_SIZE="1.3609467455621302" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="65" I2="0.0" ID="CMP-008.12.02" LOG_CI_END="0.2430025051560326" LOG_CI_START="0.02467975765180608" LOG_EFFECT_SIZE="0.13384113140391937" NO="2" P_CHI2="1.0" P_Z="0.01625751504271144" STUDIES="1" TAU2="0.0" TOTAL_1="208" TOTAL_2="200" WEIGHT="100.0" Z="2.403082594008637">
<NAME>32 weeks post-injection</NAME>
<DICH_DATA CI_END="1.7498567823555562" CI_START="1.0584729350037783" EFFECT_SIZE="1.3609467455621302" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="65" LOG_CI_END="0.2430025051560326" LOG_CI_START="0.024679757651805988" LOG_EFFECT_SIZE="0.13384113140391937" ORDER="150540" O_E="0.0" SE="0.12824386259901244" STUDY_ID="STD-Jubb-2003" TOTAL_1="208" TOTAL_2="200" VAR="0.01644648829431438" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="1.1399272935440874" CI_END="0.3559452696693888" CI_START="-4.59465312393988" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.1193539271352457" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.13" NO="13" P_CHI2="0.5655461644516749" P_Q="0.5655461644516749" P_Z="0.09332302224524074" Q="1.1399272935440874" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="272" TOTAL_2="270" UNITS="" WEIGHT="300.0" Z="1.6781233448630475">
<NAME>WOMAC function (0-100 mm VAS)</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hyalgan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours saline</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.0634502642080915E-32" CI_END="2.9201678511678333" CI_START="-5.520167851167835" DF="0" EFFECT_SIZE="-1.300000000000001" ESTIMABLE="YES" I2="100.0" ID="CMP-008.13.01" NO="1" P_CHI2="0.0" P_Z="0.5460056405498513" STUDIES="1" TAU2="0.0" TOTAL_1="96" TOTAL_2="93" WEIGHT="100.0" Z="0.603756359879616">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="2.9201678511678333" CI_START="-5.520167851167835" EFFECT_SIZE="-1.3000000000000007" ESTIMABLE="YES" MEAN_1="26.91" MEAN_2="28.21" ORDER="150541" SD_1="14.89" SD_2="14.71" SE="2.153186428146629" STUDY_ID="STD-Tsai-2003" TOTAL_1="96" TOTAL_2="93" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.253613590551006" CI_START="-5.373613590551003" DF="0" EFFECT_SIZE="-1.0599999999999987" ESTIMABLE="YES" I2="0.0" ID="CMP-008.13.02" NO="2" P_CHI2="1.0" P_Z="0.6300694532055646" STUDIES="1" TAU2="0.0" TOTAL_1="88" TOTAL_2="89" WEIGHT="100.0" Z="0.48162909820280747">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="3.253613590551006" CI_START="-5.373613590551003" EFFECT_SIZE="-1.0599999999999987" ESTIMABLE="YES" MEAN_1="24.25" MEAN_2="25.31" ORDER="150542" SD_1="14.65" SD_2="14.63" SE="2.200863701872197" STUDY_ID="STD-Tsai-2003" TOTAL_1="88" TOTAL_2="89" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.28075290027218447" CI_START="-8.380752900272178" DF="0" EFFECT_SIZE="-4.049999999999997" ESTIMABLE="YES" I2="0.0" ID="CMP-008.13.03" NO="3" P_CHI2="1.0" P_Z="0.06681685487018822" STUDIES="1" TAU2="0.0" TOTAL_1="88" TOTAL_2="88" WEIGHT="100.0" Z="1.8329039592372798">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="0.28075290027218447" CI_START="-8.380752900272178" EFFECT_SIZE="-4.049999999999997" ESTIMABLE="YES" MEAN_1="20.85" MEAN_2="24.9" ORDER="150543" SD_1="14.42" SD_2="14.89" SE="2.209608408334341" STUDY_ID="STD-Tsai-2003" TOTAL_1="88" TOTAL_2="88" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="7.078612029971181" CI_END="-1.1038475469652815" CI_START="-2.2829882892341438" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.6934179180997126" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.14" NO="14" P_CHI2="0.8523751212234929" P_Q="0.5344360810276214" P_Z="1.806408687760528E-8" Q="2.1873921027355023" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="376" TOTAL_2="300" UNITS="" WEIGHT="400.0" Z="5.629587734987184">
<NAME>Lequesne Index (0-24)</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hyalgan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="4.623443315133507" CI_END="-0.6459552599959367" CI_START="-2.3605848368394935" DF="5" EFFECT_SIZE="-1.503270048417715" ESTIMABLE="YES" I2="0.0" ID="CMP-008.14.01" NO="1" P_CHI2="0.4635389718072521" P_Z="5.887931161155595E-4" STUDIES="6" TAU2="0.0" TOTAL_1="169" TOTAL_2="131" WEIGHT="100.0" Z="3.4367249856501587">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="0.5838242421787347" CI_START="-4.3838242421787355" EFFECT_SIZE="-1.9000000000000004" ESTIMABLE="YES" MEAN_1="11.5" MEAN_2="13.4" ORDER="150544" SD_1="3.0" SD_2="3.4" SE="1.267280552995271" STUDY_ID="STD-Carrabba-1995" TOTAL_1="20" TOTAL_2="10" WEIGHT="11.913487335874748"/>
<CONT_DATA CI_END="0.858985701256691" CI_START="-4.458985701256692" EFFECT_SIZE="-1.8000000000000007" ESTIMABLE="YES" MEAN_1="11.6" MEAN_2="13.4" ORDER="150545" SD_1="3.7" SD_2="3.4" SE="1.3566502865514016" STUDY_ID="STD-Carrabba-1995a" TOTAL_1="20" TOTAL_2="10" WEIGHT="10.395577648147158"/>
<CONT_DATA CI_END="-0.06337950716654062" CI_START="-5.136620492833458" EFFECT_SIZE="-2.5999999999999996" ESTIMABLE="YES" MEAN_1="11.5" MEAN_2="14.1" ORDER="150546" SD_1="3.0" SD_2="3.5" SE="1.2942179105544784" STUDY_ID="STD-Carrabba-1995b" TOTAL_1="20" TOTAL_2="10" WEIGHT="11.422722782934235"/>
<CONT_DATA CI_END="0.20836954976890754" CI_START="-5.208369549768907" EFFECT_SIZE="-2.5" ESTIMABLE="YES" MEAN_1="11.6" MEAN_2="14.1" ORDER="150547" SD_1="3.7" SD_2="3.5" SE="1.3818465906170627" STUDY_ID="STD-Carrabba-1995c" TOTAL_1="20" TOTAL_2="10" WEIGHT="10.019932265731786"/>
<CONT_DATA CI_END="1.2088360170363823" CI_START="-1.7088360170363823" EFFECT_SIZE="-0.25" ESTIMABLE="YES" MEAN_1="8.53" MEAN_2="8.78" ORDER="150548" SD_1="3.81" SD_2="3.59" SE="0.7443177673383259" STUDY_ID="STD-Dougados-1993" TOTAL_1="49" TOTAL_2="50" WEIGHT="34.5356533483077"/>
<CONT_DATA CI_END="-0.2601427299999195" CI_START="-3.93985727000008" EFFECT_SIZE="-2.0999999999999996" ESTIMABLE="YES" MEAN_1="10.0" MEAN_2="12.1" ORDER="150549" SD_1="4.6" SD_2="3.8" SE="0.9387199379746972" STUDY_ID="STD-Huskisson-1999" TOTAL_1="40" TOTAL_2="41" WEIGHT="21.712626619004368"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.26777661210217113" CI_END="-1.2682904431159174" CI_START="-3.4111774269648665" DF="4" EFFECT_SIZE="-2.339733935040392" ESTIMABLE="YES" I2="0.0" ID="CMP-008.14.02" NO="2" P_CHI2="0.9917982256495231" P_Z="1.8688069483116602E-5" STUDIES="5" TAU2="0.0" TOTAL_1="120" TOTAL_2="81" WEIGHT="100.0" Z="4.28001502706276">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="0.15034694211756783" CI_START="-4.750346942117569" EFFECT_SIZE="-2.3000000000000007" ESTIMABLE="YES" MEAN_1="11.6" MEAN_2="13.9" ORDER="150550" SD_1="2.6" SD_2="3.5" SE="1.2501999840025595" STUDY_ID="STD-Carrabba-1995" TOTAL_1="20" TOTAL_2="10" WEIGHT="19.11980164288255"/>
<CONT_DATA CI_END="0.9735371469814029" CI_START="-4.773537146981404" EFFECT_SIZE="-1.9000000000000004" ESTIMABLE="YES" MEAN_1="12.0" MEAN_2="13.9" ORDER="150551" SD_1="4.3" SD_2="3.5" SE="1.4661173213627892" STUDY_ID="STD-Carrabba-1995a" TOTAL_1="20" TOTAL_2="10" WEIGHT="13.90288437675061"/>
<CONT_DATA CI_END="-0.5126288202861788" CI_START="-5.087371179713823" EFFECT_SIZE="-2.8000000000000007" ESTIMABLE="YES" MEAN_1="11.6" MEAN_2="14.4" ORDER="150552" SD_1="2.6" SD_2="3.2" SE="1.1670475568716128" STUDY_ID="STD-Carrabba-1995b" TOTAL_1="20" TOTAL_2="10" WEIGHT="21.94144637872645"/>
<CONT_DATA CI_END="0.335887883690138" CI_START="-5.135887883690138" EFFECT_SIZE="-2.4000000000000004" ESTIMABLE="YES" MEAN_1="12.0" MEAN_2="14.4" ORDER="150553" SD_1="4.3" SD_2="3.2" SE="1.395886814895821" STUDY_ID="STD-Carrabba-1995c" TOTAL_1="20" TOTAL_2="10" WEIGHT="15.337054127701018"/>
<CONT_DATA CI_END="-0.2339266252771579" CI_START="-4.166073374722844" EFFECT_SIZE="-2.200000000000001" ESTIMABLE="YES" MEAN_1="10.2" MEAN_2="12.4" ORDER="150554" SD_1="4.8" SD_2="4.2" SE="1.0031170930848623" STUDY_ID="STD-Huskisson-1999" TOTAL_1="40" TOTAL_2="41" WEIGHT="29.69881347393937"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.60448959543593" CI_START="-3.4044895954359307" DF="0" EFFECT_SIZE="-1.4000000000000004" ESTIMABLE="YES" I2="0.0" ID="CMP-008.14.03" NO="3" P_CHI2="1.0" P_Z="0.171029947606003" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="41" WEIGHT="100.0" Z="1.3689018813586462">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="0.60448959543593" CI_START="-3.4044895954359307" EFFECT_SIZE="-1.4000000000000004" ESTIMABLE="YES" MEAN_1="11.2" MEAN_2="12.6" ORDER="150555" SD_1="4.4" SD_2="4.8" SE="1.022717565856867" STUDY_ID="STD-Huskisson-1999" TOTAL_1="40" TOTAL_2="41" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.4783171579010752" CI_START="-2.6983171579010756" DF="0" EFFECT_SIZE="-1.1100000000000003" ESTIMABLE="YES" I2="0.0" ID="CMP-008.14.04" NO="4" P_CHI2="1.0" P_Z="0.17077230872078072" STUDIES="1" TAU2="0.0" TOTAL_1="47" TOTAL_2="47" WEIGHT="100.0" Z="1.3697264504240534">
<NAME>45 to 52 weeks post-injection</NAME>
<CONT_DATA CI_END="0.4783171579010752" CI_START="-2.6983171579010756" EFFECT_SIZE="-1.1100000000000003" ESTIMABLE="YES" MEAN_1="7.06" MEAN_2="8.17" ORDER="150556" SD_1="4.09" SD_2="3.76" SE="0.8103807878254491" STUDY_ID="STD-Dougados-1993" TOTAL_1="47" TOTAL_2="47" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.5925960285174877" CI_END="10.88928232980313" CI_START="0.47158544051696616" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="5.680433885160048" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.15" NO="15" P_CHI2="0.4414171551119075" P_Q="0.4414171551119075" P_Z="0.0325646419675748" Q="0.5925960285174877" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="38" TOTAL_2="32" UNITS="" WEIGHT="200.0" Z="2.1374102068422745">
<NAME>Flexion (degrees)</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Hyalgan</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="11.112584255088336" CI_START="-4.112584255088335" DF="0" EFFECT_SIZE="3.5" ESTIMABLE="YES" I2="0.0" ID="CMP-008.15.01" NO="1" P_CHI2="1.0" P_Z="0.3675229922957506" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="16" WEIGHT="100.0" Z="0.901122892834319">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="11.112584255088334" CI_START="-4.1125842550883345" EFFECT_SIZE="3.5" ESTIMABLE="YES" MEAN_1="123.5" MEAN_2="120.0" ORDER="150557" SD_1="10.2" SD_2="12.4" SE="3.8840429289188103" STUDY_ID="STD-Corrado-1995" TOTAL_1="19" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="14.742696362339213" CI_START="0.4573036376607762" DF="0" EFFECT_SIZE="7.599999999999994" ESTIMABLE="YES" I2="0.0" ID="CMP-008.15.02" NO="2" P_CHI2="1.0" P_Z="0.03702859728328396" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="16" WEIGHT="100.0" Z="2.085448621481942">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="14.742696362339213" CI_START="0.4573036376607762" EFFECT_SIZE="7.599999999999994" ESTIMABLE="YES" MEAN_1="125.5" MEAN_2="117.9" ORDER="150558" SD_1="9.9" SD_2="11.4" SE="3.6442998027922426" STUDY_ID="STD-Corrado-1995" TOTAL_1="19" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.674434404171457" CI_END="0.6501199103016213" CI_START="-3.7140139939777277" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.5319470418380532" ESTIMABLE="YES" I2="14.42814992910357" I2_Q="0.0" ID="CMP-008.16" NO="16" P_CHI2="0.3223622629351176" P_Q="0.35613457658202086" P_Z="0.1688163975532072" Q="0.8514782096358571" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="115" TOTAL_2="108" UNITS="" WEIGHT="200.0" Z="1.3760169115255751">
<NAME>Synovial fluid volume (ml)</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hyalgan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.5539201878521991" CI_END="1.9783032323522312" CI_START="-3.490521165074539" DF="2" EFFECT_SIZE="-0.756108966361154" ESTIMABLE="YES" I2="0.0" ID="CMP-008.16.01" NO="1" P_CHI2="0.7580847681665828" P_Z="0.5878449789856549" STUDIES="3" TAU2="0.0" TOTAL_1="82" TOTAL_2="77" WEIGHT="100.0" Z="0.541961575198123">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="14.397594879493777" CI_START="-8.997594879493779" EFFECT_SIZE="2.6999999999999993" ESTIMABLE="YES" MEAN_1="14.1" MEAN_2="11.4" ORDER="150559" SD_1="24.1" SD_2="12.3" SE="5.9682703211706505" STUDY_ID="STD-Corrado-1995" TOTAL_1="21" TOTAL_2="19" WEIGHT="5.464303496638133"/>
<CONT_DATA CI_END="3.0601167723587537" CI_START="-4.000116772358753" EFFECT_SIZE="-0.46999999999999975" ESTIMABLE="YES" MEAN_1="6.05" MEAN_2="6.52" ORDER="150560" SD_1="4.16" SD_2="4.65" SE="1.8011130817728611" STUDY_ID="STD-Creamer-1994" TOTAL_1="12" TOTAL_2="12" WEIGHT="59.99980272858121"/>
<CONT_DATA CI_END="2.8529526488500565" CI_START="-6.452952648850058" EFFECT_SIZE="-1.8000000000000007" ESTIMABLE="YES" MEAN_1="6.1" MEAN_2="7.9" ORDER="150561" SD_1="11.08" SD_2="12.0" SE="2.3739990558765127" STUDY_ID="STD-Dougados-1993" TOTAL_1="49" TOTAL_2="46" WEIGHT="34.535893774780654"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.2690360066834017" CI_END="0.7284880052658202" CI_START="-6.513030403558259" DF="1" EFFECT_SIZE="-2.8922711991462196" ESTIMABLE="YES" I2="69.40994232074705" ID="CMP-008.16.02" NO="2" P_CHI2="0.07059915781939374" P_Z="0.1174366760482463" STUDIES="2" TAU2="0.0" TOTAL_1="33" TOTAL_2="31" WEIGHT="100.0" Z="1.5656239655322757">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="-1.3933431133583811" CI_START="-14.806656886641623" EFFECT_SIZE="-8.100000000000001" ESTIMABLE="YES" MEAN_1="2.3" MEAN_2="10.4" ORDER="150562" SD_1="6.2" SD_2="13.7" SE="3.4218265945409576" STUDY_ID="STD-Corrado-1995" TOTAL_1="21" TOTAL_2="19" WEIGHT="29.14654692715944"/>
<CONT_DATA CI_END="3.5514921341400836" CI_START="-5.051492134140084" EFFECT_SIZE="-0.75" ESTIMABLE="YES" MEAN_1="5.67" MEAN_2="6.42" ORDER="150563" SD_1="4.15" SD_2="6.37" SE="2.194679171693819" STUDY_ID="STD-Creamer-1994" TOTAL_1="12" TOTAL_2="12" WEIGHT="70.85345307284055"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.7695796219173098" CI_START="0.03042037808268916" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.39999999999999947" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.17" NO="17" P_CHI2="1.0" P_Q="1.0" P_Z="0.03389739682695658" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="136" TOTAL_2="137" UNITS="" WEIGHT="100.0" Z="2.1212901018428703">
<NAME>Joint space width (mm)</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Hyalgan</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.7695796219173098" CI_START="0.03042037808268916" DF="0" EFFECT_SIZE="0.39999999999999947" ESTIMABLE="YES" I2="0.0" ID="CMP-008.17.01" NO="1" P_CHI2="1.0" P_Z="0.03389739682695658" STUDIES="1" TAU2="0.0" TOTAL_1="136" TOTAL_2="137" WEIGHT="100.0" Z="2.1212901018428703">
<NAME>45 to 52 weeks post-injection (after three courses of treatment)</NAME>
<CONT_DATA CI_END="0.7695796219173098" CI_START="0.03042037808268916" EFFECT_SIZE="0.39999999999999947" ESTIMABLE="YES" MEAN_1="4.8" MEAN_2="4.4" ORDER="150564" SD_1="1.7" SD_2="1.4" SE="0.18856449650733748" STUDY_ID="STD-Jubb-2001a" TOTAL_1="136" TOTAL_2="137" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="15.095315517712288" CI_END="1.5616945619339315" CI_START="1.169350375374079" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3513578808802282" ESTIMABLE="YES" EVENTS_1="203" EVENTS_2="150" I2="47.00342639004071" I2_Q="51.97414974633341" ID="CMP-008.18" LOG_CI_END="0.19359609801904115" LOG_CI_START="0.0679446594016408" LOG_EFFECT_SIZE="0.13077037871034103" METHOD="MH" NO="18" P_CHI2="0.057318426259676314" P_Q="0.1002084454416361" P_Z="4.510884951640066E-5" Q="6.246635893283246" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="317" TOTAL_2="315" WEIGHT="400.0" Z="4.079622729945226">
<NAME>Patient global assessment (number of patients improved)</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Hyalgan</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.489671999421501" CI_END="2.1484843622219665" CI_START="0.9747157580130543" DF="2" EFFECT_SIZE="1.4471218206157965" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="21" I2="55.45331596032623" ID="CMP-008.18.01" LOG_CI_END="0.3321321970120445" LOG_CI_START="-0.011122012736221362" LOG_EFFECT_SIZE="0.16050509213791156" NO="1" P_CHI2="0.1059450316671986" P_Z="0.06680974880826546" STUDIES="3" TAU2="0.0" TOTAL_1="51" TOTAL_2="48" WEIGHT="100.0" Z="1.8329517365936923">
<NAME>1 to 4 weeks post-injection (number of patients improved (much better/better or excellent/good))</NAME>
<DICH_DATA CI_END="6.744963285949765" CI_START="1.1105034070006143" EFFECT_SIZE="2.736842105263158" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="4" LOG_CI_END="0.8289795900712559" LOG_CI_START="0.04551989529268447" LOG_EFFECT_SIZE="0.4372497426819702" ORDER="150565" O_E="0.0" SE="0.4602081029009686" STUDY_ID="STD-Corrado-1995" TOTAL_1="19" TOTAL_2="16" VAR="0.2117914979757085" WEIGHT="20.34805890227577"/>
<DICH_DATA CI_END="1.6322215169727634" CI_START="0.4690692972973324" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.21277909870122907" LOG_CI_START="-0.3287629926566026" LOG_EFFECT_SIZE="-0.057991946977686754" ORDER="150566" O_E="0.0" SE="0.3181045051401759" STUDY_ID="STD-Creamer-1994" TOTAL_1="12" TOTAL_2="12" VAR="0.1011904761904762" WEIGHT="37.483266398929054"/>
<DICH_DATA CI_END="2.4351651446763345" CI_START="0.7300440307567179" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="9" LOG_CI_END="0.3865284189344891" LOG_CI_START="-0.1366509457178893" LOG_EFFECT_SIZE="0.12493873660829993" ORDER="150567" O_E="0.0" SE="0.30731814857642953" STUDY_ID="STD-Formiguera-Sala-1995" TOTAL_1="20" TOTAL_2="20" VAR="0.09444444444444443" WEIGHT="42.168674698795186"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.6773166646414739" CI_END="4.161383018076905" CI_START="1.434579975447751" DF="1" EFFECT_SIZE="2.4433249370277084" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="11" I2="0.0" ID="CMP-008.18.02" LOG_CI_END="0.6192376905542687" LOG_CI_START="0.15672476445199102" LOG_EFFECT_SIZE="0.3879812275031299" NO="2" P_CHI2="0.4105126052517831" P_Z="0.0010081201510219683" STUDIES="2" TAU2="0.0" TOTAL_1="39" TOTAL_2="36" WEIGHT="100.00000000000001" Z="3.288250726275349">
<NAME>5 to 13 weeks post-injection (number of patients improved (excellent/very good/good/better/somewhat better)</NAME>
<DICH_DATA CI_END="7.61245362454534" CI_START="1.3099980191433578" EFFECT_SIZE="3.1578947368421053" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="4" LOG_CI_END="0.8815246599049182" LOG_CI_START="0.11727063895671115" LOG_EFFECT_SIZE="0.49939764943081466" ORDER="150568" O_E="0.0" SE="0.4489265950233938" STUDY_ID="STD-Corrado-1995" TOTAL_1="19" TOTAL_2="16" VAR="0.20153508771929823" WEIGHT="38.28715365239295"/>
<DICH_DATA CI_END="3.8796150733699806" CI_START="1.0310301213788842" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="7" LOG_CI_END="0.5887886380157871" LOG_CI_START="0.013271353312175308" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="150569" O_E="0.0" SE="0.3380617018914066" STUDY_ID="STD-Formiguera-Sala-1995" TOTAL_1="20" TOTAL_2="20" VAR="0.11428571428571425" WEIGHT="61.71284634760706"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.353896072451546" CI_END="1.499558124535914" CI_START="1.0320228349899294" DF="2" EFFECT_SIZE="1.2440169721172358" ESTIMABLE="YES" EVENTS_1="111" EVENTS_2="91" I2="54.06413091358285" ID="CMP-008.18.03" LOG_CI_END="0.1759633041575518" LOG_CI_START="0.01368930678770872" LOG_EFFECT_SIZE="0.09482630547263024" NO="3" P_CHI2="0.1133871378359751" P_Z="0.021983894711575087" STUDIES="3" TAU2="0.0" TOTAL_1="180" TOTAL_2="183" WEIGHT="100.0" Z="2.2906460249421094">
<NAME>14 to 26 weeks post-injection (number of patients improved (better/somewhat/much; excellent/fair)</NAME>
<DICH_DATA CI_END="1.3362501588761244" CI_START="0.6570913409788766" EFFECT_SIZE="0.937037037037037" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="27" LOG_CI_END="0.12588776985314504" LOG_CI_START="-0.18237425581948385" LOG_EFFECT_SIZE="-0.02824324298316941" ORDER="150570" O_E="0.0" SE="0.181074639801739" STUDY_ID="STD-Henderson-1994" TOTAL_1="40" TOTAL_2="44" VAR="0.03278802517932952" WEIGHT="28.592312629251943"/>
<DICH_DATA CI_END="2.3543964764511975" CI_START="1.1125087595905605" EFFECT_SIZE="1.618421052631579" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="19" LOG_CI_END="0.37187959913447555" LOG_CI_START="0.04630343918273759" LOG_EFFECT_SIZE="0.20909151915860658" ORDER="150571" O_E="0.0" SE="0.19124504798363465" STUDY_ID="STD-Huskisson-1999" TOTAL_1="40" TOTAL_2="41" VAR="0.03657466837826272" WEIGHT="20.86572060186836"/>
<DICH_DATA CI_END="1.65794521458088" CI_START="0.96230542781576" EFFECT_SIZE="1.263111111111111" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="45" LOG_CI_END="0.21957017555181912" LOG_CI_START="-0.016687064591642185" LOG_EFFECT_SIZE="0.10144155548008844" ORDER="150572" O_E="0.0" SE="0.13877867235246916" STUDY_ID="STD-Lin-2004" TOTAL_1="100" TOTAL_2="98" VAR="0.019259519899913986" WEIGHT="50.541966768879696"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6198947395390217" CI_START="0.8487813397611551" DF="0" EFFECT_SIZE="1.1725768321513002" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="27" I2="0.0" ID="CMP-008.18.04" LOG_CI_END="0.2094867950842494" LOG_CI_START="-0.07120417685393922" LOG_EFFECT_SIZE="0.06914130911515509" NO="4" P_CHI2="1.0" P_Z="0.33425553576897127" STUDIES="1" TAU2="0.0" TOTAL_1="47" TOTAL_2="48" WEIGHT="100.0" Z="0.9655777296570608">
<NAME>45 to 52 weeks post-injection (number of patients rating treatment effective)</NAME>
<DICH_DATA CI_END="1.6198947395390217" CI_START="0.8487813397611551" EFFECT_SIZE="1.1725768321513002" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="27" LOG_CI_END="0.2094867950842494" LOG_CI_START="-0.07120417685393922" LOG_EFFECT_SIZE="0.06914130911515509" ORDER="150573" O_E="0.0" SE="0.1648792663592117" STUDY_ID="STD-Dougados-1993" TOTAL_1="47" TOTAL_2="48" VAR="0.02718517247515188" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.4596900166183944" CI_END="3.696478509446245" CI_START="1.2154938541871214" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="2.11968085106383" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="10" I2="31.4923039402119" I2_Q="0.0" ID="CMP-008.19" LOG_CI_END="0.5677881856434944" LOG_CI_START="0.08475276729340823" LOG_EFFECT_SIZE="0.3262704764684513" METHOD="MH" NO="19" P_CHI2="0.22697974960990097" P_Q="1.0" P_Z="0.008102955300874274" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="31" TOTAL_2="30" WEIGHT="100.0" Z="2.6477494560592145">
<NAME>Patient global assessment (number of joints fairly good/good/very good)</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Hyalgan</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.4596900166183944" CI_END="3.696478509446245" CI_START="1.2154938541871214" DF="1" EFFECT_SIZE="2.11968085106383" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="10" I2="31.4923039402119" ID="CMP-008.19.01" LOG_CI_END="0.5677881856434944" LOG_CI_START="0.08475276729340823" LOG_EFFECT_SIZE="0.3262704764684513" NO="1" P_CHI2="0.22697974960990097" P_Z="0.008102955300874274" STUDIES="2" TAU2="0.0" TOTAL_1="31" TOTAL_2="30" WEIGHT="100.0" Z="2.6477494560592145">
<NAME>5 to 13 weeks post-injection</NAME>
<DICH_DATA CI_END="5.252295374718217" CI_START="1.3717785530999445" EFFECT_SIZE="2.6842105263157894" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="6" LOG_CI_END="0.7203491416373771" LOG_CI_START="0.1372840086528376" LOG_EFFECT_SIZE="0.4288165751451074" ORDER="150574" O_E="0.0" SE="0.3424953453340751" STUDY_ID="STD-Bragantini-1987" TOTAL_1="19" TOTAL_2="18" VAR="0.11730306157550738" WEIGHT="60.63829787234043"/>
<DICH_DATA CI_END="3.5481063888087543" CI_START="0.44037574660341444" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.5499966335328186" LOG_CI_START="-0.3561766075167057" LOG_EFFECT_SIZE="0.09691001300805642" ORDER="150575" O_E="0.0" SE="0.5322906474223771" STUDY_ID="STD-Creamer-1994" TOTAL_1="12" TOTAL_2="12" VAR="0.2833333333333334" WEIGHT="39.361702127659576"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.6313419619376025" CI_END="1.3367727557072375" CI_START="0.9110686100605369" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1035813048928413" ESTIMABLE="YES" EVENTS_1="162" EVENTS_2="147" I2="0.0" I2_Q="0.0" ID="CMP-008.20" LOG_CI_END="0.12605758577329" LOG_CI_START="-0.040448916277603005" LOG_EFFECT_SIZE="0.04280433474784349" METHOD="MH" NO="20" P_CHI2="0.9988094697760644" P_Q="0.7739085697722358" P_Z="0.31359474964033696" Q="0.5126031083399636" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="753" TOTAL_2="751" WEIGHT="300.0" Z="1.0077078486980284">
<NAME>Safety: total withdrawals overall</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hyalgan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.2303079734614215" CI_START="0.11262690892131584" DF="0" EFFECT_SIZE="0.6031746031746031" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-008.20.01" LOG_CI_END="0.5092439293895648" LOG_CI_START="-0.948357835063108" LOG_EFFECT_SIZE="-0.21955695283677157" NO="1" P_CHI2="1.0" P_Z="0.5548860217439243" STUDIES="5" TAU2="0.0" TOTAL_1="101" TOTAL_2="99" WEIGHT="100.0" Z="0.5904544445677418">
<NAME>5 to 13 weeks post-injection</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="150576" O_E="0.0" SE="0.0" STUDY_ID="STD-Carrabba-1995" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="150577" O_E="0.0" SE="0.0" STUDY_ID="STD-Carrabba-1995a" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="150578" O_E="0.0" SE="0.0" STUDY_ID="STD-Carrabba-1995b" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="150579" O_E="0.0" SE="0.0" STUDY_ID="STD-Carrabba-1995c" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.2303079734614215" CI_START="0.11262690892131588" EFFECT_SIZE="0.6031746031746031" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5092439293895648" LOG_CI_START="-0.9483578350631079" LOG_EFFECT_SIZE="-0.21955695283677157" ORDER="150580" O_E="0.0" SE="0.8562024916845998" STUDY_ID="STD-Corrado-1995" TOTAL_1="21" TOTAL_2="19" VAR="0.7330827067669172" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.11443232154406366" CI_END="1.4050684662026893" CI_START="0.8736548510901483" DF="3" EFFECT_SIZE="1.1079462449107238" ESTIMABLE="YES" EVENTS_1="99" EVENTS_2="91" I2="0.0" ID="CMP-008.20.02" LOG_CI_END="0.14769748706640942" LOG_CI_START="-0.05866010726529608" LOG_EFFECT_SIZE="0.04451868990055667" NO="2" P_CHI2="0.9900509530962193" P_Z="0.39773786993147386" STUDIES="4" TAU2="0.0" TOTAL_1="359" TOTAL_2="364" WEIGHT="100.0" Z="0.8456682113064542">
<NAME>14 to 26 weeks post-injection</NAME>
<DICH_DATA CI_END="1.5426516090010658" CI_START="0.8429761645398162" EFFECT_SIZE="1.1403589507593188" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="53" LOG_CI_END="0.18826785647643052" LOG_CI_START="-0.07418470503739036" LOG_EFFECT_SIZE="0.05704157571952007" ORDER="150581" O_E="0.0" SE="0.1541659337943505" STUDY_ID="STD-Altman-1998" TOTAL_1="164" TOTAL_2="168" VAR="0.02376713514268406" WEIGHT="58.06671374812983"/>
<DICH_DATA CI_END="1.8207345542754831" CI_START="0.6434149813449996" EFFECT_SIZE="1.0823529411764705" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="17" LOG_CI_END="0.26024663441849294" LOG_CI_START="-0.19150883115596792" LOG_EFFECT_SIZE="0.03436890163126251" ORDER="150582" O_E="0.0" SE="0.2653633967040583" STUDY_ID="STD-Henderson-1994" TOTAL_1="45" TOTAL_2="46" VAR="0.07041773231031542" WEIGHT="18.645140356106175"/>
<DICH_DATA CI_END="2.4995506170228596" CI_START="0.493915943460679" EFFECT_SIZE="1.1111111111111112" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" LOG_CI_END="0.39786193583601337" LOG_CI_START="-0.30634695471466306" LOG_EFFECT_SIZE="0.04575749056067514" ORDER="150583" O_E="0.0" SE="0.41365578819969523" STUDY_ID="STD-Huskisson-1999" TOTAL_1="50" TOTAL_2="50" VAR="0.17111111111111113" WEIGHT="9.980633955327423"/>
<DICH_DATA CI_END="2.1182897885510963" CI_START="0.4720789409479224" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" LOG_CI_END="0.32598537265517247" LOG_CI_START="-0.3259853726551724" LOG_EFFECT_SIZE="0.0" ORDER="150584" O_E="0.0" SE="0.3829708431025352" STUDY_ID="STD-Lin-2004" TOTAL_1="100" TOTAL_2="100" VAR="0.14666666666666664" WEIGHT="13.307511940436564"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0025739116977939493" CI_END="1.5642420740015348" CI_START="0.810047822125801" DF="2" EFFECT_SIZE="1.125660199759452" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="53" I2="0.0" ID="CMP-008.20.03" LOG_CI_END="0.1943039630894708" LOG_CI_START="-0.09148934127903126" LOG_EFFECT_SIZE="0.05140731090521977" NO="3" P_CHI2="0.9987138722785531" P_Z="0.4807478005454574" STUDIES="3" TAU2="0.0" TOTAL_1="293" TOTAL_2="288" WEIGHT="100.0" Z="0.705100339134387">
<NAME>45 to 52 weeks post-injection</NAME>
<DICH_DATA CI_END="2.9345202957120105" CI_START="0.44508891313109283" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.46753711752492083" LOG_CI_START="-0.35155322356954727" LOG_EFFECT_SIZE="0.05799194697768673" ORDER="150585" O_E="0.0" SE="0.4811377209214701" STUDY_ID="STD-Dougados-1993" TOTAL_1="55" TOTAL_2="55" VAR="0.23149350649350647" WEIGHT="13.06803325837996"/>
<DICH_DATA CI_END="1.6278432549944228" CI_START="0.7784585596636986" EFFECT_SIZE="1.125703564727955" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="41" LOG_CI_END="0.21161258435644983" LOG_CI_START="-0.10876450164230707" LOG_EFFECT_SIZE="0.05142404135707137" ORDER="150586" O_E="0.0" SE="0.18819108620782243" STUDY_ID="STD-Jubb-2003" TOTAL_1="208" TOTAL_2="200" VAR="0.03541588492808006" WEIGHT="78.04214819850442"/>
<DICH_DATA CI_END="3.428174309881966" CI_START="0.3529575484280615" EFFECT_SIZE="1.1" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.53506289606775" LOG_CI_START="-0.45227752575129987" LOG_EFFECT_SIZE="0.04139268515822508" ORDER="150587" O_E="0.0" SE="0.5799686511904212" STUDY_ID="STD-St.-J.-Dixon-1988" TOTAL_1="30" TOTAL_2="33" VAR="0.3363636363636364" WEIGHT="8.88981854311562"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.2020418713054455" CI_END="1.360500786134866" CI_START="0.47692997239405516" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8055207026348807" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="29" I2="6.3097823022243835" I2_Q="0.0" ID="CMP-008.21" LOG_CI_END="0.133698797063175" LOG_CI_START="-0.32154538371769326" LOG_EFFECT_SIZE="-0.09392329332725911" METHOD="MH" NO="21" P_CHI2="0.3615109789681743" P_Q="0.8747686028455551" P_Z="0.4186667876674033" Q="0.024839127516947116" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="369" TOTAL_2="373" WEIGHT="200.0" Z="0.8087364100516816">
<NAME>Safety: withdrawals due to lack of efficacy</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hyalgan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="15.587881829843488" CI_START="0.06415239805612773" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-008.21.01" LOG_CI_END="1.1927871047905638" LOG_CI_START="-1.1927871047905636" LOG_EFFECT_SIZE="0.0" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="55" TOTAL_2="55" WEIGHT="100.0" Z="0.0">
<NAME>During treatment phase</NAME>
<DICH_DATA CI_END="15.587881829843488" CI_START="0.06415239805612773" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1927871047905638" LOG_CI_START="-1.1927871047905636" LOG_EFFECT_SIZE="0.0" ORDER="150588" O_E="0.0" SE="1.4012980994907414" STUDY_ID="STD-Dougados-1993" TOTAL_1="55" TOTAL_2="55" VAR="1.9636363636363638" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.1901303123693214" CI_END="1.3621101157585354" CI_START="0.46813039833651937" DF="2" EFFECT_SIZE="0.7985268630849219" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="28" I2="37.306636276102694" ID="CMP-008.21.02" LOG_CI_END="0.1342122182472579" LOG_CI_START="-0.329633156776498" LOG_EFFECT_SIZE="-0.09771046926462004" NO="2" P_CHI2="0.20289543896820839" P_Z="0.4089487647894897" STUDIES="3" TAU2="0.0" TOTAL_1="314" TOTAL_2="318" WEIGHT="100.00000000000001" Z="0.8257450046207965">
<NAME>14 to 26 weeks post-injection</NAME>
<DICH_DATA CI_END="2.0805218666502974" CI_START="0.5693986854034996" EFFECT_SIZE="1.0884146341463414" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="16" LOG_CI_END="0.3181722846642492" LOG_CI_START="-0.2445835398632209" LOG_EFFECT_SIZE="0.03679437240051411" ORDER="150589" O_E="0.0" SE="0.33056555701369433" STUDY_ID="STD-Altman-1998" TOTAL_1="164" TOTAL_2="168" VAR="0.109273587483774" WEIGHT="56.84575389948007"/>
<DICH_DATA CI_END="1.1193966438997731" CI_START="0.05583364961883524" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="0.04898400049996404" LOG_CI_START="-1.2531039831558888" LOG_EFFECT_SIZE="-0.6020599913279624" ORDER="150590" O_E="0.0" SE="0.7648529270389177" STUDY_ID="STD-Huskisson-1999" TOTAL_1="50" TOTAL_2="50" VAR="0.585" WEIGHT="28.769497400346623"/>
<DICH_DATA CI_END="3.265390579782977" CI_START="0.1722611694547684" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5139351355343384" LOG_CI_START="-0.7638126087509385" LOG_EFFECT_SIZE="-0.12493873660829995" ORDER="150591" O_E="0.0" SE="0.7505553499465134" STUDY_ID="STD-Lin-2004" TOTAL_1="100" TOTAL_2="100" VAR="0.5633333333333332" WEIGHT="14.384748700173311"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="21.42006440712882" CI_START="0.18674080170686877" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-008.22" LOG_CI_END="1.3308207723603833" LOG_CI_START="-0.728760781032421" LOG_EFFECT_SIZE="0.3010299956639812" METHOD="MH" NO="22" P_CHI2="1.0" P_Q="1.0" P_Z="0.5666855710842817" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="55" TOTAL_2="55" WEIGHT="100.0" Z="0.5729396330975248">
<NAME>Safety: withdrawals due to painful injection</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hyalgan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="21.42006440712882" CI_START="0.18674080170686877" DF="0" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-008.22.01" LOG_CI_END="1.3308207723603833" LOG_CI_START="-0.728760781032421" LOG_EFFECT_SIZE="0.3010299956639812" NO="1" P_CHI2="1.0" P_Z="0.5666855710842817" STUDIES="1" TAU2="0.0" TOTAL_1="55" TOTAL_2="55" WEIGHT="100.0" Z="0.5729396330975248">
<NAME>During treatment phase</NAME>
<DICH_DATA CI_END="21.42006440712882" CI_START="0.18674080170686877" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3308207723603833" LOG_CI_START="-0.728760781032421" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="150592" O_E="0.0" SE="1.209808399556047" STUDY_ID="STD-Dougados-1993" TOTAL_1="55" TOTAL_2="55" VAR="1.4636363636363638" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="18" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-008.23" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="23" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="472" TOTAL_2="469" WEIGHT="0.0" Z="0.0">
<NAME>Safety: number of patients with local adverse reaction and study drug discontinued</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hyalgan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="50.49624356357138" CI_START="0.7481252211826526" EFFECT_SIZE="6.146341463414634" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.703259071974279" LOG_CI_START="-0.12602570385066192" LOG_EFFECT_SIZE="0.7886166840618086" ORDER="150593" O_E="0.0" SE="1.0745309324252494" STUDY_ID="STD-Altman-1998" TOTAL_1="164" TOTAL_2="168" VAR="1.154616724738676" WEIGHT="0.0"/>
<DICH_DATA CI_END="21.42006440712882" CI_START="0.18674080170686877" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3308207723603833" LOG_CI_START="-0.728760781032421" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="150594" O_E="0.0" SE="1.209808399556047" STUDY_ID="STD-Dougados-1993" TOTAL_1="55" TOTAL_2="55" VAR="1.4636363636363638" WEIGHT="0.0"/>
<DICH_DATA CI_END="197.5080325690915" CI_START="0.6395590664692011" EFFECT_SIZE="11.23913043478261" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.2955847628966213" LOG_CI_START="-0.19411934007188417" LOG_EFFECT_SIZE="1.0507327114123683" ORDER="150595" O_E="0.0" SE="1.4624645143177724" STUDY_ID="STD-Henderson-1994" TOTAL_1="45" TOTAL_2="46" VAR="2.138802455638718" WEIGHT="0.0"/>
<DICH_DATA CI_END="6.617636342381762" CI_START="0.3880859524388369" EFFECT_SIZE="1.6025641025641026" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.8207028977835963" LOG_CI_START="-0.41107207714844435" LOG_EFFECT_SIZE="0.20481541031757602" ORDER="150596" O_E="0.0" SE="0.7235507176595439" STUDY_ID="STD-Jubb-2003" TOTAL_1="208" TOTAL_2="200" VAR="0.523525641025641" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="98" EVENTS_2="66" I2="0.0" I2_Q="0.0" ID="CMP-008.24" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="24" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="337" TOTAL_2="329" WEIGHT="0.0" Z="0.0">
<NAME>Safety: number of patients with local adverse reaction but study drug continued</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hyalgan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="150597" O_E="0.0" SE="0.0" STUDY_ID="STD-Bunyaratavej-2001" TOTAL_1="24" TOTAL_2="25" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="69.5152908317231" CI_START="0.12946791838627933" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.84208034406391" LOG_CI_START="-0.8878378346245852" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="150598" O_E="0.0" SE="1.6035674514745464" STUDY_ID="STD-Carrabba-1995" TOTAL_1="20" TOTAL_2="20" VAR="2.5714285714285716" WEIGHT="0.0"/>
<DICH_DATA CI_END="69.5152908317231" CI_START="0.12946791838627933" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.84208034406391" LOG_CI_START="-0.8878378346245852" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="150599" O_E="0.0" SE="1.6035674514745464" STUDY_ID="STD-Carrabba-1995a" TOTAL_1="20" TOTAL_2="20" VAR="2.5714285714285716" WEIGHT="0.0"/>
<DICH_DATA CI_END="7.723921203524791" CI_START="0.014385324265142151" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8878378346245852" LOG_CI_START="-1.84208034406391" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="150600" O_E="0.0" SE="1.6035674514745464" STUDY_ID="STD-Carrabba-1995b" TOTAL_1="20" TOTAL_2="20" VAR="2.5714285714285716" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.847709019383875" CI_START="1.09576315582536" EFFECT_SIZE="2.0533333333333332" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="10" LOG_CI_END="0.5852022213558538" LOG_CI_START="0.039716693533672104" LOG_EFFECT_SIZE="0.312459457444763" ORDER="150601" O_E="0.0" SE="0.3204208992396605" STUDY_ID="STD-Henderson-1994" TOTAL_1="45" TOTAL_2="44" VAR="0.10266955266955266" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.7501553537142722" CI_START="0.9823219949806838" EFFECT_SIZE="1.3111888111888113" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="55" LOG_CI_END="0.2430766008384578" LOG_CI_START="-0.007746131641106033" LOG_EFFECT_SIZE="0.11766523459867587" ORDER="150602" O_E="0.0" SE="0.14733451465104572" STUDY_ID="STD-Jubb-2003" TOTAL_1="208" TOTAL_2="200" VAR="0.021707459207459208" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="17" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-008.25" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="25" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="258" TOTAL_2="250" WEIGHT="0.0" Z="0.0">
<NAME>Safety: number of patients discontinued due to adverse events</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hyalgan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="21.357023897403046" CI_START="0.1872920131201609" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3295407336099563" LOG_CI_START="-0.7274807422819939" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="150603" O_E="0.0" SE="1.2083045973594573" STUDY_ID="STD-Huskisson-1999" TOTAL_1="50" TOTAL_2="50" VAR="1.46" WEIGHT="0.0"/>
<DICH_DATA CI_END="6.072142812407073" CI_START="0.9516370925192861" EFFECT_SIZE="2.4038461538461537" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="6" LOG_CI_END="0.783341977299639" LOG_CI_START="-0.02152863855312438" LOG_EFFECT_SIZE="0.38090666937325723" ORDER="150604" O_E="0.0" SE="0.47278498392571755" STUDY_ID="STD-Jubb-2003" TOTAL_1="208" TOTAL_2="200" VAR="0.22352564102564101" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.05559840443336494" CI_END="3.20338536033964" CI_START="1.0360699320650804" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.8217934165720775" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-008.26" LOG_CI_END="0.5056091864946463" LOG_CI_START="0.015389070163039887" LOG_EFFECT_SIZE="0.26049912832884303" METHOD="MH" NO="26" P_CHI2="0.9725836641712017" P_Q="0.8920598390824717" P_Z="0.0372494912471363" Q="0.018414014549119468" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="413" TOTAL_2="405" WEIGHT="200.0" Z="2.083019005214543">
<NAME>Safety: number of patients with serious or severe adverse events</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hyalgan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.03641648263882033" CI_END="6.849500655641423" CI_START="0.40554456703204045" DF="1" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="0.0" ID="CMP-008.26.01" LOG_CI_END="0.8356589115794044" LOG_CI_START="-0.39196141234669163" LOG_EFFECT_SIZE="0.2218487496163564" NO="1" P_CHI2="0.8486580447394458" P_Z="0.47870454344302504" STUDIES="2" TAU2="0.0" TOTAL_1="150" TOTAL_2="150" WEIGHT="100.0" Z="0.7083876843496753">
<NAME>14 to 26 weeks post-injection</NAME>
<DICH_DATA CI_END="21.357023897403046" CI_START="0.1872920131201609" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3295407336099563" LOG_CI_START="-0.7274807422819939" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="150605" O_E="0.0" SE="1.2083045973594573" STUDY_ID="STD-Huskisson-1999" TOTAL_1="50" TOTAL_2="50" VAR="1.46" WEIGHT="33.333333333333336"/>
<DICH_DATA CI_END="8.785112528092341" CI_START="0.2561151030001183" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9437473287244922" LOG_CI_START="-0.5915648106131298" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="150606" O_E="0.0" SE="0.9018499505645788" STUDY_ID="STD-Lin-2004" TOTAL_1="100" TOTAL_2="100" VAR="0.8133333333333332" WEIGHT="66.66666666666667"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.4321288410332857" CI_START="1.0019388015067785" DF="0" EFFECT_SIZE="1.8543956043956045" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="14" I2="0.0" ID="CMP-008.26.02" LOG_CI_END="0.535563582760444" LOG_CI_START="8.411956034938199E-4" LOG_EFFECT_SIZE="0.2682023891819689" NO="2" P_CHI2="1.0" P_Z="0.04928352676069605" STUDIES="2" TAU2="0.0" TOTAL_1="263" TOTAL_2="255" WEIGHT="100.0" Z="1.966130597819769">
<NAME>45 to 52 weeks post-injection</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="150607" O_E="0.0" SE="0.0" STUDY_ID="STD-Dougados-1993" TOTAL_1="55" TOTAL_2="55" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.4321288410332857" CI_START="1.0019388015067785" EFFECT_SIZE="1.8543956043956045" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="14" LOG_CI_END="0.535563582760444" LOG_CI_START="8.411956034938199E-4" LOG_EFFECT_SIZE="0.2682023891819689" ORDER="150608" O_E="0.0" SE="0.31409857713449796" STUDY_ID="STD-Jubb-2003" TOTAL_1="208" TOTAL_2="200" VAR="0.09865791615791615" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-008.27" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="27" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="31" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>Safety: number of knee joints with local adverse reaction</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hyalgan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="92.65437839592954" CI_START="0.2435125073483976" EFFECT_SIZE="4.75" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9668659467878138" LOG_CI_START="-0.6134787275380805" LOG_EFFECT_SIZE="0.6766936096248666" ORDER="150609" O_E="0.0" SE="1.515707234611167" STUDY_ID="STD-Bragantini-1987" TOTAL_1="19" TOTAL_2="18" VAR="2.2973684210526315" WEIGHT="0.0"/>
<DICH_DATA CI_END="7.431806760962594" CI_START="0.30275275883365027" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.8710944087710151" LOG_CI_START="-0.5189118906596526" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="150610" O_E="0.0" SE="0.8164965809277259" STUDY_ID="STD-Creamer-1994" TOTAL_1="12" TOTAL_2="12" VAR="0.6666666666666665" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="59" EVENTS_2="43" I2="0.0" I2_Q="0.0" ID="CMP-008.28" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="28" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="239" TOTAL_2="243" WEIGHT="0.0" Z="0.0">
<NAME>Safety: number of patients with injection site pain or painful intra-articular injection</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hyalgan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.8565439323968613" CI_START="1.0960031219658917" EFFECT_SIZE="1.76940133037694" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="22" LOG_CI_END="0.45584090770719793" LOG_CI_START="0.03981179123833974" LOG_EFFECT_SIZE="0.24782634947276885" ORDER="150611" O_E="0.0" SE="0.24437756239114702" STUDY_ID="STD-Altman-1998" TOTAL_1="164" TOTAL_2="168" VAR="0.05972039300023895" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.708906765755429" CI_START="0.585169431146787" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="18" LOG_CI_END="0.23271836920261207" LOG_CI_START="-0.23271836920261205" LOG_EFFECT_SIZE="0.0" ORDER="150612" O_E="0.0" SE="0.2733998440882414" STUDY_ID="STD-Dougados-1993" TOTAL_1="55" TOTAL_2="55" VAR="0.07474747474747473" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.372816405310655" CI_START="0.22868556722059719" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6407612436759104" LOG_CI_START="-0.6407612436759105" LOG_EFFECT_SIZE="0.0" ORDER="150613" O_E="0.0" SE="0.7527726527090809" STUDY_ID="STD-Formiguera-Sala-1995" TOTAL_1="20" TOTAL_2="20" VAR="0.5666666666666665" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.5212782279989011E-31" CI_END="1.7082586139080698" CI_START="0.559719549416231" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9778270509977826" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="22" I2="100.0" I2_Q="0.0" ID="CMP-008.29" LOG_CI_END="0.23255361933373275" LOG_CI_START="-0.25202952415397684" LOG_EFFECT_SIZE="-0.009737952410122066" METHOD="MH" NO="29" P_CHI2="0.0" P_Q="1.0" P_Z="0.9372131735244972" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="164" TOTAL_2="168" WEIGHT="100.0" Z="0.0787730083619318">
<NAME>Safety: number of patients with local joint pain or swelling</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hyalgan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.5212782279989011E-31" CI_END="1.7082586139080698" CI_START="0.559719549416231" DF="0" EFFECT_SIZE="0.9778270509977826" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="22" I2="100.0" ID="CMP-008.29.01" LOG_CI_END="0.23255361933373275" LOG_CI_START="-0.25202952415397684" LOG_EFFECT_SIZE="-0.009737952410122066" NO="1" P_CHI2="0.0" P_Z="0.9372131735244972" STUDIES="1" TAU2="0.0" TOTAL_1="164" TOTAL_2="168" WEIGHT="100.0" Z="0.0787730083619318">
<NAME>14 to 26 weeks post-injection</NAME>
<DICH_DATA CI_END="1.70825861390807" CI_START="0.559719549416231" EFFECT_SIZE="0.9778270509977827" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="22" LOG_CI_END="0.2325536193337328" LOG_CI_START="-0.25202952415397684" LOG_EFFECT_SIZE="-0.009737952410122017" ORDER="150614" O_E="0.0" SE="0.284646537209927" STUDY_ID="STD-Altman-1998" TOTAL_1="164" TOTAL_2="168" VAR="0.08102365114560237" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.2320881926483615E-31" CI_END="1.5214210975234366" CI_START="0.5397472137629242" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9061913696060039" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="26" I2="100.0" I2_Q="0.0" ID="CMP-008.30" LOG_CI_END="0.18224943431579393" LOG_CI_START="-0.26780959086591405" LOG_EFFECT_SIZE="-0.04278007827506006" METHOD="MH" NO="30" P_CHI2="0.0" P_Q="1.0" P_Z="0.709441488690907" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="164" TOTAL_2="168" WEIGHT="100.0" Z="0.372606293768109">
<NAME>Safety: number of patients with local skin rash or ecchymosis</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hyalgan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.2320881926483615E-31" CI_END="1.5214210975234366" CI_START="0.5397472137629242" DF="0" EFFECT_SIZE="0.9061913696060039" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="26" I2="100.0" ID="CMP-008.30.01" LOG_CI_END="0.18224943431579393" LOG_CI_START="-0.26780959086591405" LOG_EFFECT_SIZE="-0.04278007827506006" NO="1" P_CHI2="0.0" P_Z="0.709441488690907" STUDIES="1" TAU2="0.0" TOTAL_1="164" TOTAL_2="168" WEIGHT="100.0" Z="0.372606293768109">
<NAME>14 to 26 weeks post-injection</NAME>
<DICH_DATA CI_END="1.5214210975234363" CI_START="0.5397472137629242" EFFECT_SIZE="0.9061913696060038" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="26" LOG_CI_END="0.18224943431579385" LOG_CI_START="-0.26780959086591405" LOG_EFFECT_SIZE="-0.042780078275060106" ORDER="150615" O_E="0.0" SE="0.26436689921983986" STUDY_ID="STD-Altman-1998" TOTAL_1="164" TOTAL_2="168" VAR="0.06988985740311296" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1412979013897038" CI_START="0.6085696644167797" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8334022323274081" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="59" I2="0.0" I2_Q="0.0" ID="CMP-008.31" LOG_CI_END="0.05739901868925579" LOG_CI_START="-0.21568969986603978" LOG_EFFECT_SIZE="-0.07914534058839198" METHOD="MH" NO="31" P_CHI2="1.0" P_Q="1.0" P_Z="0.2559332129979025" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="164" TOTAL_2="168" WEIGHT="100.0" Z="1.1360558423506975">
<NAME>Safety: number of patients with gastrointestinal complaints</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hyalgan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1412979013897038" CI_START="0.6085696644167797" DF="0" EFFECT_SIZE="0.8334022323274081" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="59" I2="0.0" ID="CMP-008.31.01" LOG_CI_END="0.05739901868925579" LOG_CI_START="-0.21568969986603978" LOG_EFFECT_SIZE="-0.07914534058839198" NO="1" P_CHI2="1.0" P_Z="0.2559332129979025" STUDIES="1" TAU2="0.0" TOTAL_1="164" TOTAL_2="168" WEIGHT="100.0" Z="1.1360558423506975">
<NAME>14 to 26 weeks post-injection</NAME>
<DICH_DATA CI_END="1.1412979013897038" CI_START="0.6085696644167797" EFFECT_SIZE="0.8334022323274081" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="59" LOG_CI_END="0.05739901868925579" LOG_CI_START="-0.21568969986603978" LOG_EFFECT_SIZE="-0.07914534058839198" ORDER="150616" O_E="0.0" SE="0.1604136650903392" STUDY_ID="STD-Altman-1998" TOTAL_1="164" TOTAL_2="168" VAR="0.025732543947715507" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.3495556025216855" CI_START="0.7090100519410729" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.7560975609756098" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-008.32" LOG_CI_END="0.6384448870163119" LOG_CI_START="-0.14934760759324597" LOG_EFFECT_SIZE="0.24454863971153296" METHOD="MH" NO="32" P_CHI2="1.0" P_Q="1.0" P_Z="0.22366722964878172" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="164" TOTAL_2="168" WEIGHT="100.0" Z="1.2168344572523961">
<NAME>Safety: number of patients with pruritis (local)</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hyalgan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.3495556025216855" CI_START="0.7090100519410729" DF="0" EFFECT_SIZE="1.7560975609756098" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" I2="0.0" ID="CMP-008.32.01" LOG_CI_END="0.6384448870163119" LOG_CI_START="-0.14934760759324597" LOG_EFFECT_SIZE="0.24454863971153296" NO="1" P_CHI2="1.0" P_Z="0.22366722964878172" STUDIES="1" TAU2="0.0" TOTAL_1="164" TOTAL_2="168" WEIGHT="100.0" Z="1.2168344572523961">
<NAME>14 to 26 weeks post-injection</NAME>
<DICH_DATA CI_END="4.3495556025216855" CI_START="0.709010051941073" EFFECT_SIZE="1.7560975609756098" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" LOG_CI_END="0.6384448870163119" LOG_CI_START="-0.1493476075932459" LOG_EFFECT_SIZE="0.24454863971153296" ORDER="150617" O_E="0.0" SE="0.46275321096939503" STUDY_ID="STD-Altman-1998" TOTAL_1="164" TOTAL_2="168" VAR="0.21414053426248544" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.090584536706145" CI_END="4.443698811108584" CI_START="1.3267183143994616" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="2.4280726093700067" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-008.33" LOG_CI_END="0.6477446152764023" LOG_CI_START="0.12277872430534877" LOG_EFFECT_SIZE="0.38526166979087556" METHOD="MH" NO="33" P_CHI2="0.5796724582812227" P_Q="0.4109032183155139" P_Z="0.004017880379020618" Q="0.6761868423947955" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="169" TOTAL_2="172" WEIGHT="200.0" Z="2.8767545107250214">
<NAME>Safety: number of patients with treatment related adverse events</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hyalgan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-008.33.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>5 to 13 weeks post-injection</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="150618" O_E="0.0" SE="0.0" STUDY_ID="STD-Formiguera-Sala-1995" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.3296805450471122" CI_END="4.065041815976749" CI_START="1.1821743381448675" DF="1" EFFECT_SIZE="2.1921651667548967" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="10" I2="0.0" ID="CMP-008.33.02" LOG_CI_END="0.6090650174219816" LOG_CI_START="0.07268152773910735" LOG_EFFECT_SIZE="0.34087327258054445" NO="2" P_CHI2="0.5658474046245758" P_Z="0.012733907391311878" STUDIES="3" TAU2="0.0" TOTAL_1="119" TOTAL_2="119" WEIGHT="100.00000000000001" Z="2.491125660654365">
<NAME>14 to 26 weeks post-injection</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="150619" O_E="0.0" SE="0.0" STUDY_ID="STD-Bunyaratavej-2001" TOTAL_1="24" TOTAL_2="25" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.847709019383875" CI_START="1.09576315582536" EFFECT_SIZE="2.0533333333333332" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="10" LOG_CI_END="0.5852022213558538" LOG_CI_START="0.039716693533672104" LOG_EFFECT_SIZE="0.312459457444763" ORDER="150620" O_E="0.0" SE="0.3204208992396605" STUDY_ID="STD-Henderson-1994" TOTAL_1="45" TOTAL_2="44" VAR="0.10266955266955266" WEIGHT="95.28851244044469"/>
<DICH_DATA CI_END="101.58460526662178" CI_START="0.24610028197072092" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.006827897373713" LOG_CI_START="-0.6088878887016753" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="150621" O_E="0.0" SE="1.5364844007426468" STUDY_ID="STD-Huskisson-1999" TOTAL_1="50" TOTAL_2="50" VAR="2.3607843137254902" WEIGHT="4.71148755955532"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="142.76828732579966" CI_START="0.4128561675293032" DF="0" EFFECT_SIZE="7.67741935483871" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-008.33.03" LOG_CI_END="2.154631749674504" LOG_CI_START="-0.3842012232300252" LOG_EFFECT_SIZE="0.8852152632222393" NO="3" P_CHI2="1.0" P_Z="0.17169996202796092" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="33" WEIGHT="100.0" Z="1.366761857118811">
<NAME>45 to 52 weeks post-injection</NAME>
<DICH_DATA CI_END="142.76828732579966" CI_START="0.4128561675293032" EFFECT_SIZE="7.67741935483871" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.154631749674504" LOG_CI_START="-0.3842012232300252" LOG_EFFECT_SIZE="0.8852152632222393" ORDER="150622" O_E="0.0" SE="1.491323055710021" STUDY_ID="STD-St.-J.-Dixon-1988" TOTAL_1="30" TOTAL_2="33" VAR="2.2240444564922743" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.254718653642042" CI_START="0.4230560572203372" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7285714285714285" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-008.34" LOG_CI_END="0.09854635460686233" LOG_CI_START="-0.3736020824395033" LOG_EFFECT_SIZE="-0.1375278639163205" METHOD="MH" NO="34" P_CHI2="1.0" P_Q="1.0" P_Z="0.2535369746866113" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="50" TOTAL_2="30" WEIGHT="100.0" Z="1.141800497457725">
<NAME>Safety: number of patients reporting adverse events</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hyalgan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.254718653642042" CI_START="0.4230560572203372" DF="0" EFFECT_SIZE="0.7285714285714285" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="14" I2="0.0" ID="CMP-008.34.01" LOG_CI_END="0.09854635460686233" LOG_CI_START="-0.3736020824395033" LOG_EFFECT_SIZE="-0.1375278639163205" NO="1" P_CHI2="1.0" P_Z="0.2535369746866113" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="30" WEIGHT="100.0" Z="1.141800497457725">
<NAME>14 to 26 weeks post-injection</NAME>
<DICH_DATA CI_END="1.2547186536420418" CI_START="0.4230560572203373" EFFECT_SIZE="0.7285714285714285" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="14" LOG_CI_END="0.09854635460686226" LOG_CI_START="-0.3736020824395032" LOG_EFFECT_SIZE="-0.1375278639163205" ORDER="150623" O_E="0.0" SE="0.27734232909349193" STUDY_ID="STD-Huskisson-1999" TOTAL_1="50" TOTAL_2="30" VAR="0.07691876750700277" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.5162144019112673" CI_START="0.9798763313626929" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2188940092165899" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="62" I2="0.0" I2_Q="0.0" ID="CMP-008.35" LOG_CI_END="0.18076061751189954" LOG_CI_START="-0.008828732466549442" LOG_EFFECT_SIZE="0.08596594252267505" METHOD="MH" NO="35" P_CHI2="1.0" P_Q="1.0" P_Z="0.07549881565508207" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="105" TOTAL_2="115" WEIGHT="100.0" Z="1.7774221100566683">
<NAME>Number of patients with none/slight/mild pain</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hyalgan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5162144019112673" CI_START="0.9798763313626929" DF="0" EFFECT_SIZE="1.2188940092165899" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="62" I2="0.0" ID="CMP-008.35.01" LOG_CI_END="0.18076061751189954" LOG_CI_START="-0.008828732466549442" LOG_EFFECT_SIZE="0.08596594252267505" NO="1" P_CHI2="1.0" P_Z="0.07549881565508207" STUDIES="1" TAU2="0.0" TOTAL_1="105" TOTAL_2="115" WEIGHT="100.0" Z="1.7774221100566683">
<NAME>14 to 26 weeks post-injection</NAME>
<DICH_DATA CI_END="1.5162144019112673" CI_START="0.9798763313626929" EFFECT_SIZE="1.2188940092165899" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="62" LOG_CI_END="0.18076061751189954" LOG_CI_START="-0.008828732466549442" LOG_EFFECT_SIZE="0.08596594252267505" ORDER="150624" O_E="0.0" SE="0.11136572265975898" STUDY_ID="STD-Altman-1998" TOTAL_1="105" TOTAL_2="115" VAR="0.012402324183530355" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="3.0754614025392764" CI_END="0.42305377719860804" CI_START="-0.13557929146639133" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="0.14373724286610837" ESTIMABLE="YES" I2="67.48455372665893" I2_Q="0.0" ID="CMP-008.36" NO="36" P_CHI2="0.07948228940482327" P_Q="1.0" P_Z="0.3131645238481623" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="136" TOTAL_2="137" UNITS="" WEIGHT="100.0" Z="1.0086041627571487">
<NAME>Joint space width (mm) (after three courses of treatment and stratified subgroups)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Hyalgan</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="3.0754614025392764" CI_END="0.42305377719860804" CI_START="-0.13557929146639133" DF="1" EFFECT_SIZE="0.14373724286610837" ESTIMABLE="YES" I2="67.48455372665893" ID="CMP-008.36.01" NO="1" P_CHI2="0.07948228940482327" P_Z="0.3131645238481623" STUDIES="2" TAU2="0.0" TOTAL_1="136" TOTAL_2="137" WEIGHT="100.0" Z="1.0086041627571487">
<NAME>45 to 52 weeks post-injection</NAME>
<CONT_DATA CI_END="0.8000559185934935" CI_START="-5.591859349446393E-5" EFFECT_SIZE="0.39999999999999947" ESTIMABLE="YES" MEAN_1="5.8" MEAN_2="5.4" ORDER="150625" SD_1="1.4" SD_2="1.0" SE="0.20411391318875446" STUDY_ID="STD-Jubb-2001b" TOTAL_1="76" TOTAL_2="63" WEIGHT="48.74744857322174"/>
<CONT_DATA CI_END="0.2901565477307091" CI_START="-0.49015654773070927" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" MEAN_1="3.5" MEAN_2="3.6" ORDER="150626" SD_1="1.1" SD_2="1.2" SE="0.19906312095947387" STUDY_ID="STD-Jubb-2001c" TOTAL_1="60" TOTAL_2="74" WEIGHT="51.25255142677827"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" NO="9">
<NAME>Hyalgan versus arthroscopy</NAME>
<CONT_OUTCOME CHI2="1.6567937589969342" CI_END="1.0892232431874163" CI_START="-0.7695364196870332" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="0.15984341175019154" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-009.01" NO="1" P_CHI2="0.7985503209880737" P_Q="0.7985503209880737" P_Z="0.736046880143157" Q="1.6567937589969342" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="75" TOTAL_2="72" UNITS="" WEIGHT="500.0" Z="0.3370928866746588">
<NAME>Pain (0-10 cm VAS)</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>Arthroscopy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hyalgan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Arthroscopy</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.5890854230218694" CI_START="-1.38908542302187" DF="0" EFFECT_SIZE="0.09999999999999964" ESTIMABLE="YES" I2="0.0" ID="CMP-009.01.01" NO="1" P_CHI2="1.0" P_Z="0.8952832851063328" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="15" WEIGHT="100.0" Z="0.13162199792155657">
<NAME>Pre-trial</NAME>
<CONT_DATA CI_END="1.5890854230218694" CI_START="-1.38908542302187" EFFECT_SIZE="0.09999999999999964" ESTIMABLE="YES" MEAN_1="7.6" MEAN_2="7.5" ORDER="150627" SD_1="1.7" SD_2="2.5" SE="0.7597514213360987" STUDY_ID="STD-Forster-2003" TOTAL_1="18" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.280255801360752" CI_START="-0.8802558013607533" DF="0" EFFECT_SIZE="1.1999999999999993" ESTIMABLE="YES" I2="0.0" ID="CMP-009.01.02" NO="2" P_CHI2="1.0" P_Z="0.2582195443399625" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="13" WEIGHT="100.0" Z="1.1306094086648306">
<NAME>1 week post-injection</NAME>
<CONT_DATA CI_END="3.280255801360752" CI_START="-0.8802558013607533" EFFECT_SIZE="1.1999999999999993" ESTIMABLE="YES" MEAN_1="6.6" MEAN_2="5.4" ORDER="150628" SD_1="2.4" SD_2="3.2" SE="1.0613745036998357" STUDY_ID="STD-Forster-2003" TOTAL_1="17" TOTAL_2="13" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.506277202340491" CI_START="-2.506277202340491" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-009.01.03" NO="3" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="15" WEIGHT="100.0" Z="0.0">
<NAME>5 to 12 weeks post-injection</NAME>
<CONT_DATA CI_END="2.506277202340491" CI_START="-2.506277202340491" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="6.0" MEAN_2="6.0" ORDER="150629" SD_1="3.4" SD_2="3.7" SE="1.2787363554175921" STUDY_ID="STD-Forster-2003" TOTAL_1="16" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="7.2254939744334E-33" CI_END="1.6599091297012274" CI_START="-3.459909129701228" DF="0" EFFECT_SIZE="-0.9000000000000002" ESTIMABLE="YES" I2="100.0" ID="CMP-009.01.04" NO="4" P_CHI2="0.0" P_Z="0.4907765180638979" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="15" WEIGHT="100.0" Z="0.6890742978411604">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="1.6599091297012274" CI_START="-3.459909129701228" EFFECT_SIZE="-0.9000000000000004" ESTIMABLE="YES" MEAN_1="5.3" MEAN_2="6.2" ORDER="150630" SD_1="3.4" SD_2="3.5" SE="1.3061000864778456" STUDY_ID="STD-Forster-2003" TOTAL_1="13" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.470209067231446" CI_START="-2.470209067231446" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-009.01.05" NO="5" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="14" WEIGHT="99.99999999999999" Z="0.0">
<NAME>45 to 52 weeks post-injection</NAME>
<CONT_DATA CI_END="2.470209067231446" CI_START="-2.470209067231446" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="5.7" MEAN_2="5.7" ORDER="150631" SD_1="2.7" SD_2="3.6" SE="1.2603339075187807" STUDY_ID="STD-Forster-2003" TOTAL_1="11" TOTAL_2="14" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.42009705560522204" CI_END="30.25170925402559" CI_START="11.43424182781815" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="20.84297554092187" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-009.02" NO="2" P_CHI2="0.9807986793159983" P_Q="0.9807986793159983" P_Z="1.412762994815302E-5" Q="0.42009705560522204" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="75" TOTAL_2="72" UNITS="" WEIGHT="500.0" Z="4.341868165953246">
<NAME>Knee Society Function scale</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>Arthroscopy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Arthroscopy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Hyalgan</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="38.52657233674394" CI_START="6.273427663256076" DF="0" EFFECT_SIZE="22.400000000000006" ESTIMABLE="YES" I2="0.0" ID="CMP-009.02.01" NO="1" P_CHI2="1.0" P_Z="0.0064807057368562035" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="15" WEIGHT="100.0" Z="2.7224131909088376">
<NAME>Pre-trial</NAME>
<CONT_DATA CI_END="38.52657233674394" CI_START="6.273427663256076" EFFECT_SIZE="22.400000000000006" ESTIMABLE="YES" MEAN_1="64.4" MEAN_2="42.0" ORDER="150632" SD_1="24.5" SD_2="22.7" SE="8.227994220275614" STUDY_ID="STD-Forster-2003" TOTAL_1="18" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="40.123854625121275" CI_START="-6.323854625121278" DF="0" EFFECT_SIZE="16.9" ESTIMABLE="YES" I2="0.0" ID="CMP-009.02.02" NO="2" P_CHI2="1.0" P_Z="0.15379161092722832" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="13" WEIGHT="100.0" Z="1.4262658750411439">
<NAME>1 week post-injection</NAME>
<CONT_DATA CI_END="40.123854625121275" CI_START="-6.323854625121278" EFFECT_SIZE="16.9" ESTIMABLE="YES" MEAN_1="66.5" MEAN_2="49.6" ORDER="150633" SD_1="28.5" SD_2="34.7" SE="11.84912315139874" STUDY_ID="STD-Forster-2003" TOTAL_1="17" TOTAL_2="13" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="38.89725176272567" CI_START="-6.497251762725671" DF="0" EFFECT_SIZE="16.200000000000003" ESTIMABLE="YES" I2="0.0" ID="CMP-009.02.03" NO="3" P_CHI2="1.0" P_Z="0.16183991946337997" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="15" WEIGHT="100.0" Z="1.3989101800285935">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="38.89725176272567" CI_START="-6.497251762725671" EFFECT_SIZE="16.200000000000003" ESTIMABLE="YES" MEAN_1="67.5" MEAN_2="51.3" ORDER="150634" SD_1="30.8" SD_2="33.5" SE="11.58044328454946" STUDY_ID="STD-Forster-2003" TOTAL_1="16" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="45.32033801427765" CI_START="1.6796619857223476" DF="0" EFFECT_SIZE="23.5" ESTIMABLE="YES" I2="0.0" ID="CMP-009.02.04" NO="4" P_CHI2="1.0" P_Z="0.034786416056927415" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="15" WEIGHT="100.0" Z="2.1108359369389005">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="45.32033801427765" CI_START="1.679661985722344" EFFECT_SIZE="23.5" ESTIMABLE="YES" MEAN_1="73.5" MEAN_2="50.0" ORDER="150635" SD_1="27.9" SD_2="31.0" SE="11.13303008952904" STUDY_ID="STD-Forster-2003" TOTAL_1="13" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="49.253712966866004" CI_START="-1.4537129668660072" DF="0" EFFECT_SIZE="23.9" ESTIMABLE="YES" I2="0.0" ID="CMP-009.02.05" NO="5" P_CHI2="1.0" P_Z="0.06466240439952772" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="14" WEIGHT="100.0" Z="1.847584978646921">
<NAME>45 to 52 weeks post -injection</NAME>
<CONT_DATA CI_END="49.253712966866004" CI_START="-1.4537129668660072" EFFECT_SIZE="23.9" ESTIMABLE="YES" MEAN_1="75.0" MEAN_2="51.1" ORDER="150636" SD_1="32.8" SD_2="31.2" SE="12.935805538700128" STUDY_ID="STD-Forster-2003" TOTAL_1="11" TOTAL_2="14" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.8256432012816708" CI_END="0.2743304466785199" CI_START="-3.3442391488975938" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.534954351109537" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-009.03" NO="3" P_CHI2="0.7677876297778745" P_Q="0.7677876297778745" P_Z="0.0963550792262478" Q="1.8256432012816708" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="75" TOTAL_2="72" UNITS="" WEIGHT="500.0" Z="1.6627870027790714">
<NAME>Lequesne Index (0-24)</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>Arthroscopy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hyalgan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Arthroscopy</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.0376947858939127" CI_START="-4.837694785893913" DF="0" EFFECT_SIZE="-1.9000000000000004" ESTIMABLE="YES" I2="0.0" ID="CMP-009.03.01" NO="1" P_CHI2="1.0" P_Z="0.20492752014372606" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="15" WEIGHT="100.0" Z="1.2676373285977516">
<NAME>Pre-trial</NAME>
<CONT_DATA CI_END="1.0376947858939127" CI_START="-4.837694785893913" EFFECT_SIZE="-1.9000000000000004" ESTIMABLE="YES" MEAN_1="11.4" MEAN_2="13.3" ORDER="150637" SD_1="4.9" SD_2="3.7" SE="1.4988514121004644" STUDY_ID="STD-Forster-2003" TOTAL_1="18" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="4.92441949246421" CI_START="-3.724419492464211" DF="0" EFFECT_SIZE="0.5999999999999996" ESTIMABLE="YES" I2="0.0" ID="CMP-009.03.02" NO="2" P_CHI2="1.0" P_Z="0.7856689095219626" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="13" WEIGHT="100.0" Z="0.2719390181210003">
<NAME>1 week post-injection</NAME>
<CONT_DATA CI_END="4.92441949246421" CI_START="-3.724419492464211" EFFECT_SIZE="0.5999999999999996" ESTIMABLE="YES" MEAN_1="11.1" MEAN_2="10.5" ORDER="150638" SD_1="5.7" SD_2="6.2" SE="2.206377018442522" STUDY_ID="STD-Forster-2003" TOTAL_1="17" TOTAL_2="13" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.801490324412546" CI_START="-5.001490324412545" DF="0" EFFECT_SIZE="-0.5999999999999996" ESTIMABLE="YES" I2="0.0" ID="CMP-009.03.03" NO="3" P_CHI2="1.0" P_Z="0.7893326375958712" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="15" WEIGHT="100.0" Z="0.26717732041839404">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="3.801490324412546" CI_START="-5.001490324412545" EFFECT_SIZE="-0.5999999999999996" ESTIMABLE="YES" MEAN_1="10.9" MEAN_2="11.5" ORDER="150639" SD_1="6.6" SD_2="5.9" SE="2.2456995940389413" STUDY_ID="STD-Forster-2003" TOTAL_1="16" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.5845714837995066" CI_START="-7.584571483799507" DF="0" EFFECT_SIZE="-3.0" ESTIMABLE="YES" I2="0.0" ID="CMP-009.03.04" NO="4" P_CHI2="1.0" P_Z="0.1996536156663492" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="15" WEIGHT="100.0" Z="1.2825390495922964">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="1.5845714837995066" CI_START="-7.584571483799507" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="8.7" MEAN_2="11.7" ORDER="150640" SD_1="6.4" SD_2="5.9" SE="2.339110065267536" STUDY_ID="STD-Forster-2003" TOTAL_1="13" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.303081531688404" CI_START="-8.103081531688401" DF="0" EFFECT_SIZE="-2.8999999999999986" ESTIMABLE="YES" I2="0.0" ID="CMP-009.03.05" NO="5" P_CHI2="1.0" P_Z="0.27465317799479905" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="14" WEIGHT="100.0" Z="1.0924094732226362">
<NAME>45 to 52 weeks post-injection</NAME>
<CONT_DATA CI_END="2.303081531688404" CI_START="-8.103081531688401" EFFECT_SIZE="-2.8999999999999986" ESTIMABLE="YES" MEAN_1="8.3" MEAN_2="11.2" ORDER="150641" SD_1="6.5" SD_2="6.7" SE="2.654682214943563" STUDY_ID="STD-Forster-2003" TOTAL_1="11" TOTAL_2="14" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="6.572041156561997" CI_START="0.6449677085523482" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.0588235294117645" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-009.04" LOG_CI_END="0.8177002744848443" LOG_CI_START="-0.1904620285408409" LOG_EFFECT_SIZE="0.3136191229720017" METHOD="MH" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.2226881958753475" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="17" TOTAL_2="15" WEIGHT="100.0" Z="1.219411168307691">
<NAME>Clinical outcome (number of patients requiring further intervention)</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>Arthroscopy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hyalgan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Arthroscopy</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.572041156561997" CI_START="0.6449677085523482" DF="0" EFFECT_SIZE="2.0588235294117645" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" I2="0.0" ID="CMP-009.04.01" LOG_CI_END="0.8177002744848443" LOG_CI_START="-0.1904620285408409" LOG_EFFECT_SIZE="0.3136191229720017" NO="1" P_CHI2="1.0" P_Z="0.2226881958753475" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="15" WEIGHT="100.0" Z="1.219411168307691">
<NAME>45 to 52 weeks post-injection</NAME>
<DICH_DATA CI_END="6.572041156561997" CI_START="0.6449677085523482" EFFECT_SIZE="2.0588235294117645" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.8177002744848443" LOG_CI_START="-0.1904620285408409" LOG_EFFECT_SIZE="0.3136191229720017" ORDER="150642" O_E="0.0" SE="0.592199527281173" STUDY_ID="STD-Forster-2003" TOTAL_1="17" TOTAL_2="15" VAR="0.3507002801120448" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.4123848800922896" CI_START="0.10363188812161511" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" I2="0.0" I2_Q="100.0" ID="CMP-009.05" LOG_CI_END="0.3824465978153869" LOG_CI_START="-0.9845065891433492" LOG_EFFECT_SIZE="-0.3010299956639812" METHOD="MH" NO="5" P_CHI2="1.0" P_Q="0.0" P_Z="0.3880026266668175" Q="1.911780254999901E-32" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="19" TOTAL_2="19" WEIGHT="100.0" Z="0.8632452894459834">
<NAME>Safety: total withdrawals overall</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>Arthroscopy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hyalgan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Arthroscopy</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.4123848800922896" CI_START="0.10363188812161511" DF="0" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" I2="0.0" ID="CMP-009.05.01" LOG_CI_END="0.3824465978153869" LOG_CI_START="-0.9845065891433492" LOG_EFFECT_SIZE="-0.3010299956639812" NO="1" P_CHI2="1.0" P_Z="0.3880026266668175" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="19" WEIGHT="100.0" Z="0.8632452894459834">
<NAME>45 to 52 weeks post-injection</NAME>
<DICH_DATA CI_END="2.41238488009229" CI_START="0.10363188812161507" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.382446597815387" LOG_CI_START="-0.9845065891433494" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="150643" O_E="0.0" SE="0.8029550685469663" STUDY_ID="STD-Forster-2003" TOTAL_1="19" TOTAL_2="19" VAR="0.6447368421052633" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-009.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="19" TOTAL_2="19" WEIGHT="0.0" Z="0.0">
<NAME>Safety: number of patients with pain at injection site</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>Arthroscopy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hyalgan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Arthroscopy</GRAPH_LABEL_2>
<DICH_DATA CI_END="97.69696229084639" CI_START="0.2558933196466676" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9898810603325618" LOG_CI_START="-0.5919410516605246" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="150644" O_E="0.0" SE="1.5165750888103102" STUDY_ID="STD-Forster-2003" TOTAL_1="19" TOTAL_2="19" VAR="2.3000000000000003" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-010" NO="10">
<NAME>Hyalgan versus NSAID</NAME>
<CONT_OUTCOME CHI2="1.256559359897147" CI_END="3.178175803877296" CI_START="-3.92318215246541" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.3725031742940571" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-010.01" NO="1" P_CHI2="0.5335091630881381" P_Q="0.5335091630881381" P_Z="0.8370872709677073" Q="1.256559359897147" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="356" TOTAL_2="379" UNITS="" WEIGHT="300.0" Z="0.20562061798084774">
<NAME>Pain after 50 foot walk (0-100 mm VAS)</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>Naproxen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hyalgan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Naproxen</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="5.987744894990963" CI_START="-5.987744894990963" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-010.01.01" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="136" TOTAL_2="143" WEIGHT="100.0" Z="0.0">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="5.987744894990963" CI_START="-5.987744894990963" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="25.0" MEAN_2="25.0" ORDER="150645" SD_1="24.0" SD_2="27.0" SE="3.055028022056288" STUDY_ID="STD-Altman-1998" TOTAL_1="136" TOTAL_2="143" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="8.331254827773051" CI_START="-4.331254827773051" DF="0" EFFECT_SIZE="2.0" ESTIMABLE="YES" I2="0.0" ID="CMP-010.01.02" NO="2" P_CHI2="1.0" P_Z="0.5358246730168114" STUDIES="1" TAU2="0.0" TOTAL_1="115" TOTAL_2="125" WEIGHT="100.0" Z="0.6191391873668903">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="8.331254827773051" CI_START="-4.331254827773051" EFFECT_SIZE="2.0" ESTIMABLE="YES" MEAN_1="23.0" MEAN_2="21.0" ORDER="150646" SD_1="25.0" SD_2="25.0" SE="3.230291412348993" STUDY_ID="STD-Altman-1998" TOTAL_1="115" TOTAL_2="125" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.145239031072908" CI_START="-9.145239031072908" DF="0" EFFECT_SIZE="-3.0" ESTIMABLE="YES" I2="0.0" ID="CMP-010.01.03" NO="3" P_CHI2="1.0" P_Z="0.33865777069474134" STUDIES="1" TAU2="0.0" TOTAL_1="105" TOTAL_2="111" WEIGHT="100.0" Z="0.9568207068738842">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="3.145239031072908" CI_START="-9.145239031072908" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="18.0" MEAN_2="21.0" ORDER="150647" SD_1="21.0" SD_2="25.0" SE="3.135383649672019" STUDY_ID="STD-Altman-1998" TOTAL_1="105" TOTAL_2="111" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.2839660036419496" CI_START="0.6322558471154455" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9009966777408638" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="43" I2="0.0" I2_Q="0.0" ID="CMP-010.02" LOG_CI_END="0.1085535248027972" LOG_CI_START="-0.1991071456004324" LOG_EFFECT_SIZE="-0.04527681039881761" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.5640237135275157" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="105" TOTAL_2="113" WEIGHT="100.0" Z="0.5768752801599536">
<NAME>Number of patients with moderate or marked pain</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>Naproxen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hyalgan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Naproxen</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2839660036419496" CI_START="0.6322558471154455" DF="0" EFFECT_SIZE="0.9009966777408638" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="43" I2="0.0" ID="CMP-010.02.01" LOG_CI_END="0.1085535248027972" LOG_CI_START="-0.1991071456004324" LOG_EFFECT_SIZE="-0.04527681039881761" NO="1" P_CHI2="1.0" P_Z="0.5640237135275157" STUDIES="1" TAU2="0.0" TOTAL_1="105" TOTAL_2="113" WEIGHT="100.0" Z="0.5768752801599536">
<NAME>14 to 26 weeks post-injection</NAME>
<DICH_DATA CI_END="1.2839660036419496" CI_START="0.6322558471154455" EFFECT_SIZE="0.9009966777408638" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="43" LOG_CI_END="0.1085535248027972" LOG_CI_START="-0.1991071456004324" LOG_EFFECT_SIZE="-0.04527681039881761" ORDER="150648" O_E="0.0" SE="0.18072140073973733" STUDY_ID="STD-Altman-1998" TOTAL_1="105" TOTAL_2="113" VAR="0.03266022468533273" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.295589279803445" CI_START="0.8685864387552109" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0608163265306123" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="70" I2="0.0" I2_Q="0.0" ID="CMP-010.03" LOG_CI_END="0.11246734583592387" LOG_CI_START="-0.06118695556296352" LOG_EFFECT_SIZE="0.02564019513648016" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.5627373139972074" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="105" TOTAL_2="113" WEIGHT="100.0" Z="0.5787804692340569">
<NAME>Number of patients with none/slight/mild pain</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>Naproxen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hyalgan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Naproxen</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.295589279803445" CI_START="0.8685864387552109" DF="0" EFFECT_SIZE="1.0608163265306123" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="70" I2="0.0" ID="CMP-010.03.01" LOG_CI_END="0.11246734583592387" LOG_CI_START="-0.06118695556296352" LOG_EFFECT_SIZE="0.02564019513648016" NO="1" P_CHI2="1.0" P_Z="0.5627373139972074" STUDIES="1" TAU2="0.0" TOTAL_1="105" TOTAL_2="113" WEIGHT="100.0" Z="0.5787804692340569">
<NAME>14 to 26 weeks post-injection</NAME>
<DICH_DATA CI_END="1.295589279803445" CI_START="0.8685864387552109" EFFECT_SIZE="1.0608163265306123" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="70" LOG_CI_END="0.11246734583592387" LOG_CI_START="-0.06118695556296352" LOG_EFFECT_SIZE="0.02564019513648016" ORDER="150649" O_E="0.0" SE="0.10200539624436186" STUDY_ID="STD-Altman-1998" TOTAL_1="105" TOTAL_2="113" VAR="0.010405100862969273" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.5960540442980338" CI_START="0.8617949291184346" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1728048780487805" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="50" I2="0.0" I2_Q="0.0" ID="CMP-010.04" LOG_CI_END="0.2030475929940524" LOG_CI_START="-0.06459606566928179" LOG_EFFECT_SIZE="0.06922576366238532" METHOD="MH" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.3106374362111579" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="164" TOTAL_2="163" WEIGHT="100.0" Z="1.013885434522677">
<NAME>Safety: total withdrawals overall</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>Naproxen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hyalgan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Naproxen</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5960540442980338" CI_START="0.8617949291184346" DF="0" EFFECT_SIZE="1.1728048780487805" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="50" I2="0.0" ID="CMP-010.04.01" LOG_CI_END="0.2030475929940524" LOG_CI_START="-0.06459606566928179" LOG_EFFECT_SIZE="0.06922576366238532" NO="1" P_CHI2="1.0" P_Z="0.3106374362111579" STUDIES="1" TAU2="0.0" TOTAL_1="164" TOTAL_2="163" WEIGHT="100.0" Z="1.013885434522677">
<NAME>14 to 26 weeks post-injection</NAME>
<DICH_DATA CI_END="1.5960540442980338" CI_START="0.8617949291184346" EFFECT_SIZE="1.1728048780487805" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="50" LOG_CI_END="0.2030475929940524" LOG_CI_START="-0.06459606566928179" LOG_EFFECT_SIZE="0.06922576366238532" ORDER="150650" O_E="0.0" SE="0.1572152099563199" STUDY_ID="STD-Altman-1998" TOTAL_1="164" TOTAL_2="163" VAR="0.024716622241609754" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.3633583832101063E-31" CI_END="3.578441725262193" CI_START="0.7977951766907341" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6896341463414637" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="10" I2="100.0" I2_Q="0.0" ID="CMP-010.05" LOG_CI_END="0.5536939491444459" LOG_CI_START="-0.09810859367537812" LOG_EFFECT_SIZE="0.22779267773453393" METHOD="MH" NO="5" P_CHI2="0.0" P_Q="1.0" P_Z="0.17070538623440168" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="164" TOTAL_2="163" WEIGHT="100.0" Z="1.3699407871903342">
<NAME>Safety: withdrawals due to lack of efficacy</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>Naproxen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hyalgan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Naproxen</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.3633583832101063E-31" CI_END="3.578441725262193" CI_START="0.7977951766907341" DF="0" EFFECT_SIZE="1.6896341463414637" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="10" I2="100.0" ID="CMP-010.05.01" LOG_CI_END="0.5536939491444459" LOG_CI_START="-0.09810859367537812" LOG_EFFECT_SIZE="0.22779267773453393" NO="1" P_CHI2="0.0" P_Z="0.17070538623440168" STUDIES="1" TAU2="0.0" TOTAL_1="164" TOTAL_2="163" WEIGHT="100.0" Z="1.3699407871903342">
<NAME>14 to 26 weeks post-injection</NAME>
<DICH_DATA CI_END="3.5784417252621927" CI_START="0.797795176690734" EFFECT_SIZE="1.6896341463414635" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="10" LOG_CI_END="0.5536939491444459" LOG_CI_START="-0.09810859367537819" LOG_EFFECT_SIZE="0.22779267773453388" ORDER="150651" O_E="0.0" SE="0.38287204012698756" STUDY_ID="STD-Altman-1998" TOTAL_1="164" TOTAL_2="163" VAR="0.14659099911100157" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.8444806978475116" CI_START="0.09549083623808219" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.28397212543554007" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="14" I2="0.0" I2_Q="100.0" ID="CMP-010.06" LOG_CI_END="-0.07341027257505209" LOG_CI_START="-1.0200383034129794" LOG_EFFECT_SIZE="-0.5467242879940157" METHOD="MH" NO="6" P_CHI2="1.0" P_Q="0.0" P_Z="0.02357710588480679" Q="1.594580784297079E-31" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="164" TOTAL_2="163" WEIGHT="100.0" Z="2.263951370620331">
<NAME>Safety: number of patients withdrawn due to gastrointestinal events</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>Naproxen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hyalgan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Naproxen</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.8444806978475116" CI_START="0.09549083623808219" DF="0" EFFECT_SIZE="0.28397212543554007" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="14" I2="0.0" ID="CMP-010.06.01" LOG_CI_END="-0.07341027257505209" LOG_CI_START="-1.0200383034129794" LOG_EFFECT_SIZE="-0.5467242879940157" NO="1" P_CHI2="1.0" P_Z="0.02357710588480679" STUDIES="1" TAU2="0.0" TOTAL_1="164" TOTAL_2="163" WEIGHT="100.0" Z="2.263951370620331">
<NAME>14 to 26 weeks post-injection</NAME>
<DICH_DATA CI_END="0.8444806978475116" CI_START="0.09549083623808219" EFFECT_SIZE="0.28397212543554007" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="14" LOG_CI_END="-0.07341027257505209" LOG_CI_START="-1.0200383034129794" LOG_EFFECT_SIZE="-0.5467242879940157" ORDER="150652" O_E="0.0" SE="0.5560539911985241" STUDY_ID="STD-Altman-1998" TOTAL_1="164" TOTAL_2="163" VAR="0.30919604112780824" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="48.98522104039897" CI_START="0.7259804762220403" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="5.963414634146342" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-010.07" LOG_CI_END="1.6900650720952046" LOG_CI_START="-0.13907505861539732" LOG_EFFECT_SIZE="0.7754950067399036" METHOD="MH" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.09652881590564882" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="164" TOTAL_2="163" WEIGHT="100.0" Z="1.6619200004215926">
<NAME>Safety: number of patients withdrawn due to injection site pain</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>Naproxen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hyalgan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Naproxen</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="48.98522104039897" CI_START="0.7259804762220403" DF="0" EFFECT_SIZE="5.963414634146342" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" I2="0.0" ID="CMP-010.07.01" LOG_CI_END="1.6900650720952046" LOG_CI_START="-0.13907505861539732" LOG_EFFECT_SIZE="0.7754950067399036" NO="1" P_CHI2="1.0" P_Z="0.09652881590564882" STUDIES="1" TAU2="0.0" TOTAL_1="164" TOTAL_2="163" WEIGHT="100.0" Z="1.6619200004215926">
<NAME>14 to 26 weeks post-injection</NAME>
<DICH_DATA CI_END="48.98522104039897" CI_START="0.7259804762220403" EFFECT_SIZE="5.963414634146342" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.6900650720952046" LOG_CI_START="-0.13907505861539732" LOG_EFFECT_SIZE="0.7754950067399036" ORDER="150653" O_E="0.0" SE="1.0744459671690818" STUDY_ID="STD-Altman-1998" TOTAL_1="164" TOTAL_2="163" VAR="1.1544341363659036" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.785321577698059" CI_START="1.5208539376158376" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.697735191637631" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-010.08" LOG_CI_END="0.6799111280537294" LOG_CI_START="0.18208750653593478" LOG_EFFECT_SIZE="0.4309993172948321" METHOD="MH" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="6.894393231423486E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="164" TOTAL_2="163" WEIGHT="100.0" Z="3.393744702927991">
<NAME>Safety: number of patients with injection site pain</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>Naproxen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hyalgan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Naproxen</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.785321577698059" CI_START="1.5208539376158376" DF="0" EFFECT_SIZE="2.697735191637631" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="14" I2="0.0" ID="CMP-010.08.01" LOG_CI_END="0.6799111280537294" LOG_CI_START="0.18208750653593478" LOG_EFFECT_SIZE="0.4309993172948321" NO="1" P_CHI2="1.0" P_Z="6.894393231423486E-4" STUDIES="1" TAU2="0.0" TOTAL_1="164" TOTAL_2="163" WEIGHT="100.0" Z="3.393744702927991">
<NAME>14 to 26 weeks post-injection</NAME>
<DICH_DATA CI_END="4.785321577698058" CI_START="1.5208539376158379" EFFECT_SIZE="2.697735191637631" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="14" LOG_CI_END="0.6799111280537293" LOG_CI_START="0.18208750653593483" LOG_EFFECT_SIZE="0.4309993172948321" ORDER="150654" O_E="0.0" SE="0.2924240595462222" STUDY_ID="STD-Altman-1998" TOTAL_1="164" TOTAL_2="163" VAR="0.08551183060149249" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.293009666540118" CI_START="1.0147620936078452" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.0871951219512197" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-010.09" LOG_CI_END="0.6327618663784152" LOG_CI_START="0.0063642358019432785" LOG_EFFECT_SIZE="0.31956305109017924" METHOD="MH" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.045522871709428626" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="164" TOTAL_2="163" WEIGHT="100.0" Z="1.9997906772095324">
<NAME>Safety: number of patients with local joint pain or swelling</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>Naproxen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hyalgan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Naproxen</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.293009666540118" CI_START="1.0147620936078452" DF="0" EFFECT_SIZE="2.0871951219512197" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="10" I2="0.0" ID="CMP-010.09.01" LOG_CI_END="0.6327618663784152" LOG_CI_START="0.0063642358019432785" LOG_EFFECT_SIZE="0.31956305109017924" NO="1" P_CHI2="1.0" P_Z="0.045522871709428626" STUDIES="1" TAU2="0.0" TOTAL_1="164" TOTAL_2="163" WEIGHT="100.0" Z="1.9997906772095324">
<NAME>14 to 26 weeks post-injection</NAME>
<DICH_DATA CI_END="4.293009666540118" CI_START="1.0147620936078452" EFFECT_SIZE="2.0871951219512197" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="10" LOG_CI_END="0.6327618663784152" LOG_CI_START="0.0063642358019432785" LOG_EFFECT_SIZE="0.31956305109017924" ORDER="150655" O_E="0.0" SE="0.3679490689188987" STUDY_ID="STD-Altman-1998" TOTAL_1="164" TOTAL_2="163" VAR="0.1353865173182845" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.302869653995364" CI_START="0.47692075213326274" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7882674516400336" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="29" I2="0.0" I2_Q="0.0" ID="CMP-010.10" LOG_CI_END="0.11490096875773642" LOG_CI_START="-0.32155377980794303" LOG_EFFECT_SIZE="-0.10332640552510329" METHOD="MH" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="0.3534051318953795" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="164" TOTAL_2="163" WEIGHT="100.0" Z="0.9280047205201044">
<NAME>Safety: number of patients with local skin rash</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>Naproxen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hyalgan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Naproxen</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.302869653995364" CI_START="0.47692075213326274" DF="0" EFFECT_SIZE="0.7882674516400336" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="29" I2="0.0" ID="CMP-010.10.01" LOG_CI_END="0.11490096875773642" LOG_CI_START="-0.32155377980794303" LOG_EFFECT_SIZE="-0.10332640552510329" NO="1" P_CHI2="1.0" P_Z="0.3534051318953795" STUDIES="1" TAU2="0.0" TOTAL_1="164" TOTAL_2="163" WEIGHT="100.0" Z="0.9280047205201044">
<NAME>14 to 26 weeks post-injection</NAME>
<DICH_DATA CI_END="1.3028696539953637" CI_START="0.4769207521332628" EFFECT_SIZE="0.7882674516400336" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="29" LOG_CI_END="0.11490096875773635" LOG_CI_START="-0.321553779807943" LOG_EFFECT_SIZE="-0.10332640552510329" ORDER="150656" O_E="0.0" SE="0.2563756797933293" STUDY_ID="STD-Altman-1998" TOTAL_1="164" TOTAL_2="163" VAR="0.06572848918949173" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.9462916250007869" CI_START="0.5201482786491867" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7015781922525107" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="68" I2="0.0" I2_Q="0.0" ID="CMP-010.11" LOG_CI_END="-0.023975003544126613" LOG_CI_START="-0.2838728344046517" LOG_EFFECT_SIZE="-0.1539239189743892" METHOD="MH" NO="11" P_CHI2="1.0" P_Q="1.0" P_Z="0.020256169699940398" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="164" TOTAL_2="163" WEIGHT="100.0" Z="2.321568722218113">
<NAME>Safety: number of patients with gastrointestinal complaints</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>Naproxen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hyalgan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Naproxen</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9462916250007869" CI_START="0.5201482786491867" DF="0" EFFECT_SIZE="0.7015781922525107" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="68" I2="0.0" ID="CMP-010.11.01" LOG_CI_END="-0.023975003544126613" LOG_CI_START="-0.2838728344046517" LOG_EFFECT_SIZE="-0.1539239189743892" NO="1" P_CHI2="1.0" P_Z="0.020256169699940398" STUDIES="1" TAU2="0.0" TOTAL_1="164" TOTAL_2="163" WEIGHT="100.0" Z="2.321568722218113">
<NAME>14 to 26 weeks post-injection</NAME>
<DICH_DATA CI_END="0.9462916250007869" CI_START="0.5201482786491867" EFFECT_SIZE="0.7015781922525107" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="68" LOG_CI_END="-0.023975003544126613" LOG_CI_START="-0.2838728344046517" LOG_EFFECT_SIZE="-0.1539239189743892" ORDER="150657" O_E="0.0" SE="0.15266527236248387" STUDY_ID="STD-Altman-1998" TOTAL_1="164" TOTAL_2="163" VAR="0.02330668538551138" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.218472717825728" CI_START="0.6881746648758441" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.7038327526132404" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-010.12" LOG_CI_END="0.6251552447349032" LOG_CI_START="-0.1623013199556474" LOG_EFFECT_SIZE="0.23142696238962793" METHOD="MH" NO="12" P_CHI2="1.0" P_Q="1.0" P_Z="0.24930697217274966" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="164" TOTAL_2="163" WEIGHT="100.0" Z="1.1520343639866018">
<NAME>Safety: number of patients with pruritis (local)</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>Naproxen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hyalgan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Naproxen</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.218472717825728" CI_START="0.6881746648758441" DF="0" EFFECT_SIZE="1.7038327526132404" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" I2="0.0" ID="CMP-010.12.01" LOG_CI_END="0.6251552447349032" LOG_CI_START="-0.1623013199556474" LOG_EFFECT_SIZE="0.23142696238962793" NO="1" P_CHI2="1.0" P_Z="0.24930697217274966" STUDIES="1" TAU2="0.0" TOTAL_1="164" TOTAL_2="163" WEIGHT="100.0" Z="1.1520343639866018">
<NAME>14 to 26 weeks post-injection</NAME>
<DICH_DATA CI_END="4.218472717825727" CI_START="0.6881746648758442" EFFECT_SIZE="1.7038327526132404" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" LOG_CI_END="0.6251552447349031" LOG_CI_START="-0.16230131995564734" LOG_EFFECT_SIZE="0.23142696238962793" ORDER="150658" O_E="0.0" SE="0.4625558840720903" STUDY_ID="STD-Altman-1998" TOTAL_1="164" TOTAL_2="163" VAR="0.21395794588971304" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-011" NO="11">
<NAME>Hyalgan versus methylprednisolone acetate</NAME>
<CONT_OUTCOME CHI2="8.518500173420383" CI_END="-2.447871919385808" CI_START="-9.435168249929468" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="MD" EFFECT_SIZE="-5.941520084657638" ESTIMABLE="YES" I2="29.565065705799533" I2_Q="0.0" ID="CMP-011.01" NO="1" P_CHI2="0.20252250686654627" P_Q="0.4642772082866119" P_Z="8.58410750351625E-4" Q="1.53454749681545" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="185" TOTAL_2="187" UNITS="" WEIGHT="300.0" Z="3.3332393041484965">
<NAME>Spontaneous pain intensity (0-100 mm VAS)</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>MPA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hyalgan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MPA</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="3.150969689433224" CI_END="0.09995774447283612" CI_START="-9.907050304215815" DF="2" EFFECT_SIZE="-4.90354627987149" ESTIMABLE="YES" I2="36.52747575747875" ID="CMP-011.01.01" NO="1" P_CHI2="0.2069073252914979" P_Z="0.05475582813633949" STUDIES="3" TAU2="0.0" TOTAL_1="85" TOTAL_2="85" WEIGHT="100.0" Z="1.9208087089193278">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="14.794476969311608" CI_START="-7.994476969311608" EFFECT_SIZE="3.4000000000000004" ESTIMABLE="YES" MEAN_1="13.0" MEAN_2="9.6" ORDER="150659" SD_1="19.68" SD_2="16.99" SE="5.813615484360829" STUDY_ID="STD-Leardini-1987" TOTAL_1="20" TOTAL_2="20" WEIGHT="19.282339138623026"/>
<CONT_DATA CI_END="-0.3736760114050135" CI_START="-19.826323988594982" EFFECT_SIZE="-10.099999999999998" ESTIMABLE="YES" MEAN_1="10.73" MEAN_2="20.83" ORDER="150660" SD_1="17.22" SD_2="14.0" SE="4.962501385390235" STUDY_ID="STD-Leardini-1991" TOTAL_1="20" TOTAL_2="20" WEIGHT="26.463729137226334"/>
<CONT_DATA CI_END="1.4729535540579954" CI_START="-12.112953554057995" EFFECT_SIZE="-5.32" ESTIMABLE="YES" MEAN_1="20.0" MEAN_2="25.32" ORDER="150661" SD_1="16.44" SD_2="16.44" SE="3.465856315544544" STUDY_ID="STD-Pietrogrande-1991" TOTAL_1="45" TOTAL_2="45" WEIGHT="54.25393172415063"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.832982987171708" CI_END="-2.6435626538724684" CI_START="-12.808332183387366" DF="2" EFFECT_SIZE="-7.725947418629917" ESTIMABLE="YES" I2="47.82131810410759" ID="CMP-011.01.02" NO="2" P_CHI2="0.14712236558632263" P_Z="0.002887909450004575" STUDIES="3" TAU2="0.0" TOTAL_1="85" TOTAL_2="85" WEIGHT="100.0" Z="2.979423909808509">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="14.989392113826279" CI_START="-10.78939211382628" EFFECT_SIZE="2.0999999999999996" ESTIMABLE="YES" MEAN_1="11.2" MEAN_2="9.1" ORDER="150662" SD_1="20.57" SD_2="21.02" SE="6.576341308052678" STUDY_ID="STD-Leardini-1987" TOTAL_1="20" TOTAL_2="20" WEIGHT="15.547845251382599"/>
<CONT_DATA CI_END="-4.325492552177154" CI_START="-23.374507447822843" EFFECT_SIZE="-13.849999999999998" ESTIMABLE="YES" MEAN_1="9.48" MEAN_2="23.33" ORDER="150663" SD_1="15.83" SD_2="14.89" SE="4.859531870458306" STUDY_ID="STD-Leardini-1991" TOTAL_1="20" TOTAL_2="20" WEIGHT="28.474101541634948"/>
<CONT_DATA CI_END="-0.5470464459420041" CI_START="-14.132953554057995" EFFECT_SIZE="-7.34" ESTIMABLE="YES" MEAN_1="19.71" MEAN_2="27.05" ORDER="150664" SD_1="16.44" SD_2="16.44" SE="3.465856315544544" STUDY_ID="STD-Pietrogrande-1991" TOTAL_1="45" TOTAL_2="45" WEIGHT="55.97805320698245"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="19.98197964818727" CI_START="-14.98197964818727" DF="0" EFFECT_SIZE="2.5" ESTIMABLE="YES" I2="0.0" ID="CMP-011.01.03" NO="3" P_CHI2="1.0" P_Z="0.779260030214947" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="17" WEIGHT="100.0" Z="0.2802834724646424">
<NAME>45 to 52 weeks post-injection</NAME>
<CONT_DATA CI_END="19.98197964818727" CI_START="-14.98197964818727" EFFECT_SIZE="2.5" ESTIMABLE="YES" MEAN_1="20.3" MEAN_2="17.8" ORDER="150665" SD_1="25.56" SD_2="24.74" SE="8.919541270188072" STUDY_ID="STD-Leardini-1987" TOTAL_1="15" TOTAL_2="17" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.8031180067206163" CI_END="1.4128018020867792" CI_START="0.7284353624020954" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0144628099173554" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="31" I2="0.0" I2_Q="0.0" ID="CMP-011.02" LOG_CI_END="0.1500812401943123" LOG_CI_START="-0.13760897923720022" LOG_EFFECT_SIZE="0.006236130478556004" METHOD="MH" NO="2" P_CHI2="0.6692760643290492" P_Q="0.6707763855584247" P_Z="0.932284842103475" Q="0.7986395821168464" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="55" TOTAL_2="57" WEIGHT="300.0" Z="0.08497050170850184">
<NAME>Number of joints with moderate or severe walking pain</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>MPA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hyalgan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MPA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.285751787512423" CI_START="0.6535386600832783" DF="0" EFFECT_SIZE="1.2222222222222223" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" I2="0.0" ID="CMP-011.02.01" LOG_CI_END="0.35902906806871127" LOG_CI_START="-0.1847287166309109" LOG_EFFECT_SIZE="0.0871501757189002" NO="1" P_CHI2="1.0" P_Z="0.5298322544242381" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.6282621066280073">
<NAME>1 to 4 weeks post-injection</NAME>
<DICH_DATA CI_END="2.285751787512423" CI_START="0.6535386600832783" EFFECT_SIZE="1.2222222222222223" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.35902906806871127" LOG_CI_START="-0.1847287166309109" LOG_EFFECT_SIZE="0.0871501757189002" ORDER="150666" O_E="0.0" SE="0.3194060143770026" STUDY_ID="STD-Leardini-1987" TOTAL_1="20" TOTAL_2="20" VAR="0.102020202020202" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5996876010856385" CI_START="0.4000781149804874" DF="0" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" I2="0.0" ID="CMP-011.02.02" LOG_CI_END="0.20403517867378299" LOG_CI_START="-0.3978552046898957" LOG_EFFECT_SIZE="-0.09691001300805639" NO="2" P_CHI2="1.0" P_Z="0.5279455450200202" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.631145273249304">
<NAME>5 to 13 weeks post-injection</NAME>
<DICH_DATA CI_END="1.5996876010856382" CI_START="0.4000781149804874" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.20403517867378293" LOG_CI_START="-0.3978552046898957" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="150667" O_E="0.0" SE="0.35355339059327373" STUDY_ID="STD-Leardini-1987" TOTAL_1="20" TOTAL_2="20" VAR="0.12499999999999999" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6014508280076654" CI_START="0.6739452155390339" DF="0" EFFECT_SIZE="1.038888888888889" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" I2="0.0" ID="CMP-011.02.03" LOG_CI_END="0.20451360834309212" LOG_CI_START="-0.17137540547670627" LOG_EFFECT_SIZE="0.016569101433192936" NO="3" P_CHI2="1.0" P_Z="0.8628168711506181" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="17" WEIGHT="100.0" Z="0.1727895249464121">
<NAME>45 to 52 weeks post-injection</NAME>
<DICH_DATA CI_END="1.6014508280076654" CI_START="0.6739452155390339" EFFECT_SIZE="1.038888888888889" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" LOG_CI_END="0.20451360834309212" LOG_CI_START="-0.17137540547670627" LOG_EFFECT_SIZE="0.016569101433192936" ORDER="150668" O_E="0.0" SE="0.22079906739837668" STUDY_ID="STD-Leardini-1987" TOTAL_1="15" TOTAL_2="17" VAR="0.04875222816399288" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.976582468673971" CI_END="0.9512845637770165" CI_START="0.6204423532306744" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7682559686340404" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="80" I2="39.71766731719888" I2_Q="73.70825500777246" ID="CMP-011.03" LOG_CI_END="-0.02168955036862121" LOG_CI_START="-0.20729856362027718" LOG_EFFECT_SIZE="-0.11449405699444919" METHOD="MH" NO="3" P_CHI2="0.1735201062241244" P_Q="0.051146368413252485" P_Z="0.015604722281368109" Q="3.8034751983773765" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="129" TOTAL_2="130" WEIGHT="200.0" Z="2.4180315839375823">
<NAME>Number of patients with moderate or severe pain under load</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>MPA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hyalgan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MPA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.3426412981754234" CI_END="1.2657951001894807" CI_START="0.7069183096992737" DF="1" EFFECT_SIZE="0.9459459459459459" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="37" I2="70.08353841179881" ID="CMP-011.03.01" LOG_CI_END="0.10236341021608386" LOG_CI_START="-0.15063076964952257" LOG_EFFECT_SIZE="-0.024133679716719363" NO="1" P_CHI2="0.067506240890578" P_Z="0.7084558897548541" STUDIES="2" TAU2="0.0" TOTAL_1="65" TOTAL_2="65" WEIGHT="100.0" Z="0.3739306816016219">
<NAME>1 to 4 weeks post-injection</NAME>
<DICH_DATA CI_END="0.9986358551201121" CI_START="0.5436779435716739" EFFECT_SIZE="0.7368421052631579" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="19" LOG_CI_END="-5.928450491188232E-4" LOG_CI_START="-0.2646582855000631" LOG_EFFECT_SIZE="-0.13262556527459096" ORDER="150669" O_E="0.0" SE="0.15511334686589623" STUDY_ID="STD-Leardini-1991" TOTAL_1="20" TOTAL_2="20" VAR="0.024060150375939837" WEIGHT="51.35135135135135"/>
<DICH_DATA CI_END="1.8759859277010924" CI_START="0.72554441427984" EFFECT_SIZE="1.1666666666666667" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="18" LOG_CI_END="0.2732295762900151" LOG_CI_START="-0.13933599702878866" LOG_EFFECT_SIZE="0.06694678963061322" ORDER="150670" O_E="0.0" SE="0.24234305999998992" STUDY_ID="STD-Pietrogrande-1991" TOTAL_1="45" TOTAL_2="45" VAR="0.058730158730158716" WEIGHT="48.648648648648646"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.21390853422081182" CI_END="0.8463266758147402" CI_START="0.4486681555320149" DF="1" EFFECT_SIZE="0.61621410939327" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="43" I2="0.0" ID="CMP-011.03.02" LOG_CI_END="-0.07246197015349466" LOG_CI_START="-0.34807475366172186" LOG_EFFECT_SIZE="-0.21026836190760825" NO="2" P_CHI2="0.6437210463931861" P_Z="0.0027846553368760865" STUDIES="2" TAU2="0.0" TOTAL_1="64" TOTAL_2="65" WEIGHT="100.0" Z="2.99056096877193">
<NAME>5 to 13 weeks post-injection</NAME>
<DICH_DATA CI_END="0.912082885603881" CI_START="0.47547261450716666" EFFECT_SIZE="0.6585365853658537" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="20" LOG_CI_END="-0.03996569333305207" LOG_CI_START="-0.3228744917884443" LOG_EFFECT_SIZE="-0.18142009256074818" ORDER="150671" O_E="0.0" SE="0.1661820286338354" STUDY_ID="STD-Leardini-1991" TOTAL_1="20" TOTAL_2="20" VAR="0.027616466640856888" WEIGHT="47.40808107054696"/>
<DICH_DATA CI_END="0.9903475683851709" CI_START="0.3374139760485009" EFFECT_SIZE="0.5780632411067194" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="23" LOG_CI_END="-0.004212360411759157" LOG_CI_START="-0.4718369324314406" LOG_EFFECT_SIZE="-0.23802464642159987" ORDER="150672" O_E="0.0" SE="0.2746849883833246" STUDY_ID="STD-Pietrogrande-1991" TOTAL_1="44" TOTAL_2="45" VAR="0.07545184284314718" WEIGHT="52.59191892945303"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.1618533582090707" CI_END="1.354730866618713" CI_START="0.5832327853887325" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8888888888888888" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="26" I2="0.0" I2_Q="0.0" ID="CMP-011.04" LOG_CI_END="0.131853026020954" LOG_CI_START="-0.2341580709157166" LOG_EFFECT_SIZE="-0.05115252244738131" METHOD="MH" NO="4" P_CHI2="0.9222613370314166" P_Q="0.9232851410112816" P_Z="0.583804241570514" Q="0.15963438208192607" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="55" TOTAL_2="57" WEIGHT="300.0" Z="0.5478364047120194">
<NAME>Number of joints with moderate or severe pain under load</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>MPA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hyalgan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MPA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.1363329557898925" CI_START="0.46809182870572613" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" I2="0.0" ID="CMP-011.04.01" LOG_CI_END="0.32966894011371894" LOG_CI_START="-0.329668940113719" LOG_EFFECT_SIZE="0.0" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.0">
<NAME>1 to 4 weeks post-injection</NAME>
<DICH_DATA CI_END="2.1363329557898925" CI_START="0.46809182870572613" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.32966894011371894" LOG_CI_START="-0.329668940113719" LOG_EFFECT_SIZE="0.0" ORDER="150673" O_E="0.0" SE="0.3872983346207417" STUDY_ID="STD-Leardini-1987" TOTAL_1="20" TOTAL_2="20" VAR="0.15000000000000002" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.102230118933325" CI_START="0.3494830898549799" DF="0" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" I2="0.0" ID="CMP-011.04.02" LOG_CI_END="0.32268025399138267" LOG_CI_START="-0.45657383325260914" LOG_EFFECT_SIZE="-0.06694678963061322" NO="2" P_CHI2="1.0" P_Z="0.7362930050296262" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.3367663993156506">
<NAME>5 to 13 weeks post-injection</NAME>
<DICH_DATA CI_END="2.102230118933325" CI_START="0.3494830898549799" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.32268025399138267" LOG_CI_START="-0.45657383325260914" LOG_EFFECT_SIZE="-0.06694678963061322" ORDER="150674" O_E="0.0" SE="0.4577377082170635" STUDY_ID="STD-Leardini-1987" TOTAL_1="20" TOTAL_2="20" VAR="0.20952380952380956" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4859664717715688" CI_START="0.45719441644674336" DF="0" EFFECT_SIZE="0.8242424242424242" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" I2="0.0" ID="CMP-011.04.03" LOG_CI_END="0.17200901044146932" LOG_CI_START="-0.3398990821288468" LOG_EFFECT_SIZE="-0.08394503584368879" NO="3" P_CHI2="1.0" P_Z="0.520348851659981" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="17" WEIGHT="100.0" Z="0.6428077591367793">
<NAME>45 to 52 weeks post-injection</NAME>
<DICH_DATA CI_END="1.4859664717715684" CI_START="0.4571944164467434" EFFECT_SIZE="0.8242424242424242" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" LOG_CI_END="0.17200901044146918" LOG_CI_START="-0.33989908212884673" LOG_EFFECT_SIZE="-0.08394503584368879" ORDER="150675" O_E="0.0" SE="0.30069734756172944" STUDY_ID="STD-Leardini-1987" TOTAL_1="15" TOTAL_2="17" VAR="0.09041889483065953" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.378699170891853" CI_END="1.4546651032985656" CI_START="0.23536554581740612" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5851307939421753" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="11" I2="52.96846708667485" I2_Q="67.73369873562046" ID="CMP-011.05" LOG_CI_END="0.16276302044881574" LOG_CI_START="-0.6282571114013792" LOG_EFFECT_SIZE="-0.23274704547628167" METHOD="MH" NO="5" P_CHI2="0.09457116171813795" P_Q="0.07833063406895657" P_Z="0.24875194912976284" Q="3.0992086505556578" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="129" TOTAL_2="130" WEIGHT="200.0" Z="1.15338613588664">
<NAME>Number of patients with at least moderate or greater night pain</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>MPA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hyalgan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MPA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.9021090005220396" CI_END="3.80031342704941" CI_START="0.37891611511580664" DF="1" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" I2="74.3728327459275" ID="CMP-011.05.01" LOG_CI_END="0.5798194160969992" LOG_CI_START="-0.4214569240017495" LOG_EFFECT_SIZE="0.07918124604762482" NO="1" P_CHI2="0.04822559167460372" P_Z="0.7565692233617288" STUDIES="2" TAU2="0.0" TOTAL_1="65" TOTAL_2="65" WEIGHT="100.0" Z="0.30998912945260176">
<NAME>1 to 4 weeks post-injection</NAME>
<DICH_DATA CI_END="2.0452762263354756" CI_START="0.03055821956723241" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.31075197027588036" LOG_CI_START="-1.514871952931805" LOG_EFFECT_SIZE="-0.6020599913279624" ORDER="150676" O_E="0.0" SE="1.0723805294763609" STUDY_ID="STD-Leardini-1991" TOTAL_1="20" TOTAL_2="20" VAR="1.15" WEIGHT="80.0"/>
<DICH_DATA CI_END="41.113473432932444" CI_START="0.6080731670794483" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.6139841692890395" LOG_CI_START="-0.2160441606170021" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="150677" O_E="0.0" SE="1.07496769977314" STUDY_ID="STD-Pietrogrande-1991" TOTAL_1="45" TOTAL_2="45" VAR="1.1555555555555557" WEIGHT="20.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.08366890811961816" CI_END="1.1292925754962353" CI_START="0.01841503134315346" DF="1" EFFECT_SIZE="0.1442080378250591" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" I2="0.0" ID="CMP-011.05.02" LOG_CI_END="0.05280647289251806" LOG_CI_START="-1.734827537621069" LOG_EFFECT_SIZE="-0.8410105323642754" NO="2" P_CHI2="0.7723856580922879" P_Z="0.06515839382726298" STUDIES="2" TAU2="0.0" TOTAL_1="64" TOTAL_2="65" WEIGHT="100.0" Z="1.8441698293480855">
<NAME>5 to 13 weeks post-injection</NAME>
<DICH_DATA CI_END="1.9371598241474748" CI_START="0.006373082312802401" EFFECT_SIZE="0.1111111111111111" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.2871654533891674" LOG_CI_START="-2.195650472267817" LOG_EFFECT_SIZE="-0.9542425094393249" ORDER="150678" O_E="0.0" SE="1.4584183648679576" STUDY_ID="STD-Leardini-1991" TOTAL_1="20" TOTAL_2="20" VAR="2.1269841269841274" WEIGHT="64.53900709219859"/>
<DICH_DATA CI_END="4.141121877590242" CI_START="0.010093286819300256" EFFECT_SIZE="0.20444444444444446" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6171180124357271" LOG_CI_START="-1.995967385295304" LOG_EFFECT_SIZE="-0.6894246864297884" ORDER="150679" O_E="0.0" SE="1.534939297608539" STUDY_ID="STD-Pietrogrande-1991" TOTAL_1="44" TOTAL_2="45" VAR="2.356038647342995" WEIGHT="35.46099290780142"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.455778215866724" CI_END="0.8464925856624634" CI_START="0.346188697295819" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.541337386018237" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="37" I2="0.0" I2_Q="31.00248817056146" ID="CMP-011.06" LOG_CI_END="-0.07237684147705528" LOG_CI_START="-0.4606871154964064" LOG_EFFECT_SIZE="-0.2665319784867308" METHOD="MH" NO="6" P_CHI2="0.48333622268580456" P_Q="0.22863615574413032" P_Z="0.007132446262660801" Q="1.4493276257149597" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="129" TOTAL_2="130" WEIGHT="199.99999999999997" Z="2.690596224276898">
<NAME>Number of patients with moderate or greater rest pain</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>MPA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hyalgan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MPA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.252767149529077" CI_END="1.2382066489956047" CI_START="0.37808232147765786" DF="1" EFFECT_SIZE="0.6842105263157895" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="19" I2="20.176706391454616" ID="CMP-011.06.01" LOG_CI_END="0.09279313178345071" LOG_CI_START="-0.42241362907543506" LOG_EFFECT_SIZE="-0.16481024864599217" NO="1" P_CHI2="0.2630247140452866" P_Z="0.2098596499587123" STUDIES="2" TAU2="0.0" TOTAL_1="65" TOTAL_2="65" WEIGHT="100.0" Z="1.2539515245907698">
<NAME>1 to 4 weeks post-injection</NAME>
<DICH_DATA CI_END="1.0681664778949462" CI_START="0.23404591435286307" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="12" LOG_CI_END="0.02863894444973777" LOG_CI_START="-0.6306989357777002" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="150680" O_E="0.0" SE="0.3872983346207417" STUDY_ID="STD-Leardini-1991" TOTAL_1="20" TOTAL_2="20" VAR="0.15000000000000002" WEIGHT="63.15789473684211"/>
<DICH_DATA CI_END="2.6188077292621585" CI_START="0.3818531573838554" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.4181036140473284" LOG_CI_START="-0.41810361404732843" LOG_EFFECT_SIZE="0.0" ORDER="150681" O_E="0.0" SE="0.49119226507533814" STUDY_ID="STD-Pietrogrande-1991" TOTAL_1="45" TOTAL_2="45" VAR="0.24126984126984127" WEIGHT="36.8421052631579"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.01875129708536545" CI_END="0.7823762686760802" CI_START="0.19465097484173566" DF="1" EFFECT_SIZE="0.39024390243902435" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="18" I2="0.0" ID="CMP-011.06.02" LOG_CI_END="-0.10658433120017574" LOG_CI_START="-0.7107434169274459" LOG_EFFECT_SIZE="-0.4086638740638108" NO="2" P_CHI2="0.8910818833470249" P_Z="0.00801330964780104" STUDIES="2" TAU2="0.0" TOTAL_1="64" TOTAL_2="65" WEIGHT="99.99999999999997" Z="2.6515084979099504">
<NAME>5 to 13 weeks post-injection</NAME>
<DICH_DATA CI_END="0.818228964055897" CI_START="0.1955442877588842" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="15" LOG_CI_END="-0.0871251512040475" LOG_CI_START="-0.7087548661400277" LOG_EFFECT_SIZE="-0.3979400086720376" ORDER="150682" O_E="0.0" SE="0.36514837167011077" STUDY_ID="STD-Leardini-1991" TOTAL_1="20" TOTAL_2="20" VAR="0.13333333333333336" WEIGHT="83.48968105065664"/>
<DICH_DATA CI_END="3.1536383867094995" CI_START="0.03685235718662263" EFFECT_SIZE="0.3409090909090909" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4988118932857775" LOG_CI_START="-1.4335347281467898" LOG_EFFECT_SIZE="-0.46736141743050624" ORDER="150683" O_E="0.0" SE="1.1350699706995329" STUDY_ID="STD-Pietrogrande-1991" TOTAL_1="44" TOTAL_2="45" VAR="1.2883838383838384" WEIGHT="16.510318949343336"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="3.34521647946029" CI_END="8.86653900476035" CI_START="1.9594655520264852" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="5.413002278393417" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-011.07" NO="7" P_CHI2="0.5018003506992167" P_Q="0.8520810938481187" P_Z="0.002126246325466577" Q="0.3201472000411656" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="145" TOTAL_2="147" UNITS="" WEIGHT="300.0" Z="3.072007149333305">
<NAME>Function: range of motion (flexion in degrees)</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>MPA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours MPA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Hyalgan</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.882010163424779" CI_END="11.141227621662551" CI_START="0.7144131509301408" DF="1" EFFECT_SIZE="5.9278203862963466" ESTIMABLE="YES" I2="46.865324139363054" ID="CMP-011.07.01" NO="1" P_CHI2="0.17010606744405232" P_Z="0.025844170565459044" STUDIES="2" TAU2="0.0" TOTAL_1="65" TOTAL_2="65" WEIGHT="100.0" Z="2.2285453522886063">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="9.760458017965297" CI_START="-7.760458017965297" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="113.4" MEAN_2="112.4" ORDER="150684" SD_1="12.97" SD_2="15.21" SE="4.469703569589376" STUDY_ID="STD-Leardini-1987" TOTAL_1="20" TOTAL_2="20" WEIGHT="35.415198082616655"/>
<CONT_DATA CI_END="15.11718800478774" CI_START="2.1428119952122504" EFFECT_SIZE="8.629999999999995" ESTIMABLE="YES" MEAN_1="121.38" MEAN_2="112.75" ORDER="150685" SD_1="15.7" SD_2="15.7" SE="3.3098506176429034" STUDY_ID="STD-Pietrogrande-1991" TOTAL_1="45" TOTAL_2="45" WEIGHT="64.58480191738334"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.1430591159943455" CI_END="10.27509412793029" CI_START="0.5445072908691966" DF="1" EFFECT_SIZE="5.409800709399743" ESTIMABLE="YES" I2="12.515460835977725" ID="CMP-011.07.02" NO="2" P_CHI2="0.2850068910561888" P_Z="0.02930815928218752" STUDIES="2" TAU2="0.0" TOTAL_1="65" TOTAL_2="65" WEIGHT="100.0" Z="2.179316567748783">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="9.75630125887685" CI_START="-4.956301258876839" EFFECT_SIZE="2.4000000000000057" ESTIMABLE="YES" MEAN_1="116.7" MEAN_2="114.3" ORDER="150686" SD_1="12.52" SD_2="11.18" SE="3.753283895470738" STUDY_ID="STD-Leardini-1987" TOTAL_1="20" TOTAL_2="20" WEIGHT="43.742042814958104"/>
<CONT_DATA CI_END="14.236599106981748" CI_START="1.263400893018252" EFFECT_SIZE="7.75" ESTIMABLE="YES" MEAN_1="121.1" MEAN_2="113.35" ORDER="150687" SD_1="16.03" SD_2="15.36" SE="3.3095501540575305" STUDY_ID="STD-Pietrogrande-1991" TOTAL_1="45" TOTAL_2="45" WEIGHT="56.257957185041896"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="15.92467098984495" CI_START="-12.92467098984495" DF="0" EFFECT_SIZE="1.5" ESTIMABLE="YES" I2="0.0" ID="CMP-011.07.03" NO="3" P_CHI2="1.0" P_Z="0.8384990643558187" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="17" WEIGHT="100.0" Z="0.20381372849889057">
<NAME>45 to 52 weeks post-injection</NAME>
<CONT_DATA CI_END="15.92467098984495" CI_START="-12.92467098984495" EFFECT_SIZE="1.5" ESTIMABLE="YES" MEAN_1="109.6" MEAN_2="108.1" ORDER="150688" SD_1="22.85" SD_2="18.14" SE="7.359661250729561" STUDY_ID="STD-Leardini-1987" TOTAL_1="15" TOTAL_2="17" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="29.50605439563264" CI_END="1.3481285034670525" CI_START="0.9749185256893604" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1464359786049558" ESTIMABLE="YES" EVENTS_1="135" EVENTS_2="108" I2="83.05432528200015" I2_Q="77.80128850730522" ID="CMP-011.08" LOG_CI_END="0.1297312910767038" LOG_CI_START="-0.011031676939419137" LOG_EFFECT_SIZE="0.059349807068642346" METHOD="MH" NO="8" P_CHI2="1.844579091681009E-5" P_Q="0.011056191893424439" P_Z="0.09838034603595879" Q="9.009531930076959" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="214" TOTAL_2="199" WEIGHT="300.0" Z="1.6527569144551726">
<NAME>Patient global (number of patients very good or good, excellent or /good)</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>MPA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours MPA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Hyalgan</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="18.532714231147242" CI_END="1.1805748508625116" CI_START="0.7528629344642356" DF="2" EFFECT_SIZE="0.9427677585572323" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="62" I2="89.20827259809211" ID="CMP-011.08.01" LOG_CI_END="0.07209352744695036" LOG_CI_START="-0.1232840838580121" LOG_EFFECT_SIZE="-0.025595278205530852" NO="1" P_CHI2="9.455265588143025E-5" P_Z="0.6075828444420892" STUDIES="3" TAU2="0.0" TOTAL_1="111" TOTAL_2="102" WEIGHT="100.0" Z="0.5135268378199205">
<NAME>1 to 4 weeks post-injection</NAME>
<DICH_DATA CI_END="0.7416487120495858" CI_START="0.3756887330669353" EFFECT_SIZE="0.5278532608695652" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="32" LOG_CI_END="-0.12980175313598166" LOG_CI_START="-0.42517182926515" LOG_EFFECT_SIZE="-0.2774867912005658" ORDER="150689" O_E="0.0" SE="0.17350184482373085" STUDY_ID="STD-Frizziero-2002" TOTAL_1="46" TOTAL_2="37" VAR="0.03010289015723798" WEIGHT="54.177401545822605"/>
<DICH_DATA CI_END="2.285751787512423" CI_START="0.6535386600832783" EFFECT_SIZE="1.2222222222222223" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.35902906806871127" LOG_CI_START="-0.1847287166309109" LOG_EFFECT_SIZE="0.0871501757189002" ORDER="150690" O_E="0.0" SE="0.3194060143770026" STUDY_ID="STD-Leardini-1991" TOTAL_1="20" TOTAL_2="20" VAR="0.102020202020202" WEIGHT="13.746779536253221"/>
<DICH_DATA CI_END="2.1921057312938896" CI_START="1.0592534072168365" EFFECT_SIZE="1.5238095238095237" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="21" LOG_CI_END="0.3408614975359149" LOG_CI_START="0.024999869636058495" LOG_EFFECT_SIZE="0.1829306835859867" ORDER="150691" O_E="0.0" SE="0.18553868376865015" STUDY_ID="STD-Pietrogrande-1991" TOTAL_1="45" TOTAL_2="45" VAR="0.03442460317460316" WEIGHT="32.07581891792418"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.691025386698221" CI_END="2.7468233769664145" CI_START="1.2644207578076958" DF="1" EFFECT_SIZE="1.8636363636363635" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="22" I2="0.0" ID="CMP-011.08.02" LOG_CI_END="0.43883073482101576" LOG_CI_START="0.10189161697404268" LOG_EFFECT_SIZE="0.2703611758975292" NO="2" P_CHI2="0.4058162240015043" P_Z="0.0016588002403837522" STUDIES="2" TAU2="0.0" TOTAL_1="65" TOTAL_2="65" WEIGHT="100.0" Z="3.145364485804338">
<NAME>5 to 13 weeks post-injection</NAME>
<DICH_DATA CI_END="2.9965801800903877" CI_START="0.6810484632081674" EFFECT_SIZE="1.4285714285714286" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.47662590269158706" LOG_CI_START="-0.1668219827201008" LOG_EFFECT_SIZE="0.1549019599857432" ORDER="150692" O_E="0.0" SE="0.3779644730092272" STUDY_ID="STD-Leardini-1991" TOTAL_1="20" TOTAL_2="20" VAR="0.14285714285714285" WEIGHT="31.81818181818182"/>
<DICH_DATA CI_END="3.265498539830193" CI_START="1.3079507030902582" EFFECT_SIZE="2.066666666666667" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="15" LOG_CI_END="0.5139494939017575" LOG_CI_START="0.11659137565542553" LOG_EFFECT_SIZE="0.31527043477859146" ORDER="150693" O_E="0.0" SE="0.23341012561230337" STUDY_ID="STD-Pietrogrande-1991" TOTAL_1="45" TOTAL_2="45" VAR="0.054480286738351244" WEIGHT="68.18181818181819"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3635401010850476" CI_START="0.8126150746248708" DF="0" EFFECT_SIZE="1.0526315789473684" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="24" I2="0.0" ID="CMP-011.08.03" LOG_CI_END="0.13466791486573704" LOG_CI_START="-0.09011512544343259" LOG_EFFECT_SIZE="0.022276394711152208" NO="3" P_CHI2="1.0" P_Z="0.697666951487748" STUDIES="1" TAU2="0.0" TOTAL_1="38" TOTAL_2="32" WEIGHT="100.0" Z="0.3884717572927659">
<NAME>14 to 26 weeks post-injection</NAME>
<DICH_DATA CI_END="1.3635401010850476" CI_START="0.8126150746248708" EFFECT_SIZE="1.0526315789473684" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="24" LOG_CI_END="0.13466791486573704" LOG_CI_START="-0.09011512544343259" LOG_EFFECT_SIZE="0.022276394711152208" ORDER="150694" O_E="0.0" SE="0.13203867057160107" STUDY_ID="STD-Frizziero-2002" TOTAL_1="38" TOTAL_2="32" VAR="0.017434210526315788" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.9447554422841495" CI_END="1.9855693925729019" CI_START="0.6390100023939582" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.126409651193286" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="18" I2="23.949658124740516" I2_Q="23.91917792438811" ID="CMP-011.09" LOG_CI_END="0.29788506958417416" LOG_CI_START="-0.19449234379699326" LOG_EFFECT_SIZE="0.051696362893590427" METHOD="MH" NO="9" P_CHI2="0.2674917347585475" P_Q="0.2676660026452765" P_Z="0.6806572355794556" Q="3.943175057990949" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="189" TOTAL_2="179" WEIGHT="400.0" Z="0.41156643927820563">
<NAME>Safety: total withdrawals overall</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>MPA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hyalgan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MPA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.377352018492142" CI_START="0.2135239424544921" DF="0" EFFECT_SIZE="0.5423076923076923" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" I2="0.0" ID="CMP-011.09.01" LOG_CI_END="0.1390449498072434" LOG_CI_START="-0.6705534204381196" LOG_EFFECT_SIZE="-0.26575423531543807" NO="1" P_CHI2="1.0" P_Z="0.1981871427416338" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="47" WEIGHT="99.99999999999999" Z="1.286733642508156">
<NAME>1 to 4 weeks post-injection</NAME>
<DICH_DATA CI_END="1.377352018492142" CI_START="0.2135239424544921" EFFECT_SIZE="0.5423076923076923" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="0.1390449498072434" LOG_CI_START="-0.6705534204381196" LOG_EFFECT_SIZE="-0.26575423531543807" ORDER="150695" O_E="0.0" SE="0.4755620902586923" STUDY_ID="STD-Frizziero-2002" TOTAL_1="52" TOTAL_2="47" VAR="0.2261593016912166" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="71.73802435585947" CI_START="0.12545647975131194" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-011.09.02" LOG_CI_END="1.8557494121620413" LOG_CI_START="-0.901506902722716" LOG_EFFECT_SIZE="0.47712125471966244" NO="2" P_CHI2="1.0" P_Z="0.4975736880191909" STUDIES="2" TAU2="0.0" TOTAL_1="65" TOTAL_2="65" WEIGHT="100.0" Z="0.6783123284265179">
<NAME>5 to 13 weeks post-injection</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="150696" O_E="0.0" SE="0.0" STUDY_ID="STD-Leardini-1991" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="71.73802435585941" CI_START="0.12545647975131194" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8557494121620408" LOG_CI_START="-0.901506902722716" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="150697" O_E="0.0" SE="1.6196260080021871" STUDY_ID="STD-Pietrogrande-1991" TOTAL_1="45" TOTAL_2="45" VAR="2.623188405797101" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.9060294155852215" CI_START="0.6660684644305468" DF="0" EFFECT_SIZE="1.8076923076923077" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" I2="0.0" ID="CMP-011.09.03" LOG_CI_END="0.6907301478222718" LOG_CI_START="-0.17648112789247272" LOG_EFFECT_SIZE="0.2571245099648995" NO="3" P_CHI2="1.0" P_Z="0.2451371095160091" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="47" WEIGHT="99.99999999999999" Z="1.1622422198289803">
<NAME>14 to 26 weeks post-injection</NAME>
<DICH_DATA CI_END="4.9060294155852215" CI_START="0.6660684644305466" EFFECT_SIZE="1.8076923076923077" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" LOG_CI_END="0.6907301478222718" LOG_CI_START="-0.17648112789247286" LOG_EFFECT_SIZE="0.2571245099648995" ORDER="150698" O_E="0.0" SE="0.5094041961198886" STUDY_ID="STD-Frizziero-2002" TOTAL_1="52" TOTAL_2="47" VAR="0.25949263502455" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.0558931308155035" CI_START="0.4586900260249003" DF="0" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="0.0" ID="CMP-011.09.04" LOG_CI_END="0.7821782025047912" LOG_CI_START="-0.3384807032720784" LOG_EFFECT_SIZE="0.2218487496163564" NO="4" P_CHI2="1.0" P_Z="0.43774909383186933" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.7759998283543329">
<NAME>45 to 52 weeks post-injection</NAME>
<DICH_DATA CI_END="6.0558931308155035" CI_START="0.4586900260249003" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.7821782025047912" LOG_CI_START="-0.3384807032720784" LOG_EFFECT_SIZE="0.2218487496163564" ORDER="150699" O_E="0.0" SE="0.6582805886043833" STUDY_ID="STD-Leardini-1987" TOTAL_1="20" TOTAL_2="20" VAR="0.43333333333333335" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="71.73802435585947" CI_START="0.12545647975131194" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-011.10" LOG_CI_END="1.8557494121620413" LOG_CI_START="-0.901506902722716" LOG_EFFECT_SIZE="0.47712125471966244" METHOD="MH" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="0.4975736880191909" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="45" TOTAL_2="45" WEIGHT="100.0" Z="0.6783123284265179">
<NAME>Safety: number of patients withdrawn due to lack of efficacy</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>MPA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hyalgan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MPA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="71.73802435585947" CI_START="0.12545647975131194" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-011.10.01" LOG_CI_END="1.8557494121620413" LOG_CI_START="-0.901506902722716" LOG_EFFECT_SIZE="0.47712125471966244" NO="1" P_CHI2="1.0" P_Z="0.4975736880191909" STUDIES="1" TAU2="0.0" TOTAL_1="45" TOTAL_2="45" WEIGHT="100.0" Z="0.6783123284265179">
<NAME>5 to 13 weeks post-injection</NAME>
<DICH_DATA CI_END="71.73802435585941" CI_START="0.12545647975131194" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8557494121620408" LOG_CI_START="-0.901506902722716" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="150700" O_E="0.0" SE="1.6196260080021871" STUDY_ID="STD-Pietrogrande-1991" TOTAL_1="45" TOTAL_2="45" VAR="2.623188405797101" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.235431290810101" CI_START="0.012595743335053401" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3018867924528302" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-011.11" LOG_CI_END="0.859464423725449" LOG_CI_START="-1.8997761976151777" LOG_EFFECT_SIZE="-0.5201558869448643" METHOD="MH" NO="11" P_CHI2="1.0" P_Q="1.0" P_Z="0.4599301569850136" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="52" TOTAL_2="47" WEIGHT="100.0" Z="0.7389618700692266">
<NAME>Safety: number of patients withdrawn due to adverse events</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>MPA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hyalgan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MPA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.235431290810101" CI_START="0.012595743335053401" DF="0" EFFECT_SIZE="0.3018867924528302" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-011.11.01" LOG_CI_END="0.859464423725449" LOG_CI_START="-1.8997761976151777" LOG_EFFECT_SIZE="-0.5201558869448643" NO="1" P_CHI2="1.0" P_Z="0.4599301569850136" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="47" WEIGHT="100.0" Z="0.7389618700692266">
<NAME>After first injection</NAME>
<DICH_DATA CI_END="7.235431290810098" CI_START="0.012595743335053412" EFFECT_SIZE="0.3018867924528302" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8594644237254488" LOG_CI_START="-1.8997761976151772" LOG_EFFECT_SIZE="-0.5201558869448643" ORDER="150701" O_E="0.0" SE="1.6207915994368403" STUDY_ID="STD-Frizziero-2002" TOTAL_1="52" TOTAL_2="47" VAR="2.626965408805031" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="71.73802435585947" CI_START="0.12545647975131194" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-011.12" LOG_CI_END="1.8557494121620413" LOG_CI_START="-0.901506902722716" LOG_EFFECT_SIZE="0.47712125471966244" METHOD="MH" NO="12" P_CHI2="1.0" P_Q="1.0" P_Z="0.4975736880191909" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="65" TOTAL_2="65" WEIGHT="100.0" Z="0.6783123284265179">
<NAME>Safety: number of patients with local or systemic reactions</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>MPA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hyalgan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MPA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="71.73802435585947" CI_START="0.12545647975131194" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-011.12.01" LOG_CI_END="1.8557494121620413" LOG_CI_START="-0.901506902722716" LOG_EFFECT_SIZE="0.47712125471966244" NO="1" P_CHI2="1.0" P_Z="0.4975736880191909" STUDIES="2" TAU2="0.0" TOTAL_1="65" TOTAL_2="65" WEIGHT="100.0" Z="0.6783123284265179">
<NAME>5 to 13 weeks post-injection</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="150702" O_E="0.0" SE="0.0" STUDY_ID="STD-Leardini-1991" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="71.73802435585941" CI_START="0.12545647975131194" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8557494121620408" LOG_CI_START="-0.901506902722716" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="150703" O_E="0.0" SE="1.6196260080021871" STUDY_ID="STD-Pietrogrande-1991" TOTAL_1="45" TOTAL_2="45" VAR="2.623188405797101" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.208499115067839" CI_START="0.3413224690073932" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-011.13" LOG_CI_END="0.7167125947102105" LOG_CI_START="-0.4668351214936107" LOG_EFFECT_SIZE="0.12493873660829993" METHOD="MH" NO="13" P_CHI2="1.0" P_Q="1.0" P_Z="0.6790213257374376" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.41379898870766496">
<NAME>Safety: number of joints with local reactions but continued in trial</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>MPA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hyalgan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MPA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.208499115067839" CI_START="0.3413224690073932" DF="0" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" ID="CMP-011.13.01" LOG_CI_END="0.7167125947102105" LOG_CI_START="-0.4668351214936107" LOG_EFFECT_SIZE="0.12493873660829993" NO="1" P_CHI2="1.0" P_Z="0.6790213257374376" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.41379898870766496">
<NAME>1 to 4 weeks post-injection</NAME>
<DICH_DATA CI_END="5.208499115067838" CI_START="0.34132246900739327" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7167125947102104" LOG_CI_START="-0.46683512149361067" LOG_EFFECT_SIZE="0.12493873660829993" ORDER="150704" O_E="0.0" SE="0.6952217871538069" STUDY_ID="STD-Leardini-1987" TOTAL_1="20" TOTAL_2="20" VAR="0.4833333333333332" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-012" NO="12">
<NAME>Hyalgan versus triamcinolone hexacetonide</NAME>
<CONT_OUTCOME CHI2="0.4778345244307427" CI_END="9.555146389637953" CI_START="-17.455807380427217" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.9503304953946325" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-012.01" NO="1" P_CHI2="0.4894048682932016" P_Q="0.4894048682932016" P_Z="0.5664508313917391" Q="0.4778345244307427" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="41" TOTAL_2="35" UNITS="" WEIGHT="200.0" Z="0.5732863462662592">
<NAME>Pain on nominated activity (0-100 mm VAS)</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>Triamcinolone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hyalgan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Triamcinolon</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="16.989258270891206" CI_START="-17.38925827089121" DF="0" EFFECT_SIZE="-0.20000000000000284" ESTIMABLE="YES" I2="0.0" ID="CMP-012.01.01" NO="1" P_CHI2="1.0" P_Z="0.9818062019251725" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="27" WEIGHT="100.0" Z="0.022804520749556044">
<NAME>End of treatment (week 4)</NAME>
<CONT_DATA CI_END="16.989258270891206" CI_START="-17.38925827089121" EFFECT_SIZE="-0.20000000000000284" ESTIMABLE="YES" MEAN_1="56.5" MEAN_2="56.7" ORDER="150705" SD_1="33.93" SD_2="31.7" SE="8.770190884362103" STUDY_ID="STD-Jones-1995" TOTAL_1="29" TOTAL_2="27" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="11.831731985247213" CI_START="-31.831731985247213" DF="0" EFFECT_SIZE="-10.0" ESTIMABLE="YES" I2="0.0" ID="CMP-012.01.02" NO="2" P_CHI2="1.0" P_Z="0.3693139114068138" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="8" WEIGHT="100.0" Z="0.8977592734577812">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="11.831731985247213" CI_START="-31.831731985247213" EFFECT_SIZE="-10.0" ESTIMABLE="YES" MEAN_1="44.3" MEAN_2="54.3" ORDER="150706" SD_1="24.94" SD_2="24.04" SE="11.138843446845518" STUDY_ID="STD-Jones-1995" TOTAL_1="12" TOTAL_2="8" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.7372375029724416" CI_END="6.318646656335391" CI_START="-21.726064102772995" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-7.703708723218803" ESTIMABLE="YES" I2="42.43734674798445" I2_Q="42.43734674798445" ID="CMP-012.02" NO="2" P_CHI2="0.1874893401724227" P_Q="0.1874893401724227" P_Z="0.28157858448979434" Q="1.7372375029724416" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="41" TOTAL_2="35" UNITS="" WEIGHT="200.0" Z="1.0767799871134014">
<NAME>Pain at rest (0-100 mm VAS)</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>Triamcinolone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hyalgan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Triamcinolon</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="16.766892362267008" CI_START="-18.166892362267014" DF="0" EFFECT_SIZE="-0.7000000000000028" ESTIMABLE="YES" I2="0.0" ID="CMP-012.02.01" NO="1" P_CHI2="1.0" P_Z="0.9373928178138264" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="27" WEIGHT="100.0" Z="0.07854716000551207">
<NAME>End of treatment (week 4)</NAME>
<CONT_DATA CI_END="16.766892362267008" CI_START="-18.166892362267014" EFFECT_SIZE="-0.7000000000000028" ESTIMABLE="YES" MEAN_1="39.9" MEAN_2="40.6" ORDER="150707" SD_1="34.47" SD_2="32.22" SE="8.911843533883086" STUDY_ID="STD-Jones-1995" TOTAL_1="29" TOTAL_2="27" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.117440000382622" CI_START="-43.917440000382626" DF="0" EFFECT_SIZE="-20.400000000000002" ESTIMABLE="YES" I2="0.0" ID="CMP-012.02.02" NO="2" P_CHI2="1.0" P_Z="0.0891019973889616" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="8" WEIGHT="100.0" Z="1.7001538128285472">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="3.117440000382622" CI_START="-43.917440000382626" EFFECT_SIZE="-20.400000000000002" ESTIMABLE="YES" MEAN_1="28.2" MEAN_2="48.6" ORDER="150708" SD_1="24.94" SD_2="27.15" SE="11.998914360613353" STUDY_ID="STD-Jones-1995" TOTAL_1="12" TOTAL_2="8" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.2118201465951817" CI_END="-1.8583028137957172" CI_START="-26.071280417886772" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-13.964791615841245" ESTIMABLE="YES" I2="17.47950363676714" I2_Q="17.47950363676714" ID="CMP-012.03" NO="3" P_CHI2="0.27097201493547185" P_Q="0.27097201493547185" P_Z="0.02377093467806931" Q="1.2118201465951817" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="41" TOTAL_2="35" UNITS="" WEIGHT="200.0" Z="2.2608114595563986">
<NAME>Pain at night (0-100 mm VAS)</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>Triamcinolone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hyalgan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Triamcinolon</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="10.10331495056262" CI_START="-24.303314950562623" DF="0" EFFECT_SIZE="-7.100000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-012.03.01" NO="1" P_CHI2="1.0" P_Z="0.4185732506115233" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="27" WEIGHT="100.0" Z="0.8088990017461306">
<NAME>End of treatment (week 4)</NAME>
<CONT_DATA CI_END="10.10331495056262" CI_START="-24.303314950562623" EFFECT_SIZE="-7.100000000000001" ESTIMABLE="YES" MEAN_1="35.9" MEAN_2="43.0" ORDER="150709" SD_1="31.77" SD_2="33.77" SE="8.777362791490136" STUDY_ID="STD-Jones-1995" TOTAL_1="29" TOTAL_2="27" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-3.6598277865187434" CI_START="-37.74017221348126" DF="0" EFFECT_SIZE="-20.700000000000003" ESTIMABLE="YES" I2="0.0" ID="CMP-012.03.02" NO="2" P_CHI2="1.0" P_Z="0.017269550918813402" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="8" WEIGHT="100.0" Z="2.380918101747901">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="-3.6598277865187434" CI_START="-37.74017221348126" EFFECT_SIZE="-20.700000000000003" ESTIMABLE="YES" MEAN_1="15.4" MEAN_2="36.1" ORDER="150710" SD_1="15.24" SD_2="21.21" SE="8.694125171631704" STUDY_ID="STD-Jones-1995" TOTAL_1="12" TOTAL_2="8" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.01900670053814411" CI_END="1.135907512771596" CI_START="0.5485273572155991" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.789351851851852" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="27" I2="0.0" I2_Q="0.0" ID="CMP-012.04" LOG_CI_END="0.05534297193123861" LOG_CI_START="-0.2608017075760673" LOG_EFFECT_SIZE="-0.1027293678224143" METHOD="MH" NO="4" P_CHI2="0.8903472846586742" P_Q="0.8965624196095534" P_Z="0.20274932338516016" Q="0.01690131841787309" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="64" TOTAL_2="62" WEIGHT="200.0" Z="1.2737577073907203">
<NAME>Safety: total withdrawals overall</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>Triamcinolone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hyalgan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Triamcinolon</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.9852451779193965" CI_START="0.1768340739014849" DF="0" EFFECT_SIZE="0.7265625" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" ID="CMP-012.04.01" LOG_CI_END="0.47498000549714203" LOG_CI_START="-0.7524340476850085" LOG_EFFECT_SIZE="-0.13872702109393326" NO="1" P_CHI2="1.0" P_Z="0.6577330277268292" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="31" WEIGHT="100.0" Z="0.4430452206762979">
<NAME>End of treatment (week 4)</NAME>
<DICH_DATA CI_END="2.9852451779193965" CI_START="0.1768340739014849" EFFECT_SIZE="0.7265625" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.47498000549714203" LOG_CI_START="-0.7524340476850085" LOG_EFFECT_SIZE="-0.13872702109393326" ORDER="150711" O_E="0.0" SE="0.7209890906367477" STUDY_ID="STD-Jones-1995" TOTAL_1="32" TOTAL_2="31" VAR="0.5198252688172043" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.907438863734836E-31" CI_END="1.1400662917313518" CI_START="0.5617522955426215" DF="0" EFFECT_SIZE="0.8002717391304349" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="23" I2="100.0" ID="CMP-012.04.02" LOG_CI_END="0.05693010510495679" LOG_CI_START="-0.25045514420575105" LOG_EFFECT_SIZE="-0.09676251955039714" NO="2" P_CHI2="0.0" P_Z="0.21721661550682436" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="31" WEIGHT="100.0" Z="1.2339632679018389">
<NAME>14 to 26 weeks post-injection</NAME>
<DICH_DATA CI_END="1.1400662917313515" CI_START="0.5617522955426215" EFFECT_SIZE="0.8002717391304348" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="23" LOG_CI_END="0.056930105104956705" LOG_CI_START="-0.25045514420575105" LOG_EFFECT_SIZE="-0.09676251955039719" ORDER="150712" O_E="0.0" SE="0.18055961702663362" STUDY_ID="STD-Jones-1995" TOTAL_1="32" TOTAL_2="31" VAR="0.0326017753008046" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.250232399883311" CI_END="1.8858770168023375" CI_START="0.5742067783992126" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0406168201000732" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" I2="20.014870827748993" I2_Q="14.783203428916588" ID="CMP-012.05" LOG_CI_END="0.27551336779388114" LOG_CI_START="-0.2409316850474569" LOG_EFFECT_SIZE="0.01729084137321213" METHOD="MH" NO="5" P_CHI2="0.26350818330722037" P_Q="0.27868789593048127" P_Z="0.8955845290845351" Q="1.1734775774701318" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="64" TOTAL_2="62" WEIGHT="200.0" Z="0.13124116948140216">
<NAME>Safety: wIthdrawals due to lack efficacy</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>Triamcinolone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hyalgan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours triamcinolon</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="97.10953275882997" CI_START="0.24207515635327403" DF="0" EFFECT_SIZE="4.848484848484849" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-012.05.01" LOG_CI_END="1.9872618645253863" LOG_CI_START="-0.6160497789693115" LOG_EFFECT_SIZE="0.6856060427780373" NO="1" P_CHI2="1.0" P_Z="0.30190864525064987" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="31" WEIGHT="100.0" Z="1.0323490503227704">
<NAME>End of treatment (week 4)</NAME>
<DICH_DATA CI_END="97.10953275882997" CI_START="0.24207515635327403" EFFECT_SIZE="4.848484848484849" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9872618645253863" LOG_CI_START="-0.6160497789693115" LOG_EFFECT_SIZE="0.6856060427780373" ORDER="150713" O_E="0.0" SE="1.5291981459892532" STUDY_ID="STD-Jones-1995" TOTAL_1="32" TOTAL_2="31" VAR="2.3384469696969696" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.6124340349358067E-31" CI_END="1.6451697253303113" CI_START="0.4860584633469978" DF="0" EFFECT_SIZE="0.8942307692307694" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="13" I2="100.0" ID="CMP-012.05.02" LOG_CI_END="0.21621070895592948" LOG_CI_START="-0.3133114904456198" LOG_EFFECT_SIZE="-0.048550390744845164" NO="2" P_CHI2="0.0" P_Z="0.7192905696821884" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="31" WEIGHT="100.0" Z="0.3594070934241738">
<NAME>14 to 26 week post-injection</NAME>
<DICH_DATA CI_END="1.645169725330311" CI_START="0.48605846334699776" EFFECT_SIZE="0.8942307692307693" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="13" LOG_CI_END="0.21621070895592942" LOG_CI_START="-0.31331149044561984" LOG_EFFECT_SIZE="-0.04855039074484522" ORDER="150714" O_E="0.0" SE="0.3110439611056309" STUDY_ID="STD-Jones-1995" TOTAL_1="32" TOTAL_2="31" VAR="0.09674834574028121" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.021477348476658813" CI_END="2.4558588563522608" CI_START="0.2653734897605059" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8072916666666666" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-012.06" LOG_CI_END="0.39020340332059655" LOG_CI_START="-0.5761424643871128" LOG_EFFECT_SIZE="-0.09296953053325814" METHOD="MH" NO="6" P_CHI2="0.8834860315213303" P_Q="0.8836002717376045" P_Z="0.7060801929171467" Q="0.021434950588948273" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="64" TOTAL_2="62" WEIGHT="200.0" Z="0.37712570125026507">
<NAME>Safety: wIthdrawals due to adverse events</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>Triamcinolone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hyalgan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours triamcinolon</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="14.815825472151083" CI_START="0.0633428467596375" DF="0" EFFECT_SIZE="0.96875" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-012.06.01" LOG_CI_END="1.1707258534544793" LOG_CI_START="-1.198302422425746" LOG_EFFECT_SIZE="-0.013788284485633297" NO="1" P_CHI2="1.0" P_Z="0.9817979432457848" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="31" WEIGHT="100.0" Z="0.022814874162185785">
<NAME>End of treatment (week 4)</NAME>
<DICH_DATA CI_END="14.815825472151076" CI_START="0.06334284675963754" EFFECT_SIZE="0.96875" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.170725853454479" LOG_CI_START="-1.1983024224257455" LOG_EFFECT_SIZE="-0.013788284485633297" ORDER="150715" O_E="0.0" SE="1.3915789361311384" STUDY_ID="STD-Jones-1995" TOTAL_1="32" TOTAL_2="31" VAR="1.936491935483871" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.621082712101819" CI_START="0.22915148660774812" DF="0" EFFECT_SIZE="0.775" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" I2="0.0" ID="CMP-012.06.02" LOG_CI_END="0.4184807259609554" LOG_CI_START="-0.6398773209483347" LOG_EFFECT_SIZE="-0.1106982974936897" NO="2" P_CHI2="1.0" P_Z="0.6818041789003317" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="31" WEIGHT="100.0" Z="0.4100024124560334">
<NAME>14 to 26 weeks post-injection</NAME>
<DICH_DATA CI_END="2.6210827121018188" CI_START="0.22915148660774817" EFFECT_SIZE="0.775" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.41848072596095537" LOG_CI_START="-0.6398773209483347" LOG_EFFECT_SIZE="-0.1106982974936897" ORDER="150716" O_E="0.0" SE="0.621684755711342" STUDY_ID="STD-Jones-1995" TOTAL_1="32" TOTAL_2="31" VAR="0.38649193548387095" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-013" NO="13">
<NAME>Hyalgan versus mucopolysaccharide polysulfuric acid ester</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="7.01796418439902" CI_START="0.9820358156009803" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="4.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-013.01" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.009384226483192214" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="33" TOTAL_2="26" UNITS="" WEIGHT="100.0" Z="2.597729946129696">
<NAME>Pain (0-30) change</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>MucoPolySulf</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours MucoPolySulf</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Hyalgan</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="7.01796418439902" CI_START="0.9820358156009803" DF="0" EFFECT_SIZE="4.0" ESTIMABLE="YES" I2="0.0" ID="CMP-013.01.01" NO="1" P_CHI2="1.0" P_Z="0.009384226483192214" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="26" WEIGHT="100.0" Z="2.597729946129696">
<NAME>End of treatment at week 6</NAME>
<CONT_DATA CI_END="7.01796418439902" CI_START="0.9820358156009803" EFFECT_SIZE="4.0" ESTIMABLE="YES" MEAN_1="5.5" MEAN_2="1.5" ORDER="150717" SD_1="6.2" SD_2="5.6" SE="1.5398059393970174" STUDY_ID="STD-Graf-1993" TOTAL_1="33" TOTAL_2="26" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="3.153868027457912" CI_START="-1.9538680274579119" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.6000000000000001" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-013.02" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.6451792443526776" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="33" TOTAL_2="26" UNITS="" WEIGHT="100.0" Z="0.46046952234042676">
<NAME>Function (0-30) change</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>MucoPolySulf</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours MucoPolySulf</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Hyalgan</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.153868027457912" CI_START="-1.9538680274579119" DF="0" EFFECT_SIZE="0.6000000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-013.02.01" NO="1" P_CHI2="1.0" P_Z="0.6451792443526776" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="26" WEIGHT="100.0" Z="0.46046952234042676">
<NAME>End of treatment at week 6</NAME>
<CONT_DATA CI_END="3.153868027457912" CI_START="-1.9538680274579119" EFFECT_SIZE="0.6000000000000001" ESTIMABLE="YES" MEAN_1="1.1" MEAN_2="0.5" ORDER="150718" SD_1="5.8" SD_2="4.2" SE="1.3030178348186483" STUDY_ID="STD-Graf-1993" TOTAL_1="33" TOTAL_2="26" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.6622533049079317" CI_START="-0.062253304907931684" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.3" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-013.03" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.10455867457509121" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="33" TOTAL_2="26" UNITS="" WEIGHT="100.0" Z="1.6231437709352476">
<NAME>Range of motion (0-10) change</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>MucoPolySulf</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours MucoPolySulf</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Hyalgan</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.6622533049079317" CI_START="-0.062253304907931684" DF="0" EFFECT_SIZE="0.3" ESTIMABLE="YES" I2="0.0" ID="CMP-013.03.01" NO="1" P_CHI2="1.0" P_Z="0.10455867457509121" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="26" WEIGHT="100.0" Z="1.6231437709352476">
<NAME>End of treatment at week 6</NAME>
<CONT_DATA CI_END="0.6622533049079317" CI_START="-0.062253304907931684" EFFECT_SIZE="0.3" ESTIMABLE="YES" MEAN_1="0.3" MEAN_2="0.0" ORDER="150719" SD_1="0.9" SD_2="0.5" SE="0.18482651097945652" STUDY_ID="STD-Graf-1993" TOTAL_1="33" TOTAL_2="26" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="10.494530625065064" CI_START="1.305469374934936" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="5.9" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-013.04" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.011840607547218558" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="33" TOTAL_2="26" UNITS="" WEIGHT="100.00000000000001" Z="2.516859381826966">
<NAME>Total Larson rating score (0-77) change</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>MucoPolySulf</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours MucoPolySulf</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Hyalgan</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="10.494530625065064" CI_START="1.305469374934936" DF="0" EFFECT_SIZE="5.9" ESTIMABLE="YES" I2="0.0" ID="CMP-013.04.01" NO="1" P_CHI2="1.0" P_Z="0.011840607547218558" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="26" WEIGHT="100.00000000000001" Z="2.516859381826966">
<NAME>End of treatment at week 6</NAME>
<CONT_DATA CI_END="10.494530625065064" CI_START="1.305469374934936" EFFECT_SIZE="5.9" ESTIMABLE="YES" MEAN_1="8.4" MEAN_2="2.5" ORDER="150720" SD_1="10.3" SD_2="7.7" SE="2.3441913531606375" STUDY_ID="STD-Graf-1993" TOTAL_1="33" TOTAL_2="26" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="2.091292566861615E-31" CI_END="2.660079047171391" CI_START="1.0270573817591728" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6528925619834713" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="11" I2="100.0" I2_Q="0.0" ID="CMP-013.05" LOG_CI_END="0.4248945423604906" LOG_CI_START="0.011594708334571758" LOG_EFFECT_SIZE="0.2182446253475312" METHOD="MH" NO="5" P_CHI2="0.0" P_Q="1.0" P_Z="0.038458563456035655" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="33" TOTAL_2="24" WEIGHT="100.0" Z="2.069933594378232">
<NAME>Patient global (number of patients symptom free or markedly improved)</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>MucoPolysulf</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours MucoPolySulf</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Hyalgan</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.091292566861615E-31" CI_END="2.660079047171391" CI_START="1.0270573817591728" DF="0" EFFECT_SIZE="1.6528925619834713" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="11" I2="100.0" ID="CMP-013.05.01" LOG_CI_END="0.4248945423604906" LOG_CI_START="0.011594708334571758" LOG_EFFECT_SIZE="0.2182446253475312" NO="1" P_CHI2="0.0" P_Z="0.038458563456035655" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="24" WEIGHT="100.0" Z="2.069933594378232">
<NAME>14 to 26 weeks post-injection</NAME>
<DICH_DATA CI_END="2.660079047171391" CI_START="1.0270573817591726" EFFECT_SIZE="1.6528925619834711" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="11" LOG_CI_END="0.4248945423604906" LOG_CI_START="0.011594708334571664" LOG_EFFECT_SIZE="0.2182446253475311" ORDER="150721" O_E="0.0" SE="0.24277436837399854" STUDY_ID="STD-Graf-1993" TOTAL_1="33" TOTAL_2="24" VAR="0.05893939393939395" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.272234400161034" CI_START="0.03917279723568498" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4090909090909091" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-013.06" LOG_CI_END="0.6306550726496672" LOG_CI_START="-1.40701541541543" LOG_EFFECT_SIZE="-0.38818017138288136" METHOD="MH" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.45521215510687896" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="33" TOTAL_2="27" WEIGHT="100.0" Z="0.7467538641593433">
<NAME>Safety: total withdrawals overall</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>MucoPolySulf</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hyalgan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MucoPolySulf</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.272234400161034" CI_START="0.03917279723568498" DF="0" EFFECT_SIZE="0.4090909090909091" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-013.06.01" LOG_CI_END="0.6306550726496672" LOG_CI_START="-1.40701541541543" LOG_EFFECT_SIZE="-0.38818017138288136" NO="1" P_CHI2="1.0" P_Z="0.45521215510687896" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="27" WEIGHT="100.0" Z="0.7467538641593433">
<NAME>14 to 26 weeks post-injection</NAME>
<DICH_DATA CI_END="4.272234400161036" CI_START="0.03917279723568497" EFFECT_SIZE="0.4090909090909091" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6306550726496675" LOG_CI_START="-1.4070154154154302" LOG_EFFECT_SIZE="-0.38818017138288136" ORDER="150722" O_E="0.0" SE="1.1969377313210294" STUDY_ID="STD-Graf-1993" TOTAL_1="33" TOTAL_2="27" VAR="1.4326599326599327" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="11.192802911282783" CI_START="0.5382738743980319" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.4545454545454546" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-013.07" LOG_CI_END="1.0489388565438449" LOG_CI_START="-0.2689966985423203" LOG_EFFECT_SIZE="0.3899710790007623" METHOD="MH" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.2460941495281056" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="33" TOTAL_2="27" WEIGHT="100.0" Z="1.1598886863686553">
<NAME>Safety: adverse events due to study medication</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>MucoPolySulf</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hyalgan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MucoPolySulf</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="11.192802911282783" CI_START="0.5382738743980319" DF="0" EFFECT_SIZE="2.4545454545454546" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" I2="0.0" ID="CMP-013.07.01" LOG_CI_END="1.0489388565438449" LOG_CI_START="-0.2689966985423203" LOG_EFFECT_SIZE="0.3899710790007623" NO="1" P_CHI2="1.0" P_Z="0.2460941495281056" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="27" WEIGHT="100.0" Z="1.1598886863686553">
<NAME>14 to 26 weeks post-injection</NAME>
<DICH_DATA CI_END="11.192802911282783" CI_START="0.5382738743980318" EFFECT_SIZE="2.4545454545454546" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.0489388565438449" LOG_CI_START="-0.26899669854232033" LOG_EFFECT_SIZE="0.3899710790007623" ORDER="150723" O_E="0.0" SE="0.7741618689438271" STUDY_ID="STD-Graf-1993" TOTAL_1="33" TOTAL_2="27" VAR="0.5993265993265993" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-014" NO="14">
<NAME>(Hyalgan plus exercise plus ultrasound) versus control warmup exercise</NAME>
<CONT_OUTCOME CHI2="19.095431987484314" CI_END="-2.951385118700532" CI_START="-3.936858646775696" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.444121882738114" ESTIMABLE="YES" I2="94.76314544412806" I2_Q="94.76314544412806" ID="CMP-014.01" NO="1" P_CHI2="1.2434309648257091E-5" P_Q="1.2434309648257091E-5" P_Z="1.0191897708094146E-42" Q="19.095431987484314" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="66" TOTAL_2="60" UNITS="" WEIGHT="200.0" Z="13.699718269891717">
<NAME>Pain (0-10 cm VAS)</NAME>
<GROUP_LABEL_1>EX+US+HA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control warmup EX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours EX+US+HA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control EX</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-1.7202170204301148" CI_START="-3.079782979569886" DF="0" EFFECT_SIZE="-2.4000000000000004" ESTIMABLE="YES" I2="0.0" ID="CMP-014.01.01" NO="1" P_CHI2="1.0" P_Z="4.5251048991706046E-12" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="32" WEIGHT="100.0" Z="6.91972836076656">
<NAME>End of treatment</NAME>
<CONT_DATA CI_END="-1.720217020430115" CI_START="-3.0797829795698854" EFFECT_SIZE="-2.4000000000000004" ESTIMABLE="YES" MEAN_1="2.5" MEAN_2="4.9" ORDER="150724" SD_1="1.6" SD_2="1.2" SE="0.34683442396489256" STUDY_ID="STD-Huang-2005" TOTAL_1="34" TOTAL_2="32" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-3.8847617884912338" CI_START="-5.315238211508765" DF="0" EFFECT_SIZE="-4.6" ESTIMABLE="YES" I2="0.0" ID="CMP-014.01.02" NO="2" P_CHI2="1.0" P_Z="1.9727263928876005E-36" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="28" WEIGHT="100.0" Z="12.60535886339981">
<NAME>One-year follow-up</NAME>
<CONT_DATA CI_END="-3.8847617884912338" CI_START="-5.315238211508765" EFFECT_SIZE="-4.6" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="6.6" ORDER="150725" SD_1="1.3" SD_2="1.5" SE="0.3649241604184942" STUDY_ID="STD-Huang-2005" TOTAL_1="32" TOTAL_2="28" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="32.032493682425006" CI_END="-3.2709744112720838" CI_START="-4.124107688355208" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.697541049813646" ESTIMABLE="YES" I2="96.87816999227674" I2_Q="96.87816999227674" ID="CMP-014.02" NO="2" P_CHI2="1.5161990329914943E-8" P_Q="1.516199066298185E-8" P_Z="9.864229523649033E-65" Q="32.032493682424985" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="66" TOTAL_2="60" UNITS="" WEIGHT="200.0" Z="16.989250058961332">
<NAME>Lequesne Index (0-26)</NAME>
<GROUP_LABEL_1>EX+US+HA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control warmup EX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours EX+US+HA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control EX</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-2.3918275444112616" CI_START="-3.408172455588739" DF="0" EFFECT_SIZE="-2.9000000000000004" ESTIMABLE="YES" I2="0.0" ID="CMP-014.02.01" NO="1" P_CHI2="1.0" P_Z="4.830485926515303E-29" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="32" WEIGHT="100.0" Z="11.18497370854375">
<NAME>End of treatment</NAME>
<CONT_DATA CI_END="-2.3918275444112616" CI_START="-3.408172455588739" EFFECT_SIZE="-2.9000000000000004" ESTIMABLE="YES" MEAN_1="4.0" MEAN_2="6.9" ORDER="150726" SD_1="0.7" SD_2="1.3" SE="0.25927642527982053" STUDY_ID="STD-Huang-2005" TOTAL_1="34" TOTAL_2="32" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="4.919399854384928E-30" CI_END="-4.815139909990397" CI_START="-6.3848600900096" DF="0" EFFECT_SIZE="-5.599999999999999" ESTIMABLE="YES" I2="100.0" ID="CMP-014.02.02" NO="2" P_CHI2="0.0" P_Z="1.9410389881147028E-44" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="28" WEIGHT="100.0" Z="13.984401109362093">
<NAME>One-year follow-up</NAME>
<CONT_DATA CI_END="-4.815139909990398" CI_START="-6.384860090009601" EFFECT_SIZE="-5.6" ESTIMABLE="YES" MEAN_1="2.5" MEAN_2="8.1" ORDER="150727" SD_1="1.6" SD_2="1.5" SE="0.4004461797259937" STUDY_ID="STD-Huang-2005" TOTAL_1="32" TOTAL_2="28" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.5605770646253496" CI_END="27.854514393874446" CI_START="18.414586150803892" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="23.13455027233917" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-014.03" NO="3" P_CHI2="0.45402793553898024" P_Q="0.45402793553898024" P_Z="7.497212380596448E-22" Q="0.5605770646253496" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="66" TOTAL_2="60" UNITS="" WEIGHT="200.0" Z="9.606616526052587">
<NAME>Range of motion (degrees)</NAME>
<GROUP_LABEL_1>EX+US+HA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control warmup EX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Control EX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours EX+US+HA</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="27.576635978363495" CI_START="16.423364021636505" DF="0" EFFECT_SIZE="22.0" ESTIMABLE="YES" I2="0.0" ID="CMP-014.03.01" NO="1" P_CHI2="1.0" P_Z="1.0577179576237072E-14" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="32" WEIGHT="100.0" Z="7.732118041625309">
<NAME>End of treatment</NAME>
<CONT_DATA CI_END="27.576635978363495" CI_START="16.423364021636505" EFFECT_SIZE="22.0" ESTIMABLE="YES" MEAN_1="120.0" MEAN_2="98.0" ORDER="150728" SD_1="13.0" SD_2="10.0" SE="2.8452747205312385" STUDY_ID="STD-Huang-2005" TOTAL_1="34" TOTAL_2="32" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="34.862511686164744" CI_START="17.137488313835256" DF="0" EFFECT_SIZE="26.0" ESTIMABLE="YES" I2="0.0" ID="CMP-014.03.02" NO="2" P_CHI2="1.0" P_Z="8.926600099830818E-9" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="28" WEIGHT="100.0" Z="5.749957281026048">
<NAME>One-year follow-up</NAME>
<CONT_DATA CI_END="34.862511686164744" CI_START="17.137488313835256" EFFECT_SIZE="26.0" ESTIMABLE="YES" MEAN_1="124.0" MEAN_2="98.0" ORDER="150729" SD_1="18.0" SD_2="17.0" SE="4.521772724433258" STUDY_ID="STD-Huang-2005" TOTAL_1="32" TOTAL_2="28" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="28.841387952914346" CI_END="23.349081825956578" CI_START="20.483387344026593" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="21.916234584991585" ESTIMABLE="YES" I2="96.53276048422991" I2_Q="96.53276048422991" ID="CMP-014.04" NO="4" P_CHI2="7.855584904792323E-8" P_Q="7.855584904792323E-8" P_Z="0.0" Q="28.841387952914346" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="66" TOTAL_2="60" UNITS="" WEIGHT="200.0" Z="29.978792738844454">
<NAME>Ambulation speed (metres per minute)</NAME>
<GROUP_LABEL_1>EX+US+HA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control warmup EX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control EX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours EX+US+HA</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="21.42774302655584" CI_START="18.172256973444153" DF="0" EFFECT_SIZE="19.799999999999997" ESTIMABLE="YES" I2="0.0" ID="CMP-014.04.01" NO="1" P_CHI2="1.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="32" WEIGHT="100.0" Z="23.84116304648267">
<NAME>End of treatment</NAME>
<CONT_DATA CI_END="21.42774302655584" CI_START="18.172256973444153" EFFECT_SIZE="19.799999999999997" ESTIMABLE="YES" MEAN_1="95.6" MEAN_2="75.8" ORDER="150730" SD_1="2.7" SD_2="3.9" SE="0.8304963965640564" STUDY_ID="STD-Huang-2005" TOTAL_1="34" TOTAL_2="32" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="32.2198259635966" CI_START="26.18017403640341" DF="0" EFFECT_SIZE="29.200000000000003" ESTIMABLE="YES" I2="0.0" ID="CMP-014.04.02" NO="2" P_CHI2="1.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="28" WEIGHT="100.0" Z="18.951737298267314">
<NAME>One-year follow-up</NAME>
<CONT_DATA CI_END="32.2198259635966" CI_START="26.18017403640341" EFFECT_SIZE="29.200000000000003" ESTIMABLE="YES" MEAN_1="99.3" MEAN_2="70.1" ORDER="150731" SD_1="6.8" SD_2="5.1" SE="1.5407558441974418" STUDY_ID="STD-Huang-2005" TOTAL_1="32" TOTAL_2="28" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.03740629967739384" CI_END="1.2031977644339984" CI_START="0.13297897048143728" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-014.05" LOG_CI_END="0.08033701632030606" LOG_CI_START="-0.8762170336643813" LOG_EFFECT_SIZE="-0.3979400086720376" METHOD="MH" NO="5" P_CHI2="0.8466402447002058" P_Q="0.8469434632485588" P_Z="0.10294404089230812" Q="0.03725667918835204" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="70" TOTAL_2="70" WEIGHT="200.0" Z="1.6307454555594345">
<NAME>Safety: total withdrawals overall</NAME>
<GROUP_LABEL_1>EX+US+HA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control warmup EX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours EX+US+HA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control EX</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.05118976192878" CI_START="0.03641566725790049" DF="0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="0.0" ID="CMP-014.05.01" LOG_CI_END="0.4844692184571428" LOG_CI_START="-1.4387117278964678" LOG_EFFECT_SIZE="-0.47712125471966244" NO="1" P_CHI2="1.0" P_Z="0.33080511422891756" STUDIES="1" TAU2="0.0" TOTAL_1="35" TOTAL_2="35" WEIGHT="100.0" Z="0.9724934903105658">
<NAME>During treatment</NAME>
<DICH_DATA CI_END="3.05118976192878" CI_START="0.03641566725790049" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4844692184571428" LOG_CI_START="-1.4387117278964678" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="150732" O_E="0.0" SE="1.1296860077873303" STUDY_ID="STD-Huang-2005" TOTAL_1="35" TOTAL_2="35" VAR="1.2761904761904763" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5241898459614025" CI_START="0.12050563771595044" DF="0" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" I2="0.0" ID="CMP-014.05.02" LOG_CI_END="0.1830390640629657" LOG_CI_START="-0.9189926346521545" LOG_EFFECT_SIZE="-0.36797678529459443" NO="2" P_CHI2="1.0" P_Z="0.1905703163903645" STUDIES="1" TAU2="0.0" TOTAL_1="35" TOTAL_2="35" WEIGHT="100.0" Z="1.3088938315751153">
<NAME>Overall</NAME>
<DICH_DATA CI_END="1.5241898459614025" CI_START="0.12050563771595044" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.1830390640629657" LOG_CI_START="-0.9189926346521545" LOG_EFFECT_SIZE="-0.36797678529459443" ORDER="150733" O_E="0.0" SE="0.6473388749701496" STUDY_ID="STD-Huang-2005" TOTAL_1="35" TOTAL_2="35" VAR="0.419047619047619" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-015" NO="15">
<NAME>(Hyalgan plus exercise plus ultrasound) versus exercise</NAME>
<CONT_OUTCOME CHI2="0.4176504015213065" CI_END="-1.2748805809424197" CI_START="-2.1681755742958613" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.7215280776191406" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-015.01" NO="1" P_CHI2="0.5181117995272386" P_Q="0.5181117995272386" P_Z="4.20945825180842E-14" Q="0.4176504015213065" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="66" TOTAL_2="56" UNITS="" WEIGHT="200.0" Z="7.554353389671308">
<NAME>Pain (0-10 cm VAS)</NAME>
<GROUP_LABEL_1>EX+US+HA</GROUP_LABEL_1>
<GROUP_LABEL_2>Exercise</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours EX+US+HA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Exercise</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-1.0209173131322218" CI_START="-2.1790826868677775" DF="0" EFFECT_SIZE="-1.5999999999999996" ESTIMABLE="YES" I2="0.0" ID="CMP-015.01.01" NO="1" P_CHI2="1.0" P_Z="6.11648323601406E-8" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="30" WEIGHT="100.0" Z="5.415361996446833">
<NAME>End of treatment</NAME>
<CONT_DATA CI_END="-1.0209173131322218" CI_START="-2.1790826868677775" EFFECT_SIZE="-1.5999999999999996" ESTIMABLE="YES" MEAN_1="2.5" MEAN_2="4.1" ORDER="150734" SD_1="1.6" SD_2="0.6" SE="0.29545577951202584" STUDY_ID="STD-Huang-2005" TOTAL_1="34" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-1.1982422500023433" CI_START="-2.6017577499976565" DF="0" EFFECT_SIZE="-1.9" ESTIMABLE="YES" I2="0.0" ID="CMP-015.01.02" NO="2" P_CHI2="1.0" P_Z="1.1170295625962329E-7" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="26" WEIGHT="100.0" Z="5.306577049756186">
<NAME>One-year follow-up</NAME>
<CONT_DATA CI_END="-1.1982422500023433" CI_START="-2.6017577499976565" EFFECT_SIZE="-1.9" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="3.9" ORDER="150735" SD_1="1.3" SD_2="1.4" SE="0.35804624754997133" STUDY_ID="STD-Huang-2005" TOTAL_1="32" TOTAL_2="26" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="5.853012580004415" CI_END="-1.9382492291699354" CI_START="-2.665723403802917" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.3019863164864263" ESTIMABLE="YES" I2="82.91478129713424" I2_Q="82.91478129713423" ID="CMP-015.02" NO="2" P_CHI2="0.015550445753765074" P_Q="0.01555044575376563" P_Z="2.4846525745344576E-35" Q="5.85301258000441" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="66" TOTAL_2="56" UNITS="" WEIGHT="200.0" Z="12.404042454135705">
<NAME>Lequesne Index (0-26)</NAME>
<GROUP_LABEL_1>EX+US+HA</GROUP_LABEL_1>
<GROUP_LABEL_2>Exercise</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours EX+US+HA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Exercise</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-1.7011496661529268" CI_START="-2.4988503338470727" DF="0" EFFECT_SIZE="-2.0999999999999996" ESTIMABLE="YES" I2="0.0" ID="CMP-015.02.01" NO="1" P_CHI2="1.0" P_Z="5.753942687131544E-25" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="30" WEIGHT="100.0" Z="10.319470784528013">
<NAME>End of treatment</NAME>
<CONT_DATA CI_END="-1.7011496661529268" CI_START="-2.4988503338470727" EFFECT_SIZE="-2.0999999999999996" ESTIMABLE="YES" MEAN_1="4.0" MEAN_2="6.1" ORDER="150736" SD_1="0.7" SD_2="0.9" SE="0.20349880762766734" STUDY_ID="STD-Huang-2005" TOTAL_1="34" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="9.63833812770033E-31" CI_END="-2.4134214225008073" CI_START="-4.1865785774991915" DF="0" EFFECT_SIZE="-3.2999999999999994" ESTIMABLE="YES" I2="100.0" ID="CMP-015.02.02" NO="2" P_CHI2="0.0" P_Z="2.979332909746312E-13" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="26" WEIGHT="100.0" Z="7.295327580806648">
<NAME>One-year follow-up</NAME>
<CONT_DATA CI_END="-2.413421422500808" CI_START="-4.1865785774991915" EFFECT_SIZE="-3.3" ESTIMABLE="YES" MEAN_1="2.5" MEAN_2="5.8" ORDER="150737" SD_1="1.6" SD_2="1.8" SE="0.45234432086120485" STUDY_ID="STD-Huang-2005" TOTAL_1="32" TOTAL_2="26" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.12396418968110307" CI_END="18.446828839848095" CI_START="7.363534463573192" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="12.905181651710643" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-015.03" NO="3" P_CHI2="0.724774219356801" P_Q="0.724774219356801" P_Z="5.011848327755071E-6" Q="0.12396418968110307" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="66" TOTAL_2="56" UNITS="" WEIGHT="200.0" Z="4.564291156146518">
<NAME>Range of motion (degrees)</NAME>
<GROUP_LABEL_1>EX+US+HA</GROUP_LABEL_1>
<GROUP_LABEL_2>Exercise</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Exercise</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours EX+US+HA</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="19.490017578519364" CI_START="4.509982421480634" DF="0" EFFECT_SIZE="12.0" ESTIMABLE="YES" I2="0.0" ID="CMP-015.03.01" NO="1" P_CHI2="1.0" P_Z="0.0016887757953727826" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="30" WEIGHT="100.0" Z="3.140121844564485">
<NAME>End of treatment</NAME>
<CONT_DATA CI_END="19.490017578519367" CI_START="4.509982421480633" EFFECT_SIZE="12.0" ESTIMABLE="YES" MEAN_1="120.0" MEAN_2="108.0" ORDER="150738" SD_1="13.0" SD_2="17.0" SE="3.8215077611627915" STUDY_ID="STD-Huang-2005" TOTAL_1="34" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="22.237321174442243" CI_START="5.762678825557758" DF="0" EFFECT_SIZE="14.0" ESTIMABLE="YES" I2="0.0" ID="CMP-015.03.02" NO="2" P_CHI2="1.0" P_Z="8.649766564312292E-4" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="26" WEIGHT="100.0" Z="3.3311188434289405">
<NAME>One-year follow-up</NAME>
<CONT_DATA CI_END="22.237321174442243" CI_START="5.762678825557758" EFFECT_SIZE="14.0" ESTIMABLE="YES" MEAN_1="124.0" MEAN_2="110.0" ORDER="150739" SD_1="18.0" SD_2="14.0" SE="4.202792112210826" STUDY_ID="STD-Huang-2005" TOTAL_1="32" TOTAL_2="26" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.4004032370457847" CI_END="14.84756444714707" CI_START="11.2613002640367" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="13.054432355591885" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-015.04" NO="4" P_CHI2="0.5268815040624881" P_Q="0.5268815040624881" P_Z="3.4139740026485047E-46" Q="0.4004032370457847" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="66" TOTAL_2="56" UNITS="" WEIGHT="200.0" Z="14.269008611286155">
<NAME>Ambulation speed (metres per minute)</NAME>
<GROUP_LABEL_1>EX+US+HA</GROUP_LABEL_1>
<GROUP_LABEL_2>Exercise</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Exercise</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours EX+US+HA</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="14.802508004083034" CI_START="10.597491995916943" DF="0" EFFECT_SIZE="12.699999999999989" ESTIMABLE="YES" I2="0.0" ID="CMP-015.04.01" NO="1" P_CHI2="1.0" P_Z="2.4543008192501148E-32" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="30" WEIGHT="100.0" Z="11.838976382168147">
<NAME>End of treatment</NAME>
<CONT_DATA CI_END="14.802508004083034" CI_START="10.597491995916943" EFFECT_SIZE="12.699999999999989" ESTIMABLE="YES" MEAN_1="95.6" MEAN_2="82.9" ORDER="150740" SD_1="2.7" SD_2="5.3" SE="1.072727876974965" STUDY_ID="STD-Huang-2005" TOTAL_1="34" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="17.43413432753161" CI_START="10.565865672468393" DF="0" EFFECT_SIZE="14.0" ESTIMABLE="YES" I2="0.0" ID="CMP-015.04.02" NO="2" P_CHI2="1.0" P_Z="1.3469593644250342E-15" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="26" WEIGHT="99.99999999999999" Z="7.9902220374948945">
<NAME>One-year follow-up</NAME>
<CONT_DATA CI_END="17.43413432753161" CI_START="10.565865672468393" EFFECT_SIZE="14.0" ESTIMABLE="YES" MEAN_1="99.3" MEAN_2="85.3" ORDER="150741" SD_1="6.8" SD_2="6.5" SE="1.752141546793523" STUDY_ID="STD-Huang-2005" TOTAL_1="32" TOTAL_2="26" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.17266870924284503" CI_END="0.819123247181723" CI_START="0.09965857194517423" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.2857142857142857" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-015.05" LOG_CI_END="-0.08665074836908122" LOG_CI_START="-1.00148534033147" LOG_EFFECT_SIZE="-0.5440680443502757" METHOD="MH" NO="5" P_CHI2="0.6777511416260023" P_Q="0.6796386723323184" P_Z="0.019740215506859424" Q="0.1705331693718105" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="70" TOTAL_2="70" WEIGHT="200.0" Z="2.3312493459134997">
<NAME>Safety: total withdrawals overall</NAME>
<GROUP_LABEL_1>EX+US+HA</GROUP_LABEL_1>
<GROUP_LABEL_2>Exercise</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours EX+US+HA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Exercise</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6255589437326217" CI_START="0.024606920686709565" DF="0" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" I2="0.0" ID="CMP-015.05.01" LOG_CI_END="0.2110027218934795" LOG_CI_START="-1.608942730565517" LOG_EFFECT_SIZE="-0.6989700043360187" NO="1" P_CHI2="1.0" P_Z="0.13219780848060272" STUDIES="1" TAU2="0.0" TOTAL_1="35" TOTAL_2="35" WEIGHT="100.0" Z="1.5054913134032708">
<NAME>During treatment</NAME>
<DICH_DATA CI_END="1.6255589437326217" CI_START="0.024606920686709565" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.2110027218934795" LOG_CI_START="-1.608942730565517" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="150742" O_E="0.0" SE="1.0690449676496976" STUDY_ID="STD-Huang-2005" TOTAL_1="35" TOTAL_2="35" VAR="1.142857142857143" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1287863795390662" CI_START="0.09843413521385927" DF="0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" I2="0.0" ID="CMP-015.05.02" LOG_CI_END="0.052611760378898885" LOG_CI_START="-1.0068542698182237" LOG_EFFECT_SIZE="-0.47712125471966244" NO="2" P_CHI2="1.0" P_Z="0.07751247675283696" STUDIES="1" TAU2="0.0" TOTAL_1="35" TOTAL_2="35" WEIGHT="100.0" Z="1.7653052553938118">
<NAME>Overall</NAME>
<DICH_DATA CI_END="1.1287863795390662" CI_START="0.09843413521385927" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" LOG_CI_END="0.052611760378898885" LOG_CI_START="-1.0068542698182237" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="150743" O_E="0.0" SE="0.6223355905792206" STUDY_ID="STD-Huang-2005" TOTAL_1="35" TOTAL_2="35" VAR="0.38730158730158726" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-016" NO="16">
<NAME>(Hyalgan plus exercise plus ultrasound) versus (exercise plus ultrasound)</NAME>
<CONT_OUTCOME CHI2="0.032579357458083255" CI_END="-0.020753883454242228" CI_START="-1.0942799948646664" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.5575169391594543" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-016.01" NO="1" P_CHI2="0.8567620420679709" P_Q="0.8567620420679709" P_Z="0.04177589023730497" Q="0.032579357458083255" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="66" TOTAL_2="61" UNITS="" WEIGHT="200.0" Z="2.0357457725698103">
<NAME>Pain (0-10 cm VAS)</NAME>
<GROUP_LABEL_1>EX+US+HA</GROUP_LABEL_1>
<GROUP_LABEL_2>EX+US</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours EX+US+HA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours EX+US</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.3235210731832888" CI_START="-1.3235210731832887" DF="0" EFFECT_SIZE="-0.5" ESTIMABLE="YES" I2="0.0" ID="CMP-016.01.01" NO="1" P_CHI2="1.0" P_Z="0.23405027205254747" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="32" WEIGHT="100.0" Z="1.1899901826214898">
<NAME>End of treatment</NAME>
<CONT_DATA CI_END="0.3235210731832888" CI_START="-1.3235210731832887" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="2.5" MEAN_2="3.0" ORDER="150744" SD_1="1.6" SD_2="1.8" SE="0.42017153359914666" STUDY_ID="STD-Huang-2005" TOTAL_1="34" TOTAL_2="32" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.10775791257665668" CI_START="-1.307757912576657" DF="0" EFFECT_SIZE="-0.6000000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-016.01.02" NO="2" P_CHI2="1.0" P_Z="0.09660211968661198" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="29" WEIGHT="100.0" Z="1.6615545652365467">
<NAME>One-year follow-up</NAME>
<CONT_DATA CI_END="0.10775791257665668" CI_START="-1.307757912576657" EFFECT_SIZE="-0.6000000000000001" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="2.6" ORDER="150745" SD_1="1.3" SD_2="1.5" SE="0.361107611241513" STUDY_ID="STD-Huang-2005" TOTAL_1="32" TOTAL_2="29" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.7625930144381954" CI_END="-0.1113876666355737" CI_START="-0.8877416306088126" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.4995646486221932" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-016.02" NO="2" P_CHI2="0.38251829854551134" P_Q="0.38251829854551134" P_Z="0.011656468339414338" Q="0.7625930144381954" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="66" TOTAL_2="61" UNITS="" WEIGHT="200.0" Z="2.522377072019836">
<NAME>Lequesne Index (0-26)</NAME>
<GROUP_LABEL_1>EX+US+HA</GROUP_LABEL_1>
<GROUP_LABEL_2>EX+US</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours EX+US+HA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours EX+US</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.04790329571088936" CI_START="-0.8479032957108901" DF="0" EFFECT_SIZE="-0.40000000000000036" ESTIMABLE="YES" I2="0.0" ID="CMP-016.02.01" NO="1" P_CHI2="1.0" P_Z="0.08005868496256625" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="32" WEIGHT="99.99999999999999" Z="1.7503456690840367">
<NAME>End of treatment</NAME>
<CONT_DATA CI_END="0.04790329571088936" CI_START="-0.8479032957108901" EFFECT_SIZE="-0.40000000000000036" ESTIMABLE="YES" MEAN_1="4.0" MEAN_2="4.4" ORDER="150746" SD_1="0.7" SD_2="1.1" SE="0.22852628887259854" STUDY_ID="STD-Huang-2005" TOTAL_1="34" TOTAL_2="32" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.02195056422969599" CI_START="-1.5780494357703037" DF="0" EFFECT_SIZE="-0.7999999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-016.02.02" NO="2" P_CHI2="1.0" P_Z="0.04387751040672464" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="29" WEIGHT="100.0" Z="2.0152590767959127">
<NAME>One-year follow-up</NAME>
<CONT_DATA CI_END="-0.02195056422969599" CI_START="-1.5780494357703037" EFFECT_SIZE="-0.7999999999999998" ESTIMABLE="YES" MEAN_1="2.5" MEAN_2="3.3" ORDER="150747" SD_1="1.6" SD_2="1.5" SE="0.39697129228264316" STUDY_ID="STD-Huang-2005" TOTAL_1="32" TOTAL_2="29" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="11.191168583599021" CI_START="0.8088314164009791" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="6.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-016.03" NO="3" P_CHI2="1.0" P_Q="0.9999999999999998" P_Z="0.02349156253332978" Q="4.672344396509439E-32" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="66" TOTAL_2="61" UNITS="" WEIGHT="200.0" Z="2.265344251079456">
<NAME>Range of motion (degrees)</NAME>
<GROUP_LABEL_1>EX+US+HA</GROUP_LABEL_1>
<GROUP_LABEL_2>EX+US</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours EX+US</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours EX+US+HA</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="12.790034414751858" CI_START="-0.7900344147518581" DF="0" EFFECT_SIZE="6.0" ESTIMABLE="YES" I2="0.0" ID="CMP-016.03.01" NO="1" P_CHI2="1.0" P_Z="0.08328813497338827" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="32" WEIGHT="100.00000000000001" Z="1.731918159603332">
<NAME>End of treatment</NAME>
<CONT_DATA CI_END="12.790034414751858" CI_START="-0.7900344147518581" EFFECT_SIZE="6.0" ESTIMABLE="YES" MEAN_1="120.0" MEAN_2="114.0" ORDER="150748" SD_1="13.0" SD_2="15.0" SE="3.464366931387915" STUDY_ID="STD-Huang-2005" TOTAL_1="34" TOTAL_2="32" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="4.672344396509439E-32" CI_END="14.053429929137629" CI_START="-2.0534299291376295" DF="0" EFFECT_SIZE="5.999999999999999" ESTIMABLE="YES" I2="100.0" ID="CMP-016.03.02" NO="2" P_CHI2="0.0" P_Z="0.1442294683413459" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="29" WEIGHT="100.0" Z="1.460220553318898">
<NAME>One-year follow-up</NAME>
<CONT_DATA CI_END="14.053429929137629" CI_START="-2.0534299291376286" EFFECT_SIZE="6.0" ESTIMABLE="YES" MEAN_1="124.0" MEAN_2="118.0" ORDER="150749" SD_1="18.0" SD_2="14.0" SE="4.10896832424578" STUDY_ID="STD-Huang-2005" TOTAL_1="32" TOTAL_2="29" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.045017073836695266" CI_END="6.642432423360358" CI_START="4.041710675490604" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="5.342071549425481" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-016.04" NO="4" P_CHI2="0.83197278101479" P_Q="0.83197278101479" P_Z="8.157379067451431E-16" Q="0.045017073836695266" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="66" TOTAL_2="61" UNITS="" WEIGHT="200.0" Z="8.051817037548293">
<NAME>Ambulation speed (metres per minute)</NAME>
<GROUP_LABEL_1>EX+US+HA</GROUP_LABEL_1>
<GROUP_LABEL_2>EX+US</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours EX+US</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours EX+US+HA</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="6.806162176592617" CI_START="3.993837823407366" DF="0" EFFECT_SIZE="5.3999999999999915" ESTIMABLE="YES" I2="0.0" ID="CMP-016.04.01" NO="1" P_CHI2="1.0" P_Z="5.202609477651673E-14" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="32" WEIGHT="100.0" Z="7.526731761597137">
<NAME>End of treatment</NAME>
<CONT_DATA CI_END="6.806162176592617" CI_START="3.993837823407366" EFFECT_SIZE="5.3999999999999915" ESTIMABLE="YES" MEAN_1="95.6" MEAN_2="90.2" ORDER="150750" SD_1="2.7" SD_2="3.1" SE="0.7174428651160191" STUDY_ID="STD-Huang-2005" TOTAL_1="34" TOTAL_2="32" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="8.417023244499687" CI_START="1.5829767555003138" DF="0" EFFECT_SIZE="5.0" ESTIMABLE="YES" I2="0.0" ID="CMP-016.04.02" NO="2" P_CHI2="1.0" P_Z="0.004131530055561587" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="29" WEIGHT="100.0" Z="2.8679406669166925">
<NAME>One-year follow-up</NAME>
<CONT_DATA CI_END="8.417023244499687" CI_START="1.5829767555003138" EFFECT_SIZE="5.0" ESTIMABLE="YES" MEAN_1="99.3" MEAN_2="94.3" ORDER="150751" SD_1="6.8" SD_2="6.8" SE="1.7434112419680818" STUDY_ID="STD-Huang-2005" TOTAL_1="32" TOTAL_2="29" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.09617579319416096" CI_END="1.3650431156485663" CI_START="0.14470668503659606" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4444444444444444" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-016.05" LOG_CI_END="0.13514636902698354" LOG_CI_START="-0.8395114052497086" LOG_EFFECT_SIZE="-0.35218251811136253" METHOD="MH" NO="5" P_CHI2="0.7564680348498813" P_Q="0.7571314776633213" P_Z="0.15665096899307918" Q="0.09563548564422372" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="70" TOTAL_2="70" WEIGHT="200.0" Z="1.4164254771273983">
<NAME>Safety: total withdrawals overall</NAME>
<GROUP_LABEL_1>EX+US+HA</GROUP_LABEL_1>
<GROUP_LABEL_2>EX+US</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours EX+US+HA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>FavoursEX+US</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.05118976192878" CI_START="0.03641566725790049" DF="0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="0.0" ID="CMP-016.05.01" LOG_CI_END="0.4844692184571428" LOG_CI_START="-1.4387117278964678" LOG_EFFECT_SIZE="-0.47712125471966244" NO="1" P_CHI2="1.0" P_Z="0.33080511422891756" STUDIES="1" TAU2="0.0" TOTAL_1="35" TOTAL_2="35" WEIGHT="100.0" Z="0.9724934903105658">
<NAME>During treatment</NAME>
<DICH_DATA CI_END="3.05118976192878" CI_START="0.03641566725790049" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4844692184571428" LOG_CI_START="-1.4387117278964678" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="150752" O_E="0.0" SE="1.1296860077873303" STUDY_ID="STD-Huang-2005" TOTAL_1="35" TOTAL_2="35" VAR="1.2761904761904763" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8425677190843581" CI_START="0.13568022353296982" DF="0" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" I2="0.0" ID="CMP-016.05.02" LOG_CI_END="0.265423458259286" LOG_CI_START="-0.8674834495872482" LOG_EFFECT_SIZE="-0.3010299956639812" NO="2" P_CHI2="1.0" P_Z="0.2976053455506491" STUDIES="1" TAU2="0.0" TOTAL_1="35" TOTAL_2="35" WEIGHT="100.0" Z="1.0415824030752145">
<NAME>Overall</NAME>
<DICH_DATA CI_END="1.8425677190843581" CI_START="0.13568022353296982" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.265423458259286" LOG_CI_START="-0.8674834495872482" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="150753" O_E="0.0" SE="0.6654751256486924" STUDY_ID="STD-Huang-2005" TOTAL_1="35" TOTAL_2="35" VAR="0.44285714285714284" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-017" NO="17">
<NAME>Hyalgan versus conventional therapy (three courses of treatment)</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="3.0600111001790715" CI_START="-31.86001110017907" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-14.399999999999999" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-017.01" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.10599400610748556" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="19" TOTAL_2="17" UNITS="" WEIGHT="100.0" Z="1.6164641142231184">
<NAME>Pain overall (0-100 mm VAS)</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>Convent Care</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hyalgan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours convent care</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.0600111001790715" CI_START="-31.86001110017907" DF="0" EFFECT_SIZE="-14.399999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-017.01.01" NO="1" P_CHI2="1.0" P_Z="0.10599400610748556" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="17" WEIGHT="100.0" Z="1.6164641142231184">
<NAME>45 to 52 weeks post-injection</NAME>
<CONT_DATA CI_END="3.0600111001790715" CI_START="-31.86001110017907" EFFECT_SIZE="-14.399999999999999" ESTIMABLE="YES" MEAN_1="32.4" MEAN_2="46.8" ORDER="150754" SD_1="25.5" SD_2="27.7" SE="8.908332621365194" STUDY_ID="STD-Listrat-1997" TOTAL_1="19" TOTAL_2="17" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.0080576239765846" CI_START="-3.8080576239765835" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.8999999999999995" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-017.02" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.5441301378515948" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="19" TOTAL_2="17" UNITS="" WEIGHT="100.0" Z="0.6065793096884835">
<NAME>Lequesne Index (0-24)</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>Convent Care</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hyalgan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Convent Care</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.0080576239765846" CI_START="-3.8080576239765835" DF="0" EFFECT_SIZE="-0.8999999999999995" ESTIMABLE="YES" I2="0.0" ID="CMP-017.02.01" NO="1" P_CHI2="1.0" P_Z="0.5441301378515948" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="17" WEIGHT="100.0" Z="0.6065793096884835">
<NAME>45 to 52 weeks post-injection</NAME>
<CONT_DATA CI_END="2.0080576239765846" CI_START="-3.8080576239765835" EFFECT_SIZE="-0.8999999999999995" ESTIMABLE="YES" MEAN_1="7.2" MEAN_2="8.1" ORDER="150755" SD_1="4.8" SD_2="4.1" SE="1.4837301332651882" STUDY_ID="STD-Listrat-1997" TOTAL_1="19" TOTAL_2="17" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.2106522069096597" CI_START="-0.01065220690965929" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.1" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-017.03" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.052238136834775586" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="19" TOTAL_2="17" UNITS="" WEIGHT="100.0" Z="1.9411660730346219">
<NAME>Joint space width (mm)</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>Conventional care</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Convent care</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Hyalgan</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.2106522069096597" CI_START="-0.01065220690965929" DF="0" EFFECT_SIZE="1.1" ESTIMABLE="YES" I2="0.0" ID="CMP-017.03.01" NO="1" P_CHI2="1.0" P_Z="0.052238136834775586" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="17" WEIGHT="100.0" Z="1.9411660730346219">
<NAME>45 to 52 weeks post-injection</NAME>
<CONT_DATA CI_END="2.2106522069096597" CI_START="-0.01065220690965929" EFFECT_SIZE="1.1" ESTIMABLE="YES" MEAN_1="4.0" MEAN_2="2.9" ORDER="150756" SD_1="1.8" SD_2="1.6" SE="0.5666697019283733" STUDY_ID="STD-Listrat-1997" TOTAL_1="19" TOTAL_2="17" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.8111010985079434E-33" CI_END="0.5842889351289076" CI_START="-0.984288935128907" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.19999999999999976" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-017.04" NO="4" P_CHI2="0.0" P_Q="1.0" P_Z="0.6172112550482705" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="19" TOTAL_2="17" UNITS="" WEIGHT="100.00000000000001" Z="0.49980661380053976">
<NAME>Quality of life (AIMS: total of 12 items)</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>Conventional care</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hyalgan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours convent care</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="4.8111010985079434E-33" CI_END="0.5842889351289076" CI_START="-0.984288935128907" DF="0" EFFECT_SIZE="-0.19999999999999976" ESTIMABLE="YES" I2="100.0" ID="CMP-017.04.01" NO="1" P_CHI2="0.0" P_Z="0.6172112550482705" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="17" WEIGHT="100.00000000000001" Z="0.49980661380053976">
<NAME>45 to 52 weeks post-injection</NAME>
<CONT_DATA CI_END="0.5842889351289076" CI_START="-0.984288935128907" EFFECT_SIZE="-0.19999999999999973" ESTIMABLE="YES" MEAN_1="2.2" MEAN_2="2.4" ORDER="150757" SD_1="1.3" SD_2="1.1" SE="0.40015476881987544" STUDY_ID="STD-Listrat-1997" TOTAL_1="19" TOTAL_2="17" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-4.084984261786875" CI_START="-40.51501573821312" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-22.299999999999997" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-017.05" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.016416823520773026" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="19" TOTAL_2="17" UNITS="" WEIGHT="99.99999999999999" Z="2.3995146358040342">
<NAME>Arthroscopy overall assessment (0-100 mm VAS)</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>Convent Care</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hyalgan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours convent care</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-4.084984261786875" CI_START="-40.51501573821312" DF="0" EFFECT_SIZE="-22.299999999999997" ESTIMABLE="YES" I2="0.0" ID="CMP-017.05.01" NO="1" P_CHI2="1.0" P_Z="0.016416823520773026" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="17" WEIGHT="99.99999999999999" Z="2.3995146358040342">
<NAME>45 to 52 weeks post-injection</NAME>
<CONT_DATA CI_END="-4.084984261786875" CI_START="-40.51501573821312" EFFECT_SIZE="-22.299999999999997" ESTIMABLE="YES" MEAN_1="47.0" MEAN_2="69.3" ORDER="150758" SD_1="26.6" SD_2="28.9" SE="9.293546147730693" STUDY_ID="STD-Listrat-1997" TOTAL_1="19" TOTAL_2="17" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-5.1326384921894554" CI_START="-31.26736150781054" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-18.2" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-017.06" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.006337186082159761" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="19" TOTAL_2="17" UNITS="" WEIGHT="100.00000000000001" Z="2.7298046738285864">
<NAME>SFA scoring (0-100 mm VAS)</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>Convent Care</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hyalgan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours convent care</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-5.1326384921894554" CI_START="-31.26736150781054" DF="0" EFFECT_SIZE="-18.2" ESTIMABLE="YES" I2="0.0" ID="CMP-017.06.01" NO="1" P_CHI2="1.0" P_Z="0.006337186082159761" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="17" WEIGHT="100.00000000000001" Z="2.7298046738285864">
<NAME>45 to 52 weeks post-injection</NAME>
<CONT_DATA CI_END="-5.1326384921894554" CI_START="-31.26736150781054" EFFECT_SIZE="-18.2" ESTIMABLE="YES" MEAN_1="29.8" MEAN_2="48.0" ORDER="150759" SD_1="18.5" SD_2="21.2" SE="6.667143687784176" STUDY_ID="STD-Listrat-1997" TOTAL_1="19" TOTAL_2="17" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.818388771820756" CI_START="0.04682581889604179" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.475" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" I2_Q="99.99999999999999" ID="CMP-017.07" LOG_CI_END="0.6829018381373769" LOG_CI_START="-1.3295146188876439" LOG_EFFECT_SIZE="-0.3233063903751334" METHOD="MH" NO="7" P_CHI2="1.0" P_Q="0.0" P_Z="0.5288521522083023" Q="8.820831685027792E-33" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="20" TOTAL_2="19" WEIGHT="100.0" Z="0.6297591921342852">
<NAME>Safety: total withdrawals</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>Conventional Care</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hyalgan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours convent care</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.818388771820756" CI_START="0.04682581889604179" DF="0" EFFECT_SIZE="0.475" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-017.07.01" LOG_CI_END="0.6829018381373769" LOG_CI_START="-1.3295146188876439" LOG_EFFECT_SIZE="-0.3233063903751334" NO="1" P_CHI2="1.0" P_Z="0.5288521522083023" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="19" WEIGHT="100.0" Z="0.6297591921342852">
<NAME>45 to 52 weeks post-injection</NAME>
<DICH_DATA CI_END="4.818388771820756" CI_START="0.04682581889604179" EFFECT_SIZE="0.475" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6829018381373769" LOG_CI_START="-1.3295146188876439" LOG_EFFECT_SIZE="-0.3233063903751334" ORDER="150760" O_E="0.0" SE="1.1821033884786185" STUDY_ID="STD-Listrat-1997" TOTAL_1="20" TOTAL_2="19" VAR="1.3973684210526316" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-018" NO="18">
<NAME>Hyalgan versus Hylan G-F 20</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-018.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="25" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>Safety: number of patients with local reaction (acute inflammation and pain)</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>Hylan G-F 20</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hyalgan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Hylan G-F 20</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5011706496794115" CI_START="0.0052478213760789585" EFFECT_SIZE="0.08875739644970414" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" LOG_CI_END="0.17643006466265282" LOG_CI_START="-2.2800209557786375" LOG_EFFECT_SIZE="-1.0517954455579923" ORDER="150761" O_E="0.0" SE="1.442931489035873" STUDY_ID="STD-Brown-2003" TOTAL_1="25" TOTAL_2="29" VAR="2.082051282051282" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-019" NO="19">
<NAME>Hyalgan versus Hyalgan</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0305609717961906" CI_START="0.6992811566061738" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8489121676067687" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="68" I2="0.0" I2_Q="0.0" ID="CMP-019.01" LOG_CI_END="0.013073691342114684" LOG_CI_START="-0.15534817445133633" LOG_EFFECT_SIZE="-0.07113724155461086" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.09778646150448148" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="73" TOTAL_2="86" WEIGHT="100.0" Z="1.6556808790795967">
<NAME>Patient global (number of patients assessing response as satisfactory)</NAME>
<GROUP_LABEL_1>Hyalgan 5-inj</GROUP_LABEL_1>
<GROUP_LABEL_2>Hyalgan 3-inj</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hyalgan 5inj</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Hyalgan 3inj</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0305609717961906" CI_START="0.6992811566061738" DF="0" EFFECT_SIZE="0.8489121676067687" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="68" I2="0.0" ID="CMP-019.01.01" LOG_CI_END="0.013073691342114684" LOG_CI_START="-0.15534817445133633" LOG_EFFECT_SIZE="-0.07113724155461086" NO="1" P_CHI2="1.0" P_Z="0.09778646150448148" STUDIES="1" TAU2="0.0" TOTAL_1="73" TOTAL_2="86" WEIGHT="100.0" Z="1.6556808790795967">
<NAME>45 to 52 weeks post-injection</NAME>
<DICH_DATA CI_END="1.0305609717961906" CI_START="0.6992811566061738" EFFECT_SIZE="0.8489121676067687" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="68" LOG_CI_END="0.013073691342114684" LOG_CI_START="-0.15534817445133633" LOG_EFFECT_SIZE="-0.07113724155461086" ORDER="150762" O_E="0.0" SE="0.09893183766875459" STUDY_ID="STD-Karras-2001" TOTAL_1="73" TOTAL_2="86" VAR="0.00978750850451681" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-020" NO="20">
<NAME>Hylan G-F 20 versus placebo</NAME>
<CONT_OUTCOME CHI2="62.410171147595406" CI_END="-10.075598782303988" CI_START="-22.27355166139525" CI_STUDY="95" CI_TOTAL="95" DF="14" EFFECT_MEASURE="MD" EFFECT_SIZE="-16.17457522184962" ESTIMABLE="YES" I2="77.5677590005465" I2_Q="5.130255487031239" ID="CMP-020.01" NO="1" P_CHI2="4.413928644808607E-8" P_Q="0.3485141946020254" P_Z="2.0160311069975963E-7" Q="2.108153669294006" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="126.45145724856442" TOTALS="SUB" TOTAL_1="655" TOTAL_2="512" UNITS="" WEIGHT="300.00000000000006" Z="5.197853314288414">
<NAME>Pain on weight bearing (0-100 mm VAS)</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hylan G-F 20</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="14.218464388458562" CI_END="-4.693877288109379" CI_START="-20.390739402180465" DF="5" EFFECT_SIZE="-12.54230834514492" ESTIMABLE="YES" I2="64.83445846614345" ID="CMP-020.01.01" NO="1" P_CHI2="0.014279682653386305" P_Z="0.001735304916562979" STUDIES="6" TAU2="61.251196922641405" TOTAL_1="265" TOTAL_2="216" WEIGHT="100.00000000000003" Z="3.132151185483605">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="12.702252786622653" CI_START="-10.702252786622653" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="45.0" MEAN_2="44.0" ORDER="150763" SD_1="25.67" SD_2="30.39" SE="5.970646848068908" STUDY_ID="STD-Karlsson-2002b-_x0028_SvP_x0029_" TOTAL_1="86" TOTAL_2="33" WEIGHT="16.548039153451935"/>
<CONT_DATA CI_END="7.086806891171957" CI_START="-15.086806891171957" EFFECT_SIZE="-4.0" ESTIMABLE="YES" MEAN_1="47.0" MEAN_2="51.0" ORDER="150764" SD_1="27.13" SD_2="27.71" SE="5.656638070200919" STUDY_ID="STD-Moreland-1993" TOTAL_1="46" TOTAL_2="48" WEIGHT="17.19596248456463"/>
<CONT_DATA CI_END="-1.1392747723402383" CI_START="-28.860725227659763" EFFECT_SIZE="-15.0" ESTIMABLE="YES" MEAN_1="32.0" MEAN_2="47.0" ORDER="150765" SD_1="23.98" SD_2="24.5" SE="7.071928533887047" STUDY_ID="STD-Scale-1994a-_x0028_2-inj_x0029_" TOTAL_1="23" TOTAL_2="24" WEIGHT="14.411769348901311"/>
<CONT_DATA CI_END="-8.144480551054334" CI_START="-35.855519448945664" EFFECT_SIZE="-22.0" ESTIMABLE="YES" MEAN_1="22.0" MEAN_2="44.0" ORDER="150766" SD_1="19.36" SD_2="19.36" SE="7.069272475533344" STUDY_ID="STD-Scale-1994b-_x0028_3-inj_x0029_" TOTAL_1="15" TOTAL_2="15" WEIGHT="14.416636060744871"/>
<CONT_DATA CI_END="-13.684110155200875" CI_START="-30.315889844799123" EFFECT_SIZE="-22.0" ESTIMABLE="YES" MEAN_1="31.0" MEAN_2="53.0" ORDER="150767" SD_1="22.65" SD_2="23.24" SE="4.242878905119586" STUDY_ID="STD-Wobig-1998" TOTAL_1="57" TOTAL_2="60" WEIGHT="20.23264241993268"/>
<CONT_DATA CI_END="-1.9122424095623067" CI_START="-24.087757590437693" EFFECT_SIZE="-13.0" ESTIMABLE="YES" MEAN_1="40.0" MEAN_2="53.0" ORDER="150768" SD_1="24.66" SD_2="24.0" SE="5.657123129759786" STUDY_ID="STD-Wobig-1999c-_x0028_NEhyl_x0029_" TOTAL_1="38" TOTAL_2="36" WEIGHT="17.19495053240459"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="23.37487630892116" CI_END="-9.682427909605442" CI_START="-35.239335677957285" DF="4" EFFECT_SIZE="-22.460881793781365" ESTIMABLE="YES" I2="82.88760998288843" ID="CMP-020.01.02" NO="2" P_CHI2="1.0655775781942545E-4" P_Z="5.7093610959002E-4" STUDIES="5" TAU2="173.64954704415743" TOTAL_1="218" TOTAL_2="167" WEIGHT="99.99999999999999" Z="3.445058359629701">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="8.645230951544209" CI_START="-18.645230951544207" EFFECT_SIZE="-5.0" ESTIMABLE="YES" MEAN_1="41.0" MEAN_2="46.0" ORDER="150769" SD_1="31.53" SD_2="34.9" SE="6.9619804543226556" STUDY_ID="STD-Karlsson-2002b-_x0028_SvP_x0029_" TOTAL_1="86" TOTAL_2="33" WEIGHT="19.137062621628143"/>
<CONT_DATA CI_END="-12.139274772340238" CI_START="-39.86072522765976" EFFECT_SIZE="-26.0" ESTIMABLE="YES" MEAN_1="27.0" MEAN_2="53.0" ORDER="150770" SD_1="23.98" SD_2="24.5" SE="7.071928533887047" STUDY_ID="STD-Scale-1994a-_x0028_2-inj_x0029_" TOTAL_1="23" TOTAL_2="24" WEIGHT="19.005039523186984"/>
<CONT_DATA CI_END="-18.144480551054336" CI_START="-45.855519448945664" EFFECT_SIZE="-32.0" ESTIMABLE="YES" MEAN_1="11.0" MEAN_2="43.0" ORDER="150771" SD_1="19.36" SD_2="19.36" SE="7.069272475533344" STUDY_ID="STD-Scale-1994b-_x0028_3-inj_x0029_" TOTAL_1="15" TOTAL_2="15" WEIGHT="19.008231604619205"/>
<CONT_DATA CI_END="-28.684110155200877" CI_START="-45.31588984479912" EFFECT_SIZE="-37.0" ESTIMABLE="YES" MEAN_1="23.0" MEAN_2="60.0" ORDER="150772" SD_1="22.65" SD_2="23.24" SE="4.242878905119586" STUDY_ID="STD-Wobig-1998" TOTAL_1="57" TOTAL_2="60" WEIGHT="22.179311483196038"/>
<CONT_DATA CI_END="0.08597955873084473" CI_START="-22.085979558730845" EFFECT_SIZE="-11.0" ESTIMABLE="YES" MEAN_1="32.0" MEAN_2="43.0" ORDER="150773" SD_1="24.33" SD_2="23.66" SE="5.656215954056114" STUDY_ID="STD-Wobig-1999c-_x0028_NEhyl_x0029_" TOTAL_1="37" TOTAL_2="35" WEIGHT="20.670354767369627"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="13.617183704170277" CI_END="-5.832351469818313" CI_START="-35.56387384069447" DF="3" EFFECT_SIZE="-20.69811265525639" ESTIMABLE="YES" I2="77.96901279167405" ID="CMP-020.01.03" NO="3" P_CHI2="0.0034753790521624417" P_Z="0.006354104967013095" STUDIES="4" TAU2="177.87939602347174" TOTAL_1="172" TOTAL_2="129" WEIGHT="100.00000000000001" Z="2.7289255387738667">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="12.55735665976795" CI_START="-14.55735665976795" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="43.0" MEAN_2="44.0" ORDER="150774" SD_1="33.78" SD_2="33.78" SE="6.917145808140684" STUDY_ID="STD-Karlsson-2002b-_x0028_SvP_x0029_" TOTAL_1="86" TOTAL_2="33" WEIGHT="25.48566407037517"/>
<CONT_DATA CI_END="-23.692163603746103" CI_START="-54.3078363962539" EFFECT_SIZE="-39.0" ESTIMABLE="YES" MEAN_1="18.0" MEAN_2="57.0" ORDER="150775" SD_1="23.24" SD_2="22.91" SE="7.810264125769736" STUDY_ID="STD-Scale-1994a-_x0028_2-inj_x0029_" TOTAL_1="15" TOTAL_2="21" WEIGHT="24.082358581739058"/>
<CONT_DATA CI_END="-6.367651240005305" CI_START="-39.6323487599947" EFFECT_SIZE="-23.0" ESTIMABLE="YES" MEAN_1="22.0" MEAN_2="45.0" ORDER="150776" SD_1="23.24" SD_2="23.24" SE="8.486048157613373" STUDY_ID="STD-Scale-1994b-_x0028_3-inj_x0029_" TOTAL_1="15" TOTAL_2="15" WEIGHT="23.021046230919474"/>
<CONT_DATA CI_END="-9.91406482661416" CI_START="-32.08593517338584" EFFECT_SIZE="-21.0" ESTIMABLE="YES" MEAN_1="35.0" MEAN_2="56.0" ORDER="150777" SD_1="29.93" SD_2="30.98" SE="5.656193308055802" STUDY_ID="STD-Wobig-1998" TOTAL_1="56" TOTAL_2="60" WEIGHT="27.410931116966317"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="6.144654321906108" CI_END="-4.2378156177932365" CI_START="-11.937785157665646" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-8.087800387729441" ESTIMABLE="YES" I2="67.45138301971089" I2_Q="83.65505017597715" ID="CMP-020.02" NO="2" P_CHI2="0.046313420793620996" P_Q="0.013380539900985533" P_Z="3.8322674813114706E-5" Q="6.1180977045904354" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="86" TOTAL_2="68" UNITS="" WEIGHT="200.0" Z="4.1173662809999785">
<NAME>Pain walking (0-100 mm VAS)</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hylan G-F 20</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.02655661731567184" CI_END="1.0992342318990698" CI_START="-9.009416097272364" DF="1" EFFECT_SIZE="-3.9550909326866472" ESTIMABLE="YES" I2="0.0" ID="CMP-020.02.01" NO="1" P_CHI2="0.8705483678611758" P_Z="0.12510263236871663" STUDIES="2" TAU2="0.0" TOTAL_1="66" TOTAL_2="58" WEIGHT="100.00000000000001" Z="1.5337034186011156">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="1.3819598300167035" CI_START="-9.661959830016706" EFFECT_SIZE="-4.140000000000001" ESTIMABLE="YES" MEAN_1="46.66" MEAN_2="50.8" ORDER="150778" SD_1="9.66" SD_2="5.72" SE="2.817378213871897" STUDY_ID="STD-Cubukcu-2004" TOTAL_1="20" TOTAL_2="10" WEIGHT="83.77990637602164"/>
<CONT_DATA CI_END="9.549791194554173" CI_START="-15.549791194554173" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="57.0" MEAN_2="60.0" ORDER="150779" SD_1="27.13" SD_2="34.64" SE="6.403072349056067" STUDY_ID="STD-Moreland-1993" TOTAL_1="46" TOTAL_2="48" WEIGHT="16.220093623978368"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-7.8577977542241575" CI_START="-19.742202245775836" DF="0" EFFECT_SIZE="-13.799999999999997" ESTIMABLE="YES" I2="0.0" ID="CMP-020.02.02" NO="2" P_CHI2="1.0" P_Z="5.319795911490523E-6" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="10" WEIGHT="100.0" Z="4.551764121774906">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="-7.8577977542241575" CI_START="-19.742202245775836" EFFECT_SIZE="-13.799999999999997" ESTIMABLE="YES" MEAN_1="40.0" MEAN_2="53.8" ORDER="150780" SD_1="9.08" SD_2="7.12" SE="3.0317915495627332" STUDY_ID="STD-Cubukcu-2004" TOTAL_1="20" TOTAL_2="10" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="27.475258205881474" CI_END="-0.5756746555834273" CI_START="-1.1215052029640558" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.8485899292737416" ESTIMABLE="YES" I2="81.8018088764324" I2_Q="34.2240621369954" ID="CMP-020.03" NO="3" P_CHI2="4.6085447019339476E-5" P_Q="0.21864356417374675" P_Z="1.0997238570713255E-9" Q="3.040625591938373" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="156" TOTAL_2="104" UNITS="" WEIGHT="300.0" Z="6.094219925951152">
<NAME>WOMAC pain</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline/Arthro</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hylan G-F 20</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Saline/arthr</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.6439747811029766" CI_END="-0.660223041258991" CI_START="-1.855821476207332" DF="1" EFFECT_SIZE="-1.2580222587331615" ESTIMABLE="YES" I2="0.0" ID="CMP-020.03.01" NO="1" P_CHI2="0.4222753815624073" P_Z="3.713913087846459E-5" STUDIES="2" TAU2="0.0" TOTAL_1="41" TOTAL_2="19" WEIGHT="100.0" Z="4.124592750864989">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="-0.6498251138098228" CI_START="-2.376000768232926" EFFECT_SIZE="-1.5129129410213744" ESTIMABLE="YES" MEAN_1="11.4" MEAN_2="14.1" ORDER="150781" SD_1="1.83" SD_2="1.52" SE="0.44035902395119414" STUDY_ID="STD-Cubukcu-2004" TOTAL_1="20" TOTAL_2="10" WEIGHT="47.97342235149593"/>
<CONT_DATA CI_END="-0.1942023712189631" CI_START="-1.8517755415405641" EFFECT_SIZE="-1.0229889563797636" ESTIMABLE="YES" MEAN_1="10.0" MEAN_2="13.5" ORDER="150782" SD_1="3.3" SD_2="3.4" SE="0.4228580686676711" STUDY_ID="STD-Kotevoglu-2005" TOTAL_1="21" TOTAL_2="9" WEIGHT="52.026577648504066"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="23.79065783284013" CI_END="-0.35690815483890315" CI_START="-1.016552726662956" DF="2" EFFECT_SIZE="-0.6867304407509295" ESTIMABLE="YES" I2="91.59333880528834" ID="CMP-020.03.02" NO="2" P_CHI2="6.822232468062239E-6" P_Z="4.486448432719313E-5" STUDIES="3" TAU2="0.0" TOTAL_1="94" TOTAL_2="76" WEIGHT="100.0" Z="4.08088533871283">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="-2.028290398794498" CI_START="-4.3263710427360325" EFFECT_SIZE="-3.1773307207652652" ESTIMABLE="YES" MEAN_1="9.36" MEAN_2="14.6" ORDER="150783" SD_1="1.52" SD_2="1.77" SE="0.5862558348185226" STUDY_ID="STD-Cubukcu-2004" TOTAL_1="20" TOTAL_2="10" WEIGHT="8.239283687799825"/>
<CONT_DATA CI_END="0.07032057919593082" CI_START="-0.6821936032924824" EFFECT_SIZE="-0.30593651204827577" ESTIMABLE="YES" MEAN_1="26.0" MEAN_2="34.0" ORDER="150784" SD_1="29.12" SD_2="22.65" SE="0.19197143121612156" STUDY_ID="STD-Dickson-2001" TOTAL_1="53" TOTAL_2="57" WEIGHT="76.84057520501318"/>
<CONT_DATA CI_END="-0.418619655115851" CI_START="-2.1263666420440455" EFFECT_SIZE="-1.2724931485799482" ESTIMABLE="YES" MEAN_1="10.0" MEAN_2="14.0" ORDER="150785" SD_1="3.0" SD_2="3.2" SE="0.43565774687664793" STUDY_ID="STD-Kotevoglu-2005" TOTAL_1="21" TOTAL_2="9" WEIGHT="14.920141107186987"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.25228568917467165" CI_START="-1.9218387339111862" DF="0" EFFECT_SIZE="-1.087062211542929" ESTIMABLE="YES" I2="0.0" ID="CMP-020.03.03" NO="3" P_CHI2="1.0" P_Z="0.010701334884917084" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="9" WEIGHT="100.0" Z="2.5523031931157956">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="-0.25228568917467165" CI_START="-1.9218387339111862" EFFECT_SIZE="-1.087062211542929" ESTIMABLE="YES" MEAN_1="10.0" MEAN_2="13.0" ORDER="150786" SD_1="2.5" SD_2="3.1" SE="0.4259142152370492" STUDY_ID="STD-Kotevoglu-2005" TOTAL_1="21" TOTAL_2="9" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="24.458471128139266" CI_END="-9.609038084666494" CI_START="-14.743601245895015" CI_STUDY="95" CI_TOTAL="95" DF="13" EFFECT_MEASURE="MD" EFFECT_SIZE="-12.176319665280754" ESTIMABLE="YES" I2="46.848681048409404" I2_Q="75.08733926830713" ID="CMP-020.04" NO="4" P_CHI2="0.027165450198307184" P_Q="0.01806064059200818" P_Z="1.4598996888106176E-20" Q="8.028046548459118" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="435" TOTAL_2="433" UNITS="" WEIGHT="300.0" Z="9.295882535209481">
<NAME>Pain at night (0-100 mm VAS)</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hylan G-F 20</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="3.618039487999082" CI_END="-4.117940674153747" CI_START="-11.951684209257344" DF="5" EFFECT_SIZE="-8.034812441705546" ESTIMABLE="YES" I2="0.0" ID="CMP-020.04.01" NO="1" P_CHI2="0.6056069772514023" P_Z="5.8064675196761944E-5" STUDIES="6" TAU2="0.0" TOTAL_1="198" TOTAL_2="193" WEIGHT="100.0" Z="4.02054086598814">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="-2.891013261402411" CI_START="-16.448986738597593" EFFECT_SIZE="-9.670000000000002" ESTIMABLE="YES" MEAN_1="27.33" MEAN_2="37.0" ORDER="150787" SD_1="7.69" SD_2="9.49" SE="3.458730258346262" STUDY_ID="STD-Cubukcu-2004" TOTAL_1="20" TOTAL_2="10" WEIGHT="33.3848276586778"/>
<CONT_DATA CI_END="4.858497830896802" CI_START="-22.858497830896802" EFFECT_SIZE="-9.0" ESTIMABLE="YES" MEAN_1="36.0" MEAN_2="45.0" ORDER="150788" SD_1="33.91" SD_2="34.64" SE="7.070792086084675" STUDY_ID="STD-Moreland-1993" TOTAL_1="46" TOTAL_2="48" WEIGHT="7.988153301940128"/>
<CONT_DATA CI_END="8.860725227659762" CI_START="-18.860725227659763" EFFECT_SIZE="-5.0" ESTIMABLE="YES" MEAN_1="18.0" MEAN_2="23.0" ORDER="150789" SD_1="23.98" SD_2="24.5" SE="7.071928533887047" STUDY_ID="STD-Scale-1994a-_x0028_2-inj_x0029_" TOTAL_1="23" TOTAL_2="24" WEIGHT="7.985586140860443"/>
<CONT_DATA CI_END="1.0877873346829343" CI_START="-21.087787334682936" EFFECT_SIZE="-10.0" ESTIMABLE="YES" MEAN_1="7.0" MEAN_2="17.0" ORDER="150790" SD_1="14.97" SD_2="15.49" SE="5.657138305673975" STUDY_ID="STD-Scale-1994b-_x0028_3-inj_x0029_" TOTAL_1="14" TOTAL_2="15" WEIGHT="12.479262847308023"/>
<CONT_DATA CI_END="-2.684110155200875" CI_START="-19.315889844799123" EFFECT_SIZE="-11.0" ESTIMABLE="YES" MEAN_1="15.0" MEAN_2="26.0" ORDER="150791" SD_1="22.65" SD_2="23.24" SE="4.242878905119586" STUDY_ID="STD-Wobig-1998" TOTAL_1="57" TOTAL_2="60" WEIGHT="22.185092892390582"/>
<CONT_DATA CI_END="9.799201482971133" CI_START="-9.799201482971133" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="12.0" MEAN_2="12.0" ORDER="150792" SD_1="18.49" SD_2="24.0" SE="4.999684463727897" STUDY_ID="STD-Wobig-1999c-_x0028_NEhyl_x0029_" TOTAL_1="38" TOTAL_2="36" WEIGHT="15.977077158823027"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="11.848385984398668" CI_END="-10.380307719595216" CI_START="-18.56731935441704" DF="4" EFFECT_SIZE="-14.473813537006128" ESTIMABLE="YES" I2="66.2401275138488" ID="CMP-020.04.02" NO="2" P_CHI2="0.018515067466152058" P_Z="4.207258590843272E-12" STUDIES="5" TAU2="0.0" TOTAL_1="151" TOTAL_2="144" WEIGHT="100.0" Z="6.930038582288563">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="-13.760712581968523" CI_START="-28.919287418031477" EFFECT_SIZE="-21.34" ESTIMABLE="YES" MEAN_1="22.66" MEAN_2="44.0" ORDER="150793" SD_1="9.3" SD_2="10.31" SE="3.867054434579374" STUDY_ID="STD-Cubukcu-2004" TOTAL_1="20" TOTAL_2="10" WEIGHT="29.169841605074986"/>
<CONT_DATA CI_END="3.8607252276597617" CI_START="-23.860725227659763" EFFECT_SIZE="-10.0" ESTIMABLE="YES" MEAN_1="16.0" MEAN_2="26.0" ORDER="150794" SD_1="23.98" SD_2="24.5" SE="7.071928533887047" STUDY_ID="STD-Scale-1994a-_x0028_2-inj_x0029_" TOTAL_1="23" TOTAL_2="24" WEIGHT="8.722056896059723"/>
<CONT_DATA CI_END="-4.686042721368482" CI_START="-21.31395727863152" EFFECT_SIZE="-13.0" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="15.0" ORDER="150795" SD_1="11.22" SD_2="11.62" SE="4.241892883854475" STUDY_ID="STD-Scale-1994b-_x0028_3-inj_x0029_" TOTAL_1="14" TOTAL_2="15" WEIGHT="24.2423795650674"/>
<CONT_DATA CI_END="-9.684110155200875" CI_START="-26.315889844799123" EFFECT_SIZE="-18.0" ESTIMABLE="YES" MEAN_1="12.0" MEAN_2="30.0" ORDER="150796" SD_1="22.65" SD_2="23.24" SE="4.242878905119586" STUDY_ID="STD-Wobig-1998" TOTAL_1="57" TOTAL_2="60" WEIGHT="24.23111328819143"/>
<CONT_DATA CI_END="12.085979558730845" CI_START="-10.085979558730845" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="13.0" MEAN_2="12.0" ORDER="150797" SD_1="24.33" SD_2="23.66" SE="5.656215954056114" STUDY_ID="STD-Wobig-1999c-_x0028_NEhyl_x0029_" TOTAL_1="37" TOTAL_2="35" WEIGHT="13.634608645606459"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.9639991072823881" CI_END="-11.019932848672951" CI_START="-23.222042160938322" DF="2" EFFECT_SIZE="-17.120987504805637" ESTIMABLE="YES" I2="0.0" ID="CMP-020.04.03" NO="3" P_CHI2="0.6175473845416635" P_Z="3.795377454601255E-8" STUDIES="3" TAU2="0.0" TOTAL_1="86" TOTAL_2="96" WEIGHT="100.0" Z="5.500117730538415">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="-6.6921636037461045" CI_START="-37.3078363962539" EFFECT_SIZE="-22.0" ESTIMABLE="YES" MEAN_1="10.0" MEAN_2="32.0" ORDER="150798" SD_1="23.24" SD_2="22.91" SE="7.810264125769736" STUDY_ID="STD-Scale-1994a-_x0028_2-inj_x0029_" TOTAL_1="15" TOTAL_2="21" WEIGHT="15.88481668106573"/>
<CONT_DATA CI_END="-1.9141530855284952" CI_START="-24.085846914471503" EFFECT_SIZE="-13.0" ESTIMABLE="YES" MEAN_1="3.0" MEAN_2="16.0" ORDER="150799" SD_1="15.49" SD_2="15.49" SE="5.656148277170015" STUDY_ID="STD-Scale-1994b-_x0028_3-inj_x0029_" TOTAL_1="15" TOTAL_2="15" WEIGHT="30.288103248739805"/>
<CONT_DATA CI_END="-9.684191017152534" CI_START="-26.315808982847464" EFFECT_SIZE="-18.0" ESTIMABLE="YES" MEAN_1="16.0" MEAN_2="34.0" ORDER="150800" SD_1="22.45" SD_2="23.24" SE="4.242837648263696" STUDY_ID="STD-Wobig-1998" TOTAL_1="56" TOTAL_2="60" WEIGHT="53.82708007019446"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="8.039199360050452" CI_END="-10.746966881319254" CI_START="-17.309092823710273" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-14.028029852514763" ESTIMABLE="YES" I2="75.12190069649613" I2_Q="86.83322503128687" ID="CMP-020.05" NO="5" P_CHI2="0.017960208884581053" P_Q="0.005853500498103403" P_Z="5.304767879826167E-17" Q="7.594874237436258" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="86" TOTAL_2="68" UNITS="" WEIGHT="200.0" Z="8.379733496844048">
<NAME>Pain at rest (0-100 mm VAS)</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hylan G-F 20</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.44432512261419005" CI_END="-4.817008376210376" CI_START="-14.068801057672038" DF="1" EFFECT_SIZE="-9.442904716941207" ESTIMABLE="YES" I2="0.0" ID="CMP-020.05.01" NO="1" P_CHI2="0.5050422813081057" P_Z="6.31017638073539E-5" STUDIES="2" TAU2="0.0" TOTAL_1="66" TOTAL_2="58" WEIGHT="100.00000000000001" Z="4.000900969545759">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="-5.092645870305916" CI_START="-14.907354129694085" EFFECT_SIZE="-10.0" ESTIMABLE="YES" MEAN_1="29.0" MEAN_2="39.0" ORDER="150801" SD_1="7.83" SD_2="5.66" SE="2.503798114864695" STUDY_ID="STD-Cubukcu-2004" TOTAL_1="20" TOTAL_2="10" WEIGHT="88.85809433882413"/>
<CONT_DATA CI_END="8.858497830896802" CI_START="-18.858497830896802" EFFECT_SIZE="-5.0" ESTIMABLE="YES" MEAN_1="39.0" MEAN_2="44.0" ORDER="150802" SD_1="33.91" SD_2="34.64" SE="7.070792086084675" STUDY_ID="STD-Moreland-1993" TOTAL_1="46" TOTAL_2="48" WEIGHT="11.141905661175883"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-14.015516748766823" CI_START="-23.324483251233183" DF="0" EFFECT_SIZE="-18.67" ESTIMABLE="YES" I2="0.0" ID="CMP-020.05.02" NO="2" P_CHI2="1.0" P_Z="3.7870999144202026E-15" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="10" WEIGHT="99.99999999999999" Z="7.861780914490955">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="-14.015516748766823" CI_START="-23.324483251233183" EFFECT_SIZE="-18.67" ESTIMABLE="YES" MEAN_1="22.33" MEAN_2="41.0" ORDER="150803" SD_1="6.98" SD_2="5.66" SE="2.3747799898095825" STUDY_ID="STD-Cubukcu-2004" TOTAL_1="20" TOTAL_2="10" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="9.086806891171955" CI_START="-13.086806891171955" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-020.06" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.7236634829108127" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="46" TOTAL_2="48" UNITS="" WEIGHT="100.0" Z="0.3535669023153468">
<NAME>Pain overall (0-100 mm VAS)</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hylan G-F 20</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="9.086806891171955" CI_START="-13.086806891171955" DF="0" EFFECT_SIZE="-2.0" ESTIMABLE="YES" I2="0.0" ID="CMP-020.06.01" NO="1" P_CHI2="1.0" P_Z="0.7236634829108127" STUDIES="1" TAU2="0.0" TOTAL_1="46" TOTAL_2="48" WEIGHT="100.0" Z="0.3535669023153468">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="9.086806891171957" CI_START="-13.086806891171957" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="55.0" MEAN_2="57.0" ORDER="150804" SD_1="27.13" SD_2="27.71" SE="5.656638070200919" STUDY_ID="STD-Moreland-1993" TOTAL_1="46" TOTAL_2="48" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="12.26922538552773" CI_END="-7.873251268752954" CI_START="-12.44517929634823" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="-10.159215282550592" ESTIMABLE="YES" I2="59.24763102079946" I2_Q="66.29920444675281" ID="CMP-020.07" NO="7" P_CHI2="0.03127937936423897" P_Q="0.05144268954155162" P_Z="3.0276331423686727E-18" Q="5.934578003774433" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="156" TOTAL_2="104" UNITS="" WEIGHT="300.0" Z="8.710415362973741">
<NAME>WOMAC physical function</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline/Arthro</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hylan G-F 20</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours saline/arthr</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="3.6321906567195503" CI_END="-3.5593606374935765" CI_START="-10.617119140840149" DF="1" EFFECT_SIZE="-7.0882398891668625" ESTIMABLE="YES" I2="72.46840558465728" ID="CMP-020.07.01" NO="1" P_CHI2="0.05667236478469917" P_Z="8.255558186542261E-5" STUDIES="2" TAU2="0.0" TOTAL_1="41" TOTAL_2="19" WEIGHT="99.99999999999999" Z="3.936857541940475">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="-1.7535138792555314" CI_START="-9.44648612074447" EFFECT_SIZE="-5.600000000000001" ESTIMABLE="YES" MEAN_1="40.9" MEAN_2="46.5" ORDER="150805" SD_1="4.96" SD_2="5.12" SE="1.9625289806777377" STUDY_ID="STD-Cubukcu-2004" TOTAL_1="20" TOTAL_2="10" WEIGHT="84.16766075354403"/>
<CONT_DATA CI_END="-6.131212386006014" CI_START="-23.868787613993987" EFFECT_SIZE="-15.0" ESTIMABLE="YES" MEAN_1="31.0" MEAN_2="46.0" ORDER="150806" SD_1="9.4" SD_2="12.1" SE="4.524974787266425" STUDY_ID="STD-Kotevoglu-2005" TOTAL_1="21" TOTAL_2="9" WEIGHT="15.832339246455962"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.7024567250337417" CI_END="-8.763097105675199" CI_START="-15.060821930319237" DF="2" EFFECT_SIZE="-11.911959517997218" ESTIMABLE="YES" I2="25.993264518415966" ID="CMP-020.07.02" NO="2" P_CHI2="0.258922215294626" P_Z="1.221514315875508E-13" STUDIES="3" TAU2="0.0" TOTAL_1="94" TOTAL_2="76" WEIGHT="100.0" Z="7.414427365645745">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="-7.6290165496426745" CI_START="-15.370983450357325" EFFECT_SIZE="-11.5" ESTIMABLE="YES" MEAN_1="35.9" MEAN_2="47.4" ORDER="150807" SD_1="4.65" SD_2="5.31" SE="1.9750278479049352" STUDY_ID="STD-Cubukcu-2004" TOTAL_1="20" TOTAL_2="10" WEIGHT="66.17054939196586"/>
<CONT_DATA CI_END="-1.9332755188804711" CI_START="-16.06672448111953" EFFECT_SIZE="-9.0" ESTIMABLE="YES" MEAN_1="38.0" MEAN_2="47.0" ORDER="150808" SD_1="21.84" SD_2="15.1" SE="3.605537926646076" STUDY_ID="STD-Dickson-2001" TOTAL_1="53" TOTAL_2="57" WEIGHT="19.855053016944446"/>
<CONT_DATA CI_END="-9.576605572316728" CI_START="-26.42339442768327" EFFECT_SIZE="-18.0" ESTIMABLE="YES" MEAN_1="30.0" MEAN_2="48.0" ORDER="150809" SD_1="9.2" SD_2="11.4" SE="4.297729189988149" STUDY_ID="STD-Kotevoglu-2005" TOTAL_1="21" TOTAL_2="9" WEIGHT="13.974397591089689"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-7.102667029562953" CI_START="-26.89733297043705" DF="0" EFFECT_SIZE="-17.0" ESTIMABLE="YES" I2="0.0" ID="CMP-020.07.03" NO="3" P_CHI2="1.0" P_Z="7.612812784798778E-4" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="9" WEIGHT="100.0" Z="3.366501646120693">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="-7.102667029562953" CI_START="-26.89733297043705" EFFECT_SIZE="-17.0" ESTIMABLE="YES" MEAN_1="31.0" MEAN_2="48.0" ORDER="150810" SD_1="10.5" SD_2="13.5" SE="5.049752469181039" STUDY_ID="STD-Kotevoglu-2005" TOTAL_1="21" TOTAL_2="9" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.705737474488066" CI_END="0.2054170910986156" CI_START="-1.8159027219556663" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.8052428154285253" ESTIMABLE="YES" I2="63.04149942746374" I2_Q="63.04149942746374" ID="CMP-020.08" NO="8" P_CHI2="0.09998790372335609" P_Q="0.09998790372335609" P_Z="0.11838215455025318" Q="2.705737474488066" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="141" TOTAL_2="123" UNITS="" WEIGHT="200.0" Z="1.561600402723763">
<NAME>Lequesne Index (0-24)</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hylan G-F 20</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours saline</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.21500898910106647" CI_START="-2.984991010898933" DF="0" EFFECT_SIZE="-1.5999999999999996" ESTIMABLE="YES" I2="0.0" ID="CMP-020.08.01" NO="1" P_CHI2="1.0" P_Z="0.023559786877333424" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="57" WEIGHT="100.0" Z="2.264233017100011">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="-0.21500898910106647" CI_START="-2.984991010898933" EFFECT_SIZE="-1.5999999999999996" ESTIMABLE="YES" MEAN_1="10.9" MEAN_2="12.5" ORDER="150811" SD_1="3.64" SD_2="3.77" SE="0.7066410514803158" STUDY_ID="STD-Dickson-2001" TOTAL_1="53" TOTAL_2="57" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.5781287584722445" CI_START="-1.3781287584722453" DF="0" EFFECT_SIZE="0.09999999999999964" ESTIMABLE="YES" I2="0.0" ID="CMP-020.08.02" NO="2" P_CHI2="1.0" P_Z="0.8945115917707607" STUDIES="1" TAU2="0.0" TOTAL_1="88" TOTAL_2="66" WEIGHT="100.0" Z="0.13259764910912192">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="1.5781287584722445" CI_START="-1.3781287584722453" EFFECT_SIZE="0.09999999999999964" ESTIMABLE="YES" MEAN_1="9.0" MEAN_2="8.9" ORDER="150812" SD_1="4.44" SD_2="4.77" SE="0.7541611836398708" STUDY_ID="STD-Karlsson-2002b-_x0028_SvP_x0029_" TOTAL_1="88" TOTAL_2="66" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="20.093353678608523" CI_END="31.206170312574844" CI_START="21.24199315232381" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="MD" EFFECT_SIZE="26.224081732449328" ESTIMABLE="YES" I2="65.16260992582721" I2_Q="86.73265267190112" ID="CMP-020.09" NO="9" P_CHI2="0.005371546838597863" P_Q="0.006043495060200632" P_Z="5.928044436079979E-25" Q="7.537301732367419" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="263" TOTAL_2="267" UNITS="" WEIGHT="200.0" Z="10.316608164750965">
<NAME>Function: improvment in most painful knee movement (0-100 mm VAS)</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Hylan G-F 20</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="3.526140188947392" CI_END="26.31208769991634" CI_START="12.263128878076001" DF="3" EFFECT_SIZE="19.28760828899617" ESTIMABLE="YES" I2="14.92113644819246" ID="CMP-020.09.01" NO="1" P_CHI2="0.3173877558970961" P_Z="7.382204711028653E-8" STUDIES="4" TAU2="0.0" TOTAL_1="132" TOTAL_2="135" WEIGHT="100.0" Z="5.381611274364419">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="35.30831433459099" CI_START="4.691685665409011" EFFECT_SIZE="20.0" ESTIMABLE="YES" MEAN_1="56.0" MEAN_2="36.0" ORDER="150813" SD_1="28.14" SD_2="24.5" SE="7.810507976340902" STUDY_ID="STD-Scale-1994a-_x0028_2-inj_x0029_" TOTAL_1="22" TOTAL_2="24" WEIGHT="21.05588719610787"/>
<CONT_DATA CI_END="49.40202129446885" CI_START="10.597978705531144" EFFECT_SIZE="30.0" ESTIMABLE="YES" MEAN_1="71.0" MEAN_2="41.0" ORDER="150814" SD_1="27.11" SD_2="27.11" SE="9.899172355976702" STUDY_ID="STD-Scale-1994b-_x0028_3-inj_x0029_" TOTAL_1="15" TOTAL_2="15" WEIGHT="13.107936656114706"/>
<CONT_DATA CI_END="33.086660353651624" CI_START="10.91333964634838" EFFECT_SIZE="22.0" ESTIMABLE="YES" MEAN_1="60.0" MEAN_2="38.0" ORDER="150815" SD_1="30.2" SD_2="30.98" SE="5.656563304786099" STUDY_ID="STD-Wobig-1998" TOTAL_1="57" TOTAL_2="60" WEIGHT="40.14456922800166"/>
<CONT_DATA CI_END="22.858572863767414" CI_START="-4.858572863767412" EFFECT_SIZE="9.0" ESTIMABLE="YES" MEAN_1="45.0" MEAN_2="36.0" ORDER="150816" SD_1="30.82" SD_2="30.0" SE="7.070830368864972" STUDY_ID="STD-Wobig-1999c-_x0028_NEhyl_x0029_" TOTAL_1="38" TOTAL_2="36" WEIGHT="25.691606919775754"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="9.02991175729371" CI_END="40.31235031597879" CI_START="26.17797184200273" DF="3" EFFECT_SIZE="33.24516107899076" ESTIMABLE="YES" I2="66.77708397784933" ID="CMP-020.09.02" NO="2" P_CHI2="0.028895858397643637" P_Z="2.9716545978111575E-20" STUDIES="4" TAU2="0.0" TOTAL_1="131" TOTAL_2="132" WEIGHT="100.00000000000001" Z="9.21997645598987">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="50.6286670593572" CI_START="17.371332940642798" EFFECT_SIZE="34.0" ESTIMABLE="YES" MEAN_1="65.0" MEAN_2="31.0" ORDER="150817" SD_1="28.14" SD_2="28.77" SE="8.484169704403756" STUDY_ID="STD-Scale-1994a-_x0028_2-inj_x0029_" TOTAL_1="22" TOTAL_2="23" WEIGHT="18.062529324352933"/>
<CONT_DATA CI_END="68.07032727408554" CI_START="31.929672725914454" EFFECT_SIZE="50.0" ESTIMABLE="YES" MEAN_1="88.0" MEAN_2="38.0" ORDER="150818" SD_1="23.24" SD_2="27.11" SE="9.219724146271044" STUDY_ID="STD-Scale-1994b-_x0028_3-inj_x0029_" TOTAL_1="15" TOTAL_2="15" WEIGHT="15.295419920765639"/>
<CONT_DATA CI_END="48.08652529855965" CI_START="25.91347470144035" EFFECT_SIZE="37.0" ESTIMABLE="YES" MEAN_1="74.0" MEAN_2="37.0" ORDER="150819" SD_1="30.2" SD_2="30.72" SE="5.656494397860748" STUDY_ID="STD-Wobig-1998" TOTAL_1="57" TOTAL_2="59" WEIGHT="40.6352125999905"/>
<CONT_DATA CI_END="30.858076136000435" CI_START="3.1419238639995655" EFFECT_SIZE="17.0" ESTIMABLE="YES" MEAN_1="62.0" MEAN_2="45.0" ORDER="150820" SD_1="30.41" SD_2="29.58" SE="7.070576931673832" STUDY_ID="STD-Wobig-1999c-_x0028_NEhyl_x0029_" TOTAL_1="37" TOTAL_2="35" WEIGHT="26.006838154890925"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.2642413220590747" CI_END="1.16813980509867" CI_START="-0.9811755317075083" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="0.09348213669558085" ESTIMABLE="YES" I2="55.83509627451673" I2_Q="55.83509627451674" ID="CMP-020.10" NO="10" P_CHI2="0.13239114328179713" P_Q="0.13239114328179713" P_Z="0.8646224307916088" Q="2.264241322059075" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="40" TOTAL_2="20" UNITS="" WEIGHT="200.0" Z="0.1704930104797473">
<NAME>15 metre walking time</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hylan G-F 20</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Saline</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.2148374408989886" CI_START="-0.6148374408989941" DF="0" EFFECT_SIZE="0.7999999999999972" ESTIMABLE="YES" I2="0.0" ID="CMP-020.10.01" NO="1" P_CHI2="1.0" P_Z="0.2677607178225454" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="10" WEIGHT="100.0" Z="1.1082341633790418">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="2.2148374408989886" CI_START="-0.6148374408989941" EFFECT_SIZE="0.7999999999999972" ESTIMABLE="YES" MEAN_1="17.4" MEAN_2="16.6" ORDER="150821" SD_1="2.37" SD_2="1.55" SE="0.721869101707505" STUDY_ID="STD-Cubukcu-2004" TOTAL_1="20" TOTAL_2="10" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.7345348630883326E-32" CI_END="0.7822159263127976" CI_START="-2.5222159263128" DF="0" EFFECT_SIZE="-0.8700000000000011" ESTIMABLE="YES" I2="99.99999999999999" ID="CMP-020.10.02" NO="2" P_CHI2="0.0" P_Z="0.30204893087888773" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="10" WEIGHT="100.0" Z="1.0320495277849207">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="0.7822159263127977" CI_START="-2.5222159263128" EFFECT_SIZE="-0.870000000000001" ESTIMABLE="YES" MEAN_1="16.13" MEAN_2="17.0" ORDER="150822" SD_1="2.46" SD_2="2.02" SE="0.8429827993500223" STUDY_ID="STD-Cubukcu-2004" TOTAL_1="20" TOTAL_2="10" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.9946301136461215" CI_END="-0.7047554485264848" CI_START="-1.5789862665716266" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.1418708575490557" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-020.11" NO="11" P_CHI2="0.736746725282647" P_Q="0.8314945222216923" P_Z="3.0555470243682775E-7" Q="0.3690612490305125" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="103" TOTAL_2="56" UNITS="" WEIGHT="300.0" Z="5.119988244743971">
<NAME>WOMAC stiffness (2 to 10 Likert)</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hylan G-F 20</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours saline</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.0858509957063691" CI_END="-0.4374231103223388" CI_START="-1.730337351018358" DF="1" EFFECT_SIZE="-1.0838802306703483" ESTIMABLE="YES" I2="7.906333009394279" ID="CMP-020.11.01" NO="1" P_CHI2="0.29739277873574044" P_Z="0.0010156068900149774" STUDIES="2" TAU2="0.0" TOTAL_1="41" TOTAL_2="19" WEIGHT="100.0" Z="3.2861672472958943">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="0.03845463292961093" CI_START="-1.6384546329296106" EFFECT_SIZE="-0.7999999999999998" ESTIMABLE="YES" MEAN_1="4.2" MEAN_2="5.0" ORDER="150823" SD_1="1.03" SD_2="1.14" SE="0.4277908367415085" STUDY_ID="STD-Cubukcu-2004" TOTAL_1="20" TOTAL_2="10" WEIGHT="59.445681332807354"/>
<CONT_DATA CI_END="-0.48487115471216735" CI_START="-2.5151288452878324" EFFECT_SIZE="-1.5" ESTIMABLE="YES" MEAN_1="4.0" MEAN_2="5.5" ORDER="150824" SD_1="1.3" SD_2="1.3" SE="0.5179323973782373" STUDY_ID="STD-Kotevoglu-2005" TOTAL_1="21" TOTAL_2="9" WEIGHT="40.55431866719264"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.5397178689092398" CI_END="-0.5477100616717957" CI_START="-2.1336480521998693" DF="1" EFFECT_SIZE="-1.3406790569358324" ESTIMABLE="YES" I2="0.0" ID="CMP-020.11.02" NO="2" P_CHI2="0.46254975913280116" P_Z="9.206138787080102E-4" STUDIES="2" TAU2="0.0" TOTAL_1="41" TOTAL_2="19" WEIGHT="100.0" Z="3.3137268696696154">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="-0.547652644739482" CI_START="-2.6523473552605172" EFFECT_SIZE="-1.5999999999999996" ESTIMABLE="YES" MEAN_1="3.5" MEAN_2="5.1" ORDER="150825" SD_1="1.07" SD_2="1.52" SE="0.5369217820129856" STUDY_ID="STD-Cubukcu-2004" TOTAL_1="20" TOTAL_2="10" WEIGHT="56.77984282263878"/>
<CONT_DATA CI_END="0.20618253548824628" CI_START="-2.2061825354882463" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="4.0" MEAN_2="5.0" ORDER="150826" SD_1="1.1" SD_2="1.7" SE="0.6154105611136022" STUDY_ID="STD-Kotevoglu-2005" TOTAL_1="21" TOTAL_2="9" WEIGHT="43.220157177361216"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.10574379196475314" CI_START="-1.8942562080352467" DF="0" EFFECT_SIZE="-1.0" ESTIMABLE="YES" I2="0.0" ID="CMP-020.11.03" NO="3" P_CHI2="1.0" P_Z="0.02839934544882877" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="18" WEIGHT="100.0" Z="2.1917253321016954">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="-0.10574379196475314" CI_START="-1.8942562080352467" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="4.0" MEAN_2="5.0" ORDER="150827" SD_1="1.0" SD_2="1.7" SE="0.4562615512779958" STUDY_ID="STD-Kotevoglu-2005" TOTAL_1="21" TOTAL_2="18" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="6.718769750775219" CI_END="-7.155005888533468" CI_START="-20.972750408100836" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-14.063878148317151" ESTIMABLE="YES" I2="70.23264564514601" I2_Q="70.23264564514601" ID="CMP-020.12" NO="12" P_CHI2="0.03475673794424128" P_Q="0.03475673794424128" P_Z="6.614210251268873E-5" Q="6.718769750775219" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="63" TOTAL_2="27" UNITS="" WEIGHT="300.0" Z="3.989753119928799">
<NAME>Patient global assessment (0-100 mm VAS; where 100 is worst severity)</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hylan G-F 20</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Saline</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-6.840526449505871" CI_START="-33.15947355049413" DF="0" EFFECT_SIZE="-20.0" ESTIMABLE="YES" I2="0.0" ID="CMP-020.12.01" NO="1" P_CHI2="1.0" P_Z="0.0028939108538434248" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="9" WEIGHT="100.0" Z="2.978787832232786">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="-6.840526449505871" CI_START="-33.15947355049413" EFFECT_SIZE="-20.0" ESTIMABLE="YES" MEAN_1="50.0" MEAN_2="70.0" ORDER="150828" SD_1="13.5" SD_2="18.1" SE="6.714140491506158" STUDY_ID="STD-Kotevoglu-2005" TOTAL_1="21" TOTAL_2="9" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-9.434011622484544" CI_START="-30.565988377515456" DF="0" EFFECT_SIZE="-20.0" ESTIMABLE="YES" I2="0.0" ID="CMP-020.12.02" NO="2" P_CHI2="1.0" P_Z="2.0730087312639697E-4" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="9" WEIGHT="100.0" Z="3.709949158586773">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="-9.434011622484544" CI_START="-30.565988377515456" EFFECT_SIZE="-20.0" ESTIMABLE="YES" MEAN_1="50.0" MEAN_2="70.0" ORDER="150829" SD_1="12.1" SD_2="14.1" SE="5.390909455917876" STUDY_ID="STD-Kotevoglu-2005" TOTAL_1="21" TOTAL_2="9" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="12.681503829773908" CI_START="-12.681503829773908" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-020.12.03" NO="3" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="9" WEIGHT="100.0" Z="0.0">
<NAME>14 to 26 weeks post injection</NAME>
<CONT_DATA CI_END="12.681503829773908" CI_START="-12.681503829773908" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="70.0" MEAN_2="70.0" ORDER="150830" SD_1="16.1" SD_2="16.3" SE="6.470273907992183" STUDY_ID="STD-Kotevoglu-2005" TOTAL_1="21" TOTAL_2="9" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="29" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-020.13" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="13" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="42" TOTAL_2="48" WEIGHT="0.0" Z="0.0">
<NAME>Patient global assessment (number of patients good or very good) 5 to 13 weeks post-injection</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>Arthro+dummy caps</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Arthro+caps</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Hylan G-F 20</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.0607920406127294" CI_START="1.0076043863213253" EFFECT_SIZE="1.4409937888198758" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="23" LOG_CI_END="0.314034168309451" LOG_CI_START="0.0032900494086489586" LOG_EFFECT_SIZE="0.15866210885904997" ORDER="150831" O_E="0.0" SE="0.18253263365052763" STUDY_ID="STD-Dickson-2001" TOTAL_1="42" TOTAL_2="48" VAR="0.033318162347397734" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="37.73565902388106" CI_END="1.1144160871761712" CI_START="0.7661010370492582" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.9402585621127147" ESTIMABLE="YES" I2="76.14987989396359" I2_Q="88.59432929604515" ID="CMP-020.14" NO="14" P_CHI2="1.9441171583367556E-5" P_Q="0.0030663597009183974" P_Z="3.6254064589761046E-26" Q="8.767568571423471" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="305" TOTAL_2="288" UNITS="" WEIGHT="200.0" Z="10.581643929682993">
<NAME>Patient global evaluation of efficacy due to treatment</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Hylan G-F 20</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="4.358203520760151" CI_END="0.9348033438626773" CI_START="0.46143126515611854" DF="4" EFFECT_SIZE="0.6981173045093979" ESTIMABLE="YES" I2="8.219063636056944" ID="CMP-020.14.01" NO="1" P_CHI2="0.3596935574359067" P_Z="7.4252705110622715E-9" STUDIES="5" TAU2="0.0" TOTAL_1="153" TOTAL_2="145" WEIGHT="100.00000000000001" Z="5.7810117468748965">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="1.3029516476720382" CI_START="-0.2422964402119996" EFFECT_SIZE="0.5303276037300193" ESTIMABLE="YES" MEAN_1="2.6" MEAN_2="2.3" ORDER="150832" SD_1="0.49" SD_2="0.66" SE="0.39420318436276314" STUDY_ID="STD-Cubukcu-2004" TOTAL_1="20" TOTAL_2="10" WEIGHT="9.384450465231337"/>
<CONT_DATA CI_END="1.3367190602951053" CI_START="0.15055289876935862" EFFECT_SIZE="0.743635979532232" ESTIMABLE="YES" MEAN_1="61.0" MEAN_2="39.0" ORDER="150833" SD_1="28.77" SD_2="29.39" SE="0.30259896887954935" STUDY_ID="STD-Scale-1994a-_x0028_2-inj_x0029_" TOTAL_1="23" TOTAL_2="24" WEIGHT="15.926275167496481"/>
<CONT_DATA CI_END="1.9555047323516392" CI_START="0.38900845553504304" EFFECT_SIZE="1.1722565939433411" ESTIMABLE="YES" MEAN_1="79.0" MEAN_2="51.0" ORDER="150834" SD_1="23.24" SD_2="23.24" SE="0.3996237403270976" STUDY_ID="STD-Scale-1994b-_x0028_3-inj_x0029_" TOTAL_1="15" TOTAL_2="15" WEIGHT="9.131592904937746"/>
<CONT_DATA CI_END="1.2228884579278583" CI_START="0.4652045087093574" EFFECT_SIZE="0.8440464833186079" ESTIMABLE="YES" MEAN_1="71.0" MEAN_2="45.0" ORDER="150835" SD_1="30.2" SD_2="30.98" SE="0.19329027349354763" STUDY_ID="STD-Wobig-1998" TOTAL_1="57" TOTAL_2="60" WEIGHT="39.03274564176072"/>
<CONT_DATA CI_END="0.8117424031456668" CI_START="-0.1073844764850862" EFFECT_SIZE="0.3521789633302903" ESTIMABLE="YES" MEAN_1="53.0" MEAN_2="42.0" ORDER="150836" SD_1="30.82" SD_2="31.0" SE="0.23447545130438838" STUDY_ID="STD-Wobig-1999c-_x0028_NEhyl_x0029_" TOTAL_1="38" TOTAL_2="36" WEIGHT="26.524935820573717"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="24.609886931697446" CI_END="1.4833286117740532" CI_START="0.9689681432150061" DF="4" EFFECT_SIZE="1.2261483774945297" ESTIMABLE="YES" I2="83.74636985898536" ID="CMP-020.14.02" NO="2" P_CHI2="6.0262378518860515E-5" P_Z="9.237228878784701E-21" STUDIES="5" TAU2="0.0" TOTAL_1="152" TOTAL_2="143" WEIGHT="100.0" Z="9.344445409360302">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="4.703385388758875" CI_START="2.2755007855174547" EFFECT_SIZE="3.4894430871381648" ESTIMABLE="YES" MEAN_1="3.6" MEAN_2="1.8" ORDER="150837" SD_1="0.54" SD_2="0.41" SE="0.6193696982169733" STUDY_ID="STD-Cubukcu-2004" TOTAL_1="20" TOTAL_2="10" WEIGHT="4.488271134431743"/>
<CONT_DATA CI_END="1.6975000092433317" CI_START="0.465804658486798" EFFECT_SIZE="1.0816523338650648" ESTIMABLE="YES" MEAN_1="66.0" MEAN_2="34.0" ORDER="150838" SD_1="28.77" SD_2="29.39" SE="0.31421377139375756" STUDY_ID="STD-Scale-1994a-_x0028_2-inj_x0029_" TOTAL_1="23" TOTAL_2="24" WEIGHT="17.43928046926562"/>
<CONT_DATA CI_END="2.9094954569799314" CI_START="1.1096700079686665" EFFECT_SIZE="2.009582732474299" ESTIMABLE="YES" MEAN_1="91.0" MEAN_2="43.0" ORDER="150839" SD_1="23.24" SD_2="23.24" SE="0.4591475821005024" STUDY_ID="STD-Scale-1994b-_x0028_3-inj_x0029_" TOTAL_1="15" TOTAL_2="15" WEIGHT="8.167222549742448"/>
<CONT_DATA CI_END="1.7752832414446225" CI_START="0.9637391532967158" EFFECT_SIZE="1.369511197370669" ESTIMABLE="YES" MEAN_1="82.0" MEAN_2="40.0" ORDER="150840" SD_1="30.2" SD_2="30.72" SE="0.20703035733035474" STUDY_ID="STD-Wobig-1998" TOTAL_1="57" TOTAL_2="59" WEIGHT="40.17084152888024"/>
<CONT_DATA CI_END="1.0320290922844508" CI_START="0.08875456194112114" EFFECT_SIZE="0.560391827112786" ESTIMABLE="YES" MEAN_1="67.0" MEAN_2="50.0" ORDER="150841" SD_1="30.41" SD_2="29.58" SE="0.2406356794777248" STUDY_ID="STD-Wobig-1999c-_x0028_NEhyl_x0029_" TOTAL_1="37" TOTAL_2="35" WEIGHT="29.73438431767995"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.9373617529637388" CI_END="-6.925329324939064" CI_START="-26.173036478300588" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-16.549182901619826" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-020.15" NO="15" P_CHI2="0.6258273056029198" P_Q="0.6258273056029198" P_Z="7.507141876980314E-4" Q="0.9373617529637385" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="63" TOTAL_2="27" UNITS="" WEIGHT="300.0" Z="3.370354941739247">
<NAME>Physician global assessment (0-100 mm VAS; where 100 is worst severity)</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hylan G-F 20</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Saline</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-2.3597883546527854" CI_START="-37.640211645347215" DF="0" EFFECT_SIZE="-20.0" ESTIMABLE="YES" I2="0.0" ID="CMP-020.15.01" NO="1" P_CHI2="1.0" P_Z="0.02627285085257922" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="9" WEIGHT="100.0" Z="2.2221547268759836">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="-2.3597883546527854" CI_START="-37.640211645347215" EFFECT_SIZE="-20.0" ESTIMABLE="YES" MEAN_1="50.0" MEAN_2="70.0" ORDER="150842" SD_1="21.1" SD_2="23.2" SE="9.00027336445514" STUDY_ID="STD-Kotevoglu-2005" TOTAL_1="21" TOTAL_2="9" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-3.899278694032418" CI_START="-36.10072130596758" DF="0" EFFECT_SIZE="-20.0" ESTIMABLE="YES" I2="0.0" ID="CMP-020.15.02" NO="2" P_CHI2="1.0" P_Z="0.014907073693868013" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="9" WEIGHT="100.0" Z="2.434628793697102">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="-3.899278694032418" CI_START="-36.10072130596758" EFFECT_SIZE="-20.0" ESTIMABLE="YES" MEAN_1="50.0" MEAN_2="70.0" ORDER="150843" SD_1="18.4" SD_2="21.5" SE="8.214804676498149" STUDY_ID="STD-Kotevoglu-2005" TOTAL_1="21" TOTAL_2="9" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="4.51627662302508E-32" CI_END="6.382796479626018" CI_START="-26.382796479626023" DF="0" EFFECT_SIZE="-10.000000000000002" ESTIMABLE="YES" I2="100.0" ID="CMP-020.15.03" NO="3" P_CHI2="0.0" P_Z="0.23155809092974933" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="9" WEIGHT="100.0" Z="1.1963549611188211">
<NAME>14 to 26 weeks post injection</NAME>
<CONT_DATA CI_END="6.38279647962602" CI_START="-26.38279647962602" EFFECT_SIZE="-10.0" ESTIMABLE="YES" MEAN_1="60.0" MEAN_2="70.0" ORDER="150844" SD_1="18.1" SD_2="22.1" SE="8.358723225963042" STUDY_ID="STD-Kotevoglu-2005" TOTAL_1="21" TOTAL_2="9" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.0088859554062473" CI_START="0.8746967596473771" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3255813953488371" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="22" I2="0.0" I2_Q="0.0" ID="CMP-020.16" LOG_CI_END="0.3029552825204683" LOG_CI_START="-0.05814248233465867" LOG_EFFECT_SIZE="0.12240640009290485" METHOD="MH" NO="16" P_CHI2="1.0" P_Q="1.0" P_Z="0.18391619085965683" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="86" TOTAL_2="66" WEIGHT="100.0" Z="1.328793246646359">
<NAME>Number of survivors (patients not requiring additional treatment for study knee)</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours saline</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Hylan G-F 20</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.0088859554062473" CI_START="0.8746967596473771" DF="0" EFFECT_SIZE="1.3255813953488371" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="22" I2="0.0" ID="CMP-020.16.01" LOG_CI_END="0.3029552825204683" LOG_CI_START="-0.05814248233465867" LOG_EFFECT_SIZE="0.12240640009290485" NO="1" P_CHI2="1.0" P_Z="0.18391619085965683" STUDIES="1" TAU2="0.0" TOTAL_1="86" TOTAL_2="66" WEIGHT="100.0" Z="1.328793246646359">
<NAME>45 to 52 weeks post-injection</NAME>
<DICH_DATA CI_END="2.0088859554062473" CI_START="0.8746967596473771" EFFECT_SIZE="1.3255813953488371" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="22" LOG_CI_END="0.3029552825204683" LOG_CI_START="-0.05814248233465867" LOG_EFFECT_SIZE="0.12240640009290485" ORDER="150845" O_E="0.0" SE="0.21211061453866548" STUDY_ID="STD-Karlsson-2002b-_x0028_SvP_x0029_" TOTAL_1="86" TOTAL_2="66" VAR="0.04499091279997033" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.20732436606491358" CI_END="1.1479092002411868" CI_START="0.5658213105781893" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8059227556690712" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="33" I2="0.0" I2_Q="0.0" ID="CMP-020.17" LOG_CI_END="0.05990753667364447" LOG_CI_START="-0.2473206996994161" LOG_EFFECT_SIZE="-0.09370658151288581" METHOD="MH" NO="17" P_CHI2="0.6488726826008264" P_Q="0.6582348868165309" P_Z="0.2318514799725615" Q="0.19567483910894426" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="156" TOTAL_2="114" WEIGHT="200.0" Z="1.1956031584063573">
<NAME>Number of clinical failures</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hylan G-F 20</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Saline</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.865151740637007" CI_START="0.23199745431259128" DF="0" EFFECT_SIZE="0.6578073089700996" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" I2="0.0" ID="CMP-020.17.01" LOG_CI_END="0.27071416989301006" LOG_CI_START="-0.6345167805576346" LOG_EFFECT_SIZE="-0.18190130533231227" NO="1" P_CHI2="1.0" P_Z="0.4308789376504929" STUDIES="1" TAU2="0.0" TOTAL_1="86" TOTAL_2="66" WEIGHT="100.0" Z="0.7876885053801397">
<NAME>14 to 26 weeks post-injection</NAME>
<DICH_DATA CI_END="1.865151740637007" CI_START="0.23199745431259128" EFFECT_SIZE="0.6578073089700996" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.27071416989301006" LOG_CI_START="-0.6345167805576346" LOG_EFFECT_SIZE="-0.18190130533231227" ORDER="150846" O_E="0.0" SE="0.5317371412601815" STUDY_ID="STD-Karlsson-2002b-_x0028_SvP_x0029_" TOTAL_1="86" TOTAL_2="66" VAR="0.2827443873955502" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2151650917222618" CI_START="0.5861440630428598" DF="0" EFFECT_SIZE="0.843956043956044" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="26" I2="0.0" ID="CMP-020.17.02" LOG_CI_END="0.08463528497409198" LOG_CI_START="-0.2319956295532552" LOG_EFFECT_SIZE="-0.0736801722895816" NO="2" P_CHI2="1.0" P_Z="0.36167966503490456" STUDIES="1" TAU2="0.0" TOTAL_1="70" TOTAL_2="48" WEIGHT="100.0" Z="0.9121692003944447">
<NAME>45 to 52 weeks post-injection</NAME>
<DICH_DATA CI_END="1.215165091722262" CI_START="0.5861440630428598" EFFECT_SIZE="0.843956043956044" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="26" LOG_CI_END="0.08463528497409206" LOG_CI_START="-0.2319956295532552" LOG_EFFECT_SIZE="-0.0736801722895816" ORDER="150847" O_E="0.0" SE="0.18599056654166857" STUDY_ID="STD-Karlsson-2002b-_x0028_SvP_x0029_" TOTAL_1="70" TOTAL_2="48" VAR="0.034592490842490844" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-020.18" NO="18" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="40" TOTAL_2="20" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Need for paracetamol (pill count)</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hylan G-F 20</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Saline</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-020.18.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="0.0" MEAN_2="0.1" ORDER="150848" SD_1="0.0" SD_2="0.51" SE="0.0" STUDY_ID="STD-Cubukcu-2004" TOTAL_1="20" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-020.18.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="0.0" MEAN_2="0.7" ORDER="150849" SD_1="0.0" SD_2="0.47" SE="0.0" STUDY_ID="STD-Cubukcu-2004" TOTAL_1="20" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="2.016847928420651" CI_END="1.7422924883787085" CI_START="0.5601357846727123" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9878868204948279" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-020.19" LOG_CI_END="0.24112106423422044" LOG_CI_START="-0.25170668123331524" LOG_EFFECT_SIZE="-0.00529280849954742" METHOD="MH" NO="19" P_CHI2="0.7326600358541553" P_Q="0.41772073787646435" P_Z="0.9664199830755327" Q="1.7458860979369604" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="239" TOTAL_2="236" WEIGHT="300.0" Z="0.04209874192995809">
<NAME>Safety: total withdrawals overall</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hylan G-F 20</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.974851177531529" CI_START="0.1217484442701766" DF="0" EFFECT_SIZE="0.6956521739130435" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-020.19.01" LOG_CI_END="0.5993208728700279" LOG_CI_START="-0.9145365795933641" LOG_EFFECT_SIZE="-0.1576078533616681" NO="1" P_CHI2="1.0" P_Z="0.6831972514257316" STUDIES="1" TAU2="0.0" TOTAL_1="46" TOTAL_2="48" WEIGHT="99.99999999999999" Z="0.4081040995859675">
<NAME>1 to 4 weeks post-injection</NAME>
<DICH_DATA CI_END="3.974851177531529" CI_START="0.1217484442701766" EFFECT_SIZE="0.6956521739130435" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5993208728700279" LOG_CI_START="-0.9145365795933641" LOG_EFFECT_SIZE="-0.1576078533616681" ORDER="150850" O_E="0.0" SE="0.8892473612922432" STUDY_ID="STD-Moreland-1993" TOTAL_1="46" TOTAL_2="48" VAR="0.7907608695652173" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.3379225567918319" CI_END="3.055649605401161" CI_START="0.637438115907237" DF="2" EFFECT_SIZE="1.3956315872534586" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="9" I2="0.0" ID="CMP-020.19.02" LOG_CI_END="0.48510355174742403" LOG_CI_START="-0.1955619712462476" LOG_EFFECT_SIZE="0.1447707902505882" NO="2" P_CHI2="0.8445416327219667" P_Z="0.40443331977099817" STUDIES="4" TAU2="0.0" TOTAL_1="167" TOTAL_2="162" WEIGHT="100.0" Z="0.8337297110527908">
<NAME>5 to 13 weeks post-injection</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="150851" O_E="0.0" SE="0.0" STUDY_ID="STD-Cubukcu-2004" TOTAL_1="20" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.1488945730241564" CI_START="0.5739312571739289" EFFECT_SIZE="1.3443396226415094" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.49815812042685126" LOG_CI_START="-0.2411401222673337" LOG_EFFECT_SIZE="0.12850899907975877" ORDER="150852" O_E="0.0" SE="0.4342674473438866" STUDY_ID="STD-Dickson-2001" TOTAL_1="53" TOTAL_2="57" VAR="0.18858821582257532" WEIGHT="83.57405215096385"/>
<DICH_DATA CI_END="75.89889669454996" CI_START="0.13116281519644074" EFFECT_SIZE="3.1551724137931036" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8802354628131162" LOG_CI_START="-0.8821892704781316" LOG_EFFECT_SIZE="0.49902309616749224" ORDER="150853" O_E="0.0" SE="1.6226619625582437" STUDY_ID="STD-Wobig-1998" TOTAL_1="57" TOTAL_2="60" VAR="2.633031844733371" WEIGHT="5.283835943427436"/>
<DICH_DATA CI_END="14.547791543916547" CI_START="0.06150856162258902" EFFECT_SIZE="0.9459459459459459" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1627970693983896" LOG_CI_START="-1.2110644288318284" LOG_EFFECT_SIZE="-0.024133679716719363" ORDER="150854" O_E="0.0" SE="1.394417994864361" STUDY_ID="STD-Wobig-1999c-_x0028_NEhyl_x0029_" TOTAL_1="37" TOTAL_2="35" VAR="1.9444015444015446" WEIGHT="11.142111905608715"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6589782903130412" CI_START="0.2354611885405028" DF="0" EFFECT_SIZE="0.625" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" I2="0.0" ID="CMP-020.19.03" LOG_CI_END="0.21984070280619275" LOG_CI_START="-0.6280806681180423" LOG_EFFECT_SIZE="-0.2041199826559248" NO="3" P_CHI2="1.0" P_Z="0.3453517829350472" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="26" WEIGHT="100.0" Z="0.9436436637856618">
<NAME>14 to 26 weeks post-injection</NAME>
<DICH_DATA CI_END="1.658978290313041" CI_START="0.2354611885405028" EFFECT_SIZE="0.625" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.2198407028061927" LOG_CI_START="-0.6280806681180423" LOG_EFFECT_SIZE="-0.2041199826559248" ORDER="150855" O_E="0.0" SE="0.49807321055937454" STUDY_ID="STD-Kotevoglu-2005" TOTAL_1="26" TOTAL_2="26" VAR="0.24807692307692306" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-020.20" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="20" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="26" TOTAL_2="26" WEIGHT="0.0" Z="0.0">
<NAME>Safety: number of patients withdrawn due to noncomplinance</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hylan G-F 20</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Saline</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.180743077657695" CI_START="0.04825562593098698" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7143920553787599" LOG_CI_START="-1.3164520467067224" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="150856" O_E="0.0" SE="1.1929278784054478" STUDY_ID="STD-Kotevoglu-2005" TOTAL_1="26" TOTAL_2="26" VAR="1.423076923076923" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.3725026228465484" CI_START="0.7814931357379175" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.8485347672550327" ESTIMABLE="NO" EVENTS_1="24" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-020.21" LOG_CI_END="0.6407300786624217" LOG_CI_START="-0.10707483226313987" LOG_EFFECT_SIZE="0.26682762319964093" METHOD="MH" NO="21" P_CHI2="0.0" P_Q="0.0" P_Z="0.1619068419521763" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="SUB" TOTAL_1="236" TOTAL_2="233" WEIGHT="0.0" Z="1.3986870744254272">
<NAME>Safety: number of patients with local reaction</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hylan G-F 20</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="150857" O_E="0.0" SE="0.0" STUDY_ID="STD-Cubukcu-2004" TOTAL_1="20" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="6.069473321024872" CI_START="0.5885354150295246" EFFECT_SIZE="1.89" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.7831510067759924" LOG_CI_START="-0.23022739842950407" LOG_EFFECT_SIZE="0.2764618041732441" ORDER="150858" O_E="0.0" SE="0.5952634915217162" STUDY_ID="STD-Dickson-2001" TOTAL_1="50" TOTAL_2="54" VAR="0.3543386243386243" WEIGHT="0.0"/>
<DICH_DATA CI_END="70.41836692752118" CI_START="0.12780756488237435" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.84768594912681" LOG_CI_START="-0.8934434396874849" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="150859" O_E="0.0" SE="1.6101529717988263" STUDY_ID="STD-Kotevoglu-2005" TOTAL_1="26" TOTAL_2="26" VAR="2.592592592592592" WEIGHT="0.0"/>
<DICH_DATA CI_END="492.56005847758513" CI_START="1.8558088772636276" EFFECT_SIZE="30.23404255319149" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="0" LOG_CI_END="2.692459192143623" LOG_CI_START="0.2685332478398816" LOG_EFFECT_SIZE="1.4804962199917522" ORDER="150860" O_E="0.0" SE="1.4238260983109534" STUDY_ID="STD-Moreland-1993" TOTAL_1="46" TOTAL_2="48" VAR="2.0272807582313925" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.288789168578021" CI_START="0.010316419099458985" EFFECT_SIZE="0.2103448275862069" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6323346973993207" LOG_CI_START="-1.9864710231756986" LOG_EFFECT_SIZE="-0.677068162888189" ORDER="150861" O_E="0.0" SE="1.5382994435631525" STUDY_ID="STD-Wobig-1998" TOTAL_1="57" TOTAL_2="60" VAR="2.3663651780667045" WEIGHT="0.0"/>
<DICH_DATA CI_END="6.354285749898555" CI_START="0.14082050569819843" EFFECT_SIZE="0.9459459459459459" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8030667409937645" LOG_CI_START="-0.8513341004272031" LOG_EFFECT_SIZE="-0.024133679716719363" ORDER="150862" O_E="0.0" SE="0.9718032436669186" STUDY_ID="STD-Wobig-1999c-_x0028_NEhyl_x0029_" TOTAL_1="37" TOTAL_2="35" VAR="0.9444015444015444" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="68.25874292736694" CI_START="0.13185124152633113" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-020.22" LOG_CI_END="1.8341582859242351" LOG_CI_START="-0.87991577648491" LOG_EFFECT_SIZE="0.47712125471966244" METHOD="MH" NO="22" P_CHI2="1.0" P_Q="1.0" P_Z="0.4907574432545426" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.6891046110061">
<NAME>Safety: number of patients with local adverse reactions but study drug continued</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hylan G-F 20</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="68.25874292736694" CI_START="0.13185124152633113" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-020.22.01" LOG_CI_END="1.8341582859242351" LOG_CI_START="-0.87991577648491" LOG_EFFECT_SIZE="0.47712125471966244" NO="1" P_CHI2="1.0" P_Z="0.4907574432545426" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.6891046110061">
<NAME>1 to 4 weeks post-injection</NAME>
<DICH_DATA CI_END="68.25874292736694" CI_START="0.13185124152633113" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8341582859242351" LOG_CI_START="-0.87991577648491" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="150863" O_E="0.0" SE="1.5942605391424158" STUDY_ID="STD-Scale-1994b-_x0028_3-inj_x0029_" TOTAL_1="15" TOTAL_2="15" VAR="2.5416666666666665" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.955160648281688" CI_START="0.7911751562201086" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.98" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-020.23" LOG_CI_END="0.6950577390496065" LOG_CI_START="-0.10172735852654446" LOG_EFFECT_SIZE="0.2966651902615311" METHOD="MH" NO="23" P_CHI2="1.0" P_Q="1.0" P_Z="0.14442811817203505" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="50" TOTAL_2="54" WEIGHT="99.99999999999999" Z="1.4594979001191788">
<NAME>Safety: number of patients with one or more probable or possible related systemic adverse events</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.955160648281688" CI_START="0.7911751562201086" DF="0" EFFECT_SIZE="1.98" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="6" I2="0.0" ID="CMP-020.23.01" LOG_CI_END="0.6950577390496065" LOG_CI_START="-0.10172735852654446" LOG_EFFECT_SIZE="0.2966651902615311" NO="1" P_CHI2="1.0" P_Z="0.14442811817203505" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="54" WEIGHT="99.99999999999999" Z="1.4594979001191788">
<NAME>5 to 13 weeks post-injection</NAME>
<DICH_DATA CI_END="4.955160648281688" CI_START="0.7911751562201086" EFFECT_SIZE="1.98" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="6" LOG_CI_END="0.6950577390496065" LOG_CI_START="-0.10172735852654446" LOG_EFFECT_SIZE="0.2966651902615311" ORDER="150864" O_E="0.0" SE="0.4680355104660746" STUDY_ID="STD-Dickson-2001" TOTAL_1="50" TOTAL_2="54" VAR="0.21905723905723906" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="139.4415091070306" CI_START="0.38869386741526146" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="7.362068965517241" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-020.24" LOG_CI_END="2.1443920742834446" LOG_CI_START="-0.4103923113592713" LOG_EFFECT_SIZE="0.8669998814620866" METHOD="MH" NO="24" P_CHI2="1.0" P_Q="1.0" P_Z="0.18342622607263817" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="114" TOTAL_2="105" WEIGHT="100.0" Z="1.3302794175632089">
<NAME>Safety: number of patients reporting systemic reactions</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="139.4415091070306" CI_START="0.38869386741526146" DF="0" EFFECT_SIZE="7.362068965517241" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-020.24.01" LOG_CI_END="2.1443920742834446" LOG_CI_START="-0.4103923113592713" LOG_EFFECT_SIZE="0.8669998814620866" NO="1" P_CHI2="1.0" P_Z="0.18342622607263817" STUDIES="3" TAU2="0.0" TOTAL_1="114" TOTAL_2="105" WEIGHT="100.0" Z="1.3302794175632089">
<NAME>5 to 13 weeks post-injection</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="150865" O_E="0.0" SE="0.0" STUDY_ID="STD-Cubukcu-2004" TOTAL_1="20" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="139.4415091070306" CI_START="0.38869386741526146" EFFECT_SIZE="7.362068965517241" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1443920742834446" LOG_CI_START="-0.4103923113592713" LOG_EFFECT_SIZE="0.8669998814620866" ORDER="150866" O_E="0.0" SE="1.5006929945131984" STUDY_ID="STD-Wobig-1998" TOTAL_1="57" TOTAL_2="60" VAR="2.25207946378099" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="150867" O_E="0.0" SE="0.0" STUDY_ID="STD-Wobig-1999c-_x0028_NEhyl_x0029_" TOTAL_1="37" TOTAL_2="35" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-021" NO="21">
<NAME>Hylan G-F 20 versus NSAID</NAME>
<CONT_OUTCOME CHI2="0.4931461783624802" CI_END="-0.32118729097304843" CI_START="-16.939639119771016" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-8.630413205372033" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-021.01" NO="1" P_CHI2="0.4825272611938649" P_Q="0.4825272611938649" P_Z="0.04177797568040798" Q="0.4931461783624799" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="52" TOTAL_2="63" UNITS="" WEIGHT="200.0" Z="2.035725015601718">
<NAME>Pain on motion (0-100 mm VAS)</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>NSAID</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hylan G-F 20</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NSAID</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="5.087863436725147" CI_START="-17.087863436725147" DF="0" EFFECT_SIZE="-6.0" ESTIMABLE="YES" I2="0.0" ID="CMP-021.01.01" NO="1" P_CHI2="1.0" P_Z="0.28887190450466205" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="32" WEIGHT="100.0" Z="1.0605996343975204">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="5.087863436725147" CI_START="-17.087863436725147" EFFECT_SIZE="-6.0" ESTIMABLE="YES" MEAN_1="38.0" MEAN_2="44.0" ORDER="150868" SD_1="20.0" SD_2="22.63" SE="5.657177133960011" STUDY_ID="STD-Adams-1995" TOTAL_1="25" TOTAL_2="32" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="7.696764507140119E-32" CI_END="0.5494358825330714" CI_START="-24.549435882533068" DF="0" EFFECT_SIZE="-11.999999999999998" ESTIMABLE="YES" I2="100.0" ID="CMP-021.01.02" NO="2" P_CHI2="0.0" P_Z="0.06090928616868935" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="31" WEIGHT="100.00000000000001" Z="1.8741533910075077">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="0.5494358825330696" CI_START="-24.549435882533068" EFFECT_SIZE="-12.0" ESTIMABLE="YES" MEAN_1="40.0" MEAN_2="52.0" ORDER="150869" SD_1="25.98" SD_2="22.27" SE="6.4028910640814924" STUDY_ID="STD-Adams-1995" TOTAL_1="27" TOTAL_2="31" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.9137489235186909" CI_START="-23.08625107648131" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-12.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-021.02" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.03387909464904918" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="53" TOTAL_2="55" UNITS="" WEIGHT="100.0" Z="2.1215077714030612">
<NAME>WOMAC pain (0-100 mm VAS)</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>NSAID</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hylan G-F 20</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NSAID</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.9137489235186909" CI_START="-23.08625107648131" DF="0" EFFECT_SIZE="-12.0" ESTIMABLE="YES" I2="0.0" ID="CMP-021.02.01" NO="1" P_CHI2="1.0" P_Z="0.03387909464904918" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="55" WEIGHT="100.0" Z="2.1215077714030612">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="-0.9137489235186909" CI_START="-23.08625107648131" EFFECT_SIZE="-12.0" ESTIMABLE="YES" MEAN_1="26.0" MEAN_2="38.0" ORDER="150870" SD_1="29.12" SD_2="29.66" SE="5.656354486066195" STUDY_ID="STD-Dickson-2001" TOTAL_1="53" TOTAL_2="55" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="4.342903260126459" CI_START="-10.342903260126459" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-021.03" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.423271495108996" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="52" TOTAL_2="63" UNITS="" WEIGHT="200.0" Z="0.8007584664160344">
<NAME>Pain at rest (0-100 mm VAS)</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>NSAID</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hylan G-F 20</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NSAID</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="8.087863436725147" CI_START="-14.087863436725147" DF="0" EFFECT_SIZE="-3.0" ESTIMABLE="YES" I2="0.0" ID="CMP-021.03.01" NO="1" P_CHI2="1.0" P_Z="0.5959040756300706" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="32" WEIGHT="100.0" Z="0.5302998171987602">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="8.087863436725147" CI_START="-14.087863436725147" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="17.0" MEAN_2="20.0" ORDER="150871" SD_1="20.0" SD_2="22.63" SE="5.657177133960011" STUDY_ID="STD-Adams-1995" TOTAL_1="25" TOTAL_2="32" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="6.799871298443524" CI_START="-12.799871298443524" DF="0" EFFECT_SIZE="-3.0" ESTIMABLE="YES" I2="0.0" ID="CMP-021.03.02" NO="2" P_CHI2="1.0" P_Z="0.5485083349787145" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="31" WEIGHT="100.0" Z="0.5999968545050223">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="6.799871298443524" CI_START="-12.799871298443524" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="25.0" MEAN_2="28.0" ORDER="150872" SD_1="15.59" SD_2="22.27" SE="5.000026212595567" STUDY_ID="STD-Adams-1995" TOTAL_1="27" TOTAL_2="31" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.1951203638356514" CI_END="3.8743123656425302" CI_START="-13.873988507472106" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.999838070914788" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-021.04" NO="4" P_CHI2="0.6586887266165906" P_Q="0.6586887266165907" P_Z="0.2694738779865118" Q="0.19512036383565134" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="52" TOTAL_2="63" UNITS="" WEIGHT="200.00000000000003" Z="1.104275008360899">
<NAME>Pain at night (0-100 mm VAS)</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>NSAID</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hylan G-F 20</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NSAID</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.9238795695011915E-32" CI_END="5.550451983004975" CI_START="-19.550451983004972" DF="0" EFFECT_SIZE="-6.999999999999999" ESTIMABLE="YES" I2="100.0" ID="CMP-021.04.01" NO="1" P_CHI2="0.0" P_Z="0.27432022218969787" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="32" WEIGHT="100.00000000000001" Z="1.0931676333536664">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="5.550451983004974" CI_START="-19.550451983004976" EFFECT_SIZE="-7.0" ESTIMABLE="YES" MEAN_1="14.0" MEAN_2="21.0" ORDER="150873" SD_1="25.0" SD_2="22.63" SE="6.403409492215846" STUDY_ID="STD-Adams-1995" TOTAL_1="25" TOTAL_2="32" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="4.8104778169625744E-33" CI_END="9.54943588253307" CI_START="-15.54943588253307" DF="0" EFFECT_SIZE="-2.9999999999999996" ESTIMABLE="YES" I2="100.0" ID="CMP-021.04.02" NO="2" P_CHI2="0.0" P_Z="0.6393996559151406" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="31" WEIGHT="100.00000000000001" Z="0.4685383477518769">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="9.54943588253307" CI_START="-15.54943588253307" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="25.0" MEAN_2="28.0" ORDER="150874" SD_1="25.98" SD_2="22.27" SE="6.4028910640814924" STUDY_ID="STD-Adams-1995" TOTAL_1="27" TOTAL_2="31" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.0438143155995956E-32" CI_END="3.6567067358701904" CI_START="-13.656706735870188" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.999999999999999" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-021.05" NO="5" P_CHI2="0.9999999999999999" P_Q="0.9999999999999999" P_Z="0.25761367255837664" Q="4.0438143155995956E-32" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="52" TOTAL_2="63" UNITS="" WEIGHT="200.0" Z="1.1320494296166281">
<NAME>Pain overall (0-100 mm VAS)</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>NSAID</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hylan G-F 20</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NSAID</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="8.857991846606422" CI_START="-18.857991846606424" DF="0" EFFECT_SIZE="-5.0" ESTIMABLE="YES" I2="0.0" ID="CMP-021.05.01" NO="1" P_CHI2="1.0" P_Z="0.47946695009199436" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="32" WEIGHT="100.00000000000001" Z="0.7071601737953161">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="8.857991846606422" CI_START="-18.857991846606424" EFFECT_SIZE="-5.0" ESTIMABLE="YES" MEAN_1="38.0" MEAN_2="43.0" ORDER="150875" SD_1="25.0" SD_2="28.28" SE="7.0705339260907305" STUDY_ID="STD-Adams-1995" TOTAL_1="25" TOTAL_2="32" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="6.085737936337997" CI_START="-16.085737936338" DF="0" EFFECT_SIZE="-5.0" ESTIMABLE="YES" I2="0.0" ID="CMP-021.05.02" NO="2" P_CHI2="1.0" P_Z="0.37669487903346044" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="31" WEIGHT="100.0" Z="0.8840024885107008">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="6.085737936337997" CI_START="-16.085737936338" EFFECT_SIZE="-5.0" ESTIMABLE="YES" MEAN_1="47.0" MEAN_2="52.0" ORDER="150876" SD_1="20.78" SD_2="22.27" SE="5.656092675059789" STUDY_ID="STD-Adams-1995" TOTAL_1="27" TOTAL_2="31" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="3.066325423678528" CI_START="-11.066325423678528" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-021.06" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.2672287253171741" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="53" TOTAL_2="55" UNITS="" WEIGHT="100.0" Z="1.1094671513272893">
<NAME>WOMAC function (0-100 mm VAS)</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>NSAID</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hylan G-F 20</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NSAID</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.066325423678528" CI_START="-11.066325423678528" DF="0" EFFECT_SIZE="-4.0" ESTIMABLE="YES" I2="0.0" ID="CMP-021.06.01" NO="1" P_CHI2="1.0" P_Z="0.2672287253171741" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="55" WEIGHT="100.0" Z="1.1094671513272893">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="3.066325423678528" CI_START="-11.066325423678528" EFFECT_SIZE="-4.0" ESTIMABLE="YES" MEAN_1="38.0" MEAN_2="42.0" ORDER="150877" SD_1="21.84" SD_2="14.83" SE="3.605334322169591" STUDY_ID="STD-Dickson-2001" TOTAL_1="53" TOTAL_2="55" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.3862486171525057" CI_START="-2.3862486171525057" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-021.07" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.15740247978277347" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="53" TOTAL_2="55" UNITS="" WEIGHT="100.0" Z="1.413861814027283">
<NAME>Lequesne Index (0-24)</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>NSAID</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hylan G-F 20</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NSAID</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.3862486171525057" CI_START="-2.3862486171525057" DF="0" EFFECT_SIZE="-1.0" ESTIMABLE="YES" I2="0.0" ID="CMP-021.07.01" NO="1" P_CHI2="1.0" P_Z="0.15740247978277347" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="55" WEIGHT="100.0" Z="1.413861814027283">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="0.3862486171525057" CI_START="-2.3862486171525057" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="10.9" MEAN_2="11.9" ORDER="150878" SD_1="3.64" SD_2="3.71" SE="0.707282699114401" STUDY_ID="STD-Dickson-2001" TOTAL_1="53" TOTAL_2="55" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="5.810949941197993" CI_END="1.288149648834465" CI_START="0.8102979147619538" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.021657953696789" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="47" I2="82.79110971322808" I2_Q="80.59249878408541" ID="CMP-021.08" LOG_CI_END="0.10996631945836721" LOG_CI_START="-0.09135527871419011" LOG_EFFECT_SIZE="0.009305520372088559" METHOD="MH" NO="8" P_CHI2="0.015926722414570604" P_Q="0.023211007155451657" P_Z="0.856220357106036" Q="5.1526468496623234" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="69" TOTAL_2="73" WEIGHT="200.0" Z="0.1811875621120862">
<NAME>Patient overall assessment of treatment (number of patients excellent, very good, good)</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>NSAID</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours NSAID</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Hylan G-F 20</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.057016417397405" CI_START="0.6494985327997833" DF="0" EFFECT_SIZE="0.8285714285714286" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="35" I2="0.0" ID="CMP-021.08.01" LOG_CI_END="0.024081732747094273" LOG_CI_START="-0.1874218256497334" LOG_EFFECT_SIZE="-0.08167004645131952" NO="1" P_CHI2="1.0" P_Z="0.1301166264619404" STUDIES="1" TAU2="0.0" TOTAL_1="42" TOTAL_2="42" WEIGHT="100.0" Z="1.5136421427007107">
<NAME>5 to 13 weeks post-injection (numbe of patients very good or good)</NAME>
<DICH_DATA CI_END="1.057016417397405" CI_START="0.6494985327997834" EFFECT_SIZE="0.8285714285714286" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="35" LOG_CI_END="0.024081732747094273" LOG_CI_START="-0.1874218256497333" LOG_EFFECT_SIZE="-0.08167004645131952" ORDER="150879" O_E="0.0" SE="0.12423823716179574" STUDY_ID="STD-Dickson-2001" TOTAL_1="42" TOTAL_2="42" VAR="0.015435139573070605" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.7607668910500593" CI_START="0.9582999644671979" DF="0" EFFECT_SIZE="1.626543209876543" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="12" I2="0.0" ID="CMP-021.08.02" LOG_CI_END="0.4410297379668258" LOG_CI_START="-0.01849852795495694" LOG_EFFECT_SIZE="0.21126560500593444" NO="2" P_CHI2="1.0" P_Z="0.07151938225048993" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="31" WEIGHT="100.0" Z="1.8021654278571702">
<NAME>14 to 26 weeks post-injection (number of patients excellent/very good/good)</NAME>
<DICH_DATA CI_END="2.76076689105006" CI_START="0.9582999644671978" EFFECT_SIZE="1.626543209876543" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="12" LOG_CI_END="0.44102973796682593" LOG_CI_START="-0.01849852795495699" LOG_EFFECT_SIZE="0.21126560500593444" ORDER="150880" O_E="0.0" SE="0.2699291781040575" STUDY_ID="STD-Adams-1995" TOTAL_1="27" TOTAL_2="31" VAR="0.07286176119193197" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.5557261971171572" CI_END="1.756004334072968" CI_START="0.48191393112914205" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9199146437104452" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-021.09" LOG_CI_END="0.2445255834730743" LOG_CI_START="-0.3170305189673894" LOG_EFFECT_SIZE="-0.03625246774715755" METHOD="MH" NO="9" P_CHI2="0.45598746836310455" P_Q="0.4566931575688905" P_Z="0.8002222958570685" Q="0.5539872736361008" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="84" TOTAL_2="89" WEIGHT="200.0" Z="0.2530594212273272">
<NAME>Safety: total withdrawals overall</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>NSAID</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hylan G-F 20</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NSAID</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6614596983074192" CI_START="0.3835280426572192" DF="0" EFFECT_SIZE="0.7982583454281568" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="13" I2="0.0" ID="CMP-021.09.01" LOG_CI_END="0.2204898111488987" LOG_CI_START="-0.41620287597566263" LOG_EFFECT_SIZE="-0.09785653241338196" NO="1" P_CHI2="1.0" P_Z="0.5468589102604771" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="55" WEIGHT="100.0" Z="0.6024736362165335">
<NAME>5 to 13 weeks post-injection</NAME>
<DICH_DATA CI_END="1.6614596983074192" CI_START="0.3835280426572192" EFFECT_SIZE="0.7982583454281568" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="13" LOG_CI_END="0.2204898111488987" LOG_CI_START="-0.41620287597566263" LOG_EFFECT_SIZE="-0.09785653241338196" ORDER="150881" O_E="0.0" SE="0.3739964360965982" STUDY_ID="STD-Dickson-2001" TOTAL_1="53" TOTAL_2="55" VAR="0.13987333421295686" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.023475405477417" CI_START="0.3550297758267155" DF="0" EFFECT_SIZE="1.4623655913978495" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" ID="CMP-021.09.02" LOG_CI_END="0.7798471414085989" LOG_CI_START="-0.44973522177603414" LOG_EFFECT_SIZE="0.1650559598162824" NO="2" P_CHI2="1.0" P_Z="0.5987485590507582" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="34" WEIGHT="100.0" Z="0.526201003462225">
<NAME>14 to 26 weeks post-injection</NAME>
<DICH_DATA CI_END="6.023475405477417" CI_START="0.3550297758267155" EFFECT_SIZE="1.4623655913978495" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7798471414085989" LOG_CI_START="-0.44973522177603414" LOG_EFFECT_SIZE="0.1650559598162824" ORDER="150882" O_E="0.0" SE="0.7222627666655135" STUDY_ID="STD-Adams-1995" TOTAL_1="31" TOTAL_2="34" VAR="0.5216635041113219" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.837825245101581" CI_START="0.5674030757908312" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.82" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-021.10" LOG_CI_END="0.7662510902710407" LOG_CI_START="-0.24610831430089106" LOG_EFFECT_SIZE="0.2600713879850748" METHOD="MH" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="0.3139275786760606" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="50" TOTAL_2="52" WEIGHT="100.0" Z="1.007015001901672">
<NAME>Safety: number of patients with local reactions</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>NSAID</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hylan G-F 20</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NSAID</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.837825245101581" CI_START="0.5674030757908312" DF="0" EFFECT_SIZE="1.82" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" I2="0.0" ID="CMP-021.10.01" LOG_CI_END="0.7662510902710407" LOG_CI_START="-0.24610831430089106" LOG_EFFECT_SIZE="0.2600713879850748" NO="1" P_CHI2="1.0" P_Z="0.3139275786760606" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="52" WEIGHT="100.0" Z="1.007015001901672">
<NAME>5 to 13 weeks post-injection</NAME>
<DICH_DATA CI_END="5.837825245101581" CI_START="0.5674030757908312" EFFECT_SIZE="1.82" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.7662510902710407" LOG_CI_START="-0.24610831430089106" LOG_EFFECT_SIZE="0.2600713879850748" ORDER="150883" O_E="0.0" SE="0.5946649255054258" STUDY_ID="STD-Dickson-2001" TOTAL_1="50" TOTAL_2="52" VAR="0.3536263736263736" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.8283549355739092" CI_START="0.25278748397258355" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4576" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="25" I2="0.0" I2_Q="0.0" ID="CMP-021.11" LOG_CI_END="-0.08178353576111988" LOG_CI_START="-0.5972444326689444" LOG_EFFECT_SIZE="-0.3395139842150322" METHOD="MH" NO="11" P_CHI2="1.0" P_Q="1.0" P_Z="0.009825701706762491" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="50" TOTAL_2="52" WEIGHT="100.00000000000001" Z="2.581903633431801">
<NAME>Safety: number of patients with probable or possible related systemic adverse events</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>NSAID</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hylan G-F 20</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NSAID</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.8283549355739092" CI_START="0.25278748397258355" DF="0" EFFECT_SIZE="0.4576" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="25" I2="0.0" ID="CMP-021.11.01" LOG_CI_END="-0.08178353576111988" LOG_CI_START="-0.5972444326689444" LOG_EFFECT_SIZE="-0.3395139842150322" NO="1" P_CHI2="1.0" P_Z="0.009825701706762491" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="52" WEIGHT="100.00000000000001" Z="2.581903633431801">
<NAME>5 to 13 weeks post-injection</NAME>
<DICH_DATA CI_END="0.8283549355739092" CI_START="0.25278748397258355" EFFECT_SIZE="0.4576" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="25" LOG_CI_END="-0.08178353576111988" LOG_CI_START="-0.5972444326689444" LOG_EFFECT_SIZE="-0.3395139842150322" ORDER="150884" O_E="0.0" SE="0.3027842824162471" STUDY_ID="STD-Dickson-2001" TOTAL_1="50" TOTAL_2="52" VAR="0.09167832167832168" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="77.69018514756" CI_START="0.13858380620474225" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.2812499999999996" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-021.12" LOG_CI_END="1.8903661564393435" LOG_CI_START="-0.8582875149392794" LOG_EFFECT_SIZE="0.516039320750032" METHOD="MH" NO="12" P_CHI2="1.0" P_Q="1.0" P_Z="0.46176881646088275" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="31" TOTAL_2="34" WEIGHT="100.0" Z="0.7359373745833071">
<NAME>Safety: withdrawals due to adverse events</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>NSAID</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hylan G-F 20</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NSAID</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="77.69018514756" CI_START="0.13858380620474225" DF="0" EFFECT_SIZE="3.2812499999999996" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-021.12.01" LOG_CI_END="1.8903661564393435" LOG_CI_START="-0.8582875149392794" LOG_EFFECT_SIZE="0.516039320750032" NO="1" P_CHI2="1.0" P_Z="0.46176881646088275" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="34" WEIGHT="100.0" Z="0.7359373745833071">
<NAME>14 to 26 weeks post-injection</NAME>
<DICH_DATA CI_END="77.69018514756" CI_START="0.1385838062047422" EFFECT_SIZE="3.28125" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8903661564393435" LOG_CI_START="-0.8582875149392795" LOG_EFFECT_SIZE="0.5160393207500321" ORDER="150885" O_E="0.0" SE="1.6145727726229122" STUDY_ID="STD-Adams-1995" TOTAL_1="31" TOTAL_2="34" VAR="2.606845238095238" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-022" NO="22">
<NAME>(Hylan G-F 20 + NSAID + arthrocentesis) versus (NSAID + arthrocentesis)</NAME>
<CONT_OUTCOME CHI2="0.3905673911867633" CI_END="-4.659767938343202" CI_START="-20.340636102048116" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-12.500202020195658" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-022.01" NO="1" P_CHI2="0.5320016772706393" P_Q="0.5320016772706393" P_Z="0.0017791385072743339" Q="0.3905673911867633" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="64" TOTAL_2="63" UNITS="" WEIGHT="200.0" Z="3.1248200677773856">
<NAME>Pain on motion (0-100 mm VAS)</NAME>
<GROUP_LABEL_1>Hylan G-F20+NSAID+AR</GROUP_LABEL_1>
<GROUP_LABEL_2>NSAID+ARTHRO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HYLAN+NSAID</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NSAID</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.0884962425353564" CI_START="-21.088496242535356" DF="0" EFFECT_SIZE="-10.0" ESTIMABLE="YES" I2="0.0" ID="CMP-022.01.01" NO="1" P_CHI2="1.0" P_Z="0.07713362359477928" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.0" Z="1.7675651789659745">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="1.0884962425353564" CI_START="-21.088496242535356" EFFECT_SIZE="-10.0" ESTIMABLE="YES" MEAN_1="34.0" MEAN_2="44.0" ORDER="150886" SD_1="22.63" SD_2="22.63" SE="5.6575" STUDY_ID="STD-Adams-1995" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-3.912399761336113" CI_START="-26.08760023866389" DF="0" EFFECT_SIZE="-15.0" ESTIMABLE="YES" I2="0.0" ID="CMP-022.01.02" NO="2" P_CHI2="1.0" P_Z="0.008012039514071584" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="31" WEIGHT="100.0" Z="2.651562027424214">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="-3.912399761336113" CI_START="-26.08760023866389" EFFECT_SIZE="-15.0" ESTIMABLE="YES" MEAN_1="37.0" MEAN_2="52.0" ORDER="150887" SD_1="22.63" SD_2="22.27" SE="5.657042846767319" STUDY_ID="STD-Adams-1995" TOTAL_1="32" TOTAL_2="31" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.4999683921192104" CI_END="-2.5484069351130936" CI_START="-15.85264964163877" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-9.200528288375931" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-022.02" NO="2" P_CHI2="0.4795140632721302" P_Q="0.4795140632721303" P_Z="0.006711703595758756" Q="0.4999683921192102" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="64" TOTAL_2="63" UNITS="" WEIGHT="200.0" Z="2.7108200717225053">
<NAME>Pain at rest (0-100 mm VAS)</NAME>
<GROUP_LABEL_1>Hylan GF20+NSAID+ART</GROUP_LABEL_1>
<GROUP_LABEL_2>NSAID+ARTHRO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HYLAN+NSAID</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NSAID+AR</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.4646276042708588E-32" CI_END="5.0884962425353555" CI_START="-17.088496242535356" DF="0" EFFECT_SIZE="-6.000000000000001" ESTIMABLE="YES" I2="100.0" ID="CMP-022.02.01" NO="1" P_CHI2="0.0" P_Z="0.28889942400088586" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.0" Z="1.060539107379585">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="5.088496242535356" CI_START="-17.088496242535356" EFFECT_SIZE="-6.0" ESTIMABLE="YES" MEAN_1="14.0" MEAN_2="20.0" ORDER="150888" SD_1="22.63" SD_2="22.63" SE="5.6575" STUDY_ID="STD-Adams-1995" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-2.6855345981326924" CI_START="-19.31446540186731" DF="0" EFFECT_SIZE="-11.0" ESTIMABLE="YES" I2="0.0" ID="CMP-022.02.02" NO="2" P_CHI2="1.0" P_Z="0.009513628123943263" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="31" WEIGHT="100.0" Z="2.593023458260903">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="-2.6855345981326924" CI_START="-19.31446540186731" EFFECT_SIZE="-11.0" ESTIMABLE="YES" MEAN_1="11.0" MEAN_2="22.0" ORDER="150889" SD_1="16.97" SD_2="16.7" SE="4.242152135167151" STUDY_ID="STD-Adams-1995" TOTAL_1="32" TOTAL_2="31" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.9998525214381142" CI_END="-7.159889150460594" CI_START="-22.840757314165508" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-15.00032323231305" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-022.03" NO="3" P_CHI2="0.3173464492894763" P_Q="0.3173464492894763" P_Z="1.7697263980791006E-4" Q="0.9998525214381142" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="64" TOTAL_2="63" UNITS="" WEIGHT="200.0" Z="3.749804281862757">
<NAME>Pain at night (0-100 mm VAS)</NAME>
<GROUP_LABEL_1>Hylan G-F20+NSAID+AR</GROUP_LABEL_1>
<GROUP_LABEL_2>NSAID+ARTHRO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hylan+NSAID</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NSAID</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.08849624253535637" CI_START="-22.088496242535356" DF="0" EFFECT_SIZE="-11.0" ESTIMABLE="YES" I2="0.0" ID="CMP-022.03.01" NO="1" P_CHI2="1.0" P_Z="0.051856669822158946" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.0" Z="1.9443216968625718">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="0.08849624253535637" CI_START="-22.088496242535356" EFFECT_SIZE="-11.0" ESTIMABLE="YES" MEAN_1="10.0" MEAN_2="21.0" ORDER="150890" SD_1="22.63" SD_2="22.63" SE="5.6575" STUDY_ID="STD-Adams-1995" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-7.912399761336113" CI_START="-30.08760023866389" DF="0" EFFECT_SIZE="-19.0" ESTIMABLE="YES" I2="0.0" ID="CMP-022.03.02" NO="2" P_CHI2="1.0" P_Z="7.832555061575502E-4" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="31" WEIGHT="100.0" Z="3.3586452347373377">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="-7.912399761336113" CI_START="-30.08760023866389" EFFECT_SIZE="-19.0" ESTIMABLE="YES" MEAN_1="9.0" MEAN_2="28.0" ORDER="150891" SD_1="22.63" SD_2="22.27" SE="5.657042846767319" STUDY_ID="STD-Adams-1995" TOTAL_1="32" TOTAL_2="31" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.12329064896355826" CI_END="-5.375737375919453" CI_START="-21.993886730252687" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-13.68481205308607" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-022.04" NO="4" P_CHI2="0.7254926264938049" P_Q="0.7254926264938046" P_Z="0.0012465657727745987" Q="0.12329064896355843" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="64" TOTAL_2="63" UNITS="" WEIGHT="200.0" Z="3.2280055001737584">
<NAME>Pain overall (0-100 mm VAS)</NAME>
<GROUP_LABEL_1>Hylan G-F20+NSAID+AR</GROUP_LABEL_1>
<GROUP_LABEL_2>NSAID+ARTHRO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="7.696935514243579E-32" CI_END="0.5492964728552536" CI_START="-24.54929647285525" DF="0" EFFECT_SIZE="-11.999999999999998" ESTIMABLE="YES" I2="100.0" ID="CMP-022.04.01" NO="1" P_CHI2="0.0" P_Z="0.06090641742837583" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.00000000000001" Z="1.8741742109093233">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="0.5492964728552518" CI_START="-24.549296472855254" EFFECT_SIZE="-12.0" ESTIMABLE="YES" MEAN_1="31.0" MEAN_2="43.0" ORDER="150892" SD_1="22.63" SD_2="28.28" SE="6.4028199353878446" STUDY_ID="STD-Adams-1995" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-3.912399761336113" CI_START="-26.08760023866389" DF="0" EFFECT_SIZE="-15.0" ESTIMABLE="YES" I2="0.0" ID="CMP-022.04.02" NO="2" P_CHI2="1.0" P_Z="0.008012039514071584" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="31" WEIGHT="100.0" Z="2.651562027424214">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="-3.912399761336113" CI_START="-26.08760023866389" EFFECT_SIZE="-15.0" ESTIMABLE="YES" MEAN_1="37.0" MEAN_2="52.0" ORDER="150893" SD_1="22.63" SD_2="22.27" SE="5.657042846767319" STUDY_ID="STD-Adams-1995" TOTAL_1="32" TOTAL_2="31" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.7049340681971523" CI_START="0.7348821047043695" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1193415637860082" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-022.05" LOG_CI_END="0.23170758897555274" LOG_CI_START="-0.13378232810377969" LOG_EFFECT_SIZE="0.04896263043588653" METHOD="MH" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.5994923217994637" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="27" TOTAL_2="32" WEIGHT="100.00000000000001" Z="0.5251307232196633">
<NAME>Patient overall assessment of treatment (number of patients excellent, very good, or good)</NAME>
<GROUP_LABEL_1>Hylan+NSAID+ARTHRO</GROUP_LABEL_1>
<GROUP_LABEL_2>NSAID+ARTHRO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours NSAID+ARTHRO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Hylan+NSAID</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7049340681971523" CI_START="0.7348821047043695" DF="0" EFFECT_SIZE="1.1193415637860082" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="18" I2="0.0" ID="CMP-022.05.01" LOG_CI_END="0.23170758897555274" LOG_CI_START="-0.13378232810377969" LOG_EFFECT_SIZE="0.04896263043588653" NO="1" P_CHI2="1.0" P_Z="0.5994923217994637" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="32" WEIGHT="100.00000000000001" Z="0.5251307232196633">
<NAME>14 to 26 weeks post-injection</NAME>
<DICH_DATA CI_END="1.7049340681971523" CI_START="0.7348821047043695" EFFECT_SIZE="1.1193415637860082" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="18" LOG_CI_END="0.23170758897555274" LOG_CI_START="-0.13378232810377969" LOG_EFFECT_SIZE="0.04896263043588653" ORDER="150894" O_E="0.0" SE="0.21469058649666786" STUDY_ID="STD-Adams-1995" TOTAL_1="27" TOTAL_2="32" VAR="0.04609204793028322" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.815413845187853E-32" CI_END="5.928500850011565" CI_START="0.39564619984337923" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5315315315315317" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="100.0" I2_Q="0.0" ID="CMP-022.06" LOG_CI_END="0.7729448864705876" LOG_CI_START="-0.40269300128735447" LOG_EFFECT_SIZE="0.18512594259161652" METHOD="MH" NO="6" P_CHI2="0.0" P_Q="1.0" P_Z="0.5370598176405718" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="37" TOTAL_2="34" WEIGHT="100.0" Z="0.617265203617366">
<NAME>Safety: total withdrawals overall</NAME>
<GROUP_LABEL_1>Hylan+NSAID+ARTHRO</GROUP_LABEL_1>
<GROUP_LABEL_2>NSAID+ARTHRO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GF+NSAID+AR</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NSAID+AR</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.815413845187853E-32" CI_END="5.928500850011565" CI_START="0.39564619984337923" DF="0" EFFECT_SIZE="1.5315315315315317" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="100.0" ID="CMP-022.06.01" LOG_CI_END="0.7729448864705876" LOG_CI_START="-0.40269300128735447" LOG_EFFECT_SIZE="0.18512594259161652" NO="1" P_CHI2="0.0" P_Z="0.5370598176405718" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="34" WEIGHT="100.0" Z="0.617265203617366">
<NAME>14 to 26 weeks post-injection</NAME>
<DICH_DATA CI_END="5.928500850011561" CI_START="0.39564619984337923" EFFECT_SIZE="1.5315315315315314" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.7729448864705873" LOG_CI_START="-0.40269300128735447" LOG_EFFECT_SIZE="0.18512594259161647" ORDER="150895" O_E="0.0" SE="0.6905755147704151" STUDY_ID="STD-Adams-1995" TOTAL_1="37" TOTAL_2="34" VAR="0.4768945416004239" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-023" NO="23">
<NAME>Hylan G-F 20 versus betamethasone</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="14" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-023.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="50" TOTAL_2="50" WEIGHT="0.0" Z="0.0">
<NAME>Safety: total withdrawals overall</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>Betamethasone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hylan G-F 20</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours betamethason</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.260256722518963" CI_START="0.7421971005247052" EFFECT_SIZE="1.5555555555555556" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="9" LOG_CI_END="0.5132517990813117" LOG_CI_START="-0.1294807466034855" LOG_EFFECT_SIZE="0.19188552623891317" ORDER="150896" O_E="0.0" SE="0.37754427891266285" STUDY_ID="STD-Leopold-2003" TOTAL_1="50" TOTAL_2="50" VAR="0.14253968253968255" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="12" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-023.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="50" TOTAL_2="50" WEIGHT="0.0" Z="0.0">
<NAME>Safety: wIthdrawals due to lack of efficacy</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>Betamethasone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hylan G-F 20</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours betamethason</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.352169880572859" CI_START="0.6712070331040301" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" LOG_CI_END="0.5253260196019995" LOG_CI_START="-0.17314350149063712" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="150897" O_E="0.0" SE="0.4102844541697057" STUDY_ID="STD-Leopold-2003" TOTAL_1="50" TOTAL_2="50" VAR="0.16833333333333333" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-023.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="38" TOTAL_2="42" WEIGHT="0.0" Z="0.0">
<NAME>Safety: wIthdrawals due to acute local reaction</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>Betamethasone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hylan G-F 20</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours betamethason</GRAPH_LABEL_2>
<DICH_DATA CI_END="78.8367378957761" CI_START="0.13877829923443655" EFFECT_SIZE="3.3076923076923075" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8967286457548713" LOG_CI_START="-0.857678439209372" LOG_EFFECT_SIZE="0.5195251032727497" ORDER="150898" O_E="0.0" SE="1.617952356242962" STUDY_ID="STD-Leopold-2003" TOTAL_1="38" TOTAL_2="42" VAR="2.6177698270721526" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-024" NO="24">
<NAME>Hylan G-F 20 versus triamcinolone hexacetonide</NAME>
<CONT_OUTCOME CHI2="3.424597200681035E-31" CI_END="-0.21408108488662267" CI_START="-0.5859189151133777" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.4000000000000002" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-024.01" NO="1" P_CHI2="0.9999999999999996" P_Q="0.9999999999999996" P_Z="2.477775359820065E-5" Q="3.424597200681035E-31" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="226" TOTAL_2="204" UNITS="" WEIGHT="200.0" Z="4.216814590048195">
<NAME>WOMAC pain walking on a flat surface (Question 1: 0-4 Likert)</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>Triamcinolone hexace</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hylan G-F 20</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours TH</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.1490420470518607" CI_START="-0.6509579529481395" DF="0" EFFECT_SIZE="-0.40000000000000013" ESTIMABLE="YES" I2="0.0" ID="CMP-024.01.01" NO="1" P_CHI2="1.0" P_Z="0.0017842749401038632" STUDIES="1" TAU2="0.0" TOTAL_1="113" TOTAL_2="102" WEIGHT="100.0" Z="3.1239719028869866">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="-0.1490420470518607" CI_START="-0.6509579529481395" EFFECT_SIZE="-0.40000000000000013" ESTIMABLE="YES" MEAN_1="1.2" MEAN_2="1.6" ORDER="150899" SD_1="0.85" SD_2="1.01" SE="0.12804212471640486" STUDY_ID="STD-Caborn-2004" TOTAL_1="113" TOTAL_2="102" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.12320517851512375" CI_START="-0.6767948214848765" DF="0" EFFECT_SIZE="-0.40000000000000013" ESTIMABLE="YES" I2="0.0" ID="CMP-024.01.02" NO="2" P_CHI2="1.0" P_Z="0.004620422171530336" STUDIES="1" TAU2="0.0" TOTAL_1="113" TOTAL_2="102" WEIGHT="100.0" Z="2.832370886168684">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="-0.12320517851512375" CI_START="-0.6767948214848765" EFFECT_SIZE="-0.40000000000000013" ESTIMABLE="YES" MEAN_1="1.4" MEAN_2="1.8" ORDER="150900" SD_1="1.06" SD_2="1.01" SE="0.14122444272864124" STUDY_ID="STD-Caborn-2004" TOTAL_1="113" TOTAL_2="102" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.005109119818437644" CI_END="-2.357128009816413" CI_START="-7.840978032684876" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-5.099053021250644" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-024.02" NO="2" P_CHI2="0.9430172479263351" P_Q="0.9430172479263351" P_Z="2.6752697429826725E-4" Q="0.005109119818437644" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="226" TOTAL_2="204" UNITS="" WEIGHT="200.0" Z="3.6448700220593664">
<NAME>WOMAC physical function subscale (0-68 Likert)</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>Triamcinolone hexace</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hylan G-F 20</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours TH</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-1.1405634247895016" CI_START="-8.859436575210498" DF="0" EFFECT_SIZE="-5.0" ESTIMABLE="YES" I2="0.0" ID="CMP-024.02.01" NO="1" P_CHI2="1.0" P_Z="0.011111134303806225" STUDIES="1" TAU2="0.0" TOTAL_1="113" TOTAL_2="102" WEIGHT="100.0" Z="2.539184083408801">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="-1.1405634247895016" CI_START="-8.859436575210498" EFFECT_SIZE="-5.0" ESTIMABLE="YES" MEAN_1="23.5" MEAN_2="28.5" ORDER="150901" SD_1="13.18" SD_2="15.45" SE="1.9691364768195954" STUDY_ID="STD-Caborn-2004" TOTAL_1="113" TOTAL_2="102" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-1.303840678964073" CI_START="-9.096159321035925" DF="0" EFFECT_SIZE="-5.199999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-024.02.02" NO="2" P_CHI2="1.0" P_Z="0.008900268109116661" STUDIES="1" TAU2="0.0" TOTAL_1="113" TOTAL_2="102" WEIGHT="100.0" Z="2.615861385488323">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="-1.3038406789640735" CI_START="-9.096159321035925" EFFECT_SIZE="-5.199999999999999" ESTIMABLE="YES" MEAN_1="25.5" MEAN_2="30.7" ORDER="150902" SD_1="14.46" SD_2="14.64" SE="1.9878729159149522" STUDY_ID="STD-Caborn-2004" TOTAL_1="113" TOTAL_2="102" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="6.589271365855942E-4" CI_END="-3.5345596027856225" CI_START="-11.167796981515858" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-7.35117829215074" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-024.03" NO="3" P_CHI2="0.9795208912138373" P_Q="0.9795208912138373" P_Z="1.5995567922056218E-4" Q="6.589271365855942E-4" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="226" TOTAL_2="204" UNITS="" WEIGHT="200.0" Z="3.775080999497188">
<NAME>WOMAC total score (0-96 Likert)</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>Triamcinolone hexace</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hylan G-F 20</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours TH</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-2.0649821348322837" CI_START="-12.735017865167713" DF="0" EFFECT_SIZE="-7.399999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-024.03.01" NO="1" P_CHI2="1.0" P_Z="0.006556054727014115" STUDIES="1" TAU2="0.0" TOTAL_1="113" TOTAL_2="102" WEIGHT="100.0" Z="2.7185913622316336">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="-2.0649821348322828" CI_START="-12.735017865167714" EFFECT_SIZE="-7.399999999999999" ESTIMABLE="YES" MEAN_1="32.7" MEAN_2="40.1" ORDER="150903" SD_1="18.28" SD_2="21.31" SE="2.7219979077420073" STUDY_ID="STD-Caborn-2004" TOTAL_1="113" TOTAL_2="102" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-1.8377410007841704" CI_START="-12.762258999215824" DF="0" EFFECT_SIZE="-7.299999999999997" ESTIMABLE="YES" I2="0.0" ID="CMP-024.03.02" NO="2" P_CHI2="1.0" P_Z="0.008808951762730468" STUDIES="1" TAU2="0.0" TOTAL_1="113" TOTAL_2="102" WEIGHT="100.0" Z="2.619380935469453">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="-1.8377410007841695" CI_START="-12.762258999215824" EFFECT_SIZE="-7.299999999999997" ESTIMABLE="YES" MEAN_1="35.6" MEAN_2="42.9" ORDER="150904" SD_1="20.3" SD_2="20.5" SE="2.786918046607708" STUDY_ID="STD-Caborn-2004" TOTAL_1="113" TOTAL_2="102" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.11827006036795973" CI_END="-9.360820561812167" CI_START="-19.029029974169767" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-14.194925267990966" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-024.04" NO="4" P_CHI2="0.7309184293025016" P_Q="0.7309184293025016" P_Z="8.65071850582918E-9" Q="0.11827006036795973" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="226" TOTAL_2="204" UNITS="" WEIGHT="200.0" Z="5.755262655552177">
<NAME>Patient global overall assessment (0-100 mm VAS)</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>Triamcinolone hexace</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hylan G-F 20</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours TH</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-6.774810674615691" CI_START="-20.025189325384307" DF="0" EFFECT_SIZE="-13.399999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-024.04.01" NO="1" P_CHI2="1.0" P_Z="7.364520170956732E-5" STUDIES="1" TAU2="0.0" TOTAL_1="113" TOTAL_2="102" WEIGHT="100.0" Z="3.964191225782556">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="-6.77481067461569" CI_START="-20.025189325384307" EFFECT_SIZE="-13.399999999999999" ESTIMABLE="YES" MEAN_1="36.7" MEAN_2="50.1" ORDER="150905" SD_1="24.98" SD_2="24.54" SE="3.380260748484644" STUDY_ID="STD-Caborn-2004" TOTAL_1="113" TOTAL_2="102" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-8.03068452904262" CI_START="-22.169315470957383" DF="0" EFFECT_SIZE="-15.100000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-024.04.02" NO="2" P_CHI2="1.0" P_Z="2.8333006303095257E-5" STUDIES="1" TAU2="0.0" TOTAL_1="113" TOTAL_2="102" WEIGHT="99.99999999999999" Z="4.1864670332142895">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="-8.03068452904262" CI_START="-22.169315470957383" EFFECT_SIZE="-15.100000000000001" ESTIMABLE="YES" MEAN_1="40.3" MEAN_2="55.4" ORDER="150906" SD_1="26.79" SD_2="26.06" SE="3.606859884528103" STUDY_ID="STD-Caborn-2004" TOTAL_1="113" TOTAL_2="102" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="1.1611504403910107" CI_END="1.5814570512611315" CI_START="1.1407537812613202" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3431504424778757" ESTIMABLE="YES" EVENTS_1="186" EVENTS_2="125" I2="0.0" I2_Q="0.0" ID="CMP-024.05" LOG_CI_END="0.19905740197189897" LOG_CI_START="0.05719191700481621" LOG_EFFECT_SIZE="0.1281246594883576" METHOD="MH" NO="5" P_CHI2="0.5595765857392958" P_Q="0.566000533136557" P_Z="3.9974653133471405E-4" Q="1.138321100546868" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="339" TOTAL_2="306" WEIGHT="300.0" Z="3.5402510792093893">
<NAME>Number of responders (greater than or equal to one category on WOMAC pain Q1)</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>Triamcinolone hexace</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours TH</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Hylan G-F 20</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5285842453655356" CI_START="0.9565750203072322" DF="0" EFFECT_SIZE="1.2092168976456839" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="53" I2="0.0" ID="CMP-024.05.01" LOG_CI_END="0.18428937913612506" LOG_CI_START="-0.019280964342556797" LOG_EFFECT_SIZE="0.08250420739678412" NO="1" P_CHI2="1.0" P_Z="0.11212997478102418" STUDIES="1" TAU2="0.0" TOTAL_1="113" TOTAL_2="102" WEIGHT="100.0" Z="1.5886918723763317">
<NAME>1 to 4 weeks post-injection</NAME>
<DICH_DATA CI_END="1.5285842453655356" CI_START="0.9565750203072322" EFFECT_SIZE="1.2092168976456839" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="53" LOG_CI_END="0.18428937913612506" LOG_CI_START="-0.019280964342556797" LOG_EFFECT_SIZE="0.08250420739678412" ORDER="150907" O_E="0.0" SE="0.11957822744882975" STUDY_ID="STD-Caborn-2004" TOTAL_1="113" TOTAL_2="102" VAR="0.014298952479804061" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.900947363166235" CI_START="1.0907479103846858" DF="0" EFFECT_SIZE="1.4399494310998735" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="42" I2="0.0" ID="CMP-024.05.02" LOG_CI_END="0.27897009150882096" LOG_CI_START="0.03772438965402661" LOG_EFFECT_SIZE="0.1583472405814238" NO="2" P_CHI2="1.0" P_Z="0.010083982158113344" STUDIES="1" TAU2="0.0" TOTAL_1="113" TOTAL_2="102" WEIGHT="100.0" Z="2.572936107916173">
<NAME>5 to 13 weeks post-injection</NAME>
<DICH_DATA CI_END="1.900947363166235" CI_START="1.0907479103846858" EFFECT_SIZE="1.4399494310998735" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="42" LOG_CI_END="0.27897009150882096" LOG_CI_START="0.03772438965402661" LOG_EFFECT_SIZE="0.1583472405814238" ORDER="150908" O_E="0.0" SE="0.14170891945498992" STUDY_ID="STD-Caborn-2004" TOTAL_1="113" TOTAL_2="102" VAR="0.020081417853100823" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.089537436117372" CI_START="0.9982360861138474" DF="0" EFFECT_SIZE="1.4442477876106194" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="30" I2="0.0" ID="CMP-024.05.03" LOG_CI_END="0.32005015636194" LOG_CI_START="-7.667344930947834E-4" LOG_EFFECT_SIZE="0.15964171093442261" NO="3" P_CHI2="1.0" P_Z="0.05110517400644938" STUDIES="1" TAU2="0.0" TOTAL_1="113" TOTAL_2="102" WEIGHT="100.0" Z="1.9505955751139472">
<NAME>14 to 26 weeks post-injection</NAME>
<DICH_DATA CI_END="2.089537436117372" CI_START="0.9982360861138474" EFFECT_SIZE="1.4442477876106194" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="30" LOG_CI_END="0.32005015636194" LOG_CI_START="-7.667344930947834E-4" LOG_EFFECT_SIZE="0.15964171093442261" ORDER="150909" O_E="0.0" SE="0.18844942975746923" STUDY_ID="STD-Caborn-2004" TOTAL_1="113" TOTAL_2="102" VAR="0.035513187575915324" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.213285081513112" CI_END="1.0442997629798907" CI_START="0.8806995807087497" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9590173947278727" ESTIMABLE="YES" EVENTS_1="155" EVENTS_2="143" I2="86.13669099862844" I2_Q="41.11796533469365" ID="CMP-024.06" LOG_CI_END="0.018825179434059737" LOG_CI_START="-0.055172210419494876" LOG_EFFECT_SIZE="-0.01817351549271755" METHOD="MH" NO="6" P_CHI2="0.007236616530613582" P_Q="0.19250911244913627" P_Z="0.33568736021434054" Q="1.698310878155177" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="196" TOTAL_2="172" WEIGHT="200.0" Z="0.9627214124363074">
<NAME>Analgesic usage</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>Triamcinolone hexace</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hylan G-F 20</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours TH</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0553510902931698" CI_START="0.9705592695634292" DF="0" EFFECT_SIZE="1.0120675784392599" ESTIMABLE="YES" EVENTS_1="111" EVENTS_2="99" I2="0.0" ID="CMP-024.06.01" LOG_CI_END="0.023396963151710425" LOG_CI_START="-0.012977938216499691" LOG_EFFECT_SIZE="0.005209512467605365" NO="1" P_CHI2="1.0" P_Z="0.5745240622383978" STUDIES="1" TAU2="0.0" TOTAL_1="113" TOTAL_2="102" WEIGHT="100.0" Z="0.5614012095957094">
<NAME>From week 0 to prior to week 12</NAME>
<DICH_DATA CI_END="1.0553510902931698" CI_START="0.9705592695634291" EFFECT_SIZE="1.0120675784392599" ESTIMABLE="YES" EVENTS_1="111" EVENTS_2="99" LOG_CI_END="0.023396963151710425" LOG_CI_START="-0.012977938216499741" LOG_EFFECT_SIZE="0.005209512467605365" ORDER="150910" O_E="0.0" SE="0.02136679712235239" STUDY_ID="STD-Caborn-2004" TOTAL_1="113" TOTAL_2="102" VAR="4.5654001926776627E-4" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.007251904630018E-30" CI_END="1.1059153370320576" CI_START="0.643158500948166" DF="0" EFFECT_SIZE="0.8433734939759038" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="44" I2="100.0" ID="CMP-024.06.02" LOG_CI_END="0.04372188097666401" LOG_CI_START="-0.19168198570029796" LOG_EFFECT_SIZE="-0.07398005236181698" NO="2" P_CHI2="0.0" P_Z="0.217982571727816" STUDIES="1" TAU2="0.0" TOTAL_1="83" TOTAL_2="70" WEIGHT="100.0" Z="1.2319104205924167">
<NAME>From week 12 prior to week 26</NAME>
<DICH_DATA CI_END="1.1059153370320574" CI_START="0.6431585009481658" EFFECT_SIZE="0.8433734939759037" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="44" LOG_CI_END="0.04372188097666392" LOG_CI_START="-0.191681985700298" LOG_EFFECT_SIZE="-0.07398005236181705" ORDER="150911" O_E="0.0" SE="0.13827739655398072" STUDY_ID="STD-Caborn-2004" TOTAL_1="83" TOTAL_2="70" VAR="0.019120638397746838" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="30" EVENTS_2="35" I2="0.0" I2_Q="0.0" ID="CMP-024.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="113" TOTAL_2="103" WEIGHT="0.0" Z="0.0">
<NAME>Safety: total withdrawals overall</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>Triamcinolone hexace</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hylan G-F 20</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours TH</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1749802636191022" CI_START="0.5195094016260782" EFFECT_SIZE="0.7812895069532237" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="35" LOG_CI_END="0.07003057173685805" LOG_CI_START="-0.28440658855457956" LOG_EFFECT_SIZE="-0.10718800840886072" ORDER="150912" O_E="0.0" SE="0.20819814244742998" STUDY_ID="STD-Caborn-2004" TOTAL_1="113" TOTAL_2="103" VAR="0.04334646651856035" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="11" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-024.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="113" TOTAL_2="103" WEIGHT="0.0" Z="0.0">
<NAME>Safety: withdrawals due to adverse event</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>Triamcinolone hexace</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hylan G-F 20</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours TH</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.2621900721667636" CI_START="0.4443997855010102" EFFECT_SIZE="1.002654867256637" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.35452909211252487" LOG_CI_START="-0.3522261593525699" LOG_EFFECT_SIZE="0.0011514663799774962" ORDER="150913" O_E="0.0" SE="0.4151515332055144" STUDY_ID="STD-Caborn-2004" TOTAL_1="113" TOTAL_2="103" VAR="0.17235079552288934" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-024.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="113" TOTAL_2="102" WEIGHT="0.0" Z="0.0">
<NAME>Safety: withdrawals due to lack of efficacy</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>Triamcinolone hexace</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hylan G-F 20</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours TH</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.48097973501461166" CI_START="0.0017660971118506393" EFFECT_SIZE="0.029145444255800793" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="15" LOG_CI_END="-0.31787322124931133" LOG_CI_START="-2.752985419681835" LOG_EFFECT_SIZE="-1.5354293204655731" ORDER="150914" O_E="0.0" SE="1.430396959359051" STUDY_ID="STD-Caborn-2004" TOTAL_1="113" TOTAL_2="102" VAR="2.046035461343619" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-025" NO="25">
<NAME>Hylan G-F 20 versus physical therapy</NAME>
<CONT_OUTCOME CHI2="18.689030030888514" CI_END="6.85250109726741" CI_START="-2.4965541051907336" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="2.1779734960383386" ESTIMABLE="YES" I2="78.59707008127788" I2_Q="78.59707008127788" ID="CMP-025.01" NO="1" P_CHI2="9.045682888345619E-4" P_Q="9.045682888345619E-4" P_Z="0.36114063594885504" Q="18.689030030888514" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="100" TOTAL_2="100" UNITS="" WEIGHT="500.0" Z="0.9131937974642728">
<NAME>Spontaneous pain (0-100 mm VAS)</NAME>
<GROUP_LABEL_1>Synvisc</GROUP_LABEL_1>
<GROUP_LABEL_2>Phys therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Synvisc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours phys therapy</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="30.79419657028503" CI_START="10.205803429714967" DF="0" EFFECT_SIZE="20.5" ESTIMABLE="YES" I2="0.0" ID="CMP-025.01.01" NO="1" P_CHI2="1.0" P_Z="9.496908791219133E-5" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="3.9030983534015222">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="30.79419657028503" CI_START="10.205803429714967" EFFECT_SIZE="20.5" ESTIMABLE="YES" MEAN_1="64.0" MEAN_2="43.5" ORDER="150915" SD_1="18.4" SD_2="14.6" SE="5.252237618387043" STUDY_ID="STD-Atamaz-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="6.477011266192486" CI_START="-14.477011266192486" DF="0" EFFECT_SIZE="-4.0" ESTIMABLE="YES" I2="0.0" ID="CMP-025.01.02" NO="2" P_CHI2="1.0" P_Z="0.4542845024370076" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.7482912577805546">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="6.477011266192486" CI_START="-14.477011266192486" EFFECT_SIZE="-4.0" ESTIMABLE="YES" MEAN_1="45.5" MEAN_2="49.5" ORDER="150916" SD_1="18.2" SD_2="15.5" SE="5.345512136362614" STUDY_ID="STD-Atamaz-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="12.625921518972383" CI_START="-8.225921518972378" DF="0" EFFECT_SIZE="2.200000000000003" ESTIMABLE="YES" I2="0.0" ID="CMP-025.01.03" NO="3" P_CHI2="1.0" P_Z="0.6791839619717936" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.413576944555125">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="12.625921518972383" CI_START="-8.225921518972378" EFFECT_SIZE="2.200000000000003" ESTIMABLE="YES" MEAN_1="50.7" MEAN_2="48.5" ORDER="150917" SD_1="18.3" SD_2="15.2" SE="5.319445459820037" STUDY_ID="STD-Atamaz-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="11.150740328570533" CI_START="-9.150740328570533" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" I2="0.0" ID="CMP-025.01.04" NO="4" P_CHI2="1.0" P_Z="0.8468917605282206" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.00000000000001" Z="0.19308581651167744">
<NAME>37 weeks post-injection</NAME>
<CONT_DATA CI_END="11.150740328570533" CI_START="-9.150740328570533" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="51.7" MEAN_2="50.7" ORDER="150918" SD_1="15.4" SD_2="17.3" SE="5.179044313384469" STUDY_ID="STD-Atamaz-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.4681833116641343" CI_START="-21.468183311664134" DF="0" EFFECT_SIZE="-10.5" ESTIMABLE="YES" I2="0.0" ID="CMP-025.01.05" NO="5" P_CHI2="1.0" P_Z="0.06061385319029703" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="1.8763017769574597">
<NAME>45 to 52 weeks post-injection</NAME>
<CONT_DATA CI_END="0.4681833116641343" CI_START="-21.468183311664134" EFFECT_SIZE="-10.5" ESTIMABLE="YES" MEAN_1="49.0" MEAN_2="59.5" ORDER="150919" SD_1="13.3" SD_2="21.2" SE="5.596114723627457" STUDY_ID="STD-Atamaz-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="8.377361055067599" CI_END="-1.9364784560025674" CI_START="-3.7473369578225277" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.8419077069125476" ESTIMABLE="YES" I2="52.252266868928416" I2_Q="52.252266868928416" ID="CMP-025.02" NO="2" P_CHI2="0.07869310189502354" P_Q="0.07869310189502354" P_Z="7.659933074986021E-10" Q="8.377361055067599" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="100" TOTAL_2="100" UNITS="" WEIGHT="500.0" Z="6.151818871918897">
<NAME>WOMAC pain</NAME>
<GROUP_LABEL_1>Synvisc</GROUP_LABEL_1>
<GROUP_LABEL_2>Phys therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Synvisc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours phys therapy</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-1.1504543585442075" CI_START="-4.8495456414557925" DF="0" EFFECT_SIZE="-3.0" ESTIMABLE="YES" I2="0.0" ID="CMP-025.02.01" NO="1" P_CHI2="1.0" P_Z="0.0014773272728661106" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="3.1791007595746876">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="-1.1504543585442075" CI_START="-4.8495456414557925" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="8.3" MEAN_2="11.3" ORDER="150920" SD_1="3.4" SD_2="2.5" SE="0.9436630754670864" STUDY_ID="STD-Atamaz-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-1.0820935725520453" CI_START="-5.1179064274479575" DF="0" EFFECT_SIZE="-3.1000000000000014" ESTIMABLE="YES" I2="0.0" ID="CMP-025.02.02" NO="2" P_CHI2="1.0" P_Z="0.0026040070986053897" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="3.0109861733075203">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="-1.0820935725520453" CI_START="-5.1179064274479575" EFFECT_SIZE="-3.1000000000000014" ESTIMABLE="YES" MEAN_1="8.7" MEAN_2="11.8" ORDER="150921" SD_1="3.8" SD_2="2.6" SE="1.0295630140987" STUDY_ID="STD-Atamaz-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="8.011668276943976E-33" CI_END="1.531066514029987" CI_START="-3.3310665140299878" DF="0" EFFECT_SIZE="-0.9000000000000002" ESTIMABLE="YES" I2="100.0" ID="CMP-025.02.03" NO="3" P_CHI2="0.0" P_Z="0.4680876277060352" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.00000000000001" Z="0.7255941274769625">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="1.531066514029987" CI_START="-3.3310665140299878" EFFECT_SIZE="-0.9000000000000004" ESTIMABLE="YES" MEAN_1="10.4" MEAN_2="11.3" ORDER="150922" SD_1="4.9" SD_2="2.6" SE="1.2403628501370074" STUDY_ID="STD-Atamaz-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.09300249098400637" CI_START="-3.706997509015994" DF="0" EFFECT_SIZE="-1.9000000000000004" ESTIMABLE="YES" I2="0.0" ID="CMP-025.02.04" NO="4" P_CHI2="1.0" P_Z="0.039318369082979816" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="2.060839349277234">
<NAME>37 weeks post-injection</NAME>
<CONT_DATA CI_END="-0.09300249098400637" CI_START="-3.706997509015994" EFFECT_SIZE="-1.9000000000000004" ESTIMABLE="YES" MEAN_1="10.4" MEAN_2="12.3" ORDER="150923" SD_1="2.6" SD_2="3.2" SE="0.9219544457292888" STUDY_ID="STD-Atamaz-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-3.0990730196357514" CI_START="-7.50092698036425" DF="0" EFFECT_SIZE="-5.300000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-025.02.05" NO="5" P_CHI2="1.0" P_Z="2.361431109992056E-6" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="4.719742731466323">
<NAME>45 to 52 weeks post-injection</NAME>
<CONT_DATA CI_END="-3.0990730196357514" CI_START="-7.50092698036425" EFFECT_SIZE="-5.300000000000001" ESTIMABLE="YES" MEAN_1="10.2" MEAN_2="15.5" ORDER="150924" SD_1="2.9" SD_2="4.1" SE="1.1229425630903835" STUDY_ID="STD-Atamaz-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.34446051933502514" CI_END="4.874413568880573" CI_START="-2.455389850836209" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="1.209511859022182" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-025.03" NO="3" P_CHI2="0.9867662269411568" P_Q="0.9867662269411568" P_Z="0.5177364482032651" Q="0.34446051933502514" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="100" TOTAL_2="100" UNITS="" WEIGHT="500.0" Z="0.6468385430858287">
<NAME>WOMAC physical function</NAME>
<GROUP_LABEL_1>Synvisc</GROUP_LABEL_1>
<GROUP_LABEL_2>Phys Therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Synvisc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Phys Therapy</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="11.350056717057385" CI_START="-6.3500567170573845" DF="0" EFFECT_SIZE="2.5" ESTIMABLE="YES" I2="0.0" ID="CMP-025.03.01" NO="1" P_CHI2="1.0" P_Z="0.5798125198473777" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.5536585942897031">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="11.350056717057385" CI_START="-6.3500567170573845" EFFECT_SIZE="2.5" ESTIMABLE="YES" MEAN_1="40.1" MEAN_2="37.6" ORDER="150925" SD_1="15.7" SD_2="12.7" SE="4.5154180315891015" STUDY_ID="STD-Atamaz-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="11.354069652310635" CI_START="-5.754069652310626" DF="0" EFFECT_SIZE="2.8000000000000043" ESTIMABLE="YES" I2="0.0" ID="CMP-025.03.02" NO="2" P_CHI2="1.0" P_Z="0.5211626942817189" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.6415541817840781">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="11.354069652310635" CI_START="-5.754069652310626" EFFECT_SIZE="2.8000000000000043" ESTIMABLE="YES" MEAN_1="41.7" MEAN_2="38.9" ORDER="150926" SD_1="14.0" SD_2="13.6" SE="4.364401448079679" STUDY_ID="STD-Atamaz-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="9.300230470625388" CI_START="-9.300230470625388" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-025.03.03" NO="3" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.0">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="9.300230470625388" CI_START="-9.300230470625388" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="41.9" MEAN_2="41.9" ORDER="150927" SD_1="14.6" SD_2="15.4" SE="4.74510273861378" STUDY_ID="STD-Atamaz-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="7.684239834110186" CI_START="-6.884239834110189" DF="0" EFFECT_SIZE="0.3999999999999986" ESTIMABLE="YES" I2="0.0" ID="CMP-025.03.04" NO="4" P_CHI2="1.0" P_Z="0.9142910652196853" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="99.99999999999999" Z="0.10762764703940962">
<NAME>37 weeks post-injection</NAME>
<CONT_DATA CI_END="7.684239834110187" CI_START="-6.88423983411019" EFFECT_SIZE="0.3999999999999986" ESTIMABLE="YES" MEAN_1="38.6" MEAN_2="38.2" ORDER="150928" SD_1="11.5" SD_2="12.0" SE="3.7165171868296265" STUDY_ID="STD-Atamaz-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="8.235672831068957" CI_START="-6.835672831068966" DF="0" EFFECT_SIZE="0.6999999999999957" ESTIMABLE="YES" I2="0.0" ID="CMP-025.03.05" NO="5" P_CHI2="1.0" P_Z="0.8555324951374109" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.18206400674953535">
<NAME>45 to 52 weeks post-injection</NAME>
<CONT_DATA CI_END="8.235672831068959" CI_START="-6.835672831068967" EFFECT_SIZE="0.6999999999999957" ESTIMABLE="YES" MEAN_1="38.9" MEAN_2="38.2" ORDER="150929" SD_1="11.7" SD_2="12.6" SE="3.844801685392889" STUDY_ID="STD-Atamaz-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.192391845195549" CI_END="2.9728148669864174" CI_START="-7.386085694596104" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.206635413804843" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-025.04" NO="4" P_CHI2="0.7004224332472304" P_Q="0.7004224332472304" P_Z="0.4037084815668498" Q="2.192391845195549" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="100" TOTAL_2="100" UNITS="" WEIGHT="500.0" Z="0.835016402050956">
<NAME>SF-36 pain</NAME>
<GROUP_LABEL_1>Synvisc</GROUP_LABEL_1>
<GROUP_LABEL_2>Phys therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Phys therapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Synvisc</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="11.782528918895613" CI_START="-11.182528918895619" DF="0" EFFECT_SIZE="0.29999999999999716" ESTIMABLE="YES" I2="0.0" ID="CMP-025.04.01" NO="1" P_CHI2="1.0" P_Z="0.9591603423945593" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.051207290616478864">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="11.782528918895613" CI_START="-11.182528918895619" EFFECT_SIZE="0.29999999999999716" ESTIMABLE="YES" MEAN_1="59.4" MEAN_2="59.1" ORDER="150930" SD_1="20.9" SD_2="15.8" SE="5.858540773947041" STUDY_ID="STD-Atamaz-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="5.019093128680756E-33" CI_END="14.885863479688116" CI_START="-9.685863479688127" DF="0" EFFECT_SIZE="2.599999999999994" ESTIMABLE="YES" I2="100.0" ID="CMP-025.04.02" NO="2" P_CHI2="0.0" P_Z="0.6783043987630002" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.4147780388597879">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="14.885863479688116" CI_START="-9.685863479688127" EFFECT_SIZE="2.5999999999999943" ESTIMABLE="YES" MEAN_1="58.8" MEAN_2="56.2" ORDER="150931" SD_1="21.9" SD_2="17.5" SE="6.268412877276034" STUDY_ID="STD-Atamaz-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="15.41880794296429" CI_START="-13.218807942964288" DF="0" EFFECT_SIZE="1.1000000000000014" ESTIMABLE="YES" I2="0.0" ID="CMP-025.04.03" NO="3" P_CHI2="1.0" P_Z="0.8803161693442332" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.15056842661636635">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="15.41880794296429" CI_START="-13.218807942964288" EFFECT_SIZE="1.1000000000000014" ESTIMABLE="YES" MEAN_1="55.7" MEAN_2="54.6" ORDER="150932" SD_1="27.2" SD_2="18.1" SE="7.305648499620003" STUDY_ID="STD-Atamaz-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.0939185984269013" CI_START="-17.093918598426903" DF="0" EFFECT_SIZE="-7.5" ESTIMABLE="YES" I2="0.0" ID="CMP-025.04.04" NO="4" P_CHI2="1.0" P_Z="0.12547494487983368" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.00000000000001" Z="1.5321924751853426">
<NAME>37 weeks post-injection</NAME>
<CONT_DATA CI_END="2.0939185984269013" CI_START="-17.093918598426903" EFFECT_SIZE="-7.5" ESTIMABLE="YES" MEAN_1="43.8" MEAN_2="51.3" ORDER="150933" SD_1="14.5" SD_2="16.4" SE="4.8949463735571195" STUDY_ID="STD-Atamaz-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="8.184163825419354" CI_START="-15.184163825419354" DF="0" EFFECT_SIZE="-3.5" ESTIMABLE="YES" I2="0.0" ID="CMP-025.04.05" NO="5" P_CHI2="1.0" P_Z="0.5571307244586133" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.5871086753308155">
<NAME>45 to 52 weeks post-injection</NAME>
<CONT_DATA CI_END="8.184163825419354" CI_START="-15.184163825419354" EFFECT_SIZE="-3.5" ESTIMABLE="YES" MEAN_1="46.7" MEAN_2="50.2" ORDER="150934" SD_1="19.1" SD_2="18.6" SE="5.961417616641197" STUDY_ID="STD-Atamaz-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.8340181163955454" CI_END="8.45751826145757" CI_START="-4.226911425085628" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="2.115303418185971" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-025.05" NO="5" P_CHI2="0.7662530563299301" P_Q="0.7662530563299301" P_Z="0.513303819700118" Q="1.8340181163955454" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="100" TOTAL_2="100" UNITS="" WEIGHT="500.0" Z="0.6537019981934767">
<NAME>SF-36 physical functioning</NAME>
<GROUP_LABEL_1>Synvisc</GROUP_LABEL_1>
<GROUP_LABEL_2>Phys Therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Phys therapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Synvisc</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="19.001877909361568" CI_START="-12.001877909361566" DF="0" EFFECT_SIZE="3.5" ESTIMABLE="YES" I2="0.0" ID="CMP-025.05.01" NO="1" P_CHI2="1.0" P_Z="0.6581137587325846" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.44251889906496555">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="19.001877909361568" CI_START="-12.001877909361566" EFFECT_SIZE="3.5" ESTIMABLE="YES" MEAN_1="57.2" MEAN_2="53.7" ORDER="150935" SD_1="26.7" SD_2="23.2" SE="7.909266716959291" STUDY_ID="STD-Atamaz-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="20.884616774060362" CI_START="-4.484616774060358" DF="0" EFFECT_SIZE="8.200000000000003" ESTIMABLE="YES" I2="0.0" ID="CMP-025.05.02" NO="2" P_CHI2="1.0" P_Z="0.2051469932004254" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="1.2670232738993406">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="20.884616774060362" CI_START="-4.484616774060358" EFFECT_SIZE="8.200000000000003" ESTIMABLE="YES" MEAN_1="61.7" MEAN_2="53.5" ORDER="150936" SD_1="17.7" SD_2="22.9" SE="6.471862174057788" STUDY_ID="STD-Atamaz-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="17.040709599062687" CI_START="-13.64070959906268" DF="0" EFFECT_SIZE="1.7000000000000028" ESTIMABLE="YES" I2="0.0" ID="CMP-025.05.03" NO="3" P_CHI2="1.0" P_Z="0.8280557029798795" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.21719587038670488">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="17.040709599062687" CI_START="-13.64070959906268" EFFECT_SIZE="1.7000000000000028" ESTIMABLE="YES" MEAN_1="55.7" MEAN_2="54.0" ORDER="150937" SD_1="28.3" SD_2="20.6" SE="7.827036476214992" STUDY_ID="STD-Atamaz-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="8.878996952576653" CI_START="-17.27899695257666" DF="0" EFFECT_SIZE="-4.200000000000003" ESTIMABLE="YES" I2="0.0" ID="CMP-025.05.04" NO="4" P_CHI2="1.0" P_Z="0.5290908220654134" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.629394499051894">
<NAME>37 weeks post-injection</NAME>
<CONT_DATA CI_END="8.878996952576653" CI_START="-17.27899695257666" EFFECT_SIZE="-4.200000000000003" ESTIMABLE="YES" MEAN_1="45.0" MEAN_2="49.2" ORDER="150938" SD_1="21.4" SD_2="20.8" SE="6.673080248281149" STUDY_ID="STD-Atamaz-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="16.093631616057984" CI_START="-14.093631616057984" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" I2="0.0" ID="CMP-025.05.05" NO="5" P_CHI2="1.0" P_Z="0.8966821722974678" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.12985370482044">
<NAME>45 to 52 weeks post-injection</NAME>
<CONT_DATA CI_END="16.093631616057984" CI_START="-14.093631616057984" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="54.0" MEAN_2="53.0" ORDER="150939" SD_1="25.9" SD_2="22.7" SE="7.700973964376194" STUDY_ID="STD-Atamaz-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-026" NO="26">
<NAME>(Hylan G-F 20 + physiotherapy) versus physiotherapy</NAME>
<CONT_OUTCOME CHI2="0.002345735322864387" CI_END="1.23946148155716" CI_START="-2.71864308056674" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.7395907995047901" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-026.01" NO="1" P_CHI2="0.9613713400368231" P_Q="0.9613713400368231" P_Z="0.4638894893241522" Q="0.002345735322864387" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="24" TOTAL_2="18" UNITS="" WEIGHT="200.0" Z="0.7324573202021422">
<NAME>Lequesne Index (0-24)</NAME>
<GROUP_LABEL_1>Hylan G-F 20+PT</GROUP_LABEL_1>
<GROUP_LABEL_2>PT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HylanGF20+PT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PT</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.8462774459622362" CI_START="-3.2462774459622383" DF="0" EFFECT_SIZE="-0.7000000000000011" ESTIMABLE="YES" I2="0.0" ID="CMP-026.01.01" NO="1" P_CHI2="1.0" P_Z="0.5900138894804385" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="9" WEIGHT="100.0" Z="0.5388159060803256">
<NAME>End of treatment</NAME>
<CONT_DATA CI_END="1.8462774459622362" CI_START="-3.2462774459622383" EFFECT_SIZE="-0.7000000000000011" ESTIMABLE="YES" MEAN_1="8.6" MEAN_2="9.3" ORDER="150940" SD_1="2.2" SD_2="3.4" SE="1.2991450179936717" STUDY_ID="STD-Bayramoglu-2003" TOTAL_1="12" TOTAL_2="9" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.3452859226439187" CI_START="-3.94528592264392" DF="0" EFFECT_SIZE="-0.8000000000000007" ESTIMABLE="YES" I2="0.0" ID="CMP-026.01.02" NO="2" P_CHI2="1.0" P_Z="0.6181213306569981" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="9" WEIGHT="100.0" Z="0.49851467440327724">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="2.3452859226439187" CI_START="-3.94528592264392" EFFECT_SIZE="-0.8000000000000007" ESTIMABLE="YES" MEAN_1="8.6" MEAN_2="9.4" ORDER="150941" SD_1="2.5" SD_2="4.3" SE="1.6047672036086036" STUDY_ID="STD-Bayramoglu-2003" TOTAL_1="12" TOTAL_2="9" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.6383177444548793" CI_START="0.15259555165422625" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-026.02" LOG_CI_END="0.21439813508057673" LOG_CI_START="-0.8164581264085391" LOG_EFFECT_SIZE="-0.3010299956639812" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.2523355863576091" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="1.144694894543998">
<NAME>Safety: total withdrawls overall</NAME>
<GROUP_LABEL_1>Hylan G-F 20+PT</GROUP_LABEL_1>
<GROUP_LABEL_2>PT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HylanGF20+PT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PT</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6383177444548793" CI_START="0.15259555165422625" DF="0" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" I2="0.0" ID="CMP-026.02.01" LOG_CI_END="0.21439813508057673" LOG_CI_START="-0.8164581264085391" LOG_EFFECT_SIZE="-0.3010299956639812" NO="1" P_CHI2="1.0" P_Z="0.2523355863576091" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="1.144694894543998">
<NAME>5 to 13 weeks post-injection</NAME>
<DICH_DATA CI_END="1.6383177444548798" CI_START="0.15259555165422625" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.21439813508057684" LOG_CI_START="-0.8164581264085391" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="150942" O_E="0.0" SE="0.6055300708194984" STUDY_ID="STD-Bayramoglu-2003" TOTAL_1="15" TOTAL_2="15" VAR="0.3666666666666667" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-026.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="12" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Safety: number of patients with adverse events</NAME>
<GROUP_LABEL_1>Hylan G-F 20+PT</GROUP_LABEL_1>
<GROUP_LABEL_2>PT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HylanGF20+PT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PT</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-026.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>End of treatment</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="150943" O_E="0.0" SE="0.0" STUDY_ID="STD-Bayramoglu-2003" TOTAL_1="12" TOTAL_2="9" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-027" NO="27">
<NAME>Hylan G-F 20 versus progressive knee exercises</NAME>
<CONT_OUTCOME CHI2="14.538071299299656" CI_END="1.794450821435781" CI_START="0.35982323483650525" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="1.0771370281361432" ESTIMABLE="YES" I2="72.48603396110259" I2_Q="72.48603396110258" ID="CMP-027.01" NO="1" P_CHI2="0.005761744198870211" P_Q="0.005761744198870544" P_Z="0.0032490896864027148" Q="14.538071299299652" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="233" TOTAL_2="265" UNITS="" WEIGHT="500.0" Z="2.9431328398831913">
<NAME>Pain during activity</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>Exercise</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Exercise</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Hylan G-F 20</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.6094562455862667" CI_START="0.19054375441373383" DF="0" EFFECT_SIZE="1.9000000000000004" ESTIMABLE="YES" I2="0.0" ID="CMP-027.01.01" NO="1" P_CHI2="1.0" P_Z="0.029374003550600904" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="53" WEIGHT="100.00000000000001" Z="2.1784304688939042">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="3.6094562455862667" CI_START="0.19054375441373406" EFFECT_SIZE="1.9000000000000004" ESTIMABLE="YES" MEAN_1="10.8" MEAN_2="8.9" ORDER="150944" SD_1="4.0" SD_2="4.9" SE="0.8721875805220091" STUDY_ID="STD-Karatosun-2005" TOTAL_1="52" TOTAL_2="53" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.231436263420291" CI_START="0.16856373657971124" DF="0" EFFECT_SIZE="1.700000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-027.01.02" NO="2" P_CHI2="1.0" P_Z="0.029578047329637588" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="53" WEIGHT="100.0" Z="2.175695360821994">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="3.231436263420291" CI_START="0.16856373657971124" EFFECT_SIZE="1.700000000000001" ESTIMABLE="YES" MEAN_1="10.8" MEAN_2="9.1" ORDER="150945" SD_1="3.8" SD_2="4.2" SE="0.781359390019441" STUDY_ID="STD-Karatosun-2005" TOTAL_1="52" TOTAL_2="53" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="4.150671908459189" CI_START="0.8493280915408112" DF="0" EFFECT_SIZE="2.5" ESTIMABLE="YES" I2="0.0" ID="CMP-027.01.03" NO="3" P_CHI2="1.0" P_Z="0.0029932176114822314" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="53" WEIGHT="100.00000000000001" Z="2.968433603455414">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="4.150671908459189" CI_START="0.8493280915408112" EFFECT_SIZE="2.5" ESTIMABLE="YES" MEAN_1="11.1" MEAN_2="8.6" ORDER="150946" SD_1="3.9" SD_2="4.7" SE="0.8421950206633786" STUDY_ID="STD-Karatosun-2005" TOTAL_1="52" TOTAL_2="53" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="6.405275465094248E-32" CI_END="0.019568221851796963" CI_START="-3.419568221851795" DF="0" EFFECT_SIZE="-1.699999999999999" ESTIMABLE="YES" I2="100.0" ID="CMP-027.01.04" NO="4" P_CHI2="0.0" P_Z="0.05266470195931629" STUDIES="1" TAU2="0.0" TOTAL_1="46" TOTAL_2="53" WEIGHT="100.0" Z="1.9376601238477988">
<NAME>45 to 52 weeks post-injection</NAME>
<CONT_DATA CI_END="0.01956822185179674" CI_START="-3.4195682218517955" EFFECT_SIZE="-1.6999999999999993" ESTIMABLE="YES" MEAN_1="8.5" MEAN_2="10.2" ORDER="150947" SD_1="4.4" SD_2="4.3" SE="0.8773468468887851" STUDY_ID="STD-Karatosun-2005" TOTAL_1="46" TOTAL_2="53" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.2591191173519567" CI_START="-0.659119117351955" DF="0" EFFECT_SIZE="0.8000000000000007" ESTIMABLE="YES" I2="0.0" ID="CMP-027.01.05" NO="5" P_CHI2="1.0" P_Z="0.28255332046689796" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="53" WEIGHT="100.0" Z="1.0746012227415924">
<NAME>74 weeks post-injection</NAME>
<CONT_DATA CI_END="2.2591191173519567" CI_START="-0.659119117351955" EFFECT_SIZE="0.8000000000000007" ESTIMABLE="YES" MEAN_1="12.9" MEAN_2="12.1" ORDER="150948" SD_1="3.4" SD_2="3.1" SE="0.7444622089289911" STUDY_ID="STD-Karatay-2005" TOTAL_1="31" TOTAL_2="53" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="5.24195046421406" CI_END="0.7381737597250413" CI_START="-0.4268548097108209" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="0.15565947500711022" ESTIMABLE="YES" I2="23.6925257629322" I2_Q="23.6925257629322" ID="CMP-027.02" NO="2" P_CHI2="0.2633605259100342" P_Q="0.2633605259100342" P_Z="0.6004582778049353" Q="5.24195046421406" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="233" TOTAL_2="265" UNITS="" WEIGHT="500.0" Z="0.5237416023438463">
<NAME>Pain at rest</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>Exercise</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Exercise</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Hylan G-F 20</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.246238218493153" CI_START="-0.44623821849315215" DF="0" EFFECT_SIZE="0.9000000000000004" ESTIMABLE="YES" I2="0.0" ID="CMP-027.02.01" NO="1" P_CHI2="1.0" P_Z="0.19009646532087007" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="53" WEIGHT="100.0" Z="1.3102937963390033">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="2.246238218493153" CI_START="-0.44623821849315215" EFFECT_SIZE="0.9000000000000004" ESTIMABLE="YES" MEAN_1="13.1" MEAN_2="12.2" ORDER="150949" SD_1="3.1" SD_2="3.9" SE="0.6868688553014789" STUDY_ID="STD-Karatosun-2005" TOTAL_1="52" TOTAL_2="53" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.2441077303792767" CI_START="-1.2441077303792767" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-027.02.02" NO="2" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="53" WEIGHT="100.0" Z="0.0">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="1.2441077303792767" CI_START="-1.2441077303792767" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="12.7" MEAN_2="12.7" ORDER="150950" SD_1="3.1" SD_2="3.4" SE="0.634760505903496" STUDY_ID="STD-Karatosun-2005" TOTAL_1="52" TOTAL_2="53" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.7563468801878044" CI_START="-0.9563468801878037" DF="0" EFFECT_SIZE="0.40000000000000036" ESTIMABLE="YES" I2="0.0" ID="CMP-027.02.03" NO="3" P_CHI2="1.0" P_Z="0.563255611791339" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="53" WEIGHT="100.0" Z="0.578012605232276">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="1.7563468801878044" CI_START="-0.9563468801878037" EFFECT_SIZE="0.40000000000000036" ESTIMABLE="YES" MEAN_1="12.8" MEAN_2="12.4" ORDER="150951" SD_1="2.9" SD_2="4.1" SE="0.6920264305295889" STUDY_ID="STD-Karatosun-2005" TOTAL_1="52" TOTAL_2="53" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.20752422859085384" CI_START="-2.607524228590856" DF="0" EFFECT_SIZE="-1.200000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-027.02.04" NO="4" P_CHI2="1.0" P_Z="0.09472395184458562" STUDIES="1" TAU2="0.0" TOTAL_1="46" TOTAL_2="53" WEIGHT="100.0" Z="1.6709884872125664">
<NAME>45 to 52 weeks post-injection</NAME>
<CONT_DATA CI_END="0.20752422859085384" CI_START="-2.607524228590856" EFFECT_SIZE="-1.200000000000001" ESTIMABLE="YES" MEAN_1="11.7" MEAN_2="12.9" ORDER="150952" SD_1="3.7" SD_2="3.4" SE="0.7181378023745468" STUDY_ID="STD-Karatosun-2005" TOTAL_1="46" TOTAL_2="53" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.6944918842040966" CI_START="-0.6944918842040966" DF="0" EFFECT_SIZE="0.5" ESTIMABLE="YES" I2="0.0" ID="CMP-027.02.05" NO="5" P_CHI2="1.0" P_Z="0.41197817565255956" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="53" WEIGHT="100.0" Z="0.8204174555133125">
<NAME>74 weeks post-injection</NAME>
<CONT_DATA CI_END="1.6944918842040966" CI_START="-0.6944918842040966" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="13.7" MEAN_2="13.2" ORDER="150953" SD_1="2.5" SD_2="3.0" SE="0.6094458335082155" STUDY_ID="STD-Karatosun-2005" TOTAL_1="31" TOTAL_2="53" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.8336100384098644" CI_END="0.32333073457713096" CI_START="-0.1716400635969464" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="0.07584533549009229" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-027.03" NO="3" P_CHI2="0.9338862348751639" P_Q="0.9338862348751639" P_Z="0.5480676910178974" Q="0.8336100384098641" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="233" TOTAL_2="265" UNITS="" WEIGHT="500.0" Z="0.6006581661153189">
<NAME>Pain during climbing stairs</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>Exercise</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Exercise</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Hylan G-F 20</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.7355884090115354" CI_START="-0.3355884090115351" DF="0" EFFECT_SIZE="0.20000000000000018" ESTIMABLE="YES" I2="0.0" ID="CMP-027.03.01" NO="1" P_CHI2="1.0" P_Z="0.4642345804681758" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="53" WEIGHT="100.0" Z="0.7318918600786385">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="0.7355884090115354" CI_START="-0.3355884090115351" EFFECT_SIZE="0.20000000000000018" ESTIMABLE="YES" MEAN_1="3.2" MEAN_2="3.0" ORDER="150954" SD_1="1.4" SD_2="1.4" SE="0.2732644136505509" STUDY_ID="STD-Karatosun-2005" TOTAL_1="52" TOTAL_2="53" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.6355884090115349" CI_START="-0.4355884090115356" DF="0" EFFECT_SIZE="0.09999999999999964" ESTIMABLE="YES" I2="0.0" ID="CMP-027.03.02" NO="2" P_CHI2="1.0" P_Z="0.7144054234099715" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="53" WEIGHT="100.0" Z="0.36594593003931764">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="0.6355884090115349" CI_START="-0.4355884090115356" EFFECT_SIZE="0.09999999999999964" ESTIMABLE="YES" MEAN_1="3.3" MEAN_2="3.2" ORDER="150955" SD_1="1.4" SD_2="1.4" SE="0.2732644136505509" STUDY_ID="STD-Karatosun-2005" TOTAL_1="52" TOTAL_2="53" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.5355884090115353" CI_START="-0.5355884090115353" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-027.03.03" NO="3" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="53" WEIGHT="100.0" Z="0.0">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="0.5355884090115353" CI_START="-0.5355884090115353" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="3.2" MEAN_2="3.2" ORDER="150956" SD_1="1.4" SD_2="1.4" SE="0.2732644136505509" STUDY_ID="STD-Karatosun-2005" TOTAL_1="52" TOTAL_2="53" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.4198192148093596E-33" CI_END="0.4529385551414281" CI_START="-0.6529385551414283" DF="0" EFFECT_SIZE="-0.10000000000000007" ESTIMABLE="YES" I2="100.0" ID="CMP-027.03.04" NO="4" P_CHI2="0.0" P_Z="0.7229917398157097" STUDIES="1" TAU2="0.0" TOTAL_1="46" TOTAL_2="53" WEIGHT="100.0" Z="0.3544632520766697">
<NAME>45 to 52 weeks post-injection</NAME>
<CONT_DATA CI_END="0.4529385551414281" CI_START="-0.6529385551414283" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" MEAN_1="3.1" MEAN_2="3.2" ORDER="150957" SD_1="1.4" SD_2="1.4" SE="0.2821166916856314" STUDY_ID="STD-Karatosun-2005" TOTAL_1="46" TOTAL_2="53" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.8204359982299728" CI_START="-0.42043599822997335" DF="0" EFFECT_SIZE="0.19999999999999973" ESTIMABLE="YES" I2="0.0" ID="CMP-027.03.05" NO="5" P_CHI2="1.0" P_Z="0.5275161729886649" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="53" WEIGHT="100.0" Z="0.6318021488538982">
<NAME>74 weeks post-injection</NAME>
<CONT_DATA CI_END="0.8204359982299728" CI_START="-0.42043599822997335" EFFECT_SIZE="0.19999999999999973" ESTIMABLE="YES" MEAN_1="3.9" MEAN_2="3.7" ORDER="150958" SD_1="1.4" SD_2="1.4" SE="0.316554795457413" STUDY_ID="STD-Karatosun-2005" TOTAL_1="31" TOTAL_2="53" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.6529566664355233" CI_END="-0.014599947409352693" CI_START="-0.4461321197650002" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.23036603358717644" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-027.04" NO="4" P_CHI2="0.6174714888421658" P_Q="0.6174714888421658" P_Z="0.036386111702475105" Q="2.6529566664355233" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="233" TOTAL_2="265" UNITS="" WEIGHT="500.0" Z="2.092586175568383">
<NAME>Pain during transfer activity</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>Exercise</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Exercise</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Hylan G-F 20</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.19916446108636476" CI_START="-0.7991644610863644" DF="0" EFFECT_SIZE="-0.2999999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-027.04.01" NO="1" P_CHI2="1.0" P_Z="0.23881782408921837" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="53" WEIGHT="100.0" Z="1.177946831555949">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="0.19916446108636476" CI_START="-0.7991644610863644" EFFECT_SIZE="-0.2999999999999998" ESTIMABLE="YES" MEAN_1="4.0" MEAN_2="4.3" ORDER="150959" SD_1="1.4" SD_2="1.2" SE="0.25468042526480594" STUDY_ID="STD-Karatosun-2005" TOTAL_1="52" TOTAL_2="53" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.2610299788002478" CI_START="-0.6610299788002482" DF="0" EFFECT_SIZE="-0.20000000000000018" ESTIMABLE="YES" I2="0.0" ID="CMP-027.04.02" NO="2" P_CHI2="1.0" P_Z="0.39518363654494804" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="53" WEIGHT="100.0" Z="0.8502544626883174">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="0.2610299788002478" CI_START="-0.6610299788002482" EFFECT_SIZE="-0.20000000000000018" ESTIMABLE="YES" MEAN_1="4.2" MEAN_2="4.4" ORDER="150960" SD_1="1.3" SD_2="1.1" SE="0.23522369922957442" STUDY_ID="STD-Karatosun-2005" TOTAL_1="52" TOTAL_2="53" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.45907577915274456" CI_START="-0.45907577915274456" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-027.04.03" NO="3" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="53" WEIGHT="100.0" Z="0.0">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="0.45907577915274456" CI_START="-0.45907577915274456" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="4.3" MEAN_2="4.3" ORDER="150961" SD_1="1.2" SD_2="1.2" SE="0.23422664027190077" STUDY_ID="STD-Karatosun-2005" TOTAL_1="52" TOTAL_2="53" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.05296426953726491" CI_START="-0.947035730462735" DF="0" EFFECT_SIZE="-0.5" ESTIMABLE="YES" I2="0.0" ID="CMP-027.04.04" NO="4" P_CHI2="1.0" P_Z="0.02836664041747503" STUDIES="1" TAU2="0.0" TOTAL_1="46" TOTAL_2="53" WEIGHT="100.0" Z="2.1921782208675564">
<NAME>45 to 52 weeks post-injection</NAME>
<CONT_DATA CI_END="-0.05296426953726491" CI_START="-0.947035730462735" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="4.1" MEAN_2="4.6" ORDER="150962" SD_1="1.3" SD_2="0.9" SE="0.22808364540822987" STUDY_ID="STD-Karatosun-2005" TOTAL_1="46" TOTAL_2="53" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.2290102131785207E-33" CI_END="0.4761191412135459" CI_START="-0.676119141213547" DF="0" EFFECT_SIZE="-0.10000000000000055" ESTIMABLE="YES" I2="100.00000000000001" ID="CMP-027.04.05" NO="5" P_CHI2="0.0" P_Z="0.7337050474817085" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="53" WEIGHT="100.0" Z="0.3402011570751782">
<NAME>74 weeks post-injection</NAME>
<CONT_DATA CI_END="0.4761191412135459" CI_START="-0.676119141213547" EFFECT_SIZE="-0.10000000000000053" ESTIMABLE="YES" MEAN_1="4.1" MEAN_2="4.2" ORDER="150963" SD_1="1.3" SD_2="1.3" SE="0.2939437386390264" STUDY_ID="STD-Karatosun-2005" TOTAL_1="31" TOTAL_2="53" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.7344281305939204" CI_END="0.8204109556879411" CI_START="0.006562700911931063" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="0.41348682829993605" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-027.05" NO="5" P_CHI2="0.44313846331189466" P_Q="0.44313846331189466" P_Z="0.04641787796672296" Q="3.7344281305939204" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="233" TOTAL_2="265" UNITS="" WEIGHT="500.0" Z="1.991573458058513">
<NAME>Walking distance</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>Exercise</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Exercise</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Hylan G-F 20</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.7862640875536782" CI_START="0.013735912446318888" DF="0" EFFECT_SIZE="0.8999999999999986" ESTIMABLE="YES" I2="0.0" ID="CMP-027.05.01" NO="1" P_CHI2="1.0" P_Z="0.04655340482909658" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="53" WEIGHT="100.0" Z="1.9903408147283246">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="1.7862640875536782" CI_START="0.013735912446318888" EFFECT_SIZE="0.8999999999999986" ESTIMABLE="YES" MEAN_1="10.2" MEAN_2="9.3" ORDER="150964" SD_1="2.0" SD_2="2.6" SE="0.45218386385893705" STUDY_ID="STD-Karatosun-2005" TOTAL_1="52" TOTAL_2="53" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.1413757796970776" CI_START="-0.341375779697077" DF="0" EFFECT_SIZE="0.40000000000000036" ESTIMABLE="YES" I2="0.0" ID="CMP-027.05.02" NO="2" P_CHI2="1.0" P_Z="0.2902953408774245" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="53" WEIGHT="100.0" Z="1.0574739764716286">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="1.1413757796970776" CI_START="-0.341375779697077" EFFECT_SIZE="0.40000000000000036" ESTIMABLE="YES" MEAN_1="10.5" MEAN_2="10.1" ORDER="150965" SD_1="1.5" SD_2="2.3" SE="0.3782598994394565" STUDY_ID="STD-Karatosun-2005" TOTAL_1="52" TOTAL_2="53" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.613746067158805" CI_START="-0.21374606715880284" DF="0" EFFECT_SIZE="0.7000000000000011" ESTIMABLE="YES" I2="0.0" ID="CMP-027.05.03" NO="3" P_CHI2="1.0" P_Z="0.13323050987015395" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="53" WEIGHT="100.0" Z="1.5014836599450978">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="1.613746067158805" CI_START="-0.21374606715880284" EFFECT_SIZE="0.7000000000000011" ESTIMABLE="YES" MEAN_1="10.4" MEAN_2="9.7" ORDER="150966" SD_1="1.9" SD_2="2.8" SE="0.4662055396764003" STUDY_ID="STD-Karatosun-2005" TOTAL_1="52" TOTAL_2="53" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.7130521005972439" CI_START="-1.3130521005972453" DF="0" EFFECT_SIZE="-0.3000000000000007" ESTIMABLE="YES" I2="0.0" ID="CMP-027.05.04" NO="4" P_CHI2="1.0" P_Z="0.5616357530789347" STUDIES="1" TAU2="0.0" TOTAL_1="46" TOTAL_2="53" WEIGHT="100.0" Z="0.5804135789416643">
<NAME>45 to 52 weeks post-injection</NAME>
<CONT_DATA CI_END="0.7130521005972439" CI_START="-1.3130521005972453" EFFECT_SIZE="-0.3000000000000007" ESTIMABLE="YES" MEAN_1="9.6" MEAN_2="9.9" ORDER="150967" SD_1="2.7" SD_2="2.4" SE="0.5168728142905024" STUDY_ID="STD-Karatosun-2005" TOTAL_1="46" TOTAL_2="53" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="5.730045268508102E-34" CI_END="1.2362903209919485" CI_START="-1.0362903209919492" DF="0" EFFECT_SIZE="0.09999999999999966" ESTIMABLE="YES" I2="100.0" ID="CMP-027.05.05" NO="5" P_CHI2="0.0" P_Z="0.8630539267814769" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="53" WEIGHT="100.0" Z="0.1724879591360996">
<NAME>74 weeks post-injection</NAME>
<CONT_DATA CI_END="1.2362903209919485" CI_START="-1.0362903209919492" EFFECT_SIZE="0.09999999999999964" ESTIMABLE="YES" MEAN_1="10.4" MEAN_2="10.3" ORDER="150968" SD_1="2.8" SD_2="2.1" SE="0.5797506127433268" STUDY_ID="STD-Karatosun-2005" TOTAL_1="31" TOTAL_2="53" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.3262626212399235" CI_END="1.5038544866584125" CI_START="-2.1923658075079633" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.34425566042477546" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-027.06" NO="6" P_CHI2="0.988056362188728" P_Q="0.988056362188728" P_Z="0.7150433527145599" Q="0.3262626212399235" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="233" TOTAL_2="265" UNITS="" WEIGHT="500.0" Z="0.36509117001035524">
<NAME>Range of motion (degrees)</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>Exercise</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Exercise</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Hylan G-F 20</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.433169310407574" CI_START="-5.033169310407568" DF="0" EFFECT_SIZE="-0.7999999999999972" ESTIMABLE="YES" I2="0.0" ID="CMP-027.06.01" NO="1" P_CHI2="1.0" P_Z="0.7110835462332175" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="53" WEIGHT="100.0" Z="0.3704012461247559">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="3.433169310407574" CI_START="-5.033169310407568" EFFECT_SIZE="-0.7999999999999972" ESTIMABLE="YES" MEAN_1="116.3" MEAN_2="117.1" ORDER="150969" SD_1="12.1" SD_2="9.9" SE="2.1598199476104" STUDY_ID="STD-Karatosun-2005" TOTAL_1="52" TOTAL_2="53" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.235881928517748" CI_START="-4.835881928517771" DF="0" EFFECT_SIZE="-0.8000000000000114" ESTIMABLE="YES" I2="0.0" ID="CMP-027.06.02" NO="2" P_CHI2="1.0" P_Z="0.6976403611106206" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="53" WEIGHT="100.0" Z="0.38850769556777587">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="3.235881928517748" CI_START="-4.835881928517771" EFFECT_SIZE="-0.8000000000000114" ESTIMABLE="YES" MEAN_1="117.1" MEAN_2="117.9" ORDER="150970" SD_1="11.8" SD_2="9.1" SE="2.0591612704887847" STUDY_ID="STD-Karatosun-2005" TOTAL_1="52" TOTAL_2="53" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.8443585771428737" CI_START="-3.8443585771428737" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-027.06.03" NO="3" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="53" WEIGHT="100.0" Z="0.0">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="3.8443585771428737" CI_START="-3.8443585771428737" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="117.8" MEAN_2="117.8" ORDER="150971" SD_1="10.9" SD_2="9.1" SE="1.9614434793020092" STUDY_ID="STD-Karatosun-2005" TOTAL_1="52" TOTAL_2="53" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.3677073501125747" CI_START="-4.567707350112563" DF="0" EFFECT_SIZE="-0.5999999999999943" ESTIMABLE="YES" I2="0.0" ID="CMP-027.06.04" NO="4" P_CHI2="1.0" P_Z="0.7669342614213759" STUDIES="1" TAU2="0.0" TOTAL_1="46" TOTAL_2="53" WEIGHT="100.0" Z="0.29638738116374874">
<NAME>45 to 52 weeks post-injection</NAME>
<CONT_DATA CI_END="3.3677073501125747" CI_START="-4.567707350112563" EFFECT_SIZE="-0.5999999999999943" ESTIMABLE="YES" MEAN_1="117.2" MEAN_2="117.8" ORDER="150972" SD_1="10.8" SD_2="9.1" SE="2.024377683166292" STUDY_ID="STD-Karatosun-2005" TOTAL_1="46" TOTAL_2="53" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="5.445829354020258" CI_START="-4.045829354020281" DF="0" EFFECT_SIZE="0.6999999999999886" ESTIMABLE="YES" I2="0.0" ID="CMP-027.06.05" NO="5" P_CHI2="1.0" P_Z="0.7725120255604999" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="53" WEIGHT="100.0" Z="0.2890906281777269">
<NAME>74 weeks post-injection</NAME>
<CONT_DATA CI_END="5.445829354020258" CI_START="-4.045829354020281" EFFECT_SIZE="0.6999999999999886" ESTIMABLE="YES" MEAN_1="118.6" MEAN_2="117.9" ORDER="150973" SD_1="11.5" SD_2="9.2" SE="2.421386000689179" STUDY_ID="STD-Karatosun-2005" TOTAL_1="31" TOTAL_2="53" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.18266902417514" CI_END="2.4844911381572183" CI_START="-1.584165412915838" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="0.45016286262069005" ESTIMABLE="YES" I2="4.367283739625175" I2_Q="4.367283739625175" ID="CMP-027.07" NO="7" P_CHI2="0.3818484405147875" P_Q="0.3818484405147875" P_Z="0.664501015323403" Q="4.18266902417514" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="233" TOTAL_2="265" UNITS="" WEIGHT="500.0" Z="0.43370728732623476">
<NAME>Hospital for Special Surgery Knee Score (100 points)</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>Exercise</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Exercise</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Hylan G-F 20</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="8.995401116690143E-33" CI_END="6.088577270967161" CI_START="-3.0885772709671606" DF="0" EFFECT_SIZE="1.4999999999999998" ESTIMABLE="YES" I2="99.99999999999999" ID="CMP-027.07.01" NO="1" P_CHI2="0.0" P_Z="0.5217113132089066" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="53" WEIGHT="100.0" Z="0.6407097022015305">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="6.088577270967161" CI_START="-3.0885772709671606" EFFECT_SIZE="1.5" ESTIMABLE="YES" MEAN_1="81.3" MEAN_2="79.8" ORDER="150974" SD_1="10.8" SD_2="13.1" SE="2.3411538717860494" STUDY_ID="STD-Karatosun-2005" TOTAL_1="52" TOTAL_2="53" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="4.860859415740579" CI_START="-3.5008594157405657" DF="0" EFFECT_SIZE="0.6800000000000068" ESTIMABLE="YES" I2="0.0" ID="CMP-027.07.02" NO="2" P_CHI2="1.0" P_Z="0.7498931381758351" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="53" WEIGHT="100.0" Z="0.3187802738521813">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="4.860859415740579" CI_START="-3.5008594157405657" EFFECT_SIZE="0.6800000000000068" ESTIMABLE="YES" MEAN_1="82.2" MEAN_2="81.52" ORDER="11" SD_1="10.0" SD_2="11.8" SE="2.1331307354209863" STUDY_ID="STD-Karatosun-2005" TOTAL_1="52" TOTAL_2="53" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="7.184356309224433" CI_START="-1.7843563092244272" DF="0" EFFECT_SIZE="2.700000000000003" ESTIMABLE="YES" I2="0.0" ID="CMP-027.07.03" NO="3" P_CHI2="1.0" P_Z="0.23796810305566307" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="53" WEIGHT="99.99999999999999" Z="1.180080794956587">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="7.184356309224433" CI_START="-1.7843563092244272" EFFECT_SIZE="2.700000000000003" ESTIMABLE="YES" MEAN_1="82.7" MEAN_2="80.0" ORDER="150976" SD_1="9.8" SD_2="13.4" SE="2.287978934611279" STUDY_ID="STD-Karatosun-2005" TOTAL_1="52" TOTAL_2="53" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.0283267770387896" CI_START="-8.948326777038805" DF="0" EFFECT_SIZE="-3.960000000000008" ESTIMABLE="YES" I2="0.0" ID="CMP-027.07.04" NO="4" P_CHI2="1.0" P_Z="0.11972616435058833" STUDIES="1" TAU2="0.0" TOTAL_1="46" TOTAL_2="53" WEIGHT="100.0" Z="1.5559240053206853">
<NAME>45 to 52 weeks post-injection</NAME>
<CONT_DATA CI_END="1.0283267770387896" CI_START="-8.948326777038805" EFFECT_SIZE="-3.960000000000008" ESTIMABLE="YES" MEAN_1="78.8" MEAN_2="82.76" ORDER="13" SD_1="12.3" SD_2="13.0" SE="2.545111449182782" STUDY_ID="STD-Karatosun-2005" TOTAL_1="46" TOTAL_2="53" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="5.111945169698881" CI_START="-4.111945169698881" DF="0" EFFECT_SIZE="0.5" ESTIMABLE="YES" I2="0.0" ID="CMP-027.07.05" NO="5" P_CHI2="1.0" P_Z="0.8317265101273397" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="53" WEIGHT="100.00000000000001" Z="0.21248778036405216">
<NAME>74 weeks post-injection</NAME>
<CONT_DATA CI_END="5.111945169698881" CI_START="-4.111945169698881" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="88.8" MEAN_2="88.3" ORDER="150978" SD_1="11.1" SD_2="9.1" SE="2.353076488179026" STUDY_ID="STD-Karatosun-2005" TOTAL_1="31" TOTAL_2="53" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="21" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-027.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="52" TOTAL_2="53" WEIGHT="0.0" Z="0.0">
<NAME>Safety: total withdrawals overall</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>Exercise</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hylan G-F 20</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Exercise</GRAPH_LABEL_2>
<DICH_DATA CI_END="704.8718515464585" CI_START="2.72309331414149" EFFECT_SIZE="43.81132075471698" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="0" LOG_CI_END="2.848110167736075" LOG_CI_START="0.43506252386745686" LOG_EFFECT_SIZE="1.6415863458017659" ORDER="150979" O_E="0.0" SE="1.4174361307869063" STUDY_ID="STD-Karatosun-2005" TOTAL_1="52" TOTAL_2="53" VAR="2.009125184860156" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-028" NO="28">
<NAME>Hylan G-F 20 versus appropriate care</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="-2.1497959260430184" CI_START="-4.17020407395698" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.1599999999999993" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-028.01" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="8.736916501754104E-10" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="127" TOTAL_2="127" UNITS="" WEIGHT="100.0" Z="6.130925771152964">
<NAME>WOMAC pain (0-20 Likert)</NAME>
<GROUP_LABEL_1>Synvisc+AC</GROUP_LABEL_1>
<GROUP_LABEL_2>Appro Care</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Synvisc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Appro Care</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-2.1497959260430184" CI_START="-4.17020407395698" DF="0" EFFECT_SIZE="-3.1599999999999993" ESTIMABLE="YES" I2="0.0" ID="CMP-028.01.01" NO="1" P_CHI2="1.0" P_Z="8.736916501754104E-10" STUDIES="1" TAU2="0.0" TOTAL_1="127" TOTAL_2="127" WEIGHT="100.0" Z="6.130925771152964">
<NAME>45 to 52 weeks post-injection</NAME>
<CONT_DATA CI_END="-2.1497959260430184" CI_START="-4.17020407395698" EFFECT_SIZE="-3.1599999999999993" ESTIMABLE="YES" MEAN_1="6.94" MEAN_2="10.1" ORDER="150980" SD_1="3.97" SD_2="4.24" SE="0.5154197127729601" STUDY_ID="STD-Raynauld-2002" TOTAL_1="127" TOTAL_2="127" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-8.987202837955756" CI_START="-16.41279716204425" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-12.700000000000003" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-028.02" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="2.024351181543377E-11" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="251" TOTAL_2="246" UNITS="" WEIGHT="100.0" Z="6.70425598740588">
<NAME>WOMAC pain (0-100 mm VAS)</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>Convent Care</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hylan G-F 20</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Convent Care</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-8.987202837955756" CI_START="-16.41279716204425" DF="0" EFFECT_SIZE="-12.700000000000003" ESTIMABLE="YES" I2="0.0" ID="CMP-028.02.01" NO="1" P_CHI2="1.0" P_Z="2.024351181543377E-11" STUDIES="1" TAU2="0.0" TOTAL_1="251" TOTAL_2="246" WEIGHT="100.0" Z="6.70425598740588">
<NAME>36 weeks post-injection</NAME>
<CONT_DATA CI_END="-8.987202837955756" CI_START="-16.41279716204425" EFFECT_SIZE="-12.700000000000003" ESTIMABLE="YES" MEAN_1="25.4" MEAN_2="38.1" ORDER="150981" SD_1="19.6" SD_2="22.5" SE="1.8943190749066392" STUDY_ID="STD-Kahan-2003a" TOTAL_1="251" TOTAL_2="246" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-8.145959822208294" CI_START="-16.054040177791702" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-12.099999999999998" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-028.03" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="2.000017759067828E-9" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="253" TOTAL_2="253" UNITS="" WEIGHT="100.0" Z="5.997805572673665">
<NAME>Pain on walking (0-100 mm VAS)</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>Convent Care</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hylan G-F 20</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Convent care</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-8.145959822208294" CI_START="-16.054040177791702" DF="0" EFFECT_SIZE="-12.099999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-028.03.01" NO="1" P_CHI2="1.0" P_Z="2.000017759067828E-9" STUDIES="1" TAU2="0.0" TOTAL_1="253" TOTAL_2="253" WEIGHT="100.0" Z="5.997805572673665">
<NAME>36 weeks post-injection</NAME>
<CONT_DATA CI_END="-8.145959822208294" CI_START="-16.054040177791702" EFFECT_SIZE="-12.099999999999998" ESTIMABLE="YES" MEAN_1="23.8" MEAN_2="35.9" ORDER="150982" SD_1="21.3" SD_2="24.0" SE="2.0174045079300784" STUDY_ID="STD-Kahan-2003a" TOTAL_1="253" TOTAL_2="253" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-6.129781669681506" CI_START="-13.090218330318486" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-9.609999999999996" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-028.04" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="6.22934574247619E-8" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="124" TOTAL_2="107" UNITS="" WEIGHT="100.0" Z="5.412089732228443">
<NAME>WOMAC function (0-68 Likert)</NAME>
<GROUP_LABEL_1>Synvisc+AC</GROUP_LABEL_1>
<GROUP_LABEL_2>Appro Care</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Synvisc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Appro Care</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-6.129781669681506" CI_START="-13.090218330318486" DF="0" EFFECT_SIZE="-9.609999999999996" ESTIMABLE="YES" I2="0.0" ID="CMP-028.04.01" NO="1" P_CHI2="1.0" P_Z="6.22934574247619E-8" STUDIES="1" TAU2="0.0" TOTAL_1="124" TOTAL_2="107" WEIGHT="100.0" Z="5.412089732228443">
<NAME>45 to 52 weeks post-injection</NAME>
<CONT_DATA CI_END="-6.129781669681506" CI_START="-13.090218330318486" EFFECT_SIZE="-9.609999999999996" ESTIMABLE="YES" MEAN_1="24.26" MEAN_2="33.87" ORDER="150983" SD_1="12.95" SD_2="13.88" SE="1.7756542251643437" STUDY_ID="STD-Raynauld-2002" TOTAL_1="124" TOTAL_2="107" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-9.382683550246181" CI_START="-17.01731644975381" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-13.199999999999996" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-028.05" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="1.2234800656946601E-11" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="251" TOTAL_2="247" UNITS="" WEIGHT="100.0" Z="6.777411549832923">
<NAME>WOMAC function (0-100 mm VAS)</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>Convent Care</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hylan G-F 20</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Convent care</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-9.382683550246181" CI_START="-17.01731644975381" DF="0" EFFECT_SIZE="-13.199999999999996" ESTIMABLE="YES" I2="0.0" ID="CMP-028.05.01" NO="1" P_CHI2="1.0" P_Z="1.2234800656946601E-11" STUDIES="1" TAU2="0.0" TOTAL_1="251" TOTAL_2="247" WEIGHT="100.0" Z="6.777411549832923">
<NAME>36 weeks post-injection</NAME>
<CONT_DATA CI_END="-9.382683550246181" CI_START="-17.01731644975381" EFFECT_SIZE="-13.199999999999996" ESTIMABLE="YES" MEAN_1="27.1" MEAN_2="40.3" ORDER="150984" SD_1="20.7" SD_2="22.7" SE="1.9476462220042403" STUDY_ID="STD-Kahan-2003a" TOTAL_1="251" TOTAL_2="247" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-1.424484911990735" CI_START="-2.9755150880092636" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.1999999999999993" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-028.06" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="2.696613079052139E-8" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="253" TOTAL_2="253" UNITS="" WEIGHT="100.0" Z="5.5600733404900655">
<NAME>Lequesne Index (0-24)</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>Convent Care</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hylan G-F 20</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Convent care</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-1.424484911990735" CI_START="-2.9755150880092636" DF="0" EFFECT_SIZE="-2.1999999999999993" ESTIMABLE="YES" I2="0.0" ID="CMP-028.06.01" NO="1" P_CHI2="1.0" P_Z="2.696613079052139E-8" STUDIES="1" TAU2="0.0" TOTAL_1="253" TOTAL_2="253" WEIGHT="100.0" Z="5.5600733404900655">
<NAME>36 weeks post-injection</NAME>
<CONT_DATA CI_END="-1.424484911990735" CI_START="-2.9755150880092636" EFFECT_SIZE="-2.1999999999999993" ESTIMABLE="YES" MEAN_1="7.5" MEAN_2="9.7" ORDER="150985" SD_1="4.4" SD_2="4.5" SE="0.395678233950434" STUDY_ID="STD-Kahan-2003a" TOTAL_1="253" TOTAL_2="253" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-9.484583270920513" CI_START="-16.915416729079492" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-13.200000000000003" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-028.07" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="3.324162581032459E-12" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="250" TOTAL_2="245" UNITS="" WEIGHT="100.0" Z="6.96329011855919">
<NAME>WOMAC total score (0-100 mm VAS)</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>Convent Care</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hylan G-F 20</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Convent care</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-9.484583270920513" CI_START="-16.915416729079492" DF="0" EFFECT_SIZE="-13.200000000000003" ESTIMABLE="YES" I2="0.0" ID="CMP-028.07.01" NO="1" P_CHI2="1.0" P_Z="3.324162581032459E-12" STUDIES="1" TAU2="0.0" TOTAL_1="250" TOTAL_2="245" WEIGHT="100.0" Z="6.96329011855919">
<NAME>36 weeks post-injection</NAME>
<CONT_DATA CI_END="-9.484583270920513" CI_START="-16.915416729079492" EFFECT_SIZE="-13.200000000000003" ESTIMABLE="YES" MEAN_1="26.5" MEAN_2="39.7" ORDER="150986" SD_1="20.0" SD_2="22.1" SE="1.895655613259337" STUDY_ID="STD-Kahan-2003a" TOTAL_1="250" TOTAL_2="245" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="93" EVENTS_2="35" I2="0.0" I2_Q="0.0" ID="CMP-028.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="127" TOTAL_2="128" WEIGHT="0.0" Z="0.0">
<NAME>Patient global assessment (number of patients improved in study knee)</NAME>
<GROUP_LABEL_1>Synvisc+AC</GROUP_LABEL_1>
<GROUP_LABEL_2>Appro Care</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Appro Care</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Synvisc+AC</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.6198397473458086" CI_START="1.9813124171687062" EFFECT_SIZE="2.6780652418447692" ESTIMABLE="YES" EVENTS_1="93" EVENTS_2="35" LOG_CI_END="0.5586893444602509" LOG_CI_START="0.29695296133089105" LOG_EFFECT_SIZE="0.42782115289557093" ORDER="150987" O_E="0.0" SE="0.1537452470661779" STUDY_ID="STD-Raynauld-2002" TOTAL_1="127" TOTAL_2="128" VAR="0.023637600995440086" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.66127180090998" CI_START="1.2514277312878952" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.441860465116279" ESTIMABLE="YES" EVENTS_1="186" EVENTS_2="129" I2="0.0" I2_Q="99.99999999999999" ID="CMP-028.09" LOG_CI_END="0.22044069324516316" LOG_CI_START="0.09740577459217147" LOG_EFFECT_SIZE="0.1589232339186673" METHOD="MH" NO="9" P_CHI2="1.0" P_Q="0.0" P_Z="4.119740751689683E-7" Q="5.899680479724334E-31" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="253" TOTAL_2="253" WEIGHT="100.0" Z="5.063340037078952">
<NAME>Patient global evaluation of effectiveness (good or satisfactory)</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>Convent care</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Convent care</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Hylan G-F20</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.66127180090998" CI_START="1.2514277312878952" DF="0" EFFECT_SIZE="1.441860465116279" ESTIMABLE="YES" EVENTS_1="186" EVENTS_2="129" I2="0.0" ID="CMP-028.09.01" LOG_CI_END="0.22044069324516316" LOG_CI_START="0.09740577459217147" LOG_EFFECT_SIZE="0.1589232339186673" NO="1" P_CHI2="1.0" P_Z="4.119740751689683E-7" STUDIES="1" TAU2="0.0" TOTAL_1="253" TOTAL_2="253" WEIGHT="100.0" Z="5.063340037078952">
<NAME>36 weeks post-injection</NAME>
<DICH_DATA CI_END="1.66127180090998" CI_START="1.2514277312878952" EFFECT_SIZE="1.441860465116279" ESTIMABLE="YES" EVENTS_1="186" EVENTS_2="129" LOG_CI_END="0.22044069324516316" LOG_CI_START="0.09740577459217147" LOG_EFFECT_SIZE="0.1589232339186673" ORDER="150988" O_E="0.0" SE="0.072271320249437" STUDY_ID="STD-Kahan-2003a" TOTAL_1="253" TOTAL_2="253" VAR="0.005223143730596682" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.426976406743608" CI_START="1.1779749078920985" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2965116279069768" ESTIMABLE="YES" EVENTS_1="223" EVENTS_2="172" I2="0.0" I2_Q="0.0" ID="CMP-028.10" LOG_CI_END="0.15441679266211256" LOG_CI_START="0.07113603961911101" LOG_EFFECT_SIZE="0.11277641614061179" METHOD="MH" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="1.1068006198897135E-7" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="253" TOTAL_2="253" WEIGHT="100.0" Z="5.3082544493076105">
<NAME>Number of responders (20% decrease in pain on walking)</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>Convent care</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Convent care</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Hylan G-F 20</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.426976406743608" CI_START="1.1779749078920985" DF="0" EFFECT_SIZE="1.2965116279069768" ESTIMABLE="YES" EVENTS_1="223" EVENTS_2="172" I2="0.0" ID="CMP-028.10.01" LOG_CI_END="0.15441679266211256" LOG_CI_START="0.07113603961911101" LOG_EFFECT_SIZE="0.11277641614061179" NO="1" P_CHI2="1.0" P_Z="1.1068006198897135E-7" STUDIES="1" TAU2="0.0" TOTAL_1="253" TOTAL_2="253" WEIGHT="100.0" Z="5.3082544493076105">
<NAME>36 weeks post-injection</NAME>
<DICH_DATA CI_END="1.426976406743608" CI_START="1.1779749078920985" EFFECT_SIZE="1.2965116279069768" ESTIMABLE="YES" EVENTS_1="223" EVENTS_2="172" LOG_CI_END="0.15441679266211256" LOG_CI_START="0.07113603961911101" LOG_EFFECT_SIZE="0.11277641614061179" ORDER="150989" O_E="0.0" SE="0.04891952658383531" STUDY_ID="STD-Kahan-2003a" TOTAL_1="253" TOTAL_2="253" VAR="0.00239312008118657" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.687115804065676" CI_START="0.22050963414236852" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.38925011826325956" ESTIMABLE="NO" EVENTS_1="16" EVENTS_2="46" I2="0.0" I2_Q="0.0" ID="CMP-028.11" LOG_CI_END="-0.16297006231692818" LOG_CI_START="-0.6565724313051414" LOG_EFFECT_SIZE="-0.40977124681103483" METHOD="MH" NO="11" P_CHI2="0.0" P_Q="0.0" P_Z="0.0011371791681505775" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="SUB" TOTAL_1="385" TOTAL_2="388" WEIGHT="0.0" Z="3.254185701320571">
<NAME>Safety: total withdrawals overall</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>Convent care</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hylan G-F 20</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours convent care</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.00147789398699" CI_START="0.274203253745588" EFFECT_SIZE="0.524031007751938" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="25" LOG_CI_END="6.413673835397371E-4" LOG_CI_START="-0.5619273960987657" LOG_EFFECT_SIZE="-0.280643014357613" ORDER="150990" O_E="0.0" SE="0.3304556764297975" STUDY_ID="STD-Kahan-2003a" TOTAL_1="258" TOTAL_2="260" VAR="0.10920095408467502" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.47070719286687845" CI_START="0.04404185295231074" EFFECT_SIZE="0.1439820022497188" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="21" LOG_CI_END="-0.3272491651976993" LOG_CI_START="-1.3561344174469911" LOG_EFFECT_SIZE="-0.8416917913223453" ORDER="150991" O_E="0.0" SE="0.6043722902353726" STUDY_ID="STD-Raynauld-2002" TOTAL_1="127" TOTAL_2="128" VAR="0.36526586520434945" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-028.12" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="12" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="253" TOTAL_2="253" WEIGHT="0.0" Z="0.0">
<NAME>Safety: wIthdrawals due to lack of effectiveness</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>Convent care</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hylan G-F 20</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours convent care</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8805497861538445" CI_START="0.14146556618058076" EFFECT_SIZE="0.35294117647058826" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="17" LOG_CI_END="-0.055246084057147" LOG_CI_START="-0.8493492579321136" LOG_EFFECT_SIZE="-0.45229767099463025" ORDER="150992" O_E="0.0" SE="0.46646013520826235" STUDY_ID="STD-Kahan-2003a" TOTAL_1="253" TOTAL_2="253" VAR="0.2175850577385104" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-028.13" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="13" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="253" TOTAL_2="253" WEIGHT="0.0" Z="0.0">
<NAME>Safety: wIthdrawals due to adverse events</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>Convent care</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hylan G-F 20</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours convent care</GRAPH_LABEL_2>
<DICH_DATA CI_END="21.91714815361037" CI_START="0.18250549624272577" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3407840433467348" LOG_CI_START="-0.7387240520187723" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="150993" O_E="0.0" SE="1.2215133489487862" STUDY_ID="STD-Kahan-2003a" TOTAL_1="253" TOTAL_2="253" VAR="1.492094861660079" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="64" EVENTS_2="73" I2="0.0" I2_Q="0.0" ID="CMP-028.14" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="14" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="124" TOTAL_2="107" WEIGHT="0.0" Z="0.0">
<NAME>Safety: number of patients reporting mild, moderate or severe side effects at month 12</NAME>
<GROUP_LABEL_1>Hylan G-F 20 +AC</GROUP_LABEL_1>
<GROUP_LABEL_2>AC</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HylanGF20+AC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours AC</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.936971290266308" CI_START="0.6108184250870106" EFFECT_SIZE="0.7565178965974371" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="73" LOG_CI_END="-0.028273716123898052" LOG_CI_START="-0.21408787110329022" LOG_EFFECT_SIZE="-0.12118079361359414" ORDER="150994" O_E="0.0" SE="0.10914815442979638" STUDY_ID="STD-Raynauld-2002" TOTAL_1="124" TOTAL_2="107" VAR="0.011913319615430679" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1880916170762927" CI_START="0.8435249818393591" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0010918837538214" ESTIMABLE="NO" EVENTS_1="162" EVENTS_2="159" I2="0.0" I2_Q="0.0" ID="CMP-028.15" LOG_CI_END="0.07484993160184983" LOG_CI_START="-0.07390205081721424" LOG_EFFECT_SIZE="4.739403923178107E-4" METHOD="MH" NO="15" P_CHI2="0.0" P_Q="0.0" P_Z="0.9900352176042604" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="SUB" TOTAL_1="385" TOTAL_2="388" WEIGHT="0.0" Z="0.012489327330708264">
<NAME>Safety: total number of patients reporting side effects from baseline</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>Appro/Convent Care</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours hylanGF20</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Appro/ConCar</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7321975995021417" CI_START="1.1060209911704428" EFFECT_SIZE="1.3841412160268982" ESTIMABLE="YES" EVENTS_1="114" EVENTS_2="83" LOG_CI_END="0.23859743241486867" LOG_CI_START="0.043763369521104295" LOG_EFFECT_SIZE="0.14118040096798648" ORDER="150995" O_E="0.0" SE="0.11444649298796286" STUDY_ID="STD-Kahan-2003a" TOTAL_1="258" TOTAL_2="260" VAR="0.013097999757243833" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.8298452813669293" CI_START="0.4882819369642073" EFFECT_SIZE="0.6365520099461252" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="76" LOG_CI_END="-0.08100287113243998" LOG_CI_START="-0.3113293412941453" LOG_EFFECT_SIZE="-0.19616610621329264" ORDER="150996" O_E="0.0" SE="0.13529490870740088" STUDY_ID="STD-Raynauld-2002" TOTAL_1="127" TOTAL_2="128" VAR="0.018304712322143937" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="24" EVENTS_2="63" I2="0.0" I2_Q="0.0" ID="CMP-028.16" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="16" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="385" TOTAL_2="388" WEIGHT="0.0" Z="0.0">
<NAME>Safety: number of patients with gastrointestinal adverse events</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>AC/CC</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours hylanGF20</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours AC/CC</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.6021913116211092" CI_START="0.14214593023886674" EFFECT_SIZE="0.29257314328582146" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="31" LOG_CI_END="-0.22026551475190348" LOG_CI_START="-0.8472655700228163" LOG_EFFECT_SIZE="-0.53376554238736" ORDER="150997" O_E="0.0" SE="0.36830293616646365" STUDY_ID="STD-Kahan-2003a" TOTAL_1="258" TOTAL_2="260" VAR="0.1356470527888382" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.8287745037949223" CI_START="0.2693138427628597" EFFECT_SIZE="0.47244094488188976" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="32" LOG_CI_END="-0.08156361791676482" LOG_CI_START="-0.5697413232278616" LOG_EFFECT_SIZE="-0.3256524705723132" ORDER="150998" O_E="0.0" SE="0.2867580006183527" STUDY_ID="STD-Raynauld-2002" TOTAL_1="127" TOTAL_2="128" VAR="0.08223015091863517" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-029" NO="29">
<NAME>Hylan G-F 20 versus gaseous oxygen</NAME>
<CONT_OUTCOME CHI2="0.7316949105661537" CI_END="14.475050033973275" CI_START="3.6334943036743015" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="9.054272168823788" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-029.01" NO="1" P_CHI2="0.8657248906417736" P_Q="0.8657248906417736" P_Z="0.0010614599502064225" Q="0.7316949105661537" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="224" TOTAL_2="212" UNITS="" WEIGHT="400.0" Z="3.273708644511781">
<NAME>Pain under load (0-100 mm VAS)</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>Oxygen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hylan G-F 20</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Oxygen</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="20.508561183956406" CI_START="-2.228561183956405" DF="0" EFFECT_SIZE="9.14" ESTIMABLE="YES" I2="0.0" ID="CMP-029.01.01" NO="1" P_CHI2="1.0" P_Z="0.11508220189426155" STUDIES="1" TAU2="0.0" TOTAL_1="56" TOTAL_2="53" WEIGHT="100.0" Z="1.5757553246031588">
<NAME>End of treatment</NAME>
<CONT_DATA CI_END="20.508561183956406" CI_START="-2.228561183956405" EFFECT_SIZE="9.14" ESTIMABLE="YES" MEAN_1="41.57" MEAN_2="32.43" ORDER="150999" SD_1="30.62" SD_2="29.93" SE="5.800392901925834" STUDY_ID="STD-Auerbach-2002" TOTAL_1="56" TOTAL_2="53" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="23.697932947531378" CI_START="1.9620670524686208" DF="0" EFFECT_SIZE="12.829999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-029.01.02" NO="2" P_CHI2="1.0" P_Z="0.020678116357330457" STUDIES="1" TAU2="0.0" TOTAL_1="56" TOTAL_2="53" WEIGHT="100.0" Z="2.3138105510083053">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="23.697932947531378" CI_START="1.9620670524686208" EFFECT_SIZE="12.829999999999998" ESTIMABLE="YES" MEAN_1="43.0" MEAN_2="30.17" ORDER="151000" SD_1="29.56" SD_2="28.33" SE="5.544965638785327" STUDY_ID="STD-Auerbach-2002" TOTAL_1="56" TOTAL_2="53" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="18.953201323323228" CI_START="-2.913201323323234" DF="0" EFFECT_SIZE="8.019999999999996" ESTIMABLE="YES" I2="0.0" ID="CMP-029.01.03" NO="3" P_CHI2="1.0" P_Z="0.15051276444731254" STUDIES="1" TAU2="0.0" TOTAL_1="56" TOTAL_2="53" WEIGHT="100.0" Z="1.4377226478468745">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="18.953201323323228" CI_START="-2.913201323323234" EFFECT_SIZE="8.019999999999996" ESTIMABLE="YES" MEAN_1="40.87" MEAN_2="32.85" ORDER="151001" SD_1="29.41" SD_2="28.82" SE="5.578266442425946" STUDY_ID="STD-Auerbach-2002" TOTAL_1="56" TOTAL_2="53" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="16.800598996007054" CI_START="-3.7605989960070634" DF="0" EFFECT_SIZE="6.519999999999996" ESTIMABLE="YES" I2="0.0" ID="CMP-029.01.04" NO="4" P_CHI2="1.0" P_Z="0.21386138302854818" STUDIES="1" TAU2="0.0" TOTAL_1="56" TOTAL_2="53" WEIGHT="100.0" Z="1.2430175697120802">
<NAME>45 to 52 weeks post-injection</NAME>
<CONT_DATA CI_END="16.800598996007054" CI_START="-3.7605989960070634" EFFECT_SIZE="6.519999999999996" ESTIMABLE="YES" MEAN_1="35.23" MEAN_2="28.71" ORDER="151002" SD_1="27.87" SD_2="26.89" SE="5.245299953008888" STUDY_ID="STD-Auerbach-2002" TOTAL_1="56" TOTAL_2="53" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.068092985614939" CI_END="7.523770698572421" CI_START="-2.2411908647642234" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="2.641289916904099" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-029.02" NO="2" P_CHI2="0.7847816289947891" P_Q="0.784781628994789" P_Z="0.2890138615249722" Q="1.0680929856149395" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="224" TOTAL_2="212" UNITS="" WEIGHT="400.0" Z="1.0602874524970327">
<NAME>Pain at rest (0-100 mm VAS)</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>Oxygen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hylan G-F 20</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Oxygen</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="10.651908216561242" CI_START="-7.831908216561249" DF="0" EFFECT_SIZE="1.4099999999999966" ESTIMABLE="YES" I2="0.0" ID="CMP-029.02.01" NO="1" P_CHI2="1.0" P_Z="0.7649219935211322" STUDIES="1" TAU2="0.0" TOTAL_1="56" TOTAL_2="53" WEIGHT="100.0" Z="0.29902365977290984">
<NAME>End of treatment</NAME>
<CONT_DATA CI_END="10.651908216561242" CI_START="-7.831908216561249" EFFECT_SIZE="1.4099999999999966" ESTIMABLE="YES" MEAN_1="18.33" MEAN_2="16.92" ORDER="151003" SD_1="24.8" SD_2="24.42" SE="4.715345939752076" STUDY_ID="STD-Auerbach-2002" TOTAL_1="56" TOTAL_2="53" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.030868504169567E-32" CI_END="16.89918861299893" CI_START="-3.0991886129989323" DF="0" EFFECT_SIZE="6.8999999999999995" ESTIMABLE="YES" I2="100.0" ID="CMP-029.02.02" NO="2" P_CHI2="0.0" P_Z="0.1762202498554519" STUDIES="1" TAU2="0.0" TOTAL_1="56" TOTAL_2="53" WEIGHT="100.0" Z="1.35248488819838">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="16.89918861299893" CI_START="-3.0991886129989332" EFFECT_SIZE="6.899999999999999" ESTIMABLE="YES" MEAN_1="21.33" MEAN_2="14.43" ORDER="151004" SD_1="29.18" SD_2="23.95" SE="5.10172058867982" STUDY_ID="STD-Auerbach-2002" TOTAL_1="56" TOTAL_2="53" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="13.962420135421167" CI_START="-8.082420135421172" DF="0" EFFECT_SIZE="2.9399999999999977" ESTIMABLE="YES" I2="0.0" ID="CMP-029.02.03" NO="3" P_CHI2="1.0" P_Z="0.6011277832048044" STUDIES="1" TAU2="0.0" TOTAL_1="56" TOTAL_2="53" WEIGHT="100.0" Z="0.5227793936134132">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="13.962420135421166" CI_START="-8.08242013542117" EFFECT_SIZE="2.9399999999999977" ESTIMABLE="YES" MEAN_1="20.38" MEAN_2="17.44" ORDER="151005" SD_1="30.8" SD_2="27.9" SE="5.623787080969146" STUDY_ID="STD-Auerbach-2002" TOTAL_1="56" TOTAL_2="53" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="9.21551504583991" CI_START="-9.03551504583991" DF="0" EFFECT_SIZE="0.08999999999999986" ESTIMABLE="YES" I2="0.0" ID="CMP-029.02.04" NO="4" P_CHI2="1.0" P_Z="0.9845778035332443" STUDIES="1" TAU2="0.0" TOTAL_1="56" TOTAL_2="53" WEIGHT="100.0" Z="0.019330060574391295">
<NAME>45 to 52 weeks post-injection</NAME>
<CONT_DATA CI_END="9.21551504583991" CI_START="-9.03551504583991" EFFECT_SIZE="0.08999999999999986" ESTIMABLE="YES" MEAN_1="14.52" MEAN_2="14.43" ORDER="151006" SD_1="24.11" SD_2="24.47" SE="4.655960577755922" STUDY_ID="STD-Auerbach-2002" TOTAL_1="56" TOTAL_2="53" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.7166850844696053" CI_END="1.8104977236297723" CI_START="0.28761788610918837" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="1.0490578048694803" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-029.03" NO="3" P_CHI2="0.8692726317858924" P_Q="0.8692726317858924" P_Z="0.006927716649743988" Q="0.7166850844696053" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="224" TOTAL_2="212" UNITS="" WEIGHT="400.0" Z="2.7002990841252608">
<NAME>WOMAC pain (0-20 Likert)</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>Oxygen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hylan G-F 20</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Oxygen</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.7487184572651833" CI_START="-0.14871845726518362" DF="0" EFFECT_SIZE="1.2999999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-029.03.01" NO="1" P_CHI2="1.0" P_Z="0.07861768259294052" STUDIES="1" TAU2="0.0" TOTAL_1="56" TOTAL_2="53" WEIGHT="100.0" Z="1.7587635244959643">
<NAME>End of treatment</NAME>
<CONT_DATA CI_END="2.7487184572651833" CI_START="-0.14871845726518362" EFFECT_SIZE="1.2999999999999998" ESTIMABLE="YES" MEAN_1="5.3" MEAN_2="4.0" ORDER="151007" SD_1="3.7" SD_2="4.0" SE="0.7391556521918208" STUDY_ID="STD-Auerbach-2002" TOTAL_1="56" TOTAL_2="53" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.902223637235825" CI_START="-0.10222363723582428" DF="0" EFFECT_SIZE="1.4000000000000004" ESTIMABLE="YES" I2="0.0" ID="CMP-029.03.02" NO="2" P_CHI2="1.0" P_Z="0.06776114709936694" STUDIES="1" TAU2="0.0" TOTAL_1="56" TOTAL_2="53" WEIGHT="100.0" Z="1.8265919336784615">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="2.902223637235825" CI_START="-0.10222363723582428" EFFECT_SIZE="1.4000000000000004" ESTIMABLE="YES" MEAN_1="5.7" MEAN_2="4.3" ORDER="151008" SD_1="4.2" SD_2="3.8" SE="0.7664547150280173" STUDY_ID="STD-Auerbach-2002" TOTAL_1="56" TOTAL_2="53" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.237959741869126" CI_START="-1.0379597418691269" DF="0" EFFECT_SIZE="0.5999999999999996" ESTIMABLE="YES" I2="0.0" ID="CMP-029.03.03" NO="3" P_CHI2="1.0" P_Z="0.4727861667998732" STUDIES="1" TAU2="0.0" TOTAL_1="56" TOTAL_2="53" WEIGHT="100.0" Z="0.7179531710480788">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="2.237959741869126" CI_START="-1.0379597418691269" EFFECT_SIZE="0.5999999999999996" ESTIMABLE="YES" MEAN_1="4.6" MEAN_2="4.0" ORDER="151009" SD_1="4.8" SD_2="3.9" SE="0.8357091022024608" STUDY_ID="STD-Auerbach-2002" TOTAL_1="56" TOTAL_2="53" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.3206859405224853" CI_START="-0.7206859405224857" DF="0" EFFECT_SIZE="0.7999999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-029.03.04" NO="4" P_CHI2="1.0" P_Z="0.302496435546454" STUDIES="1" TAU2="0.0" TOTAL_1="56" TOTAL_2="53" WEIGHT="100.0" Z="1.0310946828990284">
<NAME>45 to 52 weeks post-injection</NAME>
<CONT_DATA CI_END="2.3206859405224853" CI_START="-0.7206859405224857" EFFECT_SIZE="0.7999999999999998" ESTIMABLE="YES" MEAN_1="4.5" MEAN_2="3.7" ORDER="151010" SD_1="4.2" SD_2="3.9" SE="0.7758744306106959" STUDY_ID="STD-Auerbach-2002" TOTAL_1="56" TOTAL_2="53" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.15260835867661843" CI_END="6.175874513153055" CI_START="0.8279666496112434" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="3.501920581382149" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-029.04" NO="4" P_CHI2="0.984850788804903" P_Q="0.984850788804903" P_Z="0.0102627044310291" Q="0.15260835867661843" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="224" TOTAL_2="212" UNITS="" WEIGHT="400.0" Z="2.566849837866478">
<NAME>WOMAC physical function (0-68 Likert)</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>Oxygen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hylan G-F 20</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Oxygen</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="8.428844837158882" CI_START="-1.8288448371588846" DF="0" EFFECT_SIZE="3.299999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-029.04.01" NO="1" P_CHI2="1.0" P_Z="0.20728022588221406" STUDIES="1" TAU2="0.0" TOTAL_1="56" TOTAL_2="53" WEIGHT="100.0" Z="1.2610795128996435">
<NAME>End of treatment</NAME>
<CONT_DATA CI_END="8.42884483715888" CI_START="-1.8288448371588837" EFFECT_SIZE="3.299999999999999" ESTIMABLE="YES" MEAN_1="17.7" MEAN_2="14.4" ORDER="151011" SD_1="13.5" SD_2="13.8" SE="2.6168056543969973" STUDY_ID="STD-Auerbach-2002" TOTAL_1="56" TOTAL_2="53" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="7.894737887367887" CI_START="-2.2947378873678854" DF="0" EFFECT_SIZE="2.8000000000000007" ESTIMABLE="YES" I2="0.0" ID="CMP-029.04.02" NO="2" P_CHI2="1.0" P_Z="0.28140431112326336" STUDIES="1" TAU2="0.0" TOTAL_1="56" TOTAL_2="53" WEIGHT="100.0" Z="1.0771700680262841">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="7.894737887367886" CI_START="-2.2947378873678845" EFFECT_SIZE="2.8000000000000007" ESTIMABLE="YES" MEAN_1="16.6" MEAN_2="13.8" ORDER="151012" SD_1="13.2" SD_2="13.9" SE="2.5994038296389768" STUDY_ID="STD-Auerbach-2002" TOTAL_1="56" TOTAL_2="53" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="9.706711058914635" CI_START="-1.506711058914635" DF="0" EFFECT_SIZE="4.1" ESTIMABLE="YES" I2="0.0" ID="CMP-029.04.03" NO="3" P_CHI2="1.0" P_Z="0.1517846876452928" STUDIES="1" TAU2="0.0" TOTAL_1="56" TOTAL_2="53" WEIGHT="100.0" Z="1.4332560126916596">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="9.706711058914635" CI_START="-1.506711058914635" EFFECT_SIZE="4.1" ESTIMABLE="YES" MEAN_1="16.7" MEAN_2="12.6" ORDER="151013" SD_1="16.3" SD_2="13.5" SE="2.8606194313465227" STUDY_ID="STD-Auerbach-2002" TOTAL_1="56" TOTAL_2="53" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="9.633792101833928" CI_START="-1.6337921018339276" DF="0" EFFECT_SIZE="4.0" ESTIMABLE="YES" I2="0.0" ID="CMP-029.04.04" NO="4" P_CHI2="1.0" P_Z="0.16405050474736968" STUDIES="1" TAU2="0.0" TOTAL_1="56" TOTAL_2="53" WEIGHT="100.0" Z="1.3915770756979415">
<NAME>45 to 52 weeks post-injection</NAME>
<CONT_DATA CI_END="9.633792101833928" CI_START="-1.6337921018339276" EFFECT_SIZE="4.0" ESTIMABLE="YES" MEAN_1="15.1" MEAN_2="11.1" ORDER="151014" SD_1="15.8" SD_2="14.2" SE="2.8744365438715" STUDY_ID="STD-Auerbach-2002" TOTAL_1="56" TOTAL_2="53" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.8183789992611237" CI_END="0.8888702116510521" CI_START="0.17089805475309078" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="0.5298841332020714" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-029.05" NO="5" P_CHI2="0.6109438074637517" P_Q="0.6109438074637517" P_Z="0.0038155729651044466" Q="1.8183789992611237" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="224" TOTAL_2="212" UNITS="" WEIGHT="400.0" Z="2.8930197559259523">
<NAME>WOMAC stiffness (0-8 Likert)</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>Oxygen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hylan G-F 20</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Oxygen</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.9361346329256124" CI_START="-0.536134632925612" DF="0" EFFECT_SIZE="0.20000000000000018" ESTIMABLE="YES" I2="0.0" ID="CMP-029.05.01" NO="1" P_CHI2="1.0" P_Z="0.594378704800214" STUDIES="1" TAU2="0.0" TOTAL_1="56" TOTAL_2="53" WEIGHT="100.0" Z="0.5325015009144703">
<NAME>End of treatment</NAME>
<CONT_DATA CI_END="0.9361346329256124" CI_START="-0.536134632925612" EFFECT_SIZE="0.20000000000000018" ESTIMABLE="YES" MEAN_1="2.2" MEAN_2="2.0" ORDER="151015" SD_1="1.8" SD_2="2.1" SE="0.37558579582693774" STUDY_ID="STD-Auerbach-2002" TOTAL_1="56" TOTAL_2="53" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.1760859282050065" CI_START="-0.1760859282050069" DF="0" EFFECT_SIZE="0.4999999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-029.05.02" NO="2" P_CHI2="1.0" P_Z="0.14719988281776009" STUDIES="1" TAU2="0.0" TOTAL_1="56" TOTAL_2="53" WEIGHT="100.0" Z="1.4494932543143701">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="1.1760859282050065" CI_START="-0.1760859282050069" EFFECT_SIZE="0.4999999999999998" ESTIMABLE="YES" MEAN_1="2.3" MEAN_2="1.8" ORDER="151016" SD_1="1.8" SD_2="1.8" SE="0.3449481386075898" STUDY_ID="STD-Auerbach-2002" TOTAL_1="56" TOTAL_2="53" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.61360091529647" CI_START="0.18639908470353006" DF="0" EFFECT_SIZE="0.9000000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-029.05.03" NO="3" P_CHI2="1.0" P_Z="0.013438789452445695" STUDIES="1" TAU2="0.0" TOTAL_1="56" TOTAL_2="53" WEIGHT="100.0" Z="2.471924500479652">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="1.61360091529647" CI_START="0.18639908470353006" EFFECT_SIZE="0.9000000000000001" ESTIMABLE="YES" MEAN_1="2.6" MEAN_2="1.7" ORDER="151017" SD_1="2.0" SD_2="1.8" SE="0.36408878985800913" STUDY_ID="STD-Auerbach-2002" TOTAL_1="56" TOTAL_2="53" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.2531767820377124" CI_START="-0.253176782037712" DF="0" EFFECT_SIZE="0.5000000000000002" ESTIMABLE="YES" I2="0.0" ID="CMP-029.05.04" NO="4" P_CHI2="1.0" P_Z="0.19321346716495805" STUDIES="1" TAU2="0.0" TOTAL_1="56" TOTAL_2="53" WEIGHT="100.0" Z="1.3011314417030968">
<NAME>45 to 52 weeks post-injection</NAME>
<CONT_DATA CI_END="1.2531767820377124" CI_START="-0.253176782037712" EFFECT_SIZE="0.5000000000000002" ESTIMABLE="YES" MEAN_1="2.2" MEAN_2="1.7" ORDER="151018" SD_1="1.9" SD_2="2.1" SE="0.3842809296388477" STUDY_ID="STD-Auerbach-2002" TOTAL_1="56" TOTAL_2="53" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-029.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="56" TOTAL_2="53" WEIGHT="0.0" Z="0.0">
<NAME>Safety: total number of withdrawals</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>Oxygen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hylan G-F 20</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Oxygen</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.163967799192376" CI_START="0.24686352168563272" EFFECT_SIZE="1.4196428571428572" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.911901283077271" LOG_CI_START="-0.6075430797767314" LOG_EFFECT_SIZE="0.1521791016502699" ORDER="151019" O_E="0.0" SE="0.8925291401113403" STUDY_ID="STD-Auerbach-2002" TOTAL_1="56" TOTAL_2="53" VAR="0.7966082659478885" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-029.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="56" TOTAL_2="53" WEIGHT="0.0" Z="0.0">
<NAME>Safety: number of patients having total knee replacements</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>Oxygen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hylan G-F 20</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Oxygen</GRAPH_LABEL_2>
<DICH_DATA CI_END="26.452169503692602" CI_START="0.3047592510785017" EFFECT_SIZE="2.8392857142857144" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4224612969701906" LOG_CI_START="-0.5160431023416885" LOG_EFFECT_SIZE="0.4532090973142511" ORDER="151020" O_E="0.0" SE="1.1386870799073328" STUDY_ID="STD-Auerbach-2002" TOTAL_1="56" TOTAL_2="53" VAR="1.2966082659478886" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-030" NO="30">
<NAME>Hylan G-F 20 versus hyaluronan (Also see Artzal, BioHy (Arthrease), Hyalgan and Orthovisc versus Hylan G-F 20)</NAME>
<CONT_OUTCOME CHI2="7.371514649605946" CI_END="-0.5690212242093771" CI_START="-7.940010653317849" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.254515938763613" ESTIMABLE="YES" I2="18.605601627329907" I2_Q="0.0" ID="CMP-030.01" NO="1" P_CHI2="0.28785140528955644" P_Q="0.530276969034134" P_Z="0.02366207132152879" Q="1.2687117495506994" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="408" TOTAL_2="416" UNITS="" WEIGHT="300.0" Z="2.2625722345220822">
<NAME>Pain on weight bearing (0-100 mm VAS)</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>HA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hylan G-F 20</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours HA</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.785956914987136" CI_END="3.318632836009914" CI_START="-7.448573015141463" DF="2" EFFECT_SIZE="-2.0649700895657745" ESTIMABLE="YES" I2="0.0" ID="CMP-030.01.01" NO="1" P_CHI2="0.40943449131405807" P_Z="0.45218538869409" STUDIES="3" TAU2="0.0" TOTAL_1="162" TOTAL_2="164" WEIGHT="100.0" Z="0.7517766560149083">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="8.405787554550447" CI_START="-6.405787554550447" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="45.0" MEAN_2="44.0" ORDER="151021" SD_1="25.67" SD_2="24.4" SE="3.778532469456762" STUDY_ID="STD-Karlsson-2002c-_x0028_AvS_x0029_" TOTAL_1="86" TOTAL_2="90" WEIGHT="52.84495614609916"/>
<CONT_DATA CI_END="3.0877593671528754" CI_START="-19.087759367152877" EFFECT_SIZE="-8.0" ESTIMABLE="YES" MEAN_1="40.0" MEAN_2="48.0" ORDER="151022" SD_1="24.66" SD_2="24.98" SE="5.657124036263781" STUDY_ID="STD-Wobig-1999a-_x0028_Healon_x0029_" TOTAL_1="38" TOTAL_2="39" WEIGHT="23.57536670819481"/>
<CONT_DATA CI_END="8.086745882575094" CI_START="-14.086745882575094" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="40.0" MEAN_2="43.0" ORDER="151023" SD_1="24.66" SD_2="23.66" SE="5.656606942793812" STUDY_ID="STD-Wobig-1999b-_x0028_Artz_x0029_" TOTAL_1="38" TOTAL_2="35" WEIGHT="23.579677145706036"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="4.316845985068113" CI_END="-0.7311901353082462" CI_START="-12.458061373475235" DF="2" EFFECT_SIZE="-6.594625754391741" ESTIMABLE="YES" I2="53.66987826487298" ID="CMP-030.01.02" NO="2" P_CHI2="0.11550720668964265" P_Z="0.02749776571229937" STUDIES="3" TAU2="0.0" TOTAL_1="160" TOTAL_2="162" WEIGHT="100.00000000000001" Z="2.2043780830578">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="7.8338729581659585" CI_START="-9.833872958165959" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="41.0" MEAN_2="42.0" ORDER="151024" SD_1="31.53" SD_2="28.07" SE="4.507160860019072" STUDY_ID="STD-Karlsson-2002c-_x0028_AvS_x0029_" TOTAL_1="86" TOTAL_2="90" WEIGHT="44.055691597118845"/>
<CONT_DATA CI_END="5.086752073082991" CI_START="-17.08675207308299" EFFECT_SIZE="-6.0" ESTIMABLE="YES" MEAN_1="32.0" MEAN_2="38.0" ORDER="151025" SD_1="24.33" SD_2="24.33" SE="5.656610101274246" STUDY_ID="STD-Wobig-1999a-_x0028_Healon_x0029_" TOTAL_1="37" TOTAL_2="37" WEIGHT="27.97020506040432"/>
<CONT_DATA CI_END="-4.914020441269155" CI_START="-27.085979558730845" EFFECT_SIZE="-16.0" ESTIMABLE="YES" MEAN_1="32.0" MEAN_2="48.0" ORDER="151026" SD_1="24.33" SD_2="23.66" SE="5.656215954056114" STUDY_ID="STD-Wobig-1999b-_x0028_Artz_x0029_" TOTAL_1="37" TOTAL_2="35" WEIGHT="27.974103342476837"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="4.983747525990264" CI_START="-14.983747525990264" DF="0" EFFECT_SIZE="-5.0" ESTIMABLE="YES" I2="0.0" ID="CMP-030.01.03" NO="3" P_CHI2="1.0" P_Z="0.32630814881132686" STUDIES="1" TAU2="0.0" TOTAL_1="86" TOTAL_2="90" WEIGHT="100.0" Z="0.9815772982228185">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="4.983747525990264" CI_START="-14.983747525990264" EFFECT_SIZE="-5.0" ESTIMABLE="YES" MEAN_1="43.0" MEAN_2="48.0" ORDER="151027" SD_1="33.78" SD_2="33.78" SE="5.093842338298454" STUDY_ID="STD-Karlsson-2002c-_x0028_AvS_x0029_" TOTAL_1="86" TOTAL_2="90" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.6372737861460094" CI_END="-0.729286731889716" CI_START="-10.58768365985118" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-5.6584851958704485" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-030.02" NO="2" P_CHI2="0.6509681418144331" P_Q="0.4876704343260535" P_Z="0.02445241431050748" Q="0.4816621528907454" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="150" TOTAL_2="146" UNITS="" WEIGHT="200.0" Z="2.249945355619283">
<NAME>Pain at night (0-100 mm VAS)</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>HA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hylan G-F 20</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours HA</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.1399841955597678" CI_END="-0.7307486166104429" CI_START="-13.409065792292216" DF="1" EFFECT_SIZE="-7.069907204451329" ESTIMABLE="YES" I2="12.279485637169838" ID="CMP-030.02.01" NO="1" P_CHI2="0.28565570950664754" P_Z="0.028822959913326066" STUDIES="2" TAU2="0.0" TOTAL_1="76" TOTAL_2="74" WEIGHT="100.0" Z="2.185899485358114">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="-1.6864142028508642" CI_START="-18.313585797149138" EFFECT_SIZE="-10.0" ESTIMABLE="YES" MEAN_1="12.0" MEAN_2="22.0" ORDER="151028" SD_1="18.49" SD_2="18.73" SE="4.241703349003165" STUDY_ID="STD-Wobig-1999a-_x0028_Healon_x0029_" TOTAL_1="38" TOTAL_2="39" WEIGHT="58.14153149216184"/>
<CONT_DATA CI_END="6.798056724899627" CI_START="-12.798056724899627" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="12.0" MEAN_2="15.0" ORDER="151029" SD_1="18.49" SD_2="23.66" SE="4.999100392754891" STUDY_ID="STD-Wobig-1999b-_x0028_Artz_x0029_" TOTAL_1="38" TOTAL_2="35" WEIGHT="41.85846850783817"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.015627437695496606" CI_END="4.339209592129897" CI_START="-11.339279273607492" DF="1" EFFECT_SIZE="-3.500034840738797" ESTIMABLE="YES" I2="0.0" ID="CMP-030.02.02" NO="2" P_CHI2="0.9005158347950174" P_Z="0.3815320385319725" STUDIES="2" TAU2="0.0" TOTAL_1="74" TOTAL_2="72" WEIGHT="100.0" Z="0.8750769658005292">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="8.086752073082991" CI_START="-14.086752073082991" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="13.0" MEAN_2="16.0" ORDER="151030" SD_1="24.33" SD_2="24.33" SE="5.656610101274246" STUDY_ID="STD-Wobig-1999a-_x0028_Healon_x0029_" TOTAL_1="37" TOTAL_2="37" WEIGHT="49.996515926120274"/>
<CONT_DATA CI_END="7.085979558730845" CI_START="-15.085979558730845" EFFECT_SIZE="-4.0" ESTIMABLE="YES" MEAN_1="13.0" MEAN_2="17.0" ORDER="151031" SD_1="24.33" SD_2="23.66" SE="5.656215954056114" STUDY_ID="STD-Wobig-1999b-_x0028_Artz_x0029_" TOTAL_1="37" TOTAL_2="35" WEIGHT="50.003484073879726"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-030.02.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>14 to 26 weeks post-injection</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.200598573742263" CI_END="12.928940816151233" CI_START="-0.9288896378626665" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="6.000025589144283" ESTIMABLE="YES" I2="28.58160694638012" I2_Q="70.4180454475574" ID="CMP-030.03" NO="3" P_CHI2="0.2406021022583934" P_Q="0.06597455736281665" P_Z="0.08965669657436287" Q="3.380439241184046" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="150" TOTAL_2="146" UNITS="" WEIGHT="200.0" Z="1.697211421378777">
<NAME>Function: improvement in knee movement (0-100 mm VAS)</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>HA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Hylan G-F 20</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.010001538218452982" CI_END="9.299102853137633" CI_START="-10.299029687306106" DF="1" EFFECT_SIZE="-0.4999634170842366" ESTIMABLE="YES" I2="0.0" ID="CMP-030.03.01" NO="1" P_CHI2="0.9203382204430941" P_Z="0.9203440285987803" STUDIES="2" TAU2="0.0" TOTAL_1="76" TOTAL_2="74" WEIGHT="100.0" Z="0.1000003739183299">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="13.857465480720585" CI_START="-13.857465480720585" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="45.0" MEAN_2="45.0" ORDER="151032" SD_1="30.82" SD_2="31.22" SE="7.07026536713251" STUDY_ID="STD-Wobig-1999a-_x0028_Healon_x0029_" TOTAL_1="38" TOTAL_2="39" WEIGHT="50.00365829157634"/>
<CONT_DATA CI_END="12.858479410799212" CI_START="-14.858479410799212" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="45.0" MEAN_2="46.0" ORDER="151033" SD_1="30.82" SD_2="29.58" SE="7.070782687903007" STUDY_ID="STD-Wobig-1999b-_x0028_Artz_x0029_" TOTAL_1="38" TOTAL_2="35" WEIGHT="49.99634170842366"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.8101577943397629" CI_END="22.2986137592804" CI_START="2.7008827472874426" DF="1" EFFECT_SIZE="12.499748253283922" ESTIMABLE="YES" I2="0.0" ID="CMP-030.03.02" NO="2" P_CHI2="0.36807365968807904" P_Z="0.012412561187620635" STUDIES="2" TAU2="0.0" TOTAL_1="74" TOTAL_2="72" WEIGHT="99.99999999999999" Z="2.5001931475905637">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="21.857300885427613" CI_START="-5.857300885427611" EFFECT_SIZE="8.0" ESTIMABLE="YES" MEAN_1="62.0" MEAN_2="54.0" ORDER="151034" SD_1="30.41" SD_2="30.41" SE="7.070181388399089" STUDY_ID="STD-Wobig-1999a-_x0028_Healon_x0029_" TOTAL_1="37" TOTAL_2="37" WEIGHT="50.002797185734174"/>
<CONT_DATA CI_END="30.858076136000435" CI_START="3.1419238639995655" EFFECT_SIZE="17.0" ESTIMABLE="YES" MEAN_1="62.0" MEAN_2="45.0" ORDER="151035" SD_1="30.41" SD_2="29.58" SE="7.070576931673832" STUDY_ID="STD-Wobig-1999b-_x0028_Artz_x0029_" TOTAL_1="37" TOTAL_2="35" WEIGHT="49.99720281426581"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.1755374614650504" CI_END="12.678700490863147" CI_START="-1.1791299631507508" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="5.749785263856198" ESTIMABLE="YES" I2="5.527803201668587" I2_Q="11.123187326903262" ID="CMP-030.04" NO="4" P_CHI2="0.3653448643815683" P_Q="0.2888116473406106" P_Z="0.10385893596175423" Q="1.1251528603733365" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="150" TOTAL_2="146" UNITS="" WEIGHT="200.0" Z="1.6264266002378642">
<NAME>Patient global evaluation of treatment efficacy (improvement: 0-100 mm VAS)</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>HA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Hylan G-F 20</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.36005537586430736" CI_END="11.79884677272729" CI_START="-7.79928576771645" DF="1" EFFECT_SIZE="1.9997805025054196" ESTIMABLE="YES" I2="0.0" ID="CMP-030.04.01" NO="1" P_CHI2="0.5484757221686105" P_Z="0.6891661948973081" STUDIES="2" TAU2="0.0" TOTAL_1="76" TOTAL_2="74" WEIGHT="100.0" Z="0.399986861381568">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="12.857465480720585" CI_START="-14.857465480720585" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="53.0" MEAN_2="54.0" ORDER="151036" SD_1="30.82" SD_2="31.22" SE="7.07026536713251" STUDY_ID="STD-Wobig-1999a-_x0028_Healon_x0029_" TOTAL_1="38" TOTAL_2="39" WEIGHT="50.00365829157634"/>
<CONT_DATA CI_END="18.858479410799212" CI_START="-8.858479410799212" EFFECT_SIZE="5.0" ESTIMABLE="YES" MEAN_1="53.0" MEAN_2="48.0" ORDER="151037" SD_1="30.82" SD_2="29.58" SE="7.070782687903007" STUDY_ID="STD-Wobig-1999b-_x0028_Artz_x0029_" TOTAL_1="38" TOTAL_2="35" WEIGHT="49.99634170842366"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.6903292252274067" CI_END="19.298501871851037" CI_START="-0.29922914014192337" DF="1" EFFECT_SIZE="9.499636365854556" ESTIMABLE="YES" I2="40.83992721208107" ID="CMP-030.04.02" NO="2" P_CHI2="0.1935576590444481" P_Z="0.057418380288174045" STUDIES="2" TAU2="0.0" TOTAL_1="74" TOTAL_2="72" WEIGHT="99.99999999999999" Z="1.9001123274840246">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="16.857300885427613" CI_START="-10.85730088542761" EFFECT_SIZE="3.0" ESTIMABLE="YES" MEAN_1="67.0" MEAN_2="64.0" ORDER="151038" SD_1="30.41" SD_2="30.41" SE="7.070181388399089" STUDY_ID="STD-Wobig-1999a-_x0028_Healon_x0029_" TOTAL_1="37" TOTAL_2="37" WEIGHT="50.002797185734174"/>
<CONT_DATA CI_END="29.858076136000435" CI_START="2.1419238639995655" EFFECT_SIZE="16.0" ESTIMABLE="YES" MEAN_1="67.0" MEAN_2="51.0" ORDER="151039" SD_1="30.41" SD_2="29.58" SE="7.070576931673832" STUDY_ID="STD-Wobig-1999b-_x0028_Artz_x0029_" TOTAL_1="37" TOTAL_2="35" WEIGHT="49.99720281426581"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.7469489464372177" CI_END="5.552651449554343" CI_START="0.17243144779065395" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.978494623655914" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-030.05" LOG_CI_END="0.7445004128411752" LOG_CI_START="-0.7633835253068583" LOG_EFFECT_SIZE="-0.009441556232841508" METHOD="MH" NO="5" P_CHI2="0.38744396671331693" P_Q="1.0" P_Z="0.9804183080821852" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="74" TOTAL_2="72" WEIGHT="99.99999999999999" Z="0.024544475481457544">
<NAME>Safety: total withdrawals overall</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>HA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hylan G-F 20</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours HA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.7469489464372177" CI_END="5.552651449554343" CI_START="0.17243144779065395" DF="1" EFFECT_SIZE="0.978494623655914" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-030.05.01" LOG_CI_END="0.7445004128411752" LOG_CI_START="-0.7633835253068583" LOG_EFFECT_SIZE="-0.009441556232841508" NO="1" P_CHI2="0.38744396671331693" P_Z="0.9804183080821852" STUDIES="2" TAU2="0.0" TOTAL_1="74" TOTAL_2="72" WEIGHT="99.99999999999999" Z="0.024544475481457544">
<NAME>5 to 13 weeks post-injection</NAME>
<DICH_DATA CI_END="5.2785971193237735" CI_START="0.04736106854694505" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.722518516418179" LOG_CI_START="-1.3245785077461414" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="151040" O_E="0.0" SE="1.202474925287819" STUDY_ID="STD-Wobig-1999a-_x0028_Healon_x0029_" TOTAL_1="37" TOTAL_2="37" VAR="1.445945945945946" WEIGHT="79.56989247311827"/>
<DICH_DATA CI_END="67.52677800793181" CI_START="0.11962013537682785" EFFECT_SIZE="2.8421052631578947" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8294760281629698" LOG_CI_START="-0.9221957104226909" LOG_EFFECT_SIZE="0.45364015887013953" ORDER="151041" O_E="0.0" SE="1.6163456002399996" STUDY_ID="STD-Wobig-1999b-_x0028_Artz_x0029_" TOTAL_1="37" TOTAL_2="35" VAR="2.6125730994152048" WEIGHT="20.430107526881716"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.2531285073315037" CI_END="17.859230557102176" CI_START="0.4738619556031165" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="2.9090909090909096" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-030.06" LOG_CI_END="1.2518627439140562" LOG_CI_START="-0.32434815759069424" LOG_EFFECT_SIZE="0.463757293161681" METHOD="MH" NO="6" P_CHI2="0.6148807994332308" P_Q="1.0" P_Z="0.24877397455647288" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="74" TOTAL_2="72" WEIGHT="100.0" Z="1.1533324522713801">
<NAME>Safety: number of patients with local reactions</NAME>
<GROUP_LABEL_1>Hylan G-F 20</GROUP_LABEL_1>
<GROUP_LABEL_2>HA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hylan G-F 20</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours HA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.2531285073315037" CI_END="17.859230557102176" CI_START="0.4738619556031165" DF="1" EFFECT_SIZE="2.9090909090909096" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" I2="0.0" ID="CMP-030.06.01" LOG_CI_END="1.2518627439140562" LOG_CI_START="-0.32434815759069424" LOG_EFFECT_SIZE="0.463757293161681" NO="1" P_CHI2="0.6148807994332308" P_Z="0.24877397455647288" STUDIES="2" TAU2="0.0" TOTAL_1="74" TOTAL_2="72" WEIGHT="100.0" Z="1.1533324522713801">
<NAME>5 to 13 weeks post-injection</NAME>
<DICH_DATA CI_END="19.947940337978004" CI_START="0.1794297992656363" EFFECT_SIZE="1.8918918918918919" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2998980606228403" LOG_CI_START="-0.7461054287283166" LOG_EFFECT_SIZE="0.27689631594726183" ORDER="151042" O_E="0.0" SE="1.2018325775254823" STUDY_ID="STD-Wobig-1999b-_x0028_Artz_x0029_" TOTAL_1="37" TOTAL_2="35" VAR="1.4444015444015446" WEIGHT="67.27272727272727"/>
<DICH_DATA CI_END="100.71785029996066" CI_START="0.24821816515686448" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.003106447711124" LOG_CI_START="-0.6051664390390866" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="151043" O_E="0.0" SE="1.5321124048360917" STUDY_ID="STD-Wobig-1999c-_x0028_NEhyl_x0029_" TOTAL_1="37" TOTAL_2="37" VAR="2.3473684210526318" WEIGHT="32.72727272727273"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-031" NO="31">
<NAME>NRD-101 (Suvenyl) versus placebo (saline plus oral placebo)</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-031.01" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="131" TOTAL_2="43" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Pain (0-100 mm VAS) change between baseline and 45 to 52 weeks post-injection</NAME>
<GROUP_LABEL_1>NRD-101</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline+oral placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours NRD-101</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours saline+PL po</GRAPH_LABEL_2>
<CONT_DATA CI_END="10.533551026676623" CI_START="-8.533551026676623" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="-33.5" MEAN_2="-34.5" ORDER="151044" SD_1="28.5" SD_2="27.4" SE="4.864146026088263" STUDY_ID="STD-Pham-2004" TOTAL_1="131" TOTAL_2="43" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-031.02" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="131" TOTAL_2="43" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Lequesne Index (0-100 modified scale) change between baseline and 45 to 52 weeks post-injection</NAME>
<GROUP_LABEL_1>NRD-101</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline+oral placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours NRD-101</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours saline+PL po</GRAPH_LABEL_2>
<CONT_DATA CI_END="4.687816223160482" CI_START="-6.887816223160485" EFFECT_SIZE="-1.1000000000000014" ESTIMABLE="YES" MEAN_1="-20.0" MEAN_2="-18.9" ORDER="151045" SD_1="16.5" SD_2="16.9" SE="2.953021723263304" STUDY_ID="STD-Pham-2004" TOTAL_1="131" TOTAL_2="43" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-031.03" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="131" TOTAL_2="43" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Patient global assessment (0-100 mm VAS) change between baseline and 45 to 52 weeks post-injection</NAME>
<GROUP_LABEL_1>NRD-101</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline+oral placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours NRD-101</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours saline+PL po</GRAPH_LABEL_2>
<CONT_DATA CI_END="11.935289622039665" CI_START="-9.13528962203966" EFFECT_SIZE="1.4000000000000021" ESTIMABLE="YES" MEAN_1="-29.7" MEAN_2="-31.1" ORDER="151046" SD_1="26.9" SD_2="31.7" SE="5.375246537763287" STUDY_ID="STD-Pham-2004" TOTAL_1="131" TOTAL_2="43" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-031.04" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="131" TOTAL_2="43" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Percentage of painful days (0-100 mm VAS) change between baseline and 45 to 52 weeks post-injection</NAME>
<GROUP_LABEL_1>NRD-101</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline+oral placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours NRD-101</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours saline+PL po</GRAPH_LABEL_2>
<CONT_DATA CI_END="16.186331700543004" CI_START="-9.986331700543001" EFFECT_SIZE="3.1000000000000014" ESTIMABLE="YES" MEAN_1="-43.5" MEAN_2="-46.6" ORDER="151047" SD_1="40.3" SD_2="37.2" SE="6.67682253539673" STUDY_ID="STD-Pham-2004" TOTAL_1="131" TOTAL_2="43" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="86" EVENTS_2="57" I2="0.0" I2_Q="0.0" ID="CMP-031.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="120" TOTAL_2="75" WEIGHT="0.0" Z="0.0">
<NAME>Patient assessment of treatment efficacy (no. of patients rating very good or good versus mod, bad or very bad</NAME>
<GROUP_LABEL_1>NRD-101</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline+oral placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours NRD-101</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours saline+PL po</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1174931971081041" CI_START="0.7957237814866697" EFFECT_SIZE="0.9429824561403509" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="57" LOG_CI_END="0.04824488798526789" LOG_CI_START="-0.09923766215496473" LOG_EFFECT_SIZE="-0.025496387084848436" ORDER="151048" O_E="0.0" SE="0.08663198000276992" STUDY_ID="STD-Pham-2004" TOTAL_1="120" TOTAL_2="75" VAR="0.007505099959200326" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="23" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-031.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="131" TOTAL_2="85" WEIGHT="0.0" Z="0.0">
<NAME>Joint space width (percentage of progressors: joint space narrowing greater than 0.5 mm)</NAME>
<GROUP_LABEL_1>NRD 101</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline+oral placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours NRD-101</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours saline+PL po</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5435216545717139" CI_START="0.4992756234774714" EFFECT_SIZE="0.8778625954198473" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="17" LOG_CI_END="0.18851272672063044" LOG_CI_START="-0.3016596373249355" LOG_EFFECT_SIZE="-0.05657345530215257" ORDER="151049" O_E="0.0" SE="0.28792967303269984" STUDY_ID="STD-Pham-2003" TOTAL_1="131" TOTAL_2="85" VAR="0.08290349661271744" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="9" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-031.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="131" TOTAL_2="85" WEIGHT="0.0" Z="0.0">
<NAME>Safety: total withdrawals overall</NAME>
<GROUP_LABEL_1>NRD-101</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline+oral placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours NRD-101</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours saline+PL po</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.3663392199490616" CI_START="0.40521208889384525" EFFECT_SIZE="1.16793893129771" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="5" LOG_CI_END="0.5271578769188086" LOG_CI_START="-0.3923176065951394" LOG_EFFECT_SIZE="0.06742013516183457" ORDER="151050" O_E="0.0" SE="0.5401044504931417" STUDY_ID="STD-Pham-2004" TOTAL_1="131" TOTAL_2="85" VAR="0.2917128174424986" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-031.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="131" TOTAL_2="85" WEIGHT="0.0" Z="0.0">
<NAME>Safety: withdrawals due to inefficacy</NAME>
<GROUP_LABEL_1>NRD-101</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline+oral placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours NRD-101</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours saline+PL po</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.5225688110283735" CI_START="0.029879669076725263" EFFECT_SIZE="0.3244274809160305" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.5468594855168178" LOG_CI_START="-1.5246242167277233" LOG_EFFECT_SIZE="-0.48888236560545273" ORDER="151051" O_E="0.0" SE="1.216799780708144" STUDY_ID="STD-Pham-2004" TOTAL_1="131" TOTAL_2="85" VAR="1.4806017063313877" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-031.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="131" TOTAL_2="85" WEIGHT="0.0" Z="0.0">
<NAME>Safety: number of withdrawals due to adverse events</NAME>
<GROUP_LABEL_1>NRD-101</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline+oral placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours NRD-101</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours saline+PL po</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.930175105174711" CI_START="0.24300266882417923" EFFECT_SIZE="1.297709923664122" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.8407442080967096" LOG_CI_START="-0.6143889566516902" LOG_EFFECT_SIZE="0.11317762572250965" ORDER="151052" O_E="0.0" SE="0.8547524239985445" STUDY_ID="STD-Pham-2004" TOTAL_1="131" TOTAL_2="85" VAR="0.7306017063313875" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="31" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-031.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="131" TOTAL_2="85" WEIGHT="0.0" Z="0.0">
<NAME>Safety: number of patients reporting knee pain during or after IA injection</NAME>
<GROUP_LABEL_1>NRD-101</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline+oral placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours NRD-101</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours saline+PL po</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.153073848843368" CI_START="0.734040050484762" EFFECT_SIZE="1.2571564885496183" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="16" LOG_CI_END="0.33305892605903664" LOG_CI_START="-0.1342802435852839" LOG_EFFECT_SIZE="0.09938934123687634" ORDER="151053" O_E="0.0" SE="0.2745173416152731" STUDY_ID="STD-Pham-2004" TOTAL_1="131" TOTAL_2="85" VAR="0.07535977084751655" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="12" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-031.11" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="11" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="131" TOTAL_2="85" WEIGHT="0.0" Z="0.0">
<NAME>Safety: number of patients reporting diarrhoea</NAME>
<GROUP_LABEL_1>NRD-101</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline+oral placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours NRD-101</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours saline+PL po</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.712125004480768" CI_START="0.45619652151655976" EFFECT_SIZE="1.1123227917121048" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" LOG_CI_END="0.4333097027116484" LOG_CI_START="-0.3408480305278554" LOG_EFFECT_SIZE="0.04623083609189651" ORDER="151054" O_E="0.0" SE="0.4547440846474681" STUDY_ID="STD-Pham-2004" TOTAL_1="131" TOTAL_2="85" VAR="0.20679218252186365" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-032" NO="32">
<NAME>NRD-101 (Suvenyl) versus Diacerein</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-032.01" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="131" TOTAL_2="85" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Pain (0-100 mm VAS) change between baseline and 45 to 52 weeks post-injection</NAME>
<GROUP_LABEL_1>NRD-101</GROUP_LABEL_1>
<GROUP_LABEL_2>Diacerein</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours NRD-101</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Diacerein</GRAPH_LABEL_2>
<CONT_DATA CI_END="7.725875625212392" CI_START="-6.925875625212395" EFFECT_SIZE="0.3999999999999986" ESTIMABLE="YES" MEAN_1="-33.5" MEAN_2="-33.9" ORDER="151055" SD_1="28.5" SD_2="25.7" SE="3.7377603277396756" STUDY_ID="STD-Pham-2004" TOTAL_1="131" TOTAL_2="85" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-032.02" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="131" TOTAL_2="85" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Lequesne Index (0-100 modified scale) change between baseline and 45 to 52 weeks post-injection</NAME>
<GROUP_LABEL_1>NRD-101</GROUP_LABEL_1>
<GROUP_LABEL_2>Diacerein</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours NRD-101</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Diacerein</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.0130015423556262" CI_START="-5.413001542355625" EFFECT_SIZE="-1.1999999999999993" ESTIMABLE="YES" MEAN_1="-20.0" MEAN_2="-18.8" ORDER="151056" SD_1="16.5" SD_2="14.7" SE="2.1495300809541624" STUDY_ID="STD-Pham-2004" TOTAL_1="131" TOTAL_2="85" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-032.03" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="131" TOTAL_2="85" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Patient global assessment (0-100 mm VAS) change between baseline and 45 to 52 weeks post-injection</NAME>
<GROUP_LABEL_1>NRD-101</GROUP_LABEL_1>
<GROUP_LABEL_2>Diacerein</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours NRD-101</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Diacerein</GRAPH_LABEL_2>
<CONT_DATA CI_END="9.97391840364857" CI_START="-3.7739184036485742" EFFECT_SIZE="3.099999999999998" ESTIMABLE="YES" MEAN_1="-29.7" MEAN_2="-32.8" ORDER="151057" SD_1="26.9" SD_2="24.0" SE="3.5071656713435364" STUDY_ID="STD-Pham-2004" TOTAL_1="131" TOTAL_2="85" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-032.04" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="131" TOTAL_2="85" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Percentage of painful days (0-100 mm VAS) change between baseline and 45 to 52 weeks post-injection</NAME>
<GROUP_LABEL_1>NRD-101</GROUP_LABEL_1>
<GROUP_LABEL_2>Diacerein</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours NRD-101</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Diacerein</GRAPH_LABEL_2>
<CONT_DATA CI_END="12.69242511142145" CI_START="-8.492425111421447" EFFECT_SIZE="2.1000000000000014" ESTIMABLE="YES" MEAN_1="-43.5" MEAN_2="-45.6" ORDER="151058" SD_1="40.3" SD_2="37.8" SE="5.404397833313849" STUDY_ID="STD-Pham-2004" TOTAL_1="131" TOTAL_2="85" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="86" EVENTS_2="49" I2="0.0" I2_Q="0.0" ID="CMP-032.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="120" TOTAL_2="75" WEIGHT="0.0" Z="0.0">
<NAME>Patient assessment of treatment efficacy (no. of patients rating very good or good versus mod, bad or very bad</NAME>
<GROUP_LABEL_1>NRD-101</GROUP_LABEL_1>
<GROUP_LABEL_2>Diacerein</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours NRD-101</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Diacerein</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3392463463207969" CI_START="0.8984715026652751" EFFECT_SIZE="1.096938775510204" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="49" LOG_CI_END="0.1268604702213905" LOG_CI_START="-0.046495693103131994" LOG_EFFECT_SIZE="0.040182388559129256" ORDER="151059" O_E="0.0" SE="0.10183026846367264" STUDY_ID="STD-Pham-2004" TOTAL_1="120" TOTAL_2="75" VAR="0.010369403575383645" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="23" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-032.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="131" TOTAL_2="85" WEIGHT="0.0" Z="0.0">
<NAME>Joint space width (percentage progressors: joint space narrowing greater than 0.5 mm)</NAME>
<GROUP_LABEL_1>NRD 101</GROUP_LABEL_1>
<GROUP_LABEL_2>Diacerein</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours NRD-101</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Diacerein</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6604165765741847" CI_START="0.5239549002070975" EFFECT_SIZE="0.9327290076335878" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="16" LOG_CI_END="0.22021706045615747" LOG_CI_START="-0.2807060936157644" LOG_EFFECT_SIZE="-0.030244516579803427" ORDER="151060" O_E="0.0" SE="0.29424474031145015" STUDY_ID="STD-Pham-2003" TOTAL_1="131" TOTAL_2="85" VAR="0.08657996720095273" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="9" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-032.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="131" TOTAL_2="85" WEIGHT="0.0" Z="0.0">
<NAME>Safety: total withdrawals overall</NAME>
<GROUP_LABEL_1>NRD-101</GROUP_LABEL_1>
<GROUP_LABEL_2>Diacerein</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours NRD-101</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Diacerein</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.3663392199490616" CI_START="0.40521208889384525" EFFECT_SIZE="1.16793893129771" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="5" LOG_CI_END="0.5271578769188086" LOG_CI_START="-0.3923176065951394" LOG_EFFECT_SIZE="0.06742013516183457" ORDER="151061" O_E="0.0" SE="0.5401044504931417" STUDY_ID="STD-Pham-2004" TOTAL_1="131" TOTAL_2="85" VAR="0.2917128174424986" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-032.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="131" TOTAL_2="85" WEIGHT="0.0" Z="0.0">
<NAME>Safety: withdrawals due to inefficacy</NAME>
<GROUP_LABEL_1>NRD-101</GROUP_LABEL_1>
<GROUP_LABEL_2>Diacerein</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours NRD-101</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Diacerein</GRAPH_LABEL_2>
<DICH_DATA CI_END="10.234729031590598" CI_START="0.04113570180456992" EFFECT_SIZE="0.648854961832061" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.0100763490363582" LOG_CI_START="-1.3857810889193012" LOG_EFFECT_SIZE="-0.18785236994147156" ORDER="151062" O_E="0.0" SE="1.4073385187407426" STUDY_ID="STD-Pham-2004" TOTAL_1="131" TOTAL_2="85" VAR="1.9806017063313877" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-032.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="131" TOTAL_2="85" WEIGHT="0.0" Z="0.0">
<NAME>Safety: number of withdrawlals due to adverse events</NAME>
<GROUP_LABEL_1>NRD-101</GROUP_LABEL_1>
<GROUP_LABEL_2>Diacerein</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours NRD-101</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Diacerein</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.930175105174711" CI_START="0.24300266882417923" EFFECT_SIZE="1.297709923664122" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.8407442080967096" LOG_CI_START="-0.6143889566516902" LOG_EFFECT_SIZE="0.11317762572250965" ORDER="151063" O_E="0.0" SE="0.8547524239985445" STUDY_ID="STD-Pham-2004" TOTAL_1="131" TOTAL_2="85" VAR="0.7306017063313875" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="31" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-032.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="131" TOTAL_2="85" WEIGHT="0.0" Z="0.0">
<NAME>Safety: number of patients reporting knee pain during or after IA injection</NAME>
<GROUP_LABEL_1>NRD-101</GROUP_LABEL_1>
<GROUP_LABEL_2>Diacerein</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours NRD-101</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Diacerein</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.205542272081649" CI_START="1.214430585015998" EFFECT_SIZE="2.5143129770992365" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="8" LOG_CI_END="0.7164659775556353" LOG_CI_START="0.08437269624607968" LOG_EFFECT_SIZE="0.40041933690085757" ORDER="151064" O_E="0.0" SE="0.3712947223534379" STUDY_ID="STD-Pham-2004" TOTAL_1="131" TOTAL_2="85" VAR="0.13785977084751655" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="12" EVENTS_2="35" I2="0.0" I2_Q="0.0" ID="CMP-032.11" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="11" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="131" TOTAL_2="85" WEIGHT="0.0" Z="0.0">
<NAME>Safety: number of patients reporting diarrhoea</NAME>
<GROUP_LABEL_1>NRD-101</GROUP_LABEL_1>
<GROUP_LABEL_2>Diacerein</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours NRD-101</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Diacerein</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.40378736542464577" CI_START="0.12256569659241665" EFFECT_SIZE="0.22246455834242093" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="35" LOG_CI_END="-0.3938472743279991" LOG_CI_START="-0.9116310621602456" LOG_EFFECT_SIZE="-0.6527391682441224" ORDER="151065" O_E="0.0" SE="0.304148760043748" STUDY_ID="STD-Pham-2004" TOTAL_1="131" TOTAL_2="85" VAR="0.09250646823614941" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-033" NO="33">
<NAME>NRD-101 (Suvenyl) versus Artz (end of treatment)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="48" EVENTS_2="43" I2="0.0" I2_Q="0.0" ID="CMP-033.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="67" TOTAL_2="70" WEIGHT="0.0" Z="0.0">
<NAME>Spontaneous pain (number of patients improved)</NAME>
<GROUP_LABEL_1>NRD-101</GROUP_LABEL_1>
<GROUP_LABEL_2>Artz</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Artz</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NRD-101</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.48122789750966" CI_START="0.9182694907520574" EFFECT_SIZE="1.166261714682402" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="43" LOG_CI_END="0.17062188297530487" LOG_CI_START="-0.037029844756442734" LOG_EFFECT_SIZE="0.06679601910943107" ORDER="151066" O_E="0.0" SE="0.12197565276225848" STUDY_ID="STD-Yamamoto-1994" TOTAL_1="67" TOTAL_2="70" VAR="0.014878059866779056" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="39" EVENTS_2="39" I2="0.0" I2_Q="0.0" ID="CMP-033.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="54" TOTAL_2="53" WEIGHT="0.0" Z="0.0">
<NAME>Pain during the night (number of patients improved)</NAME>
<GROUP_LABEL_1>NRD-101</GROUP_LABEL_1>
<GROUP_LABEL_2>Artz</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Artz</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NRD-101</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2365777748138522" CI_START="0.7790095520971938" EFFECT_SIZE="0.9814814814814815" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="39" LOG_CI_END="0.09222143659723821" LOG_CI_START="-0.10845721704159716" LOG_EFFECT_SIZE="-0.00811789022217945" ORDER="151067" O_E="0.0" SE="0.11787963452280838" STUDY_ID="STD-Yamamoto-1994" TOTAL_1="54" TOTAL_2="53" VAR="0.013895608235230877" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="60" EVENTS_2="48" I2="0.0" I2_Q="0.0" ID="CMP-033.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="94" TOTAL_2="84" WEIGHT="0.0" Z="0.0">
<NAME>Pressure pain (number of patients improved)</NAME>
<GROUP_LABEL_1>NRD-101</GROUP_LABEL_1>
<GROUP_LABEL_2>Artz</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Artz</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NRD-101</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.419587534048674" CI_START="0.8789430045282471" EFFECT_SIZE="1.1170212765957446" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="48" LOG_CI_END="0.15216217698321707" LOG_CI_START="-0.056039286042738314" LOG_EFFECT_SIZE="0.04806144547023937" ORDER="151068" O_E="0.0" SE="0.1222985699953097" STUDY_ID="STD-Yamamoto-1994" TOTAL_1="94" TOTAL_2="84" VAR="0.014956940222897668" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="31" EVENTS_2="57" I2="0.0" I2_Q="0.0" ID="CMP-033.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="53" TOTAL_2="86" WEIGHT="0.0" Z="0.0">
<NAME>Passive movement pain (number of patients improved)</NAME>
<GROUP_LABEL_1>NRD-101</GROUP_LABEL_1>
<GROUP_LABEL_2>Artz</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Artz</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NRD-101</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.158726077676897" CI_START="0.6721064427575495" EFFECT_SIZE="0.8824892419728567" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="57" LOG_CI_END="0.06398078107690046" LOG_CI_START="-0.17256194146778048" LOG_EFFECT_SIZE="-0.054290580195440016" ORDER="151069" O_E="0.0" SE="0.1389463661281063" STUDY_ID="STD-Yamamoto-1994" TOTAL_1="53" TOTAL_2="86" VAR="0.019306092660205765" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-033.05" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="95" TOTAL_2="86" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Passive flexion (degrees)</NAME>
<GROUP_LABEL_1>NRD-101</GROUP_LABEL_1>
<GROUP_LABEL_2>Artz</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Artz</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NRD-101</GRAPH_LABEL_2>
<CONT_DATA CI_END="4.734664781207924" CI_START="-2.7346647812079232" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="137.1" MEAN_2="136.1" ORDER="151070" SD_1="11.6" SD_2="13.8" SE="1.9054762284748508" STUDY_ID="STD-Yamamoto-1994" TOTAL_1="95" TOTAL_2="86" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-033.06" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="95" TOTAL_2="86" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Passive extension (degrees)</NAME>
<GROUP_LABEL_1>NRD-101</GROUP_LABEL_1>
<GROUP_LABEL_2>Artz</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Artz</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NRD-101</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.3926867690933424" CI_START="-1.7926867690933428" EFFECT_SIZE="-0.20000000000000018" ESTIMABLE="YES" MEAN_1="4.0" MEAN_2="4.2" ORDER="151071" SD_1="5.3" SD_2="5.6" SE="0.8126102222572723" STUDY_ID="STD-Yamamoto-1994" TOTAL_1="95" TOTAL_2="86" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="50" EVENTS_2="43" I2="0.0" I2_Q="0.0" ID="CMP-033.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="81" TOTAL_2="72" WEIGHT="0.0" Z="0.0">
<NAME>Patient global assessment</NAME>
<GROUP_LABEL_1>NRD-101</GROUP_LABEL_1>
<GROUP_LABEL_2>Artz</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours NRD-101</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Artz</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3347547011483263" CI_START="0.8003806737093031" EFFECT_SIZE="1.0335917312661498" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="43" LOG_CI_END="0.1254014591640961" LOG_CI_START="-0.09670340654599412" LOG_EFFECT_SIZE="0.014349026309050952" ORDER="151072" O_E="0.0" SE="0.13046549755492373" STUDY_ID="STD-Yamamoto-1994" TOTAL_1="81" TOTAL_2="72" VAR="0.01702124605225381" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-033.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="100" TOTAL_2="101" WEIGHT="0.0" Z="0.0">
<NAME>Safety: total withdrawals overall</NAME>
<GROUP_LABEL_1>NRD-101</GROUP_LABEL_1>
<GROUP_LABEL_2>Artz</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours NRD-101</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Artz</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9991386046947534" CI_START="0.16335671470712926" EFFECT_SIZE="0.404" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="15" LOG_CI_END="-3.742604440525115E-4" LOG_CI_START="-0.7868630093347375" LOG_EFFECT_SIZE="-0.393618634889395" ORDER="151073" O_E="0.0" SE="0.4619873842804838" STUDY_ID="STD-Yamamoto-1994" TOTAL_1="100" TOTAL_2="101" VAR="0.21343234323432342" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-033.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="100" TOTAL_2="99" WEIGHT="0.0" Z="0.0">
<NAME>Safety: number of adverse events</NAME>
<GROUP_LABEL_1>NRD-101</GROUP_LABEL_1>
<GROUP_LABEL_2>Artz</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours NRD-101</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Artz</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.8650252463210677" CI_START="0.11270301543686599" EFFECT_SIZE="0.66" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5871523350724857" LOG_CI_START="-0.9480644639887482" LOG_EFFECT_SIZE="-0.1804560644581313" ORDER="151074" O_E="0.0" SE="0.9017939472142864" STUDY_ID="STD-Yamamoto-1994" TOTAL_1="100" TOTAL_2="99" VAR="0.8132323232323232" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-034" NO="34">
<NAME>Orthovisc versus placebo</NAME>
<CONT_OUTCOME CHI2="47.63363565375422" CI_END="-2.5397599464250913" CI_START="-3.343845084209076" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.9418025153170837" ESTIMABLE="YES" I2="85.30450194714814" I2_Q="89.33995973793078" ID="CMP-034.01" NO="1" P_CHI2="4.198711633929264E-8" P_Q="3.390350079790494E-6" P_Z="1.2071165558574332E-46" Q="28.14248282602332" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="162" TOTAL_2="126" UNITS="" WEIGHT="400.0" Z="14.341334539626313">
<NAME>WOMAC pain (5 to 25 Likert)</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Orthovisc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours saline</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="15.765305935037315" CI_END="-1.9498325684530207" CI_START="-2.8500655118384066" DF="2" EFFECT_SIZE="-2.3999490401457138" ESTIMABLE="YES" I2="87.31391570679807" ID="CMP-034.01.01" NO="1" P_CHI2="3.7723245685183926E-4" P_Z="1.4619419036459954E-25" STUDIES="3" TAU2="0.0" TOTAL_1="62" TOTAL_2="48" WEIGHT="99.99999999999997" Z="10.45021450943145">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="-4.789503736476009" CI_START="-10.210496263523991" EFFECT_SIZE="-7.5" ESTIMABLE="YES" MEAN_1="10.2" MEAN_2="17.7" ORDER="151075" SD_1="3.9" SD_2="4.8" SE="1.382931668593933" STUDY_ID="STD-Hizmetli-1999" TOTAL_1="20" TOTAL_2="20" WEIGHT="2.7577328090038855"/>
<CONT_DATA CI_END="-1.396164098076416" CI_START="-6.603835901923584" EFFECT_SIZE="-4.0" ESTIMABLE="YES" MEAN_1="9.5" MEAN_2="13.5" ORDER="151076" SD_1="3.1" SD_2="3.4" SE="1.3285121167849558" STUDY_ID="STD-Kotevoglu-2005" TOTAL_1="20" TOTAL_2="9" WEIGHT="2.988288959361603"/>
<CONT_DATA CI_END="-1.7363662304284047" CI_START="-2.663633769571594" EFFECT_SIZE="-2.1999999999999993" ESTIMABLE="YES" MEAN_1="8.9" MEAN_2="11.1" ORDER="151077" SD_1="0.7" SD_2="0.8" SE="0.23655218832013172" STUDY_ID="STD-Sezgin-2005" TOTAL_1="22" TOTAL_2="19" WEIGHT="94.25397823163449"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.8249051833122621" CI_END="-3.8868000942484144" CI_START="-6.91977386276802" DF="1" EFFECT_SIZE="-5.403286978508217" ESTIMABLE="YES" I2="0.0" ID="CMP-034.01.02" NO="2" P_CHI2="0.36374996248626446" P_Z="2.8810246661979207E-12" STUDIES="2" TAU2="0.0" TOTAL_1="40" TOTAL_2="29" WEIGHT="100.0" Z="6.9834088154210825">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="-4.028635399855858" CI_START="-7.87136460014414" EFFECT_SIZE="-5.949999999999999" ESTIMABLE="YES" MEAN_1="11.75" MEAN_2="17.7" ORDER="151078" SD_1="3.1" SD_2="3.1" SE="0.9803060746521977" STUDY_ID="STD-Hizmetli-1999" TOTAL_1="20" TOTAL_2="20" WEIGHT="62.29565369022189"/>
<CONT_DATA CI_END="-2.0303071142859554" CI_START="-6.9696928857140446" EFFECT_SIZE="-4.5" ESTIMABLE="YES" MEAN_1="9.5" MEAN_2="14.0" ORDER="151079" SD_1="3.0" SD_2="3.2" SE="1.2600705447623868" STUDY_ID="STD-Kotevoglu-2005" TOTAL_1="20" TOTAL_2="9" WEIGHT="37.70434630977811"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.900941709381328" CI_END="-3.181397597947732" CI_START="-6.076087203578072" DF="1" EFFECT_SIZE="-4.628742400762902" ESTIMABLE="YES" I2="65.52843523997365" ID="CMP-034.01.03" NO="3" P_CHI2="0.08852795946851977" P_Z="3.6537235546581073E-10" STUDIES="2" TAU2="0.0" TOTAL_1="40" TOTAL_2="29" WEIGHT="100.0" Z="6.268145905220966">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="-3.7713420485464635" CI_START="-7.428657951453532" EFFECT_SIZE="-5.599999999999998" ESTIMABLE="YES" MEAN_1="12.8" MEAN_2="18.4" ORDER="151080" SD_1="3.0" SD_2="2.9" SE="0.9330058949438638" STUDY_ID="STD-Hizmetli-1999" TOTAL_1="20" TOTAL_2="20" WEIGHT="62.64393849088091"/>
<CONT_DATA CI_END="-0.6319467445393641" CI_START="-5.3680532554606355" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="10.0" MEAN_2="13.0" ORDER="151081" SD_1="2.8" SD_2="3.1" SE="1.2082126376502516" STUDY_ID="STD-Kotevoglu-2005" TOTAL_1="20" TOTAL_2="9" WEIGHT="37.35606150911909"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-3.581814589835127" CI_START="-7.018185410164874" DF="0" EFFECT_SIZE="-5.300000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-034.01.04" NO="4" P_CHI2="1.0" P_Z="1.4866840918405264E-9" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="6.0458021914325855">
<NAME>45 to 52 weeks post-injection</NAME>
<CONT_DATA CI_END="-3.581814589835127" CI_START="-7.018185410164874" EFFECT_SIZE="-5.300000000000001" ESTIMABLE="YES" MEAN_1="13.8" MEAN_2="19.1" ORDER="151082" SD_1="2.4" SD_2="3.1" SE="0.8766413177577247" STUDY_ID="STD-Hizmetli-1999" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="61" EVENTS_2="60" I2="0.0" I2_Q="0.0" ID="CMP-034.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="66" TOTAL_2="69" WEIGHT="0.0" Z="0.0">
<NAME>WOMAC pain (number of patients who improved)</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Orthovisc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours saline</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.191879576006714" CI_START="0.9478401513579738" EFFECT_SIZE="1.062878787878788" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="60" LOG_CI_END="0.07623237778863358" LOG_CI_START="-0.023264898143613433" LOG_EFFECT_SIZE="0.026483739822510084" ORDER="151083" O_E="0.0" SE="0.058445192402061" STUDY_ID="STD-Brandt-2001" TOTAL_1="66" TOTAL_2="69" VAR="0.003415840514913929" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.0188936151698984" CI_START="0.9971213294849175" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4188311688311688" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="28" I2="0.0" I2_Q="0.0" ID="CMP-034.03" LOG_CI_END="0.30511343456426465" LOG_CI_START="-0.0012519936243095158" LOG_EFFECT_SIZE="0.15193072046997755" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.05190210821829229" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="66" TOTAL_2="69" WEIGHT="100.0" Z="1.9439447983869094">
<NAME>WOMAC pain (number of patients who achieved greater than 5 unit improvement (relative to baseline score))</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Orthovisc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours saline</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.0188936151698984" CI_START="0.9971213294849175" DF="0" EFFECT_SIZE="1.4188311688311688" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="28" I2="0.0" ID="CMP-034.03.01" LOG_CI_END="0.30511343456426465" LOG_CI_START="-0.0012519936243095158" LOG_EFFECT_SIZE="0.15193072046997755" NO="1" P_CHI2="1.0" P_Z="0.05190210821829229" STUDIES="1" TAU2="0.0" TOTAL_1="66" TOTAL_2="69" WEIGHT="100.0" Z="1.9439447983869094">
<NAME>14 to 26 weeks post-injection</NAME>
<DICH_DATA CI_END="2.018893615169898" CI_START="0.9971213294849176" EFFECT_SIZE="1.4188311688311688" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="28" LOG_CI_END="0.30511343456426454" LOG_CI_START="-0.0012519936243094675" LOG_EFFECT_SIZE="0.15193072046997755" ORDER="151084" O_E="0.0" SE="0.17996056905129623" STUDY_ID="STD-Brandt-2001" TOTAL_1="66" TOTAL_2="69" VAR="0.03238580641326636" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.9312414755200518" CI_END="1.2497939252008752" CI_START="0.9765270205737498" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1047432000730226" ESTIMABLE="YES" EVENTS_1="281" EVENTS_2="258" I2="23.688228803010904" I2_Q="0.0" ID="CMP-034.04" LOG_CI_END="0.09683840938711812" LOG_CI_START="-0.010315735249938028" LOG_EFFECT_SIZE="0.043261337068590026" METHOD="MH" NO="4" P_CHI2="0.2689852331947725" P_Q="0.7141180751721239" P_Z="0.11351441765875661" Q="0.1341985194358615" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0029449606199416045" TOTALS="SUB" TOTAL_1="388" TOTAL_2="400" WEIGHT="200.0" Z="1.5825923087656606">
<NAME>Number of patients with a 20% improvement from baseline in WOMAC pain score</NAME>
<GROUP_LABEL_1>Orthovisc 3 or 4 inj</GROUP_LABEL_1>
<GROUP_LABEL_2>Arthrocentesis</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Arthrocentes</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Ortho 3/4inj</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.2978095573320774" CI_END="1.4415251428795206" CI_START="0.91029859703601" DF="1" EFFECT_SIZE="1.1455209797971233" ESTIMABLE="YES" EVENTS_1="150" EVENTS_2="134" I2="69.67684207911029" ID="CMP-034.04.01" LOG_CI_END="0.15882222169377705" LOG_CI_START="-0.040816126608574185" LOG_EFFECT_SIZE="0.05900304754260141" NO="1" P_CHI2="0.06937240000382106" P_Z="0.2466464457233707" STUDIES="2" TAU2="0.019248346501531673" TOTAL_1="194" TOTAL_2="200" WEIGHT="100.0" Z="1.158533409487654">
<NAME>5 to 13 weeks post-injection</NAME>
<DICH_DATA CI_END="1.2331392651012472" CI_START="0.8298754538113928" EFFECT_SIZE="1.0116086235489221" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="67" LOG_CI_END="0.09101212659539186" LOG_CI_START="-0.08098708085416031" LOG_EFFECT_SIZE="0.00501252287061575" ORDER="151085" O_E="0.0" SE="0.10103318586567517" STUDY_ID="STD-Neustadt-2005a-_x002d_3inj" TOTAL_1="90" TOTAL_2="100" VAR="0.010207704646168063" WEIGHT="46.68620954196894"/>
<DICH_DATA CI_END="1.496752639789432" CI_START="1.0899678712324388" EFFECT_SIZE="1.2772675086107923" ESTIMABLE="YES" EVENTS_1="89" EVENTS_2="67" LOG_CI_END="0.17515003277394273" LOG_CI_START="0.03741369651666933" LOG_EFFECT_SIZE="0.10628186464530603" ORDER="151086" O_E="0.0" SE="0.08090700572338293" STUDY_ID="STD-Neustadt-2005b_x002d_4inj" TOTAL_1="104" TOTAL_2="100" VAR="0.0065459435751235185" WEIGHT="53.31379045803106"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.13306326238110233" CI_END="1.260056614729035" CI_START="0.9405720806436922" DF="1" EFFECT_SIZE="1.0886570037640577" ESTIMABLE="YES" EVENTS_1="131" EVENTS_2="124" I2="0.0" ID="CMP-034.04.02" LOG_CI_END="0.1003900585398208" LOG_CI_START="-0.02660791672574598" LOG_EFFECT_SIZE="0.03689107090703737" NO="2" P_CHI2="0.7152769406288455" P_Z="0.2548357262841163" STUDIES="2" TAU2="0.0" TOTAL_1="194" TOTAL_2="200" WEIGHT="100.00000000000001" Z="1.1386822534407908">
<NAME>14 to 26 weeks post-injection</NAME>
<DICH_DATA CI_END="1.3101899302394582" CI_START="0.8532992583607083" EFFECT_SIZE="1.0573476702508962" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="62" LOG_CI_END="0.11733425724044616" LOG_CI_START="-0.06889863183131521" LOG_EFFECT_SIZE="0.02421781270456548" ORDER="151087" O_E="0.0" SE="0.10939412090842121" STUDY_ID="STD-Neustadt-2005a-_x002d_3inj" TOTAL_1="90" TOTAL_2="100" VAR="0.01196707368932628" WEIGHT="46.502985205580195"/>
<DICH_DATA CI_END="1.363715944948016" CI_START="0.9143048359444349" EFFECT_SIZE="1.1166253101736974" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="62" LOG_CI_END="0.13472391842255793" LOG_CI_START="-0.038908983154089395" LOG_EFFECT_SIZE="0.04790746763423427" ORDER="151088" O_E="0.0" SE="0.10199282588284721" STUDY_ID="STD-Neustadt-2005b_x002d_4inj" TOTAL_1="104" TOTAL_2="100" VAR="0.010402536531568788" WEIGHT="53.49701479441982"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.179895763918002" CI_END="1.4458057648362936" CI_START="1.101419918503319" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2619188831607282" ESTIMABLE="YES" EVENTS_1="226" EVENTS_2="184" I2="0.0" I2_Q="0.0" ID="CMP-034.05" LOG_CI_END="0.16010995206927123" LOG_CI_START="0.041952926165473775" LOG_EFFECT_SIZE="0.10103143911737252" METHOD="MH" NO="5" P_CHI2="0.5359192039558106" P_Q="0.6548827629690129" P_Z="8.029476069126851E-4" Q="0.19979947473745366" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="388" TOTAL_2="400" WEIGHT="200.0" Z="3.3517766795776684">
<NAME>Number of patients with a 40% improvement from baseline in WOMAC pain score</NAME>
<GROUP_LABEL_1>Orthovisc 3 or 4 inj</GROUP_LABEL_1>
<GROUP_LABEL_2>Arthrocentesis</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Arthrocentes</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Ortho 3/4inj</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.233473641829495" CI_END="1.5655006056014744" CI_START="1.0799607591829394" DF="1" EFFECT_SIZE="1.3002612131901496" ESTIMABLE="YES" EVENTS_1="119" EVENTS_2="94" I2="18.928141949041205" ID="CMP-034.05.01" LOG_CI_END="0.19465323995633727" LOG_CI_START="0.03340797550553643" LOG_EFFECT_SIZE="0.11403060773093684" NO="1" P_CHI2="0.26673263902382127" P_Z="0.005569192218342417" STUDIES="2" TAU2="0.0" TOTAL_1="194" TOTAL_2="200" WEIGHT="100.0" Z="2.77212338668146">
<NAME>5 to 13 weeks post-injection</NAME>
<DICH_DATA CI_END="1.5344330721774582" CI_START="0.8745073719856942" EFFECT_SIZE="1.1583924349881796" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="47" LOG_CI_END="0.18594795042968235" LOG_CI_START="-0.05823652512273976" LOG_EFFECT_SIZE="0.06385571265347129" ORDER="151089" O_E="0.0" SE="0.14343516967214093" STUDY_ID="STD-Neustadt-2005a-_x002d_3inj" TOTAL_1="90" TOTAL_2="100" VAR="0.020573647898875856" WEIGHT="48.163693599160545"/>
<DICH_DATA CI_END="1.8342458323686917" CI_START="1.1180884072737634" EFFECT_SIZE="1.4320785597381342" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="47" LOG_CI_END="0.26345754097764923" LOG_CI_START="0.04847614458186876" LOG_EFFECT_SIZE="0.15596684277975903" ORDER="151090" O_E="0.0" SE="0.12628113641795644" STUDY_ID="STD-Neustadt-2005b_x002d_4inj" TOTAL_1="104" TOTAL_2="100" VAR="0.01594692541501052" WEIGHT="51.836306400839455"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.7360131658514879" CI_END="1.491935412912001" CI_START="1.0006949832466445" DF="1" EFFECT_SIZE="1.2218724495744433" ESTIMABLE="YES" EVENTS_1="107" EVENTS_2="90" I2="0.0" ID="CMP-034.05.02" LOG_CI_END="0.17375002258500055" LOG_CI_START="3.017225551126106E-4" LOG_EFFECT_SIZE="0.08702587257005658" NO="2" P_CHI2="0.3909410325999114" P_Z="0.04920824387648205" STUDIES="2" TAU2="0.0" TOTAL_1="194" TOTAL_2="200" WEIGHT="100.0" Z="1.9667829080030357">
<NAME>14 to 26 weeks post-injection</NAME>
<DICH_DATA CI_END="1.4989276607382054" CI_START="0.8236340775955505" EFFECT_SIZE="1.1111111111111112" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="45" LOG_CI_END="0.1757806740088519" LOG_CI_START="-0.08426569288750158" LOG_EFFECT_SIZE="0.04575749056067514" ORDER="151091" O_E="0.0" SE="0.15275252316519466" STUDY_ID="STD-Neustadt-2005a-_x002d_3inj" TOTAL_1="90" TOTAL_2="100" VAR="0.02333333333333333" WEIGHT="48.163693599160545"/>
<DICH_DATA CI_END="1.7324371223365056" CI_START="1.0130577229688098" EFFECT_SIZE="1.3247863247863247" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="45" LOG_CI_END="0.23865748113790666" LOG_CI_START="0.005634191710353042" LOG_EFFECT_SIZE="0.12214583642412982" ORDER="151092" O_E="0.0" SE="0.13687903369363083" STUDY_ID="STD-Neustadt-2005b_x002d_4inj" TOTAL_1="104" TOTAL_2="100" VAR="0.018735869864902124" WEIGHT="51.83630640083946"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.8958678035389207" CI_END="1.424686980852833" CI_START="1.0466256539478804" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2211117651575256" ESTIMABLE="YES" EVENTS_1="195" EVENTS_2="164" I2="0.0" I2_Q="0.0" ID="CMP-034.06" LOG_CI_END="0.15371945562784903" LOG_CI_START="0.019791375570337427" LOG_EFFECT_SIZE="0.08675541559909326" METHOD="MH" NO="6" P_CHI2="0.5942986301796662" P_Q="0.9745278559962528" P_Z="0.011109490762757945" Q="0.0010195265063547745" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="388" TOTAL_2="400" WEIGHT="200.0" Z="2.5392358341134957">
<NAME>Number of patients with a 50% improvement from baseline in WOMAC pain score</NAME>
<GROUP_LABEL_1>Orthovisc 3 or 4 inj</GROUP_LABEL_1>
<GROUP_LABEL_2>Arthrocentesis</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Arthrocentes</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Ortho 3/4inj</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.9734342594196194" CI_END="1.5013811394880237" CI_START="0.9884062547445427" DF="1" EFFECT_SIZE="1.218184923985456" ESTIMABLE="YES" EVENTS_1="102" EVENTS_2="86" I2="0.0" ID="CMP-034.06.01" LOG_CI_END="0.17649095591046188" LOG_CI_START="-0.005064514997552565" LOG_EFFECT_SIZE="0.08571322045645467" NO="1" P_CHI2="0.3238253850620232" P_Z="0.0642246649178059" STUDIES="2" TAU2="0.0" TOTAL_1="194" TOTAL_2="200" WEIGHT="100.0" Z="1.850617051123819">
<NAME>5 to 13 weeks post-injection</NAME>
<DICH_DATA CI_END="1.4882283720242828" CI_START="0.7914200907897145" EFFECT_SIZE="1.0852713178294573" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="43" LOG_CI_END="0.1726695797984521" LOG_CI_START="-0.10159292904047401" LOG_EFFECT_SIZE="0.03553832537898904" ORDER="151093" O_E="0.0" SE="0.16110315531329938" STUDY_ID="STD-Neustadt-2005a-_x002d_3inj" TOTAL_1="90" TOTAL_2="100" VAR="0.025954226651901065" WEIGHT="48.163693599160545"/>
<DICH_DATA CI_END="1.7739778876808754" CI_START="1.014730487428816" EFFECT_SIZE="1.3416815742397137" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="43" LOG_CI_END="0.24894820212590538" LOG_CI_START="0.006350708884648043" LOG_EFFECT_SIZE="0.12764945550527673" ORDER="151094" O_E="0.0" SE="0.1425029684068736" STUDY_ID="STD-Neustadt-2005b_x002d_4inj" TOTAL_1="104" TOTAL_2="100" VAR="0.020307096004770417" WEIGHT="51.836306400839455"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.9216493087055921" CI_END="1.5378599649312188" CI_START="0.9747347089693417" DF="1" EFFECT_SIZE="1.2243387951677565" ESTIMABLE="YES" EVENTS_1="93" EVENTS_2="78" I2="0.0" ID="CMP-034.06.02" LOG_CI_END="0.18691679110488865" LOG_CI_START="-0.011113569027717825" LOG_EFFECT_SIZE="0.08790161103858542" NO="2" P_CHI2="0.3370424323134359" P_Z="0.08186331229735329" STUDIES="2" TAU2="0.0" TOTAL_1="194" TOTAL_2="200" WEIGHT="100.0" Z="1.7399755441873648">
<NAME>14 to 26 weeks post-injection</NAME>
<DICH_DATA CI_END="1.5274694739336365" CI_START="0.76732689493117" EFFECT_SIZE="1.0826210826210827" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="39" LOG_CI_END="0.18397253974297365" LOG_CI_START="-0.11501957944100148" LOG_EFFECT_SIZE="0.03447648015098611" ORDER="151095" O_E="0.0" SE="0.17562945084352663" STUDY_ID="STD-Neustadt-2005a-_x002d_3inj" TOTAL_1="90" TOTAL_2="100" VAR="0.030845704003598734" WEIGHT="48.163693599160545"/>
<DICH_DATA CI_END="1.8395052570584873" CI_START="0.9996050764697127" EFFECT_SIZE="1.356015779092702" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="39" LOG_CI_END="0.26470103332410677" LOG_CI_START="-1.715469861782453E-4" LOG_EFFECT_SIZE="0.13226474316896425" ORDER="151096" O_E="0.0" SE="0.15558746481467972" STUDY_ID="STD-Neustadt-2005b_x002d_4inj" TOTAL_1="104" TOTAL_2="100" VAR="0.024207459207459203" WEIGHT="51.83630640083946"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="1.4072577874683228" CI_END="2.170148830804966" CI_START="-7.892574062300767" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.8612126157479003" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-034.07" NO="7" P_CHI2="0.7038345763984675" P_Q="0.981517267839884" P_Z="0.2650288575573281" Q="5.366979370986334E-4" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="388" TOTAL_2="200" UNITS="" WEIGHT="200.0" Z="1.1145837440917001">
<NAME>WOMAC pain on standing (0 to 100 mm VAS; change from baseline)</NAME>
<GROUP_LABEL_1>Orthovisc 3 or 4 inj</GROUP_LABEL_1>
<GROUP_LABEL_2>Arthrocentesis</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Ortho 3/4inj</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Arthrocentes</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.1177797542227998" CI_END="4.146607211680603" CI_START="-9.755650288946397" DF="1" EFFECT_SIZE="-2.8045215386328968" ESTIMABLE="YES" I2="10.536937511870837" ID="CMP-034.07.01" NO="1" P_CHI2="0.2903970692578868" P_Z="0.42907678814912087" STUDIES="2" TAU2="0.0" TOTAL_1="194" TOTAL_2="100" WEIGHT="100.0" Z="0.7907724640173626">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="10.902631692453323" CI_START="-8.902631692453323" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="-25.4" MEAN_2="-26.4" ORDER="151097" SD_1="29.6" SD_2="28.1" SE="5.052455948458246" STUDY_ID="STD-Neustadt-2005a-_x002d_3inj" TOTAL_1="90" TOTAL_2="50" WEIGHT="49.273046151561374"/>
<CONT_DATA CI_END="3.2596881472652175" CI_START="-16.259688147265216" EFFECT_SIZE="-6.5" ESTIMABLE="YES" MEAN_1="-32.9" MEAN_2="-26.4" ORDER="151098" SD_1="30.6" SD_2="28.1" SE="4.979524228122758" STUDY_ID="STD-Neustadt-2005b_x002d_4inj" TOTAL_1="104" TOTAL_2="50" WEIGHT="50.72695384843862"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.28894133530842436" CI_END="4.368339741215491" CI_START="-10.215537814421307" DF="1" EFFECT_SIZE="-2.9235990366029077" ESTIMABLE="YES" I2="0.0" ID="CMP-034.07.02" NO="2" P_CHI2="0.5908998210249004" P_Z="0.4319731566434868" STUDIES="2" TAU2="0.0" TOTAL_1="194" TOTAL_2="100" WEIGHT="99.99999999999999" Z="0.7858196553169696">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="9.473742913585902" CI_START="-11.273742913585899" EFFECT_SIZE="-0.8999999999999986" ESTIMABLE="YES" MEAN_1="-25.5" MEAN_2="-24.6" ORDER="151099" SD_1="30.2" SD_2="29.9" SE="5.292823233188293" STUDY_ID="STD-Neustadt-2005a-_x002d_3inj" TOTAL_1="90" TOTAL_2="50" WEIGHT="49.41002408492726"/>
<CONT_DATA CI_END="5.352051458616332" CI_START="-15.152051458616329" EFFECT_SIZE="-4.899999999999999" ESTIMABLE="YES" MEAN_1="-29.5" MEAN_2="-24.6" ORDER="151100" SD_1="31.4" SD_2="29.9" SE="5.230734615270078" STUDY_ID="STD-Neustadt-2005b_x002d_4inj" TOTAL_1="104" TOTAL_2="50" WEIGHT="50.58997591507273"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="9.234142919841638" CI_END="-6.309854543256414" CI_START="-9.308599389565833" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="MD" EFFECT_SIZE="-7.809226966411123" ESTIMABLE="YES" I2="24.194372333582557" I2_Q="33.79322161047487" ID="CMP-034.08" NO="8" P_CHI2="0.23628009934175165" P_Q="0.2095190774426855" P_Z="1.8232634536988766E-24" Q="4.531258087124571" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="162" TOTAL_2="126" UNITS="" WEIGHT="400.0" Z="10.208139995706384">
<NAME>WOMAC physical function (17 to 85 Likert)</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Orthovisc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours saline</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="3.1178504669632146" CI_END="-5.5634054823131756" CI_START="-8.838596618675059" DF="2" EFFECT_SIZE="-7.201001050494117" ESTIMABLE="YES" I2="35.853241802580754" ID="CMP-034.08.01" NO="1" P_CHI2="0.2103621424972969" P_Z="6.780603136596121E-18" STUDIES="3" TAU2="0.0" TOTAL_1="62" TOTAL_2="48" WEIGHT="100.00000000000001" Z="8.618552092981798">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="-3.6681325744132014" CI_START="-20.8318674255868" EFFECT_SIZE="-12.25" ESTIMABLE="YES" MEAN_1="39.85" MEAN_2="52.1" ORDER="151101" SD_1="11.0" SD_2="16.2" SE="4.378584246077721" STUDY_ID="STD-Hizmetli-1999" TOTAL_1="20" TOTAL_2="20" WEIGHT="3.641243365159378"/>
<CONT_DATA CI_END="-3.9399029170495794" CI_START="-22.06009708295042" EFFECT_SIZE="-13.0" ESTIMABLE="YES" MEAN_1="33.0" MEAN_2="46.0" ORDER="151102" SD_1="10.1" SD_2="12.1" SE="4.622583452765107" STUDY_ID="STD-Kotevoglu-2005" TOTAL_1="20" TOTAL_2="9" WEIGHT="3.2669885014989535"/>
<CONT_DATA CI_END="-5.102729688056229" CI_START="-8.497270311943765" EFFECT_SIZE="-6.799999999999997" ESTIMABLE="YES" MEAN_1="32.2" MEAN_2="39.0" ORDER="151103" SD_1="2.6" SD_2="2.9" SE="0.8659701531924155" STUDY_ID="STD-Sezgin-2005" TOTAL_1="22" TOTAL_2="19" WEIGHT="93.09176813334167"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.1559521249910416" CI_END="-7.140250513139531" CI_START="-18.595455069889205" DF="1" EFFECT_SIZE="-12.867852791514368" ESTIMABLE="YES" I2="13.491226982453984" ID="CMP-034.08.02" NO="2" P_CHI2="0.28230666612658284" P_Z="1.0660138629684553E-5" STUDIES="2" TAU2="0.0" TOTAL_1="40" TOTAL_2="29" WEIGHT="100.0" Z="4.403330888555951">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="-2.576824959571888" CI_START="-17.72317504042811" EFFECT_SIZE="-10.149999999999999" ESTIMABLE="YES" MEAN_1="41.35" MEAN_2="51.5" ORDER="151104" SD_1="10.4" SD_2="13.8" SE="3.8639358172723317" STUDY_ID="STD-Hizmetli-1999" TOTAL_1="20" TOTAL_2="20" WEIGHT="57.199168637568974"/>
<CONT_DATA CI_END="-7.7451894869220865" CI_START="-25.254810513077913" EFFECT_SIZE="-16.5" ESTIMABLE="YES" MEAN_1="31.5" MEAN_2="48.0" ORDER="151105" SD_1="10.5" SD_2="11.4" SE="4.466822136597785" STUDY_ID="STD-Kotevoglu-2005" TOTAL_1="20" TOTAL_2="9" WEIGHT="42.80083136243102"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.4290822407628134" CI_END="-4.791946412955394" CI_START="-16.965485904429247" DF="1" EFFECT_SIZE="-10.87871615869232" ESTIMABLE="YES" I2="0.0" ID="CMP-034.08.03" NO="3" P_CHI2="0.5124396426724646" P_Z="4.6006721226975406E-4" STUDIES="2" TAU2="0.0" TOTAL_1="40" TOTAL_2="29" WEIGHT="100.00000000000001" Z="3.502989723572898">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="-1.5953219952949125" CI_START="-17.00467800470508" EFFECT_SIZE="-9.299999999999997" ESTIMABLE="YES" MEAN_1="43.2" MEAN_2="52.5" ORDER="151106" SD_1="10.5" SD_2="14.1" SE="3.931030399271926" STUDY_ID="STD-Hizmetli-1999" TOTAL_1="20" TOTAL_2="20" WEIGHT="62.411520031135225"/>
<CONT_DATA CI_END="-3.5720520538547387" CI_START="-23.42794794614526" EFFECT_SIZE="-13.5" ESTIMABLE="YES" MEAN_1="34.5" MEAN_2="48.0" ORDER="151107" SD_1="10.4" SD_2="13.5" SE="5.065372641770791" STUDY_ID="STD-Kotevoglu-2005" TOTAL_1="20" TOTAL_2="9" WEIGHT="37.58847996886479"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.2196950521444645" CI_START="-15.419695052144467" DF="0" EFFECT_SIZE="-7.100000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-034.08.04" NO="4" P_CHI2="1.0" P_Z="0.09440080233501837" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="1.6726267252605007">
<NAME>45 to 52 weeks post-injection</NAME>
<CONT_DATA CI_END="1.2196950521444645" CI_START="-15.419695052144467" EFFECT_SIZE="-7.100000000000001" ESTIMABLE="YES" MEAN_1="45.8" MEAN_2="52.9" ORDER="151108" SD_1="11.1" SD_2="15.4" SE="4.2448203731135665" STUDY_ID="STD-Hizmetli-1999" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="5.977050909946589" CI_START="2.022949090053411" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="4.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-034.09" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="7.326391467643402E-5" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="22" TOTAL_2="19" UNITS="" WEIGHT="100.0" Z="3.9654294680616067">
<NAME>Range of motion: flexion (degrees)</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Saline</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Orthovisc</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="5.977050909946589" CI_START="2.022949090053411" DF="0" EFFECT_SIZE="4.0" ESTIMABLE="YES" I2="0.0" ID="CMP-034.09.01" NO="1" P_CHI2="1.0" P_Z="7.326391467643402E-5" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="19" WEIGHT="100.0" Z="3.9654294680616067">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="5.977050909946589" CI_START="2.022949090053411" EFFECT_SIZE="4.0" ESTIMABLE="YES" MEAN_1="125.2" MEAN_2="121.2" ORDER="151109" SD_1="3.0" SD_2="3.4" SE="1.0087179792798817" STUDY_ID="STD-Sezgin-2005" TOTAL_1="22" TOTAL_2="19" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.204809136163329" CI_START="-0.40480913616333203" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.3999999999999986" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-034.10" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="0.3299939388307056" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="22" TOTAL_2="19" UNITS="" WEIGHT="100.0" Z="0.9741261108856427">
<NAME>25 metre walking time (sec)</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Orthovisc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours saline</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.204809136163329" CI_START="-0.40480913616333203" DF="0" EFFECT_SIZE="0.3999999999999986" ESTIMABLE="YES" I2="0.0" ID="CMP-034.10.01" NO="1" P_CHI2="1.0" P_Z="0.3299939388307056" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="19" WEIGHT="100.0" Z="0.9741261108856427">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="1.204809136163329" CI_START="-0.40480913616333203" EFFECT_SIZE="0.3999999999999986" ESTIMABLE="YES" MEAN_1="26.4" MEAN_2="26.0" ORDER="151110" SD_1="1.2" SD_2="1.4" SE="0.4106244515264374" STUDY_ID="STD-Sezgin-2005" TOTAL_1="22" TOTAL_2="19" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.12968472838583034" CI_START="-0.7296847283858247" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.29999999999999716" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-034.11" NO="11" P_CHI2="1.0" P_Q="1.0" P_Z="0.1711806333873638" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="22" TOTAL_2="19" UNITS="" WEIGHT="100.0" Z="1.3684200450196977">
<NAME>Knee circumference (mm)</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Orthovisc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours saline</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.12968472838583034" CI_START="-0.7296847283858247" DF="0" EFFECT_SIZE="-0.29999999999999716" ESTIMABLE="YES" I2="0.0" ID="CMP-034.11.01" NO="1" P_CHI2="1.0" P_Z="0.1711806333873638" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="19" WEIGHT="100.0" Z="1.3684200450196977">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="0.12968472838583034" CI_START="-0.7296847283858247" EFFECT_SIZE="-0.29999999999999716" ESTIMABLE="YES" MEAN_1="40.0" MEAN_2="40.3" ORDER="151111" SD_1="0.7" SD_2="0.7" SE="0.21923093065746402" STUDY_ID="STD-Sezgin-2005" TOTAL_1="22" TOTAL_2="19" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="23.692512817839344" CI_END="-0.585782218197799" CI_START="-2.2173104312749445" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.4015463247363718" ESTIMABLE="YES" I2="87.33777196591346" I2_Q="0.0" ID="CMP-034.12" NO="12" P_CHI2="2.8958403514467435E-5" P_Q="0.8756220615606455" P_Z="7.588854668620925E-4" Q="0.2656414509768248" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="1.2859419489972521" TOTALS="SUB" TOTAL_1="82" TOTAL_2="46" UNITS="" WEIGHT="300.0" Z="3.3673709067731323">
<NAME>WOMAC stiffness (2 to 10 Likert)</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Orthovisc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Saline</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="14.229531573427993" CI_END="1.021570836780167" CI_START="-2.8898458234893645" DF="1" EFFECT_SIZE="-0.9341374933545986" ESTIMABLE="YES" I2="92.97236177565125" ID="CMP-034.12.01" NO="1" P_CHI2="1.618124002698007E-4" P_Z="0.34918557881705636" STUDIES="2" TAU2="1.8594472355130234" TOTAL_1="42" TOTAL_2="28" WEIGHT="100.00000000000001" Z="0.9361701923401706">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="-0.9772860267291545" CI_START="-3.0227139732708457" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="3.5" MEAN_2="5.5" ORDER="151112" SD_1="1.3" SD_2="1.3" SE="0.5218024317476662" STUDY_ID="STD-Kotevoglu-2005" TOTAL_1="20" TOTAL_2="9" WEIGHT="46.706874667729934"/>
<CONT_DATA CI_END="0.18415059787964033" CI_START="-0.18415059787964033" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="3.4" MEAN_2="3.4" ORDER="151113" SD_1="0.3" SD_2="0.3" SE="0.09395611313891314" STUDY_ID="STD-Sezgin-2005" TOTAL_1="22" TOTAL_2="19" WEIGHT="53.29312533227008"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.16260480418427892" CI_START="-2.837395195815721" DF="0" EFFECT_SIZE="-1.5" ESTIMABLE="YES" I2="0.0" ID="CMP-034.12.02" NO="2" P_CHI2="1.0" P_Z="0.027930390696104788" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="9" WEIGHT="100.0" Z="2.198262702010764">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="-0.16260480418427914" CI_START="-2.837395195815721" EFFECT_SIZE="-1.5" ESTIMABLE="YES" MEAN_1="3.5" MEAN_2="5.0" ORDER="151114" SD_1="1.7" SD_2="1.7" SE="0.6823570261315633" STUDY_ID="STD-Kotevoglu-2005" TOTAL_1="20" TOTAL_2="9" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.2892385169437113" CI_START="-2.710761483056289" DF="0" EFFECT_SIZE="-1.5" ESTIMABLE="YES" I2="0.0" ID="CMP-034.12.03" NO="3" P_CHI2="1.0" P_Z="0.015174838879317924" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="9" WEIGHT="100.0" Z="2.4281793052987317">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="-0.2892385169437113" CI_START="-2.710761483056289" EFFECT_SIZE="-1.5" ESTIMABLE="YES" MEAN_1="3.5" MEAN_2="5.0" ORDER="151115" SD_1="1.1" SD_2="1.7" SE="0.6177468017813699" STUDY_ID="STD-Kotevoglu-2005" TOTAL_1="20" TOTAL_2="9" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.1333155475945333" CI_END="12.927020451106856" CI_START="-25.123181402755833" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-6.098080475824488" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-034.13" NO="13" P_CHI2="0.7690383093619712" P_Q="0.8600518415080064" P_Z="0.5298574513261175" Q="0.031084589702637923" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="444" TOTAL_2="228" UNITS="" WEIGHT="200.0" Z="0.6282236374643336">
<NAME>WOMAC total score (0 to 100 mm VAS; change from baseline)</NAME>
<GROUP_LABEL_1>Orthovisc 3 or 4 inj</GROUP_LABEL_1>
<GROUP_LABEL_2>Arthrocentesis</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Ortho 3/4inj</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours arthrocente</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.7933335029798185" CI_END="19.037005104633664" CI_START="-34.63872048677783" DF="1" EFFECT_SIZE="-7.800857691072084" ESTIMABLE="YES" I2="0.0" ID="CMP-034.13.01" NO="1" P_CHI2="0.3730940958842377" P_Z="0.5688844866140406" STUDIES="2" TAU2="0.0" TOTAL_1="222" TOTAL_2="114" WEIGHT="100.00000000000001" Z="0.5696951444833374">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="43.13129440584543" CI_START="-33.731294405845425" EFFECT_SIZE="4.700000000000003" ESTIMABLE="YES" MEAN_1="-121.1" MEAN_2="-125.8" ORDER="151116" SD_1="123.2" SD_2="117.6" SE="19.60816357289551" STUDY_ID="STD-Neustadt-2005a-_x002d_3inj" TOTAL_1="107" TOTAL_2="57" WEIGHT="48.766976675934096"/>
<CONT_DATA CI_END="17.794963559656765" CI_START="-57.19496355965677" EFFECT_SIZE="-19.700000000000003" ESTIMABLE="YES" MEAN_1="-145.5" MEAN_2="-125.8" ORDER="151117" SD_1="119.1" SD_2="117.6" SE="19.130434975036405" STUDY_ID="STD-Neustadt-2005b_x002d_4inj" TOTAL_1="115" TOTAL_2="57" WEIGHT="51.23302332406592"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.3088974549120771" CI_END="22.595748882487563" CI_START="-31.351778195854948" DF="1" EFFECT_SIZE="-4.3780146566836935" ESTIMABLE="YES" I2="0.0" ID="CMP-034.13.02" NO="2" P_CHI2="0.5783576456548396" P_Z="0.750397923917548" STUDIES="2" TAU2="0.0" TOTAL_1="222" TOTAL_2="114" WEIGHT="100.0" Z="0.31811471315182166">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="41.86989668789566" CI_START="-35.06989668789568" EFFECT_SIZE="3.3999999999999915" ESTIMABLE="YES" MEAN_1="-108.4" MEAN_2="-111.8" ORDER="151118" SD_1="124.6" SD_2="117.0" SE="19.627858976665543" STUDY_ID="STD-Neustadt-2005a-_x002d_3inj" TOTAL_1="107" TOTAL_2="57" WEIGHT="49.163302897492244"/>
<CONT_DATA CI_END="25.93144090806056" CI_START="-49.73144090806057" EFFECT_SIZE="-11.900000000000006" ESTIMABLE="YES" MEAN_1="-123.7" MEAN_2="-111.8" ORDER="151119" SD_1="123.4" SD_2="117.0" SE="19.302110246142348" STUDY_ID="STD-Neustadt-2005b_x002d_4inj" TOTAL_1="115" TOTAL_2="57" WEIGHT="50.83669710250775"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="6.628289302461029" CI_END="-7.128291297130039" CI_START="-21.029749550778696" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-14.079020423954368" ESTIMABLE="YES" I2="69.82630195007607" I2_Q="69.82630195007607" ID="CMP-034.14" NO="14" P_CHI2="0.0363652278959502" P_Q="0.0363652278959502" P_Z="7.18735720364291E-5" Q="6.628289302461029" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="60" TOTAL_2="27" UNITS="" WEIGHT="300.0" Z="3.969996883069706">
<NAME>Patient global assessment (0 to 100 mm VAS; where 100 is worst severity)</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Orthovisc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Saline</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-6.777342821338067" CI_START="-33.22265717866193" DF="0" EFFECT_SIZE="-20.0" ESTIMABLE="YES" I2="0.0" ID="CMP-034.14.01" NO="1" P_CHI2="1.0" P_Z="0.003031221527073505" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="9" WEIGHT="99.99999999999999" Z="2.9645538836217376">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="-6.777342821338067" CI_START="-33.22265717866193" EFFECT_SIZE="-20.0" ESTIMABLE="YES" MEAN_1="50.0" MEAN_2="70.0" ORDER="151120" SD_1="13.5" SD_2="18.1" SE="6.746377628854696" STUDY_ID="STD-Kotevoglu-2005" TOTAL_1="20" TOTAL_2="9" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-9.37083142263589" CI_START="-30.629168577364112" DF="0" EFFECT_SIZE="-20.0" ESTIMABLE="YES" I2="0.0" ID="CMP-034.14.02" NO="2" P_CHI2="1.0" P_Z="2.2611507344367135E-4" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="9" WEIGHT="100.0" Z="3.68789707355662">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="-9.37083142263589" CI_START="-30.629168577364112" EFFECT_SIZE="-20.0" ESTIMABLE="YES" MEAN_1="50.0" MEAN_2="70.0" ORDER="151121" SD_1="12.1" SD_2="14.1" SE="5.423144844091849" STUDY_ID="STD-Kotevoglu-2005" TOTAL_1="20" TOTAL_2="9" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="12.774637361587818" CI_START="-12.774637361587818" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-034.14.03" NO="3" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="9" WEIGHT="100.00000000000001" Z="0.0">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="12.774637361587818" CI_START="-12.774637361587818" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="70.0" MEAN_2="70.0" ORDER="151122" SD_1="16.1" SD_2="16.3" SE="6.5177918892145605" STUDY_ID="STD-Kotevoglu-2005" TOTAL_1="20" TOTAL_2="9" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.123077073847186" CI_END="0.747305693046894" CI_START="-8.229687265407257" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.7411907861801814" ESTIMABLE="YES" I2="3.940891336875417" I2_Q="0.0" ID="CMP-034.15" NO="15" P_CHI2="0.3730359199439939" P_Q="0.9751430548730375" P_Z="0.10233391074528925" Q="9.708585862499778E-4" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="444" TOTAL_2="228" UNITS="" WEIGHT="200.0" Z="1.633642631589839">
<NAME>Patient global assessment (0 to 100 mm VAS; change from baseline)</NAME>
<GROUP_LABEL_1>Orthovisc 3 or 4 inj</GROUP_LABEL_1>
<GROUP_LABEL_2>Arthrocentesis</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Ortho 3/4inj</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours arthrocentes</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.8726244188461956" CI_END="2.4884652254197173" CI_START="-10.11140323426132" DF="1" EFFECT_SIZE="-3.811469004420802" ESTIMABLE="YES" I2="46.59900885965468" ID="CMP-034.15.01" NO="1" P_CHI2="0.1711750071239181" P_Z="0.2357088388457942" STUDIES="2" TAU2="0.0" TOTAL_1="222" TOTAL_2="114" WEIGHT="100.0" Z="1.185780946961508">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="9.724498455384834" CI_START="-8.324498455384836" EFFECT_SIZE="0.6999999999999993" ESTIMABLE="YES" MEAN_1="-27.5" MEAN_2="-28.2" ORDER="151123" SD_1="30.0" SD_2="27.0" SE="4.604420553933096" STUDY_ID="STD-Neustadt-2005a-_x002d_3inj" TOTAL_1="107" TOTAL_2="57" WEIGHT="48.733306767945415"/>
<CONT_DATA CI_END="0.6986970087820534" CI_START="-16.89869700878205" EFFECT_SIZE="-8.099999999999998" ESTIMABLE="YES" MEAN_1="-36.3" MEAN_2="-28.2" ORDER="151124" SD_1="29.1" SD_2="27.0" SE="4.489213617283302" STUDY_ID="STD-Neustadt-2005b_x002d_4inj" TOTAL_1="115" TOTAL_2="57" WEIGHT="51.26669323205458"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.2494817964147402" CI_END="2.7278134498672215" CI_START="-10.065294208330526" DF="1" EFFECT_SIZE="-3.6687403792316524" ESTIMABLE="YES" I2="19.966821215851454" ID="CMP-034.15.02" NO="2" P_CHI2="0.26365156251205346" P_Z="0.26095518256786343" STUDIES="2" TAU2="0.0" TOTAL_1="222" TOTAL_2="114" WEIGHT="100.0" Z="1.1241364028253396">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="9.296925422821612" CI_START="-9.096925422821617" EFFECT_SIZE="0.09999999999999787" ESTIMABLE="YES" MEAN_1="-26.1" MEAN_2="-26.2" ORDER="151125" SD_1="30.6" SD_2="27.5" SE="4.69239511305605" STUDY_ID="STD-Neustadt-2005a-_x002d_3inj" TOTAL_1="107" TOTAL_2="57" WEIGHT="48.37341946258012"/>
<CONT_DATA CI_END="1.702446626894183" CI_START="-16.10244662689418" EFFECT_SIZE="-7.199999999999999" ESTIMABLE="YES" MEAN_1="-33.4" MEAN_2="-26.2" ORDER="151126" SD_1="29.1" SD_2="27.5" SE="4.542148068594905" STUDY_ID="STD-Neustadt-2005b_x002d_4inj" TOTAL_1="115" TOTAL_2="57" WEIGHT="51.62658053741988"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.7897633252394485" CI_START="1.0104883417716763" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.2" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-034.16" LOG_CI_END="0.6803140543160355" LOG_CI_START="0.004531307328377029" LOG_EFFECT_SIZE="0.3424226808222063" METHOD="MH" NO="16" P_CHI2="1.0" P_Q="1.0" P_Z="0.047005774702163834" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="1.9862481689353793">
<NAME>Patient global assessment (number patients rating treatment as effective or very effective)</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours saline</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Orthovisc</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.7897633252394485" CI_START="1.0104883417716763" DF="0" EFFECT_SIZE="2.2" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="5" I2="0.0" ID="CMP-034.16.01" LOG_CI_END="0.6803140543160355" LOG_CI_START="0.004531307328377029" LOG_EFFECT_SIZE="0.3424226808222063" NO="1" P_CHI2="1.0" P_Z="0.047005774702163834" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="1.9862481689353793">
<NAME>5 to 13 weeks post-injection</NAME>
<DICH_DATA CI_END="4.78976332523945" CI_START="1.0104883417716761" EFFECT_SIZE="2.2" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="5" LOG_CI_END="0.6803140543160356" LOG_CI_START="0.004531307328376933" LOG_EFFECT_SIZE="0.3424226808222063" ORDER="151127" O_E="0.0" SE="0.3969581307590986" STUDY_ID="STD-Guler-1996" TOTAL_1="15" TOTAL_2="15" VAR="0.1575757575757576" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.9173379874390535" CI_END="6.259647664952004" CI_START="-13.264678505467588" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.502515420257792" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-034.17" NO="17" P_CHI2="0.6321244797858283" P_Q="0.6321244797858283" P_Z="0.4819278691379191" Q="0.9173379874390535" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="60" TOTAL_2="27" UNITS="" WEIGHT="300.0" Z="0.7032052239940545">
<NAME>Physician global assessment (0 to 100 mm VAS; where 100 is worst severity)</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Orthovisc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Saline</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="17.619732236832043" CI_START="-17.619732236832043" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-034.17.01" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="9" WEIGHT="100.0" Z="0.0">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="17.619732236832043" CI_START="-17.619732236832043" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="70.0" MEAN_2="70.0" ORDER="151128" SD_1="20.5" SD_2="23.2" SE="8.98982449464084" STUDY_ID="STD-Kotevoglu-2005" TOTAL_1="20" TOTAL_2="9" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="16.67393915031071" CI_START="-16.67393915031071" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-034.17.02" NO="2" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="9" WEIGHT="100.0" Z="0.0">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="16.67393915031071" CI_START="-16.67393915031071" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="70.0" MEAN_2="70.0" ORDER="151129" SD_1="20.5" SD_2="21.5" SE="8.507268134431353" STUDY_ID="STD-Kotevoglu-2005" TOTAL_1="20" TOTAL_2="9" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="6.495140939447872" CI_START="-26.49514093944787" DF="0" EFFECT_SIZE="-10.0" ESTIMABLE="YES" I2="0.0" ID="CMP-034.17.03" NO="3" P_CHI2="1.0" P_Z="0.2347519375851479" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="9" WEIGHT="100.0" Z="1.1882068736089613">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="6.495140939447872" CI_START="-26.49514093944787" EFFECT_SIZE="-10.0" ESTIMABLE="YES" MEAN_1="60.0" MEAN_2="70.0" ORDER="151130" SD_1="18.2" SD_2="22.1" SE="8.416042881175082" STUDY_ID="STD-Kotevoglu-2005" TOTAL_1="20" TOTAL_2="9" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.6107612648909269" CI_END="-0.45249305051212607" CI_START="-7.848188971659759" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.150341011085943" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-034.18" NO="18" P_CHI2="0.8939644767004257" P_Q="0.9710432663397229" P_Z="0.027821223088908543" Q="0.0013176797069648148" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="444" TOTAL_2="228" UNITS="" WEIGHT="200.0" Z="2.199798096627456">
<NAME>Physician global assessment (0 to 100 VAS; change from baseline)</NAME>
<GROUP_LABEL_1>Orthovisc 3 or 4 inj</GROUP_LABEL_1>
<GROUP_LABEL_2>Arthrocentesis</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Ortho 3/4inj</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours arthrocentes</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.1999791764093013" CI_END="1.0391188660486224" CI_START="-9.478297571193096" DF="1" EFFECT_SIZE="-4.219589352572236" ESTIMABLE="YES" I2="0.0" ID="CMP-034.18.01" NO="1" P_CHI2="0.6547376648333111" P_Z="0.11579390587107903" STUDIES="2" TAU2="0.0" TOTAL_1="222" TOTAL_2="114" WEIGHT="100.0" Z="1.5726758011227349">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="4.498391923370474" CI_START="-10.498391923370473" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="-23.0" MEAN_2="-20.0" ORDER="151131" SD_1="23.2" SD_2="23.4" SE="3.825780464598754" STUDY_ID="STD-Neustadt-2005a-_x002d_3inj" TOTAL_1="107" TOTAL_2="57" WEIGHT="49.18377697615681"/>
<CONT_DATA CI_END="1.9769677229949725" CI_START="-12.77696772299497" EFFECT_SIZE="-5.399999999999999" ESTIMABLE="YES" MEAN_1="-25.4" MEAN_2="-20.0" ORDER="151132" SD_1="22.9" SD_2="23.4" SE="3.763828203570857" STUDY_ID="STD-Neustadt-2005b_x002d_4inj" TOTAL_1="115" TOTAL_2="57" WEIGHT="50.81622302384319"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.4094644087746608" CI_END="1.1182573855371771" CI_START="-9.28347275600236" DF="1" EFFECT_SIZE="-4.082607685232592" ESTIMABLE="YES" I2="0.0" ID="CMP-034.18.02" NO="2" P_CHI2="0.5222414904470236" P_Z="0.1239154579855658" STUDIES="2" TAU2="0.0" TOTAL_1="222" TOTAL_2="114" WEIGHT="100.0" Z="1.5385448222901108">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="5.240625244757953" CI_START="-9.840625244757955" EFFECT_SIZE="-2.3000000000000007" ESTIMABLE="YES" MEAN_1="-18.3" MEAN_2="-16.0" ORDER="151133" SD_1="26.3" SD_2="21.8" SE="3.84732847350127" STUDY_ID="STD-Neustadt-2005a-_x002d_3inj" TOTAL_1="107" TOTAL_2="57" WEIGHT="47.57036219904141"/>
<CONT_DATA CI_END="1.4826905792281266" CI_START="-12.882690579228125" EFFECT_SIZE="-5.699999999999999" ESTIMABLE="YES" MEAN_1="-21.7" MEAN_2="-16.0" ORDER="151134" SD_1="24.2" SD_2="21.8" SE="3.664705390448127" STUDY_ID="STD-Neustadt-2005b_x002d_4inj" TOTAL_1="115" TOTAL_2="57" WEIGHT="52.429637800958595"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-2.337025933099114" CI_START="-5.662974066900886" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-034.19" NO="19" P_CHI2="1.0" P_Q="1.0" P_Z="2.4247342544765147E-6" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="22" TOTAL_2="19" UNITS="" WEIGHT="100.0" Z="4.714358506365979">
<NAME>Synovial fluid effusion volume (ml)</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Orthovisc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours saline</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-2.337025933099114" CI_START="-5.662974066900886" DF="0" EFFECT_SIZE="-4.0" ESTIMABLE="YES" I2="0.0" ID="CMP-034.19.01" NO="1" P_CHI2="1.0" P_Z="2.4247342544765147E-6" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="19" WEIGHT="100.0" Z="4.714358506365979">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="-2.337025933099114" CI_START="-5.662974066900886" EFFECT_SIZE="-4.0" ESTIMABLE="YES" MEAN_1="7.6" MEAN_2="11.6" ORDER="151135" SD_1="2.6" SD_2="2.8" SE="0.8484717474495516" STUDY_ID="STD-Sezgin-2005" TOTAL_1="22" TOTAL_2="19" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-9.712219350610786" CI_START="-14.087780649389218" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-11.900000000000002" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-034.20" NO="20" P_CHI2="1.0" P_Q="1.0" P_Z="1.5519552432121695E-26" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="22" TOTAL_2="19" UNITS="" WEIGHT="100.0" Z="10.660836324033726">
<NAME>Interleukin 6 level in the synovial fluid (pg/ml)</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Orthovisc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Saline</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-9.712219350610786" CI_START="-14.087780649389218" DF="0" EFFECT_SIZE="-11.900000000000002" ESTIMABLE="YES" I2="0.0" ID="CMP-034.20.01" NO="1" P_CHI2="1.0" P_Z="1.5519552432121695E-26" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="19" WEIGHT="100.0" Z="10.660836324033726">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="-9.712219350610786" CI_START="-14.087780649389218" EFFECT_SIZE="-11.900000000000002" ESTIMABLE="YES" MEAN_1="22.3" MEAN_2="34.2" ORDER="151136" SD_1="3.4" SD_2="3.7" SE="1.1162351281177363" STUDY_ID="STD-Sezgin-2005" TOTAL_1="22" TOTAL_2="19" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-3.063539309725982" CI_START="-6.536460690274019" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.800000000000001" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-034.21" NO="21" P_CHI2="1.0" P_Q="1.0" P_Z="6.033094900685108E-8" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="22" TOTAL_2="21" UNITS="" WEIGHT="99.99999999999999" Z="5.41781750573788">
<NAME>Interleukin 8 level in the synovial fluid (pg/ml)</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Orthovisc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Saline</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-3.063539309725982" CI_START="-6.536460690274019" DF="0" EFFECT_SIZE="-4.800000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-034.21.01" NO="1" P_CHI2="1.0" P_Z="6.033094900685108E-8" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="21" WEIGHT="99.99999999999999" Z="5.41781750573788">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="-3.063539309725982" CI_START="-6.536460690274019" EFFECT_SIZE="-4.800000000000001" ESTIMABLE="YES" MEAN_1="17.0" MEAN_2="21.8" ORDER="151137" SD_1="2.8" SD_2="3.0" SE="0.8859656115984778" STUDY_ID="STD-Sezgin-2005" TOTAL_1="22" TOTAL_2="21" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.9269411418115894" CI_START="-21.526941141811584" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-9.299999999999997" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-034.22" NO="22" P_CHI2="1.0" P_Q="1.0" P_Z="0.13601957061565187" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="22" TOTAL_2="19" UNITS="" WEIGHT="100.0" Z="1.4907788337911165">
<NAME>Tumor necrosis factor alpha levels in synovial fluid</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Orthovisc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Saline</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.9269411418115894" CI_START="-21.526941141811584" DF="0" EFFECT_SIZE="-9.299999999999997" ESTIMABLE="YES" I2="0.0" ID="CMP-034.22.01" NO="1" P_CHI2="1.0" P_Z="0.13601957061565187" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="19" WEIGHT="100.0" Z="1.4907788337911165">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="2.9269411418115894" CI_START="-21.526941141811584" EFFECT_SIZE="-9.299999999999997" ESTIMABLE="YES" MEAN_1="58.7" MEAN_2="68.0" ORDER="151138" SD_1="19.1" SD_2="20.6" SE="6.238349907577964" STUDY_ID="STD-Sezgin-2005" TOTAL_1="22" TOTAL_2="19" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="108" EVENTS_2="106" I2="0.0" I2_Q="0.0" ID="CMP-034.23" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="23" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="410" TOTAL_2="405" WEIGHT="0.0" Z="0.0">
<NAME>Safety: total withdrawals overall</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline/arthrocentesi</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Orthovisc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours saline/arthr</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3120803816771682" CI_START="0.4963699825042462" EFFECT_SIZE="0.8070175438596491" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="28" LOG_CI_END="0.11796044193712446" LOG_CI_START="-0.30419448991895914" LOG_EFFECT_SIZE="-0.09311702399091736" ORDER="151139" O_E="0.0" SE="0.24797589667287848" STUDY_ID="STD-Brandt-2001" TOTAL_1="114" TOTAL_2="112" VAR="0.0614920453307181" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.8599949262593907" CI_START="0.3024201797857781" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.2695117595401988" LOG_CI_START="-0.5193892327567986" LOG_EFFECT_SIZE="-0.12493873660829995" ORDER="151140" O_E="0.0" SE="0.46340434799814917" STUDY_ID="STD-Kotevoglu-2005" TOTAL_1="26" TOTAL_2="26" VAR="0.21474358974358973" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.8734606820100346" CI_START="0.9007526727183535" EFFECT_SIZE="1.299047619047619" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="35" LOG_CI_END="0.27264458306351763" LOG_CI_START="-0.045394440562473555" LOG_EFFECT_SIZE="0.11362507125052203" ORDER="151141" O_E="0.0" SE="0.18681769679646443" STUDY_ID="STD-Neustadt-2005a-_x002d_3inj" TOTAL_1="120" TOTAL_2="124" VAR="0.03490085183633571" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.4425296818227857" CI_START="0.6505769512583877" EFFECT_SIZE="0.96875" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="35" LOG_CI_END="0.15912475806293525" LOG_CI_START="-0.18670132703420186" LOG_EFFECT_SIZE="-0.013788284485633297" ORDER="151142" O_E="0.0" SE="0.2031399542527882" STUDY_ID="STD-Neustadt-2005b_x002d_4inj" TOTAL_1="128" TOTAL_2="124" VAR="0.04126584101382488" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="151143" O_E="0.0" SE="0.0" STUDY_ID="STD-Sezgin-2005" TOTAL_1="22" TOTAL_2="19" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="30" EVENTS_2="45" I2="0.0" I2_Q="0.0" ID="CMP-034.24" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="24" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="383" TOTAL_2="377" WEIGHT="0.0" Z="0.0">
<NAME>Safety: withdrawals due to lack of efficacy</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline/Arthrocentesi</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Orthovisc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Saline/Arthr</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7067857648560478" CI_START="0.42476773151896235" EFFECT_SIZE="0.8514619883040936" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="15" LOG_CI_END="0.23217901204628055" LOG_CI_START="-0.37184848287655137" LOG_EFFECT_SIZE="-0.06983473541513545" ORDER="151144" O_E="0.0" SE="0.3548087405019932" STUDY_ID="STD-Brandt-2001" TOTAL_1="114" TOTAL_2="112" VAR="0.12588924233661075" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.2519170223228397" CI_START="0.2427382470835401" EFFECT_SIZE="0.5512605042016807" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="15" LOG_CI_END="0.09757554457604654" LOG_CI_START="-0.6148617886097874" LOG_EFFECT_SIZE="-0.25864312201687045" ORDER="151145" O_E="0.0" SE="0.41848921613503476" STUDY_ID="STD-Neustadt-2005a-_x002d_3inj" TOTAL_1="119" TOTAL_2="123" VAR="0.17513322402131584" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.2684521669423392" CI_START="0.2620708333114158" EFFECT_SIZE="0.5765625" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="15" LOG_CI_END="0.10327409471527862" LOG_CI_START="-0.5815813103649323" LOG_EFFECT_SIZE="-0.2391536078248268" ORDER="151146" O_E="0.0" SE="0.4022874550330457" STUDY_ID="STD-Neustadt-2005b_x002d_4inj" TOTAL_1="128" TOTAL_2="123" VAR="0.16183519647696476" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="151147" O_E="0.0" SE="0.0" STUDY_ID="STD-Sezgin-2005" TOTAL_1="22" TOTAL_2="19" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="9" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-034.25" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="25" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="114" TOTAL_2="112" WEIGHT="0.0" Z="0.0">
<NAME>Safety: number of patients with treatment related adverse events</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Orthovisc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours saline</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.8646822875066713" CI_START="0.3465142871373918" EFFECT_SIZE="0.8038277511961722" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="11" LOG_CI_END="0.2706048455083027" LOG_CI_START="-0.4602788542786851" LOG_EFFECT_SIZE="-0.09483700438519116" ORDER="151148" O_E="0.0" SE="0.42932470318753985" STUDY_ID="STD-Brandt-2001" TOTAL_1="114" TOTAL_2="112" VAR="0.1843197007670692" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-034.26" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="26" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="26" TOTAL_2="26" WEIGHT="0.0" Z="0.0">
<NAME>Safety: number of patients withdrawn due to noncompliance</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Orthovisc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Saline</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.180743077657695" CI_START="0.04825562593098698" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7143920553787599" LOG_CI_START="-1.3164520467067224" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="151149" O_E="0.0" SE="1.1929278784054478" STUDY_ID="STD-Kotevoglu-2005" TOTAL_1="26" TOTAL_2="26" VAR="1.423076923076923" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="92" EVENTS_2="81" I2="0.0" I2_Q="0.0" ID="CMP-034.27" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="27" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="361" TOTAL_2="358" WEIGHT="0.0" Z="0.0">
<NAME>Safety: number of patients with reported musculoskeletal adverse events</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline/Arthro</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Orthovisc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours saline/arthr</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2509414787471693" CI_START="0.5864324173061233" EFFECT_SIZE="0.8565002249212775" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="39" LOG_CI_END="0.09723699310536307" LOG_CI_START="-0.23178203040643328" LOG_EFFECT_SIZE="-0.06727251865053507" ORDER="151150" O_E="0.0" SE="0.19326740308126242" STUDY_ID="STD-Brandt-2001" TOTAL_1="114" TOTAL_2="112" VAR="0.037352289093775165" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.9332991559079649" CI_START="0.6628790924097903" EFFECT_SIZE="1.1320528211284513" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="21" LOG_CI_END="0.2862990613268391" LOG_CI_START="-0.1785656786657576" LOG_EFFECT_SIZE="0.05386669133054075" ORDER="151151" O_E="0.0" SE="0.2730638493892262" STUDY_ID="STD-Neustadt-2005a-_x002d_3inj" TOTAL_1="119" TOTAL_2="123" VAR="0.07456386584326201" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.591045930764906" CI_START="0.9899486577796914" EFFECT_SIZE="1.6015625" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="21" LOG_CI_END="0.41347511167395506" LOG_CI_START="-0.004387328858183199" LOG_EFFECT_SIZE="0.20454389140788592" ORDER="151152" O_E="0.0" SE="0.2454544660210182" STUDY_ID="STD-Neustadt-2005b_x002d_4inj" TOTAL_1="128" TOTAL_2="123" VAR="0.06024789488966317" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="42" EVENTS_2="41" I2="0.0" I2_Q="0.0" ID="CMP-034.28" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="28" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="361" TOTAL_2="358" WEIGHT="0.0" Z="0.0">
<NAME>Safety: number of patients with general body adverse events</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline/Arthro</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Orthovisc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours saline/arthr</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5254951592084027" CI_START="0.5274708042639034" EFFECT_SIZE="0.897025171624714" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="23" LOG_CI_END="0.18341083385163834" LOG_CI_START="-0.27780157375156755" LOG_EFFECT_SIZE="-0.047195369949964594" ORDER="151153" O_E="0.0" SE="0.2709184512643611" STUDY_ID="STD-Brandt-2001" TOTAL_1="114" TOTAL_2="112" VAR="0.07339680723548" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.3617397999947283" CI_START="0.6630616194226822" EFFECT_SIZE="1.4929971988795518" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="9" LOG_CI_END="0.5265640958376512" LOG_CI_START="-0.178446110008893" LOG_EFFECT_SIZE="0.17405899291437907" ORDER="151154" O_E="0.0" SE="0.4141264847710627" STUDY_ID="STD-Neustadt-2005a-_x002d_3inj" TOTAL_1="119" TOTAL_2="123" VAR="0.17150074538883722" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.142616399258972" CI_START="0.3405185803192668" EFFECT_SIZE="0.8541666666666666" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.3309444246128407" LOG_CI_START="-0.4678591859245441" LOG_EFFECT_SIZE="-0.06845738065585175" ORDER="151155" O_E="0.0" SE="0.4692211949713036" STUDY_ID="STD-Neustadt-2005b_x002d_4inj" TOTAL_1="128" TOTAL_2="123" VAR="0.2201685298102981" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="9" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-034.29" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="29" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="361" TOTAL_2="358" WEIGHT="0.0" Z="0.0">
<NAME>Safety: number of patients with local skin rash</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline/Arthro</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Orthovisc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours saline/arthr</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.6059451010968786" CI_START="0.2572163601633615" EFFECT_SIZE="0.8187134502923976" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.4159652622814674" LOG_CI_START="-0.589701411709299" LOG_EFFECT_SIZE="-0.08686807471391583" ORDER="151156" O_E="0.0" SE="0.5907335824324987" STUDY_ID="STD-Brandt-2001" TOTAL_1="114" TOTAL_2="112" VAR="0.3489661654135338" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.2785349657498615" CI_START="0.029304925383131505" EFFECT_SIZE="0.25840336134453784" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.357655697529266" LOG_CI_START="-1.5330593800914565" LOG_EFFECT_SIZE="-0.5877018412810951" ORDER="151157" O_E="0.0" SE="1.1106153957849896" STUDY_ID="STD-Neustadt-2005a-_x002d_3inj" TOTAL_1="119" TOTAL_2="123" VAR="1.2334665573546493" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.154473619402955" CI_START="0.16465916569721528" EFFECT_SIZE="0.720703125" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.4989268997890359" LOG_CI_START="-0.7834140894225767" LOG_EFFECT_SIZE="-0.14224359481677037" ORDER="151158" O_E="0.0" SE="0.7532534447531721" STUDY_ID="STD-Neustadt-2005b_x002d_4inj" TOTAL_1="128" TOTAL_2="123" VAR="0.5673907520325202" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="32" EVENTS_2="36" I2="0.0" I2_Q="0.0" ID="CMP-034.30" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="30" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="361" TOTAL_2="358" WEIGHT="0.0" Z="0.0">
<NAME>Safety: number patients with gastrointestinal complaints</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline/Arthro</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Orthovisc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours saline/arthr</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.390455209992918" CI_START="0.3281064318730293" EFFECT_SIZE="0.6754385964912281" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="16" LOG_CI_END="0.14315700372429468" LOG_CI_START="-0.48398525605227616" LOG_EFFECT_SIZE="-0.17041412616399074" ORDER="151159" O_E="0.0" SE="0.3683864677970108" STUDY_ID="STD-Brandt-2001" TOTAL_1="114" TOTAL_2="112" VAR="0.13570858965595808" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.5774972895443584" CI_START="0.5015375489038739" EFFECT_SIZE="1.1369747899159663" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.4111982172585425" LOG_CI_START="-0.299696546848358" LOG_EFFECT_SIZE="0.0557508352050922" ORDER="151160" O_E="0.0" SE="0.41758310342222915" STUDY_ID="STD-Neustadt-2005a-_x002d_3inj" TOTAL_1="119" TOTAL_2="123" VAR="0.1743756482637401" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.227803552121741" CI_START="0.41448936466000824" EFFECT_SIZE="0.9609375" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" LOG_CI_END="0.3478768920712628" LOG_CI_START="-0.3824866084882037" LOG_EFFECT_SIZE="-0.017304858208470435" ORDER="151161" O_E="0.0" SE="0.42901913558626614" STUDY_ID="STD-Neustadt-2005b_x002d_4inj" TOTAL_1="128" TOTAL_2="123" VAR="0.18405741869918701" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="35" EVENTS_2="28" I2="0.0" I2_Q="0.0" ID="CMP-034.31" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="31" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="361" TOTAL_2="358" WEIGHT="0.0" Z="0.0">
<NAME>Safety: number of patients with reported respiratory adverse events</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline/Arthro</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Orthovisc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours saline/arthr</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.438722239136615" CI_START="0.8257825278474848" EFFECT_SIZE="1.4191033138401559" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="18" LOG_CI_END="0.38716233869846295" LOG_CI_START="-0.08313431029602114" LOG_EFFECT_SIZE="0.15201401420122088" ORDER="151162" O_E="0.0" SE="0.276254579625318" STUDY_ID="STD-Brandt-2001" TOTAL_1="114" TOTAL_2="112" VAR="0.07631659276396119" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.0051331353884385" CI_START="0.22752679899826636" EFFECT_SIZE="0.826890756302521" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.4778637171652931" LOG_CI_START="-0.6429674430876715" LOG_EFFECT_SIZE="-0.08255186296118927" ORDER="151163" O_E="0.0" SE="0.658381771736315" STUDY_ID="STD-Neustadt-2005a-_x002d_3inj" TOTAL_1="119" TOTAL_2="123" VAR="0.4334665573546492" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.2374634961553" CI_START="0.28522356468353977" EFFECT_SIZE="0.9609375" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.5102048802529535" LOG_CI_START="-0.5448145966698944" LOG_EFFECT_SIZE="-0.017304858208470435" ORDER="151164" O_E="0.0" SE="0.619723663175118" STUDY_ID="STD-Neustadt-2005b_x002d_4inj" TOTAL_1="128" TOTAL_2="123" VAR="0.384057418699187" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="53" EVENTS_2="68" I2="0.0" I2_Q="0.0" ID="CMP-034.32" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="32" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="361" TOTAL_2="358" WEIGHT="0.0" Z="0.0">
<NAME>Safety: number of patients with nervous system adverse events</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline/Arthro</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Orthovisc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours saline/arthr</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7720308076621079" CI_START="0.4787376982783619" EFFECT_SIZE="0.9210526315789473" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="16" LOG_CI_END="0.2484712680484064" LOG_CI_START="-0.31990237258147547" LOG_EFFECT_SIZE="-0.035715552266534535" ORDER="151165" O_E="0.0" SE="0.33386549000088916" STUDY_ID="STD-Brandt-2001" TOTAL_1="114" TOTAL_2="112" VAR="0.11146616541353382" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.2348004893553775" CI_START="0.4146845179006888" EFFECT_SIZE="0.7155785391079509" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="26" LOG_CI_END="0.09159679292238203" LOG_CI_START="-0.38228217856367136" LOG_EFFECT_SIZE="-0.14534269282064471" ORDER="151166" O_E="0.0" SE="0.2783588535896482" STUDY_ID="STD-Neustadt-2005a-_x002d_3inj" TOTAL_1="119" TOTAL_2="123" VAR="0.07748365137174319" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.2530684106035919" CI_START="0.4360424761997287" EFFECT_SIZE="0.7391826923076923" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="26" LOG_CI_END="0.09797478171770829" LOG_CI_START="-0.36047120274832267" LOG_EFFECT_SIZE="-0.13124821051530722" ORDER="151167" O_E="0.0" SE="0.2692934406195692" STUDY_ID="STD-Neustadt-2005b_x002d_4inj" TOTAL_1="128" TOTAL_2="123" VAR="0.07251895716072546" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-034.33" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="33" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="114" TOTAL_2="112" WEIGHT="0.0" Z="0.0">
<NAME>Safety: number of patients with urinary adverse events</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Orthovisc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours saline</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7795727048636287" CI_START="0.2410616299007972" EFFECT_SIZE="0.6549707602339181" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" LOG_CI_END="0.250315735906071" LOG_CI_START="-0.6178719113500155" LOG_EFFECT_SIZE="-0.18377808772197224" ORDER="151168" O_E="0.0" SE="0.5099777215963899" STUDY_ID="STD-Brandt-2001" TOTAL_1="114" TOTAL_2="112" VAR="0.2600772765246449" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-034.34" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="34" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="26" TOTAL_2="26" WEIGHT="0.0" Z="0.0">
<NAME>Safety: number of patients withdrawn due to local adverse events</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Orthovisc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Saline</GRAPH_LABEL_2>
<DICH_DATA CI_END="70.41836692752118" CI_START="0.12780756488237435" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.84768594912681" LOG_CI_START="-0.8934434396874849" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="151169" O_E="0.0" SE="1.6101529717988263" STUDY_ID="STD-Kotevoglu-2005" TOTAL_1="26" TOTAL_2="26" VAR="2.592592592592592" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-035" NO="35">
<NAME>Orthovisc versus betamethasone</NAME>
<CONT_OUTCOME CHI2="9.948186528497402" CI_END="0.448857540809215" CI_START="-7.0001528775967845" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.275647668393785" ESTIMABLE="YES" I2="89.94791666666666" I2_Q="89.94791666666666" ID="CMP-035.01" NO="1" P_CHI2="0.001610087012095418" P_Q="0.001610087012095418" P_Z="0.08475125809928348" Q="9.948186528497402" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="40" TOTAL_2="40" UNITS="" WEIGHT="200.0" Z="1.7237595587813013">
<NAME>WOMAC function (0-100 mm VAS)</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>Betamethasone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Orthovisc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Betamethason</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="8.392572973326786" CI_START="-2.3925729733267938" DF="0" EFFECT_SIZE="2.9999999999999964" ESTIMABLE="YES" I2="0.0" ID="CMP-035.01.01" NO="1" P_CHI2="1.0" P_Z="0.27555084840017896" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="1.0903685462772195">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="8.392572973326786" CI_START="-2.3925729733267938" EFFECT_SIZE="2.9999999999999964" ESTIMABLE="YES" MEAN_1="34.3" MEAN_2="31.3" ORDER="151170" SD_1="8.8" SD_2="8.6" SE="2.751363298439521" STUDY_ID="STD-Tekeoglu-1998" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-3.849730768504142" CI_START="-14.150269231495859" DF="0" EFFECT_SIZE="-9.0" ESTIMABLE="YES" I2="0.0" ID="CMP-035.01.02" NO="2" P_CHI2="1.0" P_Z="6.147977760511078E-4" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="3.425000726755633">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="-3.849730768504142" CI_START="-14.150269231495859" EFFECT_SIZE="-9.0" ESTIMABLE="YES" MEAN_1="30.9" MEAN_2="39.9" ORDER="151171" SD_1="8.7" SD_2="7.9" SE="2.6277366686941823" STUDY_ID="STD-Tekeoglu-1998" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.1064687388435264" CI_END="0.2511675555618442" CI_START="-12.520251889858717" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-6.134542167148436" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-035.02" NO="2" P_CHI2="0.7442008432396678" P_Q="0.7442008432396678" P_Z="0.05971755375478988" Q="0.1064687388435264" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="40" TOTAL_2="40" UNITS="" WEIGHT="200.0" Z="1.8828732014693135">
<NAME>Flexion (degrees)</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>Betamethasone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Betamethason</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Orthovisc</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="4.886090557516033" CI_START="-14.686090557516044" DF="0" EFFECT_SIZE="-4.900000000000006" ESTIMABLE="YES" I2="0.0" ID="CMP-035.02.01" NO="1" P_CHI2="1.0" P_Z="0.3264079178257824" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.9813748879393136">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="4.886090557516033" CI_START="-14.686090557516044" EFFECT_SIZE="-4.900000000000006" ESTIMABLE="YES" MEAN_1="117.3" MEAN_2="122.2" ORDER="151172" SD_1="19.2" SD_2="11.4" SE="4.992995093127972" STUDY_ID="STD-Tekeoglu-1998" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.377047436009958" CI_START="-15.477047436009952" DF="0" EFFECT_SIZE="-7.049999999999997" ESTIMABLE="YES" I2="0.0" ID="CMP-035.02.02" NO="2" P_CHI2="1.0" P_Z="0.1010696224081035" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="1.639690080770426">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="1.377047436009958" CI_START="-15.477047436009952" EFFECT_SIZE="-7.049999999999997" ESTIMABLE="YES" MEAN_1="121.2" MEAN_2="128.25" ORDER="151173" SD_1="16.3" SD_2="10.2" SE="4.299593003994681" STUDY_ID="STD-Tekeoglu-1998" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="3.766299307370698" CI_END="1.8679034279429807" CI_START="0.8364993482134648" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="20" I2="73.44873791514694" I2_Q="73.38839413768135" ID="CMP-035.03" LOG_CI_END="0.27135441911268565" LOG_CI_START="-0.07753439309657278" LOG_EFFECT_SIZE="0.09691001300805642" METHOD="MH" NO="3" P_CHI2="0.05229525252121814" P_Q="0.05256302127608714" P_Z="0.27622929979009725" Q="3.7577589461294947" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="40" TOTAL_2="40" WEIGHT="200.0" Z="1.0888290400276603">
<NAME>Patient global assessment (number of patients good or very good)</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>Betamethasone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Betamethason</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Orthovisc</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4673694533734563" CI_START="0.4732580761088689" DF="0" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="12" I2="0.0" ID="CMP-035.03.01" LOG_CI_END="0.16653947400723612" LOG_CI_START="-0.32490196610248573" LOG_EFFECT_SIZE="-0.0791812460476248" NO="1" P_CHI2="1.0" P_Z="0.5276611014146648" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.6315803993643679">
<NAME>1 to 4 weeks post-injection</NAME>
<DICH_DATA CI_END="1.4673694533734565" CI_START="0.47325807610886883" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="12" LOG_CI_END="0.16653947400723618" LOG_CI_START="-0.3249019661024858" LOG_EFFECT_SIZE="-0.0791812460476248" ORDER="151174" O_E="0.0" SE="0.2886751345948129" STUDY_ID="STD-Tekeoglu-1998" TOTAL_1="20" TOTAL_2="20" VAR="0.08333333333333336" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.3940273482543373" CI_START="1.0358269510728026" DF="0" EFFECT_SIZE="1.875" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="8" I2="0.0" ID="CMP-035.03.02" LOG_CI_END="0.5307153374360166" LOG_CI_START="0.015287206691458673" LOG_EFFECT_SIZE="0.27300127206373764" NO="2" P_CHI2="1.0" P_Z="0.03787304725583759" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="2.0762260694060735">
<NAME>5 to 13 weeks post-injection</NAME>
<DICH_DATA CI_END="3.3940273482543373" CI_START="1.0358269510728026" EFFECT_SIZE="1.875" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="8" LOG_CI_END="0.5307153374360166" LOG_CI_START="0.015287206691458673" LOG_EFFECT_SIZE="0.27300127206373764" ORDER="151175" O_E="0.0" SE="0.30276503540974914" STUDY_ID="STD-Tekeoglu-1998" TOTAL_1="20" TOTAL_2="20" VAR="0.09166666666666666" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-035.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Safety: total withdrawals overall</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>Betamethasone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Orthovisc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Betamethason</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="151176" O_E="0.0" SE="0.0" STUDY_ID="STD-Tekeoglu-1998" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-035.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Safety: number of patients withdrawn due to adverse events</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>Betamethasone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Orthovisc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Betamethason</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="151177" O_E="0.0" SE="0.0" STUDY_ID="STD-Tekeoglu-1998" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-035.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Safety: number of patients with local adverse events</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>Betamethasone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Orthovisc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours betamethason</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="151178" O_E="0.0" SE="0.0" STUDY_ID="STD-Tekeoglu-1998" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-035.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Safety: number of patients with systemic adverse events</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>Betamethasone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Orthovisc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Betamethason</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="151179" O_E="0.0" SE="0.0" STUDY_ID="STD-Tekeoglu-1998" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-036" NO="36">
<NAME>Orthovisc versus 6-methylprednisolone acetate</NAME>
<CONT_OUTCOME CHI2="11.176171777714988" CI_END="-3.4321373684676013" CI_START="-14.646461982795252" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-9.039299675631426" ESTIMABLE="YES" I2="82.10478471717882" I2_Q="82.10478471717882" ID="CMP-036.01" NO="1" P_CHI2="0.003742190626845665" P_Q="0.003742190626845665" P_Z="0.001579557288296229" Q="11.176171777714988" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="84" TOTAL_2="81" UNITS="" WEIGHT="300.0" Z="3.1596556045946755">
<NAME>Pain on weight bearing (0-100 mm VAS)</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>6-MPA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Orthovisc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 6-MPA</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="15.00420914154019" CI_START="-4.944209141540195" DF="0" EFFECT_SIZE="5.029999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-036.01.01" NO="1" P_CHI2="1.0" P_Z="0.32295137564758325" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="27" WEIGHT="100.0" Z="0.9884110812533177">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="15.00420914154019" CI_START="-4.944209141540195" EFFECT_SIZE="5.029999999999998" ESTIMABLE="YES" MEAN_1="31.83" MEAN_2="26.8" ORDER="151180" SD_1="21.57" SD_2="15.83" SE="5.088975726194707" STUDY_ID="STD-Tascioglu-2003" TOTAL_1="28" TOTAL_2="27" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-6.765395301326116" CI_START="-24.514604698673885" DF="0" EFFECT_SIZE="-15.64" ESTIMABLE="YES" I2="0.0" ID="CMP-036.01.02" NO="2" P_CHI2="1.0" P_Z="5.521176926545474E-4" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="27" WEIGHT="100.0" Z="3.454107282410787">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="-6.765395301326116" CI_START="-24.514604698673885" EFFECT_SIZE="-15.64" ESTIMABLE="YES" MEAN_1="22.86" MEAN_2="38.5" ORDER="151181" SD_1="17.05" SD_2="16.53" SE="4.527942742150179" STUDY_ID="STD-Tascioglu-2003" TOTAL_1="28" TOTAL_2="27" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-4.892607732806866" CI_START="-25.90739226719313" DF="0" EFFECT_SIZE="-15.399999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-036.01.03" NO="3" P_CHI2="1.0" P_Z="0.004071202078453541" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="27" WEIGHT="100.0" Z="2.872591466500928">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="-4.892607732806866" CI_START="-25.90739226719313" EFFECT_SIZE="-15.399999999999999" ESTIMABLE="YES" MEAN_1="40.96" MEAN_2="56.36" ORDER="151182" SD_1="23.15" SD_2="16.1" SE="5.361012931907985" STUDY_ID="STD-Tascioglu-2003" TOTAL_1="28" TOTAL_2="27" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="7.485097649744241" CI_END="1.2603727088675765" CI_START="-5.618627270591228" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.1791272808618256" ESTIMABLE="YES" I2="73.28024170708932" I2_Q="73.28024170708932" ID="CMP-036.02" NO="2" P_CHI2="0.023693730529427914" P_Q="0.023693730529427914" P_Z="0.21432756530928587" Q="7.485097649744241" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="84" TOTAL_2="81" UNITS="" WEIGHT="300.0" Z="1.2417534528191387">
<NAME>Pain at rest (0-100 mm VAS)</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>6-MPA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Orthovisc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 6-MPA</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="9.151599994291864" CI_START="-2.0915999942918644" DF="0" EFFECT_SIZE="3.5299999999999994" ESTIMABLE="YES" I2="0.0" ID="CMP-036.02.01" NO="1" P_CHI2="1.0" P_Z="0.21842381366339403" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="27" WEIGHT="100.0" Z="1.2307301964656978">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="9.151599994291864" CI_START="-2.0915999942918644" EFFECT_SIZE="3.5299999999999994" ESTIMABLE="YES" MEAN_1="11.83" MEAN_2="8.3" ORDER="151183" SD_1="11.47" SD_2="9.76" SE="2.8682159665352662" STUDY_ID="STD-Tascioglu-2003" TOTAL_1="28" TOTAL_2="27" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-1.8968107073750309" CI_START="-13.503189292624967" DF="0" EFFECT_SIZE="-7.699999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-036.02.02" NO="2" P_CHI2="1.0" P_Z="0.009306329403124184" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="27" WEIGHT="100.0" Z="2.6005911439314686">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="-1.8968107073750309" CI_START="-13.503189292624967" EFFECT_SIZE="-7.699999999999999" ESTIMABLE="YES" MEAN_1="12.0" MEAN_2="19.7" ORDER="151184" SD_1="10.15" SD_2="11.72" SE="2.960865270178322" STUDY_ID="STD-Tascioglu-2003" TOTAL_1="28" TOTAL_2="27" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.6663578681366635" CI_START="-9.466357868136669" DF="0" EFFECT_SIZE="-2.900000000000002" ESTIMABLE="YES" I2="0.0" ID="CMP-036.02.03" NO="3" P_CHI2="1.0" P_Z="0.38670487074935656" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="27" WEIGHT="100.0" Z="0.8656085564186711">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="3.6663578681366635" CI_START="-9.466357868136669" EFFECT_SIZE="-2.900000000000002" ESTIMABLE="YES" MEAN_1="23.56" MEAN_2="26.46" ORDER="151185" SD_1="10.11" SD_2="14.3" SE="3.350244147306409" STUDY_ID="STD-Tascioglu-2003" TOTAL_1="28" TOTAL_2="27" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="5.831208710153573" CI_END="-5.0685494954131585" CI_START="-17.6992756328526" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-11.38391256413288" ESTIMABLE="YES" I2="65.70179358324961" I2_Q="65.70179358324961" ID="CMP-036.03" NO="3" P_CHI2="0.05417136747043527" P_Q="0.05417136747043527" P_Z="4.109017799774358E-4" Q="5.831208710153573" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="84" TOTAL_2="81" UNITS="" WEIGHT="300.0" Z="3.5329811423457347">
<NAME>Pain on walking (0-100 mm VAS)</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>6-MPA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Orthovisc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 6-MPA</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="10.65509439014233" CI_START="-11.455094390142326" DF="0" EFFECT_SIZE="-0.3999999999999986" ESTIMABLE="YES" I2="0.0" ID="CMP-036.03.01" NO="1" P_CHI2="1.0" P_Z="0.9434644278540887" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="27" WEIGHT="100.0" Z="0.07091622795324913">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="10.65509439014233" CI_START="-11.455094390142326" EFFECT_SIZE="-0.3999999999999986" ESTIMABLE="YES" MEAN_1="37.6" MEAN_2="38.0" ORDER="151186" SD_1="25.0" SD_2="16.01" SE="5.640457925422865" STUDY_ID="STD-Tascioglu-2003" TOTAL_1="28" TOTAL_2="27" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-7.669208232189822" CI_START="-29.190791767810175" DF="0" EFFECT_SIZE="-18.43" ESTIMABLE="YES" I2="0.0" ID="CMP-036.03.02" NO="2" P_CHI2="1.0" P_Z="7.884190103571528E-4" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="27" WEIGHT="100.0" Z="3.356828848145628">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="-7.6692082321898205" CI_START="-29.19079176781018" EFFECT_SIZE="-18.43" ESTIMABLE="YES" MEAN_1="32.03" MEAN_2="50.46" ORDER="151187" SD_1="22.15" SD_2="18.46" SE="5.4903007671007895" STUDY_ID="STD-Tascioglu-2003" TOTAL_1="28" TOTAL_2="27" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-3.89340197223998" CI_START="-25.906598027760033" DF="0" EFFECT_SIZE="-14.900000000000006" ESTIMABLE="YES" I2="0.0" ID="CMP-036.03.03" NO="3" P_CHI2="1.0" P_Z="0.007971635576972143" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="27" WEIGHT="100.0" Z="2.6532688207556965">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="-3.89340197223998" CI_START="-25.906598027760033" EFFECT_SIZE="-14.900000000000006" ESTIMABLE="YES" MEAN_1="51.16" MEAN_2="66.06" ORDER="151188" SD_1="20.81" SD_2="20.83" SE="5.61571442872352" STUDY_ID="STD-Tascioglu-2003" TOTAL_1="28" TOTAL_2="27" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="5.783055264028993" CI_END="-0.40760733302712565" CI_START="-1.3647901531446458" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.8861987430858858" ESTIMABLE="YES" I2="65.4162046065833" I2_Q="65.4162046065833" ID="CMP-036.04" NO="4" P_CHI2="0.05549145357039931" P_Q="0.05549145357039931" P_Z="2.842694549365084E-4" Q="5.783055264028993" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="84" TOTAL_2="81" UNITS="" WEIGHT="300.0" Z="3.629228571778475">
<NAME>Lequesne Index (0-24)</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>6-MPA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Orthovisc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 6-MPA</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.135342561577585E-33" CI_END="0.7072440904233342" CI_START="-0.9072440904233335" DF="0" EFFECT_SIZE="-0.09999999999999966" ESTIMABLE="YES" I2="100.0" ID="CMP-036.04.01" NO="1" P_CHI2="0.0" P_Z="0.8081627030710743" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="27" WEIGHT="100.0" Z="0.24279694429378923">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="0.7072440904233342" CI_START="-0.9072440904233335" EFFECT_SIZE="-0.09999999999999964" ESTIMABLE="YES" MEAN_1="7.86" MEAN_2="7.96" ORDER="151189" SD_1="1.47" SD_2="1.58" SE="0.4118667979568871" STUDY_ID="STD-Tascioglu-2003" TOTAL_1="28" TOTAL_2="27" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.6700057266347519" CI_START="-2.1299942733652486" DF="0" EFFECT_SIZE="-1.4000000000000004" ESTIMABLE="YES" I2="0.0" ID="CMP-036.04.02" NO="2" P_CHI2="1.0" P_Z="1.706862221651667E-4" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="27" WEIGHT="100.0" Z="3.758864526027805">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="-0.6700057266347519" CI_START="-2.1299942733652486" EFFECT_SIZE="-1.4000000000000004" ESTIMABLE="YES" MEAN_1="7.66" MEAN_2="9.06" ORDER="151190" SD_1="1.6" SD_2="1.13" SE="0.37245290174888424" STUDY_ID="STD-Tascioglu-2003" TOTAL_1="28" TOTAL_2="27" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.11656486325957927" CI_START="-2.1634351367404183" DF="0" EFFECT_SIZE="-1.1399999999999988" ESTIMABLE="YES" I2="0.0" ID="CMP-036.04.03" NO="3" P_CHI2="1.0" P_Z="0.029021419089949256" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="27" WEIGHT="100.0" Z="2.1831954582798097">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="-0.11656486325957927" CI_START="-2.1634351367404183" EFFECT_SIZE="-1.1399999999999988" ESTIMABLE="YES" MEAN_1="8.46" MEAN_2="9.6" ORDER="151191" SD_1="2.04" SD_2="1.83" SE="0.5221703790544853" STUDY_ID="STD-Tascioglu-2003" TOTAL_1="28" TOTAL_2="27" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.8692816821098446" CI_END="5.714558155034279" CI_START="0.4569888826344668" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="3.085773518834373" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-036.05" NO="5" P_CHI2="0.6474972012107119" P_Q="0.6474972012107119" P_Z="0.021409451583248567" Q="0.8692816821098446" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="84" TOTAL_2="81" UNITS="" WEIGHT="300.0" Z="2.3006848404689477">
<NAME>Flexion (active range in degrees)</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>6-MPA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 6-MPA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Orthovisc</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="6.903029012654973" CI_START="-2.58302901265498" DF="0" EFFECT_SIZE="2.1599999999999966" ESTIMABLE="YES" I2="0.0" ID="CMP-036.05.01" NO="1" P_CHI2="1.0" P_Z="0.3720833439108716" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="27" WEIGHT="100.0" Z="0.8925777589196608">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="6.903029012654973" CI_START="-2.58302901265498" EFFECT_SIZE="2.1599999999999966" ESTIMABLE="YES" MEAN_1="116.36" MEAN_2="114.2" ORDER="151192" SD_1="7.79" SD_2="9.98" SE="2.4199572288406235" STUDY_ID="STD-Tascioglu-2003" TOTAL_1="28" TOTAL_2="27" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="6.544655889331561" CI_START="-1.824655889331562" DF="0" EFFECT_SIZE="2.3599999999999994" ESTIMABLE="YES" I2="0.0" ID="CMP-036.05.02" NO="2" P_CHI2="1.0" P_Z="0.2690073964940066" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="27" WEIGHT="100.0" Z="1.105351342103636">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="6.544655889331561" CI_START="-1.824655889331562" EFFECT_SIZE="2.3599999999999994" ESTIMABLE="YES" MEAN_1="115.76" MEAN_2="113.4" ORDER="151193" SD_1="7.72" SD_2="8.1" SE="2.135067747335968" STUDY_ID="STD-Tascioglu-2003" TOTAL_1="28" TOTAL_2="27" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="9.814060984153368" CI_START="0.18593901584663275" DF="0" EFFECT_SIZE="5.0" ESTIMABLE="YES" I2="0.0" ID="CMP-036.05.03" NO="3" P_CHI2="1.0" P_Z="0.041783912626646845" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="27" WEIGHT="100.0" Z="2.035665928404048">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="9.814060984153368" CI_START="0.18593901584663275" EFFECT_SIZE="5.0" ESTIMABLE="YES" MEAN_1="114.6" MEAN_2="109.6" ORDER="151194" SD_1="8.19" SD_2="9.91" SE="2.456198696570991" STUDY_ID="STD-Tascioglu-2003" TOTAL_1="28" TOTAL_2="27" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-036.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="30" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>Safety: total withdrawals overall</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>6-MPA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Orthovisc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 6-MPA</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.7086562974712898" CI_START="0.11983975024794946" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.569216586623787" LOG_CI_START="-0.9213991047351496" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="151195" O_E="0.0" SE="0.8755950357709131" STUDY_ID="STD-Tascioglu-2003" TOTAL_1="30" TOTAL_2="30" VAR="0.7666666666666666" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-036.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="30" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>Safety: number of patients withdrawn due to increased pain</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>6-MPA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Orthovisc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 6-MPA</GRAPH_LABEL_2>
<DICH_DATA CI_END="15.259760455310136" CI_START="0.0655318281652329" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1835477162038213" LOG_CI_START="-1.1835477162038213" LOG_EFFECT_SIZE="0.0" ORDER="151196" O_E="0.0" SE="1.390443574307614" STUDY_ID="STD-Tascioglu-2003" TOTAL_1="30" TOTAL_2="30" VAR="1.9333333333333331" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-036.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="28" TOTAL_2="27" WEIGHT="0.0" Z="0.0">
<NAME>Safety: number of patients reporting musculoskeletal adverse events</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>6-MPA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Orthovisc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 6-MPA</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.738675139046553" CI_START="0.4874721478113713" EFFECT_SIZE="1.35" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.5727177300782947" LOG_CI_START="-0.3120501930882824" LOG_EFFECT_SIZE="0.13033376849500614" ORDER="151197" O_E="0.0" SE="0.5197170577399015" STUDY_ID="STD-Tascioglu-2003" TOTAL_1="28" TOTAL_2="27" VAR="0.2701058201058201" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-036.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="28" TOTAL_2="27" WEIGHT="0.0" Z="0.0">
<NAME>Safety: number of patients reporting skin adverse events</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>6-MPA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Orthovisc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 6-MPA</GRAPH_LABEL_2>
<DICH_DATA CI_END="20.05141597482389" CI_START="0.1854925238083944" EFFECT_SIZE="1.9285714285714286" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3021450466987943" LOG_CI_START="-0.7316735897372958" LOG_EFFECT_SIZE="0.2852357284807493" ORDER="151198" O_E="0.0" SE="1.1946751346071773" STUDY_ID="STD-Tascioglu-2003" TOTAL_1="28" TOTAL_2="27" VAR="1.4272486772486772" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-036.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="28" TOTAL_2="27" WEIGHT="0.0" Z="0.0">
<NAME>Safety: number of patients reporting gastrointestinal adverse events</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>6-MPA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Orthovisc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 6-MPA</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.991740530856307" CI_START="0.26178973205737016" EFFECT_SIZE="1.4464285714285714" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.902641375137019" LOG_CI_START="-0.5820473913921204" LOG_EFFECT_SIZE="0.16029699187244933" ORDER="151199" O_E="0.0" SE="0.8721135307871393" STUDY_ID="STD-Tascioglu-2003" TOTAL_1="28" TOTAL_2="27" VAR="0.7605820105820105" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-036.11" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="11" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="28" TOTAL_2="27" WEIGHT="0.0" Z="0.0">
<NAME>Safety: number of patients reporting general adverse events</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>6-MPA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Orthovisc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 6-MPA</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.5710385234076076" CI_START="0.23146368107607704" EFFECT_SIZE="0.7714285714285715" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.4101085839855311" LOG_CI_START="-0.6355171443681078" LOG_EFFECT_SIZE="-0.11270428019128831" ORDER="151200" O_E="0.0" SE="0.6142057287657592" STUDY_ID="STD-Tascioglu-2003" TOTAL_1="28" TOTAL_2="27" VAR="0.3772486772486773" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-036.12" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="12" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="28" TOTAL_2="27" WEIGHT="0.0" Z="0.0">
<NAME>Safety: number of patients reporting knee pain after injection</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>6-MPA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Orthovisc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 6-MPA</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.3485519533246864" CI_START="0.39986824469224624" EFFECT_SIZE="1.1571428571428573" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.5248570414735398" LOG_CI_START="-0.39808308374475404" LOG_EFFECT_SIZE="0.06338697886439296" ORDER="151201" O_E="0.0" SE="0.5421395981805276" STUDY_ID="STD-Tascioglu-2003" TOTAL_1="28" TOTAL_2="27" VAR="0.29391534391534396" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-037" NO="37">
<NAME>Orthovisc versus (Orthovisc plus triamcinolone acetonide)</NAME>
<CONT_OUTCOME CHI2="6.086295390967663" CI_END="8.241865841178422" CI_START="-0.47451152410990494" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="3.8836771585342587" ESTIMABLE="YES" I2="34.278575996554814" I2_Q="34.278575996554814" ID="CMP-037.01" NO="1" P_CHI2="0.19279585473549488" P_Q="0.19279585473549488" P_Z="0.08071252241943037" Q="6.086295390967663" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="120" TOTAL_2="80" UNITS="" WEIGHT="500.0" Z="1.7465667304908408">
<NAME>Pain (0-100 mm VAS)</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>OR+TA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Orthovisc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours OR+TA</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="22.22628454768326" CI_START="3.7737154523167398" DF="0" EFFECT_SIZE="13.0" ESTIMABLE="YES" I2="0.0" ID="CMP-037.01.01" NO="1" P_CHI2="1.0" P_Z="0.00575146152621655" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="16" WEIGHT="100.0" Z="2.7616243209644638">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="22.22628454768326" CI_START="3.7737154523167398" EFFECT_SIZE="13.0" ESTIMABLE="YES" MEAN_1="53.5" MEAN_2="40.5" ORDER="151202" SD_1="14.1" SD_2="14.9" SE="4.707374533643993" STUDY_ID="STD-Ozturk-2005" TOTAL_1="24" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="7.358143895070931" CI_START="-11.358143895070931" DF="0" EFFECT_SIZE="-2.0" ESTIMABLE="YES" I2="0.0" ID="CMP-037.01.02" NO="2" P_CHI2="1.0" P_Z="0.6753047215874597" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="16" WEIGHT="100.00000000000001" Z="0.4188787876135128">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="7.358143895070931" CI_START="-11.358143895070931" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="51.4" MEAN_2="53.4" ORDER="151203" SD_1="14.0" SD_2="15.3" SE="4.774650947102486" STUDY_ID="STD-Ozturk-2005" TOTAL_1="24" TOTAL_2="16" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="13.994594119339697" CI_START="-3.9945941193396965" DF="0" EFFECT_SIZE="5.0" ESTIMABLE="YES" I2="0.0" ID="CMP-037.01.03" NO="3" P_CHI2="1.0" P_Z="0.2759231998688759" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="16" WEIGHT="100.00000000000001" Z="1.08952330618557">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="13.994594119339697" CI_START="-3.9945941193396965" EFFECT_SIZE="5.0" ESTIMABLE="YES" MEAN_1="54.8" MEAN_2="49.8" ORDER="151204" SD_1="13.3" SD_2="14.8" SE="4.589162959262469" STUDY_ID="STD-Ozturk-2005" TOTAL_1="24" TOTAL_2="16" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="12.61811732255816" CI_START="-8.61811732255816" DF="0" EFFECT_SIZE="2.0" ESTIMABLE="YES" I2="0.0" ID="CMP-037.01.04" NO="4" P_CHI2="1.0" P_Z="0.7119983771941829" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="16" WEIGHT="100.0" Z="0.3691735408453467">
<NAME>34 weeks post-injection</NAME>
<CONT_DATA CI_END="12.61811732255816" CI_START="-8.61811732255816" EFFECT_SIZE="2.0" ESTIMABLE="YES" MEAN_1="61.5" MEAN_2="59.5" ORDER="151205" SD_1="19.5" SD_2="14.7" SE="5.417506345173949" STUDY_ID="STD-Ozturk-2005" TOTAL_1="24" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="10.408125112788106" CI_START="-11.608125112788109" DF="0" EFFECT_SIZE="-0.6000000000000014" ESTIMABLE="YES" I2="0.0" ID="CMP-037.01.05" NO="5" P_CHI2="1.0" P_Z="0.9149252607524848" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="16" WEIGHT="100.0" Z="0.10682821812752696">
<NAME>45 to 52 weeks post-injection</NAME>
<CONT_DATA CI_END="10.408125112788106" CI_START="-11.608125112788109" EFFECT_SIZE="-0.6000000000000014" ESTIMABLE="YES" MEAN_1="61.5" MEAN_2="62.1" ORDER="151206" SD_1="19.8" SD_2="15.6" SE="5.616493568054716" STUDY_ID="STD-Ozturk-2005" TOTAL_1="24" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.6343761334174902" CI_END="0.9320180327316774" CI_START="-1.504796772368578" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.2863893698184503" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-037.02" NO="2" P_CHI2="0.8026008541358884" P_Q="0.8026008541358884" P_Z="0.645018238062673" Q="1.6343761334174902" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="120" TOTAL_2="80" UNITS="" WEIGHT="500.0" Z="0.46069389370456615">
<NAME>WOMAC pain (0-20 Likert)</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>Orthovisc+TA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Orthovisc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours OR+TA</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="7.921350634834098E-33" CI_END="3.2448864975258567" CI_START="-1.6448864975258588" DF="0" EFFECT_SIZE="0.799999999999999" ESTIMABLE="YES" I2="100.0" ID="CMP-037.02.01" NO="1" P_CHI2="0.0" P_Z="0.5213103966508317" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="16" WEIGHT="100.0" Z="0.6413267811077428">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="3.2448864975258567" CI_START="-1.6448864975258588" EFFECT_SIZE="0.7999999999999989" ESTIMABLE="YES" MEAN_1="12.6" MEAN_2="11.8" ORDER="151207" SD_1="4.1" SD_2="3.7" SE="1.2474139916910771" STUDY_ID="STD-Ozturk-2005" TOTAL_1="24" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.3361966008457582" CI_START="-3.5361966008457575" DF="0" EFFECT_SIZE="-1.0999999999999996" ESTIMABLE="YES" I2="0.0" ID="CMP-037.02.02" NO="2" P_CHI2="1.0" P_Z="0.3761729371910536" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="16" WEIGHT="100.0" Z="0.8849697853800425">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="1.3361966008457582" CI_START="-3.5361966008457575" EFFECT_SIZE="-1.0999999999999996" ESTIMABLE="YES" MEAN_1="13.1" MEAN_2="14.2" ORDER="151208" SD_1="4.2" SD_2="3.6" SE="1.2429802894656052" STUDY_ID="STD-Ozturk-2005" TOTAL_1="24" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.7316315947577952" CI_START="-4.131631594757794" DF="0" EFFECT_SIZE="-1.1999999999999993" ESTIMABLE="YES" I2="0.0" ID="CMP-037.02.03" NO="3" P_CHI2="1.0" P_Z="0.4223974500167319" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="16" WEIGHT="100.0" Z="0.8022688750024806">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="1.7316315947577952" CI_START="-4.131631594757794" EFFECT_SIZE="-1.1999999999999993" ESTIMABLE="YES" MEAN_1="12.4" MEAN_2="13.6" ORDER="151209" SD_1="3.4" SD_2="5.3" SE="1.4957578903909103" STUDY_ID="STD-Ozturk-2005" TOTAL_1="24" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.7905316007630367" CI_START="-2.990531600763036" DF="0" EFFECT_SIZE="-0.09999999999999964" ESTIMABLE="YES" I2="0.0" ID="CMP-037.02.04" NO="4" P_CHI2="1.0" P_Z="0.9459397885411935" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="16" WEIGHT="100.0" Z="0.06780635036208081">
<NAME>34 weeks post-injection</NAME>
<CONT_DATA CI_END="2.7905316007630367" CI_START="-2.990531600763036" EFFECT_SIZE="-0.09999999999999964" ESTIMABLE="YES" MEAN_1="13.3" MEAN_2="13.4" ORDER="151210" SD_1="4.2" SD_2="4.8" SE="1.4747881203752624" STUDY_ID="STD-Ozturk-2005" TOTAL_1="24" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.234283112611917" CI_START="-3.034283112611918" DF="0" EFFECT_SIZE="0.09999999999999964" ESTIMABLE="YES" I2="0.0" ID="CMP-037.02.05" NO="5" P_CHI2="1.0" P_Z="0.9501383139003989" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="16" WEIGHT="100.0" Z="0.062533086965036">
<NAME>45 to 52 weeks post-injection</NAME>
<CONT_DATA CI_END="3.234283112611917" CI_START="-3.034283112611918" EFFECT_SIZE="0.09999999999999964" ESTIMABLE="YES" MEAN_1="13.5" MEAN_2="13.4" ORDER="151211" SD_1="4.0" SD_2="5.5" SE="1.5991534218662906" STUDY_ID="STD-Ozturk-2005" TOTAL_1="24" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.5267894734357036" CI_END="8.0535698942325" CI_START="1.6267066928684413" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="4.840138293550471" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-037.03" NO="3" P_CHI2="0.9708411785205224" P_Q="0.9708411785205224" P_Z="0.0031558084119675373" Q="0.5267894734357036" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="120" TOTAL_2="80" UNITS="" WEIGHT="500.0" Z="2.9521389948174512">
<NAME>WOMAC physical function (0-68 Likert)</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>OR+TA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Orthovisc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours OR+TA</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="13.41325622401304" CI_START="-3.4132562240130397" DF="0" EFFECT_SIZE="5.0" ESTIMABLE="YES" I2="0.0" ID="CMP-037.03.01" NO="1" P_CHI2="1.0" P_Z="0.2440971362762352" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="16" WEIGHT="100.0" Z="1.1648070214157644">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="13.41325622401304" CI_START="-3.4132562240130397" EFFECT_SIZE="5.0" ESTIMABLE="YES" MEAN_1="45.6" MEAN_2="40.6" ORDER="151212" SD_1="13.3" SD_2="13.3" SE="4.292556542046554" STUDY_ID="STD-Ozturk-2005" TOTAL_1="24" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="14.223107541129476" CI_START="-0.6231075411294817" DF="0" EFFECT_SIZE="6.799999999999997" ESTIMABLE="YES" I2="0.0" ID="CMP-037.03.02" NO="2" P_CHI2="1.0" P_Z="0.0725833906668535" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="16" WEIGHT="100.0" Z="1.7954414672058558">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="14.223107541129476" CI_START="-0.6231075411294809" EFFECT_SIZE="6.799999999999997" ESTIMABLE="YES" MEAN_1="47.3" MEAN_2="40.5" ORDER="151213" SD_1="11.0" SD_2="12.2" SE="3.7873693596831384" STUDY_ID="STD-Ozturk-2005" TOTAL_1="24" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="12.58121784079997" CI_START="-1.9812178407999763" DF="0" EFFECT_SIZE="5.299999999999997" ESTIMABLE="YES" I2="0.0" ID="CMP-037.03.03" NO="3" P_CHI2="1.0" P_Z="0.15367844048956347" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="16" WEIGHT="100.00000000000001" Z="1.426658197184359">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="12.58121784079997" CI_START="-1.9812178407999763" EFFECT_SIZE="5.299999999999997" ESTIMABLE="YES" MEAN_1="44.9" MEAN_2="39.6" ORDER="151214" SD_1="10.9" SD_2="11.9" SE="3.714975325176019" STUDY_ID="STD-Ozturk-2005" TOTAL_1="24" TOTAL_2="16" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="10.327420384608466" CI_START="-1.7274203846084726" DF="0" EFFECT_SIZE="4.299999999999997" ESTIMABLE="YES" I2="0.0" ID="CMP-037.03.04" NO="4" P_CHI2="1.0" P_Z="0.16203777867547497" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="16" WEIGHT="100.0" Z="1.3982507599840632">
<NAME>34 weeks post-injection</NAME>
<CONT_DATA CI_END="10.327420384608466" CI_START="-1.7274203846084726" EFFECT_SIZE="4.299999999999997" ESTIMABLE="YES" MEAN_1="44.0" MEAN_2="39.7" ORDER="151215" SD_1="10.4" SD_2="8.9" SE="3.0752709907692144" STUDY_ID="STD-Ozturk-2005" TOTAL_1="24" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="10.51695968171473" CI_START="-4.316959681714727" DF="0" EFFECT_SIZE="3.1000000000000014" ESTIMABLE="YES" I2="0.0" ID="CMP-037.03.05" NO="5" P_CHI2="1.0" P_Z="0.41267886158017597" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="16" WEIGHT="100.00000000000001" Z="0.8191885371917629">
<NAME>45 to 52 weeks post-injection</NAME>
<CONT_DATA CI_END="10.51695968171473" CI_START="-4.316959681714727" EFFECT_SIZE="3.1000000000000014" ESTIMABLE="YES" MEAN_1="46.0" MEAN_2="42.9" ORDER="151216" SD_1="11.3" SD_2="12.0" SE="3.784232639078452" STUDY_ID="STD-Ozturk-2005" TOTAL_1="24" TOTAL_2="16" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.6121786742429756" CI_END="0.8178949170270573" CI_START="-1.6681471921141107" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.4251261375435267" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-037.04" NO="4" P_CHI2="0.9617007937086853" P_Q="0.9617007937086853" P_Z="0.502648674172939" Q="0.6121786742429756" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="120" TOTAL_2="80" UNITS="" WEIGHT="500.0" Z="0.6703280812566633">
<NAME>50 foot walking time (seconds)</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>OR+TA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Orthovisc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours OR+TA</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.2628782797041516" CI_START="-3.0628782797041487" DF="0" EFFECT_SIZE="0.10000000000000142" ESTIMABLE="YES" I2="0.0" ID="CMP-037.04.01" NO="1" P_CHI2="1.0" P_Z="0.9505885275040774" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="16" WEIGHT="100.00000000000001" Z="0.06196773353931955">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="3.2628782797041516" CI_START="-3.0628782797041487" EFFECT_SIZE="0.10000000000000142" ESTIMABLE="YES" MEAN_1="22.3" MEAN_2="22.2" ORDER="151217" SD_1="7.0" SD_2="3.0" SE="1.613743060919757" STUDY_ID="STD-Ozturk-2005" TOTAL_1="24" TOTAL_2="16" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.556229683404362" CI_START="-3.1562296834043635" DF="0" EFFECT_SIZE="0.1999999999999993" ESTIMABLE="YES" I2="0.0" ID="CMP-037.04.02" NO="2" P_CHI2="1.0" P_Z="0.907022045402391" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="16" WEIGHT="100.0" Z="0.1167955813174249">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="3.556229683404362" CI_START="-3.1562296834043635" EFFECT_SIZE="0.1999999999999993" ESTIMABLE="YES" MEAN_1="21.9" MEAN_2="21.7" ORDER="151218" SD_1="7.6" SD_2="2.9" SE="1.7123935490028765" STUDY_ID="STD-Ozturk-2005" TOTAL_1="24" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.9185402430823246" CI_START="-3.318540243082323" DF="0" EFFECT_SIZE="-0.1999999999999993" ESTIMABLE="YES" I2="0.0" ID="CMP-037.04.03" NO="3" P_CHI2="1.0" P_Z="0.8999713594047524" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="16" WEIGHT="100.0" Z="0.12569752716115953">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="2.9185402430823246" CI_START="-3.318540243082323" EFFECT_SIZE="-0.1999999999999993" ESTIMABLE="YES" MEAN_1="22.3" MEAN_2="22.5" ORDER="151219" SD_1="7.0" SD_2="2.8" SE="1.591121197981683" STUDY_ID="STD-Ozturk-2005" TOTAL_1="24" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.946236999439843" CI_START="-2.9462369994398427" DF="0" EFFECT_SIZE="-1.0" ESTIMABLE="YES" I2="0.0" ID="CMP-037.04.04" NO="4" P_CHI2="1.0" P_Z="0.3139092758259755" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="16" WEIGHT="100.0" Z="1.0070530901961898">
<NAME>34 weeks post-injection</NAME>
<CONT_DATA CI_END="0.946236999439843" CI_START="-2.9462369994398427" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="22.4" MEAN_2="23.4" ORDER="151220" SD_1="2.3" SD_2="3.5" SE="0.992996307478868" STUDY_ID="STD-Ozturk-2005" TOTAL_1="24" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.1033534419638227" CI_START="-3.5033534419638284" DF="0" EFFECT_SIZE="-0.20000000000000284" ESTIMABLE="YES" I2="0.0" ID="CMP-037.04.05" NO="5" P_CHI2="1.0" P_Z="0.9055406800258243" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="16" WEIGHT="99.99999999999999" Z="0.11866510919733096">
<NAME>45 to 52 weeks post-injection</NAME>
<CONT_DATA CI_END="3.1033534419638227" CI_START="-3.5033534419638284" EFFECT_SIZE="-0.20000000000000284" ESTIMABLE="YES" MEAN_1="22.4" MEAN_2="22.6" ORDER="151221" SD_1="7.2" SD_2="3.3" SE="1.6854153790683175" STUDY_ID="STD-Ozturk-2005" TOTAL_1="24" TOTAL_2="16" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.14023334349428468" CI_END="-0.7724623611903985" CI_START="-7.603981760306863" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.188222060748631" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-037.05" NO="5" P_CHI2="0.9976537666723528" P_Q="0.9976537666723528" P_Z="0.016252156982595353" Q="0.14023334349428468" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="120" TOTAL_2="80" UNITS="" WEIGHT="500.0" Z="2.4032031291267653">
<NAME>Range of motion (degrees)</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>OR+TA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours OR+TA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Orthovisc</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="4.551056426354826" CI_START="-10.551056426354826" DF="0" EFFECT_SIZE="-3.0" ESTIMABLE="YES" I2="0.0" ID="CMP-037.05.01" NO="1" P_CHI2="1.0" P_Z="0.43616548976668656" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="16" WEIGHT="100.0" Z="0.7786846795500115">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="4.551056426354826" CI_START="-10.551056426354826" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="115.9" MEAN_2="118.9" ORDER="151222" SD_1="13.7" SD_2="10.6" SE="3.852650602723619" STUDY_ID="STD-Ozturk-2005" TOTAL_1="24" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.2049820846730945" CI_START="-12.004982084673106" DF="0" EFFECT_SIZE="-4.900000000000006" ESTIMABLE="YES" I2="0.0" ID="CMP-037.05.02" NO="2" P_CHI2="1.0" P_Z="0.1764704384414323" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="16" WEIGHT="100.0" Z="1.351702708014379">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="2.2049820846730945" CI_START="-12.004982084673106" EFFECT_SIZE="-4.900000000000006" ESTIMABLE="YES" MEAN_1="115.0" MEAN_2="119.9" ORDER="151223" SD_1="12.5" SD_2="10.3" SE="3.6250574708087964" STUDY_ID="STD-Ozturk-2005" TOTAL_1="24" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.2643927401017923" CI_START="-11.664392740101798" DF="0" EFFECT_SIZE="-4.200000000000003" ESTIMABLE="YES" I2="0.0" ID="CMP-037.05.03" NO="3" P_CHI2="1.0" P_Z="0.27010727092501075" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="16" WEIGHT="100.0" Z="1.1028155968861804">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="3.2643927401017923" CI_START="-11.664392740101798" EFFECT_SIZE="-4.200000000000003" ESTIMABLE="YES" MEAN_1="114.7" MEAN_2="118.9" ORDER="151224" SD_1="13.4" SD_2="10.6" SE="3.8084336237706267" STUDY_ID="STD-Ozturk-2005" TOTAL_1="24" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.92786173167271" CI_START="-12.527861731672704" DF="0" EFFECT_SIZE="-4.299999999999997" ESTIMABLE="YES" I2="0.0" ID="CMP-037.05.04" NO="4" P_CHI2="1.0" P_Z="0.3056909516329428" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="16" WEIGHT="100.0" Z="1.0243056347288502">
<NAME>34 weeks post-injection</NAME>
<CONT_DATA CI_END="3.92786173167271" CI_START="-12.527861731672704" EFFECT_SIZE="-4.299999999999997" ESTIMABLE="YES" MEAN_1="113.5" MEAN_2="117.8" ORDER="151225" SD_1="15.1" SD_2="11.4" SE="4.197965777214801" STUDY_ID="STD-Ozturk-2005" TOTAL_1="24" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.4957162545579363" CI_START="-12.495716254557937" DF="0" EFFECT_SIZE="-4.5" ESTIMABLE="YES" I2="0.0" ID="CMP-037.05.05" NO="5" P_CHI2="1.0" P_Z="0.2699966112334461" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="16" WEIGHT="100.0" Z="1.1030704004037812">
<NAME>45 to 52 weeks post-injection</NAME>
<CONT_DATA CI_END="3.4957162545579363" CI_START="-12.495716254557937" EFFECT_SIZE="-4.5" ESTIMABLE="YES" MEAN_1="113.7" MEAN_2="118.2" ORDER="151226" SD_1="15.6" SD_2="10.2" SE="4.07952203082665" STUDY_ID="STD-Ozturk-2005" TOTAL_1="24" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.2207899064832795" CI_END="0.9199264768061519" CI_START="0.2776347655773633" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="0.5987806211917576" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-037.06" NO="6" P_CHI2="0.6952249614307368" P_Q="0.6952249614307368" P_Z="2.578058927821073E-4" Q="2.2207899064832795" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="120" TOTAL_2="80" UNITS="" WEIGHT="500.0" Z="3.654378319568026">
<NAME>WOMAC stiffness (0-8 Likert)</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>OR+TA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Orthovisc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours OR+TA</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.5773219798374072" CI_START="0.02267802016259235" DF="0" EFFECT_SIZE="0.7999999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-037.06.01" NO="1" P_CHI2="1.0" P_Z="0.04368037801786874" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="16" WEIGHT="100.0" Z="2.0171450548201606">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="1.5773219798374072" CI_START="0.02267802016259235" EFFECT_SIZE="0.7999999999999998" ESTIMABLE="YES" MEAN_1="3.9" MEAN_2="3.1" ORDER="151227" SD_1="1.4" SD_2="1.1" SE="0.3966001344763598" STUDY_ID="STD-Ozturk-2005" TOTAL_1="24" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.9941281318091051" CI_START="-0.5941281318091047" DF="0" EFFECT_SIZE="0.20000000000000018" ESTIMABLE="YES" I2="0.0" ID="CMP-037.06.02" NO="2" P_CHI2="1.0" P_Z="0.6215787838218007" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="16" WEIGHT="100.0" Z="0.49361404187383673">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="0.9941281318091051" CI_START="-0.5941281318091047" EFFECT_SIZE="0.20000000000000018" ESTIMABLE="YES" MEAN_1="3.5" MEAN_2="3.3" ORDER="151228" SD_1="1.0" SD_2="1.4" SE="0.4051748593714406" STUDY_ID="STD-Ozturk-2005" TOTAL_1="24" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.0325756559408301" CI_START="-0.23257565594083018" DF="0" EFFECT_SIZE="0.3999999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-037.06.03" NO="3" P_CHI2="1.0" P_Z="0.21521420425906035" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="16" WEIGHT="99.99999999999999" Z="1.2393546707863732">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="1.0325756559408301" CI_START="-0.23257565594083018" EFFECT_SIZE="0.3999999999999999" ESTIMABLE="YES" MEAN_1="3.6" MEAN_2="3.2" ORDER="151229" SD_1="1.0" SD_2="1.0" SE="0.3227486121839514" STUDY_ID="STD-Ozturk-2005" TOTAL_1="24" TOTAL_2="16" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.4818919108540478" CI_START="0.11810808914595194" DF="0" EFFECT_SIZE="0.7999999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-037.06.04" NO="4" P_CHI2="1.0" P_Z="0.021479829322033454" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="16" WEIGHT="100.0" Z="2.2994424228734567">
<NAME>34 weeks post-injection</NAME>
<CONT_DATA CI_END="1.4818919108540478" CI_START="0.11810808914595194" EFFECT_SIZE="0.7999999999999998" ESTIMABLE="YES" MEAN_1="3.9" MEAN_2="3.1" ORDER="151230" SD_1="1.3" SD_2="0.9" SE="0.3479104290858017" STUDY_ID="STD-Ozturk-2005" TOTAL_1="24" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.5441843275135108" CI_START="0.05581567248648889" DF="0" EFFECT_SIZE="0.7999999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-037.06.05" NO="5" P_CHI2="1.0" P_Z="0.03512051381968472" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="16" WEIGHT="100.0" Z="2.1069661502695056">
<NAME>45 to 52 weeks post-injection</NAME>
<CONT_DATA CI_END="1.5441843275135108" CI_START="0.05581567248648889" EFFECT_SIZE="0.7999999999999998" ESTIMABLE="YES" MEAN_1="3.9" MEAN_2="3.1" ORDER="151231" SD_1="1.4" SD_2="1.0" SE="0.37969285832981725" STUDY_ID="STD-Ozturk-2005" TOTAL_1="24" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.22044065036320887" CI_END="9.187381941031127" CI_START="1.0482519259657836" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="5.117816933498456" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-037.07" NO="7" P_CHI2="0.9943541618665084" P_Q="0.9943541618665084" P_Z="0.013708288189816233" Q="0.22044065036320887" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="120" TOTAL_2="80" UNITS="" WEIGHT="500.0" Z="2.464817947510245">
<NAME>WOMAC total score (0-96 Likert)</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>OR+TA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Orthovisc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours OR+TA</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="16.90898649586567" CI_START="-3.3089864958656747" DF="0" EFFECT_SIZE="6.799999999999997" ESTIMABLE="YES" I2="0.0" ID="CMP-037.07.01" NO="1" P_CHI2="1.0" P_Z="0.18736755341604644" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="16" WEIGHT="100.0" Z="1.318406657316546">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="16.90898649586567" CI_START="-3.3089864958656747" EFFECT_SIZE="6.799999999999997" ESTIMABLE="YES" MEAN_1="62.3" MEAN_2="55.5" ORDER="151232" SD_1="15.8" SD_2="16.1" SE="5.157740946060268" STUDY_ID="STD-Ozturk-2005" TOTAL_1="24" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="15.384543301060082" CI_START="-3.5845433010600853" DF="0" EFFECT_SIZE="5.899999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-037.07.02" NO="2" P_CHI2="1.0" P_Z="0.2227590203752141" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="16" WEIGHT="100.00000000000001" Z="1.2192244941824282">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="15.384543301060082" CI_START="-3.5845433010600853" EFFECT_SIZE="5.899999999999999" ESTIMABLE="YES" MEAN_1="63.9" MEAN_2="58.0" ORDER="151233" SD_1="14.2" SD_2="15.5" SE="4.839141624985434" STUDY_ID="STD-Ozturk-2005" TOTAL_1="24" TOTAL_2="16" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="13.842352220614062" CI_START="-4.842352220614062" DF="0" EFFECT_SIZE="4.5" ESTIMABLE="YES" I2="0.0" ID="CMP-037.07.03" NO="3" P_CHI2="1.0" P_Z="0.34513370019714673" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="16" WEIGHT="100.00000000000001" Z="0.9440703713749006">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="13.842352220614062" CI_START="-4.842352220614062" EFFECT_SIZE="4.5" ESTIMABLE="YES" MEAN_1="60.9" MEAN_2="56.4" ORDER="151234" SD_1="12.7" SD_2="16.0" SE="4.766593822287217" STUDY_ID="STD-Ozturk-2005" TOTAL_1="24" TOTAL_2="16" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="12.79382439577064" CI_START="-2.9938243957706288" DF="0" EFFECT_SIZE="4.900000000000006" ESTIMABLE="YES" I2="0.0" ID="CMP-037.07.04" NO="4" P_CHI2="1.0" P_Z="0.22374697704641644" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="16" WEIGHT="100.0" Z="1.2166249263654545">
<NAME>34 weeks post-injection</NAME>
<CONT_DATA CI_END="12.79382439577064" CI_START="-2.9938243957706288" EFFECT_SIZE="4.900000000000006" ESTIMABLE="YES" MEAN_1="61.2" MEAN_2="56.3" ORDER="151235" SD_1="13.3" SD_2="11.9" SE="4.027535433322303" STUDY_ID="STD-Ozturk-2005" TOTAL_1="24" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="13.03864953752644" CI_START="-5.2386495375264435" DF="0" EFFECT_SIZE="3.8999999999999986" ESTIMABLE="YES" I2="0.0" ID="CMP-037.07.05" NO="5" P_CHI2="1.0" P_Z="0.4029118860432567" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="16" WEIGHT="100.0" Z="0.8364320689088567">
<NAME>45 to 52 weeks post-injection</NAME>
<CONT_DATA CI_END="13.03864953752644" CI_START="-5.2386495375264435" EFFECT_SIZE="3.8999999999999986" ESTIMABLE="YES" MEAN_1="63.4" MEAN_2="59.5" ORDER="151236" SD_1="13.9" SD_2="14.8" SE="4.662661972164256" STUDY_ID="STD-Ozturk-2005" TOTAL_1="24" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-037.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="24" TOTAL_2="23" WEIGHT="0.0" Z="0.0">
<NAME>Safety: total withdrawals overall</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>OR+TA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Orthovisc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours OR+TA</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.88394405137381" CI_START="0.016234108233971586" EFFECT_SIZE="0.11979166666666667" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="8" LOG_CI_END="-0.05357522248531646" LOG_CI_START="-1.7895715628865971" LOG_EFFECT_SIZE="-0.9215733926859567" ORDER="151237" O_E="0.0" SE="1.0197328436721884" STUDY_ID="STD-Ozturk-2005" TOTAL_1="24" TOTAL_2="23" VAR="1.039855072463768" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-037.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="24" TOTAL_2="23" WEIGHT="0.0" Z="0.0">
<NAME>Safety: withdrawals due to lack of efficacy</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>OR+TA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Orthovisc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours OR+TA</GRAPH_LABEL_2>
<DICH_DATA CI_END="67.28973413262064" CI_START="0.12326397342650598" EFFECT_SIZE="2.88" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8279488123721221" LOG_CI_START="-0.9091638368536604" LOG_EFFECT_SIZE="0.45939248775923086" ORDER="151238" O_E="0.0" SE="1.6077935190813526" STUDY_ID="STD-Ozturk-2005" TOTAL_1="24" TOTAL_2="23" VAR="2.585" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-037.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="24" TOTAL_2="23" WEIGHT="0.0" Z="0.0">
<NAME>Safety: number of patients reporting adverse events (local reactions)</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>OR+TA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Orthovisc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours OR+TA</GRAPH_LABEL_2>
<DICH_DATA CI_END="19.725639100100512" CI_START="0.18623534033391048" EFFECT_SIZE="1.9166666666666667" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2950310830171046" LOG_CI_START="-0.7299379030771684" LOG_EFFECT_SIZE="0.28254658996996806" ORDER="151239" O_E="0.0" SE="1.1894768061899181" STUDY_ID="STD-Ozturk-2005" TOTAL_1="24" TOTAL_2="23" VAR="1.414855072463768" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-038" NO="38">
<NAME>Orthovisc versus (Orthovisc plus lidocaine trigger point injection)(1 week post-injection)</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-038.01" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="17" TOTAL_2="16" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Pain at rest (0 to 4 point scale)</NAME>
<GROUP_LABEL_1>Orthovisc+lido</GROUP_LABEL_1>
<GROUP_LABEL_2>Orthovisc</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Ortho+lidoca</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lido</GRAPH_LABEL_2>
<CONT_DATA CI_END="-1.2521202267451386" CI_START="-2.207879773254861" EFFECT_SIZE="-1.73" ESTIMABLE="YES" MEAN_1="0.52" MEAN_2="2.25" ORDER="151240" SD_1="0.7" SD_2="0.7" SE="0.24382069110673257" STUDY_ID="STD-Yentur-2003" TOTAL_1="17" TOTAL_2="16" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-038.02" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="17" TOTAL_2="16" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Pain/restrictions walking (0 to 4 point scale)</NAME>
<GROUP_LABEL_1>Orthovisc+lidocaine</GROUP_LABEL_1>
<GROUP_LABEL_2>Orthovisc</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Ortho+lidoca</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Orthovisc</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.6352249051775544" CI_START="-1.604775094822446" EFFECT_SIZE="-1.12" ESTIMABLE="YES" MEAN_1="0.88" MEAN_2="2.0" ORDER="151241" SD_1="0.6" SD_2="0.8" SE="0.24733877696033693" STUDY_ID="STD-Yentur-2003" TOTAL_1="17" TOTAL_2="16" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-038.03" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="17" TOTAL_2="16" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Pain/restrictions going up or down stairs (0 to 4 point scale)</NAME>
<GROUP_LABEL_1>Ortho+lidocaine</GROUP_LABEL_1>
<GROUP_LABEL_2>Orthovisc</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Ortho+lidoca</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Orthovisc</GRAPH_LABEL_2>
<CONT_DATA CI_END="-1.0052249051775544" CI_START="-1.974775094822446" EFFECT_SIZE="-1.4900000000000002" ESTIMABLE="YES" MEAN_1="0.88" MEAN_2="2.37" ORDER="151242" SD_1="0.6" SD_2="0.8" SE="0.24733877696033693" STUDY_ID="STD-Yentur-2003" TOTAL_1="17" TOTAL_2="16" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-038.04" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="17" TOTAL_2="16" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Range of motion (degrees)</NAME>
<GROUP_LABEL_1>Orthovisc+lidocaine</GROUP_LABEL_1>
<GROUP_LABEL_2>Orthovisc</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Orthovisc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Ortho+lido</GRAPH_LABEL_2>
<CONT_DATA CI_END="17.161288936450894" CI_START="-1.9612889364508757" EFFECT_SIZE="7.6000000000000085" ESTIMABLE="YES" MEAN_1="124.4" MEAN_2="116.8" ORDER="151243" SD_1="15.0" SD_2="13.0" SE="4.878298280922053" STUDY_ID="STD-Yentur-2003" TOTAL_1="17" TOTAL_2="16" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-038.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="17" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>Safety: total withdrawals overall</NAME>
<GROUP_LABEL_1>Orthovisc+lidocaine</GROUP_LABEL_1>
<GROUP_LABEL_2>Orthovisc</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Ortho+lidoca</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Orthovisc</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.649243330266568" CI_START="0.01452576500886906" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8836184764944177" LOG_CI_START="-1.8378609859337425" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="151244" O_E="0.0" SE="1.5986105077709065" STUDY_ID="STD-Yentur-2003" TOTAL_1="17" TOTAL_2="17" VAR="2.555555555555556" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-039" NO="39">
<NAME>Orthovisc versus physical therapy</NAME>
<CONT_OUTCOME CHI2="6.139451457679289" CI_END="10.0586397344041" CI_START="-0.9697621162872503" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="4.544438809058424" ESTIMABLE="YES" I2="34.84759953600156" I2_Q="34.84759953600156" ID="CMP-039.01" NO="1" P_CHI2="0.18897335902631518" P_Q="0.18897335902631518" P_Z="0.10625172441340848" Q="6.139451457679289" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="100" TOTAL_2="100" UNITS="" WEIGHT="500.0" Z="1.615272369702823">
<NAME>Spontaneous pain (0-100 mm VAS)</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>Physical therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Orthovisc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours therapy</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="10.323173118227118" CI_START="-11.52317311822712" DF="0" EFFECT_SIZE="-0.6000000000000014" ESTIMABLE="YES" I2="0.0" ID="CMP-039.01.01" NO="1" P_CHI2="1.0" P_Z="0.9142661576687837" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.10765904540702749">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="10.323173118227118" CI_START="-11.52317311822712" EFFECT_SIZE="-0.6000000000000014" ESTIMABLE="YES" MEAN_1="42.9" MEAN_2="43.5" ORDER="151245" SD_1="20.2" SD_2="14.6" SE="5.573149917237109" STUDY_ID="STD-Atamaz-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="20.19838914806337" CI_START="-2.398389148063373" DF="0" EFFECT_SIZE="8.899999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-039.01.02" NO="2" P_CHI2="1.0" P_Z="0.12261049161100035" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="1.5439085372091699">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="20.19838914806337" CI_START="-2.398389148063373" EFFECT_SIZE="8.899999999999999" ESTIMABLE="YES" MEAN_1="58.4" MEAN_2="49.5" ORDER="151246" SD_1="20.6" SD_2="15.5" SE="5.764590184913408" STUDY_ID="STD-Atamaz-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="31.701401617947866" CI_START="3.6985983820521415" DF="0" EFFECT_SIZE="17.700000000000003" ESTIMABLE="YES" I2="0.0" ID="CMP-039.01.03" NO="3" P_CHI2="1.0" P_Z="0.013222990078673722" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="2.4777064091847376">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="31.701401617947866" CI_START="3.6985983820521398" EFFECT_SIZE="17.700000000000003" ESTIMABLE="YES" MEAN_1="66.2" MEAN_2="48.5" ORDER="151247" SD_1="28.1" SD_2="15.2" SE="7.143703521283621" STUDY_ID="STD-Atamaz-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.18390698946604E-33" CI_END="14.14822329767335" CI_START="-11.14822329767335" DF="0" EFFECT_SIZE="1.4999999999999998" ESTIMABLE="YES" I2="100.0" ID="CMP-039.01.04" NO="4" P_CHI2="0.0" P_Z="0.8161967168767253" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.23243944288609186">
<NAME>37 weeks post-injection</NAME>
<CONT_DATA CI_END="14.14822329767335" CI_START="-11.14822329767335" EFFECT_SIZE="1.5" ESTIMABLE="YES" MEAN_1="52.2" MEAN_2="50.7" ORDER="151248" SD_1="23.1" SD_2="17.3" SE="6.453293732660866" STUDY_ID="STD-Atamaz-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="10.908823743341296" CI_START="-16.50882374334129" DF="0" EFFECT_SIZE="-2.799999999999997" ESTIMABLE="YES" I2="0.0" ID="CMP-039.01.05" NO="5" P_CHI2="1.0" P_Z="0.6889217620226923" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.4003187479434734">
<NAME>45 to 52 weeks post-injection</NAME>
<CONT_DATA CI_END="10.908823743341296" CI_START="-16.50882374334129" EFFECT_SIZE="-2.799999999999997" ESTIMABLE="YES" MEAN_1="56.7" MEAN_2="59.5" ORDER="151249" SD_1="23.0" SD_2="21.2" SE="6.994426352460936" STUDY_ID="STD-Atamaz-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="9.865980125610104" CI_END="-0.691293123442636" CI_START="-2.413034456167017" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.5521637898048266" ESTIMABLE="YES" I2="59.45663837679134" I2_Q="59.45663837679134" ID="CMP-039.02" NO="2" P_CHI2="0.04274683043375549" P_Q="0.04274683043375549" P_Z="4.095582587076738E-4" Q="9.865980125610104" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="100" TOTAL_2="100" UNITS="" WEIGHT="500.0" Z="3.5338468889643098">
<NAME>WOMAC pain</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>Physical Therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Orthovisc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours physical the</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.3873414429551667" CI_START="-3.612658557044833" DF="0" EFFECT_SIZE="-2.0" ESTIMABLE="YES" I2="0.0" ID="CMP-039.02.01" NO="1" P_CHI2="1.0" P_Z="0.015068685486632996" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="2.430724068623245">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="-0.3873414429551667" CI_START="-3.612658557044833" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="9.3" MEAN_2="11.3" ORDER="151250" SD_1="2.7" SD_2="2.5" SE="0.8228000972289685" STUDY_ID="STD-Atamaz-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.9507266753862584" CI_START="-2.1507266753862613" DF="0" EFFECT_SIZE="-0.6000000000000014" ESTIMABLE="YES" I2="0.0" ID="CMP-039.02.02" NO="2" P_CHI2="1.0" P_Z="0.4482473482488655" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.7583402087483399">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="0.9507266753862584" CI_START="-2.1507266753862613" EFFECT_SIZE="-0.6000000000000014" ESTIMABLE="YES" MEAN_1="11.2" MEAN_2="11.8" ORDER="151251" SD_1="2.4" SD_2="2.6" SE="0.7912016177940993" STUDY_ID="STD-Atamaz-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.1088304601362213" CI_START="-1.908830460136222" DF="0" EFFECT_SIZE="0.5999999999999996" ESTIMABLE="YES" I2="0.0" ID="CMP-039.02.03" NO="3" P_CHI2="1.0" P_Z="0.6392585704421614" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.46873569554005645">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="3.1088304601362213" CI_START="-1.908830460136222" EFFECT_SIZE="0.5999999999999996" ESTIMABLE="YES" MEAN_1="11.9" MEAN_2="11.3" ORDER="151252" SD_1="5.1" SD_2="2.6" SE="1.2800390619039719" STUDY_ID="STD-Atamaz-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.9954462379508295E-32" CI_END="0.2772368233007063" CI_START="-4.077236823300707" DF="0" EFFECT_SIZE="-1.9000000000000001" ESTIMABLE="YES" I2="100.0" ID="CMP-039.02.04" NO="4" P_CHI2="0.0" P_Z="0.08719314406161625" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="1.7103934357405348">
<NAME>37 weeks post-injection</NAME>
<CONT_DATA CI_END="0.2772368233007061" CI_START="-4.077236823300707" EFFECT_SIZE="-1.9000000000000004" ESTIMABLE="YES" MEAN_1="10.4" MEAN_2="12.3" ORDER="151253" SD_1="3.8" SD_2="3.2" SE="1.1108555261599053" STUDY_ID="STD-Atamaz-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-1.937450600205667" CI_START="-6.662549399794335" DF="0" EFFECT_SIZE="-4.300000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-039.02.05" NO="5" P_CHI2="1.0" P_Z="3.6072351838992E-4" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="3.5672672640224588">
<NAME>45 to 52 weeks post-injection</NAME>
<CONT_DATA CI_END="-1.937450600205667" CI_START="-6.662549399794335" EFFECT_SIZE="-4.300000000000001" ESTIMABLE="YES" MEAN_1="11.2" MEAN_2="15.5" ORDER="151254" SD_1="3.5" SD_2="4.1" SE="1.2054044964243331" STUDY_ID="STD-Atamaz-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.7627732663922118" CI_END="2.6549281306169537" CI_START="-4.420640397263839" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.8828561333234426" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-039.03" NO="3" P_CHI2="0.9433680048291475" P_Q="0.9433680048291475" P_Z="0.6247637111032651" Q="0.7627732663922118" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="100" TOTAL_2="100" UNITS="" WEIGHT="500.0" Z="0.48911015928284785">
<NAME>WOMAC physical function</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>Physical Therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Orthovisc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours phys therapy</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="5.10873432153034" CI_START="-9.908734321530337" DF="0" EFFECT_SIZE="-2.3999999999999986" ESTIMABLE="YES" I2="0.0" ID="CMP-039.03.01" NO="1" P_CHI2="1.0" P_Z="0.5310139799178265" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.6264589159065402">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="5.10873432153034" CI_START="-9.908734321530337" EFFECT_SIZE="-2.3999999999999986" ESTIMABLE="YES" MEAN_1="35.2" MEAN_2="37.6" ORDER="151255" SD_1="11.5" SD_2="12.7" SE="3.83105729531679" STUDY_ID="STD-Atamaz-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="5.191137274401697" CI_START="-10.591137274401689" DF="0" EFFECT_SIZE="-2.6999999999999957" ESTIMABLE="YES" I2="0.0" ID="CMP-039.03.02" NO="2" P_CHI2="1.0" P_Z="0.5024668190603023" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.6706134457227992">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="5.191137274401697" CI_START="-10.591137274401689" EFFECT_SIZE="-2.6999999999999957" ESTIMABLE="YES" MEAN_1="36.2" MEAN_2="38.9" ORDER="151256" SD_1="11.8" SD_2="13.6" SE="4.026164427839479" STUDY_ID="STD-Atamaz-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="9.302885856235893E-36" CI_END="8.817836129657245" CI_START="-9.017836129657248" DF="0" EFFECT_SIZE="-0.10000000000000143" ESTIMABLE="YES" I2="100.0" ID="CMP-039.03.03" NO="3" P_CHI2="0.0" P_Z="0.9824654872224573" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="99.99999999999999" Z="0.021978021978022295">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="8.817836129657245" CI_START="-9.017836129657248" EFFECT_SIZE="-0.10000000000000142" ESTIMABLE="YES" MEAN_1="41.8" MEAN_2="41.9" ORDER="151257" SD_1="13.3" SD_2="15.4" SE="4.55" STUDY_ID="STD-Atamaz-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="8.775821297907793" CI_START="-5.975821297907795" DF="0" EFFECT_SIZE="1.3999999999999986" ESTIMABLE="YES" I2="0.0" ID="CMP-039.03.04" NO="4" P_CHI2="1.0" P_Z="0.7098783086627467" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.37201953077881844">
<NAME>37 weeks post-injection</NAME>
<CONT_DATA CI_END="8.775821297907793" CI_START="-5.975821297907795" EFFECT_SIZE="1.3999999999999986" ESTIMABLE="YES" MEAN_1="39.6" MEAN_2="38.2" ORDER="151258" SD_1="11.8" SD_2="12.0" SE="3.763243282064023" STUDY_ID="STD-Atamaz-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="7.525226845599404" CI_START="-8.725226845599407" DF="0" EFFECT_SIZE="-0.6000000000000014" ESTIMABLE="YES" I2="0.0" ID="CMP-039.03.05" NO="5" P_CHI2="1.0" P_Z="0.8849226614807532" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.1447317611028843">
<NAME>45 to 52 weeks post-injection</NAME>
<CONT_DATA CI_END="7.525226845599404" CI_START="-8.725226845599407" EFFECT_SIZE="-0.6000000000000014" ESTIMABLE="YES" MEAN_1="37.6" MEAN_2="38.2" ORDER="151259" SD_1="13.6" SD_2="12.6" SE="4.145600077190274" STUDY_ID="STD-Atamaz-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="9.77859930781997" CI_END="-9.941708770674609" CI_START="-20.18494738776745" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-15.06332807922103" ESTIMABLE="YES" I2="59.094345988784" I2_Q="59.094345988784" ID="CMP-039.04" NO="4" P_CHI2="0.04432700036385562" P_Q="0.04432700036385562" P_Z="8.189970752321857E-9" Q="9.77859930781997" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="100" TOTAL_2="100" UNITS="" WEIGHT="500.0" Z="5.764501175110434">
<NAME>SF-36 pain</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>Phys therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Phys therapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Orthovisc</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.5931972840561546" CI_START="-23.793197284056156" DF="0" EFFECT_SIZE="-11.600000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-039.04.01" NO="1" P_CHI2="1.0" P_Z="0.06223580676891316" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="1.8646120202117715">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="0.5931972840561546" CI_START="-23.793197284056156" EFFECT_SIZE="-11.600000000000001" ESTIMABLE="YES" MEAN_1="47.5" MEAN_2="59.1" ORDER="151260" SD_1="22.9" SD_2="15.8" SE="6.221133337262592" STUDY_ID="STD-Atamaz-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-17.415388337350485" CI_START="-38.98461166264952" DF="0" EFFECT_SIZE="-28.200000000000003" ESTIMABLE="YES" I2="0.0" ID="CMP-039.04.02" NO="2" P_CHI2="1.0" P_Z="2.975597711273456E-7" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="5.124986053549821">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="-17.415388337350482" CI_START="-38.98461166264953" EFFECT_SIZE="-28.200000000000003" ESTIMABLE="YES" MEAN_1="28.0" MEAN_2="56.2" ORDER="151261" SD_1="17.3" SD_2="17.5" SE="5.502453997990352" STUDY_ID="STD-Atamaz-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-5.734797502339433" CI_START="-31.665202497660573" DF="0" EFFECT_SIZE="-18.700000000000003" ESTIMABLE="YES" I2="0.0" ID="CMP-039.04.03" NO="3" P_CHI2="1.0" P_Z="0.004700105296895894" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="99.99999999999999" Z="2.826899658336409">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="-5.734797502339433" CI_START="-31.665202497660573" EFFECT_SIZE="-18.700000000000003" ESTIMABLE="YES" MEAN_1="35.9" MEAN_2="54.6" ORDER="151262" SD_1="23.4" SD_2="18.1" SE="6.6150207860595565" STUDY_ID="STD-Atamaz-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.7700813459263482" CI_START="-15.770081345926348" DF="0" EFFECT_SIZE="-6.0" ESTIMABLE="YES" I2="0.0" ID="CMP-039.04.04" NO="4" P_CHI2="1.0" P_Z="0.2287238982768175" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="99.99999999999999" Z="1.2036526095193247">
<NAME>37 weeks post-injection</NAME>
<CONT_DATA CI_END="3.7700813459263482" CI_START="-15.770081345926348" EFFECT_SIZE="-6.0" ESTIMABLE="YES" MEAN_1="45.3" MEAN_2="51.3" ORDER="151263" SD_1="15.1" SD_2="16.4" SE="4.984826977940157" STUDY_ID="STD-Atamaz-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.025764722530910333" CI_START="-25.02576472253091" DF="0" EFFECT_SIZE="-12.5" ESTIMABLE="YES" I2="0.0" ID="CMP-039.04.05" NO="5" P_CHI2="1.0" P_Z="0.050473110907788825" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="1.955932459970427">
<NAME>45 to 52 weeks post-injection</NAME>
<CONT_DATA CI_END="0.025764722530910333" CI_START="-25.02576472253091" EFFECT_SIZE="-12.5" ESTIMABLE="YES" MEAN_1="37.7" MEAN_2="50.2" ORDER="151264" SD_1="21.7" SD_2="18.6" SE="6.390813719707374" STUDY_ID="STD-Atamaz-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="9.63098784965522" CI_END="-3.2954127081432354" CI_START="-14.05343684896128" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-8.674424778552257" ESTIMABLE="YES" I2="58.467396466052065" I2_Q="58.467396466052065" ID="CMP-039.05" NO="5" P_CHI2="0.047124262987869536" P_Q="0.047124262987869536" P_Z="0.001573787894466365" Q="9.63098784965522" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="100" TOTAL_2="100" UNITS="" WEIGHT="500.0" Z="3.1607216957353756">
<NAME>SF-36 physical functioning</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>Phys Therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Phys Therapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Orthovisc</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="12.728117756470473" CI_START="-11.728117756470473" DF="0" EFFECT_SIZE="0.5" ESTIMABLE="YES" I2="0.0" ID="CMP-039.05.01" NO="1" P_CHI2="1.0" P_Z="0.9361245675063051" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.08014168752598677">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="12.728117756470473" CI_START="-11.728117756470473" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="54.2" MEAN_2="53.7" ORDER="151265" SD_1="15.5" SD_2="23.2" SE="6.238950232210543" STUDY_ID="STD-Atamaz-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.7496530740763188" CI_START="-23.25034692592368" DF="0" EFFECT_SIZE="-12.0" ESTIMABLE="YES" I2="0.0" ID="CMP-039.05.02" NO="2" P_CHI2="1.0" P_Z="0.03656718528235327" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="2.090563781663083">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="-0.7496530740763188" CI_START="-23.25034692592368" EFFECT_SIZE="-12.0" ESTIMABLE="YES" MEAN_1="41.5" MEAN_2="53.5" ORDER="151266" SD_1="11.6" SD_2="22.9" SE="5.740078396677174" STUDY_ID="STD-Atamaz-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="4.394817672062334" CI_START="-23.394817672062334" DF="0" EFFECT_SIZE="-9.5" ESTIMABLE="YES" I2="0.0" ID="CMP-039.05.03" NO="3" P_CHI2="1.0" P_Z="0.18023125574723087" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="1.3400433379250596">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="4.394817672062334" CI_START="-23.394817672062334" EFFECT_SIZE="-9.5" ESTIMABLE="YES" MEAN_1="44.5" MEAN_2="54.0" ORDER="151267" SD_1="24.1" SD_2="20.6" SE="7.089322957800696" STUDY_ID="STD-Atamaz-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="11.500830844514677" CI_START="-11.500830844514677" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-039.05.04" NO="4" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.0">
<NAME>37 weeks post-injection</NAME>
<CONT_DATA CI_END="11.500830844514677" CI_START="-11.500830844514677" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="49.2" MEAN_2="49.2" ORDER="151268" SD_1="16.0" SD_2="20.8" SE="5.86787866268552" STUDY_ID="STD-Atamaz-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-10.24201286367599" CI_START="-33.75798713632401" DF="0" EFFECT_SIZE="-22.0" ESTIMABLE="YES" I2="0.0" ID="CMP-039.05.05" NO="5" P_CHI2="1.0" P_Z="2.4519512810495E-4" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="3.6672269802603203">
<NAME>45 to 52 weeks post-injection</NAME>
<CONT_DATA CI_END="-10.24201286367599" CI_START="-33.75798713632401" EFFECT_SIZE="-22.0" ESTIMABLE="YES" MEAN_1="31.0" MEAN_2="53.0" ORDER="151269" SD_1="14.3" SD_2="22.7" SE="5.999083263299485" STUDY_ID="STD-Atamaz-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-040" NO="40">
<NAME>(Orthovisc + physiotherapy) versus physiotherapy</NAME>
<CONT_OUTCOME CHI2="1.47470157135085" CI_END="-0.265445410247525" CI_START="-8.011515578007348" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.138480494127436" ESTIMABLE="YES" I2="32.18967013888891" I2_Q="32.18967013888891" ID="CMP-040.01" NO="1" P_CHI2="0.2246056801956705" P_Q="0.2246056801956705" P_Z="0.036233831112815" Q="1.47470157135085" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="40" TOTAL_2="40" UNITS="" WEIGHT="200.0" Z="2.094293633685763">
<NAME>Activity pain (0-100 mm VAS)</NAME>
<GROUP_LABEL_1>Orthovisc+PT</GROUP_LABEL_1>
<GROUP_LABEL_2>PT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Orthovisc+PT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PT</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.8217441682723123" CI_START="-7.221744168272311" DF="0" EFFECT_SIZE="-1.6999999999999993" ESTIMABLE="YES" I2="0.0" ID="CMP-040.01.01" NO="1" P_CHI2="1.0" P_Z="0.5462283713267861" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.6034214321017004">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="3.8217441682723123" CI_START="-7.221744168272311" EFFECT_SIZE="-1.6999999999999993" ESTIMABLE="YES" MEAN_1="12.5" MEAN_2="14.2" ORDER="151270" SD_1="9.3" SD_2="8.5" SE="2.8172681803477637" STUDY_ID="STD-Kalay-1997" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-1.0660904290496882" CI_START="-11.933909570950313" DF="0" EFFECT_SIZE="-6.5" ESTIMABLE="YES" I2="0.0" ID="CMP-040.01.02" NO="2" P_CHI2="1.0" P_Z="0.019052940453731057" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="2.344493542479462">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="-1.0660904290496882" CI_START="-11.933909570950313" EFFECT_SIZE="-6.5" ESTIMABLE="YES" MEAN_1="6.1" MEAN_2="12.6" ORDER="151271" SD_1="8.2" SD_2="9.3" SE="2.7724537868105217" STUDY_ID="STD-Kalay-1997" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.2086832514656933" CI_END="0.4126710351105056" CI_START="-4.493434780951102" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.040381872920298" ESTIMABLE="YES" I2="68.83456790123455" I2_Q="68.83456790123455" ID="CMP-040.02" NO="2" P_CHI2="0.07324845822074932" P_Q="0.07324845822074932" P_Z="0.1030499206343721" Q="3.2086832514656933" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="40" TOTAL_2="40" UNITS="" WEIGHT="200.0" Z="1.6302440817888582">
<NAME>Spontaneous pain (0-100 mm VAS)</NAME>
<GROUP_LABEL_1>Orthovisc+PT</GROUP_LABEL_1>
<GROUP_LABEL_2>PT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Orthovisc+PT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PT</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="4.0259333713991" CI_START="-3.225933371399101" DF="0" EFFECT_SIZE="0.39999999999999947" ESTIMABLE="YES" I2="0.0" ID="CMP-040.02.01" NO="1" P_CHI2="1.0" P_Z="0.8288192139356341" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.00000000000001" Z="0.21621621621621592">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="4.0259333713991" CI_START="-3.225933371399101" EFFECT_SIZE="0.39999999999999947" ESTIMABLE="YES" MEAN_1="5.8" MEAN_2="5.4" ORDER="151272" SD_1="5.8" SD_2="5.9" SE="1.85" STUDY_ID="STD-Kalay-1997" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.7689260285044721" CI_START="-7.431073971495527" DF="0" EFFECT_SIZE="-4.1" ESTIMABLE="YES" I2="0.0" ID="CMP-040.02.02" NO="2" P_CHI2="1.0" P_Z="0.01584828236768633" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="2.412390840124882">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="-0.7689260285044721" CI_START="-7.431073971495527" EFFECT_SIZE="-4.1" ESTIMABLE="YES" MEAN_1="1.7" MEAN_2="5.8" ORDER="151273" SD_1="4.1" SD_2="6.4" SE="1.699558766268469" STUDY_ID="STD-Kalay-1997" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.241121012527445" CI_END="0.6927308279384994" CI_START="-4.690380317800311" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.9988247449309056" ESTIMABLE="YES" I2="19.427679500520348" I2_Q="19.427679500520348" ID="CMP-040.03" NO="3" P_CHI2="0.26525520021057636" P_Q="0.26525520021057636" P_Z="0.14552417098905276" Q="1.241121012527445" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="40" TOTAL_2="40" UNITS="" WEIGHT="200.0" Z="1.4555242889878537">
<NAME>Night pain (0-100 mm VAS)</NAME>
<GROUP_LABEL_1>Orthovisc+PT</GROUP_LABEL_1>
<GROUP_LABEL_2>PT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Orthovisc+PT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PT</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.9544764389004197" CI_START="-4.354476438900418" DF="0" EFFECT_SIZE="-0.1999999999999993" ESTIMABLE="YES" I2="0.0" ID="CMP-040.03.01" NO="1" P_CHI2="1.0" P_Z="0.9248277016878566" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.0943543194125707">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="3.9544764389004197" CI_START="-4.354476438900418" EFFECT_SIZE="-0.1999999999999993" ESTIMABLE="YES" MEAN_1="5.4" MEAN_2="5.6" ORDER="151274" SD_1="6.9" SD_2="6.5" SE="2.1196697856034086" STUDY_ID="STD-Kalay-1997" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.23337532216093715" CI_START="-6.833375322160938" DF="0" EFFECT_SIZE="-3.3000000000000003" ESTIMABLE="YES" I2="0.0" ID="CMP-040.03.02" NO="2" P_CHI2="1.0" P_Z="0.06717361609450663" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="1.8305106475432564">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="0.23337532216093715" CI_START="-6.833375322160938" EFFECT_SIZE="-3.3000000000000003" ESTIMABLE="YES" MEAN_1="1.6" MEAN_2="4.9" ORDER="151275" SD_1="4.0" SD_2="7.0" SE="1.8027756377319946" STUDY_ID="STD-Kalay-1997" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.5206411976555326" CI_END="1.2830148973856277" CI_START="-2.9891373463652213" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.8530612244897968" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-040.04" NO="4" P_CHI2="0.47056836118351597" P_Q="0.47056836118351597" P_Z="0.4337861243180119" Q="0.5206411976555326" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="32" TOTAL_2="18" UNITS="" WEIGHT="200.0" Z="0.782729257391675">
<NAME>Lequesne (0-24)</NAME>
<GROUP_LABEL_1>Orthovisc+PT</GROUP_LABEL_1>
<GROUP_LABEL_2>PT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Orthovisc+PT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PT</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.5766156447650754" CI_START="-2.9766156447650776" DF="0" EFFECT_SIZE="-0.20000000000000107" ESTIMABLE="YES" I2="0.0" ID="CMP-040.04.01" NO="1" P_CHI2="1.0" P_Z="0.8877305336758704" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="9" WEIGHT="100.0" Z="0.14117647058823607">
<NAME>End of treatment</NAME>
<CONT_DATA CI_END="2.5766156447650754" CI_START="-2.9766156447650776" EFFECT_SIZE="-0.20000000000000107" ESTIMABLE="YES" MEAN_1="9.1" MEAN_2="9.3" ORDER="151276" SD_1="3.4" SD_2="3.4" SE="1.4166666666666665" STUDY_ID="STD-Bayramoglu-2003" TOTAL_1="16" TOTAL_2="9" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.5434879895393014" CI_START="-5.143487989539302" DF="0" EFFECT_SIZE="-1.8000000000000007" ESTIMABLE="YES" I2="0.0" ID="CMP-040.04.02" NO="2" P_CHI2="1.0" P_Z="0.2913493822650163" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="9" WEIGHT="100.0" Z="1.0551660969651673">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="1.5434879895393014" CI_START="-5.143487989539302" EFFECT_SIZE="-1.8000000000000007" ESTIMABLE="YES" MEAN_1="7.6" MEAN_2="9.4" ORDER="151277" SD_1="3.7" SD_2="4.3" SE="1.7058925653289083" STUDY_ID="STD-Bayramoglu-2003" TOTAL_1="16" TOTAL_2="9" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.2286564473611112" CI_END="0.9575593038635887" CI_START="-1.5269841129461357" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.28471240454127356" ESTIMABLE="YES" I2="55.129916897506945" I2_Q="55.129916897506945" ID="CMP-040.05" NO="5" P_CHI2="0.1354716993710634" P_Q="0.1354716993710634" P_Z="0.6532887780824046" Q="2.2286564473611112" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="40" TOTAL_2="40" UNITS="" WEIGHT="200.0" Z="0.449198074042294">
<NAME>25 m walk time (sec)</NAME>
<GROUP_LABEL_1>Orthovisc+PT</GROUP_LABEL_1>
<GROUP_LABEL_2>PT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Orthovisc+PT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PT</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.5908277654916025" CI_START="-1.0908277654916025" DF="0" EFFECT_SIZE="0.75" ESTIMABLE="YES" I2="0.0" ID="CMP-040.05.01" NO="1" P_CHI2="1.0" P_Z="0.42455770661644265" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.7985391224324981">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="2.5908277654916025" CI_START="-1.0908277654916025" EFFECT_SIZE="0.75" ESTIMABLE="YES" MEAN_1="15.3" MEAN_2="14.55" ORDER="151278" SD_1="3.39" SD_2="2.48" SE="0.9392150978343566" STUDY_ID="STD-Kalay-1997" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.5333854431305225" CI_START="-2.833385443130523" DF="0" EFFECT_SIZE="-1.1500000000000004" ESTIMABLE="YES" I2="0.0" ID="CMP-040.05.02" NO="2" P_CHI2="1.0" P_Z="0.18058895378272033" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="99.99999999999999" Z="1.3389438476012177">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="0.5333854431305223" CI_START="-2.833385443130523" EFFECT_SIZE="-1.1500000000000004" ESTIMABLE="YES" MEAN_1="13.25" MEAN_2="14.4" ORDER="151279" SD_1="2.79" SD_2="2.64" SE="0.8588859062762644" STUDY_ID="STD-Kalay-1997" TOTAL_1="20" TOTAL_2="20" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-040.06" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="40" TOTAL_2="40" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Flexion (degrees)</NAME>
<GROUP_LABEL_1>Orthovisc+PT</GROUP_LABEL_1>
<GROUP_LABEL_2>PT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Orthovisc+PT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PT</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-040.06.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>1 to 4 weeks post -injection</NAME>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="130.0" MEAN_2="129.75" ORDER="151280" SD_1="0.0" SD_2="1.12" SE="0.0" STUDY_ID="STD-Kalay-1997" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-040.06.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="130.0" MEAN_2="129.75" ORDER="151281" SD_1="0.0" SD_2="1.12" SE="0.0" STUDY_ID="STD-Kalay-1997" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.2961368445440336" CI_START="1.0918096847761147" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5833333333333333" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-040.07" LOG_CI_END="0.36099776746258483" LOG_CI_START="0.03814694234782339" LOG_EFFECT_SIZE="0.1995723549052041" METHOD="MH" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.015387453762845154" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="2.4231291822469707">
<NAME>Patient global assessment (number of patients evaluating treatment as effective or very effective)</NAME>
<GROUP_LABEL_1>Orthovisc+PT</GROUP_LABEL_1>
<GROUP_LABEL_2>PT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ORTHOVISC+PT</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.2961368445440336" CI_START="1.0918096847761147" DF="0" EFFECT_SIZE="1.5833333333333333" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="12" I2="0.0" ID="CMP-040.07.01" LOG_CI_END="0.36099776746258483" LOG_CI_START="0.03814694234782339" LOG_EFFECT_SIZE="0.1995723549052041" NO="1" P_CHI2="1.0" P_Z="0.015387453762845154" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="2.4231291822469707">
<NAME>5 to 13 weeks post-injection</NAME>
<DICH_DATA CI_END="2.2961368445440336" CI_START="1.091809684776115" EFFECT_SIZE="1.5833333333333333" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="12" LOG_CI_END="0.36099776746258483" LOG_CI_START="0.03814694234782348" LOG_EFFECT_SIZE="0.1995723549052041" ORDER="151282" O_E="0.0" SE="0.18964417280976953" STUDY_ID="STD-Kalay-1997" TOTAL_1="20" TOTAL_2="20" VAR="0.03596491228070173" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1837405743054112" CI_START="0.004427911009896366" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.07239819004524888" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-040.08" LOG_CI_END="0.07325653389648668" LOG_CI_START="-2.353801115954858" LOG_EFFECT_SIZE="-1.1402722910291858" METHOD="MH" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.06552669247402321" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="36" TOTAL_2="35" WEIGHT="100.0" Z="1.8416477442330754">
<NAME>Safety: total withdrawals overall</NAME>
<GROUP_LABEL_1>HA+PT</GROUP_LABEL_1>
<GROUP_LABEL_2>PT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HA+PT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PT</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1837405743054112" CI_START="0.004427911009896366" DF="0" EFFECT_SIZE="0.07239819004524888" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" I2="0.0" ID="CMP-040.08.01" LOG_CI_END="0.07325653389648668" LOG_CI_START="-2.353801115954858" LOG_EFFECT_SIZE="-1.1402722910291858" NO="1" P_CHI2="1.0" P_Z="0.06552669247402321" STUDIES="2" TAU2="0.0" TOTAL_1="36" TOTAL_2="35" WEIGHT="100.0" Z="1.8416477442330754">
<NAME>5 to 13 weeks post-injection</NAME>
<DICH_DATA CI_END="1.1837405743054112" CI_START="0.004427911009896366" EFFECT_SIZE="0.07239819004524888" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" LOG_CI_END="0.07325653389648668" LOG_CI_START="-2.353801115954858" LOG_EFFECT_SIZE="-1.1402722910291858" ORDER="151283" O_E="0.0" SE="1.4256656776518082" STUDY_ID="STD-Bayramoglu-2003" TOTAL_1="16" TOTAL_2="15" VAR="2.0325226244343892" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="151284" O_E="0.0" SE="0.0" STUDY_ID="STD-Kalay-1997" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="97.99788802329087" CI_START="0.2551075385834675" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-040.09" LOG_CI_END="1.991216716205615" LOG_CI_START="-0.5932767075335773" LOG_EFFECT_SIZE="0.6989700043360189" METHOD="MH" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.28908317907355985" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="36" TOTAL_2="29" WEIGHT="100.0" Z="1.0601350517583272">
<NAME>Safety: number of patients with local reactions</NAME>
<GROUP_LABEL_1>HA+PT</GROUP_LABEL_1>
<GROUP_LABEL_2>PT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HA+PT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PT</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-040.09.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>End of treatment</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="151285" O_E="0.0" SE="0.0" STUDY_ID="STD-Bayramoglu-2003" TOTAL_1="16" TOTAL_2="9" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="97.99788802329087" CI_START="0.2551075385834675" DF="0" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-040.09.02" LOG_CI_END="1.991216716205615" LOG_CI_START="-0.5932767075335773" LOG_EFFECT_SIZE="0.6989700043360189" NO="2" P_CHI2="1.0" P_Z="0.28908317907355985" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="1.0601350517583272">
<NAME>1 to 4 weeks post-injection</NAME>
<DICH_DATA CI_END="97.99788802329087" CI_START="0.2551075385834674" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.991216716205615" LOG_CI_START="-0.5932767075335774" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="151286" O_E="0.0" SE="1.5181442305531794" STUDY_ID="STD-Kalay-1997" TOTAL_1="20" TOTAL_2="20" VAR="2.304761904761905" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-040.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="36" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>Safety: number of patients withdrawn due to adverse events</NAME>
<GROUP_LABEL_1>HA+PT</GROUP_LABEL_1>
<GROUP_LABEL_2>PT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HA+PT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PT</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-040.10.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>End of treatment</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="151287" O_E="0.0" SE="0.0" STUDY_ID="STD-Bayramoglu-2003" TOTAL_1="16" TOTAL_2="9" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-040.10.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>5 to 13 weeks post-injection</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="151288" O_E="0.0" SE="0.0" STUDY_ID="STD-Kalay-1997" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-040.11" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="11" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="36" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>Safety: number of patients with systemic adverse events</NAME>
<GROUP_LABEL_1>HA+PT</GROUP_LABEL_1>
<GROUP_LABEL_2>PT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HA+PT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PT</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-040.11.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>End of treatment</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="151289" O_E="0.0" SE="0.0" STUDY_ID="STD-Bayramoglu-2003" TOTAL_1="16" TOTAL_2="9" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-040.11.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>5 to 13 weeks post-injection</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="151290" O_E="0.0" SE="0.0" STUDY_ID="STD-Kalay-1997" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-041" NO="41">
<NAME>(Orthovisc + physiotherapy) versus (Hylan G-F 20 + physiotherapy)</NAME>
<CONT_OUTCOME CHI2="0.8991757555574058" CI_END="1.3675211126266036" CI_START="-1.7172838301355537" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.17488135875447505" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-041.01" NO="1" P_CHI2="0.3430029369695011" P_Q="0.3430029369695011" P_Z="0.8241383422204019" Q="0.8991757555574058" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="32" TOTAL_2="24" UNITS="" WEIGHT="200.0" Z="0.222225502802319">
<NAME>Lequesne Index (0-24)</NAME>
<GROUP_LABEL_1>Orthovisc+PT</GROUP_LABEL_1>
<GROUP_LABEL_2>Hylan G-F 20 + PT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Orthovisc+PT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours G-F20+PT</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.579625540563686" CI_START="-1.5796255405636859" DF="0" EFFECT_SIZE="0.5" ESTIMABLE="YES" I2="0.0" ID="CMP-041.01.01" NO="1" P_CHI2="1.0" P_Z="0.637476482264358" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="12" WEIGHT="100.0" Z="0.47123002346105125">
<NAME>End of treatment</NAME>
<CONT_DATA CI_END="2.579625540563686" CI_START="-1.5796255405636859" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="9.1" MEAN_2="8.6" ORDER="151291" SD_1="3.4" SD_2="2.2" SE="1.0610529361598002" STUDY_ID="STD-Bayramoglu-2003" TOTAL_1="16" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.2994799424872725" CI_START="-3.2994799424872725" DF="0" EFFECT_SIZE="-1.0" ESTIMABLE="YES" I2="0.0" ID="CMP-041.01.02" NO="2" P_CHI2="1.0" P_Z="0.39401932686898167" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="12" WEIGHT="99.99999999999999" Z="0.852350980900501">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="1.2994799424872725" CI_START="-3.2994799424872725" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="7.6" MEAN_2="8.6" ORDER="151292" SD_1="3.7" SD_2="2.5" SE="1.1732256105853356" STUDY_ID="STD-Bayramoglu-2003" TOTAL_1="16" TOTAL_2="12" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-042" NO="42">
<NAME>Orthovisc versus hylan G-F 20</NAME>
<CONT_OUTCOME CHI2="6.781500129051944" CI_END="0.35758082569785254" CI_START="-0.056743407778546584" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.15041870895965298" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-042.01" NO="1" P_CHI2="0.5603804636371814" P_Q="0.9115722263745643" P_Z="0.15470318950403095" Q="0.9882515880176674" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="180" TOTAL_2="183" UNITS="" WEIGHT="500.0" Z="1.4231137275668215">
<NAME>WOMAC pain (0-20 or 5-25 Likert)</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>Hylan G-F 20</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Orthovisc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Hylan G-F 20</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.1242286867237075" CI_END="0.42705883672611356" CI_START="-0.28781008259768204" DF="2" EFFECT_SIZE="0.06962437706421573" ESTIMABLE="YES" I2="0.0" ID="CMP-042.01.01" NO="1" P_CHI2="0.5700027578733854" P_Z="0.7026246729450384" STUDIES="3" TAU2="0.0" TOTAL_1="60" TOTAL_2="61" WEIGHT="100.0" Z="0.3817798418792079">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="0.9434191191835527" CI_START="-0.30489973763587364" EFFECT_SIZE="0.31925969077383953" ESTIMABLE="YES" MEAN_1="9.3" MEAN_2="8.3" ORDER="151293" SD_1="2.7" SD_2="3.4" SE="0.31845453964103576" STUDY_ID="STD-Atamaz-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="32.794557030996"/>
<CONT_DATA CI_END="0.6707149153966948" CI_START="-0.5690969863243555" EFFECT_SIZE="0.05080896453616972" ESTIMABLE="YES" MEAN_1="6.4" MEAN_2="6.2" ORDER="151294" SD_1="4.1" SD_2="3.6" SE="0.31628435815671313" STUDY_ID="STD-Karatay-2004" TOTAL_1="20" TOTAL_2="20" WEIGHT="33.24613995100731"/>
<CONT_DATA CI_END="0.46033364569301244" CI_START="-0.7663908326347182" EFFECT_SIZE="-0.1530285934708529" ESTIMABLE="YES" MEAN_1="9.5" MEAN_2="10.0" ORDER="151295" SD_1="3.1" SD_2="3.3" SE="0.3129456683908421" STUDY_ID="STD-Kotevoglu-2005" TOTAL_1="20" TOTAL_2="21" WEIGHT="33.95930301799669"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="4.234325515806172" CI_END="0.725009997269952" CI_START="-0.16393991308942657" DF="1" EFFECT_SIZE="0.2805350420902627" ESTIMABLE="YES" I2="76.38348784789612" ID="CMP-042.01.02" NO="2" P_CHI2="0.03961451300761154" P_Z="0.21606784636526932" STUDIES="2" TAU2="0.0" TOTAL_1="40" TOTAL_2="41" WEIGHT="100.0" Z="1.2370518799558867">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="1.4158506239676" CI_START="0.126183859113158" EFFECT_SIZE="0.771017241540379" ESTIMABLE="YES" MEAN_1="11.2" MEAN_2="8.7" ORDER="151296" SD_1="2.4" SD_2="3.8" SE="0.3290026691886098" STUDY_ID="STD-Atamaz-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="47.51159002969555"/>
<CONT_DATA CI_END="0.450060579689026" CI_START="-0.7769423001191336" EFFECT_SIZE="-0.16344086021505375" ESTIMABLE="YES" MEAN_1="9.5" MEAN_2="10.0" ORDER="151297" SD_1="3.0" SD_2="3.0" SE="0.3130166904817134" STUDY_ID="STD-Kotevoglu-2005" TOTAL_1="20" TOTAL_2="21" WEIGHT="52.488409970304446"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.4346943385043977" CI_END="0.5812370172968856" CI_START="-0.2925485966193253" DF="1" EFFECT_SIZE="0.14434421033878014" ESTIMABLE="YES" I2="0.0" ID="CMP-042.01.03" NO="3" P_CHI2="0.5096944738996683" P_Z="0.5172767653162448" STUDIES="2" TAU2="0.0" TOTAL_1="40" TOTAL_2="41" WEIGHT="100.0" Z="0.6475488933101432">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="0.9174785656898616" CI_START="-0.3295166761122152" EFFECT_SIZE="0.29398094478882325" ESTIMABLE="YES" MEAN_1="11.9" MEAN_2="10.4" ORDER="151298" SD_1="5.1" SD_2="4.9" SE="0.31811687654421617" STUDY_ID="STD-Atamaz-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="49.09985252359387"/>
<CONT_DATA CI_END="0.612372069532854" CI_START="-0.612372069532854" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="10.0" MEAN_2="10.0" ORDER="151299" SD_1="2.8" SD_2="2.5" SE="0.3124404705204619" STUDY_ID="STD-Kotevoglu-2005" TOTAL_1="20" TOTAL_2="21" WEIGHT="50.90014747640613"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.6197950323045617" CI_START="-0.6197950323045617" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-042.01.04" NO="4" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.0">
<NAME>37 weeks post-injection</NAME>
<CONT_DATA CI_END="0.6197950323045617" CI_START="-0.6197950323045617" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="10.4" MEAN_2="10.4" ORDER="151300" SD_1="3.8" SD_2="2.6" SE="0.31622776601683794" STUDY_ID="STD-Atamaz-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.928732480641538" CI_START="-0.31882409712839793" DF="0" EFFECT_SIZE="0.30495419175657007" ESTIMABLE="YES" I2="0.0" ID="CMP-042.01.05" NO="5" P_CHI2="1.0" P_Z="0.3379660702656333" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.9581917861325591">
<NAME>45 to 52 weeks post-injection</NAME>
<CONT_DATA CI_END="0.928732480641538" CI_START="-0.31882409712839793" EFFECT_SIZE="0.30495419175657007" ESTIMABLE="YES" MEAN_1="11.2" MEAN_2="10.2" ORDER="151301" SD_1="3.5" SD_2="2.9" SE="0.3182600771265449" STUDY_ID="STD-Atamaz-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="21.651179506521185" CI_END="7.794896938821932" CI_START="-3.27799583015068" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="2.2584505543356257" ESTIMABLE="YES" I2="81.5252559390807" I2_Q="81.5252559390807" ID="CMP-042.02" NO="2" P_CHI2="2.3514260854351487E-4" P_Q="2.3514260854351487E-4" P_Z="0.4239908320253586" Q="21.651179506521185" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="100" TOTAL_2="100" UNITS="" WEIGHT="500.0" Z="0.7995167730271544">
<NAME>Spontaneous pain (0-100 mm VAS)</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>Synvisc</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Orthovisc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Synvisc</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-9.124956877885086" CI_START="-33.07504312211492" DF="0" EFFECT_SIZE="-21.1" ESTIMABLE="YES" I2="0.0" ID="CMP-042.02.01" NO="1" P_CHI2="1.0" P_Z="5.534601979965243E-4" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="3.453452288403233">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="-9.124956877885086" CI_START="-33.07504312211492" EFFECT_SIZE="-21.1" ESTIMABLE="YES" MEAN_1="42.9" MEAN_2="64.0" ORDER="151302" SD_1="20.2" SD_2="18.4" SE="6.109828148156051" STUDY_ID="STD-Atamaz-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="24.94700436813335" CI_START="0.8529956318666461" DF="0" EFFECT_SIZE="12.899999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-042.02.02" NO="2" P_CHI2="1.0" P_Z="0.035839786604855824" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="2.0987404526428595">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="24.94700436813335" CI_START="0.8529956318666461" EFFECT_SIZE="12.899999999999999" ESTIMABLE="YES" MEAN_1="58.4" MEAN_2="45.5" ORDER="151303" SD_1="20.6" SD_2="18.2" SE="6.146543744251724" STUDY_ID="STD-Atamaz-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="30.196462914372535" CI_START="0.8035370856274646" DF="0" EFFECT_SIZE="15.5" ESTIMABLE="YES" I2="0.0" ID="CMP-042.02.03" NO="3" P_CHI2="1.0" P_Z="0.03872227530375244" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="2.0671260790690664">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="30.196462914372535" CI_START="0.8035370856274646" EFFECT_SIZE="15.5" ESTIMABLE="YES" MEAN_1="66.2" MEAN_2="50.7" ORDER="151304" SD_1="28.1" SD_2="18.3" SE="7.498333148106985" STUDY_ID="STD-Atamaz-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="12.667335811972997" CI_START="-11.667335811972997" DF="0" EFFECT_SIZE="0.5" ESTIMABLE="YES" I2="0.0" ID="CMP-042.02.04" NO="4" P_CHI2="1.0" P_Z="0.9358061653564562" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.08054203544753795">
<NAME>37 weeks post-injection</NAME>
<CONT_DATA CI_END="12.667335811972997" CI_START="-11.667335811972997" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="52.2" MEAN_2="51.7" ORDER="151305" SD_1="23.1" SD_2="15.4" SE="6.2079384661898835" STUDY_ID="STD-Atamaz-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="19.343984212759345" CI_START="-3.943984212759341" DF="0" EFFECT_SIZE="7.700000000000003" ESTIMABLE="YES" I2="0.0" ID="CMP-042.02.05" NO="5" P_CHI2="1.0" P_Z="0.19494237388854113" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="1.2960961132548676">
<NAME>45 to 52 weeks post-injection</NAME>
<CONT_DATA CI_END="19.343984212759345" CI_START="-3.943984212759341" EFFECT_SIZE="7.700000000000003" ESTIMABLE="YES" MEAN_1="56.7" MEAN_2="49.0" ORDER="151306" SD_1="23.0" SD_2="13.3" SE="5.940917437568039" STUDY_ID="STD-Atamaz-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="18.496838083205535" CI_END="-5.943015001762547" CI_START="-16.74920627248846" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-11.346110637125504" ESTIMABLE="YES" I2="78.37468229971772" I2_Q="78.37468229971772" ID="CMP-042.03" NO="3" P_CHI2="9.865551025427521E-4" P_Q="9.865551025427521E-4" P_Z="3.8586751138383724E-5" Q="18.496838083205535" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="100" TOTAL_2="100" UNITS="" WEIGHT="500.0" Z="4.115782824169639">
<NAME>SF-36 pain</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>Synvisc</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Synvisc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Orthovisc</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.6876544105809668" CI_START="-25.487654410580966" DF="0" EFFECT_SIZE="-11.899999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-042.03.01" NO="1" P_CHI2="1.0" P_Z="0.08606568772841817" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="1.7165266874806688">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="1.6876544105809668" CI_START="-25.487654410580966" EFFECT_SIZE="-11.899999999999999" ESTIMABLE="YES" MEAN_1="47.5" MEAN_2="59.4" ORDER="151307" SD_1="22.9" SD_2="20.9" SE="6.932604128320035" STUDY_ID="STD-Atamaz-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-18.568662633549316" CI_START="-43.03133736645068" DF="0" EFFECT_SIZE="-30.799999999999997" ESTIMABLE="YES" I2="0.0" ID="CMP-042.03.02" NO="2" P_CHI2="1.0" P_Z="7.997498625777296E-7" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="4.9354284748464154">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="-18.568662633549316" CI_START="-43.03133736645068" EFFECT_SIZE="-30.799999999999997" ESTIMABLE="YES" MEAN_1="28.0" MEAN_2="58.8" ORDER="151308" SD_1="17.3" SD_2="21.9" SE="6.240592920548496" STUDY_ID="STD-Atamaz-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-4.075029275445987" CI_START="-35.524970724554024" DF="0" EFFECT_SIZE="-19.800000000000004" ESTIMABLE="YES" I2="0.0" ID="CMP-042.03.03" NO="3" P_CHI2="1.0" P_Z="0.013591717509396304" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="2.467876575013065">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="-4.075029275445987" CI_START="-35.524970724554024" EFFECT_SIZE="-19.800000000000004" ESTIMABLE="YES" MEAN_1="35.9" MEAN_2="55.7" ORDER="151309" SD_1="23.4" SD_2="27.2" SE="8.023091673413685" STUDY_ID="STD-Atamaz-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="10.674850796490936" CI_START="-7.6748507964909365" DF="0" EFFECT_SIZE="1.5" ESTIMABLE="YES" I2="0.0" ID="CMP-042.03.04" NO="4" P_CHI2="1.0" P_Z="0.7486383775578771" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.3204352901231385">
<NAME>37 weeks post-injection</NAME>
<CONT_DATA CI_END="10.674850796490936" CI_START="-7.6748507964909365" EFFECT_SIZE="1.5" ESTIMABLE="YES" MEAN_1="45.3" MEAN_2="43.8" ORDER="151310" SD_1="15.1" SD_2="14.5" SE="4.681132341645555" STUDY_ID="STD-Atamaz-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.6694655302701715" CI_START="-21.669465530270173" DF="0" EFFECT_SIZE="-9.0" ESTIMABLE="YES" I2="0.0" ID="CMP-042.03.05" NO="5" P_CHI2="1.0" P_Z="0.16383207317750903" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="99.99999999999999" Z="1.3922983427134616">
<NAME>45 to 52 weeks post-injection</NAME>
<CONT_DATA CI_END="3.6694655302701715" CI_START="-21.669465530270173" EFFECT_SIZE="-9.0" ESTIMABLE="YES" MEAN_1="37.7" MEAN_2="46.7" ORDER="151311" SD_1="21.7" SD_2="19.1" SE="6.464131805586888" STUDY_ID="STD-Atamaz-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.42388107004837255" CI_END="2.2062834006610443" CI_START="-2.2210523546927488" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.007384477015852112" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-042.04" NO="4" P_CHI2="0.9352662402845066" P_Q="0.9352662402845066" P_Z="0.9947833423275814" Q="0.42388107004837255" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="145" TOTAL_2="140" UNITS="" WEIGHT="400.0" Z="0.006538157391036803">
<NAME>Hospital for Special Surgery Knee Score</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>Hylan G-F 20</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hylan G-F 20</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Orthovisc</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.6382793766398027" CI_START="-4.038279376639808" DF="0" EFFECT_SIZE="-0.20000000000000284" ESTIMABLE="YES" I2="0.0" ID="CMP-042.04.01" NO="1" P_CHI2="1.0" P_Z="0.9186556966626799" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="40" WEIGHT="100.0" Z="0.10212721859011309">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="3.6382793766398027" CI_START="-4.038279376639808" EFFECT_SIZE="-0.20000000000000284" ESTIMABLE="YES" MEAN_1="86.5" MEAN_2="86.7" ORDER="151312" SD_1="9.5" SD_2="7.8" SE="1.9583417893980009" STUDY_ID="STD-Karatosun-2005a" TOTAL_1="39" TOTAL_2="40" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="5.043848141563861" CI_START="-3.0438481415638607" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" I2="0.0" ID="CMP-042.04.02" NO="2" P_CHI2="1.0" P_Z="0.627904819276854" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="34" WEIGHT="100.0" Z="0.4846779394099813">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="5.043848141563861" CI_START="-3.0438481415638607" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="87.3" MEAN_2="86.3" ORDER="151313" SD_1="9.9" SD_2="7.7" SE="2.0632257395856346" STUDY_ID="STD-Karatosun-2005a" TOTAL_1="39" TOTAL_2="34" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.6524484801135966" CI_START="-5.652448480113597" DF="0" EFFECT_SIZE="-1.0" ESTIMABLE="YES" I2="0.0" ID="CMP-042.04.03" NO="3" P_CHI2="1.0" P_Z="0.6735536959303489" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="34" WEIGHT="100.0" Z="0.42127580625937394">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="3.6524484801135966" CI_START="-5.652448480113597" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="84.7" MEAN_2="85.7" ORDER="151314" SD_1="10.3" SD_2="9.7" SE="2.37374182220261" STUDY_ID="STD-Karatosun-2005a" TOTAL_1="37" TOTAL_2="34" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="5.78856928010224" CI_START="-5.988569280102257" DF="0" EFFECT_SIZE="-0.10000000000000853" ESTIMABLE="YES" I2="0.0" ID="CMP-042.04.04" NO="4" P_CHI2="1.0" P_Z="0.9734479424055389" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="32" WEIGHT="100.0" Z="0.033284213725106905">
<NAME>45 to 52 weeks post-injection</NAME>
<CONT_DATA CI_END="5.78856928010224" CI_START="-5.988569280102257" EFFECT_SIZE="-0.10000000000000853" ESTIMABLE="YES" MEAN_1="86.6" MEAN_2="86.7" ORDER="151315" SD_1="10.6" SD_2="13.0" SE="3.004427288741289" STUDY_ID="STD-Karatosun-2005a" TOTAL_1="30" TOTAL_2="32" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.0471715429617547" CI_END="1.2015738141525085" CI_START="-0.7439203056889412" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="0.22882675423178364" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-042.05" NO="5" P_CHI2="0.7898399135783003" P_Q="0.7898399135783003" P_Z="0.6447574500507727" Q="1.0471715429617547" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="145" TOTAL_2="140" UNITS="" WEIGHT="400.0" Z="0.4610573657555385">
<NAME>Pain during activity (Hospital for Special Surgery)</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>Hylan G-F 20</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hylan G-F 20</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Orthovisc</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.7121410794575602" CI_START="-1.7121410794575602" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-042.05.01" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="40" WEIGHT="100.0" Z="0.0">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="1.7121410794575602" CI_START="-1.7121410794575602" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="11.2" MEAN_2="11.2" ORDER="151316" SD_1="4.3" SD_2="3.4" SE="0.8735574188927503" STUDY_ID="STD-Karatosun-2005a" TOTAL_1="39" TOTAL_2="40" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.790335301854096" CI_START="-0.7903353018540964" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" I2="0.0" ID="CMP-042.05.02" NO="2" P_CHI2="1.0" P_Z="0.2736275616254533" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="34" WEIGHT="100.0" Z="1.0947468792635033">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="2.790335301854096" CI_START="-0.7903353018540964" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="11.3" MEAN_2="10.3" ORDER="151317" SD_1="4.3" SD_2="3.5" SE="0.9134531634132222" STUDY_ID="STD-Karatosun-2005a" TOTAL_1="39" TOTAL_2="34" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.8811473688575397" CI_START="-2.081147368857539" DF="0" EFFECT_SIZE="-0.09999999999999964" ESTIMABLE="YES" I2="0.0" ID="CMP-042.05.03" NO="3" P_CHI2="1.0" P_Z="0.9211932523404526" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="34" WEIGHT="100.0" Z="0.09893075171234193">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="1.8811473688575397" CI_START="-2.081147368857539" EFFECT_SIZE="-0.09999999999999964" ESTIMABLE="YES" MEAN_1="10.5" MEAN_2="10.6" ORDER="151318" SD_1="4.7" SD_2="3.8" SE="1.0108080477419876" STUDY_ID="STD-Karatosun-2005a" TOTAL_1="37" TOTAL_2="34" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.2913066238045503" CI_START="-2.891306623804548" DF="0" EFFECT_SIZE="-0.29999999999999893" ESTIMABLE="YES" I2="0.0" ID="CMP-042.05.04" NO="4" P_CHI2="1.0" P_Z="0.8204949836994914" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="32" WEIGHT="100.0" Z="0.22690838280601855">
<NAME>45 to 52 weeks post-injection</NAME>
<CONT_DATA CI_END="2.2913066238045503" CI_START="-2.891306623804548" EFFECT_SIZE="-0.29999999999999893" ESTIMABLE="YES" MEAN_1="10.8" MEAN_2="11.1" ORDER="151319" SD_1="4.8" SD_2="5.6" SE="1.3221195104830727" STUDY_ID="STD-Karatosun-2005a" TOTAL_1="30" TOTAL_2="32" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.5563820596825835" CI_END="1.1298485419610607" CI_START="-0.22453075905503178" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="0.45265889145301447" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-042.06" NO="6" P_CHI2="0.46518773433514593" P_Q="0.46518773433514593" P_Z="0.19015753137142838" Q="2.5563820596825835" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="145" TOTAL_2="140" UNITS="" WEIGHT="400.0" Z="1.3101132361726675">
<NAME>Pain at rest (Hospital for Special Surgery)</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>Hylan G-F 20</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hylan G-F 20</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Orthovisc</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.1896358439528525" CI_START="0.0103641560471468" DF="0" EFFECT_SIZE="1.0999999999999996" ESTIMABLE="YES" I2="0.0" ID="CMP-042.06.01" NO="1" P_CHI2="1.0" P_Z="0.04786034592839827" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="40" WEIGHT="100.0" Z="1.9786063343629736">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="2.1896358439528525" CI_START="0.0103641560471468" EFFECT_SIZE="1.0999999999999996" ESTIMABLE="YES" MEAN_1="14.1" MEAN_2="13.0" ORDER="151320" SD_1="2.1" SD_2="2.8" SE="0.5559468707321977" STUDY_ID="STD-Karatosun-2005a" TOTAL_1="39" TOTAL_2="40" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.5536506430447865" CI_START="-1.1536506430447844" DF="0" EFFECT_SIZE="0.20000000000000107" ESTIMABLE="YES" I2="0.0" ID="CMP-042.06.02" NO="2" P_CHI2="1.0" P_Z="0.772136075478757" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="34" WEIGHT="100.0" Z="0.28958195301137524">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="1.5536506430447865" CI_START="-1.1536506430447844" EFFECT_SIZE="0.20000000000000107" ESTIMABLE="YES" MEAN_1="13.4" MEAN_2="13.2" ORDER="151321" SD_1="3.1" SD_2="2.8" SE="0.6906507740561607" STUDY_ID="STD-Karatosun-2005a" TOTAL_1="39" TOTAL_2="34" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.1475801546283608" CI_START="-1.7475801546283622" DF="0" EFFECT_SIZE="-0.3000000000000007" ESTIMABLE="YES" I2="0.0" ID="CMP-042.06.03" NO="3" P_CHI2="1.0" P_Z="0.684604721500513" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="34" WEIGHT="100.0" Z="0.40618765978659926">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="1.1475801546283608" CI_START="-1.7475801546283622" EFFECT_SIZE="-0.3000000000000007" ESTIMABLE="YES" MEAN_1="13.2" MEAN_2="13.5" ORDER="151322" SD_1="3.5" SD_2="2.7" SE="0.7385748748684614" STUDY_ID="STD-Karatosun-2005a" TOTAL_1="37" TOTAL_2="34" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.0805628275784382" CI_START="-1.4805628275784368" DF="0" EFFECT_SIZE="0.3000000000000007" ESTIMABLE="YES" I2="0.0" ID="CMP-042.06.04" NO="4" P_CHI2="1.0" P_Z="0.7412287554380645" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="32" WEIGHT="100.0" Z="0.3302265925441575">
<NAME>45 to 52 weeks post-injection</NAME>
<CONT_DATA CI_END="2.0805628275784382" CI_START="-1.4805628275784368" EFFECT_SIZE="0.3000000000000007" ESTIMABLE="YES" MEAN_1="13.4" MEAN_2="13.1" ORDER="151323" SD_1="3.0" SD_2="4.1" SE="0.9084671155303311" STUDY_ID="STD-Karatosun-2005a" TOTAL_1="30" TOTAL_2="32" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.7328467824630039" CI_END="0.1930112138116269" CI_START="-0.4813434543149737" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.1441661202516734" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-042.07" NO="7" P_CHI2="0.8654522196050158" P_Q="0.8654522196050158" P_Z="0.4020210549497538" Q="0.7328467824630039" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="145" TOTAL_2="140" UNITS="" WEIGHT="400.0" Z="0.8380171943322373">
<NAME>Pain during climbing stairs (Hospital for Special Surgery)</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>Hylan G-F 20</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hylan G-F 20</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Orthovisc</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.6615925354286123" CI_START="-0.6615925354286123" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-042.07.01" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="40" WEIGHT="100.0" Z="0.0">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="0.6615925354286123" CI_START="-0.6615925354286123" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="3.5" MEAN_2="3.5" ORDER="151324" SD_1="1.5" SD_2="1.5" SE="0.33755341457657884" STUDY_ID="STD-Karatosun-2005a" TOTAL_1="39" TOTAL_2="40" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.5898092569213585" CI_START="-0.7898092569213587" DF="0" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" I2="0.0" ID="CMP-042.07.02" NO="2" P_CHI2="1.0" P_Z="0.7763097641615823" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="34" WEIGHT="100.0" Z="0.28413129642351276">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="0.5898092569213585" CI_START="-0.7898092569213587" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" MEAN_1="3.5" MEAN_2="3.6" ORDER="151325" SD_1="1.5" SD_2="1.5" SE="0.3519499655924731" STUDY_ID="STD-Karatosun-2005a" TOTAL_1="39" TOTAL_2="34" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.5518759827529609" CI_START="-0.7518759827529611" DF="0" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" I2="0.0" ID="CMP-042.07.03" NO="3" P_CHI2="1.0" P_Z="0.7636698367490227" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="34" WEIGHT="100.0" Z="0.30066516276038596">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="0.5518759827529609" CI_START="-0.7518759827529611" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" MEAN_1="3.0" MEAN_2="3.1" ORDER="151326" SD_1="1.4" SD_2="1.4" SE="0.3325958986465443" STUDY_ID="STD-Karatosun-2005a" TOTAL_1="37" TOTAL_2="34" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.2973267974100796" CI_START="-1.0973267974100795" DF="0" EFFECT_SIZE="-0.3999999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-042.07.04" NO="4" P_CHI2="1.0" P_Z="0.2608973060815941" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="32" WEIGHT="100.0" Z="1.1242728613439192">
<NAME>45 to 52 weeks post-injection</NAME>
<CONT_DATA CI_END="0.2973267974100796" CI_START="-1.0973267974100795" EFFECT_SIZE="-0.3999999999999999" ESTIMABLE="YES" MEAN_1="3.0" MEAN_2="3.4" ORDER="151327" SD_1="1.4" SD_2="1.4" SE="0.35578551591279445" STUDY_ID="STD-Karatosun-2005a" TOTAL_1="30" TOTAL_2="32" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.129765755095772" CI_END="0.4395495203901455" CI_START="-0.17458051610424474" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="0.13248450214295038" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-042.08" NO="8" P_CHI2="0.5459145211029082" P_Q="0.5459145211029082" P_Z="0.3977565370839069" Q="2.1297657550957725" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="145" TOTAL_2="140" UNITS="" WEIGHT="400.0" Z="0.8456347590231382">
<NAME>Pain during transfer activity (Hospital for Special Surgery)</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>Hylan G-F 20</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hylan G-F 20</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Orthovisc</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.39612042881471243" CI_START="-0.7961204288147128" DF="0" EFFECT_SIZE="-0.20000000000000018" ESTIMABLE="YES" I2="0.0" ID="CMP-042.08.01" NO="1" P_CHI2="1.0" P_Z="0.5108124470479128" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="40" WEIGHT="99.99999999999999" Z="0.6575731646832241">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="0.3961204288147123" CI_START="-0.7961204288147127" EFFECT_SIZE="-0.20000000000000018" ESTIMABLE="YES" MEAN_1="4.0" MEAN_2="4.2" ORDER="151328" SD_1="1.4" SD_2="1.3" SE="0.3041486647289615" STUDY_ID="STD-Karatosun-2005a" TOTAL_1="39" TOTAL_2="40" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.8169574684838476E-32" CI_END="0.9568903146856922" CI_START="-0.1568903146856913" DF="0" EFFECT_SIZE="0.4000000000000004" ESTIMABLE="YES" I2="100.0" ID="CMP-042.08.02" NO="2" P_CHI2="0.0" P_Z="0.15919274232749533" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="34" WEIGHT="100.0" Z="1.4077917556503081">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="0.9568903146856921" CI_START="-0.15689031468569137" EFFECT_SIZE="0.40000000000000036" ESTIMABLE="YES" MEAN_1="4.5" MEAN_2="4.1" ORDER="151329" SD_1="1.1" SD_2="1.3" SE="0.28413293258364514" STUDY_ID="STD-Karatosun-2005a" TOTAL_1="39" TOTAL_2="34" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.7518759827529611" CI_START="-0.5518759827529609" DF="0" EFFECT_SIZE="0.10000000000000009" ESTIMABLE="YES" I2="0.0" ID="CMP-042.08.03" NO="3" P_CHI2="1.0" P_Z="0.7636698367490227" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="34" WEIGHT="100.0" Z="0.30066516276038596">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="0.7518759827529611" CI_START="-0.5518759827529609" EFFECT_SIZE="0.10000000000000009" ESTIMABLE="YES" MEAN_1="3.9" MEAN_2="3.8" ORDER="151330" SD_1="1.4" SD_2="1.4" SE="0.3325958986465443" STUDY_ID="STD-Karatosun-2005a" TOTAL_1="37" TOTAL_2="34" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.8720800049100934" CI_START="-0.47208000491009305" DF="0" EFFECT_SIZE="0.20000000000000018" ESTIMABLE="YES" I2="0.0" ID="CMP-042.08.04" NO="4" P_CHI2="1.0" P_Z="0.5597228820439655" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="32" WEIGHT="100.0" Z="0.5832531752829778">
<NAME>45 to 52 weeks post-injection</NAME>
<CONT_DATA CI_END="0.8720800049100934" CI_START="-0.47208000491009305" EFFECT_SIZE="0.20000000000000018" ESTIMABLE="YES" MEAN_1="4.3" MEAN_2="4.1" ORDER="151331" SD_1="1.3" SD_2="1.4" SE="0.34290426263511703" STUDY_ID="STD-Karatosun-2005a" TOTAL_1="30" TOTAL_2="32" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="5.88827696262375" CI_END="0.23506637308509734" CI_START="-0.1783462542212235" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.028360059431936927" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-042.09" NO="9" P_CHI2="0.6597451114033022" P_Q="0.8971756818608347" P_Z="0.7880015467392639" Q="1.0816304893586264" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="180" TOTAL_2="183" UNITS="" WEIGHT="500.0" Z="0.2689066149149141">
<NAME>WOMAC physical function (0-68 or 17-85 Likert)</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>Hylan G-F 20</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Orthovisc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Hylan G-F 20</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.6443431677078486" CI_END="0.42598382412828006" CI_START="-0.2913854938665674" DF="2" EFFECT_SIZE="0.06729916513085633" ESTIMABLE="YES" I2="24.366851306457843" ID="CMP-042.09.01" NO="1" P_CHI2="0.2665559864858851" P_Z="0.7130645274086875" STUDIES="3" TAU2="0.0" TOTAL_1="60" TOTAL_2="61" WEIGHT="100.00000000000001" Z="0.367743466405235">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="0.276007003607495" CI_START="-0.9740067329287834" EFFECT_SIZE="-0.3489998646606442" ESTIMABLE="YES" MEAN_1="35.2" MEAN_2="40.1" ORDER="151332" SD_1="11.5" SD_2="15.7" SE="0.3188869148607391" STUDY_ID="STD-Atamaz-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="32.93487539587069"/>
<CONT_DATA CI_END="0.9696475442961455" CI_START="-0.2801158329114345" EFFECT_SIZE="0.3447658556923555" ESTIMABLE="YES" MEAN_1="27.8" MEAN_2="24.3" ORDER="151333" SD_1="10.0" SD_2="9.9" SE="0.3188230465114548" STUDY_ID="STD-Karatay-2004" TOTAL_1="20" TOTAL_2="20" WEIGHT="32.94807210069031"/>
<CONT_DATA CI_END="0.8152965168688607" CI_START="-0.41286941406097377" EFFECT_SIZE="0.2012135514039435" ESTIMABLE="YES" MEAN_1="33.0" MEAN_2="31.0" ORDER="151334" SD_1="10.1" SD_2="9.4" SE="0.3133133926483983" STUDY_ID="STD-Kotevoglu-2005" TOTAL_1="20" TOTAL_2="21" WEIGHT="34.117052503439005"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.5971555477021266" CI_END="0.31128136490051955" CI_START="-0.565730013528869" DF="1" EFFECT_SIZE="-0.12722432431417474" ESTIMABLE="YES" I2="37.38869069836507" ID="CMP-042.09.02" NO="2" P_CHI2="0.20630682801944455" P_Z="0.5695954942867257" STUDIES="2" TAU2="0.0" TOTAL_1="40" TOTAL_2="41" WEIGHT="100.0" Z="0.5686473396953824">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="0.21082546887455317" CI_START="-1.0435752651177488" EFFECT_SIZE="-0.41637489812159784" ESTIMABLE="YES" MEAN_1="36.2" MEAN_2="41.7" ORDER="151335" SD_1="11.8" SD_2="14.0" SE="0.3200060674295178" STUDY_ID="STD-Atamaz-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="48.880749569216185"/>
<CONT_DATA CI_END="0.7625785717384438" CI_START="-0.4640497542666867" EFFECT_SIZE="0.14926440873587857" ESTIMABLE="YES" MEAN_1="31.5" MEAN_2="30.0" ORDER="151336" SD_1="10.5" SD_2="9.2" SE="0.3129211392863895" STUDY_ID="STD-Kotevoglu-2005" TOTAL_1="20" TOTAL_2="21" WEIGHT="51.11925043078382"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.5651477578551474" CI_END="0.5987138755002741" CI_START="-0.27576938441834764" DF="1" EFFECT_SIZE="0.1614722455409632" ESTIMABLE="YES" I2="0.0" ID="CMP-042.09.03" NO="3" P_CHI2="0.45219364978440135" P_Z="0.46918250476206513" STUDIES="2" TAU2="0.0" TOTAL_1="40" TOTAL_2="41" WEIGHT="100.00000000000001" Z="0.7238098206535079">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="0.6127787245372364" CI_START="-0.6268155732922939" EFFECT_SIZE="-0.007018424377528805" ESTIMABLE="YES" MEAN_1="41.8" MEAN_2="41.9" ORDER="151337" SD_1="13.3" SD_2="14.6" SE="0.3162288459398468" STUDY_ID="STD-Atamaz-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="49.76727491622223"/>
<CONT_DATA CI_END="0.9453206865878812" CI_START="-0.2885172827487008" EFFECT_SIZE="0.32840170191959017" ESTIMABLE="YES" MEAN_1="34.5" MEAN_2="31.0" ORDER="151338" SD_1="10.4" SD_2="10.5" SE="0.3147603678100563" STUDY_ID="STD-Kotevoglu-2005" TOTAL_1="20" TOTAL_2="21" WEIGHT="50.23272508377779"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.7042236199236374" CI_START="-0.53597448386753" DF="0" EFFECT_SIZE="0.08412456802805372" ESTIMABLE="YES" I2="0.0" ID="CMP-042.09.04" NO="4" P_CHI2="1.0" P_Z="0.790320217645443" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.26589481639416984">
<NAME>37 weeks post-injection</NAME>
<CONT_DATA CI_END="0.7042236199236374" CI_START="-0.53597448386753" EFFECT_SIZE="0.08412456802805372" ESTIMABLE="YES" MEAN_1="39.6" MEAN_2="38.6" ORDER="151339" SD_1="11.8" SD_2="11.5" SE="0.3163828809033461" STUDY_ID="STD-Atamaz-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.5197861532703922" CI_START="-0.720670620316761" DF="0" EFFECT_SIZE="-0.10044223352318439" ESTIMABLE="YES" I2="0.0" ID="CMP-042.09.05" NO="5" P_CHI2="1.0" P_Z="0.7509368413248338" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.00000000000001" Z="0.31740430529137126">
<NAME>45 to 52 weeks post-injection</NAME>
<CONT_DATA CI_END="0.5197861532703922" CI_START="-0.720670620316761" EFFECT_SIZE="-0.10044223352318439" ESTIMABLE="YES" MEAN_1="37.6" MEAN_2="38.9" ORDER="151340" SD_1="13.6" SD_2="11.7" SE="0.3164488693087521" STUDY_ID="STD-Atamaz-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="14.81785589313371" CI_END="-6.304173802000367" CI_START="-17.135428265639934" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-11.71980103382015" ESTIMABLE="YES" I2="73.00554122777292" I2_Q="73.00554122777292" ID="CMP-042.10" NO="10" P_CHI2="0.005094301191914674" P_Q="0.005094301191914674" P_Z="2.220299711346549E-5" Q="14.81785589313371" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="100" TOTAL_2="100" UNITS="" WEIGHT="500.0" Z="4.241500928516488">
<NAME>SF-36 physical functioning</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>Synvisc</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Synvisc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Orthovisc</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="4.138221589803239E-33" CI_END="10.530425086368128" CI_START="-16.530425086368126" DF="0" EFFECT_SIZE="-2.9999999999999996" ESTIMABLE="YES" I2="100.0" ID="CMP-042.10.01" NO="1" P_CHI2="0.0" P_Z="0.6638759106318689" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.4345681614647968">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="10.530425086368128" CI_START="-16.530425086368126" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="54.2" MEAN_2="57.2" ORDER="151341" SD_1="15.5" SD_2="26.7" SE="6.903404956975941" STUDY_ID="STD-Atamaz-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-10.925310428785599" CI_START="-29.474689571214405" DF="0" EFFECT_SIZE="-20.200000000000003" ESTIMABLE="YES" I2="0.0" ID="CMP-042.10.02" NO="2" P_CHI2="1.0" P_Z="1.9657699986331836E-5" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="4.268743679636183">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="-10.925310428785599" CI_START="-29.474689571214405" EFFECT_SIZE="-20.200000000000003" ESTIMABLE="YES" MEAN_1="41.5" MEAN_2="61.7" ORDER="151342" SD_1="11.6" SD_2="17.7" SE="4.732071428032337" STUDY_ID="STD-Atamaz-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="5.090708475313576" CI_START="-27.490708475313582" DF="0" EFFECT_SIZE="-11.200000000000003" ESTIMABLE="YES" I2="0.0" ID="CMP-042.10.03" NO="3" P_CHI2="1.0" P_Z="0.1778218819519638" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="1.347491833158353">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="5.090708475313576" CI_START="-27.490708475313582" EFFECT_SIZE="-11.200000000000003" ESTIMABLE="YES" MEAN_1="44.5" MEAN_2="55.7" ORDER="151343" SD_1="24.1" SD_2="28.3" SE="8.3117386869415" STUDY_ID="STD-Atamaz-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="15.910354263690701" CI_START="-7.5103542636906955" DF="0" EFFECT_SIZE="4.200000000000003" ESTIMABLE="YES" I2="0.0" ID="CMP-042.10.04" NO="4" P_CHI2="1.0" P_Z="0.48208397677562764" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.7029547142388364">
<NAME>37 weeks post-injection</NAME>
<CONT_DATA CI_END="15.910354263690701" CI_START="-7.5103542636906955" EFFECT_SIZE="4.200000000000003" ESTIMABLE="YES" MEAN_1="49.2" MEAN_2="45.0" ORDER="151344" SD_1="16.0" SD_2="21.4" SE="5.974780330689991" STUDY_ID="STD-Atamaz-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.8839882288440973E-31" CI_END="-10.033834595853772" CI_START="-35.966165404146224" DF="0" EFFECT_SIZE="-22.999999999999996" ESTIMABLE="YES" I2="100.0" ID="CMP-042.10.05" NO="5" P_CHI2="0.0" P_Z="5.076686305335778E-4" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="3.4766772009561255">
<NAME>45 to 52 weeks post-injection</NAME>
<CONT_DATA CI_END="-10.033834595853776" CI_START="-35.966165404146224" EFFECT_SIZE="-23.0" ESTIMABLE="YES" MEAN_1="31.0" MEAN_2="54.0" ORDER="151345" SD_1="14.3" SD_2="25.9" SE="6.615512073906297" STUDY_ID="STD-Atamaz-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.511593231285115" CI_END="2.806522395899233" CI_START="-1.7677363687479715" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="0.519393013575631" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-042.11" NO="11" P_CHI2="0.67959724635658" P_Q="0.67959724635658" P_Z="0.6562505510439505" Q="1.511593231285115" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="145" TOTAL_2="140" UNITS="" WEIGHT="400.0" Z="0.4450957642788597">
<NAME>Range of motion (degrees)</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>Hylan G-F 20</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hylan G-F 20</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Orthovisc</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="7.490868656526669" CI_START="-2.690868656526658" DF="0" EFFECT_SIZE="2.4000000000000057" ESTIMABLE="YES" I2="0.0" ID="CMP-042.11.01" NO="1" P_CHI2="1.0" P_Z="0.3554913456396922" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="40" WEIGHT="100.0" Z="0.9239903600470162">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="7.490868656526669" CI_START="-2.690868656526658" EFFECT_SIZE="2.4000000000000057" ESTIMABLE="YES" MEAN_1="123.0" MEAN_2="120.6" ORDER="151346" SD_1="8.8" SD_2="13.8" SE="2.5974296959958374" STUDY_ID="STD-Karatosun-2005a" TOTAL_1="39" TOTAL_2="40" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="4.673733463263543" CI_START="-2.8737334632635325" DF="0" EFFECT_SIZE="0.9000000000000057" ESTIMABLE="YES" I2="0.0" ID="CMP-042.11.02" NO="2" P_CHI2="1.0" P_Z="0.6401901126001213" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="34" WEIGHT="100.0" Z="0.46743300852004915">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="4.673733463263543" CI_START="-2.8737334632635325" EFFECT_SIZE="0.9000000000000057" ESTIMABLE="YES" MEAN_1="121.9" MEAN_2="121.0" ORDER="151347" SD_1="10.6" SD_2="5.3" SE="1.9254095958039361" STUDY_ID="STD-Karatosun-2005a" TOTAL_1="39" TOTAL_2="34" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.879552171389065" CI_START="-6.479552171389059" DF="0" EFFECT_SIZE="-1.7999999999999972" ESTIMABLE="YES" I2="0.0" ID="CMP-042.11.03" NO="3" P_CHI2="1.0" P_Z="0.4509066087723882" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="34" WEIGHT="100.0" Z="0.7539044427674094">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="2.879552171389065" CI_START="-6.479552171389059" EFFECT_SIZE="-1.7999999999999972" ESTIMABLE="YES" MEAN_1="118.0" MEAN_2="119.8" ORDER="151348" SD_1="10.9" SD_2="9.2" SE="2.387570490223684" STUDY_ID="STD-Karatosun-2005a" TOTAL_1="37" TOTAL_2="34" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="5.920002660908195" CI_START="-4.520002660908189" DF="0" EFFECT_SIZE="0.7000000000000028" ESTIMABLE="YES" I2="0.0" ID="CMP-042.11.04" NO="4" P_CHI2="1.0" P_Z="0.7926813918424681" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="32" WEIGHT="100.0" Z="0.2628302854043647">
<NAME>45 to 52 weeks post-injection</NAME>
<CONT_DATA CI_END="5.920002660908195" CI_START="-4.520002660908189" EFFECT_SIZE="0.7000000000000028" ESTIMABLE="YES" MEAN_1="122.0" MEAN_2="121.3" ORDER="151349" SD_1="11.4" SD_2="9.4" SE="2.663315602777861" STUDY_ID="STD-Karatosun-2005a" TOTAL_1="30" TOTAL_2="32" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.40630084561113833" CI_END="-0.2828028927131603" CI_START="-1.524325965601444" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.9035644291573022" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-042.12" NO="12" P_CHI2="0.9389378481457693" P_Q="0.9389378481457693" P_Z="0.004332595213249331" Q="0.40630084561113833" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="145" TOTAL_2="140" UNITS="" WEIGHT="400.0" Z="2.852872858399405">
<NAME>Walking distance</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>Hylan G-F 20</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hylan G-F 20</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Orthovisc</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.08756969849783824" CI_START="-2.4875696984978406" DF="0" EFFECT_SIZE="-1.200000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-042.12.01" NO="1" P_CHI2="1.0" P_Z="0.06775035494295562" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="40" WEIGHT="100.0" Z="1.826663662706578">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="0.08756969849783824" CI_START="-2.4875696984978406" EFFECT_SIZE="-1.200000000000001" ESTIMABLE="YES" MEAN_1="8.7" MEAN_2="9.9" ORDER="151350" SD_1="3.2" SD_2="2.6" SE="0.6569353869020169" STUDY_ID="STD-Karatosun-2005a" TOTAL_1="39" TOTAL_2="40" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.30853858839462633" CI_START="-2.108538588394627" DF="0" EFFECT_SIZE="-0.9000000000000004" ESTIMABLE="YES" I2="0.0" ID="CMP-042.12.02" NO="2" P_CHI2="1.0" P_Z="0.14440352923520186" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="34" WEIGHT="100.00000000000001" Z="1.4595873090235638">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="0.30853858839462633" CI_START="-2.108538588394627" EFFECT_SIZE="-0.9000000000000004" ESTIMABLE="YES" MEAN_1="9.2" MEAN_2="10.1" ORDER="151351" SD_1="3.2" SD_2="2.0" SE="0.6166126510116638" STUDY_ID="STD-Karatosun-2005a" TOTAL_1="39" TOTAL_2="34" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.26654058595309005" CI_START="-2.0665405859530908" DF="0" EFFECT_SIZE="-0.9000000000000004" ESTIMABLE="YES" I2="0.0" ID="CMP-042.12.03" NO="3" P_CHI2="1.0" P_Z="0.13049936186606334" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="34" WEIGHT="100.0" Z="1.5121356319076098">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="0.26654058595309005" CI_START="-2.0665405859530908" EFFECT_SIZE="-0.9000000000000004" ESTIMABLE="YES" MEAN_1="9.1" MEAN_2="10.0" ORDER="151352" SD_1="2.8" SD_2="2.2" SE="0.5951847050020376" STUDY_ID="STD-Karatosun-2005a" TOTAL_1="37" TOTAL_2="34" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.721795555253137" CI_START="-1.9217955552531363" DF="0" EFFECT_SIZE="-0.5999999999999996" ESTIMABLE="YES" I2="0.0" ID="CMP-042.12.04" NO="4" P_CHI2="1.0" P_Z="0.3736363962658007" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="32" WEIGHT="100.0" Z="0.88968251258707">
<NAME>45 to 52 weeks post-injection</NAME>
<CONT_DATA CI_END="0.7217955552531368" CI_START="-1.921795555253136" EFFECT_SIZE="-0.5999999999999996" ESTIMABLE="YES" MEAN_1="9.6" MEAN_2="10.2" ORDER="151353" SD_1="2.4" SD_2="2.9" SE="0.6743978795933451" STUDY_ID="STD-Karatosun-2005a" TOTAL_1="30" TOTAL_2="32" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="4.814969199344678" CI_START="-4.814969199344678" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-042.13" NO="13" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="60" TOTAL_2="63" UNITS="" WEIGHT="300.0" Z="0.0">
<NAME>Patient global assessment (0-100 mm VAS where 100 is worst severity)</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>Hylan G-F 20</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Orthovisc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Hylan G-F 20</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="8.267022938693527" CI_START="-8.267022938693527" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-042.13.01" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="21" WEIGHT="100.0" Z="0.0">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="8.267022938693527" CI_START="-8.267022938693527" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="50.0" MEAN_2="50.0" ORDER="151354" SD_1="13.5" SD_2="13.5" SE="4.217946352026235" STUDY_ID="STD-Kotevoglu-2005" TOTAL_1="20" TOTAL_2="21" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="7.409702041347532" CI_START="-7.409702041347532" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-042.13.02" NO="2" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="21" WEIGHT="100.0" Z="0.0">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="7.409702041347532" CI_START="-7.409702041347532" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="50.0" MEAN_2="50.0" ORDER="151355" SD_1="12.1" SD_2="12.1" SE="3.780529693297589" STUDY_ID="STD-Kotevoglu-2005" TOTAL_1="20" TOTAL_2="21" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="9.859190319478948" CI_START="-9.859190319478948" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-042.13.03" NO="3" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="21" WEIGHT="100.0" Z="0.0">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="9.859190319478948" CI_START="-9.859190319478948" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="70.0" MEAN_2="70.0" ORDER="151356" SD_1="16.1" SD_2="16.1" SE="5.030291575379437" STUDY_ID="STD-Kotevoglu-2005" TOTAL_1="20" TOTAL_2="21" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="7.7044482936867045" CI_END="19.24630222375953" CI_START="5.533111256885829" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="12.389706740322678" ESTIMABLE="YES" I2="74.0409705697049" I2_Q="74.04097056970491" ID="CMP-042.14" NO="14" P_CHI2="0.021232488762458313" P_Q="0.0212324887624582" P_Z="3.976947892815421E-4" Q="7.704448293686705" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="60" TOTAL_2="63" UNITS="" WEIGHT="300.0" Z="3.5416088128147276">
<NAME>Physician global assessment (0-100 mm VAS where 100 is worst severity)</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>Hylan G-F 20</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Orthovisc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Hylan G-F 20</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="32.73418272739385" CI_START="7.265817272606149" DF="0" EFFECT_SIZE="20.0" ESTIMABLE="YES" I2="0.0" ID="CMP-042.14.01" NO="1" P_CHI2="1.0" P_Z="0.002082046972537309" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="21" WEIGHT="100.00000000000001" Z="3.0782721223620704">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="32.73418272739385" CI_START="7.265817272606149" EFFECT_SIZE="20.0" ESTIMABLE="YES" MEAN_1="70.0" MEAN_2="50.0" ORDER="151357" SD_1="20.5" SD_2="21.1" SE="6.497151390453834" STUDY_ID="STD-Kotevoglu-2005" TOTAL_1="20" TOTAL_2="21" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.3989435307939946E-31" CI_END="31.943629545655085" CI_START="8.056370454344922" DF="0" EFFECT_SIZE="20.000000000000004" ESTIMABLE="YES" I2="100.0" ID="CMP-042.14.02" NO="2" P_CHI2="0.0" P_Z="0.0010306480575553308" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="21" WEIGHT="100.0" Z="3.2820240732484223">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="31.94362954565508" CI_START="8.056370454344918" EFFECT_SIZE="20.0" ESTIMABLE="YES" MEAN_1="70.0" MEAN_2="50.0" ORDER="151358" SD_1="20.5" SD_2="18.4" SE="6.093800518716113" STUDY_ID="STD-Kotevoglu-2005" TOTAL_1="20" TOTAL_2="21" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="11.115342003612376" CI_START="-11.115342003612376" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-042.14.03" NO="3" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="21" WEIGHT="100.0" Z="0.0">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="11.115342003612376" CI_START="-11.115342003612376" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="60.0" MEAN_2="60.0" ORDER="151359" SD_1="18.2" SD_2="18.1" SE="5.671197068562879" STUDY_ID="STD-Kotevoglu-2005" TOTAL_1="20" TOTAL_2="21" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.470765103977464" CI_END="0.10401952774653428" CI_START="-0.5167188461500507" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.20634965920175818" ESTIMABLE="YES" I2="32.897391604604366" I2_Q="0.0" ID="CMP-042.15" NO="15" P_CHI2="0.2149131282628961" P_Q="0.4347361862383512" P_Z="0.1925452289930403" Q="1.6660329609719096" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="80" TOTAL_2="83" UNITS="" WEIGHT="300.0" Z="1.3030865087936054">
<NAME>WOMAC stiffness (0-8 or 2-10 Likert)</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>Hylan G-F 20</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Orthovisc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Hylan G-F 20</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.8047321430055554" CI_END="0.43405925312996846" CI_START="-0.4456457390777027" DF="1" EFFECT_SIZE="-0.0057932429738671515" ESTIMABLE="YES" I2="64.34597141499586" ID="CMP-042.15.01" NO="1" P_CHI2="0.09398663929876205" P_Z="0.9794053411248584" STUDIES="2" TAU2="0.0" TOTAL_1="40" TOTAL_2="41" WEIGHT="100.0" Z="0.025814443894366074">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="1.000359921774712" CI_START="-0.2512292956753051" EFFECT_SIZE="0.37456531304970336" ESTIMABLE="YES" MEAN_1="3.2" MEAN_2="2.6" ORDER="151360" SD_1="1.8" SD_2="1.3" SE="0.31928883064239777" STUDY_ID="STD-Karatay-2004" TOTAL_1="20" TOTAL_2="20" WEIGHT="49.40267748267335"/>
<CONT_DATA CI_END="0.2411914958428783" CI_START="-0.9955339276046649" EFFECT_SIZE="-0.37717121588089325" ESTIMABLE="YES" MEAN_1="3.5" MEAN_2="4.0" ORDER="151361" SD_1="1.3" SD_2="1.3" SE="0.3154969767818887" STUDY_ID="STD-Kotevoglu-2005" TOTAL_1="20" TOTAL_2="21" WEIGHT="50.597322517326646"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.2730977104178334" CI_START="-0.9616366415726911" DF="0" EFFECT_SIZE="-0.3442694655774289" ESTIMABLE="YES" I2="0.0" ID="CMP-042.15.02" NO="2" P_CHI2="1.0" P_Z="0.27441271327648153" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="21" WEIGHT="100.0" Z="1.0929569626386983">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="0.2730977104178334" CI_START="-0.9616366415726911" EFFECT_SIZE="-0.3442694655774289" ESTIMABLE="YES" MEAN_1="3.5" MEAN_2="4.0" ORDER="151362" SD_1="1.7" SD_2="1.1" SE="0.31498904105635395" STUDY_ID="STD-Kotevoglu-2005" TOTAL_1="20" TOTAL_2="21" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.064278644576794E-32" CI_END="0.15451838959402797" CI_START="-1.0885476265782636" DF="0" EFFECT_SIZE="-0.4670146184921179" ESTIMABLE="YES" I2="100.0" ID="CMP-042.15.03" NO="3" P_CHI2="0.0" P_Z="0.140831872165629" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="21" WEIGHT="99.99999999999999" Z="1.472700275914224">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="0.15451838959402803" CI_START="-1.0885476265782636" EFFECT_SIZE="-0.46701461849211784" ESTIMABLE="YES" MEAN_1="3.5" MEAN_2="4.0" ORDER="151363" SD_1="1.1" SD_2="1.0" SE="0.31711450464841134" STUDY_ID="STD-Kotevoglu-2005" TOTAL_1="20" TOTAL_2="21" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="4.467369286615086" CI_START="-5.667369286615085" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.5999999999999996" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-042.16" NO="16" P_CHI2="1.0" P_Q="1.0" P_Z="0.8164845651263094" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="20" TOTAL_2="20" UNITS="" WEIGHT="100.0" Z="0.23206881602851662">
<NAME>Synovial fluid intercellular adhesion molecule-1 (ICAM-1)</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>Hylan G-F 20</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Orthovisc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Hylan G-F 20</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="4.467369286615086" CI_START="-5.667369286615085" DF="0" EFFECT_SIZE="-0.5999999999999996" ESTIMABLE="YES" I2="0.0" ID="CMP-042.16.01" NO="1" P_CHI2="1.0" P_Z="0.8164845651263094" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.23206881602851662">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="4.467369286615086" CI_START="-5.667369286615085" EFFECT_SIZE="-0.5999999999999996" ESTIMABLE="YES" MEAN_1="12.0" MEAN_2="12.6" ORDER="151364" SD_1="7.5" SD_2="8.8" SE="2.5854400012377003" STUDY_ID="STD-Karatay-2004" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="4.227990036063976" CI_START="-10.227990036063975" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-042.17" NO="17" P_CHI2="1.0" P_Q="1.0" P_Z="0.4159376337957392" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="20" TOTAL_2="20" UNITS="" WEIGHT="100.0" Z="0.8134892168199607">
<NAME>Synovial fluid vascular cell adhesion molecule-1 (VCAM-1)</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>Hylan G-F 20</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Orthovisc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Hylan G-F 20</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="4.227990036063976" CI_START="-10.227990036063975" DF="0" EFFECT_SIZE="-3.0" ESTIMABLE="YES" I2="0.0" ID="CMP-042.17.01" NO="1" P_CHI2="1.0" P_Z="0.4159376337957392" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.8134892168199607">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="4.227990036063976" CI_START="-10.227990036063975" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="31.6" MEAN_2="34.6" ORDER="151365" SD_1="12.8" SD_2="10.4" SE="3.687817782917155" STUDY_ID="STD-Karatay-2004" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="22" EVENTS_2="19" I2="0.0" I2_Q="0.0" ID="CMP-042.18" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="18" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="72" TOTAL_2="72" WEIGHT="0.0" Z="0.0">
<NAME>Safety: total withdrawals overall</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>Hylan G-F 20</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Orthovisc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Hylan G-F 20</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.060584622841761" CI_START="0.6338601358571301" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="14" LOG_CI_END="0.31399045456969255" LOG_CI_START="-0.19800656061431912" LOG_EFFECT_SIZE="0.05799194697768673" ORDER="151366" O_E="0.0" SE="0.3007495811451883" STUDY_ID="STD-Karatosun-2005a" TOTAL_1="46" TOTAL_2="46" VAR="0.09045031055900621" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.4463915302281247" CI_START="0.4178283248928142" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.5373646143071551" LOG_CI_START="-0.3790021222119055" LOG_EFFECT_SIZE="0.07918124604762482" ORDER="151367" O_E="0.0" SE="0.538278357119799" STUDY_ID="STD-Kotevoglu-2005" TOTAL_1="26" TOTAL_2="26" VAR="0.2897435897435898" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-042.19" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="19" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="46" TOTAL_2="46" WEIGHT="0.0" Z="0.0">
<NAME>Safety: withdrawals due to lack of efficacy</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>Hylan G-F 20</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Orthovisc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Hylan G-F 20</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.361421829214613" CI_START="0.3582547300363671" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6396280929198433" LOG_CI_START="-0.4458080669037306" LOG_EFFECT_SIZE="0.09691001300805642" ORDER="151368" O_E="0.0" SE="0.637590573276013" STUDY_ID="STD-Karatosun-2005a" TOTAL_1="46" TOTAL_2="46" VAR="0.4065217391304348" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-042.20" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="20" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="46" TOTAL_2="46" WEIGHT="0.0" Z="0.0">
<NAME>Safety: number of patients with local adverse event</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>Hylan G-F 20</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Orthovisc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Hylan G-F 20</GRAPH_LABEL_2>
<DICH_DATA CI_END="26.450125630660757" CI_START="0.34026303412212444" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4224277391527982" LOG_CI_START="-0.4681852297134733" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="151369" O_E="0.0" SE="1.1105554165971787" STUDY_ID="STD-Atamaz-2005" TOTAL_1="20" TOTAL_2="20" VAR="1.2333333333333332" WEIGHT="0.0"/>
<DICH_DATA CI_END="15.149704352020958" CI_START="0.06600788878540728" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.180404157621246" LOG_CI_START="-1.180404157621246" LOG_EFFECT_SIZE="0.0" ORDER="151370" O_E="0.0" SE="1.3867504905630728" STUDY_ID="STD-Kotevoglu-2005" TOTAL_1="26" TOTAL_2="26" VAR="1.923076923076923" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-042.21" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="21" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="26" TOTAL_2="26" WEIGHT="0.0" Z="0.0">
<NAME>Safety: withdrawals due to noncompliance</NAME>
<GROUP_LABEL_1>Orthovisc</GROUP_LABEL_1>
<GROUP_LABEL_2>Hylan G-F 20</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Orthovisc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Hylan G-F 20</GRAPH_LABEL_2>
<DICH_DATA CI_END="15.149704352020958" CI_START="0.06600788878540728" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.180404157621246" LOG_CI_START="-1.180404157621246" LOG_EFFECT_SIZE="0.0" ORDER="151371" O_E="0.0" SE="1.3867504905630728" STUDY_ID="STD-Kotevoglu-2005" TOTAL_1="26" TOTAL_2="26" VAR="1.923076923076923" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-043" NO="43">
<NAME>Orthovisc versus Orthovisc</NAME>
<CONT_OUTCOME CHI2="0.15258682595960035" CI_END="2.8706641524104377" CI_START="-42.77706942997064" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-19.9532026387801" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-043.01" NO="1" P_CHI2="0.6960756191180026" P_Q="0.6960756191180026" P_Z="0.0866297522619478" Q="0.15258682595960035" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="230" TOTAL_2="214" UNITS="" WEIGHT="200.0" Z="1.7134501750305142">
<NAME>WOMAC total score (0 to 100 mm VAS; change from baseline)</NAME>
<GROUP_LABEL_1>Orthovisc 4 injectio</GROUP_LABEL_1>
<GROUP_LABEL_2>Ortho 3 inj + 1 arth</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Ortho 4 inj</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Orth3inj1art</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="7.517872625271291" CI_START="-56.317872625271306" DF="0" EFFECT_SIZE="-24.400000000000006" ESTIMABLE="YES" I2="0.0" ID="CMP-043.01.01" NO="1" P_CHI2="1.0" P_Z="0.13405066469392782" STUDIES="1" TAU2="0.0" TOTAL_1="115" TOTAL_2="107" WEIGHT="100.0" Z="1.4983179419330377">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="7.517872625271291" CI_START="-56.317872625271306" EFFECT_SIZE="-24.400000000000006" ESTIMABLE="YES" MEAN_1="-145.5" MEAN_2="-121.1" ORDER="151372" SD_1="119.1" SD_2="123.2" SE="16.284928129820447" STUDY_ID="STD-Neustadt-2005a-_x002d_3inj" TOTAL_1="115" TOTAL_2="107" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="17.35023041519152" CI_START="-47.95023041519151" DF="0" EFFECT_SIZE="-15.299999999999997" ESTIMABLE="YES" I2="0.0" ID="CMP-043.01.02" NO="2" P_CHI2="1.0" P_Z="0.35838582177492595" STUDIES="1" TAU2="0.0" TOTAL_1="115" TOTAL_2="107" WEIGHT="100.0" Z="0.9184452477710616">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="17.35023041519152" CI_START="-47.95023041519151" EFFECT_SIZE="-15.299999999999997" ESTIMABLE="YES" MEAN_1="-123.7" MEAN_2="-108.4" ORDER="151373" SD_1="123.4" SD_2="124.6" SE="16.65858692952134" STUDY_ID="STD-Neustadt-2005a-_x002d_3inj" TOTAL_1="115" TOTAL_2="107" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.07030833249573229" CI_END="-2.5116870206011574" CI_START="-13.598966553519062" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-8.05532678706011" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-043.02" NO="2" P_CHI2="0.7908883817844654" P_Q="0.7908883817844654" P_Z="0.004399830782782628" Q="0.07030833249573229" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="230" TOTAL_2="214" UNITS="" WEIGHT="200.0" Z="2.8479755271730767">
<NAME>Patient global assessment (0 to 100 mm VAS; change from baseline)</NAME>
<GROUP_LABEL_1>Orthovisc 4 inj</GROUP_LABEL_1>
<GROUP_LABEL_2>Ortho3inj+1arthrocen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Ortho 4 inj</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Orth3inj1art</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.9878029785379505" CI_START="-16.612197021462045" DF="0" EFFECT_SIZE="-8.799999999999997" ESTIMABLE="YES" I2="0.0" ID="CMP-043.02.01" NO="1" P_CHI2="1.0" P_Z="0.02725898152998161" STUDIES="1" TAU2="0.0" TOTAL_1="115" TOTAL_2="107" WEIGHT="100.0" Z="2.2077890530114384">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="-0.9878029785379505" CI_START="-16.612197021462045" EFFECT_SIZE="-8.799999999999997" ESTIMABLE="YES" MEAN_1="-36.3" MEAN_2="-27.5" ORDER="151374" SD_1="29.1" SD_2="30.2" SE="3.9858880484966352" STUDY_ID="STD-Neustadt-2005a-_x002d_3inj" TOTAL_1="115" TOTAL_2="107" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.5678806803644116" CI_START="-15.167880680364405" DF="0" EFFECT_SIZE="-7.299999999999997" ESTIMABLE="YES" I2="0.0" ID="CMP-043.02.02" NO="2" P_CHI2="1.0" P_Z="0.06898782299594683" STUDIES="1" TAU2="0.0" TOTAL_1="115" TOTAL_2="107" WEIGHT="100.0" Z="1.818499500488067">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="0.5678806803644116" CI_START="-15.167880680364405" EFFECT_SIZE="-7.299999999999997" ESTIMABLE="YES" MEAN_1="-33.4" MEAN_2="-26.1" ORDER="151375" SD_1="29.1" SD_2="30.6" SE="4.014298600599423" STUDY_ID="STD-Neustadt-2005a-_x002d_3inj" TOTAL_1="115" TOTAL_2="107" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.04728740172156117" CI_END="1.6335306862238248" CI_START="-7.340537791439347" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.8535035526077612" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-043.03" NO="3" P_CHI2="0.8278524751235042" P_Q="0.8278524751235042" P_Z="0.2126074062974559" Q="0.04728740172156117" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="230" TOTAL_2="214" UNITS="" WEIGHT="200.0" Z="1.246427795105181">
<NAME>Physician global assessment (0 to 100 mm VAS; change from baseline)</NAME>
<GROUP_LABEL_1>Orthovisc 4 inj</GROUP_LABEL_1>
<GROUP_LABEL_2>Ortho3inj+1arthrocen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Ortho 4 inj</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Orth3inj1art</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.669678836222169" CI_START="-8.469678836222165" DF="0" EFFECT_SIZE="-2.3999999999999986" ESTIMABLE="YES" I2="0.0" ID="CMP-043.03.01" NO="1" P_CHI2="1.0" P_Z="0.43834818805891185" STUDIES="1" TAU2="0.0" TOTAL_1="115" TOTAL_2="107" WEIGHT="100.0" Z="0.7749855782853732">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="3.669678836222169" CI_START="-8.469678836222165" EFFECT_SIZE="-2.3999999999999986" ESTIMABLE="YES" MEAN_1="-25.4" MEAN_2="-23.0" ORDER="151376" SD_1="22.9" SD_2="23.2" SE="3.0968318214513224" STUDY_ID="STD-Neustadt-2005a-_x002d_3inj" TOTAL_1="115" TOTAL_2="107" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.2629880859616494" CI_START="-10.062988085961646" DF="0" EFFECT_SIZE="-3.3999999999999986" ESTIMABLE="YES" I2="0.0" ID="CMP-043.03.02" NO="2" P_CHI2="1.0" P_Z="0.3172459228399761" STUDIES="1" TAU2="0.0" TOTAL_1="115" TOTAL_2="107" WEIGHT="100.0" Z="1.0001334928808303">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="3.2629880859616494" CI_START="-10.062988085961646" EFFECT_SIZE="-3.3999999999999986" ESTIMABLE="YES" MEAN_1="-21.7" MEAN_2="-18.3" ORDER="151377" SD_1="24.2" SD_2="26.3" SE="3.3995461847862756" STUDY_ID="STD-Neustadt-2005a-_x002d_3inj" TOTAL_1="115" TOTAL_2="107" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.31940355717396096" CI_END="0.27745365970248237" CI_START="-11.857358367910368" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-5.789952354103943" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-043.04" NO="4" P_CHI2="0.5719664318805675" P_Q="0.5719664318805675" P_Z="0.06143694021095367" Q="0.31940355717396096" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="208" TOTAL_2="180" UNITS="" WEIGHT="200.0" Z="1.8703376797965974">
<NAME>WOMAC pain on standing (0 to 100 mm VAS; change from baseline)</NAME>
<GROUP_LABEL_1>Orthovisc 4 inj</GROUP_LABEL_1>
<GROUP_LABEL_2>Ortho3inj+1arthrocen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Ortho 4 inj</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Orth3inj1art</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.98430640606046" CI_START="-15.98430640606046" DF="0" EFFECT_SIZE="-7.5" ESTIMABLE="YES" I2="0.0" ID="CMP-043.04.01" NO="1" P_CHI2="1.0" P_Z="0.0831705501302079" STUDIES="1" TAU2="0.0" TOTAL_1="104" TOTAL_2="90" WEIGHT="100.0" Z="1.7325788556563895">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="0.98430640606046" CI_START="-15.98430640606046" EFFECT_SIZE="-7.5" ESTIMABLE="YES" MEAN_1="-32.9" MEAN_2="-25.4" ORDER="151378" SD_1="30.6" SD_2="29.6" SE="4.328807301044094" STUDY_ID="STD-Neustadt-2005a-_x002d_3inj" TOTAL_1="104" TOTAL_2="90" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="4.680264807927273" CI_START="-12.680264807927273" DF="0" EFFECT_SIZE="-4.0" ESTIMABLE="YES" I2="0.0" ID="CMP-043.04.02" NO="2" P_CHI2="1.0" P_Z="0.36642950244638417" STUDIES="1" TAU2="0.0" TOTAL_1="104" TOTAL_2="90" WEIGHT="100.0" Z="0.9031816553569253">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="4.680264807927273" CI_START="-12.680264807927273" EFFECT_SIZE="-4.0" ESTIMABLE="YES" MEAN_1="-29.5" MEAN_2="-25.5" ORDER="151379" SD_1="31.4" SD_2="30.2" SE="4.428787914673991" STUDY_ID="STD-Neustadt-2005a-_x002d_3inj" TOTAL_1="104" TOTAL_2="90" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="1.9070175322248573" CI_END="1.317572819487438" CI_START="1.023135074531428" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1610576923076923" ESTIMABLE="YES" EVENTS_1="161" EVENTS_2="120" I2="47.56209719617357" I2_Q="46.679964085255634" ID="CMP-043.05" LOG_CI_END="0.11977462709340908" LOG_CI_START="0.009932973156129678" LOG_EFFECT_SIZE="0.06485380012476939" METHOD="MH" NO="5" P_CHI2="0.16729517042766284" P_Q="0.1708503853324479" P_Z="0.02064344549429256" Q="1.8754676039583729" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="208" TOTAL_2="180" WEIGHT="200.0" Z="2.3144427992260366">
<NAME>Number of patients with a 20% improvement from baseline in WOMAC pain score</NAME>
<GROUP_LABEL_1>Orthovisc 4 inj</GROUP_LABEL_1>
<GROUP_LABEL_2>Ortho3inj+1arthrocen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Ortho3in1art</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Ortho 4 inj</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4859025200590996" CI_START="1.0728731194436474" DF="0" EFFECT_SIZE="1.2626103404791928" ESTIMABLE="YES" EVENTS_1="89" EVENTS_2="61" I2="0.0" ID="CMP-043.05.01" LOG_CI_END="0.17199031925695596" LOG_CI_START="0.03054836429242446" LOG_EFFECT_SIZE="0.10126934177469024" NO="1" P_CHI2="1.0" P_Z="0.005007007867076866" STUDIES="1" TAU2="0.0" TOTAL_1="104" TOTAL_2="90" WEIGHT="100.0" Z="2.806582568322718">
<NAME>5 to 13 weeks post-injection</NAME>
<DICH_DATA CI_END="1.4859025200590996" CI_START="1.0728731194436474" EFFECT_SIZE="1.2626103404791928" ESTIMABLE="YES" EVENTS_1="89" EVENTS_2="61" LOG_CI_END="0.17199031925695596" LOG_CI_START="0.03054836429242446" LOG_EFFECT_SIZE="0.10126934177469024" ORDER="151380" O_E="0.0" SE="0.08308370449513472" STUDY_ID="STD-Neustadt-2005a-_x002d_3inj" TOTAL_1="104" TOTAL_2="90" VAR="0.006902901952634868" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.286125153563714" CI_START="0.8671536925665764" DF="0" EFFECT_SIZE="1.0560625814863103" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="59" I2="0.0" ID="CMP-043.05.02" LOG_CI_END="0.10928323208543557" LOG_CI_START="-0.06190392222609805" LOG_EFFECT_SIZE="0.023689654929668777" NO="2" P_CHI2="1.0" P_Z="0.5875034396902349" STUDIES="1" TAU2="0.0" TOTAL_1="104" TOTAL_2="90" WEIGHT="100.0" Z="0.5424574134089021">
<NAME>14 to 26 weeks post-injection</NAME>
<DICH_DATA CI_END="1.286125153563714" CI_START="0.8671536925665764" EFFECT_SIZE="1.0560625814863103" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="59" LOG_CI_END="0.10928323208543557" LOG_CI_START="-0.06190392222609805" LOG_EFFECT_SIZE="0.023689654929668777" ORDER="151381" O_E="0.0" SE="0.10055618183267521" STUDY_ID="STD-Neustadt-2005a-_x002d_3inj" TOTAL_1="104" TOTAL_2="90" VAR="0.010111545704766042" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.04166016608339858" CI_END="1.4452643453625575" CI_START="1.0217936672051706" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2152209492635024" ESTIMABLE="YES" EVENTS_1="132" EVENTS_2="94" I2="0.0" I2_Q="0.0" ID="CMP-043.06" LOG_CI_END="0.15994728877600975" LOG_CI_START="0.009363206717381676" LOG_EFFECT_SIZE="0.08465524774669572" METHOD="MH" NO="6" P_CHI2="0.8382690400933573" P_Q="0.8386010306438189" P_Z="0.02754529413252995" Q="0.041486923917549164" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="208" TOTAL_2="180" WEIGHT="200.0" Z="2.2037022030155855">
<NAME>Number of patients with a 40% improvement from baseline in WOMAC pain score</NAME>
<GROUP_LABEL_1>Orthovisc 4 inj</GROUP_LABEL_1>
<GROUP_LABEL_2>Ortho 3inj+1arthroce</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Ortho3in1art</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Orth 4 inj</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5585088024285418" CI_START="0.9806476698875419" DF="0" EFFECT_SIZE="1.2362637362637363" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="49" I2="0.0" ID="CMP-043.06.01" LOG_CI_END="0.1927092595068897" LOG_CI_START="-0.008486999254314268" LOG_EFFECT_SIZE="0.0921111301262877" NO="1" P_CHI2="1.0" P_Z="0.07271571826007754" STUDIES="1" TAU2="0.0" TOTAL_1="104" TOTAL_2="90" WEIGHT="100.0" Z="1.7946108812796489">
<NAME>5 to 13 weeks post-injection</NAME>
<DICH_DATA CI_END="1.5585088024285418" CI_START="0.9806476698875419" EFFECT_SIZE="1.2362637362637363" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="49" LOG_CI_END="0.1927092595068897" LOG_CI_START="-0.008486999254314268" LOG_EFFECT_SIZE="0.0921111301262877" ORDER="151382" O_E="0.0" SE="0.11818367833387435" STUDY_ID="STD-Neustadt-2005a-_x002d_3inj" TOTAL_1="104" TOTAL_2="90" VAR="0.01396738182452468" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5466512316866214" CI_START="0.9191455733597056" DF="0" EFFECT_SIZE="1.1923076923076923" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="45" I2="0.0" ID="CMP-043.06.02" LOG_CI_END="0.18939239176618172" LOG_CI_START="-0.036615700039272336" LOG_EFFECT_SIZE="0.0763883458634547" NO="2" P_CHI2="1.0" P_Z="0.18520623974696893" STUDIES="1" TAU2="0.0" TOTAL_1="104" TOTAL_2="90" WEIGHT="100.00000000000001" Z="1.3248942153791279">
<NAME>14 to 26 weeks post-injection</NAME>
<DICH_DATA CI_END="1.5466512316866214" CI_START="0.9191455733597056" EFFECT_SIZE="1.1923076923076923" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="45" LOG_CI_END="0.18939239176618172" LOG_CI_START="-0.036615700039272336" LOG_EFFECT_SIZE="0.0763883458634547" ORDER="151383" O_E="0.0" SE="0.13275827188462125" STUDY_ID="STD-Neustadt-2005a-_x002d_3inj" TOTAL_1="104" TOTAL_2="90" VAR="0.017624758753791013" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.003934639440351862" CI_END="1.5251653045752875" CI_START="1.0146520330440298" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2439903846153846" ESTIMABLE="YES" EVENTS_1="115" EVENTS_2="80" I2="0.0" I2_Q="0.0" ID="CMP-043.07" LOG_CI_END="0.18331691710852577" LOG_CI_START="0.006317129895899462" LOG_EFFECT_SIZE="0.0948170235022126" METHOD="MH" NO="7" P_CHI2="0.9499841322833206" P_Q="0.9500365734196936" P_Z="0.035740596983657016" Q="0.003926382104198225" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="208" TOTAL_2="180" WEIGHT="200.0" Z="2.0998663796401202">
<NAME>Number of patients with a 50% improvement from baseline in WOMAC pain score</NAME>
<GROUP_LABEL_1>Orthovisc 4 inj</GROUP_LABEL_1>
<GROUP_LABEL_2>Ortho3inj+1arthrocen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Ortho3in1art</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Ortho 4 inj</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6282967402256696" CI_START="0.9386176289887773" DF="0" EFFECT_SIZE="1.2362637362637363" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="42" I2="0.0" ID="CMP-043.07.01" LOG_CI_END="0.21173355343954672" LOG_CI_START="-0.027511293186971292" LOG_EFFECT_SIZE="0.0921111301262877" NO="1" P_CHI2="1.0" P_Z="0.13124696186898696" STUDIES="1" TAU2="0.0" TOTAL_1="104" TOTAL_2="90" WEIGHT="99.99999999999999" Z="1.509202811834324">
<NAME>5 to 13 weeks post-injection</NAME>
<DICH_DATA CI_END="1.6282967402256694" CI_START="0.9386176289887773" EFFECT_SIZE="1.2362637362637363" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="42" LOG_CI_END="0.21173355343954667" LOG_CI_START="-0.027511293186971292" LOG_EFFECT_SIZE="0.0921111301262877" ORDER="151384" O_E="0.0" SE="0.1405336071895073" STUDY_ID="STD-Neustadt-2005a-_x002d_3inj" TOTAL_1="104" TOTAL_2="90" VAR="0.019749694749694742" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6944373734058167" CI_START="0.9258721144244364" DF="0" EFFECT_SIZE="1.2525303643724697" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="38" I2="0.0" ID="CMP-043.07.02" LOG_CI_END="0.22902552189756603" LOG_CI_START="-0.03344899586160955" LOG_EFFECT_SIZE="0.09778826301797822" NO="2" P_CHI2="1.0" P_Z="0.14417477148386806" STUDIES="1" TAU2="0.0" TOTAL_1="104" TOTAL_2="90" WEIGHT="100.0" Z="1.460419664828719">
<NAME>14 to 26 weeks post-injection</NAME>
<DICH_DATA CI_END="1.6944373734058165" CI_START="0.9258721144244364" EFFECT_SIZE="1.2525303643724697" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="38" LOG_CI_END="0.22902552189756598" LOG_CI_START="-0.03344899586160955" LOG_EFFECT_SIZE="0.09778826301797822" ORDER="151385" O_E="0.0" SE="0.15417883100155697" STUDY_ID="STD-Neustadt-2005a-_x002d_3inj" TOTAL_1="104" TOTAL_2="90" VAR="0.02377111192900666" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="35" EVENTS_2="44" I2="0.0" I2_Q="0.0" ID="CMP-043.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="128" TOTAL_2="120" WEIGHT="0.0" Z="0.0">
<NAME>Safety: total withdrawals overall</NAME>
<GROUP_LABEL_1>Orthovisc 4-injectio</GROUP_LABEL_1>
<GROUP_LABEL_2>Orthovisc 3inj+1arth</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Ortho 4inj</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Ortho3inj1ar</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.07690962032897" CI_START="0.5164092726700804" EFFECT_SIZE="0.7457386363636364" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="44" LOG_CI_END="0.032179256650399814" LOG_CI_START="-0.28700596812271045" LOG_EFFECT_SIZE="-0.12741335573615534" ORDER="151386" O_E="0.0" SE="0.18749098102406944" STUDY_ID="STD-Neustadt-2005a-_x002d_3inj" TOTAL_1="128" TOTAL_2="120" VAR="0.03515286796536797" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="9" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-043.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="128" TOTAL_2="120" WEIGHT="0.0" Z="0.0">
<NAME>Safety: total withdrawals due to lack of efficacy</NAME>
<GROUP_LABEL_1>Orthovisc 4 injectio</GROUP_LABEL_1>
<GROUP_LABEL_2>Ortho 3inj+1arthroce</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Ortho 4 inj</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Orth3inj1art</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.6444855879813565" CI_START="0.42063595570787893" EFFECT_SIZE="1.0546875" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.4223412045267842" LOG_CI_START="-0.37609360683250864" LOG_EFFECT_SIZE="0.02312379884713775" ORDER="151387" O_E="0.0" SE="0.469004560508507" STUDY_ID="STD-Neustadt-2005a-_x002d_3inj" TOTAL_1="128" TOTAL_2="120" VAR="0.21996527777777777" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="75" EVENTS_2="61" I2="0.0" I2_Q="0.0" ID="CMP-043.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="128" TOTAL_2="120" WEIGHT="0.0" Z="0.0">
<NAME>Safety: number of patients reporting adverse events</NAME>
<GROUP_LABEL_1>Orthovisc 4 injectio</GROUP_LABEL_1>
<GROUP_LABEL_2>Ortho 3 inj+1arthro</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Ortho 4 inj</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Orth3in+1art</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.448436417521969" CI_START="0.917288553128224" EFFECT_SIZE="1.1526639344262295" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="61" LOG_CI_END="0.16089943559402606" LOG_CI_START="-0.03749402603264711" LOG_EFFECT_SIZE="0.06170270478068947" ORDER="151388" O_E="0.0" SE="0.11653730142298138" STUDY_ID="STD-Neustadt-2005a-_x002d_3inj" TOTAL_1="128" TOTAL_2="120" VAR="0.01358094262295082" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="10" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-043.11" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="11" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="128" TOTAL_2="119" WEIGHT="0.0" Z="0.0">
<NAME>Safety: number of patients with gastrointestinal adverse events</NAME>
<GROUP_LABEL_1>Orthovisc 4 injectio</GROUP_LABEL_1>
<GROUP_LABEL_2>Ortho3inj+Arthro1inj</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Ortho 4 inj</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Or3inAr1inj</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.9174110254680434" CI_START="0.37254041400028204" EFFECT_SIZE="0.8451704545454546" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" LOG_CI_END="0.2827152203160451" LOG_CI_START="-0.42882660714317045" LOG_EFFECT_SIZE="-0.07305569341356263" ORDER="151389" O_E="0.0" SE="0.4179631916383943" STUDY_ID="STD-Neustadt-2005a-_x002d_3inj" TOTAL_1="128" TOTAL_2="119" VAR="0.1746932295645531" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-043.12" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="12" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="128" TOTAL_2="119" WEIGHT="0.0" Z="0.0">
<NAME>Safety: number of patients with general body adverse events</NAME>
<GROUP_LABEL_1>Orthovisc 4 injectio</GROUP_LABEL_1>
<GROUP_LABEL_2>Ortho3injArthro1inj</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Ortho4inj</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Or3injAr1inj</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.331368805546675" CI_START="0.24584924323745877" EFFECT_SIZE="0.5721153846153846" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="13" LOG_CI_END="0.12429837705785106" LOG_CI_START="-0.6093311241983127" LOG_EFFECT_SIZE="-0.24251637357023081" ORDER="151390" O_E="0.0" SE="0.4309376005624702" STUDY_ID="STD-Neustadt-2005a-_x002d_3inj" TOTAL_1="128" TOTAL_2="119" VAR="0.18570721557853911" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="27" EVENTS_2="22" I2="0.0" I2_Q="0.0" ID="CMP-043.13" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="13" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="128" TOTAL_2="119" WEIGHT="0.0" Z="0.0">
<NAME>Safety: number of patients with infections</NAME>
<GROUP_LABEL_1>Orthovisc 4 injectio</GROUP_LABEL_1>
<GROUP_LABEL_2>Orho3injArthro1inj</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Ortho 4inj</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Or3injAr1inj</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.8897833051453488" CI_START="0.6888808977035179" EFFECT_SIZE="1.1409801136363635" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="22" LOG_CI_END="0.2764120079959835" LOG_CI_START="-0.16185585783309664" LOG_EFFECT_SIZE="0.05727807508144343" ORDER="151391" O_E="0.0" SE="0.25744071384892614" STUDY_ID="STD-Neustadt-2005a-_x002d_3inj" TOTAL_1="128" TOTAL_2="119" VAR="0.06627572114704468" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="35" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-043.14" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="14" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="128" TOTAL_2="119" WEIGHT="0.0" Z="0.0">
<NAME>Safety: number of patients with musculoskeletal adverse events</NAME>
<GROUP_LABEL_1>Orthovisc 4 injectio</GROUP_LABEL_1>
<GROUP_LABEL_2>Ortho3injArthro1inj</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Ortho 4 inje</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Ortho3injAr1</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.24806657758883" CI_START="0.8903181586984309" EFFECT_SIZE="1.414741847826087" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="23" LOG_CI_END="0.35180916893051456" LOG_CI_START="-0.05045476877582434" LOG_EFFECT_SIZE="0.15067720007734514" ORDER="151392" O_E="0.0" SE="0.2362918282473094" STUDY_ID="STD-Neustadt-2005a-_x002d_3inj" TOTAL_1="128" TOTAL_2="119" VAR="0.05583382809645597" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="20" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-043.15" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="15" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="128" TOTAL_2="119" WEIGHT="0.0" Z="0.0">
<NAME>Safety: number of patients with nervous system adverse events</NAME>
<GROUP_LABEL_1>Orthovisc 4 injectio</GROUP_LABEL_1>
<GROUP_LABEL_2>Ortho3injArthro1inj</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Ortho4inj</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Ortho3inAr1i</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.8557371639766749" CI_START="0.5750061627595173" EFFECT_SIZE="1.0329861111111112" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="18" LOG_CI_END="0.2685164652460727" LOG_CI_START="-0.24032750063539757" LOG_EFFECT_SIZE="0.014094482305337538" ORDER="151393" O_E="0.0" SE="0.2988974643770297" STUDY_ID="STD-Neustadt-2005a-_x002d_3inj" TOTAL_1="128" TOTAL_2="119" VAR="0.08933969421101774" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-043.16" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="16" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="128" TOTAL_2="119" WEIGHT="0.0" Z="0.0">
<NAME>Safety: number of patients with respiratory adverse events</NAME>
<GROUP_LABEL_1>Orthovisc 4injection</GROUP_LABEL_1>
<GROUP_LABEL_2>Ortho3injArthro1inj</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Ortho4inj</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Orth3injAr1i</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.2254001445930145" CI_START="0.31961427397380116" EFFECT_SIZE="1.162109375" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6258678428383633" LOG_CI_START="-0.4953738333329257" LOG_EFFECT_SIZE="0.0652470047527188" ORDER="151394" O_E="0.0" SE="0.6586229108188252" STUDY_ID="STD-Neustadt-2005a-_x002d_3inj" TOTAL_1="128" TOTAL_2="119" VAR="0.43378413865546217" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-043.17" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="17" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="128" TOTAL_2="119" WEIGHT="0.0" Z="0.0">
<NAME>Safety: number of patients with skin adverse events</NAME>
<GROUP_LABEL_1>Orthovisc 4 injectio</GROUP_LABEL_1>
<GROUP_LABEL_2>Ortho3injArthro1inj</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Ortho 4inj</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Orth3injAr1i</GRAPH_LABEL_2>
<DICH_DATA CI_END="26.445146859420372" CI_START="0.2941511223309859" EFFECT_SIZE="2.7890625" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4223459831552976" LOG_CI_START="-0.5314294902266481" LOG_EFFECT_SIZE="0.4454582464643248" ORDER="151395" O_E="0.0" SE="1.1476573844091256" STUDY_ID="STD-Neustadt-2005a-_x002d_3inj" TOTAL_1="128" TOTAL_2="119" VAR="1.3171174719887955" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-044" NO="44">
<NAME>Replasyn versus placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-044.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="19" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Safety: Number of patients with local adverse reaction but study drug continued</NAME>
<GROUP_LABEL_1>Replasyn</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Replasyn</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.8105883556187499" CI_START="0.1529935335051035" EFFECT_SIZE="0.5263157894736842" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.25781972297870237" LOG_CI_START="-0.8153269248843603" LOG_EFFECT_SIZE="-0.278753600952829" ORDER="151396" O_E="0.0" SE="0.6303716531163435" STUDY_ID="STD-Cohen-1994" TOTAL_1="19" TOTAL_2="20" VAR="0.3973684210526316" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-045" NO="45">
<NAME>SLM-10 versus Artz (end of treatment)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="59" EVENTS_2="60" I2="0.0" I2_Q="0.0" ID="CMP-045.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="82" TOTAL_2="74" WEIGHT="0.0" Z="0.0">
<NAME>Pain in movement (number of patients improved)</NAME>
<GROUP_LABEL_1>SLM-10</GROUP_LABEL_1>
<GROUP_LABEL_2>Artz</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Artz</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours SLM-10</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.056353966422787" CI_START="0.7454659131121322" EFFECT_SIZE="0.8873983739837399" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="60" LOG_CI_END="0.023809467351086744" LOG_CI_START="-0.12757221013956654" LOG_EFFECT_SIZE="-0.051881371394239914" ORDER="151397" O_E="0.0" SE="0.08892234670939876" STUDY_ID="STD-Kawabata-1993" TOTAL_1="82" TOTAL_2="74" VAR="0.00790718374430652" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="33" EVENTS_2="33" I2="0.0" I2_Q="0.0" ID="CMP-045.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="39" TOTAL_2="41" WEIGHT="0.0" Z="0.0">
<NAME>Pain when resting (number of patients improved)</NAME>
<GROUP_LABEL_1>SLM-10</GROUP_LABEL_1>
<GROUP_LABEL_2>Artz</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Artz</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours SLM-10</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2860313083766735" CI_START="0.8593833945946912" EFFECT_SIZE="1.0512820512820513" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="33" LOG_CI_END="0.10925154159731323" LOG_CI_START="-0.06581304221084058" LOG_EFFECT_SIZE="0.021719249693236305" ORDER="151398" O_E="0.0" SE="0.10283380311257549" STUDY_ID="STD-Kawabata-1993" TOTAL_1="39" TOTAL_2="41" VAR="0.010574791062595942" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="48" EVENTS_2="54" I2="0.0" I2_Q="0.0" ID="CMP-045.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="75" TOTAL_2="66" WEIGHT="0.0" Z="0.0">
<NAME>Pressure pain (number of patients improved)</NAME>
<GROUP_LABEL_1>SLM-10</GROUP_LABEL_1>
<GROUP_LABEL_2>Artz</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Artz</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours SLM-10</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9595411109831267" CI_START="0.6376710679038653" EFFECT_SIZE="0.7822222222222223" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="54" LOG_CI_END="-0.017936413434362634" LOG_CI_START="-0.1954032871600626" LOG_EFFECT_SIZE="-0.10666985029721264" ORDER="151399" O_E="0.0" SE="0.10424492010166903" STUDY_ID="STD-Kawabata-1993" TOTAL_1="75" TOTAL_2="66" VAR="0.010867003367003358" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="56" EVENTS_2="53" I2="0.0" I2_Q="0.0" ID="CMP-045.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="82" TOTAL_2="74" WEIGHT="0.0" Z="0.0">
<NAME>Patient global assessment (number of patients better or much better)</NAME>
<GROUP_LABEL_1>SLM-10</GROUP_LABEL_1>
<GROUP_LABEL_2>Artz</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Artz</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours SLM-10</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1713089201776912" CI_START="0.7762267386929618" EFFECT_SIZE="0.9535204786010124" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="53" LOG_CI_END="0.0686714506957841" LOG_CI_START="-0.11001140119044231" LOG_EFFECT_SIZE="-0.020669975247329133" ORDER="151400" O_E="0.0" SE="0.10495919169235117" STUDY_ID="STD-Kawabata-1993" TOTAL_1="82" TOTAL_2="74" VAR="0.011016431920711719" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-045.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="87" TOTAL_2="85" WEIGHT="0.0" Z="0.0">
<NAME>Safety: total withdrawals overall</NAME>
<GROUP_LABEL_1>SLM-10</GROUP_LABEL_1>
<GROUP_LABEL_2>Artz</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0282655452240064" CI_START="0.08354809882546985" EFFECT_SIZE="0.29310344827586204" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="10" LOG_CI_END="0.012105283854904524" LOG_CI_START="-1.0780634282242314" LOG_EFFECT_SIZE="-0.5329790721846633" ORDER="151401" O_E="0.0" SE="0.6403704978974415" STUDY_ID="STD-Kawabata-1993" TOTAL_1="87" TOTAL_2="85" VAR="0.4100743745774172" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-045.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="85" TOTAL_2="79" WEIGHT="0.0" Z="0.0">
<NAME>Safety: local adverse events related to study drug resulting in withdrawals</NAME>
<GROUP_LABEL_1>SLM-10</GROUP_LABEL_1>
<GROUP_LABEL_2>Artz</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SLM-10</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Artz</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.0252891554587835" CI_START="0.04297296143821805" EFFECT_SIZE="0.4647058823529412" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7011610561437089" LOG_CI_START="-1.3668047163193737" LOG_EFFECT_SIZE="-0.3328218300878325" ORDER="151402" O_E="0.0" SE="1.2147333313404822" STUDY_ID="STD-Kawabata-1993" TOTAL_1="85" TOTAL_2="79" VAR="1.4755770662695458" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-045.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="85" TOTAL_2="79" WEIGHT="0.0" Z="0.0">
<NAME>Safety: local adverse events no specific causal relationship to study drug and continuation in trial</NAME>
<GROUP_LABEL_1>SLM-10</GROUP_LABEL_1>
<GROUP_LABEL_2>Artz</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SLM-10</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Artz</GRAPH_LABEL_2>
<DICH_DATA CI_END="14.608862157989533" CI_START="0.05912891907884081" EFFECT_SIZE="0.9294117647058824" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1646163913107368" LOG_CI_START="-1.228200060158439" LOG_EFFECT_SIZE="-0.03179183442385129" ORDER="151403" O_E="0.0" SE="1.4055522282254564" STUDY_ID="STD-Kawabata-1993" TOTAL_1="85" TOTAL_2="79" VAR="1.9755770662695458" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-046" NO="46">
<NAME>Suplasyn versus placebo: 1 week post-injection</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-046.01" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="25" TOTAL_2="28" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Pain after walking (0-10 cm VAS)</NAME>
<GROUP_LABEL_1>Suplasyn</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline+Lactose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Suplasyn</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Saline+lacto</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.27042594315234003" CI_START="-1.61042594315234" EFFECT_SIZE="-0.6699999999999999" ESTIMABLE="YES" MEAN_1="2.89" MEAN_2="3.56" ORDER="151404" SD_1="1.72" SD_2="1.77" SE="0.4798179714373834" STUDY_ID="STD-Petrella-2002" TOTAL_1="25" TOTAL_2="28" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-046.02" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="25" TOTAL_2="28" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>WOMAC pain (0-10 cm VAS)</NAME>
<GROUP_LABEL_1>Suplasyn</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline+Lactose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Suplasyn</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours saline+lacto</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.6173272085831958" CI_START="-2.1573272085831956" EFFECT_SIZE="-0.77" ESTIMABLE="YES" MEAN_1="2.42" MEAN_2="3.19" ORDER="151405" SD_1="2.34" SD_2="2.81" SE="0.7078330109768627" STUDY_ID="STD-Petrella-2002" TOTAL_1="25" TOTAL_2="28" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-046.03" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="25" TOTAL_2="28" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Pain at rest (0-10 cm VAS)</NAME>
<GROUP_LABEL_1>Suplasyn</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline+Lactose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Suplasyn</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours saline+lacto</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.6332054435734507" CI_START="0.026794556426549376" EFFECT_SIZE="0.8300000000000001" ESTIMABLE="YES" MEAN_1="2.6" MEAN_2="1.77" ORDER="151406" SD_1="1.64" SD_2="1.3" SE="0.40980622598631034" STUDY_ID="STD-Petrella-2002" TOTAL_1="25" TOTAL_2="28" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-046.04" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="25" TOTAL_2="28" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>WOMAC function (0-10 cm VAS)</NAME>
<GROUP_LABEL_1>Suplasyn</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline+Lactose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Suplasyn</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours saline+lacto</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.13090902107026858" CI_START="-2.690909021070268" EFFECT_SIZE="-1.2799999999999998" ESTIMABLE="YES" MEAN_1="2.45" MEAN_2="3.73" ORDER="151407" SD_1="2.23" SD_2="2.99" SE="0.719864769046441" STUDY_ID="STD-Petrella-2002" TOTAL_1="25" TOTAL_2="28" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-046.05" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="25" TOTAL_2="28" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Walk time (sec)</NAME>
<GROUP_LABEL_1>Suplasyn</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline+Lactose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Suplasyn</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours saline+lacto</GRAPH_LABEL_2>
<CONT_DATA CI_END="12.297107074064856" CI_START="-6.017107074064855" EFFECT_SIZE="3.1400000000000006" ESTIMABLE="YES" MEAN_1="74.21" MEAN_2="71.07" ORDER="151408" SD_1="17.43" SD_2="16.46" SE="4.672079255687833" STUDY_ID="STD-Petrella-2002" TOTAL_1="25" TOTAL_2="28" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-046.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="30" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>Safety: total withdrawals overall</NAME>
<GROUP_LABEL_1>Suplasyn</GROUP_LABEL_1>
<GROUP_LABEL_2>Saline+Lactose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Suplasyn</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours saline+lacto</GRAPH_LABEL_2>
<DICH_DATA CI_END="11.89447521234632" CI_START="0.5254540354594692" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.075345285599021" LOG_CI_START="-0.2794652682549458" LOG_EFFECT_SIZE="0.3979400086720376" ORDER="151409" O_E="0.0" SE="0.7958224257542215" STUDY_ID="STD-Petrella-2002" TOTAL_1="30" TOTAL_2="30" VAR="0.6333333333333333" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-047" NO="47">
<NAME>Suplasyn versus NSAID: 1 week post-injection</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.5349392890318967" CI_START="-0.37493928903189677" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.08" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-047.01" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.145702670097806" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="SUB" TOTAL_1="25" TOTAL_2="29" UNITS="" WEIGHT="0.0" Z="1.4548793336330426">
<NAME>Pain after walking (0-10 cm VAS)</NAME>
<GROUP_LABEL_1>Suplasyn</GROUP_LABEL_1>
<GROUP_LABEL_2>NSAID</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Suplasyn</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NSAID</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.5349392890318967" CI_START="-0.37493928903189677" EFFECT_SIZE="1.08" ESTIMABLE="YES" MEAN_1="2.89" MEAN_2="1.81" ORDER="151410" SD_1="2.72" SD_2="2.72" SE="0.7423296042724623" STUDY_ID="STD-Petrella-2002" TOTAL_1="25" TOTAL_2="29" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-047.02" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="25" TOTAL_2="29" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>WOMAC pain (0-10 cm VAS)</NAME>
<GROUP_LABEL_1>Suplasyn</GROUP_LABEL_1>
<GROUP_LABEL_2>NSAID</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Suplasyn</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NSAID</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.9176197598417066" CI_START="-1.7976197598417065" EFFECT_SIZE="-0.43999999999999995" ESTIMABLE="YES" MEAN_1="2.42" MEAN_2="2.86" ORDER="151411" SD_1="2.34" SD_2="2.75" SE="0.6926758708580555" STUDY_ID="STD-Petrella-2002" TOTAL_1="25" TOTAL_2="29" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-047.03" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="25" TOTAL_2="29" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Pain at rest (0-10 cm VAS)</NAME>
<GROUP_LABEL_1>Suplasyn</GROUP_LABEL_1>
<GROUP_LABEL_2>NSAID</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Suplasyn</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NSAID</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.3602453756138644" CI_START="-0.32024537561386435" EFFECT_SIZE="1.02" ESTIMABLE="YES" MEAN_1="2.6" MEAN_2="1.58" ORDER="151412" SD_1="2.64" SD_2="2.34" SE="0.683811226219231" STUDY_ID="STD-Petrella-2002" TOTAL_1="25" TOTAL_2="29" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-047.04" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="25" TOTAL_2="29" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>WOMAC function (0-10 cm VAS)</NAME>
<GROUP_LABEL_1>Suplasyn</GROUP_LABEL_1>
<GROUP_LABEL_2>NSAID</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Suplasyn</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NSAID</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.9809245910424993" CI_START="-1.6009245910424985" EFFECT_SIZE="-0.3099999999999996" ESTIMABLE="YES" MEAN_1="2.45" MEAN_2="2.76" ORDER="151413" SD_1="2.23" SD_2="2.61" SE="0.6586470982248385" STUDY_ID="STD-Petrella-2002" TOTAL_1="25" TOTAL_2="29" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-047.05" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="25" TOTAL_2="29" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Walk time (sec)</NAME>
<GROUP_LABEL_1>Suplasyn</GROUP_LABEL_1>
<GROUP_LABEL_2>NSAID</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Suplasyn</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NSAID</GRAPH_LABEL_2>
<CONT_DATA CI_END="7.4005977773273806" CI_START="-10.380597777327399" EFFECT_SIZE="-1.490000000000009" ESTIMABLE="YES" MEAN_1="74.21" MEAN_2="75.7" ORDER="151414" SD_1="17.43" SD_2="15.63" SE="4.536102626096852" STUDY_ID="STD-Petrella-2002" TOTAL_1="25" TOTAL_2="29" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-047.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="30" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>Safety: total withdrawals overall</NAME>
<GROUP_LABEL_1>Suplasyn</GROUP_LABEL_1>
<GROUP_LABEL_2>NSAID</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Suplasyn</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NSAID</GRAPH_LABEL_2>
<DICH_DATA CI_END="40.28498862817757" CI_START="0.6205785542288472" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.6051432453855428" LOG_CI_START="-0.20720323671350535" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="151415" O_E="0.0" SE="1.064581294844754" STUDY_ID="STD-Petrella-2002" TOTAL_1="30" TOTAL_2="30" VAR="1.133333333333333" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-048" NO="48">
<NAME>(Suplasyn + NSAID) versus NSAID: 1 week post-injection</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-048.01" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="26" TOTAL_2="29" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Pain after walking (0-10 cm VAS)</NAME>
<GROUP_LABEL_1>SUPLASYN+NSAID</GROUP_LABEL_1>
<GROUP_LABEL_2>NSAID</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Suplasyn+NSA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NSAID</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.5723901277245564" CI_START="-1.092390127724557" EFFECT_SIZE="0.23999999999999977" ESTIMABLE="YES" MEAN_1="2.05" MEAN_2="1.81" ORDER="151416" SD_1="2.32" SD_2="2.72" SE="0.6798033730386273" STUDY_ID="STD-Petrella-2002" TOTAL_1="26" TOTAL_2="29" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-048.02" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="26" TOTAL_2="29" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>WOMAC pain (0-10 cm VAS)</NAME>
<GROUP_LABEL_1>Suplasyn+NSAID</GROUP_LABEL_1>
<GROUP_LABEL_2>NSAID</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Suplasyn+NSA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NSAID</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.1416907898508244" CI_START="-1.6816907898508244" EFFECT_SIZE="-0.27" ESTIMABLE="YES" MEAN_1="2.59" MEAN_2="2.86" ORDER="151417" SD_1="2.59" SD_2="2.75" SE="0.7202636379984843" STUDY_ID="STD-Petrella-2002" TOTAL_1="26" TOTAL_2="29" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-048.03" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="26" TOTAL_2="29" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Pain at rest (0-10 cm VAS)</NAME>
<GROUP_LABEL_1>Suplasyn+NSAID</GROUP_LABEL_1>
<GROUP_LABEL_2>NSAID</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Suplasyn+NSA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NSAID</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.218681411269314" CI_START="-1.258681411269314" EFFECT_SIZE="-0.020000000000000018" ESTIMABLE="YES" MEAN_1="1.56" MEAN_2="1.58" ORDER="151418" SD_1="2.34" SD_2="2.34" SE="0.6319919248720257" STUDY_ID="STD-Petrella-2002" TOTAL_1="26" TOTAL_2="29" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-048.04" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="26" TOTAL_2="29" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>WOMAC function (0-10 cm VAS)</NAME>
<GROUP_LABEL_1>Suplasyn+NSAID</GROUP_LABEL_1>
<GROUP_LABEL_2>NSAID</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Suplasyn+NSA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NSAID</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.3600021720821036" CI_START="-1.4200021720821032" EFFECT_SIZE="-0.029999999999999805" ESTIMABLE="YES" MEAN_1="2.73" MEAN_2="2.76" ORDER="151419" SD_1="2.64" SD_2="2.61" SE="0.7091978133507876" STUDY_ID="STD-Petrella-2002" TOTAL_1="26" TOTAL_2="29" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-048.05" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="26" TOTAL_2="29" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Walk time (sec)</NAME>
<GROUP_LABEL_1>Suplasyn+NSAID</GROUP_LABEL_1>
<GROUP_LABEL_2>NSAID</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Suplasyn+NSA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NSAID</GRAPH_LABEL_2>
<CONT_DATA CI_END="5.183709401831978" CI_START="-12.143709401831986" EFFECT_SIZE="-3.480000000000004" ESTIMABLE="YES" MEAN_1="72.22" MEAN_2="75.7" ORDER="151420" SD_1="17.0" SD_2="15.63" SE="4.420341123699321" STUDY_ID="STD-Petrella-2002" TOTAL_1="26" TOTAL_2="29" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-048.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="30" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>Safety: total withdrawals overall</NAME>
<GROUP_LABEL_1>Suplasyn+NSAID</GROUP_LABEL_1>
<GROUP_LABEL_2>NSAID</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Suplasyn+NSA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NSAID</GRAPH_LABEL_2>
<DICH_DATA CI_END="33.72924445563291" CI_START="0.4743657991226642" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.52800661298213" LOG_CI_START="-0.32388663032620535" LOG_EFFECT_SIZE="0.6020599913279624" ORDER="151421" O_E="0.0" SE="1.0878112581387145" STUDY_ID="STD-Petrella-2002" TOTAL_1="30" TOTAL_2="30" VAR="1.1833333333333331" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-049" NO="49">
<NAME>Zeel compositum versus Hyalart (end of treatment (5 weeks))</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-049.01" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="54" TOTAL_2="54" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Pain during movement (0-100 mm VAS )</NAME>
<GROUP_LABEL_1>Zeel</GROUP_LABEL_1>
<GROUP_LABEL_2>Hyalart</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Zeel</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Hyalart</GRAPH_LABEL_2>
<CONT_DATA CI_END="13.136517608685743" CI_START="-3.136517608685743" EFFECT_SIZE="5.0" ESTIMABLE="YES" MEAN_1="31.0" MEAN_2="26.0" ORDER="151422" SD_1="23.25" SD_2="19.75" SE="4.1513607764558715" STUDY_ID="STD-Nahler-1998" TOTAL_1="54" TOTAL_2="54" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-049.02" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="54" TOTAL_2="54" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Pain during the night (0-100 mm VAS)</NAME>
<GROUP_LABEL_1>Zeel</GROUP_LABEL_1>
<GROUP_LABEL_2>Hyalart</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Zeel</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Hyalart</GRAPH_LABEL_2>
<CONT_DATA CI_END="10.153984995184242" CI_START="-6.153984995184242" EFFECT_SIZE="2.0" ESTIMABLE="YES" MEAN_1="9.0" MEAN_2="7.0" ORDER="151423" SD_1="23.75" SD_2="19.25" SE="4.160272872104709" STUDY_ID="STD-Nahler-1998" TOTAL_1="54" TOTAL_2="54" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="48" EVENTS_2="53" I2="0.0" I2_Q="0.0" ID="CMP-049.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="55" TOTAL_2="57" WEIGHT="0.0" Z="0.0">
<NAME>Patient global: number of patients with noticeable improvements in symptoms</NAME>
<GROUP_LABEL_1>Zeel</GROUP_LABEL_1>
<GROUP_LABEL_2>Hyalart</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hyalart</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Zeel</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0620566060335004" CI_START="0.8294828349344847" EFFECT_SIZE="0.9385934819897084" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="53" LOG_CI_END="0.02614766461065087" LOG_CI_START="-0.08119259670455943" LOG_EFFECT_SIZE="-0.027522466046954287" ORDER="151424" O_E="0.0" SE="0.06305220083941743" STUDY_ID="STD-Nahler-1998" TOTAL_1="55" TOTAL_2="57" VAR="0.003975580030694231" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-049.04" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="55" TOTAL_2="57" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Patient assessment of improvement (0-100 mm VAS)</NAME>
<GROUP_LABEL_1>Zeel</GROUP_LABEL_1>
<GROUP_LABEL_2>Hyalart</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Zeel</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Hyalart</GRAPH_LABEL_2>
<CONT_DATA CI_END="5.12109156414216" CI_START="-13.12109156414216" EFFECT_SIZE="-4.0" ESTIMABLE="YES" MEAN_1="59.0" MEAN_2="63.0" ORDER="151425" SD_1="24.25" SD_2="25.0" SE="4.65370365786727" STUDY_ID="STD-Nahler-1998" TOTAL_1="55" TOTAL_2="57" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-049.05" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="55" TOTAL_2="57" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Patient assessment of tolerance (0-100 mm VAS)</NAME>
<GROUP_LABEL_1>Zeel</GROUP_LABEL_1>
<GROUP_LABEL_2>Hyalart</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Zeel</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Hyalart</GRAPH_LABEL_2>
<CONT_DATA CI_END="4.0918106882522185" CI_START="-10.091810688252218" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="94.0" MEAN_2="97.0" ORDER="151426" SD_1="21.75" SD_2="16.0" SE="3.6183372471083732" STUDY_ID="STD-Nahler-1998" TOTAL_1="55" TOTAL_2="57" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-049.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="57" TOTAL_2="57" WEIGHT="0.0" Z="0.0">
<NAME>Safety: number of patients with side effects</NAME>
<GROUP_LABEL_1>Zeel</GROUP_LABEL_1>
<GROUP_LABEL_2>Hyalart</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Zeel</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Hyalart</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.129493492360862" CI_START="0.18859582009104037" EFFECT_SIZE="0.46153846153846156" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="13" LOG_CI_END="0.052883733051946574" LOG_CI_START="-0.7244679368983328" LOG_EFFECT_SIZE="-0.3357921019231931" ORDER="151427" O_E="0.0" SE="0.45662021888161936" STUDY_ID="STD-Nahler-1998" TOTAL_1="57" TOTAL_2="57" VAR="0.20850202429149797" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-049.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="57" TOTAL_2="57" WEIGHT="0.0" Z="0.0">
<NAME>Safety: number of patients withdrawn due to lack of efficacy</NAME>
<GROUP_LABEL_1>Zeel</GROUP_LABEL_1>
<GROUP_LABEL_2>Hyalart</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Zeel</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Hyalart</GRAPH_LABEL_2>
<DICH_DATA CI_END="21.44220934672241" CI_START="0.1865479408077614" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.331269531844238" LOG_CI_START="-0.7292095405162755" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="151428" O_E="0.0" SE="1.2103356066404698" STUDY_ID="STD-Nahler-1998" TOTAL_1="57" TOTAL_2="57" VAR="1.4649122807017543" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-050" NO="50">
<NAME>HA/hylan versus placebo</NAME>
<CONT_OUTCOME CHI2="303.13217637878694" CI_END="-5.6944281292470045" CI_START="-10.226359069782669" CI_STUDY="95" CI_TOTAL="95" DF="59" EFFECT_MEASURE="MD" EFFECT_SIZE="-7.960393599514837" ESTIMABLE="YES" I2="80.53654326478527" I2_Q="67.52576719830363" ID="CMP-050.01" NO="1" P_CHI2="-6.661338147750939E-16" P_Q="0.026287254152644435" P_Z="5.762429149454321E-12" Q="9.238093531937997" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="27" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="68.29500609505247" TOTALS="SUB" TOTAL_1="3527" TOTAL_2="3123" UNITS="" WEIGHT="400.0" Z="6.885402695906092">
<NAME>Pain on weight bearing (0-100 mm VAS)</NAME>
<GROUP_LABEL_1>HA</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="126.39976329197205" CI_END="-4.103556130534832" CI_START="-11.287352905762093" DF="25" EFFECT_SIZE="-7.695454518148463" ESTIMABLE="YES" I2="80.22148194830693" ID="CMP-050.01.01" NO="1" P_CHI2="9.992007221626409E-16" P_Z="2.679538552993574E-5" STUDIES="27" TAU2="61.976262132440205" TOTAL_1="1343" TOTAL_2="1199" WEIGHT="100.0" Z="4.199120373852691">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="5.690624720637078" CI_START="-5.690624720637078" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="25.0" MEAN_2="25.0" ORDER="151429" SD_1="24.0" SD_2="25.0" SE="2.903433310777136" STUDY_ID="STD-Altman-1998" TOTAL_1="136" TOTAL_2="149" WEIGHT="4.770249305179361"/>
<CONT_DATA CI_END="-14.873041393873494" CI_START="-43.30695860612651" EFFECT_SIZE="-29.09" ESTIMABLE="YES" MEAN_1="17.12" MEAN_2="46.21" ORDER="151430" SD_1="13.03" SD_2="28.04" SE="7.253683597386513" STUDY_ID="STD-Bragantini-1987" TOTAL_1="19" TOTAL_2="18" WEIGHT="2.930872265062487"/>
<CONT_DATA CI_END="-4.119597714777017" CI_START="-25.080402285222988" EFFECT_SIZE="-14.600000000000001" ESTIMABLE="YES" MEAN_1="41.8" MEAN_2="56.4" ORDER="151431" SD_1="14.4" SD_2="13.5" SE="5.347242279904662" STUDY_ID="STD-Carrabba-1995" TOTAL_1="20" TOTAL_2="10" WEIGHT="3.7082676538829054"/>
<CONT_DATA CI_END="0.6590435935414085" CI_START="-21.459043593541406" EFFECT_SIZE="-10.399999999999999" ESTIMABLE="YES" MEAN_1="46.0" MEAN_2="56.4" ORDER="151432" SD_1="16.5" SD_2="13.5" SE="5.642472862141209" STUDY_ID="STD-Carrabba-1995a" TOTAL_1="20" TOTAL_2="10" WEIGHT="3.580019152495254"/>
<CONT_DATA CI_END="-6.7146313278825325" CI_START="-29.08536867211748" EFFECT_SIZE="-17.900000000000006" ESTIMABLE="YES" MEAN_1="41.8" MEAN_2="59.7" ORDER="151433" SD_1="14.4" SD_2="14.9" SE="5.706925617177782" STUDY_ID="STD-Carrabba-1995b" TOTAL_1="20" TOTAL_2="10" WEIGHT="3.5523204190951407"/>
<CONT_DATA CI_END="-1.9707167535723205" CI_START="-25.429283246427687" EFFECT_SIZE="-13.700000000000003" ESTIMABLE="YES" MEAN_1="46.0" MEAN_2="59.7" ORDER="151434" SD_1="16.5" SD_2="14.9" SE="5.984438152408295" STUDY_ID="STD-Carrabba-1995c" TOTAL_1="20" TOTAL_2="10" WEIGHT="3.4344603962417786"/>
<CONT_DATA CI_END="11.69620203698966" CI_START="-24.096202036989666" EFFECT_SIZE="-6.200000000000003" ESTIMABLE="YES" MEAN_1="35.4" MEAN_2="41.6" ORDER="151435" SD_1="28.6" SD_2="25.4" SE="9.13088310711453" STUDY_ID="STD-Corrado-1995" TOTAL_1="19" TOTAL_2="16" WEIGHT="2.310675675040503"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="41.12" MEAN_2="33.93" ORDER="151436" SD_1="0.0" SD_2="3.12" SE="0.0" STUDY_ID="STD-Creamer-1994" TOTAL_1="12" TOTAL_2="12" WEIGHT="0.0"/>
<CONT_DATA CI_END="1.3819598300167035" CI_START="-9.661959830016706" EFFECT_SIZE="-4.140000000000001" ESTIMABLE="YES" MEAN_1="46.66" MEAN_2="50.8" ORDER="151437" SD_1="9.66" SD_2="5.72" SE="2.817378213871897" STUDY_ID="STD-Cubukcu-2004" TOTAL_1="20" TOTAL_2="10" WEIGHT="4.803839451592008"/>
<CONT_DATA CI_END="7.666620266223497" CI_START="-10.646620266223486" EFFECT_SIZE="-1.4899999999999949" ESTIMABLE="YES" MEAN_1="34.13" MEAN_2="35.62" ORDER="151438" SD_1="23.49" SD_2="23.68" SE="4.671830879776232" STUDY_ID="STD-Dougados-1993" TOTAL_1="52" TOTAL_2="50" WEIGHT="4.007708641146338"/>
<CONT_DATA CI_END="-6.400284704048909" CI_START="-32.5397152959511" EFFECT_SIZE="-19.470000000000002" ESTIMABLE="YES" MEAN_1="14.55" MEAN_2="34.02" ORDER="151439" SD_1="18.78" SD_2="20.72" SE="6.668344622168234" STUDY_ID="STD-Grecomoro-1987" TOTAL_1="20" TOTAL_2="16" WEIGHT="3.155254982037135"/>
<CONT_DATA CI_END="-6.131739296864264" CI_START="-15.268260703135727" EFFECT_SIZE="-10.699999999999996" ESTIMABLE="YES" MEAN_1="28.1" MEAN_2="38.8" ORDER="151440" SD_1="7.6" SD_2="6.5" SE="2.3307880854799317" STUDY_ID="STD-Henderson-1994" TOTAL_1="18" TOTAL_2="19" WEIGHT="4.982359716594759"/>
<CONT_DATA CI_END="12.375911279045194" CI_START="4.624088720954799" EFFECT_SIZE="8.499999999999996" ESTIMABLE="YES" MEAN_1="39.8" MEAN_2="31.3" ORDER="151441" SD_1="7.3" SD_2="6.1" SE="1.9775420924149067" STUDY_ID="STD-Henderson-1994a" TOTAL_1="22" TOTAL_2="25" WEIGHT="5.097445584877724"/>
<CONT_DATA CI_END="-0.8904573366637738" CI_START="-24.569542663336236" EFFECT_SIZE="-12.730000000000004" ESTIMABLE="YES" MEAN_1="35.29" MEAN_2="48.02" ORDER="151442" SD_1="27.83" SD_2="30.42" SE="6.040693990667702" STUDY_ID="STD-Huskisson-1999" TOTAL_1="45" TOTAL_2="48" WEIGHT="3.410864928566681"/>
<CONT_DATA CI_END="4.805741037713539" CI_START="-4.8257410377135495" EFFECT_SIZE="-0.010000000000005116" ESTIMABLE="YES" MEAN_1="43.87" MEAN_2="43.88" ORDER="151443" SD_1="24.05" SD_2="25.36" SE="2.4570558825057476" STUDY_ID="STD-Jubb-2003" TOTAL_1="205" TOTAL_2="200" WEIGHT="4.938073021020059"/>
<CONT_DATA CI_END="11.532726048091009" CI_START="-11.532726048091009" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="44.0" MEAN_2="44.0" ORDER="151444" SD_1="24.44" SD_2="30.39" SE="5.884152024761516" STUDY_ID="STD-Karlsson-2002a-_x0028_AvP_x0029_" TOTAL_1="90" TOTAL_2="33" WEIGHT="3.4767782465567847"/>
<CONT_DATA CI_END="12.702252786622653" CI_START="-10.702252786622653" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="45.0" MEAN_2="44.0" ORDER="151445" SD_1="25.67" SD_2="30.39" SE="5.970646848068908" STUDY_ID="STD-Karlsson-2002b-_x0028_SvP_x0029_" TOTAL_1="86" TOTAL_2="33" WEIGHT="3.4402607700665118"/>
<CONT_DATA CI_END="11.571109890444557" CI_START="-2.77110989044456" EFFECT_SIZE="4.399999999999999" ESTIMABLE="YES" MEAN_1="36.64" MEAN_2="32.24" ORDER="151446" SD_1="25.49" SD_2="24.81" SE="3.658796767190294" STUDY_ID="STD-Lohmander-1996" TOTAL_1="96" TOTAL_2="93" WEIGHT="4.456494778767022"/>
<CONT_DATA CI_END="7.086806891171957" CI_START="-15.086806891171957" EFFECT_SIZE="-4.0" ESTIMABLE="YES" MEAN_1="47.0" MEAN_2="51.0" ORDER="151447" SD_1="27.13" SD_2="27.71" SE="5.656638070200919" STUDY_ID="STD-Moreland-1993" TOTAL_1="46" TOTAL_2="48" WEIGHT="3.5739217380409514"/>
<CONT_DATA CI_END="2.704259431523397" CI_START="-16.104259431523403" EFFECT_SIZE="-6.700000000000003" ESTIMABLE="YES" MEAN_1="28.9" MEAN_2="35.6" ORDER="151448" SD_1="17.2" SD_2="17.7" SE="4.798179714373834" STUDY_ID="STD-Petrella-2002" TOTAL_1="25" TOTAL_2="28" WEIGHT="3.9512922762850935"/>
<CONT_DATA CI_END="4.05887678746089" CI_START="-8.578876787460885" EFFECT_SIZE="-2.259999999999998" ESTIMABLE="YES" MEAN_1="29.14" MEAN_2="31.4" ORDER="151449" SD_1="22.6" SD_2="22.4" SE="3.223975969611371" STUDY_ID="STD-Puhl-1993" TOTAL_1="95" TOTAL_2="100" WEIGHT="4.640786942105659"/>
<CONT_DATA CI_END="-1.1392747723402383" CI_START="-28.860725227659763" EFFECT_SIZE="-15.0" ESTIMABLE="YES" MEAN_1="32.0" MEAN_2="47.0" ORDER="151450" SD_1="23.98" SD_2="24.5" SE="7.071928533887047" STUDY_ID="STD-Scale-1994a-_x0028_2-inj_x0029_" TOTAL_1="23" TOTAL_2="24" WEIGHT="2.9990156058484767"/>
<CONT_DATA CI_END="-8.144480551054334" CI_START="-35.855519448945664" EFFECT_SIZE="-22.0" ESTIMABLE="YES" MEAN_1="22.0" MEAN_2="44.0" ORDER="151451" SD_1="19.36" SD_2="19.36" SE="7.069272475533344" STUDY_ID="STD-Scale-1994b-_x0028_3-inj_x0029_" TOTAL_1="15" TOTAL_2="15" WEIGHT="3.000021784594708"/>
<CONT_DATA CI_END="-0.2941778169601754" CI_START="-28.44582218303982" EFFECT_SIZE="-14.369999999999997" ESTIMABLE="YES" MEAN_1="50.54" MEAN_2="64.91" ORDER="151452" SD_1="29.11" SD_2="26.52" SE="7.181673895065476" STUDY_ID="STD-St.-J.-Dixon-1988" TOTAL_1="28" TOTAL_2="33" WEIGHT="2.9577020985560503"/>
<CONT_DATA CI_END="2.861866541770418" CI_START="-5.5018665417704185" EFFECT_SIZE="-1.3200000000000003" ESTIMABLE="YES" MEAN_1="22.6" MEAN_2="23.92" ORDER="151453" SD_1="14.31" SD_2="15.0" SE="2.1336445846742325" STUDY_ID="STD-Tsai-2003" TOTAL_1="96" TOTAL_2="93" WEIGHT="5.048273277638634"/>
<CONT_DATA CI_END="-13.684110155200875" CI_START="-30.315889844799123" EFFECT_SIZE="-22.0" ESTIMABLE="YES" MEAN_1="31.0" MEAN_2="53.0" ORDER="151454" SD_1="22.65" SD_2="23.24" SE="4.242878905119586" STUDY_ID="STD-Wobig-1998" TOTAL_1="57" TOTAL_2="60" WEIGHT="4.199328247033563"/>
<CONT_DATA CI_END="-1.9122424095623067" CI_START="-24.087757590437693" EFFECT_SIZE="-13.0" ESTIMABLE="YES" MEAN_1="40.0" MEAN_2="53.0" ORDER="151455" SD_1="24.66" SD_2="24.0" SE="5.657123129759786" STUDY_ID="STD-Wobig-1999c-_x0028_NEhyl_x0029_" TOTAL_1="38" TOTAL_2="36" WEIGHT="3.573713041674434"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="113.82612891398279" CI_END="-8.228528391385318" CI_START="-17.7662559783515" DF="20" EFFECT_SIZE="-12.997392184868408" ESTIMABLE="YES" I2="82.42934184723634" ID="CMP-050.01.02" NO="2" P_CHI2="4.551914400963142E-15" P_Z="9.2017088829759E-8" STUDIES="21" TAU2="92.8051475020991" TOTAL_1="1122" TOTAL_2="968" WEIGHT="100.0" Z="5.341821800424793">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="5.403743355349907" CI_START="-7.403743355349907" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="23.0" MEAN_2="24.0" ORDER="151456" SD_1="25.0" SD_2="26.0" SE="3.2672760345913585" STUDY_ID="STD-Altman-1998" TOTAL_1="115" TOTAL_2="129" WEIGHT="5.721056368093258"/>
<CONT_DATA CI_END="-16.613339936162475" CI_START="-46.10666006383753" EFFECT_SIZE="-31.360000000000003" ESTIMABLE="YES" MEAN_1="15.59" MEAN_2="46.95" ORDER="151457" SD_1="8.11" SD_2="30.93" SE="7.523944409263283" STUDY_ID="STD-Bragantini-1987" TOTAL_1="19" TOTAL_2="18" WEIGHT="3.9622309335021395"/>
<CONT_DATA CI_END="-7.174883908394788" CI_START="-28.2251160916052" EFFECT_SIZE="-17.699999999999996" ESTIMABLE="YES" MEAN_1="42.1" MEAN_2="59.8" ORDER="151458" SD_1="12.5" SD_2="14.5" SE="5.370055865631195" STUDY_ID="STD-Carrabba-1995" TOTAL_1="20" TOTAL_2="10" WEIGHT="4.8668480936421465"/>
<CONT_DATA CI_END="-0.12813395451847676" CI_START="-23.871866045481525" EFFECT_SIZE="-12.0" ESTIMABLE="YES" MEAN_1="47.8" MEAN_2="59.8" ORDER="151459" SD_1="17.7" SD_2="14.5" SE="6.0571858152115485" STUDY_ID="STD-Carrabba-1995a" TOTAL_1="20" TOTAL_2="10" WEIGHT="4.5717432999813985"/>
<CONT_DATA CI_END="-10.994964738197057" CI_START="-31.205035261802948" EFFECT_SIZE="-21.1" ESTIMABLE="YES" MEAN_1="42.1" MEAN_2="63.2" ORDER="151460" SD_1="12.5" SD_2="13.7" SE="5.155724973270005" STUDY_ID="STD-Carrabba-1995b" TOTAL_1="20" TOTAL_2="10" WEIGHT="4.958814905081956"/>
<CONT_DATA CI_END="-3.8989186463893297" CI_START="-26.90108135361068" EFFECT_SIZE="-15.400000000000006" ESTIMABLE="YES" MEAN_1="47.8" MEAN_2="63.2" ORDER="151461" SD_1="17.7" SD_2="13.7" SE="5.86800647579738" STUDY_ID="STD-Carrabba-1995c" TOTAL_1="20" TOTAL_2="10" WEIGHT="4.652802420674959"/>
<CONT_DATA CI_END="1.5140343122868245" CI_START="-28.51403431228683" EFFECT_SIZE="-13.500000000000004" ESTIMABLE="YES" MEAN_1="29.7" MEAN_2="43.2" ORDER="151462" SD_1="22.9" SD_2="22.3" SE="7.660362348857231" STUDY_ID="STD-Corrado-1995" TOTAL_1="19" TOTAL_2="16" WEIGHT="3.9080516965621777"/>
<CONT_DATA CI_END="22.75925279680046" CI_START="-22.75925279680046" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="41.8" MEAN_2="41.8" ORDER="151463" SD_1="29.58" SD_2="27.26" SE="11.61207704647766" STUDY_ID="STD-Creamer-1994" TOTAL_1="12" TOTAL_2="12" WEIGHT="2.6006063679742013"/>
<CONT_DATA CI_END="-7.8577977542241575" CI_START="-19.742202245775836" EFFECT_SIZE="-13.799999999999997" ESTIMABLE="YES" MEAN_1="40.0" MEAN_2="53.8" ORDER="151464" SD_1="9.08" SD_2="7.12" SE="3.0317915495627332" STUDY_ID="STD-Cubukcu-2004" TOTAL_1="20" TOTAL_2="10" WEIGHT="5.804257223082874"/>
<CONT_DATA CI_END="-2.5494546081667426" CI_START="-26.210545391833257" EFFECT_SIZE="-14.379999999999999" ESTIMABLE="YES" MEAN_1="20.8" MEAN_2="35.18" ORDER="151465" SD_1="16.77" SD_2="18.92" SE="6.03610346167128" STUDY_ID="STD-Grecomoro-1987" TOTAL_1="20" TOTAL_2="16" WEIGHT="4.580762114483977"/>
<CONT_DATA CI_END="0.48040130648918655" CI_START="-26.040401306489187" EFFECT_SIZE="-12.780000000000001" ESTIMABLE="YES" MEAN_1="37.4" MEAN_2="50.18" ORDER="151466" SD_1="32.44" SD_2="30.96" SE="6.765635190792046" STUDY_ID="STD-Huskisson-1999" TOTAL_1="43" TOTAL_2="45" WEIGHT="4.272050079166646"/>
<CONT_DATA CI_END="1.3279371002361273" CI_START="-8.707937100236137" EFFECT_SIZE="-3.690000000000005" ESTIMABLE="YES" MEAN_1="46.51" MEAN_2="50.2" ORDER="151467" SD_1="26.38" SD_2="25.27" SE="2.5602190345419507" STUDY_ID="STD-Jubb-2003" TOTAL_1="207" TOTAL_2="200" WEIGHT="5.958303820427575"/>
<CONT_DATA CI_END="9.244501408129867" CI_START="-17.244501408129867" EFFECT_SIZE="-4.0" ESTIMABLE="YES" MEAN_1="42.0" MEAN_2="46.0" ORDER="151468" SD_1="28.07" SD_2="34.9" SE="6.757522848685386" STUDY_ID="STD-Karlsson-2002a-_x0028_AvP_x0029_" TOTAL_1="90" TOTAL_2="33" WEIGHT="4.275434679059325"/>
<CONT_DATA CI_END="8.645230951544209" CI_START="-18.645230951544207" EFFECT_SIZE="-5.0" ESTIMABLE="YES" MEAN_1="41.0" MEAN_2="46.0" ORDER="151469" SD_1="31.53" SD_2="34.9" SE="6.9619804543226556" STUDY_ID="STD-Karlsson-2002b-_x0028_SvP_x0029_" TOTAL_1="86" TOTAL_2="33" WEIGHT="4.190544253417328"/>
<CONT_DATA CI_END="6.980103345061149" CI_START="-8.060103345061147" EFFECT_SIZE="-0.5399999999999991" ESTIMABLE="YES" MEAN_1="34.69" MEAN_2="35.23" ORDER="151470" SD_1="27.25" SD_2="25.49" SE="3.8368579241143017" STUDY_ID="STD-Lohmander-1996" TOTAL_1="96" TOTAL_2="93" WEIGHT="5.505764551974127"/>
<CONT_DATA CI_END="-1.181123212539112" CI_START="-13.818876787460887" EFFECT_SIZE="-7.5" ESTIMABLE="YES" MEAN_1="26.5" MEAN_2="34.0" ORDER="151471" SD_1="22.6" SD_2="22.4" SE="3.223975969611371" STUDY_ID="STD-Puhl-1993" TOTAL_1="95" TOTAL_2="100" WEIGHT="5.736638147304495"/>
<CONT_DATA CI_END="-12.139274772340238" CI_START="-39.86072522765976" EFFECT_SIZE="-26.0" ESTIMABLE="YES" MEAN_1="27.0" MEAN_2="53.0" ORDER="151472" SD_1="23.98" SD_2="24.5" SE="7.071928533887047" STUDY_ID="STD-Scale-1994a-_x0028_2-inj_x0029_" TOTAL_1="23" TOTAL_2="24" WEIGHT="4.145269525004709"/>
<CONT_DATA CI_END="-18.144480551054336" CI_START="-45.855519448945664" EFFECT_SIZE="-32.0" ESTIMABLE="YES" MEAN_1="11.0" MEAN_2="43.0" ORDER="151473" SD_1="19.36" SD_2="19.36" SE="7.069272475533344" STUDY_ID="STD-Scale-1994b-_x0028_3-inj_x0029_" TOTAL_1="15" TOTAL_2="15" WEIGHT="4.146359985737271"/>
<CONT_DATA CI_END="3.9021575258539265" CI_START="-4.822157525853928" EFFECT_SIZE="-0.46000000000000085" ESTIMABLE="YES" MEAN_1="19.32" MEAN_2="19.78" ORDER="151474" SD_1="14.76" SD_2="14.85" SE="2.2256314709158276" STUDY_ID="STD-Tsai-2003" TOTAL_1="88" TOTAL_2="89" WEIGHT="6.055900865764276"/>
<CONT_DATA CI_END="-28.684110155200877" CI_START="-45.31588984479912" EFFECT_SIZE="-37.0" ESTIMABLE="YES" MEAN_1="23.0" MEAN_2="60.0" ORDER="151475" SD_1="22.65" SD_2="23.24" SE="4.242878905119586" STUDY_ID="STD-Wobig-1998" TOTAL_1="57" TOTAL_2="60" WEIGHT="5.342761600609877"/>
<CONT_DATA CI_END="0.08597955873084473" CI_START="-22.085979558730845" EFFECT_SIZE="-11.0" ESTIMABLE="YES" MEAN_1="32.0" MEAN_2="43.0" ORDER="151476" SD_1="24.33" SD_2="23.66" SE="5.656215954056114" STUDY_ID="STD-Wobig-1999c-_x0028_NEhyl_x0029_" TOTAL_1="37" TOTAL_2="35" WEIGHT="4.743799068455269"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="39.83352764829317" CI_END="-3.2448321245418246" CI_START="-14.832451559955585" DF="9" EFFECT_SIZE="-9.038641842248705" ESTIMABLE="YES" I2="77.405967958789" ID="CMP-050.01.03" NO="3" P_CHI2="8.144771427742725E-6" P_Z="0.002230837910860518" STUDIES="10" TAU2="59.06889785033714" TOTAL_1="796" TOTAL_2="695" WEIGHT="99.99999999999997" Z="3.057644855995681">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="0.3966112686337935" CI_START="-12.396611268633794" EFFECT_SIZE="-6.0" ESTIMABLE="YES" MEAN_1="18.0" MEAN_2="24.0" ORDER="151477" SD_1="21.0" SD_2="27.0" SE="3.263637147972844" STUDY_ID="STD-Altman-1998" TOTAL_1="105" TOTAL_2="113" WEIGHT="12.533532511552544"/>
<CONT_DATA CI_END="-1.519673798801378" CI_START="-26.960326201198626" EFFECT_SIZE="-14.240000000000002" ESTIMABLE="YES" MEAN_1="39.44" MEAN_2="53.68" ORDER="151478" SD_1="27.81" SD_2="29.86" SE="6.490081604322801" STUDY_ID="STD-Huskisson-1999" TOTAL_1="39" TOTAL_2="40" WEIGHT="8.635638080616394"/>
<CONT_DATA CI_END="4.933680562726676" CI_START="-5.093680562726672" EFFECT_SIZE="-0.0799999999999983" ESTIMABLE="YES" MEAN_1="50.06" MEAN_2="50.14" ORDER="151479" SD_1="25.68" SD_2="25.79" SE="2.5580472918247206" STUDY_ID="STD-Jubb-2003" TOTAL_1="206" TOTAL_2="199" WEIGHT="13.31820399668992"/>
<CONT_DATA CI_END="17.47355089842189" CI_START="-9.47355089842189" EFFECT_SIZE="4.0" ESTIMABLE="YES" MEAN_1="48.0" MEAN_2="44.0" ORDER="151480" SD_1="33.78" SD_2="33.78" SE="6.8743869809341085" STUDY_ID="STD-Karlsson-2002a-_x0028_AvP_x0029_" TOTAL_1="90" TOTAL_2="33" WEIGHT="8.218497225627493"/>
<CONT_DATA CI_END="12.55735665976795" CI_START="-14.55735665976795" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="43.0" MEAN_2="44.0" ORDER="151481" SD_1="33.78" SD_2="33.78" SE="6.917145808140684" STUDY_ID="STD-Karlsson-2002b-_x0028_SvP_x0029_" TOTAL_1="86" TOTAL_2="33" WEIGHT="8.173166901136936"/>
<CONT_DATA CI_END="5.63673524098208" CI_START="-9.13673524098208" EFFECT_SIZE="-1.75" ESTIMABLE="YES" MEAN_1="33.65" MEAN_2="35.4" ORDER="151482" SD_1="25.74" SD_2="26.06" SE="3.7688117226886337" STUDY_ID="STD-Lohmander-1996" TOTAL_1="96" TOTAL_2="93" WEIGHT="11.925847482731"/>
<CONT_DATA CI_END="-23.692163603746103" CI_START="-54.3078363962539" EFFECT_SIZE="-39.0" ESTIMABLE="YES" MEAN_1="18.0" MEAN_2="57.0" ORDER="151483" SD_1="23.24" SD_2="22.91" SE="7.810264125769736" STUDY_ID="STD-Scale-1994a-_x0028_2-inj_x0029_" TOTAL_1="15" TOTAL_2="21" WEIGHT="7.277813682374684"/>
<CONT_DATA CI_END="-6.367651240005305" CI_START="-39.6323487599947" EFFECT_SIZE="-23.0" ESTIMABLE="YES" MEAN_1="22.0" MEAN_2="45.0" ORDER="151484" SD_1="23.24" SD_2="23.24" SE="8.486048157613373" STUDY_ID="STD-Scale-1994b-_x0028_3-inj_x0029_" TOTAL_1="15" TOTAL_2="15" WEIGHT="6.666371449871013"/>
<CONT_DATA CI_END="-0.759754882886094" CI_START="-9.460245117113905" EFFECT_SIZE="-5.109999999999999" ESTIMABLE="YES" MEAN_1="15.57" MEAN_2="20.68" ORDER="151485" SD_1="13.88" SD_2="15.52" SE="2.2195535996722815" STUDY_ID="STD-Tsai-2003" TOTAL_1="88" TOTAL_2="88" WEIGHT="13.654760449503453"/>
<CONT_DATA CI_END="-9.91406482661416" CI_START="-32.08593517338584" EFFECT_SIZE="-21.0" ESTIMABLE="YES" MEAN_1="35.0" MEAN_2="56.0" ORDER="151486" SD_1="29.93" SD_2="30.98" SE="5.656193308055802" STUDY_ID="STD-Wobig-1998" TOTAL_1="56" TOTAL_2="60" WEIGHT="9.596168219896555"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.38379834242484934" CI_END="2.194529956632909" CI_START="-7.396198266183784" DF="2" EFFECT_SIZE="-2.6008341547754377" ESTIMABLE="YES" I2="0.0" ID="CMP-050.01.04" NO="4" P_CHI2="0.8253901462345212" P_Z="0.2877754208770005" STUDIES="3" TAU2="0.0" TOTAL_1="266" TOTAL_2="261" WEIGHT="100.0" Z="1.063014435336473">
<NAME>45 to 52 weeks post-injection</NAME>
<CONT_DATA CI_END="8.818260121201416" CI_START="-10.498260121201415" EFFECT_SIZE="-0.8399999999999999" ESTIMABLE="YES" MEAN_1="28.51" MEAN_2="29.35" ORDER="151487" SD_1="23.77" SD_2="24.26" SE="4.927774284315701" STUDY_ID="STD-Dougados-1993" TOTAL_1="47" TOTAL_2="48" WEIGHT="24.651615294441772"/>
<CONT_DATA CI_END="2.8249839003311923" CI_START="-8.544983900331191" EFFECT_SIZE="-2.8599999999999994" ESTIMABLE="YES" MEAN_1="47.59" MEAN_2="50.45" ORDER="151488" SD_1="29.37" SD_2="29.21" SE="2.9005552883489796" STUDY_ID="STD-Jubb-2003" TOTAL_1="208" TOTAL_2="200" WEIGHT="71.15160467527419"/>
<CONT_DATA CI_END="14.857955616414245" CI_START="-31.95795561641424" EFFECT_SIZE="-8.549999999999997" ESTIMABLE="YES" MEAN_1="48.45" MEAN_2="57.0" ORDER="151489" SD_1="28.89" SD_2="29.46" SE="11.943053954589578" STUDY_ID="STD-St.-J.-Dixon-1988" TOTAL_1="11" TOTAL_2="13" WEIGHT="4.1967800302840415"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="46.961898251074295" CI_END="-0.8466604188767519" CI_START="-9.897460797123495" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="MD" EFFECT_SIZE="-5.372060608000123" ESTIMABLE="YES" I2="76.5767560306224" I2_Q="0.0" ID="CMP-050.02" NO="2" P_CHI2="2.184262191895492E-6" P_Q="1.0" P_Z="0.01998363074585964" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="42.58525145412699" TOTALS="SUB" TOTAL_1="310" TOTAL_2="267" UNITS="" WEIGHT="100.00000000000001" Z="2.3266550745617485">
<NAME>Pain at rest (0-100 mm VAS)</NAME>
<GROUP_LABEL_1>HA</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="46.961898251074295" CI_END="-0.8466604188767519" CI_START="-9.897460797123495" DF="11" EFFECT_SIZE="-5.372060608000123" ESTIMABLE="YES" I2="76.5767560306224" ID="CMP-050.02.01" NO="1" P_CHI2="2.184262191895492E-6" P_Z="0.01998363074585964" STUDIES="12" TAU2="42.58525145412699" TOTAL_1="310" TOTAL_2="267" WEIGHT="100.00000000000001" Z="2.3266550745617485">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="0.7967507572555448" CI_START="-18.99675075725554" EFFECT_SIZE="-9.099999999999998" ESTIMABLE="YES" MEAN_1="28.3" MEAN_2="37.4" ORDER="151490" SD_1="11.6" SD_2="13.7" SE="5.049455416181036" STUDY_ID="STD-Carrabba-1995" TOTAL_1="20" TOTAL_2="10" WEIGHT="7.830398960640946"/>
<CONT_DATA CI_END="3.505832190740861" CI_START="-17.705832190740857" EFFECT_SIZE="-7.099999999999998" ESTIMABLE="YES" MEAN_1="30.3" MEAN_2="37.4" ORDER="151491" SD_1="14.5" SD_2="13.7" SE="5.411238305600669" STUDY_ID="STD-Carrabba-1995a" TOTAL_1="20" TOTAL_2="10" WEIGHT="7.418050492581118"/>
<CONT_DATA CI_END="-1.6666199819037804" CI_START="-22.533380018096217" EFFECT_SIZE="-12.099999999999998" ESTIMABLE="YES" MEAN_1="28.3" MEAN_2="40.4" ORDER="151500" SD_1="11.6" SD_2="14.7" SE="5.323250886441479" STUDY_ID="STD-Carrabba-1995b" TOTAL_1="20" TOTAL_2="10" WEIGHT="7.516839639098481"/>
<CONT_DATA CI_END="1.008259067420349" CI_START="-21.208259067420343" EFFECT_SIZE="-10.099999999999998" ESTIMABLE="YES" MEAN_1="30.3" MEAN_2="40.4" ORDER="151501" SD_1="14.5" SD_2="14.7" SE="5.667583259203167" STUDY_ID="STD-Carrabba-1995c" TOTAL_1="20" TOTAL_2="10" WEIGHT="7.1360510348498245"/>
<CONT_DATA CI_END="13.883122745417381" CI_START="-13.28312274541738" EFFECT_SIZE="0.3000000000000007" ESTIMABLE="YES" MEAN_1="9.4" MEAN_2="9.1" ORDER="151492" SD_1="22.2" SD_2="18.8" SE="6.930292011771297" STUDY_ID="STD-Corrado-1995" TOTAL_1="19" TOTAL_2="16" WEIGHT="5.88330745017672"/>
<CONT_DATA CI_END="-5.092645870305916" CI_START="-14.907354129694085" EFFECT_SIZE="-10.0" ESTIMABLE="YES" MEAN_1="29.0" MEAN_2="39.0" ORDER="151493" SD_1="7.83" SD_2="5.66" SE="2.503798114864695" STUDY_ID="STD-Cubukcu-2004" TOTAL_1="20" TOTAL_2="10" WEIGHT="10.912277244973946"/>
<CONT_DATA CI_END="3.1932044397273325" CI_START="-10.833204439727332" EFFECT_SIZE="-3.8200000000000003" ESTIMABLE="YES" MEAN_1="10.87" MEAN_2="14.69" ORDER="151494" SD_1="16.94" SD_2="18.7" SE="3.578231281312613" STUDY_ID="STD-Dougados-1993" TOTAL_1="52" TOTAL_2="48" WEIGHT="9.624858399953105"/>
<CONT_DATA CI_END="-9.455872583719946" CI_START="-17.744127416280058" EFFECT_SIZE="-13.600000000000001" ESTIMABLE="YES" MEAN_1="17.7" MEAN_2="31.3" ORDER="151495" SD_1="5.6" SD_2="7.2" SE="2.114389574996481" STUDY_ID="STD-Henderson-1994" TOTAL_1="18" TOTAL_2="19" WEIGHT="11.3293179121331"/>
<CONT_DATA CI_END="4.892916330110964" CI_START="-2.2929163301109625" EFFECT_SIZE="1.3000000000000007" ESTIMABLE="YES" MEAN_1="25.3" MEAN_2="24.0" ORDER="151496" SD_1="6.5" SD_2="6.0" SE="1.8331542612269556" STUDY_ID="STD-Henderson-1994a" TOTAL_1="22" TOTAL_2="25" WEIGHT="11.603068870665455"/>
<CONT_DATA CI_END="8.858497830896802" CI_START="-18.858497830896802" EFFECT_SIZE="-5.0" ESTIMABLE="YES" MEAN_1="39.0" MEAN_2="44.0" ORDER="151497" SD_1="33.91" SD_2="34.64" SE="7.070792086084675" STUDY_ID="STD-Moreland-1993" TOTAL_1="46" TOTAL_2="48" WEIGHT="5.75829990034182"/>
<CONT_DATA CI_END="16.332054435734506" CI_START="0.267945564265494" EFFECT_SIZE="8.3" ESTIMABLE="YES" MEAN_1="26.0" MEAN_2="17.7" ORDER="151498" SD_1="16.4" SD_2="13.0" SE="4.098062259863103" STUDY_ID="STD-Petrella-2002" TOTAL_1="25" TOTAL_2="28" WEIGHT="8.978054655555109"/>
<CONT_DATA CI_END="11.17139038197434" CI_START="-15.451390381974342" EFFECT_SIZE="-2.1400000000000006" ESTIMABLE="YES" MEAN_1="20.5" MEAN_2="22.64" ORDER="151499" SD_1="24.69" SD_2="28.35" SE="6.791650503260718" STUDY_ID="STD-St.-J.-Dixon-1988" TOTAL_1="28" TOTAL_2="33" WEIGHT="6.009475439030379"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="122.32897356760782" CI_END="-0.7097101179317856" CI_START="-1.4513875966222582" CI_STUDY="95" CI_TOTAL="95" DF="17" EFFECT_MEASURE="SMD" EFFECT_SIZE="-1.0805488572770219" ESTIMABLE="YES" I2="86.10304696899581" I2_Q="0.0" ID="CMP-050.03" NO="3" P_CHI2="0.0" P_Q="0.8956795550261003" P_Z="1.1235554014152728E-8" Q="0.22034514395729207" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.4049944886338077" TOTALS="SUB" TOTAL_1="703" TOTAL_2="623" UNITS="" WEIGHT="300.0" Z="5.7109374482778925">
<NAME>WOMAC pain</NAME>
<GROUP_LABEL_1>HA</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="51.412117918042576" CI_END="-0.5166489433917014" CI_START="-1.9325034917540294" DF="6" EFFECT_SIZE="-1.2245762175728654" ESTIMABLE="YES" I2="88.32959962947888" ID="CMP-050.03.01" NO="1" P_CHI2="2.4479470672744696E-9" P_Z="6.980198622181043E-4" STUDIES="7" TAU2="0.7728419075008355" TOTAL_1="224" TOTAL_2="188" WEIGHT="100.0" Z="3.3903557191566707">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="-0.6498251138098228" CI_START="-2.376000768232926" EFFECT_SIZE="-1.5129129410213744" ESTIMABLE="YES" MEAN_1="11.4" MEAN_2="14.1" ORDER="151502" SD_1="1.83" SD_2="1.52" SE="0.44035902395119414" STUDY_ID="STD-Cubukcu-2004" TOTAL_1="20" TOTAL_2="10" WEIGHT="13.494703372684686"/>
<CONT_DATA CI_END="-1.0707266647767173" CI_START="-2.567999990506223" EFFECT_SIZE="-1.8193633276414702" ESTIMABLE="YES" MEAN_1="10.2" MEAN_2="17.7" ORDER="151503" SD_1="3.1" SD_2="4.8" SE="0.38196449974076235" STUDY_ID="STD-Hizmetli-1999" TOTAL_1="20" TOTAL_2="20" WEIGHT="14.200023260170779"/>
<CONT_DATA CI_END="-0.1942023712189631" CI_START="-1.8517755415405641" EFFECT_SIZE="-1.0229889563797636" ESTIMABLE="YES" MEAN_1="10.0" MEAN_2="13.5" ORDER="151504" SD_1="3.3" SD_2="3.4" SE="0.4228580686676711" STUDY_ID="STD-Kotevoglu-2002" TOTAL_1="21" TOTAL_2="9" WEIGHT="13.7089270586684"/>
<CONT_DATA CI_END="-0.36213181288922724" CI_START="-2.0739945801762576" EFFECT_SIZE="-1.2180631965327424" ESTIMABLE="YES" MEAN_1="9.5" MEAN_2="13.5" ORDER="151505" SD_1="3.1" SD_2="3.4" SE="0.43670771013906" STUDY_ID="STD-Kotevoglu-2005" TOTAL_1="20" TOTAL_2="9" WEIGHT="13.539553986692153"/>
<CONT_DATA CI_END="0.25472783687742667" CI_START="-0.8298753433678032" EFFECT_SIZE="-0.28757375324518825" ESTIMABLE="YES" MEAN_1="24.2" MEAN_2="31.9" ORDER="151506" SD_1="24.3" SD_2="28.1" SE="0.2766895689921961" STUDY_ID="STD-Petrella-2002" TOTAL_1="25" TOTAL_2="28" WEIGHT="15.359226645963231"/>
<CONT_DATA CI_END="-1.9859817955198975" CI_START="-3.783928177541645" EFFECT_SIZE="-2.8849549865307713" ESTIMABLE="YES" MEAN_1="8.9" MEAN_2="11.1" ORDER="151507" SD_1="0.7" SD_2="0.8" SE="0.4586682194682451" STUDY_ID="STD-Sezgin-2005" TOTAL_1="22" TOTAL_2="19" WEIGHT="13.26878297637827"/>
<CONT_DATA CI_END="0.10356500084912085" CI_START="-0.467979505946504" EFFECT_SIZE="-0.18220725254869158" ESTIMABLE="YES" MEAN_1="23.21" MEAN_2="25.88" ORDER="151508" SD_1="14.14" SD_2="15.05" SE="0.14580484929924606" STUDY_ID="STD-Tsai-2003" TOTAL_1="96" TOTAL_2="93" WEIGHT="16.428782699442486"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="51.69397467297967" CI_END="-0.4729758392770881" CI_START="-1.5674238541802707" DF="6" EFFECT_SIZE="-1.0201998467286795" ESTIMABLE="YES" I2="88.39323143953142" ID="CMP-050.03.02" NO="2" P_CHI2="2.1486437074003106E-9" P_Z="2.581891468020366E-4" STUDIES="7" TAU2="0.42887689959572045" TOTAL_1="330" TOTAL_2="309" WEIGHT="100.0" Z="3.653997137174908">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="-2.028290398794498" CI_START="-4.3263710427360325" EFFECT_SIZE="-3.1773307207652652" ESTIMABLE="YES" MEAN_1="9.36" MEAN_2="14.6" ORDER="151509" SD_1="1.52" SD_2="1.77" SE="0.5862558348185226" STUDY_ID="STD-Cubukcu-2004" TOTAL_1="20" TOTAL_2="10" WEIGHT="10.09008178889071"/>
<CONT_DATA CI_END="0.024045294285382324" CI_START="-0.5031212832749743" EFFECT_SIZE="-0.239537994494796" ESTIMABLE="YES" MEAN_1="3.84" MEAN_2="4.61" ORDER="151515" SD_1="3.27" SD_2="3.14" SE="0.13448374095610413" STUDY_ID="STD-Day-2004" TOTAL_1="108" TOTAL_2="115" WEIGHT="17.440653204723777"/>
<CONT_DATA CI_END="0.07032057919593082" CI_START="-0.6821936032924824" EFFECT_SIZE="-0.30593651204827577" ESTIMABLE="YES" MEAN_1="26.0" MEAN_2="34.0" ORDER="151510" SD_1="29.12" SD_2="22.65" SE="0.19197143121612156" STUDY_ID="STD-Dickson-2001" TOTAL_1="53" TOTAL_2="57" WEIGHT="16.737860877326394"/>
<CONT_DATA CI_END="-1.1107644164782378" CI_START="-2.6200623299434658" EFFECT_SIZE="-1.8654133732108518" ESTIMABLE="YES" MEAN_1="11.8" MEAN_2="17.7" ORDER="151511" SD_1="3.1" SD_2="3.1" SE="0.3850320529791306" STUDY_ID="STD-Hizmetli-1999" TOTAL_1="20" TOTAL_2="20" WEIGHT="13.507128289929257"/>
<CONT_DATA CI_END="-0.418619655115851" CI_START="-2.1263666420440455" EFFECT_SIZE="-1.2724931485799482" ESTIMABLE="YES" MEAN_1="10.0" MEAN_2="14.0" ORDER="151512" SD_1="3.0" SD_2="3.2" SE="0.43565774687664793" STUDY_ID="STD-Kotevoglu-2002" TOTAL_1="21" TOTAL_2="9" WEIGHT="12.600037446844372"/>
<CONT_DATA CI_END="-0.5484818602127003" CI_START="-2.3096506938001116" EFFECT_SIZE="-1.429066277006406" ESTIMABLE="YES" MEAN_1="9.5" MEAN_2="14.0" ORDER="151513" SD_1="3.0" SD_2="3.2" SE="0.4492860194062968" STUDY_ID="STD-Kotevoglu-2005" TOTAL_1="20" TOTAL_2="9" WEIGHT="12.359112646293399"/>
<CONT_DATA CI_END="0.1923117360832991" CI_START="-0.3973731788468756" EFFECT_SIZE="-0.10253072138178826" ESTIMABLE="YES" MEAN_1="21.48" MEAN_2="22.97" ORDER="151514" SD_1="14.5" SD_2="14.44" SE="0.15043258947142246" STUDY_ID="STD-Tsai-2003" TOTAL_1="88" TOTAL_2="89" WEIGHT="17.26512574599209"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="14.826340760578567" CI_END="-0.3176726705993399" CI_START="-1.7547670512327267" DF="3" EFFECT_SIZE="-1.0362198609160334" ESTIMABLE="YES" I2="79.76574227960121" ID="CMP-050.03.03" NO="3" P_CHI2="0.001971242076894808" P_Z="0.004706383933728672" STUDIES="4" TAU2="0.4129948587686016" TOTAL_1="149" TOTAL_2="126" WEIGHT="100.0" Z="2.8264721299173186">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="-1.1063438433466346" CI_START="-2.6143026013359694" EFFECT_SIZE="-1.860323222341302" ESTIMABLE="YES" MEAN_1="12.8" MEAN_2="18.4" ORDER="151516" SD_1="3.0" SD_2="2.9" SE="0.384690425406773" STUDY_ID="STD-Hizmetli-1999" TOTAL_1="20" TOTAL_2="20" WEIGHT="23.958841036267216"/>
<CONT_DATA CI_END="-0.25228568917467165" CI_START="-1.9218387339111862" EFFECT_SIZE="-1.087062211542929" ESTIMABLE="YES" MEAN_1="10.0" MEAN_2="13.0" ORDER="151517" SD_1="2.5" SD_2="3.1" SE="0.4259142152370492" STUDY_ID="STD-Kotevoglu-2002" TOTAL_1="21" TOTAL_2="9" WEIGHT="22.611909162506503"/>
<CONT_DATA CI_END="-0.1734608411709858" CI_START="-1.8429650328565348" EFFECT_SIZE="-1.0082129370137602" ESTIMABLE="YES" MEAN_1="10.0" MEAN_2="13.0" ORDER="151518" SD_1="2.8" SD_2="3.1" SE="0.425901752495042" STUDY_ID="STD-Kotevoglu-2005" TOTAL_1="20" TOTAL_2="9" WEIGHT="22.61231301911462"/>
<CONT_DATA CI_END="-0.0805865474105974" CI_START="-0.6769332093972158" EFFECT_SIZE="-0.37875987840390657" ESTIMABLE="YES" MEAN_1="16.48" MEAN_2="22.14" ORDER="151519" SD_1="14.53" SD_2="15.22" SE="0.1521320459688353" STUDY_ID="STD-Tsai-2003" TOTAL_1="88" TOTAL_2="88" WEIGHT="30.81693678211166"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="86.94163883496364" CI_END="-0.5747170483781021" CI_START="-1.1879003089448117" CI_STUDY="95" CI_TOTAL="95" DF="17" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.8813086786614569" ESTIMABLE="YES" I2="80.44665337828502" I2_Q="0.0" ID="CMP-050.04" NO="4" P_CHI2="2.1879720257800273E-11" P_Q="0.858230775604027" P_Z="1.7609026700171887E-8" Q="0.30576452910688245" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.26078048981818247" TOTALS="SUB" TOTAL_1="703" TOTAL_2="623" UNITS="" WEIGHT="300.0" Z="5.633987032987893">
<NAME>WOMAC physical function</NAME>
<GROUP_LABEL_1>HA</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="38.58542722791433" CI_END="-0.4246327625405114" CI_START="-1.6209549342979557" DF="6" EFFECT_SIZE="-1.0227938484192336" ESTIMABLE="YES" I2="84.45008794496553" ID="CMP-050.04.01" NO="1" P_CHI2="8.629507070034848E-7" P_Z="8.042250045258643E-4" STUDIES="7" TAU2="0.5230355542445265" TOTAL_1="224" TOTAL_2="188" WEIGHT="100.0" Z="3.3513365443456147">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="-0.2726759927187167" CI_START="-1.901571519560644" EFFECT_SIZE="-1.0871237561396803" ESTIMABLE="YES" MEAN_1="40.9" MEAN_2="46.5" ORDER="151520" SD_1="4.96" SD_2="5.12" SE="0.4155422088595625" STUDY_ID="STD-Cubukcu-2004" TOTAL_1="20" TOTAL_2="10" WEIGHT="13.387865291608835"/>
<CONT_DATA CI_END="-0.2158317754540643" CI_START="-1.5184399445518761" EFFECT_SIZE="-0.8671358600029702" ESTIMABLE="YES" MEAN_1="39.85" MEAN_2="52.1" ORDER="151521" SD_1="11.0" SD_2="16.2" SE="0.33230410848684433" STUDY_ID="STD-Hizmetli-1999" TOTAL_1="20" TOTAL_2="20" WEIGHT="14.703470479823467"/>
<CONT_DATA CI_END="-0.5532489728217617" CI_START="-2.2960608645923366" EFFECT_SIZE="-1.4246549187070492" ESTIMABLE="YES" MEAN_1="31.0" MEAN_2="46.0" ORDER="151522" SD_1="9.4" SD_2="12.1" SE="0.4446030400348304" STUDY_ID="STD-Kotevoglu-2002" TOTAL_1="21" TOTAL_2="9" WEIGHT="12.923529492081078"/>
<CONT_DATA CI_END="-0.32585936583836306" CI_START="-2.0289817286274427" EFFECT_SIZE="-1.177420547232903" ESTIMABLE="YES" MEAN_1="33.0" MEAN_2="46.0" ORDER="151523" SD_1="10.1" SD_2="12.1" SE="0.43447797414215045" STUDY_ID="STD-Kotevoglu-2005" TOTAL_1="20" TOTAL_2="9" WEIGHT="13.085131163116623"/>
<CONT_DATA CI_END="0.07323572129554001" CI_START="-1.021581020251915" EFFECT_SIZE="-0.4741726494781875" ESTIMABLE="YES" MEAN_1="24.5" MEAN_2="37.3" ORDER="151524" SD_1="22.3" SD_2="29.9" SE="0.2792951172019562" STUDY_ID="STD-Petrella-2002" TOTAL_1="25" TOTAL_2="28" WEIGHT="15.496577864516032"/>
<CONT_DATA CI_END="-1.6049035165754437" CI_START="-3.2580202098270474" EFFECT_SIZE="-2.4314618632012457" ESTIMABLE="YES" MEAN_1="32.2" MEAN_2="39.0" ORDER="151525" SD_1="2.6" SD_2="2.9" SE="0.42172119138187675" STUDY_ID="STD-Sezgin-2005" TOTAL_1="22" TOTAL_2="19" WEIGHT="13.289045470110139"/>
<CONT_DATA CI_END="0.19783301972249467" CI_START="-0.3727828693297486" EFFECT_SIZE="-0.08747492480362697" ESTIMABLE="YES" MEAN_1="26.91" MEAN_2="28.21" ORDER="151526" SD_1="14.89" SD_2="14.71" SE="0.1455679526647399" STUDY_ID="STD-Tsai-2003" TOTAL_1="96" TOTAL_2="93" WEIGHT="17.114380238743827"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="36.94373580586128" CI_END="-0.3887981044474046" CI_START="-1.3082776891467351" DF="6" EFFECT_SIZE="-0.8485378967970699" ESTIMABLE="YES" I2="83.75908697612526" ID="CMP-050.04.02" NO="2" P_CHI2="1.8059265113334888E-6" P_Z="2.974747800668747E-4" STUDIES="7" TAU2="0.2830075017370447" TOTAL_1="330" TOTAL_2="309" WEIGHT="99.99999999999999" Z="3.6174891643373606">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="-1.3143391821776764" CI_START="-3.2790150954650357" EFFECT_SIZE="-2.296677138821356" ESTIMABLE="YES" MEAN_1="35.9" MEAN_2="47.4" ORDER="151527" SD_1="4.65" SD_2="5.31" SE="0.5012020447274725" STUDY_ID="STD-Cubukcu-2004" TOTAL_1="20" TOTAL_2="10" WEIGHT="10.299477406578719"/>
<CONT_DATA CI_END="0.04167445771367506" CI_START="-0.4852194302766192" EFFECT_SIZE="-0.22177248628147206" ESTIMABLE="YES" MEAN_1="15.37" MEAN_2="17.81" ORDER="151533" SD_1="11.41" SD_2="10.53" SE="0.1344141760119997" STUDY_ID="STD-Day-2004" TOTAL_1="108" TOTAL_2="115" WEIGHT="18.274848532590486"/>
<CONT_DATA CI_END="-0.09965413129868489" CI_START="-0.8586863112781646" EFFECT_SIZE="-0.4791702212884248" ESTIMABLE="YES" MEAN_1="38.0" MEAN_2="47.0" ORDER="151528" SD_1="21.84" SD_2="15.1" SE="0.19363421623219323" STUDY_ID="STD-Dickson-2001" TOTAL_1="53" TOTAL_2="57" WEIGHT="17.167128410718306"/>
<CONT_DATA CI_END="-0.16652772492739365" CI_START="-1.4618340619846628" EFFECT_SIZE="-0.8141808934560282" ESTIMABLE="YES" MEAN_1="41.35" MEAN_2="51.5" ORDER="151529" SD_1="10.4" SD_2="13.8" SE="0.33044136200320007" STUDY_ID="STD-Hizmetli-1999" TOTAL_1="20" TOTAL_2="20" WEIGHT="14.028832556228988"/>
<CONT_DATA CI_END="-0.8555738214969995" CI_START="-2.6901409545003574" EFFECT_SIZE="-1.7728573879986784" ESTIMABLE="YES" MEAN_1="30.0" MEAN_2="48.0" ORDER="151530" SD_1="9.2" SD_2="11.4" SE="0.46801041944499727" STUDY_ID="STD-Kotevoglu-2002" TOTAL_1="21" TOTAL_2="9" WEIGHT="10.959446036150407"/>
<CONT_DATA CI_END="-0.6003632278270669" CI_START="-2.376549451903028" EFFECT_SIZE="-1.4884563398650474" ESTIMABLE="YES" MEAN_1="31.5" MEAN_2="48.0" ORDER="151531" SD_1="10.5" SD_2="11.4" SE="0.45311705676387204" STUDY_ID="STD-Kotevoglu-2005" TOTAL_1="20" TOTAL_2="9" WEIGHT="11.267335132154518"/>
<CONT_DATA CI_END="0.2226485171463078" CI_START="-0.3668362927217677" EFFECT_SIZE="-0.07209388778772996" ESTIMABLE="YES" MEAN_1="24.25" MEAN_2="25.31" ORDER="151532" SD_1="14.65" SD_2="14.63" SE="0.15038154132368156" STUDY_ID="STD-Tsai-2003" TOTAL_1="88" TOTAL_2="89" WEIGHT="18.002931925578572"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="9.848117878382467" CI_END="-0.23723729882522449" CI_START="-1.3709062200924211" DF="3" EFFECT_SIZE="-0.8040717594588228" ESTIMABLE="YES" I2="69.53732645112547" ID="CMP-050.04.03" NO="3" P_CHI2="0.019902335080192013" P_Z="0.005431406031702533" STUDIES="4" TAU2="0.22108436414969854" TOTAL_1="149" TOTAL_2="126" WEIGHT="99.99999999999997" Z="2.7802679600027727">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="-0.025035945417898553" CI_START="-1.3018951192390982" EFFECT_SIZE="-0.6634655323284984" ESTIMABLE="YES" MEAN_1="43.2" MEAN_2="51.5" ORDER="151534" SD_1="10.5" SD_2="13.8" SE="0.3257353665406359" STUDY_ID="STD-Hizmetli-1999" TOTAL_1="20" TOTAL_2="20" WEIGHT="25.563427524061574"/>
<CONT_DATA CI_END="-0.5721292622938499" CI_START="-2.3201501757531213" EFFECT_SIZE="-1.4461397190234855" ESTIMABLE="YES" MEAN_1="31.0" MEAN_2="48.0" ORDER="151535" SD_1="10.5" SD_2="13.5" SE="0.44593189651632303" STUDY_ID="STD-Kotevoglu-2002" TOTAL_1="21" TOTAL_2="9" WEIGHT="19.91725378069428"/>
<CONT_DATA CI_END="-0.38649183528950093" CI_START="-2.1043826059002346" EFFECT_SIZE="-1.2454372205948678" ESTIMABLE="YES" MEAN_1="34.5" MEAN_2="48.0" ORDER="151536" SD_1="9.0" SD_2="13.5" SE="0.4382454943461301" STUDY_ID="STD-Kotevoglu-2005" TOTAL_1="20" TOTAL_2="9" WEIGHT="20.244889366301347"/>
<CONT_DATA CI_END="0.021774221418020046" CI_START="-0.5720300564744585" EFFECT_SIZE="-0.27512791752821925" ESTIMABLE="YES" MEAN_1="20.85" MEAN_2="24.9" ORDER="151537" SD_1="14.42" SD_2="14.89" SE="0.15148346668008467" STUDY_ID="STD-Tsai-2003" TOTAL_1="88" TOTAL_2="88" WEIGHT="34.27442932894277"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="28.46060265093311" CI_END="-0.44169975571689274" CI_START="-1.2260246575067253" CI_STUDY="95" CI_TOTAL="95" DF="18" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.833862206611809" ESTIMABLE="YES" I2="36.75467726116526" I2_Q="59.79750555953794" ID="CMP-050.05" NO="5" P_CHI2="0.05538303495367214" P_Q="0.05853711749196011" P_Z="3.079485982174952E-5" Q="7.462223530539515" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="918" TOTAL_2="743" UNITS="" WEIGHT="400.0" Z="4.167507341150774">
<NAME>Lequesne Index (0-24)</NAME>
<GROUP_LABEL_1>HA</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="10.673129865019673" CI_END="-0.15766800123173208" CI_START="-1.4817065941566039" DF="6" EFFECT_SIZE="-0.8196872976941679" ESTIMABLE="YES" I2="43.784062633168936" ID="CMP-050.05.01" NO="1" P_CHI2="0.09901957869892797" P_Z="0.01523460691986756" STUDIES="7" TAU2="0.0" TOTAL_1="264" TOTAL_2="231" WEIGHT="100.0" Z="2.4267534053015174">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="0.5838242421787347" CI_START="-4.3838242421787355" EFFECT_SIZE="-1.9000000000000004" ESTIMABLE="YES" MEAN_1="11.5" MEAN_2="13.4" ORDER="151538" SD_1="3.0" SD_2="3.4" SE="1.267280552995271" STUDY_ID="STD-Carrabba-1995" TOTAL_1="20" TOTAL_2="10" WEIGHT="7.103944728434508"/>
<CONT_DATA CI_END="0.858985701256691" CI_START="-4.458985701256692" EFFECT_SIZE="-1.8000000000000007" ESTIMABLE="YES" MEAN_1="11.6" MEAN_2="13.4" ORDER="151539" SD_1="3.7" SD_2="3.4" SE="1.3566502865514016" STUDY_ID="STD-Carrabba-1995a" TOTAL_1="20" TOTAL_2="10" WEIGHT="6.198823816281347"/>
<CONT_DATA CI_END="-0.06337950716654062" CI_START="-5.136620492833458" EFFECT_SIZE="-2.5999999999999996" ESTIMABLE="YES" MEAN_1="11.5" MEAN_2="14.1" ORDER="151540" SD_1="3.0" SD_2="3.5" SE="1.2942179105544784" STUDY_ID="STD-Carrabba-1995b" TOTAL_1="20" TOTAL_2="10" WEIGHT="6.811304617233324"/>
<CONT_DATA CI_END="0.20836954976890754" CI_START="-5.208369549768907" EFFECT_SIZE="-2.5" ESTIMABLE="YES" MEAN_1="11.6" MEAN_2="14.1" ORDER="151541" SD_1="3.7" SD_2="3.5" SE="1.3818465906170627" STUDY_ID="STD-Carrabba-1995c" TOTAL_1="20" TOTAL_2="10" WEIGHT="5.974828611608179"/>
<CONT_DATA CI_END="1.2088360170363823" CI_START="-1.7088360170363823" EFFECT_SIZE="-0.25" ESTIMABLE="YES" MEAN_1="8.53" MEAN_2="8.78" ORDER="151542" SD_1="3.81" SD_2="3.59" SE="0.7443177673383259" STUDY_ID="STD-Dougados-1993" TOTAL_1="49" TOTAL_2="50" WEIGHT="20.593413635314697"/>
<CONT_DATA CI_END="-0.2601427299999195" CI_START="-3.93985727000008" EFFECT_SIZE="-2.0999999999999996" ESTIMABLE="YES" MEAN_1="10.0" MEAN_2="12.1" ORDER="151543" SD_1="4.6" SD_2="3.8" SE="0.9387199379746972" STUDY_ID="STD-Huskisson-1999" TOTAL_1="40" TOTAL_2="41" WEIGHT="12.947115740499283"/>
<CONT_DATA CI_END="1.2319292110947269" CI_START="-0.8519292110947261" EFFECT_SIZE="0.1900000000000004" ESTIMABLE="YES" MEAN_1="7.19" MEAN_2="7.0" ORDER="151544" SD_1="3.9" SD_2="3.5" SE="0.5316063046634179" STUDY_ID="STD-Puhl-1993" TOTAL_1="95" TOTAL_2="100" WEIGHT="40.37056885062866"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="7.128147677294582" CI_END="-0.7273694220984499" CI_START="-2.042264399357179" DF="6" EFFECT_SIZE="-1.3848169107278145" ESTIMABLE="YES" I2="15.826659720983217" ID="CMP-050.05.02" NO="2" P_CHI2="0.30915892839374715" P_Z="3.6533234424016004E-5" STUDIES="7" TAU2="0.0" TOTAL_1="268" TOTAL_2="238" WEIGHT="100.0" Z="4.128377272939374">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="0.15034694211756783" CI_START="-4.750346942117569" EFFECT_SIZE="-2.3000000000000007" ESTIMABLE="YES" MEAN_1="11.6" MEAN_2="13.9" ORDER="151545" SD_1="2.6" SD_2="3.5" SE="1.2501999840025595" STUDY_ID="STD-Carrabba-1995" TOTAL_1="20" TOTAL_2="10" WEIGHT="7.198913934594272"/>
<CONT_DATA CI_END="0.9735371469814029" CI_START="-4.773537146981404" EFFECT_SIZE="-1.9000000000000004" ESTIMABLE="YES" MEAN_1="12.0" MEAN_2="13.9" ORDER="151546" SD_1="4.3" SD_2="3.5" SE="1.4661173213627892" STUDY_ID="STD-Carrabba-1995a" TOTAL_1="20" TOTAL_2="10" WEIGHT="5.234660376725215"/>
<CONT_DATA CI_END="-0.5126288202861788" CI_START="-5.087371179713823" EFFECT_SIZE="-2.8000000000000007" ESTIMABLE="YES" MEAN_1="11.6" MEAN_2="14.4" ORDER="151547" SD_1="2.6" SD_2="3.2" SE="1.1670475568716128" STUDY_ID="STD-Carrabba-1995b" TOTAL_1="20" TOTAL_2="10" WEIGHT="8.261308722298713"/>
<CONT_DATA CI_END="0.335887883690138" CI_START="-5.135887883690138" EFFECT_SIZE="-2.4000000000000004" ESTIMABLE="YES" MEAN_1="12.0" MEAN_2="14.4" ORDER="151548" SD_1="4.3" SD_2="3.2" SE="1.395886814895821" STUDY_ID="STD-Carrabba-1995c" TOTAL_1="20" TOTAL_2="10" WEIGHT="5.774648437141827"/>
<CONT_DATA CI_END="-0.21500898910106647" CI_START="-2.984991010898933" EFFECT_SIZE="-1.5999999999999996" ESTIMABLE="YES" MEAN_1="10.9" MEAN_2="12.5" ORDER="151549" SD_1="3.64" SD_2="3.77" SE="0.7066410514803158" STUDY_ID="STD-Dickson-2001" TOTAL_1="53" TOTAL_2="57" WEIGHT="22.53347814151541"/>
<CONT_DATA CI_END="-0.2339266252771579" CI_START="-4.166073374722844" EFFECT_SIZE="-2.200000000000001" ESTIMABLE="YES" MEAN_1="10.2" MEAN_2="12.4" ORDER="151550" SD_1="4.8" SD_2="4.2" SE="1.0031170930848623" STUDY_ID="STD-Huskisson-1999" TOTAL_1="40" TOTAL_2="41" WEIGHT="11.182082646659998"/>
<CONT_DATA CI_END="0.6819292110947262" CI_START="-1.4019292110947268" EFFECT_SIZE="-0.3600000000000003" ESTIMABLE="YES" MEAN_1="6.43" MEAN_2="6.79" ORDER="151551" SD_1="3.9" SD_2="3.5" SE="0.5316063046634179" STUDY_ID="STD-Puhl-1993" TOTAL_1="95" TOTAL_2="100" WEIGHT="39.814907741064566"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.197101578079338" CI_END="0.8745577066325594" CI_START="-0.7526546222897295" DF="3" EFFECT_SIZE="0.060951542171415" ESTIMABLE="YES" I2="6.165008313490843" ID="CMP-050.05.03" NO="3" P_CHI2="0.362222897145719" P_Z="0.8832652013068774" STUDIES="4" TAU2="0.0" TOTAL_1="339" TOTAL_2="227" WEIGHT="100.0" Z="0.1468312712911517">
<NAME>14 to 26 weeks post-injection</NAME>
<CONT_DATA CI_END="0.60448959543593" CI_START="-3.4044895954359307" EFFECT_SIZE="-1.4000000000000004" ESTIMABLE="YES" MEAN_1="11.2" MEAN_2="12.6" ORDER="151552" SD_1="4.4" SD_2="4.8" SE="1.022717565856867" STUDY_ID="STD-Huskisson-1999" TOTAL_1="40" TOTAL_2="41" WEIGHT="16.4748264470304"/>
<CONT_DATA CI_END="3.017252071274438" CI_START="-0.8172520712744387" EFFECT_SIZE="1.0999999999999996" ESTIMABLE="YES" MEAN_1="10.0" MEAN_2="8.9" ORDER="151553" SD_1="4.96" SD_2="4.77" SE="0.9782078070808841" STUDY_ID="STD-Karlsson-2002a-_x0028_AvP_x0029_" TOTAL_1="92" TOTAL_2="33" WEIGHT="18.008188569536507"/>
<CONT_DATA CI_END="1.973278578509903" CI_START="-1.7732785785099037" EFFECT_SIZE="0.09999999999999964" ESTIMABLE="YES" MEAN_1="9.0" MEAN_2="8.9" ORDER="151554" SD_1="4.44" SD_2="4.77" SE="0.9557719393244395" STUDY_ID="STD-Karlsson-2002b-_x0028_SvP_x0029_" TOTAL_1="88" TOTAL_2="33" WEIGHT="18.86356301425639"/>
<CONT_DATA CI_END="1.3511665202998535" CI_START="-1.0311665202998532" EFFECT_SIZE="0.16000000000000014" ESTIMABLE="YES" MEAN_1="7.98" MEAN_2="7.82" ORDER="151555" SD_1="4.4" SD_2="4.98" SE="0.6077491880950991" STUDY_ID="STD-Lohmander-1996" TOTAL_1="119" TOTAL_2="120" WEIGHT="46.65342196917671"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.4783171579010752" CI_START="-2.6983171579010756" DF="0" EFFECT_SIZE="-1.1100000000000003" ESTIMABLE="YES" I2="0.0" ID="CMP-050.05.04" NO="4" P_CHI2="1.0" P_Z="0.17077230872078072" STUDIES="1" TAU2="0.0" TOTAL_1="47" TOTAL_2="47" WEIGHT="100.0" Z="1.3697264504240534">
<NAME>45 to 52 weeks post-injection</NAME>
<CONT_DATA CI_END="0.4783171579010752" CI_START="-2.6983171579010756" EFFECT_SIZE="-1.1100000000000003" ESTIMABLE="YES" MEAN_1="7.06" MEAN_2="8.17" ORDER="151556" SD_1="4.09" SD_2="3.76" SE="0.8103807878254491" STUDY_ID="STD-Dougados-1993" TOTAL_1="47" TOTAL_2="47" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="38.486850660393955" CI_END="1.1879085123462734" CI_START="0.9418588757174678" CI_STUDY="95" CI_TOTAL="95" DF="17" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0577533625064355" ESTIMABLE="YES" EVENTS_1="658" EVENTS_2="575" I2="55.82906964769046" I2_Q="0.0" ID="CMP-050.06" LOG_CI_END="0.07478299442198146" LOG_CI_START="-0.0260141652417519" LOG_EFFECT_SIZE="0.024384414590114756" METHOD="MH" NO="6" P_CHI2="0.0021057695735208215" P_Q="0.9356682830106179" P_Z="0.34298079042693885" Q="0.4219665119964958" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="14" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.02489271277441279" TOTALS="SUB" TOTAL_1="1028" TOTAL_2="987" WEIGHT="400.0" Z="0.9482920856134729">
<NAME>Patient global assessment (number of patients improved)</NAME>
<GROUP_LABEL_1>HA</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours HA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="11.819431422694693" CI_END="1.3578055116133232" CI_START="0.8866717826494924" DF="5" EFFECT_SIZE="1.097236452854849" ESTIMABLE="YES" EVENTS_1="207" EVENTS_2="183" I2="57.6967806556294" ID="CMP-050.06.01" LOG_CI_END="0.1328375672330507" LOG_CI_START="-0.052237112257729826" LOG_EFFECT_SIZE="0.04030022748766044" NO="1" P_CHI2="0.03734756837634834" P_Z="0.3933439102394132" STUDIES="6" TAU2="0.03295798767779072" TOTAL_1="298" TOTAL_2="296" WEIGHT="100.0" Z="0.8535688908057281">
<NAME>1 to 4 weeks post-injection (much better/better or excellent/good)</NAME>
<DICH_DATA CI_END="0.8648391739347688" CI_START="0.20499223890721752" EFFECT_SIZE="0.42105263157894735" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="12" LOG_CI_END="-0.06306464671618688" LOG_CI_START="-0.6882625812055839" LOG_EFFECT_SIZE="-0.3756636139608854" ORDER="151557" O_E="0.0" SE="0.36724436149875955" STUDY_ID="STD-Corrado-1995" TOTAL_1="19" TOTAL_2="16" VAR="0.13486842105263158" WEIGHT="7.0422090746800885"/>
<DICH_DATA CI_END="3.5481063888087543" CI_START="0.44037574660341444" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.5499966335328186" LOG_CI_START="-0.3561766075167057" LOG_EFFECT_SIZE="0.09691001300805642" ORDER="151558" O_E="0.0" SE="0.5322906474223771" STUDY_ID="STD-Creamer-1994" TOTAL_1="12" TOTAL_2="12" VAR="0.2833333333333334" WEIGHT="3.7366458705036134"/>
<DICH_DATA CI_END="2.4351651446763345" CI_START="0.7300440307567179" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="9" LOG_CI_END="0.3865284189344891" LOG_CI_START="-0.1366509457178893" LOG_EFFECT_SIZE="0.12493873660829993" ORDER="151562" O_E="0.0" SE="0.30731814857642953" STUDY_ID="STD-Formiguera-Sala-1995" TOTAL_1="20" TOTAL_2="20" VAR="0.09444444444444443" WEIGHT="9.276656958937927"/>
<DICH_DATA CI_END="1.283147931553661" CI_START="0.8118479008713992" EFFECT_SIZE="1.0206473214285714" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="56" LOG_CI_END="0.10827672820183723" LOG_CI_START="-0.09052532790121633" LOG_EFFECT_SIZE="0.008875700150310464" ORDER="151559" O_E="0.0" SE="0.11677731184098247" STUDY_ID="STD-Lohmander-1996" TOTAL_1="96" TOTAL_2="93" VAR="0.013636940560806065" WEIGHT="25.364748980412674"/>
<DICH_DATA CI_END="1.5629983902311049" CI_START="1.121074612629637" EFFECT_SIZE="1.3237211998261122" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="67" LOG_CI_END="0.19395853072929037" LOG_CI_START="0.049634517835825565" LOG_EFFECT_SIZE="0.121796524282558" ORDER="151560" O_E="0.0" SE="0.08477663958900697" STUDY_ID="STD-Shichikawa-1983a" TOTAL_1="103" TOTAL_2="105" VAR="0.007187078620004384" WEIGHT="29.439947857235495"/>
<DICH_DATA CI_END="1.426768394289991" CI_START="0.896468756317216" EFFECT_SIZE="1.130952380952381" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="35" LOG_CI_END="0.15435348030082482" LOG_CI_START="-0.047464841846892605" LOG_EFFECT_SIZE="0.0534443192269661" ORDER="151561" O_E="0.0" SE="0.11854908144637581" STUDY_ID="STD-Shichikawa-1983b" TOTAL_1="48" TOTAL_2="50" VAR="0.014053884711779447" WEIGHT="25.139791258230197"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="12.417732160310017" CI_END="1.3717182340791207" CI_START="0.8660045330351057" DF="5" EFFECT_SIZE="1.089914771328212" ESTIMABLE="YES" EVENTS_1="191" EVENTS_2="181" I2="59.73499882707108" ID="CMP-050.06.02" LOG_CI_END="0.1372649116974308" LOG_CI_START="-0.062479834695147306" LOG_EFFECT_SIZE="0.03739253850114172" NO="2" P_CHI2="0.029491225848647384" P_Z="0.46306038468650945" STUDIES="6" TAU2="0.04074200686312535" TOTAL_1="287" TOTAL_2="292" WEIGHT="100.0" Z="0.7338168344986151">
<NAME>5 to 13 weeks post-injection (excellent/very good/good/better/somewhat better)</NAME>
<DICH_DATA CI_END="1.4513260344279721" CI_START="0.665060809781157" EFFECT_SIZE="0.9824561403508771" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="12" LOG_CI_END="0.16176498586807744" LOG_CI_START="-0.17713864320065942" LOG_EFFECT_SIZE="-0.0076868286662910065" ORDER="151563" O_E="0.0" SE="0.19907366931499593" STUDY_ID="STD-Corrado-1995" TOTAL_1="19" TOTAL_2="16" VAR="0.03963032581453635" WEIGHT="17.128501175251976"/>
<DICH_DATA CI_END="1.0065623062319746" CI_START="0.35087297429821307" EFFECT_SIZE="0.5942857142857143" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="25" LOG_CI_END="0.002840662896042687" LOG_CI_START="-0.45485008167107077" LOG_EFFECT_SIZE="-0.22600470938751407" ORDER="151564" O_E="0.0" SE="0.26884980896444727" STUDY_ID="STD-Dickson-2001" TOTAL_1="42" TOTAL_2="48" VAR="0.0722802197802198" WEIGHT="12.180414734451086"/>
<DICH_DATA CI_END="3.8796150733699806" CI_START="1.0310301213788842" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="7" LOG_CI_END="0.5887886380157871" LOG_CI_START="0.013271353312175308" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="151568" O_E="0.0" SE="0.3380617018914066" STUDY_ID="STD-Formiguera-Sala-1995" TOTAL_1="20" TOTAL_2="20" VAR="0.11428571428571425" WEIGHT="8.880073734718481"/>
<DICH_DATA CI_END="4.78976332523945" CI_START="1.0104883417716761" EFFECT_SIZE="2.2" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="5" LOG_CI_END="0.6803140543160356" LOG_CI_START="0.004531307328376933" LOG_EFFECT_SIZE="0.3424226808222063" ORDER="151565" O_E="0.0" SE="0.3969581307590986" STUDY_ID="STD-Guler-1996" TOTAL_1="15" TOTAL_2="15" VAR="0.1575757575757576" WEIGHT="6.941675641726619"/>
<DICH_DATA CI_END="1.302855469951321" CI_START="0.7779265204588712" EFFECT_SIZE="1.0067401960784315" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="51" LOG_CI_END="0.11489624066726953" LOG_CI_START="-0.10906142263283067" LOG_EFFECT_SIZE="0.002917409017219421" ORDER="151566" O_E="0.0" SE="0.1315538400307916" STUDY_ID="STD-Lohmander-1996" TOTAL_1="96" TOTAL_2="93" VAR="0.01730641282684711" WEIGHT="23.715677396207933"/>
<DICH_DATA CI_END="1.2539112922540723" CI_START="0.9961227082399657" EFFECT_SIZE="1.1176088369070825" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="81" LOG_CI_END="0.09826681349050403" LOG_CI_START="-0.0016871593383636651" LOG_EFFECT_SIZE="0.048289827076070185" ORDER="151567" O_E="0.0" SE="0.05871345841982211" STUDY_ID="STD-Puhl-1993" TOTAL_1="95" TOTAL_2="100" VAR="0.00344727019961618" WEIGHT="31.153657317643898"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="9.9849065969077" CI_END="1.473985895340633" CI_START="0.7343768499338519" DF="3" EFFECT_SIZE="1.0404139169903401" ESTIMABLE="YES" EVENTS_1="143" EVENTS_2="127" I2="69.95465134416888" ID="CMP-050.06.03" LOG_CI_END="0.1684933277529919" LOG_CI_START="-0.13408102203618424" LOG_EFFECT_SIZE="0.017206152858403833" NO="3" P_CHI2="0.018694909263462844" P_Z="0.8236054724119661" STUDIES="4" TAU2="0.08307241393812057" TOTAL_1="276" TOTAL_2="276" WEIGHT="100.0" Z="0.22291010416751997">
<NAME>14 to 26 weeks post-injection (better/somewhat/much)</NAME>
<DICH_DATA CI_END="1.8470147956345102" CI_START="0.6551111571276426" EFFECT_SIZE="1.1" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="17" LOG_CI_END="0.26647037439892435" LOG_CI_START="-0.18368500408247418" LOG_EFFECT_SIZE="0.04139268515822508" ORDER="151569" O_E="0.0" SE="0.2644234976250346" STUDY_ID="STD-Henderson-1994" TOTAL_1="40" TOTAL_2="44" VAR="0.06991978609625668" WEIGHT="20.64762631088332"/>
<DICH_DATA CI_END="0.8553121626770518" CI_START="0.25379187911033735" EFFECT_SIZE="0.4659090909090909" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="22" LOG_CI_END="-0.0678753521893134" LOG_CI_START="-0.5955222786715529" LOG_EFFECT_SIZE="-0.33169881543043317" ORDER="151570" O_E="0.0" SE="0.30994241651007765" STUDY_ID="STD-Huskisson-1999" TOTAL_1="40" TOTAL_2="41" VAR="0.09606430155210643" WEIGHT="17.634161518173364"/>
<DICH_DATA CI_END="1.65794521458088" CI_START="0.96230542781576" EFFECT_SIZE="1.263111111111111" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="45" LOG_CI_END="0.21957017555181912" LOG_CI_START="-0.016687064591642185" LOG_EFFECT_SIZE="0.10144155548008844" ORDER="151572" O_E="0.0" SE="0.13877867235246916" STUDY_ID="STD-Lin-2004" TOTAL_1="100" TOTAL_2="98" VAR="0.019259519899913986" WEIGHT="30.86940367793214"/>
<DICH_DATA CI_END="1.7159680784572462" CI_START="0.995023418899065" EFFECT_SIZE="1.306686046511628" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="43" LOG_CI_END="0.2345092045623262" LOG_CI_START="-0.002166697566891321" LOG_EFFECT_SIZE="0.11617125349771745" ORDER="151571" O_E="0.0" SE="0.13902459647531268" STUDY_ID="STD-Lohmander-1996" TOTAL_1="96" TOTAL_2="93" VAR="0.019327838425123523" WEIGHT="30.848808493011177"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.4229889509218843" CI_END="1.2293566735612893" CI_START="0.8245888722805661" DF="1" EFFECT_SIZE="1.0068335677173719" ESTIMABLE="YES" EVENTS_1="117" EVENTS_2="84" I2="29.72538547455696" ID="CMP-050.06.04" LOG_CI_END="0.08967790313588454" LOG_CI_START="-0.08376253024258483" LOG_EFFECT_SIZE="0.002957686446649873" NO="4" P_CHI2="0.2329123085479724" P_Z="0.9467037581161354" STUDIES="2" TAU2="0.0073368009721005" TOTAL_1="167" TOTAL_2="123" WEIGHT="100.0" Z="0.06684668390266574">
<NAME>45 to 52 weeks post-injection (number of patients rating treatment effective or very good or good)</NAME>
<DICH_DATA CI_END="1.6198947395390217" CI_START="0.8487813397611551" EFFECT_SIZE="1.1725768321513002" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="27" LOG_CI_END="0.2094867950842494" LOG_CI_START="-0.07120417685393922" LOG_EFFECT_SIZE="0.06914130911515509" ORDER="151573" O_E="0.0" SE="0.1648792663592117" STUDY_ID="STD-Dougados-1993" TOTAL_1="47" TOTAL_2="48" VAR="0.02718517247515188" WEIGHT="30.06632100528375"/>
<DICH_DATA CI_END="1.1174931971081041" CI_START="0.7957237814866697" EFFECT_SIZE="0.9429824561403509" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="57" LOG_CI_END="0.04824488798526789" LOG_CI_START="-0.09923766215496473" LOG_EFFECT_SIZE="-0.025496387084848436" ORDER="151574" O_E="0.0" SE="0.08663198000276992" STUDY_ID="STD-Pham-2004" TOTAL_1="120" TOTAL_2="75" VAR="0.007505099959200326" WEIGHT="69.93367899471625"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="1.0940893850732232" CI_END="5.848537539347583" CI_START="2.3418711409520396" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="4.095204340149811" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-050.07" NO="7" P_CHI2="0.7785011484061516" P_Q="0.3211617755499899" P_Z="4.698348915113094E-6" Q="0.9842103318568836" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="108" TOTAL_2="101" UNITS="" WEIGHT="200.0" Z="4.57782526430128">
<NAME>Flexion (degrees)</NAME>
<GROUP_LABEL_1>HA</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours HA</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.10987905321633953" CI_END="5.679147929414787" CI_START="2.0618039632645346" DF="2" EFFECT_SIZE="3.8704759463396607" ESTIMABLE="YES" I2="0.0" ID="CMP-050.07.01" NO="1" P_CHI2="0.9465423908358884" P_Z="2.7379527662640676E-5" STUDIES="3" TAU2="0.0" TOTAL_1="89" TOTAL_2="85" WEIGHT="99.99999999999999" Z="4.194233962178438">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="11.112584255088334" CI_START="-4.1125842550883345" EFFECT_SIZE="3.5" ESTIMABLE="YES" MEAN_1="123.5" MEAN_2="120.0" ORDER="151575" SD_1="10.2" SD_2="12.4" SE="3.8840429289188103" STUDY_ID="STD-Corrado-1995" TOTAL_1="19" TOTAL_2="16" WEIGHT="5.644888887153831"/>
<CONT_DATA CI_END="5.977050909946589" CI_START="2.022949090053411" EFFECT_SIZE="4.0" ESTIMABLE="YES" MEAN_1="125.2" MEAN_2="121.2" ORDER="151576" SD_1="3.0" SD_2="3.4" SE="1.0087179792798817" STUDY_ID="STD-Sezgin-2005" TOTAL_1="22" TOTAL_2="19" WEIGHT="83.69199435236496"/>
<CONT_DATA CI_END="8.58882608586999" CI_START="-2.4888260858699676" EFFECT_SIZE="3.0500000000000114" ESTIMABLE="YES" MEAN_1="135.65" MEAN_2="132.6" ORDER="151577" SD_1="14.48" SD_2="13.45" SE="2.8259836045761717" STUDY_ID="STD-Shichikawa-1983b" TOTAL_1="48" TOTAL_2="50" WEIGHT="10.663116760481197"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="14.742696362339213" CI_START="0.4573036376607762" DF="0" EFFECT_SIZE="7.599999999999994" ESTIMABLE="YES" I2="0.0" ID="CMP-050.07.02" NO="2" P_CHI2="1.0" P_Z="0.03702859728328396" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="16" WEIGHT="100.0" Z="2.085448621481942">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="14.742696362339213" CI_START="0.4573036376607762" EFFECT_SIZE="7.599999999999994" ESTIMABLE="YES" MEAN_1="125.5" MEAN_2="117.9" ORDER="151578" SD_1="9.9" SD_2="11.4" SE="3.6442998027922426" STUDY_ID="STD-Corrado-1995" TOTAL_1="19" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="6.875161480686923" CI_END="1.215302248316915" CI_START="0.8880632068468114" CI_STUDY="95" CI_TOTAL="95" DF="21" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0388768993140907" ESTIMABLE="YES" EVENTS_1="247" EVENTS_2="239" I2="0.0" I2_Q="0.0" ID="CMP-050.08" LOG_CI_END="0.08468430135155686" LOG_CI_START="-0.051556122726026" LOG_EFFECT_SIZE="0.01656408931276541" METHOD="MH" NO="8" P_CHI2="0.9983746956015335" P_Q="0.9364065336488223" P_Z="0.633658220089813" Q="0.41844434079153775" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="25" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1646" TOTAL_2="1615" WEIGHT="400.0" Z="0.47658422541664497">
<NAME>Safety: total withdrawals overall</NAME>
<GROUP_LABEL_1>HA</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.4987092360206236" CI_END="2.1508618496075624" CI_START="0.6092247233362311" DF="3" EFFECT_SIZE="1.1447087905933202" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="17" I2="0.0" ID="CMP-050.08.01" LOG_CI_END="0.33261251644050355" LOG_CI_START="-0.21522248059760088" LOG_EFFECT_SIZE="0.05869501792145136" NO="1" P_CHI2="0.6825682989776878" P_Z="0.6744993981880497" STUDIES="5" TAU2="0.0" TOTAL_1="261" TOTAL_2="264" WEIGHT="99.99999999999999" Z="0.4199809133039967">
<NAME>1 to 4 weeks post-injection</NAME>
<DICH_DATA CI_END="3.974851177531529" CI_START="0.1217484442701766" EFFECT_SIZE="0.6956521739130435" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5993208728700279" LOG_CI_START="-0.9145365795933641" LOG_EFFECT_SIZE="-0.1576078533616681" ORDER="151579" O_E="0.0" SE="0.8892473612922432" STUDY_ID="STD-Moreland-1993" TOTAL_1="46" TOTAL_2="48" VAR="0.7907608695652173" WEIGHT="17.51411551912995"/>
<DICH_DATA CI_END="11.89447521234632" CI_START="0.5254540354594692" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.075345285599021" LOG_CI_START="-0.2794652682549458" LOG_EFFECT_SIZE="0.3979400086720376" ORDER="151580" O_E="0.0" SE="0.7958224257542215" STUDY_ID="STD-Petrella-2002" TOTAL_1="30" TOTAL_2="30" VAR="0.6333333333333333" WEIGHT="11.92990477390011"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="151581" O_E="0.0" SE="0.0" STUDY_ID="STD-Sezgin-2005" TOTAL_1="22" TOTAL_2="19" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.0719863976682027" CI_START="0.4328672143979603" EFFECT_SIZE="1.1531531531531531" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.4874192883677038" LOG_CI_START="-0.36364530664528194" LOG_EFFECT_SIZE="0.06188699086121093" ORDER="151582" O_E="0.0" SE="0.49991955594831694" STUDY_ID="STD-Shichikawa-1983a" TOTAL_1="111" TOTAL_2="112" VAR="0.2499195624195624" WEIGHT="41.56742605076406"/>
<DICH_DATA CI_END="2.9798976264045933" CI_START="0.24026876796596888" EFFECT_SIZE="0.8461538461538461" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.47420134426038957" LOG_CI_START="-0.6193026785576131" LOG_EFFECT_SIZE="-0.07255066714861173" ORDER="151583" O_E="0.0" SE="0.6423296759355064" STUDY_ID="STD-Shichikawa-1983b" TOTAL_1="52" TOTAL_2="55" VAR="0.4125874125874126" WEIGHT="28.988553656205873"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.1569593812274865" CI_END="1.6673204173616876" CI_START="0.7342972074002199" DF="5" EFFECT_SIZE="1.106484851369442" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="38" I2="0.0" ID="CMP-050.08.02" LOG_CI_END="0.22201906840636432" LOG_CI_START="-0.13412812345088188" LOG_EFFECT_SIZE="0.043945472477741235" NO="2" P_CHI2="0.9489392814209437" P_Z="0.6286093777701915" STUDIES="8" TAU2="0.0" TOTAL_1="426" TOTAL_2="432" WEIGHT="100.0" Z="0.48368509037405477">
<NAME>5 to 13 weeks post-injection</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="151584" O_E="0.0" SE="0.0" STUDY_ID="STD-Carrabba-1995" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.2303079734614215" CI_START="0.11262690892131588" EFFECT_SIZE="0.6031746031746031" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5092439293895648" LOG_CI_START="-0.9483578350631079" LOG_EFFECT_SIZE="-0.21955695283677157" ORDER="151585" O_E="0.0" SE="0.8562024916845998" STUDY_ID="STD-Corrado-1995" TOTAL_1="21" TOTAL_2="19" VAR="0.7330827067669172" WEIGHT="8.383575748669763"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="151586" O_E="0.0" SE="0.0" STUDY_ID="STD-Cubukcu-2004" TOTAL_1="20" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.9155730159818447" CI_START="0.5965250436906131" EFFECT_SIZE="1.0689655172413792" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="19" LOG_CI_END="0.28229871065668155" LOG_CI_START="-0.22437131878604846" LOG_EFFECT_SIZE="0.028963695935316558" ORDER="151591" O_E="0.0" SE="0.2976204833517548" STUDY_ID="STD-Day-2004" TOTAL_1="116" TOTAL_2="124" VAR="0.08857795211053215" WEIGHT="48.88201309541841"/>
<DICH_DATA CI_END="3.1488945730241564" CI_START="0.5739312571739289" EFFECT_SIZE="1.3443396226415094" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.49815812042685126" LOG_CI_START="-0.2411401222673337" LOG_EFFECT_SIZE="0.12850899907975877" ORDER="151587" O_E="0.0" SE="0.4342674473438866" STUDY_ID="STD-Dickson-2001" TOTAL_1="53" TOTAL_2="57" VAR="0.18858821582257532" WEIGHT="20.517380187220663"/>
<DICH_DATA CI_END="2.8857455806366734" CI_START="0.38133719930936605" EFFECT_SIZE="1.0490196078431373" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.46025803923280545" LOG_CI_START="-0.4186908273862213" LOG_EFFECT_SIZE="0.0207836059232921" ORDER="151588" O_E="0.0" SE="0.516298915119076" STUDY_ID="STD-Puhl-1993" TOTAL_1="102" TOTAL_2="107" VAR="0.26656456975313486" WEIGHT="18.184470523430427"/>
<DICH_DATA CI_END="75.89889669454996" CI_START="0.13116281519644074" EFFECT_SIZE="3.1551724137931036" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8802354628131162" LOG_CI_START="-0.8821892704781316" LOG_EFFECT_SIZE="0.49902309616749224" ORDER="151589" O_E="0.0" SE="1.6226619625582437" STUDY_ID="STD-Wobig-1998" TOTAL_1="57" TOTAL_2="60" VAR="2.633031844733371" WEIGHT="1.2971785872291484"/>
<DICH_DATA CI_END="14.547791543916547" CI_START="0.06150856162258902" EFFECT_SIZE="0.9459459459459459" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1627970693983896" LOG_CI_START="-1.2110644288318284" LOG_EFFECT_SIZE="-0.024133679716719363" ORDER="151590" O_E="0.0" SE="1.394417994864361" STUDY_ID="STD-Wobig-1999c-_x0028_NEhyl_x0029_" TOTAL_1="37" TOTAL_2="35" VAR="1.9444015444015446" WEIGHT="2.7353818580315803"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.9214636044653126" CI_END="1.2039112188418446" CI_START="0.8341547233401917" DF="8" EFFECT_SIZE="1.0021218636868332" ESTIMABLE="YES" EVENTS_1="166" EVENTS_2="167" I2="0.0" ID="CMP-050.08.03" LOG_CI_END="0.08059446151588577" LOG_CI_START="-0.07875338669967441" LOG_EFFECT_SIZE="9.205374081056897E-4" NO="3" P_CHI2="0.8641388458849885" P_Z="0.9819334066101325" STUDIES="9" TAU2="0.0" TOTAL_1="743" TOTAL_2="746" WEIGHT="100.00000000000003" Z="0.02264505214865927">
<NAME>14 to 26 weeks post-injection</NAME>
<DICH_DATA CI_END="1.5426516090010658" CI_START="0.8429761645398162" EFFECT_SIZE="1.1403589507593188" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="53" LOG_CI_END="0.18826785647643052" LOG_CI_START="-0.07418470503739036" LOG_EFFECT_SIZE="0.05704157571952007" ORDER="151592" O_E="0.0" SE="0.1541659337943505" STUDY_ID="STD-Altman-1998" TOTAL_1="164" TOTAL_2="168" VAR="0.02376713514268406" WEIGHT="31.466612097977876"/>
<DICH_DATA CI_END="1.6801995878217237" CI_START="0.7475470669205133" EFFECT_SIZE="1.1207266721717588" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="35" LOG_CI_END="0.22536087383369227" LOG_CI_START="-0.12636145817363656" LOG_EFFECT_SIZE="0.04949970783002785" ORDER="151593" O_E="0.0" SE="0.20660343887472774" STUDY_ID="STD-Altman-2004" TOTAL_1="173" TOTAL_2="174" VAR="0.04268498095486336" WEIGHT="20.972636282885258"/>
<DICH_DATA CI_END="1.3120803816771682" CI_START="0.4963699825042462" EFFECT_SIZE="0.8070175438596491" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="28" LOG_CI_END="0.11796044193712446" LOG_CI_START="-0.30419448991895914" LOG_EFFECT_SIZE="-0.09311702399091736" ORDER="151594" O_E="0.0" SE="0.24797589667287848" STUDY_ID="STD-Brandt-2001" TOTAL_1="114" TOTAL_2="112" VAR="0.0614920453307181" WEIGHT="16.975508641431784"/>
<DICH_DATA CI_END="1.8207345542754831" CI_START="0.6434149813449996" EFFECT_SIZE="1.0823529411764705" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="17" LOG_CI_END="0.26024663441849294" LOG_CI_START="-0.19150883115596792" LOG_EFFECT_SIZE="0.03436890163126251" ORDER="151595" O_E="0.0" SE="0.2653633967040583" STUDY_ID="STD-Henderson-1994" TOTAL_1="45" TOTAL_2="46" VAR="0.07041773231031542" WEIGHT="10.103885018236323"/>
<DICH_DATA CI_END="2.4995506170228596" CI_START="0.493915943460679" EFFECT_SIZE="1.1111111111111112" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" LOG_CI_END="0.39786193583601337" LOG_CI_START="-0.30634695471466306" LOG_EFFECT_SIZE="0.04575749056067514" ORDER="151596" O_E="0.0" SE="0.41365578819969523" STUDY_ID="STD-Huskisson-1999" TOTAL_1="50" TOTAL_2="50" VAR="0.17111111111111113" WEIGHT="5.40855021564415"/>
<DICH_DATA CI_END="1.658978290313041" CI_START="0.2354611885405028" EFFECT_SIZE="0.625" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.2198407028061927" LOG_CI_START="-0.6280806681180423" LOG_EFFECT_SIZE="-0.2041199826559248" ORDER="151597" O_E="0.0" SE="0.49807321055937454" STUDY_ID="STD-Kotevoglu-2002" TOTAL_1="26" TOTAL_2="26" VAR="0.24807692307692306" WEIGHT="4.807600191683688"/>
<DICH_DATA CI_END="1.8599949262593907" CI_START="0.3024201797857781" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.2695117595401988" LOG_CI_START="-0.5193892327567986" LOG_EFFECT_SIZE="-0.12493873660829995" ORDER="151598" O_E="0.0" SE="0.46340434799814917" STUDY_ID="STD-Kotevoglu-2005" TOTAL_1="26" TOTAL_2="26" VAR="0.21474358974358973" WEIGHT="4.807600191683688"/>
<DICH_DATA CI_END="2.454657533133506" CI_START="0.146659969930893" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.3899909091493468" LOG_CI_START="-0.8336884083820596" LOG_EFFECT_SIZE="-0.2218487496163564" ORDER="151599" O_E="0.0" SE="0.7187952884282609" STUDY_ID="STD-Lohmander-1996" TOTAL_1="120" TOTAL_2="120" VAR="0.5166666666666667" WEIGHT="3.0047501198023054"/>
<DICH_DATA CI_END="2.885527355394007" CI_START="0.17965520203124696" EFFECT_SIZE="0.72" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.46022519586538974" LOG_CI_START="-0.7455602030028528" LOG_EFFECT_SIZE="-0.14266750356873156" ORDER="151600" O_E="0.0" SE="0.7082843120291925" STUDY_ID="STD-Tamir-2001" TOTAL_1="25" TOTAL_2="24" VAR="0.5016666666666666" WEIGHT="2.452857240654943"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.00582833912559926" CI_END="2.07593485899868" CI_START="0.6259676403456832" DF="2" EFFECT_SIZE="1.139942123618016" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="17" I2="0.0" ID="CMP-050.08.04" LOG_CI_END="0.3172137216131843" LOG_CI_START="-0.20344811724093395" LOG_EFFECT_SIZE="0.05688280218612516" NO="4" P_CHI2="0.9970900725106141" P_Z="0.6684648473464536" STUDIES="3" TAU2="0.0" TOTAL_1="216" TOTAL_2="173" WEIGHT="100.0" Z="0.4282558670705996">
<NAME>45 to 52 weeks post-injection</NAME>
<DICH_DATA CI_END="2.9345202957120105" CI_START="0.44508891313109283" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.46753711752492083" LOG_CI_START="-0.35155322356954727" LOG_EFFECT_SIZE="0.05799194697768673" ORDER="151601" O_E="0.0" SE="0.4811377209214701" STUDY_ID="STD-Dougados-1993" TOTAL_1="55" TOTAL_2="55" VAR="0.23149350649350647" WEIGHT="39.26689916153447"/>
<DICH_DATA CI_END="3.3663392199490616" CI_START="0.40521208889384525" EFFECT_SIZE="1.16793893129771" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="5" LOG_CI_END="0.5271578769188086" LOG_CI_START="-0.3923176065951394" LOG_EFFECT_SIZE="0.06742013516183457" ORDER="151602" O_E="0.0" SE="0.5401044504931417" STUDY_ID="STD-Pham-2004" TOTAL_1="131" TOTAL_2="85" VAR="0.2917128174424986" WEIGHT="34.02092453810196"/>
<DICH_DATA CI_END="3.428174309881966" CI_START="0.3529575484280615" EFFECT_SIZE="1.1" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.53506289606775" LOG_CI_START="-0.45227752575129987" LOG_EFFECT_SIZE="0.04139268515822508" ORDER="151603" O_E="0.0" SE="0.5799686511904212" STUDY_ID="STD-St.-J.-Dixon-1988" TOTAL_1="30" TOTAL_2="33" VAR="0.3363636363636364" WEIGHT="26.712176300363584"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-050.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="260" TOTAL_2="263" WEIGHT="0.0" Z="0.0">
<NAME>Safety: number of patients with local adverse reaction and study drug discontinued</NAME>
<GROUP_LABEL_1>Artz</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="21.42006440712882" CI_START="0.18674080170686877" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3308207723603833" LOG_CI_START="-0.728760781032421" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="151604" O_E="0.0" SE="1.209808399556047" STUDY_ID="STD-Dougados-1993" TOTAL_1="55" TOTAL_2="55" VAR="1.4636363636363638" WEIGHT="0.0"/>
<DICH_DATA CI_END="197.5080325690915" CI_START="0.6395590664692011" EFFECT_SIZE="11.23913043478261" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.2955847628966213" LOG_CI_START="-0.19411934007188417" LOG_EFFECT_SIZE="1.0507327114123683" ORDER="151605" O_E="0.0" SE="1.4624645143177724" STUDY_ID="STD-Henderson-1994" TOTAL_1="45" TOTAL_2="46" VAR="2.138802455638718" WEIGHT="0.0"/>
<DICH_DATA CI_END="8.02101644252152" CI_START="0.013604027359635033" EFFECT_SIZE="0.3303303303303303" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9042294066142395" LOG_CI_START="-1.8663325033104288" LOG_EFFECT_SIZE="-0.4810515483480948" ORDER="151606" O_E="0.0" SE="1.6274417803923888" STUDY_ID="STD-Shichikawa-1983a" TOTAL_1="110" TOTAL_2="109" VAR="2.6485667485667483" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.3053967308370975" CI_START="0.010415832375271113" EFFECT_SIZE="0.21176470588235294" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6340131767129504" LOG_CI_START="-1.9823060179349237" LOG_EFFECT_SIZE="-0.6741464206109866" ORDER="151607" O_E="0.0" SE="1.5368388459250457" STUDY_ID="STD-Shichikawa-1983b" TOTAL_1="50" TOTAL_2="53" VAR="2.3618736383442265" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-050.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="169" TOTAL_2="169" WEIGHT="0.0" Z="0.0">
<NAME>Safety: number of patients with local adverse reaction but study drug continued</NAME>
<GROUP_LABEL_1>HA</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="151608" O_E="0.0" SE="0.0" STUDY_ID="STD-Bunyaratavej-2001" TOTAL_1="24" TOTAL_2="25" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="69.5152908317231" CI_START="0.12946791838627933" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.84208034406391" LOG_CI_START="-0.8878378346245852" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="151609" O_E="0.0" SE="1.6035674514745464" STUDY_ID="STD-Carrabba-1995" TOTAL_1="20" TOTAL_2="20" VAR="2.5714285714285716" WEIGHT="0.0"/>
<DICH_DATA CI_END="68.25874292736694" CI_START="0.13185124152633113" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8341582859242351" LOG_CI_START="-0.87991577648491" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="151610" O_E="0.0" SE="1.5942605391424158" STUDY_ID="STD-Scale-1994b-_x0028_3-inj_x0029_" TOTAL_1="15" TOTAL_2="15" VAR="2.5416666666666665" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.1810593797957405" CI_START="0.028137153083214017" EFFECT_SIZE="0.24772727272727274" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.33866748949735104" LOG_CI_START="-1.5507198465884786" LOG_EFFECT_SIZE="-0.6060261785455637" ORDER="151611" O_E="0.0" SE="1.109835473834967" STUDY_ID="STD-Shichikawa-1983a" TOTAL_1="110" TOTAL_2="109" VAR="1.2317347789824855" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.2351306590292737" CI_END="2.7228059303597103" CI_START="0.7208111374821145" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4009385567560162" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="14" I2="7.268042122905369" I2_Q="0.0" ID="CMP-050.11" LOG_CI_END="0.43501668784107156" LOG_CI_START="-0.14217851155499814" LOG_EFFECT_SIZE="0.1464190881430367" METHOD="MH" NO="11" P_CHI2="0.3567738278287881" P_Q="0.9218501461411976" P_Z="0.3200371417633544" Q="0.00962428753468146" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="474" TOTAL_2="429" WEIGHT="200.0" Z="0.9943815877533846">
<NAME>Safety: number of patients discontinued due to adverse events</NAME>
<GROUP_LABEL_1>HA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.2192465216698194" CI_END="2.932648840826164" CI_START="0.6893500599164035" DF="2" EFFECT_SIZE="1.4218374218374221" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="12" I2="37.87366122670834" ID="CMP-050.11.01" LOG_CI_END="0.4672600631095107" LOG_CI_START="-0.16156018232687255" LOG_EFFECT_SIZE="0.15284994039131902" NO="1" P_CHI2="0.19996307767234012" P_Z="0.34067464218846233" STUDIES="3" TAU2="0.0" TOTAL_1="343" TOTAL_2="344" WEIGHT="100.0" Z="0.9528331200538216">
<NAME>14 to 26 weeks post-injection</NAME>
<DICH_DATA CI_END="5.60200150707377" CI_START="0.8477099345987852" EFFECT_SIZE="2.179190751445087" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="6" LOG_CI_END="0.7483432213232749" LOG_CI_START="-0.07175272716928" LOG_EFFECT_SIZE="0.33829524707699743" ORDER="151612" O_E="0.0" SE="0.4817284196849432" STUDY_ID="STD-Altman-2004" TOTAL_1="173" TOTAL_2="174" VAR="0.23206227033215274" WEIGHT="49.92784992784993"/>
<DICH_DATA CI_END="21.357023897403046" CI_START="0.1872920131201609" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3295407336099563" LOG_CI_START="-0.7274807422819939" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="151613" O_E="0.0" SE="1.2083045973594573" STUDY_ID="STD-Huskisson-1999" TOTAL_1="50" TOTAL_2="50" VAR="1.46" WEIGHT="8.345358345358346"/>
<DICH_DATA CI_END="2.021608484389742" CI_START="0.0791448993390522" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.3056970515849466" LOG_CI_START="-1.1015770689290219" LOG_EFFECT_SIZE="-0.3979400086720376" ORDER="151614" O_E="0.0" SE="0.8266397845091497" STUDY_ID="STD-Lohmander-1996" TOTAL_1="120" TOTAL_2="120" VAR="0.6833333333333333" WEIGHT="41.72679172679173"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.930175105174711" CI_START="0.24300266882417923" DF="0" EFFECT_SIZE="1.297709923664122" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" ID="CMP-050.11.02" LOG_CI_END="0.8407442080967096" LOG_CI_START="-0.6143889566516902" LOG_EFFECT_SIZE="0.11317762572250965" NO="2" P_CHI2="1.0" P_Z="0.7604538112535596" STUDIES="1" TAU2="0.0" TOTAL_1="131" TOTAL_2="85" WEIGHT="100.0" Z="0.3048849076437997">
<NAME>45 to 52 weeks post-injection</NAME>
<DICH_DATA CI_END="6.930175105174711" CI_START="0.24300266882417923" EFFECT_SIZE="1.297709923664122" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.8407442080967096" LOG_CI_START="-0.6143889566516902" LOG_EFFECT_SIZE="0.11317762572250965" ORDER="151615" O_E="0.0" SE="0.8547524239985445" STUDY_ID="STD-Pham-2004" TOTAL_1="131" TOTAL_2="85" VAR="0.7306017063313875" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.368479504452048" CI_END="1.3426694759450857" CI_START="0.6115684116280653" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9061645759712873" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="47" I2="25.4910073386175" I2_Q="0.0" ID="CMP-050.12" LOG_CI_END="0.12796911584079518" LOG_CI_START="-0.21355495460358834" LOG_EFFECT_SIZE="-0.04279291938139657" METHOD="MH" NO="12" P_CHI2="0.251534560022982" P_Q="0.3897211893397964" P_Z="0.6233087354322369" Q="0.739811838277176" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="654" TOTAL_2="608" WEIGHT="200.0" Z="0.4911664391428119">
<NAME>Safety: withdrawals due to lack of efficacy</NAME>
<GROUP_LABEL_1>HA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-050.12.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="19" WEIGHT="0.0" Z="0.0">
<NAME>1 to 4 weeks post-injection</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="151616" O_E="0.0" SE="0.0" STUDY_ID="STD-Sezgin-2005" TOTAL_1="22" TOTAL_2="19" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.587401915743196" CI_END="1.3991519455626387" CI_START="0.6282774903230384" DF="3" EFFECT_SIZE="0.9375796888471353" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="45" I2="34.60350640512875" ID="CMP-050.12.02" LOG_CI_END="0.1458648807077818" LOG_CI_START="-0.2018484997359373" LOG_EFFECT_SIZE="-0.027991809514077745" NO="2" P_CHI2="0.20462553630258762" P_Z="0.7523333535397225" STUDIES="4" TAU2="0.0" TOTAL_1="501" TOTAL_2="504" WEIGHT="100.0" Z="0.3155641490683337">
<NAME>14 to 26 weeks post-injection</NAME>
<DICH_DATA CI_END="2.0805218666502974" CI_START="0.5693986854034996" EFFECT_SIZE="1.0884146341463414" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="16" LOG_CI_END="0.3181722846642492" LOG_CI_START="-0.2445835398632209" LOG_EFFECT_SIZE="0.03679437240051411" ORDER="151617" O_E="0.0" SE="0.33056555701369433" STUDY_ID="STD-Altman-1998" TOTAL_1="164" TOTAL_2="168" VAR="0.109273587483774" WEIGHT="35.18763459596331"/>
<DICH_DATA CI_END="4.511333178647983" CI_START="0.6228721126648293" EFFECT_SIZE="1.676300578034682" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.6543049025366259" LOG_CI_START="-0.2056011129963045" LOG_EFFECT_SIZE="0.22435189477016065" ORDER="151618" O_E="0.0" SE="0.5051130501274698" STUDY_ID="STD-Altman-2004" TOTAL_1="173" TOTAL_2="174" VAR="0.2551391934090758" WEIGHT="13.317791307815348"/>
<DICH_DATA CI_END="1.7067857648560478" CI_START="0.42476773151896235" EFFECT_SIZE="0.8514619883040936" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="15" LOG_CI_END="0.23217901204628055" LOG_CI_START="-0.37184848287655137" LOG_EFFECT_SIZE="-0.06983473541513545" ORDER="151619" O_E="0.0" SE="0.3548087405019932" STUDY_ID="STD-Brandt-2001" TOTAL_1="114" TOTAL_2="112" VAR="0.12588924233661075" WEIGHT="33.686198050703325"/>
<DICH_DATA CI_END="1.1193966438997731" CI_START="0.05583364961883524" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="0.04898400049996404" LOG_CI_START="-1.2531039831558888" LOG_EFFECT_SIZE="-0.6020599913279624" ORDER="151620" O_E="0.0" SE="0.7648529270389177" STUDY_ID="STD-Huskisson-1999" TOTAL_1="50" TOTAL_2="50" VAR="0.585" WEIGHT="17.808376045518017"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.5225688110283735" CI_START="0.029879669076725263" DF="0" EFFECT_SIZE="0.3244274809160305" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-050.12.03" LOG_CI_END="0.5468594855168178" LOG_CI_START="-1.5246242167277233" LOG_EFFECT_SIZE="-0.48888236560545273" NO="3" P_CHI2="1.0" P_Z="0.35490032395342985" STUDIES="1" TAU2="0.0" TOTAL_1="131" TOTAL_2="85" WEIGHT="100.0" Z="0.9251261095853073">
<NAME>45 to 52 weeks post-injection</NAME>
<DICH_DATA CI_END="3.5225688110283735" CI_START="0.029879669076725263" EFFECT_SIZE="0.3244274809160305" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.5468594855168178" LOG_CI_START="-1.5246242167277233" LOG_EFFECT_SIZE="-0.48888236560545273" ORDER="151621" O_E="0.0" SE="1.216799780708144" STUDY_ID="STD-Pham-2004" TOTAL_1="131" TOTAL_2="85" VAR="1.4806017063313877" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.12425985622220782" CI_END="2.4418714594309163" CI_START="1.1860314600923794" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.701803858376975" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="33" I2="0.0" I2_Q="0.0" ID="CMP-050.13" LOG_CI_END="0.38772279886802297" LOG_CI_START="0.07409620906476203" LOG_EFFECT_SIZE="0.23090950396639254" METHOD="MH" NO="13" P_CHI2="0.7244595504449451" P_Q="1.0" P_Z="0.0039008407832887434" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="189" TOTAL_2="192" WEIGHT="100.0" Z="2.8860710550469557">
<NAME>Safety: number of adverse events for injection site pain</NAME>
<GROUP_LABEL_1>HA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.12425985622220782" CI_END="2.4418714594309163" CI_START="1.1860314600923794" DF="1" EFFECT_SIZE="1.701803858376975" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="33" I2="0.0" ID="CMP-050.13.01" LOG_CI_END="0.38772279886802297" LOG_CI_START="0.07409620906476203" LOG_EFFECT_SIZE="0.23090950396639254" NO="1" P_CHI2="0.7244595504449451" P_Z="0.0039008407832887434" STUDIES="2" TAU2="0.0" TOTAL_1="189" TOTAL_2="192" WEIGHT="100.0" Z="2.8860710550469557">
<NAME>14 to 26 weeks post-injection</NAME>
<DICH_DATA CI_END="2.8565439323968613" CI_START="1.0960031219658917" EFFECT_SIZE="1.76940133037694" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="22" LOG_CI_END="0.45584090770719793" LOG_CI_START="0.03981179123833974" LOG_EFFECT_SIZE="0.24782634947276885" ORDER="151622" O_E="0.0" SE="0.24437756239114702" STUDY_ID="STD-Altman-1998" TOTAL_1="164" TOTAL_2="168" VAR="0.05972039300023895" WEIGHT="65.94452650582636"/>
<DICH_DATA CI_END="2.5871893412858213" CI_START="0.9538364017356238" EFFECT_SIZE="1.5709090909090908" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="11" LOG_CI_END="0.41282821335766945" LOG_CI_START="-0.020526107388370518" LOG_EFFECT_SIZE="0.1961510529846494" ORDER="151623" O_E="0.0" SE="0.25455447314470786" STUDY_ID="STD-Tamir-2001" TOTAL_1="25" TOTAL_2="24" VAR="0.0647979797979798" WEIGHT="34.05547349417364"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.024650426870076576" CI_END="1.427913987994794" CI_START="0.5541127408850433" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8895084786756605" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="32" I2="0.0" I2_Q="100.0" ID="CMP-050.14" LOG_CI_END="0.15470204801140056" LOG_CI_START="-0.25640186385840696" LOG_EFFECT_SIZE="-0.05084990792350322" METHOD="MH" NO="14" P_CHI2="0.8752412845409527" P_Q="0.0" P_Z="0.627775429311002" Q="3.302646284148142E-33" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="278" TOTAL_2="280" WEIGHT="100.0" Z="0.48486032494289083">
<NAME>Safety: number of adverse events local skin rash</NAME>
<GROUP_LABEL_1>HA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.024650426870076576" CI_END="1.427913987994794" CI_START="0.5541127408850433" DF="1" EFFECT_SIZE="0.8895084786756605" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="32" I2="0.0" ID="CMP-050.14.01" LOG_CI_END="0.15470204801140056" LOG_CI_START="-0.25640186385840696" LOG_EFFECT_SIZE="-0.05084990792350322" NO="1" P_CHI2="0.8752412845409527" P_Z="0.627775429311002" STUDIES="2" TAU2="0.0" TOTAL_1="278" TOTAL_2="280" WEIGHT="100.0" Z="0.48486032494289083">
<NAME>14 to 26 weeks post-injection</NAME>
<DICH_DATA CI_END="1.5214210975234363" CI_START="0.5397472137629242" EFFECT_SIZE="0.9061913696060038" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="26" LOG_CI_END="0.18224943431579385" LOG_CI_START="-0.26780959086591405" LOG_EFFECT_SIZE="-0.042780078275060106" ORDER="151624" O_E="0.0" SE="0.26436689921983986" STUDY_ID="STD-Altman-1998" TOTAL_1="164" TOTAL_2="168" VAR="0.06988985740311296" WEIGHT="80.92902636317218"/>
<DICH_DATA CI_END="2.6059451010968786" CI_START="0.2572163601633615" EFFECT_SIZE="0.8187134502923976" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.4159652622814674" LOG_CI_START="-0.589701411709299" LOG_EFFECT_SIZE="-0.08686807471391583" ORDER="151625" O_E="0.0" SE="0.5907335824324987" STUDY_ID="STD-Brandt-2001" TOTAL_1="114" TOTAL_2="112" VAR="0.3489661654135338" WEIGHT="19.07097363682782"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.804747827153251" CI_END="2.0334049262636698" CI_START="0.9944682648207547" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4220255513525086" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="42" I2="82.7727227818195" I2_Q="0.0" ID="CMP-050.15" LOG_CI_END="0.30822387137334634" LOG_CI_START="-0.002409071396394569" LOG_EFFECT_SIZE="0.15290739998847588" METHOD="MH" NO="15" P_CHI2="0.015982992847337174" P_Q="1.0" P_Z="0.05366094276227788" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="278" TOTAL_2="280" WEIGHT="100.0" Z="1.9295635181180564">
<NAME>Safety: number of patients with gastrointestinal complaints</NAME>
<GROUP_LABEL_1>HA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.804747827153251" CI_END="2.0334049262636698" CI_START="0.9944682648207547" DF="1" EFFECT_SIZE="1.4220255513525086" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="42" I2="82.7727227818195" ID="CMP-050.15.01" LOG_CI_END="0.30822387137334634" LOG_CI_START="-0.002409071396394569" LOG_EFFECT_SIZE="0.15290739998847588" NO="1" P_CHI2="0.015982992847337174" P_Z="0.05366094276227788" STUDIES="2" TAU2="0.0" TOTAL_1="278" TOTAL_2="280" WEIGHT="100.0" Z="1.9295635181180564">
<NAME>14 to 26 weeks post-injection</NAME>
<DICH_DATA CI_END="2.895673752269871" CI_START="1.2351423608209247" EFFECT_SIZE="1.8911819887429644" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="26" LOG_CI_END="0.46174962949665366" LOG_CI_START="0.09171701666921478" LOG_EFFECT_SIZE="0.27673332308293425" ORDER="151626" O_E="0.0" SE="0.2173589884658122" STUDY_ID="STD-Altman-1998" TOTAL_1="164" TOTAL_2="168" VAR="0.047244929866881086" WEIGHT="61.409912619676376"/>
<DICH_DATA CI_END="1.390455209992918" CI_START="0.3281064318730293" EFFECT_SIZE="0.6754385964912281" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="16" LOG_CI_END="0.14315700372429468" LOG_CI_START="-0.48398525605227616" LOG_EFFECT_SIZE="-0.17041412616399074" ORDER="151627" O_E="0.0" SE="0.3683864677970108" STUDY_ID="STD-Brandt-2001" TOTAL_1="114" TOTAL_2="112" VAR="0.13570858965595808" WEIGHT="38.590087380323624"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.692187463096815" CI_END="2.407419957542415" CI_START="0.9129166275987292" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4824890248678058" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="21" I2="45.83156949667707" I2_Q="0.0" ID="CMP-050.16" LOG_CI_END="0.38155185651286366" LOG_CI_START="-0.03956888273637588" LOG_EFFECT_SIZE="0.17099148688824392" METHOD="MH" NO="16" P_CHI2="0.15785266243638507" P_Q="1.0" P_Z="0.11146471018967583" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="233" TOTAL_2="231" WEIGHT="100.0" Z="1.5916440333068502">
<NAME>Safety: number of patients with treatment related adverse events</NAME>
<GROUP_LABEL_1>HA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.692187463096815" CI_END="2.407419957542415" CI_START="0.9129166275987292" DF="2" EFFECT_SIZE="1.4824890248678058" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="21" I2="45.83156949667707" ID="CMP-050.16.01" LOG_CI_END="0.38155185651286366" LOG_CI_START="-0.03956888273637588" LOG_EFFECT_SIZE="0.17099148688824392" NO="1" P_CHI2="0.15785266243638507" P_Z="0.11146471018967583" STUDIES="4" TAU2="0.0" TOTAL_1="233" TOTAL_2="231" WEIGHT="100.0" Z="1.5916440333068502">
<NAME>14 to 26 weeks post-injection</NAME>
<DICH_DATA CI_END="1.8646822875066713" CI_START="0.3465142871373918" EFFECT_SIZE="0.8038277511961722" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="11" LOG_CI_END="0.2706048455083027" LOG_CI_START="-0.4602788542786851" LOG_EFFECT_SIZE="-0.09483700438519116" ORDER="151628" O_E="0.0" SE="0.42932470318753985" STUDY_ID="STD-Brandt-2001" TOTAL_1="114" TOTAL_2="112" VAR="0.1843197007670692" WEIGHT="51.11697876423561"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="151629" O_E="0.0" SE="0.0" STUDY_ID="STD-Bunyaratavej-2001" TOTAL_1="24" TOTAL_2="25" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.847709019383875" CI_START="1.09576315582536" EFFECT_SIZE="2.0533333333333332" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="10" LOG_CI_END="0.5852022213558538" LOG_CI_START="0.039716693533672104" LOG_EFFECT_SIZE="0.312459457444763" ORDER="151630" O_E="0.0" SE="0.3204208992396605" STUDY_ID="STD-Henderson-1994" TOTAL_1="45" TOTAL_2="44" VAR="0.10266955266955266" WEIGHT="46.579903771506565"/>
<DICH_DATA CI_END="101.58460526662178" CI_START="0.24610028197072092" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.006827897373713" LOG_CI_START="-0.6088878887016753" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="151631" O_E="0.0" SE="1.5364844007426468" STUDY_ID="STD-Huskisson-1999" TOTAL_1="50" TOTAL_2="50" VAR="2.3607843137254902" WEIGHT="2.3031174642578245"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="142.76828732579966" CI_START="0.4128561675293032" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="7.67741935483871" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-050.17" LOG_CI_END="2.154631749674504" LOG_CI_START="-0.3842012232300252" LOG_EFFECT_SIZE="0.8852152632222393" METHOD="MH" NO="17" P_CHI2="1.0" P_Q="1.0" P_Z="0.17169996202796092" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="30" TOTAL_2="33" WEIGHT="100.0" Z="1.366761857118811">
<NAME>Safety: number of patients with possible study medication related events</NAME>
<GROUP_LABEL_1>Hyalgan</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hyalgan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="142.76828732579966" CI_START="0.4128561675293032" DF="0" EFFECT_SIZE="7.67741935483871" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-050.17.01" LOG_CI_END="2.154631749674504" LOG_CI_START="-0.3842012232300252" LOG_EFFECT_SIZE="0.8852152632222393" NO="1" P_CHI2="1.0" P_Z="0.17169996202796092" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="33" WEIGHT="100.0" Z="1.366761857118811">
<NAME>45 to 52 weeks post-injection</NAME>
<DICH_DATA CI_END="142.76828732579966" CI_START="0.4128561675293032" EFFECT_SIZE="7.67741935483871" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.154631749674504" LOG_CI_START="-0.3842012232300252" LOG_EFFECT_SIZE="0.8852152632222393" ORDER="151632" O_E="0.0" SE="1.491323055710021" STUDY_ID="STD-St.-J.-Dixon-1988" TOTAL_1="30" TOTAL_2="33" VAR="2.2240444564922743" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.01772133133623864" CI_END="1.0723883911520367" CI_START="0.3404581804571367" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6042378673957621" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="22" I2="0.0" I2_Q="0.0" ID="CMP-050.18" LOG_CI_END="0.03035210399985708" LOG_CI_START="-0.46793622622433256" LOG_EFFECT_SIZE="-0.21879206111223776" METHOD="MH" NO="18" P_CHI2="0.8940973047312062" P_Q="1.0" P_Z="0.08521626859798229" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="236" TOTAL_2="156" WEIGHT="100.0" Z="1.7211904589069384">
<NAME>Safety: number of serious adverse events</NAME>
<GROUP_LABEL_1>HA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.01772133133623864" CI_END="1.0723883911520367" CI_START="0.3404581804571367" DF="1" EFFECT_SIZE="0.6042378673957621" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="22" I2="0.0" ID="CMP-050.18.01" LOG_CI_END="0.03035210399985708" LOG_CI_START="-0.46793622622433256" LOG_EFFECT_SIZE="-0.21879206111223776" NO="1" P_CHI2="0.8940973047312062" P_Z="0.08521626859798229" STUDIES="2" TAU2="0.0" TOTAL_1="236" TOTAL_2="156" WEIGHT="100.0" Z="1.7211904589069384">
<NAME>45 to 52 weeks post-injection</NAME>
<DICH_DATA CI_END="1.2594656771213009" CI_START="0.2696958594714073" EFFECT_SIZE="0.5828144458281445" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" LOG_CI_END="0.10018633662973951" LOG_CI_START="-0.5691257210388533" LOG_EFFECT_SIZE="-0.2344696922045569" ORDER="151633" O_E="0.0" SE="0.3931572158226506" STUDY_ID="STD-Karlsson-2002a-_x0028_AvP_x0029_" TOTAL_1="146" TOTAL_2="78" VAR="0.15457259635341827" WEIGHT="54.88721804511278"/>
<DICH_DATA CI_END="1.4876656562845585" CI_START="0.2670505354014781" EFFECT_SIZE="0.6303030303030303" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" LOG_CI_END="0.17250533715995064" LOG_CI_START="-0.5734065469902027" LOG_EFFECT_SIZE="-0.20045060491512595" ORDER="151634" O_E="0.0" SE="0.4381523330731756" STUDY_ID="STD-Karlsson-2002b-_x0028_SvP_x0029_" TOTAL_1="90" TOTAL_2="78" VAR="0.19197746697746698" WEIGHT="45.11278195488722"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.017893797093503985" CI_END="2.200091300947212" CI_START="0.1085632228544005" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4887218045112782" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-050.19" LOG_CI_END="0.3424407038562119" LOG_CI_START="-0.9643172725046721" LOG_EFFECT_SIZE="-0.3109382843242302" METHOD="MH" NO="19" P_CHI2="0.8935862764360721" P_Q="1.0" P_Z="0.35095809417905777" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="236" TOTAL_2="156" WEIGHT="100.0" Z="0.932732533054556">
<NAME>Safety: number of adverse events probably or possibly related to treatment</NAME>
<GROUP_LABEL_1>HA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.017893797093503985" CI_END="2.200091300947212" CI_START="0.1085632228544005" DF="1" EFFECT_SIZE="0.4887218045112782" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" ID="CMP-050.19.01" LOG_CI_END="0.3424407038562119" LOG_CI_START="-0.9643172725046721" LOG_EFFECT_SIZE="-0.3109382843242302" NO="1" P_CHI2="0.8935862764360721" P_Z="0.35095809417905777" STUDIES="2" TAU2="0.0" TOTAL_1="236" TOTAL_2="156" WEIGHT="100.0" Z="0.932732533054556">
<NAME>45 to 52 weeks post-injection</NAME>
<DICH_DATA CI_END="3.719891046399816" CI_START="0.07672789329176388" EFFECT_SIZE="0.5342465753424658" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.570530219817302" LOG_CI_START="-1.1150467260052153" LOG_EFFECT_SIZE="-0.2722582530939567" ORDER="151635" O_E="0.0" SE="0.9901162417165946" STUDY_ID="STD-Karlsson-2002a-_x0028_AvP_x0029_" TOTAL_1="146" TOTAL_2="78" VAR="0.980330172110994" WEIGHT="54.88721804511279"/>
<DICH_DATA CI_END="4.68788670786645" CI_START="0.040055954735996414" EFFECT_SIZE="0.43333333333333335" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.670977107544383" LOG_CI_START="-1.3973329123700344" LOG_EFFECT_SIZE="-0.36317790241282566" ORDER="151636" O_E="0.0" SE="1.2149355439974485" STUDY_ID="STD-Karlsson-2002b-_x0028_SvP_x0029_" TOTAL_1="90" TOTAL_2="78" VAR="1.4760683760683762" WEIGHT="45.11278195488722"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.6518543354562312" CI_END="1.3930925418223694" CI_START="0.9064152578178394" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.123708296427517" ESTIMABLE="YES" EVENTS_1="99" EVENTS_2="66" I2="0.0" I2_Q="0.0" ID="CMP-050.20" LOG_CI_END="0.14397996715466377" LOG_CI_START="-0.04267279254192113" LOG_EFFECT_SIZE="0.050653587306371324" METHOD="MH" NO="20" P_CHI2="0.41945076138211" P_Q="1.0" P_Z="0.28742610529083557" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="176" TOTAL_2="132" WEIGHT="99.99999999999999" Z="1.0637850409458425">
<NAME>Safety: number of patients reporting adverse events</NAME>
<GROUP_LABEL_1>HA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.6518543354562312" CI_END="1.3930925418223694" CI_START="0.9064152578178394" DF="1" EFFECT_SIZE="1.123708296427517" ESTIMABLE="YES" EVENTS_1="99" EVENTS_2="66" I2="0.0" ID="CMP-050.20.01" LOG_CI_END="0.14397996715466377" LOG_CI_START="-0.04267279254192113" LOG_EFFECT_SIZE="0.050653587306371324" NO="1" P_CHI2="0.41945076138211" P_Z="0.28742610529083557" STUDIES="2" TAU2="0.0" TOTAL_1="176" TOTAL_2="132" WEIGHT="99.99999999999999" Z="1.0637850409458425">
<NAME>45 to 52 weeks post-injection</NAME>
<DICH_DATA CI_END="1.6369665683247576" CI_START="0.9125581361277179" EFFECT_SIZE="1.2222222222222223" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="33" LOG_CI_END="0.21403980993097635" LOG_CI_START="-0.03973945849317597" LOG_EFFECT_SIZE="0.0871501757189002" ORDER="151637" O_E="0.0" SE="0.14907119849998596" STUDY_ID="STD-Karlsson-2002a-_x0028_AvP_x0029_" TOTAL_1="90" TOTAL_2="66" VAR="0.02222222222222222" WEIGHT="50.48715677590788"/>
<DICH_DATA CI_END="1.4057139250478898" CI_START="0.7448545839466911" EFFECT_SIZE="1.0232558139534884" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="33" LOG_CI_END="0.14789694698943026" LOG_CI_START="-0.12792850517622842" LOG_EFFECT_SIZE="0.009984220906600923" ORDER="151638" O_E="0.0" SE="0.16202123596011633" STUDY_ID="STD-Karlsson-2002b-_x0028_SvP_x0029_" TOTAL_1="86" TOTAL_2="66" VAR="0.026250880902043694" WEIGHT="49.51284322409211"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-051" NO="51">
<NAME>HA/hylan versus NSAID</NAME>
<CONT_OUTCOME CHI2="1.8100974286834397" CI_END="13.01574759617943" CI_START="-6.453907588992568" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="3.280920003593431" ESTIMABLE="YES" I2="44.75435497815484" I2_Q="0.0" ID="CMP-051.01" NO="1" P_CHI2="0.17849669412890146" P_Q="1.0" P_Z="0.5088914136964591" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="26.10073982325991" TOTALS="SUB" TOTAL_1="161" TOTAL_2="172" UNITS="" WEIGHT="100.0" Z="0.6605648617852851">
<NAME>Pain after walking (0-100 mm VAS)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.8100974286834397" CI_END="13.01574759617943" CI_START="-6.453907588992568" DF="1" EFFECT_SIZE="3.280920003593431" ESTIMABLE="YES" I2="44.75435497815484" ID="CMP-051.01.01" NO="1" P_CHI2="0.17849669412890146" P_Z="0.5088914136964591" STUDIES="2" TAU2="26.10073982325991" TOTAL_1="161" TOTAL_2="172" WEIGHT="100.0" Z="0.6605648617852851">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="5.987744894990963" CI_START="-5.987744894990963" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="25.0" MEAN_2="25.0" ORDER="151639" SD_1="24.0" SD_2="27.0" SE="3.055028022056288" STUDY_ID="STD-Altman-1998" TOTAL_1="136" TOTAL_2="143" WEIGHT="69.62111107783859"/>
<CONT_DATA CI_END="25.349392890318963" CI_START="-3.749392890318969" EFFECT_SIZE="10.799999999999997" ESTIMABLE="YES" MEAN_1="28.9" MEAN_2="18.1" ORDER="151640" SD_1="27.2" SD_2="27.2" SE="7.423296042724622" STUDY_ID="STD-Petrella-2002" TOTAL_1="25" TOTAL_2="29" WEIGHT="30.37888892216141"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="22.849216950454668" CI_END="0.9744277498557096" CI_START="0.805077437536577" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8857142857142857" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="87" I2="91.24696481136873" I2_Q="80.42570589230824" ID="CMP-051.02" LOG_CI_END="-0.011250356651262311" LOG_CI_START="-0.09416234438074363" LOG_EFFECT_SIZE="-0.052706350516002975" METHOD="MH" NO="2" P_CHI2="1.092347785502934E-5" P_Q="0.006043713154953001" P_Z="0.012707597806922145" Q="10.217482117089967" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="90" TOTAL_2="90" WEIGHT="300.0" Z="2.491860383445572">
<NAME>Patient general satisfaction wtih treatment (excellent or good vs satisfactory or bad)</NAME>
<GROUP_LABEL_1>Hyaluronic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>Celecoxib</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours celecoxib</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours HA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.83753776411426" CI_START="0.4599860024765307" DF="0" EFFECT_SIZE="0.6206896551724138" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="29" I2="0.0" ID="CMP-051.02.01" LOG_CI_END="-0.0769956017517963" LOG_CI_START="-0.3372553838395037" LOG_EFFECT_SIZE="-0.20712549279565" NO="1" P_CHI2="1.0" P_Z="0.0018107175206540378" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="3.1196407136218736">
<NAME>HA arm versus regular dose celecoxib</NAME>
<DICH_DATA CI_END="0.83753776411426" CI_START="0.4599860024765307" EFFECT_SIZE="0.6206896551724138" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="29" LOG_CI_END="-0.0769956017517963" LOG_CI_START="-0.3372553838395037" LOG_EFFECT_SIZE="-0.20712549279565" ORDER="151641" O_E="0.0" SE="0.15287788430501822" STUDY_ID="STD-Wu-2004" TOTAL_1="30" TOTAL_2="30" VAR="0.02337164750957854" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1327158768972028" CI_START="0.9437015292707156" DF="0" EFFECT_SIZE="1.0338983050847457" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="29" I2="0.0" ID="CMP-051.02.02" LOG_CI_END="0.05412098791282871" LOG_CI_START="-0.02516534117558308" LOG_EFFECT_SIZE="0.014477823368622805" NO="2" P_CHI2="1.0" P_Z="0.4741236562509008" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.7157857528096957">
<NAME>HA + low dose celecoxib arm versus regular dose celecoxib</NAME>
<DICH_DATA CI_END="1.1327158768972028" CI_START="0.9437015292707155" EFFECT_SIZE="1.0338983050847457" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="29" LOG_CI_END="0.05412098791282871" LOG_CI_START="-0.025165341175583132" LOG_EFFECT_SIZE="0.014477823368622805" ORDER="151642" O_E="0.0" SE="0.046573182180191866" STUDY_ID="STD-Wu-2004" TOTAL_1="30" TOTAL_2="30" VAR="0.002169061298389341" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0985301733966537" CI_START="0.9103072671258554" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="29" I2="0.0" ID="CMP-051.02.03" LOG_CI_END="0.040811990213924856" LOG_CI_START="-0.0408119902139249" LOG_EFFECT_SIZE="0.0" NO="3" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.0">
<NAME>HA + voluntary dose of celecoxib arm versus regular dose of celecoxib</NAME>
<DICH_DATA CI_END="1.0985301733966537" CI_START="0.9103072671258554" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="29" LOG_CI_END="0.040811990213924856" LOG_CI_START="-0.0408119902139249" LOG_EFFECT_SIZE="0.0" ORDER="151643" O_E="0.0" SE="0.04794633014853841" STUDY_ID="STD-Wu-2004" TOTAL_1="30" TOTAL_2="30" VAR="0.0022988505747126436" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.09004329355850153" CI_END="1.588076848944542" CI_START="0.8862164502519969" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1863304041450715" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="58" I2="0.0" I2_Q="0.0" ID="CMP-051.03" LOG_CI_END="0.20087151463075742" LOG_CI_START="-0.05246019270729479" LOG_EFFECT_SIZE="0.0742056609617313" METHOD="MH" NO="3" P_CHI2="0.955976789275333" P_Q="0.9752892828599783" P_Z="0.2508772645990992" Q="9.594658402296674E-4" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="326" TOTAL_2="282" WEIGHT="200.0" Z="1.1482212350142487">
<NAME>Safety: total withdrawals overall</NAME>
<GROUP_LABEL_1>HA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.08956247452224725" CI_END="1.606997010331231" CI_START="0.8788916569632512" DF="1" EFFECT_SIZE="1.1884343756156697" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="53" I2="0.0" ID="CMP-051.03.01" LOG_CI_END="0.2060150687995257" LOG_CI_START="-0.05606465812650906" LOG_EFFECT_SIZE="0.07497520533650834" NO="1" P_CHI2="0.7647341328464239" P_Z="0.2621157085362841" STUDIES="2" TAU2="0.0" TOTAL_1="195" TOTAL_2="197" WEIGHT="100.0" Z="1.1214045734603815">
<NAME>14 to 26 weeks post-injection</NAME>
<DICH_DATA CI_END="6.023475405477417" CI_START="0.3550297758267155" EFFECT_SIZE="1.4623655913978495" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7798471414085989" LOG_CI_START="-0.44973522177603414" LOG_EFFECT_SIZE="0.1650559598162824" ORDER="151644" O_E="0.0" SE="0.7222627666655135" STUDY_ID="STD-Adams-1995" TOTAL_1="31" TOTAL_2="34" VAR="0.5216635041113219" WEIGHT="5.397658192687044"/>
<DICH_DATA CI_END="1.5960540442980338" CI_START="0.8617949291184346" EFFECT_SIZE="1.1728048780487805" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="50" LOG_CI_END="0.2030475929940524" LOG_CI_START="-0.06459606566928179" LOG_EFFECT_SIZE="0.06922576366238532" ORDER="151645" O_E="0.0" SE="0.1572152099563199" STUDY_ID="STD-Altman-1998" TOTAL_1="164" TOTAL_2="163" VAR="0.024716622241609754" WEIGHT="94.60234180731295"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.3663392199490625" CI_START="0.4052120888938452" DF="0" EFFECT_SIZE="1.16793893129771" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="5" I2="0.0" ID="CMP-051.03.02" LOG_CI_END="0.5271578769188087" LOG_CI_START="-0.3923176065951395" LOG_EFFECT_SIZE="0.06742013516183457" NO="2" P_CHI2="1.0" P_Z="0.7737853955876439" STUDIES="1" TAU2="0.0" TOTAL_1="131" TOTAL_2="85" WEIGHT="100.0" Z="0.28742699314834697">
<NAME>45 to 52 weeks post-injection</NAME>
<DICH_DATA CI_END="3.3663392199490616" CI_START="0.40521208889384525" EFFECT_SIZE="1.16793893129771" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="5" LOG_CI_END="0.5271578769188086" LOG_CI_START="-0.3923176065951394" LOG_EFFECT_SIZE="0.06742013516183457" ORDER="151646" O_E="0.0" SE="0.5401044504931417" STUDY_ID="STD-Pham-2004" TOTAL_1="131" TOTAL_2="85" VAR="0.2917128174424986" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-051.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="161" TOTAL_2="115" WEIGHT="0.0" Z="0.0">
<NAME>Safety: number of withdrawals due to inefficacy</NAME>
<GROUP_LABEL_1>Hyaluronic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>Celecoxib regular</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Celecoxib</GRAPH_LABEL_2>
<DICH_DATA CI_END="10.234729031590598" CI_START="0.04113570180456992" EFFECT_SIZE="0.648854961832061" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.0100763490363582" LOG_CI_START="-1.3857810889193012" LOG_EFFECT_SIZE="-0.18785236994147156" ORDER="151647" O_E="0.0" SE="1.4073385187407426" STUDY_ID="STD-Pham-2004" TOTAL_1="131" TOTAL_2="85" VAR="1.9806017063313877" WEIGHT="0.0"/>
<DICH_DATA CI_END="251.4242022543601" CI_START="0.8949019147025976" EFFECT_SIZE="15.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="2.400407080826505" LOG_CI_START="-0.04822456271514261" LOG_EFFECT_SIZE="1.1760912590556813" ORDER="151648" O_E="0.0" SE="1.438338348338483" STUDY_ID="STD-Wu-2004" TOTAL_1="30" TOTAL_2="30" VAR="2.0688172043010753" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-052" NO="52">
<NAME>HA/hylan versus Methylprednisolone acetate</NAME>
<CONT_OUTCOME CHI2="4.99803735175405" CI_END="6.104191174601816" CI_START="1.3979240435855256" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="3.751057609093671" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-052.01" NO="1" P_CHI2="0.4161199295582566" P_Q="0.9308294427272493" P_Z="0.001782176677812819" Q="0.0075344682652562665" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="186" TOTAL_2="184" UNITS="" WEIGHT="200.0" Z="3.1243181116117027">
<NAME>Function: range of motion (active flexion in degrees)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.9798284944776885" CI_END="7.374663001403473" CI_START="0.35793916899145684" DF="2" EFFECT_SIZE="3.8663010851974646" ESTIMABLE="YES" I2="32.88204325495703" ID="CMP-052.01.01" NO="1" P_CHI2="0.22539204621408593" P_Z="0.030778205313484592" STUDIES="3" TAU2="0.0" TOTAL_1="93" TOTAL_2="92" WEIGHT="100.0" Z="2.159928496935091">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="9.760458017965297" CI_START="-7.760458017965297" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="113.4" MEAN_2="112.4" ORDER="151649" SD_1="12.97" SD_2="15.21" SE="4.469703569589376" STUDY_ID="STD-Leardini-1987" TOTAL_1="20" TOTAL_2="20" WEIGHT="16.0381824836008"/>
<CONT_DATA CI_END="15.11718800478774" CI_START="2.1428119952122504" EFFECT_SIZE="8.629999999999995" ESTIMABLE="YES" MEAN_1="121.38" MEAN_2="112.75" ORDER="151650" SD_1="15.7" SD_2="15.7" SE="3.3098506176429034" STUDY_ID="STD-Pietrogrande-1991" TOTAL_1="45" TOTAL_2="45" WEIGHT="29.247975301502898"/>
<CONT_DATA CI_END="6.903029012654973" CI_START="-2.58302901265498" EFFECT_SIZE="2.1599999999999966" ESTIMABLE="YES" MEAN_1="116.36" MEAN_2="114.2" ORDER="151651" SD_1="7.79" SD_2="9.98" SE="2.4199572288406235" STUDY_ID="STD-Tascioglu-2003" TOTAL_1="28" TOTAL_2="27" WEIGHT="54.713842214896296"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.0106743890111045" CI_END="6.829399865303636" CI_START="0.484236239744825" DF="2" EFFECT_SIZE="3.6568180525242306" ESTIMABLE="YES" I2="0.5308860086666952" ID="CMP-052.01.02" NO="2" P_CHI2="0.3659213443248359" P_Z="0.023876143735913916" STUDIES="3" TAU2="0.0" TOTAL_1="93" TOTAL_2="92" WEIGHT="99.99999999999999" Z="2.2591164243876163">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="9.75630125887685" CI_START="-4.956301258876839" EFFECT_SIZE="2.4000000000000057" ESTIMABLE="YES" MEAN_1="116.7" MEAN_2="114.3" ORDER="151652" SD_1="12.52" SD_2="11.18" SE="3.753283895470738" STUDY_ID="STD-Leardini-1987" TOTAL_1="20" TOTAL_2="20" WEIGHT="18.599730337098027"/>
<CONT_DATA CI_END="14.236599106981748" CI_START="1.263400893018252" EFFECT_SIZE="7.75" ESTIMABLE="YES" MEAN_1="121.1" MEAN_2="113.35" ORDER="151653" SD_1="16.03" SD_2="15.36" SE="3.3095501540575305" STUDY_ID="STD-Pietrogrande-1991" TOTAL_1="45" TOTAL_2="45" WEIGHT="23.921672734497047"/>
<CONT_DATA CI_END="6.544655889331561" CI_START="-1.824655889331562" EFFECT_SIZE="2.3599999999999994" ESTIMABLE="YES" MEAN_1="115.76" MEAN_2="113.4" ORDER="151654" SD_1="7.72" SD_2="8.1" SE="2.135067747335968" STUDY_ID="STD-Tascioglu-2003" TOTAL_1="28" TOTAL_2="27" WEIGHT="57.47859692840491"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-053" NO="53">
<NAME>HA versus HA</NAME>
<DICH_OUTCOME CHI2="0.0012056017681378178" CI_END="1.0303007479672777" CI_START="0.7608703664121517" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8853955656205742" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="117" I2="0.0" I2_Q="100.0" ID="CMP-053.01" LOG_CI_END="0.012964015110591297" LOG_CI_START="-0.11868933001995881" LOG_EFFECT_SIZE="-0.05286265745468374" METHOD="MH" NO="1" P_CHI2="0.9723015988874748" P_Q="0.0" P_Z="0.11549544968570002" Q="3.220338207997703E-32" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="135" TOTAL_2="160" WEIGHT="100.0" Z="1.5739653957978392">
<NAME>Pain in movement (number of patients improved)</NAME>
<GROUP_LABEL_1>SLM-10 and NRD 101</GROUP_LABEL_1>
<GROUP_LABEL_2>Artz</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Artz</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NRD101/SLM10</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0012056017681378178" CI_END="1.0303007479672777" CI_START="0.7608703664121517" DF="1" EFFECT_SIZE="0.8853955656205742" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="117" I2="0.0" ID="CMP-053.01.01" LOG_CI_END="0.012964015110591297" LOG_CI_START="-0.11868933001995881" LOG_EFFECT_SIZE="-0.05286265745468374" NO="1" P_CHI2="0.9723015988874748" P_Z="0.11549544968570002" STUDIES="2" TAU2="0.0" TOTAL_1="135" TOTAL_2="160" WEIGHT="100.0" Z="1.5739653957978392">
<NAME>1 to 4 weeks post-injection</NAME>
<DICH_DATA CI_END="1.056353966422787" CI_START="0.7454659131121322" EFFECT_SIZE="0.8873983739837399" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="60" LOG_CI_END="0.023809467351086744" LOG_CI_START="-0.12757221013956654" LOG_EFFECT_SIZE="-0.051881371394239914" ORDER="151655" O_E="0.0" SE="0.08892234670939876" STUDY_ID="STD-Kawabata-1993" TOTAL_1="82" TOTAL_2="74" VAR="0.00790718374430652" WEIGHT="59.20239344296355"/>
<DICH_DATA CI_END="1.158726077676897" CI_START="0.6721064427575495" EFFECT_SIZE="0.8824892419728567" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="57" LOG_CI_END="0.06398078107690046" LOG_CI_START="-0.17256194146778048" LOG_EFFECT_SIZE="-0.054290580195440016" ORDER="151656" O_E="0.0" SE="0.1389463661281063" STUDY_ID="STD-Yamamoto-1994" TOTAL_1="53" TOTAL_2="86" VAR="0.019306092660205765" WEIGHT="40.79760655703645"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.087792620437693" CI_END="1.099457845261578" CI_START="0.8022551291719049" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9391728784783936" ESTIMABLE="YES" EVENTS_1="108" EVENTS_2="102" I2="80.34511084467174" I2_Q="0.0" ID="CMP-053.02" LOG_CI_END="0.04117858256334207" LOG_CI_START="-0.09568749758685648" LOG_EFFECT_SIZE="-0.027254457511757202" METHOD="MH" NO="2" P_CHI2="0.02409487647109354" P_Q="1.0" P_Z="0.4350470486866169" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="169" TOTAL_2="150" WEIGHT="100.0" Z="0.7805842774572044">
<NAME>Pressure pain (number of patients improved)</NAME>
<GROUP_LABEL_1>NRD 101 AND SLM-10</GROUP_LABEL_1>
<GROUP_LABEL_2>Artz</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Artz</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NRD101/SLM10</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.087792620437693" CI_END="1.099457845261578" CI_START="0.8022551291719049" DF="1" EFFECT_SIZE="0.9391728784783936" ESTIMABLE="YES" EVENTS_1="108" EVENTS_2="102" I2="80.34511084467174" ID="CMP-053.02.01" LOG_CI_END="0.04117858256334207" LOG_CI_START="-0.09568749758685648" LOG_EFFECT_SIZE="-0.027254457511757202" NO="1" P_CHI2="0.02409487647109354" P_Z="0.4350470486866169" STUDIES="2" TAU2="0.0" TOTAL_1="169" TOTAL_2="150" WEIGHT="100.0" Z="0.7805842774572044">
<NAME>1 to 4 weeks post-injection</NAME>
<DICH_DATA CI_END="0.9595411109831267" CI_START="0.6376710679038653" EFFECT_SIZE="0.7822222222222223" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="54" LOG_CI_END="-0.017936413434362634" LOG_CI_START="-0.1954032871600626" LOG_EFFECT_SIZE="-0.10666985029721264" ORDER="151657" O_E="0.0" SE="0.10424492010166903" STUDY_ID="STD-Kawabata-1993" TOTAL_1="75" TOTAL_2="66" VAR="0.010867003367003358" WEIGHT="53.12093800567685"/>
<DICH_DATA CI_END="1.419587534048674" CI_START="0.8789430045282471" EFFECT_SIZE="1.1170212765957446" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="48" LOG_CI_END="0.15216217698321707" LOG_CI_START="-0.056039286042738314" LOG_EFFECT_SIZE="0.04806144547023937" ORDER="151658" O_E="0.0" SE="0.1222985699953097" STUDY_ID="STD-Yamamoto-1994" TOTAL_1="94" TOTAL_2="84" VAR="0.014956940222897668" WEIGHT="46.87906199432316"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="1.5101133029919167" CI_END="1.0657047534412905" CI_START="-0.33175168648544073" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="0.3669765334779249" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-053.03" NO="3" P_CHI2="0.4699841003603238" P_Q="0.8158387428228672" P_Z="0.30329851359289717" Q="0.05424260032098496" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="244" TOTAL_2="250" UNITS="" WEIGHT="200.0" Z="1.0293856298315835">
<NAME>Lequesne Index (0-24)</NAME>
<GROUP_LABEL_1>HA</GROUP_LABEL_1>
<GROUP_LABEL_2>HA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours HA</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.5093103054667574" CI_START="-0.5893103054667574" DF="0" EFFECT_SIZE="0.45999999999999996" ESTIMABLE="YES" I2="0.0" ID="CMP-053.03.01" NO="1" P_CHI2="1.0" P_Z="0.39022177147242876" STUDIES="1" TAU2="0.0" TOTAL_1="114" TOTAL_2="119" WEIGHT="100.0" Z="0.859215265676229">
<NAME>1 to 4 weeks post-injection</NAME>
<CONT_DATA CI_END="1.5093103054667574" CI_START="-0.5893103054667574" EFFECT_SIZE="0.45999999999999996" ESTIMABLE="YES" MEAN_1="7.92" MEAN_2="7.46" ORDER="151659" SD_1="4.09" SD_2="4.08" SE="0.5353722383388588" STUDY_ID="STD-McDonald-2000" TOTAL_1="114" TOTAL_2="119" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.4558707026709317" CI_END="1.2294414670887994" CI_START="-0.6437055174794319" DF="1" EFFECT_SIZE="0.2928679748046837" ESTIMABLE="YES" I2="31.31258166227221" ID="CMP-053.03.02" NO="2" P_CHI2="0.22758857432480573" P_Z="0.5399532059258858" STUDIES="2" TAU2="0.0" TOTAL_1="130" TOTAL_2="131" WEIGHT="100.0" Z="0.6128837593326143">
<NAME>5 to 13 weeks post-injection</NAME>
<CONT_DATA CI_END="1.2994799424872725" CI_START="-3.2994799424872725" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="7.6" MEAN_2="8.6" ORDER="151660" SD_1="3.7" SD_2="2.5" SE="1.1732256105853356" STUDY_ID="STD-Bayramoglu-2003" TOTAL_1="16" TOTAL_2="12" WEIGHT="16.589162915826844"/>
<CONT_DATA CI_END="1.5754880927563024" CI_START="-0.47548809275630277" EFFECT_SIZE="0.5499999999999998" ESTIMABLE="YES" MEAN_1="6.91" MEAN_2="6.36" ORDER="151661" SD_1="4.22" SD_2="3.74" SE="0.5232178248402632" STUDY_ID="STD-McDonald-2000" TOTAL_1="114" TOTAL_2="119" WEIGHT="83.41083708417315"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="6.863517631998342" CI_END="1.0300991731470706" CI_START="0.8531864143878612" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="0.937478863762405" ESTIMABLE="YES" EVENTS_1="284" EVENTS_2="286" I2="12.581269230992353" I2_Q="8.935360220414506" ID="CMP-053.04" LOG_CI_END="0.012879038566485685" LOG_CI_START="-0.06895606860394983" LOG_EFFECT_SIZE="-0.02803851501873205" METHOD="MH" NO="4" P_CHI2="0.33365389239589993" P_Q="0.34842801588279637" P_Z="0.17925452383935953" Q="3.294363220742161" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="451" TOTAL_2="416" WEIGHT="400.0" Z="1.343053892561005">
<NAME>Patient global assessment</NAME>
<GROUP_LABEL_1>HA</GROUP_LABEL_1>
<GROUP_LABEL_2>HA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours HA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.3699477358564523" CI_END="1.1393433024726554" CI_START="0.8392110659849394" DF="2" EFFECT_SIZE="0.977828976555143" ESTIMABLE="YES" EVENTS_1="123" EVENTS_2="108" I2="0.0" ID="CMP-053.04.01" LOG_CI_END="0.056654603714723785" LOG_CI_START="-0.07612879809320425" LOG_EFFECT_SIZE="-0.009737097189240224" NO="1" P_CHI2="0.8311260501011115" P_Z="0.7737670277276176" STUDIES="3" TAU2="0.0" TOTAL_1="193" TOTAL_2="165" WEIGHT="100.0" Z="0.2874509847621266">
<NAME>1 to 4 weeks post-injection</NAME>
<DICH_DATA CI_END="1.1713089201776912" CI_START="0.7762267386929618" EFFECT_SIZE="0.9535204786010124" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="53" LOG_CI_END="0.0686714506957841" LOG_CI_START="-0.11001140119044231" LOG_EFFECT_SIZE="-0.020669975247329133" ORDER="151662" O_E="0.0" SE="0.10495919169235117" STUDY_ID="STD-Kawabata-1993" TOTAL_1="82" TOTAL_2="74" VAR="0.011016431920711719" WEIGHT="48.057058612540864"/>
<DICH_DATA CI_END="1.4278283381719885" CI_START="0.5637986685990651" EFFECT_SIZE="0.8972222222222223" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="12" LOG_CI_END="0.1546759971698448" LOG_CI_START="-0.24887595404221347" LOG_EFFECT_SIZE="-0.04709997843618436" ORDER="151663" O_E="0.0" SE="0.2370484137563386" STUDY_ID="STD-Roman-2000" TOTAL_1="30" TOTAL_2="19" VAR="0.05619195046439629" WEIGHT="12.673555846240479"/>
<DICH_DATA CI_END="1.3347547011483263" CI_START="0.8003806737093031" EFFECT_SIZE="1.0335917312661498" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="43" LOG_CI_END="0.1254014591640961" LOG_CI_START="-0.09670340654599412" LOG_EFFECT_SIZE="0.014349026309050952" ORDER="151664" O_E="0.0" SE="0.13046549755492373" STUDY_ID="STD-Yamamoto-1994" TOTAL_1="81" TOTAL_2="72" VAR="0.01702124605225381" WEIGHT="39.26938554121866"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.2376710234637116" CI_END="1.0503946718521466" CI_START="0.7813264016857066" DF="1" EFFECT_SIZE="0.9059255429162356" ESTIMABLE="YES" EVENTS_1="102" EVENTS_2="107" I2="69.11360071011217" ID="CMP-053.04.02" LOG_CI_END="0.021352510119617578" LOG_CI_START="-0.10716750026141007" LOG_EFFECT_SIZE="-0.04290749507089624" NO="2" P_CHI2="0.07196292198125998" P_Z="0.1906355898321329" STUDIES="2" TAU2="0.0" TOTAL_1="155" TOTAL_2="146" WEIGHT="100.0" Z="1.308701186009258">
<NAME>5 to 13 weeks post-injection</NAME>
<DICH_DATA CI_END="1.1251161063215809" CI_START="0.8204515213900787" EFFECT_SIZE="0.9607826086956521" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="92" LOG_CI_END="0.05119734176553092" LOG_CI_START="-0.08594707532360356" LOG_EFFECT_SIZE="-0.017374866779036314" ORDER="151665" O_E="0.0" SE="0.08055930947397096" STUDY_ID="STD-McDonald-2000" TOTAL_1="125" TOTAL_2="127" VAR="0.006489802342923026" WEIGHT="83.24715615305067"/>
<DICH_DATA CI_END="0.9702648476493332" CI_START="0.4134037341277338" EFFECT_SIZE="0.6333333333333333" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="15" LOG_CI_END="-0.013109702669022845" LOG_CI_START="-0.38362560486464414" LOG_EFFECT_SIZE="-0.1983676537668335" ORDER="151666" O_E="0.0" SE="0.21764287503300353" STUDY_ID="STD-Roman-2000" TOTAL_1="30" TOTAL_2="19" VAR="0.04736842105263159" WEIGHT="16.75284384694933"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.701808202048378" CI_START="0.6650130814090729" DF="0" EFFECT_SIZE="2.111111111111111" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="3" I2="0.0" ID="CMP-053.04.03" LOG_CI_END="0.8261919946744322" LOG_CI_START="-0.17716981164742399" LOG_EFFECT_SIZE="0.3245110915135041" NO="3" P_CHI2="1.0" P_Z="0.20487011730702376" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="19" WEIGHT="100.0" Z="1.2677980125271489">
<NAME>14 to 26 weeks post-injection</NAME>
<DICH_DATA CI_END="6.701808202048378" CI_START="0.6650130814090729" EFFECT_SIZE="2.111111111111111" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="3" LOG_CI_END="0.8261919946744322" LOG_CI_START="-0.17716981164742399" LOG_EFFECT_SIZE="0.3245110915135041" ORDER="151667" O_E="0.0" SE="0.5893796917545019" STUDY_ID="STD-Roman-2000" TOTAL_1="30" TOTAL_2="19" VAR="0.3473684210526316" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0305609717961906" CI_START="0.6992811566061738" DF="0" EFFECT_SIZE="0.8489121676067687" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="68" I2="0.0" ID="CMP-053.04.04" LOG_CI_END="0.013073691342114684" LOG_CI_START="-0.15534817445133633" LOG_EFFECT_SIZE="-0.07113724155461086" NO="4" P_CHI2="1.0" P_Z="0.09778646150448148" STUDIES="1" TAU2="0.0" TOTAL_1="73" TOTAL_2="86" WEIGHT="100.0" Z="1.6556808790795967">
<NAME>45 to 52 weeks post-injection</NAME>
<DICH_DATA CI_END="1.0305609717961906" CI_START="0.6992811566061738" EFFECT_SIZE="0.8489121676067687" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="68" LOG_CI_END="0.013073691342114684" LOG_CI_START="-0.15534817445133633" LOG_EFFECT_SIZE="-0.07113724155461086" ORDER="151668" O_E="0.0" SE="0.09893183766875459" STUDY_ID="STD-Karras-2001" TOTAL_1="73" TOTAL_2="86" VAR="0.00978750850451681" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK MODIFIED="2014-11-05 17:02:26 -0500" MODIFIED_BY="[Empty name]">
<FEEDBACK_ITEM ID="FBK-01" MODIFIED="2014-11-05 17:02:26 -0500" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2014-11-05 17:00:08 -0500" MODIFIED_BY="[Empty name]">New feedback</TITLE>
<DATE_SUBMITTED>
<DATE DAY="21" MONTH="9" YEAR="2014"/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2014-11-05 17:00:17 -0500" MODIFIED_BY="[Empty name]">
<P>Date of Submission: 21-Sep-2014<BR/>Name: Jos Verbeek<BR/>Email Address: <A HREF="mailto:jos.verbeek@ttl.fi">jos.verbeek@ttl.fi</A>
<BR/>Affiliation: Finnish Institute of Occupational Health<BR/>Role: senior researcher<BR/>
<BR/>Comment: I promised a friend to find out about Hyalgan proposed by a doctor for his osteoarthritic knee. I would like to give my friend an estimate of the reduction in pain that he could expect from the injections. I was impressed by the conclusion of the review: overall, these analyses strongly support the evidence for efficacy of Hyalgan.<BR/>
<BR/>It took me several hours to find my way through the 673 pages of the review where the text lacks links to the analyses. I was surprised to find the data not being in concordance with the strong conclusions. At three months follow-up, in ten trials, the median pain level on weight bearing was 43 out of 100 in the control group and the pooled mean difference 6.2. This means that the pain level decreased with 15% as a result of the injections. At one year follow-up there is no significant difference anymore.<BR/>Given that the review is sponsored by the pharmaceutical industry producing the very product and that there are two more recent reviews, as mentioned by Hilda Bastian in her comment in Pubmed commons (see altmetrics), with conclusions opposite to this review, I strongly believe that the authors&#8217; conclusions are wrong and that they should amend their conclusions or that this review should be retracted.<BR/>
<BR/>Based on the data presented above, my friend thought that it would be wise not to take these injections, and I fully agree.<BR/>
<BR/>
<BR/>I agree with the conflict of interest statement below:<BR/>
<BR/>I certify that I have no affiliations with or involvement in any organization or entity with a financial interest in the subject matter of my feedback.<BR/>
<BR/>
</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY MODIFIED="2014-11-05 17:01:36 -0500" MODIFIED_BY="[Empty name]">
<P>Dear Jos,<BR/>Thank you for this feedback. We have a new author team working on an update of this review and have shared this feedback with them. The updated review is expected by December 2015.<BR/>
<BR/>We appreciate you taking the time to send us these comments.<BR/>
<BR/>Thanks and best wishes,<BR/>Lara Maxwell, Cochrane Musculoskeletal Group, Co-Managing Editor</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS MODIFIED="2014-11-05 17:02:26 -0500" MODIFIED_BY="[Empty name]">
<P>Lara Maxwell, Cochrane Musculoskeletal Group, Co-Managing Editor, on behalf of the CMSG co-ordinating editors</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
</FEEDBACK>
<APPENDICES MODIFIED="2008-11-09 22:58:03 -0500" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2008-11-09 22:58:03 -0500" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2008-11-09 22:58:00 -0500" MODIFIED_BY="[Empty name]">Search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-11-09 22:58:03 -0500" MODIFIED_BY="[Empty name]">
<P>1 osteoarthritis.tw,sh.<BR/>2 knee joint/<BR/>3 knee.tw,sh.<BR/>4 1 and (2 or 3)<BR/>5 osteoarthritis, knee/<BR/>6 4 or 5<BR/>7 hyaluronic.sh,tw,rn.<BR/>8 hyaluronan.tw.<BR/>9 sodium hyaluronate.tw.<BR/>10 (hylan or healonid).tw.<BR/>11 (hyalgan or hylectin or hyalflex).tw.<BR/>12 (hylartil or replasyn or suplasyn).tw.<BR/>13 (polyreumin or polireumin).tw.<BR/>14 nrd 101.tw<BR/>15 (artz or artzal).tw.<BR/>16 slm 10.tw.<BR/>17 (neovisc or orthovisc).tw.<BR/>18 adant.tw.<BR/>19 etapharm.tw.<BR/>20 or/7-19<BR/>21 6 and 20<BR/>22 clinical trial.pt.<BR/>23 randomized controlled trial.pt.<BR/>24 tu.fs.<BR/>25 dt.fs.<BR/>26 random$.tw.<BR/>27 (double adj blind$).tw.<BR/>28 placebo$.tw.<BR/>29 (single adj blind$).tw.<BR/>30 random allocation.tw.<BR/>31 or/22-30<BR/>32 21 and 31<BR/>33 meta-analysis.pt,sh.<BR/>34 (meta-anal: or metaanal:).tw.<BR/>35 (quantitativ: review: or quantitativ: overv<BR/>36 (methodologic: review: or methodologic: ove<BR/>37 (systematic: review: or systematic: overvie<BR/>38 review.pt. and medline.tw.<BR/>39 or/33-38<BR/>40 21 and 39<BR/>41 32 or 40<BR/>42 limit 41 to human</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>